PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Si, ML; Zhu, S; Wu, H; Lu, Z; Wu, F; Mo, YY				Si, M.-L.; Zhu, S.; Wu, H.; Lu, Z.; Wu, F.; Mo, Y.-Y.			miR-21-mediated tumor growth	ONCOGENE			English	Article						miRNA; miR-21; post-transcriptional regulation; Bcl-2; MCF-7	HUMAN MICRORNA GENES; SMALL RNAS; C-ELEGANS; RT-PCR; EXPRESSION; ACCUMULATION; INHIBITION; BIOGENESIS; MECHANISMS; MIRNAS	MicroRNAs (miRNAs) are B22 nucleotide non-coding RNA molecules that dregulate gene expression post-transcriptionally. Although aberrant expression of miRNAs in various human cancers suggests a role for miRNAs in tumorigenesis, it remains largely unclear as to whether knockdown of a specific miRNA affects tumor growth. In this study, we profiled miRNA expression in matched normal breast tissue and breast tumor tissues by TaqMan real-time polymerase chain reaction miRNA array methods. Consistent with previous findings, we found that miR-21 was highly overexpressed in breast tumors compared to the matched normal breast tissues among 157 human miRNAs analysed. To better evaluate the role of miR-21 in tumorigenesis, we transfected breast cancer MCF-7 cells with anti-miR-21 oligonucleotides and found that anti-miR-21 suppressed both cell growth in vitro and tumor growth in the xenograft mouse model. Furthermore, this anti-miR-21-mediated cell growth inhibition was associated with increased apoptosis and decreased cell proliferation, which could be in part owing to downregulation of the antiapoptotic Bcl-2 in anti-miR-21-treated tumor cells. Together, these results suggest that miR-21 functions as an oncogene and modulates tumorigenesis through regulation of genes such as bcl-2 and thus, it may serve as a novel therapeutic target.	So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA	Southern Illinois University System; Southern Illinois University	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 801 N Rutledge,POB 19626, Springfield, IL 62794 USA.	ymo@siumed.edu	zhu, shoumin/F-4564-2011; Mo, Yin-Yuan/B-6141-2011; Mo, Yin-Yuan/R-8255-2019		NCI NIH HHS [CA102630, R01 CA102630] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102630] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Fitzgerald K, 2005, CURR OPIN DRUG DISC, V8, P557; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lao KQ, 2006, BIOCHEM BIOPH RES CO, V343, P85, DOI 10.1016/j.bbrc.2006.02.106; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; Tang FC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj009; TANIZAWA A, 1994, J NATL CANCER I, V86, P836, DOI 10.1093/jnci/86.11.836; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	25	1259	1403	5	153	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2799	2803		10.1038/sj.onc.1210083	http://dx.doi.org/10.1038/sj.onc.1210083			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072344				2022-12-25	WOS:000246210600014
J	Huang, W; Chang, HY; Fei, T; Wu, H; Chen, YG				Huang, W.; Chang, H. Y.; Fei, T.; Wu, H.; Chen, Y-G			GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN	ONCOGENE			English	Article						PTEN; cyclin D2; gene expression; GSK3 beta; beta-catenin; TCF	GERM-CELL TUMORS; PROTEIN-KINASE-A; BETA-CATENIN; COWDEN-DISEASE; TRANSCRIPTIONAL ACTIVATION; INDUCED PROLIFERATION; COLON-CARCINOMA; GENE; PATHWAY; SURVIVAL	PTEN, encoding a lipid phosphatase, is a tumor suppressor gene and is mutated in various types of cancers. It is reported to regulate G1 to S phase transition of the cell cycle by influencing the expression, protein stability and subcellular location of cyclin D1. Here, we provide evidence that PTEN modulates the transcription and protein stability of cyclin D2. Targeted deletion of Pten in mouse embryonic fibroblasts (MEFs) endowed cells with greater potential to overcome G1 arrest than wild-type MEFs and led to the elevated expression of cyclin D2, which was suppressed by the introduction of PTEN. We further de fined a pathway involving GSK3 beta and beta-catenin/TCF in PTEN-mediated suppression of cyclin D2 transcription. LiCl, an inhibitor of GSK3b, abolished inhibitory effect of PTEN on cyclin D2 expression, and TCF members could directly bind to the promoter of cyclin D2 and regulate its transcription in a CREB-dependent manner. Our results indicate that the downregulation of cyclin D2 expression by PTEN is mediated by the GSK3 beta/beta-catenin/TCF pathway in cooperation with CREB, and suggest a convergence from the PI-3 kinase/PTEN pathway and the Wnt pathway in modulation of cyclin D2 expression.	Tsing Hua Univ, Dept Mol Biol & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Tsinghua University; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chen, YG (corresponding author), Tsing Hua Univ, Dept Mol Biol & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	ygchen@tsinghua.edu.cn	Chen, Ye-Guang/L-6998-2019; Fei, Teng/A-5963-2010; Fei, Teng/G-5324-2015	Fei, Teng/0000-0001-5707-0673; FEI, TENG/0000-0001-9620-0450				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Anzelon AN, 2003, NAT IMMUNOL, V4, P287, DOI 10.1038/ni892; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; Chaganti RSK, 2000, CANCER RES, V60, P1475; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Vizio D, 2005, ONCOGENE, V24, P1882, DOI 10.1038/sj.onc.1208368; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Jena N, 2002, CANCER RES, V62, P535; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6; Mohamedali A, 2003, J LEUKOCYTE BIOL, V74, P1139, DOI 10.1189/jlb.0803363; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Piatelli MJ, 2004, J IMMUNOL, V172, P2753, DOI 10.4049/jimmunol.172.5.2753; Pradeep A, 2004, ONCOGENE, V23, P3689, DOI 10.1038/sj.onc.1207454; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; RAVNIK SE, 1995, DEV GENET, V16, P171, DOI 10.1002/dvg.1020160209; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; White PC, 2006, ONCOGENE, V25, P2170, DOI 10.1038/sj.onc.1209255; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Xu LF, 2000, GENE DEV, V14, P585; Zhu XY, 2001, CANCER RES, V61, P4569	52	65	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2471	2482		10.1038/sj.onc.1210033	http://dx.doi.org/10.1038/sj.onc.1210033			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043650				2022-12-25	WOS:000245831000007
J	Frost, P; Shi, Y; Hoang, B; Lichtenstein, A				Frost, P.; Shi, Y.; Hoang, B.; Lichtenstein, A.			AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; angiogenesis; internal ribosome entry sites; cap-independent translation; drug resistance; xenograft	ENDOTHELIAL GROWTH-FACTOR; BONE-MARROW ANGIOGENESIS; MESSENGER-RNA CONTAINS; RIBOSOME ENTRY SITE; MAMMALIAN TARGET; PROGNOSTIC VALUE; CYCLIN D1; IN-VIVO; TRANSLATION; ACTIVATION	We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in immunodeficient mice. This antitumor effect was associated with prevention of cell proliferation, induction of apoptosis and inhibition of angiogenesis. Interestingly, myeloma tumors with heightened AKT activation were particularly sensitive to a CCI-779-induced antitumor response. To investigate whether part of the differential sensitivity was due to an AKT-regulated effect on angiogenesis, we compared the effects of mTOR inhibitors against isogenic MM cell lines that only differ by their degree of AKT activity. In this model, heightened AKT activity significantly sensitized MM cells to the following inhibitory effects of mTOR inhibition: angiogenesis in vivo, vascular endothelial growth factor (VEGF) expression in vitro and in vivo and VEGF translation (but not transcription). Assessment of p70S6 kinase activity indicated that rapamycin induced comparable mTOR inhibition in both cell lines suggesting that an adverse effect on VEGF cap-dependent translation would be comparable. Internal ribosome entry site (IRES)-mediated cap-independent translation is a salvage pathway for protein expression when mTOR is inhibited, so we analyzed a possible regulatory role of AKT on VEGF IRES activity. We found that elevated AKT activity inhibited VEGF IRES function. These results support a mechanism whereby AKT prevents VEGF IRES activity in myeloma cells during mTOR inhibition resulting in a more complete abrogation of VEGF translation, and ultimately, angiogenesis.	VA W Los Angeles Hosp, Dept Hematol Oncol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Frost, P (corresponding author), VA W Los Angeles Hosp, Dept Hematol Oncol, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	pfrost@ucla.edu		Frost, Patrick/0000-0003-3348-5983	NATIONAL CANCER INSTITUTE [K01CA111623, R01CA096920, R01CA111448] Funding Source: NIH RePORTER; NCI NIH HHS [K01CA111623, R01CA96920, R01CA111448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bellamy WT, 1999, CANCER RES, V59, P728; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood-2004-03-1153; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kumar S, 2004, LEUKEMIA, V18, P624, DOI 10.1038/sj.leu.2403285; Kumar S, 2003, BLOOD, V101, P1715, DOI 10.1182/blood-2002-08-2441; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; LeBlanc R, 2002, CANCER RES, V62, P4996; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Rajkumar SV, 2000, CLIN CANCER RES, V6, P3111; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Sugawara M, 2002, HUM PATHOL, V33, P524, DOI 10.1053/hupa.2002.124783; Tu YP, 2000, CANCER RES, V60, P6763; Yan HJ, 2006, CANCER RES, V66, P2305, DOI 10.1158/0008-5472.CAN-05-2447; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	33	59	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2255	2262		10.1038/sj.onc.1210019	http://dx.doi.org/10.1038/sj.onc.1210019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016437				2022-12-25	WOS:000245466000001
J	Nandi, S; Reinert, LS; Hachem, A; Mazan-Mamczarz, K; Hagner, P; He, H; Gartenhaus, RB				Nandi, S.; Reinert, L. S.; Hachem, A.; Mazan-Mamczarz, K.; Hagner, P.; He, H.; Gartenhaus, R. B.			Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage	ONCOGENE			English	Article						lymphoma; stability; phosphorylation	KINASE SIGNALING PATHWAYS; CELL-CYCLE PROGRESSION; B-CELL; CANDIDATE ONCOGENE; PROTEIN STABILITY; APOPTOSIS; PROLIFERATION; INHIBITION; ACTIVATION; EXPRESSION	We discovered a novel oncogene in a T-cell lymphoma cell line, multiple copies in T-cell lymphoma-1 (MCT-1), that has been shown to decrease cell-doubling time, shorten the duration of G(1) transit time and/or G(1)-S transition, and transform NIH3T3 fibroblasts. We subsequently demonstrated that there were significantly increased levels of MCT-1 protein in a subset of primary diffuse large B-cell lymphomas. Levels of MCT-1 protein were shown to be increased after exposure to DNA damaging agents. This increase did not require new protein synthesis, suggesting that post-translational mechanisms were involved. Phosphorylation is one potential mechanism by which the activity of molecules involved in cell cycle/survival is rapidly modulated. The RAS/mitogen-activated/extracellular-regulated kinase (MEK)/extracellular signal-regulated kinases (ERK) pathway plays a prominent role in the regulation of cell growth and proliferation through phosphorylation-dependent regulation of several substrates. The MCT-1 protein is predicted to have numerous putative phosphorylation sites. Using a combination of genetic and pharmacological approaches, we established that phosphorylation of MCT-1 protein by p44/p42 mitogen-activated protein kinases is critical for stabilization of MCT-1 protein and for its ability to promote cell proliferation. Our data suggests that targeting the RAS/MEK/ERK signal transduction cascade may provide a potential therapeutic approach in lymphomas and related malignancies that exhibit high levels of MCT-1 protein.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Calif San Diego, Dept Med, La Jolla, CA USA	University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego	Gartenhaus, RB (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 9-011 BRB,655 W Baltimore St, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu		Reinert, Line/0000-0002-8317-0886				Chang FM, 2003, INT J ONCOL, V22, P469; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; Herbert GB, 2001, ONCOGENE, V20, P6777, DOI 10.1038/sj.onc.1204881; Hsu HL, 2005, ONCOGENE, V24, P4956, DOI 10.1038/sj.onc.1208680; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Levenson AS, 2005, CANCER RES, V65, P10651, DOI 10.1158/0008-5472.CAN-05-0845; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prosniak M, 1998, CANCER RES, V58, P4233; Scarpa A, 1999, GENE CHROMOSOME CANC, V26, P203, DOI 10.1002/(SICI)1098-2264(199911)26:3<203::AID-GCC3>3.0.CO;2-E; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538; Shi B, 2003, BLOOD, V102, P297, DOI 10.1182/blood-2002-11-3486; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Werner CA, 1997, AM J PATHOL, V151, P335; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Yang CM, 2003, J BIOMED SCI, V10, P208, DOI 10.1159/000068713	21	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2283	2289		10.1038/sj.onc.1210030	http://dx.doi.org/10.1038/sj.onc.1210030			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016429	Bronze			2022-12-25	WOS:000245466000004
J	Tong, S; Liss, AS; You, M; Bose, HR				Tong, S.; Liss, A. S.; You, M.; Bose, H. R., Jr.			The activation of TC10, a Rho small GTPase, contributes to v-Rel-mediated transformation	ONCOGENE			English	Article						v-Rel; NF-kappa B; TC10; Rho; GTPase; transformation	STIMULATED GLUT4 TRANSLOCATION; KAPPA-B FAMILY; C-REL; DNA-BINDING; CELL-TRANSFORMATION; PROTEINS; CDC42; EXPRESSION; MUTATIONS; GENES	v-Rel is the oncogenic member of the Rel/NF-kappa B family of transcription factors and transforms hematopoietic cells and fibroblasts. Differential display was employed to identify target genes that exhibit altered expression in v-Rel transformed cells. One of the cDNAs identified encodes the chicken ortholog of TC10, a member of the Rho small GTPase family. The expression of TC10 was increased in v-Rel-transformed chicken embryonic fibroblasts (CEFs) 3 to 6-fold relative to control cells at both the RNA and protein levels. An elevated level of active, GTP-bound TC10 was also detected in v-Rel-transformed cells relative to control cells. Expression of a dominant-negative TC10 mutant (TC10T32N) decreased the colony formation potential of v-Rel-transformed cells. Furthermore, overexpression of wild-type TC10 or a gain-of-function mutant (TC10Q76L) greatly enhanced the ability of v-Rel transformed CEFs to form colonies in soft agar. In addition to enhance the transformation potential of v-Rel, the overexpression of wild-type TC10 or the gain-of-function mutant alone enhanced the saturation density of CEFs and was sufficient for their anchorage-independent growth in vitro. These results indicate that elevated TC10 activity contributes to v-Rel-mediated transformation of CEFs and demonstrate for the first time that a Rho factor alone is capable of inducing the in vitro transformation of primary cells.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Bose, HR (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019		NCI NIH HHS [CA33192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham MT, 2001, LARYNGOSCOPE, V111, P1285, DOI 10.1097/00005537-200107000-00027; AKIYAMA Y, 1974, BIKEN J, V17, P105; Anastasiadis PZ, 2001, J BIOL CHEM, V276, P9050, DOI 10.1074/jbc.M006570200; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Benard V, 2002, METHOD ENZYMOL, V345, P349; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Chiang SH, 2002, J BIOL CHEM, V277, P13067, DOI 10.1074/jbc.M109471200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; del Peso L, 1997, ONCOGENE, V15, P3047; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; Dransart E, 2005, TRAFFIC, V6, P957, DOI 10.1111/j.1600-0854.2005.00335.x; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; FRYKBERG L, 1987, ONCOGENE, V1, P415; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hrdlickova R, 2006, J VIROL, V80, P281, DOI 10.1128/JVI.80.1.281-295.2006; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HRDLICKOVA R, 1999, ENCY VIROLOGY, V3, P1496; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Keely PJ, 2001, LANCET, V358, P1744, DOI 10.1016/S0140-6736(01)06840-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MOSCOW JA, 1994, ONCOGENE, V9, P189; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Murphy GA, 2001, CELL GROWTH DIFFER, V12, P157; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; NAZERIAN K, 1977, AVIAN DIS, V21, P69, DOI 10.2307/1589365; Nehyba J, 2002, MOL CELL BIOL, V22, P3942, DOI 10.1128/MCB.22.11.3942-3957.2002; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OKUNO H, 1991, ONCOGENE, V6, P1491; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; PERONA R, 1993, ONCOGENE, V8, P1285; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO A, 1990, CANCER RES, V50, P4764; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Ridley AJ, 1997, INT J BIOCHEM CELL B, V29, P1225, DOI 10.1016/S1357-2725(97)00052-6; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tanabe K, 2000, J NEUROSCI, V20, P4138; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; van Golen KL, 2000, CANCER RES, V60, P5832; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WARBURG O, 1930, METABOLISM TUMORS; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Whitmire KH, 1998, ADV ORGANOMET CHEM, V42, P1, DOI 10.1016/S0065-3055(08)60542-0; You MJ, 1998, METHODS, V16, P373, DOI 10.1006/meth.1998.0692; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806; ZHANG JY, 1989, J VIROL, V63, P1107, DOI 10.1128/JVI.63.3.1107-1115.1989; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	88	1	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2318	2329		10.1038/sj.onc.1210023	http://dx.doi.org/10.1038/sj.onc.1210023			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016434				2022-12-25	WOS:000245466000008
J	Cao, Y; Kamioka, Y; Yokoi, N; Kobayashi, T; Hino, O; Onodera, M; Mochizuki, N; Nakae, J				Cao, Yongheng; Kamioka, Yuji; Yokoi, Norihide; Kobayashi, Toshiyuki; Hino, Okio; Onodera, Masafumi; Mochizuki, Naoki; Nakae, Jun			Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FOXO1; TUBEROUS SCLEROSIS COMPLEX; TUMOR-SUPPRESSOR PROTEINS; CELL-GROWTH; GENE-PRODUCT; CAENORHABDITIS-ELEGANS; GAP ACTIVITY; FACTOR FKHR; RHEB; MTOR	Both TSC2 ( tuberin) and forkhead transcription factor FoxO1 are phosphorylated and inhibited by Akt and play important roles in insulin signaling. However, little is known about the relationship between TSC2 and FoxO1. Here we identified TSC2 as a FoxO1-binding protein by using a yeast two-hybrid screening with a murine islet cDNA library. Among FoxOs, only FoxO1 can be associated with TSC2. The physical association between the C terminus of TSC2 ( amino acids 1280-1499) and FoxO1 degrades the TSC1-TSC2 complex and inhibits GTPase-activating protein activity of TSC2 toward Rheb. Overexpression of wild type FoxO1 enhances p70 S6K phosphorylation, whereas overexpression of TSC2 can reverse these effects. Knockdown of endogenous FOXO1 in human vascular endothelial cells decreased phosphorylation of p70 S6K. Prolonged overexpression of wild type FoxO1 enhanced phosphorylation of serine 307 of IRS1 and decreased phosphorylation of Akt and FoxO1 itself even in the presence of serum. These data suggest a novel mechanism by which FoxO1 regulates the insulin signaling pathway through negative regulation of TSC2 function.	Kobe Univ, Grad Sch Med, Div Diabet Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Struct Analysis, Suita, Osaka 5658565, Japan; Kobe Univ, Grad Sch Med, Div Cell & Mol Med, Kobe, Hyogo 6500017, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Toshima Ku, Tokyo 1708455, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Adv Biomed Appl, Tsukuba, Ibaraki 3058575, Japan	Kobe University; National Cerebral & Cardiovascular Center - Japan; Kobe University; Japanese Foundation for Cancer Research; University of Tsukuba	Nakae, J (corresponding author), Kobe Univ, Grad Sch Med, Div Diabet Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	nakaej@med.kobe-u.ac.jp	Nakae, Jun/Q-6141-2019					Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Craparo A, 1997, J BIOL CHEM, V272, P11663; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Kamioka Y, 2004, J BIOL CHEM, V279, P40091, DOI 10.1074/jbc.M404899200; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Nabekura T, 2006, MOL THER, V13, P301, DOI 10.1016/j.ymthe.2005.09.021; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakae J, 2006, J CLIN INVEST, V116, P2473, DOI 10.1172/JCI25518; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Nishimura M, 2004, DNA RES, V11, P315, DOI 10.1093/dnares/11.5.315; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Okamoto H, 2006, J CLIN INVEST, V116, P775, DOI 10.1172/JCI24967; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Sparagana Steven P., 2000, Current Opinion in Neurology, V13, P115, DOI 10.1097/00019052-200004000-00001; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tsuchiya H, 1996, CANCER RES, V56, P429; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	64	53	54	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40242	40251		10.1074/jbc.M608116200	http://dx.doi.org/10.1074/jbc.M608116200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17077083	hybrid			2022-12-25	WOS:000243033900055
J	Gangwani, L				Gangwani, Laxman			Deficiency of the zinc finger protein ZPR1 causes defects in transcription and cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; HISTONE GENE-TRANSCRIPTION; COILED BODIES; S-PHASE; SINGLE NUCLEOTIDE; CAJAL BODIES; SMN PROTEIN; SURVIVAL; COMPLEX; RNA	The zinc finger protein ZPR1 is present in both the cytoplasm and nucleoplasm. Cell cycle analysis demonstrates that ZPR1 undergoes major changes in subcellular distribution during proliferation. ZPR1 is diffusely localized throughout the cell during the G(1) and G(2)/M phases of the cell cycle. In contrast, ZPR1 redistributes to the nucleus during S phase and ZPR1 exhibits prominent co-localization with the survival motor neurons protein and the histone gene-specific transcription factor NPAT in subnuclear foci, including Cajal bodies that associate with histone gene clusters. ZPR1 deficiency causes disruption of survival motor neurons and NPAT localization within the nucleus, blocks S phase progression, and arrests cells in both the G(1) and G(2) phases of the cell cycle. These changes in subnuclear architecture and cell cycle progression may be caused by transcriptional defects in ZPR1-deficient cells, including decreased histone gene expression.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Gangwani, L (corresponding author), 373 Plantat St, Worcester, MA 01605 USA.	laxman.gangwani@umassmed.edu	Gangwani, Laxman/R-3688-2019					ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; Ansari H, 2002, MOL CELL BIOL, V22, P6993, DOI 10.1128/MCB.22.20.6993-7003.2002; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; Cusco I, 2006, J NEUROL, V253, P21, DOI 10.1007/s00415-005-0912-y; DiFruscio M, 1997, MOL CELL BIOL, V17, P4080, DOI 10.1128/MCB.17.7.4080; Doran B, 2006, P NATL ACAD SCI USA, V103, P7471, DOI 10.1073/pnas.0602057103; FREY MR, 1995, P NATL ACAD SCI USA, V92, P5915, DOI 10.1073/pnas.92.13.5915; Frugier T, 2002, CURR OPIN GENET DEV, V12, P294, DOI 10.1016/S0959-437X(02)00301-5; Galcheva-Gargova Z, 1998, MOL BIOL CELL, V9, P2963, DOI 10.1091/mbc.9.10.2963; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; Gangwani L, 2005, MOL CELL BIOL, V25, P2744, DOI 10.1128/MCB.25.7.2744-2756.2005; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; Gangwani L, 1998, J CELL BIOL, V143, P1471, DOI 10.1083/jcb.143.6.1471; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; Helmken C, 2003, HUM GENET, V114, P11, DOI 10.1007/s00439-003-1025-2; Jablonka S, 2000, J NEUROL, V247, P37, DOI 10.1007/s004150050555; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Matera AG, 1998, AM J HUM GENET, V63, P317, DOI 10.1086/301992; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Mitra P, 2003, MOL CELL BIOL, V23, P8110, DOI 10.1128/MCB.23.22.8110-8123.2003; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Monani UR, 2005, NEURON, V48, P885, DOI 10.1016/j.neuron.2005.12.001; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Narayanan U, 2002, HUM MOL GENET, V11, P1785, DOI 10.1093/hmg/11.15.1785; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; STEIN GS, 1994, CELL BIOL LAB HDB, V1, P282; Wirth B, 2002, AMYOTROPH LATERAL SC, V3, P87, DOI 10.1080/146608202760196057; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Yong J, 2004, MOL CELL BIOL, V24, P2747, DOI 10.1128/MCB.24.7.2747-2756.2004; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700	39	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40330	40340		10.1074/jbc.M608165200	http://dx.doi.org/10.1074/jbc.M608165200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17068332	hybrid			2022-12-25	WOS:000243033900064
J	Hassan, MQ; Tare, RS; Lee, SH; Mandeville, M; Morasso, MI; Javed, A; van Wijnen, AJ; Stein, JL; Stein, GS; Lian, JB				Hassan, Mohammad Q.; Tare, Rahul S.; Lee, Suk Hee; Mandeville, Matthew; Morasso, Maria I.; Javed, Amjad; van Wijnen, Andre J.; Stein, Janet L.; Stein, Gary S.; Lian, Jane B.			BMP2 commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; OSTEOBLAST DIFFERENTIATION; CHONDROCYTE DIFFERENTIATION; PROGRESSIVE DEVELOPMENT; OVERLAPPING EXPRESSION; PROMOTES OSTEOGENESIS; HOMEOBOX GENES; MSX2; BINDING; ROLES	Several homeodomain (HD) proteins are critical for skeletal patterning and respond directly to BMP2 as an early step in bone formation. RUNX2, the earliest transcription factor proven essential for commitment to osteoblastogenesis, is also expressed in response to BMP2. However, there is a gap in our knowledge of the regulatory cascade from BMP2 signaling to the onset of osteogenesis. Here we show that BMP2 induces DLX3, a homeodomain protein that activates Runx2 gene transcription. Small interfering RNA knockdown studies in osteoblasts validate that DLX3 is a potent regulator of Runx2. Furthermore in Runx2 null cells, DLX3 forced expression suffices to induce transcription of Runx2, osteocalcin, and alkaline phosphatase genes, thus defining DLX3 as an osteogenic regulator independent of RUNX2. Our studies further show regulation of the Runx2 gene by several homeodomain proteins: MSX2 and CDP/cut repress whereas DLX3 and DLX5 activate endogenous Runx2 expression and promoter activity in non-osseous cells and osteoblasts. These HD proteins exhibit distinct temporal expression profiles during osteoblast differentiation as well as selective association with Runx2 chromatin that is related to Runx2 transcriptional activity and recruitment of RNA polymerase II. Runx2 promoter mutagenesis shows that multiple HD elements control expression of Runx2 in relation to the stages of osteoblast maturation. Our studies establish mechanisms for commitment to the osteogenic lineage directly through BMP2 induction of HD proteins DLX3 and DLX5 that activate Runx2, thus delineating a transcriptional regulatory pathway mediating osteoblast differentiation. We propose that the three homeodomain proteins MSX2, DLX3, and DLX5 provide a key series of molecular switches that regulate expression of Runx2 throughout bone formation.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; NIAMS, Dev Skin Biol Unit, NIH, Bethesda, MD 20892 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu	Hassan, Mohammad/GZA-7507-2022; van Wijnen, Andre J./AAG-3578-2019	Hassan, Mohammad/0000-0002-1712-0004; van Wijnen, Andre J./0000-0002-4458-0946; Tare, Rahul/0000-0001-8274-8837; Javed, Amjad/0000-0002-0847-8266	NIAMS NIH HHS [AR48818, AR39588, R01 AR049069] Funding Source: Medline; NIDCR NIH HHS [DE12528] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039588, R01AR049069, P01AR048818, Z01AR041124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberg T, 2004, J HISTOCHEM CYTOCHEM, V52, P131, DOI 10.1177/002215540405200113; Acampora D, 1999, DEVELOPMENT, V126, P3795; Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258; ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; BAE JS, 2006, J CELL BIOCH; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Beanan MJ, 2000, DEV DYNAM, V218, P545, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1026>3.0.CO;2-B; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Bryan JT, 2000, J CELL SCI, V113, P4013; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Depew MJ, 2002, SCIENCE, V298, P381, DOI 10.1126/science.1075703; Depew MJ, 2005, J ANAT, V207, P501, DOI 10.1111/j.1469-7580.2005.00487.x; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ferrari D, 2002, DEV BIOL, V252, P257, DOI 10.1006/dbio.2002.0862; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Ghoul-Mazgar S, 2005, BONE, V37, P799, DOI 10.1016/j.bone.2005.03.020; Harris SE, 2003, FRONT BIOSCI, V8, pS1249, DOI 10.2741/1170; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200; Ishii M, 2005, DEVELOPMENT, V132, P4937, DOI 10.1242/dev.02072; Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lallemand Y, 2005, DEVELOPMENT, V132, P3003, DOI 10.1242/dev.01877; Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200; Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925-4773(02)00050-3; Lengner CJ, 2005, J BIOL CHEM, V280, P15872, DOI 10.1074/jbc.M411144200; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; McKeown SJ, 2005, DEV BIOL, V281, P22, DOI 10.1016/j.ydbio.2005.02.004; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; Pratap J, 2003, CANCER RES, V63, P5357; Provot S, 2006, DEVELOPMENT, V133, P651, DOI 10.1242/dev.02258; ROBINSON GW, 1994, MECH DEVELOP, V48, P199, DOI 10.1016/0925-4773(94)90060-4; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; Roca H, 2005, J BIOL CHEM, V280, P30845, DOI 10.1074/jbc.M503942200; ROSEN V, 1994, J BONE MINER RES, V9, P1759; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Semba I, 2000, DEV DYNAM, V217, P401, DOI 10.1002/(SICI)1097-0177(200004)217:4<401::AID-DVDY7>3.0.CO;2-D; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Smith N, 2005, J CELL PHYSIOL, V203, P133, DOI 10.1002/jcp.20210; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; ten Dijke P, 2003, J BONE JOINT SURG AM, V85A, P34; Vaes BLT, 2002, J BONE MINER RES, V17, P2106, DOI 10.1359/jbmr.2002.17.12.2106; van Gurp MF, 1999, CANCER RES, V59, P5980; Xu SC, 2001, DNA CELL BIOL, V20, P359, DOI 10.1089/10445490152122479; Yoshizawa T, 2004, MOL CELL BIOL, V24, P3460, DOI 10.1128/MCB.24.8.3460-3472.2004; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zaidi SK, 2003, P NATL ACAD SCI USA, V100, P14852, DOI 10.1073/pnas.2533076100; Zambotti A, 2002, J BIOL CHEM, V277, P41497, DOI 10.1074/jbc.M204271200	62	170	178	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40515	40526		10.1074/jbc.M604508200	http://dx.doi.org/10.1074/jbc.M604508200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17060321	Green Accepted, hybrid			2022-12-25	WOS:000243033900081
J	Tanaka, KJ; Ogawa, K; Takagi, M; Imamoto, N; Matsumoto, K; Tsujimoto, M				Tanaka, Kimio J.; Ogawa, Kenji; Takagi, Masatoshi; Imamoto, Naoko; Matsumoto, Ken; Tsujimoto, Masafumi			RAP55, a cytoplasmic mRNP component, represses translation in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEADENYLATION; BINDING-PROTEIN; PROCESSING BODIES; TRAILER HITCH; LSM PROTEINS; HELICASE P54; IDENTIFICATION; COMPLEX; TRANSCRIPTION; LAEVIS	mRNAs in eukaryotic cells are presumed to always associate with a set of proteins to form mRNPs. In Xenopus oocytes, a large pool of maternal mRNAs is masked from the translational apparatus as storage mRNPs. Here we identified Xenopus RAP55 (xRAP55) as a component of RNPs that associate with FRGY2, the principal component of maternal mRNPs. RAP55 is a member of the Scd6 or Lsm14 family. RAP55 localized to cytoplasmic foci in Xenopus oocytes and the processing bodies (P-bodies) in cultured human cells: in the latter cells, RAP55 is an essential constituent of the P-bodies. We isolated xRAP55-containing complexes from Xenopus oocytes and identified xRAP55-associated proteins, including a DEAD-box protein, Xp54, and a protein arginine methyltransferase, PRMT1. Recombinant xRAP55 repressed translation, together with Xp54, in an in vitro translation system. In addition, xRAP55 repressed translation in oocytes when tethered with a reporter mRNA. Domain analyses revealed that the N-terminal region of RAP55, including the Lsm domain, is important for the localization to P-bodies and translational repression. Taken together, our results suggest that xRAP55 is involved in translational repression of mRNA as a component of storage mRNPs.	RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; RIKEN, Lab Cellular Dynam, Wako, Saitama 3510198, Japan	RIKEN; RIKEN	Matsumoto, K (corresponding author), RIKEN, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	matsumok@riken.jp	Imamoto, Naoko/A-7458-2015; Matsumoto, Ken/F-9083-2013	Imamoto, Naoko/0000-0002-2886-3022; Matsumoto, Ken/0000-0002-7864-3394				Albrecht M, 2004, FEBS LETT, V569, P18, DOI 10.1016/j.febslet.2004.03.126; Anantharaman V, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-45; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Aoki K, 2003, J BIOL CHEM, V278, P48491, DOI 10.1074/jbc.M308328200; Aoki K, 2002, NUCLEIC ACIDS RES, V30, P5182, DOI 10.1093/nar/gkf638; Audhya A, 2005, J CELL BIOL, V171, P267, DOI 10.1083/jcb.200506124; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; Boag PR, 2005, DEVELOPMENT, V132, P4975, DOI 10.1242/dev.02060; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Colegrove-Otero LJ, 2005, CRIT REV BIOCHEM MOL, V40, P21, DOI 10.1080/10409230590918612; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Cosson B, 2004, BIOL CELL, V96, P519, DOI 10.1016/j.biolcel.2004.04.006; Cougot N, 2004, J CELL BIOL, V165, P31, DOI 10.1083/jcb.200309008; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; Decker CJ, 2006, J CELL BIOL, V173, P159, DOI 10.1083/jcb.200601153; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; Fenger-Gron M, 2005, MOL CELL, V20, P905, DOI 10.1016/j.molcel.2005.10.031; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; Good PJ, 2004, GENESIS, V38, P166, DOI 10.1002/gene.20015; Houston DW, 2000, CURR TOP DEV BIOL, V50, P155, DOI 10.1016/S0070-2153(00)50008-8; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Khusial P, 2005, TRENDS BIOCHEM SCI, V30, P522, DOI 10.1016/j.tibs.2005.07.006; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Kshirsagar M, 2004, GENETICS, V166, P729, DOI 10.1534/genetics.166.2.729; Ladomery M, 1997, NUCLEIC ACIDS RES, V25, P965, DOI 10.1093/nar/25.5.965; Lieb B, 1998, EXP CELL RES, V245, P272, DOI 10.1006/excr.1998.4249; Lykke-Andersen J, 2002, MOL CELL BIOL, V22, P8114, DOI 10.1128/MCB.22.23.8114-8121.2002; Martin KC, 2004, CURR OPIN NEUROBIOL, V14, P305, DOI 10.1016/j.conb.2004.05.009; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 2005, MOL CELL BIOL, V25, P1779, DOI 10.1128/MCB.25.5.1779-1792.2005; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; Matsumoto K, 2000, NUCLEIC ACIDS RES, V28, P4689, DOI 10.1093/nar/28.23.4689; Matsumoto K, 2003, BIOCHEM BIOPH RES CO, V306, P53, DOI 10.1016/S0006-291X(03)00909-4; Matsumoto K, 1999, MOL CELL BIOL, V19, P6940; MATSUMOTO K, 2006, RECENT DEV NUCL ACID, P115; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Minshall N, 2001, RNA, V7, P1728, DOI 10.1017/S135583820101158X; Minshall N, 2004, NUCLEIC ACIDS RES, V32, P1325, DOI 10.1093/nar/gkh303; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Skabkin MA, 2004, NUCLEIC ACIDS RES, V32, P5621, DOI 10.1093/nar/gkh889; Smillie DA, 2002, J CELL SCI, V115, P395; Squirrell JM, 2006, MOL BIOL CELL, V17, P336, DOI 10.1091/mbc.E05-09-0874; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; STEEDMAN HF, 1957, NATURE, V179, P1345, DOI 10.1038/1791345a0; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; Tanaka KJ, 2004, DEV BIOL, V272, P217, DOI 10.1016/j.ydbio.2004.04.032; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; Weston A, 2006, NUCLEIC ACIDS RES, V34, P3082, DOI 10.1093/nar/gkl409; Wilczynska A, 2005, J CELL SCI, V118, P981, DOI 10.1242/jcs.01692; Wilhelm JE, 2005, DEV CELL, V9, P675, DOI 10.1016/j.devcel.2005.09.015; Wilusz CJ, 2005, NAT STRUCT MOL BIOL, V12, P1031, DOI 10.1038/nsmb1037; Wu L, 1997, MOL CELL BIOL, V17, P6402, DOI 10.1128/MCB.17.11.6402; Yang WH, 2006, RNA, V12, P547, DOI 10.1261/rna.2302706	64	90	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40096	40106		10.1074/jbc.M609059200	http://dx.doi.org/10.1074/jbc.M609059200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074753	hybrid			2022-12-25	WOS:000243033900039
J	Lee, JN; Song, B; DeBose-Boyd, RA; Ye, J				Lee, Joon No; Song, Baoliang; DeBose-Boyd, Russell A.; Ye, Jin			Sterol-regulated degradation of Insig-1 mediated by the membrane-bound ubiquitin ligase gp78	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; AUTOCRINE MOTILITY FACTOR; ELEMENT-BINDING PROTEINS; LOW-DENSITY LIPOPROTEIN; HMG COA REDUCTASE; ENDOPLASMIC-RETICULUM; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; FACTOR-RECEPTOR; CHOLESTEROL; SREBPS	Insig-1 and Insig-2, closely related endoplasmic reticulum membrane proteins, mediate transcriptional and post-transcriptional mechanisms that assure cholesterol homeostasis through their sterol-induced binding to Scap (SREBP cleavage activating protein) and 3-hydroxy-3-methylglutaryl coenzyme A reductase. Recent studies show that Insig-1 ( but not Insig-2) is ubiquitinated and rapidly degraded when cells are depleted of sterols. Conversely, ubiquitination of Insig-1 is blocked, and the protein is stabilized when intracellular sterols accumulate. Here, we report that the ubiquitin ligase gp78, which binds with much higher affinity to Insig-1 than Insig-2, is required for ubiquitination and degradation of Insig-1 in sterol-depleted cells. Sterols prevent Insig-1 ubiquitination and degradation by displacing gp78 from Insig-1, an event that results from sterol-induced binding of Scap to Insig-1. In addition to providing a mechanism for sterol-regulated degradation of Insig-1, these results help to explain why Scap is subject to endoplasmic reticulum retention upon Insig-1 binding, whereas 3-hydroxy-3-methylglutaryl coenzyme A reductase is ubiquitinated and degraded.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lee, JN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	jin.ye@utsouthwestern.edu		Song, Bao-Liang/0000-0002-6397-5935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHANG TY, 1981, J BIOL CHEM, V256, P6174; EDWARD GM, 1998, ELECTROPHORESIS, V20, P418; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gong Y, 2006, CELL METAB, V3, P15, DOI 10.1016/j.cmet.2005.11.014; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; Lee JN, 2004, J BIOL CHEM, V279, P45257, DOI 10.1074/jbc.M408235200; Lee JN, 2006, P NATL ACAD SCI USA, V103, P4958, DOI 10.1073/pnas.0600422103; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shimizu K, 1999, FEBS LETT, V456, P295, DOI 10.1016/S0014-5793(99)00966-7; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WATANABE H, 1991, J BIOL CHEM, V266, P13442; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	30	116	124	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39308	39315		10.1074/jbc.M608999200	http://dx.doi.org/10.1074/jbc.M608999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17043353	hybrid			2022-12-25	WOS:000242898700038
J	McKinnon, CM; Ravier, MA; Rutter, GA				McKinnon, Caroline M.; Ravier, Magalie A.; Rutter, Guy A.			FoxO1 is required for the regulation of preproglucagon gene expression by insulin in pancreatic alpha TC1-9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON GENE; TRANSCRIPTION FACTORS; GLUCOSE-HOMEOSTASIS; BINDING-PROTEINS; IN-VIVO; BETA; PROMOTER; FORKHEAD; ELEMENT; FOXA2	Forkhead/winged helix box gene, group O-1 (FoxO1) is a member of a family of nuclear transcription factors regulated by insulin-dependent phosphorylation and implicated in the development of the endocrine pancreas. We show here firstly that FoxO1 protein is expressed in both primary mouse islet alpha and beta cells. Examined in clonal alpha TC1-9 cells, insulin caused endogenous FoxO1 to translocate from the nucleus to the cytoplasm. Demonstrating the importance of nuclear exclusion of FoxO1 for the inhibition of preproglucagon gene expression, FoxO1 silencing by RNA interference reduced preproglucagon mRNA levels by > 40% in the absence of insulin and abolished the decrease in mRNA levels elicited by the hormone. Electrophoretic mobility shift assay and chromatin immunoprecipitation revealed direct binding of FoxO1 to a forkhead consensus binding site, termed GL3, in the preproglucagon gene promoter region, localized -1798 bp upstream of the transcriptional start site. Deletion or mutation of this site diminished FoxO1 binding and eliminated transcriptional regulation by glucose or insulin. FoxO1 silencing also abolished the acute regulation by insulin, but not glucose, of glucagon secretion, demonstrating the importance of FoxO1 expression in maintaining the alpha-cell phenotype.	Univ Bristol, Sch Med Sci, Henry Wellcome Labs Integrated Cell Signalling, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol		g.rutter@imperial.ac.uk	Ravier, Magalie/K-9911-2019; Ravier, Magalie A/N-6934-2017	Ravier, Magalie/0000-0001-6607-6559; Ravier, Magalie A/0000-0001-6607-6559; Rutter, Guy/0000-0001-6360-0343				Amemiya-Kudo M, 2005, J BIOL CHEM, V280, P34577, DOI 10.1074/jbc.M506718200; Arden KC, 2002, ARCH BIOCHEM BIOPHYS, V403, P292, DOI 10.1016/S0003-9861(02)00207-2; Ayyanathan K, 2000, CANCER RES, V60, P5803; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; Diraison F, 2004, BIOCHEM J, V378, P769, DOI 10.1042/BJ20031277; Gauthier BR, 2002, MOL ENDOCRINOL, V16, P170, DOI 10.1210/me.16.1.170; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kushner JA, 2005, J BIOL CHEM, V280, P39388, DOI 10.1074/jbc.M504155200; Lee CS, 2002, DIABETES, V51, P2546, DOI 10.2337/diabetes.51.8.2546; Lee CS, 2005, DEV BIOL, V278, P484, DOI 10.1016/j.ydbio.2004.10.012; Linseman DA, 2002, J NEUROSCI, V22, P9287; Liu YF, 2002, BIOCHEM J, V366, P633, DOI 10.1042/BJ20020095; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Ogata K, 2003, CURR OPIN STRUC BIOL, V13, P40, DOI 10.1016/S0959-440X(03)00012-5; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; Ravier MA, 2005, DIABETES, V54, P1789, DOI 10.2337/diabetes.54.6.1789; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Ritz-Laser B, 2003, DIABETOLOGIA, V46, P810, DOI 10.1007/s00125-003-1115-7; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sharma SK, 2005, BIOCHEM J, V389, P831, DOI 10.1042/BJ20050334; Shih DQ, 1999, P NATL ACAD SCI USA, V96, P10152, DOI 10.1073/pnas.96.18.10152; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Varadi A, 2002, J CELL SCI, V115, P4177, DOI 10.1242/jcs.00083; Wang HY, 2002, J BIOL CHEM, V277, P17564, DOI 10.1074/jbc.M111037200; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Xavier GD, 2004, BIOCHEM J, V377, P149, DOI 10.1042/BJ20031260	38	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39358	39369		10.1074/jbc.M605022200	http://dx.doi.org/10.1074/jbc.M605022200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17062568	hybrid			2022-12-25	WOS:000242898700043
J	Qian, XG; He, YJ; Ma, XF; Fodje, MN; Grochulski, P; Luo, Y				Qian, Xinguo; He, Yujiong; Ma, Xinfeng; Fodje, Michel N.; Grochulski, Pawel; Luo, Yu			Calcium stiffens archaeal Rad51 recombinase from Methanococcus voltae for homologous recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECA; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; STRAND EXCHANGE; DNA-REPAIR; PROTEIN; DMC1; HYDROLYSIS; PROGRAM; COMPLEX	Archaeal RadA or Rad51 recombinases are close homologues of eukaryal Rad51 and DMC1. These and bacterial RecA orthologues play a key role in DNA repair by forming helical nucleoprotein filaments in which a hallmark strand exchange reaction between homologous DNA substrates occurs. Recent studies have discovered the stimulatory role by calcium on human and yeast recombinases. Here we report that the strand exchange activity but not the ATPase activity of an archaeal RadA/Rad51 recombinase from Methanococcus voltae (MvRadA) is also subject to calcium stimulation. Crystallized MvRadA filaments in the presence of CaCl2 resemble that of the recently reported ATPase active form in the presence of an activating dose of KCl. At the ATPase center, one Ca2+ ion takes the place of two K+ ions in the K+-bound form. The terminal phosphate of the nonhydrolyzable ATP analogue is in a staggered conformation in the Ca2+-bound form. In comparison, an eclipsed conformation was seen in the K+-bound form. Despite the changes in the ATPase center, both forms harbor largely ordered L2 regions in essentially identical conformations. These data suggest a unified stimulation mechanism by potassium and calcium because of the existence of a conserved ATPase center promiscuous in binding cations.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Canadian Light Source Inc, Saskatoon, SK S7N 0X4, Canada	University of Saskatchewan; University of Saskatchewan	Luo, Y (corresponding author), Univ Saskatchewan, Dept Biochem, A3 Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	Yu.Luo@usask.ca		Fodje, Michel/0000-0003-1367-8868				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bell CE, 2005, MOL MICROBIOL, V58, P358, DOI 10.1111/j.1365-2958.2005.04876.x; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bugreev DV, 2005, J BIOL CHEM, V280, P26886, DOI 10.1074/jbc.M502248200; Bugreev DV, 2004, P NATL ACAD SCI USA, V101, P9988, DOI 10.1073/pnas.0402105101; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Courcelle J, 2001, BIOESSAYS, V23, P463, DOI 10.1002/bies.1065; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kelley JA, 1997, J BIOL CHEM, V272, P25778, DOI 10.1074/jbc.272.41.25778; Keramisanou D, 2006, NAT STRUCT MOL BIOL, V13, P594, DOI 10.1038/nsmb1108; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee MH, 2005, J BIOL CHEM, V280, P40980, DOI 10.1074/jbc.M505896200; Liu YL, 2004, J MOL BIOL, V337, P817, DOI 10.1016/j.jmb.2004.02.022; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; McGrew DA, 2003, CRIT REV BIOCHEM MOL, V38, P385, DOI 10.1080/10409230390242489; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Qian XG, 2005, BIOCHEMISTRY-US, V44, P13753, DOI 10.1021/bi051222i; Qian XG, 2006, J MOL BIOL, V360, P537, DOI 10.1016/j.jmb.2006.05.058; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Ristic D, 2005, NUCLEIC ACIDS RES, V33, P3292, DOI 10.1093/nar/gki640; Sandler SJ, 1996, NUCLEIC ACIDS RES, V24, P2125, DOI 10.1093/nar/24.11.2125; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; Seitz EM, 2000, MOL MICROBIOL, V37, P555, DOI 10.1046/j.1365-2958.2000.02009.x; Shim KS, 2006, DNA REPAIR, V5, P718, DOI 10.1016/j.dnarep.2006.03.006; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Wu Y, 2005, J BIOL CHEM, V280, P722, DOI 10.1074/jbc.M411093200	37	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39380	39387		10.1074/jbc.M607785200	http://dx.doi.org/10.1074/jbc.M607785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17050545	hybrid			2022-12-25	WOS:000242898700045
J	Campanini, B; Schiaretti, F; Abbruzzetti, S; Kessler, D; Mozzarelli, A				Campanini, Barbara; Schiaretti, Francesca; Abbruzzetti, Stefania; Kessler, Dorothea; Mozzarelli, Andrea			Sulfur mobilization in cyanobacteria: The catalytic mecahnism of L-cystine C-S lyase (C-DES) from synechocystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-6803; NIFS-LIKE PROTEIN; GLUTAMIC ASPARTIC TRANSAMINASE; CYSTEINE DESULFURASE ACTIVITY; O-ACETYLSERINE SULFHYDRYLASE; CYSTATHIONINE BETA-SYNTHASE; TRYPTOPHAN INDOLE-LYASE; DNA MICROARRAY ANALYSIS; TYROSINE PHENOL-LYASE; ESCHERICHIA-COLI	Sulfur mobilization represents one of the key steps in ubiquitous Fe-S clusters assembly and is performed by a recently characterized set of proteins encompassing cysteine desulfurases, assembly factors, and shuttle proteins. Despite the evolutionary conservation of these proteins, some degree of variability among organisms was observed, which might reflect functional specialization. (L)-Cyst(e)ine lyase (C-DES), a pyridoxal 5'-phosphate-dependent enzyme identified in the cyanobacterium Synechocystis, was reported to use preferentially cystine over cysteine with production of cysteine persulfide, pyruvate, and ammonia. In this study, we demonstrate that C-DES sequences are present in all cyanobacterial genomes and constitute a new family of sulfur-mobilizing enzymes, distinct from cysteine desulfurases. The functional properties of C-DES from Synechocystis sp.PCC 6714 were investigated under pre-steady-state and steady-state conditions. Single wavelength and rapid scanning stopped-flow kinetic data indicate that the internal aldimine reacts with cystine forming an external aldimine that rapidly decays to a transient quinonoid species and stable tautomers of the alpha-aminoacrylate Schiff base. In the presence of cysteine, the transient formation of a dipolar species precedes the selective and stable accumulation of the enolimine tautomer of the external aldimine, with no formation of the alpha-aminoacrylate Schiff base under reducing conditions. Effective sulfur mobilization from cystine might represent a mechanism that allows adaptation of cyanobacteria to different environmental conditions and to light-dark cycles.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Dept Phys, I-43100 Parma, Italy; Heidelberg Univ, Biochemzentrum, D-69120 Heidelberg, Germany	University of Parma; University of Parma; Ruprecht Karls University Heidelberg	Mozzarelli, A (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Vle GP Usberti 23A, I-43100 Parma, Italy.	andrea.mozzarelli@unipr.it	abbruzzetti, stefania/M-8640-2015; Mozzarelli, Andrea/C-3615-2014; Campanini, Barbara/L-9723-2017; abbruzzetti, stefania/AAE-5518-2020	abbruzzetti, stefania/0000-0001-7685-8554; Mozzarelli, Andrea/0000-0003-3762-0062; Campanini, Barbara/0000-0003-0359-0627; abbruzzetti, stefania/0000-0001-7685-8554				Allakhverdiev SI, 2002, PLANT PHYSIOL, V130, P1443, DOI 10.1104/pp.011114; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banerjee R, 2003, BBA-PROTEINS PROTEOM, V1647, P30, DOI 10.1016/S1570-9639(03)00044-X; Behshad E, 2004, BIOCHEMISTRY-US, V43, P12220, DOI 10.1021/bi049143e; Beinert H, 2000, EUR J BIOCHEM, V267, P5657, DOI 10.1046/j.1432-1327.2000.01637.x; BERNASCONI CF, 1976, RELAXATION KINETICS, P141; Binkowski TA, 2003, NUCLEIC ACIDS RES, V31, P3352, DOI 10.1093/nar/gkg512; Breitinger U, 2001, PLANT PHYSIOL, V126, P631, DOI 10.1104/pp.126.2.631; Bui BTS, 2000, EUR J BIOCHEM, V267, P2688; Burja AM, 2003, TRENDS BIOTECHNOL, V21, P504, DOI 10.1016/j.tibtech.2003.08.008; CAVALLINI D, 1970, EUR J BIOCHEM, V14, P169, DOI 10.1111/j.1432-1033.1970.tb00275.x; Clausen T, 2000, P NATL ACAD SCI USA, V97, P3856, DOI 10.1073/pnas.97.8.3856; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; DONOSO J, 1993, BIOCHEM J, V292, P225, DOI 10.1042/bj2920225; EVERETT SA, 1995, METHOD ENZYMOL, V251, P55, DOI 10.1016/0076-6879(95)51110-5; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Gill RT, 2002, J BACTERIOL, V184, P3671, DOI 10.1128/JB.184.13.3671-3681.2002; GOLDBERG JM, 1991, BIOCHEMISTRY-US, V30, P305, DOI 10.1021/bi00215a041; Goldsmith-Fischman S, 2004, J MOL BIOL, V344, P549, DOI 10.1016/j.jmb.2004.08.074; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HAMAMOTO A, 1986, PLANT PHYSIOL, V80, P702, DOI 10.1104/pp.80.3.702; HENDLER RW, 1994, J BIOCHEM BIOPH METH, V28, P1, DOI 10.1016/0165-022X(94)90061-2; Henry ER, 1997, BIOPHYS J, V72, P652, DOI 10.1016/S0006-3495(97)78703-4; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; Hester G, 1999, J MOL BIOL, V286, P829, DOI 10.1006/jmbi.1998.2506; Hihara Y, 2003, J BACTERIOL, V185, P1719, DOI 10.1128/JB.185.5.1719-1725.2003; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Huang LX, 2002, J BACTERIOL, V184, P6845, DOI 10.1128/JB.184.24.6845-6858.2002; Iciek M, 2001, POL J PHARMACOL, V53, P215; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; JENKINS WT, 1959, J BIOL CHEM, V234, P1179; JENKINS WT, 1959, J BIOL CHEM, V234, P51; Jones PR, 2003, J BIOL CHEM, V278, P10291, DOI 10.1074/jbc.M212207200; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kaiser JT, 2003, J BIOL CHEM, V278, P357, DOI 10.1074/jbc.M209862200; KALLEN RG, 1985, TRANSAMINASES, P37; Kaneko T, 1996, DNA Res, V3, P109; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Kato S, 2000, BIOSCI BIOTECH BIOCH, V64, P2412, DOI 10.1271/bbb.64.2412; Kessler D, 2005, PHOTOSYNTH RES, V86, P391, DOI 10.1007/s11120-005-5913-2; Kessler D, 2004, BIOCHEM BIOPH RES CO, V320, P571, DOI 10.1016/j.bbrc.2004.06.007; Kessler D, 2006, FEMS MICROBIOL REV, V30, P825, DOI 10.1111/j.1574-6976.2006.00036.x; Lancaster JE, 2000, PLANT PHYSIOL, V122, P1269, DOI 10.1104/pp.122.4.1269; Lang T, 1999, J BIOL CHEM, V274, P189, DOI 10.1074/jbc.274.1.189; Leibrecht I, 1997, J BIOL CHEM, V272, P10442; Leon S, 2003, BIOCHEM J, V371, P823, DOI 10.1042/BJ20021946; Li H, 2004, J BACTERIOL, V186, P3331, DOI 10.1128/JB.186.11.3331-3345.2004; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Maniscalco SJ, 2004, ARCH BIOCHEM BIOPHYS, V425, P165, DOI 10.1016/j.abb.2004.02.041; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; Miles EW, 2004, J BIOL CHEM, V279, P29871, DOI 10.1074/jbc.R400005200; Mueller EG, 2006, NAT CHEM BIOL, V2, P185, DOI 10.1038/nchembio779; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; OUZOUNIS C, 1993, FEBS LETT, V322, P159, DOI 10.1016/0014-5793(93)81559-I; OUZOUNIS C, 1994, TRENDS BIOCHEM SCI, V19, P199, DOI 10.1016/0968-0004(94)90021-3; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Phillips RS, 2003, BBA-PROTEINS PROTEOM, V1647, P167, DOI 10.1016/S1570-9639(03)00089-X; Pioselli B, 2004, PROTEIN SCI, V13, P913, DOI 10.1110/ps.03492904; Ramirez EC, 1998, J FOOD BIOCHEM, V22, P427, DOI 10.1111/j.1745-4514.1998.tb00254.x; ROY M, 1988, BIOCHEMISTRY-US, V27, P8661, DOI 10.1021/bi00423a023; Seidler A, 2001, BIOCHEM SOC T, V29, P418, DOI 10.1042/BST0290418; Singh AK, 2003, PLANT PHYSIOL, V132, P1825, DOI 10.1104/pp.103.024018; Smith AD, 2005, BIOCHEMISTRY-US, V44, P12955, DOI 10.1021/bi051257i; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; STAL LJ, 1995, NEW PHYTOL, V131, P1, DOI 10.1111/j.1469-8137.1995.tb03051.x; Tai CH, 2000, ADV ENZYMOL RAMB, V74, P185; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tirupati B, 2004, BIOCHEMISTRY-US, V43, P12210, DOI 10.1021/bi0491447; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; TOOHEY JI, 1989, BIOCHEM J, V264, P625, DOI 10.1042/bj2640625; Ukai K, 1997, BIOSCI BIOTECH BIOCH, V61, P1890, DOI 10.1271/bbb.61.1890; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; VAZQUEZ MA, 1991, BIOCHEM J, V279, P759, DOI 10.1042/bj2790759; Woehl EU, 1996, BIOCHEMISTRY-US, V35, P4776, DOI 10.1021/bi952938o; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	85	15	17	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38769	38780		10.1074/jbc.M607098200	http://dx.doi.org/10.1074/jbc.M607098200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17020883	hybrid			2022-12-25	WOS:000242709500075
J	Stewart, JA; Campbell, JL; Bambara, RA				Stewart, Jason A.; Campbell, Judith L.; Bambara, Robert A.			Flap endonuclease disengages Dna2 helicase/nuclease from Okazaki fragment flaps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION-PROTEIN-A; ESSENTIAL IN-VIVO; LAGGING-STRAND; POLYMERASE-DELTA; LIGATABLE NICK; YEAST; MATURATION; MECHANISM; HELICASE	Okazaki fragments contain an initiator RNA/DNA primer that must be removed before the fragments are joined. In eukaryotes, the primer region is raised into a flap by the strand displacement activity of DNA polymerase delta. The Dna2 helicase/nuclease and then flap endonuclease 1 (FEN1) are proposed to act sequentially in flap removal. Dna2 and FEN1 both employ a tracking mechanism to enter the flap 5' end and move toward the base for cleavage. In the current model, Dna2 must enter first, but FEN1 makes the final cut at the flap base, raising the issue of how FEN1 passes the Dna2. To address this, nuclease-inactive Dna2 was incubated with a DNA flap substrate and found to bind with high affinity. FEN1 was then added, and surprisingly, there was little inhibition of FEN1 cleavage activity. FEN1 was later shown, by gel shift analysis, to remove the wild type Dna2 from the flap. RNA can be cleaved by FEN1 but not by Dna2. Pre-bound wild type Dna2 was shown to bind an RNA flap but not inhibit subsequent FEN1 cleavage. These results indicate that there is a novel interaction between the two proteins in which FEN1 disengages the Dna2 tracking mechanism. This interaction is consistent with the idea that the two proteins have evolved a special ability to cooperate in Okazaki fragment processing.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; CALTECH, Braun Labs, Pasadena, CA 91125 USA	University of Rochester; California Institute of Technology	Bambara, RA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	Robert_Bambara@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 021441, GM 25508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bae KH, 2003, NUCLEIC ACIDS RES, V31, P3006, DOI 10.1093/nar/gkg422; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bae SH, 2002, J BIOL CHEM, V277, P26632, DOI 10.1074/jbc.M111026200; Bae SH, 2001, NUCLEIC ACIDS RES, V29, P3069, DOI 10.1093/nar/29.14.3069; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Budd ME, 2005, PLOS GENET, V1, P634, DOI 10.1371/journal.pgen.0010061; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Garg P, 2005, CELL CYCLE, V4, P221; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Hubscher U, 2001, MOL CELLS, V12, P149; Jin YH, 2003, J BIOL CHEM, V278, P1626, DOI 10.1074/jbc.M209803200; Kang HY, 2000, GENETICS, V155, P1055; Kao HI, 2004, J BIOL CHEM, V279, P50840, DOI 10.1074/jbc.M409231200; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Kao HI, 2003, CRIT REV BIOCHEM MOL, V38, P433, DOI 10.1080/10409230390259382; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; KORNBERG A, 1992, DNA REPLICATION, P140; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; Masuda-Sasa T, 2006, NUCLEIC ACIDS RES, V34, P1865, DOI 10.1093/nar/gkl070; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Rossi ML, 2006, CHEM REV, V106, P453, DOI 10.1021/cr040497l; Rytkonen AK, 2006, FEBS J, V273, P2984, DOI 10.1111/j.1742-4658.2006.05310.x; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Tuteja N, 2004, EUR J BIOCHEM, V271, P1835, DOI 10.1111/j.1432-1033.2004.04093.x; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	26	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38565	38572		10.1074/jbc.M606884200	http://dx.doi.org/10.1074/jbc.M606884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17038322	hybrid, Green Accepted			2022-12-25	WOS:000242709500051
J	Avvakumov, GV; Walker, JR; Xue, S; Finerty, PJ; Mackenzie, F; Newman, EM; Dhe-Paganon, S				Avvakumov, George V.; Walker, John R.; Xue, Sheng; Finerty, Patrick J., Jr.; Mackenzie, Farrell; Newman, Elena M.; Dhe-Paganon, Sirano			Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY SYNDROME CORONAVIRUS; DOA4 DEUBIQUITINATING ENZYME; SRC HOMOLOGY-3 DOMAIN; PAPAIN-LIKE PROTEASE; UBIQUITIN ISOPEPTIDASE; DENSITY MODIFICATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DEGRADATION; UBPY	Ubiquitin-specific protease 8 (USP8) hydrolyzes mono and polyubiquitylated targets such as epidermal growth factor receptors and is involved in clathrin- mediated internalization. In 1182 residues, USP8 contains multiple domains, including coiled-coil, rhodanese, and catalytic domains. We report the first high- resolution crystal structures of these domains and discuss their implications for USP8 function. The amino-terminal domain is a homodimer with a novel fold. It is composed of two five-helix bundles, where the first helices are swapped, and carboxyl-terminal helices are extended in an antiparallel fashion. The structure of the rhodanese domain, determined in complex with the E3 ligase NRDP1, reveals the canonical rhodanese fold but with a distorted primordial active site. The USP8 recognition domain of NRDP1 has a novel protein fold that interacts with a conserved peptide loop of the rhodanese domain. A consensus sequence of this loop is found in other NRDP1 targets, suggesting a common mode of interaction. The structure of the carboxyl-terminal catalytic domain of USP8 exhibits the conserved tripartite architecture but shows unique traits. Notably, the active site, including the ubiquitin binding pocket, is in a closed conformation, incompatible with substrate binding. The presence of a zinc ribbon subdomain near the ubiquitin binding site further suggests a polyubiquitin- specific binding site and a mechanism for substrate induced conformational changes.	Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1L5, Canada	University of Toronto; Structural Genomics Consortium; University of Toronto	Dhe-Paganon, S (corresponding author), Univ Toronto, Struct Genom Consortium, 100 Coll St, Toronto, ON M5G 1L5, Canada.	sirano.dhepaganon@utoronto.ca		/0000-0002-5255-895X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguilar RC, 2005, P NATL ACAD SCI USA, V102, P2679, DOI 10.1073/pnas.0500213102; Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005; Chubb JR, 2000, J CELL SCI, V113, P709; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; Das C, 2006, P NATL ACAD SCI USA, V103, P4675, DOI 10.1073/pnas.0510403103; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Gnesutta N, 2001, J BIOL CHEM, V276, P39448, DOI 10.1074/jbc.M103454200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko T, 2003, J BIOL CHEM, V278, P48162, DOI 10.1074/jbc.M306677200; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee HJ, 2005, FEBS LETT, V579, P4867, DOI 10.1016/j.febslet.2005.07.048; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Qiu XB, 2004, EMBO J, V23, P800, DOI 10.1038/sj.emboj.7600075; Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103; Renatus M, 2006, STRUCTURE, V14, P1293, DOI 10.1016/j.str.2006.06.012; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004	40	120	126	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38061	38070		10.1074/jbc.M606704200	http://dx.doi.org/10.1074/jbc.M606704200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035239	hybrid			2022-12-25	WOS:000242477100084
J	Boadu, E; Choi, HY; Lee, DWK; Waddington, EI; Chan, T; Asztalos, B; Vance, JE; Chan, A; Castro, G; Francis, GA				Boadu, Emmanuel; Choi, Hong Y.; Lee, Diana W. K.; Waddington, Emma I.; Chan, Teddy; Asztalos, Bela; Vance, Jean E.; Chan, Alicia; Castro, Graciela; Francis, Gordon A.			Correction of apolipoprotein A-I-mediated lipid efflux and high density lipoprotein particle formation in human Niemann-Pick type C disease fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTORS; PHOSPHOLIPID TRANSFER PROTEIN; CELLULAR CHOLESTEROL EFFLUX; CENTRAL-NERVOUS-SYSTEM; TANGIER-DISEASE; PLASMA-LIPOPROTEINS; ABCA1 TRANSPORTER; EXPRESSION; ABCG1; GENE	Impaired cell cholesterol trafficking in Niemann-Pick type C (NPC) disease results in the first known instance of impaired regulation of the ATP-binding cassette transporter A1 (ABCA1), a lipid transporter mediating the rate-limiting step in high density lipoprotein (HDL) formation, as a cause of low plasma HDL-cholesterol in humans. We show here that treatment of human NPC1(-/)-fibroblasts with the liver X receptor (LXR) agonist TO-901317 increases ABCA1 expression and activity in humanNPC1(-/)-fibroblasts, as indicated by near normalization of efflux of radiolabeled phosphatidylcholine and a marked increase in efflux of cholesterol mass to apoA-I. LXR agonist treatment prior to and during apoA-I incubation resulted in reduction in filipin staining of unesterified cholesterol in late endosomes/lysosomes, as well as cholesterol mass, in NPC1(-/)-cells. HDL species in human NPC disease plasma showed the same pattern of diminished large, cholesterol-rich alpha-1 HDL particles as seen in isolated heterozygous ABCA1 deficiency. Incubating NPC1(-/)-fibroblasts with the LXR agonist normalized the pattern of HDL particle formation by these cells. ABCG1, another LXR target gene involved in cholesterol efflux to HDL, also showed diminished expression in NPC1(-/)-fibroblasts and increased expression upon LXR agonist treatment. These results suggest that NPC1 mutations can be largely bypassed and that NPC1 protein function is non-essential for the trafficking and removal of cellular cholesterol if the downstream defects in ABCA1 and ABCG1 regulation in NPC disease cells are corrected using an LXR agonist.	Univ Alberta, Heritage Med Res Ctr 328, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Tufts Univ, Human Nutr Ctr Aging, Jean Mayer US Dept Agr, Boston, MA 02111 USA; Univ Lille 2, Inst Pasteur, INSERM, UMR 545, F-59019 Lille, France	University of Alberta; University of Alberta; University of Alberta; University of Alberta; Tufts University; United States Department of Agriculture (USDA); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Francis, GA (corresponding author), Univ Alberta, Heritage Med Res Ctr 328, Dept Med, Edmonton, AB T6G 2S2, Canada.	gordon.francis@ualberta.ca			NHLBI NIH HHS [R01 HL064738] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amigo L, 2002, HEPATOLOGY, V36, P819, DOI 10.1053/jhep.2002.35617; Assmann G, 2001, METABOLIC MOL BASES, P2937; Asztalos BF, 2001, ATHEROSCLEROSIS, V156, P217, DOI 10.1016/S0021-9150(00)00643-2; Boadu E, 2006, J MOL MED, V84, P266, DOI 10.1007/s00109-005-0001-9; Cao GQ, 2002, J BIOL CHEM, V277, P39561, DOI 10.1074/jbc.M207187200; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Chen WG, 2005, J BIOL CHEM, V280, P29277, DOI 10.1074/jbc.M505566200; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; CHUNG BH, 1980, J LIPID RES, V21, P284; Costet P, 2000, J BIOL CHEM, V275, P28240; Engel T, 2001, BIOCHEM BIOPH RES CO, V288, P483, DOI 10.1006/bbrc.2001.5756; FIELDING CJ, 1995, J LIPID RES, V36, P211; FOLCH J, 1957, J BIOL CHEM, V226, P497; Francis GA, 2002, TRENDS MOL MED, V8, P455, DOI 10.1016/S1471-4914(02)02400-0; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Francis GA, 1996, BIOCHEMISTRY-US, V35, P15188, DOI 10.1021/bi9618169; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Garver WS, 2002, J LIPID RES, V43, P579; HAVEL RJ, 2001, METABOLIC MOL BASES, P2705; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Karten B, 2002, J NEUROCHEM, V83, P1154, DOI 10.1046/j.1471-4159.2002.01220.x; Karten B, 2006, J BIOL CHEM, V281, P4049, DOI 10.1074/jbc.M508915200; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LANGMADE SJ, 2006, P NATL ACAD SCI US; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2005, PHYSIOL REV, V85, P1343, DOI 10.1152/physrev.00005.2005; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; RUBINS HB, 1993, AM J CARDIOL, V71, P45, DOI 10.1016/0002-9149(93)90708-K; Sahoo D, 2004, J LIPID RES, V45, P1122, DOI 10.1194/jlr.M300529-JLR200; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SCHAEFER EJ, 1978, NEW ENGL J MED, V299, P905, DOI 10.1056/NEJM197810262991701; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Settasatian N, 2001, J BIOL CHEM, V276, P26898, DOI 10.1074/jbc.M010708200; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Vaughan AM, 2005, J BIOL CHEM, V280, P30150, DOI 10.1074/jbc.M505368200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wang N, 2006, ARTERIOSCL THROM VAS, V26, P1310, DOI 10.1161/01.ATV.0000218998.75963.02; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Xie CL, 1999, P NATL ACAD SCI USA, V96, P11992, DOI 10.1073/pnas.96.21.11992; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495	57	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37081	37090		10.1074/jbc.M606890200	http://dx.doi.org/10.1074/jbc.M606890200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17020879	hybrid			2022-12-25	WOS:000242220800069
J	Diveu, C; Venereau, E; Froger, J; Ravon, E; Grimaud, L; Rousseau, F; Chevalier, S; Gascan, H				Diveu, Caroline; Venereau, Emilie; Froger, Josy; Ravon, Elisa; Grimaud, Linda; Rousseau, Franccis; Chevalier, Sylvie; Gascan, Hugues			Molecular and functional characterization of a soluble form of oncostatin M/interleukin-31 shared receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; SIGNAL-TRANSDUCING RECEPTOR; CILIARY NEUROTROPHIC FACTOR; CNTF RECEPTOR; LIF RECEPTOR; INTERLEUKIN-6 RECEPTOR; EXPRESSING GP130; FUSION PROTEIN; GROWTH-FACTOR; T-CELLS	Activation of the signaling transduction pathways mediated by oncostatin M (OSM) requires the binding of the cytokine to either type IOSM receptor (leukemia inhibitory factor receptor/gp130) or to type II OSM receptor (OSMR/gp130). In the present work we have developed an enzyme-linked immunosorbent assay detecting a soluble form of OSMR (sOSMR) secreted by glioblastoma, hepatoma, and melanoma tumor cell lines. sOSMR was also present in sera of healthy individuals, with increased levels in multiple myeloma. Molecular cloning of a corresponding cDNA was carried out, and it encoded for a 70-kDa protein consisting of a half cytokine binding domain containing the canonical WSXWS motif, an immunoglobulinlike domain, and the first half of a second cytokine binding domain with cysteines in fixed positions. Analysis of the soluble receptor distribution revealed a preferential expression in lung, liver, pancreas, and placenta. sOSMR was able to bind OSM and interleukin-31 when associated to soluble gp130 or soluble interleukin-31R, respectively, and to neutralize both cytokine properties. We have also shown that OSM could positively regulate the synthesis of its own soluble receptor in tumor cells.	CHU Angers, INSERM, U565, F-49033 Angers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Gascan, H (corresponding author), CHU Angers, INSERM, U565, 4 Rue Larrey, F-49033 Angers, France.	gascan@univ-angers.fr	Venereau, Emilie/AAN-4856-2020	Venereau, Emilie/0000-0002-6590-7434				Aasland D, 2002, J MOL BIOL, V315, P637, DOI 10.1006/jmbi.2001.5282; Althoff K, 2001, BIOCHEM J, V353, P663, DOI 10.1042/0264-6021:3530663; Ancey C, 2003, J BIOL CHEM, V278, P16968, DOI 10.1074/jbc.C300081200; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Benigni F, 1996, BLOOD, V87, P1851, DOI 10.1182/blood.V87.5.1851.bloodjournal8751851; Boulanger MJ, 2003, MOL CELL, V12, P577, DOI 10.1016/S1097-2765(03)00365-4; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Boulay JL, 2003, IMMUNITY, V19, P159, DOI 10.1016/S1074-7613(03)00211-5; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; BROWN TJ, 1987, J IMMUNOL, V139, P2977; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Derouet D, 2004, P NATL ACAD SCI USA, V101, P4827, DOI 10.1073/pnas.0306178101; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2003, J BIOL CHEM, V278, P49850, DOI 10.1074/jbc.M307286200; Diveu C, 2004, EUR CYTOKINE NETW, V15, P291; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Friedrich M, 2001, J NEUROCHEM, V76, P1589, DOI 10.1046/j.1471-4159.2001.00202.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gomez-Lechon MJ, 1999, LIFE SCI, V65, P2019, DOI 10.1016/S0024-3205(99)00296-9; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 1999, J IMMUNOL, V163, P6651; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HONDA M, 1992, J IMMUNOL, V148, P2175; Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; Lauta VM, 2003, CANCER, V97, P2440, DOI 10.1002/cncr.11072; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; LU C, 1993, CANCER RES, V53, P2708; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MULLBERG J, 1993, FEBS LETT, V332, P174, DOI 10.1016/0014-5793(93)80507-Q; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; Nandurkar HH, 1996, ONCOGENE, V12, P585; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; Nishimoto N, 2003, J RHEUMATOL, V30, P1426; Olivier C, 2000, J BIOL CHEM, V275, P5648, DOI 10.1074/jbc.275.8.5648; Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Pflanz S, 2004, J IMMUNOL, V172, P2225, DOI 10.4049/jimmunol.172.4.2225; Pflanz S, 1999, FEBS LETT, V450, P117, DOI 10.1016/S0014-5793(99)00477-9; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; Renne C, 1998, J BIOL CHEM, V273, P27213, DOI 10.1074/jbc.273.42.27213; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SPORENO E, 1994, J BIOL CHEM, V269, P10991; Suda T, 2002, CYTOKINE, V17, P335, DOI 10.1006/cyto.2002.1023; Takashima S, 1996, J BIOL CHEM, V271, P24901, DOI 10.1074/jbc.271.40.24901; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; Wallace PM, 1999, J IMMUNOL, V162, P5547; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zhang JG, 1998, J BIOL CHEM, V273, P10798, DOI 10.1074/jbc.273.17.10798	61	29	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36673	36682		10.1074/jbc.M607005200	http://dx.doi.org/10.1074/jbc.M607005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028186	hybrid			2022-12-25	WOS:000242220800024
J	Kee, Y; Munoz, W; Lyon, N; Huibregtse, JM				Kee, Younghoon; Munoz, William; Lyon, Nancy; Huibregtse, Jon M.			The deubiquitinating enzyme Ubp2 modulates Rsp5-dependent Lys(63)-linked polyubiquitin conjugates in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RSP5 UBIQUITIN LIGASE; FUNCTIONAL DIVERSITY; TRANSCRIPTION FACTOR; DNA-REPAIR; PROTEINS; COMPLEX; ACTIVATION; SUBSTRATE; PATHWAY; BINDING	The functions of Lys63-linked polyubiquitin chains are poorly understood, as are the enzymes that specifically generate Lys63-linked conjugates. Rsp5 is a HECT ( homologous to E6AP C terminus) ubiquitin ligase involved in numerous processes, and an associated deubiquitinating enzyme, Ubp2, modulates its activity. Adramatic increase in Lys63-linked conjugates was observed in ubp2 Delta cells. The formation of these was Rsp5-dependent, and ubp2 Delta phenotypes could be suppressed by prevention of formation of Lys(63) conjugates. Cell wall integrity was impaired in rsp5-1 cells and in cells defective in Lys(63)-polyubiquitination, as assayed by calcofluor white sensitivity, and ubp2 and rup1 Delta mutants suppressed the calcofluor white sensitivity of rsp5-1. A large fraction of the Lys63 conjugates in ubp2 Delta cells bound to Rsp5, and a proteomics approach was used to identify Rsp5 substrates subject to Ubp2 regulation. Two closely related proteins, Csr2 and Ecm21, were among the identified proteins. Both were efficiently Lys63-polyubiquitinated by Rsp5 and deubiquitinated by Ubp2. Together, these results indicate that Ubp2 modulates Lys63-polyubiquitination of Rsp5 substrates in vivo, including ubiquitination of two newly identified Rsp5 substrates.	Univ Texas, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Huibregtse, JM (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	huibreg@mail.utexas.edu	Kee, Younghoon/J-4107-2019		NATIONAL CANCER INSTITUTE [R01CA072943, P30CA033572] Funding Source: NIH RePORTER; NCI NIH HHS [CA072943, CA33572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Canning M, 2004, J BIOL CHEM, V279, P38160, DOI 10.1074/jbc.M402885200; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; HETTELD B, 2005, CURR BIOL, V15, P1217; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kaminska J, 2005, ACTA BIOCHIM POL, V52, P207; Katzmann DJ, 2004, MOL BIOL CELL, V15, P468, DOI 10.1091/mbc.E03-07-0473; Kee Y, 2005, EMBO J, V24, P2414, DOI 10.1038/sj.emboj.7600710; Krsmanovic T, 2004, FEBS LETT, V577, P215, DOI 10.1016/j.febslet.2004.10.006; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Mayor T, 2005, MOL CELL PROTEOMICS, V4, P741, DOI 10.1074/mcp.M400220-MCP200; Neumann S, 2003, EMBO REP, V4, P1156, DOI 10.1038/sj.embor.7400026; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Saeki Y, 2005, METHOD ENZYMOL, V399, P215, DOI 10.1016/S0076-6879(05)99014-9; Salvat C, 2004, J BIOL CHEM, V279, P18935, DOI 10.1074/jbc.M312201200; Santos B, 2000, MOL BIOL CELL, V11, P435, DOI 10.1091/mbc.11.2.435; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Stamenova SD, 2004, J BIOL CHEM, V279, P16017, DOI 10.1074/jbc.M313479200; Tagwerker C, 2006, MOL CELL PROTEOMICS, V5, P737, DOI 10.1074/mcp.M500368-MCP200; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Wang GL, 1999, MOL CELL BIOL, V19, P342; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; YSASHIRODA H, 1996, MOL CELL BIOL, V16, P3255	43	80	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36724	36731		10.1074/jbc.M608756200	http://dx.doi.org/10.1074/jbc.M608756200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028178	hybrid			2022-12-25	WOS:000242220800029
J	Kitatani, K; Idkowiak-Baldys, J; Bielawski, J; Taha, TA; Jenkins, RW; Senkal, CE; Ogretmen, B; Obeid, LM; Hannun, YA				Kitatani, Kazuyuki; Idkowiak-Baldys, Jolanta; Bielawski, Jacek; Taha, Tarek A.; Jenkins, Russell W.; Senkal, Can E.; Ogretmen, Besim; Obeid, Lina M.; Hannun, Yusuf A.			Protein kinase C-induced activation of a ceramide/protein phosphatase 1 pathway leading to dephosphorylation of p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; SIGNAL-REGULATED KINASE-1/2; STRESS-INDUCED APOPTOSIS; CELL-PERMEABLE CERAMIDE; NECROSIS-FACTOR-ALPHA; SERINE PALMITOYLTRANSFERASE; SPHINGOMYELIN CYCLE; MITOCHONDRIAL POOL; PROMOTES APOPTOSIS; EPITHELIAL-CELLS	Recently we showed that, in human breast cancer cells, activation of protein kinase C by 4 beta-phorbol 12-myristate 13-acetate (PMA) produced ceramide formed from the salvage pathway ( Becker, K. P., Kitatani, K., Idkowiak-Baldys, J., Bielawski, J., and Hannun, Y.A. (2005) J. Biol. Chem. 280, 2606-2612). In this study, we investigated intracellular signaling events mediated by this novel activated pathway of ceramide generation. PMA treatment resulted in transient activation of mitogen-activated protein kinases (ERK1/2, JNK1/2, and p38) followed by dephosphorylation/inactivation. Interestingly, fumonisin B1 (FB1), an inhibitor of the salvage pathway, attenuated loss of phosphorylation of p38, suggesting a role for ceramide in p38 dephosphorylation. This was confirmed by knock-down of longevity-assurance homologue 5, which partially suppressed the formation of C16-ceramide induced by PMA and increased the phosphorylation of p38. These results demonstrate a role for the salvage pathway in feedback inhibition of p38. To determine which protein phosphatases act in this pathway, specific knock-down of serine/threonine protein phosphatases was performed, and it was observed that knock-down of protein phosphatase 1 (PP1) catalytic subunits significantly increased p38 phosphorylation, suggesting activation of PP1 results in an inhibitory effect on p38. Moreover, PMA recruited PP1 catalytic subunits to mitochondria, and this was significantly suppressed by FB1. In addition, phospho-p38 resided in PMA-stimulated mitochondria. Upon PMA treatment, a mitochondria-enriched/purified fraction exhibited significant increases in C16-ceramide, a major ceramide specie, which was suppressed by FB1. Taken together, these data suggest that accumulation of C16-ceramide in mitochondria formed from the protein kinase C-dependent salvage pathway results at least in part from the action of longevity-assurance homologue 5, and the generated ceramide modulates the p38 cascade via PP1.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Div Gen Internal Med, Charleston, SC 29401 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [R01CA088932, R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NCI NIH HHS [CA88932, CA87584] Funding Source: Medline; NIA NIH HHS [AG16583] Funding Source: Medline; NIGMS NIH HHS [GM08716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker KP, 2005, J BIOL CHEM, V280, P2606, DOI 10.1074/jbc.M409066200; Bionda C, 2004, BIOCHEM J, V382, P527, DOI 10.1042/BJ20031819; Birbes H, 2005, BIOCHEM J, V386, P445, DOI 10.1042/BJ20041627; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Dai Q, 2004, ONCOGENE, V23, P3650, DOI 10.1038/sj.onc.1207430; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Garzotto M, 1998, CANCER RES, V58, P2260; Ghias K, 2005, MOL CANCER THER, V4, P569, DOI 10.1158/1535-7163.MCT-04-0303; Goldkorn T, 1998, J CELL SCI, V111, P3209; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hsu YW, 2001, J IMMUNOL, V166, P5388, DOI 10.4049/jimmunol.166.9.5388; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jenkins GM, 2002, J BIOL CHEM, V277, P42572, DOI 10.1074/jbc.M207346200; KIM MY, 1991, J BIOL CHEM, V266, P484; Kitatani K, 2001, ARCH BIOCHEM BIOPHYS, V395, P208, DOI 10.1006/abbi.2001.2573; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kong JY, 2005, MOL CELL BIOCHEM, V278, P39, DOI 10.1007/s11010-005-1979-6; Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552; Lahiri S, 2005, J BIOL CHEM, V280, P33735, DOI 10.1074/jbc.M506485200; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Maher P, 2002, ONCOGENE, V21, P1978, DOI 10.1038/sj.onc.1205268; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Okada T, 2004, INT J ONCOL, V25, P1383; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Plummer G, 2005, BIOCHEM J, V385, P685, DOI 10.1042/BJ20040929; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Reyes JG, 1996, J BIOL CHEM, V271, P21375, DOI 10.1074/jbc.271.35.21375; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2001, LEUKEMIA, V15, P1153, DOI 10.1038/sj.leu.2402197; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Siskind LJ, 2006, MITOCHONDRION, V6, P118, DOI 10.1016/j.mito.2006.03.002; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; Stoica BA, 2005, MOL CELL NEUROSCI, V29, P355, DOI 10.1016/j.mcn.2005.02.009; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; TETTAMANTI G, 2004, GLYCOCONJ J, V20, P301; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watanabe M, 2004, CANCER RES, V64, P1000, DOI 10.1158/0008-5472.CAN-03-1383; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	71	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36793	36802		10.1074/jbc.M608137200	http://dx.doi.org/10.1074/jbc.M608137200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17030510	hybrid			2022-12-25	WOS:000242220800037
J	Park, CH; Kang, JS; Shin, YH; Chang, MY; Chung, S; Koh, HC; Zhu, MH; Oh, SB; Lee, YS; Panagiotakos, G; Tabar, V; Studer, L; Lee, SH				Park, Chang-Hwan; Kang, Jin Sun; Shin, Yeon Ho; Chang, Mi-Yoon; Chung, Seungsoo; Koh, Hyun-Chul; Zhu, Mei Hong; Oh, Seog Bae; Lee, Yong-Sung; Panagiotakos, Georgia; Tabar, Vivian; Studer, Lorenz; Lee, Sang-Hun			Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons	FASEB JOURNAL			English	Article						Parkinson's disease; neural precursor cell; transplantation; dopaminergic differentiation; dopamine neuron; Bcl-XL; Sonic hedgehog; Mash1	NEURAL PROGENITOR CELLS; LOOP-HELIX FACTORS; STEM-CELLS; NIGRAL TRANSPLANTS; PRECURSOR CELLS; PRONEURAL GENES; GROWTH-FACTOR; DIFFERENTIATION; NURR1; INDUCTION	Neural precursor cells provide an expandable source of neurons and glia for basic and translational applications. However, little progress has been made in directing naive neural precursors toward specific neuronal fates such as midbrain dopamine (DA) neurons. We have recently demonstrated that transgenic expression of the nuclear orphan receptor Nurr1 is sufficient to drive dopaminergic differentiation of forebrain embryonic rat neural precursors in vitro. However, Nurr1-induced DA neurons exhibit immature neuronal morphologies and functional properties and are unable to induce behavioral recovery in rodent models of Parkinson's disease (PD). Here, we report on the identification of key genetic factors that drive morphological and functional differentiation of Nurr1-derived DA neurons. We show that coexpression of Nurr1, Bcl-XL, and Sonic hedgehog (SHH) or Nurr1 and the proneural bHLH factor Mash1 is sufficient to drive naive rat forebrain precursors into neurons exhibiting the biochemical, electrophysiological, and functional properties of DA neuron in vitro. On transplantation into the striatum of Parkinsonian rats, precursor cells engineered with Nurr1/SHH/Bcl-XL or Nurr1/Mash1 survived in vivo and differentiated into mature DA neurons that can reverse the behavioral deficits in the grafted animals.-Park, C.-H., Kang, J. S., Shin, Y. H., Chang, M.-Y., Chung, S., Koh, H.-C., Zhu, M. H., Oh, S. B., Lee, Y.-S., Panagiotakos, G., Tabar, V., Studer, L., and Lee, S.-H. Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons.	Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea; Hanyang Univ, Inst Mental Hlth, Seoul 133791, South Korea; Yonsei Univ, Coll Med, Dept Physiol, Seoul 120749, South Korea; Seoul Natl Univ, Coll Dent, Dept Physiol, Seoul 151, South Korea; Seoul Natl Univ, Dent Res Inst, Seoul 151, South Korea; Sloan Kettering Canc Inst, Lab Stem Cell & Tumor Biol, New York, NY USA	Hanyang University; Hanyang University; Hanyang University; Hanyang University; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University (SNU); Memorial Sloan Kettering Cancer Center	Lee, SH (corresponding author), Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, 17 Haengdang Dong, Seoul 133791, South Korea.	leesh@hanyang.ac.kr	OH, Seog Bae/AAQ-2478-2020; Studer, Lorenz/ABH-1491-2021; lee, sang hun/Q-4650-2019; Zhu, Mei Hong/E-7786-2012	Studer, Lorenz/0000-0003-0741-7987; lee, sang hun/0000-0002-9005-5966; PANAGIOTAKOS, GEORGIA/0000-0001-9444-2480; Chung, Seungsoo/0000-0002-3119-9628				Andersson E, 2006, DEVELOPMENT, V133, P507, DOI 10.1242/dev.02224; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Campos-Ortega JA, 1998, INT J DEV BIOL, V42, P291; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; Chang MY, 2004, DEV BRAIN RES, V153, P89, DOI 10.1016/j.devbrainres.2004.08.003; Chang MY, 2003, MOL CELL NEUROSCI, V23, P414, DOI 10.1016/S1044-7431(03)00068-X; Charron F, 2003, CELL, V113, P11, DOI 10.1016/S0092-8674(03)00199-5; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Dass B, 2005, J NEURAL TRANSM, V112, P763, DOI 10.1007/s00702-004-0227-7; Holm KH, 2001, NEUROSCIENCE, V104, P397, DOI 10.1016/S0306-4522(01)00098-7; Hynes M, 2000, NAT NEUROSCI, V3, P41, DOI 10.1038/71114; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Jonas EA, 2003, J NEUROSCI, V23, P8423; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kele J, 2006, DEVELOPMENT, V133, P495, DOI 10.1242/dev.02223; Kim JY, 2003, J NEUROCHEM, V85, P1443, DOI 10.1046/j.1471-4159.2003.01780.x; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lee JY, 2003, NEUROREPORT, V14, P1401, DOI 10.1097/01.wnr.0000078542.07662.4b; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Miao NN, 1997, J NEUROSCI, V17, P5891; Modolell J, 1997, PERSPECT DEV NEUROBI, V4, P285; Oh YJ, 1996, NEUROSCI LETT, V202, P161, DOI 10.1016/0304-3940(95)12235-4; OLSSON M, 1995, J NEUROSCI, V15, P3863; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Park CH, 2005, J NEUROCHEM, V92, P1265, DOI 10.1111/j.1471-4159.2004.03006.x; Park CH, 2006, J CELL SCI, V119, P2310, DOI 10.1242/jcs.02955; Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060; Quinn SM, 1999, J NEUROSCI RES, V57, P590, DOI 10.1002/(SICI)1097-4547(19990901)57:5<590::AID-JNR2>3.0.CO;2-X; Rafuse VF, 2005, NEUROSCIENCE, V131, P899, DOI 10.1016/j.neuroscience.2004.11.048; RAYPORT S, 1992, J NEUROSCI, V12, P4264; Rohrbacher J, 2000, NEUROSCIENCE, V97, P703, DOI 10.1016/S0306-4522(00)00046-4; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Shim JW, 2004, J NEUROSCI, V24, P843, DOI 10.1523/JNEUROSCI.3977-03.2004; So PL, 2006, DEV BIOL, V298, P167, DOI 10.1016/j.ydbio.2006.06.027; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; Tsuboi K, 2002, EXP NEUROL, V173, P95, DOI 10.1006/exnr.2001.7825; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Yan J, 2001, J NEUROCHEM, V76, P307, DOI 10.1046/j.1471-4159.2001.00073.x; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	43	40	44	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2553	+		10.1096/fj.06-6159fje	http://dx.doi.org/10.1096/fj.06-6159fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077287				2022-12-25	WOS:000242490700021
J	Rother, S; Clausing, E; Kieser, A; Strasser, K				Roether, Susanne; Clausing, Emanuel; Kieser, Anja; Straesser, Katja			Swt1, a novel yeast protein, functions in transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; COUPLING TRANSCRIPTION; GENOME INSTABILITY; BINDING PROTEIN; QUALITY-CONTROL; ELONGATION; COMPLEX; YRA1P; CLEAVAGE	The conserved TREX complex couples transcription to nuclear mRNA export. Here, we report that the uncharacterized open reading frame YOR166c genetically interacts with TREX complex components and encodes a novel protein named Swt1 for "synthetically lethal with TREX." Co-immunoprecipitation experiments show that Swt1 also interacts with the TREX complex biochemically. Consistent with a potential role in transcription as suggested by its interaction with TREX, Swt1 localizes mainly to the nucleus. Importantly, deletion of Swt1 leads to decreased transcription. Taken together, these data suggest that Swt1 functions in gene expression in conjunction with the TREX complex.	Univ Munich, Gene Ctr, Mol Biol Lab, Dept Chem & Biochem, D-81377 Munich, Germany	University of Munich	Strasser, K (corresponding author), Univ Munich, Gene Ctr, Mol Biol Lab, Dept Chem & Biochem, Feodor Lynen Str 25, D-81377 Munich, Germany.	strasser@lmb.uni-muenchen.de		Strasser, Katja/0000-0003-3533-5516				Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; Arcus VL, 2004, J BIOL CHEM, V279, P16471, DOI 10.1074/jbc.M313833200; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Bleichert F, 2006, P NATL ACAD SCI USA, V103, P9464, DOI 10.1073/pnas.0603673103; Butler JS, 2002, TRENDS CELL BIOL, V12, P90, DOI 10.1016/S0962-8924(01)02225-5; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Chavez S, 1997, GENE DEV, V11, P3459, DOI 10.1101/gad.11.24.3459; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Clissold PM, 2000, CURR BIOL, V10, pR888, DOI 10.1016/S0960-9822(00)00858-7; Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; HURT EC, 1988, EUR J CELL BIOL, V46, P554; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Jensen TH, 2003, MOL CELL, V11, P1129, DOI 10.1016/S1097-2765(03)00191-6; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Libri D, 2002, MOL CELL BIOL, V22, P8254, DOI 10.1128/MCB.22.23.8254-8266.2002; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Milligan L, 2005, MOL CELL BIOL, V25, P9996, DOI 10.1128/MCB.25.22.9996-10004.2005; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Reed R, 2005, CURR OPIN CELL BIOL, V17, P269, DOI 10.1016/j.ceb.2005.04.011; Rosonina E, 2005, MOL CELL, V20, P167, DOI 10.1016/j.molcel.2005.10.004; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; SIMS RJ, 2004, GENE DEV, V18, P2437, DOI DOI 10.1101/GAD.1235904; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Weilbaecher RG, 2003, J BIOL CHEM, V278, P24189, DOI 10.1074/jbc.M211197200; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001; Zorio DAR, 2004, EXP CELL RES, V296, P91, DOI 10.1016/j.yexcr.2004.03.019	39	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36518	36525		10.1074/jbc.M607510200	http://dx.doi.org/10.1074/jbc.M607510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17030511	hybrid			2022-12-25	WOS:000242220800007
J	Tian, LJ; Chen, L; McClafferty, H; Sailer, CA; Ruth, P; Knaus, HG; Shipston, MJ				Tian, Lijun; Chen, Lie; McClafferty, Heather; Sailer, Claudia A.; Ruth, Peter; Knaus, Hans-Guenther; Shipston, Michael J.			A noncanonical SH3 domain binding motif links BK channels to the actin cytoskeleton via the SH3 adapter cortactin	FASEB JOURNAL			English	Article						KCNMA1; Src homology 3 domain; macromolecular signaling complex	CA2+-ACTIVATED K+ CHANNELS; ACTIVATED POTASSIUM CHANNEL; DEPENDENT PROTEIN-KINASE; RAT HIPPOCAMPAL-NEURONS; LARGE-CONDUCTANCE; TRANSMITTER RELEASE; SIGNALING COMPLEX; ALPHA-SUBUNITS; ION CHANNELS; MICE LACKING	Calcium-activated potassium (BK) channels play a central role in regulating multiple physiological processes, from the control of blood flow to neuronal excitability. Coordinated regulation of BK channel activity by changes in actin cytoskeleton dynamics has been implicated in several of these processes and related disease states such as epilepsy and stroke. However, how BK channels interact with the actin cytoskeleton is essentially unknown. Here we demonstrate noncanonical Src homology domain 3 (SH3) binding site motifs in the intracellular C terminus of the BK channel pore-forming alpha-subunit that are conserved from fish to humans. These noncanonical motifs target multiple SH3 domain cellular signaling proteins to BK channels, including the SH3 adapter protein cortactin (EMS1). We demonstrate that cortactin provides a molecular bridge between BK channels and the cortical actin cytoskeleton in cells. Disruption of the SH3-mediated interaction prevents the regulation of BK channel activity controlled by changes in actin cytoskeletal dynamics. Targeting of cortactin to BK channels via a novel, noncanonical SH3 domain binding motif has important implications for the coordination of BK channel function in normal physiology and disease.	Univ Edinburgh, Sch Biomed Sci, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; Med Univ Innsbruck, Div Mol & Cellular Pharmacol, Innsbruck, Austria; Univ Tubingen, Inst Pharmazeut, Tubingen, Germany	University of Edinburgh; Medical University of Innsbruck; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Shipston, MJ (corresponding author), Univ Edinburgh, Sch Biomed Sci, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland.	mike.shipston@ed.ac.uk	Shipston, Mike/C-7309-2013	Shipston, Mike/0000-0001-7544-582X; Chen, Lie/0000-0001-9764-4299	Wellcome Trust [067683] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANKER G, 1988, NATURE, V336, P185, DOI 10.1038/336185a0; Berry DM, 2002, CURR BIOL, V12, P1336, DOI 10.1016/S0960-9822(02)01038-2; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Brainard AM, 2005, AM J PHYSIOL-CELL PH, V289, pC49, DOI 10.1152/ajpcell.00399.2004; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Carre-Pierrat M, 2006, J MOL BIOL, V358, P387, DOI 10.1016/j.jmb.2006.02.037; Chen L, 2005, J BIOL CHEM, V280, P33599, DOI 10.1074/jbc.M505383200; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Daly RJ, 2004, BIOCHEM J, V382, P13, DOI 10.1042/BJ20040737; Du W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585; Edgerton JR, 2003, J PHYSIOL-LONDON, V548, P53, DOI 10.1113/jphysiol.2002.027854; Ehrhardt AG, 1996, J PHYSIOL-LONDON, V496, P663, DOI 10.1113/jphysiol.1996.sp021717; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gribkoff VK, 2001, NEUROSCIENTIST, V7, P166, DOI 10.1177/107385840100700211; Gribkoff VK, 2001, NAT MED, V7, P471, DOI 10.1038/86546; Grunnet M, 2004, J BIOL CHEM, V279, P36445, DOI 10.1074/jbc.M402254200; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Harvey J, 2000, J PHYSIOL-LONDON, V527, P95, DOI 10.1111/j.1469-7793.2000.00095.x; Hegle AP, 2006, P NATL ACAD SCI USA, V103, P2886, DOI 10.1073/pnas.0505909103; Hu H, 2001, J NEUROSCI, V21, P9585, DOI 10.1523/JNEUROSCI.21-24-09585.2001; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Knaus HG, 1996, J NEUROSCI, V16, P955; Kraft R, 2000, J MEMBRANE BIOL, V175, P25, DOI 10.1007/s002320001052; LANCASTER B, 1991, J NEUROSCI, V11, P23; Lesage F, 2004, P NATL ACAD SCI USA, V101, P671, DOI 10.1073/pnas.0307681100; Levitan IB, 2006, NAT NEUROSCI, V9, P305, DOI 10.1038/nn1647; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; Li CY, 2005, PHARMACOL THERAPEUT, V108, P208, DOI 10.1016/j.pharmthera.2005.04.004; Liu GX, 2004, EMBO J, V23, P2196, DOI 10.1038/sj.emboj.7600228; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Lu R, 2006, J PHYSIOL-LONDON, V570, P65, DOI 10.1113/jphysiol.2005.098913; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Mayer BJ, 2001, J CELL SCI, V114, P1253; McCartney CE, 2005, P NATL ACAD SCI USA, V102, P17870, DOI 10.1073/pnas.0505270102; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; O'Malley D, 2005, FASEB J, V19, P1917, DOI 10.1096/fj.05-4166fje; Park SM, 2004, FEBS LETT, V570, P143, DOI 10.1016/j.febslet.2004.06.037; Petrecca K, 2000, J NEUROSCI, V20, P8736; Piao L, 2003, PFLUG ARCH EUR J PHY, V446, P523, DOI 10.1007/s00424-003-1079-y; Raffaelli G, 2004, J PHYSIOL-LONDON, V557, P147, DOI 10.1113/jphysiol.2004.062661; Rezzonico R, 2002, J BONE MINER RES, V17, P869, DOI 10.1359/jbmr.2002.17.5.869; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sailer CA, 2006, EUR J NEUROSCI, V24, P442, DOI 10.1111/j.1460-9568.2006.04936.x; Sausbier M, 2005, CIRCULATION, V112, P60, DOI 10.1161/01.CIR.0000156448.74296.FE; Schubert R, 2001, TRENDS PHARMACOL SCI, V22, P505, DOI 10.1016/S0165-6147(00)01775-2; Shanley LJ, 2002, J PHYSIOL-LONDON, V545, P933, DOI 10.1113/jphysiol.2002.029488; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tang XD, 2004, NAT STRUCT MOL BIOL, V11, P171, DOI 10.1038/nsmb725; Tian L, 2004, P NATL ACAD SCI USA, V101, P11897, DOI 10.1073/pnas.0402590101; Tian LJ, 2003, J BIOL CHEM, V278, P8669, DOI 10.1074/jbc.M211661200; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wang XL, 2005, J BIOL CHEM, V280, P11656, DOI 10.1074/jbc.M410987200; Wang ZR, 2004, AM J PHYSIOL-HEART C, V286, pH749, DOI 10.1152/ajpheart.00398.2003; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Werner ME, 2005, J PHYSIOL-LONDON, V567, P545, DOI 10.1113/jphysiol.2005.093823; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P1261, DOI 10.1073/pnas.031573798	61	65	66	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2588	+		10.1096/fj.06-6152fje	http://dx.doi.org/10.1096/fj.06-6152fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065230				2022-12-25	WOS:000242490700033
J	Yin, H; Litvinov, RI; Vilaire, G; Zhu, H; Li, W; Caputo, GA; Moore, DT; Lear, JD; Weisel, JW; DeGrado, WF; Bennett, JS				Yin, Hang; Litvinov, Rustem I.; Vilaire, Gaston; Zhu, Hua; Li, Wei; Caputo, Gregory A.; Moore, David T.; Lear, James D.; Weisel, John W.; DeGrado, William F.; Bennett, Joel S.			Activation of platelet alpha IIb beta 3 by an exogenous peptide corresponding to the transmembrane domain of alpha IIb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT ACTIVATION; DE-NOVO DESIGN; INTEGRIN; FIBRINOGEN; HELICES; ASSOCIATION; ALPHA(IIB)BETA(3); STABILIZES; DISRUPTION; MOLECULES	A transmembrane domain heterodimer, acting in concert with a membrane-proximal cytoplasmic domain clasp, is thought to maintain integrins in a low affinity state. To test whether helix-helix interactions between the alpha IIb and beta 3 transmembrane domains regulate the activity of integrin alpha IIb beta 3, we synthesized a soluble peptide corresponding to the alpha IIb transmembrane domain, designated alpha IIb-TM, and we studied its ability to affect alpha IIb beta 3 activity in human platelets. alpha IIb-TM was alpha-helical in detergent micelles and phospholipid vesicles, readily inserted into membrane bilayers, bound to intact purified alpha IIb beta 3, and specifically associated with the transmembrane domain of alpha IIb, rather than the transmembrane domains of beta 3, alpha 2, and beta 1, other integrin subunits present in platelets. When added to suspensions of gel-filtered platelets, alpha IIb-TM rapidly induced platelet aggregation that was not inhibited by preincubating platelets with the prostaglandin E-1 or the ADP scavenger apyrase but was prevented by the divalent cation chelator EDTA. Furthermore, alpha IIb-TM induced fibrinogen binding to platelets but not the binding of osteopontin, a specific ligand for platelet alpha v beta 3. The peptide also induced fibrinogen binding to recombinant alpha IIb beta 3 expressed by Chinese hamster ovary cells, confirming that its effect was independent of platelet signal transduction. Finally, transmission electron microscopy of purified alpha IIb beta 3 revealed that alpha IIb-TM shifted the integrin from a closed configuration with its stalks touching to an open configuration with separated stalks. These observations demonstrate that transmembrane domain interactions regulate integrin function in situ and that it is possible to target intra-membranous protein-protein interactions in a way that can have functional consequences.	Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Bennett, JS (corresponding author), Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA.	bennetts@mail.med.upenn.edu	Litvinov, Rustem/E-5291-2011; YIN, HANG/O-2097-2014	Litvinov, Rustem/0000-0003-0643-1496; YIN, HANG/0000-0002-9762-4818; Caputo, Gregory/0000-0002-4510-2815	NCI NIH HHS [CA101968] Funding Source: Medline; NHLBI NIH HHS [HL54500, HL40387, P01 HL040387] Funding Source: Medline; NIGMS NIH HHS [GM60610, GM54616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA101968] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, P50HL054500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054616, R01GM060610, R37GM054616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arkin IT, 1997, J AM CHEM SOC, V119, P8973, DOI 10.1021/ja964253x; Basani RB, 2001, J BIOL CHEM, V276, P13975, DOI 10.1074/jbc.M011511200; Bennett JS, 2005, J CLIN INVEST, V115, P3363, DOI 10.1172/JCI26989; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Bilgicer B, 2004, P NATL ACAD SCI USA, V101, P15324, DOI 10.1073/pnas.0403314101; Caputo GA, 2003, BIOCHEMISTRY-US, V42, P3275, DOI 10.1021/bi026697d; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; Gerber D, 2004, J BIOL CHEM, V279, P21177, DOI 10.1074/jbc.M400847200; Hammond K, 2002, BIOCHEMISTRY-US, V41, P3243, DOI 10.1021/bi011163i; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Heuck AP, 2003, J BIOL CHEM, V278, P31218, DOI 10.1074/jbc.M303151200; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kharakoz DP, 1997, BIOCHEMISTRY-US, V36, P10276, DOI 10.1021/bi961781c; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kochendoerfer GG, 1999, BIOCHEMISTRY-US, V38, P11905, DOI 10.1021/bi990720m; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Li W, 2005, P NATL ACAD SCI USA, V102, P1424, DOI 10.1073/pnas.0409334102; Litvinov RI, 2006, BIOCHEMISTRY-US, V45, P4957, DOI 10.1021/bi0526581; Litvinov RI, 2003, J BIOL CHEM, V278, P51285, DOI 10.1074/jbc.M304581200; Litvinov RI, 2004, BLOOD, V104, P3979, DOI 10.1182/blood-2004-04-1411; Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Moebius J, 2005, MOL CELL PROTEOMICS, V4, P1754, DOI 10.1074/mcp.M500209-MCP200; Partridge AW, 2005, J BIOL CHEM, V280, P7294, DOI 10.1074/jbc.M412701200; Partridge AW, 2003, J BIOL CHEM, V278, P22056, DOI 10.1074/jbc.M210685200; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Schneider D, 2004, J BIOL CHEM, V279, P9840, DOI 10.1074/jbc.M312749200; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; White SH, 2005, CURR OPIN STRUC BIOL, V15, P378, DOI 10.1016/j.sbi.2005.07.004; Yin H, 2005, J AM CHEM SOC, V127, P5463, DOI 10.1021/ja0446404	44	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36732	36741		10.1074/jbc.M605877200	http://dx.doi.org/10.1074/jbc.M605877200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17032655	hybrid			2022-12-25	WOS:000242220800030
J	Dupont, DM; Blouse, GE; Hansen, M; Mathiasen, L; Kjelgaard, S; Jensen, JK; Christensen, A; Gils, A; Declerck, PJ; Andreasen, PA; Wind, T				Dupont, Daniel M.; Blouse, Grant E.; Hansen, Martin; Mathiasen, Lisa; Kjelgaard, Signe; Jensen, Jan K.; Christensen, Anni; Gils, Ann; Declerck, Paul J.; Andreasen, Peter A.; Wind, Troels			Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; MONOCLONAL-ANTIBODIES; UROKINASE-TYPE; PHAGE DISPLAY; PROTEIN; TYPE-1; PAI-1; BINDING; IDENTIFICATION; EPITOPE	Latency transition of plasminogen activator inhibitor-1 (PAI-1) occurs spontaneously in the absence of proteases and results in stabilization of the molecule through insertion of its reactive center loop (RCL) as a strand in beta-sheet A and detachment of beta-strand 1C (s1C) at the C-terminal hinge of the RCL. This is one of the largest structural rearrangements known for a folded protein domain without a concomitant change in covalent structure. Yet, the sequence of conformational changes during latency transition remains largely unknown. We have now mapped the epitope for the monoclonal antibody H4B3 to the cleft revealed upon s1C detachment and shown that H4B3 inactivates recombinant PAI-1 in a time-dependent manner. With fluorescence spectroscopy, we show that insertion of the RCL is accelerated in the presence of H4B3, demonstrating that the loss of activity is the result of latency transition. Considering that the epitope for H4B3 appears to be occluded by s1C in active PAI-1, this finding suggests the existence of a pre-latent conformation on the path from active to latent PAI-1 characterized by at least partial detachment of s1C. Functional characterization of mutated PAI-1 variants suggests that a salt-bridge between Arg(273) and Asp(224) may stabilize the pre-latent conformation. The binding of H4B3 and of a peptide targeting the cleft revealed upon s1C detachment was hindered by the glycans attached to Asn(267). Conclusively, we have provided evidence for the existence of an equilibrium between active PAI-1 and a pre-latent form, characterized by reversible detachment of s1C and formation of a glycan-shielded cleft in the molecule.	Aarhus Univ, Dept Mol Biol, Lab Cellular Prot Sci, DK-8000 Aarhus C, Denmark; Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol, B-3000 Louvain, Belgium	Aarhus University; KU Leuven	Andreasen, PA (corresponding author), Aarhus Univ, Dept Mol Biol, Lab Cellular Prot Sci, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	pa@mb.au.dk	Declerck, Paul J/A-2330-2017; Dupont, Daniel M./H-7556-2019	Declerck, Paul J/0000-0003-1259-9105; Dupont, Daniel Miotto/0000-0003-1378-1670				AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Bjorquist P, 1999, BBA-PROTEIN STRUCT M, V1431, P24, DOI 10.1016/S0167-4838(99)00031-X; Bjorquist P, 1997, BBA-PROTEIN STRUCT M, V1341, P87, DOI 10.1016/S0167-4838(97)00065-4; Blouse GE, 2003, BIOCHEMISTRY-US, V42, P12260, DOI 10.1021/bi034737n; Bodker JS, 2003, EUR J BIOCHEM, V270, P1672, DOI 10.1046/j.1432-1033.2003.03523.x; Carrell RW, 2001, THROMB HAEMOSTASIS, V86, P14; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; De Taeye B, 2003, J BIOL CHEM, V278, P23899, DOI 10.1074/jbc.M302226200; DECLERCK PJ, 1995, THROMB HAEMOSTASIS, V74, P1305; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gils A, 2003, THROMB HAEMOSTASIS, V90, P206, DOI 10.1160/TH03-01-0034; Gils A, 1997, FEBS LETT, V415, P192, DOI 10.1016/S0014-5793(97)01122-8; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Gorlatova NV, 2003, J BIOL CHEM, V278, P16329, DOI 10.1074/jbc.M208420200; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hagglof P, 2004, J MOL BIOL, V335, P823, DOI 10.1016/j.jmb.2003.11.005; Hansen M, 2005, J BIOL CHEM, V280, P38424, DOI 10.1074/jbc.M505933200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jensen JK, 2006, BIOCHEM J, V399, P387, DOI 10.1042/BJ20060533; KEIJER J, 1991, BLOOD, V78, P401; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; Naessens D, 2003, THROMB HAEMOSTASIS, V90, P52, DOI 10.1055/s-0037-1613598; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; Offersen BV, 2003, AM J PATHOL, V163, P1887, DOI 10.1016/S0002-9440(10)63547-X; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Stoop AA, 2000, J MOL BIOL, V301, P1135, DOI 10.1006/jmbi.2000.4035; Stoop AA, 2001, J MOL BIOL, V305, P773, DOI 10.1006/jmbi.2000.4356; Stout TJ, 2000, BIOCHEMISTRY-US, V39, P8460, DOI 10.1021/bi000290w; Sui GC, 2000, THROMB HAEMOSTASIS, V83, P896, DOI 10.1055/s-0037-1613940; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; Wind T, 2003, EUR J BIOCHEM, V270, P1680, DOI 10.1046/j.1432-1033.2003.03524.x; Wind T, 2001, EUR J BIOCHEM, V268, P1095, DOI 10.1046/j.1432-1327.2001.2680041095.x; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1	43	35	36	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36071	36081		10.1074/jbc.M606851200	http://dx.doi.org/10.1074/jbc.M606851200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17018527	hybrid			2022-12-25	WOS:000242100500056
J	Hou, JH; Gomes, AS; Paul, DL; Goodenough, DA				Hou, Jianghui; Gomes, Antonio S.; Paul, David L.; Goodenough, Daniel A.			Study of claudin function by RNA interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; DOMAIN PROTEIN-1 MUPP1; EPITHELIAL-CELLS; PARACELLULAR CONDUCTANCE; SELECTIVE CHANNELS; MAMMALIAN-CELLS; EXPRESSION; PERMEABILITY; MEMBRANE; OCCLUDIN	Claudins are tight junction proteins that play a key selectivity role in the paracellular conductance of ions. Numerous studies of claudin function have been carried out using the overexpression strategy to add new claudin channels to an existing paracellular protein background. Here, we report the systematic knockdown of endogenous claudin gene expression in Madin-Darby canine kidney (MDCK) cells and in LLC-PK1 cells using small interfering RNA against claudins 1-4 and 7. In MDCK cells ( showing cation selectivity), claudins 2, 4, and 7 are powerful effectors of paracellular Na+ permeation. Removal of claudin-2 depressed the permeation of Na+ and resulted in the loss of cation selectivity. Loss of claudin-4 or -7 expression elevated the permeation of Na+ and enhanced the proclivity of the tight junction for cations. On the other hand, LLC-PK1 cells express little endogenous claudin- 2 and show anion selectivity. In LLC-PK1 cells, claudin- 4 and -7 are powerful effectors of paracellular Cl- permeation. Knockdown of claudin- 4 or -7 expression depressed the permeation of Cl- and caused the tight junction to lose the anion selectivity. In conclusion, claudin- 2 functions as a paracellular channel to Na+ to increase the cation selectivity of the tight junction; claudin- 4 and -7 function either as paracellular barriers to Na+ or as paracellular channels to Cl-, depending upon the cellular background, to decrease the cation selectivity of the tight junction.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Goodenough, DA (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	Daniel_goodenough@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018974, R01GM037751, R37GM018974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18974, GM37751] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandre MD, 2005, J CELL SCI, V118, P2683, DOI 10.1242/jcs.02406; Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Anderson JM, 2004, CURR OPIN CELL BIOL, V16, P140, DOI 10.1016/j.ceb.2004.01.005; Ben-Yosef T, 2003, HUM MOL GENET, V12, P2049, DOI 10.1093/hmg/ddg210; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; HILLE B, 2001, ION CHANNELS EXCITAB, P184; Hou JH, 2005, J CELL SCI, V118, P5109, DOI 10.1242/jcs.02631; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jeansonne B, 2003, CELL MOL BIOL, V49, P13; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P14877, DOI 10.1073/pnas.0406172101; KIMIZUKA H, 1964, J THEOR BIOL, V6, P290, DOI 10.1016/0022-5193(64)90035-9; Lipschutz JH, 2005, J BIOL CHEM, V280, P3780, DOI 10.1074/jbc.M408122200; Mitic LL, 2003, PROTEIN SCI, V12, P218, DOI 10.1110/ps.0233903; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Sasaki H, 2003, P NATL ACAD SCI USA, V100, P3971, DOI 10.1073/pnas.0630649100; Schneeberger EE, 2003, AM J PHYSIOL-CELL PH, V284, pC1331, DOI 10.1152/ajpcell.00037.2003; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Van Itallie CM, 2003, AM J PHYSIOL-RENAL, V285, pF1078, DOI 10.1152/ajprenal.00116.2003; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; Wen HJ, 2004, MOL CELL BIOL, V24, P8408, DOI 10.1128/MCB.24.19.8408-8417.2004; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Yamauchi K, 2004, P NATL ACAD SCI USA, V101, P4690, DOI 10.1073/pnas.0306924101; Yu ASL, 2003, J BIOL CHEM, V278, P17350, DOI 10.1074/jbc.M213286200	35	181	186	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36117	36123		10.1074/jbc.M608853200	http://dx.doi.org/10.1074/jbc.M608853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17018523				2022-12-25	WOS:000242100500061
J	Aiyar, SE; Blair, AL; Hopkinson, DA; Bekiranov, S; Li, R				Aiyar, S. E.; Blair, A. L.; Hopkinson, D. A.; Bekiranov, S.; Li, R.			Regulation of clustered gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells	ONCOGENE			English	Article						COBRA1; clustered gene expression; estrogen; transcription; NELF	INTESTINAL TREFOIL FACTOR; TRANSCRIPTION ELONGATION-FACTOR; X-CHROMOSOME INACTIVATION; APOLIPOPROTEIN-D; PROSTATE-CANCER; TISSUE INHIBITOR; RETINOIC ACID; MESSENGER-RNA; ESTROGEN; NELF	Eucaryotic genes that are coordinately expressed tend to be clustered. Furthermore, gene clusters across chromosomal regions are often upregulated in various tumors. However, relatively little is known about how gene clusters are coordinately expressed in physiological or pathological conditions. Cofactor of BRCA1 (COBRA1), a subunit of the human negative elongation factor, has been shown to repress estrogen-stimulated transcription of trefoil factor 1 (TFF1 or pS2) by stalling RNA polymerase II. Here, we carried out a genome-wide study to identify additional physiological target genes of COBRA1 in breast cancer cells. The study identified a total of 134 genes that were either activated or repressed upon small hairpin RNA-mediated reduction of COBRA1. Interestingly, many COBRA1-regulated genes reside as clusters on the chromosomes and have been previously implicated in cancer development. Detailed examination of two such clusters on chromosome 21 (21q22) and chromosome X (Xp11) reveal s that COBRA1 is physically associated with a subset of its regulated genes in each cluster. In addition, COBRA1 was shown to regulate both estrogen-dependent and - independent transcription of the gene cluster at 21q22, which encompasses the previously identified COBRA1-regulated TFF1 (pS2) locus. Thus, COBRA1 plays a critical role in the regulation of clustered gene expression at preferred chromosomal domains in breast cancer cells.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	rl2t@virginia.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064604] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK064604] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; Anderson CL, 2002, HUM GENET, V110, P271, DOI 10.1007/s00439-002-0676-8; Anderson CL, 1999, AM J HUM GENET, V65, P699, DOI 10.1086/302556; Balleine RL, 1999, HISTOL HISTOPATHOL, V14, P571, DOI 10.14670/HH-14.571; Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; BLAIS Y, 1995, INT J CANCER, V62, P732, DOI 10.1002/ijc.2910620614; Bodey B, 2002, EXPERT OPIN BIOL TH, V2, P577, DOI 10.1517/14712598.2.6.577; Burton JD, 2004, CLIN CANCER RES, V10, P6606, DOI 10.1158/1078-0432.CCR-04-0182; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Carsol JL, 2002, MOL ENDOCRINOL, V16, P1696, DOI 10.1210/me.16.7.1696; CHEN L, 1990, ONCOGENE, V5, P1391; Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618; Chinery R, 1996, GENOMICS, V32, P281, DOI 10.1006/geno.1996.0117; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Clark JW, 1999, BRIT J CANCER, V81, P1002, DOI 10.1038/sj.bjc.6690799; De Backer O, 1999, CANCER RES, V59, P3157; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634; Gallagher PG, 2003, TOXICON, V41, P429, DOI 10.1016/S0041-0101(02)00359-8; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gonzalez MA, 2003, J CLIN ONCOL, V21, P4306, DOI 10.1200/JCO.2003.04.121; Gott P, 1996, EUR J HUM GENET, V4, P308; HAHNEL E, 1994, PATHOBIOLOGY, V62, P82, DOI 10.1159/000163882; HIROTA S, 1995, LAB INVEST, V72, P64; Hoevel T, 2002, J CELL PHYSIOL, V191, P60, DOI 10.1002/jcp.10076; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Jazaeri Amir A, 2004, J Transl Med, V2, P32, DOI 10.1186/1479-5876-2-32; Koon N, 2004, NEOPLASIA, V6, P143, DOI 10.1593/neo.03385; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; LOPEZBOADO YS, 1994, J BIOL CHEM, V269, P26871; Mashino K, 2001, BRIT J CANCER, V85, P713, DOI 10.1054/bjoc.2001.1974; May FEB, 1997, J PATHOL, V183, P4; McChesney PA, 2006, CANCER RES, V66, P1346, DOI 10.1158/0008-5472.CAN-05-3593; Mikhitarian K, 2005, CLIN CANCER RES, V11, P3697, DOI 10.1158/1078-0432.CCR-04-2164; Moggs JG, 2005, J MOL ENDOCRINOL, V34, P535, DOI 10.1677/jme.1.01677; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Nakopoulou L, 2003, APMIS, V111, P1027, DOI 10.1111/j.1600-0463.2003.apm1111105.x; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; PAGANI A, 1994, VIRCHOWS ARCH, V425, P459; Palangat M, 2005, P NATL ACAD SCI USA, V102, P15036, DOI 10.1073/pnas.0409405102; Poulsom R, 1997, J PATHOL, V183, P30, DOI 10.1002/(SICI)1096-9896(199709)183:1<30::AID-PATH1085>3.0.CO;2-K; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Schmitt H, 1996, CYTOGENET CELL GENET, V72, P299, DOI 10.1159/000134208; SHEIKH MS, 1993, MOL CELL ENDOCRINOL, V92, P153, DOI 10.1016/0303-7207(93)90002-2; Shetty A, 2005, BRIT J CANCER, V93, P1295, DOI 10.1038/sj.bjc.6602829; Singer GAC, 2005, MOL BIOL EVOL, V22, P767, DOI 10.1093/molbev/msi062; Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Tian W, 2004, CANCER SCI, V95, P491, DOI 10.1111/j.1349-7006.2004.tb03238.x; Toi M, 1998, BREAST CANCER RES TR, V52, P113, DOI 10.1023/A:1006167202856; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; TOMASETTO C, 1992, GENOMICS, V13, P1328, DOI 10.1016/0888-7543(92)90059-2; Vestergaard EM, 2006, CLIN CANCER RES, V12, P807, DOI 10.1158/1078-0432.CCR-05-1545; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wu CH, 2005, NUCLEIC ACIDS RES, V33, P1269, DOI 10.1093/nar/gki274; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Wu YM, 2005, ENDOCRINOLOGY, V146, P237, DOI 10.1210/en.2004-0889; Wurtz SO, 2005, ENDOCR-RELAT CANCER, V12, P215, DOI 10.1677/erc.1.00719; Xu XQ, 2005, J BIOL CHEM, V280, P23987, DOI 10.1074/jbc.M503869200; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong HJ, 2004, BIOCHEM BIOPH RES CO, V325, P568, DOI 10.1016/j.bbrc.2004.10.079; Zhou Y, 2003, CANCER RES, V63, P5781	71	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2543	2553		10.1038/sj.onc.1210047	http://dx.doi.org/10.1038/sj.onc.1210047			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043641	Bronze			2022-12-25	WOS:000245831200002
J	Klampfer, L; Huang, J; Kaler, P; Sasazuki, T; Shirasawa, S; Augenlicht, L				Klampfer, L.; Huang, J.; Kaler, P.; Sasazuki, T.; Shirasawa, S.; Augenlicht, L.			STAT1-independent inhibition of cyclooxygenase-2 expression by IFN gamma; a common pathway of IFN gamma-mediated gene repression but not gene activation	ONCOGENE			English	Article						STAT1; COX-2; JAK; IFN; colon ucancer	COLORECTAL-CANCER PREVENTION; CELL LUNG-CANCER; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; SIGNALING PATHWAY; BINDING PROTEIN; DNA-BINDING; KI-RAS	Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in the synthesis of prostaglandins, promotes the development of colorectal cancer, and is a key molecular target of nonsteroidal anti-inflammatory drugs, compounds that reduce the relative risk of developing colon cancer. In this study, we showed that interferon gamma (IFN gamma) inhibits the expression of COX-2 protein in intestinal epithelial cells (IECs) through a pathway that requires Janus-activated kinase (JAK) activity. In contrast, we demonstrated that transcriptional inhibition of COX-2 by IFN beta or IFN gamma occurs in cells with silenced signal transducer and activator of transcription 1 (STAT1) expression and that IFNs retained the ability to inhibit COX-2 transcription in cells with activated RasV12, in which IFN gamma failed to induce STAT1. Thus, unlike the activity of JAK, STAT1 is not required for the inhibition of COX-2 expression by IFN gamma. In contrast to COX-2, the activation of genes in response to IFN gamma, such as interferon regulatory factor-1, was severely impaired by both STAT1 silencing and by constitutive Ras signaling. To determine whether there is a general differential requirement for STAT1 in gene activation and gene repression in response to IFN gamma in intestinal cells, we performed genome-wide analysis of IFN gamma target genes in an IEC line in which STAT1 expression was silenced by small interfering RNA. The results confirmed that the activation of the majority of genes by IFN gamma required STAT1. In contrast, the repression of several genes, as we showed for COX-2 specifically, was largely unaffected in cells with silenced STAT1. Our results therefore demonstrate that in general gene activation by IFNc is more sensitive to STAT1 deficiency than gene repression, and suggest that IFNc activates and represses gene expression via distinct pathways that can be distinguished, at least in part, by their requirement for STAT1.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Int Med Ctr Japan, Inst Res, Shinjuku Ku, Tokyo, Japan	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; National Center for Global Health & Medicine - Japan	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NATIONAL CANCER INSTITUTE [U54CA100926, R01CA111361] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111361, U54 CA100926] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Araki Y, 2003, CANCER RES, V63, P728; Battcock SA, 2006, J VIROL, V80, P4422, DOI 10.1128/JVI.80.9.4422-4430.2006; Biasco G, 2002, DIGEST LIVER DIS, V34, P339, DOI 10.1016/S1590-8658(02)80127-X; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Blanco JCG, 2000, J EXP MED, V191, P2131, DOI 10.1084/jem.191.12.2131; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Clifford JL, 2002, CLIN CANCER RES, V8, P2067; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Guy-Grand D, 1998, EUR J IMMUNOL, V28, P730, DOI 10.1002/(SICI)1521-4141(199802)28:02<730::AID-IMMU730>3.0.CO;2-U; Hanna N, 2004, AM J REPROD IMMUNOL, V51, P311, DOI 10.1111/j.1600-0897.2004.00162.x; Higaki S, 1999, J GASTROEN HEPATOL, V14, P709, DOI 10.1046/j.1440-1746.1999.01938.x; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Janabi N, 2004, J NEUROIMMUNOL, V156, P113, DOI 10.1016/j.jneuroim.2004.07.012; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Klampfer L, 2003, J BIOL CHEM, V278, P46278, DOI 10.1074/jbc.M304721200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lindner Daniel J, 2002, Curr Oncol Rep, V4, P510, DOI 10.1007/s11912-002-0065-4; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Muller-Tidow C, 2004, LUNG CANCER, V45, pS145, DOI 10.1016/j.lungcan.2004.07.000; Navarro A, 2003, J LEUKOCYTE BIOL, V73, P540, DOI 10.1189/jlb.1002508; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Sheng HM, 2001, CANCER RES, V61, P2670; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sol VVD, 2005, J IMMUNOL, V174, P2825, DOI 10.4049/jimmunol.174.5.2825; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Wright KL, 2004, BRIT J PHARMACOL, V141, P1091, DOI 10.1038/sj.bjp.0705719	50	19	20	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2071	2081		10.1038/sj.onc.1210015	http://dx.doi.org/10.1038/sj.onc.1210015			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016440				2022-12-25	WOS:000245313400009
J	Qiao, H; Di Stefano, L; Tian, C; Li, YY; Yin, YH; Qian, XP; Pang, XW; Li, Y; McNutt, MA; Helin, K; Zhang, Y; Chen, WF				Qiao, Huan; Di Stefano, Luisa; Tian, Chan; Li, Yun-Yan; Yin, Yan-Hui; Qian, Xiao-Ping; Pang, Xue-Wen; Li, Yan; McNutt, Michael Allen; Helin, Kristian; Zhang, Yu; Chen, Wei-Feng			Human TFDP3, a novel DP protein, inhibits DNA binding and transactivation by E2F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR FAMILY; CELL-CYCLE PROGRESSION; MEMBER; GROWTH; APOPTOSIS; EXPRESSION; INDUCTION; PRB; IDENTIFICATION; ORGANIZATION	The two known DP proteins, TFDP1 and -2, bind E2Fs to form heterodimers essential for high affinity DNA binding and efficient transcriptional activation/repression. Here we report the identification of a new member of the DP family, human TFDP3. Despite the high degree of sequence similarity, TFDP3 is apparently distinct from TFDP1 in function. Although TFDP3 retained the capacity to bind to E2F proteins, the resulting heterodimers failed to interact with the E2F consensus sequence. In contrast to the stimulatory effect of TFDP1, TFDP3 inhibited E2F-mediated transcriptional activation. Consistent with this observation, we found that ectopic expression of TFDP3 impaired cell cycle progression from G(1) to S phase instead of facilitating such a transition as TFDP1 does. Sequence substitution analysis indicated that the DNA binding domain of TFDP3 was primarily responsible for the lack of DNA binding ability of E2F-TFDP3 heterodimers and the inhibition of E2F-mediated transcriptional activation. Fine mapping further revealed four amino acids in this region, which were critical for the functional conversion from activation by TFDP1 to suppression by TFDP3. In conclusion, these studies identify a new DP protein and a novel mechanism whereby E2F function is regulated.	Peking Univ, Hlth Sci Ctr, Dept Immunol, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100083, Peoples R China; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	Peking University; Peking University; IRCCS European Institute of Oncology (IEO)	Zhang, Y (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Immunol, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	zhangyu007@hsc.pku.edu.cn; wfchen@public.bta.net.cn	Helin, Kristian/HDM-8306-2022; Di Stefano, Luisa/ABB-6457-2020; Chen, Wei/GZK-7348-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Di Stefano, Luisa/0000-0003-3437-9066; 				BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bargou RC, 1996, J EXP MED, V183, P1205, DOI 10.1084/jem.183.3.1205; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chan RCF, 2004, BRIT J CANCER, V90, P1636, DOI 10.1038/sj.bjc.6601706; Christensen J, 2005, NUCLEIC ACIDS RES, V33, P5458, DOI 10.1093/nar/gki855; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; Humbert PO, 2000, GENE DEV, V14, P690; Ishida H, 2005, J BIOL CHEM, V280, P24642, DOI 10.1074/jbc.M500189200; JOOSS K, 1995, ONCOGENE, V10, P1529; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Logan N, 2005, ONCOGENE, V24, P5000, DOI 10.1038/sj.onc.1208703; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Maehara K, 2005, J CELL BIOL, V168, P553, DOI 10.1083/jcb.200411093; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Milton A, 2006, ONCOGENE, V25, P3212, DOI 10.1038/sj.onc.1209343; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Tsantoulis PK, 2005, EUR J CANCER, V41, P2403, DOI 10.1016/j.ejca.2005.08.005; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Wang Y, 2002, J IMMUNOL, V169, P1102, DOI 10.4049/jimmunol.169.2.1102; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU CL, 1995, MOL CELL BIOL, V15, P2536; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	51	28	32	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					454	466		10.1074/jbc.M606169200	http://dx.doi.org/10.1074/jbc.M606169200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17062573	hybrid			2022-12-25	WOS:000243166500051
J	Tenca, P; Brotherton, D; Montagnoli, A; Rainoldi, S; Albanese, C; Santocanale, C				Tenca, Pierluigi; Brotherton, Deborah; Montagnoli, Alessia; Rainoldi, Sonia; Albanese, Clara; Santocanale, Corrado			Cdc7 is an active kinase in human cancer cells undergoing replication stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; HUMAN CDC7-RELATED KINASE; DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; REGULATORY SUBUNIT; ALKYLATION DAMAGE; RESPONSE PATHWAY; MAMMALIAN-CELLS; NUCLEAR ANTIGEN	Cdc7 kinase promotes and regulates DNA replication in eukaryotic organisms. Multiple mechanisms modulating kinase activity in response to DNA replication stress have been reported, supporting the opposing notions that Cdc7 either plays an active role under these conditions or, conversely, is a final target inactivated by a checkpoint response. We have developed new immunological reagents to study the properties of human Cdc7 kinase in cells challenged with the ribonucleotide reductase inhibitor hydroxyurea or with the DNA topoisomerase II inhibitor etoposide. We show that Cdc7(.)Dbf4 and Cdc7(.)Drf1 complexes are stable and active in multiple cell lines upon drug treatment, with Cdc7(.)Dbf4 accumulating on chromatin-enriched fractions. Cdc7 depletion by small interfering RNA in hydroxyurea and etoposide impairs hyper-phosphorylation of Mcm2 at specific Cdc7-dependent phosphorylation sites and drug-induced hyper-phosphorylation of chromatin-bound Mcm4 Furthermore, sustained inhibition of Cdc7 in the presence of these drugs increases cell death supporting the notion that the Cdc7 kinase plays a role in maintaining cell viability during replication stress.	Nerviano Med Sci Oncol, Dept Cell Biol, I-20014 Nerviano, Italy	Nerviano Medical Sciences S.r.l	Santocanale, C (corresponding author), Nerviano Med Sci Oncol, Dept Cell Biol, Via Pasteur 10, I-20014 Nerviano, Italy.	corrado.santocanale@nervianoms.com		Santocanale, Corrado/0000-0003-1337-5656				Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Cho WH, 2006, P NATL ACAD SCI USA, V103, P11521, DOI 10.1073/pnas.0604990103; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Fung AD, 2002, MOL CELL BIOL, V22, P4477, DOI 10.1128/MCB.22.13.4477-4490.2002; Gabrielse C, 2006, GENETICS, V173, P541, DOI 10.1534/genetics.106.057521; Gerard A, 2006, EMBO REP, V7, P817, DOI 10.1038/sj.embor.7400750; HOLLINGSWORTH RE, 1992, GENETICS, V132, P53; Ishimi Y, 2003, J BIOL CHEM, V278, P24644, DOI 10.1074/jbc.M213252200; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Krude T, 1996, J CELL SCI, V109, P309; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Matsumoto S, 2005, J BIOL CHEM, V280, P42536, DOI 10.1074/jbc.M510575200; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Pessoa-Brandao L, 2004, GENETICS, V167, P1597, DOI 10.1534/genetics.103.021675; Petersen P, 2006, MOL CELL BIOL, V26, P1997, DOI 10.1128/MCB.26.5.1997-2011.2006; Rialland M, 2002, J CELL SCI, V115, P1435; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sclafani RA, 2000, J CELL SCI, V113, P2111; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Silva T, 2006, J BIOL CHEM, V281, P11569, DOI 10.1074/jbc.M510278200; Sommariva E, 2005, MOL CELL BIOL, V25, P2770, DOI 10.1128/MCB.25.7.2770-2784.2005; Takahashi TS, 2005, GENE DEV, V19, P2295, DOI 10.1101/gad.1339805; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Treuner K, 1999, J BIOL CHEM, V274, P15556, DOI 10.1074/jbc.274.22.15556; Tsuji T, 2006, MOL BIOL CELL, V17, P4459, DOI 10.1091/mbc.E06-03-0241; Varrin AE, 2005, MOL CELL BIOL, V25, P7494, DOI 10.1128/MCB.25.17.7494-7504.2005; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoo HY, 2004, J BIOL CHEM, V279, P53353, DOI 10.1074/jbc.M408026200; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200	51	64	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					208	215		10.1074/jbc.M604457200	http://dx.doi.org/10.1074/jbc.M604457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17062569	hybrid			2022-12-25	WOS:000243166500025
J	Haidar, B; Kiss, RS; Sarov-Blat, L; Brunet, R; Harder, C; McPherson, R; Marcel, YL				Haidar, Bassam; Kiss, Robert S.; Sarov-Blat, Lea; Brunet, Roch; Harder, Christopher; McPherson, Ruth; Marcel, Yves L.			Cathepsin D, a lysosomal protease, regulates ABCA1-mediated lipid efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER 1; APOLIPOPROTEIN-A-I; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; NEURONAL CEROID-LIPOFUSCINOSIS; FAMILIAL HDL DEFICIENCY; DENSITY-LIPOPROTEIN CHOLESTEROL; SPHINGOLIPID STORAGE DISEASES; D GENE-EXPRESSION; TANGIER-DISEASE; ABCA1 TRANSPORTER	To identify genes involved in the regulation of plasma high density lipoprotein (HDL) cholesterol (HDL-C) levels, patients with low HDL-C and age- and sex-matched controls (normal HDL-C) were extensively characterized. Comparative transcriptome analysis was carried out in cholesterol-loaded monocyte-derived macrophages from low HDL subjects segregated into groups with or without cholesterol efflux defects or ABCA1 mutations. Clusters of differentially regulated genes were evident in the low HDL groups as compared with controls. Of particular note, expression of cathepsin D (CTSD), a lysosomal proteinase, was reduced by similar to 50% in monocyte-derived macrophages of low HDL-C subjects, most significantly those with cholesterol efflux defects but without mutations in ABCA1 (p < 0.01). These results were verified by reverse transcription-PCR and replicated in a second cohort. We show here that blocking the activity or expression of CTSD, by pepstatin or CTSD small interfering RNA, respectively, reduced ABCA1 expression and protein abundance in both macrophages and CHO cells and apolipoprotein A-I-mediated lipid efflux by more than 70%. Conversely, expression of CTSD increased both ABCA1 mRNA expression and cellular ABCA1 protein. Consistent with its role in the proteolytic processing of prosaposin, inactivation of CTSD function resulted in the accumulation of glycosphingolipid and free cholesterol in late endosomes/lysosomes, a phenotype similar to NPC1 deficiency. Inhibition of CTSD also caused retention of ABCA1 in lysosomal compartments, reducing its trafficking to the plasma membrane. These studies demonstrate a novel and potentially important role for CTSD in intracellular cholesterol trafficking and ABCA1-mediated efflux. Therefore, decreased CTSD expression may contribute to low plasma HDL-C levels.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Microbiol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Immunol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Med Cardiol, Ottawa, ON K1Y 4W7, Canada; GlaxoSmithKline, King Of Prussia, PA 19406 USA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; GlaxoSmithKline	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ylmarcel@ottawaheart.ca						Aouizerat BE, 2006, J LIPID RES, V47, P787, DOI 10.1194/jlr.M500476-JLR200; ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P871; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Awano T, 2006, MOL GENET METAB, V87, P341, DOI 10.1016/j.ymgme.2005.11.005; Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; Chapman HA, 2004, DEV CELL, V6, P610, DOI 10.1016/S1534-5807(04)00141-8; CHOI HY, 2003, J BIOL CHEM; Ciaffoni F, 2006, J LIPID RES, V47, P1045, DOI 10.1194/jlr.M500547-JLR200; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; Daum U, 1999, J LIPID RES, V40, P486; Daum U, 1999, J MOL MED, V77, P614, DOI 10.1007/s001099900034; DEAN RT, 1975, NATURE, V257, P414, DOI 10.1038/257414a0; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; Eberhart GP, 1998, J CLIN ENDOCR METAB, V83, P836, DOI 10.1210/jc.83.3.836; Elkhalil L, 1997, METABOLISM, V46, P474, DOI 10.1016/S0026-0495(97)90180-3; Elleder M, 2005, NEUROPEDIATRICS, V36, P171, DOI 10.1055/s-2005-865608; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; Fusek Martin, 2005, Biomedical Papers (Olomouc), V149, P43; Garner B, 2002, BIOCHEM BIOPH RES CO, V290, P1361, DOI 10.1006/bbrc.2002.6356; GINSBERG H, 1984, CLIN GENET, V26, P109; Glaros EN, 2005, J BIOL CHEM, V280, P24515, DOI 10.1074/jbc.M413862200; Gopalakrishnan MM, 2004, BIOCHEM J, V383, P507, DOI 10.1042/BJ20040175; Haidar B, 2004, J BIOL CHEM, V279, P9963, DOI 10.1074/jbc.M313487200; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Hulkova H, 2001, HUM MOL GENET, V10, P927, DOI 10.1093/hmg/10.9.927; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Kiss RS, 2006, J BIOL CHEM, V281, P12081, DOI 10.1074/jbc.M600621200; Lambert G, 2001, J BIOL CHEM, V276, P15090, DOI 10.1074/jbc.M008466200; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Liaudet-Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007; Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; MAY FEB, 1993, GENE, V134, P277, DOI 10.1016/0378-1119(93)90107-E; McGovern MM, 2004, J PEDIATR-US, V145, P77, DOI 10.1016/j.jpeds.2004.02.048; Miccoli R, 1997, J LIPID RES, V38, P1242; Miettinen HE, 1998, ARTERIOSCL THROM VAS, V18, P591, DOI 10.1161/01.ATV.18.4.591; Moss CX, 2005, EUR J IMMUNOL, V35, P3442, DOI 10.1002/eji.200535320; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Pagano RE, 2003, PHILOS T R SOC B, V358, P885, DOI 10.1098/rstb.2003.1275; Pocovi M, 1998, LANCET, V351, P1919, DOI 10.1016/S0140-6736(97)09490-7; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; Qin SC, 2000, J LIPID RES, V41, P269; REDECKER B, 1991, DNA CELL BIOL, V10, P423, DOI 10.1089/dna.1991.10.423; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Riemenschneider M, 2006, HUM MUTAT, V27, P532, DOI 10.1002/humu.20326; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Sandhoff K, 2003, PHILOS T R SOC B, V358, P847, DOI 10.1098/rstb.2003.1265; Sebzda T, 2005, J EXP THER ONCOL, V5, P145; Sheikh MS, 1996, J STEROID BIOCHEM, V57, P283, DOI 10.1016/0960-0760(95)00267-7; Siintola E, 2006, BRAIN, V129, P1438, DOI 10.1093/brain/awl107; Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232-JLR200; Tsukamoto T, 2006, CANCER-AM CANCER SOC, V106, P1489, DOI 10.1002/cncr.21764; Vruchte DT, 2004, J BIOL CHEM, V279, P26167, DOI 10.1074/jbc.M311591200; Wille A, 2004, BIOL CHEM, V385, P665, DOI 10.1515/BC.2004.082; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883	71	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39971	39981		10.1074/jbc.M605095200	http://dx.doi.org/10.1074/jbc.M605095200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17032648	hybrid			2022-12-25	WOS:000243033900025
J	Salinas, GD; Blair, LAC; Needleman, LA; Gonzales, JD; Chen, Y; Li, M; Singer, JD; Marshall, J				Salinas, Gregory D.; Blair, Leslie A. C.; Needleman, Leigh A.; Gonzales, Justina D.; Chen, Ying; Li, Min; Singer, Jeffrey D.; Marshall, John			Actinfilin is a Cul3 substrate adaptor, linking GluR6 kainate receptor subunits to the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSSY FIBER SYNAPSES; CUL3-BASED E3 LIGASE; PROTEIN-DEGRADATION; HIPPOCAMPAL-NEURONS; BETA(2)-ADRENERGIC RECEPTOR; METABOTROPIC REGULATION; DIFFERENTIAL REGULATION; POSTSYNAPTIC DENSITY; SYNAPTIC ACTIVATION; SURFACE EXPRESSION	Kainate receptors have been implicated in excitotoxic neuronal death induced by diseases such as epilepsy and stroke. Actinfilin, a synaptic member of the BTB-Kelch protein family, is known to bind to the actin cytoskeleton. However, little is understood about its function at the synapse. Here, we report that actinfilin is able to bind to GluR6, a kainate-type glutamate receptor subunit, and target GluR6 for degradation. Like many members of its protein family, actinfilin acts as a substrate adaptor, binding Cullin 3 (Cul3) and linking GluR6 to the E3 ubiquitin-ligase complex. We map this interaction to the Kelch repeat domain of actinfilin and the GluR6 C terminus. Co-immunoprecipitation and immunofluorescence studies show that GluR6 is ubiquitinated, and that GluR6 levels are decreased by actinfilin overexpression but increased when actinfilin levels are reduced by specific RNA interference. Furthermore, actinfilin-Cul3 interactions appear to be important for regulating surface GluR6 expression. Synaptic GluR6 levels are elevated in mice with lowered neuronal Cul3 expression and when dominant-negative forms of Cul3 are transfected into hippocampal neurons. Together our data demonstrate that actinfilin acts as a scaffold, linking GluR6 to the Cul3 ubiquitin ligase to provide a novel mechanism for kainate receptor degradation.	Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA; Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Johns Hopkins Univ Hosp, Dept Neurosci, Sch Med, Baltimore, MD 21205 USA	Brown University; Brown University; Johns Hopkins University; Johns Hopkins Medicine	Marshall, J (corresponding author), Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.	John_Marshall@brown.edu		McEvoy, Justina/0000-0003-0382-1288	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039309, R01NS039063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM070959] Funding Source: Medline; NINDS NIH HHS [R01 NS39063, R01 NS39309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allison DW, 1998, J NEUROSCI, V18, P2423; Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Belanger C, 2001, FEBS LETT, V499, P59, DOI 10.1016/S0014-5793(01)02513-3; Bingol B, 2006, NATURE, V441, P1144, DOI 10.1038/nature04769; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chen Y, 2005, NEUROPHARMACOLOGY, V49, P1026, DOI 10.1016/j.neuropharm.2005.05.022; Chen Y, 2002, J BIOL CHEM, V277, P30495, DOI 10.1074/jbc.M202076200; Christensen JK, 2004, J NEUROSCI, V24, P8986, DOI 10.1523/JNEUROSCI.2156-04.2004; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Contractor A, 2001, NEURON, V29, P209, DOI 10.1016/S0896-6273(01)00191-X; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Fisahn A, 2005, J PHYSIOL-LONDON, V562, P199, DOI 10.1113/jphysiol.2004.077412; Fisahn A, 2004, J NEUROSCI, V24, P9658, DOI 10.1523/JNEUROSCI.2973-04.2004; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Hara T, 2004, MOL BIOL CELL, V15, P1172, DOI 10.1091/mbc.E03-07-0531; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Hirbec H, 2003, NEURON, V37, P625, DOI 10.1016/S0896-6273(02)01191-1; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Jaskolski F, 2004, J NEUROSCI, V24, P2506, DOI 10.1523/JNEUROSCI.5116-03.2004; Jiang S, 2005, J NEUROCHEM, V92, P1191, DOI 10.1111/j.1471-4159.2004.02946.x; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kato A, 2005, P NATL ACAD SCI USA, V102, P5600, DOI 10.1073/pnas.0501769102; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Lerma J, 2006, CURR OPIN PHARMACOL, V6, P89, DOI 10.1016/j.coph.2005.08.004; Liu XM, 2006, J BIOL CHEM, V281, P17432, DOI 10.1074/jbc.M513490200; Martin S, 2004, EMBO J, V23, P4749, DOI 10.1038/sj.emboj.7600483; McMahon M, 2006, J BIOL CHEM, V281, P24756, DOI 10.1074/jbc.M601119200; Mehta S, 2001, J BIOL CHEM, V276, P16092, DOI 10.1074/jbc.M100643200; Melyan Z, 2004, J NEUROSCI, V24, P4530, DOI 10.1523/JNEUROSCI.5356-03.2004; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; Nasu-Nishimura Y, 2006, J NEUROSCI, V26, P7014, DOI 10.1523/JNEUROSCI.0573-06.2006; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Pinheiro P, 2006, CELL TISSUE RES, V326, P457, DOI 10.1007/s00441-006-0265-6; Pintard L, 2004, EMBO J, V23, P1681, DOI 10.1038/sj.emboj.7600186; Piserchio A, 2004, CHEM BIOL, V11, P469, DOI 10.1016/j.chembiol.2004.03.013; Ren Z, 2003, J BIOL CHEM, V278, P52700, DOI 10.1074/jbc.M309585200; Ren Z, 2003, J NEUROSCI, V23, P6608; Ruiz A, 2005, J NEUROSCI, V25, P11710, DOI 10.1523/JNEUROSCI.4041-05.2005; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Schaefer H, 2006, MOL BIOL CELL, V17, P1250, DOI 10.1091/mbc.E05-08-0794; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Ten Brinke A, 2002, BIOCHEM J, V361, P663, DOI 10.1042/0264-6021:3610663; van den Heuvel S, 2004, CURR BIOL, V14, pR59, DOI 10.1016/j.cub.2003.12.044; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wang W, 2005, CURR BIOL, V15, P2050, DOI 10.1016/j.cub.2005.10.052; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yan S, 2004, J NEUROSCI, V24, P679, DOI 10.1523/JNEUROSCI.4985-03.2004; Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200	59	58	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40164	40173		10.1074/jbc.M608194200	http://dx.doi.org/10.1074/jbc.M608194200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17062563	hybrid			2022-12-25	WOS:000243033900046
J	Teusink, B; Wiersma, A; Molenaar, D; Francke, C; de Vos, WM; Siezen, RJ; Smid, EJ				Teusink, Bas; Wiersma, Anne; Molenaar, Douwe; Francke, Christof; de Vos, Willem M.; Siezen, Roland J.; Smid, Eddy J.			Analysis of growth of Lactobacillus plantarum WCFS1 on a complex medium using a genome-scale metabolic model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOCOCCUS-LACTIS; ADAPTIVE EVOLUTION; NETWORK; BALANCE; ENERGY; QUANTIFICATION; PREDICTIONS; ENERGETICS; MEMBRANE; PATHWAYS	A genome-scale metabolic model of the lactic acid bacterium Lactobacillus plantarum WCFS1 was constructed based on genomic content and experimental data. The complete model includes 721 genes, 643 reactions, and 531 metabolites. Different stoichiometric modeling techniques were used for interpretation of complex fermentation data, as L. plantarum is adapted to nutrient-rich environments and only grows in media supplemented with vitamins and amino acids. (i) Based on experimental input and output fluxes, maximal ATP production was estimated and related to growth rate. (ii) Optimization of ATP production further identified amino acid catabolic pathways that were not previously associated with free-energy metabolism. (iii) Genome-scale elementary flux mode analysis identified 28 potential futile cycles. (iv) Flux variability analysis supplemented the elementary mode analysis in identifying parallel pathways, e. g. pathways with identical end products but different co-factor usage. Strongly increased flexibility in the metabolic network was observed when strict coupling between catabolic ATP production and anabolic consumption was relaxed. These results illustrate how a genome-scale metabolic model and associated constraint-based modeling techniques can be used to analyze the physiology of growth on a complex medium rather than a minimal salts medium. However, optimization of biomass formation using the Flux Balance Analysis approach, reported to successfully predict growth rate and by product formation in Escherichia coli and Saccharomyces cerevisiae, predicted too high biomass yields that were incompatible with the observed lactate production. The reason is that this approach assumes optimal efficiency of substrate to biomass conversion, and can therefore not predict the metabolically inefficient lactate formation.	Wageningen Ctr Food Sci, NL-6700 AN Wageningen, Netherlands; NIZO Food Res, NL-6710 BA Ede, Netherlands; Radboud Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6710 BA Nijmegen, Netherlands	Wageningen University & Research; NIZO Food Research; Radboud University Nijmegen	Teusink, B (corresponding author), POB 20, NL-6710 BA Ede, Netherlands.	Bas.Teusink@nizo.nl	Siezen, Roland J/P-5745-2015; Molenaar, Douwe/D-2017-2010; Francke, Christof/C-3915-2013; Francke, C/AAW-2402-2021	Molenaar, Douwe/0000-0001-7108-4545; Teusink, Bas/0000-0003-3929-0423				Beard DA, 2002, BIOPHYS J, V83, P79, DOI 10.1016/S0006-3495(02)75150-3; Bertsekas D.P., 1998, NETWORK OPTIMIZATION; Burgard AP, 2004, GENOME RES, V14, P301, DOI 10.1101/gr.1926504; Christiansen T, 2002, METAB ENG, V4, P159, DOI 10.1006/mben.2001.0219; COOK GM, 1994, APPL ENVIRON MICROB, V60, P1942, DOI 10.1128/AEM.60.6.1942-1948.1994; Dandekar T, 2003, BIOSYSTEMS, V70, P255, DOI 10.1016/S0303-2647(03)00067-4; Dauner M, 2001, J BACTERIOL, V183, P7308, DOI 10.1128/JB.183.24.7308-7317.2001; Dekel E, 2005, NATURE, V436, P588, DOI 10.1038/nature03842; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Famili I, 2003, P NATL ACAD SCI USA, V100, P13134, DOI 10.1073/pnas.2235812100; Fell D., 1997, UNDERSTANDING CONTRO; Fischer E, 2005, NAT GENET, V37, P636, DOI 10.1038/ng1555; Fong SS, 2004, NAT GENET, V36, P1056, DOI 10.1038/ng1432; Fong SS, 2003, J BACTERIOL, V185, P6400, DOI 10.1128/JB.185.21.6400-6408.2003; Francke C, 2005, TRENDS MICROBIOL, V13, P550, DOI 10.1016/j.tim.2005.09.001; Fuhrer T, 2005, J BACTERIOL, V187, P1581, DOI 10.1128/JB.187.5.1581-1590.2005; Hofmeyr JHS, 1995, J BIOENERG BIOMEMBR, V27, P479, DOI 10.1007/BF02110188; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Kerr B, 2002, NATURE, V418, P171, DOI 10.1038/nature00823; Kharchenko P, 2004, BIOINFORMATICS, V20, P178, DOI 10.1093/bioinformatics/bth930; Klapa MI, 2003, EUR J BIOCHEM, V270, P3525, DOI 10.1046/j.1432-1033.2003.03732.x; Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100; Konings WN, 2002, ANTON LEEUW INT J G, V82, P3, DOI 10.1023/A:1020604203977; Kuepfer L, 2005, GENOME RES, V15, P1421, DOI 10.1101/gr.3992505; Mahadevan R, 2003, METAB ENG, V5, P264, DOI 10.1016/j.ymben.2003.09.002; Melchiorsen CR, 2001, BIOTECHNOL BIOENG, V74, P271, DOI 10.1002/bit.1117; Neves AR, 2005, FEMS MICROBIOL REV, V29, P531, DOI 10.1016/j.femsre.2005.04.005; NIELSEN J, 1992, CHEM ENG SCI, V47, P4225, DOI 10.1016/0009-2509(92)85104-J; Novak L, 2000, J BACTERIOL, V182, P1136, DOI 10.1128/JB.182.4.1136-1143.2000; Oliveira AP, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-39; Patil KR, 2005, P NATL ACAD SCI USA, V102, P2685, DOI 10.1073/pnas.0406811102; Patil KR, 2004, CURR OPIN BIOTECH, V15, P64, DOI 10.1016/j.copbio.2003.11.003; Pfeiffer T, 1999, BIOINFORMATICS, V15, P251, DOI 10.1093/bioinformatics/15.3.251; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Pfeiffer T, 2005, TRENDS BIOCHEM SCI, V30, P20, DOI 10.1016/j.tibs.2004.11.006; Price ND, 2004, NAT REV MICROBIOL, V2, P886, DOI 10.1038/nrmicro1023; Reed JL, 2006, NAT REV GENET, V7, P130, DOI 10.1038/nrg1769; RUSSELL JB, 1995, MICROBIOL REV, V59, P48, DOI 10.1128/MMBR.59.1.48-62.1995; Schuster S, 2000, NAT BIOTECHNOL, V18, P326, DOI 10.1038/73786; Schuster S, 2002, BIOINFORMATICS, V18, P351, DOI 10.1093/bioinformatics/18.2.351; Smit G, 2005, FEMS MICROBIOL REV, V29, P591, DOI 10.1016/j.femsre.2005.04.002; STARRENBURG MJC, 1991, APPL ENVIRON MICROB, V57, P3535, DOI 10.1128/AEM.57.12.3535-3540.1991; TEMPEST DW, 1992, FEMS MICROBIOL LETT, V100, P169, DOI 10.1016/0378-1097(92)90205-3; TEMPEST DW, 1984, ANNU REV MICROBIOL, V38, P459, DOI 10.1146/annurev.mi.38.100184.002331; Teusink B, 2005, APPL ENVIRON MICROB, V71, P7253, DOI 10.1128/AEM.71.11.7253-7262.2005; Teusink B, 2006, NAT REV MICROBIOL, V4, P46, DOI 10.1038/nrmicro1319; VANDIJKEN JP, 1993, ANTON LEEUW INT J G, V63, P343, DOI 10.1007/BF00871229; VARMA A, 1994, APPL ENVIRON MICROB, V60, P3724, DOI 10.1128/AEM.60.10.3724-3731.1994; WESTERHOFT HV, 1987, THERMODYNAMICS CONTR; Wiechert W, 2001, METAB ENG, V3, P195, DOI 10.1006/mben.2001.0187	51	211	218	1	57	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40041	40048		10.1074/jbc.M606263200	http://dx.doi.org/10.1074/jbc.M606263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17062565	Green Published, hybrid			2022-12-25	WOS:000243033900033
J	van der Woning, SP; van Rotterdam, W; Nabuurs, SB; Venselaar, H; Jacobs-Oomen, S; Wingens, M; Vriend, G; Stortelers, C; van Zoelen, EJJ				van der Woning, Sebastian P.; van Rotterdam, Walter; Nabuurs, Sander B.; Venselaar, Hanka; Jacobs-Oomen, Saskia; Wingens, Miriam; Vriend, Gert; Stortelers, Catelijne; van Zoelen, Everardus J. J.			Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; EGF-RECEPTOR; CRYSTAL-STRUCTURE; ERBB-2/ERBB-3 HETERODIMERS; EXTRACELLULAR DOMAIN; TYROSINE KINASE; WILD-TYPE; CANCER; AFFINITY; BINDING	Epidermal growth factor (EGF)-like growth factors bind their ErbB receptors in a highly selective manner, but the molecular basis for this specificity is poorly understood. We have previously shown that certain residues in human EGF (Ser(2)-Asp(3)) and TGF alpha (Glu(26)) are not essential for their binding to ErbB1 but prevent binding to ErbB3 and ErbB4. In the present study, we have used a phage display approach to affinity-optimize the C-terminal linear region of EGF-like growth factors for binding to each ErbB receptor and thereby shown that Arg(45) in EGF impairs binding to both ErbB3 and ErbB4. By omitting all these so-called negative constraints from EGF, we designed a ligand designated panerbin that binds ErbB1, ErbB3, and ErbB4 with similarly high affinity as their wild-type ligands. Homology models, based on the known crystal structure of TGF alpha-bound ErbB1, showed that panerbin is able to bind ErbB1, ErbB3, and ErbB4 in a highly similar manner with respect to position and number of interaction sites. Upon in silico introduction of the experimentally known negative constraints into panerbin, we found that Arg45 induced local charge repulsion and Glu26 induced steric hindrance in a receptor-specific manner, whereas Ser2-Asp3 impaired binding due to a disordered conformation. Furthermore, radiolabeled panerbin was used to quantify the level of all three receptors on human breast cancer cells in a single radioreceptor assay. It is concluded that the ErbB specificity of EGF-like growth factors primarily results from the presence of a limited number of residues that impair the unintended interaction with other ErbB receptors.	Radboud Univ Nijmegen, Dept Cell Biol, Fac Sci, NL-6525 ED Nijmegen, Netherlands; Radboud Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	van der Woning, SP (corresponding author), Radboud Univ Nijmegen, Dept Cell Biol, Fac Sci, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	b.vanderwoning@science.ru.nl	van Zoelen, Everardus J./D-9192-2012; Vriend, Gert/D-6730-2011; Vriend, G./H-8112-2014; Venselaar, Hanka/D-2009-2016	Venselaar, Hanka/0000-0001-9824-6559				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; Bieche I, 2003, INT J CANCER, V106, P758, DOI 10.1002/ijc.11273; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Grazul-Bilska AT, 2003, DRUG TODAY, V39, P787, DOI 10.1358/dot.2003.39.10.799472; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hobbs SS, 2005, GROWTH FACTORS, V23, P273, DOI 10.1080/08977190500199345; Hobbs SS, 2004, ONCOGENE, V23, P883, DOI 10.1038/sj.onc.1207250; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jorissen RN, 2000, PROTEIN SCI, V9, P310; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; KIENHUIS CBM, 1991, CLIN CHEM, V37, P1749; Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; Luo C, 2005, PROTEINS, V59, P742, DOI 10.1002/prot.20443; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Reich A, 2002, EMBO J, V21, P4287, DOI 10.1093/emboj/cdf439; Reissmann PT, 1999, J CANCER RES CLIN, V125, P61, DOI 10.1007/s004320050243; Shyu WC, 2004, NEUROBIOL AGING, V25, P935, DOI 10.1016/j.neurobiolaging.2003.10.012; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stein RA, 2000, J MOL EVOL, V50, P397, DOI 10.1007/s002390010043; Stortelers C, 2003, J BIOL CHEM, V278, P12055, DOI 10.1074/jbc.M211948200; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P8732, DOI 10.1021/bi025878c; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P4292, DOI 10.1021/bi012016n; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wingens M, 2006, BIOCHEMISTRY-US, V45, P4703, DOI 10.1021/bi060087m; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	32	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40033	40040		10.1074/jbc.M603168200	http://dx.doi.org/10.1074/jbc.M603168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17032651	hybrid			2022-12-25	WOS:000243033900032
J	Ellis, J; Pediani, JD; Canals, M; Milasta, S; Milligan, G				Ellis, James; Pediani, John D.; Canals, Meritxell; Milasta, Sandra; Milligan, Graeme			Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ACTIVATION; HYPOCRETINS OREXINS; PROTEIN; ANTAGONIST; BINDING; SLEEP; MAS; HOMODIMERIZATION; OLIGOMERIZATION; NEUROPEPTIDES	Following inducible expression in HEK293 cells, the human orexin-1 receptor was targeted to the cell surface but became internalized following exposure to the peptide agonist orexin A. By contrast, constitutive expression of the human cannabinoid CB1 receptor resulted in a predominantly punctate, intracellular distribution pattern consistent with spontaneous, agonist-independent internalization. Expression of the orexin-1 receptor in the presence of the CB1 receptor resulted in both receptors displaying the spontaneous internalization phenotype. Single cell fluorescence resonance energy transfer imaging indicated the two receptors were present as heterodimers/oligomers in intracellular vesicles. Addition of the CB1 receptor antagonist SR-141716A to cells expressing only the CB1 receptor resulted in re-localization of the receptor to the cell surface. Although SR-141716A has no significant affinity for the orexin-1 receptor, in cells co-expressing the CB1 receptor, the orexin-1 receptor was also re-localized to the cell surface by treatment with SR-141716A. Treatment of cells co-expressing the orexin-1 and CB1 receptors with the orexin-1 receptor antagonist SB-674042 also resulted in re-localization of both receptors to the cell surface. Treatment with SR-141716A resulted in decreased potency of orexin A to activate the mitogen-activated protein kinases ERK1/2 only in cells co-expressing the two receptors. Treatment with SB-674042 also reduced the potency of a CB1 receptor agonist to phosphorylate ERK1/2 only when the two receptors were co-expressed. These studies introduce an entirely novel pharmacological paradigm, whereby ligands modulate the function of receptors for which they have no significant inherent affinity by acting as regulators of receptor heterodimers.	Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Pediani, John/F-2708-2019; Milligan, Graeme/F-9426-2011	Pediani, John/0000-0001-6615-537X; Milligan, Graeme/0000-0002-6946-3519; Canals, Meritxell/0000-0002-7942-5006	Medical Research Council [G9811527] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9811527] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Armstrong D, 2001, J BIOL CHEM, V276, P22621, DOI 10.1074/jbc.M006936200; Backberg M, 2002, EUR J NEUROSCI, V15, P315, DOI 10.1046/j.0953-816x.2001.01859.x; Baumann CR, 2005, LANCET NEUROL, V4, P673, DOI 10.1016/S1474-4422(05)70196-4; Black Shawn C, 2004, Curr Opin Investig Drugs, V5, P389; Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102; Boyd ST, 2005, ANN PHARMACOTHER, V39, P684, DOI 10.1345/aph.1E499; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Canals M, 2006, J BIOL CHEM, V281, P16757, DOI 10.1074/jbc.M601121200; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; Ciruela F, 2006, J NEUROSCI, V26, P2080, DOI 10.1523/JNEUROSCI.3574-05.2006; De Vries TJ, 2005, TRENDS PHARMACOL SCI, V26, P420, DOI 10.1016/j.tips.2005.06.002; El-Asmar L, 2005, MOL PHARMACOL, V67, P460, DOI 10.1124/mol.104.003624; Fernandez Jose R, 2004, Curr Opin Investig Drugs, V5, P430; Franco R, 2005, TRENDS BIOCHEM SCI, V30, P360, DOI 10.1016/j.tibs.2005.05.010; Fuxe K, 2005, J MOL NEUROSCI, V26, P209, DOI 10.1385/JMN:26:2-3:209; Hakak Y, 2003, FEBS LETT, V550, P11, DOI 10.1016/S0014-5793(03)00762-2; Harris GC, 2005, NATURE, V437, P556, DOI 10.1038/nature04071; Hervieu GJ, 2001, NEUROSCIENCE, V103, P777, DOI 10.1016/S0306-4522(01)00033-1; Hilairet S, 2003, J BIOL CHEM, V278, P23731, DOI 10.1074/jbc.M212369200; Ishii Y, 2005, BEHAV BRAIN RES, V157, P331, DOI 10.1016/j.bbr.2004.07.012; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kearn CS, 2005, MOL PHARMACOL, V67, P1697, DOI 10.1124/mol.104.006882; Kirkham Tim C, 2004, Treat Endocrinol, V3, P345, DOI 10.2165/00024677-200403060-00003; Kostenis E, 2005, CIRCULATION, V111, P1806, DOI 10.1161/01.CIR.0000160867.23556.7D; Lange JHM, 2004, CURR OPIN DRUG DISC, V7, P498; Langmead CJ, 2004, BRIT J PHARMACOL, V141, P340, DOI 10.1038/sj.bjp.0705610; Le Foll B, 2005, J PHARMACOL EXP THER, V312, P875, DOI 10.1124/jpet.104.077974; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; Leterrier C, 2006, J NEUROSCI, V26, P3141, DOI 10.1523/JNEUROSCI.5437-05.2006; Leterrier C, 2004, J BIOL CHEM, V279, P36013, DOI 10.1074/jbc.M403990200; Mackie K, 2005, HANDB EXP PHARMACOL, V168, P299; Mackie K, 2005, LIFE SCI, V77, P1667, DOI 10.1016/j.lfs.2005.05.011; MACKIE K, 2006, ANN REV PHARM TOXICO, V6, P101; Meyer BH, 2006, P NATL ACAD SCI USA, V103, P2138, DOI 10.1073/pnas.0507686103; Mieda M, 2004, P NATL ACAD SCI USA, V101, P4649, DOI 10.1073/pnas.0400590101; Mieda M, 2002, CURR OPIN NEUROBIOL, V12, P339, DOI 10.1016/S0959-4388(02)00331-8; Milasta S, 2006, MOL PHARMACOL, V69, P479, DOI 10.1124/mol.105.018788; Milasta S, 2005, BIOCHEM J, V387, P573, DOI 10.1042/BJ20041745; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; Milligan G, 2003, LIFE SCI, V74, P181, DOI 10.1016/j.lfs.2003.09.005; Milligan G, 2006, DRUG DISCOV TODAY, V11, P541, DOI 10.1016/j.drudis.2006.04.007; Park PSH, 2002, BIOCHEMISTRY-US, V41, P5588, DOI 10.1021/bi011746s; Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742-4658.2005.04728.x; Pin JP, 2004, BIOCHEM PHARMACOL, V68, P1565, DOI 10.1016/j.bcp.2004.06.035; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V287, P1038; Rodgers RJ, 2002, NEUROPEPTIDES, V36, P303, DOI 10.1016/S0143-4179(02)00085-9; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Smart D, 2002, EUR J PHARMACOL, V440, P199, DOI 10.1016/S0014-2999(02)01429-2; So CH, 2005, MOL PHARMACOL, V68, P568, DOI 10.1124/mol.105.012229; Springael JY, 2006, MOL PHARMACOL, V69, P1652, DOI 10.1124/mol.105.019414; Strange PG, 2005, J MOL NEUROSCI, V26, P155, DOI 10.1385/JMN:26:2-3:155; Taheri S, 2002, ANNU REV NEUROSCI, V25, P283, DOI 10.1146/annurev.neuro.25.112701.142826; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Wilson S, 2005, J BIOL CHEM, V280, P28663, DOI 10.1074/jbc.M413475200; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	59	172	183	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38812	38824		10.1074/jbc.M602494200	http://dx.doi.org/10.1074/jbc.M602494200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17015451	hybrid, Green Accepted			2022-12-25	WOS:000242709500079
J	Sato, K; Yang, XL; Yudate, T; Chung, JS; Wu, JM; Luby-Phelps, K; Kimberly, RP; Underhill, D; Cruz, PD; Ariizumi, K				Sato, Kota; Yang, Xiao-li; Yudate, Tatsuo; Chung, Jin-Sung; Wu, Jianming; Luby-Phelps, Kate; Kimberly, Robert P.; Underhill, David; Cruz, Ponciano D., Jr.; Ariizumi, Kiyoshi			Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor gamma chain to induce innate immune responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; TOLL-LIKE RECEPTORS; BETA-GLUCAN RECEPTOR; CANDIDA-ALBICANS; DC-SIGN; CELL-WALL; MOLECULAR-CLONING; DENDRITIC CELLS; IN-VIVO; IDENTIFICATION	Antigen presenting cells recognize pathogens via pattern recognition receptors (PRR), which upon ligation transduce intracellular signals that can induce innate immune responses. Because some C-type lectin-like receptors (e.g. dectin-1 and DC-SIGN) were shown to act as PRR for particular microbes, we considered a similar role for dectin-2. Binding assays using soluble dectin-2 receptors showed the extracellular domain to bind preferentially to hyphal (rather than yeast/conidial) components of Candida albicans, Microsporum audouinii, and Trichophyton rubrum. Selective binding for hyphae was also observed using RAW macrophages expressing dectin-2, the ligation of which by hyphae or cross-linking with dectin-2-specific antibody led to protein tyrosine phosphorylation. Because dectin-2 lacks an intracellular signaling motif, we searched for a signal adaptor that permits it to transduce intracellular signals. First, we found that the Fc receptor gamma(FcR gamma) chain can bind to dectin-2. Second, ligation of dectin-2 on RAW cells induced tyrosine phosphorylation of FcR gamma, activation of NF-kappa B, internalization of a surrogate ligand, and up-regulated secretion of tumor necrosis factor alpha and interleukin-1 receptor antagonist. Finally, these dectin-2-induced events were blocked by PP2, an inhibitor of Src kinases that are mediators for FcR9 gamma chain-dependent signaling. We conclude that dectin-2 is a PRR for fungi that employs signaling through FcR gamma to induce innate immune responses.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75390 USA; Dallas Vet Affairs Med Ctr, Med Serv, Dermatol Sect, Dallas, TX 75390 USA; Inst Syst Biol, Seattle, WA 98103 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Institute for Systems Biology (ISB); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Alabama System; University of Alabama Birmingham	Ariizumi, K (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Kiyoshi.Ariizumi@UTSouthwestern.edu	Sato, Kota/G-1129-2012; UNDERHILL, DAVID/ABE-2185-2021	Luby-Phelps, Katherine/0000-0002-8378-1409; Underhill, David/0000-0002-2989-658X; Kimberly, Robert/0000-0002-5330-3086				Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; ARIIZUMI K, 1995, J IMMUNOL, V154, P6031; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Bates EEM, 1999, J IMMUNOL, V163, P1973; Bernard M, 2001, MED MYCOL, V39, P9, DOI 10.1080/mmy.39.1.9.17; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; CASANOVA M, 1989, INFECT IMMUN, V57, P262, DOI 10.1128/IAI.57.1.262-271.1989; Cervera AM, 1998, MOL MICROBIOL, V30, P67, DOI 10.1046/j.1365-2958.1998.01039.x; Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Colmenares M, 2004, J IMMUNOL, V172, P1186, DOI 10.4049/jimmunol.172.2.1186; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Douglas CM, 2001, MED MYCOL, V39, P55, DOI 10.1080/mmy.39.1.55.66; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Fontaine T, 1997, BIOCHEM SOC T, V25, P194, DOI 10.1042/bst0250194; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gough PJ, 2000, MICROBES INFECT, V2, P305, DOI 10.1016/S1286-4579(00)00297-5; Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105-2896.2005.00325.x; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Kanazawa N, 2003, J BIOL CHEM, V278, P32645, DOI 10.1074/jbc.M304226200; LI RK, 1993, J BIOL CHEM, V268, P18293; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; McGreal EP, 2006, GLYCOBIOLOGY, V16, P422, DOI 10.1093/glycob/cwj077; Palmowski MJ, 2004, J IMMUNOL, V172, P1582, DOI 10.4049/jimmunol.172.3.1582; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Taylor PR, 2005, EUR J IMMUNOL, V35, P2163, DOI 10.1002/eji.200425785; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Trinel PA, 2002, J BIOL CHEM, V277, P37260, DOI 10.1074/jbc.M202295200; Trinel PA, 2002, INFECT IMMUN, V70, P5274, DOI 10.1128/IAI.70.9.5274-5278.2002; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Underhill DM, 2003, EUR J IMMUNOL, V33, P1767, DOI 10.1002/eji.200324037; VanKooten C, 1996, ADV IMMUNOL, V61, P1; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; XU S, 1995, J IMMUNOL, V154, P2697; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	50	325	344	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38854	38866		10.1074/jbc.M606542200	http://dx.doi.org/10.1074/jbc.M606542200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050534	hybrid			2022-12-25	WOS:000242709500083
J	Xu, JS; Tian, J; Grumelli, SM; Haley, KJ; Shapiro, SD				Xu, Jingsong; Tian, Jun; Grumelli, Sandra M.; Haley, Kathleen J.; Shapiro, Steven D.			Stage-specific effects of cAMP signaling during distal lung epithelial development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY-CELL CULTURE; MOUSE LUNG; BRANCHING MORPHOGENESIS; DEFICIENT MICE; FETAL LUNG; DIFFERENTIATION; GROWTH; EXPRESSION; PROLIFERATION; ALVEOGENESIS	cAMP signaling is postulated to play a role in distal lung epithelial differentiation based on several observations. First, it enhances fibroblast growth factor-induced transdifferentiation of early tracheal epithelium into respiratory epithelium. Second, there are cAMP-responsive elements in the heterologous promoters of Sftpb and Sftpa genes. Third, cAMP augments the effect of dexamethasone in maintaining differentiation of human fetal type II pneumocyte culture. However, this concept has not been thoroughly tested in vivo. In the current study, we modulated cAMP signaling in developing distal lung epithelium in vivo using an inducible transgenic system that expressed a mutant form of G alpha(s) (G alpha(s)Q227L). We failed to demonstrate the ability of cAMP to promote distal epithelial maturation during embryonic stages. The results argue against its physiological role in this process. In addition, induction of cAMP signaling at the late pseudoglandular stage but not during the canalicular or saccular stage surprisingly delayed distal differentiation by suppressing the expression of Sftpc, Sftpa, and Aquaporin5 as well as the formation of lamellar bodies. This stage-specific inhibitory effect was observed in the absence of cellular toxicity or changes in branching. Transgenic lungs did not show significant changes in the known pathways that are important for distal differentiation. Therefore, we propose the existence of yet-to-be identified cAMP-sensitive novel regulators of early distal lung epithelial differentiation. Although the delay of differentiation seemed to be reversible at later stages, it still led to pronounced permanent postnatal airspace enlargement due to impaired paracrine function of distal epithelium in regulating alveolar myofibroblast development.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Xu, JS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	jxu@rics.bwh.harvard.edu	Grumelli, Sandra/Z-3263-2019		NHLBI NIH HHS [P01 HL 29594, R01 HL 54853] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL054853] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alcorn JL, 1997, AM J RESP CELL MOL, V17, P672, DOI 10.1165/ajrcmb.17.6.2858; ALESCIO T, 1972, J EMBRYOL EXP MORPH, V27, P155; Bates SR, 2002, AM J PHYSIOL-LUNG C, V282, pL267, DOI 10.1152/ajplung.00227.2001; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bellusci S, 1997, DEVELOPMENT, V124, P53; Besnard V, 2005, AM J PHYSIOL-LUNG C, V289, pL750, DOI 10.1152/ajplung.00151.2005; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Chuang PT, 2003, TRENDS CELL BIOL, V13, P86, DOI 10.1016/S0962-8924(02)00031-4; Cole TJ, 2004, AM J RESP CELL MOL, V30, P613, DOI 10.1165/rcmb.2003-0236OC; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Grier David G, 2004, Treat Respir Med, V3, P295, DOI 10.2165/00151829-200403050-00004; Hoang T, 2004, J BIOL CHEM, V279, P49120, DOI 10.1074/jbc.M409746200; Houghton AM, 2006, J CLIN INVEST, V116, P753, DOI 10.1172/JCI25617; Jobe AH, 2001, CURR OPIN PEDIATR, V13, P124, DOI 10.1097/00008480-200104000-00006; Jobe AH, 2000, ANNU REV PHYSIOL, V62, P825, DOI 10.1146/annurev.physiol.62.1.825; Lania A, 2001, EUR J ENDOCRINOL, V145, P543, DOI 10.1530/eje.0.1450543; Lebeche D, 1999, MECH DEVELOP, V86, P125, DOI 10.1016/S0925-4773(99)00124-0; Li JX, 1998, J BIOL CHEM, V273, P4592, DOI 10.1074/jbc.273.8.4592; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu YR, 2003, DEV BIOL, V261, P10, DOI 10.1016/S0012-1606(03)00359-2; Liu Yuru, 2002, Gene Expression Patterns, V2, P229, DOI 10.1016/S1567-133X(02)00057-1; MIYAZONO K, 2002, SCI STKE, pPE40; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; Muglia LJ, 1999, AM J RESP CELL MOL, V20, P181, DOI 10.1165/ajrcmb.20.2.3381; Nishiyama M, 2003, NATURE, V423, P990, DOI 10.1038/nature01751; Okubo T, 2005, DEVELOPMENT, V132, P1363, DOI 10.1242/dev.01678; Pearson GW, 2006, MOL CELL BIOL, V26, P3039, DOI 10.1128/MCB.26.8.3039-3047.2006; Porter SE, 2001, AM J PHYSIOL-LUNG C, V280, pL1282, DOI 10.1152/ajplung.2001.280.6.L1282; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; Shannon JM, 1999, DEVELOPMENT, V126, P1675; Shu WG, 2005, DEV BIOL, V283, P226, DOI 10.1016/j.ydbio.2005.04.014; Stahlman MT, 2000, LAB INVEST, V80, P395, DOI 10.1038/labinvest.3780044; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Weaver M, 1999, DEVELOPMENT, V126, P4005; Weinstein M, 1998, DEVELOPMENT, V125, P3615; Xu JS, 2000, DEVELOPMENT, V127, P1833; Xu JS, 2005, AM J RESP CELL MOL, V32, P381, DOI 10.1165/rcmb.2004-0343OC; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Yang HH, 2002, DEVELOPMENT, V129, P2233	46	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38894	38904		10.1074/jbc.M609339200	http://dx.doi.org/10.1074/jbc.M609339200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17018522	hybrid			2022-12-25	WOS:000242709500087
J	Carissimi, C; Saieva, L; Gabanella, F; Pellizzoni, L				Carissimi, Claudia; Saieva, Luciano; Gabanella, Francesca; Pellizzoni, Livio			Gemin8 is required for the architecture and function of the survival motor neuron complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; REPEAT PROTEIN-COMPONENT; BINDS SM PROTEINS; SNRNP PROTEINS; GENE-PRODUCT; RIBONUCLEOPROTEINS; IDENTIFICATION; METHYLOSOME; IMPORT; UNRIP	The biogenesis of spliceosomal small nuclear ribonucleoproteins (snRNPs) in higher eukaryotes requires the functions of several cellular proteins and includes nuclear as well as cytoplasmic phases. In the cytoplasm, a macromolecular complex containing the survival motor neuron (SMN) protein, Gemin2-8 and Unrip mediates the ATP-dependent assembly of Sm proteins and snRNAs into snRNPs. To carry out snRNP assembly, the SMN complex binds directly to both Sm proteins and snRNAs; however, the contribution of the individual components of the SMN complex to its composition, interactions, and function is poorly characterized. Here, we have investigated the functional role of Gemin8 using novel monoclonal antibodies against components of the SMN complex and RNA interference experiments. We show that Gemin6, Gemin7, and Unrip form a stable cytoplasmic complex whose association with SMN requires Gemin8. Gemin8 binds directly to SMN and mediates its interaction with the Gemin6/Gemin7 heterodimer. Importantly, loss of Gemin6, Gemin7, and Unrip interaction with SMN as a result of Gemin8 knockdown affects snRNP assembly by impairing the SMN complex association with Sm proteins but not with snRNAs. These results reveal the essential role of Gemin8 for the proper structural organization of the SMN complex and the involvement of the heteromeric subunit containing Gemin6, Gemin7, Gemin8, and Unrip in the recruitment of Sm proteins to the snRNP assembly pathway.	CNR, Inst Cell Biol, Dulbecco Telethon Inst, I-00016 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Fondazione Telethon; Dulbecco Telethon Institute (DTI)	Pellizzoni, L (corresponding author), CNR, Inst Cell Biol, Dulbecco Telethon Inst, Via E Ramarini 32, I-00016 Rome, Italy.	livio.pellizzoni@ibc.cnr.it	carissimi, claudia/AAU-7414-2021; Gabanella, Francesca/AAY-3290-2020	carissimi, claudia/0000-0002-9885-2855; Pellizzoni, Livio/0000-0002-9168-5628; Gabanella, Francesca/0000-0001-5536-5160	Telethon [TCP02011] Funding Source: Medline	Telethon(Fondazione Telethon)		ATTLE DJ, 2006, MOL CELL, V23, P273; Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Carissimi C, 2006, J BIOL CHEM, V281, P8126, DOI 10.1074/jbc.M512243200; Carissimi C, 2005, FEBS LETT, V579, P2348, DOI 10.1016/j.febslet.2005.03.034; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; De Masi F, 2005, PROTEOMICS, V5, P4070, DOI 10.1002/pmic.200401279; Eggert C, 2006, TRENDS MOL MED, V12, P113, DOI 10.1016/j.molmed.2006.01.005; Feng WQ, 2005, HUM MOL GENET, V14, P1605, DOI 10.1093/hmg/ddi168; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gabanella F, 2005, HUM MOL GENET, V14, P3629, DOI 10.1093/hmg/ddi390; Gonsalvez GB, 2006, CURR BIOL, V16, P1077, DOI 10.1016/j.cub.2006.04.037; Grimmler M, 2005, HUM MOL GENET, V14, P3099, DOI 10.1093/hmg/ddi343; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Ma YL, 2005, STRUCTURE, V13, P883, DOI 10.1016/j.str.2005.03.014; Massenet S, 2002, MOL CELL BIOL, V22, P6533, DOI 10.1128/MCB.22.18.6533-6541.2002; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Mouaikel J, 2003, EMBO REP, V4, P616, DOI 10.1038/sj.embor.embor863; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Narayanan U, 2002, HUM MOL GENET, V11, P1785, DOI 10.1093/hmg/11.15.1785; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Shpargel KB, 2005, P NATL ACAD SCI USA, V102, P17372, DOI 10.1073/pnas.0508947102; Wan LL, 2005, MOL CELL BIOL, V25, P5543, DOI 10.1128/MCB.25.13.5543-5551.2005; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Winkler C, 2005, GENE DEV, V19, P2320, DOI 10.1101/gad.342005; Yong JS, 2004, TRENDS CELL BIOL, V14, P226, DOI 10.1016/j.tcb.2004.03.010; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188	43	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37009	37016		10.1074/jbc.M607505200	http://dx.doi.org/10.1074/jbc.M607505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023415	hybrid			2022-12-25	WOS:000242220800062
J	Gonzalez-Periz, A; Planaguma, A; Gronert, K; Miquel, R; Lopez-Parra, M; Titos, E; Horrillo, R; Ferre, N; Deulofeu, R; Arroyo, V; Rodes, J; Claria, J				Gonzalez-Periz, Ana; Planaguma, Anna; Gronert, Karsten; Miquel, Rosa; Lopez-Parra, Marta; Titos, Esther; Horrillo, Raquel; Ferre, Natalia; Deulofeu, Ramon; Arroyo, Vicente; Rodes, Juan; Claria, Joan			Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA	FASEB JOURNAL			English	Article						inflammation; liver cells; omega-3 essential fatty acids	POLYUNSATURATED FATTY-ACIDS; FISH-OIL; ANTIINFLAMMATORY ACTIONS; HEPATIC STEATOSIS; COX-2 EXPRESSION; CELL APOPTOSIS; MECHANISMS; FIBROSIS; MODEL; OMEGA-3-FATTY-ACIDS	Docosahexaenoic acid (DHA) is a omega-3 essential fatty acid that reduces the incidence and severity of a number of diseases. Recently, a novel series of DHA-derived lipid mediators with potent protective actions has been identified. In this study we demonstrate that dietary amplification of these DHA-derived products protects the liver from necroinflammatory injury. In vitro, supplementation of hepatocytes with DHA significantly reduced hydrogen peroxide-induced DNA damage, evaluated by the "comet assay," and oxidative stress, determined by measurement of malondialdehyde levels. In vivo, dietary supplementation of mice with DHA ameliorated carbon tetrachloride-induced necroinflammatory damage. In addition, hepatic cyclooxygenase-2 expression and PGE(2) levels were significantly reduced in mice fed DHA-enriched diets. In these animals, increased hepatic formation of DHA-derived lipid mediators (i.e., 17S-hydroxy- DHA (17S-HDHA) and protectin D1) was detected by HPLC-gas chromatography/mass spectrometry analysis. Consistent with these findings, synthetic 17-HDHA abrogated genotoxic and oxidative damage in hepatocytes and decreased TNF-alpha release and 5-lipoxygenase expression in macrophages. In a transactivation assay, 17-HDHA acted in a concentration-dependent manner as a PPAR gamma agonist. Taken together, these findings identify a potential role for DHA-derived products, specifically 17S-HDHA and protectin D1, in mediating the protective effects of dietary DHA in necroinflammatory liver injury.-Gonzalez-Periz, A., Planaguma, A., Gronert, K., Miquel, R., Lopez- Parra, M., Titos, E., Horrillo, R., Ferre, N., Deulofeu, R., Arroyo, V., Rodes, J., Claria, J. Docosahexaenoic acid ( DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxyDHA.	Univ Barcelona, Sch Med, Hosp Clin Barcelona,IDIBAPS, Dept Biochem & Mol Genet, E-08036 Barcelona, Spain; Univ Barcelona, Sch Med, Hosp Clin Barcelona,IDIBAPS, Pathol Lab, E-08036 Barcelona, Spain; Univ Barcelona, Sch Med, Hosp Clin Barcelona,IDIBAPS, Liver Unit, E-08036 Barcelona, Spain; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; New York Medical College	Claria, J (corresponding author), Univ Barcelona, Sch Med, Hosp Clin Barcelona,IDIBAPS, Dept Biochem & Mol Genet, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Claria, Joan/M-7772-2019; Titos, Esther/AAA-5394-2019; Arroyo, Vicente/F-9189-2015; Horrillo, Raquel/B-4348-2009; Ferré, Natalia/ABE-5700-2020	Titos, Esther/0000-0002-2543-2243; Arroyo, Vicente/0000-0002-2728-1848; Ferré, Natalia/0000-0002-2838-1525; Claria, Joan/0000-0003-4333-7749	NATIONAL EYE INSTITUTE [R01EY016136] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY016136-03, R01 EY016136, EY016136] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alwayn IPJ, 2005, TRANSPLANTATION, V79, P606, DOI 10.1097/01.TP.0000150023.86487.44; Ariel A, 2005, J BIOL CHEM, V280, P43079, DOI 10.1074/jbc.M509796200; Arita M, 2005, P NATL ACAD SCI USA, V102, P7671, DOI 10.1073/pnas.0409271102; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Aronson AJ, 2001, UROLOGY, V58, P283, DOI 10.1016/S0090-4295(01)01116-5; Bagga D, 2003, P NATL ACAD SCI USA, V100, P1751, DOI 10.1073/pnas.0334211100; BALDIE G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P125, DOI 10.1016/0167-4889(93)90133-A; BILLIAR TR, 1988, SURGERY, V104, P343; Cabre E, 1999, NUTRITION, V15, P322; Cabre E, 1996, NUTRITION, V12, P542, DOI 10.1016/S0899-9007(96)00122-0; Calder PC, 2002, P NUTR SOC, V61, P345, DOI 10.1079/PNS2002166; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Diehl AM, 2000, IMMUNOL REV, V174, P160, DOI 10.1034/j.1600-0528.2002.017411.x; Du CY, 2004, J NUTR BIOCHEM, V15, P273, DOI 10.1016/j.jnutbio.2003.11.005; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Gronert K, 2005, J BIOL CHEM, V280, P15267, DOI 10.1074/jbc.M410638200; Gronert K, 1999, METH MOL B, V120, P119; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Llor X, 2003, CLIN NUTR, V22, P71, DOI 10.1054/clnu.2002.0627; Lotersztajn S, 2005, ANNU REV PHARMACOL, V45, P605, DOI 10.1146/annurev.pharmtox.45.120403.095906; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Miyamoto A, 1997, J GASTROEN HEPATOL, V12, P644, DOI 10.1111/j.1440-1746.1997.tb00528.x; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Nanji AA, 2001, J PHARMACOL EXP THER, V299, P638; Narayanan BA, 2003, CANCER RES, V63, P972; OWEN JS, 1982, J LIPID RES, V23, P124; OWEN JS, 1981, J LIPID RES, V22, P423; Pawlosky RJ, 2004, ALCOHOL CLIN EXP RES, V28, P1569, DOI 10.1097/01.ALC.0000141810.22855.4E; Planaguma A, 2005, FASEB J, V19, P1120, DOI 10.1096/fj.04-2753fje; Rousseau D, 2003, AM J PHYSIOL-HEART C, V285, pH1294, DOI 10.1152/ajpheart.00651.2002; Rousseau D, 2001, MOL CELL BIOCHEM, V225, P109, DOI 10.1023/A:1012266005428; Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Serhan CN, 2004, PROSTAG OTH LIPID M, V73, P155, DOI 10.1016/j.prostaglandins.2004.03.005; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Thomas EL, 1997, HEPATOLOGY, V25, P178, DOI 10.1002/hep.510250133; Titos E, 2005, J LEUKOCYTE BIOL, V78, P871, DOI 10.1189/jlb.1204747; Titos E, 2003, FASEB J, V17, P1745, DOI 10.1096/fj.02-1157fje; Titos E, 2000, GASTROENTEROLOGY, V119, P794, DOI 10.1053/gast.2000.17831; Vecchini A, 2004, J LIPID RES, V45, P308, DOI 10.1194/jlr.M300396-JLR200; Wallace FA, 2000, CYTOKINE, V12, P1374, DOI 10.1006/cyto.2000.0735; Watanabe A, 1999, NUTRITION, V15, P284, DOI 10.1016/S0899-9007(99)00004-0	50	177	189	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2537	+		10.1096/fj.06-6250fje	http://dx.doi.org/10.1096/fj.06-6250fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17056761				2022-12-25	WOS:000242490700015
J	Hakata, Y; Landau, NR				Hakata, Yoshiyuki; Landau, Nathaniel R.			Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 VIF; ANTIRETROVIRAL DEFENSE; ANTIVIRAL ACTIVITY; POTENT INHIBITORS; VIRUS-REPLICATION; IN-VIVO; DNA; PROTEINS; HYPERMUTATION; DEGRADATION	APOBEC3 proteins comprise a multigene family of antiviral cytidine deaminases that are active against human immunodeficiency virus, simian immunodeficiency virus, endogenous retroelements. The Vif protein of lentiviruses binds to specific APOBEC3 proteins, notably A3F and A3G, to induce their degradation by proteasomes. APOBEC3 proteins are of two types, those with a single deaminase domain such as human (h)A3A and hA3C and those with two cytidine deaminase domains (CDD) such as hA3G, hA3F, hA3B and the mouse APOBEC3, mA3. In hA3G, both active sites are required for antiviral function but serve separate functions. CDD2 mediates the C to U deamination of the human immunodeficiency virus type 1 genome, whereas CDD1 binds the viral RNA to allow for virion packaging. Here we analyzed the role of the two domains in additional APOBEC3 family members. We analyzed APOBEC3 proteins in which either the critical glutamic acid residue or the Zn2+ coordination amino acid residues in the active sites were mutated. The separation of function of the domains is maintained in hA3B and hA3F, but in the mouse protein mA3, the roles of the two domains are reversed. Deamination is mediated by CDD1, whereas encapsidation and dimerization are mediated by CDD2. Antiviral function of each of the APOBEC3 proteins was largely attributable to deaminase activity. Deaminase-independent antiviral activity of the active site mutants was minor. These findings suggest that the two active sites have different functions but that these functions can be interchanged in different APOBEC3 family members.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA	Salk Institute	Landau, NR (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Landau@salk.edu			NIAID NIH HHS [AI58864, AI51686] Funding Source: Medline; NIDA NIH HHS [DA14494] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014494] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2006, NUCLEIC ACIDS RES, V34, P89, DOI 10.1093/nar/gkj416; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chen H, 2006, CURR BIOL, V16, P480, DOI 10.1016/j.cub.2006.01.031; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Doehle BP, 2005, VIROLOGY, V339, P281, DOI 10.1016/j.virol.2005.06.005; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Langlois MA, 2005, NUCLEIC ACIDS RES, V33, P1913, DOI 10.1093/nar/gki343; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Lochelt M, 2005, P NATL ACAD SCI USA, V102, P7982, DOI 10.1073/pnas.0501445102; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Russell RA, 2005, J VIROL, V79, P8724, DOI 10.1128/JVI.79.14.8724-8731.2005; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yu Q, 2004, J BIOL CHEM, V279, P53379, DOI 10.1074/jbc.M408802200; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang LM, 2003, Z METALLKD, V94, P98, DOI 10.3139/146.030098; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	32	54	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36624	36631		10.1074/jbc.M604980200	http://dx.doi.org/10.1074/jbc.M604980200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17020885	hybrid			2022-12-25	WOS:000242220800019
J	Ichimura, K; Casais, C; Peck, SC; Shinozaki, K; Shirasu, K				Ichimura, Kazuya; Casais, Catarina; Peck, Scott C.; Shinozaki, Kazuo; Shirasu, Ken			MEKK1 is required for MPK4 activation and regulates tissue-specific and temperature-dependent cell death in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE KINASE KINASE; SYSTEMIC ACQUIRED-RESISTANCE; DISEASE-RESISTANCE; PROTEIN-KINASE; INNATE IMMUNITY; PLANT IMMUNITY; SALICYLIC-ACID; MEDIATED RESISTANCE; DEFENSE RESPONSES; THALIANA	Innate immunity signaling pathways in both animals and plants are regulated by mitogen-activated protein kinase (MAPK) cascades. An Arabidopsis MAPK cascade (MEKK1, MKK4/MKK5, and MPK3/MPK6) has been proposed to function downstream of the flagellin receptor FLS2 based on biochemical assays using transient overexpression of candidate components. To genetically test this model, we characterized two mekk1 mutants. We show here that MEKK1 is not required for flagellin-triggered activation of MPK3 and MPK6. Instead, MEKK1 is essential for activation of MPK4, a MAPK that negatively regulates systemic acquired resistance. We also showed that MEKK1 negatively regulates temperature-sensitive and tissue-specific cell death and H2O2 accumulation that are partly dependent on both RAR1, a key component in resistance protein function, and SID2, an isochorismate synthase required for salicylic acid production upon pathogen infection.	RIKEN, Plant Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	RIKEN; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Shirasu, K (corresponding author), RIKEN, Plant Sci Ctr, Tsurumi Ku, Suehiro Cho 1-7-22, Yokohama, Kanagawa 2300045, Japan.	ken.shirasu@psc.riken.jp	Shinozaki, Kazuo/G-4202-2013; Shirasu, Ken/A-4455-2010; Shirasu, Ken/ABF-5306-2020	Shinozaki, Kazuo/0000-0002-6317-9867; Shirasu, Ken/0000-0002-0349-3870; Shirasu, Ken/0000-0002-0349-3870; Ichimura, Kazuya/0000-0001-6278-6473				Adam L, 1996, PLANT J, V9, P341, DOI 10.1046/j.1365-313X.1996.09030341.x; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Azevedo C, 2006, EMBO J, V25, P2007, DOI 10.1038/sj.emboj.7601084; Bieri S, 2004, PLANT CELL, V16, P3480, DOI 10.1105/tpc.104.026682; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Chisholm ST, 2006, CELL, V124, P803, DOI 10.1016/j.cell.2006.02.008; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DebRoy S, 2004, P NATL ACAD SCI USA, V101, P9927, DOI 10.1073/pnas.0401601101; del Pozo O, 2004, EMBO J, V23, P3072, DOI 10.1038/sj.emboj.7600283; Droillard MJ, 2004, FEBS LETT, V574, P42, DOI 10.1016/j.febslet.2004.08.001; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; Gomez-Gomez L, 2002, TRENDS PLANT SCI, V7, P251, DOI 10.1016/S1360-1385(02)02261-6; Greenberg JT, 2004, CELL MICROBIOL, V6, P201, DOI 10.1111/j.1462-5822.2004.00361.x; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hubert DA, 2003, EMBO J, V22, P5679, DOI 10.1093/emboj/cdg547; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Ichimura K, 2000, PLANT J, V24, P655, DOI 10.1046/j.1365-313x.2000.00913.x; Ichimura K, 1998, BIOCHEM BIOPH RES CO, V253, P532, DOI 10.1006/bbrc.1998.9796; Jin HL, 2002, DEV CELL, V3, P291, DOI 10.1016/S1534-5807(02)00205-8; Jin HL, 2003, PLANT J, V33, P719, DOI 10.1046/j.1365-313X.2003.01664.x; Lam E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Liu YL, 2004, PLANT J, V38, P800, DOI 10.1111/j.1365-313X.2004.02085.x; Menke FLH, 2004, PLANT CELL, V16, P897, DOI 10.1105/tpc.015552; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; Mizoguchi T, 1998, FEBS LETT, V437, P56, DOI 10.1016/S0014-5793(98)01197-1; Nakagami H, 2005, TRENDS PLANT SCI, V10, P339, DOI 10.1016/j.tplants.2005.05.009; Nakagami H, 2004, J BIOL CHEM, V279, P26959, DOI 10.1074/jbc.M312662200; Nawrath C, 1999, PLANT CELL, V11, P1393, DOI 10.1105/tpc.11.8.1393; Noutoshi Y, 2005, PLANT J, V43, P873, DOI 10.1111/j.1365-313X.2005.02500.x; Nurnberger T, 2004, IMMUNOL REV, V198, P249, DOI 10.1111/j.0105-2896.2004.0119.x; Peck SC, 2003, CURR OPIN PLANT BIOL, V6, P334, DOI 10.1016/S1369-5266(03)00056-6; Pedley KF, 2005, CURR OPIN PLANT BIOL, V8, P541, DOI 10.1016/j.pbi.2005.07.006; Petersen M, 2000, CELL, V103, P1111, DOI 10.1016/S0092-8674(00)00213-0; Rosso MG, 2003, PLANT MOL BIOL, V53, P247, DOI 10.1023/B:PLAN.0000009297.37235.4a; Shirasu K, 2003, TRENDS PLANT SCI, V8, P252, DOI 10.1016/S1360-1385(03)00104-3; Shirasu K, 1999, CELL, V99, P355, DOI 10.1016/S0092-8674(00)81522-6; Shirasu K, 2000, PLANT MOL BIOL, V44, P371, DOI 10.1023/A:1026552827716; Takahashi A, 2003, P NATL ACAD SCI USA, V100, P11777, DOI 10.1073/pnas.2033934100; Teige M, 2004, MOL CELL, V15, P141, DOI 10.1016/j.molcel.2004.06.023; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; Tor M, 2002, PLANT CELL, V14, P993, DOI 10.1105/tpc.001123; Tornero P, 2002, PLANT CELL, V14, P1005, DOI 10.1105/tpc.001032; WHITHAM S, 1994, CELL, V78, P1011; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435	51	218	230	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36969	36976		10.1074/jbc.M605319200	http://dx.doi.org/10.1074/jbc.M605319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023433	hybrid			2022-12-25	WOS:000242220800057
J	Takahashi, T; Morrow, JD; Wang, HB; Dey, SK				Takahashi, Toshifumi; Morrow, Jason D.; Wang, Haibin; Dey, Sudhansu K.			Cyclooxygenase-2-derived prostaglandin E-2 directs oocyte maturation by differentially influencing multiple signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEIC-ACID EXPRESSION; FACTOR-STIMULATED GENE-6; MOUSE OVARIAN FOLLICLES; MICE LACKING; EXTRACELLULAR-MATRIX; CUMULUS-OOPHORUS; EMBRYO IMPLANTATION; FEMALE INFERTILITY; IMPAIRED FERTILITY; MEIOTIC MATURATION	The process of oocyte maturation, which impacts ovulation and fertilization, is complex and requires an integration of the endocrine, paracrine, juxtacrine, and autocrine signaling pathways. This process involves an intimate interaction between the oocyte and encircling cumulus cells within a follicle, a unique venue for somatic and germ cell communication. Cumulus cell expansion and resumption of meiosis with germinal vesicle breakdown are major events in oocyte maturation. Cyclooxygenase-2 (COX-2)-derived prostaglandin E-2 (PGE(2)) is a known critical mediator of oocyte maturation, but the diverse function of this lipid mediator in oocyte maturation, ovulation, and fertilization has not been fully appreciated. We show here that gonadotropins in coordination with PGE(2) signaling via its cell surface G-protein-coupled EP2 and EP4 receptor subtypes direct cumulus cell expansion and survival and oocyte meiotic maturation by differentially impacting cAMP-dependent protein kinase, MAPK, NF-kappa B, and phosphatidylinositol 3-kinase/Akt pathways. This study is unique in the sense that it provides evidence for new site- and event-specific involvement of these signaling pathways under the influence of COX-2-derived PGE(2) during the critical stages of this somatic-germ cell interaction, an absolute requirement for oocyte maturation.	Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Div Reprod & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Div Reprod & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Takahashi, T (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Div Reprod & Dev Biol, Nashville, TN 37232 USA.	sk.dey@vanderbilt.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD050315, R37HD012304, R01HD012304] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA77839] Funding Source: Medline; NICHD NIH HHS [HD33994, HD050315, HD12304] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi H, 2005, ENDOCRINOLOGY, V146, P77, DOI 10.1210/en.2004-0588; BUCCIONE R, 1990, DEV BIOL, V138, P16, DOI 10.1016/0012-1606(90)90172-F; BYSKOV AG, 1995, NATURE, V374, P559, DOI 10.1038/374559a0; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Chie L, 2000, CANCER CHEMOTH PHARM, V45, P441, DOI 10.1007/s002800051017; Conti M, 2006, MOL ENDOCRINOL, V20, P715, DOI 10.1210/me.2005-0185; Conti M, 2002, BIOL REPROD, V67, P1653, DOI 10.1095/biolreprod.102.004952; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; DEKEL N, 1978, ENDOCRINOLOGY, V102, P1797, DOI 10.1210/endo-102-6-1797; Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DOWNS SM, 1982, AM J ANAT, V164, P265, DOI 10.1002/aja.1001640307; DOWNS SM, 1983, J EXP ZOOL, V228, P99, DOI 10.1002/jez.1402280111; DOWNS SM, 1983, ANAT REC, V205, P159, DOI 10.1002/ar.1092050206; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Hoshino Y, 2004, MOL REPROD DEV, V69, P77, DOI 10.1002/mrd.20150; Jamnongjit M, 2005, P NATL ACAD SCI USA, V102, P16257, DOI 10.1073/pnas.0508521102; Joyce IM, 2001, ENDOCRINOLOGY, V142, P3187, DOI 10.1210/en.142.7.3187; Kalous J, 2006, BIOL CELL, V98, P111, DOI 10.1042/BC20050020; Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Leonardsen L, 2000, J REPROD FERTIL, V120, P377, DOI 10.1530/reprod/120.2.377; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; Mood K, 2004, CELL SIGNAL, V16, P631, DOI 10.1016/j.cellsig.2003.10.005; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; NEAL P, 1975, J ENDOCRINOL, V65, P19, DOI 10.1677/joe.0.0650019; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P1008, DOI 10.1210/en.2002-220435; Park JY, 2004, SCIENCE, V303, P682, DOI 10.1126/science.1092463; PENG XR, 1991, ENDOCRINOLOGY, V129, P3200, DOI 10.1210/endo-129-6-3200; Richards JS, 2005, MOL CELL ENDOCRINOL, V234, P75, DOI 10.1016/j.mce.2005.01.004; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Sato E., 2005, Italian Journal of Anatomy and Embryology, V110, P205; Sato H, 2001, BIOCHEM BIOPH RES CO, V281, P1154, DOI 10.1006/bbrc.2001.4475; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Segi E, 2003, BIOL REPROD, V68, P804, DOI 10.1095/biolreprod.102.003590; Shimada M, 2006, MOL ENDOCRINOL, V20, P1352, DOI 10.1210/me.2005-0504; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Su YQ, 2003, DEV BIOL, V263, P126, DOI 10.1016/S0012-1606(03)00437-8; Su YQ, 2002, ENDOCRINOLOGY, V143, P2221, DOI 10.1210/en.143.6.2221; Tilley SL, 1999, J CLIN INVEST, V103, P1539, DOI 10.1172/JCI6579; Tsafriri A, 1996, DEV BIOL, V178, P393, DOI 10.1006/dbio.1996.0226; Tsafriri A, 2005, MOL CELL ENDOCRINOL, V234, P37, DOI 10.1016/j.mce.2004.09.009; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang HB, 2005, PROSTAG OTH LIPID M, V77, P84, DOI 10.1016/j.prostaglandins.2004.09.013; Wang HB, 2004, J BIOL CHEM, V279, P10649, DOI 10.1074/jbc.M312203200; Wang HB, 2003, P NATL ACAD SCI USA, V100, P14914, DOI 10.1073/pnas.2436379100; Webb RJ, 2002, DEV BIOL, V246, P441, DOI 10.1006/dbio.2002.0630; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; YOSHIMURA Y, 1993, ENDOCRINOLOGY, V133, P1609, DOI 10.1210/en.133.4.1609; YOSHIMURA Y, 1990, BIOL REPROD, V43, P1012, DOI 10.1095/biolreprod43.6.1012; Yoshioka S, 2000, ENDOCRINOLOGY, V141, P4114, DOI 10.1210/en.141.11.4114; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	62	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37117	37129		10.1074/jbc.M608202200	http://dx.doi.org/10.1074/jbc.M608202200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023426	hybrid			2022-12-25	WOS:000242220800073
J	Chen, HW; Su, SF; Chien, CT; Lin, WH; Yu, SL; Chou, CC; Chen, JJW; Yang, PC				Chen, Huei-Wen; Su, Sheng-Fang; Chien, Chiang-Ting; Lin, Wei-Hsiang; Yu, Sung-Liang; Chou, Cheng-Chung; Chen, Jeremy J. W.; Yang, Pan-Chyr			Titanium dioxide nanoparticles induce emphysema-like lung injury in mice	FASEB JOURNAL			English	Article						nanotechnology; chemokines; placenta growth factor; microarray; pulmonary emphysema	PLACENTAL GROWTH-FACTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; ALVEOLAR MACROPHAGES; RAT LUNG; PULMONARY; PARTICLES; INFLAMMATION; COMPLEMENT; PATHOPHYSIOLOGY	Titanium dioxide nanoparticles (nanoTiO(2)) have been widely used as a photocatalyst in air and water cleaning. However, these nanoparticles inhalation can induce pulmonary toxicity and its mechanism is not fully understood. In this study we investigated the pulmonary toxicity of nanoTiO(2) and its molecular pathogenesis. The adult male ICR mice were exposed to intratracheal single dose of 0.1 or 0.5 mg nanoTiO(2) (19 - 21 nm) and lung tissues were collected at 3rd day, 1st wk, and 2nd wk for morphometric, microarray gene expression, and pathway analyses. NanoTiO(2) can induce pulmonary emphysema, macrophages accumulation, extensive disruption of alveolar septa, type II pneumocyte hyperplasia, and epithelial cell apoptosis. NanoTiO2 induced differential expression of hundreds of genes include activation of pathways involved in cell cycle, apoptosis, chemokines, and complement cascades. In particular, nanoTiO(2) up-regulates placenta growth factor ( PlGF) and other chemokines (CXCL1, CXCL5, and CCL3) expressions that may cause pulmonary emphysema and alveolar epithelial cell apoptosis. Cultured human THP-1 cell-derived macrophages treated with nanoTiO2 in vitro also resulted in upregulations of PlGF, CXCL1, CXCL5, and CCL3. These results indicated that nanoTiO2 can induce severe pulmonary emphysema, which may be caused by activation of PlGF and related inflammatory pathways.	Natl Yang Ming Univ, Sch Med, Dept Pharmacol, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan; Natl Taiwan Univ, Ctr Genom Med, Taipei 10764, Taiwan; Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; Natl Chung Hsing Univ, Coll Life Sci, Inst Life Sci, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Coll Life Sci, Inst Biomed Sci & Mol Biol, Taichung 40227, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Chung Hsing University; National Chung Hsing University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Yang, PC (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.	pcyang@ha.mc.ntu.edu.tw	Yang, Pan-Chyr/B-8808-2009; Tsou, YY/H-4160-2011; Su, Sheng-Fang/AAT-3642-2021	Tsou, YY/0000-0003-3345-4351; Su, Sheng-Fang/0000-0002-1624-5745; CHEN, HUEI-WEN/0000-0001-5051-9896; Chen, Jeremy J.W./0000-0003-1049-3825; YANG, PAN-CHYR/0000-0001-6330-6048; YU, SUNG-LIANG/0000-0003-4535-9036				Afaq F, 1998, J APPL TOXICOL, V18, P307, DOI 10.1002/(SICI)1099-1263(1998090)18:5<307::AID-JAT508>3.0.CO;2-K; *AM THOR SOC PAT I, 2005, AM J RESP CRIT CARE, V171, P3; Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209; Borders CW, 2005, SCAND J IMMUNOL, V62, P123, DOI 10.1111/j.1365-3083.2005.01643.x; Borm PJA, 2004, J NANOSCI NANOTECHNO, V4, P521, DOI 10.1166/jnn.2004.081; Chellat F, 2005, BIOMATERIALS, V26, P961, DOI 10.1016/j.biomaterials.2004.04.006; Chen HW, 2005, HUM REPROD, V20, P2492, DOI 10.1093/humrep/dei084; Chen HW, 2004, HEART, V90, P927, DOI 10.1136/hrt.2002.006734; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; Golpon HA, 2004, AM J RESP CELL MOL, V31, P595, DOI 10.1165/rcmb.2004-0008OC; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Hohr D, 2002, INT J HYG ENVIR HEAL, V205, P239, DOI 10.1078/1438-4639-00123; Hoyle GW, 1999, AM J PATHOL, V154, P1763, DOI 10.1016/S0002-9440(10)65432-6; Jeyaseelan S, 2005, AM J RESP CELL MOL, V32, P531, DOI 10.1165/rcmb.2005-0063OC; Jeyaseelan S, 2004, INFECT IMMUN, V72, P7247, DOI 10.1128/IAI.72.12.7247-7256.2004; Kader HA, 2005, AM J GASTROENTEROL, V100, P414, DOI 10.1111/j.1572-0241.2005.40819.x; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Leong BKJ, 1998, J APPL TOXICOL, V18, P149, DOI 10.1002/(SICI)1099-1263(199803/04)18:2<149::AID-JAT490>3.3.CO;2-C; Levine RJ, 2005, JAMA-J AM MED ASSOC, V293, P77, DOI 10.1001/jama.293.1.77; Linde K, 2001, BMC Complement Altern Med, V1, P3; Londhe Vedang A, 2005, J Inflamm (Lond), V2, P4, DOI 10.1186/1476-9255-2-4; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2002, BIOCHEM BIOPH RES CO, V295, P428, DOI 10.1016/S0006-291X(02)00677-0; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686; MUTASA HCF, 1988, HISTOCHEM J, V20, P558, DOI 10.1007/BF01002610; Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561; Oberdorster G, 2000, Res Rep Health Eff Inst, P5; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Oberdorster G, 1996, PARTICLE OVERLOAD IN THE RAT LUNG AND LUNG CANCER, P73; Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516; Perelman N, 2003, BLOOD, V102, P1506, DOI 10.1182/blood-2002-11-3422; Peters K, 2004, J MATER SCI-MATER M, V15, P321, DOI 10.1023/B:JMSM.0000021095.36878.1b; Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423; Steerenberg PA, 1998, EXP LUNG RES, V24, P85, DOI 10.3109/01902149809046056; Sun D, 2004, WATER SCI TECHNOL, V49, P103, DOI 10.2166/wst.2004.0030; THURLBEC.WM, 1967, AM REV RESPIR DIS, V95, P752; Tsao PN, 2004, AM J RESP CRIT CARE, V169, P505, DOI 10.1164/rccm.200306-774OC; VANBUCHEM MA, 1993, LEUKEMIA, V7, P1608; Walrath E, 2005, AM J RESP CELL MOL, V33, P48, DOI 10.1165/rcmb.2005-0060OC; Wottrich R, 2004, INT J HYG ENVIR HEAL, V207, P353, DOI 10.1078/1438-4639-00300; Yao PL, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-89; Yu SL, 2004, AM J RESP CRIT CARE, V169, P1135, DOI 10.1164/rccm.200211-1278OC	46	229	248	3	55	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2393	+		10.1096/fj.06-6485fje	http://dx.doi.org/10.1096/fj.06-6485fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023518				2022-12-25	WOS:000241702600031
J	Kioi, M; Seetharam, S; Puri, RK				Kioi, Mitomu; Seetharam, Saraswathy; Puri, Raj K.			N-linked glycosylation of IL-13R alpha 2 is essential for optimal IL-13 inhibitory activity	FASEB JOURNAL			English	Article						type I cytokine receptor; ECD; allergic and inflammatory diseases; cancer	INTERLEUKIN-13 RECEPTOR; SIGNAL-TRANSDUCTION; EXTRACELLULAR DOMAIN; GLIOMA-CELLS; BINDING; PROTEIN; ALPHA; COMPONENT; CLONING; IDENTIFICATION	A high-affinity receptor for interleukin (IL)-13 (interleukin-13R alpha 2) is over-expressed in disease-related fibroblasts and neoplastic cells and is involved in cancer, allergic, and inflammatory diseases. The extracellular domain of IL-13R alpha 2 (ECD alpha 2) could be cleaved, which serves as a decoy receptor. We have expressed and purified ECD alpha 2 in both Escherichia coli ( E. coli) and mammalian systems as a soluble fragment and studied its biological activities. Although both products of ECD alpha 2 showed IL-13 inhibitory activities, mammalian cell-derived ECD alpha 2 appeared to be superior compared with purified protein from E. coli. When expressed in E. coli, ECD alpha 2 appeared to be a monomer of 42 but a 60 kDa protein when purified from mammalian cells due to heavy glycosylation. The purified glycosylated ECD alpha 2 efficiently inhibited IL-13-induced STAT6 phosphorylation in immune and Hodgkin's lymphoma cell lines, IL-13 binding, and cytotoxicity of IL-13 cytotoxin in various cancer cell lines. The improved potency of mammalian cell-derived ECD alpha 2 was shown over ECD alpha 2/Fc fusion protein. The N-linked glycosylation of ECD alpha 2 was found to be essential for optimal IL-13 inhibitory activity as deglycosylation by PNGase F showed lower activity. ECD alpha 2 did not inhibit IL-4-induced STAT6 phosphorylation, indicating that inhibitory effects of ECD alpha 2 are receptor specific. These results indicate that glycosylated ECD alpha 2 can serve as a potent inhibitor of IL-13 in a variety of conditions in which IL-13 is a key mediator, e. g., pulmonary, allergic, fibrotic, and neoplastic diseases.	US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Tumor Vaccines & Biotechnol Branch, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Puri, RK (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Tumor Vaccines & Biotechnol Branch, NIH Bldg 29B,Rm 2NN20,29 Lincoln Dr, Bethesda, MD 20892 USA.	raj.puri@fda.hhs.gov		Kioi, Mitomu/0000-0002-7981-3340				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BASTIAN W, 1993, DIABETES, V42, P966, DOI 10.2337/diabetes.42.7.966; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Cole AR, 1999, J BIOL CHEM, V274, P7207, DOI 10.1074/jbc.274.11.7207; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Debinski W, 1995, CLIN CANCER RES, V1, P1253; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DING DXH, 1995, J BIOL CHEM, V270, P24580, DOI 10.1074/jbc.270.41.24580; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Gonzalez-Moreno O, 2005, INT J CANCER, V114, P870, DOI 10.1002/ijc.20789; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Husain SR, 2000, BLOOD, V95, P3506, DOI 10.1182/blood.V95.11.3506.011k47_3506_3513; Jakubzick C, 2004, J CLIN PATHOL, V57, P477, DOI 10.1136/jcp.2003.012799; Jakubzick C, 2003, J IMMUNOL, V171, P2684, DOI 10.4049/jimmunol.171.5.2684; Joshi BH, 2000, CANCER RES, V60, P1168; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kawakami K, 2001, J BIOL CHEM, V276, P25114, DOI 10.1074/jbc.M100936200; Kawakami K, 2001, CANCER RES, V61, P6194; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Kioi M, 2004, CELL IMMUNOL, V229, P41, DOI 10.1016/j.cellimm.2004.06.005; Kioi M, 2004, CLIN CANCER RES, V10, P6231, DOI 10.1158/1078-0432.CCR-04-0700; KITAMURA T, 1989, BLOOD, V73, P375; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; Logsdon NJ, 2004, J MOL BIOL, V342, P503, DOI 10.1016/j.jmb.2004.07.069; Mentink-Kane MM, 2004, P NATL ACAD SCI USA, V101, P586, DOI 10.1073/pnas.0305064101; Murad AM, 1997, CLIN DRUG INVEST, V13, P90, DOI 10.2165/00044011-199713020-00005; Niu LH, 2000, BLOOD, V95, P3357, DOI 10.1182/blood.V95.11.3357.011k43_3357_3362; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; Oshima Y, 2001, J BIOL CHEM, V276, P15185, DOI 10.1074/jbc.M010159200; Rahaman SO, 2005, CANCER RES, V65, P2956, DOI 10.1158/0008-5472.CAN-04-3592; Rahaman SO, 2002, CANCER RES, V62, P1103; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Yoshikawa M, 2003, BIOCHEM BIOPH RES CO, V312, P1248, DOI 10.1016/j.bbrc.2003.11.077; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	41	24	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2378	+		10.1096/fj.06-5995fje	http://dx.doi.org/10.1096/fj.06-5995fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023392				2022-12-25	WOS:000241702600026
J	Urbanska, K; Trojanek, J; Del Valle, L; Eldeen, MB; Hofmann, F; Garcia-Echeverria, C; Khalili, K; Reiss, K				Urbanska, K.; Trojanek, J.; Del Valle, L.; Eldeen, M. B.; Hofmann, F.; Garcia-Echeverria, C.; Khalili, K.; Reiss, K.			Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3 beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines	ONCOGENE			English	Article						IGF-I receptor; NVP-AEW541; GSK3 beta; medulloblastoma; anchorage-independence	GLYCOGEN-SYNTHASE KINASE-3-BETA; INTEGRIN-LINKED KINASE; VIRUS T-ANTIGEN; TUMOR-GROWTH; ANTITUMOR-ACTIVITY; INDUCED APOPTOSIS; CARCINOMA CELLS; SONIC HEDGEHOG; INSULIN; LOCALIZATION	We have previously reported that insulin-like growth factor-I (IGF-I) supports growth and survival of mouse and human medulloblastoma cell lines, and that IGF-I receptor (IGF-IR) is constitutively phosphorylated in human medulloblastoma clinical samples. Here, we demonstrate that a specific inhibitor of insulin-like growth factor-I receptor (IGF-IR), NVP-AEW541, attenuated growth and survival of mouse (BsB8) and human (D384, Daoy) medulloblastoma cell lines. Cell cycle analysis demonstrated that G1 arrest and apoptosis contributed to the action of NVP-AEW54. Interestingly, very aggressive BsB8 cells, which derive from cerebellar tumors of transgenic mice expressing viral oncoprotein (large T-antigen from human polyomavirus JC) became much more sensitive to NVP-AEW541 when exposed to anchorage-independent culture conditions. This high sensitivity to NVP-AEW54 in suspension was accompanied by the loss of GSK-3 beta constitutive phosphorylation and was independent from T-antigen-mediated cellular events (Supplementary Materials). BsB8 cells were partially rescued from NVP-AEW541 by GSK3 beta inhibitor, lithium chloride and were sensitized by GSK3b activator, sodium nitroprusside (SNP). Importantly, human medulloblastoma cells, D384, which demonstrated partial resistance to NVP-AEW541 in suspension cultures, become much more sensitive following SNP-mediated GSK3 beta dephosphorylation (activation). Our results indicate that hypersensitivity of medulloblastoma cells in anchorage-independence is linked to GSK-3 beta activity and suggest that pharmacological intervention against IGF-IR with simultaneous activation of GSK3 beta could be highly effective against medulloblastomas, which have intrinsic ability of disseminating the CNS via cerebrospinal fluid.	Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Philadelphia, PA 19122 USA; Jagiellonian Univ, Dept Cell Biol, Fac Biotechnol, Krakow, Poland; Novartis Pharma AG, Novartis Inst Biomed Res, Basel, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jagiellonian University; Novartis	Reiss, K (corresponding author), Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Biol Life Sci Bldg,Room 230,1900 N 12th St, Philadelphia, PA 19122 USA.	kreiss@temple.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206; Trojanek, Joanna/0000-0002-3200-735X	NCI NIH HHS [R01CA095518-01] Funding Source: Medline; NINDS NIH HHS [P01 NS36466-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews DW, 2001, J CLIN ONCOL, V19, P2189, DOI 10.1200/JCO.2001.19.8.2189; Araki K, 2006, INT J CANCER, V118, P2602, DOI 10.1002/ijc.21653; Arevalo JC, 2005, CURR OPIN CELL BIOL, V17, P112, DOI 10.1016/j.ceb.2005.01.004; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, ENDOCRINE, V7, P99, DOI 10.1007/BF02778073; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Beurel E, 2004, EXP CELL RES, V300, P354, DOI 10.1016/j.yexcr.2004.08.001; Blackburn RV, 1998, CANCER, V82, P1137, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1137::AID-CNCR19>3.0.CO;2-7; Chao JI, 2004, J BIOL CHEM, V279, P20267, DOI 10.1074/jbc.M312381200; Cheng ZJ, 2005, J HYPERTENS, V23, P1757, DOI 10.1097/01.hjh.0000179765.48324.b4; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Desbois-Mouthon C, 2002, HEPATOLOGY, V36, P1528, DOI 10.1053/jhep.2002.37192; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; GLICK RP, 1993, ANN NY ACAD SCI, V692, P223; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Kang UG, 2004, FEBS LETT, V560, P115, DOI 10.1016/S0014-5793(04)00082-1; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kim AJ, 2005, J CELL SCI, V118, P89, DOI 10.1242/jcs.01562; Knoepfler PS, 2006, CELL CYCLE, V5, P47, DOI 10.4161/cc.5.1.2292; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Kurihara M, 1989, No To Shinkei, V41, P719; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; Liao HT, 2005, OLIGONUCLEOTIDES, V15, P196, DOI 10.1089/oli.2005.15.196; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Patti R, 2000, INT J ONCOL, V16, P577; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Reiss Krzysztof, 2002, Expert Opin Ther Targets, V6, P539, DOI 10.1517/14728222.6.5.539; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; SELL C, 1995, CANCER RES, V55, P303; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Szatmari E, 2005, J BIOL CHEM, V280, P37526, DOI 10.1074/jbc.M502699200; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wang JY, 2004, J EXP CLIN CANC RES, V23, P373; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Zhang YH, 2005, FEBS LETT, V579, P6230, DOI 10.1016/j.febslet.2005.09.095	57	35	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2308	2317		10.1038/sj.onc.1210018	http://dx.doi.org/10.1038/sj.onc.1210018			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016438				2022-12-25	WOS:000245466000007
J	Berchner-Pfannschmidt, U; Yamac, H; Trinidad, B; Fandrey, J				Berchner-Pfannschmidt, Utta; Yamac, Hatice; Trinidad, Buena; Fandrey, Joachim			Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GROWTH-FACTOR GENE; FACTOR-I; CARBON-MONOXIDE; HIF-ALPHA; HIF-1-ALPHA; DEGRADATION; INHIBITION; EXPRESSION; PROTEIN	The transcription factor complex hypoxia-inducible factor 1 (HIF-1) plays a crucial role in cellular adaptation to low oxygen availability. O-2-dependent HIF prolyl hydroxylases (PHDs) modify HIF-1 alpha, which is sent to proteasomal degradation under normoxia. Reduced activity of PHDs under hypoxia allows stabilization of HIF-1 alpha and induction of HIF-1 target gene expression. Like hypoxia, nitric oxide (NO) was found to inhibit normoxic PHD activity leading to HIF-1 alpha accumulation. In contrast under hypoxia, NO reduced HIF-1 alpha levels due to enhanced PHD activity. Herein, we studied the role of NO in regulating PHD expression and the consequences thereof for HIF-1 alpha degradation. We report a biphasic response of HIF-1 alpha and PHDs to NO treatment both under normoxia and hypoxia. In the early phase, NO inhibits PHD activity that leads to HIF-1 alpha accumulation, whereas in the late phase, increased PHD levels reduce HIF-1 alpha. NO induces expression of PHD2 and -3 mRNA and protein under normoxia and hypoxia in a strictly HIF-1-dependent manner. NO-treated cells with elevated PHD levels displayed delayed HIF-1 alpha accumulation and accelerated degradation of HIF-1 alpha upon reoxygenation. Subsequent suppression of PHD2 and -3 expression using small interfering RNA revealed that PHD2 was exclusively responsible for regulating HIF-1 alpha degradation under NO treatment. In conclusion, we identified the induction of PHD2 as an underlying mechanism of NO-induced degradation of HIF-1 alpha.	Univ Duisburg Essen, Inst Physiol, D-45122 Essen, Germany	University of Duisburg Essen	Fandrey, J (corresponding author), Univ Duisburg Essen, Inst Physiol, Hufelandstr 55, D-45122 Essen, Germany.	joachim.fandrey@uni-essen.de	Fandrey, Joachim/AAA-3524-2021	Fandrey, Joachim/0000-0001-9585-0531				Agani FH, 2002, AM J PHYSIOL-CELL PH, V283, pC178, DOI 10.1152/ajpcell.00381.2001; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Berchner-Pfannschmidt U, 2004, J BIOL CHEM, V279, P44976, DOI 10.1074/jbc.M313995200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Callapina M, 2005, EXP CELL RES, V306, P274, DOI 10.1016/j.yexcr.2005.02.018; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Dehne N, 2004, BIOL CHEM, V385, P341, DOI 10.1515/BC.2004.030; Doege K, 2005, BLOOD, V106, P2311, DOI 10.1182/blood-2005-03-1138; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kageyama Y, 2004, FASEB J, V18, P1028, DOI 10.1096/fj.03-1233fje; Kasuno K, 2004, J BIOL CHEM, V279, P2550, DOI 10.1074/jbc.M308197200; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kohl R, 2006, FREE RADICAL BIO MED, V40, P1430, DOI 10.1016/j.freeradbiomed.2005.12.012; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; METZEN E, 1995, RESP PHYSIOL, V100, P101, DOI 10.1016/0034-5687(94)00125-J; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Quintero M, 2006, CANCER RES, V66, P770, DOI 10.1158/0008-5472.CAN-05-0333; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Stolze I, 2002, BLOOD, V100, P2623, DOI 10.1182/blood-2001-12-0169; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; Wang F, 2002, BIOCHEM BIOPH RES CO, V295, P657, DOI 10.1016/S0006-291X(02)00729-5; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wellman TL, 2003, FASEB J, V17, P379, DOI 10.1096/fj.03-0143fje; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6; Zhou J, 2006, MOL BIOL CELL, V17, P1549, DOI 10.1091/mbc.E05-08-0770; Zhou J, 2003, AM J PHYSIOL-CELL PH, V284, pC439, DOI 10.1152/ajpcell.00294.2002	52	125	133	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1788	1796		10.1074/jbc.M607065200	http://dx.doi.org/10.1074/jbc.M607065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17060326	hybrid			2022-12-25	WOS:000243451300030
J	Karatza, P; Panos, P; Georgopoulou, E; Frillingos, S				Karatza, Panayiota; Panos, Panayiotis; Georgopoulou, Ekaterini; Frillingos, Stathis			Cysteine-scanning analysis of the nucleobase-ascorbate transporter signature motif in YgfO permease of Escherichia coli - Gln-324 and Asn-325 are essential and Ile-329-Val-339 form an alpha-helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE PERMEASE; ASPERGILLUS-NIDULANS; FUNCTIONAL-CHARACTERIZATION; CONFORMATIONAL FLEXIBILITY; PURINE TRANSPORTERS; MEMBRANE-PROTEINS; SUBSTRATE-BINDING; CARRIER PROTEIN; NAT/NCS2 FAMILY; MUTAGENESIS		Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece	University of Ioannina	Frillingos, S (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.	efriligo@cc.uoi.gr	Frillingos, Stathis/AAQ-3148-2021					Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Amillis S, 2001, J MOL BIOL, V313, P765, DOI 10.1006/jmbi.2001.5087; Argyrou E, 2001, PLANT CELL, V13, P953, DOI 10.1105/tpc.13.4.953; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; Cui L, 2006, J PHYSIOL-LONDON, V572, P347, DOI 10.1113/jphysiol.2005.099457; de Koning H, 2000, MOL MEMBR BIOL, V17, P75; Diallinas G, 1998, EMBO J, V17, P3827, DOI 10.1093/emboj/17.14.3827; DIALLINAS G, 1989, GENETICS, V122, P341; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Goudela S, 2005, MOL MEMBR BIOL, V22, P263, DOI 10.1080/09687860500093016; Granseth E, 2005, J MOL BIOL, V352, P489, DOI 10.1016/j.jmb.2005.07.053; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; Karatza P, 2005, MOL MEMBR BIOL, V22, P251, DOI 10.1080/09687860500092927; Koukaki M, 2005, J MOL BIOL, V350, P499, DOI 10.1016/j.jmb.2005.04.076; Liang WJ, 2001, MOL MEMBR BIOL, V18, P87, DOI 10.1080/09687680120706; Meintanis C, 2000, MOL MEMBR BIOL, V17, P47; Mueckler M, 2005, J BIOL CHEM, V280, P39562, DOI 10.1074/jbc.M509050200; Pantazopoulou A, 2006, MOL MEMBR BIOL, V23, P337, DOI 10.1080/09687860600738239; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; Schrodt S, 2006, J BIOL CHEM, V281, P6455, DOI 10.1074/jbc.M509784200; Smirnova IN, 2003, BIOCHEMISTRY-US, V42, P3025, DOI 10.1021/bi027329c; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Vlanti A, 2006, J MOL BIOL, V357, P808, DOI 10.1016/j.jmb.2005.12.070; Weinglass AB, 1999, P NATL ACAD SCI USA, V96, P11178, DOI 10.1073/pnas.96.20.11178; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	31	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39881	39890		10.1074/jbc.M605748200	http://dx.doi.org/10.1074/jbc.M605748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17077086	hybrid			2022-12-25	WOS:000243033900015
J	Bakan, B; Hamberg, M; Perrocheau, L; Maume, D; Rogniaux, H; Tranquet, O; Rondeau, C; Blein, JP; Ponchet, M; Marion, D				Bakan, Benedicte; Hamberg, Mats; Perrocheau, Ludivine; Maume, Daniel; Rogniaux, Helene; Tranquet, Olivier; Rondeau, Corinne; Blein, Jean-Pierre; Ponchet, Michel; Marion, Didier			Specific adduction of plant lipid transfer protein by an allene oxide generated by 9-lipoxygenase and allene oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; FATTY-ACID HYDROPEROXIDES; POLLEN-TUBE ADHESION; VITRO STYLAR MATRIX; EUPHORBIA-LAGASCAE; CEREAL ALEURONE; LINOLEIC-ACID; BARLEY; EXPRESSION; LIPOXYGENASE	Lipid transfer proteins (LTPs) are ubiquitous plant lipid-binding proteins that have been associated with multiple developmental and stress responses. Although LTPs typically bind fatty acids and fatty acid derivatives in a non-covalent way, studies on the LTPs of barley seeds have identified an abundantly occurring covalently modified form, LTP1b, the lipid ligand of which has resisted clarification. In the present study, this adduct was identified as the alpha-ketol9-hydroxy-10-oxo-12(Z)-octadecenoic acid. Further studies on the formation of LTP1b demonstrated that the ligand was introduced by nucleophilic attack of the free carboxylate group of the Asp-7 residue of the protein at carbon-9 of the allene oxide fatty acid 9(S), 10-epoxy-10,12(Z)octadecadienoic acid. This reactive oxylipin was produced in barley seeds by oxygenation of linoleic acid by 9-lipoxygenase followed by dehydration of the resulting hydroperoxide by allene oxide synthase. The generation of protein-oxylipin adducts represents a new function for plant allene oxide synthases, enzymes that have earlier been implicated mainly in the biosynthesis of the jasmonate family of plant hormones. Additionally, the LTP-allene oxide synthase interaction opens new perspectives regarding the roles of LTPs in the signaling of plant defense and development.	INRA, Unite Rech Biopolymeres Interact Assemblages, F-44316 Nantes 03, France; Ecole Natl Vet, F-44307 Nantes, France; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Bourgogne, ENESAD, INRA, Unite Phytopharm & Biochim Interact Cellulaires, F-21110 Bretenieres, France; UNSA, CNRS, INRA, Unite Rech Interact Plantes Microorganismes & San, F-06903 Sophia Antipolis, France	INRAE; Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; Karolinska Institutet; INRAE; Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Cote d'Azur	Bakan, B (corresponding author), INRA, Unite Rech Biopolymeres Interact Assemblages, BP 71627, F-44316 Nantes 03, France.	bakan@nantes.inra.fr	BAKAN, Benedicte/ABC-6953-2020; , MARION/A-4973-2018; Rondeau-Mouro, Corinne/ABD-4514-2021	, MARION/0000-0002-0672-6545; Ponchet, Michel/0000-0002-0144-109X; RONDEAU-MOURO, Corinne/0000-0002-8573-1050; Hamberg, Mats/0000-0002-8910-7810; Tranquet, Olivier/0000-0002-3359-3194				Blee E, 2002, TRENDS PLANT SCI, V7, P315, DOI 10.1016/S1360-1385(02)02290-2; Blein JP, 2002, TRENDS PLANT SCI, V7, P293, DOI 10.1016/S1360-1385(02)02284-7; Brame CJ, 2004, J BIOL CHEM, V279, P13447, DOI 10.1074/jbc.M313349200; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; Buhot N, 2001, FEBS LETT, V509, P27, DOI 10.1016/S0014-5793(01)03116-7; Buhot N, 2004, MOL BIOL CELL, V15, P5047, DOI 10.1091/mbc.E04-07-0575; Charvolin D, 1999, EUR J BIOCHEM, V264, P562, DOI 10.1046/j.1432-1327.1999.00667.x; Davies SS, 2004, CHEM PHYS LIPIDS, V128, P85, DOI 10.1016/j.chemphyslip.2003.10.007; de Vries EJ, 2003, CURR OPIN BIOTECH, V14, P414, DOI 10.1016/S0958-1669(03)00102-2; Douliez JP, 2000, J CEREAL SCI, V32, P1, DOI 10.1006/jcrs.2000.0315; Douliez JP, 2001, J AGR FOOD CHEM, V49, P1805, DOI 10.1021/jf001327m; Dubreil L, 1998, PLANT SCI, V138, P121, DOI 10.1016/S0168-9452(98)00121-6; Edqvist J, 2002, PLANTA, V215, P41, DOI 10.1007/s00425-001-0717-x; Eklund DM, 2003, PLANT PHYSIOL, V132, P1249, DOI 10.1104/pp.103.020875; Elmorjani K, 2004, BIOCHEM BIOPH RES CO, V316, P1202, DOI 10.1016/j.bbrc.2004.02.173; Fath A, 2000, PLANT MOL BIOL, V44, P255, DOI 10.1023/A:1026584207243; Fath A, 2002, J EXP BOT, V53, P1273, DOI 10.1093/jexbot/53.372.1273; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K; HAMBERG M, 1989, ADV PROSTAG THROMB L, V19, P64; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P518, DOI 10.1016/0003-9861(90)90753-L; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; Hollenbach B, 1997, PLANTA, V203, P9, DOI 10.1007/s004250050159; Knight VI, 2001, PHYSIOL MOL PLANT P, V59, P277, DOI 10.1006/pmpp.2001.0366; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUHLMANN KF, 1968, J AM CHEM SOC, V90, P7355, DOI 10.1021/ja01028a038; Lindorff-Larsen K, 2001, J BIOL CHEM, V276, P33547, DOI 10.1074/jbc.M104841200; LULAI EC, 1981, PLANT PHYSIOL, V68, P950, DOI 10.1104/pp.68.4.950; Maldonado AM, 2002, NATURE, V419, P399, DOI 10.1038/nature00962; Marion D., 2003, PLANT FOOD ALLERGENS, P57; MOLINA A, 1993, FEBS LETT, V316, P119, DOI 10.1016/0014-5793(93)81198-9; Mollet JC, 2000, PLANT CELL, V12, P1737, DOI 10.1105/tpc.12.9.1737; Morrison W. R., 1993, P199; Nieuwland J, 2005, PLANT CELL, V17, P2009, DOI 10.1105/tpc.105.032094; Park SY, 2000, PLANT CELL, V12, P151, DOI 10.1105/tpc.12.1.151; Pearce RS, 1998, PLANT PHYSIOL, V117, P787, DOI 10.1104/pp.117.3.787; Prost I, 2005, PLANT PHYSIOL, V139, P1902, DOI 10.1104/pp.105.066274; Rouster J, 1998, PLANT J, V15, P435, DOI 10.1046/j.1365-313X.1998.00193.x; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; SATTLER W, 1991, ANAL BIOCHEM, V198, P184, DOI 10.1016/0003-2697(91)90526-Y; Schmitt NF, 1997, PLANT SCI, V128, P141, DOI 10.1016/S0168-9452(97)00152-0; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; SKRIVER K, 1992, PLANT MOL BIOL, V18, P585, DOI 10.1007/BF00040674; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; STERK P, 1991, PLANT CELL, V3, P907, DOI 10.1105/tpc.3.9.907; Tijet N, 2002, PROSTAG OTH LIPID M, V68-9, P423, DOI 10.1016/S0090-6980(02)00046-1; VANAARLE PGM, 1991, FEBS LETT, V280, P159, DOI 10.1016/0014-5793(91)80227-T; VICK BA, 1983, BIOCHEM BIOPH RES CO, V111, P470, DOI 10.1016/0006-291X(83)90330-3; Yubero-Serrano EM, 2003, J EXP BOT, V54, P1865, DOI 10.1093/jxb/erg211; ZIMMERMAN DC, 1966, BIOCHEM BIOPH RES CO, V23, P398, DOI 10.1016/0006-291X(66)90740-6	52	40	41	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					38981	38988		10.1074/jbc.M608580200	http://dx.doi.org/10.1074/jbc.M608580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17046828	Green Published, hybrid			2022-12-25	WOS:000242898700004
J	Tew, SR; Hardingham, TE				Tew, Simon R.; Hardingham, Timothy E.			Regulation of SOX9 mRNA in human articular chondrocytes involving p38 MAPK activation and mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-SYNTHESIS INHIBITORS; AU-RICH ELEMENTS; GENE-EXPRESSION; GROWTH-FACTORS; RHOA GTPASE; KINASE-C; TRANSCRIPTION; CYCLOHEXIMIDE; PHENOTYPE	Humanarticular chondrocytes rapidly lose their phenotype in monolayer culture. Recently we have shown that overexpression of the transcription factor SOX9 greatly enhanced re-expression of the phenotype in three-dimensional aggregate cultures. Here we show that endogenous SOX9 mRNA can be rapidly up-regulated in subcultured human articular chondrocytes if grown in alginate, in monolayer with cytochalasin D, or with specific inhibition of the RhoA effector kinases ROCK1 and -2, which all prevent actin stress fiber formation. Disruption of actin stress fibers using any of these redifferentiation stimuli also supported the superinduction of SOX9 by cycloheximide. The superinduction was blocked by inhibitors of the p38 MAPK signaling pathway and involved the stabilization of SOX9 mRNA. Furthermore stimulation of chondrocyte p38 MAPK activity with interleukin-1 beta resulted in increased levels of SOX9 mRNA, and this was again dependent on the absence of actin stress fibers in the cells. In this study of chondrocyte redifferentiation we have provided further evidence of the early involvement of SOX9 and have discovered a novel post-transcriptional regulatory mechanism activated by p38 MAPK, which stabilized SOX9 mRNA.	Univ Manchester, Fac Life Sci, UK Ctr Tissue Engn, Manchester M13 9PT, Lancs, England; Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester	Hardingham, TE (corresponding author), Univ Manchester, Fac Life Sci, UK Ctr Tissue Engn, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	timothy.e.hardingham@manchester.ac.uk	Tew, Simon Robert/G-4087-2011	Tew, Simon Robert/0000-0002-1213-5418; Hardingham, Timothy/0000-0001-8271-6763				Aigner T, 2003, MATRIX BIOL, V22, P363, DOI 10.1016/S0945-053X(03)00049-0; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Bagheri-Fam S, 2001, GENOMICS, V78, P73, DOI 10.1006/geno.2001.6648; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Chowdhury I, 2004, EUR J BIOCHEM, V271, P4436, DOI 10.1111/j.1432-1033.2004.04382.x; Colter DC, 2005, MATRIX BIOL, V24, P185, DOI 10.1016/j.matbio.2005.04.001; Faggioli L, 1997, BIOCHEM BIOPH RES CO, V233, P507, DOI 10.1006/bbrc.1997.6489; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Han JS, 2003, EUR J BIOCHEM, V270, P3408, DOI 10.1046/j.1432-1033.2003.03723.x; Hardaway Christina A, 2002, J Cosmet Laser Ther, V4, P3, DOI 10.1080/14764170260030090; Hershko DD, 2004, J CELL BIOCHEM, V91, P951, DOI 10.1002/jcb.20014; Itani OA, 2003, AM J PHYSIOL-RENAL, V284, pF778, DOI 10.1152/ajprenal.00088.2002; Jakob M, 2001, J CELL BIOCHEM, V81, P368, DOI 10.1002/1097-4644(20010501)81:2<368::AID-JCB1051>3.0.CO;2-J; Joiakim A, 2004, MOL PHARMACOL, V66, P936, DOI 10.1124/mol.66.4.936; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kinkel MD, 2003, J CELL BIOCHEM, V88, P941, DOI 10.1002/jcb.10442; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Li Y, 2004, TISSUE ENG, V10, P575, DOI 10.1089/107632704323061933; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Liu HX, 1998, BBA-GEN SUBJECTS, V1425, P505, DOI 10.1016/S0304-4165(98)00105-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lutter R, 2000, CYTOKINE, V12, P1275, DOI 10.1006/cyto.1999.0728; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Martin I, 2001, OSTEOARTHR CARTILAGE, V9, P112, DOI 10.1053/joca.2000.0366; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Murphy CL, 2004, J CELL PHYSIOL, V199, P451, DOI 10.1002/jcp.10481; Newton R, 1997, FEBS LETT, V418, P135, DOI 10.1016/S0014-5793(97)01362-8; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Oh CD, 2001, EUR J PHARMACOL, V427, P175, DOI 10.1016/S0014-2999(01)01241-9; Qin YJ, 2004, HUM MOL GENET, V13, P1213, DOI 10.1093/hmg/ddh141; Sekiya I, 2001, J ENDOCRINOL, V169, P573, DOI 10.1677/joe.0.1690573; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Stokes DG, 2001, BIOCHEM J, V360, P461, DOI 10.1042/0264-6021:3600461; Studer RK, 2004, ARTHRITIS RES THER, V6, pR56, DOI 10.1186/ar1022; Tew SR, 2005, OSTEOARTHR CARTILAGE, V13, P80, DOI 10.1016/j.joca.2004.10.011; Thomas B, 2002, BIOCHEM J, V362, P367, DOI 10.1042/0264-6021:3620367; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Velagaleti GVN, 2005, AM J HUM GENET, V76, P652, DOI 10.1086/429252; Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200; Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029; Woods A, 2005, J BIOL CHEM, V280, P11626, DOI 10.1074/jbc.M409158200; Woods A, 2006, J BIOL CHEM, V281, P13134, DOI 10.1074/jbc.M509433200; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zaucke F, 2001, BIOCHEM J, V358, P17, DOI 10.1042/0264-6021:3580017; Zhang R, 2006, P NATL ACAD SCI USA, V103, P365, DOI 10.1073/pnas.0507979103	55	98	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39471	39479		10.1074/jbc.M604322200	http://dx.doi.org/10.1074/jbc.M604322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17050539	hybrid			2022-12-25	WOS:000242898700055
J	Matias, PM; Gorynia, S; Donner, P; Carrondo, MA				Matias, Pedro M.; Gorynia, Sabine; Donner, Peter; Carrondo, Maria Armenia			Crystal structure of the human AAA(+) protein RuvBL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; BETA-CATENIN; DNA HELICASE; CONFORMATIONAL-CHANGES; REPLICATIVE HELICASE; BOX C/D; TRANSFORMATION; TRANSCRIPTION; MECHANISM; BINDING	RuvBL1 is an evolutionarily highly conserved eukaryotic protein belonging to the AAA(+)-family of ATPases (ATPase associated with diverse cellular activities). It plays important roles in essential signaling pathways such as the c-Myc and Wnt pathways in chromatin remodeling, transcriptional and developmental regulation, and DNA repair and apoptosis. Herein we present the three-dimensional structure of the selenomethionine variant of human RuvBL1 refined using diffraction data to 2.2 A of resolution. The crystal structure of the hexamer is formed of ADP-bound RuvBL1 monomers. The monomers contain three domains, of which the first and the third are involved in ATP binding and hydrolysis. Although it has been shown that ATPase activity of RuvBL1 is needed for several in vivo functions, we could only detect a marginal activity with the purified protein. Structural homology and DNA binding studies demonstrate that the second domain, which is unique among AAA(+) proteins and not present in the bacterial homolog RuvB, is a novel DNA/RNA-binding domain. We were able to demonstrate that RuvBL1 interacted with single-stranded DNA/RNA and double-stranded DNA. The structure of the RuvBL1 center dot ADP complex, combined with our biochemical results, suggest that although RuvBL1 has all the structural characteristics of a molecular motor, even of an ATP-driven helicase, one or more as yet undetermined cofactors are needed for its enzymatic activity.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Schering AG, Prot Chem Res Labs, D-13342 Berlin, Germany	Universidade Nova de Lisboa; Schering AG	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Apartado 127, P-2781901 Oeiras, Portugal.	carrondo@itqb.unl.pt	Matias, Pedro M/B-7180-2008	Matias, Pedro M/0000-0001-6170-451X; Carrondo, Maria Armenia/0000-0002-1261-1162				Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; ALLEN GC, 1991, J BIOL CHEM, V266, P22096; Ayora S, 1999, J MOL BIOL, V288, P71, DOI 10.1006/jmbi.1999.2662; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; Carlson Mary L, 2003, Mol Cancer, V2, P42, DOI 10.1186/1476-4598-2-42; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Enemark EJ, 2006, NATURE, V442, P270, DOI 10.1038/nature04943; Feng Y, 2003, CANCER RES, V63, P8726; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; FRIEDBERG EC, 2005, DNA REPAIR MUTAGENES, P569; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Gartner W, 2003, CELL MOTIL CYTOSKEL, V56, P79, DOI 10.1002/cm.10136; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gorynia S, 2006, ACTA CRYSTALLOGR F, V62, P61, DOI 10.1107/S1744309105041400; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hubbard S. J., 1993, NACCESS; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jonsson ZO, 2004, MOL CELL, V16, P465, DOI 10.1016/j.molcel.2004.09.033; Jonsson ZO, 2001, J BIOL CHEM, V276, P16279, DOI 10.1074/jbc.M011523200; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; Kaplan DL, 1999, J BIOL CHEM, V274, P6889, DOI 10.1074/jbc.274.11.6889; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; King TH, 2001, MOL CELL BIOL, V21, P7731, DOI 10.1128/MCB.21.22.7731-7746.2001; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Makino Y, 1999, J BIOL CHEM, V274, P15329, DOI 10.1074/jbc.274.22.15329; Mancini EJ, 2004, CELL, V118, P743, DOI 10.1016/j.cell.2004.09.007; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neuwald AF, 1999, GENOME RES, V9, P27; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Niedenzu T, 2001, J MOL BIOL, V306, P479, DOI 10.1006/jmbi.2000.4398; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rappas M, 2006, J MOL BIOL, V357, P481, DOI 10.1016/j.jmb.2005.12.052; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, P66; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Stein GS, 2003, TRENDS CELL BIOL, V13, P584, DOI 10.1016/j.tcb.2003.09.009; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; Teixeira MT, 2002, J MOL BIOL, V321, P551, DOI 10.1016/S0022-2836(02)00652-6; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Watkins NJ, 2004, MOL CELL, V16, P789, DOI 10.1016/j.molcel.2004.11.012; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	67	120	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38918	38929		10.1074/jbc.M605625200	http://dx.doi.org/10.1074/jbc.M605625200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17060327	hybrid			2022-12-25	WOS:000242709500089
J	Chen, CX; Rowell, EA; Thomas, RM; Hancock, WW; Wells, AD				Chen, Chunxia; Rowell, Emily A.; Thomas, Rajan M.; Hancock, Wayne W.; Wells, Andrew D.			Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; T-CELLS; IL-2 PROMOTER; SCURFIN; GENE; PHOSPHORYLATION; RECRUITMENT; EXPRESSION; REPRESSORS; TOLERANCE	Regulatory T cells (T-reg) express Foxp3, a forkhead family member that is necessary and sufficient for T-reg lineage choice and function. Ectopic expression of Foxp3 in non-T-reg leads to repression of the interleukin 2 (IL-2) and interferon gamma (IFN gamma) genes, gain of suppressor function, and induction of genes such as CD25, GITR, and CTLA-4, but the mode by which Foxp3 enforces this program is unclear. Using chromatin immunoprecipitation, we have demonstrated that Foxp3 binds to the endogenous IL-2 and IFN gamma loci in T cells, but only after T cell receptor stimulation. This activation-induced Foxp3 binding was abrogated by cyclosporin A, suggesting a role for the phosphatase calcineurin in Foxp3 function. We have also shown that binding of Foxp3 to the IL-2 and IFN gamma genes induces active deacetylation of histone H3, a process that inhibits chromatin remodeling and opposes gene transcription. Conversely, binding of Foxp3 to the GITR, CD25, and CTLA-4 genes results in increased histone acetylation. These data indicate that Foxp3 may regulate transcription through direct chromatin remodeling and show that Foxp3 function is influenced by signals from the TCR.	Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Wells, AD (corresponding author), 916E Abramson Res Ctr, 3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	adwells@mail.med.upenn.edu	Thomas, Rajan M/AAW-7207-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059881] Funding Source: NIH RePORTER; NIAID NIH HHS [AI059881] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Arden KC, 2002, ARCH BIOCHEM BIOPHYS, V403, P292, DOI 10.1016/S0003-9861(02)00207-2; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Grant C, 2006, PLOS PATHOG, V2, P303, DOI 10.1371/journal.ppat.0020033; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Kasprowicz DJ, 2003, J IMMUNOL, V171, P1216, DOI 10.4049/jimmunol.171.3.1216; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nirula A, 1997, J BIOL CHEM, V272, P7736, DOI 10.1074/jbc.272.12.7736; Northrop JK, 2006, J IMMUNOL, V177, P1062, DOI 10.4049/jimmunol.177.2.1062; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; Su L, 2004, J IMMUNOL, V173, P4994, DOI 10.4049/jimmunol.173.8.4994; Thomas RM, 2005, J IMMUNOL, V174, P4639, DOI 10.4049/jimmunol.174.8.4639; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; von Herrath MG, 2003, NAT REV IMMUNOL, V3, P223, DOI 10.1038/nri1029; Wang B, 2003, J BIOL CHEM, V278, P24259, DOI 10.1074/jbc.M207174200; Ward SB, 1998, NUCLEIC ACIDS RES, V26, P2923, DOI 10.1093/nar/26.12.2923; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Zhu NH, 2003, J IMMUNOL, V170, P325, DOI 10.4049/jimmunol.170.1.325	34	172	178	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36828	36834		10.1074/jbc.M608848200	http://dx.doi.org/10.1074/jbc.M608848200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028180	hybrid			2022-12-25	WOS:000242220800041
J	Okkenhaug, H; Weylandt, KH; Carmena, D; Wells, DJ; Higgins, CF; Sardini, A				Okkenhaug, Hanneke; Weylandt, Karsten-Henrich; Carmena, David; Wells, Dominic J.; Higgins, Christopher F.; Sardini, Alessandro			The human ClC-4 protein, a member of the CLC chloride channel/transporter family, is localized to the endoplasmic reticulum by its N-terminus	FASEB JOURNAL			English	Article						CLC family proteins; targeting motif; sarcoplasmic reticulum	SKELETAL-MUSCLE; MOLECULAR-BASIS; CHANNEL; MEMBRANE; GENE; ACIDIFICATION; COLOCALIZES; EXPRESSION; MUTATIONS; TRANSPORT	Despite considerable similarity in their amino acid sequences and structural features, the mammalian members of the CLC chloride channel/transporter family have different subcellular locations. The subcellular location and function of one of these members, hClC-4, is controversial. To characterize its cellular function, we investigated its tissue distribution and subcellular location. Expression was high in excitable tissues such as the nervous system and skeletal muscle. When heterologously expressed in HEK293 cells and in skeletal muscle fibers, hClC-4 localizes to the endoplasmic/sarcoplasmic reticulum (ER/SR) membranes, in contrast to hClC-3, which localizes to vesicular structures. This location was confirmed by identification of endogenous ClC-4 in membrane fractions from mouse brain homogenate enriched for the sarco-endoplasmic reticulum ATPase SERCA2, an ER/SR marker. To identify the motif responsible for ER localization of hClC-4, we generated hClC-4 truncations and chimeras between hClC-4 and hClC-3 or the unrelated plasma membrane protein Ly49E. A stretch of amino acids, residues 14-63, at the N-terminus constitutes a novel motif both necessary and sufficient for targeting hClC-4 and other membrane proteins to the ER.	Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Cellular & Mol Neurosci, Div Neurosci & Psychol Med,Gene Targeting Unit, London, England	Imperial College London; Imperial College London	Sardini, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	a.sardini@csc.mrc.ac.uk	Carmena, David/S-4049-2019	Carmena, David/0000-0002-4015-8553; Okkenhaug, Hanneke/0000-0003-0669-4069; Wells, Dominic/0000-0002-1425-6344				Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Buyse G, 1998, BIOCHEM J, V330, P1015, DOI 10.1042/bj3301015; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Gays F, 2005, J IMMUNOL, V175, P2938, DOI 10.4049/jimmunol.175.5.2938; Guerini D, 2002, FASEB J, V16, P519, DOI 10.1096/fj.01-0362com; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Haug K, 2003, NAT GENET, V33, P527, DOI 10.1038/ng1121; Hebeisen S, 2003, BIOPHYS J, V84, P2306, DOI 10.1016/S0006-3495(03)75036-X; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hui D, 2000, J BIOL CHEM, V275, P2713, DOI 10.1074/jbc.275.4.2713; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; JONASSEN I, 1995, PROTEIN SCI, V4, P1587, DOI 10.1002/pro.5560040817; Kawasaki Masanobu, 1999, American Journal of Physiology, V277, pC948; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Kuwana T, 1998, P NATL ACAD SCI USA, V95, P1056, DOI 10.1073/pnas.95.3.1056; Li XH, 2002, AM J PHYSIOL-CELL PH, V282, pC1483, DOI 10.1152/ajpcell.00504.2001; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Ludwig M, 2004, AM J MED GENET A, V128A, P434, DOI 10.1002/ajmg.a.30204; McMahon JM, 2001, GENE THER, V8, P1264, DOI 10.1038/sj.gt.3301522; Mohammad-Panah R, 2003, J BIOL CHEM, V278, P29267, DOI 10.1074/jbc.M304357200; Mohammad-Panah R, 2002, J BIOL CHEM, V277, P566, DOI 10.1074/jbc.M106968200; Newton T, 2003, BIOCHEM J, V371, P775, DOI 10.1042/BJ20021477; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Picollo A, 2005, NATURE, V436, P420, DOI 10.1038/nature03720; Ryan MM, 1999, AM J HUM GENET, V65, P1104, DOI 10.1086/302588; Salazar G, 2004, J BIOL CHEM, V279, P25430, DOI 10.1074/jbc.M402331200; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Suzuki T, 2006, J CELL PHYSIOL, V206, P792, DOI 10.1002/jcp.20516; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Toomey JA, 1998, EUR J IMMUNOL, V28, P47, DOI 10.1002/(SICI)1521-4141(199801)28:01<47::AID-IMMU47>3.0.CO;2-A; Vanoye CG, 2002, J PHYSIOL-LONDON, V539, P373, DOI 10.1113/jphysiol.2001.013115; VANSLEGTENHORST MA, 1994, HUM MOL GENET, V3, P547; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wang T, 2004, GASTROENTEROLOGY, V126, P1157, DOI 10.1053/j.gastro.2004.01.015; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang AH, 2005, GENE, V350, P25, DOI 10.1016/j.gene.2005.01.019	49	25	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2390	+		10.1096/fj.05-5588fje	http://dx.doi.org/10.1096/fj.05-5588fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023393				2022-12-25	WOS:000241702600030
J	Vincan, E; Darcy, PK; Farrelly, CA; Faux, MC; Brabletz, T; Ramsay, RG				Vincan, E.; Darcy, P. K.; Farrelly, C. A.; Faux, M. C.; Brabletz, T.; Ramsay, R. G.			Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids	ONCOGENE			English	Article						frizzled-7; Wnt signalling; colorectal cancer; carcinoma morphogenesis	EPITHELIAL-MESENCHYMAL TRANSITIONS; LAMININ-5 GAMMA-2 CHAIN; BETA-CATENIN EXPRESSION; TRANSCRIPTIONAL ACTIVATION; EPIGENETIC INACTIVATION; SIGNALING CONTROLS; WNT; DIFFERENTIATION; RECEPTOR; XENOPUS	Progression of colorectal cancer (CRC) involves spatial and temporal occurrences of epithelial-mesenchymal transition (EMT), whereby tumour cells acquire a more invasive and metastatic phenotype. Subsequently, the disseminated mesenchymal tumour cells must undergo a reverse transition (mesenchymal-epithelial transition, MET) at the site of metastases, as most metastases recapitulate the pathology of their corresponding primary tumours. Importantly, initiation of tumour growth at the secondary site is the rate-limiting step in metastasis. However, investigation of this dynamic reversible EMT and MET that underpins CRC morphogenesis has been hindered by a lack of suitable in vitro models. To this end, we have established a unique in vitro model of CRC morphogenesis, which we term LIM1863-Mph (morphogenetic). LIM1863-Mph cells spontaneously undergo cyclic transitions between two-dimensional monolayer (migratory, mesenchymal) and three-dimensional sphere (carcinoid, epithelial) states. Using RNAi, we demonstrate that FZD7 is necessary for MET of the monolayer cells as loss of FZD7 results in the persistence of a mesenchymal state (increased SNAI2/decreased E-cadherin). Moreover, FZD7 is also required for migration of the LIM1863-Mph monolayer cells. During development, FZD7 orchestrates either migratory or epithelialization events depending on the context. Our findings strongly implicate similar functional diversity for FZD7 during CRC morphogenesis.	Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3001, Australia; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Parkville, Vic, Australia; Univ Erlangen Nurnberg, Dept Pathol, Erlangen, Germany	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Ludwig Institute for Cancer Research; University of Erlangen Nuremberg	Vincan, E (corresponding author), Peter MacCallum Canc Ctr, Div Res, St Andrews Pl, Melbourne, Vic 3001, Australia.	Elizabeth.Vincan@petermac.org	Ramsay, Robert G/C-3291-2015	Ramsay, Robert G/0000-0001-5003-0433; Darcy, Phillip/0000-0002-5303-9561; Vincan, Elizabeth/0000-0002-8607-4849				Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; BATES R, 2005, 2 EMT M VANC; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Burstyn-Cohen T, 2004, DEVELOPMENT, V131, P5327, DOI 10.1242/dev.01424; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carroll TJ, 2005, DEV CELL, V9, P283, DOI 10.1016/j.devcel.2005.05.016; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; De Calisto J, 2005, DEVELOPMENT, V132, P2587, DOI 10.1242/dev.01857; Djiane A, 2000, DEVELOPMENT, V127, P3091; Eckhardt BL, 2005, MOL CANCER RES, V3, P1; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilles C, 2001, J CELL SCI, V114, P2967; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; HAYWARD IP, 1995, IMMUNOL CELL BIOL, V73, P249, DOI 10.1038/icb.1995.41; HAYWARD IP, 1992, INT J CANCER, V50, P752, DOI 10.1002/ijc.2910500515; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hlubek F, 2004, INT J CANCER, V108, P321, DOI 10.1002/ijc.11522; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kao KR, 1998, BIOL CELL, V90, P585, DOI 10.1016/S0248-4900(99)80016-1; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2002, SEMIN CELL DEV BIOL, V13, P243, DOI 10.1016/S1084-9521(02)00050-2; Linker C, 2005, DEVELOPMENT, V132, P3895, DOI 10.1242/dev.01961; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Minobe S, 2000, DEV GENES EVOL, V210, P258, DOI 10.1007/s004270050312; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; PYKE C, 1995, CANCER RES, V55, P4132; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Schmidt C, 2004, DEV BIOL, V271, P198, DOI 10.1016/j.ydbio.2004.03.016; Schubert FR, 2002, MECH DEVELOP, V114, P143, DOI 10.1016/S0925-4773(02)00039-4; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tada M, 2002, SEMIN CELL DEV BIOL, V13, P251, DOI 10.1016/S1084-9521(02)00052-6; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; Thompson MA, 1998, CANCER RES, V58, P5168; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vincan E, 2005, DIFFERENTIATION, V73, P142, DOI 10.1111/j.1432-0436.2005.00015.x; Vincan E, 2004, FRONT BIOSCI-LANDMRK, V9, P1023, DOI 10.2741/1311; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621	53	53	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2340	2352		10.1038/sj.onc.1210026	http://dx.doi.org/10.1038/sj.onc.1210026			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016432				2022-12-25	WOS:000245466000010
J	Berlingieri, MT; Pallante, P; Guida, M; Nappi, C; Masciullo, V; Scambia, G; Ferraro, A; Leone, V; Sboner, A; Barbareschi, M; Ferro, A; Troncone, G; Fusco, A				Berlingieri, M. T.; Pallante, P.; Guida, M.; Nappi, C.; Masciullo, V.; Scambia, G.; Ferraro, A.; Leone, V.; Sboner, A.; Barbareschi, M.; Ferro, A.; Troncone, G.; Fusco, A.			UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas	ONCOGENE			English	Article						UbcH10; ovarian; carcinomas; immunohistochemistry	CANCER; OVEREXPRESSION; BREAST	The UbcH10 gene codes for a protein that belongs to the ubiquitin-conjugating enzyme family. Previous studies of our group suggest UbcH10 expression as a valid indicator of the proliferative and aggressive status of thyroid carcinomas. Therefore, to better understand the process of ovarian carcinogenesis, and to look for possible tools to be used as prognostic markers in these neoplasias, we decided to extend the analysis of the UbcH10 expression to the ovarian neoplastic disease. We found that the UbcH10 gene was upregulated in some ovarian carcinoma cell lines analysed. Then, immunohistochemical studies demonstrate that UbcH10 expression significantly correlates with the tumor grade and the undifferentiated histotype of the ovarian carcinomas. Furthermore, a significant relationship between UbcH10 expression and overall survival was observed. Finally, the block of UbcH10 protein synthesis by RNA interference inhibited the growth of ovarian carcinoma cell lines, suggesting a role of UbcH10 overexpression in ovarian carcinogenesis. Therefore, all these data taken together suggest the possibility to use UbcH10 detection as a marker for the diagnosis and prognosis of these neoplastic diseases and open the perspective of a therapy of some ovarian carcinomas based on the suppression of the UbcH10 synthesis and/or function.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Mol, Ist Endocrinol & Oncol Sperimenatle,CNR, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Ginecol & Ostetr, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Fisiopatol Riproduz Umana, I-80131 Naples, Italy; Univ Naples Federico II, Chirurg Napoli, I-80131 Naples, Italy; Univ Cattolica S Cuore, Ist Clin Ostet & Ginecol, Rome, Italy; European Sch Mol Med, SEMM, Naples, Italy; Naples Oncogenom Ctr, CEINGE, NOGEC, Naples, Italy; Ctr Sci & Technol Res, SRA Div ITC Irst, Trento, Italy; UO Anatomia Patol Osped S Chiara Largo Medaglie O, Trento, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Anat Patol & Citopatol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare, Ist Endocrinol & Oncol Sperimenatle,CNR, I-80131 Naples, Italy.	afusco@napoli.com	Ferro, Antonella/AAA-8241-2020; Pallante, Pierlorenzo/AAX-8758-2020; Ferraro, Angelo/A-4172-2014; Sboner, Andrea/C-6487-2008; Barbareschi, Mattia/AAF-2043-2020; Ferraro, Angelo/H-3193-2019	Ferro, Antonella/0000-0003-4109-6769; Ferraro, Angelo/0000-0002-2044-7569; Sboner, Andrea/0000-0001-6915-3070; Ferraro, Angelo/0000-0002-2044-7569; Fusco, Alfredo/0000-0003-3332-5197				ALDOVINI D, 2006, INT J CANCER, P27; [Anonymous], 2003, WHO CLASSIFICATION T; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Liu Xueli, 2004, J Biopharm Stat, V14, P671, DOI 10.1081/BIP-200025657; Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; PIERANTONI GM, 2005, CELL DEATH DIFFER, P1; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; Troncone G, 2003, J CLIN PATHOL, V56, P587, DOI 10.1136/jcp.56.8.587; VACHERLAVENU MC, 1993, B CANCER, V80, P135; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705	17	63	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2136	2140		10.1038/sj.onc.1210010	http://dx.doi.org/10.1038/sj.onc.1210010			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016443				2022-12-25	WOS:000245313400016
J	Andersson, MX; Goksor, M; Sandelius, AS				Andersson, Mats X.; Goksor, Mattias; Sandelius, Anna Stina			Optical manipulation reveals strong attracting forces at membrane contact sites between endoplasmic reticulum and chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRAFFICKING; PLASMA-MEMBRANE; PHOSPHATE DEPRIVATION; PHOSPHOLIPIDS; PHOSPHATIDYLCHOLINE; BIOSYNTHESIS; MITOCHONDRIA; SUBFRACTION; DEFICIENT; DIFFUSION	Eukaryote cells depend on membrane lipid trafficking from biogenic membranes, like the endoplasmic reticulum (ER), to other membranes in the cell. Two major routes for membrane lipid transport are recognized: vesicular trafficking and lipid transfer at zones of close contact between membranes. Specific ER regions involved in such membrane contact sites (MCSs) have been isolated, and lipid transfer at MCSs as well as protein-protein interactions between the partaking membranes have been demonstrated (reviewed by Holthuis, J. C. M., and Levine, T. P. (2005) Nat. Rev. 6, 209 - 220). Here we present the first demonstration of the physical association between membranes involved in MCSs: by using optical imaging and manipulation, strong attracting forces between ER and chloroplasts are revealed. We used Arabidopsis thaliana expressing green fluorescent protein in the ER lumen and observed leaf protoplasts by confocal microscopy. The ER network was evident, with ER branch end points apparently localized at chloroplast surfaces. After rupture of a protoplast using a laser scalpel, the cell content was released. ER fragments remained attached to the released chloroplasts and could be stretched out by optical tweezers. The applied force, 400 pN, could not drag a chloroplast free from its attached ER, which could reflect protein-protein interactions at the ER-chloroplast MCSs. Aschloroplasts rely on import of ER-synthesized lipids, we propose that lipid transfer occurs at these MCSs. We suggest that lipid transfer at the MCSs also occurs in the opposite direction, for example to channel plastid-synthesized acyl groups to supply substrates for ER-localized synthesis of membrane and storage lipids.	Univ Gothenburg, Dept Plant & Environm Sci, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Phys, SE-40530 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Sandelius, AS (corresponding author), Univ Gothenburg, Dept Plant & Environm Sci, POB 461, SE-40530 Gothenburg, Sweden.	annastina.sandelius@botany.gu.se	Andersson, Mats/E-7958-2010	Andersson, Mats/0000-0003-4279-6572				Andersson MX, 2005, J BIOL CHEM, V280, P27578, DOI 10.1074/jbc.M503273200; Andersson MX, 2004, BBA-MOL CELL BIOL L, V1684, P46, DOI 10.1016/j.bbalip.2004.06.003; Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; Benning C, 2006, CURR OPIN PLANT BIOL, V9, P241, DOI 10.1016/j.pbi.2006.03.012; CAHOON EB, 1994, PLANT PHYSIOL, V104, P845, DOI 10.1104/pp.104.3.845; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; Douce R, 1982, METHODS CHLOROPLAST, P139; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; GHISLAIN LP, 1994, REV SCI INSTRUM, V65, P2762, DOI 10.1063/1.1144613; Goksor M, 2003, EMBO REP, V4, P867, DOI 10.1038/sj.embor.embor916; GRABSKI S, 1993, PLANT CELL, V5, P25, DOI 10.1105/tpc.5.1.25; Hanson MR, 2001, J EXP BOT, V52, P529, DOI 10.1093/jexbot/52.356.529; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; Jouhet J, 2004, J CELL BIOL, V167, P863, DOI 10.1083/jcb.200407022; Kaneko Y, 1996, PROTOPLASMA, V195, P59, DOI 10.1007/BF01279186; Kelly AA, 2003, PLANT CELL, V15, P2694, DOI 10.1105/tpc.016675; Kelly AA, 2004, CURR OPIN PLANT BIOL, V7, P262, DOI 10.1016/j.pbi.2004.03.009; Kjellberg JM, 2000, BBA-MOL CELL BIOL L, V1485, P100, DOI 10.1016/S1388-1981(00)00040-8; Koo AJK, 2004, J BIOL CHEM, V279, P16101, DOI 10.1074/jbc.M311305200; Kunst L, 2003, PROG LIPID RES, V42, P51, DOI 10.1016/S0163-7827(02)00045-0; Mathur J, 1998, METH MOL B, V82, P35; Matsushima R, 2002, PLANT PHYSIOL, V130, P1807, DOI 10.1104/pp.009464; MIQUEL M, 1992, J BIOL CHEM, V267, P1502; Moreau P, 1998, PROG LIPID RES, V37, P371, DOI 10.1016/S0163-7827(98)00016-2; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; Rantfors M, 2000, PHYSIOL PLANTARUM, V110, P262, DOI 10.1034/j.1399-3054.2000.110217.x; Staehelin LA, 1997, PLANT J, V11, P1151, DOI 10.1046/j.1365-313X.1997.11061151.x; VANCE JE, 1991, J BIOL CHEM, V266, P89; Villarejo A, 2005, NAT CELL BIOL, V7, P1224, DOI 10.1038/ncb1330; WHATLEY JM, 1991, NEW PHYTOL, V117, P209, DOI 10.1111/j.1469-8137.1991.tb04901.x; WOODING FBP, 1965, AM J BOT, V52, P526, DOI 10.2307/2440270	34	152	156	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1170	1174		10.1074/jbc.M608124200	http://dx.doi.org/10.1074/jbc.M608124200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17077082	hybrid			2022-12-25	WOS:000243295200042
J	Wang, YD; Oeser, JK; Yang, CM; Sarkar, S; Hackl, SI; Hasty, AH; McGuinness, OP; Paradee, W; Hutton, JC; Powell, DR; O'Brien, RM				Wang, Yingda; Oeser, James K.; Yang, Chunmei; Sarkar, Suparna; Hackl, Seija I.; Hasty, Alyssa H.; McGuinness, Owen P.; Paradee, William; Hutton, John C.; Powell, David R.; O'Brien, Richard M.			Deletion of the gene encoding the ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein (UGRP)/glucose-6-phosphatase catalytic subunit-beta results in lowered plasma cholesterol and elevated glucagon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; GLUCOSE-PRODUCTION; IN-VIVO; BLOOD-GLUCOSE; MICE LACKING; METABOLISM; IDENTIFICATION; TYPE-1A; CLONING; LIVER	In liver, glucose-6-phosphatase catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose and inorganic phosphate, the final step in the gluconeogenic and glycogenolytic pathways. Mutations in the glucose-6-phosphatase catalytic subunit (G6Pase) give rise to glycogen storage disease (GSD) type 1a, which is characterized in part by hypoglycemia, growth retardation, hypertriglyceridemia, hypercholesterolemia, and hepatic glycogen accumulation. Recently, a novel G6Pase isoform was identified, designated UGRP/G6Pase-beta. The activity of UGRP relative to G6Pase in vitro is disputed, raising the question as to whether G6P is a physiologically important substrate for this protein. To address this issue we have characterized the phenotype of UGRP knock-out mice. G6P hydrolytic activity was decreased by similar to 50% in homogenates of UGRP(-/-) mouse brain relative to wild type tissue, consistent with the ability of UGRP to hydrolyze G6P. In addition, female, but not male, UGRP(-/-) mice exhibit growth retardation as do G6Pase(-/-) mice and patients with GSD type 1a. However, in contrast to G6Pase(-/-) mice and patients with GSD type 1a, UGRP(-/-) mice exhibit no change in hepatic glycogen content, blood glucose, or triglyceride levels. Although UGRP(-/-) mice are not hypoglycemic, female UGRP(-/-) mice have elevated (similar to 60%) plasma glucagon and reduced (similar to 20%) plasma cholesterol. We hypothesize that the hyperglucagonemia prevents hypoglycemia and that the hypocholesterolemia is secondary to the hyperglucagonemia. As such, the phenotype of UGRP(-/-) mice is mild, indicating that G6Pase is the major glucose-6-phosphatase of physiological importance for glucose homeostasis in vivo.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Lexicon Genet Inc, The Woodlands, TX 77381 USA; Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Aurora, CO 80045 USA	Vanderbilt University; Lexicon Pharmaceuticals; University of Colorado System; University of Colorado Anschutz Medical Campus	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 761 PRB, Nashville, TN 37232 USA.		Hasty, Alyssa/AAA-2757-2020	Hasty, Alyssa/0000-0001-7302-8045	NIDDK NIH HHS [DK56374, P30 DK57516, DK59637, P60 DK20593, DK61645, DK064877, U24 DK059637] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061645, R21DK064877, P30DK057516, P60DK020593, R01DK056374, U24DK059637] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arden SD, 1999, DIABETES, V48, P531, DOI 10.2337/diabetes.48.3.531; ASSIMACO.F, 1973, AM J PHYSIOL, V225, P25, DOI 10.1152/ajplegacy.1973.225.1.25; BOTHAM KM, 1992, BIOCHEM SOC T, V20, P454, DOI 10.1042/bst0200454; Boustead JN, 2004, J MOL ENDOCRINOL, V32, P33, DOI 10.1677/jme.0.0320033; Brissova Marcela, 2003, Methods Mol Med, V83, P23; Burcelin R, 2000, J BIOL CHEM, V275, P10930, DOI 10.1074/jbc.275.15.10930; BYERS SO, 1975, P SOC EXP BIOL MED, V149, P151, DOI 10.3181/00379727-149-38762; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chen LY, 2003, HUM MOL GENET, V12, P2547, DOI 10.1093/hmg/ddg263; Cherrington AD, 1999, DIABETES, V48, P1198, DOI 10.2337/diabetes.48.5.1198; Cherrington AD, 1998, DIABETOLOGIA, V41, P987, DOI 10.1007/s001250051021; Chou Janice Yang, 2002, Current Molecular Medicine (Hilversum), V2, P121, DOI 10.2174/1566524024605798; Ebert DH, 1999, DIABETES, V48, P543, DOI 10.2337/diabetes.48.3.543; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Gelling RW, 2003, P NATL ACAD SCI USA, V100, P1438, DOI 10.1073/pnas.0237106100; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; Ghosh A, 2005, J BIOL CHEM, V280, P11114, DOI 10.1074/jbc.M410894200; Ghosh A, 2004, J BIOL CHEM, V279, P12479, DOI 10.1074/jbc.M313271200; GOODWIN GW, 1995, J BIOL CHEM, V270, P9234, DOI 10.1074/jbc.270.16.9234; Guionie O, 2003, FEBS LETT, V551, P159, DOI 10.1016/S0014-5793(03)00903-7; Hornbuckle LA, 2004, AM J PHYSIOL-ENDOC M, V286, pE795, DOI 10.1152/ajpendo.00455.2003; Hutton JC, 2003, P NATL ACAD SCI USA, V100, P8626, DOI 10.1073/pnas.1633447100; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Martin CC, 2002, J MOL ENDOCRINOL, V29, P205, DOI 10.1677/jme.0.0290205; Martin CC, 2001, J BIOL CHEM, V276, P25197, DOI 10.1074/jbc.M101549200; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Moses SW, 2002, EUR J PEDIATR, V161, pS2, DOI 10.1007/s00431-002-0997-6; Petrolonis AJ, 2004, J BIOL CHEM, V279, P13976, DOI 10.1074/jbc.M307756200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; Shieh JJ, 2005, DIABETOLOGIA, V48, P1851, DOI 10.1007/s00125-005-1848-6; Shieh JJ, 2004, FEBS LETT, V562, P160, DOI 10.1016/S0014-5793(04)00223-6; Shieh JJ, 2003, J BIOL CHEM, V278, P47098, DOI 10.1074/jbc.M309472200; Shieh JJ, 2004, J BIOL CHEM, V279, P26215, DOI 10.1074/jbc.M402036200; TALENTE GM, 1994, ANN INTERN MED, V120, P218, DOI 10.7326/0003-4819-120-3-199402010-00008; TSALIKIAN E, 1984, AM J PHYSIOL, V247, pE513, DOI 10.1152/ajpendo.1984.247.4.E513; UNGER RH, 1976, PHYSIOL REV, V56, P778, DOI 10.1152/physrev.1976.56.4.778; van de Werve G, 2000, EUR J BIOCHEM, V267, P1533, DOI 10.1046/j.1432-1327.2000.01160.x; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Wattler S, 1999, BIOTECHNIQUES, V26, P1150, DOI 10.2144/99266rr02; YEN TT, 1980, RES COMMUN CHEM PATH, V30, P29	44	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39982	39989		10.1074/jbc.M605858200	http://dx.doi.org/10.1074/jbc.M605858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17023421	hybrid			2022-12-25	WOS:000243033900026
J	Hase, ME; Yalamanchili, P; Visa, N				Hase, Manuela E.; Yalamanchili, Prakash; Visa, Neus			The Drosophila heterogeneous nuclear ribonucleoprotein M protein, HRP59, regulates alternative splicing and controls the production of its own mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT BINDING-PROTEIN; HNRNP M-PROTEIN; IN-VIVO; COMPLEXES; MELANOGASTER; ENHANCERS; ISOFORMS; DECAY; IDENTIFICATION; EXPRESSION	The Drosophila heterogeneous nuclear ribonucleoprotein M, HRP59, is a nuclear protein that associates co-transcriptionally with pre-mRNA and is necessary for the correct expression of a subset of mRNAs. We show here that the hrp59 pre-mRNA is alternatively spliced to generate two different mRNAs that differ in the presence of exon 3. Exon 3-containing transcripts make up the majority of hrp59 transcripts and encode for the functional protein, HRP59-1. Transcripts that lack exon 3 contain a premature translation termination codon and are targeted to the nonsense mediated decay pathway. We show that exon 3 inclusion is itself inhibited by HRP59 and that changes in the HRP59 protein levels affect the splicing activity of the cell. We propose that the ability of HRP59 to regulate the alternative splicing of its own pre-mRNA serves in a negative feedback loop that controls the levels of the HRP59 protein and maintains the homeostasis of the splicing environment.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Hase, ME (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.	manuela.hase@biosci.ki.se	Visa, Neus/C-9459-2016; Visa, Neus/R-8037-2019	Visa, Neus/0000-0003-3145-3953; Visa, Neus/0000-0003-3145-3953; Dahinden, Manuela/0000-0002-8546-5469				Benoist P, 1998, J BIOL CHEM, V273, P7538, DOI 10.1074/jbc.273.13.7538; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DATAR KV, 1993, NUCLEIC ACIDS RES, V21, P439, DOI 10.1093/nar/21.3.439; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Gatfield D, 2004, NATURE, V429, P575, DOI 10.1038/nature02559; HAYNES SR, 1990, MOL BIOL REP, V14, P93, DOI 10.1007/BF00360430; Heinrichs V, 1997, P NATL ACAD SCI USA, V94, P115, DOI 10.1073/pnas.94.1.115; Herranz R, 2005, MOL BIOL EVOL, V22, P2231, DOI 10.1093/molbev/msi223; Kafasla P, 2000, BIOCHEM J, V350, P495, DOI 10.1042/0264-6021:3500495; Kafasla P, 2002, BIOCHEM J, V363, P793, DOI 10.1042/0264-6021:3630793; Kiesler E, 2005, J CELL BIOL, V168, P1013, DOI 10.1083/jcb.200407173; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; MARTINEZCONTERA.R, 2006, PLOS BIOL, V4, P185; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MATUNIS MJ, 1992, J CELL BIOL, V116, P245, DOI 10.1083/jcb.116.2.245; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Norvell A, 1999, GENE DEV, V13, P864, DOI 10.1101/gad.13.7.864; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Philipps DL, 2004, RNA, V10, P1838, DOI 10.1261/rna.7136104; RAYCHAUDHURI G, 1992, MOL CELL BIOL, V12, P847, DOI 10.1128/MCB.12.2.847; SHEN J, 1995, P NATL ACAD SCI USA, V92, P1822, DOI 10.1073/pnas.92.6.1822; SIEBEL CW, 1994, GENE DEV, V8, P1713, DOI 10.1101/gad.8.14.1713; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; VALCARCEL J, 1997, CURR BIOL, V7, P705; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Zu K, 1998, RNA, V4, P1585, DOI 10.1017/S135583829898102X; Zu K, 1996, MOL BIOL CELL, V7, P1059, DOI 10.1091/mbc.7.7.1059	35	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39135	39141		10.1074/jbc.M604235200	http://dx.doi.org/10.1074/jbc.M604235200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17077090	hybrid			2022-12-25	WOS:000242898700021
J	Stahelin, RV; Karathanassis, D; Bruzik, KS; Waterfield, MD; Bravo, J; Williams, RL; Cho, WW				Stahelin, Robert V.; Karathanassis, Dimitrios; Bruzik, Karol S.; Waterfield, Michael D.; Bravo, Jeronimo; Williams, Roger L.; Cho, Wonhwa			Structural and membrane binding analysis of the phox homology domain of phosphoinositide 3-kinase-C2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ALPHA; PX-DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; CRYSTAL-STRUCTURE; PROTEIN INTERACTIONS; LIPID PRODUCTS; CLATHRIN; LOCALIZATION; ACTIVATION; ROLES	Phox homology (PX) domains, which have been identified in a variety of proteins involved in cell signaling and membrane trafficking, have been shown to interact with phosphoinositides (PIs) with different affinities and specificities. To elucidate the structural origin of diverse PI specificities of PX domains, we determined the crystal structure of the PX domain from phosphoinositide 3-kinase C2 alpha (PI3K-C2 alpha), which binds phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2). To delineate the mechanism by which this PX domain interacts with membranes, we measured the membrane binding of the wild type domain and mutants by surface plasmon resonance and monolayer techniques. This PX domain contains a signature PI-binding site that is optimized for PtdIns( 4,5) P-2 binding. The membrane binding of the PX domain is initiated by nonspecific electrostatic interactions followed by the membrane penetration of hydrophobic residues. Membrane penetration is specifically enhanced by PtdIns( 4,5) P-2. Furthermore, the PX domain displayed significantly higher PtdIns( 4,5) P-2 membrane affinity and specificity when compared with the PI3K-C2 alpha C2 domain, demonstrating that high affinity PtdIns( 4,5) P-2 binding was facilitated by the PX domain in full-length PI3K-C2 alpha. Together, these studies provide new structural insight into the diverse PI specificities of PX domains and elucidate the mechanism by which the PI3K-C2 alpha PX domain interacts with PtdIns( 4,5) P-2-containing membranes and thereby mediates the membrane recruitment of PI3K-C2 alpha.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60607 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; MRC Laboratory Molecular Biology; Ludwig Institute for Cancer Research; University of London; University College London	Cho, WW (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Bravo, Jeronimo/K-9103-2014; Stahelin, Robert/L-3567-2019	Bravo, Jeronimo/0000-0001-6695-2846; Williams, Roger/0000-0001-7754-4207; Stahelin, Robert/0000-0001-5443-7863	Medical Research Council [MC_U105184308] Funding Source: Medline; NIGMS NIH HHS [GM68849] Funding Source: Medline; MRC [MC_U105184308] Funding Source: UKRI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068849] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Ago T, 2001, BIOCHEM BIOPH RES CO, V287, P733, DOI 10.1006/bbrc.2001.5629; Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECK KA, 1991, J BIOL CHEM, V266, P4442; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; BRUZIK KS, 1995, TETRAHEDRON LETT, V36, P2415, DOI 10.1016/0040-4039(95)00317-6; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantrell DA, 2001, J CELL SCI, V114, P1439; Catz SD, 2002, P NATL ACAD SCI USA, V99, P11652, DOI 10.1073/pnas.172382799; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; CHO W, 2006, SCI STKE 2006; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Cremona O, 2001, J CELL SCI, V114, P1041; Czech MP, 2003, ANNU REV PHYSIOL, V65, P791, DOI 10.1146/annurev.physiol.65.092101.142522; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; DINITTO JP, 2003, SCI STKE; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; Dunn R, 2004, J CELL BIOL, V165, P135, DOI 10.1083/jcb.200309026; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gaidarov I, 2005, J BIOL CHEM, V280, P40766, DOI 10.1074/jbc.M507731200; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Leslie NR, 2001, CHEM REV, V101, P2365, DOI 10.1021/cr000091i; Li LY, 2006, J BIOL CHEM, V281, P15845, DOI 10.1074/jbc.M600888200; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Liu LJ, 2006, J BIOL CHEM, V281, P4254, DOI 10.1074/jbc.M510791200; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Meunier FA, 2005, MOL BIOL CELL, V16, P4841, DOI 10.1091/mbc.E05-02-0171; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Stahelin RV, 2004, J BIOL CHEM, V279, P54918, DOI 10.1074/jbc.M407798200; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Winters MJ, 2005, MOL CELL, V20, P21, DOI 10.1016/j.molcel.2005.08.020; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xing Y, 2004, J BIOL CHEM, V279, P30662, DOI 10.1074/jbc.M404107200; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081; Zhou CZ, 2003, J BIOL CHEM, V278, P50371, DOI 10.1074/jbc.M304392200	86	54	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39396	39406		10.1074/jbc.M607079200	http://dx.doi.org/10.1074/jbc.M607079200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17038310	hybrid			2022-12-25	WOS:000242898700047
J	Zhang, Y; Ge, GX; Greenspan, DS				Zhang, Yue; Ge, Gaoxiang; Greenspan, Daniel S.			Inhibition of bone morphogenetic protein 1 by native and altered forms of alpha(2)-macroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; HUMAN ALPHA-2-MACROGLOBULIN; METALLOPROTEINASE; COLLAGEN; FAMILY; KERATINOCYTES; LAMININ-5; CLEAVAGE; COMPLEX; ALPHA	The four mammalian bone morphogenetic protein 1 (BMP1)-like proteinases act to proteolytically convert procollagens to the major fibrous components of the extracellular matrix. They also activate lysyl oxidase, an enzyme necessary to the covalent cross-linking that gives collagen fibrils much of their tensile strength. Thus, these four proteinases are attractive targets for interventions designed to limit the excess formation of fibrous collagenous matrix that characterizes fibrosis. Although it has previously been reported that the serum protein alpha(2)-macroglobulin is unable to inhibit the astacin-like proteinases meprin alpha and meprin beta, we herein demonstrate alpha(2)-macroglobulin to be a potent inhibitor of the similar BMP1-like proteinases. BMP1 is shown to cleave the alpha(2)-macroglobulin "bait" region, at a single specific site, which resembles the sites at which BMP1-like proteinases cleave the C-propeptides of procollagens I-III. alpha(2)-Macroglobulin is an irreversible inhibitor that is shown to bind bone morphogenetic protein 1 in a covalent complex. It is also demonstrated that genetically modified alpha(2)-macroglobulin, in which the native bait region is replaced by sequences flanking the probiglycan BMP1 cleavage site, is enhanced similar to 24- fold in its ability to inhibit BMP1, and is capable of inhibiting the biosynthetic processing of procollagen I by cells. These findings suggest possible therapeutic interventions involving ectopic expression of modified versions of alpha(2)-macroglobulin in the treatment of fibrotic conditions.	Univ Wisconsin, Dept Pathol & Lab Med, Program Cellular & Mol Biol, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Program Cellular & Mol Biol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), 1300 Univ Ave, Madison, WI 53706 USA.	dsgreens@wisc.edu		Greenspan, Daniel/0000-0001-8096-7446	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR047746, R01AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071679] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM71679] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; BIRK DE, 1990, J CELL SCI, V95, P649; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BYERS PH, 1995, DISORDERS COLLAGEN B; Canty EG, 2004, J CELL BIOL, V165, P553, DOI 10.1083/jcb.200312071; Colige A, 2005, J BIOL CHEM, V280, P34397, DOI 10.1074/jbc.M506458200; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FEINMAN RD, 1994, ANN NY ACAD SCI, V737, P245, DOI 10.1111/j.1749-6632.1994.tb44316.x; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ge GX, 2005, MOL CELL BIOL, V25, P5846, DOI 10.1128/MCB.25.14.5846-5858.2005; Greenspan DS, 2005, TOP CURR CHEM, V247, P149, DOI 10.1007/b103822; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kruse MN, 2004, BIOCHEM J, V378, P383, DOI 10.1042/BJ20031163; Lee HX, 2006, CELL, V124, P147, DOI 10.1016/j.cell.2005.12.018; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Prockop D.J., 1994, ASSEMBLY COLLAGEN FI; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STOCKER W, 1991, COMP BIOCHEM PHYS B, V98, P501, DOI 10.1016/0305-0491(91)90244-8; SWENSON RP, 1979, J BIOL CHEM, V254, P4452; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; VanRompaey L, 1997, BIOCHEM J, V326, P507; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100	31	35	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39096	39104		10.1074/jbc.M601362200	http://dx.doi.org/10.1074/jbc.M601362200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17071617	hybrid			2022-12-25	WOS:000242898700016
J	Freire-de-Lima, CG; Xiao, YQ; Gardai, SJ; Bratton, DL; Schiemann, WP; Henson, PM				Freire-de-Lima, Celio G.; Xiao, Yi Qun; Gardai, Shyra J.; Bratton, Donna L.; Schiemann, William P.; Henson, Peter M.			Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; 15-HYDROXYEICOSATETRAENOIC ACID; PROINFLAMMATORY CYTOKINES; PROSTAGLANDIN E-2; IMMUNE-RESPONSES; GENE-EXPRESSION; PPAR-GAMMA; PHOSPHATIDYLSERINE; PHAGOCYTOSIS; RECEPTOR	Apoptotic cells are rapidly engulfed by adjacent tissue cells or macrophages before they can release pro-inflammatory/proimmunogenic intracellular contents. In addition, recognition of the apoptotic cells is actively anti-inflammatory and anti-immunogenic with generation of anti-inflammatory mediators such as transforming growth factor-beta (TGF-beta) and anti-inflammatory eicosanoids. Here, we have investigated the role played by the induction of TGF-beta in the coordinate expression of anti-inflammatory eicosanoids or peroxisome proliferator-activated receptor-gamma and in the suppression of pro-inflammatory lipid mediators and nitric oxide ( NO). By use of a dominant negative TGF beta II receptor, TGF-beta signaling was blocked, and its participation in the consequences of apoptotic cell stimulation was determined. The induction of TGF-beta itself could be attributed to exposed phosphatidylserine on the apoptotic cells, which therefore appears to drive the balanced inflammatory mediator responses. Arachidonic acid release, COX-2, and prostaglandin synthase expression were shown to be significantly dependent on the TGF-beta production. On the other hand, a requirement for TGF-beta was also shown in the inhibition of thromboxane synthase and thromboxanes, of 5-lipoxygenase and sulfidopeptide leukotrienes, as well as of inducible nitric-oxide synthase and NO. TGF-beta-dependent induction of arginase was also found and would further limit the NO generation. Finally, apoptotic cells stimulated production of 15-lipoxygenase and 15-hydroxyeicosatetraenoic acid, a potentially anti-inflammatory pathway acting through peroxisome proliferator-activated receptor-beta, and lipoxin A(4) production, which were also up-regulated by a TGF-beta-dependent pathway in this system. These results strongly suggest that the apoptotic cell inhibition of pro-inflammatory mediator production is pleiotropic and significantly dependent on the stimulation of TGF-beta production.	Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, Denver, CO 80206 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944970 Rio De Janeiro, Brazil	National Jewish Health; Universidade Federal do Rio de Janeiro	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	hensonp@njc.org	de Lima, Celio Geraldo Freire/A-9057-2012		NHLBI NIH HHS [HL 81151, HL 67671] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067671, R01HL081151, P50HL067671] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bannenberg GL, 2004, J EXP MED, V199, P515, DOI 10.1084/jem.20031325; Bradbury DA, 2002, AM J PHYSIOL-LUNG C, V283, pL717, DOI 10.1152/ajplung.00070.2002; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; deCathelineau AM, 2003, ESSAYS BIOCHEM, V39, P105, DOI 10.1042/bse0390105; DIAZ A, 1989, J BIOL CHEM, V264, P11554; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Flores AM, 2005, CHEM-BIOL INTERACT, V151, P121, DOI 10.1016/j.cbi.2004.11.001; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; Gardai SJ, 2006, J LEUKOCYTE BIOL, V79, P896, DOI 10.1189/jlb.1005550; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Henson PM, 2006, TRENDS IMMUNOL, V27, P244, DOI 10.1016/j.it.2006.03.005; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hoffmann PR, 2005, J IMMUNOL, V174, P1393, DOI 10.4049/jimmunol.174.3.1393; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; Kowal-Bielecka O, 2005, ARTHRITIS RHEUM-US, V52, P3783, DOI 10.1002/art.21432; Kurosaka K, 1998, J IMMUNOL, V161, P6245; Kurosaka K, 2003, J IMMUNOL, V171, P4672, DOI 10.4049/jimmunol.171.9.4672; Kurosaka K, 2001, CELL IMMUNOL, V211, P1, DOI 10.1006/cimm.2001.1824; Luo J, 1998, J NEUROCHEM, V71, P526; Machado FS, 2006, NAT MED, V12, P330, DOI 10.1038/nm1355; Manaka J, 2004, J BIOL CHEM, V279, P48466, DOI 10.1074/jbc.M408597200; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; McDonald PP, 1999, J IMMUNOL, V163, P6164; MEAGHER LC, 1992, J LEUKOCYTE BIOL, V52, P269, DOI 10.1002/jlb.52.3.269; Mitani T, 2005, NITRIC OXIDE-BIOL CH, V13, P78, DOI 10.1016/j.niox.2005.05.001; Nair MG, 2003, IMMUNOL LETT, V85, P173, DOI 10.1016/S0165-2478(02)00225-0; Nataraj C, 2001, J CLIN INVEST, V108, P1229, DOI 10.1172/JCI13640; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Patel VA, 2006, J BIOL CHEM, V281, P4663, DOI 10.1074/jbc.M508342200; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RISTIMAKI A, 1990, ARTERIOSCLEROSIS, V10, P653, DOI 10.1161/01.ATV.10.4.653; SCHMIDT HHHW, 1989, BIOCHEM BIOPH RES CO, V165, P284, DOI 10.1016/0006-291X(89)91067-X; Seabra SH, 2004, BIOCHEM BIOPH RES CO, V324, P744, DOI 10.1016/j.bbrc.2004.09.114; Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Stern M, 1996, AM J PATHOL, V149, P911; TAKATA S, 1994, AM J PATHOL, V145, P541; Uchimura E, 1997, BIOCHEM BIOPH RES CO, V239, P799, DOI 10.1006/bbrc.1997.7556; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Vuolteenaho K, 2005, INFLAMM RES, V54, P420, DOI 10.1007/s00011-005-1373-6; Waiser J, 2002, NEPHROL DIAL TRANSPL, V17, P1568, DOI 10.1093/ndt/17.9.1568; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xiao YQ, 2006, J IMMUNOL, V176, P1209, DOI 10.4049/jimmunol.176.2.1209; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200	56	242	250	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38376	38384		10.1074/jbc.M605146200	http://dx.doi.org/10.1074/jbc.M605146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17056601	hybrid			2022-12-25	WOS:000242709500031
J	Masuda-Sasa, T; Polaczek, P; Campbell, JL				Masuda-Sasa, Taro; Polaczek, Piotr; Campbell, Judith L.			Single strand annealing and ATP-independent strand exchange activities of yeast and human DNA2 - Possible role in Okazaki fragment maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL IN-VIVO; FLAP ENDONUCLEASE-1; POLYMERASE-DELTA; GENOME STABILITY; LIGATABLE NICK; REPLICATION; HELICASE; PROTEIN; NUCLEASE; HELICASE/NUCLEASE	The Dna2 protein is a multifunctional enzyme with 5'-3' DNA helicase, DNA-dependent ATPase, 3' exo/endonuclease, and 5' exo/endonuclease. The enzyme is highly specific for structures containing single-stranded flaps adjacent to duplex regions. We report here two novel activities of both the yeast and human Dna2 helicase/nuclease protein: single strand annealing and ATP-independent strand exchange on short duplexes. These activities are independent of ATPase/helicase and nuclease activities in that mutations eliminating either nuclease or ATPase/helicase do not inhibit strand annealing or strand exchange. ATP inhibits strand exchange. A model rationalizing the multiple catalytic functions of Dna2 and leading to its coordination with other enzymes in processing single-stranded flaps during DNA replication and repair is presented.	CALTECH, Braun Labs 14775, Pasadena, CA 91125 USA	California Institute of Technology	Campbell, JL (corresponding author), CALTECH, Braun Labs 14775, Pasadena, CA 91125 USA.	jcampbel@its.caltech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508, P20GM125508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bae SH, 2002, J BIOL CHEM, V277, P26632, DOI 10.1074/jbc.M111026200; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Budd ME, 2005, PLOS GENET, V1, P634, DOI 10.1371/journal.pgen.0010061; Budd ME, 2006, MOL CELL BIOL, V26, P2490, DOI 10.1128/MCB.26.7.2490-2500.2006; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Cheok CF, 2005, BIOCHEM SOC T, V33, P1456, DOI 10.1042/BST0331456; Choe W, 2002, MOL CELL BIOL, V22, P4202, DOI 10.1128/MCB.22.12.4202-4217.2002; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; Formosa T, 1999, GENETICS, V151, P1459; Garg P, 2004, GENE DEV, V18, P2764, DOI 10.1101/gad.1252304; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Imamura O, 2003, P NATL ACAD SCI USA, V100, P8193, DOI 10.1073/pnas.1431624100; Jin YH, 2003, J BIOL CHEM, V278, P1626, DOI 10.1074/jbc.M209803200; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Kao HI, 2004, J BIOL CHEM, V279, P50840, DOI 10.1074/jbc.M409231200; Kao HI, 2004, J BIOL CHEM, V279, P15014, DOI 10.1074/jbc.M313216200; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; Kim JH, 2006, NUCLEIC ACIDS RES, V34, P1854, DOI 10.1093/nar/gkl102; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; Loeillet S, 2005, DNA REPAIR, V4, P459, DOI 10.1016/j.dnarep.2004.11.010; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Machwe A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-1; Machwe A, 2005, J BIOL CHEM, V280, P23397, DOI 10.1074/jbc.M414130200; Masuda-Sasa T, 2006, NUCLEIC ACIDS RES, V34, P1865, DOI 10.1093/nar/gkl070; Reuven NB, 2004, J MOL BIOL, V342, P57, DOI 10.1016/j.jmb.2004.07.012; Reuven NB, 2004, J VIROL, V78, P4599, DOI 10.1128/JVI.78.9.4599-4608.2004; Sharma S, 2004, J BIOL CHEM, V279, P9847, DOI 10.1074/jbc.M309898200; SHARMA S, 2004, HUM MOL GENET, pDH234; Wang WS, 2005, J BIOL CHEM, V280, P5391, DOI 10.1074/jbc.M412359200; Weitao T, 2003, MUTAT RES-FUND MOL M, V532, P157, DOI 10.1016/j.mrfmmm.2003.08.015	35	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38555	38564		10.1074/jbc.M604925200	http://dx.doi.org/10.1074/jbc.M604925200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17032657	Green Accepted, hybrid			2022-12-25	WOS:000242709500050
J	Miletic, AV; Sakata-Sogawa, K; Hiroshima, M; Hamann, MJ; Gomez, TS; Ota, N; Kloeppel, T; Kanagawa, O; Tokunaga, M; Billadeau, DD; Swat, W				Miletic, Ana V.; Sakata-Sogawa, Kumiko; Hiroshima, Michio; Hamann, Michael J.; Gomez, Timothy S.; Ota, Naruhisa; Kloeppel, Tracie; Kanagawa, Osami; Tokunaga, Makio; Billadeau, Daniel D.; Swat, Wojciech			Vav1 acidic region tyrosine 174 is required for the formation of T cell receptor-induced microclusters and is essential in T cell development and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; BIOLOGICAL-ACTIVITY; GDP/GTP EXCHANGE; RHO-FAMILY; DOMAIN; ACTIN; PHOSPHORYLATION; PROTEINS; SYK	Vav proteins are multidomain signaling molecules critical for mediating signals downstream of several surface receptors, including the antigen receptors of T and B lymphocytes. The catalytic guanine nucleotide exchange factor (GEF) activity of the Vav Dbl homology (DH) domain is thought to be controlled by an intramolecular autoinhibitory mechanism involving an N-terminal extension and phosphorylation of tyrosine residues in the acidic region (AC). Here, we report that the sequences surrounding the Vav1 AC: Tyr(142), Tyr(160), and Tyr(174) are evolutionarily conserved, conform to consensus SH2 domain binding motifs, and bind several proteins implicated in TCR signaling, including Lck, PI3K p85 alpha, and PLC gamma 1, through direct interactions with their SH2 domains. In addition, the AC tyrosines regulate tyrosine phosphorylation of Vav1. We also show that Tyr(174) is required for the maintenance of TCR-signaling microclusters and for normal T cell development and activation. In this regard, our data demonstrate that while Vav1 Tyr(174) is essential for maintaining the inhibitory constraint of the DH domain in both developing and mature T cells, constitutively activated Vav GEF disrupts TCR-signaling microclusters and leads to defective T cell development and proliferation.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; RIKEN Ctr Allergy & Immunol, Res Unit Single Mol Immunoimaging, Yokohama, Kanagawa 2300045, Japan; Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Oncol Res, Rochester, MN 55905 USA; RIKEN Ctr Allergy & Immunol, Lab Autoimmune Regulat, Yokohama, Kanagawa 2300045, Japan; Grad Univ Adv Studies, Struct Biol Ctr, Natl Inst Genet, Mishima, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Dept Genet, Mishima, Shizuoka 4118540, Japan	Washington University (WUSTL); RIKEN; Mayo Clinic; Mayo Clinic; RIKEN; Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan	Swat, W (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA.	swat@pathology.wustl.edu		Tokunaga, Makio/0000-0003-4586-8922	NIAID NIH HHS [R01 AI061077, R01 AI 061077, R01 AI 065447, R01 AI065474] Funding Source: Medline; NIAMS NIH HHS [P30 AR 048335, P30 AR048335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061077, R01AI065474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Amarasinghe GK, 2005, BIOCHEMISTRY-US, V44, P15257, DOI 10.1021/bi051126h; Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; Barda-Saad M, 2005, NAT IMMUNOL, V6, P80, DOI 10.1038/ni1143; Billadeau DD, 2000, J IMMUNOL, V164, P3971, DOI 10.4049/jimmunol.164.8.3971; Billadeau DD, 2003, NAT IMMUNOL, V4, P557, DOI 10.1038/ni929; Borowski C, 2002, CURR OPIN IMMUNOL, V14, P200, DOI 10.1016/S0952-7915(02)00322-9; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Bunnell Stephen C, 2003, Sci STKE, V2003, pPL8, DOI 10.1126/stke.2003.177.pl8; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Campi G, 2005, J EXP MED, V202, P1031, DOI 10.1084/jem.20051182; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Cella M, 2004, J EXP MED, V200, P817, DOI 10.1084/jem.20031847; Chan GD, 2001, EUR J IMMUNOL, V31, P2403, DOI 10.1002/1521-4141(200108)31:8<2403::AID-IMMU2403>3.0.CO;2-O; Colucci F, 2001, J EXP MED, V193, P1413, DOI 10.1084/jem.193.12.1413; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Gavrieli M, 2006, BIOCHEM BIOPH RES CO, V345, P1440, DOI 10.1016/j.bbrc.2006.05.036; Graham DB, 2006, J IMMUNOL, V177, P2349, DOI 10.4049/jimmunol.177.4.2349; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Llorca O, 2005, EMBO J, V24, P1330, DOI 10.1038/sj.emboj.7600617; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ogura K, 2002, J BIOMOL NMR, V22, P37, DOI 10.1023/A:1013868731495; Prisco A, 2005, IMMUNITY, V23, P263, DOI 10.1016/j.immuni.2005.07.007; Reynolds LF, 2004, J BIOL CHEM, V279, P18239, DOI 10.1074/jbc.M400257200; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Songyang Zhou, 2004, Cell, V116, pS41, DOI 10.1016/S0092-8674(04)00041-8; Swat W, 2003, INT IMMUNOL, V15, P215, DOI 10.1093/intimm/dxg021; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Upshaw JL, 2006, NAT IMMUNOL, V7, P524, DOI 10.1038/ni1325; Yabana N, 2002, ONCOGENE, V21, P7720, DOI 10.1038/sj.onc.1205927; Yohannan J, 1999, J BIOL CHEM, V274, P18769, DOI 10.1074/jbc.274.26.18769; Yokosuka T, 2005, NAT IMMUNOL, V6, P1253, DOI 10.1038/ni1272; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	52	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38257	38265		10.1074/jbc.M608913200	http://dx.doi.org/10.1074/jbc.M608913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050525	Green Accepted, hybrid			2022-12-25	WOS:000242709500018
J	Semenov, MV; He, X				Semenov, Mikhail V.; He, Xi			LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; BETA-CATENIN; MISSENSE MUTATIONS; WNT CORECEPTOR; GENE; DENSITY; MICE; SCLEROSTEOSIS; ACTIVATION; MECHANISM	The low density lipoprotein (LDL) receptor-related protein 5 (LRP5) is a co-receptor for Wnt proteins and a major regulator in bone homeostasis. Human genetic studies have shown that recessive loss-of-function mutations in LRP5 are linked to osteoporosis, while on the contrary, dominant missense LRP5 mutations are associated with high bone mass (HBM) diseases. All LRP5 HBM mutations are clustered in a single region in the LRP5 extracellular domain and presumably result in elevated Wnt signaling in bone forming cells. Here we show that LRP5 HBM mutant proteins exhibit reduced binding to a secreted bone-specific LRP5 antagonist, SOST, and consequently are more refractory to inhibition by SOST. As loss-of-function mutations in the SOST gene are associated with Sclerosteosis, another disorder of excessive bone growth, our study suggests that the SOST-LRP5 antagonistic interaction plays a central role in bone mass regulation and may represent a nodal point for therapeutic intervention for osteoporosis and other bone diseases.	Childrens Hosp, Div Neurosci, Neurobiol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Semenov, MV (corresponding author), Childrens Hosp, Div Neurosci, Neurobiol Program, Enders 470,61 Binney St, Boston, MA 02115 USA.	mikhail.semenov@childrens.harvard.edu			NIGMS NIH HHS [R01 GM 57603] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057603] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946-4955.2005; Akhter MP, 2004, BONE, V35, P162, DOI 10.1016/j.bone.2004.02.018; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91; Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005-1235; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704; Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Holmen SL, 2005, BIOCHEM BIOPH RES CO, V328, P533, DOI 10.1016/j.bbrc.2005.01.009; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Johnson M. L., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P135; Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu GZ, 2005, MOL CELL BIOL, V25, P3475, DOI 10.1128/MCB.25.9.3475-3482.2005; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Rickels MR, 2005, J BONE MINER RES, V20, P878, DOI 10.1359/JBMR.041223; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Semenov M, 2003, WNT SIGNALING DEV, P16; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	44	172	182	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38276	38284		10.1074/jbc.M609509200	http://dx.doi.org/10.1074/jbc.M609509200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17052975	hybrid			2022-12-25	WOS:000242709500020
J	Sturchler, E; Cox, JA; Durussel, I; Weibel, M; Heizmann, CW				Sturchler, Emmanuel; Cox, Jos A.; Durussel, Isabelle; Weibel, Mirjam; Heizmann, Claus W.			S100A16, a novel calcium-binding protein of the EF-hand superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY DOMAIN; KINASE-C; SUBCELLULAR-LOCALIZATION; MOLECULAR-MECHANISMS; TUMOR-SUPPRESSOR; PHOSPHORYLATION; CALMODULIN; NUCLEAR; FAMILY; CELLS	S100A16 protein is a new and unique member of the EF-hand Ca2+-binding proteins. S100 proteins are cell- and tissue-specific and are involved in many intra- and extracellular processes through interacting with specific target proteins. In the central nervous system S100 proteins are implicated in cell proliferation, differentiation, migration, and apoptosis as well as in cognition. S100 proteins became of major interest because of their close association with brain pathologies, for example depression or Alzheimer's disease. Here we report for the first time the purification and biochemical characterization of human and mouse recombinant S100A16 proteins. Flow dialysis revealed that both homodimeric S100A16 proteins bind two Ca2+ ions with the C-terminal EF-hand of each subunit, the human protein exhibiting a 2-fold higher affinity. Trp fluorescence variations indicate conformational changes in the orthologous proteins upon Ca2+ binding, whereas formation of a hydrophobic patch, implicated in target protein recognition, only occurs in the human S100A16 protein. In situ hybridization analysis and immunohistochemistry revealed a widespread distribution in the mouse brain. Furthermore, S100A16 expression was found to be astrocyte-specific. Finally, we investigated S100A16 intracellular localization in human glioblastoma cells. The protein was found to accumulate within nucleoli and to translocate to the cytoplasm in response to Ca2+ stimulation.	Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland	University of Zurich; University of Geneva	Heizmann, CW (corresponding author), Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	claus.heizmann@kispi.unizh.ch						Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Bhattacharya S, 2004, BBA-MOL CELL RES, V1742, P69, DOI 10.1016/j.bbamcr.2004.09.002; Bhattacharya S, 2003, BIOCHEMISTRY-US, V42, P14416, DOI 10.1021/bi035089a; Boni R, 1997, BRIT J DERMATOL, V137, P39, DOI 10.1046/j.1365-2133.1997.17651853.x; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; Chan WY, 2003, MICROSC RES TECHNIQ, V60, P600, DOI 10.1002/jemt.10302; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; COX JA, 1909, GUIDBOOK CALCIUM BIN, P1; Davey GE, 2001, J BIOL CHEM, V276, P30819, DOI 10.1074/jbc.M103541200; Deloulme JC, 2004, MOL CELL NEUROSCI, V27, P453, DOI 10.1016/j.mcn.2004.07.008; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Durussel I, 2002, BIOCHEMISTRY-US, V41, P5439, DOI 10.1021/bi016062z; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; FRITZ G, 2004, HDB METALLOPROTEINS, V3, P529; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; Heizmann CW, 2005, J PEDIATR-US, V147, P731, DOI 10.1016/j.jpeds.2005.08.046; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hsieh HL, 2002, J CELL SCI, V115, P3149; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Kiryushko D, 2006, MOL CELL BIOL, V26, P3625, DOI 10.1128/MCB.26.9.3625-3638.2006; Kizawa K, 2005, BRIT J DERMATOL, V152, P314, DOI 10.1111/j.1365-2133.2004.06391.x; Kozlova EN, 1999, GLIA, V27, P249, DOI 10.1002/(SICI)1098-1136(199909)27:3<249::AID-GLIA6>3.3.CO;2-5; LECLERC E, 2007, IN PRESS HDB NEUROCH; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; Mandinova A, 1998, J CELL SCI, V111, P2043; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V313, P237, DOI 10.1016/j.bbrc.2003.11.115; Markowitz J, 2005, BIOCHEMISTRY-US, V44, P7305, DOI 10.1021/bi050321t; Nacken W, 2003, MICROSC RES TECHNIQ, V60, P569, DOI 10.1002/jemt.10299; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; Nilsson M, 2004, INT J CANCER, V109, P363, DOI 10.1002/ijc.11716; Nishikawa T, 1997, J BIOL CHEM, V272, P23037, DOI 10.1074/jbc.272.37.23037; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Pascale A, 2004, P NATL ACAD SCI USA, V101, P1217, DOI 10.1073/pnas.0307674100; Rammes A, 1997, J BIOL CHEM, V272, P9496; RIDDLES PW, 1983, ANAL BIOCHEM, V132, P105, DOI 10.1016/0003-2697(83)90431-1; Ridinger K, 2000, J BIOL CHEM, V275, P8686, DOI 10.1074/jbc.275.12.8686; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Sakaguchi M, 2003, J CELL BIOL, V163, P825, DOI 10.1083/jcb.200304017; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SHEU FS, 1995, ARCH BIOCHEM BIOPHYS, V316, P335, DOI 10.1006/abbi.1995.1045; Svenningsson P, 2006, SCIENCE, V311, P77, DOI 10.1126/science.1117571; Takenaga K, 2006, GLIA, V53, P313, DOI 10.1002/glia.20284; Thorogate R, 2004, J CELL SCI, V117, P5923, DOI 10.1242/jcs.01510; Tiu SC, 2000, DEV BRAIN RES, V119, P159, DOI 10.1016/S0165-3806(99)00151-0; Tramontina F, 2006, CELL MOL NEUROBIOL, V26, P81, DOI 10.1007/s10571-006-9099-8; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Weterman MAJ, 1996, HUM GENET, V98, P16, DOI 10.1007/s004390050153; WHITAKERAZMITIA PM, 1994, PERSPECT DEV NEUROBI, V2, P233; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; Ziegler DR, 1998, NEUROCHEM RES, V23, P1259, DOI 10.1023/A:1020740115790; Zimmer DB, 2003, MICROSC RES TECHNIQ, V60, P552, DOI 10.1002/jemt.10297	64	49	58	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38905	38917		10.1074/jbc.M605798200	http://dx.doi.org/10.1074/jbc.M605798200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17030513	hybrid			2022-12-25	WOS:000242709500088
J	Futamura, M; Hosaka, H; Kadotani, A; Shimazaki, H; Sasaki, K; Ohyama, S; Nishimura, T; Eiki, J; Nagata, Y				Futamura, Mayumi; Hosaka, Hideka; Kadotani, Akito; Shimazaki, Hiroko; Sasaki, Kaori; Ohyama, Sumika; Nishimura, Teruyuki; Eiki, Jun-ichi; Nagata, Yasufumi			An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER GLUCOKINASE; RAT-LIVER; HEPATOCYTES; TRANSLOCATION; MECHANISM; TISSUE; MICE	Glucokinase (GK) plays a key role in the control of blood glucose homeostasis. We identified a small molecule GK activator, compound A, that increased the glucose affinity and maximal velocity (V-max) of GK. Compound A augmented insulin secretion from isolated rat islets and enhanced glucose utilization in primary cultured rat hepatocytes. In rat oral glucose tolerance tests, orally administrated compound A lowered plasma glucose elevation with a concomitant increase in plasma insulin and hepatic glycogen. In liver, GK activity is acutely controlled by its association to the glucokinase regulatory protein (GKRP). In order to decipher the molecular aspects of how GK activator affects the shuttling of GK between nucleus and cytoplasm, the effect of compound A on GK-GKRP interaction was further investigated. Compound A increased the level of cytoplasmic GK in both isolated rat primary hepatocytes and the liver tissues from rats. Experiments in a cell-free system revealed that compound A interacted with glucose-bound free GK, thereby impairing the association of GK and GKRP. On the other hand, compound A did not bind to glucose-unbound GK or GKRP-associated GK. Furthermore, we found that glucose- dependent GK-GKRP interaction also required ATP. Given the combined prominent role of GK on insulin secretion and hepatic glucose metabolism where the GK-GKRP mechanism is involved, activation of GK has a new therapeutic potential in the treatment of type 2 diabetes.	Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan	Merck & Company; Novartis	Nagata, Y (corresponding author), Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Okubo 3, Tsukuba, Ibaraki 3002611, Japan.	yasufumi_nagata@merck.com		Eiki, Jun-ichi/0000-0002-1622-6114				Agius L, 1997, BIOCHEM J, V325, P667, DOI 10.1042/bj3250667; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; Brocklehurst KJ, 2004, DIABETES, V53, P535, DOI 10.2337/diabetes.53.3.535; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Chu CA, 2004, AM J PHYSIOL-GASTR L, V286, pG627, DOI 10.1152/ajpgi.00218.2003; de la Iglesia N, 2000, J BIOL CHEM, V275, P10597, DOI 10.1074/jbc.275.14.10597; Efanov AM, 2005, ENDOCRINOLOGY, V146, P3696, DOI 10.1210/en.2005-0377; Eiki JI, 2006, DIABETES, V55, pA328; Farrelly D, 1999, P NATL ACAD SCI USA, V96, P14511, DOI 10.1073/pnas.96.25.14511; Gloyn AL, 2003, DIABETES, V52, P2433, DOI 10.2337/diabetes.52.9.2433; Grimsby J, 2000, J BIOL CHEM, V275, P7826, DOI 10.1074/jbc.275.11.7826; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Mookhtiar KA, 1996, DIABETES, V45, P1670, DOI 10.2337/diabetes.45.12.1670; Mukhtar M, 1999, FEBS LETT, V462, P453, DOI 10.1016/S0014-5793(99)01580-X; OKAMOTO Y, 1992, DIABETES, V41, P1555, DOI 10.2337/diabetes.41.12.1555; Shiota M, 1998, DIABETES, V47, P867, DOI 10.2337/diabetes.47.6.867; TOYODA Y, 1995, HISTOCHEM CELL BIOL, V103, P31, DOI 10.1007/BF01464473; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VanSchaftingen E, 1997, BIOCHEM SOC T, V25, P136, DOI 10.1042/bst0250136; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; Veiga-da-Cunha M, 2002, J BIOL CHEM, V277, P8466, DOI 10.1074/jbc.M105984200	23	82	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37668	37674		10.1074/jbc.M605186200	http://dx.doi.org/10.1074/jbc.M605186200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17028192	hybrid			2022-12-25	WOS:000242477100044
J	Suzuki, M; Roy, R; Zheng, HY; Woychik, N; Inouye, M				Suzuki, Motoo; Roy, Rohini; Zheng, Haiyan; Woychik, Nancy; Inouye, Masayori			Bacterial Bioreactors for high yield production of recombinant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-19 NMR; ACTIVATION; CHEY	We developed a new bacterial expression system that utilizes a combination of attributes ( low temperature, induction of an mRNA-specific endoribonuclease causing host cell growth arrest, and culture condensation) to facilitate stable, high level protein expression, almost 30% of total cellular protein, without background protein synthesis. With the use of an optimized vector, exponentially growing cultures could be condensed 40-fold without affecting protein yields, which lowered sample labeling costs to a few percent of the cost of a typical labeling experiment. Because the host cells were completely growth-arrested, toxic amino acids such as selenomethionine and fluorophenylalanine were efficiently incorporated into recombinant proteins in the absence of cytotoxicity. Therefore, this expression system using Escherichia coli as a bioreactor is especially well suited to structural genomics, large-scale protein expressions, and the production of cytotoxic proteins.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA; Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.	inouye@umdnj.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM075026, U54GM074958] Funding Source: NIH RePORTER; NCRR NIH HHS [RR13824] Funding Source: Medline; NIGMS NIH HHS [U54GM074958, U54GM75026] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellizzi JJ, 1999, STRUCTURE, V7, pR263, DOI 10.1016/S0969-2126(00)80020-9; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hendrickson WA, 2000, TRENDS BIOCHEM SCI, V25, P637, DOI 10.1016/S0968-0004(00)01721-7; Kigawa Takanori, 2002, Journal of Structural and Functional Genomics, V2, P29, DOI 10.1023/A:1013203532303; Qing GL, 2004, NAT BIOTECHNOL, V22, P877, DOI 10.1038/nbt984; Serber Z, 2001, J AM CHEM SOC, V123, P8895, DOI 10.1021/ja0112846; Serber Z, 2001, BIOCHEMISTRY-US, V40, P14317, DOI 10.1021/bi011751w; Serber Z, 2001, J AM CHEM SOC, V123, P2446, DOI 10.1021/ja0057528; Suzuki M, 2005, MOL CELL, V18, P253, DOI 10.1016/j.molcel.2005.03.011; Tian JD, 2004, NATURE, V432, P1050, DOI 10.1038/nature03151; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7	14	36	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37559	37565		10.1074/jbc.M608806200	http://dx.doi.org/10.1074/jbc.M608806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17020876	hybrid			2022-12-25	WOS:000242477100032
J	Rittner, HL; Labuz, D; Schaefer, M; Mousa, SA; Schulz, S; Schafer, M; Stein, C; Brack, A				Rittner, Heike L.; Labuz, Dominika; Schaefer, Michael; Mousa, Shaaban A.; Schulz, Stefan; Schaefer, Michael; Stein, Christoph; Brack, Alexander			Pain control by CXCR2 ligands through Ca2(+)-regulated release of opioid peptides from polymorphonuclear cells	FASEB JOURNAL			English	Article						chemokine; analgesia; inflammation; secretion; neutrophil	NEUTROPHIL ACTIVATION; INFLAMMATORY PAIN; BETA-ENDORPHIN; CALCIUM-ENTRY; IMMUNE CELLS; BONE-MARROW; CHEMOKINE; RECEPTOR; RECRUITMENT; INHIBITION	Leukocytes counteract inflammatory pain by releasing opioid peptides, which bind to opioid receptors on peripheral sensory neurons. In the early phase of inflammation, polymorphonuclear cells (PMN) are the major source of opioids. Their recruitment is governed by ligands at the chemokine receptor CXCR2. Here, we examined whether chemokines can also induce opioid peptide secretion from PMN and thus inhibit inflammatory pain. In rats with hindpaw inflammation, intraplantar injection of CXCL2/3, but not of the CXCR4 ligand CXCL12, elicited naloxone-reversible (i.e., opioid receptor mediated) mechanical and thermal analgesia, which was abolished by systemic PMN depletion. Both CXCR1/2-and CXCR4-ligands induced PMN chemotaxis, but only CXCR1/2 ligands triggered opioid release from human and rat PMN in vitro. This release was unaltered by extracellular Ca2+ chelation, was mimicked by thapsigargin and was blocked by inhibitors of the inositol 1,4,5-triphosphate receptor (IP3) and by intracellular Ca2+ chelation, indicating that it required Ca2+ from intracellular but not extracellular sources. Furthermore, release was partially reduced by phosphoinositol-3-kinase (PI3K) inhibitors. Adoptive transfer of allogenic PMN into PMN-depleted rats reconstituted CXCL2/3-induced analgesia, which was inhibited by prior ex vivo chelation of intracellular Ca2+. These findings demonstrate that, beyond cell recruitment, CXCR2 ligands induce Ca2+-regulated opioid release from PMN and thereby inhibit inflammatory pain in vivo.	Charite Univ Med Berlin, Klin Anaesthesiol & Operat Intens Med, D-12200 Berlin, Germany; Charite Univ Med Berlin, Inst Pharmakol, D-12200 Berlin, Germany; Otto Von Guericke Univ, Dept Pharmacol, Magdeburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Otto von Guericke University	Rittner, HL (corresponding author), Charite Univ Med Berlin, Klin Anaesthesiol & Operat Intens Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	heike.rittner@charite.de	Schulz, Stefan/A-6928-2017; RIttner, Heike/AAC-6523-2019; Schäfer, Michael/AAB-1395-2020	Schulz, Stefan/0000-0002-5997-8885; RIttner, Heike/0000-0003-4867-0188; Schaefer, Michael/0000-0002-1581-706X; Stein, Christoph/0000-0001-5240-6836				Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brack A, 2004, PAIN, V108, P67, DOI 10.1016/j.pain.2003.12.008; Brack A, 2004, ANESTHESIOLOGY, V100, P149, DOI 10.1097/00000542-200401000-00024; Brack A, 2004, ANESTHESIOLOGY, V101, P204, DOI 10.1097/00000542-200407000-00031; Brack A, 2004, PAIN, V112, P229, DOI 10.1016/j.pain.2004.08.029; Bras JMA, 2001, NEUROSCIENCE, V103, P1073, DOI 10.1016/S0306-4522(01)00034-3; Briones Michael A, 2003, Curr Hematol Rep, V2, P522; Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506; Cabot PJ, 2001, PAIN, V93, P207, DOI 10.1016/S0304-3959(01)00322-0; Cerchiaro GA, 2001, BIOCHEM PHARMACOL, V62, P357, DOI 10.1016/S0006-2952(01)00672-4; Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102; DEWALD B, 1988, J BIOL CHEM, V263, P16179; Fan GH, 2003, BLOOD, V101, P2115, DOI 10.1182/blood-2002-07-1965; FREVERT CW, 1995, INFLAMMATION, V19, P133, DOI 10.1007/BF01534386; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Heveker N, 2001, MOL PHARMACOL, V59, P1418, DOI 10.1124/mol.59.6.1418; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Inngjerdingen M, 2003, J IMMUNOL, V171, P2889, DOI 10.4049/jimmunol.171.6.2889; Itagaki K, 2002, J IMMUNOL, V168, P4063, DOI 10.4049/jimmunol.168.8.4063; Ito N, 2002, J BIOL CHEM, V277, P44898, DOI 10.1074/jbc.M208051200; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; Kalso E, 2002, PAIN, V98, P269, DOI 10.1016/S0304-3959(02)00019-2; KANKAANRANTA H, 1995, BIOCHEM PHARMACOL, V50, P197, DOI 10.1016/0006-2952(95)00126-K; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lenoir M, 2004, J IMMUNOL, V172, P7136, DOI 10.4049/jimmunol.172.11.7136; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; Lin TJ, 2000, J IMMUNOL, V165, P211, DOI 10.4049/jimmunol.165.1.211; Lorenzetti BB, 2002, EUR CYTOKINE NETW, V13, P456; Lyons PD, 1997, J NEUROIMMUNOL, V78, P47, DOI 10.1016/S0165-5728(97)00081-7; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3; Machelska H, 2004, BRIT J PHARMACOL, V142, P772, DOI 10.1038/sj.bjp.0705837; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Mousa SA, 2003, PAIN, V106, P297, DOI 10.1016/S0304-3959(03)00302-6; Mousa SA, 2004, ENDOCRINOLOGY, V145, P1331, DOI 10.1210/en.2003-1287; Oh SB, 2001, J NEUROSCI, V21, P5027, DOI 10.1523/JNEUROSCI.21-14-05027.2001; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Remick DG, 2001, AM J PATHOL, V159, P1149, DOI 10.1016/S0002-9440(10)61791-9; Rittner HL, 2006, J LEUKOCYTE BIOL, V79, P1022, DOI 10.1189/jlb.0805452; Rittner HL, 2005, J LEUKOCYTE BIOL, V78, P1215, DOI 10.1189/jlb.0405223; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; Schorr W, 1999, EUR J IMMUNOL, V29, P897, DOI 10.1002/(SICI)1521-4141(199903)29:03<897::AID-IMMU897>3.3.CO;2-X; SENGELOV H, 1993, J IMMUNOL, V150, P1535; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1988, PHARMACOL BIOCHEM BE, V31, P445, DOI 10.1016/0091-3057(88)90372-3; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Stumm RK, 2002, J NEUROSCI, V22, P5865; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; VINDROLA O, 1990, J CLIN INVEST, V86, P531, DOI 10.1172/JCI114740; Vocks A, 2003, CELL PHYSIOL BIOCHEM, V13, P165, DOI 10.1159/000071867; Wenk HN, 2006, J NEUROPHYSIOL, V95, P2083, DOI 10.1152/jn.00394.2005; Zhuang ZY, 2004, J NEUROSCI, V24, P8300, DOI 10.1523/JNEUROSCI.2893-04.2004; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	62	91	100	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2627	+		10.1096/fj.06-6077fje	http://dx.doi.org/10.1096/fj.06-6077fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060402				2022-12-25	WOS:000242490700046
J	Shibata, N; Jishage, KI; Arita, M; Watanabe, M; Kawase, Y; Nishikawa, K; Natori, Y; Inoue, H; Shimano, H; Yamada, N; Tsujimoto, M; Arai, H				Shibata, Norihito; Jishage, Kou-ichi; Arita, Makoto; Watanabe, Miho; Kawase, Yosuke; Nishikawa, Kiyotaka; Natori, Yasuhiro; Inoue, Hiroyasu; Shimano, Hitoshi; Yamada, Nobuhiro; Tsujimoto, Masafumi; Arai, Hiroyuki			Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis	FASEB JOURNAL			English	Article						squalene monooxygenase; peroxisome proliferator-activated receptor alpha; fasting; fibrate	HMG-COA REDUCTASE; FASTING RESPONSE; ACID SYNTHESIS; MICE LACKING; PPAR-ALPHA; RAT-LIVER; SQUALENE; GEMFIBROZIL; METABOLISM; EXPRESSION	Supernatant protein factor (SPF) is a novel cholesterol biosynthesis- accelerating protein expressed in liver and small intestine. Here, we report on the physiological role of SPF by using Spf-deficient mice. Although plasma cholesterol levels were similar in chow-fed Spf(-/-) and wild-type (WT) mice, fasting significantly decreased plasma cholesterol levels in Spf(-/-) mice but not in WT mice. While fasting reduced hepatic cholesterol synthesis rate in WT mice, a more pronounced reduction was observed in Spf(-/-) mice. The expression of cholesterogenic enzymes was dramatically suppressed by fasting both in WT and Spf(-/-) mice. In contrast, hepatic SPF expression of WT mice was up-regulated by fasting in peroxisome proliferator-activated receptor alpha (PPAR-alpha)-dependent manner. These results indicate that in WT mice, the decrease of hepatic cholesterol synthesis under fasting conditions is at least in part compensated by SPF up-regulation. Fibrates, which function as a PPAR-alpha agonist and are widely used as hypotriglycemic drugs, reduced hepatic cholesterol synthesis and plasma cholesterol levels by approximately one-half in Spf(-/-) mice but not in WT mice. These findings suggest that co-administration of fibrates and an SPF inhibitor may reduce not only plasma triglyceride but also cholesterol levels, indicating that SPF is a promising hypocholesterolemic drug target.	Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Lab Cellular Biochem, Saitama, Japan; Chugai Res Inst Med Sci Inc, Pharmacol & Pathol Res Ctr, Shizuoka, Japan; Int Med Ctr Japan, Dept Clin Pharmacol, Res Inst, Tokyo, Japan; Nara Womens Univ, Dept Food Sci & Nutr, Fac Human Life & Environm, Nara 630, Japan; Univ Tsukuba, Dept Internal Med, Inst Clin Med, Tsukuba, Ibaraki 305, Japan	University of Tokyo; RIKEN; Chugai Pharmaceutical Co., Ltd.; Chugai Research Institute for Medical Science, Inc.; National Center for Global Health & Medicine - Japan; Nara Womens University; University of Tsukuba	Arai, H (corresponding author), Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	harai@mol.f.u-tokyo.ac.jp	Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; SHIBATA, NORIHITO/0000-0001-5792-8510; Arita, Makoto/0000-0001-9902-0463				BAHNSEN M, 1984, AM J PHYSIOL, V247, pE173, DOI 10.1152/ajpendo.1984.247.2.E173; Bankir L, 1997, KIDNEY INT, pS50; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; Brown AS, 1998, J AM COLL CARDIOL, V32, P665, DOI 10.1016/S0735-1097(98)00300-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chang JT, 2004, PHARMACOEPIDEM DR S, V13, P417, DOI 10.1002/pds.977; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; COHEN BI, 1974, BIOCHIM BIOPHYS ACTA, V369, P79; DIETSCHY JM, 1967, J LIPID RES, V8, P97; Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978; FERGUSON JB, 1977, J BIOL CHEM, V252, P5381; FRIEDLANDER EJ, 1980, J BIOL CHEM, V255, P8042; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNDY SM, 1987, AM J MED, V83, P9, DOI 10.1016/0002-9343(87)90866-7; Haas MJ, 2000, METABOLISM, V49, P1572, DOI 10.1053/meta.2000.18554; Hiyoshi H, 2000, J LIPID RES, V41, P1136; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; ISHIKAWA T, 1979, J LIPID RES, V20, P254; Kaempf-Rotzoll DE, 2003, PLACENTA, V24, P439, DOI 10.1053/plac.2002.0966; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kok T, 2003, GASTROENTEROLOGY, V124, P160, DOI 10.1053/gast.2003.50007; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Mardones P, 2003, J BIOL CHEM, V278, P7884, DOI 10.1074/jbc.M211627200; Mokashi V, 2005, ARCH BIOCHEM BIOPHYS, V435, P175, DOI 10.1016/j.abb.2004.11.030; Mokashi V, 2005, ARCH BIOCHEM BIOPHYS, V433, P474, DOI 10.1016/j.abb.2004.10.002; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; Ohashi K, 2003, J BIOL CHEM, V278, P42936, DOI 10.1074/jbc.M307228200; OLIVIER P, 1988, ATHEROSCLEROSIS, V70, P107, DOI 10.1016/0021-9150(88)90104-9; Ozdemir O, 2000, ANGIOLOGY, V51, P695; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Schwarz M, 1998, J LIPID RES, V39, P1833; Shek A, 2001, ANN PHARMACOTHER, V35, P908, DOI 10.1345/aph.10315; Shibata N, 2001, P NATL ACAD SCI USA, V98, P2244, DOI 10.1073/pnas.041620398; Singh DK, 2003, J BIOL CHEM, V278, P5646, DOI 10.1074/jbc.M211750200; SOBEL AE, 1945, J BIOL CHEM, V157, P255; SPERRY WM, 1950, J BIOL CHEM, V187, P97; TCHEN TT, 1957, J BIOL CHEM, V226, P921; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; VANDENBERGHE G, 1991, J INHERIT METAB DIS, V14, P407, DOI 10.1007/BF01797914; WISS O, 1976, BIOCHEM BIOPH RES CO, V68, P353, DOI 10.1016/0006-291X(76)91151-7; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098	46	22	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2642	+		10.1096/fj.06-6368fje	http://dx.doi.org/10.1096/fj.06-6368fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077281				2022-12-25	WOS:000242490700051
J	Beltran, A; Parikh, S; Liu, Y; Cuevas, BD; Johnson, GL; Futscher, BW; Blancafort, P				Beltran, A.; Parikh, S.; Liu, Y.; Cuevas, B. D.; Johnson, G. L.; Futscher, B. W.; Blancafort, P.			Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors	ONCOGENE			English	Article						maspin; SERPINB5; metastatic cells; methylation; zinc-fingers; artificial transcription factors	ZINC-FINGER DOMAINS; BREAST-CANCER CELLS; DNA-SEQUENCES; MAMMALIAN-CELLS; EXPRESSION; RECOGNITION; FAMILY; CONSTRUCTION; ANGIOGENESIS; METHYLATION	The controlled and specific re-activation of endogenous tumor suppressors in cancer cells represents an important therapeutic strategy to block tumor growth and subsequent progression. Other than ectopic delivery of tumor suppressor-encoded cDNA, there are no therapeutic tools able to specifically re-activate tumor suppressor genes that are silenced in tumor cells. Herein, we describe a novel approach to specifically regulate dormant tumor suppressors in aggressive cancer cells. We have targeted the Mammary Serine Protease Inhibitor (maspin) (SERPINB5) tumor suppressor, which is silenced by transcriptional and aberrant promoter methylation in aggressive epithelial tumors. Maspin is a multifaceted protein, regulating tumor cell homeostasis through inhibition of cell growth, motility and invasion. We have constructed artificial transcription factors (ATFs) made of six zinc-finger (ZF) domains targeted against 18-base pair (bp) unique sequences in the maspin promoter. The ZFs were linked to the activator domain VP64 and delivered in breast tumor cells. We found that the designed ATFs specifically interact with their cognate targets in vitro with high affinity and selectivity. One ATF was able to re-activate maspin in cell lines that comprise a maspin promoter silenced by epigenetic mechanisms. Consistently, we found that this ATF was a powerful inducer of apoptosis and was able to knock down tumor cell invasion in vitro. Moreover, this ATF was able to suppress MDA-MB-231 growth in a xenograft breast cancer model in nude mice. Our work suggests that ATFs could be used in cancer therapeutics as novel molecular switches to re-activate dormant tumor suppressors.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Tucson, AZ USA; Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Arizona Center Cancer Care; University of Arizona; University of Arizona	Blancafort, P (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.	pilar_blancafort@med.unc.edu	Blancafort, Pilar/K-9029-2012	Blancafort, Pilar/0000-0002-3881-7396	NCI NIH HHS [R01 CA125273] Funding Source: Medline; NIDDK NIH HHS [R01 DK037871] Funding Source: Medline; NIGMS NIH HHS [R01 GM030324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA125273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beltran A, 2006, ASSAY DRUG DEV TECHN, V4, P317, DOI 10.1089/adt.2006.4.317; Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758; Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Dreier B, 2005, J BIOL CHEM, V280, P35588, DOI 10.1074/jbc.M506654200; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Garber K, 2004, NAT BIOTECHNOL, V22, P364, DOI 10.1038/nbt0404-364; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Khalkhali-Ellis Z, 2004, CLIN CANCER RES, V10, P449, DOI 10.1158/1078-0432.CCR-1002-03; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Lockett J, 2006, J CELL BIOCHEM, V97, P651, DOI 10.1002/jcb.20721; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Royer Y, 2004, DNA CELL BIOL, V23, P355, DOI 10.1089/104454904323145245; Sager R, 1997, ADV EXP MED BIOL, V425, P77; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Seftor REB, 1998, CANCER RES, V58, P5681; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; Stege JT, 2002, PLANT J, V32, P1077, DOI 10.1046/j.1365-313X.2002.01492.x; Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100; Watanabe M, 2005, HUM GENE THER, V16, P699, DOI 10.1089/hum.2005.16.699; YIN S, 2006, CANCER RES, V15, P4173; Zardo G, 2005, CELL RES, V15, P679, DOI 10.1038/sj.cr.7290337; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang WG, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-50; ZHOU Z, 2000, J BIOL CHEM, V9, P6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	40	68	75	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2791	2798		10.1038/sj.onc.1210072	http://dx.doi.org/10.1038/sj.onc.1210072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057734				2022-12-25	WOS:000246210600013
J	Cosaceanu, D; Budiu, RA; Carapancea, M; Castro, J; Lewensohn, R; Dricu, A				Cosaceanu, D.; Budiu, R. A.; Carapancea, M.; Castro, J.; Lewensohn, R.; Dricu, A.			Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism	ONCOGENE			English	Article						insulin-like growth factor 1 receptor; ionizing radiation; p38 kinase; Ku86; lung cancer	GROWTH-FACTOR-I; HUMAN LUNG-CANCER; PROTEIN-KINASE; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; INTRINSIC RADIOSENSITIVITY; SURVIVAL PATHWAY; CARCINOMA-CELLS; S6 KINASE; RECEPTOR	Ionizing radiation exposure results in the activation of several tyrosine kinase receptors that participate in radiation-induced DNA damage response and radioresistance. We previously showed that insulin-like growth factor 1 receptor (IGF-1R) inhibition enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) cells. In this paper, we demonstrate that in U1810 NSCLC cells gamma-radiation activates IGF-1R within 10 min, with a maximal activation effect 2 h post-irradiation. Impairment of IGF-1R tyrosine kinase activity enhances human lung cancer cells radiosensitivity by a mechanism that involves phosphatidylinositol 3-kinase (PI3-K) and p38 kinase. In an active form, IGF-1R binds and activates p38 kinase, promoting receptor signaling. Conversely, inhibition of IGF-1R phosphorylation results in IGF-1R/p38 complex disruption and p38 kinase inactivation. We have also demonstrated that in insulin-like growth factor-1-stimulated cells, Ku-DNA-binding activation is induced by ionizing radiation within 4 h, reaches a maximum level at 12 h and remains active up to 72 h. Blockade of IGF-1R activity or its downstream signaling through p38 kinase induces a decrease in radiation-mediated Ku-DNA-binding activation and downregulates the level of Ku86, without affecting Ku70 expression in the nucleus of U1810 cells. The IGF-1R signaling via PI3-K does not interfere with the p38 signaling, the Ku-DNA-binding activity or the level of Ku86. Our present study demonstrates for the first time that ionizing radiation activates IGF-1R. Inhibition of IGF-1R signaling via p38 kinase induces radiosensitivity by a novel mechanism involving nuclear Ku86.	Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Radiumhemmet Karolinska Inst Hosp, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Dricu, A (corresponding author), Canc Ctr Karolinska, Dept Oncol Pathol, R8-00, S-17176 Stockholm, Sweden.	anica.dricu@ki.se						Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; Bostedt KT, 2001, EXP CELL RES, V271, P368, DOI 10.1006/excr.2001.5388; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bredin CG, 1999, INT J CANCER, V82, P338, DOI 10.1002/(SICI)1097-0215(19990730)82:3<338::AID-IJC6>3.0.CO;2-Y; BRODIN O, 1991, ACTA ONCOL, V30, P967, DOI 10.3109/02841869109088251; CARNEY DN, 1983, CANCER RES, V43, P2806; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Cosaceanu D, 2005, CANCER LETT, V222, P173, DOI 10.1016/j.canlet.2004.10.002; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dowell JE, 2005, NEW ENGL J MED, V352, P830, DOI 10.1056/NEJMe058033; Dricu A, 1997, CANCER RES, V57, P543; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fegley AJ, 2003, J SURG RES, V113, P32, DOI 10.1016/S0022-4804(03)00120-3; GIRINSKY T, 1993, INT J RADIAT ONCOL, V25, P3, DOI 10.1016/0360-3016(93)90137-K; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Griffin RJ, 2002, CANCER RES, V62, P1702; Gupta AK, 2004, LUNG, V182, P151, DOI 10.1007/S00408/004/0310-8; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Jung, 1996, Semin Radiat Oncol, V6, P268, DOI 10.1016/S1053-4296(96)80022-1; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; Mazzarelli P, 2003, J INVEST DERMATOL, V121, P628, DOI 10.1046/j.1523-1747.2003.12416.x; Park SJ, 2004, J BIOL CHEM, V279, P6046, DOI 10.1074/jbc.M311054200; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Reiss K, 2006, J CELL PHYSIOL, V206, P295, DOI 10.1002/jcp.20455; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shahrabani-Gargir L, 2004, ENDOCRINOLOGY, V145, P5679, DOI 10.1210/en.2004-0613; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimizu T, 1999, EXP CELL RES, V251, P424, DOI 10.1006/excr.1999.4582; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; SODERDAHL G, 1988, INT J CANCER, V41, P636, DOI 10.1002/ijc.2910410426; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wan YS, 2001, INT J ONCOL, V18, P461; Watanabe H, 2004, INT J RADIAT BIOL, V80, P451, DOI 10.1080/09553000410001702355; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; Yamagishi S, 2003, MOL BRAIN RES, V119, P184, DOI 10.1016/j.molbrainres.2003.09.009; Yu D, 2003, BIOCHEM BIOPH RES CO, V311, P174, DOI 10.1016/j.bbrc.2003.09.195; Yu D, 2002, J RADIAT RES, V43, P325, DOI 10.1269/jrr.43.325; Zingg D, 2004, CANCER RES, V64, P5398, DOI 10.1158/0008-5472.CAN-03-3369	53	80	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2423	2434		10.1038/sj.onc.1210037	http://dx.doi.org/10.1038/sj.onc.1210037			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043647				2022-12-25	WOS:000245831000003
J	Han, W; Wu, L; Chen, S; Bao, L; Zhang, L; Jiang, E; Zhao, Y; Xu, A; Hei, TK; Yu, Z				Han, W.; Wu, L.; Chen, S.; Bao, L.; Zhang, L.; Jiang, E.; Zhao, Y.; Xu, A.; Hei, T. K.; Yu, Z.			Constitutive nitric oxide acting as a possible intercellular signaling molecule in the initiation of radiation-induced DNA double strand breaks in non-irradiated bystander cells	ONCOGENE			English	Article						constitutive nitric oxide; radiation-induced bystander effects; DNA double strand breaks; initiation process	IONIZING-RADIATION; TYROSINE PHOSPHORYLATION; UNIRRADIATED CELLS; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; OPIATE RECEPTOR; HISTONE H2AX; SYNTHASE; PEROXYNITRITE; IRRADIATION	The initiation and propagation of the early processes of bystander signaling induced by low-dose alpha-particle irradiation are very important for understanding the underlying mechanism of the bystander process. Our previous investigation showed that the medium collected from cell culture exposed to low-dose alpha-particle rapidly induced phosphorylated form of H2AX protein foci formation among the non-irradiated medium receptor cells in a time-dependent manner. Using N-G-methyl-L-arginine, 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate and N-omega-nitro-L-arginine (L-NNA) treatment before exposure to 1 cGy alpha-particle, we showed in the present study that nitric oxide (NO center dot) produced in the irradiated cells was important and necessary for the DNA double strand break inducing activity (DIA) of conditioned medium and the generation of NO center dot in irradiated confluent AG1522 cells is in a time-dependent manner and that almost all NO center dot was generated within 15 min post-irradiation. Concurrently, the kinetics of NO center dot production in the medium of irradiated cells after irradiation was rapid and in a time-dependent manner as well, with a maximum yield observed at 10 min after irradiation with electron spin resonance analysis. Furthermore, our results that 7-Nitroindazole and L-NNA, but not aminoguanidine hemisulfate, treatment before exposure to 1 cGy alpha-particle significantly decrease the DIA of the conditioned medium suggested that constitutive NO center dot from the irradiated cells possibly acted as an intercellular signaling molecule to initiate and activate the early process ( <= 30 min) of bystander response after low-dose irradiation.	Chinese Acad Sci, Inst Plasma Phys, Key Lab Ion Beam Bioengn, Hefei 230031, Anhui, Peoples R China; Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Columbia University	Wu, L (corresponding author), Chinese Acad Sci, Inst Plasma Phys, Key Lab Ion Beam Bioengn, POB 1126,Shushanhu Rd 350, Hefei 230031, Anhui, Peoples R China.	ljw@ipp.ac.cn	Zhao, Ye/V-6986-2019; Zhao, Ye/H-9713-2013	Zhao, Ye/0000-0003-1384-6024; Zhao, Ye/0000-0003-1384-6024	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R01ES012888] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES012888, ES09089] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Azzam EI, 2004, CURR CANCER DRUG TAR, V4, P53, DOI 10.2174/1568009043481641; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; AZZAM EI, 2003, BIOL EFF LOW LEVEL E, V11, P2; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Dahm-Daphi J, 2000, INT J RADIAT BIOL, V76, P67, DOI 10.1080/095530000139023; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; FAGAGNA FF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Femandes E, 2005, LIFE SCI, V77, P1983, DOI 10.1016/j.lfs.2005.02.018; HAN W, 2007, BR J RADIOL; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hu B, 2005, RADIAT RES, V164, P286, DOI 10.1667/RR3415.1; Hu BR, 2006, CARCINOGENESIS, V27, P245, DOI 10.1093/carcin/bgi224; Iyer R, 2000, CANCER RES, V60, P1290; Janssen YMW, 1998, AM J PHYSIOL-LUNG C, V275, pL1100, DOI 10.1152/ajplung.1998.275.6.L1100; JOURDHEUIL D, 1997, FRONT BIOSCI, V2, P189; Kiang JG, 2003, J CELL BIOCHEM, V89, P1030, DOI 10.1002/jcb.10564; Kojima H, 1998, NEUROREPORT, V9, P3345, DOI 10.1097/00001756-199810260-00001; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Lewis DA, 2001, RADIAT RES, V156, P251, DOI 10.1667/0033-7587(2001)156[0251:PODDAN]2.0.CO;2; Li NZ, 2003, J NEUROSCI, V23, P10302; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Liu SX, 2005, CANCER RES, V65, P3236, DOI 10.1158/0008-5472.CAN-05-0424; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Matsumoto H, 2000, INT J RADIAT BIOL, V76, P1649; Minetti M, 2002, FREE RADICAL BIO MED, V33, P744, DOI 10.1016/S0891-5849(02)00891-2; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Murad F, 1998, RECENT PROG HORM RES, V53, P43; Nagar S, 2003, CANCER RES, V63, P324; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; Qu XW, 2001, FASEB J, V15, P439, DOI 10.1096/fj.99-0343com; Rao CV, 2002, CANCER RES, V62, P165; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sedelnikova OA, 2004, INT J RADIAT BIOL, V80, P927, DOI 10.1080/09553000400017648; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2003, CANCER RES, V63, P8437; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2003, FASEB J, V17, P1422, DOI 10.1096/fj.02-1115com; Stefano GB, 1998, J NEUROIMMUNOL, V83, P70, DOI 10.1016/S0165-5728(97)00223-3; Stefano GB, 2000, PROG NEUROBIOL, V60, P513, DOI 10.1016/S0301-0082(99)00038-6; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vodovotz Y, 1999, CANCER RES, V59, P2142; Xiong QH, 2001, J INTERF CYTOK RES, V21, P529, DOI 10.1089/10799900152434411	57	75	80	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2330	2339		10.1038/sj.onc.1210024	http://dx.doi.org/10.1038/sj.onc.1210024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016433				2022-12-25	WOS:000245466000009
J	Liu, YE; Pu, W; Jiang, Y; Shi, D; Dackour, R; Shi, YE				Liu, Y. E.; Pu, W.; Jiang, Y.; Shi, D.; Dackour, R.; Shi, Y. E.			Chaperoning of estrogen receptor and induction of mammary gland proliferation by neuronal protein synuclein gamma	ONCOGENE			English	Article						synuclein gamma (SNCG); estrogen receptor; chaperone; hyperplasia; breast cancer; transgenic mouse	BREAST-CANCER CELLS; INHIBITOR-RELATED GENE; HEAT-SHOCK-PROTEIN; ABERRANT EXPRESSION; PARKINSONS-DISEASE; ALZHEIMER-DISEASE; GROWTH INHIBITOR; ALPHA-SYNUCLEIN; METASTASIS; PROMOTES	Synucleins are emerging as central players in the formation of pathologically insoluble deposits characteristic of neurodegenerative diseases. However, synuclein c (SNCG), previously identified as a breast cancer specific gene (BCSG1), is also highly associated with breast cancer progression. Using transgenic mouse model, we demonstrated a role of SNCG in induction of highly proliferative pregnancy-like phenotype of mammary epithelial cells and branching morphology. SNCG participated in the heat shock protein-based multiprotein chaperone complex for steroid receptor signaling. Expression of SNCG in mammary epithelium resulted in a significant stimulation of ER alpha transcriptional activity. SNCG-induced mammary gland proliferation can be effectively blocked by antiestrogen and ovariectomy, indicating that the induced proliferation is mediated by ERa signaling and requires estrogen stimulation. These data indicate the chaperone activity of SNCG on stimulation of steroid receptor signaling in mammary gland and, thus induces extensive mammary gland proliferation and contributes to the hormonal impact on mammary tumorigenesis.	Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; Sichuan Univ, W China Hosp, State Key Lab, Div Mol Oncol, Chengdu 610064, Peoples R China	Northwell Health; Sichuan University	Shi, YE (corresponding author), Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA.	eshi@lij.edu						Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; Geisler H, 2003, J STEROID BIOCHEM, V86, P245, DOI 10.1016/S0960-0760(03)00364-9; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Gupta A, 2003, CANCER RES, V63, P664; Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Jiang YF, 2003, CANCER RES, V63, P3899; Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; LU A, 2000, J BIOL CHEM, V277, P31364; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Shi YE, 1997, CANCER RES, V57, P3084; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wang MS, 2000, CANCER RES, V60, P6482; Wang MS, 2003, J BIOL CHEM, V278, P47319, DOI 10.1074/jbc.M308131200; WU K, 2006, BREAST CANC RES TREA; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	31	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2115	2125		10.1038/sj.onc.1210000	http://dx.doi.org/10.1038/sj.onc.1210000			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016445				2022-12-25	WOS:000245313400013
J	Benson, LJ; Phillips, JA; Gu, Y; Parthun, MR; Hoffman, CS; Annunziato, AT				Benson, Laura J.; Phillips, Jane A.; Gu, Yongli; Parthun, Mark R.; Hoffman, Charles S.; Annunziato, Anthony T.			Properties of the type B histone acetyltransferase Hat1 - H4 tail Interaction, site preference, and involvement in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; CHROMATIN REPLICATION; ACETYLATION SITES; YEAST; H3; PHOSPHORYLATION; SUBSTRATE; COMPLEX; TRANSCRIPTION; SUPERFAMILY	The Hat1 histone acetyltransferase catalyzes the acetylation of H4 at lysines 5 and 12, the same sites that are acetylated in newly synthesized histone H4. By performing histone acetyltransferase (HAT) assays on various synthetic H4 N-terminal peptides, we have examined the interactions between Hat1 and the H4 tail domain. It was found that acetylation requires the presence of positively charged amino acids at positions 8 and 16 of H4, positions that are normally occupied by lysine; however, lysine per se is not essential and can be replaced by arginine. In contrast, replacing Lys-8 and -16 of H4 with glutamines reduces acetylation to background levels. Similarly, phosphorylation of Ser-1 of the H4 tail depresses acetylation by both yeast Hat1p and the human HAT-B complex. These results strongly support the model proposed by Ramakrishnan and colleagues for the interaction between Hat1 and the H4 tail (Dutnall, R. N., Tafrov, S. T., Sternglanz, R., and Ramakrishnan, V. (1998) Cell 94, 427 438) and may have implications for the genetic analysis of histone acetylation. It was also found that Lys-12 of H4 is preferentially acetylated by human HAT-B, in further agreement with the proposed model of H4 tail binding. Finally, we have demonstrated that deletion of the hat1 gene from the fission yeast Schizosaccharomyces pombe causes increased sensitivity to the DNA-damaging agent methyl methanesulfonate in the absence of any additional mutations. This is in contrast to results obtained with a Saccharomyces cerevisiae hat1 Delta strain, which must also carry mutations of the acetylatable lysines of H3 for heightened methyl methanesulfonate sensitivity to be observed. Thus, although the role of Hat1 in DNA damage repair is evolutionarily conserved, the ability of H3 acetylation to compensate for Hat1 deletion appears to be more variable.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Boston College; University System of Ohio; Ohio State University	Annunziato, AT (corresponding author), Boston Coll, Dept Biol, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.	annunzia@bc.edu		Hoffman, Charles/0000-0001-8700-1863	NIGMS NIH HHS [GM35837, GM46226, R01 GM062970, GM62970] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062970, R01GM046226, R29GM046226, R01GM035837] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Ai X, 2004, MOL CELL, V14, P195, DOI 10.1016/S1097-2765(04)00184-4; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Barber CM, 2004, CHROMOSOMA, V112, P360, DOI 10.1007/s00412-004-0281-9; Barman HK, 2006, BIOCHEM BIOPH RES CO, V345, P1547, DOI 10.1016/j.bbrc.2006.05.079; Benson LJ, 2006, J BIOL CHEM, V281, P9287, DOI 10.1074/jbc.M512956200; Benson LJ, 2004, METHODS, V33, P45, DOI 10.1016/j.ymeth.2003.10.019; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Dutnall RN, 1998, COLD SPRING HARB SYM, V63, P501, DOI 10.1101/sqb.1998.63.501; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Glowczewski L, 2004, MOL CELL BIOL, V24, P10180, DOI 10.1128/MCB.24.23.10180-10192.2004; GUTZ H, 1966, J BACTERIOL, V92, P1567, DOI 10.1128/JB.92.5.1567-1568.1966; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kolle D, 1998, FEBS LETT, V421, P109, DOI 10.1016/S0014-5793(97)01544-5; LEUPOLD U., 1950, Comptes rendus des Travaux du Laboratoire Carlsberg, V24, P381; Lusser A, 1999, NUCLEIC ACIDS RES, V27, P4427, DOI 10.1093/nar/27.22.4427; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; Makowski AM, 2001, J BIOL CHEM, V276, P43499, DOI 10.1074/jbc.C100549200; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Polo SE, 2006, CURR OPIN GENET DEV, V16, P104, DOI 10.1016/j.gde.2006.02.011; Poveda A, 2004, J BIOL CHEM, V279, P16033, DOI 10.1074/jbc.M314228200; Qin S, 2006, MOL CELL BIOL, V26, P3649, DOI 10.1128/MCB.26.9.3649-3658.2006; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Ramey CJ, 2004, MOL CELL BIOL, V24, P10313, DOI 10.1128/MCB.24.23.10313-10327.2004; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Rosaleny LE, 2005, FEBS LETT, V579, P4063, DOI 10.1016/j.febslet.2005.06.028; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; RYAN CA, 1999, CURR PROTOCOLS MOL B, P1; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; VERRAULT A, 1997, CURR BIOL, V8, P96; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	48	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					836	842		10.1074/jbc.M607464200	http://dx.doi.org/10.1074/jbc.M607464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17052979	hybrid			2022-12-25	WOS:000243295200005
J	Iyer, S; Wei, S; Brew, K; Acharya, KR				Iyer, Shalini; Wei, Shuo; Brew, Keith; Acharya, K. Ravi			Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN SUBSTRATE-SPECIFICITY; AMINO-TERMINAL DOMAIN; TIMP-1; REFINEMENT	The mammalian collagenases are a subgroup of the matrix metalloproteinases (MMPs) that are uniquely able to cleave triple helical fibrillar collagens. Collagen breakdown is an essential part of extracellular matrix turnover in key physiological processes including morphogenesis and wound healing; however, unregulated collagenolysis is linked to important diseases such as arthritis and cancer. The tissue inhibitors of metalloproteinases (TIMPs) function in controlling the activity of MMPs, including collagenases. We report here the structure of a complex of the catalytic domain of fibroblast collagenase (MMP-1) with the N-terminal inhibitory domain of human TIMP-1 (N-TIMP-1) at 2.54 angstrom resolution. Comparison with the previously reported structure of the TIMP-1/stromelysin-1 (MMP-3) complex shows that the mechanisms of inhibition of both MMPs are generally similar, yet there are significant differences in the protein-protein interfaces in the two complexes. Specifically, the loop between beta-strands A and B of TIMP-1 makes contact with MMP-3 but not with MMP-1, and there are marked differences in the roles of individual residues in the C-D connector of TIMP-1 in binding to the two MMPs. Structural rearrangements in the bound MMPs are also strikingly different. This is the first crystallographic structure that contains the truncated N-terminal domain of a TIMP, which shows only minor differences from the corresponding region of the full-length protein. Differences in the interactions in the two TIMP-1 complexes provide a structural explanation for the results of previous mutational studies and a basis for designing new N-TIMP-1 variants with restricted specificity.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	State University System of Florida; Florida Atlantic University; University of Bath	Brew, K (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, 777 Glades Rd, Boca Raton, FL 33431 USA.	kbrew@fau.edu; bssskra@bath.ac.uk	Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; Acharya, K. Ravi/0000-0002-3009-4058; Wei, Shuo/0000-0001-8203-4922	NIAMS NIH HHS [AR40994] Funding Source: Medline; Wellcome Trust [067288] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arumugam S, 2003, J MOL BIOL, V327, P719, DOI 10.1016/S0022-2836(03)00180-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1997, METHOD ENZYMOL, V277, P243, DOI 10.1016/S0076-6879(97)77015-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HASTY KA, 1987, J BIOL CHEM, V262, P10048; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Iyer S, 2006, J MOL BIOL, V362, P78, DOI 10.1016/j.jmb.2006.06.079; Jozic D, 2005, J BIOL CHEM, V280, P9578, DOI 10.1074/jbc.M411084200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT GJ, 1984, EUR J CLIN INVEST, V14, P411, DOI 10.1111/j.1365-2362.1984.tb01204.x; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Moy FJ, 1997, J BIOMOL NMR, V10, P9, DOI 10.1023/A:1018362914316; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagase H, 1999, ANN NY ACAD SCI, V878, P1, DOI 10.1111/j.1749-6632.1999.tb07670.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; Wei S, 2003, J BIOL CHEM, V278, P9831, DOI 10.1074/jbc.M211793200; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wu B, 2000, J MOL BIOL, V295, P257, DOI 10.1006/jmbi.1999.3362	38	51	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					364	371		10.1074/jbc.M607625200	http://dx.doi.org/10.1074/jbc.M607625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17050530	hybrid			2022-12-25	WOS:000243166500041
J	Larbat, R; Kellner, S; Specker, S; Hehn, A; Gontier, E; Hans, J; Bourgaud, F; Matern, U				Larbat, Romain; Kellner, Sandra; Specker, Silvia; Hehn, Alain; Gontier, Eric; Hans, Joachim; Bourgaud, Frederic; Matern, Ulrich			Molecular cloning and functional characterization of psoralen synthase, the first committed monooxygenase of furanocoumarin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMMI-MAJUS L; CELL-SUSPENSION CULTURES; MECHANISM-BASED INACTIVATION; GLYCINE-MAX L.; CINNAMATE 4-HYDROXYLASE; ANGULAR FURANOCOUMARINS; PAPILIO-POLYXENES; CYTOCHROME P450S; RUTA-GRAVEOLENS; LINEAR FURANOCOUMARINS	Ammi majus L. accumulates linear furanocournarins by cytochrome P450 (CYP)-dependent conversion of 6-prenylumbelliferone via (+)-marmesin to psoralen. Relevant activities, i.e. psoralen synthase, are induced rapidly from negligible background levels upon elicitation of A. majus cultures with transient maxima at 9-10 h and were recovered in labile microsomes. Expressed sequence tags were cloned from elicited Ammi cells by a nested DD-RT-PCR strategy with CYP-specific primers, and full-size cDNAs were generated from those fragments correlated in abundance with the induction profile of furanocoumarin-specific activities. One of these cDNAs representing a transcript of maximal abundance at 4 h of elicitation was assigned CYP71AJ1. Functional expression in Escherichia coli or yeast cells initially failed but was accomplished eventually in yeast cells after swapping the N-terminal membrane anchor domain with that of CYP73A1. The recombinant enzyme was identified as psoralen synthase with narrow substrate specificity for (+)-marmesin. Psoralen synthase catalyzes a unique carbon-chain cleavage reaction concomitantly releasing acetone by syn-elimination. Related plants, i.e. Heracleum mantegazzianum, are known to produce both linear and angular furanocoumarins by analogous conversion of 8-prenylumbelliferone via (+)-columbianetin to angelicin, and it was suggested that angelicin synthase has evolved from psoralen synthase. However, (+)-columbianetin failed as substrate but competitively inhibited psoralen synthase activity. Analogy modeling and docked solutions defined the conditions for high affinity substrate binding and predicted the minimal requirements to accommodate (+)-columbianetin in the active site cavity. The studies suggested that several point mutations are necessary to pave the road toward angelicin synthase evolution.	Univ Marburg, Inst Pharmazeut Biol, D-35037 Marburg, Germany; ENSAIA, INRA, INPL, UMR Agron Environm 1121, F-54505 Vandoeuvre Les Nancy, France	Philipps University Marburg; INRAE; Universite de Lorraine	Matern, U (corresponding author), Univ Marburg, Inst Pharmazeut Biol, Deutschhausstr 17A, D-35037 Marburg, Germany.	matern@staff.uni-marburg.de	Larbat, Romain/V-4270-2019; Larbat, Romain/C-8576-2013; Larbat, Romain/GQZ-8786-2022	Larbat, Romain/0000-0002-9060-5040; Hehn, Alain/0000-0003-4507-8031; GONTIER, Eric/0000-0003-2640-4612; Bourgaud, Frederic/0000-0002-9898-2625				AFEK U, 1995, PHYTOCHEMISTRY, V39, P1347, DOI 10.1016/0031-9422(95)00125-Q; Batard Y, 2000, ARCH BIOCHEM BIOPHYS, V379, P161, DOI 10.1006/abbi.2000.1867; Baudry J, 2003, PROTEIN ENG, V16, P577, DOI 10.1093/protein/gzg075; BEIER RC, 1994, PHYTOCHEMISTRY, V36, P869, DOI 10.1016/S0031-9422(00)90453-9; BERENBAUM M, 1981, SCIENCE, V212, P927, DOI 10.1126/science.212.4497.927; BERENBAUM MR, 1991, J CHEM ECOL, V17, P207, DOI 10.1007/BF00994434; Berenbaum MR, 1998, P NATL ACAD SCI USA, V95, P13743, DOI 10.1073/pnas.95.23.13743; Berenbaum MR, 1996, RECENT ADV PHYTOCHEM, V30, P1; BERENBAUM MR, 1993, OECOLOGIA, V95, P370, DOI 10.1007/BF00320991; Boland W, 1998, TETRAHEDRON, V54, P14725, DOI 10.1016/S0040-4020(98)00902-8; BOURGAUD F, 2006, IN PRESS PHYTOCHEM R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Croteau RB, 2005, NATURWISSENSCHAFTEN, V92, P562, DOI 10.1007/s00114-005-0055-0; De Castro WV, 2006, J AGR FOOD CHEM, V54, P249, DOI 10.1021/jf0516944; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DHILLON DS, 1976, ARCH BIOCHEM BIOPHYS, V177, P74, DOI 10.1016/0003-9861(76)90417-3; DIESPERGER H, 1978, FEBS LETT, V85, P333, DOI 10.1016/0014-5793(78)80485-2; Ekiert H, 2000, PHARMAZIE, V55, P684; ELGAMAL MHA, 1993, PHYTOCHEMISTRY, V34, P819, DOI 10.1016/0031-9422(93)85365-X; EstevezBraun A, 1997, NAT PROD REP, V14, P465, DOI 10.1039/np9971400465; Fischer TC, 2001, THEOR APPL GENET, V103, P1014, DOI 10.1007/s001220100620; Frey M, 2003, PHYTOCHEMISTRY, V62, P371, DOI 10.1016/S0031-9422(02)00556-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIULIANO G, 1993, PLANT CELL, V5, P379, DOI 10.1105/tpc.5.4.379; GOTOH O, 1992, J BIOL CHEM, V267, P83; Gravot A, 2004, ARCH BIOCHEM BIOPHYS, V422, P71, DOI 10.1016/j.abb.2003.12.013; GRUENERT DC, 1985, CANCER RES, V45, P5394; Hagemeier J, 1999, PHYTOCHEMISTRY, V51, P629, DOI 10.1016/S0031-9422(99)00072-2; HAMERSKI D, 1990, PHYTOCHEMISTRY, V29, P1131, DOI 10.1016/0031-9422(90)85417-E; HAMERSKI D, 1988, EUR J BIOCHEM, V171, P369, DOI 10.1111/j.1432-1033.1988.tb13800.x; HAMERSKI D, 1990, PHYTOCHEMISTRY, V29, P1137, DOI 10.1016/0031-9422(90)85418-F; HAMERSKI D, 1988, FEBS LETT, V239, P263, DOI 10.1016/0014-5793(88)80930-X; Hehmann M, 2004, EUR J BIOCHEM, V271, P932, DOI 10.1111/j.1432-1033.2004.03995.x; Herde A., 2005, THESIS U HAMBURG; Hubner S, 2003, PHYTOCHEMISTRY, V64, P445, DOI 10.1016/S0031-9422(03)00265-6; INNOCENTI G, 1986, PLANTES MED PHYTOTH, V4, P313; IVIE GW, 1978, J AGR FOOD CHEM, V26, P1394, DOI 10.1021/jf60220a023; Jefcoate C R, 1978, Methods Enzymol, V52, P258; KANNE D, 1982, BIOCHEMISTRY-US, V21, P861, DOI 10.1021/bi00534a008; Kawase M, 2005, IN VIVO, V19, P705; Kemp CA, 2005, ARCH BIOCHEM BIOPHYS, V433, P361, DOI 10.1016/j.abb.2004.08.026; Koenigs LL, 1998, BIOCHEMISTRY-US, V37, P13184, DOI 10.1021/bi981198r; Krolicka A, 2001, PLANT SCI, V160, P259, DOI 10.1016/S0168-9452(00)00381-2; Latunde-Dada AO, 2001, J BIOL CHEM, V276, P1688, DOI 10.1074/jbc.M006277200; Li XC, 2004, P NATL ACAD SCI USA, V101, P2939, DOI 10.1073/pnas.0308691101; Lieberman S, 2001, J STEROID BIOCHEM, V78, P1, DOI 10.1016/S0960-0760(01)00068-1; MA RL, 1994, ARCH BIOCHEM BIOPHYS, V310, P332, DOI 10.1006/abbi.1994.1175; Malaiyandi V, 2005, CLIN PHARMACOL THER, V77, P145, DOI 10.1016/j.clpt.2004.10.011; Matern U., 1999, COMPREHENSIVE NATURA, V1, P623; Murray R. D., 1991, PROGR CHEM ORGANIC N, V58, P83; Murray R. D. H., 1982, NATURAL COUMARINS OC; Nedelkina S, 1999, PLANT MOL BIOL, V39, P1079, DOI 10.1023/A:1006156216654; OMURA T, 1964, J BIOL CHEM, V239, P2370; Paine MF, 2005, J PHARMACOL EXP THER, V312, P1151, DOI 10.1124/jpet.104.076836; Pan LP, 2004, ARCH BIOCHEM BIOPHYS, V422, P31, DOI 10.1016/j.abb.2003.09.047; Pande D, 2002, PLANT SCI, V162, P583, DOI 10.1016/S0168-9452(01)00597-0; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; Rupasinghe S, 2003, PROTEIN ENG, V16, P721, DOI 10.1093/protein/gzg094; Schopfer CR, 1998, MOL GEN GENET, V258, P315, DOI 10.1007/s004380050736; SPECKER S, 2004, THESI PHILIPPS U MAR; STADLER E, 1991, SYMP BIOL HUNG, V39, P71; Stanjek V, 1998, HELV CHIM ACTA, V81, P1596, DOI 10.1002/(SICI)1522-2675(19980909)81:9<1596::AID-HLCA1596>3.0.CO;2-F; Stanjek V, 1999, PHYTOCHEMISTRY, V50, P1141, DOI 10.1016/S0031-9422(98)00650-5; Stanjek V, 1999, ANGEW CHEM INT EDIT, V38, P400, DOI 10.1002/(SICI)1521-3773(19990201)38:3<400::AID-ANIE400>3.0.CO;2-K; STANJEK V, 1998, THESIS U BONN; SUEYOSHI T, 1995, ARCH BIOCHEM BIOPHYS, V322, P265, DOI 10.1006/abbi.1995.1461; Takahashi S, 2005, J BIOL CHEM, V280, P3686, DOI 10.1074/jbc.M411870200; TEUTSCH HG, 1993, P NATL ACAD SCI USA, V90, P4102, DOI 10.1073/pnas.90.9.4102; TIETJEN KG, 1983, EUR J BIOCHEM, V131, P401, DOI 10.1111/j.1432-1033.1983.tb07277.x; URRAHMAN A, 1986, ENCY PLANTA MED, V1, P373; Wen YH, 2002, DRUG METAB DISPOS, V30, P977, DOI 10.1124/dmd.30.9.977; Wen ZM, 2003, INSECT BIOCHEM MOLEC, V33, P937, DOI 10.1016/S0965-1748(03)00100-0; WENDORFF H, 1986, EUR J BIOCHEM, V161, P391, DOI 10.1111/j.1432-1033.1986.tb10458.x; Werck-Reichhart D, 2000, GENOME BIOL, V6, P1, DOI [10.1186/GB-2000-1-6-REVIEWS3003, DOI 10.1186/GB-2000-1-6-REVIEWS3003]; Werck-Reichhart Daniele, 2002, Arabidopsis Book, V1, pe0028, DOI 10.1199/tab.0028; Williams PA, 2000, J INORG BIOCHEM, V81, P183, DOI 10.1016/S0162-0134(00)00102-1; Wulff H, 1998, J MED CHEM, V41, P4542, DOI 10.1021/jm981032o; ZOBEL AM, 1991, J CHEM ECOL, V17, P1801, DOI 10.1007/BF00993729; ZOBEL AM, 1990, J CHEM ECOL, V16, P1623, DOI 10.1007/BF01014095	80	69	73	4	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					542	554		10.1074/jbc.M604762200	http://dx.doi.org/10.1074/jbc.M604762200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17068340	Green Published, hybrid			2022-12-25	WOS:000243166500060
J	Karanam, B; Jiang, LH; Wang, L; Kelleher, NL; Cole, PA				Karanam, Balasubramanyam; Jiang, Lihua; Wang, Ling; Kelleher, Neil L.; Cole, Philip A.			Kinetic and mass spectrometric analysis of p300 histone acetyltransferase domain autoacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CYCLOTRON RESONANCE; CREB-BINDING-PROTEIN; REVERSIBLE ACETYLATION; ACTIVATION LOOP; CBP; PHOSPHORYLATION; RECEPTOR; HATS; TRANSCRIPTION; COACTIVATOR	Acetylation of proteins by p300 histone acetyltransferase plays a critical role in the regulation of gene expression. The prior discovery of an autoacetylated regulatory loop in the p300 histone acetyltransferase ( HAT) domain prompted us to further explore the mechanisms of p300 autoacetylation. Here we have described a kinetic and mass spectrometric analysis of p300 HAT autoacetylation. The rate of p300 HAT autoacetylation was approximately fourth order with respect to p300 HAT domain concentration and thus appeared to be a highly cooperative process. By showing that a catalytically defective p300 HAT domain could be efficiently acetylated by active p300 HAT, we deduced that autoacetylation occurs primarily by an intermolecular mechanism. This was further confirmed using a semisynthetic biotinylated p300 HAT domain that could be physically separated from the catalytically defective p300 HAT by avidin affinity chromatography. Autoacetylation catalyzed by p300 HAT was similar to 1000-fold more efficient than PCAF (p300/CREB-binding protein-associated factor)-mediated acetylation of catalytically defective p300 HAT. Using a novel tandem mass spectrometric approach, it was found to be possible to observe up to 17 autoacetylation events within the intact p300 regulatory loop. Kinetic analysis of the site specificity of p300 autoacetylation reveals a class of rapid events followed by a slower set of modifications. Several of these rapid autoacetylation sites correlate with an acetyltransferase-activating function based on prior mutagenesis analysis.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	University of Illinois System; University of Illinois Urbana-Champaign; Johns Hopkins University	Kelleher, NL (corresponding author), Univ Illinois, Dept Chem, 1209 W Calif St, Urbana, IL 61801 USA.	kelleher@scs.uiuc.edu; pcole@jhmi.edu			NIGMS NIH HHS [GM062437, GM067725, GM067193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067725, R01GM067193, R01GM062437] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; Bandyopadhyay D, 2002, CANCER RES, V62, P6231; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BAYER EA, 1990, J CHROMATOGR, V510, P3, DOI 10.1016/S0021-9673(01)93733-1; Black JC, 2006, MOL CELL, V23, P809, DOI 10.1016/j.molcel.2006.07.018; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; Chan HM, 2001, J CELL SCI, V114, P2363; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Goodman RH, 2000, GENE DEV, V14, P1553; Greene Warner C, 2004, Novartis Found Symp, V259, P208; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guan SH, 1996, INT J MASS SPECTROM, V157, P5, DOI 10.1016/S0168-1176(96)04461-8; Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200; Horn DM, 2000, J AM SOC MASS SPECTR, V11, P320, DOI 10.1016/S1044-0305(99)00157-9; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Iyer GH, 2005, J BIOL CHEM, V280, P8800, DOI 10.1074/jbc.M407586200; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kimura A, 2005, J BIOCHEM, V138, P647, DOI 10.1093/jb/mvi184; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Marmorstein Ronen, 2004, Novartis Found Symp, V259, P78; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Patrie SM, 2004, J AM SOC MASS SPECTR, V15, P1099, DOI 10.1016/j.jasms.2004.04.031; Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050; Poux AN, 2003, BIOCHEMISTRY-US, V42, P14366, DOI 10.1021/bi035632n; Pugh BF, 2004, NAT STRUCT MOL BIOL, V11, P298, DOI 10.1038/nsmb0404-298; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Senko MW, 1996, RAPID COMMUN MASS SP, V10, P1824; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taylor GK, 2003, ANAL CHEM, V75, P4081, DOI 10.1021/ac0341721; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zubarev RA, 2000, ANAL CHEM, V72, P563, DOI 10.1021/ac990811p	47	65	68	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40292	40301		10.1074/jbc.M608813200	http://dx.doi.org/10.1074/jbc.M608813200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17065153	hybrid			2022-12-25	WOS:000243033900060
J	Sramko, M; Markus, J; Kabat, J; Wolff, L; Bies, J				Sramko, Marek; Markus, Jan; Kabat, Juraj; Wolff, Linda; Bies, Juraj			Stress-induced inactivation of the c-Myb transcription factor through conjugation of SUMO-2/3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY DOMAIN; V-MYB; PHOSPHORYLATION SITE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; TOPOISOMERASE-II; BINDING PROTEIN; HEAT-SHOCK; ACTIVATION; TRANSACTIVATION	Post-translational modifications, such as phosphorylation, acetylation, ubiquitination, and SUMOylation, play an important role in regulation of the stability and the transcriptional activity of c-Myb. Conjugation of small ubiquitin-like modifier type 1 (SUMO-1) to lysines in the negative regulatory domain strongly suppresses its transcriptional activity. Here we report conjugation of two other members of the SUMO protein family, SUMO-2 and SUMO-3, and provide evidence that this post-translational modification negatively affects transcriptional activity of c-Myb. Conjugation of SUMO-2/3 proteins is strongly enhanced by several different cellular stresses and occurs primarily on two lysines, Lys523 and Lys499. These lysines are in the negative regulatory domain of c-Myb and also serve as acceptor sites for SUMO-1. Stress-induced SUMO-2/3 conjugation is very rapid and independent of activation of stress-activated protein kinases of the SAPK and JNK families. PIAS-3 protein was identified as a new c-Myb-specific SUMO-E3 ligase that both catalyzes conjugation of SUMO-2/3 proteins to c-Myb and exerts a negative effect on c-Myb-induced reporter gene activation. Interestingly, co-expression of a SPRING finger mutant of PIAS-3 significantly suppresses SUMOylation of c-Myb under stress. These results argue that PIAS-3 SUMO-E3 ligase plays a critical role in stress-induced conjugation of SUMO-2/3 to c-Myb. We also detected stress-induced conjugation of SUMO-2/3 to c-Myb in hematopoietic cells at the levels of endogenously expressed proteins. Furthermore, according to the negative role of SUMO conjugation on c-Myb capacity, we have observed rapid stress-induced down-regulation of the targets genes c-myc and bcl-2 of c-Myb. Our findings demonstrate that SUMO-2/3 proteins conjugate to c-Myb and negatively regulate its activity in cells under stress.	Slovak Acad Sci, Canc Res Inst, Ctr Mol Med, Bratislava 83391, Slovakia; NIAID, Biol Imaging Facil, NIH, Bethesda, MD 20892 USA; NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	Slovak Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bies, J (corresponding author), Bldg 37,Rm 4124,37 Convent Dr, Bethesda, MD 20892 USA.	bies@helix.nih.gov	/ABB-3317-2021	/0000-0003-3998-9357				AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2005, EMBO J, V24, P2172, DOI 10.1038/sj.emboj.7600700; Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Corradini F, 2005, J BIOL CHEM, V280, P30254, DOI 10.1074/jbc.M504703200; Dahle O, 2004, EXP CELL RES, V297, P118, DOI 10.1016/j.yexcr.2004.03.014; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Feikova S, 2000, NEOPLASMA, V47, P212; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Ladendorff NE, 2001, ONCOGENE, V20, P125, DOI 10.1038/sj.onc.1204048; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sakamoto H, 2006, BLOOD, V108, P896, DOI 10.1182/blood-2005-09-3846; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Sitzmann J, 1995, ONCOGENE, V11, P2273; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yang SH, 2006, MOL CELL, V22, P477, DOI 10.1016/j.molcel.2006.03.037; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	58	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40065	40075		10.1074/jbc.M609404200	http://dx.doi.org/10.1074/jbc.M609404200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17077080	hybrid			2022-12-25	WOS:000243033900036
J	Antoine, M; Gand, A; Boschi-Muller, S; Branlant, G				Antoine, Mathias; Gand, Adeline; Boschi-Muller, Sandrine; Branlant, Guy			Characterization of the amino acids from Neisseria meningitidis MsrA involved in the chemical catalysis of the methionine sulfoxide reduction step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC CHARACTERIZATION; ESCHERICHIA-COLI; MECHANISM; COMPLEXES; BINDING; ENZYME	Methionine sulfoxide reductases (Msrs) are ubiquitous enzymes that reduce protein-bound methionine sulfoxide back to Met in the presence of thioredoxin. In vivo, the role of the Msrs is described as essential in protecting cells against oxidative damages and as playing a role in infection of cells by pathogenic bacteria. There exist two structurally unrelated classes of Msrs, called MsrA and MsrB, specific for the S and the R epimer of the sulfoxide function of methionine sulfoxide, respectively. Both Msrs present a similar catalytic mechanism, which implies, as a first step, a reductase step that leads to the formation of a sulfenic acid on the catalytic cysteine and a concomitant release of a mole of Met. The reductase step has been previously shown to be efficient and not rate-limiting. In the present study, the amino acids involved in the catalysis of the reductase step of the Neisseria meningitidis MsrA have been characterized. The invariant Glu-94 and to a lesser extent Tyr-82 and Tyr-134 are shown to play a major role in the stabilization of the sulfurane transition state and indirectly in the decrease of the pK(app) of the catalytic Cys-51. Ascenario of the reductase step is proposed in which the substrate binds to the active site with its sulfoxide function largely polarized via interactions with Glu-94, Tyr-82, and Tyr-134 and participates via the positive or partially positive charge borne by the sulfur of the sulfoxide in the stabilization of the catalytic Cys.	Nancy Univ, UHP, CNRS, UMR 7567,Fac Sci & Tech, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Branlant, G (corresponding author), Nancy Univ, UHP, CNRS, UMR 7567,Fac Sci & Tech, Bld Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	Guy.Branlant@maem.uhp-nancy.fr		Boschi, Sandrine/0000-0001-8962-4749				Antoine M, 2003, J BIOL CHEM, V278, P45352, DOI 10.1074/jbc.M307471200; Balta B, 2006, J PHYS CHEM A, V110, P7628, DOI 10.1021/jp0573036; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Boschi-Muller S, 2005, BBA-PROTEINS PROTEOM, V1703, P231, DOI 10.1016/j.bbapap.2004.09.016; COTTON FA, 1960, J AM CHEM SOC, V82, P2986, DOI 10.1021/ja01497a003; Dobado JA, 1999, J AM CHEM SOC, V121, P3156, DOI 10.1021/ja9828206; DREIZLER H, 1964, Z NATURFORSCH PT A, VA 19, P512; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Marchal S, 1999, BIOCHEMISTRY-US, V38, P12950, DOI 10.1021/bi990453k; Mrazkova E, 2003, J PHYS CHEM A, V107, P1032, DOI 10.1021/jp026895e; Olry A, 2004, BIOCHEMISTRY-US, V43, P11616, DOI 10.1021/bi049306z; Olry A, 2002, J BIOL CHEM, V277, P12016, DOI 10.1074/jbc.M112350200; Stener M, 2000, J MOL STRUC-THEOCHEM, V497, P91, DOI 10.1016/S0166-1280(99)00200-6; Taylor AB, 2003, J BACTERIOL, V185, P4119, DOI 10.1128/JB.185.14.4119-4126.2003; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8	15	30	33	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39062	39070		10.1074/jbc.M608844200	http://dx.doi.org/10.1074/jbc.M608844200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17062561	Green Published, hybrid			2022-12-25	WOS:000242898700012
J	Delcroix, M; Sajid, M; Caffrey, CR; Lim, KC; Dvorak, J; Hsieh, I; Bahgat, M; Dissous, C; McKerrow, JH				Delcroix, Melaine; Sajid, Mohammed; Caffrey, Conor R.; Lim, Kee-C.; Dvorak, Jan; Hsieh, Ivy; Bahgat, Mahmoud; Dissous, Colette; McKerrow, James H.			A multienzyme network functions in intestinal protein digestion by a platyhelminth parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT SCHISTOSOMA-MANSONI; CATHEPSIN-B; CYSTEINE PROTEASE; LIVER FLUKE; ASPARAGINYL ENDOPEPTIDASE; HEMOGLOBIN DEGRADATION; HAEMONCHUS-CONTORTUS; FASCIOLA-HEPATICA; ASPARTIC PROTEASE; MOLECULAR-CLONING	Proteases frequently function not only as individual enzymes but also in cascades or networks. A notable evolutionary switch occurred in one such protease network that is involved in protein digestion in the intestine. In vertebrates, this is largely the work of trypsin family serine proteases, whereas in invertebrates, cysteine proteases of the papain family and aspartic proteases assume the role. Utilizing a combination of protease class-specific inhibitors and RNA interference, we deconvoluted such a network of major endopeptidases functioning in invertebrate intestinal protein digestion, using the parasitic helminth, Schistosoma mansoni as an experimental model. We show that initial degradation of host blood proteins is ordered, occasionally redundant, and substrate-specific. Although inhibition of parasite cathepsin D had a greater effect on primary cleavage of hemoglobin, inhibition of cathepsin B predominated in albumin degradation. Nevertheless, in both cases, inhibitor combinations were synergistic. An asparaginyl endopeptidase ( legumain) also synergized with cathepsin B and L in protein digestion, either by zymogen activation or facilitating substrate cleavage. This protease network operates optimally in acidic pH compartments either in the gut lumen or in vacuoles of the intestinal lining cells. Defining the role of each of these major enzymes now provides a clearer understanding of the function of a complex protease network that is conserved throughout invertebrate evolution. It also provides insights into which of these proteases are logical targets for development of chemotherapy for schistosomiasis, a major global health problem.	Univ Calif San Francisco, Dept Pathol, Trop Dis Res Unit, San Francisco, CA 94158 USA; Univ Calif San Francisco, Sandler Ctr Basic Res Parasit Dis, San Francisco, CA 94158 USA; Inst Pasteur, INSERM, Unite 547, F-59019 Lille, France; Natl Res Ctr, Therapeut Chem Dept, Rd Nobel Project, Cairo 12311, Egypt; Natl Res Ctr, Infect Dis & Immunol Lab, Rd Nobel Project, Cairo 12311, Egypt	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian Knowledge Bank (EKB); National Research Centre (NRC)	McKerrow, JH (corresponding author), Univ Calif San Francisco, Dept Pathol, Trop Dis Res Unit, 1700 4th St, San Francisco, CA 94158 USA.	jmck@cgl.ucsf.edu	Dvorak, Jan/I-3909-2012; Dvorak, Jan/AAJ-2426-2020	Dissous, Colette/0000-0002-5003-8205; Dvorak, Jan/0000-0002-6824-9000; Bahgat, Mahmoud/0000-0002-6485-8722	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053247] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-053247] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asgian JL, 2002, J MED CHEM, V45, P4958, DOI 10.1021/jm025581c; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; Bi XN, 2000, J NEUROCHEM, V74, P1469, DOI 10.1046/j.1471-4159.2000.0741469.x; BOGITSH BJ, 1992, J PARASITOL, V78, P454, DOI 10.2307/3283643; BOGITSH BJ, 1986, EXP PARASITOL, V62, P211, DOI 10.1016/0014-4894(86)90025-1; BOGITSH BJ, 1978, EXP PARASITOL, V45, P247, DOI 10.1016/0014-4894(78)90066-8; Boldbaatar D, 2006, INSECT BIOCHEM MOLEC, V36, P25, DOI 10.1016/j.ibmb.2005.10.003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady CP, 1999, INFECT IMMUN, V67, P368, DOI 10.1128/IAI.67.1.368-374.1999; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; BROWN A, 1995, PARASITOLOGY, V110, P555, DOI 10.1017/S0031182000065276; BUTLER R, 1995, PROTEIN PEPTIDE LETT, V2, P313; Caffrey Conor R., 1998, Parasitology International, V47, P11, DOI 10.1016/S1383-5769(97)00044-5; Caffrey CR, 2004, TRENDS PARASITOL, V20, P241, DOI 10.1016/j.pt.2004.03.004; Caffrey CR, 1997, PARASITOL RES, V83, P632, DOI 10.1007/s004360050310; Caffrey CR, 2000, FEBS LETT, V466, P244, DOI 10.1016/S0014-5793(99)01798-6; CHAPPELL CL, 1986, EXP PARASITOL, V61, P160, DOI 10.1016/0014-4894(86)90148-7; Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4; Collins PR, 2004, J BIOL CHEM, V279, P17038, DOI 10.1074/jbc.M308831200; Correnti JA, 2005, MOL BIOCHEM PARASIT, V143, P209, DOI 10.1016/j.molbiopara.2005.06.007; Dalton JP, 2003, INT J PARASITOL, V33, P1173, DOI 10.1016/S0020-7519(03)00171-1; Dalton JP, 1996, PARASITOL TODAY, V12, P125, DOI 10.1016/0169-4758(96)80676-4; Dalton JP, 1996, INFECT IMMUN, V64, P1328, DOI 10.1128/IAI.64.4.1328-1334.1996; Don TA, 2004, INT J PARASITOL, V34, P1029, DOI 10.1016/j.ijpara.2004.04.013; DOTY SB, 1977, J HISTOCHEM CYTOCHEM, V25, P1381, DOI 10.1177/25.12.200672; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GREEN GDJ, 1981, J BIOL CHEM, V256, P1923; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Hola-Jamriska L, 1998, EUR J BIOCHEM, V255, P527, DOI 10.1046/j.1432-1327.1998.2550527.x; Kato D, 2005, NAT CHEM BIOL, V1, P33, DOI 10.1038/nchembio707; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; Lara FA, 2005, J EXP BIOL, V208, P3093, DOI 10.1242/jeb.01749; LAWRENCE JD, 1973, J PARASITOL, V59, P60, DOI 10.2307/3278572; Longbottom D, 1997, MOL BIOCHEM PARASIT, V88, P63, DOI 10.1016/S0166-6851(97)00074-1; MAKI J, 1982, PARASITOLOGY, V84, P137, DOI 10.1017/S0031182000051738; MAKI J, 1986, J HELMINTHOL, V60, P31, DOI 10.1017/S0022149X00008191; McCarthy E, 2004, INT J PARASITOL, V34, P703, DOI 10.1016/j.ijpara.2004.01.008; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; ORR GL, 1994, J INSECT PHYSIOL, V40, P893, DOI 10.1016/0022-1910(94)90023-X; PRATT D, 1990, MOL BIOCHEM PARASIT, V43, P181, DOI 10.1016/0166-6851(90)90143-A; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; RUPPEL A, 1987, CLIN EXP IMMUNOL, V69, P291; Sajid M, 2003, MOL BIOCHEM PARASIT, V131, P65, DOI 10.1016/S0166-6851(03)00194-4; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Semenov A, 1998, ANTIMICROB AGENTS CH, V42, P2254, DOI 10.1128/AAC.42.9.2254; SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248; Song Chul Yong, 1994, Korean Journal of Parasitology, V32, P231, DOI 10.3347/kjp.1994.32.4.231; Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; Wasilewski MM, 1996, MOL BIOCHEM PARASIT, V81, P179, DOI 10.1016/0166-6851(96)02703-X; Williamson AL, 2002, FASEB J, V16, P1458, DOI 10.1096/fj.02-0181fje; Williamson AL, 2003, TRENDS PARASITOL, V19, P417, DOI 10.1016/S1471-4922(03)00189-2; Wilson LR, 1998, EXP PARASITOL, V88, P85, DOI 10.1006/expr.1998.4234; Wippersteg V, 2005, INT J PARASITOL, V35, P583, DOI 10.1016/j.ijpara.2005.02.002; Woessner JF, 2004, HDB PROTEOLYTIC ENZY; Xing RY, 1998, BIOCHEM J, V332, P499, DOI 10.1042/bj3320499; YAMAKAMI K, 1995, EUR J BIOCHEM, V233, P490, DOI 10.1111/j.1432-1033.1995.490_2.x; YAMASAKI H, 1992, PARASITOL RES, V78, P574, DOI 10.1007/BF00936455; Yasuda Y, 1999, J BIOCHEM-TOKYO, V125, P1137, DOI 10.1093/oxfordjournals.jbchem.a022396; Yatsuda AP, 2006, INFECT IMMUN, V74, P1989, DOI 10.1128/IAI.74.3.1989-1993.2006; ZUSSMAN RA, 1970, J PARASITOL, V56, P75, DOI 10.2307/3277456	64	187	192	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39316	39329		10.1074/jbc.M607128200	http://dx.doi.org/10.1074/jbc.M607128200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17028179	hybrid			2022-12-25	WOS:000242898700039
J	Suh, JH; Huang, JS; Park, YY; Seong, HA; Kim, D; Shong, M; Ha, H; Lee, IK; Lee, K; Wang, L; Choi, HS				Suh, Ji Ho; Huang, Jiansheng; Park, Yun-Yong; Seong, Hyun-A; Kim, Dongwook; Shong, Minho; Ha, Hyunjung; Lee, In-Kyu; Lee, Keesook; Wang, Li; Choi, Hueng-Sik			Orphan nuclear receptor small heterodimer partner inhibits transforming growth factor-beta signaling by repressing SMAD3 transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAO HEPATOMA-CELLS; SHP GENE PROMOTER; TRANSCRIPTIONAL ACTIVITY; BILE-ACID; X-RECEPTOR; CROSS-TALK; DIFFERENTIAL REGULATION; ANDROGEN RECEPTOR; FUNCTIONAL INTERACTIONS; FEEDBACK-REGULATION	Orphan nuclear receptor small heterodimer partner (SHP) is an atypical member of the nuclear receptor superfamily; SHP regulates the nuclear receptor-mediated transcription of target genes but lacks a conventional DNA binding domain. In this study, we demonstrate that SHP represses transforming growth factor-beta (TGF-beta)-induced gene expression through a direct interaction with Smad, a transducer of TGF-beta signaling. Transient transfection studies demonstrate that SHP represses Smad3-induced transcription. In vivo and in vitro protein interaction assays revealed that SHP directly interacts with Smad2 and Smad3 but not with Smad4. Mapping of domains mediating the interaction between SHP and Smad3 showed that the entire N-terminal domain (1-159 amino acids) of SHP and the linker domain of Smad3 are involved in this interaction. In vitro glutathione S-transferase pulldown competition experiments revealed the SHP-mediated repression of Smad3 transactivation through competition with its co-activator p300. SHP also inhibits the activation of endogenous TGF-beta-responsive gene promoters, the p21, Smad7, and plasminogen activator inhibitor-1 (PAI-1) promoters. Moreover, adenovirus-mediated overexpression of SHP decreases PAI-1 mRNA levels, and down-regulation of SHP by a small interfering RNA increases both the transactivation of Smad3 and the PAI-1 mRNA levels. Finally, the PAI-1 gene is expressed in SHP-/- mouse hepatocytes at a higher level than in normal hepatocytes. Taken together, these data indicate that SHP is a novel co-regulator of Smad3, and this study provides new insights into regulation of TGF-beta signaling.	Chonnam Natl Univ, Hormone Res Ctr, Sch Biol Sci & Technol, Kwangju 500757, South Korea; Chungbuk Natl Univ, Dept Biochem, Sch Life Sci, Cheongju 361763, South Korea; Chungnam Natl Univ, Dept Internal Med, Lab Endocrine Cell Biol, Taejon 301721, South Korea; Kyungpook Natl Univ, Dept Internal Med, Sch Med, Taegu 702701, South Korea; Univ Kansas, Med Ctr, Dept Med & Pharmacol, Kansas City, KS 66160 USA	Chonnam National University; Chungbuk National University; Chungnam National University; Kyungpook National University; University of Kansas; University of Kansas Medical Center	Choi, HS (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Sch Biol Sci & Technol, Kwangju 500757, South Korea.	hsc@chonnam.ac.kr	Lee, In-Kyu/AAR-6374-2021; /H-7803-2012		NCRR NIH HHS [P20 RR016475] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bissell DM, 2001, HEPATOLOGY, V34, P859, DOI 10.1053/jhep.2001.28457; Borgius LJ, 2002, J BIOL CHEM, V277, P49761, DOI 10.1074/jbc.M205641200; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Chou WC, 2003, MOL BIOL CELL, V14, P1279, DOI 10.1091/mbc.E02-07-0375; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gobinet J, 2001, BIOCHEMISTRY-US, V40, P15369, DOI 10.1021/bi011384o; Gobinet J, 2005, BIOCHEMISTRY-US, V44, P6312, DOI 10.1021/bi047308d; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, MOL ENDOCRINOL, V17, P386, DOI 10.1210/me.2002-0246; Hayes SA, 2001, CANCER RES, V61, P2112; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herrera B, 2001, HEPATOLOGY, V34, P548, DOI 10.1053/jhep.2001.27447; Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Ju WJ, 2006, MOL CELL BIOL, V26, P654, DOI 10.1128/MCB.26.2.654-667.2006; Jung D, 2003, HEPATOLOGY, V37, P622, DOI 10.1053/jhep.2003.50100; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim HJ, 2003, NUCLEIC ACIDS RES, V31, P6860, DOI 10.1093/nar/gkg906; Kim HJ, 2004, J BIOL CHEM, V279, P28122, DOI 10.1074/jbc.M313302200; Kim JY, 2004, MOL ENDOCRINOL, V18, P776, DOI 10.1210/me.2003-0311; Kim JY, 2004, MOL ENDOCRINOL, V18, P2880, DOI 10.1210/me.2004-0211; Klinge CM, 2001, ARCH BIOCHEM BIOPHYS, V390, P64, DOI 10.1006/abbi.2001.2366; Lai KD, 2003, J BIOL CHEM, V278, P36418, DOI 10.1074/jbc.M303913200; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee KY, 2002, J BIOCHEM MOL BIOL, V35, P47; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Moustakas A, 2001, J CELL SCI, V114, P4359; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Ourlin JC, 2003, MOL ENDOCRINOL, V17, P1693, DOI 10.1210/me.2002-0383; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Park YY, 2004, MOL ENDOCRINOL, V18, P1082, DOI 10.1210/me.2003-0339; Pendaries V, 2003, ONCOGENE, V22, P8212, DOI 10.1038/sj.onc.1206913; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Subramaniam N, 2001, J BIOL CHEM, V276, P15741, DOI 10.1074/jbc.M011033200; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wang L, 2005, CELL METAB, V2, P227, DOI 10.1016/j.cmet.2005.08.010; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yeo MG, 2005, MOL ENDOCRINOL, V19, P950, DOI 10.1210/me.2004-0209	69	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39169	39178		10.1074/jbc.M605947200	http://dx.doi.org/10.1074/jbc.M605947200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17074765	hybrid			2022-12-25	WOS:000242898700025
J	Yu, QG; Chow, EMC; Wong, H; Gu, J; Mandelboim, O; Gray-Owen, SD; Ostrowski, MA				Yu, Qigui; Chow, Edith M. C.; Wong, Henry; Gu, Jenny; Mandelboim, Ofer; Gray-Owen, Scott D.; Ostrowski, Mario A.			CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase- and AKT-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; BILIARY GLYCOPROTEIN CD66A; ANTIGEN GENE FAMILY; FACTOR-KAPPA-B; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; C-CAM; NEISSERIA-GONORRHOEAE; CYTOLYTIC FUNCTION; INDUCED APOPTOSIS	CEACAM1 ( also known as CD66a) is a transmembrane glycoprotein that mediates homophilic intercellular interactions that influence cellular growth, immune cell activation, and tissue morphogenesis. Various studies have suggested a link between CEACAM1 and cellular apoptosis, including a recent demonstration that ERK1/2 signaling is triggered downstream of CEACAM1. In this study, we reveal that CEACAM1-long binding confers survival signals to human peripheral blood mononuclear cells. CEACAM-specific antibodies effectively protected peripheral blood mononuclear cells from apoptosis, with this effect being particularly dramatic for primary monocytes that undergo spontaneous apoptosis during in vitro culture. This protective effect was reiterated when using soluble CEACAM1, which binds to cell-surface CEACAM1 via homophilic interactions. Monocyte survival correlated with a CEACAM1-dependent up-regulation of the cellular inhibitor of apoptosis Bcl-2 and the abrogation of caspase-3 activation. CEACAM1 binding triggered a phosphatidylinositol 3-kinase-dependent activation of the protein kinase Akt without influencing the activity of extracellular signal-related kinase ERK, whereas the phosphatidylinositol 3-kinase-specific inhibitor LY294002 effectively blocked the protective effect of CEACAM1. Together, this work indicates that CEACAM1 confers a phosphatidylinositol 3-kinase- and Akt-dependent survival signal that inhibits mitochondrion-dependent apoptosis of monocytes. By controlling both ERK/MEK and PI3K/Akt pathways, CEACAM1 functions as a key regulator of contact-dependent control of cell survival, differentiation, and growth.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Div Clin Sci, Toronto, ON M5S 1A8, Canada; Lautenberg Ctr Gen & Tumor Immunol, Hadassah Med Sch, IL-92210 Jerusalem, Israel	University of Toronto; University of Toronto; Hebrew University of Jerusalem	Gray-Owen, SD (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, Rm 4381 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	scott.gray.owen@utoronto.ca	Gray-Owen, Scott/AAG-7337-2022; Gray-Owen, Scott/AFL-7380-2022	Gray-Owen, Scott D./0000-0002-1477-3616; Mandelboim, Ofer/0000-0002-9354-1855				Adam RM, 1999, ENDOCRINOLOGY, V140, P5866, DOI 10.1210/en.140.12.5866; Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Bamberger AM, 1998, AM J PATHOL, V152, P1401; Beauchemin N, 1999, EXP CELL RES, V252, P243; Blau DM, 2001, J VIROL, V75, P8173, DOI 10.1128/JVI.75.17.8173-8186.2001; Booth JW, 2003, J BIOL CHEM, V278, P14037, DOI 10.1074/jbc.M211879200; Boulton IC, 2002, NAT IMMUNOL, V3, P229, DOI 10.1038/ni769; Chen CJ, 2004, J IMMUNOL, V172, P3544, DOI 10.4049/jimmunol.172.6.3544; Chen DH, 2004, J IMMUNOL, V172, P3535, DOI 10.4049/jimmunol.172.6.3535; Ferrero E, 2003, BLOOD, V101, P186, DOI 10.1182/blood-2002-03-0768; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gao CJ, 2003, BLOOD, V102, P169, DOI 10.1182/blood-2003-01-0003; Goyal A, 2002, AM J RESP CELL MOL, V26, P224, DOI 10.1165/ajrcmb.26.2.4640; Gray-Owen SD, 2003, SCAND J INFECT DIS, V35, P614, DOI 10.1080/00365540310016042; Greicius G, 2003, J LEUKOCYTE BIOL, V74, P126, DOI 10.1189/jlb.1202594; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Hill DJ, 2003, MOL MICROBIOL, V48, P117, DOI 10.1046/j.1365-2958.2003.03433.x; Hill DJ, 2001, MOL MICROBIOL, V39, P850, DOI 10.1046/j.1365-2958.2001.02233.x; Houde C, 2003, J BIOL CHEM, V278, P16929, DOI 10.1074/jbc.M301842200; Huang J, 1999, J CELL SCI, V112, P4193; Iijima H, 2004, J EXP MED, V199, P471, DOI 10.1084/jem.20030437; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kammerer R, 1998, EUR J IMMUNOL, V28, P3664, DOI 10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D; KIENER PA, 1995, J IMMUNOL, V155, P4917; Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kunath T, 1995, ONCOGENE, V11, P2375; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MANGAN DF, 1991, J IMMUNOL, V146, P1541; Markel G, 2002, J IMMUNOL, V168, P2803, DOI 10.4049/jimmunol.168.6.2803; Markel G, 2002, J CLIN INVEST, V110, P943, DOI 10.1172/JCI200215643; Morales VM, 1999, J IMMUNOL, V163, P1363; Muenzner P, 2001, J BIOL CHEM, V276, P24331, DOI 10.1074/jbc.M006883200; Muenzner P, 2002, J BIOL CHEM, V277, P7438, DOI 10.1074/jbc.M108135200; Nakajima A, 2002, J IMMUNOL, V168, P1028, DOI 10.4049/jimmunol.168.3.1028; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Newman DK, 2001, BLOOD, V97, P2351, DOI 10.1182/blood.V97.8.2351; Nollau P, 1997, CANCER RES, V57, P2354; Ordonez C, 2000, CANCER RES, V60, P3419; Ostrowski MA, 2000, J IMMUNOL, V165, P6133, DOI 10.4049/jimmunol.165.11.6133; Perlman H, 2001, EUR J IMMUNOL, V31, P2421, DOI 10.1002/1521-4141(200108)31:8<2421::AID-IMMU2421>3.0.CO;2-W; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; ROSENBERG M, 1993, CANCER RES, V53, P4938; Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200; Singer BB, 2005, EUR J IMMUNOL, V35, P1949, DOI 10.1002/eji.200425691; Singer BB, 2002, J IMMUNOL, V168, P5139, DOI 10.4049/jimmunol.168.10.5139; Singer BB, 2000, CANCER RES, V60, P1236; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Sundberg U, 2004, J CELL SCI, V117, P1091, DOI 10.1242/jcs.00944; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510	52	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39179	39193		10.1074/jbc.M608864200	http://dx.doi.org/10.1074/jbc.M608864200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17071610	hybrid			2022-12-25	WOS:000242898700026
J	Ziv, I; Fuchs, Y; Preger, E; Shabtay, A; Harduf, H; Zilpa, T; Dym, N; Ron, D				Ziv, Inbal; Fuchs, Yaron; Preger, Ella; Shabtay, Ariel; Harduf, Haggar; Zilpa, Tal; Dym, Naama; Ron, Dina			The human Sef-a isoform utilizes different mechanisms to regulate receptor tyrosine kinase signaling pathways and subsequent cell fate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTORS; MAP KINASES; APOPTOSIS; EXPRESSION; RAS; ERK; IDENTIFICATION; TRANSDUCTION; ANTAGONIST	Negative feedback is among the key mechanisms for regulating receptor tyrosine kinase (RTK) signaling. Human Sef, a recently identified inhibitor of RTK signaling, encodes different isoforms, including a membrane spanning (hSef-a) and a cytosolic (hSef-b) isoform. Previously, we reported that hSef-b inhibited fibroblast proliferation and prevented the activation of mitogen-activated protein kinase ( MAPK), without affecting protein kinase B/Akt or p38 MAPK. Conflicting results were reported concerning hSef-a inhibition of MAPK activation, and the effect of hSef-a on other RTK-induced signaling pathways is unknown. Here we show that, in fibroblasts, similar to hSef-b, ectopic expression of hSef-a inhibited fibroblast growth factor-induced cell proliferation. Unlike hSef-b, however, the growth arrest was mediated via a MAPK-independent mechanism, and was accompanied by elevated p38 MAPK phosphorylation and inhibition of protein kinase B/Akt. In addition, hSef-a, but not hSef-b, mediated apoptosis in fibroblast growth factor-stimulated cells. Chemical inhibitor of p38 MAPK abrogated the effect of hSef-a on apoptosis. In epithelial cells, ectopic expression of hSef-a inhibited the activation of MAPK, whereas down-regulation of endogenous hSef-a significantly increased MAPK activation and accelerated growth factor-dependent cell proliferation. These results indicate that hSef-a is a multifunctional negative modulator of RTK signaling and clearly demonstrate that hSef-a can inhibit the activation of MAPK, although in a cell type-specific manner. Moreover, the differences between the activities of hSef-a and hSef-b suggest that hSef isoforms can control signal specificity and subsequent cell fate by utilizing different mechanisms to modulate RTK signaling.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	dinar@techunix.technion.ac.il						ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Behren A, 2005, EXP CELL RES, V303, P321, DOI 10.1016/j.yexcr.2004.10.004; Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; EISEMANN A, 1991, ONCOGENE, V6, P1195; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; GRAZIANI G, 1989, ONCOGENE, V4, P823; Harduf H, 2005, DEV DYNAM, V233, P301, DOI 10.1002/dvdy.20364; Huang S, 2000, EXP CELL RES, V261, P91, DOI 10.1006/excr.2000.5044; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Kovalenko D, 2006, CELL SIGNAL, V18, P1958, DOI 10.1016/j.cellsig.2006.03.001; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Niehrs C, 2002, NATURE, V417, P35, DOI 10.1038/417035a; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; POWIS G, 1994, CANCER RES, V54, P2419; Preger E, 2004, P NATL ACAD SCI USA, V101, P1229, DOI 10.1073/pnas.0307952100; REICHSLOTKY R, 1995, J BIOL CHEM, V270, P29813; Ren YM, 2006, BIOCHEM BIOPH RES CO, V347, P988, DOI 10.1016/j.bbrc.2006.06.193; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; SHAOUL E, 1995, ONCOGENE, V10, P1553; SHCLESSINGER J, 2000, CELL, V103, P211; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Terada Y, 1999, NEPHROL DIAL TRANSPL, V14, P45, DOI 10.1093/ndt/14.suppl_1.45; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; TSANG M, 2004, SCI STKE, pE17; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200; Yang XH, 2004, J BIOL CHEM, V279, P38099, DOI 10.1074/jbc.C400318200; Yuan BB, 2004, NUCLEIC ACIDS RES, V32, pW130, DOI 10.1093/nar/gkh366; Zhuang SG, 2003, PHOTOCHEM PHOTOBIOL, V78, P361, DOI 10.1562/0031-8655(2003)078<0361:SOAOPK>2.0.CO;2	47	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39225	39235		10.1074/jbc.M607327200	http://dx.doi.org/10.1074/jbc.M607327200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17035228	hybrid			2022-12-25	WOS:000242898700030
J	Benito, A; Gutierrez, O; Pipaon, C; Real, PJ; Gachon, F; Ritchie, AE; Fernandez-Luna, JL				Benito, Adalberto; Gutierrez, Olga; Pipaon, Carlos; Real, Pedro J.; Gachon, Frederic; Ritchie, Alistair E.; Fernandez-Luna, Jose L.			A novel role for proline- and acid-rich basic region leucine zipper (PAR bZIP) proteins in the transcriptional regulation of a BH3-only proapoptotic gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; CANCER CELLS; APOPTOSIS; EXPRESSION; P53; BCL-2; TEF; GROWTH; ACTIVATION; PROMOTER	Proline- and acid-rich (PAR) basic region leucine zipper ( bZIP) proteins thyrotroph embryonic factor (TEF), D-site-binding protein (DBP), and hepatic leukemia factor have been involved in neurotransmitter homeostasis and amino acid metabolism. Here we demonstrate a novel role for these proteins in the transcriptional control of a BH3-only gene. PAR bZIP proteins are able to transactivate the promoter of bcl-gS. This promoter is particularly responsive to TEF activation and is silenced by NFIL3, a repressor that shares the consensus binding site with PAR bZIP proteins. Consistently, transfection of TEF induces the expression of endogenous bcl-gS in cancer cells, and this induction is independent of p53. A naturally occurring variant of DBP (tDBP), lacking the transactivation domain, has been identified and shown to impede the formation of active TEF dimers in a competitive manner and to reduce the TEF-dependent induction of bcl-gS. Of note, treatment of cancer cells with etoposide induces TEF activation and promotes the expression of bcl-gS. Furthermore, blockade of bcl-gS or TEF expression by a small interfering RNA strategy or transfection with tDBP significantly reduces the etoposide-mediated apoptotic cell death. These findings represent the first described role for PAR bZIP proteins in the regulation of a gene involved in the execution of apoptosis.	Hosp Univ Marques de Valdecilla, Unidad Genet Mol, Serv Cantabro Salud, Santander 39008, Spain; Univ Geneva, Dept Biol Mol, CH-1211 Geneva 4, Switzerland	Hospital Universitario Marques de Valdecilla (HUMV); University of Geneva	Fernandez-Luna, JL (corresponding author), Hosp Univ Marques de Valdecilla, Unidad Genet Mol, Serv Cantabro Salud, Edificio Escuela Univ Enfermeria,Av Valdecilla S, Santander 39008, Spain.	fluna@humv.es	Real, Pedro J./K-2994-2014; Gachon, Frederic/A-9289-2010; Real, Pedro J./ABH-3493-2021; Pipaon, Carlos/L-4922-2014; Gachon, Frédéric/H-3111-2019	Real, Pedro J./0000-0001-7968-5353; Pipaon, Carlos/0000-0002-3851-6710; Gachon, Frédéric/0000-0002-9279-9707				Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bouillet P, 2002, J CELL SCI, V115, P1567; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Crable SC, 2003, BLOOD, V101, P4757, DOI 10.1182/blood-2002-09-2702; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; DEL PL, 1997, SCIENCE, V278, P687; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; ELLIS RE, 1991, DEVELOPMENT, V112, P591; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; Gachon F, 2004, GENE DEV, V18, P1397, DOI 10.1101/gad.301404; Gelinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; Inukai T, 2005, BLOOD, V105, P4437, DOI 10.1182/blood-2004-08-2976; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; KHATIB ZA, 1994, GENOMICS, V23, P344, DOI 10.1006/geno.1994.1510; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Miled C, 2005, CANCER RES, V65, P5096, DOI 10.1158/0008-5472.CAN-04-4232; Obata T, 2003, CLIN CANCER RES, V9, P6410; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Real PJ, 2005, CANCER RES, V65, P8151, DOI 10.1158/0008-5472.CAN-05-1134; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Thellmann M, 2003, DEVELOPMENT, V130, P4057, DOI 10.1242/dev.00597; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zhou JL, 2004, J BIOL CHEM, V279, P15929, DOI 10.1074/jbc.M313822200; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	38	12	14	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38351	38357		10.1074/jbc.M607004200	http://dx.doi.org/10.1074/jbc.M607004200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17057225	Green Published, hybrid			2022-12-25	WOS:000242709500028
J	Mouchantaf, R; Azakir, BA; McPherson, PS; Millard, SM; Wood, SA; Angers, A				Mouchantaf, Rania; Azakir, Bilal A.; McPherson, Peter S.; Millard, Susan M.; Wood, Stephen A.; Angers, Annie			The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACETS DEUBIQUITINATING ENZYME; FAT-FACETS; E3 LIGASE; EMBRYO DEVELOPMENT; DOWN-REGULATION; JNK ACTIVATION; LIQUID FACETS; BETA-CATENIN; PROTEIN; DOMAIN	Itch is a ubiquitin ligase that has been implicated in the regulation of a number of cellular processes. We previously have identified Itch as a binding partner for the endocytic protein Endophilin and found it to be localized to endosomes. Using affinity purification coupled to mass spectrometry, we have now identified the ubiquitin-protease FAM/USP9X as a binding partner of Itch. The association between Itch and FAM/USP9X was confirmed in vitro by glutathione S-transferase pulldown and in vivo through coimmunoprecipation. Itch and FAM partially colocalize in COS-7 cells at the trans-Golgi network and in peripheral vesicles. We mapped the FAM-binding domain on Itch to the WW domains, a region known to be involved in substrate recognition. However, transient overexpression of FAM/USP9X resulted in the deubiquitylation of Itch. Moreover, we show that Itch auto-ubiquitylation leads to its degradation in the proteasome. By examining the amounts of Itch and FAM in various cell lines and rat tissues, a positive correlation was found in the expression of both proteins. This observation suggests that the levels of FAM expression could have an influence on Itch in cells. Experimental decrease in FAM levels by RNA interference leads to a significant reduction in intracellular levels of endogenous Itch, which can be prevented by treatment with the proteasome inhibitor lactacystin. Accordingly, overexpression of FAM/USP9X resulted in a marked increase in endogenous Itch levels. These results demonstrate an intriguing interplay between a ubiquitin ligase and a ubiquitin protease, based on direct interaction between the two proteins.	Univ Montreal, Dept Sci Biol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Child Hlth Res Inst, Adelaide, SA 5006, Australia; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	Universite de Montreal; McGill University; University of Adelaide	Angers, A (corresponding author), Univ Montreal, Dept Sci Biol, Montreal, PQ H3C 3J7, Canada.	Annie.Angers@umontreal.ca	Angers, Annie/P-1217-2018; Azakir, Bilal/AAP-9345-2020; Millard, Susan/C-8115-2011; Wood, Stephen A/E-8357-2011	Angers, Annie/0000-0003-0131-256X; Azakir, Bilal/0000-0003-3084-0265; Millard, Susan/0000-0003-1738-3362; Wood, Stephen A/0000-0002-2576-7457				Angers A, 2004, J BIOL CHEM, V279, P11471, DOI 10.1074/jbc.M309934200; Baek KH, 2003, EXP MOL MED, V35, P1; Blondeau F, 2004, P NATL ACAD SCI USA, V101, P3833, DOI 10.1073/pnas.0308186101; Boutell C, 2005, J VIROL, V79, P12342, DOI 10.1128/JVI.79.19.12342-12354.2005; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen H, 2003, P NATL ACAD SCI USA, V100, P14908, DOI 10.1073/pnas.2136625100; Chen X, 2000, DEV GENES EVOL, V210, P603, DOI 10.1007/s004270000109; Chen X, 2002, GENE DEV, V16, P289, DOI 10.1101/gad.961502; Chen X, 2001, GENOMICS, V73, P238, DOI 10.1006/geno.2001.6512; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Dirac AMG, 2005, METHOD ENZYMOL, V398, P554, DOI 10.1016/S0076-6879(05)98045-2; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Legendre-Guillemin V, 2004, J CELL SCI, V117, P9, DOI 10.1242/jcs.00928; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu H, 2004, ONCOGENE, V23, P3385, DOI 10.1038/sj.onc.1207402; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Murray RZ, 2004, MOL BIOL CELL, V15, P1591, DOI 10.1091/mbc.E03-08-0630; Nuber U, 1998, EUR J BIOCHEM, V254, P643, DOI 10.1046/j.1432-1327.1998.2540643.x; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Overstreet E, 2004, DEVELOPMENT, V131, P5355, DOI 10.1242/dev.01434; Pantaleon M, 2001, MECH DEVELOP, V109, P151, DOI 10.1016/S0925-4773(01)00551-2; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Ramjaun AR, 2001, J BIOL CHEM, V276, P28913, DOI 10.1074/jbc.M103198200; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wendland B, 2002, NAT REV MOL CELL BIO, V3, P971, DOI 10.1038/nrm970; Wood SA, 1997, MECH DEVELOP, V63, P29, DOI 10.1016/S0925-4773(97)00672-2; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004	49	98	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38738	38747		10.1074/jbc.M605959200	http://dx.doi.org/10.1074/jbc.M605959200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17038327	hybrid			2022-12-25	WOS:000242709500072
J	Vickers, TJ; Orsomando, G; de la Garza, RD; Scott, DA; Kang, SO; Hanson, AD; Beverley, SM				Vickers, Tim J.; Orsomando, Giuseppe; de la Garza, Rocio Diaz; Scott, David A.; Kang, Song O.; Hanson, Andrew D.; Beverley, Stephen M.			Biochemical and genetic analysis of methylenetetrahydrofolate reductase in Leishmania metabolism and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE; METHOTREXATE RESISTANCE; S-ADENOSYLMETHIONINE; FOLIC-ACID; WILD-TYPE; FOLATE; PURIFICATION; METHIONINE; NADH; METHYLTETRAHYDROFOLATE	Methylenetetrahydrofolate reductase (MTHFR; EC 1.5.1.20) is the sole enzyme responsible for generation of 5-methyltetrahydrofolate, which is required for methionine synthesis and provision of methyl groups via S-adenosylmethionine. Genome analysis showed that Leishmania species, unlike Trypanosoma brucei and Trypanosoma cruzi, contain genes encoding MTHFR and two distinct methionine synthases. Leishmania MTHFR differed from those in other eukaryotes by the absence of a C-terminal regulatory domain. L. major MTHFR was expressed in yeast and recombinant enzyme was produced in Escherichia coli. MTHFR was not inhibited by S-adenosylmethionine and, uniquely among folate-metabolizing enzymes, showed dual-cofactor specificity with NADH and NADPH under physiological conditions. MTHFR null mutants (mthfr(-)) lacked 5-methyltetrahydrofolate, the most abundant intracellular folate, and could not utilize exogenous homocysteine for growth. Under conditions of methionine limitation mthfr(-) mutant cells grew poorly, whereas their growth was normal in standard culture media. Neither in vitro MTHFR activity nor the growth of mthfr(-) mutants or MTHFR overexpressors were differentially affected by antifolates known to inhibit parasite growth via targets beyond dihydrofolate reductase and pteridine reductase 1. In a mouse model of infection mthfr(-) mutants showed good infectivity and virulence, indicating that sufficient methionine is available within the parasitophorous vacuole to meet the needs of the parasite.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA	Washington University (WUSTL); State University System of Florida; University of Florida	Beverley, SM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	beverley@borcim.wustl.edu	de la Garza, Rocío Isabel Diaz/B-7449-2011; Orsomando, Giuseppe/L-2120-2015	de la Garza, Rocío Isabel Diaz/0000-0002-0006-5694; Orsomando, Giuseppe/0000-0001-6640-097X; Beverley, Stephen/0000-0001-5319-0811; Scott, David/0000-0002-8668-2449	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021903, R01AI021903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071382] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21903] Funding Source: Medline; NIGMS NIH HHS [R01 GM 071382] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandrov A, 2004, MOL CELL PROTEOMICS, V3, P934, DOI 10.1074/mcp.T400008-MCP200; ASAWAMAHASAKDA W, 1993, PARASITOLOGY, V107, P1, DOI 10.1017/S0031182000079348; AVILA JL, 1983, MOL BIOCHEM PARASIT, V7, P1, DOI 10.1016/0166-6851(83)90111-1; Bacchi CJ, 1997, ANTIMICROB AGENTS CH, V41, P2108, DOI 10.1128/AAC.41.10.2108; BACCHI CJ, 1991, ANTIMICROB AGENTS CH, V35, P1315, DOI 10.1128/AAC.35.7.1315; Bagley PJ, 2000, CLIN CHEM, V46, P404; BECK JT, 1990, MOL BIOCHEM PARASIT, V43, P221, DOI 10.1016/0166-6851(90)90147-E; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burchmore RJS, 2001, INT J PARASITOL, V31, P1311, DOI 10.1016/S0020-7519(01)00259-4; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; Chakkalath HR, 2000, INFECT IMMUN, V68, P809, DOI 10.1128/IAI.68.2.809-814.2000; Chaudhary K, 2005, NAT BIOTECHNOL, V23, P1089, DOI 10.1038/nbt0905-1089; Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; DAUBNER SC, 1982, J BIOL CHEM, V257, P140; Drummelsmith J, 2004, J BIOL CHEM, V279, P33273, DOI 10.1074/jbc.M405183200; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P10053; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15960; Fairlamb AH, 2003, TRENDS PARASITOL, V19, P488, DOI 10.1016/j.pt.2003.09.002; Girard CL, 2005, J DAIRY SCI, V88, P660, DOI 10.3168/jds.S0022-0302(05)72730-2; Goyer A, 2005, J BIOL CHEM, V280, P26137, DOI 10.1074/jbc.M503106200; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; GREEN JM, 1988, FASEB J, V2, P42, DOI 10.1096/fasebj.2.1.3335280; GREGORY JF, 1988, ANAL BIOCHEM, V170, P94, DOI 10.1016/0003-2697(88)90094-2; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Hardy LW, 1997, EXP PARASITOL, V87, P157, DOI 10.1006/expr.1997.4207; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KUTZBACH C, 1967, BIOCHIM BIOPHYS ACTA, V139, P217, DOI 10.1016/0005-2744(67)90140-4; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; Lawrence JG, 2005, CURR OPIN GENET DEV, V15, P584, DOI 10.1016/j.gde.2005.09.007; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Lye LF, 2002, J BIOL CHEM, V277, P38245, DOI 10.1074/jbc.M206543200; Ma DQ, 1996, BIOCHEM BIOPH RES CO, V227, P885, DOI 10.1006/bbrc.1996.1600; MATTHEWS RG, 1980, J BIOL CHEM, V255, P6014; MATTHEWS RG, 1986, METHOD ENZYMOL, V122, P372; Matthews RG, 1998, EUR J PEDIATR, V157, pS54, DOI 10.1007/PL00014305; MCDANIEL HG, 1984, J MOL CELL CARDIOL, V16, P303, DOI 10.1016/S0022-2828(84)80601-X; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Mottram JC, 1996, P NATL ACAD SCI USA, V93, P6008, DOI 10.1073/pnas.93.12.6008; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; Nare B, 1997, J BIOL CHEM, V272, P13883, DOI 10.1074/jbc.272.21.13883; Neuhauser W, 1997, BIOCHEM J, V326, P683, DOI 10.1042/bj3260683; Nijhout HF, 2004, J BIOL CHEM, V279, P55008, DOI 10.1074/jbc.M410818200; ODALY JA, 1988, ACTA TROP, V45, P109; OLSON JA, 1953, J BIOL CHEM, V202, P841; Ouellette M, 2004, DRUG RESIST UPDATE, V7, P257, DOI 10.1016/j.drup.2004.07.002; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; Pejchal R, 2005, BIOCHEMISTRY-US, V44, P11447, DOI 10.1021/bi050533q; PETRILLOPEIXOTO MP, 1987, ANTIMICROB AGENTS CH, V31, P1575; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; Roje S, 2002, J BIOL CHEM, V277, P4056, DOI 10.1074/jbc.M110651200; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; SACKS DL, 1985, J IMMUNOL, V135, P564; SCOTT DA, 1987, MOL BIOCHEM PARASIT, V23, P139, DOI 10.1016/0166-6851(87)90149-6; Selzer PM, 1999, P NATL ACAD SCI USA, V96, P11015, DOI 10.1073/pnas.96.20.11015; Sheppard CA, 1999, J BACTERIOL, V181, P718, DOI 10.1128/JB.181.3.718-725.1999; Smith TJ, 2001, J MOL BIOL, V307, P707, DOI 10.1006/jmbi.2001.4499; Stanger O, 2002, CURR DRUG METAB, V3, P211, DOI 10.2174/1389200024605163; STEIGER RF, 1977, T ROY SOC TROP MED H, V71, P441, DOI 10.1016/0035-9203(77)90049-9; VANONI MA, 1983, J BIOL CHEM, V258, P1510; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Vought V, 2000, BIOCHEMISTRY-US, V39, P15012, DOI 10.1021/bi0014610; Walker J, 1997, INT J PARASITOL, V27, P883, DOI 10.1016/S0020-7519(97)00039-8; Wernegreen JJ, 2005, CURR OPIN GENET DEV, V15, P572, DOI 10.1016/j.gde.2005.09.013; WOHLFARTH G, 1990, EUR J BIOCHEM, V192, P411, DOI 10.1111/j.1432-1033.1990.tb19242.x; Yamada K, 2005, P NATL ACAD SCI USA, V102, P10454, DOI 10.1073/pnas.0504786102; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022	70	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38150	38158		10.1074/jbc.M608387200	http://dx.doi.org/10.1074/jbc.M608387200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17032644	Green Published, hybrid			2022-12-25	WOS:000242709500007
J	Zhao, YY; Itoh, S; Wang, XC; Isaji, T; Miyoshi, E; Kariya, Y; Miyazaki, K; Kawasaki, N; Taniguchi, N; Gu, JG				Zhao, Yanyang; Itoh, Satsuki; Wang, Xiangchun; Isaji, Tomoya; Miyoshi, Eiji; Kariya, Yoshinobu; Miyazaki, Kaoru; Kawasaki, Nana; Taniguchi, Naoyuki; Gu, Jianguo			Deletion of core fucosylation on alpha 3 beta 1 integrin down-regulates its functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; N-LINKED GLYCANS; CELL-ADHESION; EPITHELIAL-CELLS; LIGAND-BINDING; L-FUCOSE; ALPHA 3; GLYCOSYLATION; LAMININ-5	The core fucosylation (alpha 1,6-fucosylation) of glycoprotein is widely distributed in mammalian tissues. Recently alpha 1,6-fucosylation has been further reported to be very crucial by the study of alpha 1,6-fucosyltransferase (Fut8)-knock-out mice, which shows the phenotype of emphysema-like changes in the lung and severe growth retardation. In this study, we extensively investigated the effect of core fucosylation on alpha 3 beta 1 integrin and found for the first time that Fut8 makes an important contribution to the functions of this integrin. The role of core fucosylation in alpha 3 beta 1 integrin-mediated events has been studied by using Fut8(+/+) and Fut8(-/-) embryonic fibroblasts, respectively. We found that the core fucosylation of alpha 3 beta 1 integrin, the major receptor for laminin 5, was abundant in Fut8(+/+) cells but was totally abolished in Fut8(-/-) cells, which was associated with the deficient migration mediated by alpha 3 beta 1 integrin in Fut8(-/-) cells. Moreover integrin-mediated cell signaling was reduced in Fut8(-/-) cells. The reintroduction of Fut8 potentially restored laminin 5-induced migration and intracellular signaling. Collectively, these results suggested that core fucosylation is essential for the functions of alpha 3 beta 1 integrin.	Osaka Univ, Dept Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan; Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Dis Glycom, Suita, Osaka 5650871, Japan; Tohoku Phaarmaceut Univ, Div Regulatory Glycobiol, Inst Mol Biomembrane & Glycobiol, Aoba Ku, Sendai, Miyagi 9818558, Japan	Osaka University; National Institute of Health Sciences - Japan; Yokohama City University; Osaka University; Tohoku Medical & Pharmaceutical University	Taniguchi, N (corresponding author), Osaka Univ, Dept Biochem, Grad Sch Med, B1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tani52@wd5.so-net.ne.jp; jgu@tohoku-pharm.ac.jp	Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/I-4182-2014; Isaji, Tomoya/ABC-9285-2021; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Zhao, Yanyang/0000-0001-5139-5311				Bellis SL, 2004, BBA-BIOMEMBRANES, V1663, P52, DOI 10.1016/j.bbamem.2004.03.012; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 2004, GLYCOBIOLOGY, V14, P177, DOI 10.1093/glycob/cwh016; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Gu JG, 2004, GLYCOCONJUGATE J, V21, P9, DOI 10.1023/B:GLYC.0000043741.47559.30; Guo HB, 2002, CANCER RES, V62, P6837; Hashii N, 2005, PROTEOMICS, V5, P4665, DOI 10.1002/pmic.200401330; Hintermann E, 2004, MATRIX BIOL, V23, P75, DOI 10.1016/j.matbio.2004.03.001; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ILLC D, 1995, NATURE, V377, P539; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Isaji T, 2006, J BIOL CHEM, V281, P33258, DOI 10.1074/jbc.M607771200; Ito Y, 2003, CANCER LETT, V200, P167, DOI 10.1016/S0304-3835(03)00383-5; Itoh S, 2006, J CHROMATOGR A, V1103, P296, DOI 10.1016/j.chroma.2005.11.043; Kariya Y, 2002, J BIOCHEM, V132, P607, DOI 10.1093/oxfordjournals.jbchem.a003263; Kariya Y, 2003, J CELL BIOCHEM, V88, P506, DOI 10.1002/jcb.10350; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; KORHONEN M, 1991, LAB INVEST, V65, P347; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Litynska A, 2002, ACTA BIOCHIM POL, V49, P643; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; METTE SA, 1993, AM J RESP CELL MOL, V8, P562, DOI 10.1165/ajrcmb/8.5.562; Miyoshi E, 1999, BBA-GEN SUBJECTS, V1473, P9, DOI 10.1016/S0304-4165(99)00166-X; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; Nishiuchi R, 2005, P NATL ACAD SCI USA, V102, P1939, DOI 10.1073/pnas.0409493102; Noda K, 2003, CANCER RES, V63, P6282; Okamoto O, 2003, J BIOL CHEM, V278, P44168, DOI 10.1074/jbc.M300726200; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Plopper GE, 1998, BREAST CANCER RES TR, V51, P57, DOI 10.1023/A:1006086218174; Pochec E, 2003, BBA-MOL CELL RES, V1643, P113, DOI 10.1016/j.bbamcr.2003.10.004; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sturla L, 2003, J BIOL CHEM, V278, P26727, DOI 10.1074/jbc.M304068200; Sturla L, 2005, GLYCOBIOLOGY, V15, P924, DOI 10.1093/glycob/cwi081; Toledo MS, 2005, J BIOL CHEM, V280, P16227, DOI 10.1074/jbc.M413713200; Tysnes BB, 1996, INT J CANCER, V67, P777, DOI 10.1002/(SICI)1097-0215(19960917)67:6<777::AID-IJC5>3.0.CO;2-O; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Wang H, 2004, J CELL BIOL, V164, P935, DOI 10.1083/jcb.200309112; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Wang XC, 2006, J BIOL CHEM, V281, P2572, DOI 10.1074/jbc.M510893200; WILSON JR, 1976, BIOCHEM BIOPH RES CO, V72, P909, DOI 10.1016/S0006-291X(76)80218-5; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamamoto H, 2001, CANCER RES, V61, P6822; Zhao YY, 2006, J BIOL CHEM, V281, P32122, DOI 10.1074/jbc.M607274200	55	103	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38343	38350		10.1074/jbc.M608764200	http://dx.doi.org/10.1074/jbc.M608764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17043354	hybrid			2022-12-25	WOS:000242709500027
J	Chan, SL; Liu, D; Kyriazis, GA; Bagsiyao, P; Ouyang, X; Mattson, MP				Chan, Sic. L.; Liu, Dong; Kyriazis, George A.; Bagsiyao, Pamela; Ouyang, Xin; Mattson, Mark P.			Mitochondrial uncoupling protein-4 regulates calcium homeostasis and sensitivity to store depletion-induced apoptosis in neural cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; PREVENTS NEURONAL DEATH; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; EXPRESSION; GENE; ACTIVATION; CHANNELS; MECHANISM; GADD153	An increase in the cytoplasmic-free Ca2+ concentration mediates cellular responses to environmental signals that influence a range of processes, including gene expression, motility, secretion of hormones and neurotransmitters, changes in energy metabolism, and apoptosis. Mitochondria play important roles in cellular Ca2+ homeostasis and signaling, but the roles of specific mitochondrial proteins in these processes are unknown. Uncoupling proteins (UCPs) are a family of proteins located in the inner mitochondrial membrane that can dissociate oxidative phosphorylation from respiration, thereby promoting heat production and decreasing oxyradical production. Here we show that UCP4, a neuronal UCP, influences store-operated Ca2+ entry, a process in which depletion of endoplasmic reticulum Ca2+ stores triggers Ca2+ influx through plasma membrane "store-operated" channels. PC12 neural cells expressing human UCP4 exhibit reduced Ca2+ entry in response to thapsigargin-induced endoplasmic reticulum Ca2+ store depletion. The elevations of cytoplasmic and intramitochondrial Ca2+ concentrations and mitochondrial oxidative stress induced by thapsigargin were attenuated in cells expressing UCP4. The stabilization of Ca2+ homeostasis and preservation of mitochondrial function by UCP4 was correlated with reduced mitochondrial reactive oxygen species generation, oxidative stress, and Gadd153 up-regulation and increased resistance of the cells to death. Reduced Ca2+-dependent cytosolic phospholipase A2 activation and oxidative metabolism of arachidonic acid also contributed to the stabilization of mitochondrial function in cells expressing human UCP4. These findings demonstrate that UCP4 can regulate cellular Ca2+ homeostasis, suggesting that UCPs may play roles in modulating Ca2+ signaling in physiological and pathological conditions.	Univ Cent Florida, Biomol Sci Ctr, Orlando, FL 32816 USA; NIA, Neurosci Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	State University System of Florida; University of Central Florida; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Chan, SL (corresponding author), Univ Cent Florida, Biomol Sci Ctr, 4000 Cent Florida Blvd, Orlando, FL 32816 USA.	schan@mail.ucf.edu	Mattson, Mark P/F-6038-2012	Kyriazis, George/0000-0001-9514-3482				Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Carriere A, 2004, J BIOL CHEM, V279, P40462, DOI 10.1074/jbc.M407258200; Chan SL, 2004, J BIOL CHEM, V279, P28733, DOI 10.1074/jbc.M404272200; Chang WC, 2004, J BIOL CHEM, V279, P29994, DOI 10.1074/jbc.M403969200; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; CHOI AMK, 1994, FASEB J, V8, P1048, DOI 10.1096/fasebj.8.13.7926370; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cocco T, 1999, FREE RADICAL BIO MED, V27, P51, DOI 10.1016/S0891-5849(99)00034-9; Conn KJ, 2002, J NEUROSCI RES, V68, P755, DOI 10.1002/jnr.10252; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Diano S, 2003, ENDOCRINOLOGY, V144, P5014, DOI 10.1210/en.2003-0667; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; Fridell YWC, 2005, CELL METAB, V1, P145, DOI 10.1016/j.cmet.2005.01.005; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Gunter TE, 2000, CELL CALCIUM, V28, P285, DOI 10.1054/ceca.2000.0168; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Iijima T, 2003, BRAIN RES, V993, P140, DOI 10.1016/j.brainres.2003.09.041; Ikeyama S, 2003, J BIOL CHEM, V278, P16726, DOI 10.1074/jbc.M300677200; Jacobson J, 2002, J CELL SCI, V115, P1175; Kim-Han JS, 2001, J NEUROCHEM, V79, P658, DOI 10.1046/j.1471-4159.2001.00604.x; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LI WWF, 1993, J BIOL CHEM, V268, P12003; LIU D, 2006, NEUROMOL MED, V1, P169; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Makowska A, 2000, EUR J BIOCHEM, V267, P877, DOI 10.1046/j.1432-1327.2000.01066.x; Malli R, 2005, J BIOL CHEM, V280, P12114, DOI 10.1074/jbc.M409353200; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Milhavet O, 2002, J NEUROCHEM, V83, P673, DOI 10.1046/j.1471-4159.2002.01165.x; MINTA A, 1989, J BIOL CHEM, V264, P8171; Nagy G, 2003, J IMMUNOL, V171, P5188, DOI 10.4049/jimmunol.171.10.5188; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Pecqueur C, 2001, J MOL MED, V79, P48, DOI 10.1007/s001090000150; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Silva RM, 2005, J NEUROCHEM, V95, P974, DOI 10.1111/j.1471-4159.2005.03428.x; Soboloff J, 2002, J BIOL CHEM, V277, P13812, DOI 10.1074/jbc.M112129200; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; TESTAI Y, 2001, BIOCHEM J, V358, P717; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Varadi A, 2004, CELL CALCIUM, V36, P499, DOI 10.1016/j.ceca.2004.05.003; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	62	90	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37391	37403		10.1074/jbc.M605552200	http://dx.doi.org/10.1074/jbc.M605552200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035241	hybrid, Green Submitted			2022-12-25	WOS:000242477100016
J	Fouche, N; Cesare, AJ; Willcox, S; Ozgur, S; Compton, SA; Griffith, JD				Fouche, Nicole; Cesare, Anthony J.; Willcox, Smaranda; Ozgur, Sezgin; Compton, Sarah A.; Griffith, Jack D.			The basic domain of TRF2 directs binding to DNA junctions irrespective of the presence of TTAGGG repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTIONS; REPLICATION FORK; TERMINAL DOMAIN; HUMAN TELOMERES; PROTEIN; WRN; P53; HELICASE; STRAND; BLM	The replication of long tracts of telomeric repeats may require specific factors to avoid fork regression (Fouche, N., Ozgur, S., Roy, D., and Griffith, J. (2006) Nucleic Acids Res., in press). Here we show that TRF2 binds to model replication forks and four-way junctions in vitro in a structure-specific but sequence-independent manner. A synthetic peptide encompassing the TRF2 basic domain also binds to DNA four-way junctions, whereas the TRF2 truncation mutant (TRF2(Delta B)) and a mutant basic domain peptide do not. In the absence of the basic domain, the ability of TRF2 to localize to model telomere ends and facilitate t-loop formation in vitro is diminished. We propose that TRF2 plays a key role during telomere replication in binding chickenfoot intermediates of telomere replication fork regression. Junction-specific binding would also allow TRF2 to stabilize a strand invasion structure that is thought to exist at the strand invasion site of the t-loop.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Children's Medical Research Institute - Australia	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu	Cesare, Anthony/N-7415-2019; Cesare, Anthony J/F-4691-2010	Cesare, Anthony/0000-0002-0864-1254; Cesare, Anthony J/0000-0002-0864-1254	NIEHS NIH HHS [ES013773] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; Bai YL, 2003, HUM GENET, V113, P337, DOI 10.1007/s00439-003-0972-y; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bradshaw PS, 2005, NAT GENET, V37, P193, DOI 10.1038/ng1506; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; FOUCHE N, 2006, IN PRESS NUCL ACIDS; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Lansdorp PM, 2005, TRENDS BIOCHEM SCI, V30, P388, DOI 10.1016/j.tibs.2005.05.004; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Lillard-Wetherell K, 2004, HUM MOL GENET, V13, P1919, DOI 10.1093/hmg/ddh193; Machwe A, 2004, ONCOGENE, V23, P149, DOI 10.1038/sj.onc.1206906; Miller KM, 2006, NATURE, V440, P824, DOI 10.1038/nature04638; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Ohki R, 2004, NUCLEIC ACIDS RES, V32, P1627, DOI 10.1093/nar/gkh309; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2005, J BIOL CHEM, V280, P32069, DOI 10.1074/jbc.M505211200; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Phan AT, 2000, J MOL BIOL, V299, P123, DOI 10.1006/jmbi.2000.3613; Stansel RM, 2001, EMBO J, V20, P5532; Subramanian D, 2005, J BIOL CHEM, V280, P42568, DOI 10.1074/jbc.M506348200; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200	38	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37486	37495		10.1074/jbc.M608778200	http://dx.doi.org/10.1074/jbc.M608778200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17052985	hybrid, Green Published			2022-12-25	WOS:000242477100025
J	Lieser, SA; Shaffer, J; Adams, JA				Lieser, Scot A.; Shaffer, Jennifer; Adams, Joseph A.			Src tail phosphorylation is limited by structural changes in the regulatory tyrosine kinase Csk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; CATALYTIC DOMAIN; C-SRC; ACTIVATION; RECOGNITION; DISRUPTION; CANCER; LEADS	Src family tyrosine kinases are down-regulated through phosphorylation of a single C-terminal tyrosine by the nonreceptor tyrosine kinase Csk. Despite the fundamental role of Csk in controlling cell growth and differentiation, it is unclear what limits this key signaling reaction and controls the production of catalytically repressed Src. To investigate this issue, stopped-flow fluorescence experiments were performed to determine which steps modulate catalysis. Both Src binding and phosphorylation can be monitored by changes in intrinsic tryptophan fluorescence. Association kinetics are biphasic with the initial phase corresponding to the bimolecular interaction of both proteins and the second phase representing a slow conformational change that coincides with the rate of maximum turnover. The kinetic transients for the phosphorylation reaction are also biphasic with the initial phase corresponding to the rapid phosphorylation and the release of phospho-Src. These data, along with equilibrium sedimentation and product inhibition experiments, suggest that steps involving Src association, phosphorylation, and product release are fast and that a structural change in Csk participates in limiting the catalytic cycle.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Adams, JA (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	joeadams@chem.ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068168] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM68168] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Aubol BE, 2004, J BIOL CHEM, V279, P30182, DOI 10.1074/jbc.M402797200; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Chong YP, 2005, GROWTH FACTORS, V23, P233, DOI 10.1080/08977190500178877; Cole PA, 2003, CURR OPIN CHEM BIOL, V7, P580, DOI 10.1016/j.cbpa.2003.08.009; Cowan-Jacob SW, 2005, STRUCTURE, V13, P861, DOI 10.1016/j.str.2005.03.012; Ernst M, 2002, J EXP MED, V196, P589, DOI 10.1084/jem.20020873; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; JOHNSSON MSA, 1992, CRIT REV ORAL BIOL M, V3, P61, DOI 10.1177/10454411920030010601; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Lee SS, 2006, J BIOL CHEM, V281, P8183, DOI 10.1074/jbc.M508120200; Lieser SA, 2005, BBA-PROTEINS PROTEOM, V1754, P191, DOI 10.1016/j.bbapap.2005.07.024; Lieser SA, 2005, J BIOL CHEM, V280, P7769, DOI 10.1074/jbc.M411736200; Lin XF, 2006, J MOL BIOL, V357, P1263, DOI 10.1016/j.jmb.2006.01.046; Lin XF, 2003, J BIOL CHEM, V278, P24072, DOI 10.1074/jbc.M210596200; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; Shaffer J, 1999, BIOCHEMISTRY-US, V38, P12072, DOI 10.1021/bi991109q; Shaffer J, 2001, BIOCHEMISTRY-US, V40, P11149, DOI 10.1021/bi011029y; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Wong L, 2005, J MOL BIOL, V351, P131, DOI 10.1016/j.jmb.2005.05.042; Wong L, 2004, J MOL BIOL, V341, P93, DOI 10.1016/j.jmb.2004.05.060; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	32	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38004	38012		10.1074/jbc.M607824200	http://dx.doi.org/10.1074/jbc.M607824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17018524	hybrid			2022-12-25	WOS:000242477100079
J	Lo, SC; Hannink, M				Lo, Shih-Ching; Hannink, Mark			PGAM5, a Bcl-X-L-interacting protein, is a novel substrate for the redox-regulated keap1-dependent ubiquitin ligase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOPREVENTIVE AGENT SULFORAPHANE; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; HUMAN KEAP1; DNA-DAMAGE; OLIGONUCLEOTIDE MICROARRAY; STRUCTURAL BASIS; GENE-EXPRESSION; IN-VITRO; NRF2	Keap1 is a BTB-Kelch substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex that functions as a sensor for thiol-reactive chemopreventive compounds and oxidative stress. Inhibition of Keap1-dependent ubiquitination of the bZIP transcription factor Nrf2 enables Nrf2 to activate a cyto-protective transcriptional program that counters the damaging effects of oxidative stress. In this report we have identified a member of the phosphoglycerate mutase family, PGAM5, as a novel substrate for Keap1. The N terminus of the PGAM5 protein contains a conserved NXESGE motif that binds to the substrate binding pocket in the Kelch domain of Keap1, whereas the C-terminal PGAM domain binds Bcl-XL. Keap1-dependent ubiquitination of PGAM5 results in proteasome-dependent degradation of PGAM5. Quinone-induced oxidative stress and the chemopreventive agent sulforaphane inhibit Keap1-dependent ubiquitination of PGAM5. The identification of PGAM5 as a novel substrate of Keap1 suggests that Keap1 regulates both transcriptional and post-transcriptional responses of mammalian cells to oxidative stress.	Univ Missouri, Life Sci Ctr, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Hannink, M (corresponding author), Univ Missouri, Life Sci Ctr, Dept Biochem, 1201 E Rollins St, Columbia, MO 65211 USA.	hanninkm@missouri.edu		Lo, Shih-Ching/0000-0002-5187-0730	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT003899] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT003899] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Ahmad S, 1999, CANCER LETT, V139, P129, DOI 10.1016/S0304-3835(99)00022-1; Ames B.N., 1993, DNA FREE RADICALS, P1; Andreassi MG, 2003, MUTAT RES-REV MUTAT, V543, P67, DOI 10.1016/S1383-5742(02)00089-3; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Betran E, 2002, MOL BIOL EVOL, V19, P654, DOI 10.1093/oxfordjournals.molbev.a004124; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Carpino N, 2002, MOL CELL BIOL, V22, P7491, DOI 10.1128/MCB.22.21.7491-7500.2002; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Hammond PW, 2001, J BIOL CHEM, V276, P20898, DOI 10.1074/jbc.M011641200; Hong F, 2005, J BIOL CHEM, V280, P31768, DOI 10.1074/jbc.M503346200; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Jedrzejas MJ, 2000, PROG BIOPHYS MOL BIO, V73, P263, DOI 10.1016/S0079-6107(00)00007-9; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li XC, 2004, J BIOL CHEM, V279, P54750, DOI 10.1074/jbc.M410073200; Lo SC, 2006, MOL CELL BIOL, V26, P1235, DOI 10.1128/MCB.26.4.1235-1244.2006; Lo SC, 2006, EMBO J, V25, P3605, DOI 10.1038/sj.emboj.7601243; Mathers J, 2004, BIOCHEM SOC SYMP, V71, P157, DOI 10.1042/bss0710157; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Sakamoto KM, 2003, MOL CELL PROTEOMICS, V2, P1350, DOI 10.1074/mcp.T300009-MCP200; Shen GX, 2005, PHARM RES-DORDR, V22, P1805, DOI 10.1007/s11095-005-7546-8; Strachan GD, 2005, BIOCHEM BIOPH RES CO, V336, P490, DOI 10.1016/j.bbrc.2005.08.127; Strachan GD, 2004, BIOCHEMISTRY-US, V43, P12113, DOI 10.1021/bi0494166; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wang WP, 2006, J BIOL CHEM, V281, P19676, DOI 10.1074/jbc.M602802200; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	47	140	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37893	37903		10.1074/jbc.M606539200	http://dx.doi.org/10.1074/jbc.M606539200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17046835	hybrid			2022-12-25	WOS:000242477100068
J	Miyaoka, Y; Tanaka, M; Naiki, T; Miyajima, A				Miyaoka, Yuichiro; Tanaka, Minoru; Naiki, Takahiro; Miyajima, Atsushi			Oncostatin M inhibits adipogenesis through the RAS/ERK and STAT5 signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; GENE-EXPRESSION; C/EBP-ALPHA; PPAR-GAMMA; PROLIFERATION; CYTOKINES; RECEPTOR; ACTIVATION; PROTEIN	Adipocytes play a key role in energy homeostasis and several cytokines have been shown to regulate adipogenesis. While the interleukin (IL)-6 family of cytokines was previously reported to be involved in adipogenesis, roles of this family in adipogenesis and their mechanisms of action are not fully understood. Here we show that among the IL-6 family, oncostatin M (OSM) most strongly inhibits adipogenesis of 3T3-L1 cells and mouse embryonic fibroblasts (MEFs). We also demonstrate that OSM inhibits adipogenesis through the Ras/extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription (STAT) 5 signaling pathways. In addition, OSM inhibits the early phase of the differentiation without affecting cell proliferation throughout adipogenesis including mitotic clonal expansion. CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBP beta, and peroxisome proliferator-activated receptor (PPAR) gamma are known to be required for adipogenesis. Expression of C/EBP alpha, and PPAR gamma was almost completely abrogated by OSM. In contrast, neither the mRNA nor protein level of C/EBP beta was affected by OSM. Forced expression of C/EBP beta induced differentiation in the presence of troglitazone, and OSM inhibited this C/EBP beta-induced differentiation. Taken together, our results indicate that OSM inhibits the onset of terminal differentiation of adipocytes through the Ras/ERK and STAT5 signaling pathways by possibly regulating C/EBP beta activity.	Univ Tokyo, Lab Cell Growth & Differentiat, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi, Tokyo 1130032, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Miyajima, A (corresponding author), Univ Tokyo, Lab Cell Growth & Differentiat, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi, Tokyo 1130032, Japan.	miyajima@iam.u-tokyo.ac.jp		Miyaoka, Yuichiro/0000-0002-8874-4738				Ahima RS, 2005, TRENDS ENDOCRIN MET, V16, P307, DOI 10.1016/j.tem.2005.07.010; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Clegg CH, 1996, NATURE, V384, P261, DOI 10.1038/384261a0; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; Gustafson B, 2006, J BIOL CHEM, V281, P9507, DOI 10.1074/jbc.M512077200; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KELLER DC, 1993, BLOOD, V82, P1428; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; Matsuzawa Y, 2006, NAT CLIN PRACT CARD, V3, P35, DOI 10.1038/ncpcardio0380; MORI M, 1989, BIOCHEM BIOPH RES CO, V160, P1085, DOI 10.1016/S0006-291X(89)80114-7; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakamura K, 2004, HEPATOLOGY, V39, P635, DOI 10.1002/hep.20086; Nanbu-Wakao R, 2002, MOL ENDOCRINOL, V16, P1565, DOI 10.1210/me.16.7.1565; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; OHSUMI J, 1994, ENDOCRINOLOGY, V135, P2279, DOI 10.1210/en.135.5.2279; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Sakaue H, 2002, GENE DEV, V16, P908, DOI 10.1101/gad.983202; Shim M, 2005, CANCER RES, V65, P861; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; Tong Q, 2001, Rev Endocr Metab Disord, V2, P349, DOI 10.1023/A:1011863414321; Wallace PM, 1999, J IMMUNOL, V162, P5547; Zvonic S, 2005, J BIOL CHEM, V280, P33856, DOI 10.1074/jbc.M508020200; Zvonic S, 2004, J BIOL CHEM, V279, P47572, DOI 10.1074/jbc.M403998200	36	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37913	37920		10.1074/jbc.M606089200	http://dx.doi.org/10.1074/jbc.M606089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17028188	hybrid			2022-12-25	WOS:000242477100070
J	Notari, L; Baladron, V; Aroca-Aguilar, JD; Balko, N; Heredia, R; Meyer, C; Notario, PM; Saravanamuthu, S; Nueda, ML; Sanchez-Sanchez, F; Escribano, J; Laborda, J; Becerra, SP				Notari, Luigi; Baladron, Victoriano; Aroca-Aguilar, J. Daniel; Balko, Natalia; Heredia, Raul; Meyer, Christina; Notario, Patricia M.; Saravanamuthu, Senthil; Nueda, Maria-Luisa; Sanchez-Sanchez, Francisco; Escribano, Julio; Laborda, Jorge; Becerra, S. Patricia			Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; CEREBELLAR GRANULE CELLS; MEDIATED GENE-TRANSFER; FACTOR PEDF; DOCOSAHEXAENOIC ACID; MOTOR-NEURONS; CHOROIDAL NEOVASCULARIZATION; INTERPHOTORECEPTOR MATRIX; NEUROTROPHIC ACTIVITY; NEUROPROTECTIN D1	Pigment epithelium-derived factor (PEDF) is an extracellular multifunctional protein belonging to the serpin superfamily with demonstrable neurotrophic, gliastatic, neuronotrophic, antiangiogenic, and antitumorigenic properties. We have previously provided biochemical evidence for high affinity PEDF-binding sites and proteins in plasma membranes of retina, retinoblastoma, and CNS cells. This study was designed to reveal a receptor involved in the biological activities of PEDF. Using a yeast two-hybrid screening, we identified a novel gene from pigment epithelium of the human retina that codes for a PEDF-binding partner, which we term PEDF-R. The derived polypeptide has putative transmembrane, intracellular and extracellular regions, and a phospholipase domain. Recently, PEDF-R (TTS2.2/independent phospholipase A(2) (PLA(2))zeta and mouse desnutrin/ATGL) has been described in adipose cells as a member of the new calcium-independent PLA(2)/nutrin/patatin- like phospholipase domain-containing 2 (PNPLA2) family that possesses triglyceride lipase and acylglycerol transacylase activities. Here we describe the PEDF-R gene expression in the retina and its heterologous expression by bacterial and eukaryotic systems, and we demonstrate that its protein product has specific and high binding affinity for PEDF, has a potent phospholipase A(2) activity that liberates fatty acids, and is associated with eukaryotic cell membranes. Most importantly, PEDF binding stimulates the enzymatic phospholipase A(2) activity of PEDF-R. In conclusion, we have identified a novel PEDF-R gene in the retina for a phospholipase-linked membrane protein with high affinity for PEDF, suggesting a molecular pathway by which ligand/receptor interaction on the cell surface could generate a cellular signal.	NEI, NIH, Bethesda, MD 20892 USA; US FDA, Bethesda, MD 20892 USA; Georgetown Univ, Washington, DC 20057 USA; Univ Castilla La Mancha, Sch Med, Ctr Reg Invest Biomed, Albacete 02071, Spain	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); US Food & Drug Administration (FDA); Georgetown University; Universidad de Castilla-La Mancha	Becerra, SP (corresponding author), NEI, NIH, Bldg 7,Rm 304,7 Mem Dr,MSC 0706, Bethesda, MD 20892 USA.	becerrap@nei.nih.gov	Baladron, Victoriano/L-1758-2014; Laborda, Jorge/L-5726-2014; Nueda, María-Luisa/L-3044-2014; Aroca-Aguilar, J.Daniel/B-7842-2008; Escribano, Julio/D-9742-2015; Aroca-Aguilar, Jose Daniel/R-5513-2019; , francisco/ABF-7718-2021	Baladron, Victoriano/0000-0003-4574-8760; Laborda, Jorge/0000-0002-9210-838X; Nueda, María-Luisa/0000-0002-5456-5045; Aroca-Aguilar, J.Daniel/0000-0001-6487-1612; Escribano, Julio/0000-0002-8919-8134; Aroca-Aguilar, Jose Daniel/0000-0001-6487-1612; Meyer, Christina/0000-0002-0380-195X	Intramural NIH HHS Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000306, ZIAEY000306] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abramson LP, 2003, J PEDIATR SURG, V38, P336, DOI 10.1053/jpsu.2003.50104; Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Alberdi E, 1998, BIOCHEMISTRY-US, V37, P10643, DOI 10.1021/bi9802317; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Araki T, 1998, J NEUROSCI RES, V53, P7, DOI 10.1002/(SICI)1097-4547(19980701)53:1<7::AID-JNR2>3.3.CO;2-H; Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287; Baladron V, 2002, BIOCHEM BIOPH RES CO, V291, P193, DOI 10.1006/bbrc.2002.6431; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002; Baulande S, 2001, J BIOL CHEM, V276, P33336, DOI 10.1074/jbc.M105193200; Bazan NG, 2005, BRAIN PATHOL, V15, P159; BAZAN NG, 2005, INVEST OPHTH VIS SCI, V46, P167; Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013; BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Bilak MM, 2002, J NEUROSCI, V22, P9378; Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646; Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263; Chen SY, 2003, J NEUROCHEM, V84, P972, DOI 10.1046/j.1471-4159.2003.01608.x; Crawford SE, 2001, J CELL SCI, V114, P4421; Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DeCoster MA, 1999, J NEUROSCI RES, V56, P604; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015; Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821; Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744; Garcia M, 2004, CANCER RES, V64, P5632, DOI 10.1158/0008-5472.CAN-04-0230; Gettins PGW, 2002, BIOL CHEM, V383, P1677, DOI 10.1515/BC.2002.188; Goetzl EJ, 2004, J CELL BIOCHEM, V92, P867, DOI 10.1002/jcb.20186; Guan M, 2004, CANCER GENE THER, V11, P325, DOI 10.1038/sj.cgt.7700675; Hirschberg HJHB, 2001, EUR J BIOCHEM, V268, P5037, DOI 10.1046/j.0014-2956.2001.02411.x; Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0; Houenou LJ, 1999, J COMP NEUROL, V412, P506; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110; Jablonski MM, 2000, J NEUROSCI, V20, P7149; Jacob M, 1996, J BIOL CHEM, V271, P19209, DOI 10.1074/jbc.271.32.19209; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Jimenez-Atienzar M, 2003, LIPIDS, V38, P677, DOI 10.1007/s11745-003-1114-9; Karakousis PC, 2001, MOL VIS, V7, P154; Kim HY, 2001, J MOL NEUROSCI, V16, P223, DOI 10.1385/JMN:16:2-3:223; Kuncl RW, 2002, J NEUROCHEM, V81, P178, DOI 10.1046/j.1471-4159.2002.00813.x; Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; MARCHESELLI VL, 2005, NEUROTROPHIC GROWTH; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Ortego J, 1996, INVEST OPHTH VIS SCI, V37, P2759; Perez-Mediavilla LA, 1998, BBA-GENE STRUCT EXPR, V1398, P203, DOI 10.1016/S0167-4781(98)00055-4; Rose DP, 1999, PHARMACOL THERAPEUT, V83, P217, DOI 10.1016/S0163-7258(99)00026-1; Rose DP, 1999, INT J ONCOL, V15, P1011; Rydel TJ, 2003, BIOCHEMISTRY-US, V42, P6696, DOI 10.1021/bi027156r; SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; Singh MJ, 1998, EUR PHYS J D, V4, P7, DOI 10.1007/s100530050179; Smirnova E, 2006, EMBO REP, V7, P106, DOI 10.1038/sj.embor.7400559; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Streck CJ, 2005, J PEDIATR SURG, V40, P236, DOI 10.1016/j.jpedsurg.2004.09.049; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; Taniwaki T, 1997, J NEUROCHEM, V68, P26; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Wang L, 2003, MOL THER, V8, P72, DOI 10.1016/S1525-0016(03)00128-X; WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060; Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	72	235	252	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38022	38037		10.1074/jbc.M600353200	http://dx.doi.org/10.1074/jbc.M600353200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17032652	hybrid			2022-12-25	WOS:000242477100081
J	Tadini-Buoninsegni, F; Bartolommei, G; Moncelli, MR; Guidelli, R; Inesi, G				Tadini-Buoninsegni, Francesco; Bartolommei, Gianluca; Moncelli, Maria Rosa; Guidelli, Rolando; Inesi, Giuseppe			Pre-steady state electrogenic events of Ca2+/H+ exchange and transport by the Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; SOLID SUPPORTED MEMBRANES; SR-CA-ATPASE; CHARGE TRANSLOCATION; CALCIUM-PUMP; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ACIDIC RESIDUES; CATION-BINDING; MECHANISM	Native or recombinant SERCA (sarco(endo)plasmic reticulum Ca2+ ATPase) was adsorbed on a solid supported membrane and then activated with Ca2+ and ATP concentration jumps through rapid solution exchange. The resulting electrogenic events were recorded as electrical currents flowing along the external circuit. Current transients were observed following Ca2+ jumps in the absence of ATP and following ATP jumps in the presence of Ca2+. The related charge movements are attributed to Ca2+ reaching its binding sites in the ground state of the enzyme (E-1) and to its vectorial release from the enzyme phosphorylated by ATP (E2P). The Ca2+ concentration and pH dependence as well as the time frames of the observed current transients are consistent with equilibrium and pre-steady state biochemical measurements of sequential steps within a single enzymatic cycle. Numerical integration of the current transients recorded at various pH values reveal partial charge compensation by H+ in exchange for Ca2+ at acidic (but not at alkaline) pH. Most interestingly, charge movements induced by Ca2+ and ATP vary over different pH ranges, as the protonation probability of residues involved in Ca2+/H+ exchange is lower in the E-1 than in the E2P state. Our single cycle measurements demonstrate that this difference contributes directly to the reduction of Ca2+ affinity produced by ATP utilization and results in the countertransport of two Ca2+ and two H+ within each ATPase cycle at pH 7.0. The effects of site-directed mutations indicate that Glu-771 and Asp-800, within the Ca2+ binding domain, are involved in the observed Ca2+/H+ exchange.	Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Florence	Inesi, G (corresponding author), Calif Pacific Med Ctr, Res Inst, 475 Brannan St, San Francisco, CA 94107 USA.	ginesi@cpmcri.com	Tadini-Buoninsegni, Francesco/CAJ-5745-2022	TADINI-BUONINSEGNI, Francesco/0000-0001-5594-2554	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069830] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL69830] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen JP, 1998, ACTA PHYSIOL SCAND, V163, P45; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; BAMBERG E, 1979, BIOPHYS STRUCT MECH, V5, P277, DOI 10.1007/BF02426663; Bartolommei G, 2006, J BIOL CHEM, V281, P9547, DOI 10.1074/jbc.M510550200; Bartolommei G, 2004, BIOELECTROCHEMISTRY, V63, P157, DOI 10.1016/j.bioelechem.2003.07.010; Buoninsegni FT, 2004, BIOPHYS J, V86, P3671, DOI 10.1529/biophysj.103.036608; Butscher C, 1999, J MEMBRANE BIOL, V168, P169, DOI 10.1007/s002329900507; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORNELIUS F, 1991, FEBS LETT, V284, P46, DOI 10.1016/0014-5793(91)80758-U; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; EISENRAUCH A, 1990, FEBS LETT, V268, P152, DOI 10.1016/0014-5793(90)80996-V; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FRANZINIARMSTRONG C, 1985, BIOPHYS J, V48, P607, DOI 10.1016/S0006-3495(85)83816-9; Hartung K, 1997, BIOPHYS J, V72, P2503, DOI 10.1016/S0006-3495(97)78895-7; Inesi G, 2004, J BIOL CHEM, V279, P31629, DOI 10.1074/jbc.M403211200; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; Kaplan J.H., 2004, HDB ATPASES BIOCH CE, P63; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; Lauger P., 1991, ELECTROGENIC ION PUM; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; MacLennan DH, 2000, NATURE, V405, P633, DOI 10.1038/35015206; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEISSNER G, 1981, J BIOL CHEM, V256, P636; Meyer-Lipp K, 2004, BIOCHEMISTRY-US, V43, P12606, DOI 10.1021/bi0489053; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Peinelt C, 2005, BIOPHYS J, V89, P2427, DOI 10.1529/biophysj.105.068411; Pintschovius J, 1999, BIOPHYS J, V76, P814, DOI 10.1016/S0006-3495(99)77245-0; Pintschovius J, 1999, BIOPHYS J, V76, P827, DOI 10.1016/S0006-3495(99)77246-2; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SEIFERT K, 1993, BIOPHYS J, V64, P384, DOI 10.1016/S0006-3495(93)81379-1; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; Sugita Y, 2005, J AM CHEM SOC, V127, P6150, DOI 10.1021/ja0427505; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Tadini-Buoninsegni F, 2003, BBA-BIOMEMBRANES, V1611, P70, DOI 10.1016/S0005-2736(02)00722-8; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; YU X, 1994, J BIOL CHEM, V269, P16656; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m; Zhou A, 2004, J MOL BIOL, V343, P931, DOI 10.1016/j.jmb.2004.09.002	52	64	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37720	37727		10.1074/jbc.M606040200	http://dx.doi.org/10.1074/jbc.M606040200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17032645	hybrid			2022-12-25	WOS:000242477100049
J	Tsujimura, S; Saito, K; Kohno, K; Tanaka, Y				Tsujimura, Shizuyo; Saito, Kazuyoshi; Kohno, Kimitoshi; Tanaka, Yoshiya			Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY RHEUMATOID-ARTHRITIS; BINDING-PROTEIN YB-1; P-GLYCOPROTEIN; ENDOTHELIAL-CELLS; SYNOVIAL-FLUID; POOR-PROGNOSIS; T-CELLS; EXTRACELLULAR-MATRIX; MEDIATED ADHESION; MOLECULAR-WEIGHT	P-glycoprotein, encoded by the multidrug resistance (MDR)-1 gene, expels various drugs from cells resulting in multidrug resistance. We found previously that interleukin-2, a lymphocyte-activation cytokine, induces P-glycoprotein expression on lymphocytes. Lymphocyte activation involves adhesion with the extracellular matrix, such as hyaluronan, through adhesion molecules on lymphocytes. We investigated the transcriptional regulation of MDR-1 in lymphocytes by fragmented hyaluronan. Fragmented hyaluronan (especially the 6.9-kDa form), not native high molecular hyaluronan, induced translocation of YB-1, a specific transcriptional factor for MDR-1, from the cytoplasm into the nucleus and resulted in the transcription of MDR-1 and the expression of P-glycoprotein on lymphocytes in a dose-dependent manner. Transfection of YB-1 antisense oligonucleotides inhibited P-glycoprotein expression induced by fragmented hyaluronan. The fragmented hyaluronan induced significant P-glycoprotein expression on only activated CD4+T cells, which highly expressed CD69, and resulted in excretion of intracellular dexamethasone added in vitro. Cyclosporin A, a competitive P-glycoprotein inhibitor, restored intracellular dexamethasone levels in CD4+T cells. Anti-CD44 monoclonal antibody (Hermes-1) inhibited fragmented hyaluronan-induced YB-1 activation and P-glycoprotein expression in CD4+T cells. We provide the first evidence that binding of fragmented hyaluronan to CD44 induces YB-1 activation followed by P-glycoprotein expression in accordance with activation of CD4+T cells. Our findings imply that CD4+T cell activation by fragmented hyaluronan, induced by characteristic extracellular matrix changes in inflammation, tumors, and other conditions, results in P-glycoprotein-mediated multidrug resistance.	Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Tanaka, Y (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	tanaka@med.uoeh-u.ac.jp						Advani R, 1999, ADV EXP MED BIOL, V457, P47; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; Beck WT, 1996, CANCER RES, V56, P3010; BOURGEOIS S, 1993, MOL ENDOCRINOL, V7, P840, DOI 10.1210/me.7.7.840; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; DAHL LB, 1985, ANN RHEUM DIS, V44, P817, DOI 10.1136/ard.44.12.817; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DELMAGE JM, 1986, ANN CLIN LAB SCI, V16, P303; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drach J, 1996, BLOOD, V88, P1747, DOI 10.1182/blood.V88.5.1747.bloodjournal8851747; Farrell RJ, 2003, J ENDOCRINOL, V178, P339, DOI 10.1677/joe.0.1780339; FEINBERG RN, 1983, SCIENCE, V220, P1177, DOI 10.1126/science.6857242; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; Frederick M, 1997, J INTERF CYTOK RES, V17, P435, DOI 10.1089/jir.1997.17.435; Fujii K, 1999, J IMMUNOL, V162, P2391; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Gerards AH, 2003, ANN RHEUM DIS, V62, P291, DOI 10.1136/ard.62.4.291; HAHN BH, 2001, HARRISONS PRINCIPLES; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; Kelly E, 2002, J IMMUNOL, V168, P597, DOI 10.4049/jimmunol.168.2.597; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Lesley J, 2000, J BIOL CHEM, V275, P26967; Linn SC, 1996, BRIT J CANCER, V74, P63, DOI 10.1038/bjc.1996.316; List AF, 2002, BLOOD, V100, P1910, DOI 10.1182/blood.V100.5.1910.h81702001910_1910_1912; Liu DC, 1996, P NATL ACAD SCI USA, V93, P7832, DOI 10.1073/pnas.93.15.7832; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; LUXEMBOURG AT, 1994, J IMMUNOL, V153, P604; MCBRIDE WH, 1979, J EXP MED, V149, P507, DOI 10.1084/jem.149.2.507; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200; Montano E, 1996, J INVEST ALLERG CLIN, V6, P14; Nagaya H, 1999, ANN RHEUM DIS, V58, P186, DOI 10.1136/ard.58.3.186; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Proudman SM, 2000, ARTHRITIS RHEUM, V43, P1809, DOI 10.1002/1529-0131(200008)43:8<1809::AID-ANR17>3.0.CO;2-D; RICHARD C, 1993, J BIOL CHEM, V268, P16059; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Salmon SE, 1996, J RHEUMATOL, V23, P97; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; Sturm A, 2004, J IMMUNOL, V173, P3889, DOI 10.4049/jimmunol.173.6.3889; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; SUGAWARA I, 1988, CANCER RES, V48, P1926; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Tanaka Y, 1997, J IMMUNOL, V158, P3822; Tanaka Y, 1999, J IMMUNOL, V163, P6209; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Tsujimura S, 2005, ARTHRITIS RHEUM-US, V52, P1676, DOI 10.1002/art.21032; Tsujimura S, 2004, GENES CELLS, V9, P1265, DOI 10.1111/j.1365-2443.2004.00803.x; TSURUO T, 1983, CANCER TREAT REP, V67, P889; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UNDERHILL C, 1992, J CELL SCI, V103, P293; WELLS AF, 1992, ARTHRITIS RHEUM, V35, P391, DOI 10.1002/art.1780350405; Yudoh K, 1999, ARTHRITIS RHEUM, V42, P2014, DOI 10.1002/1529-0131(199909)42:9<2014::AID-ANR32>3.0.CO;2-R; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502	65	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38089	38097		10.1074/jbc.M601030200	http://dx.doi.org/10.1074/jbc.M601030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17038319	hybrid			2022-12-25	WOS:000242477100087
J	Woodhall, DL; Groves, IJ; Reeves, MB; Wilkinson, G; Sinclair, JH				Woodhall, David L.; Groves, Ian J.; Reeves, Matthew B.; Wilkinson, Gavin; Sinclair, John H.			Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX-VIRUS TYPE-1; NUCLEAR DOMAIN 10; EPSTEIN-BARR-VIRUS; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLATION; VIRAL REPLICATION; DNA-REPLICATION; DENDRITIC CELLS; SP100 PROTEINS; PP71 PROTEIN	Upon herpesvirus infection, viral DNA becomes associated with nuclear structures known as nuclear domain 10 (ND10). The role of ND10 during herpesvirus infection has long been contentious; data arguing for a role for ND10 in repression of infection have been countered by other data showing little effect of ND10 on virus infection. Here we show that knockdown of human Daxx (hDaxx) expression, an important component of ND10, prior to infection with human cytomegalovirus resulted in increased levels of viral immediate early RNA and protein expression and that this correlated with an increased association of the major immediate early promoter with markers of transcriptionally active chromatin. Conversely, we also show that stable overexpression of hDaxx renders cells refractory to cytomegalovirus immediate early gene expression. Intriguingly, this hDaxx-mediated repression appears to be restricted to cells stably overexpressing hDaxx and is not recapitulated in transient transfection assays. Finally, hDaxx-mediated repression of cytomegalovirus major immediate early gene expression was overcome by infecting at higher virus titers, suggesting that an incoming viral structural protein or viral DNA is responsible for overcoming the repression of viral gene expression in hDaxx superexpressing cells. These data suggest that hDaxx in ND10 functions at the site of cytomegalovirus genome deposition to repress transcription of incoming viral genomes and that this repression is mediated by a direct and immediate effect of hDaxx on chromatin modification around the viral major immediate early promoter.	Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England; Univ Wales Coll Cardiff, Coll Med, Sect Infect & Immun, Cardiff CF14 4XX, S Glam, Wales	University of Cambridge; Cardiff University	Sinclair, JH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Level 5 Box 157, Cambridge CB2 2QQ, England.	js@mole.bio.cam.ac.uk	Groves, Ian John/HGU-5954-2022; Wilkinson, Gavin/J-6388-2015	Groves, Ian John/0000-0001-8882-6701; Wilkinson, Gavin/0000-0002-5623-0126; Reeves, Matthew/0000-0002-4909-1076	MRC [G9202171] Funding Source: UKRI; Medical Research Council [G9202171] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Bresnahan WA, 2000, P NATL ACAD SCI USA, V97, P14506, DOI 10.1073/pnas.97.26.14506; Cantrell SR, 2005, J VIROL, V79, P7792, DOI 10.1128/JVI.79.12.7792-7802.2005; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; DREW WL, 1988, J INFECT DIS, V158, P449, DOI 10.1093/infdis/158.2.449; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Ferrando-May E, 2005, CELL DEATH DIFFER, V12, P1263, DOI 10.1038/sj.cdd.4401626; Fortunato EA, 2002, J VIROL, V76, P5369, DOI 10.1128/JVI.76.11.5369-5379.2002; Hofmann H, 2002, J VIROL, V76, P5769, DOI 10.1128/JVI.76.11.5769-5783.2002; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Ishov AM, 2002, J VIROL, V76, P7705, DOI 10.1128/JVI.76.15.7705-7712.2002; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Jenkins PJ, 2000, J VIROL, V74, P710, DOI 10.1128/JVI.74.2.710-720.2000; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lusser A, 2002, CURR OPIN PLANT BIOL, V5, P437, DOI 10.1016/S1369-5266(02)00287-X; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Meier JL, 2001, J VIROL, V75, P1581, DOI 10.1128/JVI.75.4.1581-1593.2001; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Muller S, 1999, J VIROL, V73, P5137; Murphy JC, 2002, EMBO J, V21, P1112, DOI 10.1093/emboj/21.5.1112; Parkinson J, 2000, J VIROL, V74, P10006, DOI 10.1128/JVI.74.21.10006-10017.2000; Preston CM, 2006, J GEN VIROL, V87, P1113, DOI 10.1099/vir.0.81566-0; Reeves M, 2006, J VIROL, V80, P9998, DOI 10.1128/JVI.01297-06; Reeves MB, 2005, J GEN VIROL, V86, P2949, DOI 10.1099/vir.0.81161-0; Reeves MB, 2005, P NATL ACAD SCI USA, V102, P4140, DOI 10.1073/pnas.0408994102; RUBIN RH, 1990, REV INFECT DIS    S7, V12, P754; Saffert RT, 2006, J VIROL, V80, P3863, DOI 10.1128/JVI.80.8.3863-3871.2006; Schierling K, 2004, J VIROL, V78, P9512, DOI 10.1128/JVI.78.17.9512-9523.2004; SCHMOLKE S, 1995, J VIROL, V69, P1071, DOI 10.1128/JVI.69.2.1071-1078.1995; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tang QY, 2003, J VIROL, V77, P1357, DOI 10.1128/JVI.77.2.1357-1367.2003; Tavalai N, 2006, J VIROL, V80, P8006, DOI 10.1128/JVI.00743-06; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wilkinson GWG, 1998, J GEN VIROL, V79, P1233, DOI 10.1099/0022-1317-79-5-1233; Wu FY, 2001, J VIROL, V75, P1487, DOI 10.1128/JVI.75.3.1487-1506.2001; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001	52	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37652	37660		10.1074/jbc.M604273200	http://dx.doi.org/10.1074/jbc.M604273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035242	hybrid			2022-12-25	WOS:000242477100042
J	Hikita, A; Yana, I; Wakeyama, H; Nakamura, M; Kadono, Y; Oshima, Y; Nakamura, K; Seiki, M; Tanaka, S				Hikita, Atsuhiko; Yana, Ikuo; Wakeyama, Hidetoshi; Nakamura, Masaki; Kadono, Yuho; Oshima, Yasushi; Nakamura, Kozo; Seiki, Motoharu; Tanaka, Sakae			Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappa B ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MATRIX-METALLOPROTEINASE INHIBITOR; PROGRESSIVE JOINT DESTRUCTION; OSTEOPROTEGERIN LIGAND; INDUCED ARTHRITIS; CDNA LIBRARY; T-CELLS; DIFFERENTIATION; RANKL; FAMILY	Receptor activator of NF-kappa B ligand (RANKL) is a transmembrane glycoprotein that has an essential role in the development of osteoclasts. The extracellular portion of RANKL is cleaved proteolytically to produce soluble RANKL, but definite RANKL sheddase(s) and the physiologic function of RANKL shedding have not yet been determined. In the present study, we found that matrix metalloproteinase (MMP) 14 and a disintegrin and metalloproteinase (ADAM) 10 have strong RANKL shedding activity. In Western blot analysis, soluble RANKL was detected as two different molecular weight products, and RNA interference of MMP14 and ADAM10 resulted in a reduction of both the lower and higher molecular weight products. Suppression of MMP14 in primary osteoblasts increased membrane-bound RANKL and promoted osteoclastogenesis in cocultures with macrophages. Soluble RANKL produced by osteoblasts from MMP14-deficient mice was markedly reduced, and their osteoclastogenic activity was promoted, consistent with the findings of increased osteoclastogenesis in vivo. RANKL shedding is an important process that down-regulates local osteoclastogenesis.	Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Tanaka, S (corresponding author), Univ Tokyo, Fac Med, Dept Orthopaed Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	TANAKAS-ORT@h.u-tokyo.ac.jp	Tanaka, Sakae/Y-3061-2019; Seiki, Motoharu/K-9443-2015; Kadono, Yuho/AAO-2405-2020	Tanaka, Sakae/0000-0001-9210-9414; 				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Chesneau V, 2003, J BIOL CHEM, V278, P22331, DOI 10.1074/jbc.M302781200; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Guo LJ, 2004, ENDOCR RES, V30, P369, DOI 10.1081/ERC-200033719; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hikita A, 2005, J BIOL CHEM, V280, P41700, DOI 10.1074/jbc.M507000200; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Ishikawa T, 2005, BRIT J PHARMACOL, V144, P133, DOI 10.1038/sj.bjp.0706054; Ishikawa T, 2005, EUR J PHARMACOL, V508, P239, DOI 10.1016/j.ejphar.2004.12.014; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Ohtake Y, 2006, J CELL SCI, V119, P3822, DOI 10.1242/jcs.03158; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Suda T, 1997, METHOD ENZYMOL, V282, P223; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Tanaka S, 2003, J BONE MINER METAB, V21, P123, DOI 10.1007/s007740300021; Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105-2896.2005.00327.x; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	40	174	183	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36846	36855		10.1074/jbc.M606656200	http://dx.doi.org/10.1074/jbc.M606656200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17018528	hybrid			2022-12-25	WOS:000242220800043
J	Kim, YK; Lee, KJ; Jeon, H; Yu, YG				Kim, Yun-Kyoung; Lee, Kong Joo; Jeon, Hyesung; Yu, Yeon Gyu			Protein kinase CK2 is inhibited by human nucleolar phosphoprotein p140 in an inositol hexakisphosphate-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-2; CELL-CYCLE; BETA-SUBUNIT; MASS CHANGES; PHOSPHORYLATION; PYROPHOSPHATES; HOLOENZYME; GEMININ; COMPLEX; PROLIFERATION	Protein kinase CK2 is a ubiquitous protein kinase that can phosphorylate various proteins involved in central cellular processes, such as signal transduction, cell division, and proliferation. We have shown that the human nucleolar phosphoprotein p140 (hNopp140) is able to regulate the catalytic activity of CK2. Unphosphorylated hNopp140 and phospho-hNopp140 bind to the regulatory and catalytic subunits of CK2, respectively, and the interaction between hNopp140 and CK2 was prevented by inositol hexakisphosphate (InsP6). Phosphorylation of alpha-casein, genimin, or human phosphatidylcholine transfer protein-like protein by CK2 was inhibited by hNopp140, and InsP6 recovered the suppressed activity of CK2 by hNopp140. These observations indicated that hNopp140 serves as a negative regulator of CK2 and that InsP6 stimulates the activity of CK2 by blocking the interaction between hNopp140 and CK2.	Kookmin Univ, Dept Chem, Seoul 136702, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea	Kookmin University; Ewha Womans University; Korea Institute of Science & Technology (KIST)	Yu, YG (corresponding author), Kookmin Univ, Dept Chem, 861-1 Jeoungneung Dong, Seoul 136702, South Korea.	ygyu@kookmin.ac.kr						AHMED K, 1994, CELL MOL BIOL RES, V40, P1; Barker CJ, 2004, BIOCHEM J, V380, P465, DOI 10.1042/BJ20031872; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; COCHET C, 1983, J BIOL CHEM, V258, P1403; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; GUSE AH, 1993, J BIOL CHEM, V268, P7129; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Homma MK, 2002, P NATL ACAD SCI USA, V99, P5959, DOI 10.1073/pnas.092143199; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kim YK, 2003, PROTEIN EXPRES PURIF, V31, P260, DOI 10.1016/S1046-5928(03)00194-3; Kulartz M, 2004, BIOCHEM BIOPH RES CO, V315, P1011, DOI 10.1016/j.bbrc.2004.01.164; Kulartz M, 2003, BIOCHEM BIOPH RES CO, V305, P412, DOI 10.1016/S0006-291X(03)00773-3; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEIER UT, 1992, CELL, V70, P127; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PITTET D, 1989, J BIOL CHEM, V264, P18489; Rando OJ, 2003, NAT STRUCT BIOL, V10, P81, DOI 10.1038/nsb0203-81; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; SARNO S, 1993, BIOCHEM BIOPH RES CO, V194, P83, DOI 10.1006/bbrc.1993.1788; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Solyakov L, 2004, J BIOL CHEM, V279, P43403, DOI 10.1074/jbc.M403239200; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123	36	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36752	36757		10.1074/jbc.M604785200	http://dx.doi.org/10.1074/jbc.M604785200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17038328				2022-12-25	WOS:000242220800032
J	Liu, L; Liu, HZ; Visner, G; Fletcher, BS				Liu, Li; Liu, Hanzhong; Visner, Gary; Fletcher, Bradley S.			Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats	FASEB JOURNAL			English	Article						NOS; vasculature; remodeling; transposon	NITRIC-OXIDE SYNTHASE; LONG-TERM EXPRESSION; SMOOTH-MUSCLE-CELLS; IN-VIVO; TRANSPOSON SYSTEM; ARTERIAL-HYPERTENSION; HEMOPHILIC MICE; VIRAL VECTORS; LUNG; NO	Pulmonary hypertension (PH) is a life-threatening disorder with high mortality rates and limited treatment options. Gene therapy is an alternative treatment strategy, yet viral vectors have inherent disadvantages including immune activation. The Sleeping Beauty (SB) transposon is a nonviral method of gene delivery that overcomes some of these drawbacks. A SB-based transposon harboring a constitutively active endothelial nitric oxide synthase (eNOS) gene was administered to Sprague-Dawley rats via tail vein injection using the carrier polyethylenimine. Two days after transposon delivery, monocrotaline (MCT) was administered to induce PH. Hemodynamic, histological, and molecular measurements were performed four weeks later. Animals coinjected with transposase showed a significant reduction in pulmonary arterial pressure (PABP, 31.67 +/- 6.03 mmHg, P < 0.01), an attenuation of right ventricle (RV) to whole heart (WH) wt ratios (0.227 +/- 0.0252, P < 0.05) and a decrease in the pulmonary vessel wall thickness index (36.87%, P < 0.001), compared with those animals receiving the eNOS transposon and a nonfunctional transposase (PABP 44.33 +/- 4.04 mmHg; RV/WH ratio 0.280 +/- 0.01; wall thickness index 62.14%) or control animals receiving MCT injection alone (PABP 49.67 +/- 3.22 mmHg; RV/WH ratio 0.290 +/- 0.0265; wall thickness index 71.99%). The physiological improvements correlated with therapeutic gene expression, suggesting that transposon-based genetic approaches have utility in the treatment of PH.	Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA; Med Res Serv, Dept Vet Affairs Med Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Fletcher, BS (corresponding author), Univ Florida, Coll Med, Dept Pharmacol & Therapeut, 1600 SW Archer Rd,Box 100267, Gainesville, FL 32610 USA.	bsf@pharmacology.ufl.edu						Baus J, 2005, MOL THER, V12, P1148, DOI 10.1016/j.ymthe.2005.06.484; Belur LR, 2003, MOL THER, V8, P501, DOI 10.1016/S1525-0016(03)00211-9; Budts W, 2000, CIRCULATION, V102, P2880; Campbell AIM, 2001, CIRCULATION, V104, P2242, DOI 10.1161/hc4201.097838; Champion HC, 1999, CIRC RES, V84, P1422; Champion HC, 2000, CIRCULATION, V101, P923, DOI 10.1161/01.CIR.101.8.923; Champion HC, 2002, P NATL ACAD SCI USA, V99, P13248, DOI 10.1073/pnas.182225899; Chen LH, 1998, CIRC RES, V82, P862; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dupuy AJ, 2002, P NATL ACAD SCI USA, V99, P4495, DOI 10.1073/pnas.062630599; Galie N, 2004, CARDIOVASC RES, V61, P227, DOI 10.1016/j.cardiores.2003.11.026; Galie Nazzareno, 2003, Am J Respir Med, V2, P123; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gong FQ, 2005, PEDIATR INT, V47, P242, DOI 10.1111/j.1442-200x.2005.02060.x; Goula D, 2000, GENE THER, V7, P499, DOI 10.1038/sj.gt.3301113; Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717; Guignabert C, 2005, CIRCULATION, V111, P2812, DOI 10.1161/CIRCULATIONAHA.104.524926; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hampl V, 2000, PHYSIOL REV, V80, P1337, DOI 10.1152/physrev.2000.80.4.1337; Ichinose F, 2004, CIRCULATION, V109, P3106, DOI 10.1161/01.CIR.0000134595.80170.62; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; KOUYOUMDJIAN C, 1994, J CLIN INVEST, V94, P578, DOI 10.1172/JCI117372; Liu L, 2004, MOL THER, V10, P97, DOI 10.1016/j.ymthe.2004.04.006; LIU L, 2006, MOL THER, V3, P3; Louzier V, 2001, HUM GENE THER, V12, P503, DOI 10.1089/104303401300042401; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; Michelakis EA, 2003, HEART FAIL REV, V8, P5, DOI 10.1023/A:1022150819223; MILLER OI, 1995, LANCET, V346, P51, DOI 10.1016/S0140-6736(95)92681-X; Montini E, 2002, MOL THER, V6, P759, DOI 10.1006/mthe.2002.0812; Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923; Ohana P., 2004, GENE THER MOL BIOL, V8, P181; Ohlfest JR, 2005, BLOOD, V105, P2691, DOI 10.1182/blood-2004-09-3496; Partovian C, 2000, AM J RESP CELL MOL, V23, P762, DOI 10.1165/ajrcmb.23.6.4106; Patel JM, 1996, AM J RESP CELL MOL, V15, P410, DOI 10.1165/ajrcmb.15.3.8810647; Pilane CM, 2004, J CELL PHYSIOL, V199, P310, DOI 10.1002/jcp.10464; Roberts JD, 2000, CIRC RES, V87, P140, DOI 10.1161/01.RES.87.2.140; Rudolph C, 2000, J GENE MED, V2, P269, DOI 10.1002/1521-2254(200007/08)2:4<269::AID-JGM112>3.0.CO;2-F; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Strange JW, 2002, CLIN SCI, V102, P253, DOI 10.1042/CS20010212; Tahara N, 2004, HUM GENE THER, V15, P1270, DOI 10.1089/hum.2004.15.1270; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; Tyler RC, 1999, AM J PHYSIOL-LUNG C, V276, pL297, DOI 10.1152/ajplung.1999.276.2.L297; von der Leyen HE, 2001, CIRCULATION, V103, P2760; Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Yew NS, 2002, MOL THER, V5, P731, DOI 10.1006/mthe.2002.0598; Zhao YD, 2003, CIRC RES, V92, P984, DOI 10.1161/01.RES.0000070587.79937.F0; ZHAO YD, 2006, AM J RESP CELL MOL B, V16, P16; Zhou HL, 2006, LAB INVEST, V86, P62, DOI 10.1038/labinvest.3700361	52	48	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2594	+		10.1096/fj.06-6254fje	http://dx.doi.org/10.1096/fj.06-6254fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065228				2022-12-25	WOS:000242490700035
J	Schmidt, S; Irving, JAE; Minto, L; Matheson, E; Nicholson, L; Ploner, A; Parson, W; Kofler, A; Amort, M; Erdel, M; Hall, A; Kofler, R				Schmidt, Stefan; Irving, Julie A. E.; Minto, Lynne; Matheson, Elizabeth; Nicholson, Lindsay; Ploner, Andreas; Parson, Walther; Kofler, Anita; Amort, Melanie; Erdel, Martin; Hall, Andy; Kofler, Reinhard			Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor	FASEB JOURNAL			English	Article						apoptosis; mutation; mismatch repair; CCRF-CEM cell line; PreB 697 cell line	NF-KAPPA-B; INDUCED APOPTOSIS; BINDING DOMAIN; CELL-LINES; IN-VITRO; GENE; MECHANISMS; EXPRESSION; REPAIR; IDENTIFICATION	Glucocorticoids (GCs) specifically induce apoptosis in malignant lymphoblasts and are thus pivotal in the treatment of acute lymphoblastic leukemia (ALL). However, GC-resistance is a therapeutic problem with an unclear molecular mechanism. We generated similar to 70 GC-resistant sublines from a GC-sensitive B- and a T-ALL cell line and investigated their mechanisms of resistance. In response to GCs, all GC-resistant subclones analyzed by real-time polymerase chain reaction (PCR) showed a deficient up-regulation of the GC-receptor (GR) and its downstream target, GC-induced leucine zipper. This deficiency in GR up-regulation was confirmed by Western blotting and on retroviral overexpression of GR in resistant subclones GC-sensitivity was restored. All GC-resistant subclones were screened for GR mutations using denaturing high-pressure liquid chromatography (DHPLC), DNA-fingerprinting, and fluorescence in situ hybridization (FISH). Among the identified mutations were some previously not associated with GC resistance: A484D, P515H, L756N, Y663H, L680P, and R714W. This approach revealed three genotypes, complete loss of functional GR in the mismatch repair deficient T-ALL model, apparently normal GR genes in B-ALLs, and heterozygosity in both. In the first genotype, deficiency in GR up-regulation was fully explained by mutational events, in the second by a putative regulatory defect, and in the third by a combination thereof. In all instances, GC-resistance occurred at the level of the GR in both models.	Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; Innsbruck Med Univ, Inst Legal Med, Innsbruck, Austria; Innsbruck Med Univ, Div Human Genet, Innsbruck, Austria; Innsbruck Med Univ, Div Mol Pathophysiol, Bioctr, Innsbruck, Austria	Newcastle University - UK; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Schmidt, S (corresponding author), Tyrolean Canc Res Inst, Innrain 66, A-6020 Innsbruck, Austria.	stefan.schmidt@i-med.ac.at	Hall, Andy/AAD-8622-2020; Hall, Andrew G/B-3485-2009; Parson, Walther/AAD-6845-2020	Parson, Walther/0000-0002-5692-2392	Austrian Science Fund FWF [P 18571] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; Bachmann PS, 2005, BLOOD, V105, P2519, DOI 10.1182/blood-2004-05-2023; Bar W, 1997, INT J LEGAL MED, V110, P175, DOI 10.1007/s004140050061; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; Campbell MR, 2006, ONCOGENE, V25, P2531, DOI 10.1038/sj.onc.1209277; Cannarile L, 2001, CELL DEATH DIFFER, V8, P201, DOI 10.1038/sj.cdd.4400798; Chen J, 2004, BIOCHEM BIOPH RES CO, V321, P893, DOI 10.1016/j.bbrc.2004.07.047; CLOUSTON HJ, 2005, HUMAN CYTOGENETICS C, P33; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; FINDLEY HW, 1982, BLOOD, V60, P1305; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, CANCER RES, V56, P5033; GOMI M, 1990, CANCER RES, V50, P1873; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Gu LY, 2002, ONCOGENE, V21, P5758, DOI 10.1038/sj.onc.1205695; Haarman EG, 2003, BRIT J HAEMATOL, V120, P919, DOI 10.1046/j.1365-2141.2003.04189.x; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Hillmann AG, 2000, CANCER RES, V60, P2056; Irving JAE, 2005, CANCER RES, V65, P9712, DOI 10.1158/0008-5472.CAN-05-1227; KASPERS GJL, 1994, LEUKEMIA LYMPHOMA, V13, P187, DOI 10.3109/10428199409056282; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; KLUMPER E, 1995, BLOOD, V86, P3861, DOI 10.1182/blood.V86.10.3861.bloodjournal86103861; Kofler R, 2003, J ENDOCRINOL, V178, P19, DOI 10.1677/joe.0.1780019; Laudet V., 2002, NUCL RECEPTOR FACTS; Martinez ED, 2005, EXP CELL RES, V308, P320, DOI 10.1016/j.yexcr.2005.03.040; Matheson EC, 2003, CARCINOGENESIS, V24, P31, DOI 10.1093/carcin/24.1.31; MOALLI PA, 1994, LEUKEMIA LYMPHOMA, V15, P363, DOI 10.3109/10428199409049738; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; NORMAN MR, 1977, CANCER RES, V37, P3785; Parson W, 2005, FASEB J, V19, P434, DOI 10.1096/fj.04-3062fje; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pedersen KB, 2004, BIOCHEMISTRY-US, V43, P10851, DOI 10.1021/bi049458u; Pedersen KB, 2003, BIOCHEMISTRY-US, V42, P10978, DOI 10.1021/bi034651u; POWERS JH, 1993, CANCER RES, V53, P4059; *PRESS SYND U CAMB, 1999, CHILDH LEUK; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Ramdas J, 1999, CANCER RES, V59, P1378; Riml S, 2004, CELL DEATH DIFFER, V11, pS65, DOI 10.1038/sj.cdd.4401413; Schaaf MJM, 2002, J STEROID BIOCHEM, V83, P37, DOI 10.1016/S0960-0760(02)00263-7; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Smets LA, 1996, LEUKEMIA LYMPHOMA, V20, P199, DOI 10.3109/10428199609051608; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TISSING WJ, 2006, BLOOD; Tissing WJE, 2005, CLIN CANCER RES, V11, P6050, DOI 10.1158/1078-0432.CCR-04-2097; Tissing WJE, 2003, LEUKEMIA, V17, P17, DOI 10.1038/sj.leu.2402733; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430	52	58	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2600	+		10.1096/fj.06-6214fje	http://dx.doi.org/10.1096/fj.06-6214fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077285				2022-12-25	WOS:000242490700037
J	Zhao, LJ; Subramanian, T; Chinnadurai, G				Zhao, Ling-Jun; Subramanian, T.; Chinnadurai, G.			Changes in C-terminal binding protein 2 (CtBP2) corepressor complex induced by E1A and modulation of E1A transcriptional activity by CtBP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY EPITHELIAL-CELLS; ACETYLTRANSFERASE ACTIVITY; ONCOGENIC TRANSFORMATION; CELLULAR PHOSPHOPROTEIN; MEDIATED REPRESSION; NEGATIVE MODULATION; MOLECULAR-CLONING; ONCOPROTEIN E1A; GENE-EXPRESSION; VIRAL MECHANISM	The N-terminal region of adenovirus E1A interacts with histone acetyl transferases (HATs) such as p300, P/CAF, and GCN5. The C-terminal region interacts with the transcriptional corepressors CtBP1 and CtBP2. The functional significance of co-recruitment of HATs and CtBPs by E1A is not well understood. In this study, we have shown that E1A enhanced acetylation of CtBP2 by recruitment of p300 to the CtBP2 complex. Additionally, E1A also displaced the histone methyltransferase G9a and the E-box repressor ZEB from the CtBP2 complex through the C-terminal CtBP-binding domain. A transcriptional activation function encoded by the E1A N-terminal region was efficiently inhibited by CtBP2 but not by a mutant with an N-terminal deletion or by a mutant deficient in interaction with E1A. Two isoforms of CtBP1 (CtBP1-L and CtBP1-S) poorly inhibited transcriptional activity of the E1A N-terminal region. Thus, the N-terminal domain of CtBP2 may contribute a unique transcriptional regulatory activity of CtBP2. Our results provide new insights by which CtBP might modulate the biochemical activities of E1A.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NATIONAL CANCER INSTITUTE [R01CA084941, R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [CA-84941, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Chinnadurai G., 2006, CTBP FAMILY PROTEINS, P1; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Gopalakrishnan S, 1997, CELL GROWTH DIFFER, V8, P541; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Huh KW, 2005, P NATL ACAD SCI USA, V102, P11492, DOI 10.1073/pnas.0505337102; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meloni AR, 2005, MOL CANCER RES, V3, P575, DOI 10.1158/1541-7786.MCR-05-0088; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Nishio H, 2004, P NATL ACAD SCI USA, V101, P11257, DOI 10.1073/pnas.0401343101; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Senyuk V, 2005, ARCH BIOCHEM BIOPHYS, V441, P168, DOI 10.1016/j.abb.2005.06.024; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Ueda J, 2006, J BIOL CHEM, V281, P20120, DOI 10.1074/jbc.M603087200; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	56	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36613	36623		10.1074/jbc.M603550200	http://dx.doi.org/10.1074/jbc.M603550200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023432	hybrid			2022-12-25	WOS:000242220800018
J	Basaki, Y; Hosoi, F; Oda, Y; Fotovati, A; Maruyama, Y; Oie, S; Ono, M; Izumi, H; Kohno, K; Sakai, K; Shimoyama, T; Nishio, K; Kuwano, M				Basaki, Y.; Hosoi, F.; Oda, Y.; Fotovati, A.; Maruyama, Y.; Oie, S.; Ono, M.; Izumi, H.; Kohno, K.; Sakai, K.; Shimoyama, T.; Nishio, K.; Kuwano, M.			Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells	ONCOGENE			English	Article						Akt; microarray; ovarian carcinoma; Y-box-binding protein-1	TRANSCRIPTION FACTOR YB-1; CHEMOKINE RECEPTORS; PROGNOSTIC-FACTOR; GENE-EXPRESSION; MESSENGER-RNA; TUMOR-GROWTH; DNA; CXCR4; INVOLVEMENT; INHIBITOR	Y-box-binding protein 1 (YB-1), which is a member of the DNA-binding protein family containing a cold-shock domain, has pleiotropic functions in response to various environmental stimuli. As we previously showed that YB-1 is a global marker of multidrug resistance in ovarian cancer and other tumor types. To identify YB-1-regulated genes in ovarian cancers, we investigated the expression profile of YB-1 small-interfering RNA (siRNA)-transfected ovarian cancer cells using a high-density oligonucleotide array. YB-1 knockdown by siRNA upregulated 344 genes, including MDR1, thymidylate synthetase, S100 calcium binding protein and cyclin B, and downregulated 534 genes, including CXCR4, N-myc downstream regulated gene 1, E-cadherin and phospholipase C. Exogenous serum addition stimulated YB-1 translocation from the cytoplasm to the nucleus, and treatment with Akt inhibitors as well as Akt siRNA and integrin-linked kinase (ILK) siRNA specifically blocked YB-1 nuclear localization. Inhibition of Akt activation downregulated CXCR4 and upregulated MDR1 (ABCB1) gene expression. Administration of Akt inhibitor resulted in decrease in nuclear YB-1-positive cancer cells in a xenograft animal model. Akt activation thus regulates the nuclear translocation of YB-1, affecting the expression of drug-resistance genes and other genes associated with the malignant characteristics in ovarian cancer cells. Therefore, the Akt pathway could be a novel target of disrupting the nuclear translocation of YB-1 that has important implications for further development of therapeutic strategy against ovarian cancers.	Kyushu Univ, Stn Collaborat Res 2, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol Anat, Fukuoka 8128582, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 830, Japan; Univ Occupat & Environm Hlth, Dept Mol Biol, Kitakyushu, Fukuoka 807, Japan; Natl Canc Ctr, Res Inst, Div Pharmacol, Tokyo 104, Japan	Kyushu University; Kyushu University; Kurume University; University of Occupational & Environmental Health - Japan; National Cancer Center - Japan	Basaki, Y (corresponding author), Kyushu Univ, Stn Collaborat Res 2, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yubasaki@yahoo.co.jp						Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Ashizuka M, 2002, MOL CELL BIOL, V22, P6375, DOI 10.1128/MCB.22.18.6375-6383.2002; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Dooley S, 2006, J BIOL CHEM, V281, P1784, DOI 10.1074/jbc.M510215200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; En-Nia A, 2005, J BIOL CHEM, V280, P7702, DOI 10.1074/jbc.M413353200; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Fukuda T, 2004, NUCLEIC ACIDS RES, V32, P611, DOI 10.1093/nar/gkh223; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Hu LM, 2000, CLIN CANCER RES, V6, P880; Huang Jing, 2004, Human Genomics, V1, P287; Ise T, 1999, CANCER RES, V59, P342; Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kryczek I, 2005, CANCER RES, V65, P465; Kuwano M, 2004, MOL CANCER THER, V3, P1485; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Maruyama Y, 2006, CANCER RES, V66, P6233, DOI 10.1158/0008-5472.CAN-06-0183; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; Stein U, 2005, ONCOGENE, V24, P3606, DOI 10.1038/sj.onc.1208386; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590	42	109	118	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2736	2746		10.1038/sj.onc.1210084	http://dx.doi.org/10.1038/sj.onc.1210084			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072343				2022-12-25	WOS:000246210600008
J	Ma, C; Zhang, J; Durrin, LK; Lv, J; Zhu, D; Han, X; Sun, Y				Ma, C.; Zhang, J.; Durrin, L. K.; Lv, J.; Zhu, D.; Han, X.; Sun, Y.			The BCL2 major breakpoint region (mbr) regulates gene expression	ONCOGENE			English	Article						BCL2; mbr; t(14;18); homologous recombination; gene regulation	T(14/18) LYMPHOMA-CELLS; MAR-BINDING PROTEIN; AU-RICH ELEMENT; HEMATOPOIETIC-CELLS; CODING SEQUENCE; DOWN-REGULATION; MESSENGER-RNA; APOPTOSIS; SATB1; SITE	BCL2 expression is finely tuned by a variety of environmental and endogenous stimuli and regulated at both transcriptional and post-transcriptional levels. Our previous investigations demonstrated that the BCL2 major breakpoint region (mbr) in the 30-UTR upregulates reporter gene expression, which implies that this region possessed intrinsic regulatory function. However, the effect of the mbr on BCL2 expression, and the underlying regulatory mechanisms, remain to be elucidated. To assess the direct effect of the mbr on the transcriptional activity of the BCL2 gene, we employed targeted homologous recombination to establish a mbr(+) / mbr(-) heterozygous Nalm-6 cell line and then compared the transcriptional activity and apoptotic effect on transcription between the wild type and targeted alleles. We found that deletion of the mbr significantly decreased the transcriptional activity of the corresponding allele in the mbr(+)/mbr(-) cell. The BCL2 allele deleted of the mbr had a slower response to apoptotic stimuli than did the wild type allele. The regulatory function of the mbr was mediated through SATB1. Overexpression of SATB1 increased BCL2 expression, while knockdown of SATB1 with RNAi decreased BCL2 expression. Our results clearly indicated that the mbr could positively regulate BCL2 gene expression and this regulatory function was closely related to SATB1.	Nanjing Med Univ, Coll Basic Med, Key Lab Human Funct Genom & Jiangsu Province, Nanjing 210029, Peoples R China; Nanjing Med Univ, Dept Cell Biol & Med Genet, Nanjing 210029, Peoples R China; Nanjing Med Univ, Sch Pharm, Nanjing 210029, Peoples R China; City Hope Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; City of Hope	Sun, Y (corresponding author), Nanjing Med Univ, Coll Basic Med, Key Lab Human Funct Genom & Jiangsu Province, Hangzhong Rd 140, Nanjing 210029, Peoples R China.	hanxiao@njmu.edu.cn; yujiesun@njmu.edu.cn						Adams JM, 1999, COLD SPRING HARB SYM, V64, P351, DOI 10.1101/sqb.1999.64.351; Alvarez JD, 2000, GENE DEV, V14, P521; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHEN M, 1995, CANCER RES, V55, P991; DELIC J, 1991, BIOCHEM BIOPH RES CO, V181, P818, DOI 10.1016/0006-291X(91)91263-C; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137, DOI 10.1073/pnas.92.22.10137; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO M, 1992, J BIOCHEM-TOKYO, V112, P492, DOI 10.1093/oxfordjournals.jbchem.a123927; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; Lang G, 2005, IMMUNOLOGY, V114, P25, DOI 10.1111/j.1365-2567.2004.02073.x; MIYASHITA T, 1994, CANCER RES, V54, P3131; Narla RK, 2001, LEUKEMIA LYMPHOMA, V41, P625, DOI 10.3109/10428190109060353; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Raghavan SC, 2005, J BIOL CHEM, V280, P22749, DOI 10.1074/jbc.M502952200; Ramakrishnan M, 2000, MOL CELL BIOL, V20, P868, DOI 10.1128/MCB.20.3.868-877.2000; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Sun YJ, 2006, CELL BIOL INT, V30, P244, DOI 10.1016/j.cellbi.2005.10.025; Suzuki A, 1996, ONCOGENE, V13, P31; Tong X, 2005, J BIOL CHEM, V280, P15503, DOI 10.1074/jbc.M411978200; Tsurusawa M, 1997, INT J HEMATOL, V66, P79; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang JJ, 2006, GENE, V379, P127, DOI 10.1016/j.gene.2006.05.002; Zhang MX, 2005, P NATL ACAD SCI USA, V102, P16967, DOI 10.1073/pnas.0503853102	36	29	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2649	2657		10.1038/sj.onc.1210069	http://dx.doi.org/10.1038/sj.onc.1210069			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17057736				2022-12-25	WOS:000245831200012
J	Chen, C; Sun, X; Guo, P; Dong, XY; Sethi, P; Zhou, W; Zhou, Z; Petros, J; Frierson, HF; Vessella, RL; Atfi, A; Dong, JT				Chen, C.; Sun, X.; Guo, P.; Dong, X-Y; Sethi, P.; Zhou, W.; Zhou, Z.; Petros, J.; Frierson, H. F., Jr.; Vessella, R. L.; Atfi, A.; Dong, J-T			Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer	ONCOGENE			English	Article						WWP1; amplification; overexpression; prostate cancer; KLF5; TGF beta	GROWTH-FACTOR-BETA; KLF5 TRANSCRIPTION FACTOR; TGF-BETA; EPITHELIAL-CELLS; NEDD4 FAMILY; EXPRESSION; DEGRADATION; GENE; CARCINOMA; PROTEIN	The gene for E3 ubiquitin ligase WWP1 is located at 8q21, a region frequently amplified in human cancers, including prostate cancer. Recent studies have shown that WWP1 negatively regulates the TGFb tumor suppressor pathway by inactivating its molecular components, including Smad2, Smad4 and T beta R1. These findings suggest an oncogenic role of WWP1 in carcinogenesis, but direct supporting evidence has been lacking. In this study, we examined WWP1 for gene dosage, mRNA expression, mutation and functions in a number of human prostate cancer samples. We found that the WWP1 gene had copy number gain in 15 of 34 (44%) xenografts and cell lines from prostate cancer and 15 of 49 (31%) clinical prostate cancer samples. Consistently, WWP1 was over-expressed in 60% of xenografts and cell lines from prostate cancer. Mutation of WWP1 occurred infrequently in prostate cancer. Functionally, WWP1 overexpression promoted colony formation in the 22Rv1 prostate cancer cell line. In PC-3 prostate cancer cells, WWP1 knockdown significantly suppressed cell proliferation and enhanced TGF beta-mediated growth inhibition. These findings suggest that WWP1 is an oncogene that undergoes genomic amplification at 8q21 in human prostate cancer, and WWP1 overexpression is a common mechanism involved in the inactivation of TGFb function in human cancer.	Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA; Atlanta VA Med Ctr, Decatur, GA USA; Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Hop St Antoine, INSERM, U482, Paris, France; Nankai Univ, Coll Life Sci, Dept Genet & Cell Biol, Tianjin, Peoples R China	Emory University; Emory University; Albany Medical College; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; University of Virginia; University of Washington; University of Washington Seattle; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Nankai University	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, 1365 Clifton Rd,Room C4080, Atlanta, GA 30322 USA.	jdong2@emory.edu	guo, peng/AAG-4052-2019; Guo, Peng/GWC-0572-2022	Dong, Jin-Tang/0000-0003-2349-5782	NATIONAL CANCER INSTITUTE [R01CA087921] Funding Source: NIH RePORTER; NCI NIH HHS [CA87921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Dong JT, 2000, CANCER RES, V60, P3880; Dong JT, 2006, J CELL BIOCHEM, V97, P433, DOI 10.1002/jcb.20696; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; Gu ZN, 2005, CLIN CANCER RES, V11, P2237, DOI 10.1158/1078-0432.CCR-04-0356; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kim IY, 1996, CANCER RES, V56, P44; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Malbert-Colas L, 2003, PFLUG ARCH EUR J PHY, V447, P35, DOI 10.1007/s00424-003-1152-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Mu ZM, 2004, PROSTATE, V60, P187, DOI 10.1002/pros.20044; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Porkka K, 2002, LAB INVEST, V82, P629, DOI 10.1038/labinvest.3780457; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Sun SY, 1997, CANCER RES, V57, P4931; Sun XD, 2005, NAT GENET, V37, P407, DOI 10.1038/ng1528; van Dekken H, 2003, LAB INVEST, V83, P789, DOI 10.1097/01.LAB.0000074889.76221.49; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Wang RX, 2004, CANCER RES, V64, P1589, DOI 10.1158/0008-5472.CAN-03-3331; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zitzelsberger H, 1998, VIRCHOWS ARCH, V433, P297, DOI 10.1007/s004280050252	35	97	106	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2386	2394		10.1038/sj.onc.1210021	http://dx.doi.org/10.1038/sj.onc.1210021			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016436				2022-12-25	WOS:000245466000015
J	Bagella, L; Sun, A; Tonini, T; Abbadessa, G; Cottone, G; Paggi, MG; De Luca, A; Claudio, PP; Giordano, A				Bagella, L.; Sun, A.; Tonini, T.; Abbadessa, G.; Cottone, G.; Paggi, M. G.; De Luca, A.; Claudio, P. P.; Giordano, A.			A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo	ONCOGENE			English	Article						pRb2/p130; small molecules; peptides; cdk2 inhibitor; kinase activity	DEPENDENT KINASES; CANCER-CELLS; LUNG-CANCER; RETINOBLASTOMA PROTEIN; FLAVOPIRIDOL; EXPRESSION; INDUCTION; GENE; P107; SUPPRESSION	One strategy in the development of anticancer therapeutics has been to arrest malignant proliferation through inhibition of the enzymatic activity of cyclin-dependent kinases (cdks), which are key regulatory molecules of the cell cycle. Over the past few years, numerous compounds with remarkable cdk inhibitory activity have been studied in cancer therapy, although it is very difficult to point out the best cdk to target. An excellent candidate appears to be cdk2, whose alteration is a pathogenic hallmark of tumorigenesis. The small molecule described in our study showed an inhibitory effect on the kinase activity of cdk2, a significant growth arrest observed in a colony formation assay and a reduction in the size of the tumor in nude mice, thus suggesting its potential role as a promising new type of mechanism-based antitumor drug, also for the treatment of hyperproliferative disorders.	Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Sassari, Dept Biomed Sci, Div Biochem, I-07100 Sassari, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C, Rome, Italy; Univ Naples 2, Dept Med & Publ Hlth, Sect Clin Anat, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Sassari; University of Siena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita della Campania Vanvitelli	Giordano, A (corresponding author), Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Bio Life Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010; Sun, Ang/G-1537-2015; De Luca, Antonio/AAD-9562-2020; Claudio, Pier Paolo/AAW-7282-2021; Paggi, Marco G./K-3494-2018	Giordano, Antonio/0000-0002-5959-016X; Sun, Ang/0000-0002-8644-0407; De Luca, Antonio/0000-0002-3905-6154; Claudio, Pier Paolo/0000-0001-7790-1622; BAGELLA, Luigi/0000-0003-2815-037X				Al-Aynati MM, 2004, CLIN CANCER RES, V10, P6598, DOI 10.1158/1078-0432.CCR-04-0524; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; Andrews MJI, 2004, ORG BIOMOL CHEM, V2, P2735, DOI 10.1039/b409157d; BAGELLA L, 2006, J CELL BIOCH; BATES S, 1994, ONCOGENE, V9, P71; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424; Carlson BA, 1996, CANCER RES, V56, P2973; Caterina C, 2005, ONCOGENE, V24, P5821, DOI 10.1038/sj.onc.1208880; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Fischer PM, 2003, EXPERT OPIN INV DRUG, V12, P955, DOI 10.1517/eoid.12.6.955.21792; Gallo G, 2005, J CELL PHYSIOL, V205, P176, DOI 10.1002/jcp.20451; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Genovese C, 2006, ONCOGENE, V25, P5201, DOI 10.1038/sj.onc.1209652; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Harwell RM, 2004, J BIOL CHEM, V279, P12695, DOI 10.1074/jbc.M313407200; Howard CM, 2000, CANCER RES, V60, P2737; Hsu YL, 2004, LIFE SCI, V75, P2303, DOI 10.1016/j.lfs.2004.04.027; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee HR, 1999, INT J ONCOL, V15, P161; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Li YW, 2000, INT J ONCOL, V17, P755; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; MAYOL X, 1993, ONCOGENE, V8, P2561; Merola E, 2006, J CELL PHYSIOL, V207, P512, DOI 10.1002/jcp.20590; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Olofsson A, 2004, INT J ONCOL, V25, P1349; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pepper C, 2001, BRIT J HAEMATOL, V114, P70, DOI 10.1046/j.1365-2141.2001.02895.x; Purev E, 2006, J CELL PHYSIOL, V206, P495, DOI 10.1002/jcp.20490; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Song YC, 2004, BIOCHEM BIOPH RES CO, V317, P128, DOI 10.1016/j.bbrc.2004.03.019; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tosi GM, 2005, ONCOGENE, V24, P5827, DOI 10.1038/sj.onc.1208630; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yu CH, 2004, BIOCHEM PHARMACOL, V67, P1907, DOI 10.1016/j.bcp.2004.02.004; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	64	36	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1829	1839		10.1038/sj.onc.1209987	http://dx.doi.org/10.1038/sj.onc.1209987			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043661				2022-12-25	WOS:000245117700001
J	Kilic, M; Kasperczyk, H; Fulda, S; Debatin, KM				Kilic, M.; Kasperczyk, H.; Fulda, S.; Debatin, K-M			Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance	ONCOGENE			English	Article						hypoxia; apoptosis; Hif-1 alpha; rhabdomyosarcoma; Ewing sarcoma	PANCREATIC-CANCER CELLS; HIF-1; GENE; HIF-1-ALPHA; EXPRESSION; FACTOR-1-ALPHA; ACTIVATION; SUPPRESSION; MECHANISM; PATHWAY	Hypoxia inducible factor-1 (HIF-1) is the major transcription factor and key regulator of adoptive responses to hypoxia. Although it usually promotes tumor cell survival under hypoxia, it has also been implied to trigger apoptosis. Although the impact of hypoxia has been extensively studied in many adult solid tumors, its role in most childhood tumors, for example, in rhabdomyosarcoma (RMS) or Ewing sarcoma (ES), has not yet been addressed. Here, we report that hypoxia protects A204 RMS and A673 ES cells against anticancer drug- or tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis and that Hif-1 alpha plays a key role in conferring apoptosis resistance under hypoxia. Although a functional HIF-1 pathway and proapoptotic proteins such as p53 and Bcl-2/E1B 19 kDa interacting protein 3 were activated under hypoxia in both A204 RMS and A673 ES cells, these cells remained refractory to apoptosis. Concomitant analysis of antiapoptotic proteins revealed that hypoxia induced expression of Bcl-2 and inhibitor of apoptosis proteins (IAP)-2 as well as proteins associated with anaerobic metabolism such as the glucose transporter protein GLUT-1 and the glycolytic enzyme Aldolase A. Specific downregulation of Hif-1 alpha by RNA interference significantly enhanced apoptosis under hypoxia by preventing the hypoxia-mediated increase in GLUT-1 expression without altering expression levels of the antiapoptotic proteins Bcl-2 or cIAP-2. Moreover, glucose deprivation-induced apoptosis of A204 RMS and A673 ES cells was inhibited under hypoxic conditions in a Hif-1 alpha-dependent manner. As GLUT-1 was induced via Hif-1 alpha under hypoxia in A204 RMS and A673 ES, these findings suggest that the Hif-1 alpha-mediated increase in glucose uptake plays an important role in conferring apoptosis resistance. Thus, hypoxia-inducible genes may represent novel targets for therapeutic intervention in some pediatric tumors, which warrants further investigation.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de; klaus-michael.debatin@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Akakura N, 2001, CANCER RES, V61, P6548; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Blum R, 2005, CANCER RES, V65, P999; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Dagher R, 1999, Oncologist, V4, P34; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fulda S, 1997, CANCER RES, V57, P3823; Ganjavi H, 2005, CANCER GENE THER, V12, P397, DOI 10.1038/sj.cgt.7700798; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hochachka PW, 2001, COMP BIOCHEM PHYS B, V130, P435, DOI 10.1016/S1096-4959(01)00408-0; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284; Lin ZW, 2000, AM J PHYSIOL-ENDOC M, V278, pE958, DOI 10.1152/ajpendo.2000.278.5.E958; Mackall CL, 2002, CANCER CELL, V2, P175, DOI 10.1016/S1535-6108(02)00132-0; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MERRALL NW, 1993, CELL SIGNAL, V5, P667, DOI 10.1016/0898-6568(93)90028-K; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Murphy BJ, 1999, CANCER RES, V59, P1315; ORMEROD MG, 1992, FLOW CYTOMETRY PRACT; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; Park SY, 2002, BIOCHEM BIOPH RES CO, V291, P150, DOI 10.1006/bbrc.2002.6421; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Sasabe E, 2005, CANCER SCI, V96, P394, DOI 10.1111/j.1349-7006.2005.00065.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Sowter HM, 2003, CANCER RES, V63, P6130; Sowter HM, 2001, CANCER RES, V61, P6669; Webster KA, 2000, ADV EXP MED BIOL, V475, P161; West DC, 2000, CURR OPIN ONCOL, V12, P323, DOI 10.1097/00001622-200007000-00008; Zhang QZ, 2004, INT J CANCER, V111, P849, DOI 10.1002/ijc.20334; Zhong H, 1999, CANCER RES, V59, P5830	48	130	140	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2027	2038		10.1038/sj.onc.1210008	http://dx.doi.org/10.1038/sj.onc.1210008			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043658	Bronze			2022-12-25	WOS:000245313400005
J	Kizhatil, K; Yoon, W; Mohler, PJ; Davis, LH; Hoffman, JA; Bennett, V				Kizhatil, Krishnakumar; Yoon, Woohyun; Mohler, Peter J.; Davis, Lydia H.; Hoffman, Janis A.; Bennett, Vann			Ankyrin-G and beta(2)-spectrin collaborate in biogenesis of lateral membrane of human bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; AXON INITIAL SEGMENTS; C-TERMINAL DOMAIN; BETA-SPECTRIN; NEONATAL CARDIOMYOCYTES; INOSITOL 1,4,5-TRISPHOSPHATE; POLARIZED DISTRIBUTION; ISOFORM SPECIFICITY; CARDIAC-ARRHYTHMIA; ERYTHROID SPECTRIN	Ankyrins are a family of adapter proteins required for localization of membrane proteins to diverse specialized membrane domains including axon initial segments, specialized sites at the transverse tubule/sarcoplasmic reticulum in cardiomyocytes, and lateral membrane domains of epithelial cells. Little is currently known regarding the molecular basis for specific roles of different ankyrin isoforms. In this study, we systematically generated alanine mutants of clusters of charged residues in the spectrin-binding domains of both ankyrin-B and -G. The corresponding mutants were evaluated for activity in either restoration of abnormal localization of the inositol trisphosphate receptor in the sarcoplasmic reticulum in mutant mouse cardiomyocytes deficient in ankyrin-B or in prevention of loss of lateral membrane in human bronchial epithelial cells depleted of ankyrin- G by small interfering RNA. Interestingly, ankyrin-B and -G share two homologous sites that result in loss of function in both systems, suggesting that common molecular interactions underlie diverse roles of these isoforms. Ankyrins G and B also exhibit differences; mutations affecting spectrin binding had no effect on ankyrin- B function but did abolish activity of ankyrin- G in restoring lateral membrane biogenesis. Depletion of beta(2)-spectrin by small interfering RNA phenocopied depletion of ankyrin- G and resulted in a failure to form new lateral membrane in interphase and mitotic cells. These results demonstrate that ankyrin- G and beta(2)-spectrin are functional partners in biogenesis of the lateral membrane of epithelial cells.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of Iowa	Bennett, V (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	benne012@mc.duke.edu	Kizhatil, Krish/AAR-5868-2021					Abdi KM, 2006, J BIOL CHEM, V281, P5741, DOI 10.1074/jbc.M506697200; An XL, 2004, BIOCHEMISTRY-US, V43, P310, DOI 10.1021/bi035653h; Ango F, 2004, CELL, V119, P257, DOI 10.1016/j.cell.2004.10.004; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DRENCKHAHN D, 1987, EUR J CELL BIOL, V43, P479; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Hammarlund M, 2000, J CELL BIOL, V149, P931, DOI 10.1083/jcb.149.4.931; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; HU RJ, 1992, J BIOL CHEM, V267, P18715; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kizhatil K, 2004, J BIOL CHEM, V279, P16706, DOI 10.1074/jbc.M314296200; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; Kordeli E, 1998, J CELL SCI, V111, P2197; Lecuit T, 2000, J CELL BIOL, V150, P849, DOI 10.1083/jcb.150.4.849; Lopez C, 2005, J BIOL CHEM, V280, P8221, DOI 10.1074/jbc.M413351200; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; Mohler PJ, 2005, PLOS BIOL, V3, P2158, DOI 10.1371/journal.pbio.0030423; Mohler PJ, 2005, FRONT BIOSCI, V10, P2832, DOI 10.2741/1739; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P17533, DOI 10.1073/pnas.0403711101; Mohler PJ, 2004, J BIOL CHEM, V279, P40185, DOI 10.1074/jbc.M406018200; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P9137, DOI 10.1073/pnas.0402546101; Mohler PJ, 2004, J BIOL CHEM, V279, P25798, DOI 10.1074/jbc.M401296200; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Moorthy S, 2000, J CELL BIOL, V149, P915, DOI 10.1083/jcb.149.4.915; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; NELSON WJ, 1984, P NATL ACAD SCI-BIOL, V81, P3292, DOI 10.1073/pnas.81.11.3292; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; Pan ZM, 2006, J NEUROSCI, V26, P2599, DOI 10.1523/JNEUROSCI.4314-05.2006; Papoulas O, 2005, NAT CELL BIOL, V7, P612, DOI 10.1038/ncb1264; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; WERTMAN KF, 1992, GENETICS, V132, P337; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	41	104	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2029	2037		10.1074/jbc.M608921200	http://dx.doi.org/10.1074/jbc.M608921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17074766	hybrid			2022-12-25	WOS:000243451300054
J	Kawe, M; Forrer, P; Amstutz, P; Pluckthun, A				Kawe, Martin; Forrer, Patrik; Amstutz, Patrick; Plueckthun, Andreas			Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; COMBINATORIAL LIBRARIES; MOLECULAR RECOGNITION; HIV-1 PROTEINASE; DIRECT SELECTION; CLEAVAGE SITE; EXPRESSION; PROTEASES; DISPLAY; ACTIVATION	The specific intracellular inhibition of protein activity at the protein level is a highly valuable tool for the validation or modulation of cellular processes. We demonstrate here the use of designed ankyrin repeat proteins (DARPins) as tailor-made intracellular proteinase inhibitors. Site-specific proteolytic processing plays a critical role in the regulation of many biological processes, ranging from basic cellular functions to the propagation of viruses. The NIa(pro) proteinase of tobacco etch virus, a major plant pathogen, can be functionally expressed in Escherichia coli without harming the bacterium. To identify inhibitors of this proteinase, we first selected binders to it from combinatorial libraries of DARPins and tested this pool with a novel in vivo screen for proteinase inhibition. For this purpose, a hybrid protein consisting of the omega subunit of E. coli RNA polymerase was covalently fused to a DNA-binding protein, the lambda cI repressor, containing an NIa(pro) cleavage site in the linker between the two proteins. Thus, this transcriptional activator is inactivated by site-specific proteolytic cleavage, and inhibitors of this cleavage can be identified by the reconstitution of transcription of a reporter gene. Following this two-step approach of selection and screening, we could rapidly isolate NIapro proteinase inhibitors active inside the cell from highly diverse combinatorial DARPin libraries. These findings underline the great potential of DARPins for modulation of protein functionality in the intracellular space. In addition, our novel genetic screen can help to select and identify tailor-made proteinase inhibitors based on other protein scaffolds or even on low molecular weight compounds.	Univ Zurich, Inst Biochem, Mol Partners AG, CH-8057 Zurich, Switzerland	University of Zurich	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Mol Partners AG, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@bioc.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306; Forrer, Patrik/0000-0002-9717-0991				Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569; Amstutz P, 2006, PROTEIN ENG DES SEL, V19, P219, DOI 10.1093/protein/gzl004; Amstutz P, 2005, J BIOL CHEM, V280, P24715, DOI 10.1074/jbc.M501746200; Andrade MA, 2001, J STRUCT BIOL, V134, P117, DOI 10.1006/jsbi.2001.4392; BILLICH A, 1990, BIOL CHEM H-S, V371, P265, DOI 10.1515/bchm3.1990.371.1.265; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; CARRINGTON JC, 1987, VIROLOGY, V160, P355, DOI 10.1016/0042-6822(87)90006-7; CARRINGTON JC, 1987, J VIROL, V61, P2540, DOI 10.1128/JVI.61.8.2540-2548.1987; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DASMAHAPATRA B, 1992, P NATL ACAD SCI USA, V9, P4157; De Filippis V, 2002, BIOCHEMISTRY-US, V41, P13556, DOI 10.1021/bi0203482; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DOUGHERTY WG, 1988, EMBO J, V7, P1281, DOI 10.1002/j.1460-2075.1988.tb02942.x; Dove A, 2002, NAT BIOTECHNOL, V20, P121, DOI 10.1038/nbt0202-121; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; Dove SL, 1998, GENE DEV, V12, P745, DOI 10.1101/gad.12.5.745; Ewert S, 2004, METHODS, V34, P184, DOI 10.1016/j.ymeth.2004.04.007; Fellouse FA, 2005, J MOL BIOL, V348, P1153, DOI 10.1016/j.jmb.2005.03.041; Forrer P, 2004, CHEMBIOCHEM, V5, P183, DOI 10.1002/cbic.200300762; Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7; GALLAGHER SR, 2004, CURRENT PROTOCOLS MO; Gutierrez-Campos R, 1999, NAT BIOTECHNOL, V17, P1223, DOI 10.1038/70781; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Koch H, 2006, J MOL BIOL, V357, P427, DOI 10.1016/j.jmb.2005.12.043; Kohl A, 2005, STRUCTURE, V13, P1131, DOI 10.1016/j.str.2005.04.020; Kohl A, 2003, P NATL ACAD SCI USA, V100, P1700, DOI 10.1073/pnas.0337680100; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEGRICE SFJ, 1987, GENE, V55, P95, DOI 10.1016/0378-1119(87)90252-6; Lehesjoki AE, 2003, EMBO J, V22, P3473, DOI 10.1093/emboj/cdg338; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Lomas DA, 2002, BIOCHEM SOC T, V30, P89, DOI 10.1042/BST0300089; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; ORR GL, 1994, J INSECT PHYSIOL, V40, P893, DOI 10.1016/0022-1910(94)90023-X; Otlewski J, 2005, EMBO J, V24, P1303, DOI 10.1038/sj.emboj.7600611; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; Ritchie BC, 2003, TRANSFUS APHER SCI, V29, P259, DOI 10.1016/j.transci.2003.08.004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Sices HJ, 1998, P NATL ACAD SCI USA, V95, P2828, DOI 10.1073/pnas.95.6.2828; Skerra A, 2000, J MOL RECOGNIT, V13, P167, DOI 10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.3.CO;2-0; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH TA, 1991, P NATL ACAD SCI USA, V88, P5159, DOI 10.1073/pnas.88.12.5159; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; STUMPP MT, 2004, THESIS U ZURICH ZURI; Sun J, 2003, BIOCHEMISTRY-US, V42, P892, DOI 10.1021/bi026878f; Vanaman TC, 1999, J BIOL CHEM, V274, P20047, DOI 10.1074/jbc.274.29.20047; WANG QM, 2001, PROG DRUG RES, P229; Yang F, 2000, NAT STRUCT BIOL, V7, P230	63	34	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40252	40263		10.1074/jbc.M602506200	http://dx.doi.org/10.1074/jbc.M602506200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17050543	hybrid			2022-12-25	WOS:000243033900056
J	Winterbourn, CC; Hampton, MB; Livesey, JH; Kettle, AJ				Winterbourn, Christine C.; Hampton, Mark B.; Livesey, John H.; Kettle, Anthony J.			Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome - Implications for microbial killing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HYDROGEN PEROXIDE-CHLORIDE; HYPOCHLOROUS ACID; RESPIRATORY BURST; NADPH OXIDASE; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; PHAGOCYTIC-CELLS; COMPOUND-III; PULSE-RADIOLYSIS	Neutrophils kill bacteria by ingesting them into phagosomes where superoxide and cytoplasmic granule constituents, including myeloperoxidase, are released. Myeloperoxidase converts chloride and hydrogen peroxide to hypochlorous acid (HOCl), which is strongly microbicidal. However, the role of oxidants in killing and the species responsible are poorly understood and the subject of current debate. To assess what oxidative mechanisms are likely to operate in the narrow confines of the phagosome, we have used a kinetic model to examine the fate of superoxide and its interactions with myeloperoxidase. Known rate constants for reactions of myeloperoxidase have been used and substrate concentrations estimated from neutrophil morphology. In the model, superoxide is generated at several m(M)/s. Most react with myeloperoxidase, which is present at millimolar concentrations, and rapidly convert the enzyme to compound III. Compound III turnover by superoxide is essential to maintain enzyme activity. Superoxide stabilizes at similar to 25 mu M and hydrogen peroxide in the low micromolar range. HOCl production is efficient if there is adequate chloride supply, but further knowledge on chloride concentrations and transport mechanisms is needed to assess whether this is the case. Low myeloperoxidase concentrations also limit HOCl production by allowing more hydrogen peroxide to escape from the phagosome. In the absence of myeloperoxidase, superoxide increases to > 100 mu M but hydrogen peroxide to only similar to 30 mu M. Most of the HOCl reacts with released granule proteins before reaching the bacterium, and chloramine products may be effectors of its antimicrobial activity. Hydroxyl radicals should form only after all susceptible protein targets are consumed.	Christchurch Sch Med & Hlth Sci, Dept Pathol, Christchurch, New Zealand; Christchurch Hosp, Dept Endocrinol, Christchurch, New Zealand	University of Otago; Christchurch Hospital New Zealand	Winterbourn, CC (corresponding author), Christchurch Sch Med & Hlth Sci, Dept Pathol, POB 4345, Christchurch, New Zealand.	christine.winterbourn@chmeds.ac.nz	Kettle, Anthony J/A-8520-2008; Hampton, Mark B/A-8490-2008	Kettle, Anthony J/0000-0002-8218-7766; Hampton, Mark B/0000-0002-7349-3729				ADENIYIJONES SK, 1981, J CLIN INVEST, V68, P365, DOI 10.1172/JCI110264; Ahluwalia J, 2004, NATURE, V427, P853, DOI 10.1038/nature02356; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Aratani Y, 2000, J INFECT DIS, V182, P1276, DOI 10.1086/315843; AVILA JL, 1975, BIOCHEM J, V152, P57, DOI 10.1042/bj1520057; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2003, P NATL ACAD SCI USA, V100, P3031, DOI 10.1073/pnas.0530251100; Baggiolini M, 1984, Contemp Top Immunobiol, V14, P221; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BAKKENIST ARJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P45, DOI 10.1016/0005-2744(78)90101-8; BEAMAN BL, 1985, INFECT IMMUN, V47, P135, DOI 10.1128/IAI.47.1.135-141.1985; BEHAR D, 1970, J PHYS CHEM-US, V74, P3209, DOI 10.1021/j100711a009; BERGER RR, 1966, FED PROC, V25, P840; BIELSKI BHJ, 1974, BIOCHIM BIOPHYS ACTA, V364, P233, DOI 10.1016/0005-2744(74)90008-4; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; BRADLEY PP, 1982, BLOOD, V60, P618; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; Chapman ALP, 2002, J BIOL CHEM, V277, P9757, DOI 10.1074/jbc.M106134200; CUPERUS RA, 1986, BIOCHIM BIOPHYS ACTA, V871, P78, DOI 10.1016/0167-4838(86)90135-4; DAMIANO VV, 1988, AM J PATHOL, V131, P235; DeCoursey TE, 2005, CELL MOL LIFE SCI, V62, P2173, DOI 10.1007/s00018-005-5177-1; DRI P, 1985, INFLAMMATION, V9, P21, DOI 10.1007/BF00915408; Femling JK, 2006, J GEN PHYSIOL, V127, P659, DOI 10.1085/jgp.200609504; FOLKES LK, 1995, ARCH BIOCHEM BIOPHYS, V323, P120, DOI 10.1006/abbi.1995.0017; FOREHAND JR, 1989, METABOLIC BASIS INHE, P2779; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; HELD AM, 1978, J AM CHEM SOC, V100, P5732, DOI 10.1021/ja00486a025; HOOGLAND H, 1988, BIOCHIM BIOPHYS ACTA, V955, P337, DOI 10.1016/0167-4838(88)90213-0; IMLAY JA, 1986, J BACTERIOL, V166, P519, DOI 10.1128/jb.166.2.519-527.1986; Jantschko W, 2002, ARCH BIOCHEM BIOPHYS, V398, P12, DOI 10.1006/abbi.2001.2674; Jiang Q, 1997, CHEM RES TOXICOL, V10, P1080, DOI 10.1021/tx9700984; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kettle AJ, 2001, BIOCHEMISTRY-US, V40, P10204, DOI 10.1021/bi010940b; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P185, DOI 10.1016/0167-4838(88)90271-3; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KETTLE AJ, 1993, BIOCHEM PHARMACOL, V45, P2003, DOI 10.1016/0006-2952(93)90010-T; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; Kettle AJ, 2004, J BIOL CHEM, V279, P18521, DOI 10.1074/jbc.M400334200; Kettle AJ, 2005, BIOFACTORS, V24, P41, DOI 10.1002/biof.5520240105; Kindzelskii AL, 2002, P NATL ACAD SCI USA, V99, P9207, DOI 10.1073/pnas.132630999; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; KLEBANOFF SJ, 1971, J CLIN INVEST, V50, P2226, DOI 10.1172/JCI106718; KLEBANOFF SJ, 1970, SCIENCE, V169, P1095, DOI 10.1126/science.169.3950.1095; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; Korshunov SS, 2002, MOL MICROBIOL, V43, P95, DOI 10.1046/j.1365-2958.2002.02719.x; Kutter D, 1998, J MOL MED-JMM, V76, P669, DOI 10.1007/s001090050266; LONG CA, 1980, J PHYS CHEM-US, V84, P555, DOI 10.1021/j100442a023; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; Menegazzi R, 1996, J CELL BIOL, V135, P511, DOI 10.1083/jcb.135.2.511; Miller RA, 1997, CLIN MICROBIOL REV, V10, P1; MIYASAKI KT, 1987, INFECT IMMUN, V55, P1029, DOI 10.1128/IAI.55.5.1029-1036.1987; Murphy R, 2006, BBA-BIOENERGETICS, V1757, P996, DOI 10.1016/j.bbabio.2006.01.005; NELSON DL, 2000, LEHNINGER PRINCIPLES, P118; Olsen LF, 2003, BIOPHYS J, V84, P69, DOI 10.1016/S0006-3495(03)74833-4; Painter RG, 2006, ANAL CHEM, V78, P3133, DOI 10.1021/ac0521706; PARRY MF, 1981, ANN INTERN MED, V95, P293, DOI 10.7326/0003-4819-95-3-293; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Rada BK, 2004, BLOOD, V104, P2947, DOI 10.1182/blood-2004-03-1005; RAMSEY PG, 1982, J IMMUNOL, V128, P415; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Reeves EP, 2003, J MED MICROBIOL, V52, P643, DOI 10.1099/jmm.0.05181-0; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; ROSEN H, 1979, J EXP MED, V149, P27, DOI 10.1084/jem.149.1.27; Rosen H, 2002, J BIOL CHEM, V277, P30463, DOI 10.1074/jbc.M202331200; ROZENBERGARSKA M, 1985, INFECT IMMUN, V50, P852, DOI 10.1128/IAI.50.3.852-859.1985; Seaver LC, 2001, J BACTERIOL, V183, P7182, DOI 10.1128/JB.183.24.7182-7189.2001; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; SEGAL AW, 1978, BIOCHEM BIOPH RES CO, V84, P611, DOI 10.1016/0006-291X(78)90749-0; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0; SELVARAJ RJ, 1978, J INFECT DIS, V137, P481, DOI 10.1093/infdis/137.4.481; SHIMIZU Y, 1993, BIOCHEM PHARMACOL, V45, P1743; SIMCHOWITZ L, 1986, J GEN PHYSIOL, V88, P167, DOI 10.1085/jgp.88.2.167; Sly LM, 2002, INFECT IMMUN, V70, P5312, DOI 10.1128/IAI.70.9.5312-5315.2002; STEINBECK MJ, 1992, J BIOL CHEM, V267, P13425; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; THOMAS EL, 1988, REV INFECT DIS S2, V10, P450; THOMAS MJ, 1992, J LEUKOCYTE BIOL, V51, P591, DOI 10.1002/jlb.51.6.591; Tien M, 1999, ARCH BIOCHEM BIOPHYS, V367, P61, DOI 10.1006/abbi.1999.1226; TINGBEALL HP, 1993, BLOOD, V81, P2774; VISSERS MCM, 1987, BIOCHEM J, V245, P277, DOI 10.1042/bj2450277; Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642; Winterbourn CC, 2000, PEROXIDASE MULTIGENE FAMILY OF ENZYMES, P58; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182	92	469	481	7	73	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39860	39869		10.1074/jbc.M605898200	http://dx.doi.org/10.1074/jbc.M605898200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074761	hybrid			2022-12-25	WOS:000243033900013
J	Bose, K; Nischt, R; Page, A; Bader, BL; Paulsson, M; Smyth, N				Boese, Kerstin; Nischt, Roswitha; Page, Anton; Bader, Bernhard L.; Paulsson, Mats; Smyth, Neil			Loss of nidogen-1 and-2 results in syndactyly and changes in limb development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL ECTODERMAL RIDGE; FIBROBLAST-GROWTH-FACTOR; BASEMENT-MEMBRANE FORMATION; HEPARAN-SULFATE PROTEOGLYCANS; MOUSE LIMB; PROTEIN CORE; BINDING SITE; MICE LACKING; CELL-DEATH; LAMININ	Nidogens are two ubiquitous basement membrane proteins produced mainly by mesenchymal cells. Nidogen-mediated interactions, in particular with laminin, collagen IV, and perlecan have been considered important in the formation and maintenance of the basement membrane. However, whereas mice lacking both nidogen isoforms or carrying mutations in the high affinity nidogen-binding site upon the laminin gamma 1 chain have specific basement membrane defects in certain organs, particularly in the lung, characterization of these mice has also shown that basement membrane formation per se does not need nidogens or the laminin-nidogen interaction. Limb development requires the complex interplay of numerous growth factors whose expression is dependent upon the apical ectodermal ridge. Here, we show that lack of nidogen-1 and -2 results in a specific and time-limited failure in the ectodermal basement membrane of the limb bud. The absence of this basement membrane leads to aberrant apical ectodermal ridge formation. It also causes altered distribution of growth factors, such as fibroblast growth factors and leads to a fully penetrant soft tissue syndactyly caused by the dysregulation of interdigital apoptosis. Further, in certain animals more severe changes in bone formation occur, providing evidence for the interplay between growth factors and the extracellular matrix.	Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England; Univ Cologne, Ctr Biochem, Fac Med, D-50924 Cologne, Germany; Univ Cologne, Ctr Mol Med, Fac Med, D-50924 Cologne, Germany; Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada; Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Southampton, Biol Imaging Serv, Southampton SO16 6YD, Hants, England; Tech Univ Munich, Dept Nutrit Med, D-85350 Freising Weihenstephan, Germany	University of Southampton; University of Cologne; University of Cologne; University of British Columbia; University of Cologne; University of Southampton; Technical University of Munich	Smyth, N (corresponding author), Univ Southampton, Sch Biol Sci, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	N.R.Smyth@soton.ac.uk		Smyth, Neil/0000-0002-3734-2149				Adamska M, 2003, DEV BIOL, V255, P350, DOI 10.1016/S0012-1606(02)00114-8; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Bader BL, 2005, MOL CELL BIOL, V25, P6846, DOI 10.1128/MCB.25.15.6846-6856.2005; Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903; Chaudhry SS, 2001, HUM MOL GENET, V10, P835, DOI 10.1093/hmg/10.8.835; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; De Arcangelis A, 1999, DEVELOPMENT, V126, P3957; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Dong LJ, 2002, LAB INVEST, V82, P1617, DOI 10.1097/01.LAB.0000042240.52093.0F; Dunn NR, 1997, DEV BIOL, V188, P235, DOI 10.1006/dbio.1997.8664; EKBLOM P, 1994, DEVELOPMENT, V120, P2003; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Gregory KE, 2005, J BIOL CHEM, V280, P27970, DOI 10.1074/jbc.M504270200; Guha U, 2002, DEV BIOL, V249, P108, DOI 10.1006/dbio.2002.0752; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Kawakami Y, 2004, DEVELOPMENT, V131, P4763, DOI 10.1242/dev.01331; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; Lewandoski M, 2000, NAT GENET, V26, P460, DOI 10.1038/82609; Li L, 2004, DEVELOPMENT, V131, P5277, DOI 10.1242/dev.01415; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Lin XH, 1999, DEVELOPMENT, V126, P3715; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Macias D, 1996, ANAT EMBRYOL, V193, P533; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; Moon AM, 2000, NAT GENET, V26, P455, DOI 10.1038/82601; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; Murshed M, 2000, MOL CELL BIOL, V20, P7007, DOI 10.1128/MCB.20.18.7007-7012.2000; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; Pizette S, 1999, DEVELOPMENT, V126, P883; Poschl E, 2004, DEVELOPMENT, V131, P1619, DOI 10.1242/dev.01037; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; Revest JM, 2001, DEV BIOL, V231, P47, DOI 10.1006/dbio.2000.0144; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Salas-Vidal E, 2001, DEV DYNAM, V220, P295, DOI 10.1002/dvdy.1108; Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schymeinsky J, 2002, MOL CELL BIOL, V22, P6820, DOI 10.1128/MCB.22.19.6820-6830.2002; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sun X, 2002, NATURE, V418, P501, DOI 10.1038/nature00902; Tunggal J, 2003, J CELL SCI, V116, P803, DOI 10.1242/jcs.00293; Wang CKL, 2004, DEV BIOL, V269, P109, DOI 10.1016/j.ydbio.2004.01.016; Willem M, 2002, DEVELOPMENT, V129, P2711; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006	53	60	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39620	39629		10.1074/jbc.M607886200	http://dx.doi.org/10.1074/jbc.M607886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17023412	hybrid			2022-12-25	WOS:000242898700069
J	Debidda, M; Williams, DA; Zheng, Y				Debidda, Marcella; Williams, David A.; Zheng, Yi			Rac1 GTPase regulates cell genomic stability and senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RHO-FAMILY GTPASES; GENETIC DELETION; CROSS-TALK; RAS; ACTIVATION; GENERATION; PATHWAYS; PROMOTE; CDC42	The Rho family small GTPase Rac1 has been shown to play multiple roles in cell regulation, including actin cytoskeleton organization, transcriptional activation, microtubule dynamics, and endocytosis. Here, we report a novel role of Rac1 in regulating genomic stability and cell senescence. We observed in primary mouse embryonic fibroblasts that deletion of rac1 by gene targeting, as well as expression of the constitutively active Rac1 mutant L61Rac1, led to decreased cell growth that was associated with altered cell cycle progression at both G(1)/S and G(2)/M phases, increased apoptosis, and premature senescence. The senescence induction by either loss or gain of Rac1 activity was due at least in part to an increase in cellular reactive oxygen species (ROS). rac1 gene deletion caused a compensatory up-regulation of a closely related family member, Rac3, in mouse embryonic fibroblasts, the activity of which induced ROS production independently of Rac1. Furthermore, the Rac1-regulated ROS production and senescence correlated with the extent of DNA damage in the Rac1(-/-) and L61Rac1 cells. Treatment of these cells with a ROS inhibitor inhibited phospho-H2AX-positive nuclear focus formation. Finally, phospho-Ser(15) p53 was significantly increased in L61Rac1 and Rac1(-/-) cells, and genetic deletion of p53 from these cells readily reversed the senescence phenotype, indicating that Rac1 is functionally dependent on p53 in regulating cell senescence. Taken together, our results show that Rac1 activity serves as a regulator of cell senescence through modulation of cellular ROS, genomic stability, and p53 activity.	Univ Cincinnati, Coll Med, Cincinnati Childrens Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Res Fdn, Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL069974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL069974] Funding Source: Medline; NIDDK NIH HHS [DK 62757, R01 DK062757] Funding Source: Medline; NIGMS NIH HHS [GM 53943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander K, 2004, MOL CELL BIOL, V24, P2808, DOI 10.1128/MCB.24.7.2808-2819.2004; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Benvenuti F, 2004, SCIENCE, V305, P1150, DOI 10.1126/science.1099159; Cammarano MS, 2005, MOL CELL BIOL, V25, P9532, DOI 10.1128/MCB.25.21.9532-9542.2005; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cho KA, 2004, J BIOL CHEM, V279, P42270, DOI 10.1074/jbc.M402352200; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Deshpande SS, 2003, ARTERIOSCL THROM VAS, V23, pE1, DOI 10.1161/01.ATV.0000047869.13737.53; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Diebold BA, 2004, J BIOL CHEM, V279, P28136, DOI 10.1074/jbc.M313891200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gu Y, 2006, ONCOGENE, V25, P3963, DOI 10.1038/sj.onc.1209427; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Guo FK, 2004, ONCOGENE, V23, P5577, DOI 10.1038/sj.onc.1207752; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Mizrahi A, 2005, J BIOL CHEM, V280, P3802, DOI 10.1074/jbc.M410257200; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; VAN AL, 1997, GENE DEV, V11, P2295; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	50	45	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38519	38528		10.1074/jbc.M604607200	http://dx.doi.org/10.1074/jbc.M604607200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17032649	hybrid			2022-12-25	WOS:000242709500046
J	Liu, J; Rone, MB; Papadopoulos, V				Liu, Jun; Rone, Malena B.; Papadopoulos, Vassilios			Protein-protein interactions mediate mitochondrial cholesterol transport and steroid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; DIAZEPAM-BINDING INHIBITOR; CHAIN CLEAVAGE ENZYME; BENZODIAZEPINE-RECEPTOR; TARGETED DISRUPTION; MOLECULAR-CLONING; BREFELDIN-A; IN-VITRO; STEROIDOGENESIS; KINASE	Transport of cholesterol into the mitochondria is the rate-determining, hormone-sensitive step in steroid biosynthesis. Here we report that the mechanism underlying mitochondrial cholesterol transport involves the formation of a macromolecular signaling complex composed of the outer mitochondrial membrane translocator protein (TSPO), previously known as peripheral-type benzodiazepine receptor; the TSPO-associated protein PAP7, which binds and brings to mitochondria the regulatory subunit RI alpha of the cAMP-dependent protein kinase (PKARI alpha); and the hormone-induced PKA substrate, steroidogenic acute regulatory protein (StAR). Hormone treatment of MA-10 Leydig cells induced the co-localization of TSPO, PAP7, PKARI alpha, and StAR in mitochondria, visualized by confocal microscopy, and the formation in living cells of a high molecular weight multimeric complex identified using photoactivable amino acids. The hormone-induced recruitment of exogenous TSPO in this complex was found to parallel the increased presence of 7-azi-5 alpha-cholestan-3 beta-ol in the samples. Co-expression of Tspo, Pap7, PkarI alpha, and Star genes resulted in the stimulation of steroid formation in both steroidogenic MA-10 and non-steroidogenic COS-F2-130 cells that were engineered to metabolize cholesterol. Disruption of these protein-protein interactions and specifically the PKARI alpha-PAP7 and PAP7-TSPO interactions, using PAP7 mutants where the N0 area homologous to dual A-kinase-anchoring protein-1 or the acyl-CoA signature motif were deleted or using the peptide Ht31 known to disrupt the anchoring of PKA, inhibited both basal and hormone-induced steroidogenesis. These results suggest that the initiation of cAMP-induced protein-protein interactions results in the formation of a multivalent scaffold in the outer mitochondrial membrane that mediates the effect of hormones on mitochondrial cholesterol transport and steroidogenesis.	Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA	Georgetown University	Papadopoulos, V (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, 3900 Reservoir Rd NW, Washington, DC 20057 USA.	papadopv@georgetown.edu	Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568	NICHD NIH HHS [HD 37031] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037031] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Boujrad N, 1996, ENDOCRINOLOGY, V137, P5727, DOI 10.1210/en.137.12.5727; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; CARR DW, 1991, J BIOL CHEM, V266, P14188; Catt K J, 1980, Recent Prog Horm Res, V36, P557; Clark BJ, 1997, ENDOCRINOLOGY, V138, P4893, DOI 10.1210/en.138.11.4893; COSTA E, 1991, LIFE SCI, V49, P325, DOI 10.1016/0024-3205(91)90440-M; Culty M, 1999, J STEROID BIOCHEM, V69, P123, DOI 10.1016/S0960-0760(99)00056-4; Delavoie F, 2003, BIOCHEMISTRY-US, V42, P4506, DOI 10.1021/bi0267487; DIBARTOLOMEIS MJ, 1984, J BIOL CHEM, V259, P159; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; DOBLE A, 1987, MOL PHARMACOL, V31, P42; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Golani I, 2001, BIOCHEMISTRY-US, V40, P10213, DOI 10.1021/bi010431+; Hansson V, 1999, J STEROID BIOCHEM, V69, P367, DOI 10.1016/S0960-0760(99)00077-1; Hauet T, 2005, MOL ENDOCRINOL, V19, P540, DOI 10.1210/me.2004-0307; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang MC, 2001, ENDOCRINOLOGY, V142, P2569, DOI 10.1210/en.142.6.2569; Jefcoate C, 2002, J CLIN INVEST, V110, P881, DOI 10.1172/JCI200216771; KIMURA T, 1986, J STEROID BIOCHEM, V25, P711, DOI 10.1016/0022-4731(86)90299-2; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; Liu J, 2003, J STEROID BIOCHEM, V85, P275, DOI 10.1016/S0960-0760(03)00213-9; Liu J, 2003, FASEB J, V17, P1189, DOI 10.1096/fj.02-1066fje; Liu J, 2003, GENE, V308, P1, DOI 10.1016/S0378-1119(03)00453-0; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; MOGER WH, 1991, ENDOCRINOLOGY, V128, P1414, DOI 10.1210/endo-128-3-1414; Moss SB, 2001, TRENDS ENDOCRIN MET, V12, P434, DOI 10.1016/S1043-2760(01)00493-3; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003-0030; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; SIMPSON ER, 1983, CAN J BIOCHEM CELL B, V61, P692, DOI 10.1139/o83-088; Stocco DM, 2001, MOL ENDOCRINOL, V15, P1245, DOI 10.1210/me.15.8.1245; Suchanek M, 2005, NAT METHODS, V2, P261, DOI 10.1038/NMETH752; West LA, 2001, ENDOCRINOLOGY, V142, P502, DOI 10.1210/en.142.1.502; YAMASHINA S, 1990, CELL STRUCT FUNCT, V15, P31, DOI 10.1247/csf.15.31	50	176	183	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38879	38893		10.1074/jbc.M608820200	http://dx.doi.org/10.1074/jbc.M608820200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050526	hybrid			2022-12-25	WOS:000242709500086
J	Perry, JL; Dembla-Rajpal, N; Hall, LA; Pritchard, JB				Perry, Jennifer L.; Dembla-Rajpal, Neetu; Hall, Laura A.; Pritchard, John B.			A three-dimensional model of human organic anion transporter 1 - Aromatic amino acids required for substrate transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION TRANSPORTERS; PROTEIN-STRUCTURE; LACTOSE PERMEASE; ESCHERICHIA-COLI; PROXIMAL TUBULE; BINDING REGION; RAT-KIDNEY; MEMBRANE; RESIDUES; MECHANISM	Organic anion transporters (OATs) play a critical role in the handling of endogenous and exogenous organic anions by excretory and barrier tissues. Little is known about the OAT three-dimensional structure or substrate/protein interactions involved in transport. In this investigation, a theoretical three-dimensional model was generated for human OAT1 (hOAT1) based on fold recognition to the crystal structure of the glycerol 3-phosphate transporter (GlpT) from Escherichia coli. GlpT and hOAT1 share several sequence motifs as major facilitator superfamily members. The structural hOAT1 model shows that helices 5, 7, 8, 10, and 11 surround an electronegative putative active site (similar to 830 angstrom(3)). The site opens to the cytoplasm and is surrounded by three residues not previously examined for function (Tyr(230) (domain 5) and Lys(431) and Phe(438) (domain 10)). Effects of these residues on p-aminohippurate (PAH) and cidofovir transport were assessed by point mutations in a Xenopus oocyte expression system. Membrane protein expression was severely limited for the Y230A mutant. For the K431A and F438A mutants, [H-3] PAH uptake was less than 30% of wild-type hOAT1 uptake after protein expression correction. Reduced Vmax values for the F438A mutant confirmed lower protein expression. In addition, the F438A mutant exhibited an increased affinity for cidofovir but was not significantly different for PAH. Differences in handling of PAH and cidofovir were also observed for the Y230F mutant. Little uptake was determined for cidofovir, whereas PAH uptake was similar to wildtype hOAT1. Therefore, the hOAT1 structural model has identified two new residues, Tyr(230) and Phe(438), which are important for substrate/protein interactions.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Pritchard, JB (corresponding author), POB 12233,F1-03, Res Triangle Pk, NC 27709 USA.	pritcha3@niehs.nih.gov	Cecile, Jennifer/H-4245-2012	Cecile, Jennifer/0000-0002-2149-2222	Intramural NIH HHS Funding Source: Medline; NIEHS NIH HHS [Z01 ES048014-06, Z01 ES080031-29] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080031, Z01ES048014] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; [Anonymous], VIEW 5 0; Bleasby K, 2005, J PHARMACOL EXP THER, V314, P923, DOI 10.1124/jpet.105.084301; Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956; Burckhardt BC, 2003, REV PHYSIOL BIOCH P, V146, P95, DOI 10.1007/s10254-002-0003-8; Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; Eraly SA, 2004, MOL PHARMACOL, V65, P479, DOI 10.1124/mol.65.3.479; Feng B, 2002, BIOCHEMISTRY-US, V41, P8941, DOI 10.1021/bi0200615; Feng B, 2001, BIOCHEMISTRY-US, V40, P5511, DOI 10.1021/bi002841o; FINIDORI J, 1982, MOL CELL ENDOCRINOL, V28, P211, DOI 10.1016/0303-7207(82)90033-8; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; FRITZSCH G, 1989, BIOCHIM BIOPHYS ACTA, V978, P249, DOI 10.1016/0005-2736(89)90122-3; GEUX N, 1997, ELECTROPHORESIS, V18, P2714; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Gorboulev V, 2005, MOL PHARMACOL, V67, P1612, DOI 10.1124/mol.104.008821; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HILBERT M, 1993, PROTEINS, V17, P138, DOI 10.1002/prot.340170204; Hirai T, 2004, BIOPHYS J, V86, p611A; Hong M, 2004, J BIOL CHEM, V279, P31478, DOI 10.1074/jbc.M404686200; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PING XP, 2002, FASEB J, V16, pA458; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schomig E, 1998, FEBS LETT, V425, P79, DOI 10.1016/S0014-5793(98)00203-8; Sweet DH, 1999, CELL BIOCHEM BIOPHYS, V31, P89, DOI 10.1007/BF02738157; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tanaka K, 2004, BIOCHEM J, V380, P283, DOI 10.1042/BJ20031724; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; Uwai Y, 1998, FEBS LETT, V438, P321, DOI 10.1016/S0014-5793(98)01328-3; van Gunsteren W. F., 1987, BIOMOS BIOMOLECULAR; Werten PJL, 2002, FEBS LETT, V529, P65, DOI 10.1016/S0014-5793(02)03290-8; Wolff NA, 2001, J AM SOC NEPHROL, V12, P2012, DOI 10.1681/ASN.V12102012; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; Zhang XH, 2005, J BIOL CHEM, V280, P34813, DOI 10.1074/jbc.M506342200; Zhou F, 2004, BIOCHEM J, V384, P87, DOI 10.1042/BJ20040751; Zhou FF, 2005, MOL PHARMACOL, V67, P868, DOI 10.1124/mol.104.007583; Zhou FF, 2004, MOL PHARMACOL, V65, P1141, DOI 10.1124/mol.65.5.1141	46	65	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38071	38079		10.1074/jbc.M608834200	http://dx.doi.org/10.1074/jbc.M608834200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17038320	hybrid, Green Accepted			2022-12-25	WOS:000242477100085
J	Shan, Y; Lambrecht, RW; Donohue, SE; Bonkovsky, HL				Shan, Ying; Lambrecht, Richard W.; Donohue, Susan E.; Bonkovsky, Herbert L.			Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin	FASEB JOURNAL			English	Article						HO-1; siRNA	EMBRYO LIVER-CELLS; TRANSCRIPTION FACTOR NF-E2; PORTAL HYPERTENSIVE-RATS; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; OXIDATIVE STRESS; WEIGHT-LOSS; EPITHELIAL-CELLS; PRIMARY CULTURES; MEDIATED INDUCTION	Heme oxygenase (HO) catalyzes the conversion of heme to biliverdin with the release of iron and carbon monoxide. HO-1 is highly inducible by a large number of physical and chemical factors. CoPP is known to be a potent and effective inducer of HO-1 activity in many tissues. Here we report that CoPP up-regulates HO-1 via Bach1 and Nrf2 in human liver cells. CoPP did not influence hepatic Bach1 or Nrf2 mRNA levels, but markedly reduced Bach1 protein levels by increasing degradation of Bach1 protein (t(1/2) from 19 h to 2.8 h), and increased Nrf2 by decreasing degradation of Nrf2 protein (t(1/2) from 2.5 h to 9 h). Silencing Bach1 by Bach1-siRNA significantly increased levels of HO-1 mRNA and protein, and addition of CoPP up-regulated HO-1 mRNA and protein further. However, silencing Nrf2 mRNA by Nrf2-siRNA did not significantly change baseline HO-1 mRNA or protein levels, but significantly decreased 5-10 mu M CoPP-mediated up-regulation of HO-1 mRNA levels compared with CoPP alone. Transfection with equal amounts of non-Bach1 or non-Nrf2 related control siRNA did not reduce Bach1 or Nrf2 mRNA or protein, confirming the specificity of Bach1-and Nrf2-siRNA in Huh-7 cells. We conclude that the pathway of CoPP-mediated induction of HO-1 involves the repression of Bach1 and up-regulation of the Nrf2 protein by post-transcriptional site(s) of action. Because CoPP, unlike heme, is neither a prooxidant nor a substrate for HO-1, it might be considered as a potential therapeutic agent in situations where up-regulation of HO-1 is desired.	Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Dept Pharmacol, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Liver Biliary Pancreat Ctr, Dept Mol Microbial & Struct Biol, Farmington, CT USA	University of Connecticut; University of Connecticut; University of Connecticut	Shan, Y (corresponding author), 263 Farmington Ave,MC-1119, Farmington, CT 06030 USA.	shan@uchc.edu	Bonkovsky, Herbert L./AAH-1892-2021	Bonkovsky, Herbert L./0000-0001-7387-3230	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038825, N01DK092326, U01DK065193] Funding Source: NIH RePORTER; NIDDK NIH HHS [N0-1 DK92326, R01-DK38825, U0-1 DK065193] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Abraham NG, 2002, CELL MOL BIOL, V48, P895; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alam J, 2003, AM J PHYSIOL-RENAL, V284, pF743, DOI 10.1152/ajprenal.00376.2002; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Belcher JD, 2006, J CLIN INVEST, V116, P808, DOI 10.1172/JCI26857; Bonkovsky H. L., 2002, OXIDATIVE STRESS AGI, P690; Cable EE, 1997, MOL CELL BIOCHEM, V169, P13, DOI 10.1023/A:1006817207166; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Di Noia MA, 2006, J BIOL CHEM, V281, P15687, DOI 10.1074/jbc.M510595200; DRUMMOND GS, 1982, P NATL ACAD SCI-BIOL, V79, P2384, DOI 10.1073/pnas.79.7.2384; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Fernandez M, 1999, HEPATOLOGY, V29, P1672, DOI 10.1002/hep.510290621; Fernandez M, 2001, J HEPATOL, V34, P812, DOI 10.1016/S0168-8278(01)00010-1; Fu SH, 2004, TRANSPL P, V36, P2205, DOI 10.1016/j.transproceed.2004.06.050; GALBRAITH RA, 1987, PHARMACOLOGY, V34, P241, DOI 10.1159/000138275; GALBRAITH RA, 1990, PHARMACOLOGY, V41, P292, DOI 10.1159/000138738; GALBRAITH RA, 1991, PHARMACOLOGY, V43, P96, DOI 10.1159/000138834; GALBRAITH RA, 1991, AM J PHYSIOL, V261, pR1388, DOI 10.1152/ajpregu.1991.261.6.R1388; GALBRAITH RA, 1992, AM J PHYSIOL, V263, pR805, DOI 10.1152/ajpregu.1992.263.4.R805; GALBRAITH RA, 1992, MOL BRAIN RES, V15, P298, DOI 10.1016/0169-328X(92)90121-Q; GARDNER FH, 1953, J LAB CLIN MED, V41, P182; Gildemeister OS, 2001, MOL CELL BIOCHEM, V226, P17; Glanemann M, 2005, TRANSPLANT P, V37, P3223, DOI 10.1016/j.transproceed.2005.07.002; Hill-Kapturczak N, 2002, DNA CELL BIOL, V21, P307, DOI 10.1089/104454902753759726; Hsu BRS, 2005, TRANSPL P, V37, P1826, DOI 10.1016/j.transproceed.2005.02.085; Hsu BRS, 2004, TRANSPL P, V36, P1181, DOI 10.1016/j.transproceed.2004.04.037; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Lambrecht RW, 2005, ASCITES AND RENAL DYSFUNCTION IN LIVER DISEASE: PATHOGENESIS, DIAGNOSIS, AND TREATMENT, 2ND EDITION, P125, DOI 10.1002/9780470987476.ch10; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; LINCOLN BC, 1988, BIOCHEM J, V250, P189, DOI 10.1042/bj2500189; Lu TH, 1997, BBA-GENE STRUCT EXPR, V1352, P293, DOI 10.1016/S0167-4781(97)00028-6; Lu TH, 1998, GENE, V207, P177, DOI 10.1016/S0378-1119(97)00623-9; Lu TH, 2000, MOL CELL BIOCHEM, V209, P17, DOI 10.1023/A:1007025505842; MITANI K, 1991, BIOCHEM J, V277, P895, DOI 10.1042/bj2770895; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Numazawa S, 1997, EXP CELL RES, V237, P434, DOI 10.1006/excr.1997.3825; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PETERS LL, 1993, NATURE, V362, P768, DOI 10.1038/362768a0; Sachan DS, 2005, J AM COLL NUTR, V24, P172, DOI 10.1080/07315724.2005.10719462; Shan Y, 2004, J BIOL CHEM, V279, P51769, DOI 10.1074/jbc.M409463200; Shan Y, 1999, HEPATOLOGY, V30, p512A; Shan Y, 2004, BBA-GENE STRUCT EXPR, V1679, P87, DOI 10.1016/j.bbaexp.2004.05.003; Shan Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P159, DOI 10.1006/abbi.2001.2742; Shan Y, 1999, ARCH BIOCHEM BIOPHYS, V372, P224, DOI 10.1006/abbi.1999.1490; Shan Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P219, DOI 10.1006/abbi.2000.1921; SRIVASTAVA KK, 1993, EUR J BIOCHEM, V213, P909, DOI 10.1111/j.1432-1033.1993.tb17835.x; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; TYRRELL RM, 1994, METHOD ENZYMOL, V234, P224; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165	66	130	142	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2651	+		10.1096/fj.06-6346fje	http://dx.doi.org/10.1096/fj.06-6346fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065227				2022-12-25	WOS:000242490700054
J	Khatlani, TS; Wislez, M; Sun, M; Srinivas, H; Iwanaga, K; Ma, L; Hanna, AE; Liu, D; Girard, L; Kim, YH; Pollack, JR; Minna, JD; Wistuba, II; Kurie, JM				Khatlani, T. S.; Wislez, M.; Sun, M.; Srinivas, H.; Iwanaga, K.; Ma, L.; Hanna, A. E.; Liu, D.; Girard, L.; Kim, Y. H.; Pollack, J. R.; Minna, J. D.; Wistuba, I. I.; Kurie, J. M.			c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells	ONCOGENE			English	Article						c-Jun N-terminal kinase; lung cancer; cellular transformation	METASTASIS SUPPRESSOR GENE; NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION; BREAST; GROWTH; JNK; MUTATIONS; MKK4; PROLIFERATION; EXPRESSION	c-Jun N-terminal kinase (JNK) has been reported to either potentiate or inhibit oncogenesis, depending upon the cellular context, but its role in lung neoplasia is unclear. Here we sought to de. ne the role of JNK in lung neoplasia by examining evidence of JNK phosphorylation in non-small-cell lung cancer (NSCLC) biopsy samples and by using genetic and pharmacologic approaches to modulate JNK expression and activity in cultured cells. Immunohistochemical staining for JNK phosphorylation was detected in 114 (45%) of 252 NSCLC biopsy samples and was predominantly nuclear, providing evidence of JNK activation in a subset of NSCLC cases. Introduction of a doxycycline-inducible, constitutively active, mutant mitogen-activated protein kinase kinase 4 (MKK4) into the human bronchial epithelial cell lines BEAS-2B and HB56B increased the cells' proliferation, migration, invasion and clonogenicity. Depletion of JNK in MKK4 mutant-transformed BEAS-2B cells by introduction of JNK1/2 short hairpin RNA reversed the transformed phenotype, indicating that JNK activation is oncogenic and MKK4 confers neoplastic properties in these cells. The proliferation of NSCLC cell lines HCC827 and H2009, in which JNK and its substrate c-Jun are constitutively phosphorylated, was inhibited by SP600125, a JNK kinase inhibitor. We conclude that JNK is activated in a subset of NSCLC biopsy samples and promotes oncogenesis in the bronchial epithelium, suggesting that strategies to inhibit the JNK pathway should be considered for the prevention and treatment of NSCLC.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Hop Tenon, AP HP, Dept Pulmonol, F-75970 Paris, France; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 0432,1515 Holcombe Blvd, Houston, TX 77030 USA.	jkurie@mdanderson.org		wislez, marie/0000-0001-7518-7859	NATIONAL CANCER INSTITUTE [R01CA105155, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, R01 CA105155, P50 CA070907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmeier BE, 2005, THROMB HAEMOSTASIS, V93, P761, DOI 10.1160/TH04-09-0601; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Bost F, 1999, MOL CELL BIOL, V19, P1938; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Cazillis M, 2004, ONCOGENE, V23, P4735, DOI 10.1038/sj.onc.1207619; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GEQIANG L, 2004, J BIOL CHEM, V279, P1123; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim HL, 2001, CANCER RES, V61, P2833; Kim MH, 2005, BIOCHEM BIOPH RES CO, V333, P874, DOI 10.1016/j.bbrc.2005.06.002; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; Lee HY, 2002, CLIN CANCER RES, V8, P2970; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Lu CH, 2005, ONCOGENE, V24, P6516, DOI 10.1038/sj.onc.1208905; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; REDDEL RR, 1991, INT J CANCER, V48, P764, DOI 10.1002/ijc.2910480522; REDDEL RR, 1988, CANCER RES, V48, P1904; SUGIO K, 1992, CANCER RES, V52, P339; Teng DHF, 1997, CANCER RES, V57, P4177; Vicent S, 2004, CLIN CANCER RES, V10, P3639, DOI 10.1158/1078-0432.CCR-03-0771; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Xiao L, 2000, CANCER RES, V60, P400; Yamada SD, 2002, CANCER RES, V62, P6717; Yang YM, 2003, CLIN CANCER RES, V9, P391; Zhong CY, 2005, CARCINOGENESIS, V26, P2187, DOI 10.1093/carcin/bgi189	45	60	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2658	2666		10.1038/sj.onc.1210050	http://dx.doi.org/10.1038/sj.onc.1210050			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17057737				2022-12-25	WOS:000245831200013
J	Mangala, LS; Fok, JY; Zorrilla-Calancha, IR; Verma, A; Mehta, K				Mangala, L. S.; Fok, J. Y.; Zorrilla-Calancha, I. R.; Verma, A.; Mehta, K.			Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells	ONCOGENE			English	Article						metastasis; integrins; cell migration; invasion; transglutaminase; fibronectin	GELATIN-BINDING DOMAIN; SWISS 3T3 FIBROBLASTS; FOCAL-ADHESION KINASE; DRUG-RESISTANT; RETINOIC ACID; CROSS-LINKING; MCF-7 CELLS; IN-VITRO; FIBRONECTIN; MIGRATION	Distant metastasis is frequently observed in patients with breast cancer and is a major cause of cancer-related deaths in these patients. Currently, very little is known about the mechanisms that underlie the development of the metastatic phenotype in breast cancer cells. We previously found that metastatic breast cancer cells express high levels of tissue transglutaminase (TG2), but established no direct link between TG2 and metastasis. In this study, we hypothesized that TG2 plays a role in conferring the metastatic phenotype to breast cancer cells. The results obtained suggested that increased expression of TG2 in breast cancer cells contributes to their increased survival, invasion and motility. We further found that TG2 protein in a metastatic breast cancer MDA-MB231 cells was present on the cell surface in close association with integrins beta 1, beta 4 and beta 5. Downregulation of endogenous TG2 by small interfering RNA inhibited. bronectin (Fn)mediated cell attachment, survival and invasion. Conversely, ectopic expression of TG2 augmented invasion of breast cancer cells and attachment to Fn-coated surfaces. We conclude that TG2 expression in breast cancer cells plays an important role in the development of the metastatic phenotype.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Mehta, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 326,1515 Holcombe Blvd, Houston, TX 77030 USA.	kmehta@mdanderson.org			NCI NIH HHS [CA 16672-29, CA 092115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Akimov SS, 2001, J CELL SCI, V114, P2989; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Balklava Z, 2002, J BIOL CHEM, V277, P16567, DOI 10.1074/jbc.M109836200; Belkin AM, 2005, BLOOD, V105, P3561, DOI 10.1182/blood-2004-10-4089; Chandrashekar R, 1998, P NATL ACAD SCI USA, V95, P531, DOI 10.1073/pnas.95.2.531; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chen JSK, 2004, J CELL PHYSIOL, V200, P223, DOI 10.1002/jcp.20014; Chen JSK, 2002, BREAST CANCER RES TR, V71, P237, DOI 10.1023/A:1014461832403; Cordes N, 2003, INT J RADIAT BIOL, V79, P709, DOI 10.1080/09553000310001610240; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Han JA, 1999, J CANCER RES CLIN, V125, P89, DOI 10.1007/s004320050247; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Janiak A, 2006, MOL BIOL CELL, V17, P1606, DOI 10.1091/mbc.E05-06-0549; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Jiang DF, 2003, PROTEOMICS, V3, P724, DOI 10.1002/pmic.200300411; Jiang WG, 2003, ONCOL REP, V10, P2039; Joshi S, 2006, ONCOGENE, V25, P240, DOI 10.1038/sj.onc.1209027; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Leroy P, 2004, J LEUKOCYTE BIOL, V75, P680, DOI 10.1189/jlb.0503246; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Longtin R, 2004, J NATL CANCER I, V96, P6, DOI 10.1093/jnci/96.1.6; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehta K, 2005, PROG EXP TUMOR RES, V38, P1; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Mishra S, 2006, J BIOL CHEM, V281, P5532, DOI 10.1074/jbc.M506864200; Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; Mohan K, 2003, J IMMUNOL, V171, P3179, DOI 10.4049/jimmunol.171.6.3179; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; Parker BS, 2003, CANCER BIOL THER, V2, P14; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Priglinger SG, 2004, INVEST OPHTH VIS SCI, V45, P955, DOI 10.1167/iovs.03-0210; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Yoneda T, 2000, J Orthop Sci, V5, P75, DOI 10.1007/s007760050012; Zemskov EA, 2006, FRONT BIOSCI-LANDMRK, V11, P1057, DOI 10.2741/1863; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	47	121	123	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2459	2470		10.1038/sj.onc.1210035	http://dx.doi.org/10.1038/sj.onc.1210035			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043648				2022-12-25	WOS:000245831000006
J	Chauhan, D; Velankar, M; Brahmandam, M; Hideshima, T; Podar, K; Richardson, P; Schlossman, R; Ghobrial, I; Raje, N; Munshi, N; Anderson, KC				Chauhan, D.; Velankar, M.; Brahmandam, M.; Hideshima, T.; Podar, K.; Richardson, P.; Schlossman, R.; Ghobrial, I.; Raje, N.; Munshi, N.; Anderson, K. C.			A novel Bcl-2/Bcl-X-L/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; mitochondria; apoptosis; Bcl-2	BCL-2 FAMILY; INDUCED APOPTOSIS; CELLS; DEXAMETHASONE; ACTIVATION; MCL-1	Bcl-2 or Bcl-X-L confers resistance to chemotherapy in multiple myeloma ( MM). Here we characterized the effects of ABT-737, a potent small-molecule inhibitor of antiapoptotic proteins Bcl-2, Bcl-X-L and Bcl-w with markedly higher affinity than previously reported compounds, on human MM cells. ABT-737 induces apoptosis in MM cells, including those resistant to conventional therapy. Examination of purified patient MM cells demonstrated similar results, without significant toxicity against normal peripheral blood mononuclear cells and MM bone marrow stromal cells. Importantly, ABT-737 decreases the viability of bortezomib-, dexamethasone-(Dex) and thalidomide-refractory patient MM cells. Additionally, ABT-737 abrogates MM cell growth triggered by interleukin-6 or insulin-like growth factor-1. Mechanistic studies show that ABT-737-induced apoptosis is associated with activation of caspase-8, caspase-9 and caspase-3, followed by poly(ADP-ribose) polymerase cleavage. Combining ABT- 737 with proteasome inhibitor bortezomib, melphalan or dexamethasone induces additive anti-MM activity. Taken together, our study provides the rationale for clinical protocols evaluating ABT-737, alone and together with botezomib, mephalan or dexamethasone, to enhance MM cell killing, overcome drug resistance conferred by Bcl-2 and improve patient outcome in MM.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.	Kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [IP50CA10070, P0-1 CA 78373, R0-1 CA50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cory S, 2005, CANCER CELL, V8, P5, DOI 10.1016/j.ccr.2005.06.012; Dalton WS, 2002, CLIN CANCER RES, V8, P3643; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gazitt Y, 1998, INT J ONCOL, V13, P397; HARDIN J, 1994, BLOOD, V84, P3063; Jelinek DF, 1997, J IMMUNOL, V159, P487; Kluck RM, 1997, APOPTOSIS, V2, P337; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liu Q, 2003, BLOOD, V101, P4105, DOI 10.1182/blood-2002-10-3067; Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; van de Donk NWCJ, 2003, LEUKEMIA, V17, P211, DOI 10.1038/sj.leu.2402768; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu FH, 1997, BRIT J HAEMATOL, V97, P429, DOI 10.1046/j.1365-2141.1997.592708.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	27	177	183	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2374	2380		10.1038/sj.onc.1210028	http://dx.doi.org/10.1038/sj.onc.1210028			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016430				2022-12-25	WOS:000245466000013
J	Pazgier, M; Prahl, A; Hoover, DM; Lubkowski, J				Pazgier, Marzena; Prahl, Adam; Hoover, David M.; Lubkowski, Jacek			Studies of the biological properties of human beta-defensin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-DEFENSINS; CHEMOKINE RECEPTOR CCR6; ANTIMICROBIAL ACTIVITY; ALPHA-DEFENSINS; ANTIBACTERIAL ACTIVITIES; INDUCIBLE PEPTIDE; DISULFIDE BONDS; INNATE IMMUNITY; LIGAND-BINDING; MESSENGER-RNA	Defensins are small (30 - 45 amino acid residues) cationic proteins with broad antimicrobial activity against many bacteria and fungi, some enveloped viruses, and other activities such as chemoattraction of a range of different cell types to the sites of inflammation. These proteins represent attractive targets for developing novel antimicrobial agents and modulators of immune responses with therapeutic applicability. In this report, we present the results of functional and structural studies of 26 single-site mutants of human beta-defensin 1 (hBD1). All mutants were assayed for antimicrobial activity against Escherichia coli ( ATCC strain 25922) and for chemotactic activity with CCR6-transfected HEK293 cells. To analyze the structural implications of mutagenesis and to verify the correctness of the disulfide connectivity, we used x-ray crystallography to conduct complete structural studies for 10 mutants in which the topology of disulfides was the same as in the native hBD1. Mutations did not induce significant changes of the tertiary structure, suggesting that the observed alterations of biological properties of the mutants were solely associated with changes in the respective side chains. We found that cationic residues located near the C terminus (Arg(29), Lys(31), Lys(33), and Lys(36)) of hBD1 define most of the anti-E. coli in vitro activity of this protein. In turn, nearly all mutations altering the CCR6-mediated chemotaxis are located at one area of the protein, defined by the N-terminal alpha-helical region (Asp(1) ... Ser(8)) and a few topologically adjacent residues (Lys(22), Arg(29), and Lys(33)). These experimental results allow for the first time drafting of the CCR6-epitope for a defensin molecule.	NCI, Macromol Crystallog Lab, Program Struct Biol, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lubkowski, J (corresponding author), NCI, Macromol Crystallog Lab, Program Struct Biol, NIH, 7th St,Bldg 539,POB B,Rm 141B, Frederick, MD 21702 USA.	jacek@ncifcrf.gov	Pazgier, Marzena/B-7295-2012; Prahl, Adam/H-7654-2014	Prahl, Adam/0000-0001-7663-6548	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abiko Y, 2003, J DERMATOL SCI, V31, P225, DOI 10.1016/S0923-1811(03)00007-0; Ai LS, 2004, J BIOMED SCI, V11, P818, DOI 10.1159/000081829; Ai LS, 2002, BIOCHEMISTRY-US, V41, P8332, DOI 10.1021/bi025855y; Antcheva N, 2004, ANTIMICROB AGENTS CH, V48, P685, DOI 10.1128/AAC.48.2.685-688.2004; Bauer F, 2001, PROTEIN SCI, V10, P2470, DOI 10.1110/ps.ps.24401; Beisswenger C, 2005, CURR PROTEIN PEPT SC, V6, P255, DOI 10.2174/1389203054065428; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Braff MH, 2005, J INVEST DERMATOL, V125, P9, DOI 10.1111/j.0022-202X.2004.23587.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campopiano DJ, 2004, J BIOL CHEM, V279, P48671, DOI 10.1074/jbc.M404690200; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; FALK W, 1980, INFECT IMMUN, V29, P953; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Garcia JRC, 2001, CELL TISSUE RES, V306, P257, DOI 10.1007/s004410100433; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200; Hoover DM, 2003, ANTIMICROB AGENTS CH, V47, P2804, DOI 10.1128/AAC.47.9.2804-2809.2003; Hoover DM, 2002, J BIOL CHEM, V277, P37647, DOI 10.1074/jbc.M203907200; Kluver E, 2005, BIOCHEMISTRY-US, V44, P9804, DOI 10.1021/bi050272k; Krishnakumari V, 2003, BIOCHEMISTRY-US, V42, P9307, DOI 10.1021/bi034403y; Liao F, 1997, BIOCHEM BIOPH RES CO, V236, P212, DOI 10.1006/bbrc.1997.6936; Mandal M, 2002, PEPTIDES, V23, P413, DOI 10.1016/S0196-9781(01)00628-3; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1992, GRASP MANUAL; Niyonsaba F, 2004, IMMUNOLOGY, V111, P273, DOI 10.1111/j.0019-2805.2004.01816.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pazgier M, 2006, CELL MOL LIFE SCI, V63, P1294, DOI 10.1007/s00018-005-5540-2; Pazgier M, 2006, PROTEIN EXPRES PURIF, V49, P1, DOI 10.1016/j.pep.2006.05.004; Perez-Canadillas JM, 2001, J BIOL CHEM, V276, P28372, DOI 10.1074/jbc.M103121200; Raj PA, 2000, BIOCHEM J, V347, P633, DOI 10.1042/0264-6021:3470633; Rodriguez-Jimenez FJ, 2003, GENOMICS, V81, P175, DOI 10.1016/S0888-7543(02)00034-4; Rossi DL, 1997, J IMMUNOL, V158, P1033; Sahl HG, 2005, J LEUKOCYTE BIOL, V77, P466, DOI 10.1189/jlb.0804452; Sawai MV, 2001, BIOCHEMISTRY-US, V40, P3810, DOI 10.1021/bi002519d; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Schulz A, 2005, BIOPOLYMERS, V80, P34, DOI 10.1002/bip.20193; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Selsted ME, 2004, CURR PROTEIN PEPT SC, V5, P365, DOI 10.2174/1389203043379459; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Sun LL, 2005, J VIROL, V79, P14318, DOI 10.1128/JVI.79.22.14318-14329.2005; Takeuchi K, 2004, J BIOL CHEM, V279, P4981, DOI 10.1074/jbc.M307815200; Tanabe H, 2004, J BIOL CHEM, V279, P11976, DOI 10.1074/jbc.M310251200; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Varoga D, 2005, ARTHRITIS RHEUM-US, V52, P1736, DOI 10.1002/art.21090; Varona R, 1998, FEBS LETT, V440, P188, DOI 10.1016/S0014-5793(98)01450-1; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Xie C, 2005, PEPTIDES, V26, P2377, DOI 10.1016/j.peptides.2005.06.002; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yudin AI, 2005, BIOL REPROD, V73, P1243, DOI 10.1095/biolreprod.105.042432	58	63	66	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					1819	1829		10.1074/jbc.M607210200	http://dx.doi.org/10.1074/jbc.M607210200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17071614	hybrid			2022-12-25	WOS:000243451300033
J	Paduraru, C; Spiridon, L; Yuan, WM; Bricard, G; Valencia, X; Porcelli, SA; Illarionov, PA; Besra, GS; Petrescu, SM; Petrescu, AJ; Cresswell, P				Paduraru, Crina; Spiridon, Laurentiu; Yuan, Weiming; Bricard, Gabriel; Valencia, Xavier; Porcelli, Steven A.; Illarionov, Petr A.; Besra, Gurdyal S.; Petrescu, Stefana M.; Petrescu, Andrei-Jose; Cresswell, Peter			An N-linked glycan modulates the interaction between the CD1d heavy chain and beta(2)-microglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; ENDOPLASMIC-RETICULUM; NKT CELLS; ANTIGEN PRESENTATION; CRYSTAL-STRUCTURE; T-CELLS; ALPHA-GALACTOSYLCERAMIDE; LIPID ANTIGEN; MOUSE CD1; MOLECULES	Human CD1d molecules consist of a transmembrane CD1 (cluster of differentiation 1) heavy chain in association with beta(2)-microglobulin (beta(2)m). Assembly occurs in the endoplasmic reticulum ( ER) and involves the initial glycan-dependent association of the free heavy chain with calreticulin and calnexin and the thiol oxidoreductase ERp57. Folding and disulfide bond formation within the heavy chain occurs prior to beta 2m binding. There are four N-linked glycans on the CD1d heavy chain, and we mutated them individually to ascertain their importance for the assembly and function of CD1d-beta(2)m heterodimers. None of the four were indispensable for assembly or the ability to bind alpha-galactosyl ceramide and to present it to human NKT cells. Nor were any required for the CD1d molecule to bind and present alpha-galactosyl ceramide after lysosomal processing of a precursor lipid, galactosyl-(alpha 1-2)-galactosyl ceramide. However, one glycan, glycan 2 at Asn-42, proved to be of particular importance for the stability of the CD1d-beta(2)m heterodimer. A mutant CD1d heavy chain lacking glycan 2 assembled with beta(2)m and transported from the ER more rapidly than wild-type CD1d and dissociated more readily from beta(2)m upon exposure to detergents. A mutant expressing only glycan 1 dissociated completely from beta(2)m upon exposure to the detergent Triton X-100, whereas a mutant expressing only glycan 2 at Asn-42 was more stable. In addition, glycan 2 was not processed efficiently to the complex form in mature wild-type CD1d molecules. Modeling the glycans on the published structure indicated that glycan 2 interacts significantly with both the CD1d heavy chain and beta(2)m, which may explain these unusual properties.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Inst Biochem, Bucharest 060031 17, Romania; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Birmingham, Sch Biosci, Dept Microbial Physiol & Chem, Birmingham B15 2TT, W Midlands, England	Howard Hughes Medical Institute; Yale University; Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; Yeshiva University; Albert Einstein College of Medicine; University of Birmingham	Cresswell, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 300 Cedar St,POB 208011, New Haven, CT 06520 USA.	peter.cresswell@yale.edu	Spiridon, Laurentiu N/A-3352-2017; Petrescu, Stefana/AAJ-9505-2021; Petrescu, Stefana M/I-9240-2012; Petrescu, Andrei-Jose J/G-4576-2016	Spiridon, Laurentiu N/0000-0003-3080-1610; Petrescu, Stefana/0000-0002-4047-0811; Petrescu, Stefana M/0000-0002-4047-0811; Petrescu, Andrei-Jose J/0000-0002-4478-3946; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059167, P30AI051519, R01AI045889] Funding Source: NIH RePORTER; Medical Research Council [G0400421] Funding Source: Medline; NCI NIH HHS [CA13330] Funding Source: Medline; NIAID NIH HHS [AI45889, AI059167, AI051519, AI49833] Funding Source: Medline; MRC [G0400421] Funding Source: UKRI	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Appenzeller-Herzog C, 2005, MOL BIOL CELL, V16, P1258, DOI 10.1091/mbc.E04-08-0708; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; Brozovic S, 2004, NAT MED, V10, P535, DOI 10.1038/nm1043; Burdin N, 1998, J IMMUNOL, V161, P3271; De Silva AD, 2002, J IMMUNOL, V168, P723, DOI 10.4049/jimmunol.168.2.723; Dougan SK, 2005, J EXP MED, V202, P529, DOI 10.1084/jem.20050183; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Exley M, 2000, IMMUNOLOGY, V100, P37, DOI 10.1046/j.1365-2567.2000.00001.x; Gadola SD, 2002, NAT IMMUNOL, V3, P721, DOI 10.1038/ni821; Giabbai B, 2005, J IMMUNOL, V175, P977, DOI 10.4049/jimmunol.175.2.977; Gumperz JE, 2006, TRAFFIC, V7, P2, DOI 10.1111/j.1600-0854.2005.00364.x; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HSIEH P, 1983, J BIOL CHEM, V258, P2555; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; Jayawardena-Wolf J, 2001, IMMUNITY, V15, P897, DOI 10.1016/S1074-7613(01)00240-0; Kang SJ, 2004, NAT IMMUNOL, V5, P175, DOI 10.1038/ni1034; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; Kang SJ, 2002, EMBO J, V21, P1650, DOI 10.1093/emboj/21.7.1650; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Koch M, 2005, NAT IMMUNOL, V6, P819, DOI 10.1038/ni1225; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039; Major AS, 2006, TRENDS MOL MED, V12, P270, DOI 10.1016/j.molmed.2006.04.004; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Park JJ, 2004, P NATL ACAD SCI USA, V101, P1022, DOI 10.1073/pnas.0307847100; Prigozy TI, 2001, SCIENCE, V291, P664, DOI 10.1126/science.291.5504.664; Rauch J, 2003, J BIOL CHEM, V278, P47508, DOI 10.1074/jbc.M308089200; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Spada FM, 2000, EUR J IMMUNOL, V30, P3468, DOI 10.1002/1521-4141(2000012)30:12<3468::AID-IMMU3468>3.0.CO;2-C; Sriram V, 2005, EUR J IMMUNOL, V35, P1692, DOI 10.1002/eji.200526157; van den Elzen P, 2005, NATURE, V437, P906, DOI 10.1038/nature04001; Wormald MR, 2002, CHEM REV, V102, P371, DOI 10.1021/cr990368i; Wu D, 2005, P NATL ACAD SCI USA, V102, P1351, DOI 10.1073/pnas.0408696102; Yuan WM, 2006, NAT IMMUNOL, V7, P835, DOI 10.1038/ni1364; Zajonc DM, 2005, J EXP MED, V202, P1517, DOI 10.1084/jem.20051625; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339; Zhou DP, 2004, SCIENCE, V303, P523, DOI 10.1126/science.1092009	40	26	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40369	40378		10.1074/jbc.M608518200	http://dx.doi.org/10.1074/jbc.M608518200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17071611	hybrid			2022-12-25	WOS:000243033900067
J	Johswich, K; Martin, M; Thalmann, J; Rheinheimer, C; Monk, PN; Klos, A				Johswich, Kay; Martin, Myriam; Thalmann, Jessica; Rheinheimer, Claudia; Monk, Peter N.; Klos, Andreas			Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLATION-STIMULATING PROTEIN; HUMAN-MELANOMA CELLS; 3RD COMPONENT; CHEMOATTRACTANT RECEPTOR; PROCATHEPSIN-L; U937 CELLS; IFN-GAMMA; COMPLEMENT; C5A; PATHWAY	During complement activation the pro-inflammatory anaphylatoxins C3a and C5a are generated, which interact with the C3a receptor and C5a receptor (CD88), respectively. C5a and its degradation product C5a-des-Arg(74) also bind to the C5a receptor-like 2 (C5L2). C3a and C3a-des-Arg(77), also called acylation-stimulating protein, augment triglyceride synthesis and glucose uptake in adipocytes and skin fibroblasts. Based on data obtained using transfected HEK293 and RBL cells, C5L2 is additionally proposed as a functional receptor for C3a and C3a-des-Arg(77). Here we use I-125-ligand binding assays and flow cytometry with fluorescently labeled ligands to demonstrate that neither C3a nor C3a-des-Arg(77) binds to C5L2. C5L2 expression and its regulation are investigated on various cell lines by a novel C5L2-restricted binding assay and quantitative real time PCR. Dibutyryl cAMP and interferon-gamma induce up-regulation of this receptor on myeloblastic cell lines (U937 and HL-60), whereas tumor necrosis factor-alpha (TNF-alpha) has no effect. In contrast, epithelial HeLa cells are found to constitutively express C5L2 but not the C5a receptor. In HeLa cells, interferon-gamma and TNF-alpha drastically reduce C5L2 expression. No C5a-dependent Ca2+ signaling is observed even in these cells endogenously expressing C5L2. Taken together, C5L2 is not a receptor for C3a or C3a-des-Arg(77). Thus, this receptor is unlikely to be directly involved in lipid metabolism. Instead, the identification of stimuli modifying C5L2 expression indicates that C5L2 is a highly regulated scavenger receptor for C5a and C5a-des-Arg(74).	Hannover Med Sch, Dept Med Microbiol, D-30625 Hannover, Germany; Sch Med & Biomed Sci, Dept Neurol, Sheffield S10 2RX, S Yorkshire, England	Hannover Medical School	Klos, A (corresponding author), Hannover Med Sch, Dept Med Microbiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Klos.Andreas@mh-hannover.de	Monk, Peter/C-6155-2008	Monk, Peter/0000-0003-4637-3059; Martin, Myriam/0000-0003-1526-8678	Wellcome Trust [72231] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDO A, 1995, J LIPID RES, V36, P1415; Burg M, 1996, J IMMUNOL, V157, P5574; BURG M, 1995, J IMMUNOL, V155, P4419; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; CHARRIAUTMARLANGUE C, 1986, BIOCHEM BIOPH RES CO, V140, P1113, DOI 10.1016/0006-291X(86)90750-3; CHOY LN, 1992, J BIOL CHEM, V267, P12736; Cianflone K, 1999, SEMIN CELL DEV BIOL, V10, P31, DOI 10.1006/scdb.1998.0272; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; Frade R, 1998, CANCER RES, V58, P2733; Gao HW, 2005, FASEB J, V19, P1003, DOI 10.1096/fj.04-3424fje; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Huber-Lang M, 2005, J IMMUNOL, V174, P1104, DOI 10.4049/jimmunol.174.2.1104; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Jean D, 1995, BIOCHEM J, V312, P961, DOI 10.1042/bj3120961; Kalant D, 2005, J BIOL CHEM, V280, P23936, DOI 10.1074/jbc.M406921200; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; Lee DK, 2001, MOL BRAIN RES, V86, P13, DOI 10.1016/S0169-328X(00)00242-4; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Maslowska M, 1997, J LIPID RES, V38, P1; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; OLLERT MW, 1990, J IMMUNOL, V144, P3862; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Tao YH, 1997, BBA-LIPID LIPID MET, V1344, P221, DOI 10.1016/S0005-2760(96)00144-0; WHITE RT, 1992, J BIOL CHEM, V267, P9210	26	53	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39088	39095		10.1074/jbc.M609734200	http://dx.doi.org/10.1074/jbc.M609734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17068344	hybrid			2022-12-25	WOS:000242898700015
J	Liu, G; Clement, LC; Kanwar, YS; Avila-Casado, C; Chugh, SS				Liu, Gang; Clement, Lionel C.; Kanwar, Yashpal S.; Avila-Casado, Carmen; Chugh, Sumant S.			ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLIT DIAPHRAGM; ZINC-FINGERS; MUTATIONS; LMX1B; KIDNEY; FAMILY; MODEL; WT1	Transcriptional regulation of podocyte gene expression in primary glomerular disease is poorly understood. In this study, we demonstrate a prominent role of members of the ZHX (zinc fingers and homeoboxes) family of proteins in regulating podocyte gene expression during the development of nephrotic syndrome. While studying mechanisms of glomerular disease, rat ZHX3 was cloned from a down-regulated gene fragment; its cellular localization, DNA binding, and transcriptional repressor properties were characterized; and its ability to influence podocyte gene expression directly or via ZHX1 and ZHX2 was studied. In eukaryotic promoters, ZHX3 bound to the CdxA binding motif. ZHX proteins were mostly sequestered in the non-nuclear compartment in the normal in vivo podocyte by virtue of heterodimer formation, and loss of heterodimerization was associated with entry into the nucleus. In experimental minimal change disease, ZHX3 was transiently down-regulated prior to the onset of proteinuria, and recovery of expression was associated with migration of ZHX3 protein into the nucleus and the development of proteinuria. This expression pattern mirrored the increased nuclear ZHX3 expression noted in vivo in the podocytes in human minimal change disease biopsies. In vitro, migration of ZHX3 protein into the nucleus during recovery from transient ZHX3 knockdown reproduced the gene expression profile of in vivo minimal change disease. Severe sustained knockdown of ZHX3 caused down-regulation of genes involved in focal sclerosis, including WT1, mediated mostly by increased nuclear entry of ZHX2 and ZHX1. In summary, ZHX proteins are major transcriptional mediators of podocyte disease.	Northwestern Univ, Div Neurol, Feinburg Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Dept Pathol, Feinburg Sch Med, Chicago, IL 60611 USA; Inst Nacl Cardiol Ignacio Chavez, Dept Pathol, Mexico City 14050, DF, Mexico	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; National Institute of Cardiology - Mexico	Chugh, SS (corresponding author), Northwestern Univ, Div Neurol, Feinburg Sch Med, Dept Med, Tarry 4-753,320 E Super, Chicago, IL 60611 USA.	s-chugh@northwestern.edu	Liu, Gang/M-4073-2014	Liu, Gang/0000-0002-4536-8453	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK068203, K08DK061275] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK61275, DK068203] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Barisoni L, 2000, KIDNEY INT, V58, P173, DOI 10.1046/j.1523-1755.2000.00152.x; Charron M, 2003, BIOL REPROD, V68, P1641, DOI 10.1095/biolreprod.102.011619; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; Chugh S, 2001, KIDNEY INT, V59, P601, DOI 10.1046/j.1523-1755.2001.059002601.x; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; GLASSER RJ, 1977, LAB INVEST, V36, P519; Hamano Y, 2002, J BIOL CHEM, V277, P31154, DOI 10.1074/jbc.M204806200; Hudson BG, 2004, J AM SOC NEPHROL, V15, P2514, DOI 10.1097/01.ASN.0000141462.00630.76; Kawata H, 2003, GENE, V323, P133, DOI 10.1016/j.gene.2003.09.013; Liu G, 2003, J CLIN INVEST, V112, P209, DOI 10.1172/JCI200318242; Miner JH, 2002, J CLIN INVEST, V109, P1065, DOI 10.1172/JCi200213954; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Quaggin SE, 1999, DEVELOPMENT, V126, P5771; Sadl VS, 2002, DEV BIOL, V249, P16, DOI 10.1006/dbio.2002.0751; Yamada K, 2003, BIOCHEM J, V373, P167, DOI 10.1042/BJ20021866; Yang YX, 1999, AM J PATHOL, V154, P181, DOI 10.1016/S0002-9440(10)65264-9	17	46	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39681	39692		10.1074/jbc.M606664200	http://dx.doi.org/10.1074/jbc.M606664200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17056598	hybrid			2022-12-25	WOS:000242898700075
J	Albee, AJ; Tao, W; Wiese, C				Albee, Alison J.; Tao, Wei; Wiese, Christiane			Phosphorylation of maskin by aurora-A is regulated by RanGTP and importin beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC-SPINDLE; MICROTUBULE NUCLEATION; BINDING PROTEIN-1; EGG EXTRACTS; D-TACC; CENTROSOME; COMPLEX; TRANSPORT; KINASE; ORGANIZATION	Mitotic spindle assembly in Xenopus egg extracts is regulated at least in part by importin beta and its regulator, the small GTPase, Ran. RanGTP stabilizes microtubules near the chromosomes during spindle assembly by selectively releasing spindle assembly factors from inhibition by importin alpha/beta in the vicinity of the chromosomes. Several spindle assembly factors are regulated in this manner. We identified maskin, the Xenopus member of the transforming acidic coiled coil family of proteins, as a potential candidate in a two-step affinity chromatography approach designed to uncover additional downstream targets of importin alpha/beta in mitosis. Here, we show that although maskin lacks a canonical nuclear localization sequence, it binds importin beta in a RanGTP-regulated manner. We further show that importin beta inhibits the regulatory phosphorylation of maskin by Aurora-A. This suggests a novel mechanism by which importin beta regulates the activity of a spindle assembly factor.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wiese, C (corresponding author), 433 Babcock Dr, Madison, WI 53706 USA.	wiese@biochem.wisc.edu						Andersen SSL, 1997, J CELL BIOL, V139, P975, DOI 10.1083/jcb.139.4.975; Barros TP, 2005, J CELL BIOL, V170, P1039, DOI 10.1083/jcb.200504097; Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Blower MD, 2005, CELL, V121, P223, DOI 10.1016/j.cell.2005.02.016; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Carazo-Salas RE, 2001, NAT CELL BIOL, V3, P228, DOI 10.1038/35060009; Caudron M, 2005, SCIENCE, V309, P1373, DOI 10.1126/science.1115964; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Desai A, 1999, METHOD CELL BIOL, V61, P385; Di Fiore B, 2004, CELL CYCLE, V3, P305; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Ducat D, 2004, EXP CELL RES, V301, P60, DOI 10.1016/j.yexcr.2004.08.016; Ems-McClung SC, 2004, MOL BIOL CELL, V15, P46, DOI 10.1091/mbc.E03-07-0454; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Harlow E., 1988, ANTIBODIES LAB MANUA; Kalab P, 2006, NATURE, V440, P697, DOI 10.1038/nature04589; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Keryer G, 2003, MOL BIOL CELL, V14, P4260, DOI 10.1091/mbc.E02-11-0773; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Le Bot N, 2003, CURR BIOL, V13, P1499, DOI 10.1016/S0960-9822(03)00577-3; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Maresca TJ, 2005, CURR BIOL, V15, P1755, DOI 10.1016/j.cub.2005.08.049; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; O'Brien LL, 2005, MOL BIOL CELL, V16, P2836, DOI 10.1091/mbc.e04-10-0926; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Pascreau G, 2005, J BIOL CHEM, V280, P13415, DOI 10.1074/jbc.M410584200; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Ribbeck K, 2006, MOL BIOL CELL, V17, P2646, DOI 10.1091/mbc.E05-12-1178; Schatz CA, 2003, EMBO J, V22, P2060, DOI 10.1093/emboj/cdg195; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Stewart M, 2003, SCIENCE, V302, P1513, DOI 10.1126/science.1092863; Still IH, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-16; Trieselmann N, 2003, J CELL SCI, V116, P4791, DOI 10.1242/jcs.00798; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Wiese C, 2006, J CELL SCI, V119, P4143, DOI 10.1242/jcs.03226; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Zheng YX, 2004, ANNU REV CELL DEV BI, V20, P867, DOI 10.1146/annurev.cellbio.20.012103.094648	58	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38293	38301		10.1074/jbc.M607203200	http://dx.doi.org/10.1074/jbc.M607203200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17057251	hybrid			2022-12-25	WOS:000242709500022
J	Chen, XW; Inoue, M; Hsu, SC; Saltiel, AR				Chen, Xiao-Wei; Inoue, Mayumi; Hsu, Shu C.; Saltiel, Alan R.			RalA-exocyst-dependent recycling endosome trafficking is required for the completion of cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SEPARATION; MEMBRANE; PROTEIN; SURFACE; COMPLEXES; EFFECTOR; DELIVERY; MIDBODY; GTPASES; EXIT	In eukaryotic cells, recycling endosome-mediated trafficking contributes to the completion of cytokinesis, in a manner under the control of the centrosome. We report that the exocyst complex and its interacting GTPase RalA play a critical role in this polarized trafficking process. RalA resides in the recycling endosome and relocates from the pericentrosomal region to key cytokinetic structures including the cleavage furrow, and later, the abscission site. This event is coupled to the dynamic redistribution of the exocyst proteins. These associate with the centrosome in interphase and concentrate on the central spindle/midbody during cytokinesis. Disruption of RalA-exocyst function leads to cytokinesis failure in late stages, particularly abscission, resembling the cytokinesis defects induced by loss of centrosome function. These data suggest that RalA and the exocyst may regulate vesicle delivery to the centrosome-related abscission site during the terminal stage of cytokinesis, implicating RalA as a critical regulator of cell cycle progression.	Univ Michigan, Med Ctr, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Inst Life Sci, Ann Arbor, MI 48109 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Rutgers State University New Brunswick	Saltiel, AR (corresponding author), Univ Michigan, Med Ctr, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.	saltiel@umich.edu	Chen, Xiaowei/F-7026-2014; Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Chen, Xiao-Wei/0000-0001-6466-6248	NIDDK NIH HHS [R01 DK 061618] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061618] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albertson R, 2005, TRENDS CELL BIOL, V15, P92, DOI 10.1016/j.tcb.2004.12.008; Canman Julie C, 2004, J Cell Biol, V166, P943, DOI 10.1083/jcb.200409019; Dobbelaere J, 2004, SCIENCE, V305, P393, DOI 10.1126/science.1099892; Dong G, 2005, NAT STRUCT MOL BIOL, V12, P1094, DOI 10.1038/nsmb1017; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Folsch H, 2003, J CELL BIOL, V163, P351, DOI 10.1083/jcb.200309020; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Gromley A, 2005, CELL, V123, P75, DOI 10.1016/j.cell.2005.07.027; Gromley A, 2003, J CELL BIOL, V161, P535, DOI 10.1083/jcb.200301105; Hickson GRX, 2003, MOL BIOL CELL, V14, P2908, DOI 10.1091/mbc.E03-03-0160; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Jin RS, 2005, EMBO J, V24, P2064, DOI 10.1038/sj.emboj.7600699; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Prigent M, 2003, J CELL BIOL, V163, P1111, DOI 10.1083/jcb.200305029; Quaroni A, 1999, J CELL SCI, V112, P707; Reichl EM, 2005, TRENDS CELL BIOL, V15, P200, DOI 10.1016/j.tcb.2005.02.004; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Sivaram MVS, 2005, BIOCHEMISTRY-US, V44, P6302, DOI 10.1021/bi048008z; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Strickland LI, 2004, TRENDS CELL BIOL, V14, P115, DOI 10.1016/j.tcb.2004.01.006; Thompson HM, 2004, NAT CELL BIOL, V6, P335, DOI 10.1038/ncb1112; Thompson HM, 2002, CURR BIOL, V12, P2111, DOI 10.1016/S0960-9822(02)01390-8; Wang HY, 2003, GENETICS, V164, P1323; Wang HY, 2002, MOL BIOL CELL, V13, P515, DOI 10.1091/mbc.01-11-0542; Wilson GM, 2005, MOL BIOL CELL, V16, P849, DOI 10.1091/mbc.e04-10-0927; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200	38	75	77	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38609	38616		10.1074/jbc.M512847200	http://dx.doi.org/10.1074/jbc.M512847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17028198	hybrid			2022-12-25	WOS:000242709500056
J	Rey, O; Young, SH; Papazyan, R; Shapiro, MS; Rozengurt, E				Rey, Osvaldo; Young, Steven H.; Papazyan, Romeo; Shapiro, Mark S.; Rozengurt, Enrique			Requirement of the TRPC1 cation channel in the generation of transient Ca2+ oscillations by the calcium-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; STORE-OPERATED CHANNELS; CA2+-SENSING RECEPTOR; SPECIFICITY; ALPHA; ENTRY; PATHWAYS; FEEDBACK; INFLUX	The calcium-sensing receptor (CaR) is an allosteric protein that responds to extracellular Ca2+ ([Ca2+](o)) and aromatic amino acids with the production of different patterns of oscillations in intracellular Ca2+ concentration ([Ca2+](i)). An increase in [Ca2+] o stimulates phospholipase C-mediated production of inositol 1,4,5-trisphosphate and causes sinusoidal oscillations in [Ca2+](i). Conversely, aromatic amino acid-induced CaR activation does not stimulate phospholipase C but engages an unidentified signaling mechanism that promotes transient oscillations in [Ca2+](i). We show here that the [Ca2+](i) oscillations stimulated by aromatic amino acids were selectively abolished by TRPC1 down-regulation using either a pool of small inhibitory RNAs (siRNAs) or two different individual siRNAs that targeted different coding regions of TRPC1. Furthermore, [Ca2+](i) oscillations stimulated by aromatic amino acids were also abolished by inhibition of TRPC1 function with an antibody that binds the pore region of the channel. We also show that aromatic amino acid-stimulated [Ca2+](i) oscillations can be prevented by protein kinase C (PKC) inhibitors or siRNA-mediated PKC alpha down-regulation and impaired by either calmodulin antagonists or by the expression of a dominant-negative calmodulin mutant. We propose a model for the generation of CaR-mediated transient [Ca2+](i) oscillations that integrates its stimulation by aromatic amino acids with TRPC1 regulation by PKC and calmodulin.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Digest Dis Res Ctr,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; University of Texas Health San Antonio	Rey, O (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Digest Dis Res Ctr,Jonsson Comprehens Canc Ctr, 900 Vet Ave,Warren Hall Rm 11-147, Los Angeles, CA 90095 USA.	orey@mednet.ucla.edu		Rey, Osvaldo/0000-0003-1575-9864	NCI NIH HHS [K01 CA 097956] Funding Source: Medline; NIDCR NIH HHS [DE 55003] Funding Source: Medline; NIDDK NIH HHS [DK 56930, P30 DK 41301] Funding Source: Medline; NINDS NIH HHS [R01 NS 043394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA097956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, P30DK041301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Ahmmed GU, 2004, J BIOL CHEM, V279, P20941, DOI 10.1074/jbc.M313975200; Albert AP, 2002, J PHYSIOL-LONDON, V544, P113, DOI 10.1113/jphysiol.2002.022574; Beech DJ, 2005, PFLUG ARCH EUR J PHY, V451, P53, DOI 10.1007/s00424-005-1441-3; Beech DJ, 2003, CELL CALCIUM, V33, P433, DOI 10.1016/S0143-4160(03)00054-X; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Corbalan-Garcia S, 2003, J BIOL CHEM, V278, P4972, DOI 10.1074/jbc.M209385200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Evans JH, 2006, MOL BIOL CELL, V17, P56, DOI 10.1091/mbc.e05-06-0499; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; Geibel J, 2006, P NATL ACAD SCI USA, V103, P9390, DOI 10.1073/pnas.0602996103; Hebert SC, 1997, J EXP BIOL, V200, P295; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Kifor O, 2001, AM J PHYSIOL-RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Manning AT, 2006, EJSO-EUR J SURG ONC, V32, P693, DOI 10.1016/j.ejso.2006.03.047; Marin-Vicente C, 2005, MOL BIOL CELL, V16, P2848, DOI 10.1091/mbc.E05-01-0067; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; Mun HC, 2005, J BIOL CHEM, V280, P29067, DOI 10.1074/jbc.M500002200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Putney JW, 2001, J CELL SCI, V114, P2223; Quarles LD, 2003, CURR OPIN NEPHROL HY, V12, P349, DOI 10.1097/00041552-200307000-00002; REITWIESER GE, 2001, AM J PHYSIOL, V280, pC1412; Rey O, 2005, J BIOL CHEM, V280, P22875, DOI 10.1074/jbc.M503455200; Rosado JA, 2002, J BIOL CHEM, V277, P42157, DOI 10.1074/jbc.M207320200; Shuttleworth TJ, 2003, BIOCHEM SOC T, V31, P916; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; TANAKA T, 1980, J BIOL CHEM, V255, P1078; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Xu SZ, 2005, BRIT J PHARMACOL, V145, P405, DOI 10.1038/sj.bjp.0706197; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821; Young SH, 2002, J BIOL CHEM, V277, P46871, DOI 10.1074/jbc.M207083200; Young SH, 2002, AM J PHYSIOL-CELL PH, V282, pC1414, DOI 10.1152/ajpcell.00432.2001; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200; Zeng FN, 2004, J PHYSIOL-LONDON, V559, P739, DOI 10.1113/jphysiol.2004.065391; Zhang ZX, 2002, J BIOL CHEM, V277, P33736, DOI 10.1074/jbc.M200978200	47	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38730	38737		10.1074/jbc.M605956200	http://dx.doi.org/10.1074/jbc.M605956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046820	hybrid			2022-12-25	WOS:000242709500071
J	Rodriguez, P; Mitton, B; Waggoner, JR; Kranias, EG				Rodriguez, Patricia; Mitton, Bryan; Waggoner, Jason R.; Kranias, Evangelia G.			Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASED EXPRESSION; RABBIT; ISOFORMS; RAT	Human and experimental heart failure is characterized by increases in type-1 protein phosphatase activity, which may be partially attributed to inactivation of its endogenous regulator, protein phosphatase inhibitor-1. Inhibitor-1 represents a nodal integrator of two major second messenger pathways, adenosine 3', 5'-cyclic monophosphate (cAMP) and calcium, which mediate its phosphorylation at threonine 35 and serine 67, respectively. Here, using recombinant inhibitor-1 wild-type and mutated proteins, we identified a novel phosphorylation site in inhibitor-1, threonine 75. This phosphoamino acid was phosphorylated in vitro by protein kinase C alpha independently and to the same extent as serine 67, the previous protein kinase C alpha-identified site. Generation of specific antibodies for the phosphorylated and dephosphorylated threonine 75 revealed that this site is phosphorylated in rat and dog hearts. Adenoviral-mediated expression of the constitutively phosphorylated threonine 75 inhibitor-1 in isolated myocytes was associated with specific stimulation of type-1 protein phosphatase activity and marked inhibition of the sarcoplasmic calcium pump affinity for calcium, resulting in depressed contractility. Thus, phosphorylation of inhibitor-1 at threonine 75 represents a new mechanism of cardiac contractility regulation, partially through the alteration of sarcoplasmic reticulum calcium transport activity.	Univ Cincinnati, Dept Pharmacol & Cell Biophys, Coll Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kranias, EG (corresponding author), Univ Cincinnati, Dept Pharmacol & Cell Biophys, Coll Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	kraniaeg@email.uc.edu		Waggoner, Jason/0000-0002-2485-4778	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026057, R01HL064018, P50HL077101, R37HL026057] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 77101, HL 64018, HL 26057] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Braz JC, 2004, NAT MED, V10, P248, DOI 10.1038/nm1000; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; El-Armouche A, 2004, CARDIOVASC RES, V61, P87, DOI 10.1016/j.cardiores.2003.11.005; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Fan GC, 2004, CIRC RES, V94, P1474, DOI 10.1161/01.RES.0000129179.66631.00; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; Gergs U, 2004, J BIOL CHEM, V279, P40827, DOI 10.1074/jbc.M405770200; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KISS E, 1995, CIRC RES, V77, P759, DOI 10.1161/01.RES.77.4.759; LOWENSTEIN PR, 1995, BRAIN RES, V676, P80, DOI 10.1016/0006-8993(95)00091-4; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MACDOUGALL LK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P218, DOI 10.1016/0167-4889(89)90164-X; NEUMANN J, 1991, CIRC RES, V69, P1450, DOI 10.1161/01.RES.69.6.1450; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Neumann J., 2002, BASIC RES CARDIOL S1, V97, pI91, DOI DOI 10.1007/S003950200036; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; Pathak A, 2005, CIRC RES, V96, P756, DOI 10.1161/01.RES.0000161256.85833.fa; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Wang JW, 2003, AM J PHYSIOL-HEART C, V284, pH2277, DOI 10.1152/ajpheart.00142.2002	29	27	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38599	38608		10.1074/jbc.M604139200	http://dx.doi.org/10.1074/jbc.M604139200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046826	hybrid			2022-12-25	WOS:000242709500055
J	Zhu, XR; Cao, Y; Voodg, K; Steiner, DF				Zhu, Xiaorong; Cao, Yun; Voodg, Keith; Steiner, Donald F.			On the processing of proghrelin to ghrelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DES-ACYL GHRELIN; INSULIN-SECRETION; PEPTIDE; RECEPTOR; ENDOCRINE; MOLECULES; ISLETS; CELLS	The orexigenic hormone ghrelin is a 28-amino-acid peptide derived from a 99-amino-acid precursor and acylated at Ser-3, which was initially isolated from rat stomach. In addition to stimulating appetite and growth, it also plays various important roles in energy homeostasis and in the cardiovascular and immune systems. Although analysis of its physiological effects has yielded many significant results, much less information is available on its biosynthesis and the mechanism of its acylation. In this report, we have studied the endoproteolytic processing of this molecule from its precursor (proghrelin) into mature ghrelin in various prohormone convertase null mouse strains generated in our laboratory and have identified the convertase responsible for this event. Using Western blotting, mass spectrometry, and immunocytochemical methods, we have demonstrated that (a) in mouse stomach, prohormone convertase 1/3 (PC1/3) is the endoprotease responsible for the conversion of proghrelin to ghrelin, (b) the acylation of this peptide is processing-independent, and (c) the expression of proghrelin mRNA is increased in the processing-deficient (PC1/3 null) mouse.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	Steiner, DF (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave,MC 1027, Chicago, IL 60637 USA.	dfsteine@uchicago.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, P60DK020595, R01DK013914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13914, DK 20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ariyasu H, 2005, ENDOCRINOLOGY, V146, P355, DOI 10.1210/en.2004-0629; Cameron A, 2002, ENZYMES, P291; Date Y, 2002, DIABETES, V51, P124, DOI 10.2337/diabetes.51.1.124; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Dezaki K, 2004, DIABETES, V53, P3142, DOI 10.2337/diabetes.53.12.3142; Doi A, 2006, P NATL ACAD SCI USA, V103, P885, DOI 10.1073/pnas.0502470102; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Heller RS, 2005, DEV BIOL, V286, P217, DOI 10.1016/j.ydbio.2005.06.041; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Hosoda H, 2003, J BIOL CHEM, V278, P64, DOI 10.1074/jbc.M205366200; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Koo GC, 2001, J IMMUNOL, V166, P4195, DOI 10.4049/jimmunol.166.6.4195; Lee HM, 2002, ENDOCRINOLOGY, V143, P185, DOI 10.1210/en.143.1.185; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; Murata M, 2002, J BIOL CHEM, V277, P5667, DOI 10.1074/jbc.M103898200; Nagaya N, 2001, CIRCULATION, V104, P2034, DOI 10.1161/hc4201.097836; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Patel AD, 2006, REGUL PEPTIDES, V134, P17, DOI 10.1016/j.regpep.2005.11.001; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Sun YX, 2003, MOL CELL BIOL, V23, P7973, DOI 10.1128/MCB.23.22.7973-7981.2003; Ugleholdt R, 2004, ENDOCRINOLOGY, V145, P1349, DOI 10.1210/en.2003-0801; Wierup N, 2004, J HISTOCHEM CYTOCHEM, V52, P301, DOI 10.1177/002215540405200301; Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	27	152	156	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38867	38870		10.1074/jbc.M607955200	http://dx.doi.org/10.1074/jbc.M607955200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050541	hybrid			2022-12-25	WOS:000242709500084
J	Clarke, D; Griffin, S; Beales, L; Gelais, CS; Burgess, S; Harris, M; Rowlands, D				Clarke, Dean; Griffin, Stephen; Beales, Lucy; Gelais, Corine St.; Burgess, Stan; Harris, Mark; Rowlands, David			Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-A VIRUS; M-2 PROTON CHANNEL; M2 PROTEIN; MEMBRANE PERMEABILIZATION; SUBCELLULAR-LOCALIZATION; TRANSMEMBRANE DOMAIN; CDNA-CLONE; 2B PROTEIN; AMANTADINE; REPLICATION	The p7 protein of hepatitis C virus functions as an ion channel both in vitro and in cell-based assays and is inhibited by amantadine, long alkyl chain imino-sugar derivatives, and amiloride compounds. Future drug design will be greatly aided by information on the stoichiometry and high resolution structure of p7 ion channel complexes. Here, we have refined a bacterial expression system for p7 based on a glutathione S-transferase fusion methodology that circumvents the inherent problems of hydrophobic protein purification and the limitations of chemical synthesis. Rotational averaging and harmonic analysis of transmission electron micrographs of glutathione S-transferase FLAG-p7 fusion proteins in liposomes revealed a heptameric stoichiometry. The oligomerization of p7 protein was then confirmed by SDS-PAGE and mass spectrometry analysis of pure, concentrated FLAG-p7. The same protein was also confirmed to function as an ion channel in suspended lipid bilayers and was inhibited by amantadine. These data validate this system as a means of generating high resolution structural information on the p7 ion channel complex.	Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Rowlands, D (corresponding author), Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Garstang Bldg, Leeds LS2 9JT, W Yorkshire, England.	d.j.rowlands@leeds.ac.uk		Griffin, Stephen/0000-0002-7233-5243; Harris, Mark/0000-0002-9821-1003	Wellcome Trust [074023] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; Botting CH, 2000, RAPID COMMUN MASS SP, V14, P2030; Burgess SA, 1997, J CELL BIOL, V139, P675, DOI 10.1083/jcb.139.3.675; Carrere-Kremer S, 2002, J VIROL, V76, P3720, DOI 10.1128/JVI.76.8.3720-3730.2002; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; de Jong AS, 2004, J BIOL CHEM, V279, P19924, DOI 10.1074/jbc.M314094200; Deltenre P, 2004, J HEPATOL, V41, P462, DOI 10.1016/j.jhep.2004.05.019; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; FRANK J, 2005, 3 DIMENSIONAL ELECT; Gonzalez ME, 2003, FEBS LETT, V552, P28, DOI 10.1016/S0014-5793(03)00780-4; Griffin S, 2005, J VIROL, V79, P15525, DOI 10.1128/JVI.79.24.15525-15536.2005; Griffin SDC, 2004, J GEN VIROL, V85, P451, DOI 10.1099/vir.0.19634-0; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Harada T, 2000, J VIROL, V74, P9498, DOI 10.1128/JVI.74.20.9498-9506.2000; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; Kukol A, 1999, BIOPHYS J, V77, P1594, DOI 10.1016/S0006-3495(99)77007-4; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 1996, J HEPATOL, V24, P11; Moradpour D, 2003, ANTIVIR RES, V60, P103, DOI 10.1016/j.antiviral.2003.08.017; Orzaez M, 2005, FEBS LETT, V579, P1633, DOI 10.1016/j.febslet.2005.01.078; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; Pawlotsky JM, 2003, CURR OPIN INFECT DIS, V16, P587, DOI 10.1097/00001432-200312000-00012; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Premkumar A, 2004, FEBS LETT, V557, P99, DOI 10.1016/S0014-5793(03)01453-4; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Sakai A, 2003, P NATL ACAD SCI USA, V100, P11646, DOI 10.1073/pnas.1834545100; Salom D, 2000, BIOCHEMISTRY-US, V39, P14160, DOI 10.1021/bi001799u; Simmonds P, 1997, GUT, V40, P291, DOI 10.1136/gut.40.3.291; Song ZY, 2000, BIOPHYS J, V79, P767, DOI 10.1016/S0006-3495(00)76334-X; Stouffer AL, 2005, J MOL BIOL, V347, P169, DOI 10.1016/j.jmb.2005.01.023; Tang YJ, 2002, J BIOL CHEM, V277, P39880, DOI 10.1074/jbc.M206582200; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang JF, 2001, PROTEIN SCI, V10, P2241, DOI 10.1110/ps.17901; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	40	109	113	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37057	37068		10.1074/jbc.M602434200	http://dx.doi.org/10.1074/jbc.M602434200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17032656	hybrid			2022-12-25	WOS:000242220800067
J	Suits, MDL; Jaffer, N; Jia, ZC				Suits, Michael D. L.; Jaffer, Neilin; Jia, Zongchao			Structure of the Escherichia coli O157 : H7 heme oxygenase ChuS in complex with heme and enzymatic inactivation by mutation of the heme coordinating residue His-193	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL WATER LIGAND; CRYSTAL-STRUCTURE; PSEUDOMONAS-AERUGINOSA; SHIGELLA-DYSENTERIAE; TRANSPORT-SYSTEM; CARBON-MONOXIDE; IRON; PROTEIN; MENINGITIDIS; DEGRADATION	Heme oxygenases catalyze the oxidation of heme to biliverdin, CO, and free iron. For pathogenic microorganisms, heme uptake and degradation are critical mechanisms for iron acquisition that enable multiplication and survival within hosts they invade. Here we report the first crystal structure of the pathogenic Escherichia coli O157:H7 heme oxygenase ChuS in complex with heme at 1.45A resolution. When compared with other heme oxygenases, ChuS has a unique fold, including structural repeats and a beta-sheet core. Not surprisingly, the mode of heme coordination by ChuS is also distinct, whereby heme is largely stabilized by residues from the C-terminal domain, assisted by a distant arginine from the N-terminal domain. Upon heme binding, there is no large conformational change beyond the fine tuning of a key histidine (His-193) residue. Most intriguingly, in contrast to other heme oxygenases, the propionic side chains of heme are orientated toward the protein core, exposing the alpha-meso carbon position where O-2 is added during heme degradation. This unique orientation may facilitate presentation to an electron donor, explaining the significantly reduced concentration of ascorbic acid needed for the reaction. Based on the ChuSheme structure, we converted the histidine residue responsible for axial coordination of the heme group to an asparagine residue (H193N), as well as converting a second histidine to an alanine residue (H73A) for comparison purposes. We employed spectral analysis and CO measurement by gas chromatography to analyze catalysis by ChuS, H193N, and H73A, demonstrating that His-193 is the key residue for the heme-degrading activity of ChuS.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Jia, ZC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	jia@post.queensu.ca						Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Caignan GA, 2002, J AM CHEM SOC, V124, P14879, DOI 10.1021/ja0274960; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; COOK MN, 1995, CAN J PHYSIOL PHARM, V73, P515, DOI 10.1139/y95-065; Friedman J, 2004, BIOCHEMISTRY-US, V43, P5239, DOI 10.1021/bi049687g; Friedman J, 2003, J BIOL CHEM, V278, P34654, DOI 10.1074/jbc.M302985200; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; Hirotsu S, 2004, J BIOL CHEM, V279, P11937, DOI 10.1074/jbc.M311631200; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; Lansky IB, 2006, J BIOL CHEM, V281, P13652, DOI 10.1074/jbc.M600824200; LAW D, 1995, INFECT IMMUN, V63, P700, DOI 10.1128/IAI.63.2.700-702.1995; Liu Q, 2002, BIOTECHNIQUES, V33, P129, DOI 10.2144/02331rr04; Maki H, 2003, J BIOL CHEM, V278, P3921, DOI 10.1074/jbc.M209069200; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; McHugh JP, 2003, J BIOL CHEM, V278, P29478, DOI 10.1074/jbc.M303381200; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park HJ, 2004, BIOCHEMISTRY-US, V43, P2738, DOI 10.1021/bi035980p; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; Steiner RA, 2003, ACTA CRYSTALLOGR D, V59, P2114, DOI 10.1107/S0907444903018675; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Suits MDL, 2005, P NATL ACAD SCI USA, V102, P16955, DOI 10.1073/pnas.0504289102; Torres AG, 1997, MOL MICROBIOL, V23, P825, DOI 10.1046/j.1365-2958.1997.2641628.x; VREMAN HJ, 1984, CLIN CHEM, V30, P1382; Wegele R, 2004, J BIOL CHEM, V279, P45791, DOI 10.1074/jbc.M408303200; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; Wilks A, 2001, ARCH BIOCHEM BIOPHYS, V387, P137, DOI 10.1006/abbi.2000.2250; WILKS A, 1993, J BIOL CHEM, V268, P22357; Wyckoff EE, 2005, J BACTERIOL, V187, P5658, DOI 10.1128/JB.187.16.5658-5664.2005; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	38	37	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36776	36782		10.1074/jbc.M607684200	http://dx.doi.org/10.1074/jbc.M607684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023414	hybrid			2022-12-25	WOS:000242220800035
J	Xu, CQ; Call, ME; Wucherpfennig, KW				Xu, Chenqi; Call, Matthew E.; Wucherpfennig, Kai W.			A membrane-proximal tetracysteine motif contributes to assembly of CD3 delta epsilon and CD3 gamma epsilon dimers with the T cell receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; TCR/CD3 COMPLEX; CD3-EPSILON-GAMMA HETERODIMER; GLUCOCORTICOID RECEPTOR; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; T3-GAMMA SUBUNIT; CD3 COMPLEX; ALPHA-CHAIN; ZETA-CHAIN	Assembly of the T cell receptor (TCR) with its dimeric signaling modules, CD3 delta epsilon, CD3 gamma epsilon, and zeta zeta, is organized by transmembrane (TM) interactions. Each of the three assembly steps requires formation of a three-helix interface involving one particular basic TCR TM residue and two acidic TM residues of the respective signaling dimer. The extracellular domains of CD3 delta epsilon and CD3 gamma epsilon contribute to assembly, but TCR interaction sites on CD3 dimers have not been defined. The structures of the extracellular domains of CD3 delta epsilon and CD3 gamma epsilon demonstrated parallel beta-strands ending at the first cysteine in the CXXCXEXXX motif present in the stalk segment of each CD3 chain. Mutation of the membrane-proximal cysteines impaired assembly of either CD3 dimer with TCR, and little complex was isolated when all four membrane-proximal cysteines were mutated to alanine. These mutations had, however, no discernable effect on CD3 delta epsilon or CD3 gamma epsilon dimerization. CD3 delta epsilon assembled with a TCR alpha mutant that lacked both immunoglobulin domains, but shortening of the TCR alpha connecting peptide reduced assembly, consistent with membrane-proximal TCR alpha-CD3 delta epsilon interactions. Chelation of divalent cations did not affect assembly, indicating that coordination of a cation by the tetracysteine motif was not required. The membrane-proximal cysteines were within close proximity but only formed covalent CD3 dimers when one cysteine was mutated. The four cysteines may thus form two intrachain disulfide bonds integral to the secondary structure of CD3 stalk regions. The three-chain interaction theme first established for the TM domains thus extends into the membrane-proximal domains of TCR alpha-CD3 delta epsilon and TCR alpha-CD3 delta epsilon.	Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wucherpfennig, KW (corresponding author), Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA.	Kai_Wucherpfennig@dfci.harvard.edu		Xu, Chenqi/0000-0002-4968-6782; Call, Matthew/0000-0001-5846-6469	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054520] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI054520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCOVER A, 1990, J BIOL CHEM, V265, P4131; Arnett KL, 2004, P NATL ACAD SCI USA, V101, P16268, DOI 10.1073/pnas.0407359101; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; Borroto A, 1998, J BIOL CHEM, V273, P12807, DOI 10.1074/jbc.273.21.12807; BORST J, 1983, EUR J IMMUNOL, V13, P576, DOI 10.1002/eji.1830130712; BRENNER MB, 1985, CELL, V40, P183, DOI 10.1016/0092-8674(85)90321-6; BURNS GF, 1982, J IMMUNOL, V129, P1451; Call ME, 2002, CELL, V111, P967, DOI 10.1016/S0092-8674(02)01194-7; Call ME, 2004, EMBO J, V23, P2348, DOI 10.1038/sj.emboj.7600245; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; Exley M, 1991, Semin Immunol, V3, P283; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GEISLER C, 1992, J IMMUNOL, V148, P2437; Ghendler Y, 1998, J EXP MED, V187, P1529, DOI 10.1084/jem.187.9.1529; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; KEARSE KP, 1995, IMMUNITY, V2, P391; Kjer-Nielsen L, 2004, P NATL ACAD SCI USA, V101, P7675, DOI 10.1073/pnas.0402295101; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; KRISSANSEN GW, 1987, J IMMUNOL, V138, P3513; Kuhns MS, 2006, IMMUNITY, V24, P133, DOI 10.1016/j.immuni.2006.01.006; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; OETTGEN HC, 1987, CRC CR REV IMMUNOL, V7, P131; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; PUNT JA, 1994, J EXP MED, V180, P587, DOI 10.1084/jem.180.2.587; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; Sun ZYJ, 2001, CELL, V105, P913, DOI 10.1016/S0092-8674(01)00395-6; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WEGENER AMK, 1995, J BIOL CHEM, V270, P4675, DOI 10.1074/jbc.270.9.4675; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; Wilson DS, 2001, P NATL ACAD SCI USA, V98, P3750, DOI 10.1073/pnas.061028198	41	36	40	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36977	36984		10.1074/jbc.M607164200	http://dx.doi.org/10.1074/jbc.M607164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023417	Green Accepted, hybrid			2022-12-25	WOS:000242220800058
J	Wong, YF; Cheung, TH; Lo, KWK; Yim, SF; Siu, NSS; Chan, SCS; Ho, TWF; Wong, KWY; Yu, MY; Wang, VW; Li, C; Gardner, GJ; Bonome, T; Johnson, WB; Smith, DI; Chung, TKH; Birrer, MJ				Wong, Y. F.; Cheung, T. H.; Lo, K. W. K.; Yim, S. F.; Siu, N. S. S.; Chan, S. C. S.; Ho, T. W. F.; Wong, K. W. Y.; Yu, M. Y.; wang, V. W.; Li, C.; Gardner, G. J.; Bonome, T.; Johnson, W. B.; Smith, D. I.; Chung, T. K. H.; Birrer, M. J.			Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling	ONCOGENE			English	Article						endometrioid endometrial cancer; signaling pathway; gene expression profiling	DIFFERENT HISTOLOGIC TYPES; CLEAR-CELL-CARCINOMA; MATRIX-METALLOPROTEINASE; BREAST-CANCER; SEROUS CARCINOMA; MESSENGER-RNA; CYCLIN-E; NUCLEAR TRANSLOCATION; ENDOGENOUS INHIBITOR; MICROARRAY ANALYSIS	Endometrial cancer is the third most common gynecologic malignancy and the ninth most common malignancy for females overall in Hong Kong. Approximately 80% or more of these cancers are endometrioid endometrial adenocarcinomas. The aim of this study was to reveal genes contributing to the development of endometrioid endometrial cancer, which may impact diagnosis, prognosis and treatment of the disease. Whole-genome gene expression analysis was completed for a set of 55 microdissected sporadic endometrioid endometrial adenocarcinomas and 29 microdissected normal endometrium specimens using the Affymetrix Human U133 Plus 2.0 oligonucleotide microarray. Selected genes of interest were validated by quantitative real-time-polymerase chain reaction (qRT-PCR). Pathway analysis was performed to reveal gene interactions involved in endometrial tumorigenesis. Unsupervised hierarchical clustering displayed a distinct separation between the endometrioid adenocarcinomas and normal endometrium samples. Supervised analysis identified 117 highly differentially regulated genes (>= 4.0-fold change), which distinguished the endometrial cancer specimens from normal endometrium. Twelve novel genes including DKK4, ZIC1, KIF1A, SAA2, LOC16378, ALPP2, CCL20, CXCL5, BST2, OLFM1, KLRC1 and MBC45780 were deregulated in the endometrial cancer, and further validated in an independent set of 56 cancer and 29 normal samples using qRT-PCR. In addition, 10 genes were differentially regulated in late-stage cancer, as compared to early-stage disease, and may be involved in tumor progression. Pathway analysis of the expression data from this tumor revealed an interconnected network consisting of 21 aberrantly regulated genes involved in angiogenesis, cell proliferation and chromosomal instability. The results of this study highlight the molecular features of endometrioid endometrial cancer and provide insight into the events underlying the development and progression of endometrioid endometrial cancer.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biostat, Boston, MA 02115 USA; NCI, Cell & Canc Biol Branch, Bethesda, MD 20892 USA; Mayo Clin, Sch Med, Dept Expt Pathol, Rochester, MN USA	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic	Wong, YF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China.	yickfuwong@cuhk.edu.hk		CHUNG, Tony/0000-0002-6362-8546; Lo, Kwok Wai/0000-0002-3488-6124				ABELER VM, 1991, GYNECOL ONCOL, V40, P207; Acs G, 2004, INT J GYNECOL PATHOL, V23, P110, DOI 10.1097/00004347-200404000-00004; Albright CD, 2001, EXP MOL PATHOL, V70, P71, DOI 10.1006/exmp.2000.2354; Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; [Anonymous], 2005, HONG KONG CANC STAT; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Bein K, 1998, J BIOL CHEM, V273, P21423, DOI 10.1074/jbc.273.33.21423; BONOME T, 2000, CANCER RES, V65, P10602; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Cao QJ, 2004, INT J GYNECOL PATHOL, V23, P321, DOI 10.1097/01.pgp.0000139646.32997.3a; Cha HJ, 1998, ONCOGENE, V16, P771, DOI 10.1038/sj.onc.1201587; Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953; Dhanesuan N, 2002, BREAST CANCER RES TR, V75, P73, DOI 10.1023/A:1016536725958; Duncan RE, 2004, J BIOL CHEM, V279, P33079, DOI 10.1074/jbc.M400732200; Ferguson SE, 2005, CLIN CANCER RES, V11, P2252, DOI 10.1158/1078-0432.CCR-04-1353; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Hrzenjak A, 2004, J PATHOL, V204, P19, DOI 10.1002/path.1616; Ilvan S, 2004, GYNECOL ONCOL, V94, P232, DOI 10.1016/j.ygyno.2004.04.005; Kalsheker N, 2002, BIOCHEM SOC T, V30, P93, DOI 10.1042/bst0300093; Kamochi J, 2003, ONCOL REP, V10, P881; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; LI C, 2003, DNA CHIP ANAL CHIP A; Liu WM, 1999, CANCER RES, V59, P5695; LIU YH, 1991, J BIOL CHEM, V266, P21880; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; Massaad-Massade L, 2004, FEBS LETT, V559, P89, DOI 10.1016/S0014-5793(04)00032-8; Maxwell GL, 2005, CLIN CANCER RES, V11, P4056, DOI 10.1158/1078-0432.CCR-04-2001; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; Milde-Langosch K, 2001, J CANCER RES CLIN, V127, P537, DOI 10.1007/s004320100256; Miyashita R, 2004, INT IMMUNOL, V16, P163, DOI 10.1093/intimm/dxh013; Mizumoto H, 2002, INT J CANCER, V100, P401, DOI 10.1002/ijc.10504; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; MULLER PT, 1903, J CHIM PHYS PCB, V1, P190; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Mutter GL, 2001, GYNECOL ONCOL, V83, P177, DOI 10.1006/gyno.2001.6352; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Risinger JI, 2003, CANCER RES, V63, P6; RUTANEN EM, 1994, INT J CANCER, V59, P307, DOI 10.1002/ijc.2910590303; Saidi SA, 2004, ONCOGENE, V23, P6677, DOI 10.1038/sj.onc.1207562; Schafer KA, 1998, VET PATHOL, V35, P461, DOI 10.1177/030098589803500601; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Sivak JM, 2004, MOL CELL BIOL, V24, P245, DOI 10.1128/MCB.24.1.245-257.2004; Smid-Koopman E, 2004, GYNECOL ONCOL, V93, P292, DOI 10.1016/j.ygyno.2004.01.022; Stetler-Stevenson WG, 2005, TRENDS MOL MED, V11, P97, DOI 10.1016/j.molmed.2005.01.007; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; Suzumori N, 2004, FERTIL STERIL, V81, P305, DOI 10.1016/j.fertnstert.2003.08.011; Takeba Y, 2001, J RHEUMATOL, V28, P2176; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; Tashiro H, 1997, AM J PATHOL, V150, P177; Tong W, 1999, MOL CELL BIOL, V19, P2251; WALMER DK, 1995, CANCER RES, V55, P1168; Warren CD, 2002, MOL BIOL CELL, V13, P3029, DOI 10.1091/mbc.E02-04-0203; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang JJ, 2002, BIOCHEM BIOPH RES CO, V297, P105, DOI 10.1016/S0006-291X(02)02123-X; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903	67	90	99	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1971	1982		10.1038/sj.onc.1209986	http://dx.doi.org/10.1038/sj.onc.1209986			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043662				2022-12-25	WOS:000245117700015
J	Zhou, XY; Jamil, A; Nash, A; Chan, J; Trim, N; Iredale, JP; Benyon, RC				Zhou, Xiaoying; Jamil, Aqeel; Nash, Andrew; Chan, James; Trim, Nathan; Iredale, John P.; Benyon, R. Christopher			Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells - Implications for regulation of liver fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; INTERSTITIAL COLLAGENASE; TISSUE TRANSGLUTAMINASE; GENE-EXPRESSION; METALLOPROTEINASE; RESOLUTION; PROMOTES; GELATINASE; APOPTOSIS; CLEAVAGE	Myofibroblastic-activated hepatic stellate cells are the major source of the collagen I-rich extracellular matrix in liver fibrosis but also produce matrix metalloproteinases, which remodel this protein. We have investigated the role of collagen I proteolysis in both regulating proliferation and maintaining the activated myofibroblastic phenotype of stellate cells in vitro. Compared with stellate cells plated on normal collagen I, those plated on a collagenase- resistant form of collagen I (r/r collagen) had reduced thymidine incorporation and proliferating cell nuclear antigen expression but increased p21 expression. Collagen I was shown to be rendered resistant to matrix metalloproteinases by artificial cross-linking in vitro using tissue transglutaminase exerted similar antiproliferative effects on stellate cells to r/r collagen. Of the stellate cell activation markers examined (tissue inhibitor of metalloproteinases-1, alpha-smooth muscle actin, matrix metalloproteinases-2 and -9, and procollagen I) only the last was decreased by culture on r/r collagen relative to normal collagen I. Antagonists of integrin alpha v beta 3, an integrin reported to stimulate stellate cell proliferation, significantly inhibited adhesion, proliferation, and procollagen I synthesis of stellate cells plated on normal collagen I but had reduced effectiveness on these parameters in cells on r/r collagen. We conclude that proliferation of stellate cells is promoted by pericellular collagen I proteolysis acting via alpha v beta 3 integrin. Cross-linking of collagen I by tissue transglutaminase, a process known to occur in chronic liver fibrosis, might not only increase its resistance to matrix metalloproteinases thereby inhibiting resolution of fibrosis but also functions to constrain the fibroproliferative process.	Southampton Gen Hosp, Liver Grp, Univ Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England	University of Southampton	Benyon, RC (corresponding author), Southampton Gen Hosp, Liver Grp, Univ Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England.	rcb@soton.ac.uk		Iredale, John/0000-0003-2174-5127	Medical Research Council [G0600033] Funding Source: Medline; Medical Research Council [G9900991B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ARTHUR MJP, 1992, BIOCHEM J, V287, P701, DOI 10.1042/bj2870701; Benyon RC, 1996, GASTROENTEROLOGY, V110, P821, DOI 10.1053/gast.1996.v110.pm8608892; Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; BISSELL DM, 1988, SCAND J GASTROENTERO, V23, P1, DOI 10.3109/00365528809095908; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Gaca MDA, 2003, MATRIX BIOL, V22, P229, DOI 10.1016/S0945-053X(03)00017-9; Grenard P, 2001, J HEPATOL, V35, P367, DOI 10.1016/S0168-8278(01)00135-0; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Iimuro Y, 2003, GASTROENTEROLOGY, V124, P445, DOI 10.1053/gast.2003.50063; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; Issa R, 2004, GASTROENTEROLOGY, V126, P1795, DOI 10.1053/j.gastro.2004.03.009; ISSA R, 2000, FASEB J, V17, P47; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Johnson TS, 1999, J AM SOC NEPHROL, V10, P2146; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; MARTINEZHERNANDEZ A, 1985, LAB INVEST, V53, P166; MCGUIRE RF, 1992, HEPATOLOGY, V15, P989, DOI 10.1002/hep.1840150603; Mirza A, 1997, AM J PHYSIOL-GASTR L, V272, pG281, DOI 10.1152/ajpgi.1997.272.2.G281; Mohammed FF, 2005, HEPATOLOGY, V41, P857, DOI 10.1002/hep.20618; Nardacci R, 2003, AM J PATHOL, V162, P1293, DOI 10.1016/S0002-9440(10)63925-9; Nishio T, 2003, J HEPATOL, V38, P468, DOI 10.1016/S0168-8278(03)00013-8; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Petitclerc E, 1999, CANCER RES, V59, P2724; Piacentini M, 1999, J PATHOL, V189, P92; Pinzani M, 2001, SEMIN LIVER DIS, V21, P397, DOI 10.1055/s-2001-17554; Pinzani M, 1999, SPRINGER SEMIN IMMUN, V21, P475, DOI 10.1007/BF00870306; Pinzani M, 2004, DIGEST LIVER DIS, V36, P231, DOI 10.1016/j.dld.2004.01.003; Schnabel C, 2004, HEPATOL RES, V28, P140, DOI 10.1016/j.hepres.2003.11.004; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; Takahara T, 1997, HEPATOLOGY, V26, P1521; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; Zhou XY, 2004, LIVER INT, V24, P492, DOI 10.1111/j.1478-3231.2004.0946.x; Zhou XY, 2004, J BIOL CHEM, V279, P23996, DOI 10.1074/jbc.M311668200	41	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39757	39765		10.1074/jbc.M605621200	http://dx.doi.org/10.1074/jbc.M605621200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17060319	hybrid			2022-12-25	WOS:000243033900003
J	Chowanadisai, W; Lonnerdal, B; Kelleher, SL				Chowanadisai, Winyoo; Lonnerdal, Bo; Kelleher, Shannon L.			Identification of a mutation in SLC30A2 (ZnT-2) in women with low milk zinc concentration that results in transient neonatal zinc deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAMMARY-GLAND; LETHAL-MILK; SUPEROXIDE-DISMUTASE; PROTEIN; GENE; TRANSPORTER; LACTATION; FAMILY; METABOLISM; EXPRESSION	Breast milk normally contains adequate zinc to meet infant requirements up to six months of age; however, transient neonatal zinc deficiency has been documented in exclusively breast-fed infants of women with low milk zinc concentration. This condition is not corrected by maternal zinc supplementation, supporting the speculation that it results from an inherited genetic condition. We identified a family in which two exclusively breast-fed infants developed zinc deficiency that was associated with low milk zinc concentration in both women. Sequencing of genomic DNA detected a mis-sense mutation (Ade3 -> Gua) that substitutes a conserved histidine at amino acid 54 with arginine (H54R) in SLC30A2 (ZnT-2) that is present in both affected subjects and several other siblings. Gene knockdown of SLC30A2 in mammary epithelial cells reduced zinc secretion, illustrating the role of ZnT-2 in zinc secretion from this cell type. Expression of the H54R mutant in human embryonic kidney-293 cells resulted in reduced zinc secretion as a consequence of perinuclear, aggresomal accumulation, whereas co-expression of the H54R mutant and wild-type ZnT-2 did not abrogate increased zinc secretion in cells overexpressing wildtype ZnT-2 alone. Together, these data provide evidence that low milk zinc concentration in some women is a consequence of a genetic disorder resulting from a mutation in SLC30A2 and can result in neonatal zinc deficiency if unrecognized. Further studies are needed to evaluate the incidence and penetrance of this mutation in the human population.	Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA	University of California System; University of California Davis	Kelleher, SL (corresponding author), Univ Calif Davis, Dept Nutr, 1 Shields Ave, Davis, CA 95616 USA.	slkelleher@ucdavis.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35747] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKLAND ML, 1992, J NUTR, V122, P1214, DOI 10.1093/jn/122.6.1214; AGGETT PJ, 1979, ARCH DIS CHILD, V54, P909, DOI 10.1136/adc.54.12.909; AGGETT PJ, 1980, ARCH DIS CHILD, V55, P547, DOI 10.1136/adc.55.7.547; AOKI M, 1994, J NEUROL SCI, V126, P77, DOI 10.1016/0022-510X(94)90097-3; ATHERTON DJ, 1979, CLIN SCI, V56, P505, DOI 10.1042/cs0560505; ATKINSON SA, 1989, AM J DIS CHILD, V143, P608, DOI 10.1001/archpedi.1989.02150170110034; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; ERWAY LC, 1984, J HERED, V75, P480, DOI 10.1093/oxfordjournals.jhered.a109990; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KASPEREK K, 1977, EUR J PEDIATR, V126, P199, DOI 10.1007/BF00477045; Kelleher SL, 2005, AM J PHYSIOL-CELL PH, V288, pC1042, DOI 10.1152/ajpcell.00471.2004; Kelleher SL, 2003, J NUTR, V133, P3378, DOI 10.1093/jn/133.11.3378; Kelleher SL, 2002, J NUTR, V132, P3280, DOI 10.1093/jn/132.11.3280; Krebs NF, 2000, J NUTR, V130, p358S, DOI 10.1093/jn/130.2.358S; KREBS NF, 1995, AM J CLIN NUTR, V61, P1030, DOI 10.1093/ajcn/61.5.1030; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; Liu HB, 2000, BIOCHEMISTRY-US, V39, P8125, DOI 10.1021/bi000846f; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; Michalczyk A, 2003, HUM GENET, V113, P202, DOI 10.1007/s00439-003-0952-2; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PARKER PH, 1982, AM J DIS CHILD, V136, P77, DOI 10.1001/archpedi.1982.03970370079024; PILETZ JE, 1978, SCIENCE, V199, P181, DOI 10.1126/science.619449; SANDSTROM B, 1994, ARCH PEDIAT ADOL MED, V148, P980, DOI 10.1001/archpedi.1994.02170090094017; Shibata N, 1996, DEV NEUROSCI-BASEL, V18, P492, DOI 10.1159/000111445; Suzuki T, 2005, J BIOL CHEM, V280, P637, DOI 10.1074/jbc.M411247200; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Wanker EE, 1999, METHOD ENZYMOL, V309, P375; WEYMOUTH RD, 1982, AUST PAEDIATR J, V18, P208	34	194	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39699	39707		10.1074/jbc.M605821200	http://dx.doi.org/10.1074/jbc.M605821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17065149	hybrid			2022-12-25	WOS:000242898700077
J	Lorizate, M; Cruz, A; Huarte, N; Kunert, R; Perez-Gil, J; Nieva, JL				Lorizate, Maier; Cruz, Antonio; Huarte, Nerea; Kunert, Renate; Perez-Gil, Jesus; Nieva, Jose L.			Recognition and blocking of HIV-1 gp41 pre-transmembrane sequence by monoclonal 4E10 antibody in a raft-like membrane environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 ENVELOPE GLYCOPROTEIN; PROXIMAL EXTERNAL REGION; TRYPTOPHAN-RICH REGION; ENV-MEDIATED FUSION; INFLUENZA HEMAGGLUTININ; UNILAMELLAR VESICLES; LIPID-COMPOSITION; VIRAL FUSION; CHOLESTEROL	The conserved (664)DKWASLWNWFNITNWLWYIK(68)3 (preTM) sequence preceding the transmembrane anchor of human immunodeficiency virus (HIV-1) gp41 glycoprotein subunit is accessible to the broadly neutralizing 4E10 antibody and, therefore, constitutes a potential target for vaccine design. Recently reported structural data are compatible with preTM insertion into the viral external membrane monolayer in the gp41 pre-fusion state (Zhu, P., Liu, J., Bess, J., Chertova, E., Lifson, J. D., Grise, H., Ofek, G. A., Taylor, K. A., and Roux, K. H. ( 2006) Nature 441, 847-852). Here we demonstrate that the broadly neutralizing 4E10 antibody is able to specifically block the membrane-restructuring activity of a peptide mimic inserted into membranes. Recognition and restructuring blocking occurred in the presence of cholesterol, whereas transmembrane versions as those promoted in 1-palmitoyl-2- oleoylphosphatidylcholine: sphingomyelin mixtures could not be effectively arrested. Spectrofluorimetric assays using rhodamine- labeled peptides revealed that recognition correlated better with pore-formation blocking than with membrane-fusion inhibition. The capacity of the antibody to recognize preTM peptides in a raft-like environment was further corroborated employing planar-supported lipid layers and fluorescence microscopy. These data support that membrane-bound epitope recognition by 4E10 results in clustering reorganization of preTM at the membrane interface. We propose that this process might interfere with the formation of fusion-competent complexes at the low spike densities existing in the HIV-1 membrane. This work comprises the first experimental report on a lipid-modulated antibody capacity to bind a membrane-bound epitope sequence and arrest its restructuring activity.	Univ Basque Country, CSIC, UPV, EHU,Biophys Unit, Bilbao 48080, Spain; Univ Basque Country, Dept Biochem, Bilbao 48080, Spain; Univ Bodenkultur Wien, Inst Appl Microbiol, A-1190 Vienna, Austria; Univ Complutense, Fac Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; University of Natural Resources & Life Sciences, Vienna; Complutense University of Madrid	Nieva, JL (corresponding author), Univ Basque Country, CSIC, UPV, EHU,Biophys Unit, POB 644, Bilbao 48080, Spain.	gbpniesj@lg.ehu.es	Perez-Gil, Jesus/H-3102-2019; Kunert, Renate E/B-9185-2018; Cruz, Antonio/H-2881-2015; Nieva, Jose L/Q-2063-2019; Lorizate, Maier/S-1151-2018	Perez-Gil, Jesus/0000-0003-3587-7147; Kunert, Renate E/0000-0002-3397-3621; Cruz, Antonio/0000-0002-0465-4111; Nieva, Jose L/0000-0001-6446-5649; HUARTE ARRAYAGO, NEREA/0000-0002-6675-4150; Lorizate, Maier/0000-0001-8173-2788				ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103; Brunel FM, 2006, J VIROL, V80, P1680, DOI 10.1128/JVI.80.4.1680-1687.2006; BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359; Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Cruz A, 2000, EUR BIOPHYS J BIOPHY, V29, P204, DOI 10.1007/PL00006647; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Epand RF, 2006, BIOCHEMISTRY-US, V45, P6105, DOI 10.1021/bi060245+; Epand RF, 2005, BIOCHEMISTRY-US, V44, P5525, DOI 10.1021/bi0500224; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; John K, 2002, BIOPHYS J, V83, P1525, DOI 10.1016/S0006-3495(02)73922-2; Kunert R, 2004, AIDS RES HUM RETROV, V20, P755, DOI 10.1089/0889222041524571; Kunert R, 2000, BIOTECHNOL BIOENG, V67, P97, DOI 10.1002/(SICI)1097-0290(20000105)67:1<97::AID-BIT11>3.0.CO;2-2; Leikina E, 2005, NAT IMMUNOL, V6, P995, DOI 10.1038/ni1248; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Markovic I, 2001, J CELL BIOL, V155, P833, DOI 10.1083/jcb.200103005; Mehandru S, 2004, J VIROL, V78, P14039, DOI 10.1128/JVI.78.24.14039-14042.2004; Munoz-Barroso I, 1999, J VIROL, V73, P6089; Ohvo-Rekila H, 2000, CHEM PHYS LIPIDS, V105, P167, DOI 10.1016/S0009-3084(00)00122-5; Ruano MLF, 1998, BIOPHYS J, V74, P1101, DOI 10.1016/S0006-3495(98)77828-2; Ruiz-Arguello MB, 1998, J VIROL, V72, P1775; Saez-Cirion A, 2002, J BIOL CHEM, V277, P21776, DOI 10.1074/jbc.M202255200; Saez-Cirion A, 2003, BIOPHYS J, V85, P3769, DOI 10.1016/S0006-3495(03)74792-4; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Sanchez-Martinez S, 2006, AIDS RES HUM RETROV, V22, P998, DOI 10.1089/aid.2006.22.998; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Sot J, 2006, BIOPHYS J, V90, P903, DOI 10.1529/biophysj.105.067710; Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Yuste E, 2004, J VIROL, V78, P6775, DOI 10.1128/JVI.78.13.6775-6785.2004; Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.2634931100; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001; Zwick MB, 2005, AIDS, V19, P1725, DOI 10.1097/01.aids.0000189850.83322.41	41	40	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39598	39606		10.1074/jbc.M605998200	http://dx.doi.org/10.1074/jbc.M605998200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17050535	hybrid			2022-12-25	WOS:000242898700067
J	Choi, JY; Chowdhury, G; Zang, H; Angel, KC; Vu, CC; Peterson, LA; Guengerich, FP				Choi, Jeong-Yun; Chowdhury, Goutam; Zang, Hong; Angel, Karen C.; Vu, Choua C.; Peterson, Lisa A.; Guengerich, F. Peter			Translesion synthesis across O-6-alkylguanine DNA adducts by recombinant human DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3 O-6-SUBSTITUTED GUANINES; KINETIC-ANALYSIS; STEADY-STATE; ESCHERICHIA-COLI; NUCLEOTIDE INSERTION; MUTAGENIC PROPERTIES; BIOCHEMICAL BASIS; O-6-METHYLGUANINE; FIDELITY; REPLICATION	Previous studies have shown that replicative bacterial and viral DNA polymerases are able to bypass the mutagenic lesions O-6-methyl and -benzyl (Bz) G. Recombinant human polymerase (pol) delta also copied past these two lesions but was totally blocked by O-6-[4-oxo-4-(3-pyridyl) butyl] (Pob)G, an important mutagenic lesion formed following metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. The human translesion pols iota and kappa produced mainly only 1-base incorporation opposite O-6-MeG and O-6-BzG and had very low activity in copying O-6-PobG. Human pol eta copied past all three adducts. Steady-state kinetic analysis showed similar efficiencies of insertion opposite the O-6-alkylG adducts for dCTP and dTTP with pol eta and kappa; pol iota showed a strong preference for dTTP. pol eta, iota, and kappa showed pre-steady-state kinetic bursts for dCTP incorporation opposite G and O-6-MeG but little, if any, for O-6-BzG or O-6-PobG. Analysis of the pol eta O-6-PobG products indicated that the insertion of G was opposite the base (C) 5' of the adduct, but this product was not extended. Mass spectrometry analysis of all of the pol eta primer extension products indicated multiple components, mainly with C or T inserted opposite O-6-alkylG but with no deletions in the cases of O-6-MeG and O-6-PobG. With pol eta and O-6-BzG, products were also obtained with -1 and -2 deletions and also with A inserted (opposite O-6-BzG). The results with pol eta may be relevant to some mutations previously reported with O-6-alkylG adducts in mammalian cells.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Ewha Womans Univ, Coll Med, Dept Pharmacol, Seoul 158710, South Korea; Univ Minnesota, Div Environm Hlth Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	Vanderbilt University; Vanderbilt University; Ewha Womans University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 637 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu		Peterson, Lisa/0000-0001-8715-4480	NCI NIH HHS [R01 CA 059887, R01 CA 115309] Funding Source: Medline; NIEHS NIH HHS [R01 ES 010375, P30 ES 000267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115309, R01CA059887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES010375] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARROWS LR, 1981, TOXICOL APPL PHARM, V60, P334, DOI 10.1016/0041-008X(91)90236-8; Bauer KH, 1928, MUTATIONSTHEORIE GES; Bishop RE, 1996, CARCINOGENESIS, V17, P849, DOI 10.1093/carcin/17.4.849; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BORER PN, 1975, HDB BIOCH MOL BIOL, P589; Choi JY, 2006, CHEM RES TOXICOL, V19, P879, DOI 10.1021/tx060051v; Choi JY, 2006, J BIOL CHEM, V281, P25297, DOI 10.1074/jbc.M605699200; Choi JY, 2006, J BIOL CHEM, V281, P21062, DOI 10.1074/jbc.M602246200; Choi JY, 2006, J BIOL CHEM, V281, P12315, DOI 10.1074/jbc.M600112200; Choi JY, 2005, J MOL BIOL, V352, P72, DOI 10.1016/j.jmb.2005.06.079; Choi JY, 2004, J BIOL CHEM, V279, P19217, DOI 10.1074/jbc.M313759200; Christian NP, 2001, J AM SOC MASS SPECTR, V12, P744, DOI 10.1016/S1044-0305(01)00228-8; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; EGER BT, 1992, BIOCHEMISTRY-US, V31, P9227, DOI 10.1021/bi00153a016; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; GAFFNEY BL, 1989, BIOCHEMISTRY-US, V28, P5881, DOI 10.1021/bi00440a026; Gasiewicz TA, 1997, NEUROTOXICOLOGY, V18, P393; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GREEN CL, 1984, P NATL ACAD SCI-BIOL, V81, P13, DOI 10.1073/pnas.81.1.13; Guengerich FP, 2006, CHEM REV, V106, P420, DOI 10.1021/cr0404693; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Johnson Kenneth A., 2003, P1; LAWLEY PD, 1995, BIOESSAYS, V17, P561, DOI 10.1002/bies.950170615; LAWLEY PD, 1984, CHEM CARCINOGENS, P325; LEONARD GA, 1990, P NATL ACAD SCI USA, V87, P9573, DOI 10.1073/pnas.87.24.9573; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; MATTISON DR, 1983, AM J IND MED, V4, P191, DOI 10.1002/ajim.4700040117; Memisoglu A, 1996, CRIT REV BIOCHEM MOL, V31, P405, DOI 10.3109/10409239609108724; Mijal RS, 2005, CHEM RES TOXICOL, V18, P1619, DOI 10.1021/tx050139t; Ni JS, 1996, ANAL CHEM, V68, P1989, DOI 10.1021/ac960270t; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PAULY GT, 1995, BIOCHEMISTRY-US, V34, P8924, DOI 10.1021/bi00027a045; Pauly GT, 2002, CHEM RES TOXICOL, V15, P165, DOI 10.1021/tx0101245; Pauly GT, 2001, CHEM RES TOXICOL, V14, P894, DOI 10.1021/tx010032f; PAULY GT, 1994, BIOCHEMISTRY-US, V33, P9169, DOI 10.1021/bi00197a020; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; Ramos KS, 2005, DRUG METAB REV, V37, P595, DOI 10.1080/03602530500251253; RehaKrantz LJ, 1996, J BIOL CHEM, V271, P20088, DOI 10.1074/jbc.271.33.20088; Rozenski J, 2002, J AM SOC MASS SPECTR, V13, P200, DOI 10.1016/S1044-0305(01)00354-3; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; Staretz ME, 1997, CANCER RES, V57, P259; Stover JS, 2006, CHEM RES TOXICOL, V19, P1506, DOI 10.1021/tx0601455; SWANN PF, 1990, MUTAT RES, V233, P81, DOI 10.1016/0027-5107(90)90153-U; TAN HB, 1994, BIOCHEMISTRY-US, V33, P5335, DOI 10.1021/bi00183a042; Thomson NM, 2003, CHEM RES TOXICOL, V16, P1, DOI 10.1021/tx025585k; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; Wang LJ, 1999, CHEM RES TOXICOL, V12, P127, DOI 10.1021/tx980251+; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1039, DOI 10.1021/bi011496f; Zang H, 2006, J BIOL CHEM, V281, P2358, DOI 10.1074/jbc.M510889200; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200; Zang H, 2006, CHEM RES TOXICOL, V19, P859, DOI 10.1021/tx060056s; Zang Z, 2005, J BIOL CHEM, V280, P30873, DOI 10.1074/jbc.M505283200	64	105	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38244	38256		10.1074/jbc.M608369200	http://dx.doi.org/10.1074/jbc.M608369200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050527	hybrid			2022-12-25	WOS:000242709500017
J	Das, A; Smolenski, A; Lohmann, SM; Kukreja, RC				Das, Anindita; Smolenski, Albert; Lohmann, Suzanne M.; Kukreja, Rakesh C.			Cyclic GMP-dependent protein kinase I alpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; SENSITIVE POTASSIUM CHANNELS; NITRIC-OXIDE SYNTHASE; K-ATP CHANNELS; INDUCED CARDIOPROTECTION; ISCHEMIA-REPERFUSION; CARDIAC-HYPERTROPHY; SIGNAL-TRANSDUCTION; ACTIVATION; PATHWAY	Cyclic GMP-dependent protein kinases protein kinase G (PKG) I alpha and PKGI beta are major mediators of cGMP signaling in the cardiovascular system. PKGI alpha is present in the heart, although its role in protection against ischemia/reperfusion injury is not known. We investigated the direct effect of PKGI alpha against necrosis and apoptosis following simulated ischemia (SI) and reoxygenation (RO) in cardiomyocytes. Adult rat cardiomyocytes were infected with adenoviral vectors containing hPKGI alpha or catalytically inactive mutant hPKGI alpha K390A. After 24 h, the cells were subjected to 90 min of SI and 2h RO for necrosis (trypan blue exclusion and lactate dehydrogenase release) or 18 h RO for apoptosis studies. To evaluate the role of K-ATP channels, subgroups of cells were treated with 5-hydroxydecanoate (100 mu M), HMR1098 (30 mu M), or glibenclamide (50 mu M), the respective blockers of mitochondrial, sarcolemmal, or both types of K-ATP channels prior to SI. The necrosis observed in 33.7 +/- 1.6% of total myocytes in the SI-RO control group was reduced to 18.6 +/- 0.8% by PKGI alpha (mean +/- S.E., n = 7, p < 0.001). Theapoptosisobservedin 17.9 +/- 1.3% of total myocytes in the SI-RO control group was reduced to 6.0 +/- 0.6% by PKGI alpha (mean +/- S.E., n = 7, p < 0.001). In addition, PKGI alpha inhibited the activation of caspase-3 after SI-RO in myocytes. Myocytes infected with the inactive PKGI alpha K390A mutant showed no protection. PKGI alpha enhanced phosphorylation of Akt, ERK1/2, and JNK, increasedBcl-2, induciblenitric-oxidesynthase, endothelial nitric-oxide synthase, and decreased Bax expression. 5-Hydroxydecanoate and glibenclamide abolished PKGI alpha-mediated protection against necrosis and apoptosis. However, HMR1098, had no effect. A scavenger of reactive oxygen species, as well as inhibitors of phosphatidylinositol 3-kinase, ERK, JNK1, and NOS, also blocked PKGI alpha-mediated protection against necrosis and apoptosis. These results show that opening of mitochondrial KATP channels and generation of reactive oxygen species, in association with phosphorylation of Akt, ERK, and JNK, and increased expression of NOS and Bcl-2, play an essential role in the protective effect of PKGI alpha.	VA Virginia Commonwealth Univ, Div Cardiol, Med Ctr, Dept Internal Med, Richmond, VA 23298 USA; Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Med Univ Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	Goethe University Frankfurt; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg	Kukreja, RC (corresponding author), VA Virginia Commonwealth Univ, Div Cardiol, Med Ctr, Dept Internal Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.	rakesh@vcu.edu	Das, Anindita/K-8003-2013	Das, Anindita/0000-0003-4422-7277; Smolenski, Albert/0000-0001-9210-9406	NHLBI NIH HHS [HL 79424, HL 59469, HL 51045] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079424, R37HL051045, R01HL051045, R01HL059469] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bremer YA, 2005, PEDIATR RES, V57, P22, DOI 10.1203/01.PDR.0000147736.27672.15; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Das A, 2005, J BIOL CHEM, V280, P12944, DOI 10.1074/jbc.M404706200; Das A, 2004, AM J PHYSIOL-HEART C, V286, pH1455, DOI 10.1152/ajpheart.01040.2003; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Fryer RM, 2001, BASIC RES CARDIOL, V96, P136, DOI 10.1007/s003950170063; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; Han J, 2001, J BIOL CHEM, V276, P22140, DOI 10.1074/jbc.M010103200; Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024; Hofmann F, 2000, J CELL SCI, V113, P1671; Hofmann F, 2005, J BIOL CHEM, V280, P1, DOI 10.1074/jbc.R400035200; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Krenz M, 2002, BASIC RES CARDIOL, V97, P365, DOI 10.1007/s003950200045; Krieg T, 2004, AM J PHYSIOL-HEART C, V287, pH2606, DOI 10.1152/ajpheart.00600.2004; Krieg T, 2005, AM J PHYSIOL-HEART C, V288, pH1976, DOI 10.1152/ajpheart.00883.2004; Krieg T, 2002, AM J PHYSIOL-HEART C, V283, pH2322, DOI 10.1152/ajpheart.00474.2002; Kukreja RC, 2005, VASC PHARMACOL, V42, P219, DOI 10.1016/j.vph.2005.02.010; Kukreja RC, 2004, J MOL CELL CARDIOL, V36, P165, DOI 10.1016/j.yjmcc.2003.11.001; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Matsui T, 2001, CIRCULATION, V104, P330; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; NICHOLS CG, 1991, CIRC RES, V68, P280, DOI 10.1161/01.RES.68.1.280; O'Rourke B, 2004, CIRC RES, V94, P420, DOI 10.1161/01.RES.0000117583.66950.43; Ockaili R, 2002, AM J PHYSIOL-HEART C, V283, pH1263, DOI 10.1152/ajpheart.00324.2002; Ockaili R, 1999, AM J PHYSIOL-HEART C, V277, pH2425, DOI 10.1152/ajpheart.1999.277.6.H2425; Philipp S, 2006, AM J PHYSIOL-HEART C, V290, pH450, DOI 10.1152/ajpheart.00472.2005; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Ping PP, 1999, AM J PHYSIOL-HEART C, V276, pH1468, DOI 10.1152/ajpheart.1999.276.5.H1468; Qin QN, 2004, AM J PHYSIOL-HEART C, V287, pH712, DOI 10.1152/ajpheart.00954.2003; Salloum F, 2003, CIRC RES, V92, P595, DOI 10.1161/01.RES.0000066853.09821.98; Sasaki N, 2000, CIRCULATION, V101, P439, DOI 10.1161/01.CIR.101.4.439; Schulz R, 2001, CARDIOVASC RES, V52, P181, DOI 10.1016/S0008-6363(01)00384-4; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Strohm C, 2000, J CARDIOVASC PHARM, V36, P218, DOI 10.1097/00005344-200008000-00012; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Szewczyk A, 1996, ACTA BIOCHIM POL, V43, P713; Takimoto E, 2005, NAT MED, V11, P214, DOI 10.1038/nm1175; Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Wang YG, 2001, J MOL CELL CARDIOL, V33, P2037, DOI 10.1006/jmcc.2001.1468; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; Xu ZL, 2004, AM J PHYSIOL-HEART C, V286, pH1433, DOI 10.1152/ajpheart.00882.2003; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692	58	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38644	38652		10.1074/jbc.M606142200	http://dx.doi.org/10.1074/jbc.M606142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17038326	hybrid			2022-12-25	WOS:000242709500060
J	Deramaudt, TB; Sachdeva, MM; Wescott, MP; Chen, YT; Stoffers, DA; Rustgi, AK				Deramaudt, Therese B.; Sachdeva, Mira M.; Wescott, Melanie P.; Chen, Yuting; Stoffers, Doris A.; Rustgi, Anil K.			The PDX1 homeodomain transcription factor negatively regulates the pancreatic ductal cell-specific keratin 19 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; DIABETES-MELLITUS; HOMEOBOX FACTOR; PROTEIN PDX1; DNA-BINDING; EXPRESSION; DOMAIN; PBX; ACTIVATION; MEIS	Keratin 19 is a member of the cytokeratin family that is critical for maintenance of cellular architecture and organization, especially of epithelia. The pancreas has three distinct cell types, ductal, acinar, and islet, each with different functions. Embryologically, the pancreatic and duodenal homeobox 1 (PDX1) homeodomain protein is critical for the initiation of all pancreatic lineages; however, the later differentiation of the endocrine pancreas is uniquely dependent upon high PDX1 expression, whereas PDX1 is down-regulated in the ductal and acinar cell lineages. We find that this down-regulation may be required for normal ductal expression of cytokeratin K19. The K19 promoter-reporter gene assay demonstrates that ectopic PDX1 inhibits K19 reporter gene activity in primary pancreatic ductal cells. This is reinforced by our findings that retrovirally mediated stable transduction of PDX1 in primary pancreatic ductal cells suppresses K19 expression, and short interfering RNA to PDX1 in Min6 insulinoma cells results in the induction of normally undetectable K19. Complementary functional and biochemical approaches led to the unexpected finding that a multimeric complex of PDX1 and two members of the TALE homeodomain factor family, MEIS1a and PBX1b, regulates K19 gene transcription through a specific cis-regulatory element (-341 to -325) upstream of the K19 transcription start site. These data suggest a unifying mechanism whereby PDX1, myeloid ecotropic viral insertion site (MEIS), and pre-B-cell leukemia transcription factor 1 ( PBX) may regulate ductal and acinar lineage specification during pancreatic development. Specifically, concomitant PDX1 suppression and MEIS isoform expression result in proper ductal and acinar lineage specification. Furthermore, PDX1 may inhibit the ductal differentiation program in the pancreatic endocrine compartment, particularly beta cells.	Univ Penn, GI Div, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Univ Penn, Div Endocrinol Diabet & Metab, Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, GI Div, Dept Med, 600 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	anil2@mail.med.upenn.edu	Stoffers, Doris/H-6157-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R01DK068157, P30DK050306, P01DK049210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008216] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK 19525, R01 DK 068157, R01 DK 50306, P01 DK 49210, P30 DK 50306] Funding Source: Medline; NIGMS NIH HHS [5T32 GM 08216-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Chakrabarti SK, 2003, J BIOL CHEM, V278, P23617, DOI 10.1074/jbc.M303423200; Chao SH, 2004, J BIOL CHEM, V279, P16111, DOI 10.1074/jbc.M312304200; Deramaudt TB, 2006, MOL CELL BIOL, V26, P4185, DOI 10.1128/MCB.01055-05; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Hale MA, 2005, DEV BIOL, V286, P225, DOI 10.1016/j.ydbio.2005.07.026; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Heimberg H, 2000, DIABETES, V49, P571, DOI 10.2337/diabetes.49.4.571; Holland AM, 2005, DIABETES, V54, P2586, DOI 10.2337/diabetes.54.9.2586; Holland AM, 2002, P NATL ACAD SCI USA, V99, P12236, DOI 10.1073/pnas.192255099; Iype T, 2005, J BIOL CHEM, V280, P16798, DOI 10.1074/jbc.M414381200; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Liu AH, 2004, MOL CELL BIOL, V24, P4372, DOI 10.1128/MCB.24.10.4372-4383.2004; Liu Y, 2001, J BIOL CHEM, V276, P17985, DOI 10.1074/jbc.M100678200; Lu M, 1996, ENDOCRINOLOGY, V137, P2959, DOI 10.1210/en.137.7.2959; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Miyatsuka T, 2006, GENE DEV, V20, P1435, DOI 10.1101/gad.1412806; Moens CB, 2006, DEV BIOL, V291, P193, DOI 10.1016/j.ydbio.2005.10.032; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mosley AL, 2004, MOL ENDOCRINOL, V18, P2279, DOI 10.1210/me.2003-0463; Noguchi H, 2003, DIABETES, V52, P1732, DOI 10.2337/diabetes.52.7.1732; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; Qin P, 2002, TERATOLOGY, V66, P224, DOI 10.1002/tera.10082; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Stanojevic V, 2004, ENDOCRINOLOGY, V145, P2918, DOI 10.1210/en.2003-1188; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Taguchi M, 2004, J MOL HISTOL, V35, P785, DOI 10.1007/s10735-004-0948-9; Taguchi M, 2002, J PATHOL, V197, P638, DOI 10.1002/path.1134; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; Toivola DM, 2005, TRENDS CELL BIOL, V15, P608, DOI 10.1016/j.tcb.2005.09.004; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787	50	27	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38385	38395		10.1074/jbc.M605891200	http://dx.doi.org/10.1074/jbc.M605891200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17056599	hybrid			2022-12-25	WOS:000242709500032
J	Tong, W; Sulahian, R; Gross, AW; Hendon, N; Lodish, HF; Huang, LJS				Tong, Wei; Sulahian, Rita; Gross, Alec W.; Hendon, Natalie; Lodish, Harvey F.; Huang, Lily Jun-shen			The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; SIGNAL TRANSDUCER GP130; MPL CYTOPLASMIC DOMAIN; COMMON BETA-SUBUNIT; C-MPL; ERYTHROPOIETIN RECEPTOR; MEDIATED ENDOCYTOSIS; JUXTAMEMBRANE DOMAIN; PLATELET PRODUCTION; JANUS KINASE-1	tyrosine kinase 2(JAK2) is essential for signaling by the thrombopoietin (TpoR) and erythropoietin (EpoR) receptors. In the absence of JAK2 most EpoR molecules are retained in the endoplasmic reticulum in an Endo H-sensitive form. In contrast, we show that in the absence of JAK2 a large fraction of the TpoR is processed to the mature Endo H-resistant form and reaches the cell surface. By studying chimeras of the TpoR and EpoR we show that high surface expression of the TpoR is entirely conferred by the membrane-proximal region of the intracellular domain that includes the juxtamembrane, Box 1, and Box 2 regions. The TpoR intracellular domain shows similar effects on receptor endocytosis rate as that of the EpoR, but does stabilize the mature receptor isoform from degradation. Co-expression of JAK2 further stabilizes mature TpoR and thus further increases its surface expression. This JAK2 effect depends on the Box 1 region, the only JAK2 interacting site in the TpoR. By contrast, EpoR requires Box 1 as well as the flanking 20 residues on the C-terminal side for JAK2 interaction and JAK2-dependent surface expression. Our study suggests that whereas cell surface expression of type I cytokine receptors requires their cognate JAKs, the mechanisms governing receptor-JAK interactions differ among receptors interacting with the same JAK protein.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, LJS (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Lily.Huang@utsouthwestern.edu		Tong, Wei/0000-0001-9951-2273	NATIONAL CANCER INSTITUTE [K01CA095150, K01CA115679] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL077036, P01HL032262] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA 115679, K01 CA 95150, K01 CA115679] Funding Source: Medline; NHLBI NIH HHS [5F32 HL 077036, P01 HL 32262, R01 HL089966] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Ballmaier M, 2001, BLOOD, V97, P139, DOI 10.1182/blood.V97.1.139; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Greiser JS, 2002, J BIOL CHEM, V277, P26959, DOI 10.1074/jbc.M204113200; Gross AW, 2006, J BIOL CHEM, V281, P2024, DOI 10.1074/jbc.M510493200; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Ihara K, 1999, P NATL ACAD SCI USA, V96, P3132, DOI 10.1073/pnas.96.6.3132; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kaushansky K, 2003, J THROMB HAEMOST, V1, P1587, DOI 10.1046/j.1538-7836.2003.00273.x; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Miyakawa Y, 2000, J BIOL CHEM, V275, P32214, DOI 10.1074/jbc.M005080200; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PARDANANI A, 2006, IN PRESS BLOOD; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Royer Y, 2005, J BIOL CHEM, V280, P27251, DOI 10.1074/jbc.M501376200; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; Staerk J, 2006, BLOOD, V107, P1864, DOI 10.1182/blood-2005-06-2600; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156	33	26	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38930	38940		10.1074/jbc.M607524200	http://dx.doi.org/10.1074/jbc.M607524200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17052978	hybrid			2022-12-25	WOS:000242709500090
J	Zhang, BC; Wang, Z; Ding, J; Peterson, P; Gunning, WT; Ding, HF				Zhang, Baochun; Wang, Zhe; Ding, Jane; Peterson, Part; Gunning, William T.; Ding, Han-Fei			NF-kappa beta 2 is required for the control of autoimmunity by regulating the development of medullary thymic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROMISCUOUS GENE-EXPRESSION; SELF-TOLERANCE; T-CELLS; SPLENIC MICROARCHITECTURE; PROTEIN; MICE; AIRE; RELB; P100	Medullary thymic epithelial cells function as antigen-presenting cells in negative selection of self-reactive T cell clones, a process essential for the establishment of central self-tolerance. These cells mirror peripheral tissues through promiscuous expression of a diverse set of tissue-restricted self-antigens. The genes and signaling pathways that regulate the development of medullary thymic epithelial cells are not fully understood. Here we show that mice deficient in NF-kappa B2, a member of the NF-kappa B family, display a marked reduction in the number of mature medullary thymic epithelial cells that express CD80 and bind the lectin Ulex europaeus agglutinin-1, leading to a significant decrease in the extent of promiscuous gene expression in the thymus of NF-kappa B2(-/-) mice. Moreover, NF-kappa B2(-/-) mice manifest autoimmunity characterized by multiorgan infiltration of activated T cells and high levels of autoantibodies to multiple organs. A subpopulation of the mice also develops immune complex glomerulonephritis. These findings identify a physiological function of NF-kappa B2 in the development of medullary thymic epithelial cells and, thus, the control of self-tolerance induction.	Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; Univ Tartu, IGMP, Biomedicum, EE-50414 Tartu, Estonia	University of Tartu	Ding, HF (corresponding author), Med Univ Ohio, Dept Biochem & Canc Biol, 3035 Arlington Ave, Toledo, OH 43614 USA.	hding@meduohio.edu	Peterson, Pärt/A-5788-2009; Gunning, William T/E-4681-2010	Peterson, Pärt/0000-0001-6755-791X; Ding, Han-Fei/0000-0001-5702-3439; Zhang, Baochun/0000-0003-1759-1161	NATIONAL CANCER INSTITUTE [R01CA106550] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 106550, R01 CA106550] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Akiyama T, 2005, SCIENCE, V308, P248, DOI 10.1126/science.1105677; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bleul CC, 2006, NATURE, V441, P992, DOI 10.1038/nature04850; Boehm T, 2003, J EXP MED, V198, P757, DOI 10.1084/jem.20030794; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; BURKLY LC, 1993, J IMMUNOL, V151, P3954; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; DEGERMANN S, 1994, J IMMUNOL, V152, P3254; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derbinski J, 2005, TRENDS IMMUNOL, V26, P503, DOI 10.1016/j.it.2005.07.006; Derbinski J, 2005, J EXP MED, V202, P33, DOI 10.1084/jem.20050471; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; FARR AG, 1985, J IMMUNOL, V134, P2971; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Gordon J, 2004, NAT IMMUNOL, V5, P546, DOI 10.1038/ni1064; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; Heino M, 2000, EUR J IMMUNOL, V30, P1884, DOI 10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P; HOFFMANN MW, 1992, P NATL ACAD SCI USA, V89, P2526, DOI 10.1073/pnas.89.7.2526; Hogquist KA, 2005, NAT REV IMMUNOL, V5, P772, DOI 10.1038/nri1707; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Kajiura F, 2004, J IMMUNOL, V172, P2067, DOI 10.4049/jimmunol.172.4.2067; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kinoshita D, 2006, J IMMUNOL, V176, P3995, DOI 10.4049/jimmunol.176.7.3995; Klein L, 2000, NAT MED, V6, P56, DOI 10.1038/71540; Kuroda N, 2005, J IMMUNOL, V174, P1862, DOI 10.4049/jimmunol.174.4.1862; Kyewski B, 2004, NAT REV IMMUNOL, V4, P688, DOI 10.1038/nri1436; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; MODIGLIANI Y, 1995, P NATL ACAD SCI USA, V92, P7555, DOI 10.1073/pnas.92.16.7555; Muller SM, 2005, P NATL ACAD SCI USA, V102, P10587, DOI 10.1073/pnas.0502752102; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; NELSON AJ, 1993, J IMMUNOL, V151, P2453; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; OHKI H, 1987, SCIENCE, V237, P1032, DOI 10.1126/science.3616623; Palmer E, 2003, NAT REV IMMUNOL, V3, P383, DOI 10.1038/nri1085; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rossi SW, 2006, NATURE, V441, P988, DOI 10.1038/nature04813; Schwartz RH, 2005, NAT IMMUNOL, V6, P327, DOI 10.1038/ni1184; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SHI YF, 1991, J IMMUNOL, V146, P3340; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	53	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38617	38624		10.1074/jbc.M606705200	http://dx.doi.org/10.1074/jbc.M606705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046818	hybrid, Green Accepted			2022-12-25	WOS:000242709500057
J	Gan, BY; Yoo, Y; Guan, JL				Gan, Boyi; Yoo, Youngdong; Guan, Jun-Lin			Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of S6 kinase activation and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE/AKT PATHWAY; TUMOR-SUPPRESSOR COMPLEX; GENE-PRODUCTS; EMBRYONIC LETHALITY; MAMMALIAN TARGET; TSC2 MUTATION; MTOR; PHOSPHORYLATION; INTEGRIN; HAMARTIN	Tuberous sclerosis complex 1 (TSC1) and TSC2 tumor suppressor proteins have been shown to negatively regulate cell growth through inhibition of the mammalian target of rapamycin (mTOR) pathway. Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays a critical role in integrin signaling. Here we identify a novel interaction between FAK and TSC2 and show that TSC2 is phosphorylated by FAK. Furthermore, we show that overexpression of FAK kinase dead mutant inhibits the phosphorylation of ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein-1, two key mTOR (mammalian target of rapamycin) downstream targets, and negatively regulates the cell size and that FAK regulation of S6K phosphorylation is through TSC2. Finally, we provide data that FAK plays a positive role in cell adhesion-induced S6K phosphorylation, whereas TSC2 is required for cell suspension-induced S6K inactivation. Together, these results suggest that FAK might regulate S6K activation and cell size through its interaction with and phosphorylation of TSC2 and also provide a previously unappreciated role of TSC2 in the regulation of mTOR signaling by cell adhesion.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	jlguan@umich.edu	Gan, Boyi/HDM-4206-2022		NIGMS NIH HHS [GM52890, GM48050] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	40	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37321	37329		10.1074/jbc.M605241200	http://dx.doi.org/10.1074/jbc.M605241200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17043358	hybrid			2022-12-25	WOS:000242477100009
J	Fox, JM; Najarro, P; Smith, GL; Struyf, S; Proost, P; Pease, JE				Fox, James M.; Najarro, Pilar; Smith, Geoffrey L.; Struyf, Sofie; Proost, Paul; Pease, James E.			Structure/function relationships of CCR8 agonists and antagonists - Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CCR8; ALLERGIC AIRWAY DISEASE; T-CELLS; BETA-ARRESTIN; CUTTING EDGE; IDENTIFICATION; INTERNALIZATION; ACTIVATION; VIRUS; INFLAMMATION	We describe here the interactions of CCR8 with its ligands using both CCR8 transfectants and a T-cell line expressing the receptor endogenously. Of the CCR8 agonists reported previously, only CCL1 and vMIP-I exhibited potency in assays of intracellular calcium flux, chemotaxis, and receptor internalization, this latter mechanism being dependent upon the expression of ss-arrestins 1 and 2 but independent of G alpha(i) signaling. NH2-terminal extension of the mature CCL1 sequence by a serine residue (Ser-CCL1) resulted in a partial agonist with a reduced affinity for CCR8, suggesting that the NH2 terminus of the ligand plays a role in ligand binding to an intrahelical site. Attempts to identify key residues within this site revealed that the conserved glutamic acid residue in transmembrane helix 7, Glu-286, is crucial for trafficking of the receptor to the cell surface, while Asp-97 of transmembrane helix 2 is dispensable. CCL7 was found to inhibit both Ser-CCL1 and vMIP-I responses but not those of CCL1 itself. Similarly, vMIP-I responses were more than 2 orders of magnitude more sensitive to the specific CCR8 antagonist MC148 than those induced by CCL1, which is difficult to reconcile with the reported affinities for the receptor. Collectively, these data suggest that the CCR8 ligands are allotropic, binding to distinct sites within CCR8 and that the human immune system may have evolved to use CCL7 as a selective antagonist of viral chemokine activity at CCR8 but not those of the host ligand.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; Katholieke Univ Leuven VIB, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium	Imperial College London; Imperial College London; Flanders Institute for Biotechnology (VIB); KU Leuven	Pease, JE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, S Kensington Campus,Sir Alexander Fleming Bldg, London SW7 2AZ, England.	j.pease@imperial.ac.uk	Pease, James/X-4521-2018; Proost, Paul/V-3052-2017; Struyf, Sofie/U-2455-2017; Smith, Geoffrey L/G-2894-2012	Pease, James/0000-0003-3749-0341; Proost, Paul/0000-0002-0133-5545; Struyf, Sofie/0000-0003-4558-0769; Fox, James/0000-0002-2473-7029; Smith, Geoffrey L/0000-0002-3730-9955	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Auger GA, 2002, EUR J IMMUNOL, V32, P1052, DOI 10.1002/1521-4141(200204)32:4<1052::AID-IMMU1052>3.0.CO;2-L; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; Bernardini G, 1998, EUR J IMMUNOL, V28, P582, DOI 10.1002/(SICI)1521-4141(199802)28:02<582::AID-IMMU582>3.0.CO;2-A; Blanpain C, 1999, BLOOD, V94, P1899; Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chung CD, 2003, J IMMUNOL, V170, P581, DOI 10.4049/jimmunol.170.1.581; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; de Mendonca FL, 2005, J BIOL CHEM, V280, P4808, DOI 10.1074/jbc.M412267200; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Galliera E, 2004, J BIOL CHEM, V279, P25590, DOI 10.1074/jbc.M400363200; Garlisi CG, 1999, EUR J IMMUNOL, V29, P3210, DOI 10.1002/(SICI)1521-4141(199910)29:10<3210::AID-IMMU3210>3.0.CO;2-W; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200; Goya I, 2003, J IMMUNOL, V170, P2138, DOI 10.4049/jimmunol.170.4.2138; Haskell CA, 2006, MOL PHARMACOL, V69, P309, DOI 10.1124/mol.105.014779; Howard OMZ, 2000, BLOOD, V96, P840, DOI 10.1182/blood.V96.3.840.015k32_840_845; Jopling LA, 2002, J BIOL CHEM, V277, P6864, DOI 10.1074/jbc.M109974200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Lee HJ, 2001, VIROLOGY, V281, P170, DOI 10.1006/viro.2000.0761; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Matsukawa A, 2006, FASEB J, V20, P302, DOI 10.1096/fj.04-1728fje; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Mueller A, 2002, BRIT J PHARMACOL, V135, P1033, DOI 10.1038/sj.bjp.0704540; Najarro P, 2006, J GEN VIROL, V87, P809, DOI 10.1099/vir.0.81427-0; Najarro P, 2003, J GEN VIROL, V84, P3325, DOI 10.1099/vir.0.19591-0; Nomiyama H, 2001, INT IMMUNOL, V13, P1021, DOI 10.1093/intimm/13.8.1021; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199; Struyf S, 2004, CIRC RES, V95, P855, DOI 10.1161/01.RES.0000146674.38319.07; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Venkatesan S, 2003, MOL BIOL CELL, V14, P3305, DOI 10.1091/mbc.e02-11-0714; Wells TNC, 2006, TRENDS PHARMACOL SCI, V27, P41, DOI 10.1016/j.tips.2005.11.001; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505; Zingoni A, 1998, J IMMUNOL, V161, P547	47	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36652	36661		10.1074/jbc.M605584200	http://dx.doi.org/10.1074/jbc.M605584200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023422	hybrid			2022-12-25	WOS:000242220800022
J	Mueckler, M; Makepeace, C				Mueckler, Mike; Makepeace, Carol			Transmembrane segment 12 of the Glut1 glucose transporter is an outer helix and is not directly involved in the transport mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; SUGAR PERMEATION PATHWAY; XENOPUS-OOCYTES; ESCHERICHIA-COLI; ACCESSIBILITY; BINDING; PROTEINS; DOMAINS; FAMILY; HEPG2	A model has been proposed for the exofacial configuration of the Glut1 glucose transporter in which eight transmembrane domains form an inner helical bundle stabilized by four outer helices. The role of transmembrane segment 12, predicted to be an outer helix in this hypothetical model, was examined by cysteine-scanning mutagenesis and the substituted cysteine accessibility method using the membrane-impermeant, sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS). A previously characterized functional cysteine-less Glut1 molecule was used to produce 21 Glut1 point mutants by changing each residue along helix 12 to a cysteine residue. These mutants were then expressed in Xenopus oocytes, and their protein levels, functional activities, and sensitivities to pCMBS were determined. Strikingly, in contrast to all nine other predicted Glut1 transmembrane helices that have been previously examined by this method, none of the 21 helix 12 single-cysteine mutants exhibited significant inhibition of specific transport activity. Also unlike most other Glut1 transmembrane domains in which solvent-accessible residues lie along a single face of the helix, mutations in five consecutive residues predicted to lie close to the exofacial face of the membrane resulted in sensitivity to pCMBS-induced transport inhibition. These results suggest that helix 12 plays a passive stabilizing role in the structure of Glut1 and is not directly involved in the transport mechanism. Additionally, the pCMBS data indicate that the predicted exoplasmic end of helix 12 is completely exposed to the external solvent when the transporter is in its exofacial configuration.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK 43695, P30 DK056341-05S2, P30 DK056341, P30 DK056341-06] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BALDWIN SA, 1989, METHOD ENZYMOL, V174, P39; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Heinze M, 2004, BIOCHEMISTRY-US, V43, P931, DOI 10.1021/bi030175w; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KELLER K, 1989, J BIOL CHEM, V264, P18884; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; Mueckler M, 2004, J BIOL CHEM, V279, P46876, DOI 10.1074/jbc.M408632200; Mueckler M, 2004, J BIOL CHEM, V279, P10494, DOI 10.1074/jbc.M310786200; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Mueckler M, 2005, J BIOL CHEM, V280, P39562, DOI 10.1074/jbc.M509050200; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; Saier MH, 2000, MOL MICROBIOL, V35, P699, DOI 10.1046/j.1365-2958.2000.01759.x; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6	30	31	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36993	36998		10.1074/jbc.M608158200	http://dx.doi.org/10.1074/jbc.M608158200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17020877	hybrid			2022-12-25	WOS:000242220800060
J	Demidov, ON; Kek, C; Shreeram, S; Timofeev, O; Fornace, AJ; Appella, E; Bulavin, DV				Demidov, O. N.; Kek, C.; Shreeram, S.; Timofeev, O.; Fornace, A. J.; Appella, E.; Bulavin, D. V.			The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis	ONCOGENE			English	Article						Wip1 phosphatase; p38 MAPK; MKK6; breast cancer; ErbB2; proliferation; MMTV	TUMOR-SUPPRESSOR ACTIVITY; WIP1 PHOSPHATASE; BREAST-CANCER; PROTEIN PHOSPHATASE; IN-VIVO; PPM1D; AMPLIFICATION; KINASE; P53; ACTIVATION	There is increasing evidence for the role of wild-type p53 induced phosphatase 1( Wip1) phosphatase in the regulation of tumorigenesis. To evaluate Wip1 as a breast cancer oncogene, we generated a mouse strain with targeted expression of Wip1 to the breast epithelium. We found that these mice are prone to cancer when intercrossed with transgenics expressing the ErbB2 oncogene but not conditional knockouts for Brca2. This tumor-prone phenotype of Wip1 is fully eliminated through attenuation of proliferation by activating the MKK6/p38 mitogen-activated protein kinases ( MAPK) cascade in mice bearing a constitutively active form of MKK6. We propose that Wip1 phosphatase operates within the MKK6/p38 MAPK signaling pathway to promote ErbB2-driven mammary gland tumorigenesis.	Natl Univ Singapore, Inst Mol & Cell Biol, Cell Cycle Control & Tumorigenesis Grp, Singapore 138673, Singapore; NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	Bulavin, DV (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Cell Cycle Control & Tumorigenesis Grp, 61 Biopolis Dr, Singapore 138673, Singapore.	dvbulavin@imcb.a-star.edu.sg	Demidov, Oleg/U-2050-2017; Fornace, Albert J/A-7407-2008; Demidov, Oleg/AAC-4462-2021	Demidov, Oleg/0000-0003-4323-7174; Fornace, Albert J/0000-0001-9695-085X; Demidov, Oleg/0000-0003-4323-7174; Sathyavageeswaran, Shreeram/0000-0002-6111-1818; Timofeev, Oleg/0000-0002-3114-6403	NATIONAL CANCER INSTITUTE [Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rauta J, 2006, BREAST CANCER RES TR, V95, P257, DOI 10.1007/s10549-005-9017-7; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Timofeev O, 2005, CELL CYCLE, V4, P118, DOI 10.4161/cc.4.1.1342; Trost TM, 2005, CANCER RES, V65, P840; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634	20	82	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2502	2506		10.1038/sj.onc.1210032	http://dx.doi.org/10.1038/sj.onc.1210032			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17016428				2022-12-25	WOS:000245831000010
J	Masai, H; Taniyama, C; Ogino, K; Matsui, E; Kakusho, N; Matsumoto, S; Kim, JM; Ishii, A; Tanaka, T; Kobayashi, T; Tamai, K; Ohtani, K; Arai, K				Masai, Hisao; Taniyama, Chika; Ogino, Keiko; Matsui, Etsuko; Kakusho, Naoko; Matsumoto, Seiji; Kim, Jung-Min; Ishii, Ai; Tanaka, Taku; Kobayashi, Toshiko; Tamai, Katsuyuki; Ohtani, Kiyoshi; Arai, Ken-ichi			Phosphorylation of MCM4 by Cdc7 kinase facilitates its interaction with Cdc45 on the chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; HUMAN CDC7-RELATED KINASE; IN-VITRO PHOSPHORYLATION; DNA HELICASE ACTIVITY; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; FISSION YEAST; HETEROHEXAMERIC COMPLEXES; SACCHAROMYCES-CEREVISIAE	Cdc7 kinase, conserved from yeasts to human, plays important roles in DNA replication. However, the mechanisms by which it stimulates initiation of DNA replication remain largely unclear. We have analyzed phosphorylation of MCM subunits during cell cycle by examining mobility shift on SDS-PAGE. MCM4 on the chromatin undergoes specific phosphorylation during S phase. Cdc7 phosphorylates MCM4 in the MCM complexes as well as the MCM4 N-terminal polypeptide. Experiments with phospho-amino acid-specific antibodies indicate that the S phase-specific mobility shift is due to the phosphorylation at specific N-terminal (S/T)( S/T) P residues of the MCM4 protein. These specific phosphorylation events are not observed in mouse ES cells deficient in Cdc7 or are reduced in the cells treated with siRNA specific to Cdc7, suggesting that they are mediated by Cdc7 kinase. The N-terminal phosphorylation of MCM4 stimulates association of Cdc45 with the chromatin, suggesting that it may be an important phosphorylation event by Cdc7 for activation of replication origins. Deletion of the N-terminal non-conserved 150 amino acids of MCM4 results in growth inhibition, and addition of amino acids carrying putative Cdc7 target sequences partially restores the growth. Furthermore, combination of MCM4 N-terminal deletion with alanine substitution and deletion of the N-terminal segments of MCM2 and MCM6, respectively, which contain clusters of serine/threonine and are also likely targets of Cdc7, led to an apparent nonviable phenotype. These results are consistent with the notion that the N-terminal phosphorylation of MCM2, MCM4, and MCM6 may play functionally redundant but essential roles in initiation of DNA replication.	Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, Tokyo 1138613, Japan; Ginkgo Biomed Res Inst, Tokyo 1080071, Japan; Med & Biol Labs Co Ltd, Nagano 3960002, Japan; Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Medical & Dental University (TMDU); University of Tokyo	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp	Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				Aguda BD, 2001, CHAOS, V11, P269, DOI 10.1063/1.1336826; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Cho WH, 2006, P NATL ACAD SCI USA, V103, P11521, DOI 10.1073/pnas.0604990103; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Dolan WP, 2004, CHROMOSOMA, V113, P145, DOI 10.1007/s00412-004-0302-8; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 1997, GENETICS, V147, P1025; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fujita M, 1997, J BIOL CHEM, V272, P10928; Gomez EB, 2002, GENETICS, V160, P1305; Ishimi Y, 2003, J BIOL CHEM, V278, P24644, DOI 10.1074/jbc.M213252200; Ishimi Y, 2001, J BIOL CHEM, V276, P42744, DOI 10.1074/jbc.M106861200; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Jares P, 2000, GENE DEV, V14, P1528; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; MAINE GT, 1984, GENETICS, V106, P365; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Matsumoto S, 2005, J BIOL CHEM, V280, P42536, DOI 10.1074/jbc.M510575200; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Montagnoli A, 2004, CANCER RES, V64, P7110, DOI 10.1158/0008-5472.CAN-04-1547; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Pereverzeva I, 2000, MOL CELL BIOL, V20, P3667, DOI 10.1128/MCB.20.10.3667-3676.2000; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sclafani RA, 2000, J CELL SCI, V113, P2111; Takahashi TS, 2005, GENE DEV, V19, P2295, DOI 10.1101/gad.1339805; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tsuji T, 2006, MOL BIOL CELL, V17, P4459, DOI 10.1091/mbc.E06-03-0241; Uchiyama M, 2001, J BIOL CHEM, V276, P26189, DOI 10.1074/jbc.M100007200; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	48	145	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39249	39261		10.1074/jbc.M608935200	http://dx.doi.org/10.1074/jbc.M608935200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17046832	hybrid			2022-12-25	WOS:000242898700032
J	Quinones, M; Kimsey, HH; Ross, W; Gourse, RL; Waldor, MK				Quinones, Mariam; Kimsey, Harvey H.; Ross, Wilma; Gourse, Richard L.; Waldor, Matthew K.			LexA represses CTX Phi transcription by blocking access of the alpha C-terminal domain of RNA polymerase to promoter DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL PROMOTERS; PHAGE INTEGRATION; VIBRIO-CHOLERAE; CAMP-CRP; SUBUNIT; ACTIVATION; COMPLEX; ELEMENT; BINDING	CTX Phi is a Vibrio cholerae-specific temperate filamentous phage that encodes cholera toxin. CTX Phi lysogens can be induced with DNA damage-inducing agents such as UV light, leading to the release of CTX Phi virions and the rapid dissemination of cholera toxin genes to new V. cholerae hosts. This environmental regulation is directly mediated by LexA, the host-encoded global SOS transcription factor. LexA and a phage-encoded repressor, RstR, both repress transcription from P-rstA, the primary CTX Phi promoter. Because the LexA binding site is located upstream of the core PrstA promoter and overlaps with A-tract sequences, we speculated that LexA represses PrstA by occluding a promoter UP element, a binding site for the C-terminal domain of the alpha subunit of RNA polymerase ( RNAP) (alpha CTD). Using in vitro transcription assays, we have shown that the LexA binding site stimulates maximal rstA transcription in the absence of any added factors. The alpha CTD of RNAP is required for this stimulation, demonstrating that the LexA site contains, or overlaps with, a promoter UP element. LexA represses rstA transcription by normal RNAP but fails to repress rstA transcription catalyzed by RNAP lacking the alpha CTD. DNase I footprint analysis mapped the alpha CTD binding site to the upstream promoter region that includes the LexA binding site. The addition of free alpha subunits blocked the binding of LexA to rstA promoter DNA, indicating that LexA and the alpha CTD directly compete for binding to their respective sites. To our knowledge, this is the first report of a repressor blocking transcription initiation by occluding a promoter UP element.	Tufts Univ, Sch Med, Dept Mol Microbiol, Boston, MA 02111 USA; Howard Hughes Med Inst, Boston, MA 02111 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Tufts University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	Waldor, MK (corresponding author), Tufts Univ, Sch Med, Dept Mol Microbiol, Boston, MA 02111 USA.	matthew.waldor@tufts.edu		Quinones, Mariam/0000-0002-8520-5114; Waldor, Matthew/0000-0003-1843-7000	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037048] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM037048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aiyar SE, 2002, J BACTERIOL, V184, P1349, DOI 10.1128/JB.184.5.1349-1358.2002; Benoff B, 2002, SCIENCE, V297, P1562, DOI 10.1126/science.1076376; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Camacho A, 2004, J MOL BIOL, V336, P357, DOI 10.1016/j.jmb.2003.12.039; CHOY HE, 1995, EMBO J, V14, P4523, DOI 10.1002/j.1460-2075.1995.tb00131.x; Choy HE, 1997, J MOL BIOL, V272, P293, DOI 10.1006/jmbi.1997.1221; Courcelle J, 2001, GENETICS, V158, P41; Dumoulin P, 1996, BIOCHEMISTRY-US, V35, P4279, DOI 10.1021/bi9529162; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; Huber KE, 2002, NATURE, V417, P656, DOI 10.1038/nature00782; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; Keseler IM, 2005, NUCLEIC ACIDS RES, V33, pD334, DOI 10.1093/nar/gki108; Kimsey HH, 1998, P NATL ACAD SCI USA, V95, P7035, DOI 10.1073/pnas.95.12.7035; Kimsey HH, 2004, J BIOL CHEM, V279, P2640, DOI 10.1074/jbc.M311109200; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; Maxam A M, 1980, Methods Enzymol, V65, P499; McLeod SM, 2004, MOL MICROBIOL, V54, P935, DOI 10.1111/j.1365-2958.2004.04309.x; Meijer WJJ, 2004, NUCLEIC ACIDS RES, V32, P1166, DOI 10.1093/nar/gkh290; Nakano S, 2003, P NATL ACAD SCI USA, V100, P4233, DOI 10.1073/pnas.0637648100; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Newberry KJ, 2005, P NATL ACAD SCI USA, V102, P15839, DOI 10.1073/pnas.0506592102; Quinones M, 2005, MOL CELL, V17, P291, DOI 10.1016/j.molcel.2004.11.046; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Ross W, 2005, P NATL ACAD SCI USA, V102, P291, DOI 10.1073/pnas.0405814102; Ross W, 1998, J BACTERIOL, V180, P5375, DOI 10.1128/JB.180.20.5375-5383.1998; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Tiemann B, 2004, J BACTERIOL, V186, P7262, DOI 10.1128/JB.186.21.7262-7272.2004; Val ME, 2005, MOL CELL, V19, P559, DOI 10.1016/j.molcel.2005.07.002; Yamamoto K, 2003, MOL MICROBIOL, V47, P183, DOI 10.1046/j.1365-2958.2003.03287.x	36	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39407	39412		10.1074/jbc.M609694200	http://dx.doi.org/10.1074/jbc.M609694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17046810	hybrid			2022-12-25	WOS:000242898700048
J	Wang, HM; Kubica, N; Ellisen, LW; Jefferson, LS; Kimball, SR				Wang, Hongmei; Kubica, Neil; Ellisen, Leif W.; Jefferson, Leonard S.; Kimball, Scot R.			Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-RESPONSE GENE; TUBEROUS SCLEROSIS; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; S6 KINASE; SKELETAL-MUSCLE; RHEB BINDS; PHOSPHORYLATION; MTOR; INSULIN	The mammalian target of rapamycin ( mTOR), a critical modulator of cell growth, acts to integrate signals from hormones, nutrients, and growth-promoting stimuli to downstream effector mechanisms involved in the regulation of protein synthesis. Dexamethasone, a synthetic glucocorticoid that represses protein synthesis, acts to inhibit mTOR signaling as assessed by reduced phosphorylation of the downstream targets S6K1 and 4E-BP1. Dexamethasone has also been shown in one study to up-regulate the expression of REDD1 ( also referred to RTP801, a novel stress-induced gene linked to repression of mTOR signaling) in lymphoid, but not nonlymphoid, cells. In contrast to the findings of that study, here we demonstrate that REDD1, but not REDD2, mRNA expression is dramatically induced following acute dexamethasone treatment both in rat skeletal muscle in vivo and in L6 myoblasts in culture. In L6 myoblasts, the effect of the drug on mTOR signaling is efficiently blunted in the presence of REDD1 RNA interference oligonucleotides. Moreover, the dexamethasone-induced assembly of the mTOR regulatory complex Tuberin center dot Hamartin is disrupted in L6 myoblasts following small interfering RNA-mediated repression of REDD1 expression. Finally, overexpression of Rheb, a downstream target of Tuberin function and a positive upstream effector of mTOR, reverses the effect of dexamethasone on phosphorylation of mTOR substrates. Overall, the data support the conclusion that REDD1 functions upstream of Tuberin and Rheb to down-regulate mTOR signaling in response to dexamethasone.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02116 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kimball, SR (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, H166,500 Univ Dr, Hershey, PA 17033 USA.	skimball@psu.edu	Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-15658] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anthony JC, 2000, J NUTR, V130, P2413; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; FERRARI S, 1991, J BIOL CHEM, V266, P22770; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kimball SR, 1998, AM J PHYSIOL-CELL PH, V274, pC221, DOI 10.1152/ajpcell.1998.274.1.C221; KIMBALL SR, 1994, BBA-GEN SUBJECTS, V1201, P473, DOI 10.1016/0304-4165(94)90079-5; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Lin L, 2005, BIOCHEM J, V392, P93, DOI 10.1042/BJ20050553; Lin L, 2005, BIOCHEMISTRY-US, V44, P3909, DOI 10.1021/bi047574r; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Rannels D E, 1980, Adv Myocardiol, V1, P493; RANNELS SR, 1978, AM J PHYSIOL, V235, pE134, DOI 10.1152/ajpendo.1978.235.2.E134; RANNELS SR, 1980, AM J PHYSIOL, V238, pE564, DOI 10.1152/ajpendo.1980.238.6.E564; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Roccio M, 2006, ONCOGENE, V25, P657, DOI 10.1038/sj.onc.1209106; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schwarzer R, 2005, ONCOGENE, V24, P1138, DOI 10.1038/sj.onc.1208236; Shah OJ, 2005, CELL CYCLE, V4, P46, DOI 10.4161/cc.4.1.1343; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE74, DOI 10.1152/ajpendo.2000.279.1.E74; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE76, DOI 10.1152/ajpendo.2000.278.1.E76; Shah OJ, 2002, J BIOL CHEM, V277, P2525, DOI 10.1074/jbc.M105935200; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE1185, DOI 10.1152/ajpendo.2000.279.5.E1185; Shah OJ, 2000, BIOCHEM J, V347, P389, DOI 10.1042/0264-6021:3470389; SHOJI S, 1977, MOL CELL ENDOCRINOL, V6, P159, DOI 10.1016/0303-7207(77)90082-X; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; WOOL IG, 1959, AM J PHYSIOL, V197, P1089, DOI 10.1152/ajplegacy.1959.197.5.1089; Yoshizawa F, 1997, BIOCHEM BIOPH RES CO, V240, P825, DOI 10.1006/bbrc.1997.7652	47	190	205	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39128	39134		10.1074/jbc.M610023200	http://dx.doi.org/10.1074/jbc.M610023200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17074751	hybrid			2022-12-25	WOS:000242898700020
J	Egawa, N; Koshikawa, N; Tomari, T; Nabeshima, K; Isobe, T; Seiki, M				Egawa, Nagayasu; Koshikawa, Naohiko; Tomari, Taizo; Nabeshima, Kazuki; Isobe, Toshiaki; Seiki, Motoharu			Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGENASE-STIMULATORY FACTOR; IMMUNOGLOBULIN SUPERFAMILY MEMBER; GELATINASE-A; MELANOMA-CELLS; BREAST-CANCER; MOUSE BASIGIN; EXPRESSION; ACTIVATION; FIBROBLASTS; SURFACE	Proteolytic shedding is an important step in the functional down-regulation and turnover of most membrane proteins at the cell surface. Extracellular matrix metalloproteinase inducer ( EMMPRIN) is a multifunctional glycoprotein that has two Ig-like domains in its extracellular portion and functions in cell adhesion as an inducer of matrix metalloproteinase (MMP) expression in surrounding cells. Although the shedding of EMMPRIN is reportedly because of cleavage by metalloproteinases, the responsible proteases, cleavage sites, and stimulants are not yet known. In this study, we found that human tumor HT1080 and A431 cells shed a 22-kDa EMMPRIN fragment into the culture medium. The shedding was enhanced by phorbol 12-myristate 13-acetate and inhibited by TIMP-2 but not by TIMP-1, suggesting the involvement of membrane-type MMPs (MT-MMPs). Indeed, down-regulation of the MT1-MMP expression in A431 cells using small interfering RNA inhibited the shedding. The 22-kDa fragment was purified, and the C-terminal amino acid was determined. A synthetic peptide spanning the cutting site was cleaved by MT1-MMP in vitro. The cleavage site is located in the linker region connecting the two Ig-like domains. The N-terminal Ig-like domain is important for the MMP inducing activity of EMMPRIN and for cell-cell interactions, presumably through its ability to engage in homophilic interactions, and the 22-kDa fragment retained the ability to augment MMP-2 expression in human fibroblasts. Thus, the MT1-MMP dependent cleavage eliminates the functional N-terminal domain of EMMPRIN from the cell surface, which is expected to down-regulate its function. At the same time, the released 22-kDa fragment may mediate the expression of MMPs in tumor tissues.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Tokyo 1088639, Japan; Fukuoka Univ Hosp, Dept Pathol, Fukuoka 8140180, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Tokyo 1920397, Japan	University of Tokyo; Fukuoka University; Tokyo Metropolitan University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Isobe, Toshiaki/Q-9279-2017; Seiki, Motoharu/K-9443-2015; Koshikawa, Naohiko/S-7306-2017	Koshikawa, Naohiko/0000-0002-4539-888X				BISWAS C, 1995, CANCER RES, V55, P434; BISWAS C, 1984, CANCER LETT, V24, P201, DOI 10.1016/0304-3835(84)90137-X; BISWAS C, 1987, J CELL BIOCHEM, V35, P247, DOI 10.1002/jcb.240350307; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Davidson B, 2003, CLIN EXP METASTAS, V20, P161, DOI 10.1023/A:1022696012668; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELLIS SM, 1989, CANCER RES, V49, P3385; Fadool JM, 1996, BIOCHEM BIOPH RES CO, V229, P280, DOI 10.1006/bbrc.1996.1793; Gabison EE, 2005, BIOCHIMIE, V87, P361, DOI 10.1016/j.biochi.2004.09.023; Guo HM, 1997, J BIOL CHEM, V272, P24; Haug C, 2004, ARTERIOSCL THROM VAS, V24, P1823, DOI 10.1161/01.ATV.0000142806.59283.11; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Igakura T, 1996, BIOCHEM BIOPH RES CO, V224, P33, DOI 10.1006/bbrc.1996.0980; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; KASINRERK W, 1992, J IMMUNOL, V149, P847; KATAOKA H, 1993, CANCER RES, V53, P3154; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; MIYAUCHI T, 1991, J BIOCHEM-TOKYO, V110, P770, DOI 10.1093/oxfordjournals.jbchem.a123657; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Muramatsu T, 2003, HISTOL HISTOPATHOL, V18, P981, DOI 10.14670/HH-18.981; Nabeshima K, 2004, J PATHOL, V202, P341, DOI 10.1002/path.1518; NABESHIMA K, 1991, ARCH BIOCHEM BIOPHYS, V285, P90, DOI 10.1016/0003-9861(91)90332-D; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; Naruhashi K, 1997, BIOCHEM BIOPH RES CO, V236, P733, DOI 10.1006/bbrc.1997.6993; Nonaka T, 2005, MOL CANCER THER, V4, P1157, DOI 10.1158/1535-7163.MCT-05-0127; Polette M, 1997, J HISTOCHEM CYTOCHEM, V45, P703, DOI 10.1177/002215549704500508; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070; Sier CFM, 2006, INT J CANCER, V118, P2991, DOI 10.1002/ijc.21778; Sun JX, 2001, CANCER RES, V61, P2276; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tang Y, 2004, MOL CANCER RES, V2, P73; Taylor PM, 2002, ONCOGENE, V21, P5765, DOI 10.1038/sj.onc.1205702; Yang JM, 2003, MOL CANCER RES, V1, P420; Yoshida S, 2000, EUR J BIOCHEM, V267, P4372, DOI 10.1046/j.1432-1327.2000.01482.x	45	109	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37576	37585		10.1074/jbc.M606993200	http://dx.doi.org/10.1074/jbc.M606993200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17050542	hybrid			2022-12-25	WOS:000242477100034
J	Kretz, CA; Stafford, AR; Fredenburgh, JC; Weitz, JI				Kretz, Colin A.; Stafford, Alan R.; Fredenburgh, James C.; Weitz, Jeffrey I.			HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IB-ALPHA; FACTOR-VA; FACTOR-XA; ANTITHROMBIN-III; PROEXOSITE-I; DNA APTAMER; PHOSPHOLIPID-VESICLES; PROCOAGULANT LIPIDS; HEPARIN-COFACTOR; PPACK-THROMBIN	Incorporation of prothrombin into the prothrombinase complex is essential for rapid thrombin generation at sites of vascular injury. Prothrombin binds directly to anionic phospholipid membrane surfaces where it interacts with the enzyme, factor Xa, and its cofactor, factor Va. We demonstrate that HD1, a thrombin-directed aptamer, binds prothrombin and thrombin with similar affinities (K-d values of 86 and 34 nM, respectively) and attenuates prothrombin activation by prothrombinase by over 90% without altering the activation pathway. HD1-mediated inhibition of prothrombin activation by prothrombinase is factor Va-dependent because (a) the inhibitory activity of HD1 is lost if factor Va is omitted from the prothrombinase complex and (b) prothrombin binding to immobilized HD1 is reduced by factor Va. These data suggest that HD1 competes with factor Va for prothrombin binding. Kinetic analyses reveal that HD1 produces a 2-fold reduction in the k(cat) for prothrombin activation by prothrombinase and a 6-fold increase in the K-m, highlighting the contribution of the factor Va-prothrombin interaction to prothrombin activation. As a high affinity, prothrombin exosite 1-directed ligand, HD1 inhibits prothrombin activation more efficiently than Hir(54-65)(SO3-). These findings suggest that exosite 1 on prothrombin exists as a proexosite only for ligands whose primary target is thrombin rather than prothrombin.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Weitz, JI (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	jweitz@thrombosis.hhscr.org	Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				Adam F, 2003, TRENDS MOL MED, V9, P461, DOI 10.1016/j.molmed.2003.09.009; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Anderson JAM, 2001, J BIOL CHEM, V276, P9755, DOI 10.1074/jbc.M010048200; Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2003, J BIOL CHEM, V278, P44482, DOI 10.1074/jbc.M306917200; Anderson PJ, 2003, J BIOL CHEM, V278, P44489, DOI 10.1074/jbc.M306916200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARNI RK, 1994, CHEM PHYS LIPIDS, V67-8, P59, DOI 10.1016/0009-3084(94)90124-4; Banerjee M, 2002, BIOCHEMISTRY-US, V41, P950, DOI 10.1021/bi0116902; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Bukys MA, 2005, J BIOL CHEM, V280, P27393, DOI 10.1074/jbc.M503435200; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; CHURCH WR, 1991, J BIOL CHEM, V266, P8384; Cosmi B, 2003, THROMB RES, V109, P333, DOI 10.1016/S0049-3848(03)00246-9; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; De Candia E, 2001, J BIOL CHEM, V276, P4692, DOI 10.1074/jbc.M008160200; De Cristofaro R, 1998, CIRCULATION, V98, P1297, DOI 10.1161/01.CIR.98.13.1297; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Dougan H, 2003, NUCL MED BIOL, V30, P61, DOI 10.1016/S0969-8051(02)00378-5; Fischer BE, 1998, PROTEIN ENG, V11, P715, DOI 10.1093/protein/11.8.715; Fortenberry YM, 2004, J BIOL CHEM, V279, P43237, DOI 10.1074/jbc.M406716200; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GRIFFIN LC, 1993, GENE, V137, P25, DOI 10.1016/0378-1119(93)90247-Z; Han JH, 1997, J BIOL CHEM, V272, P28660, DOI 10.1074/jbc.272.45.28660; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; KACZMAREK E, 1987, BIOCHIM BIOPHYS ACTA, V914, P275, DOI 10.1016/0167-4838(87)90286-X; Kalafatis M, 2005, CURR OPIN HEMATOL, V12, P141, DOI 10.1097/01.moh.0000155016.30296.90; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane DA, 2005, BLOOD, V106, P2605, DOI 10.1182/blood-2005-04-1710; Malkowski MG, 1997, PROTEIN SCI, V6, P1438, DOI 10.1002/pro.5560060708; Mann K G, 1976, Methods Enzymol, V45, P123; Mann KG, 2003, J THROMB HAEMOST, V1, P1504, DOI 10.1046/j.1538-7836.2003.00298.x; Mao X, 2005, BIOPHYS CHEM, V113, P155, DOI 10.1016/j.bpc.2004.09.003; Mengwasser KE, 2005, J BIOL CHEM, V280, P26997, DOI 10.1074/jbc.M502678200; MERCOLA DA, 1972, BIOCHEMISTRY-US, V11, P3860, DOI 10.1021/bi00771a005; Monteiro RQ, 2002, THROMB HAEMOSTASIS, V87, P288; NI F, 1993, J BIOL CHEM, V268, P16899; PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651; Panizzi P, 2006, J BIOL CHEM, V281, P1169, DOI 10.1074/jbc.M507955200; Pike RN, 2005, FEBS J, V272, P4842, DOI 10.1111/j.1742-4658.2005.04880.x; RABIET MJ, 1986, J BIOL CHEM, V261, P3210; Rezaie AR, 2003, P NATL ACAD SCI USA, V100, P12051, DOI 10.1073/pnas.2135346100; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Weinreb GE, 2003, J BIOL CHEM, V278, P5679, DOI 10.1074/jbc.M208423200; Wu JR, 2002, BIOCHEMISTRY-US, V41, P935, DOI 10.1021/bi0116893; WU QY, 1994, J BIOL CHEM, V269, P3725; Yegneswaran S, 2004, J BIOL CHEM, V279, P49019, DOI 10.1074/jbc.M406645200; Yegneswaran S, 2003, J BIOL CHEM, V278, P33312, DOI 10.1074/jbc.M305906200; Zingali RB, 2001, HAEMOSTASIS, V31, P273	62	54	57	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37477	37485		10.1074/jbc.M607359200	http://dx.doi.org/10.1074/jbc.M607359200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17046833	hybrid			2022-12-25	WOS:000242477100024
J	Lee, JE; Kim, Y				Lee, Jae-Eun; Kim, Youngho			A tissue-specific variant of the human lysyl oxidase-like protein 3 (LOXL3) functions as an amine oxidase with substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; LIVER FIBROSIS; CUTIS LAXA; GENE; COLLAGEN; EXPRESSION; SEQUENCE; ELASTIN; CLONING; ENZYME	The human lysyl oxidase-like 3 (LOXL3) encodes a member of the emerging family of lysyl oxidase (LOX) that functions as a copper-dependent amine oxidase. The LOXL3 protein contains four scavenger receptor cysteine-rich domains in the N terminus in addition to the C-terminal characteristic domains of the LOX family, such as a copper binding domain, a cytokine receptor-like domain and residues for the lysyl-tyrosyl quinone cofactor. Using BLASTN searches, we identified a LOXL3 variant LOXL3-sv1 that lacked the sequences corresponding to exons 1, 2, 3, and 5 of LOXL3. LOXL3-sv1 showed an exon-intron structure distinct from LOXL3, additionally containing an 80-bp sequence corresponding to intron 3 of LOXL3 in the 5'-UTR and a 561-bp sequence corresponding to the 3'-flanking genomic region of exon 14 in the 3'-UTR. LOXL3-sv1 was predicted to encode a polypeptide of 392 amino acids that contains the C-terminal domains required for amine oxidase activity but lacks the N-terminal SRCR domains 1, 2, and 3. The recombinant LOXL3-sv1 protein showed a beta-amino-propionitrile-inhibitable amine oxidase activity toward elastin and collagen with substrate specificity. In RT-PCR assays with various human tissues, LOXL3-sv1 and LOXL3 showed distinct expression patterns. Further, luciferase reporter assays revealed a strong promoter element in intron 3 that probably functions as a regulatory region for the expression of LOXL3-sv1. These findings strongly indicate that LOXL3 encodes two variants, LOXL3 and LOXL3-sv1, both of which function as amine oxidases with distinct tissue and substrate specificities from one another.	Wonkwang Univ, Sch Med, Dept Biochem, Iksan 570749, Jeollabuk, South Korea; Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea	Wonkwang University; Sookmyung Women's University	Kim, Y (corresponding author), Wonkwang Univ, Sch Med, Dept Biochem, Sinyong Dong 344-2, Iksan 570749, Jeollabuk, South Korea.	youngkim@wonkwang.ac.kr						Asuncion L, 2001, MATRIX BIOL, V20, P487, DOI 10.1016/S0945-053X(01)00161-5; Borel A, 2001, J BIOL CHEM, V276, P48944, DOI 10.1074/jbc.M109499200; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Decitre M, 1998, LAB INVEST, V78, P143; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; FORNIERI C, 1994, J INVEST DERMATOL, V103, P583, DOI 10.1111/1523-1747.ep12396893; Giampuzzi M, 2001, J BIOL CHEM, V276, P29226, DOI 10.1074/jbc.M101695200; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Huang Y, 2001, MATRIX BIOL, V20, P153, DOI 10.1016/S0945-053X(01)00124-X; Jonasson P, 2002, BIOTECHNOL APPL BIOC, V35, P91, DOI 10.1042/BA20010099; Jourdan-Le Saux C, 1999, J BIOL CHEM, V274, P12939; Jourdan-Le Saux C, 2001, GENOMICS, V74, P211, DOI 10.1006/geno.2001.6545; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1981, ARTERIOSCLEROSIS, V1, P287, DOI 10.1161/01.ATV.1.4.287; Khakoo A, 1997, CLIN GENET, V51, P109; Kim MS, 2003, J BIOL CHEM, V278, P52071, DOI 10.1074/jbc.M308856200; Kim YH, 1999, J CELL BIOCHEM, V72, P181, DOI 10.1002/(SICI)1097-4644(19990201)72:2<181::AID-JCB3>3.0.CO;2-D; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; Li WD, 2000, J CELL BIOCHEM, V78, P550, DOI 10.1002/1097-4644(20000915)78:4<550::AID-JCB4>3.3.CO;2-#; Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Maki JM, 2001, BIOCHEM J, V355, P381, DOI 10.1042/0264-6021:3550381; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Plenz GAM, 2003, ATHEROSCLEROSIS, V166, P1, DOI 10.1016/S0021-9150(01)00766-3; Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140-6736(04)16051-0; RicardBlum S, 1996, GASTROENTEROLOGY, V111, P172, DOI 10.1053/gast.1996.v111.pm8698196; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; Sharma R, 1997, BIOSCIENCE REP, V17, P409, DOI 10.1023/A:1027361418200; Shen G, 2005, Orthod Craniofac Res, V8, P11, DOI 10.1111/j.1601-6343.2004.00308.x; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9	35	29	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37282	37290		10.1074/jbc.M600977200	http://dx.doi.org/10.1074/jbc.M600977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17018530	hybrid			2022-12-25	WOS:000242477100005
J	Nadauld, LD; Phelps, R; Moore, BC; Eisinger, A; Sandoval, IT; Chidester, S; Peterson, PW; Manos, EJ; Sklow, B; Burt, RW; Jones, DA				Nadauld, Lincoln D.; Phelps, Reid; Moore, Brent C.; Eisinger, Annie; Sandoval, Imelda T.; Chidester, Stephanie; Peterson, Peter W.; Manos, Elizabeth J.; Sklow, Bradford; Burt, Randall W.; Jones, David A.			Adenomatous polyposis coli control of C-terminal binding protein-1 stability regulates expression of intestinal retinol dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; BETA-CATENIN; TRANSCRIPTIONAL REPRESSION; IN-VITRO; CANCER; CTBP; GENE; MUTATIONS; PHOSPHORYLATION; DIFFERENTIATION	Mutations in the human adenomatous polyposis coli (APC) gene are thought to initiate colorectal tumorigenesis. The tumor suppressor function of APC is attributed primarily to its ability to regulate the WNT pathway by targeting the destruction of beta-catenin. We report here a novel role for APC in regulating degradation of the transcriptional co-repressor C-terminal-binding protein-1 (CtBP1) through a proteasome-dependent process. Further, CtBP1 suppresses the expression of intestinal retinol dehydrogenases, which are required for retinoic acid production and intestinal differentiation. In support of a role for CtBP1 in initiation of colorectal cancer, adenomas taken from individuals with familial adenomatous polyposis contain high levels of CtBP1 protein in comparison with matched, uninvolved tissue. The relationship between APC and CtBP1 is conserved between humans and zebrafish and provides a mechanistic model explaining APC control of intestinal retinoic acid biosynthesis.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	david.jones@hci.utah.edu		Chidester, Stephanie/0000-0003-4163-3480				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Brannon M, 1999, DEVELOPMENT, V126, P3159; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Eisinger AL, 2006, J BIOL CHEM, V281, P20474, DOI 10.1074/jbc.M602859200; Fang M, 2006, EMBO J, V25, P2735, DOI 10.1038/sj.emboj.7601153; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; HARAMIS AP, 2006, EMBO REP; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200; NADULD LD, 2005, J BIOL CHEM; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Phippen TM, 2000, J BIOL CHEM, V275, P37628, DOI 10.1074/jbc.M004234200; Polakis P, 2000, GENE DEV, V14, P1837; Qualtrough D, 2002, GUT, V51, P184, DOI 10.1136/gut.51.2.184; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rubinfeld B, 1997, CANCER RES, V57, P4624; Saller E, 2002, GENE DEV, V16, P1828, DOI 10.1101/gad.230002; Samowitz WS, 1999, CANCER RES, V59, P1442; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	36	39	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37828	37835		10.1074/jbc.M602119200	http://dx.doi.org/10.1074/jbc.M602119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17028196	hybrid			2022-12-25	WOS:000242477100060
J	Vicente, R; Escalada, A; Villalonga, N; Texido, L; Roura-Ferrer, M; Martin-Satue, M; Lopez-Iglesias, C; Soler, C; Solsona, C; Tamkun, MM; Felipe, A				Vicente, Ruben; Escalada, Artur; Villalonga, Nuria; Texido, Laura; Roura-Ferrer, Meritxell; Martin-Satue, Mireia; Lopez-Iglesias, Carmen; Soler, Concepcio; Solsona, Carles; Tamkun, Michael M.; Felipe, Antonio			Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; SUBUNIT COMPOSITION; EXPRESSION; CELL; PROLIFERATION; DEXAMETHASONE; TRANSCRIPTION; LOCALIZATION; MODULATION; MICROGLIA	Voltage-dependent K+ (Kv) currents in macrophages are mainly mediated by Kv1.3, but biophysical properties indicate that the channel composition could be different from that of T-lymphocytes. K+ currents in mouse bone marrow-derived and Raw-264.7 macrophages are sensitive to Kv1.3 blockers, but unlike T-cells, macrophages express Kv1.5. Because Shaker subunits (Kv1) may form heterotetrameric complexes, we investigated whether Kv1.5 has a function in Kv currents in macrophages. Kv1.3 and Kv1.5 co-localize at the membrane, and half-activation voltages and pharmacology indicate that K+ currents may be accounted for by various Kv complexes in macrophages. Co-expression of Kv1.3 and Kv1.5 in human embryonic kidney 293 cells showed that the presence of Kv1.5 leads to a positive shift in K+ current half-activation voltages and that, like Kv1.3, Kv1.3/Kv1.5 heteromers are sensitive to r-margatoxin. In addition, both proteins co-immunoprecipitateandco- localize. Fluorescence resonance energy transfer studies further demonstrated that Kv1.5 and Kv1.3 form heterotetramers. Electrophysiological and pharmacological studies of different ratios of Kv1.3 and Kv1.5 coexpressed in Xenopus oocytes suggest that various hybrids might be responsible for K+ currents in macrophages. Tumor necrosis factor-alpha-induced activation of macrophages increased Kv1.3 with no changes in Kv. 1.5, which is consistent with a hyperpolarized shift in half-activation voltage and a lower IC50 for margatoxin. Taken together, our results demonstrate that Kv1.5 co-associates with Kv1.3, generating functional heterotetramers in macrophages. Changes in the oligomeric of functional Kv channels would give rise to different biophysical and pharmacological properties, which could determine specific cellular responses.	Univ Barcelona, Dept Bioquim & Biol Mol, Mol Physiol Lab, E-08028 Barcelona, Spain; Univ Barcelona, Unitat Reconeixement Mol In Situ, Serveis Cientificotecn, E-08028 Barcelona, Spain; Univ Barcelona, Dept Fisiol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Patol & Terapeut Expt, IDIBELL, Cell & Mol Neurobiol Lab, E-08907 Lhospitalet De Llobregat, Spain; Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA	University of Barcelona; University of Barcelona; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Colorado State University	Felipe, A (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Mol Physiol Lab, Avda Diagonal 645, E-08028 Barcelona, Spain.	afelipe@ub.edu	Soler, Concepció/L-1185-2014; Felipe, Antonio/M-8297-2015; García, Rubén Vicente/L-1097-2014	Soler, Concepció/0000-0001-6502-5012; Felipe, Antonio/0000-0002-7294-6431; García, Rubén Vicente/0000-0003-0401-4808; Texido, Laura/0000-0002-2780-4434	NHLBI NIH HHS [HL49330] Funding Source: Medline; NINDS NIH HHS [NS41542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beeton C, 2005, NEUROSCIENTIST, V11, P550, DOI 10.1177/1073858405278016; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Chung S, 2001, NEUROSCI LETT, V300, P67, DOI 10.1016/S0304-3940(01)01516-6; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; FREEDMAN BD, 1992, J IMMUNOL, V149, P3784; Fuster G, 2002, METHOD FIND EXP CLIN, V24, P253, DOI 10.1358/mf.2002.24.5.802301; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; Gutman GA, 2005, PHARMACOL REV, V57, P473, DOI 10.1124/pr.57.4.10; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Jensen HL, 1999, HISTOCHEM J, V31, P525, DOI 10.1023/A:1003840006848; Jou I, 1998, GLIA, V24, P408, DOI 10.1002/(SICI)1098-1136(199812)24:4<408::AID-GLIA6>3.3.CO;2-4; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; KLUMPP DJ, 1995, J NEUROSCI, V15, P5004; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; Lampert A, 2003, PFLUG ARCH EUR J PHY, V447, P168, DOI 10.1007/s00424-003-1148-2; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Martens JR, 1999, TRENDS CARDIOVAS MED, V9, P253, DOI 10.1016/S1050-1738(00)00037-2; MI HY, 1995, J NEUROSCI, V15, P3761; Panyi G, 2004, P NATL ACAD SCI USA, V101, P1285, DOI 10.1073/pnas.0307421100; Panyi G, 2003, P NATL ACAD SCI USA, V100, P2592, DOI 10.1073/pnas.0438057100; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; Pyo H, 1997, MOL CELLS, V7, P610; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; Sobko A, 1998, J NEUROSCI, V18, P10398; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; Szabo I, 2005, J BIOL CHEM, V280, P12790, DOI 10.1074/jbc.M413548200; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; Takimoto K, 1996, BIOCHEMISTRY-US, V35, P14149, DOI 10.1021/bi961290s; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; Vicente R, 2005, J IMMUNOL, V174, P4736, DOI 10.4049/jimmunol.174.8.4736; Vicente R, 2005, J BIOL CHEM, V280, P13204; Vicente R, 2004, FEBS LETT, V572, P189, DOI 10.1016/j.febslet.2004.07.030; Vicente R, 2003, J BIOL CHEM, V278, P46307, DOI 10.1074/jbc.M304388200; Wang FC, 1999, EUR J BIOCHEM, V263, P230, DOI 10.1046/j.1432-1327.1999.00493.x	37	111	116	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37675	37685		10.1074/jbc.M605617200	http://dx.doi.org/10.1074/jbc.M605617200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17038323	hybrid, Green Published			2022-12-25	WOS:000242477100045
J	Ames, JB; Levay, K; Wingard, JN; Lusin, JD; Slepak, VZ				Ames, James B.; Levay, Konstantin; Wingard, Jennifer N.; Lusin, Jacqueline D.; Slepak, Vladlen Z.			Structural basis for calcium-induced inhibition of rhodopsin kinase by recoverin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PROTEIN-2; ROD GUANYLATE-CYCLASE; CRYSTAL-STRUCTURE; CA2+-BINDING PROTEINS; MYRISTOYLATED RECOVERIN; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; NMR-SPECTROSCOPY; RETINAL RODS; K+ CHANNELS	Recoverin, a member of the neuronal calcium sensor branch of the EF-hand superfamily, serves as a calcium sensor that regulates rhodopsin kinase (RK) activity in retinal rod cells. We report here the NMR structure of Ca2+-bound recoverin bound to a functional N-terminal fragment of rhodopsin kinase (residues 1-25, called RK25). The overall main-chain structure of recoverin in the complex is similar to structures of Ca2+-bound recoverin in the absence of target (< 1.8 angstrom root-mean-square deviation). The first eight residues of recoverin at the N terminus are solvent-exposed, enabling the N-terminal myristoyl group to interact with target membranes, and Ca2+ is bound at the second and third EF-hands of the protein. RK25 in the complex forms an amphipathic helix (residues 4-16). The hydrophobic face of the RK25 helix (Val-9, Val-10, Ala-11, Ala-14, and Phe-15) interacts with an exposed hydrophobic groove on the surface of recoverin lined by side-chain atoms of Trp-31, Phe-35, Phe-49, Ile-52, Tyr-53, Phe-56, Phe-57, Tyr-86, and Leu-90. Residues of recoverin that contact RK25 are highly conserved, suggesting a similar target binding site structure in all neuronal calcium sensor proteins. Site-specific mutagenesis and deletion analysis confirm that the hydrophobic residues at the interface are necessary and sufficient for binding. The recoverin-RK25 complex exhibits Ca2+-induced binding to rhodopsin immobilized on concanavalin-A resin. We propose that Ca2+-bound recoverin is bound between rhodopsin and RK in a ternary complex on rod outer segment disk membranes, thereby blocking RK interaction with rhodopsin at high Ca2+.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Miami, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Program Neurosci, Miami, FL 33136 USA	University of Miami; University of Miami	Ames, JB (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.	ames@chem.ucdavis.edu			NEI NIH HHS [EY012347] Funding Source: Medline; NIGMS NIH HHS [GM060019] Funding Source: Medline; NINDS NIH HHS [NS045909] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045909] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CALVERT PD, 1995, J BIOL CHEM, V270, P24127, DOI 10.1074/jbc.270.41.24127; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Clore GM, 1997, NAT STRUCT BIOL, V4, P849; Detwiler PB, 2000, METHOD ENZYMOL, V316, P133; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1989, BIOCHEM BIOPH RES CO, V162, P544, DOI 10.1016/0006-291X(89)92031-7; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Erickson MA, 1998, P NATL ACAD SCI USA, V95, P6474, DOI 10.1073/pnas.95.11.6474; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; Fisher JR, 2000, PROTEIN EXPRES PURIF, V20, P66, DOI 10.1006/prep.2000.1298; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Higgins MK, 2006, J BIOL CHEM, V281, P19426, DOI 10.1074/jbc.M602203200; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KUTUZOV MA, 1991, FEBS LETT, V293, P21, DOI 10.1016/0014-5793(91)81143-V; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; Levay K, 1998, BIOCHEMISTRY-US, V37, P13650, DOI 10.1021/bi980998z; Makino CL, 2004, J GEN PHYSIOL, V123, P729, DOI 10.1085/jgp.200308994; MCINTOSH LP, 1990, Q REV BIOPHYS, V23, P1, DOI 10.1017/S0033583500005400; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Sampath AP, 2005, NEURON, V46, P413, DOI 10.1016/j.neuron.2005.04.006; Scannevin RH, 2004, NEURON, V41, P587, DOI 10.1016/S0896-6273(04)00049-2; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; Stephen R, 2006, J MOL BIOL, V359, P266, DOI 10.1016/j.jmb.2006.03.042; Strissel KJ, 2005, J BIOL CHEM, V280, P29250, DOI 10.1074/jbc.M501789200; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; Tanaka T, 1998, J BIOMOL NMR, V11, P135, DOI 10.1023/A:1008212316986; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Wingard JN, 2005, J BIOL CHEM, V280, P37461, DOI 10.1074/jbc.M508541200; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Zhou W, 2004, NEURON, V41, P573, DOI 10.1016/S0896-6273(04)00045-5; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	57	82	84	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37237	37245		10.1074/jbc.M606913200	http://dx.doi.org/10.1074/jbc.M606913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17020884	hybrid			2022-12-25	WOS:000242220800084
J	Nakamura, K; Hihara, Y				Nakamura, Kinu; Hihara, Yukako			Photon flux density-dependent gene expression in Synechocystis sp PCC 6803 is regulated by a small, redox-responsive, LuxR-type regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MICROARRAY ANALYSIS; ARABIDOPSIS-THALIANA; HIGH-LIGHT; ACCLIMATION; TRANSCRIPTION; GERE; GENOME	The expression of many cyanobacterial genes is regulated by the redox state of the photosynthetic electron transport chain. However, factors involved in this regulation have not been identified. In this study, we demonstrate that a small LuxR-type regulator in Synechocystis sp. PCC 6803, PedR (Ss10564), senses the activity of photosynthetic electron transport to achieve the photon flux density-dependent transcriptional regulation. PedR is constitutively expressed in Synechocystis cells and exists as a dimer bridged by intermolecular disulfide bond(s). It activates the expression of chlL, chlN, chlB, and slr1957 and represses that of ndhD2, rpe, and the pedR (ssl0564)-sll0296 operon under conditions where the activity of photosynthetic electron transport is low. When the supply of reducing equivalents from photosynthetic electron transport chain increases upon the elevation of photon flux density, PedR is inactivated through its conformational change within 5 min. This mechanism enables transient induction or repression of the target genes in response to sudden changes in light environment. The fact that orthologs of PedR are conserved among all the cyanobacterial genomes sequenced so far indicates that this type of transcriptional regulation is essential for cyanobacteria to acclimate to changing environments.	Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Okubo, Saitama 3388570, Japan	Saitama University	Hihara, Y (corresponding author), Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, 255 Shimo, Okubo, Saitama 3388570, Japan.	hihara@molbiol.saitama-u.ac.jp	Hihara, Yukako/AAO-6742-2020; Hihara, Yukako/E-3461-2010; Hihara, Yukako/AAX-2065-2020	Hihara, Yukako/0000-0003-1916-2053; 				Allen JF, 2000, PHILOS T R SOC B, V355, P1351, DOI 10.1098/rstb.2000.0697; ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; Asada K., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P77; Bailey S, 2004, PLANTA, V218, P793, DOI 10.1007/s00425-003-1158-5; CUTTING S, 1989, J MOL BIOL, V207, P393, DOI 10.1016/0022-2836(89)90262-3; Danot O, 1996, J MOL BIOL, V262, P1, DOI 10.1006/jmbi.1996.0493; Ducros VMA, 2001, J MOL BIOL, V306, P759, DOI 10.1006/jmbi.2001.4443; Durnford DG, 1997, PHOTOSYNTH RES, V53, P229, DOI 10.1023/A:1005815725371; Hihara Y, 2003, J BACTERIOL, V185, P1719, DOI 10.1128/JB.185.5.1719-1725.2003; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; HIHARA Y, 1999, CURR TOP PLANT BIO, V1, P37; Huang LX, 2002, J BACTERIOL, V184, P6845, DOI 10.1128/JB.184.24.6845-6858.2002; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; Ichikawa H, 1999, J BIOL CHEM, V274, P8322, DOI 10.1074/jbc.274.12.8322; Izawa S., 1980, METHODS ENZYMOL    C, P413; Kanesaki Y, 2002, BIOCHEM BIOPH RES CO, V290, P339, DOI 10.1006/bbrc.2001.6201; Li H, 2004, J BACTERIOL, V186, P3331, DOI 10.1128/JB.186.11.3331-3345.2004; Muramatsu M, 2003, PLANTA, V216, P446, DOI 10.1007/s00425-002-0859-5; Ohkawa H, 2000, J BIOL CHEM, V275, P31630, DOI 10.1074/jbc.M003706200; PAO GM, 1994, RES MICROBIOL, V145, P356, DOI 10.1016/0923-2508(94)90082-5; Piippo M, 2006, PHYSIOL GENOMICS, V25, P142, DOI 10.1152/physiolgenomics.00256.2005; Singh AK, 2003, PLANT PHYSIOL, V132, P1825, DOI 10.1104/pp.103.024018; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Trebst A., 1980, METH ENZYMOL, V69, P675, DOI DOI 10.1016/S0076-6879(80)69067-3; Tu CJ, 2004, J BACTERIOL, V186, P3889, DOI 10.1128/JB.186.12.3889-3902.2004; Wang H, 2004, J BIOL CHEM, V279, P1468, DOI 10.1074/jbc.M309106200; ZHENG LB, 1992, J MOL BIOL, V226, P1037, DOI 10.1016/0022-2836(92)91051-P	27	36	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36758	36766		10.1074/jbc.M606797200	http://dx.doi.org/10.1074/jbc.M606797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17035238	hybrid			2022-12-25	WOS:000242220800033
J	Kapoor, M; Kojima, F; Qian, M; Yang, LH; Crofford, LJ				Kapoor, Mohit; Kojima, Fumiaki; Qian, Min; Yang, Lihua; Crofford, Leslie J.			Shunting of prostanoid biosynthesis in microsomal prostaglandin E synthase-1 null embryo fibroblasts: regulatory effects on inducible nitric oxide synthase expression and nitrite synthesis	FASEB JOURNAL			English	Article						arachidonic acid (AA); cyclooxygenase (COX); L-arginine	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLLAGEN-INDUCED ARTHRITIS; RHEUMATOID SYNOVIAL-CELLS; E-2 PRODUCTION; MICE LACKING; CYCLOOXYGENASE-2 INHIBITORS; PROINFLAMMATORY CYTOKINES; SELECTIVE INHIBITOR; PROSTACYCLIN; IDENTIFICATION	Microsomal postaglandin (PG) E synthase (mPGES)-1 is an inducible enzyme that acts downstream of cyclooxygenase (COX) and specifically catalyzes the conversion of prostaglandin (PG)H-2 to PGE(2), most prominently in inflammatory conditions. Specific inhibitors of mPGES-1 are not yet available, however, mice with genetic deletion of mPGES-1 have been generated that have given insight into the specific role of mPGES-1 in eicosanoid biosynthesis in vivo and in peritoneal macrophages. We created mouse embryo fibroblast (MEF) cell lines that would facilitate investigation of the effect of mPGES-1 genetic deletion on prostanoid biosynthesis in fibroblast lineage cells and its subsequent effect on the expression of inducible NOS ( iNOS) and nitrite biosynthesis using cells derived from mPGES-1 wild-type (WT), heterozygous (Het), and null mice. The results show that genetic deletion of mPGES-1 results in a dramatic decrease in PGE2 production in Het and null MEFs under basal conditions and after stimulation with interleukin (IL)-1 beta, suggesting that mPGES-1 is critically important for PGE2 production. Furthermore, we show that mPGES-1 gene deletion results in diversion of prostanoid production from PGE(2) to 6-keto PGF(1 alpha) (the stable metabolic product of PGI(2); prostacyclin) in a gene dose-dependent manner in Het and null MEFs compared with their WT counterparts, suggesting a shunting phenomenon within the arachidonic acid ( AA) metabolic pathway. In addition, we show that mPGES-1 gene deletion and subsequent decrease in PGE2 levels results in a differential induction profile of iNOS and nitrite levels ( the stable breakdown product of nitric oxide (NO) in mPGES-1 WT MEFs compared with null MEFs. These results provide important information regarding the therapeutic potential for pharmacologic inhibition of mPGES-1 in inflammatory conditions.	Univ Kentucky, Dept Internal Med, Div Rheumatol, Kentucky Clin, Lexington, KY 40536 USA; Univ Michigan, Sch Med, Ann Arbor, MI USA	University of Kentucky; University of Michigan System; University of Michigan	Kapoor, M (corresponding author), Univ Kentucky, Dept Internal Med, Div Rheumatol, Kentucky Clin, Rm J-509, Lexington, KY 40536 USA.	lcrofford@email.uky.edu	Crofford, Leslie J/J-8010-2013	Crofford, Leslie J/0000-0002-6347-5738	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049010] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049010, AR 049010] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; BUNTING S, 1983, BRIT MED BULL, V39, P271, DOI 10.1093/oxfordjournals.bmb.a071832; Crofford LJ, 2003, ARTHRITIS RES THER, V5, P25, DOI 10.1186/ar620; Crofford LJ, 2002, CURR OPIN RHEUMATOL, V14, P225, DOI 10.1097/00002281-200205000-00005; Cuzzocrea S, 2002, EUR J PHARMACOL, V453, P119, DOI 10.1016/S0014-2999(02)02338-5; Gibbons GH, 1997, AM J CARDIOL, V79, P3, DOI 10.1016/S0002-9149(97)00122-7; Gomez-Hernandez A, 2006, J CARDIOVASC PHARM, V47, P60; Griffon B, 1998, HEPATOLOGY, V28, P1300, DOI 10.1002/hep.510280519; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Ikeda-Matsuo Y, 2005, J NEUROCHEM, V94, P1546, DOI 10.1111/j.1471-4159.2005.03302.x; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kawai S, 1998, INFLAMM RES, V47, pS102; Kino Y, 2005, PROSTAG LEUKOTR ESS, V73, P103, DOI 10.1016/j.plefa.2005.04.014; Kojima F, 2005, FUND CLIN PHARMACOL, V19, P255, DOI 10.1111/j.1472-8206.2005.00316.x; Kojima F, 2004, ARTHRITIS RES THER, V6, pR355, DOI 10.1186/ar1195; Kojima F, 2003, ARTHRITIS RHEUM, V48, P2819, DOI 10.1002/art.11261; Kojima F, 2002, J RHEUMATOL, V29, P1836; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MONCADA S, 1989, BIOCHEM SOC T, V17, P642, DOI 10.1042/bst0170642; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; Olschewski H, 1996, ANN INTERN MED, V124, P820, DOI 10.7326/0003-4819-124-9-199605010-00006; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Patel R, 1999, J IMMUNOL, V162, P4191; Pelletier JP, 2001, J RHEUMATOL, V28, P2509; Prast H, 2001, PROG NEUROBIOL, V64, P51, DOI 10.1016/S0301-0082(00)00044-7; Saha S, 2005, AM J PHYSIOL-REG I, V288, pR1100, DOI 10.1152/ajpregu.00872.2004; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; STEWART AG, 1994, MICROSURG, V15, P693, DOI 10.1002/micr.1920151006; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Trebino CE, 2005, J BIOL CHEM, V280, P16579, DOI 10.1074/jbc.M412075200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Westman M, 2004, ARTHRITIS RHEUM-US, V50, P1774, DOI 10.1002/art.20286; White WB, 2003, AM J CARDIOL, V92, P411, DOI 10.1016/S0002-9149(03)00659-3	47	28	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2387	+		10.1096/fj.06-6366fje	http://dx.doi.org/10.1096/fj.06-6366fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023389	Green Accepted, Green Submitted			2022-12-25	WOS:000241702600029
J	Wong, KK; Maser, RS; Sahin, E; Bailey, ST; Xia, H; Ji, H; McNamara, K; Naylor, M; Bronson, RT; Ghosh, S; Welsh, R; DePinho, RA				Wong, K-K; Maser, R. S.; Sahin, E.; Bailey, S. T.; Xia, H.; Ji, H.; McNamara, K.; Naylor, M.; Bronson, R. T.; Ghosh, S.; Welsh, R.; DePinho, R. A.			Diminished lifespan and acute stress-induced death in DNA-PKcs-deficient mice with limiting telomeres	ONCOGENE			English	Article						DNAPKcs; telomere; telomerase; stress; aging; cytokines	NF-KAPPA-B; ACTIVATION; REPAIR; AGE; KU; RESTRICTION; MAINTENANCE; DYSFUNCTION; IMMUNITY; LACKING	An adequate and appropriate response to physiological and pathophysiological stresses is critical for long-term homeostasis and viability of the aging organism. Previous work has pointed to the immune system, telomeres and DNA repair pathways as important and distinct determinants of a normal healthy lifespan. In this study, we explored the genetic interactions of telomeres and DNA-PKcs, a protein involved in non-homologous end-joining (NHEJ) and immune responses, in the context of a key aspect of aging and lifespan - the capacity to mount an acute and appropriate immune-mediated stress response. We observed that the combination of DNA-PKcs deficiency and telomere dysfunction resulted in a shortened lifespan that was reduced further following viral infection or experimental activation of the innate immune response. Analysis of the innate immune response in the DNA-PKcs-deficient mice with short dysfunctional telomeres revealed high basal serum levels of tumor necrosis factor alpha (TNF alpha) and hyper-active cytokine responses upon challenge with polyinosinic-polycytidylic acid (poly-IC). We further show that serum cytokine levels become elevated in telomere dysfunctional mice as a function of age. These results raise speculation that these genetic factors may contribute to misdirected immune responses of the aged under conditions of acute and chronic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Dept Genet & Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA; Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA; Dana Farber Canc Inst, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Yale University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Yale University; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu	Bailey, Shannon/B-8045-2014; Maser, Richard/B-2970-2012	DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [P01CA095616, R01CA034461, U01CA084313, R01CA084628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84313, P01 CA95616, R01 CA84628, CA34461] Funding Source: Medline; NIA NIH HHS [K08 AG2400401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bruunsgaard H, 2003, AM J MED, V115, P278, DOI 10.1016/S0002-9343(03)00329-2; Bruunsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; DAYNES RA, 1993, J IMMUNOL, V150, P5219; ERSHLER WB, 1993, LYMPHOKINE CYTOK RES, V12, P225; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Maser RS, 2004, DNA REPAIR, V3, P979, DOI 10.1016/j.dnarep.2004.05.009; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Um JH, 2003, MECH AGEING DEV, V124, P967, DOI 10.1016/S0047-6374(03)00169-6; WOLLSCHEIDLENGE.E, 2004, SCI AGING KNOWL ENV, pPE2; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385	24	5	6	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2815	2821		10.1038/sj.onc.1210099	http://dx.doi.org/10.1038/sj.onc.1210099			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072335				2022-12-25	WOS:000246210800001
J	Huang, HC; Hu, CH; Tang, MC; Wang, WS; Chen, PM; Su, Y				Huang, H.-C.; Hu, C.-H.; Tang, M.-C.; Wang, W.-S.; Chen, P.-M.; Su, Y.			Thymosin beta 4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase	ONCOGENE			English	Article						thymosin beta 4; E-cadherin; beta-catenin; integrin-linked kinase; epithelial-mesenchymal transition	E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; REPRESSES E-CADHERIN; CELL-CELL-ADHESION; COLON-CANCER; TUMOR-CELLS; CATENIN; GENE; PHOSPHORYLATION; INVASION	The epithelial-mesenchymal transition (EMT) is crucial for the invasion and metastasis of many epithelial tumors including colorectal carcinoma (CRC). In the present study, a scattering and fibroblastic morphology with reduced intercellular contacts was found in the SW480 colon cancer cells overexpressing the gene encoding thymosin beta 4 (T beta(4)), which was accompanied by a loss of E-cadherin as well as a cytosolic accumulation of beta-catenin, two most prominent markers of EMT. Whereas E-cadherin downregulation was likely to be accounted by a ZEB1-mediated transcriptional repression, the accumulation of beta-catenin was a result of glycogen synthase kinase-3 beta inactivation mediated by integrin-linked kinase (ILK) and/or its downstream effector, Akt. Intriguingly, ILK upregulation in T beta(4)-overexpressing SW480 cells seemed to be attributed mainly to a stabilization of this kinase by complexing with particularly interesting new Cys-His protein (PINCH) more efficiently. In the meantime, a strong correlation between the expression levels of T beta(4), ILK and E-cadherin in CRC patients was also revealed by immunohistochemical analysis. Taken together, these data suggest a novel role of T beta(4) in promoting CRC progression by inducing an EMT in tumor cells via upregulating ILK and consequentially its signal transduction.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Taiwan Ocean Univ, Coll Life Sci, Inst Biosci & Biotechnol, Chilung, Taiwan; Taipei Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Taiwan Ocean University; Taipei Veterans General Hospital	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tw						Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hajra KM, 2002, CANCER RES, V62, P1613; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Keller SH, 2003, BIOCHEM BIOPH RES CO, V307, P215, DOI 10.1016/S0006-291X(03)01143-4; Kemler R, 1992, Semin Cell Biol, V3, P149; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Noe V, 2001, J CELL SCI, V114, P111; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Pecina-Slaus N, 2005, PATHOL RES PRACT, V201, P557, DOI 10.1016/j.prp.2005.07.001; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Potter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207; Provost E, 2003, J BIOL CHEM, V278, P31781, DOI 10.1074/jbc.M304953200; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Sawhney RS, 2004, J BIOL CHEM, V279, P47379, DOI 10.1074/jbc.M402031200; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang WS, 2004, ONCOGENE, V23, P6666, DOI 10.1038/sj.onc.1207888; Wang WS, 2003, ONCOGENE, V22, P3297, DOI 10.1038/sj.onc.1206404; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yang SP, 2005, MOL CELL BIOCHEM, V272, P97, DOI 10.1007/s11010-005-7642-4; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	57	88	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2781	2790		10.1038/sj.onc.1210078	http://dx.doi.org/10.1038/sj.onc.1210078			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072345				2022-12-25	WOS:000246210600012
J	Zhong, S; Fields, CR; Su, N; Pan, YX; Robertson, KD				Zhong, S.; Fields, C. R.; Su, N.; Pan, Y-X; Robertson, K. D.			Pharmacologic inhibition of epigenetic modi. cations, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer	ONCOGENE			English	Article						lung cancer; DNA methylation; 5-aza-2 '-deoxycytidine; trichostatin A; histone acetylation; microarray	PROMOTER HYPERMETHYLATION; EARLY EVENT; TUMOR; MARKER; ADENOCARCINOMA; EPIGENOME; OXYTOCIN; BINDING; OCCURS; CELLS	Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression proling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally down-regulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently down-regulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, UF Shands Canc Ctr Program Canc Genet Epigenet &, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Genet Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Robertson, KD (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, UF Shands Canc Ctr Program Canc Genet Epigenet &, Gainesville, FL 32610 USA.	keithr@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367; Robertson, Keith/0000-0002-7508-3328	NCI NIH HHS [K22CA084535, R01CA114229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA084535, R01CA114229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bottone FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cassoni P, 2004, J NEUROENDOCRINOL, V16, P362, DOI 10.1111/j.0953-8194.2004.01165.x; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002; Dutta R, 2002, PROSTATE, V52, P89, DOI 10.1002/pros.10097; Eickhoff B, 2000, BIOL CHEM, V381, P107, DOI 10.1515/BC.2000.015; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Esteller M, 1999, CANCER RES, V59, P67; Evans HK, 2001, GENOMICS, V77, P99, DOI 10.1006/geno.2001.6612; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Hai T, 1999, GENE EXPRESSION, V7, P321; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim MS, 2003, CANCER RES, V63, P7291; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Kuerbitz SJ, 2002, CARCINOGENESIS, V23, P559, DOI 10.1093/carcin/23.4.559; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Pequeux C, 2005, LUNG CANCER, V50, P177, DOI 10.1016/j.lungcan.2005.05.027; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Somech R, 2004, CANCER TREAT REV, V30, P461, DOI 10.1016/j.ctrv.2004.04.006; Suh YH, 2005, BIOCHEM BIOPH RES CO, V337, P481, DOI 10.1016/j.bbrc.2005.09.078; Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712	51	104	108	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2621	2634		10.1038/sj.onc.1210041	http://dx.doi.org/10.1038/sj.onc.1210041			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043644				2022-12-25	WOS:000245831200009
J	Safina, A; Vandette, E; Bakin, AV				Safina, A.; Vandette, E.; Bakin, A. V.			ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells	ONCOGENE			English	Article						invasion; metastasis; MMP-9; MAPK; TGF-beta; angiogenesis	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; TGF-BETA; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; MOLECULAR-BIOLOGY; METASTASIS; IDENTIFICATION; EXPRESSION	Transforming growth factor beta 1 (TGF-beta 1) is a potent tumor suppressor but, paradoxically, TGF-beta 1 enhances tumor growth and metastasis in the late stages of cancer progression. This study investigated the role of TGF-beta type I receptor, ALK5, and three mitogen-activated protein kinases (MAPKs) in metastasis by breast cancer cell line MDA-MB-231. We show that autocrine TGF-beta signaling in MDA-MB-231 cells is required for tumor cell invasion and tumor angiogenesis. Expression of kinase inactive ALK5 reduces tumor invasion and formation of new blood vessels within the tumor orthotopic xenografts in severe combined immunodeficiency (SCID) mice. In contrast, constitutively active ALK5-T204D enhances tumor invasion and angiogenesis by stimulating expression of matrix metalloproteinase MMP-9/gelatinase-B. Ablation of MMP-9 in ALK5-T204D cells by RNA interference (RNAi) reduces tumor invasion and tumor growth. Importantly, RNAi-MMP-9 reduces tumor neovasculature and increases tumor cell death. Induction of MMP-9 by TGF-beta-ALK5 signaling requires MEK-ERK but not JNK, p38 MAPK or Smad4. Dominant-negative MEK blocks and constitutively active MEK1 enhances MMP-9 expression. However, all three MAPK cascades (ERK, JNK and p38 MAPK) are required for TGF-beta-mediated cell migration. Collectively, our results show that TGF-beta-ALK5-MAPK signaling in tumor cells promotes tumor angiogenesis and MMP-9 is an important component of this program.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	andrei.bakin@roswellpark.org		Bakin, Andrei/0000-0002-7728-1969	NATIONAL CANCER INSTITUTE [R01CA095263, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, R01 CA95263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 2002, J CELL SCI, V115, P3193; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; Benckert C, 2003, CANCER RES, V63, P1083; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bhattacharya A, 2004, CLIN CANCER RES, V10, P8005, DOI 10.1158/1078-0432.CCR-04-1306; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Chantrain CF, 2004, CANCER RES, V64, P1675, DOI 10.1158/0008-5472.CAN-03-0160; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dumont N, 2003, BIOCHEM BIOPH RES CO, V301, P108, DOI 10.1016/S0006-291X(02)02977-7; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Farina AR, 1998, INT J CANCER, V75, P721; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Frey RS, 1997, CANCER RES, V57, P628; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Johansson N, 2000, J CELL SCI, V113, P227; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; PRICE JE, 1990, CANCER RES, V50, P717; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; TARIN D, 1981, CANCER RES, V41, P3604; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	65	78	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2407	2422		10.1038/sj.onc.1210046	http://dx.doi.org/10.1038/sj.onc.1210046			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17072348				2022-12-25	WOS:000245831000002
J	Yemelyanov, A; Czwornog, J; Chebotaev, D; Karseladze, A; Kulevitch, E; Yang, X; Budunova, I				Yemelyanov, A.; Czwornog, J.; Chebotaev, D.; Karseladze, A.; Kulevitch, E.; Yang, X.; Budunova, I.			Tumor suppressor activity of glucocorticoid receptor in the prostate	ONCOGENE			English	Article						prostate carcinoma; PIN; glucocorticoid receptor; PC marker; transcription factor; MAPKs	METHYLACYL-COA RACEMASE; ANDROGEN RECEPTOR; DIFFERENTIAL EXPRESSION; MOLECULAR-MECHANISMS; CANCER; APOPTOSIS; PATHWAY; KINASE; GROWTH; DEXAMETHASONE	Glucocorticoids are extensively used in combination chemotherapy of advanced prostate cancer (PC). Little is known, however, about the status of the glucocorticoid receptor (GR) in PC. We evaluated over 200 prostate samples and determined that GR expression was strongly decreased or absent in 70 - 85% of PC. Similar to PC tumors, some PC cell lines, including LNCaP, also lack GR. To understand the role of GR, we reconstituted its expression in LNCaP cells using lentiviral approach. Treatment of LNCaP-GR cells with the glucocorticoids strongly inhibited proliferation in the monolayer cultures and blocked anchorage-independent growth. This was accompanied by upregulation of p21 and p27, downregulation of cyclin D1 expression and c-Myc phosphorylation. Importantly, the activation of GR resulted in normalized expression of PC markers hepsin, AMACR, and maspin. On the signaling level, GR decreased expression and inhibited activity of the MAP-kinases (MAPKs) including p38, JNK/SAPK, Mek1/2 and Erk1/2. We also found that activation of GR inhibited activity of numerous transcription factors (TF) including AP-1, SRF, NF-kappa B, p53, ATF-2, CEBP alpha, Ets-1, Elk-1, STAT1 and others, many of which are regulated via MAPK cascade. The structural analysis of hepsin and AMACR promoters provided the mechanistic rationale for PC marker downregulation by glucocorticoids via inhibition of specific TFs. Our data suggest that GR functions as a tumor suppressor in prostate, and inhibits multiple signaling pathways and transcriptional factors involved in proliferation and transformation.	Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Chicago, IL 60611 USA; Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Dept Pathol, Moscow, Russia; Northwestern Univ, Feinberg Med Sch, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Northwestern University; Feinberg School of Medicine	Budunova, I (corresponding author), Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Ward Bldg 9-332,303 E Chicago Ave, Chicago, IL 60611 USA.	i_budunova@northwestern.edu						Ananthanarayanan V, 2005, PROSTATE, V63, P341, DOI 10.1002/pros.20196; Bourcier T, 2000, INVEST OPHTH VIS SCI, V41, P4133; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; Budunova IV, 1997, MOL CARCINOGEN, V18, P177, DOI 10.1002/(SICI)1098-2744(199703)18:3<177::AID-MC7>3.3.CO;2-U; Chen ZX, 2003, J UROLOGY, V169, P1316, DOI 10.1097/01.ju.0000050648.40164.0d; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Fakih M, 2002, UROLOGY, V60, P553, DOI 10.1016/S0090-4295(02)01741-7; Fixemer T, 2003, PROSTATE, V54, P79, DOI 10.1002/pros.10171; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Jiang X, 2004, J BIOL CHEM, V279, P38480, DOI 10.1074/jbc.M403948200; Jiang Z, 2004, ADV ANAT PATHOL, V11, P316, DOI 10.1097/01.pap.0000146924.14246.be; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Koutsilieris M, 2002, EXPERT OPIN INV DRUG, V11, P283; Li CL, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P172; Maroni Paul D, 2004, Cell Commun Signal, V2, P5, DOI 10.1186/1478-811X-2-5; Mimeault M, 2003, GROWTH FACTORS, V21, P1, DOI 10.1080/0897719031000094921; Mohler JL, 1996, CLIN CANCER RES, V2, P889; Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402-005MS; Nishimura K, 2001, J NATL CANCER I, V93, P1739, DOI 10.1093/jnci/93.22.1739; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Quinn DI, 2005, EUR J CANCER, V41, P858, DOI 10.1016/j.ejca.2004.12.035; Ray DW, 1996, J ENDOCRINOL, V149, P1, DOI 10.1677/joe.0.1490001; Ricote M, 2006, J PATHOL, V208, P401, DOI 10.1002/path.1910; ROSENBERG I, 1996, PROTEIN ANAL PURIFIC, P103; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; SCHUG J, 2005, EUR J CANCER, V41, P858; Torlakovic E, 2005, INT J CANCER, V117, P381, DOI 10.1002/ijc.21174; Weaver ICG, 2005, J NEUROSCI, V25, P11045, DOI 10.1523/JNEUROSCI.3652-05.2005; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Zha S, 2003, CANCER RES, V63, P7365	36	98	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1885	1896		10.1038/sj.onc.1209991	http://dx.doi.org/10.1038/sj.onc.1209991			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17016446				2022-12-25	WOS:000245117700006
J	Girvan, HM; Seward, HE; Toogood, HS; Cheesman, MR; Leys, D; Munro, AW				Girvan, Hazel M.; Seward, Harriet E.; Toogood, Helen S.; Cheesman, Myles R.; Leys, David; Munro, Andrew W.			Structural and spectroscopic characterization of P450BM3 mutants with unprecedented P450 heme iron ligand sets - New heme ligation states influence conformational equilibria in P450BM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; NITRIC-OXIDE; FLAVOCYTOCHROME P450BM3; CRYSTAL-STRUCTURE; DOMAIN; IDENTIFICATION; PURIFICATION; SUBSTRATE; COOA; CYTOCHROME-P-450BM-3	Two novel P450 heme iron ligand sets were generated by directed mutagenesis of the flavocytochrome P450 BM3 heme domain. The A264H and A264K variants produce Cys-Fe-His and Cys-Fe-Lys axial ligand sets, which were validated structurally and characterized by spectroscopic analysis. EPR and magnetic circular dichroism (MCD) provided fingerprints defining these P450 ligand sets. Near IR MCD spectra identified ferric low spin charge-transfer bands diagnostic of the novel ligands. For the A264K mutant, this is the first report of a Cys-Fe-Lys near-IR MCD band. Crystal structure determination showed that substrate-free A264H and A264K proteins crystallize in distinct conformations, as observed previously in substrate-free and fatty acid-bound wild-type P450 forms, respectively. This, in turn, likely reflects the positioning of the I a helix section of the protein that is required for optimal configuration of the ligands to the heme iron. One of the monomers in the asymmetric unit of the A264H crystals was in a novel conformation with a more open substrate access route to the active site. The same species was isolated for the wildtype heme domain and represents a novel conformational state of BM3 (termed SF2). The "locking" of these distinct conformations is evident from the fact that the endogenous ligands cannot be displaced by substrate or exogenous ligands. The consequent reduction of heme domain conformational heterogeneity will be important in attempts to determine atomic structure of the full-length, multidomain flavocytochrome, and thus to understand in atomic detail interactions between its heme and reductase domains.	Univ Leicester, Dept Biochem, Leicester LE6 0HQ, Leics, England; Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester M1 7DN, Lancs, England; Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England; Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England	University of Leicester; University of Manchester; University of Manchester; University of East Anglia	Leys, D (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE6 0HQ, Leics, England.	David.Leys@Manchester.ac.uk; Andrew.Munro@Manchester.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X; Girvan, Hazel/0000-0003-2299-8644; Toogood, Helen/0000-0003-4797-0293	Biotechnology and Biological Sciences Research Council [BB/C006879/2] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Baer BR, 2005, BIOCHEMISTRY-US, V44, P13914, DOI 10.1021/bi051267j; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Cheesman MR, 2001, BIOCHEMISTRY-US, V40, P10562, DOI 10.1021/bi0100081; Cheesman MR, 1998, BIOCHEMISTRY-US, V37, P3994, DOI 10.1021/bi972437y; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; Girvan HM, 2004, J BIOL CHEM, V279, P23274, DOI 10.1074/jbc.M401716200; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; Joyce MG, 2004, J BIOL CHEM, V279, P23287, DOI 10.1074/jbc.M401717200; Lawson RJ, 2004, BIOCHEMISTRY-US, V43, P12410, DOI 10.1021/bi049132l; Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; Limburg J, 2005, BIOCHEMISTRY-US, V44, P4091, DOI 10.1021/bi047686i; MCKNIGHT J, 1993, EUR J BIOCHEM, V213, P683, DOI 10.1111/j.1432-1033.1993.tb17808.x; McLean KJ, 2005, BIOCHEM SOC T, V33, P796, DOI 10.1042/BST0330796; McLean KJ, 2002, J INORG BIOCHEM, V91, P527, DOI 10.1016/S0162-0134(02)00479-8; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; MILES JS, 1992, BIOCHEM J, V288, P503, DOI 10.1042/bj2880503; Munro AW, 1996, MOL MICROBIOL, V20, P1115, DOI 10.1111/j.1365-2958.1996.tb02632.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NARHI LO, 1987, J BIOL CHEM, V262, P6683; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Neeli R, 2005, FEBS LETT, V579, P5582, DOI 10.1016/j.febslet.2005.09.023; Neeli R, 2005, J BIOL CHEM, V280, P17634, DOI 10.1074/jbc.M413826200; Noble MA, 1999, BIOCHEM J, V339, P371, DOI 10.1042/0264-6021:3390371; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSTER T, 1991, J BIOL CHEM, V266, P22718; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Quaroni LG, 2004, BIOCHEMISTRY-US, V43, P16416, DOI 10.1021/bi049163g; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Roberts GP, 2005, J INORG BIOCHEM, V99, P280, DOI 10.1016/j.jinorgbio.2004.10.032; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; SONO M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P351, DOI 10.1016/0167-4838(91)90156-T; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; WUTTKE DS, 1994, THESIS CALTECH PASAD; Youn H, 2006, BIOCHEM BIOPH RES CO, V348, P345, DOI 10.1016/j.bbrc.2006.06.200	42	55	58	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					564	572		10.1074/jbc.M607949200	http://dx.doi.org/10.1074/jbc.M607949200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17077084	hybrid			2022-12-25	WOS:000243166500062
J	Chen, H; Choudhury, DM; Craig, SW				Chen, Hui; Choudhury, Dilshad M.; Craig, Susan W.			Coincidence of actin filaments and talin is required to activate vinculin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RHO; ALPHA-ACTININ; INTRAMOLECULAR ASSOCIATION; MICROFILAMENT BUNDLES; FLUORESCENT PROTEIN; MISSENSE MUTATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; SKELETAL-MUSCLE; CHICKEN GIZZARD	Vinculin regulates cell adhesion by strengthening contacts between extracellular matrix and the cytoskeleton. Binding of the integrin ligand, talin, to the head domain of vinculin and F-actin to its tail domain is a potential mechanism for this function, but vinculin is autoinhibited by intramolecular interactions between its head and tail domain and must be activated to bind talin and actin. Because autoinhibition of vinculin occurs by synergism between two head and tail interfaces, one hypothesis is that activation could occur by two ligands that coordinately disrupt both interfaces. To test this idea we use a fluorescence resonance energy transfer probe that reports directly on activation of vinculin. Neither talin rod, VBS3 ( a talin peptide that mimics a postulated activated state of talin), nor F-actin alone can activate vinculin. But in the presence of F-actin either talin rod or VBS3 induces dose-dependent activation of vinculin. The activation data are supported by solution phase binding studies, which show that talin rod or VBS3 fails to bind vinculin, whereas the same two ligands bind tightly to vinculin head domain ( Kd similar to 100 nM). These data strongly support a combinatorial mechanism of vinculin activation; moreover, they are inconsistent with a model in which talin or activated talin is sufficient to activate vinculin. Combinatorial activation implies that at cell adhesion sites vinculin is a coincidence detector awaiting simultaneous signals from talin and actin polymerization to unleash its scaffolding activity.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Craig, SW (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	scraig@jhmi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM041605, R01GM041605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adey NB, 1997, BIOCHEM J, V324, P523, DOI 10.1042/bj3240523; Alenghat FJ, 2000, BIOCHEM BIOPH RES CO, V277, P93, DOI 10.1006/bbrc.2000.3636; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; Bois PRJ, 2005, MOL CELL BIOL, V25, P6112, DOI 10.1128/MCB.25.14.6112-6122.2005; Bois PRJ, 2006, J BIOL CHEM, V281, P7228, DOI 10.1074/jbc.M510397200; Borgon RA, 2004, STRUCTURE, V12, P1189, DOI 10.1016/j.str.2004.05.009; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; Chandrasekar I, 2005, J CELL SCI, V118, P1461, DOI 10.1242/jcs.01734; Chen H, 2005, J CELL BIOL, V169, P459, DOI 10.1083/jcb.200410100; Cohen DM, 2006, J BIOL CHEM, V281, P16006, DOI 10.1074/jbc.M600738200; Cohen DM, 2005, J BIOL CHEM, V280, P17109, DOI 10.1074/jbc.M414704200; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Gallant ND, 2005, MOL BIOL CELL, V16, P4329, DOI 10.1091/mbc.E05-02-0170; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; Gingras AR, 2006, BIOCHEMISTRY-US, V45, P1805, DOI 10.1021/bi052136l; Gingras AR, 2005, J BIOL CHEM, V280, P37217, DOI 10.1074/jbc.M508060200; Goldmann WH, 1998, EXP CELL RES, V239, P235, DOI 10.1006/excr.1997.3915; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; Hamiaux C, 2006, EMBO REP, V7, P794, DOI 10.1038/sj.embor.7400753; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Janssen MEW, 2006, MOL CELL, V21, P271, DOI 10.1016/j.molcel.2005.11.020; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kelly DF, 2006, J MOL BIOL, V357, P562, DOI 10.1016/j.jmb.2005.12.076; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Lee HS, 2004, J MOL BIOL, V343, P771, DOI 10.1016/j.jmb.2004.08.069; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; Olson TM, 2002, CIRCULATION, V105, P431, DOI 10.1161/hc0402.102930; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PARDO JV, 1983, J CELL BIOL, V97, P1081, DOI 10.1083/jcb.97.4.1081; Patel B, 2006, J BIOL CHEM, V281, P7458, DOI 10.1074/jbc.M508058200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Saunders RM, 2006, EUR J CELL BIOL, V85, P487, DOI 10.1016/j.ejcb.2006.01.014; Schmidt JM, 1999, ARCH BIOCHEM BIOPHYS, V366, P139, DOI 10.1006/abbi.1999.1204; SCHMIDT JM, 1993, BIOCHEM BIOPH RES CO, V197, P660, DOI 10.1006/bbrc.1993.2530; Schwienbacher C, 1996, FEBS LETT, V384, P71, DOI 10.1016/0014-5793(96)00286-4; Senetar MA, 2004, BIOCHEMISTRY-US, V43, P15418, DOI 10.1021/bi0487239; SHEAR CR, 1985, J CELL BIOL, V101, P240, DOI 10.1083/jcb.101.1.240; Shiu YT, 2004, BIOPHYS J, V86, P2558, DOI 10.1016/S0006-3495(04)74311-8; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Stradal TEB, 2006, CURR OPIN CELL BIOL, V18, P4, DOI 10.1016/j.ceb.2005.12.003; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011; Takahashi H, 2005, BIOCHEM BIOPH RES CO, V336, P239, DOI 10.1016/j.bbrc.2005.08.064; Vasile VC, 2006, MOL GENET METAB, V87, P169, DOI 10.1016/j.ymgme.2005.08.006; Vasile VC, 2006, BIOCHEM BIOPH RES CO, V345, P998, DOI 10.1016/j.bbrc.2006.04.151; Vaynberg J, 2005, MOL CELL, V17, P513, DOI 10.1016/j.molcel.2004.12.031; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; Xu WM, 1998, DEVELOPMENT, V125, P327; Xu WM, 1998, J CELL SCI, V111, P1535; Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zemljic-Harpf AE, 2004, AM J PATHOL, V165, P1033, DOI 10.1016/S0002-9440(10)63364-0; Zhang ZY, 2004, MOL BIOL CELL, V15, P4234, DOI 10.1091/mbc.E04-03-0264; Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004; Zigmond SH, 2004, CURR TOP DEV BIOL, V63, P145, DOI 10.1016/S0070-2153(04)63005-5	83	113	117	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40389	40398		10.1074/jbc.M607324200	http://dx.doi.org/10.1074/jbc.M607324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074767	hybrid			2022-12-25	WOS:000243033900069
J	Bibert, S; Roy, S; Schaer, D; Felley-Bosco, E; Geering, K				Bibert, Stephanie; Roy, Sophie; Schaer, Daniele; Felley-Bosco, Emanuela; Geering, Kaethi			Structural and functional properties of two human FXYD3 (mat-8) isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; XENOPUS OOCYTES; GAMMA-SUBUNIT; BETA-SUBUNIT; ION-TRANSPORT; CACO-2 CELLS; NA,K-ATPASE; EXPRESSION; PROTEIN; GENE	Six of 7 FXYD proteins have been shown to be tissue-specific modulators of Na, K-ATPase. In this study, we have identified two splice variants of human FXYD3, or Mat-8, in CaCo-2 cells. Short human FXYD3 has 72% sequence identity with mouse FXYD3, whereas long human FXYD3 is identical to short human FXYD3 but has a 26-amino acid insertion after the transmembrane domain. Short and long human FXYD3 RNAs and proteins are differentially expressed during differentiation of CaCo-2 cells. Long human FXYD3 is mainly expressed in non-differentiated cells and short human FXYD3 in differentiated cells and both FXYD3 variants can be co-immunoprecipitated with a Na, K-ATPase antibody. In contrast to mouse FXYD3, which has two transmembrane domains for lack of cleavage of the signal peptide, human FXYD3 has a cleavable signal peptide and adopts a type I topology. After co-expression in Xenopus oocytes, both human FXYD3 variants associate stably only with Na, K-ATPase isozymes but not with H, K-ATPase or Ca-ATPase. Similar to mouse FXYD3, short human FXYD3 decreases the apparent K+ and Na+ affinity of Na, K-ATPase over a large range of membrane potentials. On the other hand, long human FXYD3 decreases the apparent K+ affinity only at slightly negative and positive membrane potentials and increases the apparent Na+ affinity of Na, K-ATPase. Finally, both short and long human FXYD3 induce a hyperpolarization activated current, similar to that induced by mouse FXYD3. Thus, we have characterized two human FXYD3 isoforms that are differentially expressed in differentiated and non-differentiated cells and show different functional properties.	Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Geering, K (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	kaethi.geering@unil.ch	Felley-Bosco, Emanuela/E-7484-2017	Felley-Bosco, Emanuela/0000-0002-3408-0294; Bibert, Stephanie/0000-0001-5170-7506				Anderle P, 2003, PHARM RES-DORDR, V20, P3, DOI 10.1023/A:1022282221530; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; CLAEYS D, 1994, GASTROENTEROLOGY, V107, P924, DOI 10.1016/0016-5085(94)90215-1; Contreras RG, 1999, J CELL SCI, V112, P4223; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Crambert G, 2005, MOL BIOL CELL, V16, P2363, DOI 10.1091/mbc.E04-10-0878; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; Garty H, 2006, ANNU REV PHYSIOL, V68, P431, DOI 10.1146/annurev.physiol.68.040104.131852; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Geering K, 2006, AM J PHYSIOL-RENAL, V290, pF241, DOI 10.1152/ajprenal.00126.2005; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Grzmil M, 2004, INT J ONCOL, V24, P97; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; Jones DH, 2001, PHYSIOL GENOMICS, V6, P129, DOI 10.1152/physiolgenomics.2001.6.3.129; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Maxwell PJ, 2003, CANCER RES, V63, P4602; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1994, ONCOGENE, V9, P3417; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; Nilsson J, 2005, PROTEINS, V60, P606, DOI 10.1002/prot.20583; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Rajasekaran AK, 2003, AM J PHYSIOL-RENAL, V285, pF388, DOI 10.1152/ajprenal.00439.2002; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Vecchini F, 1997, CELL GROWTH DIFFER, V8, P261; Yamaguchi F, 2001, MOL BRAIN RES, V86, P189, DOI 10.1016/S0169-328X(00)00213-8	38	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39142	39151		10.1074/jbc.M605221200	http://dx.doi.org/10.1074/jbc.M605221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17077088	hybrid			2022-12-25	WOS:000242898700022
J	DeMali, KA; Jue, AL; Burridge, K				DeMali, Kris A.; Jue, April L.; Burridge, Keith			IpaA targets beta 1 integrins and Rho to promote actin cytoskeleton rearrangements necessary for Shigella entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING MEMBRANE PROTRUSION; EPITHELIAL-CELLS; BACTERIAL INVASION; BINDING-SITE; VINCULIN; FLEXNERI; ACTIVATION; PROTEINS; ADHESION; TALIN	Shigella invasion into the colonic epithelium involves many steps including the formation of large membrane protrusions by the epithelial cells that facilitate bacterial engulfment. IpaA, a Shigella protein secreted into target cells upon cell contact induces a loss of actin stress fibers in cells and promotes the reorganization of actin at the site of entry. The mechanism for this is not known but is thought to involve recruitment of the focal adhesion protein vinculin to IpaA. Here we have examined the mechanism for the effects of IpaA on the actin cytoskeleton. We show that IpaA-induced loss of actin stress fibers and cell rounding do not require vinculin expression or an intact vinculin binding site on IpaA. Rather, we find that cells expressing IpaA exhibited elevated Rho activity and increased myosin light chain phosphorylation. In addition, IpaA decreases integrin affinity for extracellular matrix ligands by interfering with talin recruitment to the integrin cytoplasmic tail. The combination of these two effects, namely weakened adhesion and increased contractility, account for the loss of actin stress fibers and cell rounding observed in cells exposed to IpaA.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Iowa	DeMali, KA (corresponding author), 4-470 Bowen Sci Bldg,51 Newton Rd, Iowa City, IA 52242 USA.	kris-demali@uiowa.edu	, UNC Flow Cytometry Core/AGU-9839-2022	DeMali, Kris/0000-0003-0906-1371	NATIONAL CANCER INSTITUTE [K01CA111818] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NCI NIH HHS [CA111818] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; Chen H, 2005, J CELL BIOL, V169, P459, DOI 10.1083/jcb.200410100; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lafont F, 2002, EMBO J, V21, P4449, DOI 10.1093/emboj/cdf457; Laine RO, 1997, J CELL BIOL, V138, P1255, DOI 10.1083/jcb.138.6.1255; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; MENARD R, 1993, J BACTERIOL, V175, P5899; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; MOUNIER J, 1992, INFECT IMMUN, V60, P237, DOI 10.1128/IAI.60.1.237-248.1992; Ohya K, 2005, J BIOL CHEM, V280, P24022, DOI 10.1074/jbc.M502509200; Page AL, 2001, MOL MICROBIOL, V42, P1133, DOI 10.1046/j.1365-2958.2001.02715.x; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; PARSOT C, 1995, MOL MICROBIOL, V16, P291, DOI 10.1111/j.1365-2958.1995.tb02301.x; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; ROCHLIN MW, 1989, J CELL SCI, V92, P461; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; Skoudy A, 2000, CELL MICROBIOL, V2, P19, DOI 10.1046/j.1462-5822.2000.00028.x; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tran Van Nhieu G., 1997, EMBO J, V16, P2717; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; Van Nhieu GT, 1999, EMBO J, V18, P3249, DOI 10.1093/emboj/18.12.3249; VENKATESAN MM, 1988, P NATL ACAD SCI USA, V85, P9317, DOI 10.1073/pnas.85.23.9317; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; Watarai M, 1997, J EXP MED, V185, P281, DOI 10.1084/jem.185.2.281; Xu WM, 1998, DEVELOPMENT, V125, P327; Xu WM, 1998, J CELL SCI, V111, P1535	38	38	41	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39534	39541		10.1074/jbc.M605939200	http://dx.doi.org/10.1074/jbc.M605939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17060328	hybrid, Green Published			2022-12-25	WOS:000242898700061
J	Gagnon, MG; Mukhopadhyay, A; Steinberg, SV				Gagnon, Matthieu G.; Mukhopadhyay, Alka; Steinberg, Sergey V.			Close packing of helices 3 and 12 of 16 S rRNA is required for the normal ribosome function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED 690 HAIRPIN; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; BACTERIAL RIBOSOME; SINGLE MESSENGER; RNA; SUBUNIT; TRANSLATION; NUCLEOTIDES; SENSITIVITY	The along-groove packing motif is a quasi-reciprocal arrangement of two RNA double helices in which a backbone of each helix is closely packed within the minor groove of the other helix. At the center of the inter-helix contact, a GU base pair in one helix packs against a Watson-Crick base pair in the other helix. Here, based on in vivo selection from a combinatorial gene library of 16 S rRNA and on functional characterization of the selected clones, we demonstrate that the normal ribosome performance requires that helices 3 and 12 be closely packed. In some clones the Watson-Crick and GU base pairs exchange in their positions between the two helices, which affects neither the quality of the helix packing, nor the ribosome function. On the other hand, perturbations in the close packing usually lead to a substantial drop in the ribosome activity. The functionality of the clones containing such perturbations may depend on the presence of particular elements in the vicinity of the area of contact between helices 3 and 12. Such cases do not exist in natural 16 S rRNA, and their selection enriches our knowledge of the constraints imposed on the structure of ribosomal RNA in functional ribosomes.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Steinberg, SV (corresponding author), Univ Montreal, Dept Biochim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	serguei.chteinberg@umontreal.ca		Gagnon, Matthieu/0000-0003-4516-604X				Abdi NM, 2005, RNA, V11, P1624, DOI 10.1261/rna.2118105; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Belanger F, 2004, J MOL BIOL, V338, P683, DOI 10.1016/j.jmb.2004.03.024; BROSIUS J, 1981, PLASMID, V6, P112, DOI 10.1016/0147-619X(81)90058-5; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Gagnon MG, 2002, RNA, V8, P873, DOI 10.1017/S135583820202602X; GAGNON MG, 2005, RNA 2005, P380; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; HUI A, 1987, METHOD ENZYMOL, V153, P432; Ito Y, 1999, BIOCHEM BIOPH RES CO, V264, P556, DOI 10.1006/bbrc.1999.1541; Jensen PR, 1998, APPL ENVIRON MICROB, V64, P82; Lee K, 2001, J NUTR, V131, p2994S, DOI 10.1093/jn/131.11.2994S; Lee K, 1996, RNA, V2, P1270; Lee KS, 1997, J MOL BIOL, V269, P732, DOI 10.1006/jmbi.1997.1092; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; Mokdad A, 2006, NUCLEIC ACIDS RES, V34, P1326, DOI 10.1093/nar/gkl025; Morosyuk SV, 2000, J MOL BIOL, V300, P113, DOI 10.1006/jmbi.2000.3852; Morosyuk SV, 2001, J MOL BIOL, V307, P213, DOI 10.1006/jmbi.2000.4432; Rackham O, 2005, NAT CHEM BIOL, V1, P159, DOI 10.1038/nchembio719; Rodriguez-Correa D, 2004, RNA, V10, P28, DOI 10.1261/rna.5172104; RON EZ, 1966, SCIENCE, V153, P1119, DOI 10.1126/science.153.3740.1119; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; Viviani VR, 2002, PHOTOCHEM PHOTOBIOL, V76, P538, DOI 10.1562/0031-8655(2002)076&lt;0538:TIOAGA&gt;2.0.CO;2; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Wuyts J, 2004, NUCLEIC ACIDS RES, V32, pD101, DOI 10.1093/nar/gkh065; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	31	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39349	39357		10.1074/jbc.M607725200	http://dx.doi.org/10.1074/jbc.M607725200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17060325	hybrid			2022-12-25	WOS:000242898700042
J	Krzysiak, TC; Gilbert, SP				Krzysiak, Troy C.; Gilbert, Susan P.			Dimeric Eg5 maintains processivity through alternating-site catalysis with rate-limiting ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC KINESIN EG5; SMALL-MOLECULE INHIBITOR; BIOLOGICAL EVALUATION; MONASTROL INHIBITION; MOTOR DOMAIN; MECHANISM; PATHWAY; MICROTUBULES; MODEL; ORGANIZATION	Eg5/KSP is a homotetrameric, Kinesin-5 family member whose ability to cross-link microtubules has associated it with mitotic spindle assembly and dynamics for chromosome segregation. Transient-state kinetic methodologies have been used to dissect the mechanochemical cycle of a dimeric motor, Eg5-513, to better understand the cooperative interactions that modulate processive stepping. Microtubule association, ADP release, and ATP binding are all fast steps in the pathway. However, the acid-quench analysis of the kinetics of ATP hydrolysis with substrate in excess of motor was unable to resolve a burst of product formation during the first turnover event. In addition, the kinetics of Pi release and ATP-promoted microtubule-Eg5 dissociation were observed to be no faster than the rate of ATP hydrolysis. In combination the data suggest that dimeric Eg5 is the first kinesin motor identified to have a rate-limiting ATP hydrolysis step. Furthermore, several lines of evidence implicate alternating-site catalysis as the molecular mechanism underlying dimeric Eg5 processivity. Both mantATP binding and mantADP release transients are biphasic. Analysis of ATP hydrolysis through single turnover assays indicates a surprising substrate concentration dependence, where the observed rate is reduced by half when substrate concentration is sufficiently high to require both motor domains of the dimer to participate in the reaction.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gilbert, SP (corresponding author), Univ Pittsburgh, Dept Biol Sci, 518 Langley Hall, Pittsburgh, PA 15260 USA.	spg1@pitt.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR047841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054141, R01GM054141] Funding Source: NIH RePORTER; NIAMS NIH HHS [K02-AR47841, K02 AR047841] Funding Source: Medline; NIGMS NIH HHS [R37 GM054141, R01 GM054141, GM54141] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Brier S, 2004, BIOCHEMISTRY-US, V43, P13072, DOI 10.1021/bi049264e; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Chakravarty A, 2004, MOL BIOL CELL, V15, P2116, DOI 10.1091/mbc.E03-08-0579; Cochran JC, 2006, BIOCHEMISTRY-US, V45, P12334, DOI 10.1021/bi0608562; Cochran JC, 2005, J BIOL CHEM, V280, P12658, DOI 10.1074/jbc.M413140200; Cochran JC, 2004, J BIOL CHEM, V279, P38861, DOI 10.1074/jbc.M404203200; Cochran JC, 2005, BIOCHEMISTRY-US, V44, P16633, DOI 10.1021/bi051724w; Crevel IMTC, 2004, CURR BIOL, V14, pR411, DOI 10.1016/j.cub.2004.05.030; Gartner M, 2005, CHEMBIOCHEM, V6, P1173, DOI 10.1002/cbic.200500005; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Kaiser A, 1999, J BIOL CHEM, V274, P18925, DOI 10.1074/jbc.274.27.18925; Kambara T, 2006, J BIOL CHEM, V281, P4949, DOI 10.1074/jbc.M509141200; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kim KS, 2006, BIOORG MED CHEM LETT, V16, P3937, DOI 10.1016/j.bmcl.2006.05.037; Klumpp LM, 2003, BIOCHEMISTRY-US, V42, P2595, DOI 10.1021/bi026715r; Klumpp LM, 2004, P NATL ACAD SCI USA, V101, P3444, DOI 10.1073/pnas.0307691101; Krzysiak TC, 2006, EMBO J, V25, P2263, DOI 10.1038/sj.emboj.7601108; Kwok BH, 2004, CURR BIOL, V14, P1783, DOI 10.1016/j.cub.2004.09.052; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Mackey AT, 2003, J BIOL CHEM, V278, P3527, DOI 10.1074/jbc.M206219200; Maliga Z, 2006, J BIOL CHEM, V281, P7977, DOI 10.1074/jbc.M511955200; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miyamoto DT, 2004, J CELL BIOL, V167, P813, DOI 10.1083/jcb.200407126; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Nakazawa J, 2003, CHEM BIOL, V10, P131, DOI 10.1016/S1074-5521(03)00020-6; Nalavadi V, 2005, J BIOL CHEM, V280, P38957, DOI 10.1074/jbc.M507161200; Okumura H, 2006, TOXICOL LETT, V166, P44, DOI 10.1016/j.toxlet.2006.05.011; Rosenfeld SS, 2005, J BIOL CHEM, V280, P35684, DOI 10.1074/jbc.M506561200; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sarli V, 2005, CHEMBIOCHEM, V6, P2005, DOI 10.1002/cbic.200500168; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Shirasu-Hiza M, 2004, CURR BIOL, V14, P1941, DOI 10.1016/j.cub.2004.10.029; Sunder-Plassmann N, 2005, BIOORGAN MED CHEM, V13, P6094, DOI 10.1016/j.bmc.2005.06.027; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Tarby CM, 2006, BIOORG MED CHEM LETT, V16, P2095, DOI 10.1016/j.bmcl.2006.01.056; Valentine MT, 2006, NAT CELL BIOL, V8, P470, DOI 10.1038/ncb1394; Whitehead CM, 1998, J CELL SCI, V111, P2551; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000	48	36	36	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39444	39454		10.1074/jbc.M608056200	http://dx.doi.org/10.1074/jbc.M608056200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17062577	Green Accepted, hybrid			2022-12-25	WOS:000242898700052
J	Yennawar, NH; Islam, MM; Conway, M; Wallin, R; Hutson, SM				Yennawar, Neela H.; Islam, Mohammad Mainul; Conway, Myra; Wallin, Reidar; Hutson, Susan M.			Human mitochondrial branched chain aminotransferase isozyme - Structural role of the CXXC center in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ASPARTATE-AMINOTRANSFERASE; AMINO-ACID AMINOTRANSFERASE; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; CRYSTALLOGRAPHY; ISOENZYMES; SYSTEM; MOTIF	Mammalian branched chain aminotransferases (BCATs) have a unique CXXC center. Kinetic and structural studies of three CXXC center mutants (C315A, C318A, and C315A/C318A) of human mitochondrial (hBCATm) isozyme and the oxidized hBCATm enzyme (hBCATm-Ox) have been used to elucidate the role of this center in hBCATm catalysis. X-ray crystallography revealed that the CXXC motif, through its network of hydrogen bonds, plays a crucial role in orienting the substrate optimally for catalysis. In all structures, there were changes in the structure of the beta-turn preceding the CXXC motif when compared with wild type protein. The N-terminal loop between residues 15 and 32 is flexible in the oxidized and mutant enzymes, the disorder greater in the oxidized protein. Disordering of the N-terminal loop disrupts the integrity of the side chain binding pocket, particularly for the branched chain side chain, less so for the dicarboxylate substrate side chain. The kinetic studies of the mutant and oxidized enzymes support the structural analysis. The kinetic results showed that the predominant effect of oxidation was on the second half-reaction rather than the first half-reaction. The oxidized enzyme was completely inactive, whereas the mutants showed limited activity. Model building of the second half-reaction substrate alpha-ketoisocaproate in the pyridoxamine 5'-phosphate- hBCATm structure suggests that disruption of the CXXC center results in altered substrate orientation and deprotonation of the amino group of pyridoxamine 5'-phosphate, which inhibits catalysis.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hutson, SM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.	shutson@wfubmc.edu			NIDDK NIH HHS [DK34738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK034738, R01DK034738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTEN P, 1985, TRANSAMINASES, V2, P430; Conway ME, 2004, BIOCHEMISTRY-US, V43, P7356, DOI 10.1021/bi0498050; Conway ME, 2002, BIOCHEMISTRY-US, V41, P9070, DOI 10.1021/bi020200i; Davoodi J, 1998, J BIOL CHEM, V273, P4982, DOI 10.1074/jbc.273.9.4982; DeLano WL, 2002, PYMOL USERS MANUAL; Goto M, 2005, J BIOL CHEM, V280, P37246, DOI 10.1074/jbc.M506486200; Goto M, 2003, BIOCHEMISTRY-US, V42, P3725, DOI 10.1021/bi026722f; HALL TR, 1993, J BIOL CHEM, V268, P3092; Hutson S, 2001, PROG NUCLEIC ACID RE, V70, P175, DOI 10.1016/S0079-6603(01)70017-7; Hutson SM, 2001, J NUTR, V131, p839S, DOI 10.1093/jn/131.3.839S; Hutson SM, 1998, J NEUROCHEM, V71, P863; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kagamiyama H, 2000, METHOD ENZYMOL, V324, P103; KIICK DM, 1983, BIOCHEMISTRY-US, V22, P375, DOI 10.1021/bi00271a022; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; MEHTA PK, 1993, EUR J BIOCHEM, V211, P373, DOI 10.1111/j.1432-1033.1993.tb19907.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Rigden DJ, 2003, J MOL BIOL, V328, P909, DOI 10.1016/S0022-2836(03)00350-4; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; TONEY MD, 1993, BIOCHEMISTRY-US, V32, P1471, DOI 10.1021/bi00057a010; Yennawar N, 2001, ACTA CRYSTALLOGR D, V57, P506, DOI 10.1107/S0907444901001925; Yennawar NH, 2002, BIOCHEMISTRY-US, V41, P11592, DOI 10.1021/bi020221c	32	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39660	39671		10.1074/jbc.M607552200	http://dx.doi.org/10.1074/jbc.M607552200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17050531	hybrid			2022-12-25	WOS:000242898700073
J	Walker, JL; Castagnino, P; Chung, BM; Kazanietz, MG; Assoian, RK				Walker, Janice L.; Castagnino, Paola; Chung, Betty M.; Kazanietz, Marcelo G.; Assoian, Richard K.			Post-transcriptional destabilization of p21(cip1) by protein kinase C in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; I INHIBITOR GGTI-298; PCNA BINDING DOMAINS; PROTEASOMAL DEGRADATION; GROWTH-INHIBITION; EXPRESSION; P21; ACTIVATION; CDK; P21(WAF1/CIP1)	p21(cip1) inhibits S phase entry by binding to cyclin-cdk2 (cyclin-dependent kinase-2) complexes. The levels of p21(cip1) are rapidly induced after mitogenic stimulation of quiescent fibroblasts and then down-regulate as the cells reach late G(1) phase and activate cyclin E-cdk2. In this study, we have shown that pharmacological inhibition of protein kinase C (PKC), expression of dominant negative PKC delta, or knockdown of PKC delta with small interfering RNA elevates p21cip1 protein levels in mouse embryo fibroblasts. This effect is selective, post-transcriptional, and proteasome-dependent but distinct from previously identified post-transcriptional control mechanisms involving cyclin D1 and Skp2. PKC delta inhibition results in a reduced entry into S phase, and this effect is not detected in p21(cip1)-null cells. Thus, post-transcriptional destabilization of p21(cip1) appears to be a major mitogenic effect of PKC delta in fibroblasts.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Assoian, RK (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	rka@pharm.med.upenn.edu		Chung, Betty/0000-0002-6372-7763	NCI NIH HHS [R25 CA 101871, CA 92537] Funding Source: Medline; NIGMS NIH HHS [F32 GM 065031, GM 51878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092537, R25CA101871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051878, F32GM065031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Brodie C, 2004, MOL PHARMACOL, V66, P76, DOI 10.1124/mol.66.1.76; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen XY, 2004, MOL CELL, V16, P839, DOI 10.1016/j.molcel.2004.11.011; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; COLEMAN ML, 2006, ONCOGENE; Davey G, 1999, J CELL SCI, V112, P4663; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kothapalli D, 2003, MOL PHARMACOL, V64, P249, DOI 10.1124/mol.64.2.249; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI Y, 1994, ONCOGENE, V9, P2261; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rousseau D, 1999, ONCOGENE, V18, P3290, DOI 10.1038/sj.onc.1202681; Scott MT, 2002, EMBO J, V21, P6771, DOI 10.1093/emboj/cdf684; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Slosberg ED, 1999, ONCOGENE, V18, P6658, DOI 10.1038/sj.onc.1203083; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Stewart SA, 2004, J BIOL CHEM, V279, P29109, DOI 10.1074/jbc.M404271200; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wan XZ, 2001, BIOCHEM BIOPH RES CO, V284, P99, DOI 10.1006/bbrc.2001.4923; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	45	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38127	38132		10.1074/jbc.M609622200	http://dx.doi.org/10.1074/jbc.M609622200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17043352	hybrid			2022-12-25	WOS:000242709500004
J	Ward, I; Kim, JE; Minn, K; Chini, CC; Mer, G; Chen, JJ				Ward, Irene; Kim, Ja-Eun; Minn, Kay; Chini, Claudia C.; Mer, Georges; Chen, Junjie			The tandem BRCT domain of 53BP1 is not required for its repair function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-DAMAGE CHECKPOINT; CLASS-SWITCH RECOMBINATION; SACCHAROMYCES-CEREVISIAE; TUMOR-SUPPRESSOR; PROTEIN 53BP1; HISTONE H2AX; GENE AMPLIFICATION; P53; RAD9	53BP1 plays an important role in cellular response to DNA damage. It is thought to be the mammalian homologue of budding yeast Rad9 and/or fission yeast Crb2. Rad9/Crb2 are bona fide checkpoint proteins whose activation requires their corresponding C-terminal tandem BRCT (BRCA1 C-terminal) motifs, which mediate their oligomerization and phosphorylation at multiple sites following DNA damage. Here we show that the function of human 53BP1 similarly depends on its oligomerization and phosphorylation at multiple sites but in a BRCT domain-independent manner. Moreover, unlike its proposed yeast counterparts, human 53BP1 only has limited checkpoint functions but rather acts as an adaptor in the repair of DNA double strand breaks. This difference in function may reflect the higher complexity of the DNA damage response network in metazoa including the evolution of other BRCT domain-containing proteins that may have functions redundant or overlapping with those of 53BP1.	Mayo Clin, Coll Med, Dept Oncol Res, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Biochem, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Chen, JJ (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, POB 208040, New Haven, CT 06520 USA.	Junjie.Chen@yale.edu	Kim, Ja-Eun/AAI-1896-2020; Mer, Georges/AAT-4946-2021	Kim, Ja-Eun/0000-0002-9132-1277; Mer, Georges/0000-0002-1900-1578	NATIONAL CANCER INSTITUTE [R01CA109449, R01CA092312, R01CA100109] Funding Source: NIH RePORTER; NCI NIH HHS [CA 92312, CA 100109, R01 CA109449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MM, 2005, CELL CYCLE, V4, P1854, DOI 10.4161/cc.4.12.2282; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Du LL, 2004, J BIOL CHEM, V279, P38409, DOI 10.1074/jbc.M403326200; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Iwabuchi K, 2003, J BIOL CHEM, V278, P36487, DOI 10.1074/jbc.M304066200; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Manis JP, 2004, NAT IMMUNOL, V5, P481, DOI 10.1038/ni1067; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MORALES JC, 2003, J BIOL CHEM, V10, P10; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; Sweeney FD, 2005, CURR BIOL, V15, P1364, DOI 10.1016/j.cub.2005.06.063; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	41	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38472	38477		10.1074/jbc.M607577200	http://dx.doi.org/10.1074/jbc.M607577200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17043355	Green Accepted, hybrid			2022-12-25	WOS:000242709500041
J	Govin, J; Caron, C; Escoffier, E; Ferro, M; Kuhn, L; Rousseaux, S; Eddy, EM; Garin, J; Khochbin, S				Govin, Jerome; Caron, Cecile; Escoffier, Emmanuelle; Ferro, Myriam; Kuhn, Lauriane; Rousseaux, Sophie; Eddy, Edward M.; Garin, Jerome; Khochbin, Saadi			Post-meiotic shifts in HSPA2/HSP70.2 chaperone activity during mouse spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN; HSP70-2; HISTONES; SPERMATOCYTES; CELLS; SPERMIOGENESIS; MEIOSIS; PROTEIN	HSPA2 (formerly HSP70.2) is a testis-specific member of the HSP70 family known to play a critical role in the completion of meiosis during male germ cell differentiation. Although abundantly present in post-meiotic cells, its function during spermiogenesis remained obscure. Here, using a global proteomic approach to identify genome-organizing proteins in condensing spermatids, we discovered an unexpected role for HSPA2, which acquires new functions and becomes tightly associated with major spermatid DNA-packaging proteins, transition proteins 1 and 2. Hence, HSPA2 is identified here as the first transition protein chaperone, and these data shed a new light on the yet totally unknown process of genome-condensing structure assembly in spermatids.	Inst Albert Bonniot, INSERM, U309, F-38706 La Tronche, France; Univ Grenoble 1, F-38700 Grenoble, France; Commissariat LEnergie Atom, DSV, DRDC, Lab Chim Prot, F-38054 Grenoble, France; INSERM, ERM0201, F-38054 Grenoble, France; NIEHS, Reprod & Dev Toxicol Lab, Gamete Biol Grp, NIH, Res Triangle Pk, NC 27709 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Khochbin, S (corresponding author), Inst Albert Bonniot, INSERM, U309, Domaine De La Merci, F-38706 La Tronche, France.	khochbin@ujf-grenoble.fr	Caron, Cecile/M-3485-2013; Govin, Jerome/B-2326-2014; FERRO, Myriam/O-6588-2014; Rousseaux, Sophie/G-1697-2013; Khochbin, Saadi/M-8090-2013	Govin, Jerome/0000-0001-5511-6965; FERRO, Myriam/0000-0002-4222-6847; Rousseaux, Sophie/0000-0001-5246-5350; Khochbin, Saadi/0000-0002-0455-0857; Kuhn, Lauriane/0000-0002-2637-1024	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES070077, ZIAES070077] Funding Source: NIH RePORTER; NIEHS NIH HHS [Z01 ES070077-17] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alekseev OM, 2005, J BIOL CHEM, V280, P2904, DOI 10.1074/jbc.M410397200; Allen JW, 1996, CHROMOSOMA, V104, P414, DOI 10.1007/BF00352265; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BIGGIOGERA M, 1991, CHROMOSOMA, V100, P162, DOI 10.1007/BF00337245; Caron C, 2005, PROG MOLEC, V38, P65; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Dix DJ, 1997, DEVELOPMENT, V124, P4595; Eddy EM, 1999, REV REPROD, V4, P23, DOI 10.1530/revreprod/4.1.23; EIRINLOPEZ JM, 2006, GENETICS; Govin J, 2004, EUR J BIOCHEM, V271, P3459, DOI 10.1111/j.1432-1033.2004.04266.x; Hazzouri M, 2000, EUR J CELL BIOL, V79, P950, DOI 10.1078/0171-9335-00123; Kimmins S, 2005, NATURE, V434, P583, DOI 10.1038/nature03368; Komatsu Y, 2003, J IMMUNOL METHODS, V272, P161, DOI 10.1016/S0022-1759(02)00500-8; Lewis JD, 2003, CHROMOSOMA, V111, P473, DOI 10.1007/s00412-002-0226-0; Martianov I, 2005, P NATL ACAD SCI USA, V102, P2808, DOI 10.1073/pnas.0406060102; MARUSHIGE Y, 1983, BIOCHIM BIOPHYS ACTA, V761, P48, DOI 10.1016/0304-4165(83)90361-6; Pivot-Pajot C, 2003, MOL CELL BIOL, V23, P5354, DOI 10.1128/MCB.23.15.5354-5365.2003; Polo SE, 2006, CURR OPIN GENET DEV, V16, P104, DOI 10.1016/j.gde.2006.02.011; Shackleford G M, 2001, BMC Genomics, V2, P8, DOI 10.1186/1471-2164-2-8; Zhu DH, 1997, DEVELOPMENT, V124, P3007	20	94	105	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37888	37892		10.1074/jbc.M608147200	http://dx.doi.org/10.1074/jbc.M608147200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035236	Green Accepted, hybrid			2022-12-25	WOS:000242477100067
J	Meyer, LE; Machado, LB; Santiago, APSA; da-Silva, WS; De Felice, FG; Holub, O; Oliveira, MF; Galina, A				Meyer, Laudiene Evangelista; Machado, Lilia Bender; Santiago, Ana Paula S. A.; da-Silva, Wagner Seixas; De Felice, Fernanda G.; Holub, Oliver; Oliveira, Marcus F.; Galina, Antonio			Mitochondrial creatine kinase activity prevents reactive oxygen species generation - Antioxidant role of mitochondrial kinase-dependent ADP re-cycling activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; PERMEABILITY TRANSITION; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; HIPPOCAMPAL-NEURONS; ENERGY-METABOLISM; ENZYME-ACTIVITIES; GLUCOSE-UPTAKE; CELL-DEATH	As recently demonstrated by our group (da-Silva, W. S., Gomez-Puyou, A., Gomez-Puyou, M. T., Moreno-Sanchez, R., De Felice, F. G., de Meis, L., Oliveira, M. F., and Galina, A. (2004) J. Biol. Chem. 279, 39846-39855) mitochondrial hexokinase activity (mt-HK) plays a preventive antioxidant role because of steady-state ADP re-cycling through the inner mitochondrial membrane in rat brain. In the present work we show that ADP re-cycling accomplished by the mitochondrial creatine kinase (mt-CK) regulates reactive oxygen species (ROS) generation, particularly in high glucose concentrations. Activation of mt-CK by creatine (Cr) and ATP or ADP, induced a state 3-like respiration in isolated brain mitochondria and prevention of H2O2 production obeyed the steady-state kinetics of the enzyme to phosphorylate Cr. The extension of the preventive antioxidant role of mt-CK depended on the phosphocreatine (PCr)/Cr ratio. Rat liver mitochondria, which lack mt-CK activity, only reduced state 4-induced H2O2 generation when 1 order of magnitude more exogenous CK activity was added to the medium. Simulation of hyperglycemic conditions, by the inclusion of glucose 6-phosphate in mitochondria performing 2-deoxyglucose phosphorylation via mt-HK, induced H2O2 production in a Cr-sensitive manner. Simulation of hyperglycemia in embryonic rat brain cortical neurons increased both Delta Psi(m) and ROS production and both parameters were decreased by the previous inclusion of Cr. Taken together, the results presented here indicate that mitochondrial kinase activity performed a key role as a preventive antioxidant against oxidative stress, reducing mitochondrial ROS generation through an ADP-recycling mechanism.	Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biofis & Bioquim Celular, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Programa Biol Mol & Biotecnol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Programa Biol Celular & Parasitol, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Oliveira, MF (corresponding author), Lab Bioenerget & Mitochondrial Physiol, Ave Brigadeiro Trompowsky,S-N,CCS,Bloco D,Sub Sol, BR-21941590 Rio De Janeiro, Brazil.	maroli@bioqmed.ufrj.br; galina@bioqmed.ufrj.br	da Silva, Wagner S/A-7835-2008; Galina, Antonio/A-9292-2008; De Felice, Fernanda G/M-1074-2017; Oliveira, Marcus/G-3158-2011	da Silva, Wagner S/0000-0002-0001-0386; Oliveira, Marcus/0000-0002-9890-8425				AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Brdiczka DG, 2006, BBA-MOL BASIS DIS, V1762, P148, DOI 10.1016/j.bbadis.2005.09.007; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; da-Silva WS, 2004, J BIOL CHEM, V279, P39846, DOI 10.1074/jbc.M403835200; Deshpande SB, 1997, EXP NEUROL, V145, P38, DOI 10.1006/exnr.1997.6457; Dolder M, 2003, J BIOL CHEM, V278, P17760, DOI 10.1074/jbc.M208705200; Fehr M, 2003, J BIOL CHEM, V278, P19127, DOI 10.1074/jbc.M301333200; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Gomis RR, 2002, J BIOL CHEM, V277, P23246, DOI 10.1074/jbc.M111208200; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HEMMER W, 1994, EUR J NEUROSCI, V6, P538, DOI 10.1111/j.1460-9568.1994.tb00298.x; Hersch SM, 2006, NEUROLOGY, V66, P250, DOI 10.1212/01.wnl.0000194318.74946.b6; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; in 't Zandt HJA, 2004, J NEUROCHEM, V90, P1321, DOI 10.1111/j.1471-4159.2004.02599.x; JACOBS H, 1964, BIOCHEM BIOPH RES CO, V16, P516, DOI 10.1016/0006-291X(64)90185-8; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; JACOBUS WE, 1982, ARCH BIOCHEM BIOPHYS, V219, P167, DOI 10.1016/0003-9861(82)90146-1; Kaldis P, 1996, J CELL SCI, V109, P2079; Kernec F, 1996, BIOCHEM BIOPH RES CO, V225, P819, DOI 10.1006/bbrc.1996.1257; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Klivenyi P, 2004, NEUROBIOL DIS, V15, P610, DOI 10.1016/j.nbd.2003.12.014; Kolker S, 2001, PEDIATR RES, V50, P76; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Low PA, 1997, DIABETES, V46, pS38, DOI 10.2337/diab.46.2.S38; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOS P, 1991, J NEUROCHEM, V56, P2101, DOI 10.1111/j.1471-4159.1991.tb03472.x; Matsushima K, 2006, INT J BIOL MACROMOL, V38, P83, DOI 10.1016/j.ijbiomac.2005.12.023; Matthews RT, 1998, J NEUROSCI, V18, P156; MOLLOY GR, 1992, J NEUROCHEM, V59, P1925, DOI 10.1111/j.1471-4159.1992.tb11028.x; MORRISON JF, 1965, BIOCHEM J, V97, P37, DOI 10.1042/bj0970037; NEWSHOLME EA, 1967, BIOCHIM BIOPHYS ACTA, V132, P338, DOI 10.1016/0005-2744(67)90153-2; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; PAYNE RM, 1994, MOL CELL BIOCHEM, V133, P235, DOI 10.1007/BF01267957; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Roden M, 1999, ANNU REV MED, V50, P277, DOI 10.1146/annurev.med.50.1.277; ROSENSHTRAUKH LV, 1978, BIOCHEM MED METAB B, V19, P148, DOI 10.1016/0006-2944(78)90017-0; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; SAKS VA, 1991, BIOCHIM BIOPHYS ACTA, V1074, P302, DOI 10.1016/0304-4165(91)90168-G; SAUTER A, 1993, J BIOL CHEM, V268, P13166; Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004; SCHOLTE HR, 1973, BIOCHIM BIOPHYS ACTA, V291, P764, DOI 10.1016/0005-2736(73)90479-3; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Skaff DA, 2005, J BIOL CHEM, V280, P38403, DOI 10.1074/jbc.M506943200; Streijger F, 2005, BEHAV BRAIN RES, V157, P219, DOI 10.1016/j.bbr.2004.07.002; Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanhorebeek I, 2005, LANCET, V365, P53, DOI 10.1016/S0140-6736(04)17665-4; Vincent AM, 2005, FASEB J, V19, P638, DOI 10.1096/fj.04-2513fje; Votyakova TV, 2004, ARCH BIOCHEM BIOPHYS, V431, P138, DOI 10.1016/j.abb.2004.07.025; Wyss M, 2002, NEUROSCIENCE, V112, P243, DOI 10.1016/S0306-4522(02)00088-X; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; Young JC, 2002, LIFE SCI, V71, P1731, DOI 10.1016/S0024-3205(02)01941-0; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	71	133	142	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37361	37371		10.1074/jbc.M604123200	http://dx.doi.org/10.1074/jbc.M604123200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17028195	hybrid			2022-12-25	WOS:000242477100013
J	Tate, JJ; Feller, A; Dubois, E; Cooper, TG				Tate, Jennifer J.; Feller, Andre; Dubois, Evelyne; Cooper, Terrance G.			Saccharomyces cerevisiae Sit4 phosphatase is active irrespective of the nitrogen source provided, and Gln3 phosphorylation levels become nitrogen source-responsive in a sit4-deleted strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROGRADE GENE-EXPRESSION; TOR SIGNALING PATHWAY; CATABOLITE REPRESSION; NUCLEAR-LOCALIZATION; AMMONIA METABOLISM; CARBON STARVATION; 2A PHOSPHATASES; CELL-GROWTH; PROTEINS; TAP42	Tor1,2 control of type 2A-related phosphatase activities in Saccharomyces cerevisiae has been reported to be responsible for the regulation of Gln3 phosphorylation and intracellular localization in response to the nature of the nitrogen source available. According to the model, excess nitrogen stimulates Tor1,2 to phosphorylate Tip41 and/or Tap42. Tap42 then complexes with and inactivates Sit4 phosphatase, thereby preventing it from dephosphorylating Gln3. Phosphorylated Gln3 complexes with Ure2 and is sequestered in the cytoplasm. When Tor1,2 kinase activities are inhibited by limiting nitrogen, or rapamycin-treatment, Tap42 can no longer complex with Sit4. Active Sit4 dephosphorylates Gln3, which can then localize to the nucleus and activate transcription. The paucity of experimental data directly correlating active Sit4 and Pph3 with Gln3 regulation prompted us to assay Gln3-Myc(13) phosphorylation and intracellular localization in isogenic wild type, sit4, pph3, and sit4pph3 deletion strains. We found that Sit4 actively brought about Gln3-Myc(13) dephosphorylation in both good (glutamine or ammonia) and poor (proline) nitrogen sources. This Sit4 activity masked nitrogen source-dependent changes in Gln3-Myc(13) phosphorylation which were clearly visible when SIT4 was deleted. The extent of Sit4 requirement for Gln3 nuclear localization was both nitrogen source- and strain-dependent. In some strains, Sit4 was not even required for Gln3 nuclear localization in untreated or rapamycin-treated, proline-grown cells or Msx-treated, ammonia-grown cells.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA; Univ Libre Bruxelles, Inst Rech Microbiol JM Wiame, Microbiol Lab, B-1070 Brussels, Belgium	University of Tennessee System; University of Tennessee Health Science Center; Universite Libre de Bruxelles	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NIGMS NIH HHS [R01 GM035642-19A1, GM-35642, R01 GM035642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cooper TG, 2004, TOP CURR GENET, V7, P225; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cox KH, 2004, J BIOL CHEM, V279, P19294, DOI 10.1074/jbc.M309240200; Cox KH, 2004, J BIOL CHEM, V279, P10270, DOI 10.1074/jbc.M312023200; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dilova I, 2006, FEMS YEAST RES, V6, P112, DOI 10.1111/j.1567-1364.2005.00008.x; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Giannattasio S, 2005, J BIOL CHEM, V280, P42528, DOI 10.1074/jbc.M509187200; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Lorber MI, 2005, TRANSPLANTATION, V80, P244, DOI 10.1097/01.TP.0000164352.65613.24; Magasanik B, 2005, P NATL ACAD SCI USA, V102, P16537, DOI 10.1073/pnas.0507116102; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schluter Michael, 2005, Am Heart Hosp J, V3, P182, DOI 10.1111/j.1541-9215.2005.04407.x; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Tate JJ, 2006, J BIOL CHEM, V281, P28460, DOI 10.1074/jbc.M604171200; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200; Tate JJ, 2005, J BIOL CHEM, V280, P27195, DOI 10.1074/jbc.M504052200; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; THOMAS G, 2004, TOR TARGET RAPAMYCIN, V279; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wang HM, 2003, MOL BIOL CELL, V14, P4342, DOI 10.1091/mbc.E03-02-0072; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	42	46	46	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37980	37992		10.1074/jbc.M606973200	http://dx.doi.org/10.1074/jbc.M606973200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17015442	Green Accepted, hybrid			2022-12-25	WOS:000242477100077
J	Willmarth, NE; Ethier, SP				Willmarth, Nicole E.; Ethier, Stephen P.			Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; MAMMARY EPITHELIAL-CELLS; BREAST-CANCER CELLS; NORMAL HUMAN KERATINOCYTES; FACTOR RECEPTOR; EGF RECEPTOR; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; KINASE INHIBITORS; CARCINOMA-CELLS	Amphiregulin (AR) autocrine loops have been associated with several types of cancer. We demonstrate that SUM149 breast cancer cells have a self-sustaining AR autocrine loop. SUM149 cells are epidermal growth factor (EGF)-independent for growth, and they overexpress AR mRNA, AR membrane precursor protein, and secreted AR relative to the EGF-dependent human mammary epithelial cell line MCF10A. MCF10A cells made to overexpress AR (MCF10A AR) are also EGF-independent for growth. Treatment with the pan-ErbB inhibitor CI1033 and the anti-EGF receptor (EGFR) antibody C225 demonstrated that ligand-mediated activation of EGFR is required for SUM149 cell proliferation. AR-neutralizing antibody significantly reduced both SUM149 EGFR activity and cell proliferation, confirming that an AR autocrine loop is required for mitogenesis in SUM149 cells. EGFR tyrosine phosphorylation was dramatically decreased in both SUM149 and MCF10A AR cells after inhibition of AR cleavage with the broad spectrum metalloprotease inhibitor GM6001, indicating that an AR autocrine loop is strictly dependent on AR cleavage in culture. However, a juxtacrine assay where fixed SUM149 cells and MCF10A AR cells were overlaid on top of EGF-deprived MCF10A cells showed that the AR membrane precursor can activate EGFR. SUM149 cells, MCF10A AR cells, and MCF10A cells growing in exogenous AR were all considerably more invasive and motile than MCF10A cells grown in EGF. Moreover, AR up-regulates a number of genes involved in cell motility and invasion in MCF10A cells, suggesting that an AR autocrine loop contributes to the aggressive breast cancer phenotype.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst,Breast Canc Program, Detroit, MI 48201 USA; Univ Michigan, Cellular & Mol Biol Grad Program, Ann Arbor, MI 48109 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Michigan System; University of Michigan	Ethier, SP (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst,Breast Canc Program, 4100 John Rd, Detroit, MI 48201 USA.	ethier@karmanos.org			NATIONAL CANCER INSTITUTE [R01CA070354, R01CA100724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100724, R01 CA70354] Funding Source: Medline; NIGMS NIH HHS [T32 GM007315] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Arteaga CL, 2004, SEMIN ONCOL, V31, P3, DOI 10.1053/j.seminoncol.2004.01.006; Berquin IM, 2001, ONCOGENE, V20, P4019, DOI 10.1038/sj.onc.1204537; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Brown CL, 2001, J BIOL CHEM, V276, P29538, DOI 10.1074/jbc.M102114200; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Castillo J, 2006, CANCER RES, V66, P6129, DOI 10.1158/0008-5472.CAN-06-0404; Chung E, 2005, J INVEST DERMATOL, V124, P1134, DOI 10.1111/j.0022-202X.2005.23762.x; Chung EK, 2005, EXP CELL RES, V309, P149, DOI 10.1016/j.yexcr.2005.05.012; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; Dong JY, 2005, MOL BIOL CELL, V16, P2984, DOI 10.1091/mbc.E04-11-0994; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Funatomi H, 1997, INT J CANCER, V72, P512, DOI 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Ignatoski KMW, 1999, BREAST CANCER RES TR, V54, P173, DOI 10.1023/A:1006135331912; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; Kansra S, 2005, MOL PHARMACOL, V67, P1145, DOI 10.1124/mol.104.004689; Khatri P, 2005, NUCLEIC ACIDS RES, V33, pW762, DOI 10.1093/nar/gki472; Kleer CG, 2004, BREAST CANCER RES, V6, pR110, DOI 10.1186/bcr755; LEJEUNE S, 1993, CANCER RES, V53, P3597; Lev DC, 2004, BRIT J CANCER, V91, P795, DOI 10.1038/sj.bjc.6602051; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; Ma L, 2001, J PATHOL, V194, P413, DOI 10.1002/path.902; MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3; Menashi S, 2003, CANCER RES, V63, P7575; O-charoenrat P, 2000, CANCER RES, V60, P1121; Oliveira S, 2006, EXPERT OPIN BIOL TH, V6, P605, DOI 10.1517/14712598.6.6.605; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.0.CO;2-0; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Shilo BZ, 2005, DEVELOPMENT, V132, P4017, DOI 10.1242/dev.02006; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Silvy M, 2001, BRIT J CANCER, V84, P936, DOI 10.1054/bjoc.2000.1678; Smaill JB, 2000, J MED CHEM, V43, P1380, DOI 10.1021/jm990482t; SOULE HD, 1990, CANCER RES, V50, P6075; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tada H, 1999, J CELL BIOCHEM, V72, P423, DOI 10.1002/(SICI)1097-4644(19990301)72:3<423::AID-JCB11>3.3.CO;2-G; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; Thomas SM, 2004, CANCER TREAT REV, V30, P255, DOI 10.1016/j.ctrv.2003.10.003; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Willmarth NE, 2004, BREAST CANCER RES, V6, pR531, DOI 10.1186/bcr900; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	62	107	113	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37728	37737		10.1074/jbc.M606532200	http://dx.doi.org/10.1074/jbc.M606532200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035230	hybrid			2022-12-25	WOS:000242477100050
J	Hedges, J; Chen, YI; West, M; Bussiere, C; Johnson, AW				Hedges, John; Chen, Yen-I; West, Matthew; Bussiere, Cyril; Johnson, Arlen W.			Mapping the functional domains of yeast NMD3, the nuclear export adapter for the 60 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; LEPTOMYCIN B; PROTEIN; RPL10P; GRC5; REQUIRES	Nuclear export of the large ribosomal subunit requires the adapter protein Nmd3p to provide a leucine-rich nuclear export signal that is recognized by the export receptor Crm1. Nmd3p binds to the pre-60 S subunit in the nucleus. After export to the cytoplasm, the release of Nmd3p depends on the ribosomal protein Rpl10p and the GTPase Lsg1p. Here, we have carried out a mutational analysis of Nmd3 to better define the domains responsible for nucleocytoplasmic shuttling and ribosome binding. We show that mutations in two regions of Nmd3p affect 60 S binding, suggesting that its binding to the subunit is multivalent.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Johnson, AW (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, 1 Univ Stn,A5000, Austin, TX 78712 USA.	arlen@mail.utexas.edu		Johnson, Arlen/0000-0002-4742-085X	NIGMS NIH HHS [GM53655] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, GENOME RES, V10, P1172, DOI 10.1101/gr.10.8.1172; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Hedges J, 2005, EMBO J, V24, P567, DOI 10.1038/sj.emboj.7600547; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Ho JHN, 2000, RNA, V6, P1625, DOI 10.1017/S1355838200001291; Ho JHN, 1999, MOL CELL BIOL, V19, P2389; Johnson AW, 2002, TRENDS BIOCHEM SCI, V27, P580, DOI 10.1016/S0968-0004(02)02208-9; Johnson AW, 1997, MOL CELL BIOL, V17, P6122, DOI 10.1128/MCB.17.10.6122; Kaiser C., 1994, METHODS YEAST GENETI; Karl T, 1999, CURR GENET, V34, P419, DOI 10.1007/s002940050416; Koller HT, 1996, YEAST, V12, P53, DOI 10.1002/(SICI)1097-0061(199601)12:1<53::AID-YEA886>3.0.CO;2-M; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Page AM, 1998, NUCLEIC ACIDS RES, V26, P3707, DOI 10.1093/nar/26.16.3707; Sydorskyy Y, 2003, MOL CELL BIOL, V23, P2042, DOI 10.1128/MCB.23.6.2042-2054.2003; Teakle GR, 1998, TRENDS BIOCHEM SCI, V23, P100, DOI 10.1016/S0968-0004(98)01174-8; TERAOKA H, 1978, FEBS LETT, V88, P223, DOI 10.1016/0014-5793(78)80179-3; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Trotta CR, 2003, EMBO J, V22, P2841, DOI 10.1093/emboj/cdg249; West M, 2005, MOL CELL BIOL, V25, P3802, DOI 10.1128/MCB.25.9.3802-3813.2005; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zuk D, 1999, GENETICS, V153, P35	24	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36579	36587		10.1074/jbc.M606798200	http://dx.doi.org/10.1074/jbc.M606798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17015443	hybrid			2022-12-25	WOS:000242220800014
J	Lecuona, E; Dada, LA; Sun, HY; Butti, ML; Zhou, GF; Chew, TL; Sznajder, JI				Lecuona, Emilia; Dada, Laura A.; Sun, Haiying; Butti, Maria L.; Zhou, Guofei; Chew, Teng-Leong; Sznajder, Jacob I.			Na,K-ATPase alpha 1-subunit dephosphorylation by protein phosphatase 2A is necessary for its recruitment to the plasma membrane	FASEB JOURNAL			English	Article						alveolar epithelial cells; G-protein-coupled receptor agonists; intracellular trafficking	NA+-K+-ATPASE; LUNG EDEMA CLEARANCE; KINASE-C; NA+,K+-ATPASE ACTIVITY; ALPHA-SUBUNIT; INDUCED ENDOCYTOSIS; LIQUID CLEARANCE; DOPAMINE; PHOSPHORYLATION; MECHANISMS	In alveolar epithelial cells, G-protein coupled-receptors agonists (GPCR) induce the recruitment of the Na, K-ATPase to the plasma membrane. Here we report that for the recruitment of the Na, K-ATPase to occur, dephosphorylation of its alpha 1-subunit at serine 18 is necessary, as demonstrated by in vitro phosphorylation, mutation of the serine 18 to alanine, and use of a specific phospho-antibody. Several approaches strongly suggest dephosphorylation to be mediated by protein phosphatase 2A (PP2A): 1) Na, K-ATPase dephosphorylation and recruitment were prevented by okadaic acid (OA); 2) the Na, K-ATPase alpha 1-subunit is an in vitro substrate for PP2A; and 3) glutathione S-transferase (GST)-fusion proteins binding assays demonstrate a direct interaction between the catalytic subunit of PP2A and the first 90 amino acids of the Na, K-ATPase alpha 1-subunit. Finally, GPCR agonists induced a rapid translocation of PP2A from the cytosol to the membrane fraction, which corresponded with increased coimmunoprecipitation and colocalization of PP2A and the Na, K-ATPase. Accordingly, we provide evidence that GPCR agonists promote PP2A translocation to the membrane fraction, leading to the dephosphorylation of the Na, K-ATPase alpha 1-subunit at the serine 18 residue and its recruitment to the cell plasma membrane, which is of biological and physiological importance.	Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Cell Imaging Facil, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University	Lecuona, E (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Dept Med, 240 E Huron,McGaw M410, Chicago, IL 60611 USA.	e-lecuona@northwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065161, R37HL048129, R01HL048129] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48129, HL65161] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adir Y, 2003, ISR MED ASSOC J, V5, P47; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; Barnard ML, 1997, AM J RESP CRIT CARE, V156, P709, DOI 10.1164/ajrccm.156.3.9610013; Barnard ML, 1999, AM J RESP CRIT CARE, V160, P982, DOI 10.1164/ajrccm.160.3.9812003; Bertorello AM, 2005, AM J RESP CELL MOL, V33, P432, DOI 10.1165/rcmb.2005-0297TR; Bertorello AM, 2003, MOL BIOL CELL, V14, P1149, DOI 10.1091/mbc.E02-06-0367; Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; Bertuccio CA, 2003, PFLUG ARCH EUR J PHY, V447, P87, DOI 10.1007/s00424-003-1144-6; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BlotChabaud M, 1996, J MEMBRANE BIOL, V153, P233, DOI 10.1007/s002329900126; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brismar H, 2000, CLIN EXP HYPERTENS, V22, P303, DOI 10.1081/CEH-100100079; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 2001, ENDOCRINOLOGY, V142, P3474, DOI 10.1210/en.142.8.3474; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Clausen T, 2003, PHYSIOL REV, V83, P1269, DOI 10.1152/physrev.00011.2003; Correa-Meyer E, 2002, AM J PHYSIOL-LUNG C, V282, pL883, DOI 10.1152/ajplung.00203.2001; Dada LA, 2003, J CLIN INVEST, V111, P1057, DOI 10.1172/JCI200316826; Djelidi S, 2001, J AM SOC NEPHROL, V12, P1805, DOI 10.1681/ASN.V1291805; Dunbar LA, 2001, J BIOL CHEM, V276, P29617, DOI 10.1074/jbc.R100023200; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; Groshaus HE, 2004, CRIT CARE, V8, P234, DOI 10.1186/cc2875; Holst J, 2002, MOL BIOL CELL, V13, P1083, DOI 10.1091/mbc.01-12-0587; Ibarra FR, 2002, ACTA PHYSIOL SCAND, V175, P165, DOI 10.1046/j.1365-201X.2002.00984.x; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lecuona E, 2000, FEBS LETT, V481, P217, DOI 10.1016/S0014-5793(00)02009-3; Lecuona E, 2003, MOL BIOL CELL, V14, P3888, DOI 10.1091/mbc.E02-12-0781; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mallick BN, 2000, J NEUROCHEM, V74, P1574, DOI 10.1046/j.1471-4159.2000.0741574.x; Marmorstein LY, 2002, J BIOL CHEM, V277, P30591, DOI 10.1074/jbc.M204269200; McAuley DF, 2004, CRIT CARE MED, V32, P1470, DOI 10.1097/01.CCM.0000129489.34416.0E; Morgan A, 2004, CURR BIOL, V14, pR968, DOI 10.1016/j.cub.2004.10.045; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Pagel P, 2003, ANN NY ACAD SCI, V986, P360, DOI 10.1111/j.1749-6632.2003.tb07215.x; Pedemonte CH, 2005, SEMIN NEPHROL, V25, P322, DOI 10.1016/j.semnephrol.2005.03.007; Pedemonte CH, 2001, J BIOENERG BIOMEMBR, V33, P439, DOI 10.1023/A:1010675708820; Ragolia L, 1997, J BIOL CHEM, V272, P23653, DOI 10.1074/jbc.272.38.23653; Ridge KM, 2002, MOL BIOL CELL, V13, P1381, DOI 10.1091/mbc.01-07-0323; Ridge KM, 1997, AM J PHYSIOL-LUNG C, V273, pL246, DOI 10.1152/ajplung.1997.273.1.L246; Saldias FJ, 1999, AM J RESP CRIT CARE, V159, P626, DOI 10.1164/ajrccm.159.2.9805016; Saldias FJ, 2002, AM J PHYSIOL-LUNG C, V283, pL136, DOI 10.1152/ajplung.00089.2000; Schapiro FB, 2004, MOL BIOL CELL, V15, P2884, DOI 10.1091/mbc.E03-09-0653; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Sweeney G, 2001, AM J PHYSIOL-CELL PH, V281, pC1797, DOI 10.1152/ajpcell.2001.281.6.C1797; Sznajder JI, 2002, J APPL PHYSIOL, V93, P1860, DOI 10.1152/japplphysiol.00022.2002; Teixeira VL, 2003, ANN NY ACAD SCI, V986, P587, DOI 10.1111/j.1749-6632.2003.tb07257.x; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Vastiau A, 2005, FEBS LETT, V579, P3392, DOI 10.1016/j.febslet.2005.04.079; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	56	39	39	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2618	+		10.1096/fj.06-6503fje	http://dx.doi.org/10.1096/fj.06-6503fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065225				2022-12-25	WOS:000242490700043
J	Levites, Y; Smithson, LA; Price, RW; Dakin, RS; Yuan, B; Sierks, MR; Kim, J; McGowan, E; Reed, DK; Rosenberry, TL; Das, P; Golde, TE				Levites, Yona; Smithson, Lisa A.; Price, Robert W.; Dakin, Rachel S.; Yuan, Bin; Sierks, Michael R.; Kim, Jungsu; McGowan, Eileen; Reed, Dana Kim; Rosenberry, Terrone L.; Das, Pritam; Golde, Todd E.			Insights into the mechanisms of action of anti-A beta antibodies in Alzheimer's disease mouse models	FASEB JOURNAL			English	Article						immune complex; amyloid deposits	CENTRAL-NERVOUS-SYSTEM; APP TRANSGENIC MICE; BLOOD-BRAIN-BARRIER; AMYLOID DEPOSITION; IN-VIVO; A-BETA-42 IMMUNIZATION; MICROGLIAL ACTIVATION; MEMORY DEFICITS; HALF-LIFE; PEPTIDE	A number of hypotheses regarding how anti-A beta antibodies alter amyloid deposition have been postulated, yet there is no consensus as to how A beta immunotherapy works. We have examined the in vivo binding properties, pharmacokinetics, brain penetrance, and alterations in A beta levels after a single peripheral dose of anti-A beta antibodies to both wild-type (WT) and young non-A beta depositing APP and BRI-A beta 42 mice. The rapid rise in plasma A beta observed after antibody (Ab) administration is attributable to prolongation of the half-life of A beta bound to the Ab. Only a miniscule fraction of Ab enters the brain, and despite dramatic increases in plasma A beta, we find no evidence that total brain A beta levels are significantly altered. Surprisingly, cerebral spinal fluid A beta levels transiently rise, and when Ab:A beta complex is directly injected into the lateral ventricles of mice, it is rapidly cleared from the brain into the plasma where it remains stable. When viewed in context of daily turnover of A beta, these data provide a framework to evaluate proposed mechanisms of A beta attenuation mediated by peripheral administration of an anti-A beta monoclonal antibody (mAb) effective in passive immunization paradigm. Such quantitative data suggest that the mAbs are either indirectly enhancing clearance of A beta or targeting a low abundance aggregation intermediate.	Mayo Clin Jacksonville, Dept Neurosci, Coll Med, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Dept Pharmacol, Coll Med, Jacksonville, FL 32224 USA; Arizona State Univ, Dept Chem & Mat Engn, Tempe, AZ USA	Mayo Clinic; Mayo Clinic; Arizona State University; Arizona State University-Tempe	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Neurosci, Coll Med, Birdsall 210,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu	Kim, Jungsu/F-2457-2012; Kim, Jungsu/A-1372-2009	Kim, Jungsu/0000-0002-6931-8581; Dakin, Rachel/0000-0002-3697-8516	NIA NIH HHS [AG022595-01, AG18454] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018454, R01AG022595] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2002, J NEUROSCI, V22, P7873; Banks WA, 2005, PEPTIDES, V26, P287, DOI 10.1016/j.peptides.2004.09.016; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Randall JB, 2006, NAT MED, V12, P856, DOI 10.1038/nm1438; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; Brendza RP, 2005, J CLIN INVEST, V115, P428, DOI 10.1172/JCI200523269; Bussiere T, 2004, AM J PATHOL, V165, P987, DOI 10.1016/S0002-9440(10)63360-3; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chauhan VPS, 1999, BIOCHEM BIOPH RES CO, V258, P241, DOI 10.1006/bbrc.1999.0623; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Das P, 2003, J NEUROSCI, V23, P8532; Das P, 2002, NEUROBIOL AGING, V23, P671, DOI 10.1016/S0197-4580(02)00031-3; Das P, 2001, NEUROBIOL AGING, V22, P721, DOI 10.1016/S0197-4580(01)00245-7; Deane R, 2005, J NEUROSCI, V25, P11495, DOI 10.1523/JNEUROSCI.3697-05.2005; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Dodel RC, 2004, J NEUROL NEUROSUR PS, V75, P1472, DOI 10.1136/jnnp.2003.033399; DOVEY H, 2000, J NEUROCHEM, V76, P1; Fox NC, 2005, NEUROLOGY, V64, P1563, DOI 10.1212/01.WNL.0000159743.08996.99; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Ghiso J, 2004, J BIOL CHEM, V279, P45897, DOI 10.1074/jbc.M407668200; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783; Hone E, 2003, J ALZHEIMERS DIS, V5, P1, DOI 10.3233/JAD-2003-5101; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kuo YM, 2000, BIOCHEM BIOPH RES CO, V268, P750, DOI 10.1006/bbrc.2000.2222; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lanz TA, 2005, J PHARMACOL EXP THER, V312, P399, DOI 10.1124/jpet.104.073965; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lee M, 2005, ANN NEUROL, V58, P430, DOI 10.1002/ana.20592; Levites Y, 2006, J CLIN INVEST, V116, P193, DOI 10.1172/JCI25410; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; O'Toole M, 2005, ARCH NEUROL-CHICAGO, V62, P1531, DOI 10.1001/archneur.62.10.1531; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Paris D, 2000, ANN NY ACAD SCI, V903, P446, DOI 10.1111/j.1749-6632.2000.tb06397.x; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Su GC, 1999, BRAIN RES, V818, P105, DOI 10.1016/S0006-8993(98)01143-3; Tamura Y, 2005, NEUROBIOL DIS, V20, P541, DOI 10.1016/j.nbd.2005.04.007; Taylor BM, 2003, J PROTEIN CHEM, V22, P31, DOI 10.1023/A:1023063626770; VIEIRA P, 1986, EUR J IMMUNOL, V16, P871, DOI 10.1002/eji.1830160727; VOGELWEID CM, 1988, LAB ANIM SCI, V38, P91; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; Wilcock DM, 2001, DNA CELL BIOL, V20, P731, DOI 10.1089/10445490152717596	60	98	105	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2576	+		10.1096/fj.06-6463fje	http://dx.doi.org/10.1096/fj.06-6463fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068112				2022-12-25	WOS:000242490700029
J	Liou, HL; Dixit, SS; Xu, SJ; Tint, GS; Stock, AM; Lobel, P				Liou, Heng-Ling; Dixit, Sayali S.; Xu, Sujuan; Tint, G. Stephen; Stock, Ann M.; Lobel, Peter			NPC2, the protein deficient in Niemann-Pick C2 disease, consists of multiple glycoforms that bind a variety of sterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SECRETORY PROTEIN; LIPOPROTEIN-DERIVED CHOLESTEROL; MANNOSE 6-PHOSPHATE RECEPTORS; HUMAN EPIDIDYMIS; LIPID TRANSPORT; OLIGOSACCHARIDES; HOMEOSTASIS; CELLS; HE-1; IDENTIFICATION	Niemann-Pick C disease is a fatal neurodegenerative disorder characterized by an endolysosomal accumulation of cholesterol and other lipids. One form of the disease is caused by a deficiency in NPC2, a soluble lysosomal glycoprotein that binds cholesterol. To better understand the biological function of NPC2 and how its deficiency results in disease, we have characterized the structural and functional properties of recombinant human protein. Highly purified NPC2 consists of a complex mixture of glycosylated isoforms, similar to that observed in human brain autopsy specimens. Mass spectrometric analysis revealed that of the three potential N-linked glycosylation sites present in the mature protein, Asn-19 is not utilized; Asn-39 is linked to an endoglycosidase H (Endo H)-sensitive oligosaccharide, and Asn-116 is variably utilized, either being unmodified or linked to Endo H-sensitive or Endo H-resistant oligosaccharides. All glycoforms are endocytosed and ameliorate the cholesterol storage phenotype of NPC2-deficient fibroblasts. In addition, the purified preparation contains a mixture of both free and lipid-bound protein. All glycoforms bind cholesterol, and sterol binding to NPC2 significantly alters its behavior upon cation-exchange chromatography. Based on this observation, we developed chromatography- based binding assays and determined that NPC2 forms an equimolar complex with the fluorescent cholesterol analog dehydroergosterol. In addition, we find that NPC2 binds a range of cholesterol-related molecules (cholesterol precursors, plant sterols, some oxysterols, cholesterol sulfate, cholesterol acetate, and 5-alpha-cholestan-3-one) and that 27-hydroxysterol accumulates in NPC2-deficient mouse liver. Binding was not detected for various glycolipids, phospholipids, or fatty acids. These biochemical properties support a direct and specialized function of NPC2 in lysosomal sterol transport.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Vet Affairs Med Ctr, Res Serv, E Orange, NJ 07018 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lobel, P (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, 679 Hoes Ln, Piscataway, NJ 08854 USA.	lobel@cabm.rutgers.edu		Stock, Ann/0000-0002-0446-8079	Howard Hughes Medical Institute Funding Source: Medline; NIDDK NIH HHS [R01 DK054317] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054317] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker CS, 1993, BIOL REPROD S1, V48, P86; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cheruku SR, 2006, J BIOL CHEM, V281, P31594, DOI 10.1074/jbc.M602765200; Chikh K, 2004, MOL GENET METAB, V83, P220, DOI 10.1016/j.ymgme.2004.06.013; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Frolov A, 2003, J BIOL CHEM, V278, P25517, DOI 10.1074/jbc.M302588200; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; Honda A, 1999, J LIPID RES, V40, P1520; Ioannou YA, 2001, NAT REV MOL CELL BIO, V2, P657, DOI 10.1038/35089558; Kaji H, 2003, NAT BIOTECHNOL, V21, P667, DOI 10.1038/nbt829; Kirchhoff C, 1996, BIOL REPROD, V54, P847, DOI 10.1095/biolreprod54.4.847; Klein A, 2006, HEPATOLOGY, V43, P126, DOI 10.1002/hep.20985; Ko DC, 2003, P NATL ACAD SCI USA, V100, P2518, DOI 10.1073/pnas.0530027100; Larsen LB, 1997, EUR J BIOCHEM, V243, P437, DOI 10.1111/j.1432-1033.1997.0437a.x; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Lin L, 2001, BIOCHEM J, V357, P49, DOI 10.1042/0264-6021:3570049; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 2004, BBA-MOL CELL BIOL L, V1685, P22, DOI 10.1016/j.bbalip.2004.08.008; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; Nakamura Y, 2000, GENE, V251, P55, DOI 10.1016/S0378-1119(00)00189-X; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; Ohta M, 2000, GLYCOBIOLOGY, V10, P251, DOI 10.1093/glycob/10.3.251; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; Sleat DE, 2004, P NATL ACAD SCI USA, V101, P5886, DOI 10.1073/pnas.0308456101; Sleat DE, 2006, MOL CELL PROTEOMICS, V5, P686, DOI 10.1074/mcp.M500343-MCP200; SMUTZER G, 1986, BIOCHIM BIOPHYS ACTA, V862, P361, DOI 10.1016/0005-2736(86)90239-7; Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5; Tint GS, 1998, J INHERIT METAB DIS, V21, P853, DOI 10.1023/A:1005474803278; TROTTER PJ, 1991, J LIPID RES, V32, P293; Vanier MT, 1996, AM J HUM GENET, V58, P118; VARKI A, 1983, J BIOL CHEM, V258, P2808; WANG ZX, 1995, FEBS LETT, V360, P111, DOI 10.1016/0014-5793(95)00062-E; Willenborg M, 2005, J LIPID RES, V46, P2559, DOI 10.1194/jlr.M500131-JLR200; Zhao KW, 1997, J BIOL CHEM, V272, P22758, DOI 10.1074/jbc.272.36.22758	39	91	93	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36710	36723		10.1074/jbc.M608743200	http://dx.doi.org/10.1074/jbc.M608743200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17018531	hybrid			2022-12-25	WOS:000242220800028
J	Chen, Y; Leal, AD; Patel, S; Gorski, DH				Chen, Yun; Leal, Alejandro D.; Patel, Sejal; Gorski, David H.			The homeobox gene GAX activates p21 WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FIBROBLAST-GROWTH-FACTOR; TRANSCRIPTION FACTOR; DROSOPHILA-MELANOGASTER; MELANOMA PROGRESSION; MOLECULAR-CLONING; ANGIOGENIC SWITCH; HOX GENES; IN-VITRO; INTEGRIN	Tumors secrete pro-angiogenic factors to induce the ingrowth of blood vessels from the surrounding stroma, the end targets of which are vascular endothelial cells (ECs). The homeobox gene GAX inhibits angiogenesis and induces p21(WAF1/CIP1) expression in vascular ECs. To elucidate the mechanism through which GAX activates p(21WAF1/CIP1) expression, we constructed GAX cDNAs with deletions of the N-terminal domain, the homeodomain, or the C-terminal domain and then assessed these constructs for their ability to activate p(21WAF1/CIP1). There was an absolute requirement for the homeodomain, whereas deleting the C-terminal domain decreased but did not abolish transactivation of the p21(WAF1/CIP1) promoter by GAX. Deleting the N-terminal domain did abolish transactivation. Next, we performed chromatin immunoprecipitation and found, similar to 15 kb upstream of the p21(WAF1/CIP1) ATG codon, an ATTA-containing GAX-binding site (designated A6) with a sequence similar to that of other homeodomain-binding sites. GAX was able to bind to A6 in a homeodomain-dependent manner and thereby activate the expression of a reporter gene coupled to this sequence, and this activation was abolished by mutating specific residues in this sequence. On the basis of the sequence of A6, we were then able to locate other ATTA-containing sequences that also bound GAX and activated transcription in reporter constructs. Finally, we found that the ability of these GAX deletions to induce G(0)/G(1) arrest correlates with their ability to transactivate the p21(WAF1/CIP1) promoter. We conclude that GAX activates p21(WAF1/CIP1) through multiple upstream AT-rich sequences. Given the multiple biological activities of GAX in regulating EC function, identification of a putative GAX-binding site will allow the study of how GAX activates or represses other downstream targets to inhibit angiogenesis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Surg Oncol, Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gorski, DH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Surg Oncol, Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA.	gorskidh@umdnj.edu	Gorski, David/AAE-6399-2022	Gorski, David/0000-0002-9805-6699	NCI NIH HHS [R01 CA111344] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111344] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Boudreau NJ, 2004, J BIOL CHEM, V279, P4862, DOI 10.1074/jbc.M305190200; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; CANDIA AF, 1993, NUCLEIC ACIDS RES, V21, P4982, DOI 10.1093/nar/21.21.4982; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CANDIA AF, 1995, MECH DEVELOP, V52, P27, DOI 10.1016/0925-4773(95)00384-D; Charboneau A., 2005, Angiogenesis, V8, P289; Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chen YM, 2004, J CEREBR BLOOD F MET, V24, P1280, DOI 10.1097/01.WCB.0000141770.09022.AB; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Folkman J, 2003, CANCER BIOL THER, V2, pS127; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Ford HL, 1998, CELL BIOL INT, V22, P397, DOI 10.1006/cbir.1998.0329; GORSKI DH, 1994, BIOTECHNIQUES, V16, P856; Gorski DH, 2003, J AM COLL SURGEONS, V197, P408, DOI 10.1016/S1072-7515(03)00388-0; Gorski DH, 2003, TRENDS CARDIOVAS MED, V13, P213, DOI 10.1016/S1050-1738(03)00081-1; Gorski DH, 2003, J SURG RES, V111, P91, DOI 10.1016/S0022-4804(03)00042-8; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; Gorski DH, 2002, ANN SURG ONCOL, V9, pS42; Goydos JS, 2003, CLIN CANCER RES, V9, P5962; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; KASSIS JA, 1989, MOL CELL BIOL, V9, P4304, DOI 10.1128/MCB.9.10.4304; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEPAGE DF, 1994, GENOMICS, V24, P535, DOI 10.1006/geno.1994.1663; Mace KA, 2005, J CELL SCI, V118, P2567, DOI 10.1242/jcs.02399; Maillard L, 1997, CARDIOVASC RES, V35, P536, DOI 10.1016/S0008-6363(97)00147-8; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MURTHI P, 2006, IN PRESS PLACENTA; Myers C, 2002, AM J PATHOL, V161, P2099, DOI 10.1016/S0002-9440(10)64488-4; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Nakagawa T, 2003, ARTERIOSCL THROM VAS, V23, P231, DOI 10.1161/01.ATV.0000052670.55321.87; Paraguison RC, 2005, BIOCHEM BIOPH RES CO, V336, P1033, DOI 10.1016/j.bbrc.2005.08.212; Patel S, 2005, CANCER RES, V65, P1414, DOI 10.1158/0008-5472.CAN-04-3431; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Quinn LM, 1997, GENE, V187, P55, DOI 10.1016/S0378-1119(96)00706-8; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Raman V, 2000, J BIOL CHEM, V275, P26551, DOI 10.1074/jbc.C000324200; REGULSKI M, 1985, CELL, V43, P71, DOI 10.1016/0092-8674(85)90013-3; Rhoads Kim, 2005, Lymphatic Research and Biology, V3, P240, DOI 10.1089/lrb.2005.3.240; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Scatena MT, 2002, TRENDS CARDIOVAS MED, V12, P83, DOI 10.1016/S1050-1738(01)00151-7; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; Shono T, 1996, MOL CELL BIOL, V16, P4231; Skopicki HA, 1997, CIRC RES, V80, P452, DOI 10.1161/01.RES.80.4.452; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251; Wu ZH, 2005, NAT MED, V11, P959, DOI 10.1038/nm1287; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624; Zeng Jin-Hua, 2006, Hepatobiliary Pancreat Dis Int, V5, P242	65	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					507	517		10.1074/jbc.M606604200	http://dx.doi.org/10.1074/jbc.M606604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17074759	Green Accepted, hybrid			2022-12-25	WOS:000243166500056
J	Hagren, OI; Tengholm, A				Hagren, Olof Idevall; Tengholm, Anders			Glucose and insulin synergistically activate phosphatidylinositol 3-kinase to trigger oscillations of phosphatidylinositol 3,4,5-trisphosphate in beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FEEDBACK INHIBITION; INTRACELLULAR CA2+; PANCREATIC-ISLETS; PROTEIN-KINASE; SECRETION; RECEPTOR; MEMBRANE; BINDING	In insulin-secreting beta-cells, activation of phosphatidylinositol 3'-OH-kinase with resulting formation of phosphatidylinositol 3,4,5-trisphosphate (PIP3) has been implicated in the regulation of ion channels, insulin secretion, and gene transcription as well as in cell growth and survival, but the kinetics of PIP3 signals following physiological stimulation of insulin secretion is unknown. Using evanescent wave microscopy and a green fluorescent protein-tagged PIP3-binding protein domain for real-time monitoring of plasma membrane PIP3 concentration in single MIN6 beta-cells, we now demonstrate that glucose stimulation of insulin secretion results in pronounced PIP3 oscillations via autocrine stimulation of insulin receptors. Glucose lacked effect when insulin secretion was prevented with the hyperpolarizing agent diazoxide, but the sugar dose dependently enhanced the PIP3 response to maximal insulin stimulation without affecting the rate of PIP3 degradation. We conclude that glucose is an important co-activator of phosphatidylinositol-3'-OH-kinase and that the plasma membrane PIP3 concentration in beta-cells undergoes oscillations due to pulsatile release of insulin.	Uppsala Univ, Dept Med Cell Biol, Biomed Ctr, SE-75123 Uppsala, Sweden	Uppsala University	Tengholm, A (corresponding author), Uppsala Univ, Dept Med Cell Biol, Biomed Ctr, Box 571, SE-75123 Uppsala, Sweden.	anders.tengholm@mcb.uu.se		Idevall Hagren, Olof/0000-0002-0241-6304				ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Borelli MI, 2004, AM J PHYSIOL-ENDOC M, V286, pE111, DOI 10.1152/ajpendo.00161.2003; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dryselius S, 1999, AM J PHYSIOL-ENDOC M, V276, pE512, DOI 10.1152/ajpendo.1999.276.3.E512; Dyachok O, 2006, NATURE, V439, P349, DOI 10.1038/nature04410; ELAHI D, 1982, NEW ENGL J MED, V306, P1196, DOI 10.1056/NEJM198205203062002; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; GOODNER CJ, 1988, DIABETES, V37, P1316, DOI 10.2337/diabetes.37.10.1316; GYLFE E, 1988, J BIOL CHEM, V263, P5044; Gylfe E, 2000, UPSALA J MED SCI, V105, P35, DOI 10.1517/03009734000000054; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; IVERSEN J, 1971, DIABETES, V20, P1; Khan FA, 2001, DIABETES, V50, P2192, DOI 10.2337/diabetes.50.10.2192; LANG DA, 1981, DIABETES, V30, P435, DOI 10.2337/diabetes.30.5.435; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003; Persaud SJ, 2002, FEBS LETT, V510, P225, DOI 10.1016/S0014-5793(01)03268-9; PORKSEN N, 1995, AM J PHYSIOL-ENDOC M, V269, pE478, DOI 10.1152/ajpendo.1995.269.3.E478; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Qian WJ, 2004, BIOTECHNIQUES, V37, P922, DOI 10.2144/04376BI01; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Renstrom E, 1996, NEURON, V17, P513, DOI 10.1016/S0896-6273(00)80183-X; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Sakai K, 2003, BIOCHEM BIOPH RES CO, V300, P216, DOI 10.1016/S0006-291X(02)02832-2; Tengholm A, 2002, CURR BIOL, V12, P1871, DOI 10.1016/S0960-9822(02)01223-X; Thore S, 2004, J BIOL CHEM, V279, P19396, DOI 10.1074/jbc.C400088200; Velloso LA, 1995, FEBS LETT, V377, P353, DOI 10.1016/0014-5793(95)01370-9; VERSPOHL EJ, 1980, J CLIN INVEST, V65, P1230, DOI 10.1172/JCI109778; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu H, 1999, BIOCHEM J, V344, P813, DOI 10.1042/0264-6021:3440813; Xavier GD, 2004, BIOCHEM J, V377, P149, DOI 10.1042/BJ20031260; Zawalich WS, 2001, J BIOL CHEM, V276, P37120, DOI 10.1074/jbc.M105008200	40	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39121	39127		10.1074/jbc.M607445200	http://dx.doi.org/10.1074/jbc.M607445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17074763	hybrid			2022-12-25	WOS:000242898700019
J	Raybaud, A; Dodier, Y; Bissonnette, P; Simoes, M; Bichet, DG; Sauve, R; Parent, L				Raybaud, Alexandra; Dodier, Yolaine; Bissonnette, Pierre; Simoes, Manuel; Bichet, Daniel G.; Sauve, Remy; Parent, Lucie			The role of the GX(9)GX(3)G motif in the gating of high voltage-activated Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED GXXXG MOTIF; CALCIUM-CHANNEL; POTASSIUM CHANNEL; K+ CHANNEL; MOLECULAR DETERMINANTS; DEPENDENT INACTIVATION; TRANSMEMBRANE HELICES; CRYSTAL-STRUCTURE; BETA-SUBUNIT; T-TYPE	The putative hinge point revealed by the crystal structure of the MthK potassium channel is a glycine residue that is conserved in many ion channels. In high voltage-activated (HVA) Ca-V channels, the mid-S6 glycine residue is only present in IS6 and IIS6, corresponding to G422 and G770 in Ca(V)1.2. Two additional glycine residues are found in the distal portion of IS6 (Gly(432) and Gly(436) in CaV1.2) to form a triglycine motif unique to HVA CaV channels. Lethal arrhythmias are associated with mutations of glycine residues in the human L-type Ca2+ channel. Hence, we undertook a mutational analysis to investigate the role of S6 glycine residues in channel gating. In Ca(V)1.2, alpha-helix-breaking proline mutants (G422P and G432P) as well as the double G422A/G432A channel did not produce functional channels. The macroscopic inactivation kinetics were significantly decreased with Ca(V)1.2 wild type > G770A > G422A congruent to G436A >> G432A ( from the fastest to the slowest). Mutations at position Gly432 produced mostly nonfunctional mutants. Macroscopic inactivation kinetics were markedly reduced by mutations of Gly(436) to Ala, Pro, Tyr, Glu, Arg, His, Lys, or Asp residues with stronger effects obtained with charged and polar residues. Mutations within the distal GX(3)G residues blunted Ca2+-dependent inactivation kinetics and prevented the increased voltage-dependent inactivation kinetics brought by positively charged residues in the I-II linker. In Ca(V)2.3, mutation of the distal glycine Gly(352) impacted significantly on the inactivation gating. Altogether, these data highlight the role of the GX(3)G motif in the voltage-dependent activation and inactivation gating of HVA CaV channels with the distal glycine residue being mostly involved in the inactivation gating.	Univ Montreal, Dept Physiol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Membrane Prot Res Grp, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Parent, L (corresponding author), Univ Montreal, Dept Physiol, POB 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	parent@umontreal.ca						Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Bernatchez G, 2001, J MEMBRANE BIOL, V184, P143, DOI 10.1007/s00232-001-0083-4; Bernatchez G, 2001, BBA-BIOMEMBRANES, V1514, P217, DOI 10.1016/S0005-2736(01)00373-X; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; Berrou L, 2005, J BIOL CHEM, V280, P494, DOI 10.1074/jbc.M410859200; Berrou L, 2001, BIOPHYS J, V80, P215, DOI 10.1016/S0006-3495(01)76008-0; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; Bright JN, 2002, BIOPOLYMERS, V64, P303, DOI 10.1002/bip.10197; Brosig B, 1998, PROTEIN SCI, V7, P1052; Bustos DM, 2005, J BIOL CHEM, V280, P29004, DOI 10.1074/jbc.M502140200; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Catterall WA, 2005, PHARMACOL REV, V57, P411, DOI 10.1124/pr.57.4.5; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Dafi O, 2004, BIOPHYS J, V87, P3181, DOI 10.1529/biophysj.104.045559; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; Ding SH, 2005, J GEN PHYSIOL, V126, P213, DOI 10.1085/jgp.200509287; Dodier Y, 2004, J BIOL CHEM, V279, P6853, DOI 10.1074/jbc.M310534200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Erxleben C, 2006, P NATL ACAD SCI USA, V103, P3932, DOI 10.1073/pnas.0511322103; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Hohaus A, 2005, J BIOL CHEM, V280, P38471, DOI 10.1074/jbc.M507013200; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jin TH, 2002, MOL CELL, V10, P469, DOI 10.1016/S1097-2765(02)00659-7; Karplus K, 2003, PROTEINS, V53, P491, DOI 10.1002/prot.10540; KASS RS, 1984, J GEN PHYSIOL, V84, P705, DOI 10.1085/jgp.84.5.705; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Labro AJ, 2003, J BIOL CHEM, V278, P50724, DOI 10.1074/jbc.M306097200; LACERDA AE, 1994, BIOPHYS J, V66, P1833, DOI 10.1016/S0006-3495(94)80977-4; LEDUCNADEAU A, 2006, IN PRESS AM J PHYSL; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; LEE KS, 1985, J PHYSIOL-LONDON, V364, P395, DOI 10.1113/jphysiol.1985.sp015752; Lee SF, 2004, J BIOL CHEM, V279, P4144, DOI 10.1074/jbc.M309745200; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; Magidovich E, 2004, BIOCHEMISTRY-US, V43, P13242, DOI 10.1021/bi048377v; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Page KM, 1997, J NEUROSCI, V17, P1330; PARENT L, 1995, FEBS LETT, V360, P144, DOI 10.1016/0014-5793(95)00090-V; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Randall A, 1999, MOL CELL NEUROSCI, V14, P255, DOI 10.1006/mcne.1999.0795; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; Rosenhouse-Dantsker A, 2006, BIOPHYS J, V91, P2860, DOI 10.1529/biophysj.105.080242; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; Seebohm G, 2006, BIOPHYS J, V90, P2235, DOI 10.1529/biophysj.105.067165; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shealy RT, 2003, BIOPHYS J, V84, P2929, DOI 10.1016/S0006-3495(03)70020-4; Simoes M, 2002, J GEN PHYSIOL, V120, P99, DOI 10.1085/jgp.20028586; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Splawski I, 2005, P NATL ACAD SCI USA, V102, P8089, DOI 10.1073/pnas.0502506102; Stotz SC, 2004, J PHYSIOL-LONDON, V554, P263, DOI 10.1113/jphysiol.2003.047068; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; Tang W, 2003, BIOPHYS J, V85, P1538, DOI 10.1016/S0006-3495(03)74586-X; Tanskanen AJ, 2005, BIOPHYS J, V88, P85, DOI 10.1529/biophysj.104.051508; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Tikhonov DB, 2004, BIOPHYS J, V87, P1526, DOI 10.1529/biophysj.103.037770; Van Petegem F, 2005, NAT STRUCT MOL BIOL, V12, P1108, DOI 10.1038/nsmb1027; Webster SM, 2004, NATURE, V428, P864, DOI 10.1038/nature02468; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Yarov-Yarovoy V, 2002, J BIOL CHEM, V277, P35393, DOI 10.1074/jbc.M206126200; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; Zhen XG, 2005, J GEN PHYSIOL, V126, P193, DOI 10.1085/jgp.200509292; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	85	46	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39424	39436		10.1074/jbc.M607405200	http://dx.doi.org/10.1074/jbc.M607405200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17038321	hybrid			2022-12-25	WOS:000242898700050
J	Erler, I; Al-Ansary, DMM; Wissenbach, U; Wagner, TFJ; Flockerzi, V; Niemeyer, BA				Erler, Isabell; Al-Ansary, Dalia M. M.; Wissenbach, Ulrich; Wagner, Thomas F. J.; Flockerzi, Veit; Niemeyer, Barbara A.			Trafficking and assembly of the cold-sensitive TRPM8 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE EXPRESSION; COILED COILS; GLYCOSYLATION; TRPV5; DOMAIN; THERMOSENSATION; ACTIVATION; RECEPTOR	TRPM( transient receptor potential melastatin-like) channels are distinct from many other members of the transient receptor potential family in regard to their overall size (> 1000 amino acids), the lack of N-terminal ankyrin-like repeats, and hydrophobicity predictions that may allow for more than six transmembrane regions. Common to each TRPM member is a prominent C-terminal coiled coil region. Here we have shown that TRPM8 channels assemble as multimers using the putative coiled coil region within the intracellular C terminus and that this assembly can be disturbed by a single point mutation within the coiled coil region. This mutant neither gives rise to functional channels nor do its subunits interact or form protein complexes that correspond to a multimer. However, they are still transported to the plasma membrane. Furthermore, wild-type currents can be suppressed by expressing the membrane-attached C-terminal region of TRPM8. To separate assembly from trafficking, we investigated the maturation of TRPM8 protein by identifying and mutating the relevant N-linked glycosylation site and showing that glycosylation is neither essential for multimerization nor for transport to the plasma membrane per se but appears to facilitate efficient multimerization and transport.	Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, Dept Pharmacol & Toxicol, D-66421 Homburg, Germany	Saarland University	Niemeyer, BA (corresponding author), Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, Dept Pharmacol & Toxicol, Geb 46,Med Campus, D-66421 Homburg, Germany.	barbara.niemeyer@uniklinikum-saarland.de	Niemeyer, Barbara A./AAL-8972-2021	Niemeyer, Barbara A./0000-0002-6963-0575; Alansary, Dalia/0000-0002-7541-6057				Arniges M, 2006, J BIOL CHEM, V281, P1580, DOI 10.1074/jbc.M511456200; Brauchi S, 2006, J NEUROSCI, V26, P4835, DOI 10.1523/JNEUROSCI.5080-05.2006; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chang Q, 2004, J BIOL CHEM, V279, P54304, DOI 10.1074/jbc.M406222200; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Erler I, 2004, J BIOL CHEM, V279, P34456, DOI 10.1074/jbc.M404778200; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hendriks G, 2004, J BIOL CHEM, V279, P2975, DOI 10.1074/jbc.M310767200; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Jahnel R, 2001, EUR J BIOCHEM, V268, P5489, DOI 10.1046/j.1432-1033.2001.02500.x; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Jin XS, 2006, J BIOL CHEM, V281, P25006, DOI 10.1074/jbc.C600153200; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Lee J, 2005, J GEN PHYSIOL, V126, P439, DOI 10.1085/jgp.200509314; Liman Emily R, 2006, Sci STKE, V2006, ppe12, DOI 10.1126/stke.3262006pe12; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; McCleverty CJ, 2006, PROTEIN SCI, V15, P2201, DOI 10.1110/ps.062357206; Mery L, 2002, J CELL SCI, V115, P3497; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Mitra N, 2006, TRENDS BIOCHEM SCI, V31, P156, DOI 10.1016/j.tibs.2006.01.003; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Napp J, 2005, J BIOL CHEM, V280, P29506, DOI 10.1074/jbc.M504228200; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Owsianik G, 2006, ANNU REV PHYSIOL, V68, P685, DOI 10.1146/annurev.physiol.68.040204.101406; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Togashi K, 2006, EMBO J, V25, P1804, DOI 10.1038/sj.emboj.7601083; Tominaga M, 2004, J NEUROBIOL, V61, P3, DOI 10.1002/neu.20079; Tsuruda PR, 2006, NEURON, V51, P201, DOI 10.1016/j.neuron.2006.06.023; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200	37	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38396	38404		10.1074/jbc.M607756200	http://dx.doi.org/10.1074/jbc.M607756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17065148	hybrid			2022-12-25	WOS:000242709500033
J	Garg, S; Vitvitsky, V; Gendelman, HE; Banerjee, R				Garg, Sanjay; Vitvitsky, Victor; Gendelman, Howard E.; Banerjee, Ruma			Monocyte differentiation, activation, and mycobacterial killing are linked to transsulfuration-dependent redox metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOTHIOL SYNTHASE MUTANT; HUMAN METHIONINE SYNTHASE; NONPATHOGENIC MYCOBACTERIA; S-ADENOSYLMETHIONINE; GENE-EXPRESSION; TUBERCULOSIS; GLUTATHIONE; PATHOGEN; CELLS; MACROPHAGES	Modulation of the ambient redox status by mononuclear phagocytes is central to their role in health and disease. However, little is known about the mechanism of redox regulation during mononuclear phagocyte differentiation and activation, critical cellular steps in innate immunity, and microbial clearance. An important intermediate in GSH-based redox metabolism is homocysteine, which can undergo transmethylation via methionine synthase (MS) or transsulfuration via cystathionine beta-synthase (CBS). The transsulfuration pathway generates cysteine, the limiting reagent in GSH biosynthesis. We now demonstrate that expression of CBS and MS are strongly induced during differentiation of human monocytes and are regulated at the transcriptional and posttranscriptional levels, respectively. The changes in enzyme expression are paralleled by an similar to 150% increase in S-adenosylmethionine (accompanied by a corresponding increase in phospholipid methylation) and a similar increase in GSH. Activation with lipopolysachharide or infection with Mycobacterium smegmatis diminished expression of both enzymes to a significant extent and decreased S-adenosylmethionine concentration by similar to 30% of the control value while GSH and cysteine concentrations increased similar to 100 and 300%, respectively. Blockade of the transsulfuration pathway with propargylglycine suppressed clearance of M. smegmatis by macrophages and inhibited phagolysosomal fusion, whereas N-acetylcysteine promoted phagolysosomal fusion and enhanced mycobacterial clearance 3-fold compared with untreated cells. We posit that regulation of the transsulfuration pathway during monocyte differentiation, activation, and infection can boost host defense against invading pathogens and may represent a heretofore unrecognized antimicrobial therapeutic target.	Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Banerjee, R (corresponding author), Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu	Vitvitsky, Victor/ABA-2967-2021; Gendelman, Howard E/G-8242-2012	Vitvitsky, Victor/0000-0001-6251-6115; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034239, P01NS043985, R37NS036126] Funding Source: NIH RePORTER; NCRR NIH HHS [20 RR 15635] Funding Source: Medline; NIDDK NIH HHS [DK 64959] Funding Source: Medline; NINDS NIH HHS [5R37 NS 36126-07, 5R01 NS 034239-10, 1P01 NS 43985-91A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEATTY PW, 1980, ARCH BIOCHEM BIOPHYS, V204, P80, DOI 10.1016/0003-9861(80)90009-0; BELOTSKY SM, 1990, INFLAMMATION, V14, P663, DOI 10.1007/BF00916369; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Blasi F, 2005, RESPIRATION, V72, P9, DOI 10.1159/000083394; Buchmeier NA, 2003, MOL MICROBIOL, V47, P1723, DOI 10.1046/j.1365-2958.2003.03416.x; Buchmeier NA, 2006, J BACTERIOL, V188, P6245, DOI 10.1128/JB.00393-06; Buettner M, 2005, J IMMUNOL, V174, P4203, DOI 10.4049/jimmunol.174.7.4203; Chen LH, 1997, J BIOL CHEM, V272, P3628, DOI 10.1074/jbc.272.6.3628; Clark-Curtiss JE, 2003, ANNU REV MICROBIOL, V57, P517, DOI 10.1146/annurev.micro.57.030502.090903; Dayaram YK, 2006, J BACTERIOL, V188, P1364, DOI 10.1128/JB.188.4.1364-1372.2006; DEQUAY B, 1992, AIDS, V6, P815, DOI 10.1097/00002030-199208000-00008; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; Garaci E, 1997, J LEUKOCYTE BIOL, V62, P54, DOI 10.1002/jlb.62.1.54; Garg SK, 2004, J INFECT DIS, V189, P2129, DOI 10.1086/386286; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; Kim JM, 2004, BIOCHEM BIOPH RES CO, V325, P101, DOI 10.1016/j.bbrc.2004.09.220; Lazarevic V, 2005, J IMMUNOL, V175, P1107, DOI 10.4049/jimmunol.175.2.1107; Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; McGarvey JA, 2004, CLIN EXP IMMUNOL, V136, P490, DOI 10.1111/j.1365-2249.2004.02490.x; Meister A., 1995, METABOLIC BASIS INHE, P1461; Monack DM, 2004, NAT REV MICROBIOL, V2, P747, DOI 10.1038/nrmicro955; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Newton GL, 2005, J BACTERIOL, V187, P7309, DOI 10.1128/JB.187.21.7309-7316.2005; NEWTON GL, 2006, IN PRESS J BIOL CHEM, V281; Oltean S, 2003, J BIOL CHEM, V278, P20778, DOI 10.1074/jbc.M300845200; Prudova A, 2006, P NATL ACAD SCI USA, V103, P6489, DOI 10.1073/pnas.0509531103; Raja A, 2004, INDIAN J MED RES, V120, P213; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; Roach SK, 2002, INFECT IMMUN, V70, P3040, DOI 10.1128/IAI.70.6.3040-3052.2002; Sato H, 2001, J BIOL CHEM, V276, P10407, DOI 10.1074/jbc.M007216200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Shiloh MU, 2000, CURR OPIN MICROBIOL, V3, P35, DOI 10.1016/S1369-5274(99)00048-X; Smith DA, 2001, INFECT IMMUN, V69, P1142, DOI 10.1128/IAI.69.2.1442-1150.2001; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Venketaraman Vishwanath, 2006, AIDS Res Ther, V3, P5, DOI 10.1186/1742-6405-3-5; Vitvitsky V, 2004, AM J PHYSIOL-REG I, V287, pR39, DOI 10.1152/ajpregu.00036.2004; Wagner D, 2005, J IMMUNOL, V174, P1491, DOI 10.4049/jimmunol.174.3.1491; Waly M, 2004, MOL PSYCHIATR, V9, P358, DOI 10.1038/sj.mp.4001476; Wheeler PR, 2005, J BIOL CHEM, V280, P8069, DOI 10.1074/jbc.M412540200; Wise CK, 1997, J CHROMATOGR B, V696, P145, DOI 10.1016/S0378-4347(97)00213-2; Zhang W, 2005, CANCER RES, V65, P1554, DOI 10.1158/0008-5472.CAN-04-1554	44	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38712	38720		10.1074/jbc.M606235200	http://dx.doi.org/10.1074/jbc.M606235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046819	hybrid			2022-12-25	WOS:000242709500069
J	Lee, HJ; Chen, YS; Chou, CY; Chien, CH; Lin, CH; Chang, GG; Chen, X				Lee, Hong-Jen; Chen, Yuan-Shou; Chou, Chi-Yuan; Chien, Chia-Hui; Lin, Chun-Hung; Chang, Gu-Gang; Chen, Xin			Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST ACTIVATION PROTEIN; PEPTIDASE-IV INHIBITOR; CRYSTAL-STRUCTURE; SELECTIVE-INHIBITION; REVEALS; DEGRADATION; COMPLEX; ENDOPEPTIDASE; EXPRESSION; RESIDUES	DPP8 belongs to the family of prolyl dipeptidases, which are capable of cleaving the peptide bond after a penultimate proline residue. Unlike DPP-IV, a drug target for type II diabetes, no information is available on the crystal structure of DPP8, the regulation of its enzymatic activity, or its substrate specificity. In this study, using analytical ultracentrifugation and native gel electrophoresis, we show that the DPP8 protein is predominantly dimeric when purified or in the cell extracts. Four conserved residues in the C-terminal loop of DPP8 (Phe(822), Val(833), Tyr(844), and His(859)), corresponding to those located at the dimer interface of DPP-IV, were individually mutated to Ala. Surprisingly, unlike DPP-IV, these single-site mutations abolished the enzymatic activity of DPP8 without disrupting its quaternary structure, indicating that dimerization itself is not sufficient for the optimal enzymatic activity of DPP8. Moreover, these mutations not only decreased k(cat), as did the corresponding DPP-IV mutations, but also dramatically increased K-m. We further show that the K-m effect is independent of the substrate assayed. Finally, we identified the distinctive and strict substrate selectivity of DPP8 for hydrophobic or basic residues at the P2 site, which is in sharp contrast to the much less discriminative substrate specificity of DPP-IV. Our study has identified the residues absolutely required for the optimal activity of DPP8 and its unique substrate specificity. This study extends the functional importance of the C-terminal loop to the whole family of prolyl dipeptidases.	Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Miaoli 350, Taiwan; Natl Yang Ming Univ, Fac Life Sci, Taipei 112, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Chen, X (corresponding author), Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Zhu Nan Town, Miaoli 350, Taiwan.	xchen@nhri.org.tw	Chen, Xin/D-2073-2010	Chou, Chi-Yuan/0000-0002-3400-171X				Abbott CA, 2000, EUR J BIOCHEM, V267, P6140, DOI 10.1046/j.1432-1327.2000.01617.x; Abbott CA, 1999, FEBS LETT, V458, P278, DOI 10.1016/S0014-5793(99)01166-7; Aertgeerts K, 2005, J BIOL CHEM, V280, P19441, DOI 10.1074/jbc.C500092200; Aertgeerts K, 2004, PROTEIN SCI, V13, P412, DOI 10.1110/ps.03460604; Ajami K, 2003, BIOCHEMISTRY-US, V42, P694, DOI 10.1021/bi026846s; Augeri DJ, 2005, J MED CHEM, V48, P5025, DOI 10.1021/jm050261p; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; Bergman AJ, 2006, CLIN THER, V28, P55, DOI 10.1016/j.clinthera.2006.01.015; Bjelke JR, 2006, BIOCHEM J, V396, P391, DOI 10.1042/BJ20060079; Brown PH, 2006, BIOPHYS J, V90, P4651, DOI 10.1529/biophysj.106.081372; Chen X, 2001, GENOMICS, V73, P238, DOI 10.1006/geno.2001.6512; Chen YS, 2004, PROTEIN EXPRES PURIF, V35, P142, DOI 10.1016/j.pep.2003.12.019; Chien CH, 2004, J BIOL CHEM, V279, P52338, DOI 10.1074/jbc.M406185200; Chien CH, 2006, BIOCHEMISTRY-US, V45, P7006, DOI 10.1021/bi060401c; Chou CY, 2006, J BIOL CHEM, V281, P13333, DOI 10.1074/jbc.M511077200; Demeler B, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P210; Edosada CY, 2006, J BIOL CHEM, V281, P7437, DOI 10.1074/jbc.M511112200; Edosada CY, 2006, FEBS LETT, V580, P1581, DOI 10.1016/j.febslet.2006.01.087; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Jiaang WT, 2005, BIOORG MED CHEM LETT, V15, P687, DOI 10.1016/j.bmcl.2004.11.023; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Lankas GR, 2005, DIABETES, V54, P2988, DOI 10.2337/diabetes.54.10.2988; Lee KN, 2006, BLOOD, V107, P1397, DOI 10.1182/blood-2005-08-3452; Leiting B, 2003, BIOCHEM J, V371, P525, DOI 10.1042/BJ20021643; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; NAUSCH I, 1990, BIOL CHEM H-S, V371, P1113, DOI 10.1515/bchm3.1990.371.2.1113; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Pauly RP, 1996, J BIOL CHEM, V271, P23222, DOI 10.1074/jbc.271.38.23222; POLGAR L, 1992, BIOL CHEM H-S, V373, P361, DOI 10.1515/bchm3.1992.373.2.361; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Rosenblum JS, 2003, CURR OPIN CHEM BIOL, V7, P496, DOI 10.1016/S1367-5931(03)00084-X; Strop P, 2004, J MOL BIOL, V343, P1055, DOI 10.1016/j.jmb.2004.09.003; Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6; Wang XM, 2005, HEPATOLOGY, V42, P935, DOI 10.1002/hep.20853; Weihofen WA, 2004, J BIOL CHEM, V279, P43330, DOI 10.1074/jbc.M405001200; Zhu L, 2003, J BIOL CHEM, V278, P22418, DOI 10.1074/jbc.M212355200	38	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38653	38662		10.1074/jbc.M603895200	http://dx.doi.org/10.1074/jbc.M603895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17040910	Green Submitted, hybrid			2022-12-25	WOS:000242709500061
J	Zhou, B; Zhang, JL; Liu, SJ; Reddy, S; Wang, F; Zhang, ZY				Zhou, Bo; Zhang, Jialin; Liu, Sijiu; Reddy, Sharanya; Wang, Fang; Zhang, Zhong-Yin			Mapping ERK2-MKP3 binding interfaces by hydrogen/deuterium exchange mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE-2; ERK MAP KINASE; PHOSPHATASE MKP-3; CATALYTIC ACTIVATION; DOCKING INTERACTIONS; LIGAND-BINDING; SPECIFICITY; MECHANISM; PHOSPHORYLATION	ERK2, a prototypic member of the MAPK family, plays a central role in regulating cell growth and differentiation. MKP3, an ERK2-specific phosphatase, terminates ERK2 signaling. To understand the molecular basis of ERK2 recognition by MKP3, we carried out hydrogen/deuterium exchange mass spectrometry experiments to map the interaction surfaces between the two proteins. The results show that the exquisite specificity of MKP3 for ERK2 is governed by two distinctive protein-protein interactions. To increase the "effective concentration" of the interacting molecules, the kinase interaction motif in MKP3 ((64)RRLQKGNLPVR(74)) and an MKP3-specific segment ((NSSDWNE107)-N-101) bind the common docking site in ERK2 defined by residues in L-16, L-5, beta(7)-beta(8), and alpha(d)-L-8-alpha(e), located opposite the kinase active site. In addition to this "tethering" effect, additional interactions between the (364)FTAP(367) sequence in MKP3 and the ERK2 substrate-binding site, formed by residues in the activation lip and the P+1 site (beta(9)-alpha(f) loop), L-13 (alpha f-alpha(g) loop), and the MAPK insert (L-14- alpha(1L14)-alpha(2L14)), are essential for allosteric activation of MKP3 and formation of a productive complex whereby the MKP3 catalytic site is correctly juxtaposed to carry out the dephosphorylation of phospho-Thr(183)/phospho-Tyr(185) in ERK2. This bipartite protein-protein interaction model may be applicable to the recognition of other MAPKs by their cognate regulators and substrates.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Lab Macromol Anal & Proteom, Bronx, NY 10461 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	zyzhang@iupui.edu			NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Eblaghie MC, 2003, CURR BIOL, V13, P1009, DOI 10.1016/S0960-9822(03)00381-6; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Gomez AR, 2005, DEV DYNAM, V232, P695, DOI 10.1002/dvdy.20227; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Hoofnagle AN, 2003, ANNU REV BIOPH BIOM, V32, P1, DOI 10.1146/annurev.biophys.32.110601.142417; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karlsson M, 2004, J BIOL CHEM, V279, P41882, DOI 10.1074/jbc.M406720200; Kawakami Y, 2003, NAT CELL BIOL, V5, P513, DOI 10.1038/ncb989; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim M, 2004, MOL CELL BIOL, V24, P573, DOI 10.1128/MCB.24.2.573-583.2004; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Liu SJ, 2006, P NATL ACAD SCI USA, V103, P5326, DOI 10.1073/pnas.0510506103; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Pawson T, 2000, GENE DEV, V14, P1027; Remenyi A, 2005, MOL CELL, V20, P951, DOI 10.1016/j.molcel.2005.10.030; Smith TG, 2005, DEVELOPMENT, V132, P1305, DOI 10.1242/dev.01699; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Wang F, 1998, BIOCHEMISTRY-US, V37, P15289, DOI 10.1021/bi981481q; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; Zhang ZY, 2003, PROG NUCLEIC ACID RE, V73, P171, DOI 10.1016/S0079-6603(03)01006-7; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200	42	44	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38834	38844		10.1074/jbc.M608916200	http://dx.doi.org/10.1074/jbc.M608916200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046812	hybrid			2022-12-25	WOS:000242709500081
J	Wang, JY; Shao, Y; Bennett, TA; Shankar, RA; Wightman, PD; Reddy, LG				Wang, Jianyong; Shao, Yu; Bennett, Teri A.; Shankar, Raji A.; Wightman, Paul D.; Reddy, Laxma G.			The functional effects of physical interactions among toll-like receptors 7, 8, and 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-PRODUCING CELLS; B-CELLS; INNATE IMMUNITY; ACQUIRED-IMMUNITY; CUTTING EDGE; CPG DNA; EXPRESSION; RECOGNITION; ACTIVATION; TLR9	Toll-like receptors (TLRs) TLR1, TLR2, TLR4, and TLR6 are evolutionarily conserved, highly homologous, and localized to plasma membranes of host cells and recognize pathogen-associated molecular patterns (PAMPs) derived from bacterial membranes. These receptors cooperate in a pairwise combination to elicit or inhibit the inflammatory signals in response to certain PAMPs. The other TLRs that are evolutionarily closely related and highly homologous are TLR7, TLR8, and TLR9. They are all confined to the membranes of endosomes and recognize similar molecular structures, the oligonucleotide-based PAMPs. However, the cooperative interactions among these receptors that may modulate the inflammatory signaling in response to their cognate agonists are not reported. We report here for the first time the functional effects of one TLR on the other among TLR7, TLR8, and TLR9. The results indicate that TLR8 inhibits TLR7 and TLR9, and TLR9 inhibits TLR7 but not vice versa in HEK293 cells transfected with TLRs in a pairwise combination. This is concluded by selectively activating one TLR over the other by using small molecule TLR agonists. We also show that these inhibitory interactions are the result of direct or indirect physical interactions between the TLRs. The murine TLR8 that does not respond to any known human TLR8 agonists also inhibits both murine and human TLR7. The implications of the inhibitory interactions among these TLRs in host-pathogen recognition and subsequent inflammatory responses are not obvious. However, given the complexity in expression pattern in a particular cell type and the variation in distribution and response to different pathogens and stress signals in different cell types, the inhibitory physical interactions among these TLRs may play a role in balancing the inflammatory outcome from a given cell type to a specific challenge.	3M Pharmaceut, 3M Ctr, Dept Pharmacol, 3M Pharmaceut Div, St Paul, MN 55144 USA	3M	Reddy, LG (corresponding author), 3M Pharmaceut, 3M Ctr, Dept Pharmacol, 3M Pharmaceut Div, Bldg 270-2S-06, St Paul, MN 55144 USA.	lgreddy@mmm.com						Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7; Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Bekeredjian-Ding IB, 2005, J IMMUNOL, V174, P4043, DOI 10.4049/jimmunol.174.7.4043; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Beutler B, 2002, CURR TOP MICROBIOL, V270, P1; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Edwards AD, 2003, EUR J IMMUNOL, V33, P827, DOI 10.1002/eji.200323797; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Ito T, 2005, SPRINGER SEMIN IMMUN, V26, P221, DOI 10.1007/s00281-004-0180-4; Ito T, 2002, HUM IMMUNOL, V63, P1120, DOI 10.1016/S0198-8859(02)00750-4; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Krieg AM, 2000, SPRINGER SEMIN IMMUN, V22, P55, DOI 10.1007/s002810000016; Kurt-Jones EA, 2004, J ENDOTOXIN RES, V10, P419, DOI 10.1179/096805104225006516; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977; O'Neill LAJ, 2004, SCIENCE, V303, P1481, DOI 10.1126/science.1096113; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093; Spitzer JH, 2002, EUR J IMMUNOL, V32, P1182, DOI 10.1002/1521-4141(200204)32:4<1182::AID-IMMU1182>3.0.CO;2-9; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554; Zhang Y, 2001, J INTERF CYTOK RES, V21, P871, DOI 10.1089/107999001753238123	43	105	120	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37427	37434		10.1074/jbc.M605311200	http://dx.doi.org/10.1074/jbc.M605311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17040905	hybrid			2022-12-25	WOS:000242477100019
J	Weiergraber, OH; Senin, II; Zernii, EY; Churumova, VA; Kovaleva, NA; Nazipova, AA; Permyakov, SE; Permyakov, EA; Philippov, PP; Granzin, J; Koch, KW				Weiergraeber, Oliver H.; Senin, Ivan I.; Zernii, Eugene Yu; Churumova, Valeriya A.; Kovaleva, Nadezhda A.; Nazipova, Aliya A.; Permyakov, Sergei E.; Permyakov, Eugene A.; Philippov, Pavel P.; Granzin, Joachim; Koch, Karl-Wilhelm			Tuning of a neuronal calcium sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RHODOPSIN KINASE; 3-DIMENSIONAL STRUCTURE; CA2+-MYRISTOYL SWITCH; RECOVERIN; BINDING; PROTEINS; SYSTEM; PHOSPHORYLATION; INHIBITION	Recoverin is a Ca2+-regulated signal transduction modulator expressed in the vertebrate retina that has been implicated in visual adaptation. An intriguing feature of recoverin is a cluster of charged residues at its C terminus, the functional significance of which is largely unclear. To elucidate the impact of this segment on recoverin structure and function, we have investigated a mutant lacking the C-terminal 12 amino acids. Whereas in myristoylated recoverin the truncation causes an overall decrease in Ca2+ sensitivity, results for the non-myristoylated mutant indicate that the truncation primarily affects the high affinity EF-hand 3. The three-dimensional structure of the mutant has been determined by x-ray crystallography. In addition to significant changes in average coordinates compared with wild-type recoverin, the structure provides strong indication of increased conformational flexibility, particularly in the C-terminal domain. Based on these observations, we propose a novel role of the C-terminal segment of recoverin as an internal modulator of Ca2+ sensitivity.	Carl Von Ossietzky Univ Oldenburg, Fak 5, IBU, AG Biochem, D-26111 Oldenburg, Germany; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142290, Moscow Region, Russia; Moscow MV Lomonosov State Univ, Fac Bioengn & Bioinformat, Moscow 119992, Russia; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia; Forschungszentrum Julich GmbH, Inst Biol Informationsverarbeitung, IBI 2, Biol Strukturforsch, D-52425 Julich, Germany	Carl von Ossietzky Universitat Oldenburg; Russian Academy of Sciences; Lomonosov Moscow State University; Lomonosov Moscow State University; Helmholtz Association; Research Center Julich	Koch, KW (corresponding author), Carl Von Ossietzky Univ Oldenburg, Fak 5, IBU, AG Biochem, D-26111 Oldenburg, Germany.	karl.w.koch@uni-oldenburg.de	Permyakov, Sergei/O-1386-2019; Permyakov, Eugene A./M-8707-2014; Permyakov, Sergei E./B-8156-2011; Koch, Karl-Wilhelm/C-9551-2015; Philippov, Pavel P/A-8939-2012; Zernii, Evgeni Yu./D-9446-2012; Senin, Ivan I/D-9163-2012; Weiergräber, Oliver H./G-8940-2013; Granzin, Joachim/G-8937-2013	Permyakov, Sergei/0000-0003-4086-3137; Permyakov, Eugene A./0000-0002-9099-1148; Permyakov, Sergei E./0000-0003-4086-3137; Koch, Karl-Wilhelm/0000-0003-1501-0044; Zernii, Evgeni Yu./0000-0002-3013-7863; Weiergräber, Oliver H./0000-0002-2410-3691; Granzin, Joachim/0000-0001-6604-950X				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgoyne RD, 2004, TRENDS NEUROSCI, V27, P203, DOI 10.1016/j.tins.2004.01.010; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; Erickson MA, 1998, P NATL ACAD SCI USA, V95, P6474, DOI 10.1073/pnas.95.11.6474; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GORODOVIKOVA EN, 1994, FEBS LETT, V353, P171, DOI 10.1016/0014-5793(94)01030-7; Ikura M, 2006, P NATL ACAD SCI USA, V103, P1159, DOI 10.1073/pnas.0508640103; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lange C, 1997, BIOCHEMISTRY-US, V36, P12019, DOI 10.1021/bi970938d; Leslie A. G. W., 1992, JNT CCP4 ESF EAMCB N, V26; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Makino CL, 2004, J GEN PHYSIOL, V123, P729, DOI 10.1085/jgp.200308994; Matsuda S, 1999, BIOCHEMISTRY-US, V38, P1310, DOI 10.1021/bi982117u; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nagae M, 2003, J BIOL CHEM, V278, P42240, DOI 10.1074/jbc.M303630200; Neubert TA, 1997, PROTEIN SCI, V6, P843; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Permyakov SE, 2000, PROTEIN ENG, V13, P783, DOI 10.1093/protein/13.11.783; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sampath AP, 2005, NEURON, V46, P413, DOI 10.1016/j.neuron.2005.04.006; Scannevin RH, 2004, NEURON, V41, P587, DOI 10.1016/S0896-6273(04)00049-2; Senin II, 2004, J BIOL CHEM, V279, P48647, DOI 10.1074/jbc.M402516200; Senin II, 2003, J MOL BIOL, V330, P409, DOI 10.1016/S0022-2836(03)00581-3; Senin II, 2002, ADV EXP MED BIOL, V514, P69; Senin II, 2002, J BIOL CHEM, V277, P50365, DOI 10.1074/jbc.M204338200; Strissel KJ, 2005, J BIOL CHEM, V280, P29250, DOI 10.1074/jbc.M501789200; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Valentine KG, 2003, BIOCHEMISTRY-US, V42, P6333, DOI 10.1021/bi0206816; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Weiergraber OH, 2003, J BIOL CHEM, V278, P22972, DOI 10.1074/jbc.M300447200; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	47	42	43	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37594	37602		10.1074/jbc.M603700200	http://dx.doi.org/10.1074/jbc.M603700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17015448	Green Published, hybrid			2022-12-25	WOS:000242477100036
J	Chastain, PD; Nakamura, J; Swenberg, J; Kaufman, D				Chastain, Paul D., II; Nakamura, Jun; Swenberg, James; Kaufman, David			Nonrandom AP site distribution in highly proliferative cells	FASEB JOURNAL			English	Article						abasic; apurinic/apyrimidinic; electron microscopy; oxidative damage; reactive oxygen species; methoxyamine; isolated DNA fibers	BASE-EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; APURINIC/APYRIMIDINIC SITES; ELECTRON-MICROSCOPY; IONIZING-RADIATION; MAMMALIAN-CELLS; LESIONS; CHROMATIN; DISEASE; ASSAY	Reactive oxygen species (ROS) and the oxidative DNA damage they produce [e. g., 8-oxo-guanine and apurinic/apyrimidinic (AP) sites] have been linked to the pathogenesis of several age-related and chronic diseases. The basal number of AP sites measured in DNA by immuno-slot-blot analysis ranges from 70,000 to 100,000 per genome. We used electron microscopy to determine how AP sites were distributed in isolated DNA fibers from fresh calf thymus and HeLa cell cultures. We observed that AP sites were not equally distributed throughout all the fibers. A small percentage of the analyzed DNA fibers contained a disproportionate amount of the total AP sites in nonrandom groups of 10 to > 30 closely spaced in a small region (e. g., 20 AP sites in a 6 kb length of DNA). This finding suggests that genomic sites may differ in their vulnerability to ROS damage, perhaps because of local chromatin structure. Nonrandom AP site formation also suggests that the detrimental effects of ROS in the development of disease may be related not simply to the total number of AP sites present but to how AP sites are distributed along a DNA fiber and, perhaps, to the genomic sites affected.	Univ N Carolina, Sch Med, Dept Pathol & Lab, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Chastain, PD (corresponding author), Univ N Carolina, Sch Med, Dept Pathol & Lab, Chapel Hill, NC 27599 USA.	pchastai@med.unc.edu	Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788; Nakamura, Jun/0000-0002-1756-7199	NATIONAL CANCER INSTITUTE [P30CA016086, R01CA084493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES005948, P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NCI NIH HHS [CA16086, CA-084493] Funding Source: Medline; NIEHS NIH HHS [P42-ES05948, ES07017, P30-ES10126] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYLAWSKI BP, 1989, CARCINOGENESIS, V10, P199, DOI 10.1093/carcin/10.1.199; BRYLAWSKI BP, 1991, MOL CARCINOGEN, V4, P315, DOI 10.1002/mc.2940040410; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; Georgakilas AG, 2002, NUCLEIC ACIDS RES, V30, P2800, DOI 10.1093/nar/gkf393; GRIFFITH JD, 1978, SCIENCE, V201, P525, DOI 10.1126/science.663672; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; LIUZZI M, 1985, J BIOL CHEM, V260, P5252; MACLEOD MC, 1995, CARCINOGENESIS, V16, P2009, DOI 10.1093/carcin/16.9.2009; Nakamura J, 2003, NUCLEIC ACIDS RES, V31, P1790, DOI 10.1093/nar/gkg263; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nakamura J, 1999, CANCER RES, V59, P2522; Nakamura J, 1998, CANCER RES, V58, P222; TALPAERTBORLE M, 1983, BIOCHIM BIOPHYS ACTA, V740, P410, DOI 10.1016/0167-4781(83)90089-1; Tian KG, 2002, DNA REPAIR, V1, P1039, DOI 10.1016/S1568-7864(02)00163-5; Yang N, 2004, DNA REPAIR, V3, P1323, DOI 10.1016/j.dnarep.2004.04.014; Zielinska-Park J, 2004, CARCINOGENESIS, V25, P1727, DOI 10.1093/carcin/bgh174	20	22	23	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2612	+		10.1096/fj.06-6145fje	http://dx.doi.org/10.1096/fj.06-6145fje			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068113				2022-12-25	WOS:000242490700041
J	Stagi, M; Gorlovoy, P; Larionov, S; Takahashi, K; Neumann, H				Stagi, Massimiliano; Gorlovoy, Philipp; Larionov, Sergey; Takahashi, Kazuya; Neumann, Harald			Unloading kinesin transported cargoes from the tubulin track via the inflammatory c-Jun N-terminal kinase pathway	FASEB JOURNAL			English	Article						neuroinflammation; tumor necrosis factor-alpha; synaptophysin; mitochondria	TUMOR-NECROSIS-FACTOR; DYNEIN SUPERFAMILY PROTEINS; VESICLE PRECURSOR TRANSPORT; CENTRAL-NERVOUS-SYSTEM; AXONAL-TRANSPORT; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; SCAFFOLD PROTEIN; ORGANELLE TRANSPORT; NITRIC-OXIDE	Axonal transport of mitochondria and synaptic vesicle precursors via kinesin motor proteins is essential to keep integrity of axons and synapses. Disturbance of axonal transport is an early sign of neuroinflammatory and neurodegenerative diseases. Treatment of cultured neurons by the inflammatory cytokine tumor necrosis factor-alpha (TNF) stimulated phosphorylation of c-Jun N-terminal kinase (JNK) in neurites. TNF treatment induced dissociation of the heavy chain kinesin family-5B (KIF5B) protein from tubulin in axons but not cell bodies as determined by lifetime-based Forster resonance energy transfer (FRET) analysis. Dissociation of KIF5B from tubulin after TNF treatment was dependent on JNK activity. Furthermore, TNF inhibited axonal transport of mitochondria and synaptophysin by reducing the mobile fraction via JNK. Thus, TNF produced by activated glial cells in inflammatory or degenerative neurological diseases acts on neurites by acting on the kinesin-tubulin complex and inhibits axonal mitochondria and synaptophysin transport via JNK.-Stagi, M., Gorlovoy, P., Larionov, S., Takahashi, K., and Neumann, H. Unloading kinesin transported cargoes from the tubulin track via the inflammatory c-Jun N-terminal kinase pathway.	Univ Bonn, Life & Brain Ctr, Neural Regenerat Unit, Inst Reconstruct Neurobiol, D-53127 Bonn, Germany; Univ Bonn, Hertie Fdn, D-53127 Bonn, Germany; Univ Gottingen, Inst Multiple Sclerosis Res, D-3400 Gottingen, Germany; Hertie Fdn, Gottingen, Germany; European Neurosci Inst Gottingen, Neuroimmunol Unit, Gottingen, Germany; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA	University of Bonn; University of Bonn; University of Gottingen; Yale University	Neumann, H (corresponding author), Univ Bonn, Life & Brain Ctr, Neural Regenerat Unit, Inst Reconstruct Neurobiol, Sigmund Freud Str 25, D-53127 Bonn, Germany.	hneuman1@uni-bonn.de	Stagi, Massimiliano/ABF-5894-2020; Neumann, Harald/A-9718-2010; Takahashi, Kazuya/R-3499-2019	Stagi, Massimiliano/0000-0002-5827-902X; Neumann, Harald/0000-0002-5071-5202; 				Aboul-Enein F, 2006, ACTA NEUROPATHOL, V111, P539, DOI 10.1007/s00401-006-0047-y; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cavalli V, 2005, J CELL BIOL, V168, P775, DOI 10.1083/jcb.200410136; Chen YE, 2004, MICROSC RES TECHNIQ, V63, P72, DOI 10.1002/jemt.10430; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; De Vos K, 2000, J CELL BIOL, V149, P1207, DOI 10.1083/jcb.149.6.1207; Dreyer J, 2004, J NEUROSCI, V24, P10454, DOI 10.1523/JNEUROSCI.2265-04.2004; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LSB, 2003, NEURON, V40, P415, DOI 10.1016/S0896-6273(03)00630-5; Goldstein LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/science.1059766; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Horiuchi D, 2005, CURR BIOL, V15, P2137, DOI 10.1016/j.cub.2005.10.047; Iliev AI, 2003, FASEB J, V17, P412, DOI 10.1096/fj.03-0670fje; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kenney AM, 1998, J NEUROSCI, V18, P1318; KOLLNER M, 1992, CHEM PHYS LETT, V200, P199, DOI 10.1016/0009-2614(92)87068-Z; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; MCGLADEMCCULLOH E, 1989, P NATL ACAD SCI USA, V86, P1093, DOI 10.1073/pnas.86.3.1093; Medana IM, 2002, AM J PATHOL, V160, P655, DOI 10.1016/S0002-9440(10)64885-7; Muresan Z, 2005, J NEUROSCI, V25, P3741, DOI 10.1523/JNEUROSCI.0152-05.2005; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Pendlebury ST, 2000, MAGN RESON IMAGING, V18, P369, DOI 10.1016/S0730-725X(00)00115-6; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Pilling AD, 2006, MOL BIOL CELL, V17, P2057, DOI 10.1091/mbc.E05-06-0526; Puig B, 2004, NEUROPATH APPL NEURO, V30, P491, DOI 10.1111/j.1365-2990.2004.00569.x; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Savage MJ, 2002, J NEUROSCI, V22, P3376; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wallrabe H, 2005, CURR OPIN BIOTECH, V16, P19, DOI 10.1016/j.copbio.2004.12.002; Yonekawa Y, 1998, J CELL BIOL, V141, P431, DOI 10.1083/jcb.141.2.431	45	50	50	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2573	+		10.1096/fj.06-6679fje	http://dx.doi.org/10.1096/fj.06-6679fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068110				2022-12-25	WOS:000242490700028
J	Zheng, CL; Lin, ZY; Zhao, ZZJ; Yang, YJ; Niu, HB; Shen, X				Zheng, Chunlei; Lin, Ziyang; Zhao, Zhizhuang Joe; Yang, Yajun; Niu, Hanben; Shen, Xun			MAPK-activated protein kinase-2 (MK2)-mediated formation and phosphorylation-regulated dissociation of the signal complex consisting of p38, MK2, Akt, and Hsp27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; INDUCED TNF-ALPHA; NUCLEAR EXPORT; PHOSPHATIDYLINOSITOL 3-KINASE; OXIDATIVE STRESS; GROWTH-FACTOR; LEPTOMYCIN B; HEAT-SHOCK-PROTEIN-27; INHIBITION; PATHWAY	The p38 MAPK and heat shock protein 27 (hsp27) form a signaling complex with serine/threonine kinase Akt and MAPK-activated protein kinase-2 (MK2), which plays an important role in controlling stress-induced apoptosis and reorganizing actin cytoskeleton. However, regulation of the complex is poorly understood. In this study, the interaction between p38 and hsp27 was visualized in single living L929 cells using fluorescence resonance energy transfer technology, while their association with Akt was examined by immunoprecipitation analysis. Under normal growth conditions, p38 kinase constitutively interacts with hsp27. When cells were exposed to H2O2 or stimulated by arachidonic acid, this interaction was disrupted. However, inhibition of the activation of p38 and Akt by selective inhibitors or overexpression of the kinase-dead mutant of p38 diminished such effects. Furthermore, mutation of phosphorylation sites of hsp27 renders the interaction resistant to H2O2 and arachidonic acid. It was interesting to find that the interaction disappeared in the cells from MK2-knock-out mice or the cells treated with lemptomycin B that blocks export of MK2 from nucleus to cytosol. However, MK2 is not required for the association of hsp27 with Akt. This study suggests that MK2 mediates the incorporation of p38 into the pre-existing complex of hsp27 with Akt. Phosphorylation of hsp27 finally breaks the signaling complex.	Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100101, Peoples R China; Shenzhen Univ, Minist Educ, Key Lab Opto Elect Devices & Syst, Shenzhen 518060, Peoples R China; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Shenzhen University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Shen, X (corresponding author), Chinese Acad Sci, Inst Biophys, 15 Datun Rd, Beijing 100101, Peoples R China.	shenxun@sun5.ibp.ac.cn	Zheng, Chunlei/G-1028-2011	Zheng, Chunlei/0000-0002-9737-461X				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hannigan MO, 2001, J IMMUNOL, V167, P3953, DOI 10.4049/jimmunol.167.7.3953; Hii CST, 2001, J BIOL CHEM, V276, P27246, DOI 10.1074/jbc.M103250200; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kozawa O, 2001, ARCH BIOCHEM BIOPHYS, V388, P237, DOI 10.1006/abbi.2000.2290; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Marais E, 2005, BASIC RES CARDIOL, V100, P35, DOI 10.1007/s00395-004-0495-7; Marini M, 1996, INT J RADIAT BIOL, V70, P337, DOI 10.1080/095530096145076; Mearow KM, 2002, J NEUROCHEM, V83, P452, DOI 10.1046/j.1471-4159.2002.01151.x; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Nakatsue T, 1998, BIOCHEM BIOPH RES CO, V253, P59, DOI 10.1006/bbrc.1998.9724; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; Nguyen A, 2004, FEBS LETT, V572, P307, DOI 10.1016/j.febslet.2004.06.061; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Reiling N, 2001, J IMMUNOL, V167, P3339, DOI 10.4049/jimmunol.167.6.3339; Ricci JE, 2001, EUR CYTOKINE NETW, V12, P126; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Tanabe K, 2005, J CELL BIOCHEM, V96, P56, DOI 10.1002/jcb.20455; Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yamboliev IA, 2000, AM J PHYSIOL-HEART C, V278, pH1899, DOI 10.1152/ajpheart.2000.278.6.H1899; YANO H, 1993, J BIOL CHEM, V268, P25846; Zu YL, 1998, J IMMUNOL, V160, P1982	50	76	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37215	37226		10.1074/jbc.M603622200	http://dx.doi.org/10.1074/jbc.M603622200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17015449	hybrid			2022-12-25	WOS:000242220800082
J	Stone, SJ; Levin, MC; Farese, RV				Stone, Scot J.; Levin, Malin C.; Farese, Robert V., Jr.			Membrane topology and identification of key functional amino acid residues of murine Acyl-CoA: Diacylglycerol acyltransferase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOACYLGLYCEROL ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; LEPTIN SENSITIVITY; LIVER-MICROSOMES; ENZYME; CLONING; DGAT2; OVERT; BIOSYNTHESIS; CATALYZES	Triacylglycerols are the predominant molecules of energy storage in eukaryotes. However, excessive accumulation of triacylglycerols in adipose tissue leads to obesity and, in nonadipose tissues, is associated with tissue dysfunction. Hence, it is of great importance to have a better understanding of the molecular mechanisms of triacylglycerol synthesis. The final step in triacylglycerol synthesis is catalyzed by the acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes, DGAT1 and DGAT2. Although recent studies have shed light on metabolic functions of these enzymes, little is known about the molecular aspects of their structures or functions. Here we report the topology for murine DGAT2 and the identification of key amino acids that likely contribute to enzymatic function. Our data indicate that DGAT2 is an integral membrane protein with both the N and C termini oriented toward the cytosol. A long hydrophobic region spanning amino acids 66-115 likely comprises two transmembrane domains or, alternatively, a single domain that is embedded in the membrane bilayer. The bulk of the protein lies distal to the transmembrane domains. This region shares the highest degree of homology with other enzymes of the DGAT2 family and contains a sequence HPHG that is conserved in all family members. Mutagenesis of this sequence in DGAT2 demonstrated that it is required for full enzymatic function. Additionally, a neutral lipid-binding domain that is located in the putative first transmembrane domain was also required for full enzymatic function. Our findings provide the first insights into the topography and molecular aspects of DGAT2 and related enzymes.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Stone, SJ (corresponding author), Gladstone Inst Cardiovasc Dis, 1650 Owens St, San Francisco, CA 94158 USA.	sstone@gladstone.ucsf.edu		Levin, Malin/0000-0003-1069-5275	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065599] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065599, 5R01-DK065599] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abo-Hashema KAH, 1999, J BIOL CHEM, V274, P35577, DOI 10.1074/jbc.274.50.35577; Alam M, 2006, J LIPID RES, V47, P375, DOI 10.1194/jlr.M500344-JLR200; AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Cao JS, 2003, J BIOL CHEM, V278, P25657, DOI 10.1074/jbc.M302835200; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Chen HC, 2002, ENDOCRINOLOGY, V143, P2893, DOI 10.1210/en.143.8.2893; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; Cheng JB, 2004, J BIOL CHEM, V279, P37798, DOI 10.1074/jbc.M406226200; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; GUNSTONE FD, 1994, LIPID HDB, P646; Guo ZY, 2005, J BIOL CHEM, V280, P37814, DOI 10.1074/jbc.M508384200; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin S, 2003, MOL BIOL CELL, V14, P2447, DOI 10.1091/mbc.E02-11-0725; Lockwood JF, 2003, AM J PHYSIOL-ENDOC M, V285, pE927, DOI 10.1152/ajpendo.00179.2003; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; Shockey JM, 2006, PLANT CELL, V18, P2294, DOI 10.1105/tpc.106.043695; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Turkish AR, 2005, J BIOL CHEM, V280, P14755, DOI 10.1074/jbc.M500025200; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6; Waterman IJ, 2002, INT J OBESITY, V26, P742, DOI 10.1038/sj.ijo.0801981; Waterman IJ, 2002, J LIPID RES, V43, P1555, DOI 10.1194/jlr.M200051-JLR200; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2005, J LIPID RES, V46, P2388, DOI 10.1194/jlr.M500168-JLR200; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899	34	159	174	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40273	40282		10.1074/jbc.M607986200	http://dx.doi.org/10.1074/jbc.M607986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17035227	hybrid			2022-12-25	WOS:000243033900058
J	Bukys, MA; Kim, PY; Nesheim, ME; Kalafatis, M				Bukys, Michael A.; Kim, Paul Y.; Nesheim, Michael E.; Kalafatis, Michael			A control switch for prothrombinase - Characterization of a hirudin-like pentapeptide from the COOH terminus of factor Va heavy chain that regulates the rate and pathway for prothrombin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; MACROMOLECULAR SUBSTRATE RECOGNITION; HUMAN ALPHA-THROMBIN; EXOSITE-I; FACTOR-VIII; FACTOR XA; PHOSPHOLIPID-VESICLES; PROEXOSITE-I; FRAGMENT 2; CATALYZED ACTIVATION	Membrane-bound factor Xa alone catalyzes prothrombin activation following initial cleavage at Arg(271) and prethrombin 2 formation (pre2 pathway). Factor Va directs prothrombin activation by factor Xa through the meizothrombin pathway, characterized by initial cleavage at Arg(320) (meizo pathway). We have shown previously that a pentapeptide encompassing amino acid sequence 695-699 from the COOH terminus of the heavy chain of factor Va (Asp-Tyr-Asp-Tyr-Gln, DYDYQ) inhibits prothrombin activation by prothrombinase in a competitive manner with respect to substrate. To understand the mechanism of inhibition of thrombin formation by DYDYQ, we have studied prothrombin activation by gel electrophoresis. Titration of plasma-derived prothrombin activation by prothrombinase, with increasing concentrations of peptide, resulted in complete inhibition of the meizo pathway. However, thrombin formation still occurred through the pre2 pathway. These data demonstrate that the peptide preferentially inhibits initial cleavage of prothrombin by prothrombinase at Arg320. These findings were corroborated by studying the activation of recombinant mutant prothrombin molecules rMZ-II (R155A/R284A/R271A) and rP2-II (R155A/R284A/R320A) which can be only cleaved at Arg320 and Arg(271), respectively. Cleavage of rMZ-II by prothrombinase was completely inhibited by low concentrations of DYDYQ, whereas high concentrations of pentapeptide were required to inhibit cleavage of rP2-II. The pentapeptide also interfered with prothrombin cleavage by membrane-bound factor Xa alone in the absence of factor Va increasing the rate for cleavage at Arg(271) of plasma-derived prothrombin or rP2-II. Our data demonstrate that pentapeptide DYDYQ has opposing effects on membrane-bound factor Xa for prothrombin cleavage, depending on the incorporation of factor Va in prothrombinase.	Cleveland State Univ, Sci & Res Ctr SR370, Dept Chem, Cleveland, OH 44115 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	University System of Ohio; Cleveland State University; Queens University - Canada; Queens University - Canada; Cleveland Clinic Foundation	Kalafatis, M (corresponding author), Cleveland State Univ, Sci & Res Ctr SR370, Dept Chem, 2351 Euclid Ave, Cleveland, OH 44115 USA.	m.kalafatis@csuohio.edu	Kim, Paul/GYV-3258-2022	Kim, Paul/0000-0003-0943-4924	NHLBI NIH HHS [HL-46703-6, R01 HL-73343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073343, P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2003, J BIOL CHEM, V278, P44482, DOI 10.1074/jbc.M306917200; Anderson PJ, 2003, J BIOL CHEM, V278, P44489, DOI 10.1074/jbc.M306916200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; Boskovic DS, 2001, J BIOL CHEM, V276, P28686, DOI 10.1074/jbc.M101813200; BREZNIAK DV, 1990, BIOCHEMISTRY-US, V29, P3536, DOI 10.1021/bi00466a017; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; Buckland AG, 1998, BBA-LIPID LIPID MET, V1391, P367, DOI 10.1016/S0005-2760(98)00026-5; Buckland AG, 1998, BIOCHEM J, V329, P369; Bukys MA, 2005, J BIOL CHEM, V280, P27393, DOI 10.1074/jbc.M503435200; BUTKOWSKI RJ, 1977, J BIOL CHEM, V252, P4942; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; Chen L, 2004, J BIOL CHEM, V279, P17869, DOI 10.1074/jbc.M314285200; CHURCH WR, 1991, J BIOL CHEM, V266, P8384; CORTESE JD, 1981, ACTA PHYSIOL LAT AM, V31, P161; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; ESMON CT, 1974, J BIOL CHEM, V249, P7782; ESMON CT, 1974, J BIOL CHEM, V249, P7791; ESMON CT, 1974, J BIOL CHEM, V249, P606; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; Falls LA, 2001, J BIOL CHEM, V276, P23895, DOI 10.1074/jbc.M008332200; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HORTIN GL, 1990, BLOOD, V76, P946; Jones HM, 2004, DRUG METAB DISPOS, V32, P572, DOI 10.1124/dmd.32.5.572; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KANE WH, 1981, J BIOL CHEM, V256, P1002; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SD, 1992, PROTEIN SCI, V1, P998, DOI 10.1002/pro.5560010805; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; MANN K G, 1973, Series Haematologica, V6, P479; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; Monteiro RQ, 2002, THROMB HAEMOSTASIS, V87, P288; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; OWEN WG, 1974, J BIOL CHEM, V249, P594; PIETERS J, 1989, BLOOD, V74, P1021; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; RHEE MS, 1990, CANCER RES, V50, P3979; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; ROSING J, 1980, J BIOL CHEM, V255, P274; SLUYTERMAN LA, 1973, BIOCHIM BIOPHYS ACTA, V321, P697, DOI 10.1016/0005-2744(73)90218-0; Stevens WK, 1996, J BIOL CHEM, V271, P8062, DOI 10.1074/jbc.271.14.8062; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1994, J BIOL CHEM, V269, P27441; Yegneswaran S, 2004, J BIOL CHEM, V279, P49019, DOI 10.1074/jbc.M406645200; Yegneswaran S, 2003, J BIOL CHEM, V278, P33312, DOI 10.1074/jbc.M305906200	76	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39194	39204		10.1074/jbc.M604482200	http://dx.doi.org/10.1074/jbc.M604482200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17020886	hybrid			2022-12-25	WOS:000242898700027
J	Corradi, HR; Corrigall, AV; Boix, E; Mohan, CG; Sturrock, ED; Meissner, PN; Acharya, KR				Corradi, Hazel R.; Corrigall, Anne V.; Boix, Ester; Mohan, C. Gopi; Sturrock, Edward D.; Meissner, Peter N.; Acharya, K. Ravi			Crystal structure of protoporphyrinogen oxidase from Myxococcus xanthus and its complex with the inhibitor acifluorfen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOZYGOUS VARIEGATE PORPHYRIA; HEME BIOSYNTHETIC-PATHWAY; ENZYMATIC DEFECT; PROTEIN; PURIFICATION; EXPRESSION; IDENTIFICATION; ENZYMES; PREDICTION; MUTATIONS	Protoporphyrinogen IX oxidase, a monotopic membrane protein, which catalyzes the oxidation of protoporphyrinogen IX to protoporphyrin IX in the heme/chlorophyll biosynthetic pathway, is distributed widely throughout nature. Here we present the structure of protoporphyrinogen IX oxidase from Myxococcus xanthus, an enzyme with similar catalytic properties to human protoporphyrinogen IX oxidase that also binds the common plant herbicide, acifluorfen. In the native structure, the planar porphyrinogen substrate is mimicked by a Tween 20 molecule, tracing three sides of the macrocycle. In contrast, acifluorfen does not mimic the planarity of the substrate but is accommodated by the shape of the binding pocket and held in place by electrostatic and aromatic interactions. A hydrophobic patch surrounded by positively charged residues suggests the position of the membrane anchor, differing from the one proposed for the tobacco mitochondrial protoporphyrinogen oxidase. Interestingly, there is a discrepancy between the dimerization state of the protein in solution and in the crystal. Conserved structural features are discussed in relation to a number of South African variegate porphyria-causing mutations in the human enzyme.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Cape Town, Lennox Eales Porphyria Labs, MRC, Liver Res Ctr,Dept Med,Observ 7925, ZA-7925 Cape Town, South Africa; Univ Cape Town, Sch Med, Div Med Biochem, ZA-7925 Cape Town, South Africa; Univ Cape Town, Sch Med, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa	University of Bath; University of Cape Town; University of Cape Town; University of Cape Town	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Claverton Down, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Boix, Ester/B-9038-2012; Mohan, Gopi/T-7580-2019	Boix, Ester/0000-0003-1790-2142; Mohan, PhD., FRSC, C Gopi/0000-0003-2056-7189; Acharya, K. Ravi/0000-0002-3009-4058	Wellcome Trust [070060] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akhtar M., 1991, BIOSYNTHESIS TETRAPY, P67; Bahadur RP, 2004, J MOL BIOL, V336, P943, DOI 10.1016/j.jmb.2003.12.073; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRENNER DA, 1980, NEW ENGL J MED, V302, P765, DOI 10.1056/NEJM198004033021401; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CAMADRO JM, 1991, BIOCHEM J, V277, P17, DOI 10.1042/bj2770017; CAMADRO JM, 1994, J BIOL CHEM, V269, P32085; Corrigall AV, 1998, ARCH BIOCHEM BIOPHYS, V358, P251, DOI 10.1006/abbi.1998.0834; CORRIGALL AV, 1994, BIOCHEM MOL BIOL INT, V34, P1283; Corrigall AV, 2000, MOL GENET METAB, V69, P323, DOI 10.1006/mgme.2000.2975; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; Dailey HA, 2002, BIOCHEM SOC T, V30, P590, DOI 10.1042/bst0300590; Dailey HA, 1996, J BIOL CHEM, V271, P8714, DOI 10.1074/jbc.271.15.8714; Dailey TA, 1998, J BIOL CHEM, V273, P13658, DOI 10.1074/jbc.273.22.13658; Dailey TA, 1996, PROTEIN SCI, V5, P98; DAILEY TA, 1994, J BIOL CHEM, V269, P813; Davids LM, 2006, CELL BIOL INT, V30, P416, DOI 10.1016/j.cellbi.2006.02.001; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEYBACH JC, 1981, HUM GENET, V58, P425, DOI 10.1007/BF00282829; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FERREIRA GC, 1987, J BIOL CHEM, V262, P4407; FERREIRA GC, 1988, J BIOL CHEM, V263, P3835; Frank J, 1998, J INVEST DERMATOL, V110, P452, DOI 10.1046/j.1523-1747.1998.00148.x; HIFT RJ, 1993, POSTGRAD MED J, V69, P781, DOI 10.1136/pgmj.69.816.781; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Jung SY, 2005, PLANT PHYSIOL BIOCH, V43, P423, DOI 10.1016/j.plaphy.2005.03.008; Kauppinen R, 2001, J INVEST DERMATOL, V116, P610, DOI 10.1046/j.1523-1747.2001.01293.x; Kirsch RE, 1998, SEMIN LIVER DIS, V18, P33, DOI 10.1055/s-2007-1007138; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; Koch M, 2004, EMBO J, V23, P1720, DOI 10.1038/sj.emboj.7600189; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lambert C, 2002, BIOINFORMATICS, V18, P1250, DOI 10.1093/bioinformatics/18.9.1250; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Maneli MH, 2003, BBA-PROTEINS PROTEOM, V1650, P10, DOI 10.1016/S1570-9639(03)00186-9; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Meissner PN, 1996, NAT GENET, V13, P95, DOI 10.1038/ng0596-95; MEISSNER PN, 1986, EUR J CLIN INVEST, V16, P257, DOI 10.1111/j.1365-2362.1986.tb01339.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NANDIHALLI UB, 1992, PESTIC BIOCHEM PHYS, V43, P193, DOI 10.1016/0048-3575(92)90033-V; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; POULSON R, 1975, J BIOL CHEM, V250, P1269; Roberts AG, 1998, HUM MOL GENET, V7, P1921, DOI 10.1093/hmg/7.12.1921; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang KF, 2001, FEMS MICROBIOL LETT, V202, P115, DOI 10.1111/j.1574-6968.2001.tb10789.x; Warnich L, 1996, HUM MOL GENET, V5, P981, DOI 10.1093/hmg/5.7.981; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Wendt KU, 1999, J MOL BIOL, V286, P175, DOI 10.1006/jmbi.1998.2470; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	55	65	71	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38625	38633		10.1074/jbc.M606640200	http://dx.doi.org/10.1074/jbc.M606640200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046834	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000242709500058
J	Roche, CJ; Guo, F; Friedman, JM				Roche, Camille J.; Guo, Feng; Friedman, Joel M.			Molecular level probing of preferential hydration and its modulation by osmolytes through the use of pyranine complexed to hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; PROTEIN HYDRATION; ADULT HEMOGLOBIN; EFFECTOR-BINDING; PROTON-TRANSFER; DYNAMICS; SOLVENT; STATE; STABILIZATION; FLUORESCENCE	Two spectroscopic probes are used to expose molecular level changes in hydration shell water interactions that directly relate to such issues as preferential hydration and protein stability. The major focus of the present study is on the use of pyranine (HPT) fluorescence to probe as a function of added osmolytes (PEG, urea, trehalose, and magnesium), the extent to which glycerol is preferentially excluded from the hydration shell of free HPT and HPT localized in the diphosphoglycerate (DPG) binding site of hemoglobin in both solution and in Sol-Gel matrices. The pyranine study is complemented by the use of vibronic side band luminescence from the gadolinium cation that directly exposes the changes in hydrogen bonding between first and second shell waters as a function of added osmolytes. Together the results form the basis for a water partitioning model that can account for both preferential hydration and water/osmolyte-mediated conformational changes in protein structure.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Friedman, JM (corresponding author), 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu			NHLBI NIH HHS [P01 HL 071064] Funding Source: Medline; NIAID NIH HHS [R01 AI 052258] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL071064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbruzzetti S, 2005, CELL BIOCHEM BIOPHYS, V43, P431, DOI 10.1385/CBB:43:3:431; Abbruzzetti S, 2001, J NANOSCI NANOTECHNO, V1, P407, DOI 10.1166/jnn.2001.058; ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; Allison SD, 2000, J PHARM SCI, V89, P199, DOI 10.1002/(SICI)1520-6017(200002)89:2<199::AID-JPS7>3.3.CO;2-2; Anchordoquy TJ, 2001, ARCH BIOCHEM BIOPHYS, V390, P35, DOI 10.1006/abbi.2001.2351; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; Austin RH, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128101; Bennion BJ, 2004, P NATL ACAD SCI USA, V101, P6433, DOI 10.1073/pnas.0308633101; Bennion BJ, 2003, P NATL ACAD SCI USA, V100, P5142, DOI 10.1073/pnas.0930122100; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; Chen QY, 2005, BIOPHYS J, V88, P2057, DOI 10.1529/biophysj.104.046136; Collins KD, 2004, METHODS, V34, P300, DOI 10.1016/j.ymeth.2004.03.021; Collins KD, 1997, BIOPHYS J, V72, P65, DOI 10.1016/S0006-3495(97)78647-8; Collins MD, 2005, P NATL ACAD SCI USA, V102, P16668, DOI 10.1073/pnas.0508224102; Cordone L, 2005, BBA-PROTEINS PROTEOM, V1749, P252, DOI 10.1016/j.bbapap.2005.03.004; Cottone G, 2005, PROTEINS, V59, P291, DOI 10.1002/prot.20414; Crowe JH, 1998, ANNU REV PHYSIOL, V60, P73, DOI 10.1146/annurev.physiol.60.1.73; Das TK, 1999, BIOSPECTROSCOPY, V5, pS64, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S64::AID-BSPY7>3.0.CO;2-W; Dashnau JL, 2006, J PHYS CHEM B, V110, P13670, DOI 10.1021/jp0618680; Demmel F, 1997, EUR BIOPHYS J BIOPHY, V26, P327, DOI 10.1007/s002490050087; Diehl M, 1997, BIOPHYS J, V73, P2726, DOI 10.1016/S0006-3495(97)78301-2; Doster W, 2005, BBA-PROTEINS PROTEOM, V1749, P173, DOI 10.1016/j.bbapap.2005.03.010; Eggers DK, 2001, J MOL BIOL, V314, P911, DOI 10.1006/jmbi.2001.5166; Eggers DK, 2001, PROTEIN SCI, V10, P250, DOI 10.1110/ps.36201; Fenimore PW, 2004, P NATL ACAD SCI USA, V101, P14408, DOI 10.1073/pnas.0405573101; Fenimore PW, 2002, P NATL ACAD SCI USA, V99, P16047, DOI 10.1073/pnas.212637899; Flora KK, 1999, CAN J CHEM, V77, P1617, DOI 10.1139/cjc-77-10-1617; Francia F, 2003, BIOPHYS J, V85, P2760, DOI 10.1016/S0006-3495(03)74698-0; Frauenfelder H, 2002, BIOPHYS CHEM, V98, P35, DOI 10.1016/S0301-4622(02)00083-2; FRAUENFELDER H, 1986, METHOD ENZYMOL, V127, P207; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; Gottfried DS, 1997, J BIOL CHEM, V272, P1571, DOI 10.1074/jbc.272.3.1571; GUTMAN M, 1982, EUR J BIOCHEM, V125, P175, DOI 10.1111/j.1432-1033.1982.tb06665.x; HAAS GSY, 1971, CHEM PHYS LETT, V11, P143; HIRSCH RE, 1994, METHOD ENZYMOL, V232, P231; IBEN IET, 1991, BIOPHYS J, V59, P1040, DOI 10.1016/S0006-3495(91)82319-0; Keeling-Tucker T, 2001, CHEM MATER, V13, P3331, DOI 10.1021/cm010119m; Khan I, 2000, BIOCHEMISTRY-US, V39, P16099, DOI 10.1021/bi000536x; Kiriukhin MY, 2002, BIOPHYS CHEM, V99, P155, DOI 10.1016/S0301-4622(02)00153-9; Kreilgaard L, 1998, ARCH BIOCHEM BIOPHYS, V360, P121, DOI 10.1006/abbi.1998.0948; Lichtenegger H, 1999, BIOPHYS J, V76, P414, DOI 10.1016/S0006-3495(99)77208-5; Lin TY, 1996, PROTEIN SCI, V5, P372; LIND MD, 1965, J AM CHEM SOC, V87, P1611, DOI 10.1021/ja01085a036; MACGREGOR RB, 1989, ARCH BIOCHEM BIOPHYS, V274, P312, DOI 10.1016/0003-9861(89)90444-X; MACQUARRIE R, 1971, J BIOL CHEM, V246, P5832; MACQUARRIE R, 1972, J BIOL CHEM, V247, P5686; Manjula BN, 1998, PROTEIN ENG, V11, P583, DOI 10.1093/protein/11.7.583; MARDEN MC, 1986, BIOCHEMISTRY-US, V25, P7591, DOI 10.1021/bi00371a049; Nachliel E, 2001, BIOPHYS J, V80, P1498, DOI 10.1016/S0006-3495(01)76122-X; Navati MS, 2004, J PHYS CHEM B, V108, P1321, DOI 10.1021/jp0366466; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; RICHARD V, 1993, J MOL BIOL, V233, P270, DOI 10.1006/jmbi.1993.1505; Rosgen J, 2005, BIOPHYS J, V89, P2988, DOI [10.1529/biophysj.105.067330, 10.1529/biophsyj.105.067330]; Samuni U, 2006, BIOCHEMISTRY-US, V45, P2820, DOI 10.1021/bi050010i; Samuni U, 2004, BIOCHEMISTRY-US, V43, P13674, DOI 10.1021/bi048531d; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; Shibayama N, 2001, FEBS LETT, V492, P50, DOI 10.1016/S0014-5793(01)02225-6; Shulgin IL, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2011388; STAVOLA M, 1981, J CHEM PHYS, V74, P4228, DOI 10.1063/1.441664; STAVOLA M, 1981, CHEM PHYS LETT, V80, P192, DOI 10.1016/0009-2614(81)80087-5; TANFORD C, 1969, J MOL BIOL, V39, P539, DOI 10.1016/0022-2836(69)90143-0; Timasheff SN, 2002, P NATL ACAD SCI USA, V99, P9721, DOI 10.1073/pnas.122225399; Timasheff SN, 2002, BIOCHEMISTRY-US, V41, P13473, DOI 10.1021/bi020316e; Tleugabulova D, 2004, LANGMUIR, V20, P848, DOI 10.1021/la0357561; YAM R, 1991, BIOPHYS J, V59, P4, DOI 10.1016/S0006-3495(91)82192-0; YATSIV S, 1965, J CHEM PHYS, V42, P743, DOI 10.1063/1.1696001; Zou Q, 2002, J AM CHEM SOC, V124, P1192, DOI 10.1021/ja004206b	68	33	34	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38757	38768		10.1074/jbc.M608835200	http://dx.doi.org/10.1074/jbc.M608835200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17057250	hybrid			2022-12-25	WOS:000242709500074
J	Shokri, L; Marintcheva, B; Richardson, CC; Rouzina, I; Williams, MC				Shokri, Leila; Marintcheva, Boriana; Richardson, Charles C.; Rouzina, Ioulia; Williams, Mark C.			Single molecule force spectroscopy of salt-dependent bacteriophage T7 gene 2.5 protein binding to single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; T4 GENE-32 PROTEIN; BINDING-PROTEIN; OVERSTRETCHING TRANSITION; THERMODYNAMIC ANALYSIS; DOUBLE HELIX; T7; HELICASE; REPLICATION; POLYMERASE	The gene 2.5 protein (gp2.5) encoded by bacteriophage T7 binds preferentially to single-stranded DNA. This property is essential for its role in DNA replication and recombination in the phage-infected cell. gp2.5 lowers the phage lambda DNA melting force as measured by single molecule force spectroscopy. T7 gp2.5-Delta 26C, lacking 26 acidic C-terminal residues, also reduces the melting force but at considerably lower concentrations. The equilibrium binding constants of these proteins to single-stranded DNA (ssDNA) as a function of salt concentration have been determined, and we found for example that gp2.5 binds with an affinity of (3.5 +/- 0.6) x 10(5) M-1 in a 50mM Na+ solution, whereas the truncated protein binds to ssDNA with a much higher affinity of (7.8 +/- 0.9) x 10(7) M-1 under the same solution conditions. T7 gp2.5-Delta 26C binding to single-stranded DNA also exhibits a stronger salt dependence than the full-length protein. The data are consistent with a model in which a dimeric gp2.5 must dissociate prior to binding to ssDNA, a dissociation that consists of a weak non-electrostatic and a strong electrostatic component.	Northeastern Univ, Dept Phys, Boston, MA 02115 USA; Northeastern Univ, Ctr Interdisciplinary Res Complex Syst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	Northeastern University; Northeastern University; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities	Williams, MC (corresponding author), Northeastern Univ, Dept Phys, 111 Dana Res Ctr, Boston, MA 02115 USA.	mark@neu.edu		Williams, Mark C./0000-0003-3219-376X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM072305, R01GM072462, R01GM054397] Funding Source: NIH RePORTER; NIAID NIH HHS [5T32 AI 07245-20] Funding Source: Medline; NIGMS NIH HHS [F32 GM 72305 T, GM 72462, GM 54397] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allemand JF, 2003, CURR OPIN STRUC BIOL, V13, P266, DOI 10.1016/S0959-440X(03)00067-8; ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bustamante C, 2003, NATURE, V421, P423, DOI 10.1038/nature01405; Bustamante C, 2000, CURR OPIN STRUC BIOL, V10, P279, DOI 10.1016/S0959-440X(00)00085-3; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; He ZG, 2004, J BIOL CHEM, V279, P22190, DOI 10.1074/jbc.M401100200; He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Hyland EM, 2003, J BIOL CHEM, V278, P7247, DOI 10.1074/jbc.M210605200; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1997, P NATL ACAD SCI USA, V94, P2987, DOI 10.1073/pnas.94.7.2987; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; Krautbauer R, 2002, SINGLE MOL, V3, P97, DOI 10.1002/1438-5171(200206)3:2/3<97::AID-SIMO97>3.0.CO;2-S; Krautbauer R, 2002, FEBS LETT, V510, P154, DOI 10.1016/S0014-5793(01)03257-4; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MCGHEE JD, 1976, BIOPOLYMERS, V15, P1345, DOI 10.1002/bip.1976.360150710; Mihailovic A, 2006, LANGMUIR, V22, P4699, DOI 10.1021/la053242r; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Pant K, 2005, J MOL BIOL, V349, P317, DOI 10.1016/j.jmb.2005.03.065; Pant K, 2004, J MOL BIOL, V336, P851, DOI 10.1016/j.jmb.2003.12.025; Pant K, 2003, J MOL BIOL, V327, P571, DOI 10.1016/S0022-2836(03)00153-0; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; Rezende LF, 2003, J BIOL CHEM, V278, P29098, DOI 10.1074/jbc.M303374200; Rezende LF, 2002, J BIOL CHEM, V277, P50643, DOI 10.1074/jbc.M207359200; Rouzina I, 2005, BIOPHYS J, V89, P1941, DOI 10.1529/biophysj.105.063776; Rouzina I, 2001, BIOPHYS J, V80, P894, DOI 10.1016/S0006-3495(01)76068-7; Rouzina I, 2001, BIOPHYS J, V80, P882, DOI 10.1016/S0006-3495(01)76067-5; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; Strick T, 2000, PROG BIOPHYS MOL BIO, V74, P115, DOI 10.1016/S0079-6107(00)00018-3; Vladescu ID, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.158102; Wenner JR, 2002, BIOPHYS J, V82, P3160, DOI 10.1016/S0006-3495(02)75658-0; Williams MC, 2006, CURR ORG CHEM, V10, P419, DOI 10.2174/138527206776055321; Williams MC, 2001, BIOPHYS J, V80, P874, DOI 10.1016/S0006-3495(01)76066-3; Williams MC, 2002, ACCOUNTS CHEM RES, V35, P159, DOI 10.1021/ar010045k; Williams MC, 2002, CURR OPIN STRUC BIOL, V12, P330, DOI 10.1016/S0959-440X(02)00340-8; Yu M, 2001, J BACTERIOL, V183, P1862, DOI 10.1128/JB.183.6.1862-1869.2001	43	36	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38689	38696		10.1074/jbc.M608460200	http://dx.doi.org/10.1074/jbc.M608460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050544	Green Published, hybrid			2022-12-25	WOS:000242709500066
J	Conrads, TP; Tocci, GM; Hood, BL; Zhang, CO; Guo, L; Koch, KR; Michejda, CJ; Veenstra, TD; Keay, SK				Conrads, Thomas P.; Tocci, Gillian M.; Hood, Brian L.; Zhang, Chen-Ou; Guo, Li; Koch, Kristopher R.; Michejda, Christopher J.; Veenstra, Timothy D.; Keay, Susan K.			CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER EPITHELIAL-CELLS; EPIDERMAL GROWTH-FACTOR; ENDOPLASMIC-RETICULUM; URINE; P63; EXPRESSION; SIALOGLYCOPEPTIDE; MICROTUBULES; MARKERS; SURFACE	Antiproliferative factor (APF) is a low molecular weight sialoglycopeptide that is secreted by bladder cells from interstitial cystitis patients and is a potent inhibitor of both normal bladder epithelial and bladder carcinoma cell proliferation. We hypothesized that APF may produce its antiproliferative effects by binding to a transmembrane receptor. This study demonstrates that cytoskeleton-associated protein 4/p63(CKAP4/p63), a type II transmembrane receptor, binds with high affinity to APF. The antiproliferative activity of APF is effectively inhibited by preincubation with anti-CKAP4/p63-specific antibodies, as well as by short interfering RNA knockdown of CKAP4/p63. Immunofluorescent confocal microscopy showed co-localization of antiCKAP4/p63 and rhodamine-labeled synthetic APF binding in both cell membrane and perinuclear areas. APF also inhibits the proliferation of HeLa cervical carcinoma cells that are known to express CKAP4/p63. These data indicate that CKAP4/p63 is an important epithelial cell receptor for APF.	NCI, Lab Proteom & Analyt Technol, SAIC Frederick Inc, NIH, Ft Detrick, MD 21702 USA; NCI, Mol Aspects Drug Design Sect, Struct Biophys Lab, NIH, Ft Detrick, MD 21702 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Keay, SK (corresponding author), Vet Affairs Med Ctr, Rm 3B-184,10 N Greene St, Baltimore, MD 21201 USA.	skeay@medicine.umaryland.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052596] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [R01 DK52596] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alaiya A, 2005, J PROTEOME RES, V4, P1213, DOI 10.1021/pr050149f; AUGER G, 1989, J CELL BIOCHEM, V40, P439, DOI 10.1002/jcb.240400405; DANAHEY DG, 1995, J UROLOGY, V154, P2190, DOI 10.1016/S0022-5347(01)66726-0; Fattaey HK, 1997, BREAST CANCER RES TR, V42, P125, DOI 10.1023/A:1005765431384; GILLENWATER JY, 1988, J UROLOGY, V140, P203, DOI 10.1016/S0022-5347(17)41529-1; Gupta N, 2006, AM J PHYSIOL-LUNG C, V291, pL436, DOI 10.1152/ajplung.00415.2005; Held P., 1990, INTERSTITIAL CYSTITI, DOI [10.1007/978-1-4471-3293-6_4, DOI 10.1007/978-1-4471-3293-6_4]; Keay S, 2000, J UROLOGY, V164, P2112, DOI 10.1016/S0022-5347(05)66980-7; Keay S, 1996, J UROLOGY, V156, P2073, DOI 10.1016/S0022-5347(01)65438-7; Keay S, 1997, J UROLOGY, V158, P1983, DOI 10.1016/S0022-5347(01)64198-3; Keay S, 1999, J UROLOGY, V162, P1487, DOI 10.1016/S0022-5347(05)68345-0; Keay S, 2003, PHYSIOL GENOMICS, V14, P107, DOI 10.1152/physiolgenomics.00055.2003; Keay S, 2003, UROLOGY, V61, P1278, DOI 10.1016/S0090-4295(03)00005-0; Keay SK, 2004, P NATL ACAD SCI USA, V101, P11803, DOI 10.1073/pnas.0404509101; Keay SK, 2001, UROLOGY, V57, P9, DOI 10.1016/S0090-4295(01)01127-X; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; Matthews YL, 2001, UROLOGY S6A, V57, P67; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; PARSONS CL, 1991, J UROLOGY, V145, P732, DOI 10.1016/S0022-5347(17)38437-9; Razzaq TM, 2003, J BIOL CHEM, V278, P42679, DOI 10.1074/jbc.M305695200; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SKOLUDA D, 1974, UROLOGE A, V13, P15; Slobodov G, 2004, J UROLOGY, V171, P1554, DOI 10.1097/01.ju.0000118938.09119.a5; Tran H, 2002, J CELL SCI, V115, P2031; Vedrenne C, 2005, MOL BIOL CELL, V16, P1928, DOI 10.1091/mbc.e04-07-0554; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Zhang CO, 2005, J UROLOGY, V174, P2382, DOI 10.1097/01.ju.0000180417.11976.99; Zhou Ming, 2005, Briefings in Functional Genomics & Proteomics, V4, P69, DOI 10.1093/bfgp/4.1.69	29	71	77	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37836	37843		10.1074/jbc.M604581200	http://dx.doi.org/10.1074/jbc.M604581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17030514	Green Published, hybrid			2022-12-25	WOS:000242477100061
J	Chi, CN; Engstrom, A; Gianni, S; Larsson, M; Jemth, P				Chi, Celestine N.; Engstrom, Ake; Gianni, Stefano; Larsson, Marten; Jemth, Per			Two conserved residues govern the salt and pH dependencies of the binding reaction of a PDZ domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; RECOGNITION; SPECIFICITY; MECHANISM	PDZ domains are protein-protein interaction modules found in hundreds of human proteins. Their binding reactions are sensitive to variations in salt and pH but the basis of the respective dependence has not been clear. We investigated the binding reaction between PSD-95 PDZ3 and a peptide corresponding to a native ligand with protein engineering in conjunction with stopped-flow and equilibrium fluorimetry and found that the two conserved residues Arg-318 and His-372 were responsible for the salt and pH dependencies, respectively. The basis of the salt-dependent variation of the affinity was explored by mutating all charged residues in and around the peptide- binding pocket. Arg-318 was found to be crucial, as mutation to alanine obliterated the effect of chloride on the binding constants. The direct interaction of chloride with Arg-318 was demonstrated by time-resolved urea denaturation experiments, where the Arg-318 -> Ala mutant was less stabilized by addition of chloride as compared with wild-type PDZ3. We also demonstrated that protonation of His-372 was responsible for the increase of the equilibrium dissociation constant at low pH. Both chloride concentration and pH (during ischemia) vary in the postsynaptic density, where PSD-95 is present, and the physiological buffer conditions may thus modulate the interaction between PSD-95 and its ligands through binding of chloride and protons to the "molecular switches" Arg-318 and His-372, respectively.	Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Univ Roma La Sapienza, CNR, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy	Uppsala University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Jemth, P (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Box 582, SE-75123 Uppsala, Sweden.	Per.Jemth@imbim.uu.se	gianni, stefano/C-8536-2009; Larsson, Marten/A-5992-2012	Gianni, Stefano/0000-0003-1653-1925				Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; Billups D, 2002, J PHYSIOL-LONDON, V545, P183, DOI 10.1113/jphysiol.2002.024877; Burgoyne NJ, 2006, BIOINFORMATICS, V22, P1335, DOI 10.1093/bioinformatics/btl079; COLLINS KD, 1995, P NATL ACAD SCI USA, V92, P5553, DOI 10.1073/pnas.92.12.5553; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Gianni S, 2005, J BIOL CHEM, V280, P34805, DOI 10.1074/jbc.M506017200; Harris BZ, 2003, BIOCHEMISTRY-US, V42, P2797, DOI 10.1021/bi027061p; Harris BZ, 2001, J CELL SCI, V114, P3219; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hofmeister F., 1888, ARCH EXP PATHOL PH, V24, P247, DOI [DOI 10.1007/BF01918191, 10.1007/BF01918191]; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; KONCZ C, 1994, AM J PHYSIOL-HEART C, V267, pH2114, DOI 10.1152/ajpheart.1994.267.6.H2114; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; Lewith S., 1888, ARCH EXP PATHOL PH, V24, P1; Malatesta F, 2005, BIOPHYS CHEM, V116, P251, DOI 10.1016/j.bpc.2005.04.006; MOORE WJ, 1983, BASIC PHYS CHEM, P370; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Rhodes DR, 2005, NAT BIOTECHNOL, V23, P951, DOI 10.1038/nbt1103; Sali A, 2003, NATURE, V422, P216, DOI 10.1038/nature01513; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Skelton NJ, 2003, J BIOL CHEM, V278, P7645, DOI 10.1074/jbc.M209751200; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Xiong ZG, 2006, J MEMBRANE BIOL, V209, P59, DOI 10.1007/s00232-005-0840-x; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	34	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36811	36818		10.1074/jbc.M607883200	http://dx.doi.org/10.1074/jbc.M607883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17018532	hybrid			2022-12-25	WOS:000242220800039
J	Sandquist, JC; Swenson, KI; DeMali, KA; Burridge, K; Means, AR				Sandquist, Joshua C.; Swenson, Katherine I.; DeMali, Kris A.; Burridge, Keith; Means, Anthony R.			Rho kinase differentially regulates phosphorylation of nonmuscle myosin II isoforms A and B during cell rounding and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ISOFORMS; LIGHT-CHAIN; SMOOTH-MUSCLE; MEMBRANE PROTRUSIONS; MOLECULAR-MECHANISMS; ADHESION DYNAMICS; MATRIX ADHESIONS; FOCAL ADHESIONS; CULTURED-CELLS; STRESS FIBERS	The actin-myosin cytoskeleton is generally accepted to produce the contractile forces necessary for cellular processes such as cell rounding and migration. All vertebrates examined to date are known to express at least two isoforms of non-muscle myosin II, referred to as myosin IIA and myosin IIB. Studies of myosin IIA and IIB in cultured cells and null mice suggest that these isoforms perform distinct functions. However, how each myosin II isoform contributes individually to all the cellular functions attributed to "myosin II" has yet to be fully characterized. Using isoform-specific small-interfering RNAs, we found that depletion of either isoform resulted in opposing migration phenotypes, with myosin IIA- and IIB-depleted cells exhibiting higher and lower wound healing migration rates, respectively. In addition, myosin IIA- depleted cells demonstrated impaired thrombin-induced cell rounding and undertook a more motile morphology, exhibiting decreased amounts of stress fibers and focal adhesions, with concomitant increases in cellular protrusions. Cells depleted of myosin IIB, however, were efficient in thrombin-induced cell rounding, displayed a more retractile phenotype, and maintained focal adhesions but only in the periphery. Last, we present evidence that Rho kinase preferentially regulates phosphorylation of the regulatory light chain associated with myosin IIA. Our data suggest that the myosin IIA and IIB isoforms are regulated by different signaling pathways to perform distinct cellular activities and that myosin IIA is preferentially required for Rho-mediated contractile functions.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27702 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27702 USA.	means001@mc.duke.edu		Sandquist, Joshua/0000-0003-2181-4938; DeMali, Kris/0000-0003-0906-1371	NATIONAL CANCER INSTITUTE [R01CA082845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NCI NIH HHS [CA 082845] Funding Source: Medline; NIGMS NIH HHS [GM 29860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; Eddy RJ, 2000, J CELL SCI, V113, P1287; Edwards KA, 1996, DEVELOPMENT, V122, P1499; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kolega J, 1998, J CELL SCI, V111, P2085; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MAUPIN P, 1994, J CELL SCI, V107, P3077; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PETERS DJM, 1988, DEV BIOL, V128, P158, DOI 10.1016/0012-1606(88)90278-3; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Rosenberg M, 2006, MOL BIOL CELL, V17, P1364, DOI 10.1091/mbc.e05-07-0597; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; Smilenov LB, 1999, SCIENCE, V286, P1172, DOI 10.1126/science.286.5442.1172; Somlyo AV, 2003, FASEB J, V17, P223, DOI 10.1096/fj.02-0655com; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Straussman R, 2001, J CELL SCI, V114, P3047; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; TUAZON PT, 1984, J BIOL CHEM, V259, P541; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WHEATLEY S, 1995, DEVELOPMENT, V121, P1937; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607	56	141	143	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35873	35883		10.1074/jbc.M605343200	http://dx.doi.org/10.1074/jbc.M605343200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17020881	Green Published, hybrid			2022-12-25	WOS:000242100500034
J	van Driel, M; Koedam, M; Buurman, CJ; Hewison, M; Chiba, H; Uitterlinden, AG; Pols, HAP; van Leeuwen, JPTM				van Driel, M.; Koedam, M.; Buurman, C. J.; Hewison, M.; Chiba, H.; Uitterlinden, A. G.; Pols, H. A. P.; van Leeuwen, J. P. T. M.			Evidence for auto/paracrine actions of vitamin D in bone: 1 alpha-hydroxylase expression and activity in human bone cells	FASEB JOURNAL			English	Article						calcium homeostasis; PBMCs; osteoblasts; osteoclasts	PROSTATE-CANCER CELLS; 25-HYDROXYVITAMIN D-3-1-ALPHA-HYDROXYLASE; 1,25-DIHYDROXYVITAMIN D-3; HUMAN KERATINOCYTES; D METABOLISM; D-RECEPTOR; D-1-ALPHA-HYDROXYLASE; HYPERPARATHYROIDISM; HYPERCALCEMIA; SARCOIDOSIS	Vitamin D is an important regulator of mineral homeostasis and bone metabolism. 1 alpha-Hydroxylation of 25-(OH)D-3 to form the bioactive vitamin D hormone, 1 alpha, 25-(OH)(2)D-3, is classically considered to take place in the kidney. However, 1 alpha-hydroxylase has been reported at extrarenal sites. Whether bone is a 1 alpha,25-(OH)(2)D-3 synthesizing tissue is not univocal. The aim of this study was to investigate an autocrine/paracrine function for 1 alpha,25-(OH)(2)D-3 in bone. We show that 1 alpha-hydroxlase is expressed in human osteoblasts, as well as the vitamin D binding protein receptors megalin and cubilin. Functional analyses demonstrate that after incubation with the 1 alpha-hydoxylase substrate 25-(OH)D-3, the osteoblasts can produce sufficient 1 alpha,25-(OH)(2)D-3 to modulate osteoblast activity, resulting in induced alkaline phosphatase ( ALP) activity, osteocalcin (OC) and CYP24 mRNA expression, and mineralization. The classical renal regulators of 1-hydroxylase, parathyroid hormone, and ambient calcium do not regulate 1 alpha-hydroxylase in osteoblasts. In contrast, interleukin (IL)-1 alpha strongly induces 1 alpha-hydroxylase. Besides the bone-forming cells, we demonstrate 1 alpha-hydroxylase activity in the bone resorbing cells, the osteoclasts. This is strongly dependent on osteoclast inducer RANKL. This study showing expression, activity, and functionality of 1 alpha-hydoxylase unequivocally demonstrates that vitamin D can act in an auto/paracrine manner in bone.	Erasmus MC, Dept Internal Med, NL-3015 GE Rotterdam, Netherlands; Univ Birmingham, Div Med Sci, Birmingham, W Midlands, England; Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan	Erasmus University Rotterdam; Erasmus MC; University of Birmingham; Sapporo Medical University	van Leeuwen, JPTM (corresponding author), Erasmus MC, Dept Internal Med, Rm Ee526,Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	j.vanleeuwen@erasmusmc.nl	van Driel, Marjolein/K-6745-2019; van Leeuwen, Johannes/D-5015-2014	van Leeuwen, Johannes/0000-0002-2282-4006				ADAMS JS, 1985, J EXP MED, V161, P755, DOI 10.1084/jem.161.4.755; Anderson PH, 2005, BONE, V36, P654, DOI 10.1016/j.bone.2005.01.012; BARBOUR GL, 1981, NEW ENGL J MED, V305, P440, DOI 10.1056/NEJM198108203050807; Bareis P, 2001, BIOCHEM BIOPH RES CO, V285, P1012, DOI 10.1006/bbrc.2001.5289; BIKLE DD, 1986, J CLIN INVEST, V78, P557, DOI 10.1172/JCI112609; Bland R, 1999, ENDOCRINOLOGY, V140, P2027, DOI 10.1210/en.140.5.2027; Bland R, 2004, J STEROID BIOCHEM, V89-90, P121, DOI 10.1016/j.jsbmb.2004.03.115; Bland R, 2001, KIDNEY INT, V60, P1277, DOI 10.1046/j.1523-1755.2001.00966.x; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Chen TC, 2003, J CELL BIOCHEM, V88, P315, DOI 10.1002/jcb.10342; Christakos S, 2003, J CELL BIOCHEM, V88, P695, DOI 10.1002/jcb.10423; Correa P, 2002, J CLIN ENDOCR METAB, V87, P5826, DOI 10.1210/jc.2002-021356; Cross HS, 2001, STEROIDS, V66, P287, DOI 10.1016/S0039-128X(00)00153-7; Ebert R, 2004, MOL ENDOCRINOL, V18, P2440, DOI 10.1210/me.2002-0441; Evans KN, 2004, AM J PATHOL, V165, P807, DOI 10.1016/S0002-9440(10)63343-3; Friedrich M, 2003, RECENT RES CANCER, V164, P239; HENRY HL, 1992, J STEROID BIOCHEM, V41, P401, DOI 10.1016/0960-0760(92)90365-P; Hewison M, 2004, MOL CELL ENDOCRINOL, V215, P31, DOI 10.1016/j.mce.2003.11.017; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; Hewison M, 2000, J MOL ENDOCRINOL, V25, P141, DOI 10.1677/jme.0.0250141; Hilpert J, 2002, KIDNEY INT, V62, P1672, DOI 10.1046/j.1523-1755.2002.00634.x; HOWARD GA, 1981, J BIOL CHEM, V256, P7738; Hsu JY, 2001, CANCER RES, V61, P2852; Jones G, 1999, ENDOCRINOLOGY, V140, P3303, DOI 10.1210/en.140.7.3303; KARSTEN U, 1977, ANAL BIOCHEM, V77, P464, DOI 10.1016/0003-2697(77)90259-7; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; LOWRY OH, 1954, J BIOL CHEM, V207, P19; Ma JF, 2004, MOL CELL ENDOCRINOL, V221, P67, DOI 10.1016/j.mce.2004.03.003; Miyahara T, 2002, CALCIFIED TISSUE INT, V70, P488, DOI 10.1007/s00223-001-1039-5; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; POLS HAP, 1984, BIOCHEM BIOPH RES CO, V125, P265, DOI 10.1016/S0006-291X(84)80363-0; Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005; Schuessler M, 2001, STEROIDS, V66, P399, DOI 10.1016/S0039-128X(00)00229-4; Schwartz GG, 1998, CANCER EPIDEM BIOMAR, V7, P391; Schwartz GG, 2004, CARCINOGENESIS, V25, P1015, DOI 10.1093/carcin/bgh086; Segersten U, 2002, J CLIN ENDOCR METAB, V87, P2967, DOI 10.1210/jc.87.6.2967; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; TURNBULL AP, 1980, NEW DIRECTIONS EXCEP, V1, P25; van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102; van Leeuwen JPTM, 2001, CRIT REV EUKAR GENE, V11, P199; Vanhooke JL, 2006, P NATL ACAD SCI USA, V103, P75, DOI 10.1073/pnas.0509734103; VANLEEUWEN JPTM, 1994, BBA-MOL CELL RES, V1221, P167, DOI 10.1016/0167-4889(94)90009-4; Whitlatch LW, 2002, J STEROID BIOCHEM, V81, P135, DOI 10.1016/S0960-0760(02)00053-5; Willnow TE, 2002, CURR OPIN LIPIDOL, V13, P255, DOI 10.1097/00041433-200206000-00004; Zehnder D, 1999, J AM SOC NEPHROL, V10, P2465; Zehnder D, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133621; Zehnder D, 2002, AM J PATHOL, V161, P105, DOI 10.1016/S0002-9440(10)64162-4; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888	48	154	159	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2417	+		10.1096/fj.06-6374fje	http://dx.doi.org/10.1096/fj.06-6374fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023519				2022-12-25	WOS:000241702600039
J	Vaira, V; Lee, CW; Goel, HL; Bosari, S; Languino, LR; Altieri, DC				Vaira, V.; Lee, C. W.; Goel, H. L.; Bosari, S.; Languino, L. R.; Altieri, D. C.			Regulation of survivin expression by IGF-1/mTOR signaling	ONCOGENE			English	Article						survivin; IGF-1; prostate cancer; mTOR; rapamycin	RECEPTOR TYROSINE KINASE; PROSTATE-CANCER CELLS; FACTOR-I RECEPTOR; WILD-TYPE P53; NF-KAPPA-B; INDUCED APOPTOSIS; AKT; PHOSPHORYLATION; PATHWAYS; GENE	Survivin is a dual regulator of cell proliferation and cell viability overexpressed in most human tumors. Although strategies to lower survivin levels have been pursued for rational cancer therapy, the molecular circuitries controlling survivin expression in tumors have not been completely elucidated. Here, we show that stimulation with insulin-like growth factor-1 (IGF-1) results in increased survivin expression in prostate cancer cells. This response is independent of de novo gene transcription, changes in mRNA expression or modi. cations of survivin protein stability. Instead, IGF-1 induced persistence and translation of a pool of survivin mRNA, in a reaction abolished by the mTOR (mammalian target of rapamycin) inhibitor, rapamycin. Forced expression of the mTOR target p70S6K1 reproduced the increase in survivin expression in prostate cancer cells, whereas acute ablation of endogenous p70S6K1 by small interfering RNA down-regulated survivin levels. Rapamycin, alone or in combination with suboptimal concentrations of taxol reduced survivin protein levels, and decreased viability of prostate cancer cells. Therefore, IGF-1/mTOR signaling elevates survivin in prostate cancer cells via rapid changes in mRNA translation. Antagonists of this pathway may be beneficial to lower an antiapoptotic threshold maintained by survivin in prostate cancer.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; Univ Milan, AOS Paolo & Fdn Osped Maggiore Policlin Regina El, Div Pathol, Dept Med Surg & Dent, Milan, Italy	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	Vaira, Valentina/K-6499-2016; Bosari, Silvano/K-7744-2016	Vaira, Valentina/0000-0003-4416-6216; Bosari, Silvano/0000-0002-9744-6951; Languino, Lucia/0000-0001-9011-7031	NCI NIH HHS [CA78810, F31 CA132622, CA109874, CA90917] Funding Source: Medline; NHLBI NIH HHS [HL54131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA132622, R01CA090917, R01CA078810, R01CA109874] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altieri DC, 2006, MOL CANCER THER, V5, P478, DOI 10.1158/1535-7163.MCT-05-0436; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Hopfner M, 2006, BIOCHEM PHARMACOL, V71, P1435, DOI 10.1016/j.bcp.2006.02.006; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang SX, 2006, CANCER RES, V66, P4285, DOI 10.1158/0008-5472.CAN-05-4456; Zhang M, 2005, ONCOGENE, V24, P2474, DOI 10.1038/sj.onc.1208490	38	156	166	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2678	2684		10.1038/sj.onc.1210094	http://dx.doi.org/10.1038/sj.onc.1210094			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072337				2022-12-25	WOS:000246210600002
J	Pennestri, M; Melino, S; Contessa, GM; Casavola, EC; Paci, M; Ragnini-Wilson, A; Cicero, DO				Pennestri, Matteo; Melino, Sonia; Contessa, Gian Marco; Casavola, Elena Caroli; Paci, Maurizio; Ragnini-Wilson, Antonella; Cicero, Daniel O.			Structural basis for the interaction of the myosin light chain Mlc1p with the myosin v Myo2p IQ motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESIDUAL DIPOLAR COUPLINGS; RECEPTOR-MEDIATED ENDOCYTOSIS; CALCIUM-FREE CALMODULIN; PROTEIN-STRUCTURE; SCHIZOSACCHAROMYCES-POMBE; YEAST CALMODULIN; TARGET SEQUENCE; BINDING; DOMAIN; CYTOKINESIS	Calmodulin, regulatory, and essential myosin light chain are evolutionary conserved proteins that, by binding to IQ motifs of target proteins, regulate essential intracellular processes among which are efficiency of secretory vesicles release at synapsis, intracellular signaling, and regulation of cell division. The yeast Saccharomyces cerevisiae calmodulin Cmd1 and the essential myosin light chain Mlc1p share the ability to interact with the class V myosin Myo2p and Myo4 and the class II myosin Myo1p. These myosins are required for vesicle, organelle, and mRNA transport, spindle orientation, and cytokinesis. We have used the budding yeast model system to study how calmodulin and essential myosin light chain selectively regulate class V myosin function. NMR structural analysis of uncomplexed Mlc1p and interaction studies with the first three IQ motifs of Myo2p show that the structural similarities between Mlc1p and the other members of the EF-hand superfamily of calmodulin-like proteins are mainly restricted to the C-lobe of these proteins. The N-lobe of Mlc1p presents a significantly compact and stable structure that is maintained both in the free and complexed states. The Mlc1p N-lobe interacts with the IQ motif in a manner that is regulated both by the IQ motifs sequence as well as by light chain structural features. These characteristic allows a distinctive interaction of Mlc1p with the first IQ motif of Myo2p when compared with calmodulin. This finding gives us a novel view of how calmodulin and essential light chain, through a differential binding to IQ1 of class V myosin motor, regulate this activity during vegetative growth and cytokinesis.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata	Cicero, DO (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci 1, I-00133 Rome, Italy.	cicero@scienze.uniroma2.it	Ragnini, Antonella/A-8089-2014; Cicero, Daniel/AAV-5203-2021	Ragnini, Antonella/0000-0001-7963-7554; MELINO, SONIA/0000-0001-7694-5279; Caroli Casavola, Elena/0000-0003-3486-9436; Contessa, Gian Marco/0000-0001-6535-0034	Telethon [GGP030341] Funding Source: Medline	Telethon(Fondazione Telethon)		Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Bax A, 2005, CURR OPIN STRUC BIOL, V15, P563, DOI 10.1016/j.sbi.2005.08.006; Bielli P, 2006, MOL MICROBIOL, V59, P1576, DOI 10.1111/j.1365-2958.2006.05041.x; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Chou JJ, 2000, J BIOMOL NMR, V18, P217, DOI 10.1023/A:1026563923774; Cicero DO, 2006, J MAGN RESON, V180, P222, DOI 10.1016/j.jmr.2006.02.016; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; Cui YF, 2003, ANAL BIOCHEM, V315, P175, DOI 10.1016/S0003-2697(03)00007-1; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; D'souza VM, 2001, CELL STRUCT FUNCT, V26, P555, DOI 10.1247/csf.26.555; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desautels M, 2001, J BIOL CHEM, V276, P5932, DOI 10.1074/jbc.M008715200; Escobar-Cabrera E, 2005, BIOCHEMISTRY-US, V44, P12136, DOI 10.1021/bi050641c; Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213; Geli MI, 1998, EMBO J, V17, P635, DOI 10.1093/emboj/17.3.635; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; Ishida H, 2002, BIOCHEMISTRY-US, V41, P15536, DOI 10.1021/bi020330r; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754; Luo JY, 2004, J CELL BIOL, V165, P843, DOI 10.1083/jcb.200401040; Martin SR, 2002, PROTEIN SCI, V11, P2909, DOI 10.1110/ps.0210402; May KM, 1998, CELL MOTIL CYTOSKEL, V39, P195, DOI 10.1002/(SICI)1097-0169(1998)39:3<195::AID-CM2>3.0.CO;2-4; McCollum D, 1999, J BIOL CHEM, V274, P17691, DOI 10.1074/jbc.274.25.17691; McFeeters R, 2005, J BIOMOL NMR, V31, P35, DOI 10.1007/s10858-004-6057-y; Melino S, 2005, J BIOMOL NMR, V31, P367, DOI 10.1007/s10858-005-0947-5; O'Day DH, 2004, BIOCHEM BIOPH RES CO, V320, P1051, DOI 10.1016/j.bbrc.2004.06.070; ODonoghue SI, 1996, J BIOMOL NMR, V8, P193, DOI 10.1007/BF00211165; OHYA Y, 1994, GENETICS, V138, P1041; Okano H, 1998, J BIOL CHEM, V273, P26375, DOI 10.1074/jbc.273.41.26375; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ottiger M, 1999, J BIOMOL NMR, V13, P187, DOI 10.1023/A:1008395916985; Pashkova N, 2006, EMBO J, V25, P693, DOI 10.1038/sj.emboj.7600965; Rao MV, 2002, J CELL BIOL, V159, P279, DOI 10.1083/JCB.200205062; Rudolf R, 2003, J CELL SCI, V116, P1339, DOI 10.1242/jcs.00317; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Sellers JR, 2006, CURR OPIN CELL BIOL, V18, P68, DOI 10.1016/j.ceb.2005.12.014; Shannon KB, 2000, CURR BIOL, V10, P727, DOI 10.1016/S0960-9822(00)00539-X; Slupsky CM, 2001, J BIOL CHEM, V276, P5943, DOI 10.1074/jbc.M008716200; Stevens RC, 1998, J CELL BIOL, V142, P711, DOI 10.1083/jcb.142.3.711; Terrak M, 2005, P NATL ACAD SCI USA, V102, P12718, DOI 10.1073/pnas.0503899102; Terrak M, 2003, EMBO J, V22, P362, DOI 10.1093/emboj/cdg058; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Wagner W, 2002, EMBO J, V21, P6397, DOI 10.1093/emboj/cdf650; WAGNER W, 2002, REGULATION VESICLE T; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Weisman LS, 2006, NAT REV MOL CELL BIO, V7, P243, DOI 10.1038/nrm1892; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	63	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					667	679		10.1074/jbc.M607016200	http://dx.doi.org/10.1074/jbc.M607016200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17074768	hybrid			2022-12-25	WOS:000243166500072
J	Fox, KE; Fankell, DM; Erickson, PF; Majka, SM; Crossno, JT; Klemm, DJ				Fox, Keith E.; Fankell, Dana M.; Erickson, Paul F.; Majka, Susan M.; Crossno, Joseph T., Jr.; Klemm, Dwight J.			Depletion of cAMP-response element-binding protein/ATF1 inhibits adipogenic conversion of 3T3-L1 cells ectopically expressing CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBP beta, or PPAR gamma 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; TRANSCRIPTIONAL REGULATION; ADIPOCYTE DIFFERENTIATION; MOLECULAR REGULATION; ADIPOSE-TISSUE; PPAR-GAMMA; GENE; CREB; INSULIN; FIBROBLASTS	The differentiation of preadipocytes to adipocytes is orchestrated by the expression of the "master adipogenic regulators," CCAAT/enhancer-binding protein (C/EBP) beta, peroxisome proliferator-activated receptor gamma ( PPAR gamma), and C/EBP alpha. In addition, activation of the cAMP-response element-binding protein ( CREB) is necessary and sufficient to promote adipogenic conversion and prevent apoptosis of mature adipocytes. In this report we used small interfering RNAto deplete CREB and the closely related factor ATF1 to explore the ability of the master adipogenic regulators to promote adipogenesis in the absence of CREB and probe the function of CREB in late stages of adipogenesis. Loss of CREB/ATF1 blocked adipogenic conversion of 3T3-L1 cells in culture or 3T3-F442A cells implanted into athymic mice. Loss of CREB/ATF1 prevented the expression of PPAR gamma, C/EBP alpha, and adiponectin and inhibited the loss of Pref-1. Loss of CREB/ATF1 inhibited adipogenic conversion even in cells ectopically expressing C/EBP alpha, C/EBP beta, or PPAR gamma 2 individually. CREB/ATF1 depletion did not attenuate lipid accumulation in cells expressing both PPAR gamma 2 and C/EBP alpha, but adiponectin expression was severely diminished. Conversely ectopic expression of constitutively active CREB overcame the blockade of adipogenesis due to depletion of C/EBP beta but not due to loss of PPAR gamma 2 or C/EBP alpha. Depletion of CREB/ATF1 did not suppress the expression of C/EBP beta as we had previously observed using dominant negative forms of CREB. Finally results are presented showing that CREB promotes PPAR gamma 2 gene transcription. The results indicate that CREB and ATF1 play a central role in adipogenesis because expression of individual master adipogenic regulators is unable to compensate for their loss. The data also indicate that CREB not only functions during the initiation of adipogenic conversion but also at later stages.	Univ Colorado, Hlth Sci Ctr, Cardiovasc Pulm Res Lab, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Vet Affairs Med Ctr, Res Serv, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Klemm, DJ (corresponding author), Univ Colorado, Hlth Sci Ctr, Cardiovasc Pulm Res Lab, 4200 E 9th Ave, Denver, CO 80262 USA.	Dwight.Klemm@UCHSC.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053969] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK053969] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; CAHILL MA, 1994, FEBS LETT, V344, P105, DOI 10.1016/0014-5793(94)00320-3; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Croniger CM, 2001, J BIOL CHEM, V276, P629, DOI 10.1074/jbc.M007576200; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Farmer SR, 2005, INT J OBESITY, V29, pS13, DOI 10.1038/sj.ijo.0802907; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; Garaulet M, 2006, INT J OBESITY, V30, P899, DOI 10.1038/sj.ijo.0803219; Grimaldi PA, 2001, PROG LIPID RES, V40, P269, DOI 10.1016/S0163-7827(01)00005-4; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; Korner A, 2005, BIOCHEM BIOPH RES CO, V337, P540, DOI 10.1016/j.bbrc.2005.09.064; Lee MY, 2001, BIOCHEM BIOPH RES CO, V281, P1241, DOI 10.1006/bbrc.2001.4494; Lin WC, 2002, DNA CELL BIOL, V21, P551, DOI 10.1089/104454902320308924; Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200; Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; MARQUES BG, 1998, AM J PHYSIOL, V275, pR1891; MORRISON RF, 1999, J CELL BIOCHEM, V75, P32; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Reusch JEB, 2002, J BIOL CHEM, V277, P1426, DOI 10.1074/jbc.M107923200; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tseng YH, 2005, NAT CELL BIOL, V7, P601, DOI 10.1038/ncb1259; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Zhang JW, 2004, J BIOL CHEM, V279, P4471, DOI 10.1074/jbc.M311327200; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	35	82	85	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40341	40353		10.1074/jbc.M605077200	http://dx.doi.org/10.1074/jbc.M605077200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17071615	hybrid			2022-12-25	WOS:000243033900065
J	Pardini, G; De Groot, PWJ; Coste, AT; Karababa, M; Klis, FM; de Koster, CG; Sanglard, D				Pardini, Giacomo; De Groot, Piet W. J.; Coste, Alix T.; Karababa, Mahir; Klis, Frans M.; de Koster, Chris G.; Sanglard, Dominique			The CRH family coding for cell wall glycosylphosphatidylinositol proteins with a predicted transglycosidase domain affects cell wall organization and virulence of Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-ACTIVE ENZYMES; ABC TRANSPORTERS CDR1; PROTEOMIC ANALYSIS; GENE-EXPRESSION; YEAST; CALCINEURIN; MUTANTS; CHITIN; CLASSIFICATION; IDENTIFICATION	In Candida albicans UTR2 (CSF4), CRH11, and CRH12 are members of a gene family ( the CRH family) that encode glycosylphosphatidylinositol-dependent cell wall proteins with putative transglycosidase activity. Deletion of genes of this family resulted in additive sensitivity to compounds interfering with normal cell wall formation ( Congo red, calcofluor white, SDS, and high Ca2+ concentrations), suggesting that these genes contribute to cell wall organization. A triple mutant lacking UTR2, CRH11, and CRH12 produced a defective cell wall, as inferred from increased sensitivity to cell wall- degrading enzymes, decreased ability of protoplasts to regenerate a new wall, constitutive activation of Mkc1p, the mitogen-activated protein kinase of the cell wall integrity pathway, and an increased chitin content of the cell wall. Importantly, this was accompanied by a decrease in alkali- insoluble 1,3-beta-glucan but not total glucan content, suggesting that formation of the linkage between 1,3-beta- glucan and chitin might be affected. In support of this idea, localization of a Utr2p-GFP fusion protein largely coincided with areas of chitin incorporation in C. albicans. As UTR2 and CRH11 expression is regulated by calcineurin, a serine/ threonine protein phosphatase involved in tolerance to antifungal drugs, cell wall morphogenesis, and virulence, this points to a possible relationship between calcineurin and the CRH family. Deletion of UTR2, CRH11, and CRH12 resulted in only a partial overlap with calcineurin- dependent phenotypes, suggesting that calcineurin has additional targets. Interestingly, cells deleted for UTR2, CRH11, and CRH12 were, like a calcineurin mutant, avirulent in a mouse model of systemic infection but retained the capacity to colonize target organs ( kidneys) as the wild type. In conclusion, this work establishes the role of UTR2, CRH11, and CRH12 in cell wall organization and integrity.	Univ Lausanne Hosp, Inst Microbiol, CH-1011 Lausanne, Switzerland; Univ Amsterdam, Swammerdam Inst Life Sci, NL-1018 WV Amsterdam, Netherlands	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Amsterdam	Sanglard, D (corresponding author), Univ Lausanne Hosp, Inst Microbiol, CH-1011 Lausanne, Switzerland.	Dominique.Sanglard@chuv.ch	Coste, Alix T./H-3026-2019; Klis, Frans M/B-9085-2008; Sanglard, Dominique/K-6032-2017; De Groot, Piet/L-7737-2014	Coste, Alix T./0000-0001-9481-9778; Klis, Frans M/0000-0003-0079-9492; Sanglard, Dominique/0000-0002-5244-4178; De Groot, Piet/0000-0002-3112-6947; de Koster, Chris/0000-0003-2872-2796				Alberti-Segui C, 2004, YEAST, V21, P285, DOI 10.1002/yea.1061; Bader T, 2003, INFECT IMMUN, V71, P5344, DOI 10.1128/IAI.71.9.5344-5354.2003; Bahmed K, 2003, RES MICROBIOL, V154, P215, DOI 10.1016/S0923-2508(03)00049-4; Bates S, 2006, J BIOL CHEM, V281, P90, DOI 10.1074/jbc.M510360200; Berman J, 2002, NAT REV GENET, V3, P918, DOI 10.1038/nrg948; Blankenship JR, 2003, EUKARYOT CELL, V2, P422, DOI 10.1128/EC.2.3.422-430.2003; BRADFORD DS, 1983, J BONE JOINT SURG AM, V65, P1220, DOI 10.2106/00004623-198365090-00002; Brand A, 2004, EUKARYOT CELL, V3, P900, DOI 10.1128/EC.3.4.900-909.2004; BRAUN PC, 1978, J BACTERIOL, V133, P1472, DOI 10.1128/JB.133.3.1472-1477.1978; Castillo L, 2006, FUNGAL GENET BIOL, V43, P124, DOI 10.1016/j.fgb.2005.12.002; Chauhan Neeraj, 2002, P159; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Coste AT, 2004, EUKARYOT CELL, V3, P1639, DOI 10.1128/EC.3.6.1639-1652.2004; Coutinho PM, 1999, ROY SOC CH, P3; Cruz MC, 2002, EMBO J, V21, P546, DOI 10.1093/emboj/21.4.546; Dallies N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L; de Groot PWJ, 2004, EUKARYOT CELL, V3, P955, DOI 10.1128/EC.3.4.955-965.2004; de Groot PWJ, 2003, YEAST, V20, P781, DOI 10.1002/yea.1007; de Micheli M, 2002, MOL MICROBIOL, V43, P1197, DOI 10.1046/j.1365-2958.2002.02814.x; DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0; FONZI WA, 1993, GENETICS, V134, P717; Fradin C, 2005, MOL MICROBIOL, V56, P397, DOI 10.1111/j.1365-2958.2005.04557.x; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; Hazan I, 2002, EUKARYOT CELL, V1, P856, DOI 10.1128/EC.1.6.856-864.2002; Hazan I, 2002, MOL BIOL CELL, V13, P134, DOI 10.1091/mbc.01-03-0116; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hoyer LL, 1998, CURR GENET, V33, P451, DOI 10.1007/s002940050359; Hoyer LL, 2001, GENETICS, V157, P1555; Hoyer LL, 2001, TRENDS MICROBIOL, V9, P176, DOI 10.1016/S0966-842X(01)01984-9; Hwang JS, 2006, YEAST, V23, P803, DOI 10.1002/yea.1395; Kapteyn JC, 2000, MOL MICROBIOL, V35, P601, DOI 10.1046/j.1365-2958.2000.01729.x; Kapteyn JC, 1997, J BACTERIOL, V179, P6279, DOI 10.1128/JB.179.20.6279-6284.1997; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Karababa M, 2006, MOL MICROBIOL, V59, P1429, DOI 10.1111/j.1365-2958.2005.05037.x; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; Magnelli P, 2002, ANAL BIOCHEM, V301, P136, DOI 10.1006/abio.2001.5473; Martinez-Lopez R, 2004, MICROBIOL-SGM, V150, P3341, DOI 10.1099/mic.0.27320-0; Mera N, 2004, J BIOSCI BIOENG, V97, P169; Mouyna I, 2000, J BIOL CHEM, V275, P14882, DOI 10.1074/jbc.275.20.14882; MRSA V, 1993, J BACTERIOL, V175, P2102, DOI 10.1128/JB.175.7.2102-2106.1993; Navarro-Garcia F, 2005, MICROBIOL-SGM, V151, P2737, DOI 10.1099/mic.0.28038-0; Navarro-Garcia F, 1998, MICROBIOL-UK, V144, P411, DOI 10.1099/00221287-144-2-411; Netea MG, 2006, J CLIN INVEST, V116, P1642, DOI 10.1172/JCI27114; Pardo M, 2004, MICROBIOL-SGM, V150, P4157, DOI 10.1099/mic.0.26924-0; Reuss O, 2004, GENE, V341, P119, DOI 10.1016/j.gene.2004.06.021; Rodriguez-Pena JM, 2002, J CELL SCI, V115, P2549; Rodriguez-Pena JM, 2000, MOL CELL BIOL, V20, P3245, DOI 10.1128/MCB.20.9.3245-3255.2000; Sanglard D, 2003, MOL MICROBIOL, V48, P959, DOI 10.1046/j.1365-2958.2003.03495.x; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; SIETSMA JH, 1990, J GEN MICROBIOL, V136, P2261, DOI 10.1099/00221287-136-11-2261; Sudbery P, 2004, TRENDS MICROBIOL, V12, P317, DOI 10.1016/j.tim.2004.05.008; Sundstrom P, 2002, CELL MICROBIOL, V4, P461, DOI 10.1046/j.1462-5822.2002.00206.x; Sundstrom P, 2002, INFECT IMMUN, V70, P3281, DOI 10.1128/IAI.70.6.3281-3283.2002; TABERNERO C, 1994, APPL ENVIRON MICROB, V60, P1213, DOI 10.1128/AEM.60.4.1213-1220.1994; Viladot JL, 1998, BIOCHEMISTRY-US, V37, P11332, DOI 10.1021/bi980586q; Wheeler RT, 2006, PLOS PATHOG, V2, P328, DOI 10.1371/journal.ppat.0020035; Yin QY, 2005, J BIOL CHEM, V280, P20894, DOI 10.1074/jbc.M500334200	59	84	94	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40399	40411		10.1074/jbc.M606361200	http://dx.doi.org/10.1074/jbc.M606361200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074760	hybrid			2022-12-25	WOS:000243033900070
J	Taylor, JM; Quilty, D; Banadyga, L; Barry, M				Taylor, John M.; Quilty, Douglas; Banadyga, Logan; Barry, Michele			The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; CYTOCHROME-C RELEASE; CELL-DEATH; E1B 19K; BH3-ONLY PROTEINS; MYXOMA-VIRUS; BH3 DOMAIN; ENDOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGE	Vaccinia virus, the prototypic member of the orthopoxvirus genus, encodes the mitochondrial-localized protein F1L that functions to protect cells from apoptotic death and inhibits cytochrome c release. We previously showed that F1L interacts with the pro-apoptotic Bcl-2 family member Bak and inhibits activation of Bak following an apoptotic stimulus (Wasilenko, S. T., Banadyga, L., Bond, D., and Barry, M. (2005) J. Virol. 79, 14031-14043). In addition to Bak, the pro-apoptotic protein Bax is also capable of initiating cytochrome c release suggesting that vaccinia virus infection could also inhibit Bax activity. Here we show that F1L inhibits the activity of the pro-apoptotic protein Bax by inhibiting oligomerization and N-terminal activation of Bax. F1L expression also inhibited the subcellular redistribution of Bax to the mitochondria and the insertion of Bax into the outer mitochondrial membrane. The ability of F1L to inhibit Bax activation does not require Bak, because F1L expression inhibited cytochrome c release and Bax activation in Bak-deficient cells. No interaction between Bax and F1L was detected during infection, suggesting that F1L functions upstream of Bax activation. Notably, F1L was capable of interacting with the BH3-only protein BimL as shown by co-immunoprecipitation, and F1L expression inhibited apoptosis induced by BimL. These studies suggest that, in addition to interacting with the proapoptotic protein Bak, F1L also functions to indirectly inhibit the activation of Bax, likely by interfering with the pro-apoptotic activity of BH3-only proteins such as BimL.	Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada	University of Alberta	Barry, M (corresponding author), Univ Alberta, Dept Med Microbiol & Immunol, 621 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	michele.barry@ualberta.ca	Banadyga, Logan/AAV-4687-2021	Banadyga, Logan/0000-0001-8390-2648; Taylor, John/0000-0002-4275-077X				Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2004, P NATL ACAD SCI USA, V101, P7988, DOI 10.1073/pnas.0401897101; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Boya P, 2004, BBA-BIOENERGETICS, V1659, P178, DOI 10.1016/j.bbabio.2004.08.007; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Everett H, 2000, J EXP MED, V191, P1487, DOI 10.1084/jem.191.9.1487; Everett H, 2002, J EXP MED, V196, P1127, DOI 10.1084/jem.20011247; Fischer SF, 2006, CELL DEATH DIFFER, V13, P109, DOI 10.1038/sj.cdd.4401718; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Griffiths GJ, 2001, ONCOGENE, V20, P7668, DOI 10.1038/sj.onc.1204995; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hardwick JM, 2003, CELL DEATH DIFFER, V10, pS68, DOI 10.1038/sj.cdd.4401133; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Polster BM, 2004, BBA-MOL CELL RES, V1644, P211, DOI 10.1016/j.bbamcr.2003.11.001; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Postigo A, 2006, CELL DEATH DIFFER, V13, P1651, DOI 10.1038/sj.cdd.4401853; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Stewart TL, 2005, J VIROL, V79, P1084, DOI 10.1128/JVI.79.2.1084-1098.2005; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Su J, 2006, J VIROL, V80, P1140, DOI 10.1128/JVI.80.3.1140-1151.2006; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Wang G, 2004, J VIROL, V78, P7097, DOI 10.1128/JVI.78.13.7097-7111.2004; Wang XD, 2001, GENE DEV, V15, P2922; Wasilenko ST, 2003, P NATL ACAD SCI USA, V100, P14345, DOI 10.1073/pnas.2235583100; Wasilenko ST, 2005, J VIROL, V79, P14031, DOI 10.1128/JVI.79.22.14031-14043.2005; Wasilenko ST, 2001, J VIROL, V75, P11437, DOI 10.1128/JVI.75.23.11437-11448.2001; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	63	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39728	39739		10.1074/jbc.M607465200	http://dx.doi.org/10.1074/jbc.M607465200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17074758	hybrid			2022-12-25	WOS:000242898700080
J	Warner, LR; Brown, RJ; Yingst, SMC; Oxford, JT				Warner, Lisa R.; Brown, Raquel J.; Yingst, Sorcha M. C.; Oxford, Julia Thom			Isoform-specific heparan sulfate binding within the amino-terminal noncollagenous domain of collagen alpha 1(XI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; XI COLLAGEN; MESSENGER-RNA; PRO-ALPHA-2(XI) COLLAGEN; EXPRESSION; CARTILAGE; GENE; CHAIN; PERLECAN	Collagen type XI is a constituent of the pericellular matrix of chondrocytes and plays a role in the regulation of fibrillogenesis. The amino-terminal domain of collagen type XI alpha 1 chain is a noncollagenous structure that has been identified on the surface of cartilage collagen fibrils. The biochemical composition of the amino-terminal domain varies due to alternative splicing of the primary transcript. Recombinantly expressed alpha 1(XI) aminoterminal domain isoforms were used in this study to investigate potential interactions. Purified products were analyzed for heparan sulfate binding properties. The results demonstrated that two additional binding sites exist within the alpha 1(XI) aminoterminal domain, one within the amino propeptide and one within the variable region of the amino-terminal domain. Analysis of relative affinities indicated that the site located within the amino propeptide (site 1) was of similar affinity to sites that exist within the major triple helix of collagen type XI. Substitution of amino acid residues 147 to 152 within the amino propeptide by site-directed mutagenesis resulted in altered affinity for heparan sulfate. The binding site located within the variable region (site 2) demonstrated significantly higher affinity than other sites within the molecule. Displacement of collagen type XI within the pericellular matrix was observed in cell culture in the presence of excess heparan sulfate and by treatment with heparinase. These studies suggest two additional binding sites located within the noncollagenous amino-terminal domain that may play a role in the function of collagen type XI. The localization of collagen type XI within the pericellular matrix may be dependent upon interactions with heparan sulfate proteoglycans, and these are likely to take place in an isoform-specfic manner.	Boise State Univ, Dept Biol, Biomol Res Ctr, Boise, ID 83725 USA; Boise State Univ, Mat Sci & Engn Program, Boise, ID 83725 USA	Idaho; Boise State University; Idaho; Boise State University	Oxford, JT (corresponding author), Boise State Univ, Dept Biol, Biomol Res Ctr, 1910 Univ Dr,MS 1515, Boise, ID 83725 USA.	joxford@boisestate.edu	Warner, Lisa/AAD-3405-2019; Warner, Lisa/E-7405-2011; Oxford, Julia Thom/AAH-2842-2019	Warner, Lisa/0000-0002-7542-0144; Oxford, Julia Thom/0000-0002-4850-3569	NCRR NIH HHS [P20 RR016454-096114, P20 RR016454, P20 RR016454-086155, P20RR16454] Funding Source: Medline; NIAMS NIH HHS [K02 AR048672-01, R01 AR047985-04, KO2AR48672, R01 AR047985-05, K02 AR048672-04, K02 AR048672-03, K02 AR048672-02, R01 AR047985, R01 AR047985-01, R01 AR047985-02, K02 AR048672, R01 AR047985-03, K02 AR048672-05, R01AR47985] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR048672, R01AR047985] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; Blaschke UK, 2000, J BIOL CHEM, V275, P10370, DOI 10.1074/jbc.275.14.10370; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; Chernousov MA, 2000, J BIOL CHEM, V275, P28208; CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Davies GBM, 1998, DEV DYNAM, V213, P12, DOI 10.1002/(SICI)1097-0177(199809)213:1<12::AID-AJA2>3.0.CO;2-0; Fallahi A, 2005, PROTEIN SCI, V14, P1526, DOI 10.1110/ps.051363105; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gregory KE, 2000, J BIOL CHEM, V275, P11498, DOI 10.1074/jbc.275.15.11498; GROVER J, 1995, BIOCHEM J, V309, P963, DOI 10.1042/bj3090963; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; Lees JG, 2004, ANAL BIOCHEM, V332, P285, DOI 10.1016/j.ab.2004.06.002; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Lobley A, 2001, BIOPHYS J, V80, p373A; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; MAYNE R, 1995, EXTRACELLULAR MATRIX, P73; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Morris NP, 2000, J HISTOCHEM CYTOCHEM, V48, P725, DOI 10.1177/002215540004800601; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Oxford JT, 2004, J BIOL CHEM, V279, P10939, DOI 10.1074/jbc.M310291200; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; RYAN MC, 1990, GENOMICS, V8, P41, DOI 10.1016/0888-7543(90)90224-I; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SMITH GN, 1987, COLLAGEN REL RES, V7, P315; SMITH GN, 1989, MATRIX, V9, P186; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; THOM JR, 1991, J BIOL CHEM, V266, P7262; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; Vaughan-Thomas A, 2001, J BIOL CHEM, V276, P5303, DOI 10.1074/jbc.M008764200; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; Yamaguchi K, 2005, MATRIX BIOL, V24, P283, DOI 10.1016/j.matbio.2005.03.006; YOSHIOKA H, 1995, DEV DYNAM, V204, P41, DOI 10.1002/aja.1002040106; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	50	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39507	39516		10.1074/jbc.M608551200	http://dx.doi.org/10.1074/jbc.M608551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17062562	Green Accepted, hybrid			2022-12-25	WOS:000242898700059
J	Vainauskas, S; Menon, AK				Vainauskas, Saulius; Menon, Anant K.			Ethanolamine phosphate linked to the first mannose residue of glycosylphosphatidylinositol (GPI) lipids is a major feature of the GPI structure that is recognized by human GPI transamidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID ANCHOR PRECURSORS; VARIANT SURFACE GLYCOPROTEIN; TRYPANOSOMA-BRUCEI; MEMBRANE ANCHOR; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; AFRICAN TRYPANOSOMES; MAMMALIAN-CELLS; IN-VIVO; PIG-T	Glycosylphosphatidylinositol (GPI) anchoring of proteins is catalyzed by GPI transamidase (GPIT), a multisubunit, endoplasmic reticulum (ER)-localized enzyme. GPIT recognizes ER-translocated proteins that have a GPI-directing C-terminal signal sequence and replaces this sequence with a preassembled GPI anchor. Although the GPI signal sequence has been extensively characterized, little is known about the structural features of the GPI lipid substrate that enable its recognition by GPIT. In a previous study we showed that mature GPIs could be co-immunoprecipitated with GPIT complexes containing functional subunits (Vainauskas, S., and Menon, A. K. (2004)J. Biol. Chem. 279, 6540-6545). We now use this approach, as well as a method that reconstitutes the interaction between GPIs and GPIT, to define the basis of the interaction between GPI and human GPIT. We report that (i) human GPIT can interact with GPI biosynthetic intermediates, not just mature GPIs competent for transfer to protein, (ii) the ethanolamine phosphate group on the third mannose residue of the GPI glycan is not critical for GPI recognition by GPIT, (iii) the ethanolamine phosphate residue linked to the first mannose of the GPI structure is a major feature of GPIs that is recognized by human GPIT, and (iv) the simplest GPI recognized by human GPIT is EtN-P-2Man alpha 1-4GlcN-(acyl)-phosphatidyl-inositol. These studies define the molecular characteristics of GPI that are recognized by GPIT and open the way to identifying GPIT subunits that are involved in this process.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Cornell University	Menon, AK (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	akm2003@med.cornell.edu		Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM 55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Bohme U, 2002, J CELL SCI, V115, P805; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; Eisenhaber B, 2003, BIOESSAYS, V25, P367, DOI 10.1002/bies.10254; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FIELD MC, 1993, J BIOL CHEM, V268, P9570; FIELD MC, 1992, J BIOL CHEM, V267, P5324; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Gruszynski AE, 2006, MOL BIOCHEM PARASIT, V147, P211, DOI 10.1016/j.molbiopara.2006.02.013; GUPTA D, 1988, SCIENCE, V242, P1446, DOI 10.1126/science.2904699; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HIROSE S, 1992, J BIOL CHEM, V267, P16968; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Hong YJ, 2003, MOL BIOL CELL, V14, P1780, DOI 10.1091/mbc.E02-12-0794; Imhof I, 2000, GLYCOBIOLOGY, V10, P1271, DOI 10.1093/glycob/10.12.1271; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; Mann KJ, 2001, BIOCHEMISTRY-US, V40, P1205, DOI 10.1021/bi0024512; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MORAN P, 1991, J BIOL CHEM, V266, P1250; Nagamune K, 2003, P NATL ACAD SCI USA, V100, P10682, DOI 10.1073/pnas.1833260100; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2003, J BIOL CHEM, V278, P13959, DOI 10.1074/jbc.M300586200; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PAN YT, 1992, J BIOL CHEM, V267, P21250; PITTET M, 2006, IN PRESS BIOCH BIOPH; RALTON JE, 1993, J BIOL CHEM, V268, P24183; SEVLEVER D, 1993, J BIOL CHEM, V268, P10938; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Stevens VL, 1996, BIOCHEM J, V313, P253, DOI 10.1042/bj3130253; Taron BW, 2004, J BIOL CHEM, V279, P36083, DOI 10.1074/jbc.M405081200; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; UEDA E, 1993, J BIOL CHEM, V268, P9998; Vainauskas S, 2004, J BIOL CHEM, V279, P6540, DOI 10.1074/jbc.M312191200; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; Vishwakarma RA, 2005, CHEM COMMUN, P453, DOI 10.1039/b413196g; WIEDMAN JM, 2006, FEMS YEAST RES; Zhu YH, 2006, J BIOL CHEM, V281, P19830, DOI 10.1074/jbc.M601425200	49	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38358	38364		10.1074/jbc.M608896200	http://dx.doi.org/10.1074/jbc.M608896200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17060324	hybrid			2022-12-25	WOS:000242709500029
J	Yamakoshi, Y; Hu, JCC; Iwata, T; Kobayashi, K; Fukae, M; Simmer, JP				Yamakoshi, Yasuo; Hu, Jan C-C.; Iwata, Takanori; Kobayashi, Kazuyuki; Fukae, Makoto; Simmer, James P.			Dentin sialophosphoprotein is processed by MMP-2 and MMP-20 in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPERFECTA TYPE-II; HYPOMATURATION AMELOGENESIS IMPERFECTA; RAT INCISOR DENTIN; SEQUENCE DETERMINATION; SIALOPROTEIN DSP; DEVELOPING TOOTH; DENTINOGENESIS; MUTATION; GENE; PHOSPHOPROTEIN	Dentin sialophosphoprotein ( DSPP) is a major secretory product of odontoblasts and is critical for proper tooth dentin formation. During dentinogenesis, DSPP is proteolytically cleaved into smaller subunits. These cleavages are proposed activation steps, and failure to make these cleavages is a potential cause of developmental tooth defects. We tested the hypothesis that dentin-resident matrix metalloproteinases catalyze the cleavages that process DSPP. We defined the exact DSPP cleavages that are catalyzed by proteases during crown formation by isolating DSPP-derived proteins from developing porcine molars and characterizing their N-terminal sequences and apparent size on SDS-PAGE and Western blots. The in vivo DSPP cleavage sites were on the N-terminal sides of Thr(200), Ser(330), Val(353), Leu(360), Ile(362), Ser(377), Ser(408), and Asp(458). The initial DSPP cleavage is between dentin glycoprotein (DGP) and dentin phosphoprotein (DPP), generating dentin sialoprotein (DSP)/DGP and DPP. Gelatin and casein zymograms identified MMP-2, MMP-20, and KLK4 in the dentin extracts. MMP-2 and MMP-20 were purified from over 150 g of porcine dentin powder and incubated with DSP-DGP and DPP. These enzymes show no activity in further cleaving DPP. MMP-20 cleaves DSP-DGP to generate DSP and DGP. MMP-20 also cleaves DSP at multiple sites, releasing N-terminal DSP cleavage products ranging in size from 25 to 38 kDa. MMP-2 makes multiple cleavages near the DSP C terminus, releasing larger forms of DGP, or "extended DGPs." Exact correspondence between DSPP cleavage sites that occur in vivo and those generated in vitro demonstrates that MMP-2 and MMP-20 process DSPP into smaller subunits in the dentin matrix during odontogenesis.	Univ Michigan, Dent Res Lab, Dept Biol & Mat Sci, Ann Arbor, MI 48108 USA; Univ Michigan, Dent Res Lab, Dept Orthodont & Pediat Dent, Ann Arbor, MI 48108 USA; Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Bunkyo Ku, Tokyo 1138549, Japan; Tsurumi Univ, Tsurumi Ku, Sch Dent Med, Dept Periodont & Endodont, Yokohama, Kanagawa 230, Japan; Tsurumi Univ, Tsurumi Ku, Sch Dent Med, Makoto Fukae Dept Biochem, Yokohama, Kanagawa 230, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Tokyo Medical & Dental University (TMDU); Tsurumi University; Tsurumi University	Simmer, JP (corresponding author), Univ Michigan, Dent Res Lab, Dept Biol & Mat Sci, 1210 Eisenhower Pl, Ann Arbor, MI 48108 USA.	jsimmer@umich.edu	Hu, Jan C-C./F-5679-2015; Iwata, Takanori/AAT-3219-2020	Hu, Jan C-C./0000-0002-9294-0248; Iwata, Takanori/0000-0002-5461-7298; Simmer, James/0000-0002-7192-6105	NIDCR NIH HHS [DE 15846, DE 12769, DE 11301] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012769, R56DE011301, R01DE011301, R29DE011301] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Butler W T, 1995, Connect Tissue Res, V33, P59, DOI 10.3109/03008209509016983; Butler WT, 2002, CONNECT TISSUE RES, V43, P301, DOI 10.1080/03008200290000682; BUTLER WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P178, DOI 10.1016/0003-9861(83)90021-8; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; Caron C, 2001, J DENT RES, V80, P1660, DOI 10.1177/00220345010800071201; Caterina JJ, 2002, J BIOL CHEM, V277, P49598, DOI 10.1074/jbc.M209100200; Chang SR, 1996, CALCIFIED TISSUE INT, V59, P149, DOI 10.1007/s002239900101; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; Dong J, 2005, AM J MED GENET A, V132A, P305, DOI 10.1002/ajmg.a.30460; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; Fukae M, 1998, J DENT RES, V77, P1580, DOI 10.1177/00220345980770080501; Fukae M, 2002, J DENT RES, V81, P668, DOI 10.1177/154405910208101003; Goldberg M, 2003, CONNECT TISSUE RES, V44, P143, DOI 10.1080/03008200390223927; Hu JCC, 2005, CELLS TISSUES ORGANS, V181, P219, DOI 10.1159/000091383; Huq NL, 2005, ARCH ORAL BIOL, V50, P807, DOI 10.1016/j.archoralbio.2005.02.002; JONSSON M, 1978, J CHROMATOGR, V157, P234; Kim JW, 2006, EUR J ORAL SCI, V114, P33, DOI 10.1111/j.1600-0722.2006.00284.x; Kim JW, 2005, J MED GENET, V42, P271, DOI 10.1136/jmg.2004.024505; Kim JW, 2005, HUM GENET, V116, P186, DOI 10.1007/s00439-004-1223-6; Kim JW, 2004, HUM GENET, V115, P248, DOI 10.1007/s00439-004-1143-5; LINDE A, 1980, J BIOL CHEM, V255, P5931; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Malmgren B, 2004, HUM GENET, V114, P491, DOI 10.1007/s00439-004-1084-z; MASTERS PM, 1985, CALCIFIED TISSUE INT, V37, P236, DOI 10.1007/BF02554869; Ozdemir D, 2005, J DENT RES, V84, P1031, DOI 10.1177/154405910508401112; Patel PI, 2001, NAT GENET, V27, P129, DOI 10.1038/84728; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302; Qin CL, 2003, EUR J ORAL SCI, V111, P235, DOI 10.1034/j.1600-0722.2003.00043.x; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; Ritchie HH, 1996, J BIOL CHEM, V271, P21695, DOI 10.1074/jbc.271.36.21695; Ryu O, 2002, EUR J ORAL SCI, V110, P358, DOI 10.1034/j.1600-0722.2002.21349.x; Ryu OH, 1999, J DENT RES, V78, P743, DOI 10.1177/00220345990780030601; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; VEIS A, 1967, BIOCHEMISTRY-US, V6, P2409, DOI 10.1021/bi00860a017; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Yamakoshi Y, 2005, J BIOL CHEM, V280, P1552, DOI 10.1074/jbc.M409606200; Yamakoshi Y, 2005, J BIOL CHEM, V280, P17472, DOI 10.1074/jbc.M413220200; Yamakoshi Y, 2003, EUR J ORAL SCI, V111, P60, DOI 10.1034/j.1600-0722.2003.00009.x; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	41	109	111	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38235	38243		10.1074/jbc.M607767200	http://dx.doi.org/10.1074/jbc.M607767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046814	hybrid			2022-12-25	WOS:000242709500016
J	Goswami, A; Dikshit, P; Mishra, A; Nukina, N; Jana, NR				Goswami, Anand; Dikshit, Priyanka; Mishra, Amit; Nukina, Nobuyuki; Jana, Nihar Ranjan			Expression of expanded polyglutamine proteins suppresses the activation of transcription factor NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; MOLECULAR CHAPERONES; HUNTINGTONS-DISEASE; CASPASE ACTIVATION; GLUTAMINE REPEATS; P50 SUBUNIT; CELL-DEATH; NUCLEAR; NEURONS; INVOLVEMENT	A major pathological hallmark of the polyglutamine diseases is the formation of neuronal intranuclear inclusions of the disease proteins that are ubiquitinated and often associated with various transcription factors, chaperones, and proteasome components. However, how the expanded polyglutamine proteins or their aggregates elicit complex pathogenic responses in the neuronal cells is not fully understood. Here, we have demonstrated that the expression of expanded polyglutamine proteins down-regulated the NF kappa B-dependent transcriptional activity. The expression of expanded polyglutamine proteins increased the stability and the levels of I kappa B-alpha and its phosphorylated derivatives. We have also found that various NF kappa B subunits and I kappa B-alpha aberrantly interacted with the expanded polyglutamine proteins and associated with their aggregates. Finally, we have shown that several NF kappa B-dependent genes are down-regulated in the expanded polyglutamine protein-expressing cells and down-regulation of NF kappa B activity enhances expanded polyglutamine protein-induced cell death. Because the NF kappa B pathway plays a very important role in cell survival, altered regulation of this pathway in expanded polyglutamine protein-expressing cells might be linked with the disease pathogenesis.	Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Gurgaon 122050, India; RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Wako, Saitama 3510198, Japan	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); RIKEN	Jana, NR (corresponding author), Natl Brain Res Ctr, Mol & Cellular Neurosci Lab, Gurgaon 122050, India.	nihar@nbrc.ac.in	Nukina, Nobuyuki/GPP-6265-2022	Jana, Nihar/0000-0002-6549-4211; Mishra, Amit/0000-0001-9401-4400				Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 1999, J NEUROSCI, V19, P10338; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Dikshit P, 2006, J BIOL CHEM, V281, P29228, DOI 10.1074/jbc.M602629200; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Jana NR, 2004, J BIOL CHEM, V279, P11680, DOI 10.1074/jbc.M310369200; Jana NR, 2003, J CHEM NEUROANAT, V26, P95, DOI 10.1016/S0891-0618(03)00029-2; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Khoshnan A, 2004, J NEUROSCI, V24, P7999, DOI 10.1523/JNEUROSCI.2675-04.2004; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Lin X, 1999, NEURON, V24, P499, DOI 10.1016/S0896-6273(00)81104-6; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Wang GH, 1999, NEUROREPORT, V10, P2435, DOI 10.1097/00001756-199908200-00001; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Yu ZF, 2000, J MOL NEUROSCI, V15, P31, DOI 10.1385/JMN:15:1:31; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	41	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37017	37024		10.1074/jbc.M608095200	http://dx.doi.org/10.1074/jbc.M608095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028181	hybrid			2022-12-25	WOS:000242220800063
J	Wei, BQQ; Mikkelsen, TS; McKinney, MK; Lander, ES; Cravatt, BF				Wei, Binqing Q.; Mikkelsen, Tarjei S.; McKinney, Michele K.; Lander, Eric S.; Cravatt, Benjamin F.			A second fatty acid amide hydrolase with variable distribution among placental mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; REVERSIBLE INHIBITORS; BRAIN CONSTITUENT; HYPNOTIC ACTIONS; CATALYTIC TRIAD; OLEAMIDE; ENZYME; ANANDAMIDE; SERINE; MICE	Fatty acid amides constitute a large and diverse class of lipid transmitters that includes the endogenous cannabinoid anandamide and the sleep-inducing substance oleamide. The magnitude and duration of fatty acid amide signaling are controlled by enzymatic hydrolysis in vivo. Fatty acid amide hydrolase (FAAH) activity in mammals has been primarily attributed to a single integral membrane enzyme of the amidase signature (AS) family. Here, we report the functional proteomic discovery of a second membrane-associated AS enzyme in humans that displays FAAH activity. The gene that encodes this second FAAH enzyme was found in multiple primate genomes, marsupials, and more distantly related vertebrates, but, remarkably, not in a number of lower placental mammals, including mouse and rat. The two human FAAH enzymes, which share 20% sequence identity and are referred to hereafter as FAAH-1 and FAAH-2, hydrolyzed primary fatty acid amide substrates (e. g. oleamide) at equivalent rates, whereas FAAH-1 exhibited much greater activity with N-acyl ethanolamines (e. g. anandamide) and N-acyl taurines. Both enzymes were sensitive to the principal classes of FAAH inhibitors synthesized to date, including O-aryl carbamates and alpha-keto heterocycles. These data coupled with the overlapping, but distinct tissue distributions of FAAH-1 and FAAH-2 suggest that these proteins may collaborate to control fatty acid amide catabolism in primates. The apparent loss of the FAAH-2 gene in some lower mammals should be taken into consideration when extrapolating genetic or pharmacological findings on the fatty acid amide signaling system across species.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; MIT, Broad Inst, Cambridge, MA 02142 USA; Harvard Univ, Cambridge, MA 02142 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cravatt@scripps.edu	Mikkelsen, Tarjei S/A-1306-2007	Mikkelsen, Tarjei S/0000-0002-8133-3135	NATIONAL CANCER INSTITUTE [R01CA087660, R37CA087660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA017259, R01DA015197] Funding Source: NIH RePORTER; NCI NIH HHS [CA087660, R01 CA087660, R01 CA087660-06] Funding Source: Medline; NIDA NIH HHS [P01 DA017259, R01 DA015197, DA015197, P01 DA017259-03, R01 DA015197-04, DA017259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Alexander JP, 2005, CHEM BIOL, V12, P1179, DOI 10.1016/j.chembiol.2005.08.011; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Basile AS, 1999, NEUROREPORT, V10, P947, DOI 10.1097/00001756-199904060-00010; Batkai S, 2004, CIRCULATION, V110, P1996, DOI 10.1161/01.CIR.0000143230.23252.D2; Boger DL, 2000, P NATL ACAD SCI USA, V97, P5044, DOI 10.1073/pnas.97.10.5044; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Deutsch DG, 2002, PROSTAG LEUKOTR ESS, V66, P201, DOI 10.1054/plef.2001.0358; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; Holt S, 2005, BRIT J PHARMACOL, V146, P467, DOI 10.1038/sj.bjp.0706348; Huang SM, 2001, J BIOL CHEM, V276, P42639, DOI 10.1074/jbc.M107351200; Jessani N, 2005, NAT METHODS, V2, P691, DOI 10.1038/NMETH778; Jessani N, 2005, ANGEW CHEM INT EDIT, V44, P2400, DOI 10.1002/anie.200463098; Jessani N, 2002, P NATL ACAD SCI USA, V99, P10335, DOI 10.1073/pnas.162187599; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Laposky AD, 2001, NEUROREPORT, V12, P4143, DOI 10.1097/00001756-200112210-00056; Lees G, 1998, BRIT J PHARMACOL, V124, P873, DOI 10.1038/sj.bjp.0701918; Leggett JD, 2004, BRIT J PHARMACOL, V141, P253, DOI 10.1038/sj.bjp.0705607; Leung D, 2003, NAT BIOTECHNOL, V21, P687, DOI 10.1038/nbt826; Lichtman AH, 2004, PAIN, V109, P319, DOI 10.1016/j.pain.2004.01.022; Lichtman AH, 2004, J PHARMACOL EXP THER, V311, P441, DOI 10.1124/jpet.104.069401; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; McKinney MK, 2005, ANNU REV BIOCHEM, V74, P411, DOI 10.1146/annurev.biochem.74.082803.133450; McKinney MK, 2003, J BIOL CHEM, V278, P37393, DOI 10.1074/jbc.M303922200; Mendelson WB, 1999, NEUROREPORT, V10, P3237, DOI 10.1097/00001756-199910190-00021; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; Murphy WJ, 2004, TRENDS GENET, V20, P631, DOI 10.1016/j.tig.2004.09.005; Patricelli MP, 1998, BIOCHEMISTRY-US, V37, P15177, DOI 10.1021/bi981733n; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Ross MT, 2005, NATURE, V434, P325, DOI 10.1038/nature03440; Saghatelian A, 2004, BIOCHEMISTRY-US, V43, P14332, DOI 10.1021/bi0480335; Saghatelian A, 2006, BIOCHEMISTRY-US, V45, P9007, DOI 10.1021/bi0608008; Shin S, 2003, J BIOL CHEM, V278, P24937, DOI 10.1074/jbc.M302156200; Sun YX, 2005, BBA-MOL CELL BIOL L, V1736, P211, DOI 10.1016/j.bbalip.2005.08.010; Thomas EA, 1997, P NATL ACAD SCI USA, V94, P14115, DOI 10.1073/pnas.94.25.14115; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuboi K, 2005, J BIOL CHEM, V280, P11082, DOI 10.1074/jbc.M413473200; Varvel SA, 2006, J PHARMACOL EXP THER, V317, P251, DOI 10.1124/jpet.105.095059; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Yost CS, 1998, ANESTH ANALG, V86, P1294, DOI 10.1097/00000539-199806000-00031	50	258	276	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36569	36578		10.1074/jbc.M606646200	http://dx.doi.org/10.1074/jbc.M606646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17015445	hybrid			2022-12-25	WOS:000242220800013
J	Young, SRL; Mumaw, C; Marrs, JA; Skalnik, DG				Young, Suzanne R. L.; Mumaw, Christen; Marrs, James A.; Skalnik, David G.			Antisense targeting of CXXC finger protein 1 inhibits genomic cytosine methylation and primitive hematopoiesis in zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING-PROTEIN; ACUTE MYELOID-LEUKEMIA; EMBRYONIC STEM-CELLS; DNA METHYLATION; HISTONE METHYLTRANSFERASE; PHD FINGER; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-TRITHORAX; ERYTHROID-CELLS	CXXC finger protein 1 (CFP1) binds to unmethylated CpG dinucleotides and is a component of the Set1 histone methyltransferase complex. Mice lacking CFP1 suffer a peri-implantation lethal phenotype, and CFP1-deficient embryonic stem cells are viable but unable to differentiate and exhibit a 60-80% decrease in genomic cytosine methylation. A zebrafish homolog of CFP1 has been identified, is similar to 70% similar to murine CFP1, and is widely expressed during development. Zebrafish embryos treated with a zCFP1 antisense morpholino oligonucleotide had little or no circulating red blood cells and exhibited abnormal yolk sac morphology at 48 h post-fertilization. Many of the antisense-treated zebrafish also exhibited cardiac edema, and 14% were dead at 24 h post-fertilization. Morphant zebrafish also exhibited elevated levels of apoptosis, particularly in the intermediate cell mass, the site of primitive erythropoiesis, as well as aberrations in vascular development. Genomic DNA isolated from morphant embryos exhibited a 60% reduction of global genomic cytosine methylation. A similar phenotype was observed with an independent zCFP1 antisense morpholino oligonucleotide, but not following injection of an unrelated control oligonucleotide. The morphant phenotype was rescued when mRNA encoding murine CFP1 was co-injected with the antisense oligonucleotide. Genomic data base analysis reveals the presence of a second version of zebrafish CFP1 (zCFP1b). However, the morphant phenotype observed following specific depletion of zCFP1 indicates that these related genes have nonredundant functions controlling normal zebrafish hematopoiesis and epigenetic regulation. These findings establish the importance of CFP1 during post-gastrulation development.	Indiana Univ, Sch Med, Sect Pediat Hematol Oncol, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat & Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Indiana Univ, Sch Med, Sect Pediat Hematol Oncol, Herman B Wells Ctr Pediat Res, Canc Res Bldg,Rm W327,1044 W Walnut St, Indianapolis, IN 46202 USA.	dskalnik@iupui.edu			NCRR NIH HHS [P40 RR12546] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012546] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Amaravadi L, 1999, DNA CELL BIOL, V18, P875, DOI 10.1089/104454999314737; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Ayton P, 2001, GENESIS, V30, P201, DOI 10.1002/gene.1066; Babb SG, 2004, DEV DYNAM, V230, P263, DOI 10.1002/dvdy.20057; BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002; Carlone DL, 2002, GENE, V295, P71, DOI 10.1016/S0378-1119(02)00820-X; Carlone DL, 2001, MOL CELL BIOL, V21, P7601, DOI 10.1128/MCB.21.22.7601-7606.2001; Carlone DL, 2005, MOL CELL BIOL, V25, P4881, DOI 10.1128/MCB.25.12.4881-4891.2005; Collas P, 1998, NUCLEIC ACIDS RES, V26, P4454, DOI 10.1093/nar/26.19.4454; Collas P, 1999, J CELL SCI, V112, P1045; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Davidson AJ, 2004, ONCOGENE, V23, P7233, DOI 10.1038/sj.onc.1207943; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; DORNER PH, 1993, P NATL ACAD SCI USA, V90, P7884; Ekker M, 1997, MOL BIOL EVOL, V14, P1008, DOI 10.1093/oxfordjournals.molbev.a025707; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; FLAMME I, 1992, DEVELOPMENT, V116, P435; Force A, 1999, GENETICS, V151, P1531; Fujino T, 2000, BIOCHEM BIOPH RES CO, V271, P305, DOI 10.1006/bbrc.2000.2614; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GONZANI O, 2003, CELL, V114, P99; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guo SX, 2000, LEUKEMIA RES, V24, P39, DOI 10.1016/S0145-2126(99)00158-7; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hennessy BT, 2003, EXPERT OPIN INV DRUG, V12, P1985, DOI 10.1517/eoid.12.12.1985.21990; Issa JPJ, 1997, CANCER RES, V57, P1678; Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kao WY, 1997, J CELL BIOCHEM, V65, P231, DOI 10.1002/(SICI)1097-4644(199705)65:2<231::AID-JCB8>3.0.CO;2-V; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200; Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250; Lee JH, 2002, J BIOL CHEM, V277, P42259, DOI 10.1074/jbc.M205054200; Lee KH, 1996, DEV BIOL, V180, P722, DOI 10.1006/dbio.1996.0341; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liao EC, 2002, DEVELOPMENT, V129, P649; Litz CE, 1998, LEUKEMIA LYMPHOMA, V30, P1; Liu Q, 1999, J COMP NEUROL, V410, P290, DOI 10.1002/(SICI)1096-9861(19990726)410:2<290::AID-CNE10>3.0.CO;2-S; Lubbert M, 1997, LEUKEMIA, V11, pS12; Lyons John, 2003, Curr Opin Investig Drugs, V4, P1442; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Martin CC, 1999, DEV BIOL, V206, P189, DOI 10.1006/dbio.1998.9105; Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401; Mhanni AA, 2004, DEV GENES EVOL, V214, P412, DOI 10.1007/s00427-004-0418-0; Mhanni AA, 2001, GENESIS, V30, P213, DOI 10.1002/gene.1067; Milhem M, 2004, BLOOD, V103, P4102, DOI 10.1182/blood-2003-07-2431; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; MONK M, 1987, DEVELOPMENT, V99, P371; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; O'Connell S, 2001, J BIOL CHEM, V276, P43065, DOI 10.1074/jbc.M104294200; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ono R, 2002, CANCER RES, V62, P4075; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Pillai R, 2004, DEV DYNAM, V231, P647, DOI 10.1002/dvdy.20168; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; TAHOH H, 2004, BLOOD, V103, P2950; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Van de Peer Y, 2002, NUCLEIC ACIDS RES, V30, P109, DOI 10.1093/nar/30.1.109; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Westerfield M, 2000, ZEBRAFISH BOOK GUIDE; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Yamakoshi K, 2003, GENESIS, V37, P195, DOI 10.1002/gene.10245; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	86	20	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37034	37044		10.1074/jbc.M604546200	http://dx.doi.org/10.1074/jbc.M604546200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023431	hybrid			2022-12-25	WOS:000242220800065
J	Shinmura, K; Bennett, RA; Tarapore, P; Fukasawa, K				Shinmura, K.; Bennett, R. A.; Tarapore, P.; Fukasawa, K.			Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication	ONCOGENE			English	Article						p53; centrosome; centrosome duplication	CYCLIN-E OVEREXPRESSION; NUCLEAR EXPORT SIGNAL; CHROMOSOME INSTABILITY; AMPLIFICATION; CELLS; P21; SUPPRESSION; INHIBITOR; INDUCTION; MUTANTS	Abnormal amplification of centrosomes is the major cause of mitotic defects and chromosome instability in cancer cells. Centrosomes duplicate once in each cell cycle, and abrogation of the regulatory mechanism underlying centrosome duplication leads to centrosome amplification. p53 tumor suppressor protein is involved in the regulation of centrosome duplication: loss of p53 as well as expression of certain p53 mutants result in deregulated centrosome duplication and centrosome amplification. p53 at least in part depends on its transactivation function to control centrosome duplication, primarily via upregulation of p21 cyclin-dependent kinase (CDK) inhibitor, which prevents untimely activation of CDK2/cyclin E, a key initiator of centrosome duplication. However, numerous studies have shown the presence of p53 at centrosomes, yet the role of the centrosomally localized p53 in the regulation of centrosome duplication had been enigmatic. Here, we comparatively examined wild-type p53 and p53 mutants that are transactivation(+)/centrosome-binding(-), transactivation(-)/centrosome-binding(+) and transactivation(-)/centrosome-binding(+) for their abilities to control centrosome duplication. We found that the transactivation(+)/centrosome-binding(-) and transactivation(-)/centrosome-binding(+) mutants suppress centrosome duplication only partially compared with wild-type p53. Moreover, the transactivation(-)/centrosome-binding(-) mutant almost completely lost the ability to suppress centrosome duplication. These observations provide direct evidence for the centrosomally localized p53 to participate in the regulation of centrosome duplication in a manner independent of its transactivation function in addition to its transactivation-dependent regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	Kenji.Fukasawa@uc.edu	Shinmura, Kazuya/K-8940-2012; Tarapore, Pheruza/A-8876-2013	Shinmura, Kazuya/0000-0003-4963-746X; Tarapore, Pheruza/0000-0003-0911-3661	NATIONAL CANCER INSTITUTE [R01CA095925, R01CA090522] Funding Source: NIH RePORTER; NCI NIH HHS [CA95925, CA90522] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Kaul SC, 2001, NEOPLASIA, V3, P110, DOI 10.1038/sj.neo.7900139; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Ma Z, 2006, ONCOGENE, V25, P5377, DOI 10.1038/sj.onc.1209543; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Oakley BR, 2000, CURR TOP DEV BIOL, V49, P27; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shinmura K, 2005, FEBS LETT, V579, P6621, DOI 10.1016/j.febslet.2005.10.057; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	35	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2939	2944		10.1038/sj.onc.1210085	http://dx.doi.org/10.1038/sj.onc.1210085			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072342				2022-12-25	WOS:000246210800013
J	Oyama, K; Okawa, T; Nakagawa, H; Takaoka, M; Andl, CD; Kim, SH; Klein-Szanto, A; Diehl, JA; Herlyn, M; El-Deiry, W; Rustgi, AK				Oyama, K.; Okawa, T.; Nakagawa, H.; Takaoka, M.; Andl, C. D.; Kim, S-H; Klein-Szanto, A.; Diehl, J. A.; Herlyn, M.; El-Deiry, W.; Rustgi, A. K.			AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture	ONCOGENE			English	Article						AKT; EGFR; proliferation; differentiation; organotypic culture	SIGNALING PATHWAY; IN-VITRO; KINASE-B; GROWTH; KERATINOCYTES; ACTIVATION; ARCHITECTURE; CARCINOMA; CANCER; PROLIFERATION	Epidermal growth factor receptor (EGFR) overexpression and activation is critical in the initiation and progression of cancers, especially those of epithelial origin. EGFR activation is associated with the induction of divergent signal transduction pathways and a gamut of cellular processes; however, the cell-type and tissue-type specificity conferred by certain pathways remains to be elucidated. In the context of the esophageal epithelium, a prototype stratified squamous epithelium, EGFR overexpression is relevant in the earliest events of carcinogenesis as modeled in a three-dimensional organotypic culture system. We demonstrate that the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, and not the MEK/MAPK (mitogen-activated protein kinase) pathway, is preferentially activated in EGFR-mediated esophageal epithelial hyperplasia, a premalignant lesion. The hyperplasia was abolished with direct inhibition of PI3K and of AKT but not with inhibition of the MAPK pathway. With the introduction of an inducible AKT vector in both primary and immortalized esophageal epithelial cells, we find that AKT overexpression and activation is permissive for complete epithelial formation in organotypic culture, but imposes a growth constraint in cells grown in monolayer. In organotypic culture, AKT mediates changes related to cell shape and size with an expansion of the differentiated compartment.	Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Med, Villanova, PA 19085 USA; Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Genet, Villanova, PA 19085 USA; Univ Penn, Div Hematol Oncol, Villanova, PA 19085 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Fox Chase Cancer Center; The Wistar Institute; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Med, 600 CRB,415 Curie Blvd, Villanova, PA 19085 USA.	anil2@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020; Klein-Szanto, A./E-6218-2010	El-Deiry, Wafik/0000-0002-9577-8266; 	NCI NIH HHS [F32 CA108657, P01 CA025874, CA 80999, CA 25874, F32-CA108657, R01 CA080999] Funding Source: Medline; NIDCR NIH HHS [P01 DE12467, P01 DE012467] Funding Source: Medline; NIDDK NIH HHS [P30 DK050306, P30 DK50306, K01 DK066205, K01 DK075379, K01-DK0662059, K01 DK075379-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080999, P01CA025874, F32CA108657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK066205, P30DK050306, K01DK075379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Harada H, 2003, MOL CANCER RES, V1, P729; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; ITOIZ ME, 1985, AM J PATHOL, V119, P456; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Kamei T, 2002, MOL ENDOCRINOL, V16, P1469, DOI 10.1210/me.16.7.1469; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim YT, 2002, GYNECOL ONCOL, V87, P84, DOI 10.1006/gyno.2002.6803; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Li WJ, 2005, J BIOL CHEM, V280, P6036, DOI 10.1074/jbc.M406546200; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; MURPHY GF, 2005, LEVERS HISTOPATHOLOG, P13; Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Okano Jun-ichi, 2003, Methods Mol Biol, V222, P131; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Zahir N, 2004, CURR OPIN GENET DEV, V14, P71, DOI 10.1016/j.gde.2003.12.005	33	42	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2353	2364		10.1038/sj.onc.1210025	http://dx.doi.org/10.1038/sj.onc.1210025			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043653	Green Accepted			2022-12-25	WOS:000245466000011
J	Simon, V; Guidry, J; Gettys, TW; Tobin, AB; Lanier, SM				Simon, Violaine; Guidry, Jessie; Gettys, Thomas W.; Tobin, Andrew B.; Lanier, Stephen M.			The proto-oncogene SET interacts with muscarinic receptors and attenuates receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; 3RD INTRACELLULAR LOOP; ACETYLCHOLINE-RECEPTOR; ALPHA(2)-ADRENERGIC RECEPTORS; IDENTIFICATION; PHOSPHORYLATION; ACTIVATION; RESENSITIZATION; SEQUESTRATION; SPECIFICITY	G protein-coupled receptors mediate cell responses to extracellular stimuli and likely function in the context of a larger signal transduction complex. Utilizing the third intracellular loop of a G protein-coupled receptor in glutathione S-transferase pulldown assays from rat brain lysates coupled with high sensitivity detection methods and subsequent functional studies, we report the identification of SET as a regulator of muscarinic receptor signaling. SET is a putative oncogene reported to inhibit protein phosphatase 2A and regulate gene transcription. SET binds the carboxyl region of the M3-muscarinic receptor i3 loop, and endogenous SET co-immunoprecipitates with intact M3 muscarinic receptor expressed in cells. Small interfering RNA knockdown of endogenous SET in Chinese hamster ovary cells stably expressing the M3 muscarinic receptor augmented receptor-mediated mobilization of intracellular calcium by similar to 35% with no change in agonist EC50, indicating that interaction of SET with the M3 muscarinic receptor reduces its signaling capacity. SET knockdown had no effect on the mobilization of intracellular calcium by the P2-purinergic receptor, ionomycin, or a direct activator of phospholipase C, indicating a specific regulation of M3 muscarinic receptor signaling. These data provide expanded functionality for SET and a previously unrecognized mechanism for regulation of GPCR signaling capacity.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Pennington Biomed Res Ctr, Div Expt Obes, Baton Rouge, LA 70808 USA; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Leicester	Simon, V (corresponding author), Med Univ S Carolina, Dept Pharmacol, 171 Ashley Ave, Charleston, SC 29425 USA.		Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995; simon, violaine/0000-0002-4417-127X; Guidry, Jessie/0000-0002-5601-0430; Lanier, Stephen/0000-0002-2740-7607	NCRR NIH HHS [P20 RR018766, P20 RR021945] Funding Source: Medline; NIDDK NIH HHS [R01 DK074772, DK074772, R01 DK074772-01A1, P30 DK072476] Funding Source: Medline; NIGMS NIH HHS [P30 GM118430] Funding Source: Medline; NIMH NIH HHS [MH90531] Funding Source: Medline; NINDS NIH HHS [R01 NS024821, NS24821] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021945, P20RR018766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476, R01DK074772] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM118430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024821, R01NS024821] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; Bae YS, 2003, MOL PHARMACOL, V63, P1043, DOI 10.1124/mol.63.5.1043; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Heggem MA, 2003, DEV CELL, V4, P419, DOI 10.1016/S1534-5807(03)00036-4; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Lee DK, 2004, J BIOL CHEM, V279, P7901, DOI 10.1074/jbc.M306377200; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lucas JL, 2006, PHARM RES-DORDR, V23, P647, DOI 10.1007/s11095-006-9784-9; Madeira A, 2005, FASEB J, V19, P1905, DOI 10.1096/fj.05-3839fje; Mao LM, 2005, J BIOL CHEM, V280, P12602, DOI 10.1074/jbc.M411709200; Matsumoto K, 1999, MOL CELL BIOL, V19, P6940; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Sato M, 2006, ANNU REV PHARMACOL, V46, P151, DOI 10.1146/annurev.pharmtox.46.120604.141115; Schmidt C, 2003, J BIOL CHEM, V278, P30248, DOI 10.1074/jbc.M304991200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	36	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40310	40320		10.1074/jbc.M603858200	http://dx.doi.org/10.1074/jbc.M603858200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17065150	Green Accepted, hybrid			2022-12-25	WOS:000243033900062
J	Hibbs, RE; Radic, Z; Taylor, P; Johnson, DA				Hibbs, Ryan E.; Radic, Zoran; Taylor, Palmer; Johnson, David A.			Influence of agonists and antagonists on the segmental motion of residues near the agonist binding pocket of the acetylcholine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; NICOTINIC RECEPTORS; EXTRACELLULAR DOMAIN; NANOSECOND DYNAMICS; CATALYTIC-SUBUNIT; MASS-SPECTROMETRY; REVEALS; ACHBP; LOOP	Using the Lymnaea acetylcholine-binding protein as a surrogate of the extracellular domain of the nicotinic receptor, we combined site-directed labeling with fluorescence spectroscopy to assess possible linkages between ligand binding and conformational dynamics. Specifically, 2-[(5-fluoresceinyl)aminocarbonyl]ethyl methanethiosulfonate was conjugated to a free cysteine on loop C and to five substituted cysteines at strategic locations in the subunit sequence, and the backbone flexibility around each site of conjugation was measured with time-resolved fluorescence anisotropy. The sites examined were in loop C (Cys-188 using a C187S mutant), in the beta 9 strand (T177C), in the beta 10 strand (D194C), in the beta 8-beta 9 loop (N158C and Y164C), and in the beta 7 strand (K139C). Conjugated fluorophores at these locations show distinctive anisotropy decay patterns indicating different degrees of segmental fluctuations near the agonist binding pocket. Ligand occupation and decay of anisotropy were assessed for one agonist (epibatidine) and two antagonists (alpha-bungarotoxin and d-tubocurarine). The Y164C and Cys-188 conjugates were also investigated with additional agonists (nicotine and carbamylcholine), partial agonists (lobeline and 4-hydroxy,2-methoxy-benzylidene anabaseine), and an antagonist (methyllycaconitine). With the exception of the T177C conjugate, both agonists and antagonists perturbed the backbone flexibility of each site; however, agonist-selective changes were only observed at Y164C in loop F where the agonists and partial agonists increased the range and/or rate of the fast anisotropy decay processes. The results reveal that agonists and antagonists produced distinctive changes in the flexibility of a portion of loop F.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Res Program, La Jolla, CA 92093 USA	University of California System; University of California Riverside; University of California System; University of California San Diego; University of California System; University of California San Diego	Johnson, DA (corresponding author), Univ Calif Riverside, Div Biomed Sci, B605 Stat Rd, Riverside, CA 92521 USA.	david.johnson@ucr.edu			NIGMS NIH HHS [R37-GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTELS E, 1970, BIOCHIM BIOPHYS ACTA, V203, P568, DOI 10.1016/0005-2736(70)90193-8; BIRCH DJS, 1991, TOPICS FLUORESCENCE, V1, P1; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Boyd AE, 2004, J BIOL CHEM, V279, P26612, DOI 10.1074/jbc.M401482200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Celie PHN, 2005, NAT STRUCT MOL BIOL, V12, P582, DOI 10.1038/nsmb951; Celie PHN, 2005, J BIOL CHEM, V280, P26457, DOI 10.1074/jbc.M414476200; Chakrapani S, 2003, J GEN PHYSIOL, V122, P521, DOI 10.1085/jgp.200308885; Chakrapani S, 2004, J GEN PHYSIOL, V123, P341, DOI 10.1085/jgp.200309004; CHANGEUX JP, 2005, NICOTINIC ACETYLCHOL, P51; Daly JW, 2005, CELL MOL NEUROBIOL, V25, P513, DOI 10.1007/s10571-005-3968-4; DAMLE VN, 1980, BIOCHEMISTRY-US, V19, P3924, DOI 10.1021/bi00558a006; Gangal M, 1998, BIOCHEMISTRY-US, V37, P13728, DOI 10.1021/bi980560z; Gao F, 2006, MOL PHARMACOL, V70, P1230, DOI 10.1124/mol.106.027185; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hansen SB, 2002, J BIOL CHEM, V277, P41299, DOI 10.1074/jbc.C200462200; Hansen SB, 2004, J BIOL CHEM, V279, P24197, DOI 10.1074/jbc.M402452200; Henchman RH, 2005, BIOPHYS J, V88, P2564, DOI 10.1529/biophysj.104.053934; Hibbs RE, 2005, BIOCHEMISTRY-US, V44, P16602, DOI 10.1021/bi051735p; Hibbs RE, 2004, J BIOL CHEM, V279, P28483, DOI 10.1074/jbc.M403713200; JOHNSON DA, 1984, J BIOL CHEM, V259, P5717; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Leite JF, 2003, P NATL ACAD SCI USA, V100, P13054, DOI 10.1073/pnas.2133028100; Li F, 2000, BIOCHEMISTRY-US, V39, P15626, DOI 10.1021/bi002196l; Lyford LK, 2003, MOL PHARMACOL, V64, P650, DOI 10.1124/mol.64.3.650; Meyer EM, 1998, J PHARMACOL EXP THER, V287, P918; Mitra A, 2005, P NATL ACAD SCI USA, V102, P15069, DOI 10.1073/pnas.0505090102; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; Rodrigues-Pinguet N, 2003, J PHYSIOL-LONDON, V550, P11, DOI 10.1113/jphysiol.2003.036681; Schroder GF, 2005, BIOPHYS J, V89, P3757, DOI 10.1529/biophysj.105.069500; Shi JX, 2006, J BIOL CHEM, V281, P12170, DOI 10.1074/jbc.M600154200; Shi JX, 2003, J BIOL CHEM, V278, P30905, DOI 10.1074/jbc.M303730200; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sine SM, 2006, NATURE, V440, P448, DOI 10.1038/nature04708; Thompson AJ, 2006, J BIOL CHEM, V281, P16576, DOI 10.1074/jbc.M601265200; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9	39	30	30	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39708	39718		10.1074/jbc.M604752200	http://dx.doi.org/10.1074/jbc.M604752200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17068341	hybrid			2022-12-25	WOS:000242898700078
J	Gong, NL; Bodi, I; Zobel, C; Schwartz, A; Molkentin, JD; Backx, PH				Gong, Nanling; Bodi, Ilona; Zobel, Carsten; Schwartz, Arnold; Molkentin, Jeffery D.; Backx, Peter H.			Calcineurin increases cardiac transient outward K+ currents via transcriptional up-regulation of Kv4.2 channel subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; ACTIVATED T-CELLS; GENE-EXPRESSION; I-TO; TARGETED INHIBITION; DOWN-REGULATION; ANGIOTENSIN-II; NUCLEAR FACTOR; CA2+ INFLUX; LONG QT	Fast transient outward potassium currents (I-to,I- f) are critical determinants of regional heterogeneity of cardiomyocyte repolarization as well as cardiomyocyte contractility. Additionally, I-to,I- f densities are markedly down-regulated in cardiac hypertrophy and heart disease, conditions associated with activation of the serine/threonine phosphatase calcineurin (Cn). In this study, we investigated the regulation of I-to,I- f expression by Cn in cultured neonatal rat ventricular myocytes (NRVMs) with and without alpha(1)-adrenoreceptor stimulation with phenylephrine ( PE). Overexpression of constitutively active Cn in NRVMs induced hypertrophy and caused profound increases in I-to,I- f density as well as Kv4.2 mRNA and protein expression and promoter activity, without affecting Kv4.3 or KChIP2 levels. The effects of Cn on hypertrophy, I-to,I- f, and Kv4.2 transcription were associated with NFAT activation and were abrogated by NFAT inhibition. Despite activating Cn and inducing hypertrophy in NRVMs, PE resulted in profound down-regulation of I-to,I- f densities as well as Kv4.2, Kv4.3, and KChIP2 expression. Although hypertrophy and NFAT activation were inhibited by the Cn inhibitory peptide CAIN, I-to,I- f and Kv4.2 expression were further reduced by CAIN, whereas Cn overexpression eliminated PE-induced reductions in I-to,I- f and Kv4.2 expression without affecting Kv4.3 or KChIP2 levels. We conclude that Cn increases cardiac I-to,I- f densities by positively regulating Kv4.2 gene transcription. Consistent with this conclusion, we found that I-to,I- f was increased in myocytes isolated from young mice overexpressing Cn prior to the development of heart disease. This positive regulation of Kv4.2 transcription by Cn activation is expected to minimize the reductions in Ito, f and Kv4.2 expression observed in hypertrophic cardiomyocytes.	Heart & Stroke Richard Lewar Ctr Excellence, Dept Physiol, Toronto, ON M5S 3E2, Canada; Heart & Stroke Richard Lewar Ctr Excellence, Dept Med, Toronto, ON M5S 3E2, Canada; Univ Toronto, Hlth Network, Div Cardiol, Toronto, ON M5S 3E2, Canada; Univ Cincinnati, Coll Med, Dept Surg, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Univ Cologne, Dept Internal Med 3, D-50924 Cologne, Germany; Univ Cincinnati, Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University System of Ohio; University of Cincinnati; University of Cologne; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Backx, PH (corresponding author), Heart & Stroke Richard Lewar Ctr Excellence, Dept Physiol, Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	p.backx@utoronto.ca		Molkentin, Jeffery/0000-0002-3558-6529				Antzelevitch C, 2006, J INTERN MED, V259, P48, DOI 10.1111/j.1365-2796.2005.01587.x; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Caballero R, 2004, CARDIOVASC RES, V62, P86, DOI 10.1016/j.cardiores.2003.12.029; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; DAVIS LG, 1986, BASIC METHODS MOL BI, P47; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Diedrichs H, 2004, EUR J HEART FAIL, V6, P3, DOI 10.1016/j.ejheart.2003.07.007; Dong D, 2003, CARDIOVASC RES, V57, P320, DOI 10.1016/S0008-6363(02)00661-2; Eghbali M, 2005, CIRC RES, V96, P1208, DOI 10.1161/01.RES.0000170652.71414.16; Gaborit N, 2005, CIRCULATION, V112, P471, DOI 10.1161/CIRCULATIONAHA.104.506857; Gaughan JP, 1998, AM J PHYSIOL-HEART C, V275, pH577, DOI 10.1152/ajpheart.1998.275.2.H577; Guo WN, 2002, CIRC RES, V90, P586, DOI 10.1161/01.RES.0000012664.05949.E0; Guo WN, 2000, CIRC RES, V87, P73, DOI 10.1161/01.RES.87.1.73; Im SH, 2004, MOL CELLS, V18, P1; Jia Y, 2006, CIRC RES, V98, P386, DOI 10.1161/01.RES.0000201956.86258.e1; Jia Y, 2003, CARDIOVASC RES, V60, P278, DOI 10.1016/S0008-6363(03)00528-5; Kaprielian R, 2002, AM J PHYSIOL-HEART C, V283, pH1157, DOI 10.1152/ajpheart.00518.2001; Kaprielian R, 1999, J PHYSIOL-LONDON, V517, P229, DOI 10.1111/j.1469-7793.1999.0229z.x; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Lebeche D, 2004, CIRCULATION, V110, P3435, DOI 10.1161/01.CIR.0000148176.33730.3F; Meszaros J, 1996, AM J PHYSIOL-HEART C, V271, pH2360, DOI 10.1152/ajpheart.1996.271.6.H2360; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; Murat A, 2000, J BIOL CHEM, V275, P40867, DOI 10.1074/jbc.M008071200; Nattel S, 2000, ANNU REV PHYSIOL, V62, P51, DOI 10.1146/annurev.physiol.62.1.51; Oudit GY, 2001, J MOL CELL CARDIOL, V33, P851, DOI 10.1006/jmcc.2001.1376; Perrier E, 2004, J BIOL CHEM, V279, P40634, DOI 10.1074/jbc.M407470200; Petrashevskaya NN, 2002, CARDIOVASC RES, V54, P117, DOI 10.1016/S0008-6363(02)00241-9; Piascik MT, 2001, J PHARMACOL EXP THER, V298, P403; POTREAU D, 1995, CARDIOVASC RES, V30, P440, DOI 10.1016/0008-6363(95)00073-9; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Rose J, 2005, AM J PHYSIOL-HEART C, V288, pH2077, DOI 10.1152/ajpheart.00526.2003; Rossow CF, 2004, CIRC RES, V94, P1340, DOI 10.1161/01.RES.0000128406.08418.34; Rossow CF, 2006, CIRC RES, V98, P1306, DOI 10.1161/01.RES.0000222028.92993.10; Sah R, 2003, J PHYSIOL-LONDON, V546, P5, DOI 10.1113/jphysiol.2002.026468; Sah R, 2002, CIRCULATION, V105, P1850, DOI 10.1161/01.CIR.0000014211.47830.4D; Shimizu W, 2005, CURR PHARM DESIGN, V11, P1561, DOI 10.2174/1381612053764823; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; van Rooij E, 2004, CIRC RES, V94, pE18, DOI 10.1161/01.RES.0000118597.54416.00; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Volk T, 1999, J PHYSIOL-LONDON, V519, P841, DOI 10.1111/j.1469-7793.1999.0841n.x; Wickenden AD, 1999, CIRC RES, V85, P1067; Wickenden AD, 1997, J PHYSIOL-LONDON, V504, P271, DOI 10.1111/j.1469-7793.1997.271be.x; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Xu J, 2006, J BIOL CHEM, V281, P9152, DOI 10.1074/jbc.M510217200; Zhan S, 2002, CIRCULATION, V106, P283; Zhang TT, 2001, CIRC RES, V88, P476, DOI 10.1161/01.RES.88.5.476; Zicha S, 2004, J PHYSIOL-LONDON, V561, P735, DOI 10.1113/jphysiol.2004.075861; Zobel C, 2002, CIRCULATION, V106, P2385, DOI 10.1161/01.CIR.0000033970.22130.93	53	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38498	38506		10.1074/jbc.M607774200	http://dx.doi.org/10.1074/jbc.M607774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17060317	hybrid			2022-12-25	WOS:000242709500044
J	Qi, Q; Sahu, N; August, A				Qi, Qian; Sahu, Nisebita; August, Avery			Tec kinase Itk forms membrane clusters specifically in the vicinity of recruiting receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; T-CELL RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ALLERGIC-ASTHMA; FAMILY KINASES; CYCLOPHILIN-A; CROSS-LINKING; MICE LACKING; ACTIVATION	The Tec family of tyrosine kinases transduces signals from antigen and other receptors in cells of the hematopoietic system. In particular, interleukin-2 inducible T cell kinase (Itk) plays an important role in modulating T cell development and activation. Itk is activated by receptors via a phosphatidylinositol 3-kinase-mediated pathway, which results in recruitment of Itk to the plasma membrane via its pleckstrin homology domain. We show here that membrane localization of Itk results in the formation of clusters of at least two molecules within 80 A of each other, which is dependent on the integrity of its pleckstrin homology domain. By contrast, the proline-rich region within the Tec homology domain, SH3 or SH2 domains, or kinase activity were not required for this event. More importantly, these clusters of Itk molecules form in distinct regions of the plasma membrane as only receptors that recruit phosphatidylinositol 3-kinase reside in the same membrane vicinity as the recruited Itk. Our results indicate that Itk forms dimers in the membrane and that receptors that recruit Itk do so to specific membrane regions.	Penn State Univ, Ctr Mol Immunol & Infect Dis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; Penn State Univ, Immunol & Infect Dis Grad Program, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	August, A (corresponding author), Penn State Univ, Ctr Mol Immunol & Infect Dis, Dept Vet & Biomed Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	axa45@psu.edu	Qi, Qian/E-7454-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065566, R01AI051626, R56AI065566] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI051626, R01 AI065566, AI 51626, AI 065566, R01 AI051626-03, R01 AI065566-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Au-Yeung BB, 2006, J IMMUNOL, V176, P3895, DOI 10.4049/jimmunol.176.7.3895; August A, 2002, INT J BIOCHEM CELL B, V34, P1184, DOI 10.1016/S1357-2725(02)00068-7; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Berg LJ, 2005, ANNU REV IMMUNOL, V23, P549, DOI 10.1146/annurev.immunol.22.012703.104743; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Ching KA, 1999, J IMMUNOL, V163, P6006; Ching KA, 2000, J IMMUNOL, V165, P256, DOI 10.4049/jimmunol.165.1.256; Colgan J, 2004, IMMUNITY, V21, P189, DOI 10.1016/j.immuni.2004.07.005; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Ferrara TJ, 2006, J ALLERGY CLIN IMMUN, V117, P780, DOI 10.1016/j.jaci.2005.12.1330; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; Hao SL, 2002, FEBS LETT, V525, P53, DOI 10.1016/S0014-5793(02)03066-1; King PD, 1996, INT IMMUNOL, V8, P1707, DOI 10.1093/intimm/8.11.1707; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu YL, 1998, J IMMUNOL, V161, P5404; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; Mueller C, 2003, J IMMUNOL, V170, P5056, DOI 10.4049/jimmunol.170.10.5056; Oda A, 2000, BLOOD, V95, P1663; Okamoto N, 2003, BIOCHEM BIOPH RES CO, V310, P691, DOI 10.1016/j.bbrc.2003.09.065; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Yang WC, 2001, J IMMUNOL, V166, P387, DOI 10.4049/jimmunol.166.1.387; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	33	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38529	38534		10.1074/jbc.M609180200	http://dx.doi.org/10.1074/jbc.M609180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17060314	hybrid			2022-12-25	WOS:000242709500047
J	Hoffhines, AJ; Damoc, E; Bridges, KG; Leary, JA; Moore, KL				Hoffhines, Adam J.; Damoc, Eugen; Bridges, Kristie G.; Leary, Julie A.; Moore, Kevin L.			Detection and purification of tyrosine-sulfated proteins using a novel anti-sulfotyrosine monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-SELECTIN; TYROSYLPROTEIN SULFOTRANSFERASE; POSTTRANSLATIONAL MODIFICATION; MOLECULAR-CLONING; O-SULFATION; GLYCOPROTEIN LIGAND-1; AMINO-TERMINUS; 4TH COMPONENT; FACTOR-VIII; IDENTIFICATION	Protein tyrosine O-sulfation is a post-translational modification mediated by one of two Golgi tyrosylprotein sulfotransferases (TPST1 and TPST2) that catalyze the transfer of sulfate to tyrosine residues in secreted and transmembrane proteins. Tyrosine sulfation plays a role in protein-protein interactions in several well defined systems. Although dozens of tyrosine-sulfated proteins are known, many more are likely to exist and await description. Advancing our understanding of the importance of tyrosine sulfation in biological systems requires the development of new tools for the detection and study of tyrosine-sulfated proteins. We have developed a novel anti-sulfotyrosine monoclonal antibody (called PSG2) that binds with high affinity and exquisite specificity to sulfotyrosine residues in peptides and proteins independently of sequence context. We show that it can detect tyrosine-sulfated proteins in complex biological samples and can be used as a probe to assess the role of tyrosine sulfation in protein function. We also demonstrate the utility of PSG2 in the purification of tyrosine-sulfated proteins from crude tissue samples. Finally, Western blot analysis using PSG2 showed that certain sperm/epididymal proteins are undersulfated in Tpst2(-/-) mice. This indicates that TPST1 and TPST2 have distinct macromolecular substrate specificities and provides clues as to the molecular mechanism of the infertility of Tpst2(-/-) males. PSG2 should be widely applicable for identification of tyrosine-sulfated proteins in other systems and organisms.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Ctr Hlth Sci, Dept Cell Biol, Norman, OK 73019 USA; Univ Oklahoma, Ctr Hlth Sci, Dept Med, Norman, OK 73019 USA; Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Calif Davis, Genome Ctr, Dept Chem, Davis, CA 94616 USA; Univ Calif Davis, Genome Ctr, Dept Mol Cell Biol, Davis, CA 94616 USA; Wyeth Ayerst Res, Cambridge, MA 02140 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma - Norman; University of California System; University of California Davis; University of California System; University of California Davis; Pfizer	Moore, KL (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.	kevin-moore@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL074015, HL074015] Funding Source: Medline; NIGMS NIH HHS [GM062116, GM063558, U54 GM062116] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BETTELHEIM FR, 1954, J AM CHEM SOC, V76, P2838, DOI 10.1021/ja01639a073; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Borghei A, 2006, J BIOL CHEM, V281, P9423, DOI 10.1074/jbc.M513768200; BUNDGAARD JR, 1995, EMBO J, V14, P3073, DOI 10.1002/j.1460-2075.1995.tb07310.x; Celikel R, 2003, SCIENCE, V301, P218, DOI 10.1126/science.1084183; Colvin RA, 2006, MOL CELL BIOL, V26, P5838, DOI 10.1128/MCB.00556-06; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Gao JM, 2003, J BIOL CHEM, V278, P37902, DOI 10.1074/jbc.M306061200; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; Bridges KG, 2006, PEPTIDES, V27, P1877, DOI 10.1016/j.peptides.2006.02.003; Gutierrez J, 2004, J BIOL CHEM, V279, P14726, DOI 10.1074/jbc.M309689200; Han JH, 1998, BIOCHEMISTRY-US, V37, P3203, DOI 10.1021/bi9722195; HILLE A, 1984, FEBS LETT, V177, P129, DOI 10.1016/0014-5793(84)80996-5; HORTIN G, 1986, J BIOL CHEM, V261, P1786; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; HUTTNER WB, 1982, NATURE, V299, P273, DOI 10.1038/299273a0; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; KARP DR, 1983, J BIOL CHEM, V258, P2745; KEHOE JW, 2006, IN PRESS MOL CELL PR; KORCHAGINA EY, 1992, BIOORG KHIM+, V18, P283; KRAJEWSKI T, 1968, ACTA CHEM SCAND, V22, P1339, DOI 10.3891/acta.chem.scand.22-1339; LEE RWH, 1983, J BIOL CHEM, V258, P1326; LEYTE A, 1991, J BIOL CHEM, V266, P740; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; Molina F, 1996, PEPTIDE RES, V9, P151; Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769; Moore Kevin L., 1994, Journal of Tissue Culture Methods, V16, P255, DOI 10.1007/BF01540662; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MORITA T, 1986, J BIOL CHEM, V261, P4008; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Ouyang YB, 2002, J BIOL CHEM, V277, P23781, DOI 10.1074/jbc.M202420200; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Thompson JE, 1999, J IMMUNOL METHODS, V227, P17, DOI 10.1016/S0022-1759(99)00060-5; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	54	61	72	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37877	37887		10.1074/jbc.M609398200	http://dx.doi.org/10.1074/jbc.M609398200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17046811	Green Accepted, hybrid			2022-12-25	WOS:000242477100066
J	Modzelewska, K; Newman, LP; Desai, R; Keely, PJ				Modzelewska, Katarzyna; Newman, Laura P.; Desai, Radhika; Keely, Patricia J.			Ack1 mediates Cdc42-dependent cell migration and signaling to p130(Cas)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE ACK1; ALPHA-PIX; PHOSPHORYLATION; CDC42; ADHESION; ACTIVATION; INTEGRINS; GTPASES; GROWTH; SRC	We previously showed that activation of the small GTPase Cdc42 promotes breast cell migration on a collagen matrix. Here we further define the signaling pathways that drive this response and show that Cdc42-mediated migration relies on the adaptor molecule p130(Cas). Activated Cdc42 enhanced p130(Cas) phosphorylation and its binding to Crk. Cdc42-driven migration and p130(Cas) phosphorylation were dependent on the Cdc42 effector Ack1(activated Cdc42-associated kinase). Ack1 formed a signaling complex that also included Cdc42, p130(Cas), and Crk, formation of which was regulated by collagen stimulation. The interaction between Ack1 and p130(Cas) occurred through their respective SH3 domains, while the substrate domain of p130(Cas) was the major site of Ack1-dependent phosphorylation. Signaling through this complex is functionally relevant, because treatment with either p130(Cas) or Ack1 siRNA blocked Cdc42-induced migration. These results suggest that Cdc42 exerts its effects on cell migration in part through its effector Ack1, which regulates p130(Cas) signaling.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Keely, PJ (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 3630 MSC,1300 Univ Ave, Madison, WI 53706 USA.	pjkeely@wisc.edu			NATIONAL CANCER INSTITUTE [R29CA076537] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA76537] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed I, 2006, MOL CELL BIOCHEM, V281, P17, DOI 10.1007/s11010-006-0165-9; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Coon M, 2002, J CELL BIOCHEM, V84, P655, DOI 10.1002/jcb.10078; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KEELY PJ, 1995, J CELL SCI, V108, P595; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Linseman DA, 2001, J BIOL CHEM, V276, P5622, DOI 10.1074/jbc.M006812200; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mishima W, 2004, GENES CELLS, V9, P193, DOI 10.1111/j.1356-9597.2004.00717.x; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; NUR EKA, 2005, MOL CANCER RES, V3, P297; Nur-E-Kamal MSA, 1999, ANN NY ACAD SCI, V886, P285, DOI 10.1111/j.1749-6632.1999.tb09438.x; Oda T, 2001, BIOCHEM BIOPH RES CO, V288, P1078, DOI 10.1006/bbrc.2001.5890; PATCH LA, 1995, J CELL SCI, V108, P1371; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosenberger G, 2006, EUR J CELL BIOL, V85, P265, DOI 10.1016/j.ejcb.2005.10.007; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; van der Horst EH, 2005, P NATL ACAD SCI USA, V102, P15901, DOI 10.1073/pnas.0508014102; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yeow-Fong L, 2005, FEBS LETT, V579, P5040, DOI 10.1016/j.febslet.2005.07.093; Yokoyama N, 2003, J BIOL CHEM, V278, P47713, DOI 10.1074/jbc.M306716200	46	47	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37527	37535		10.1074/jbc.M604342200	http://dx.doi.org/10.1074/jbc.M604342200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17038317	hybrid			2022-12-25	WOS:000242477100029
J	Onn, I; Kapeller, I; Abu-Elneel, K; Shlomai, J				Onn, Itay; Kapeller, Irit; Abu-Elneel, Kawther; Shlomai, Joseph			Binding of the universal minicircle sequence binding protein at the kinetoplast DNA replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; SPECIALIZED NUCLEOPROTEIN STRUCTURES; CRITHIDIA-FASCICULATA; BACTERIOPHAGE-LAMBDA; NUCLEOCAPSID PROTEIN; SV40 ORIGIN; RNA; IDENTIFICATION; TRANSCRIPTION; RECOGNIZES	Kinetoplast DNA, the mitochondrial DNA of trypanosomatids, is a remarkable DNA structure that contains, in the species Crithidia fasciculata, 5000 topologically linked duplex DNA minicircles. Their replication initiates at two conserved sequences, a dodecamer, known as the universal minicircle sequence (UMS), and a hexamer, which are located at the replication origins of the minicircle L and H strands, respectively. A UMS-binding protein (UMSBP) binds specifically the 12-mer UMS sequence and a 14-mer sequence that contains the conserved hexamer in their single-stranded DNA conformation. In vivo cross-linking analyses reveal the binding of UMSBP to kinetoplast DNA networks in the cell. Furthermore, UMSBP binds in vitro to native minicircle origin fragments, carrying the UMSBP recognition sequences. UMSBP binding at the replication origin induces conformational changes in the bound DNA through its folding, aggregation and condensation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, Kuvin Ctr Study Infect & Trop Dis, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Genet & Biotechnol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Shlomai, J (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Parasitol, Kuvin Ctr Study Infect & Trop Dis, IL-91120 Jerusalem, Israel.	shlomai@cc.huji.ac.il	Onn, Itay/AAA-7949-2020	Onn, Itay/0000-0002-7689-5520				ABELIOVICH H, 1993, MOL CELL BIOL, V13, P7766, DOI 10.1128/MCB.13.12.7766; Abu-Elneel K, 1999, J BIOL CHEM, V274, P13419, DOI 10.1074/jbc.274.19.13419; Abu-Elneel K, 2001, J CELL BIOL, V153, P725, DOI 10.1083/jcb.153.4.725; ALFANO C, 1989, J BIOL CHEM, V264, P10699; AVRAHAMI D, 1995, P NATL ACAD SCI USA, V92, P10511, DOI 10.1073/pnas.92.23.10511; Baba S, 2001, Nucleic Acids Res Suppl, P155; Bashaw JM, 2001, J VIROL, V75, P10603, DOI 10.1128/JVI.75.22.10603-10611.2001; BIRKENMEYER L, 1986, J BIOL CHEM, V261, P2362; BIRKENMEYER L, 1987, J BIOL CHEM, V262, P2384; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1989, J BIOL CHEM, V264, P10719; DODSON M, 1991, METHOD ENZYMOL, V208, P168; Drew ME, 2001, J CELL BIOL, V153, P735, DOI 10.1083/jcb.153.4.735; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304; ELIAS P, 1990, J BIOL CHEM, V265, P17167; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; Hertz-Fowler C, 2004, NUCLEIC ACIDS RES, V32, pD339, DOI 10.1093/nar/gkh007; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KATZ RA, 1989, BIOESSAYS, V11, P176, DOI 10.1002/bies.950110605; KITCHIN PA, 1985, J BIOL CHEM, V260, P3844; Krishnamoorthy G, 2003, NUCLEIC ACIDS RES, V31, P5425, DOI 10.1093/nar/gkg738; Lyonnais S, 2003, NUCLEIC ACIDS RES, V31, P5754, DOI 10.1093/nar/gkg716; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Morris JC, 2001, INT J PARASITOL, V31, P453, DOI 10.1016/S0020-7519(01)00156-4; Onn I, 2004, EUKARYOT CELL, V3, P277, DOI 10.1128/EC.3.2.277-287.2004; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; Sambrook J., 1989, MOL CLONING LAB MANU, P3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; Shlomai J, 2004, CURR MOL MED, V4, P623, DOI 10.2174/1566524043360096; SHLOMAI J, 1994, PARASITOL TODAY, V10, P341, DOI 10.1016/0169-4758(94)90244-5; Simpson L, 2000, P NATL ACAD SCI USA, V97, P6986, DOI 10.1073/pnas.97.13.6986; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; TZFATI Y, 1992, P NATL ACAD SCI USA, V89, P6891, DOI 10.1073/pnas.89.15.6891; TZFATI Y, 1995, J BIOL CHEM, V270, P21339, DOI 10.1074/jbc.270.36.21339; Tzfati Y, 1998, MOL BIOCHEM PARASIT, V94, P137, DOI 10.1016/S0166-6851(98)00052-8; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521; WOODWARD R, 1990, J CELL SCI, V95, P49; XU CX, 1993, P NATL ACAD SCI USA, V90, P1786, DOI 10.1073/pnas.90.5.1786; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	55	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37468	37476		10.1074/jbc.M606374200	http://dx.doi.org/10.1074/jbc.M606374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17046830	hybrid			2022-12-25	WOS:000242477100023
J	Berndt, S; d'Hauterive, SP; Blacher, S; Pequeux, C; Lorquet, S; Munaut, C; Applanat, M; Herve, MA; Lamande, N; Corvol, P; van den Brule, F; Frankenne, F; Poutanen, M; Huhtaniemi, I; Geenen, V; Noel, A; Foidart, JM				Berndt, Sarah; d'Hauterive, Sophie Perrier; Blacher, Silvia; Pequeux, Christel; Lorquet, Sophie; Munaut, Carine; Applanat, Martine; Herve, Marie Astrid; Lamande, Noel; Corvol, Pierre; van den Brule, Frederic; Frankenne, Francis; Poutanen, Matti; Huhtaniemi, Ilpo; Geenen, Vincent; Noel, Agnes; Foidart, Jean-Michel			Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium	FASEB JOURNAL			English	Article						angiogenesis; hCG	HUMAN CORPUS-LUTEUM; OVARIAN HYPERSTIMULATION SYNDROME; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE-C; EARLY-PREGNANCY; GROWTH-FACTOR; GRANULOSA-CELLS; MESSENGER-RNA; IN-VITRO; EXPRESSION	Successful embryo development requires an extensive endometrial angiogenesis in proximity of implantation site. The glycoprotein hCG is produced even before implantation by trophoblast in normal pregnancy. In this manuscript, we demonstrate an angiogenic effect of hCG in several in vivo (chick chorioallantoic membrane, matrigel plug assay, aortic ring assay) and in vitro experimental models. In contrast, human placental lactogen (hPL) did not display angiogenic properties. LH/hCG receptor was detected in endothelial cells by reverse-transcriptase polymerase chain reaction (RT-PCR) and by Western blotting. In mice aortic ring assay, angiostimulation by hCG was abrogated by deletion of LH/hCG receptor (LuRKO mice). Use of recombinant hCG and anti-hCG antibody (Ab) further confirmed the specificity of this angiogenic activity. By using dibutyryl cAMP, adenylate cyclase, or protein kinase A inhibitors, we demonstrate that hCG-mediated angiogenesis involves adenylyl-cyclase-protein kinase A activation. Addition of hCG to endometrial epithelial epithelial cells, but not to cultured endothelial cells, stimulated vascular endothelial growth factor (VEGF). VEGF and hCG also displayed additive activities. Altogether, these data demonstrate that peritrophoblastic angiostimulation may result from a paracrine dialogue between trophoblast, epithelial, and endothelial cells through hCG and VEGF.	Univ Liege, Lab Tumor Biol & Dev, Inst Pathol, CRCE, B-4000 Liege, Belgium; Univ Liege, Ctr Immunol, Liege, Belgium; CHR Citadelle, Dept Gynecol & Obstet, Liege, Belgium; INSERM, U135, Paris, France; Coll France, INSERM, U36, F-75231 Paris, France; Imperial Coll London, Fac Med, Inst Reprod & Dev Biol, London, England; Univ Turku, Dept Physiol, Turku, Finland	University of Liege; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Imperial College London; University of Turku	Foidart, JM (corresponding author), Univ Liege, Lab Tumor Biol & Dev, Inst Pathol, CRCE, CHU-B23, B-4000 Liege, Belgium.	jmfoidart@ulg.ac.be	Munaut, Carine/K-8138-2019; Poutanen, Matti/I-1700-2018	Poutanen, Matti/0000-0002-8953-1734; Pequeux, Christel/0000-0001-8275-1489; Noel, Agnes/0000-0002-7670-6179; Geenen, Vincent/0000-0002-8733-7284				Artini PG, 2002, EUR J OBSTET GYN R B, V101, P169, DOI 10.1016/S0301-2115(01)00568-1; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Bausero P, 1998, Angiogenesis, V2, P167, DOI 10.1023/A:1009292506879; Blacher S., 2005, IMAGE ANAL STEREOL, V24, P169, DOI [10.5566/ias.v24.p169-180, DOI 10.5566/IAS.V24.P169-180]; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Butler SA, 2003, CLIN CANCER RES, V9, P4666; Cameo Paula, 2004, Reprod Biol Endocrinol, V2, P50, DOI 10.1186/1477-7827-2-50; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; DAVIS CM, 1993, J CELL BIOCHEM, V51, P206, DOI 10.1002/jcb.240510213; Drabkin DL, 1932, J BIOL CHEM, V98, P719; Duncan WC, 2000, REV REPROD, V5, P12, DOI 10.1530/revreprod/5.1.12; Fazleabas AT, 1999, SEMIN REPROD ENDOCR, V17, P257, DOI 10.1055/s-2007-1016233; Filicori M, 2005, FERTIL STERIL, V84, P275, DOI 10.1016/j.fertnstert.2005.02.033; Gallo RC, 1998, NAT BIOTECHNOL, V16, P218, DOI 10.1038/nbt0398-218a; Hermsteiner M, 1999, PFLUG ARCH EUR J PHY, V439, P186, DOI 10.1007/s004240051143; Herve MA, 2005, EXP CELL RES, V309, P24, DOI 10.1016/j.yexcr.2005.05.022; Ilan N, 1998, J CELL SCI, V111, P3621; Islami D, 2003, MOL HUM REPROD, V9, P395, DOI 10.1093/molehr/gag053; Islami D, 2001, SEMIN REPROD MED, V19, P49, DOI 10.1055/s-2001-13910; Jones CJP, 2001, HUM REPROD, V16, P2680, DOI 10.1093/humrep/16.12.2680; Kelly RW, 2001, REPRODUCTION, V121, P3, DOI 10.1530/rep.0.1210003; Kruger EA, 1999, INVAS METAST, V18, P209, DOI 10.1159/000024514; Kunzi-Rapp K, 2001, J UROLOGY, V166, P1502, DOI 10.1016/S0022-5347(05)65820-X; LAIRD SM, 1993, HUM REPROD, V8, P793, DOI 10.1093/oxfordjournals.humrep.a138144; Leemhuis J, 2002, J PHARMACOL EXP THER, V300, P1000, DOI 10.1124/jpet.300.3.1000; LEI ZM, 1992, J CLIN ENDOCR METAB, V75, P651, DOI 10.1210/jc.75.2.651; Licht P, 2003, FERTIL STERIL, V79, P718, DOI 10.1016/S0015-0282(02)04822-7; Licht P, 2001, SEMIN REPROD MED, V19, P37, DOI 10.1055/s-2001-13909; Lovely LP, 2005, J CLIN ENDOCR METAB, V90, P2351, DOI 10.1210/jc.2004-2130; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; Neulen J, 1998, MOL HUM REPROD, V4, P203, DOI 10.1093/molehr/4.3.203; Noyes R W, 1975, Am J Obstet Gynecol, V122, P262; Ohba T, 2003, MOL CELL ENDOCRINOL, V202, P47, DOI 10.1016/S0303-7207(03)00061-3; Pabon JE, 1996, J CLIN ENDOCR METAB, V81, P2738, DOI 10.1210/jc.81.7.2738; PASSANITI A, 1992, LAB INVEST, V67, P519; Pellicer A, 1999, FERTIL STERIL, V71, P482, DOI 10.1016/S0015-0282(98)00484-1; Perrier d'Hauterive S, 2004, HUM REPROD, V19, P2633, DOI 10.1093/humrep/deh450; RAO CV, 2004, J BIOL CHEM; Rao SC, 2003, NEUROSCI LETT, V336, P135, DOI 10.1016/s0304-3940(02)01157-6; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; Robert C, 2003, REPRODUCTION, V125, P437, DOI 10.1530/rep.0.1250437; Srisuparp S, 2003, BIOL REPROD, V68, P457, DOI 10.1095/biolreprod.102.007625; Srisuparp S, 2001, ARCH MED RES, V32, P627, DOI 10.1016/S0188-4409(01)00330-7; Strakova Z, 2005, ENDOCRINOLOGY, V146, P4097, DOI 10.1210/en.2005-0380; Sugino N, 2000, J CLIN ENDOCR METAB, V85, P4379, DOI 10.1210/jc.85.11.4379; Tao YX, 1997, LIFE SCI, V60, P1297, DOI 10.1016/S0024-3205(97)00073-8; Thompson DA, 1998, LIFE SCI, V63, P1057, DOI 10.1016/S0024-3205(98)00367-1; TOTH P, 1994, J CLIN ENDOCR METAB, V79, P307, DOI 10.1210/jc.79.1.307; Wulff C, 2001, HUM REPROD, V16, P2515, DOI 10.1093/humrep/16.12.2515; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Zhang FP, 2001, MOL ENDOCRINOL, V15, P172, DOI 10.1210/me.15.1.172; Zygmunt M, 2002, J CLIN ENDOCR METAB, V87, P5290, DOI 10.1210/jc.2002-020642	52	115	121	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2630	+		10.1096/fj.06-5885fje	http://dx.doi.org/10.1096/fj.06-5885fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065221				2022-12-25	WOS:000242490700047
J	Fernando, MR; Lechner, JM; Lofgren, S; Gladyshev, VN; Lou, MF				Fernando, M. Rohan; Lechner, Joel M.; Lofgren, Stefan; Gladyshev, Vadim N.; Lou, Marjorie F.			Mitochondrial thioltransferase (glutaredoxin 2) has GSH-dependent and thioredoxin reductase-dependent peroxidase activities in vitro and in lens epithelial cells	FASEB JOURNAL			English	Article						peroxiredoxins; oxidative stress; antioxidant enzymes; peroxide removal	APOPTOSIS; OXIDATION; DAMAGE; YEAST	Thioltransferase (or Grx) belongs to the oxidoreductase family and is known to regulate redox homeostasis in cells. Mitochondrial Grx2 is a recent discovery, but its function is largely unknown. In this study we investigate Grx2 function by examining its potential peroxidase activity using lens epithelial cells (LEC). cDNA for human and mouse Grx2 was cloned into pET21d(+) vector and used to produce respective recombinant Grx2 for kinetic studies. cDNA for human Grx2 was transfected into human LEC and used for in vivo studies. Both human and mouse Grx2 showed glutathione (GSH)-dependent and thioredoxin reductase (TR)-dependent peroxidase activity. The catalytic efficiency of human and mouse Grx2 was lower than that of glutathione peroxidases (2.5 and 0.8 x 104 s(-1)M(-1), respectively), but comparable with TR-dependent peroxiredoxins (16.5 and 2.7 x 10(4) s(-1)M(-1), respectively). TR-dependent peroxidase activity increased 2-fold in the transfected cells and was completely abolished by addition of anti-Grx2 antibody (Ab). Flow cytometry (FACS) analysis and confocal microscopy revealed that cells preloaded with pure Grx2 detoxified peroxides more efficiently. Grx2 over-expression protected cells against H2O2-mediated disruption of mitochondrial transmembrane potential. These results suggest that Grx2 has a novel function as a peroxidase, accepting electrons both from GSH and TR. This unique property may play a role in protecting the mitochondria from oxidative damage.	Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68583 USA; Univ Nebraska, Ctr Redox Biol, Lincoln, NE 68583 USA; Univ Nebraska Med Ctr, Dept Ophthalmol, Omaha, NE USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Medical Center	Lou, MF (corresponding author), Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA.	mlou1@unl.edu	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Lofgren, Stefan/0000-0002-9869-085X; Gladyshev, Vadim/0000-0002-0372-7016	NEI NIH HHS [R01 EY-10590] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASS DA, 1983, J IMMUNOL, V130, P1910; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V2, P579, DOI DOI 10.1016/B978-0-12-091302-2.50011-6; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Chen KCW, 2004, EXP EYE RES, V78, P1057, DOI 10.1016/j.exer.2004.02.004; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067; FORMAN HJ, 1982, FREE RADICALS BIOL, V5; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Johansson CC, 2003, J BIOL CHEM, V278, P17573, DOI 10.1074/jbc.M300311200; Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lai J C, 1979, Methods Enzymol, V55, P51; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MACKLER B, 1962, J BIOL CHEM, V237, P2968; MATSUDA NH, 2004, J BIOL CHEM, V280, P840; Moon S, 2005, INVEST OPHTH VIS SCI, V46, P3783, DOI 10.1167/iovs.05-0237; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	23	48	54	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2645	+		10.1096/fj.06-5919fje	http://dx.doi.org/10.1096/fj.06-5919fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065220				2022-12-25	WOS:000242490700052
J	Wang, GY; Qi, X; Wei, W; Englander, EW; Greeley, GH				Wang, Guiyun; Qi, Xiang; Wei, Wei; Englander, Ella W.; Greeley, George H., Jr.			Characterization of the 5 '-regulatory regions of the rat and human apelin genes and regulation of breast apelin by USF	FASEB JOURNAL			English	Article						hormone; transcription; ChIP assay; in vivo peptide	UPSTREAM STIMULATORY FACTORS; TRANSCRIPTION FACTOR USF; FOOD-INTAKE; PEPTIDE-YY; APJ RECEPTOR; EXPRESSION; PROMOTER; LIGAND; LOCALIZATION; CLONING	Apelin, a peptide widely expressed in the body, is the endogenous ligand for the APJ receptor. To investigate how the apelin gene is regulated transcriptionally, we cloned and characterized similar to 3000 and similar to 4000 bp 5'-upstream fragments of the rat and human apelin genes. Putative CAAT-like box, but not TATA-box sites were identified. The rat (-207/-1 bp) and human (-100/+74 bp) core promoter sequences contain putative binding sites for upstream stimulatory factor (USF)-1/-2. Mutagenesis and overexpression assays showed that USF up-regulates basal and inducible apelin transcription. EMSA and supershift experiments indicated binding of USF-1/-2 to the rat (-114/-109 bp) and human (-84/-79 bp) apelin promoters. ChIP experiments show that USF is recruited to the putative USF binding site in the human apelin promoter in cultured breast cells. In concert with increased breast apelin expression during pregnancy and lactation in rats, EMSAs demonstrate an elevated binding of pregnant and lactating rat breast nuclear proteins to a consensus USF oligonucleotide. In vivo ChIP assays verified increased USF binding to the apelin promoter in breast of lactating rats. Together, our findings show that USF exerts a stimulatory role in regulation of breast apelin expression during pregnancy and lactation.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Greeley, GH (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	ggreeley@utmb.edu			NIDDK NIH HHS [P01 DK35608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Corre S, 2006, M S-MED SCI, V22, P62, DOI 10.1051/medsci/200622162; COX CM, 2006, DEV BIOL; DAVIAUD D, 2006, FASEB J; deGraffenried LA, 2004, BREAST CANCER RES TR, V85, P111, DOI 10.1023/B:BREA.0000025398.93829.78; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Devic E, 1999, PATHOL BIOL, V47, P330; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Golubovskaya V, 2004, BBA-GENE STRUCT EXPR, V1678, P111, DOI 10.1016/j.bbaexp.2004.03.002; GOMEZ G, 1995, AM J PHYSIOL-GASTR L, V268, pG71, DOI 10.1152/ajpgi.1995.268.1.G71; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Griffin MJ, 2004, IUBMB LIFE, V56, P595, DOI 10.1080/15216540400022474; Grindstaff KK, 1996, J BIOL CHEM, V271, P23211, DOI 10.1074/jbc.271.38.23211; Gualillo O, 2001, ENDOCRINOLOGY, V142, P788, DOI 10.1210/en.142.2.788; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Hadsell DL, 2003, MOL ENDOCRINOL, V17, P2251, DOI 10.1210/me.2002-0031; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Hocker M, 1997, AM J PHYSIOL-GASTR L, V272, pG822, DOI 10.1152/ajpgi.1997.272.4.G822; Ishida J, 2004, J BIOL CHEM, V279, P26274, DOI 10.1074/jbc.M404149200; ITO R, 1984, P NATL ACAD SCI-BIOL, V81, P4662, DOI 10.1073/pnas.81.15.4662; Jiang B, 2005, MOL CELL BIOL, V25, P8824, DOI 10.1128/MCB.25.20.8824-8833.2005; Jiang QP, 2000, AM J PHYSIOL-REG I, V278, pR425, DOI 10.1152/ajpregu.2000.278.2.R425; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Kleinz MJ, 2004, REGUL PEPTIDES, V118, P119, DOI 10.1016/j.regpep.2003.11.002; KOHRI K, 1993, BIOCHIM BIOPHYS ACTA, V1173, P345, DOI 10.1016/0167-4781(93)90136-2; KRASINSKI SD, 1991, MOL ENDOCRINOL, V5, P433, DOI 10.1210/mend-5-3-433; Lambrecht NWG, 2006, PHYSIOL GENOMICS, V25, P153, DOI 10.1152/physiolgenomics.00271.2005; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Lee HM, 2004, J NEUROCHEM, V88, P394, DOI 10.1046/j.1471-4159.2003.02164.x; Lee JM, 2005, MACROMOL RES, V13, P236, DOI 10.1007/BF03219058; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386; Martinez-Fuentes AJ, 2004, MOL ENDOCRINOL, V18, P1808, DOI 10.1210/me.2003-0321; MASRI B, 2006, J BIOL CHEM; Matsukawa T, 2001, ENDOCRINOLOGY, V142, P4643, DOI 10.1210/en.142.11.4643; Medhurst AD, 2003, J NEUROCHEM, V84, P1162, DOI 10.1046/j.1471-4159.2003.01587.x; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; O'Shea M, 2003, NUTR NEUROSCI, V6, P163, DOI 10.1080/1028415031000111273; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Petersenn S, 2002, ENDOCRINOLOGY, V143, P2626, DOI 10.1210/en.143.7.2626; Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x; Ross S, 2002, J BIOL CHEM, V277, P4455, DOI 10.1074/jbc.M110771200; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Sellak H, 2005, J BIOL CHEM, V280, P18425, DOI 10.1074/jbc.M500775200; Sharma SK, 2005, BIOCHEM J, V389, P831, DOI 10.1042/BJ20050334; Shoulders CC, 2004, TRENDS MOL MED, V10, P362, DOI 10.1016/j.molmed.2004.06.011; Sirito Mario, 1992, Gene Expression, V2, P231; Sunter D, 2003, NEUROSCI LETT, V353, P1, DOI 10.1016/S0304-3940(03)00351-3; Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Takahashi Y, 2001, DRUG METAB REV, V33, P37, DOI 10.1081/DMR-100000139; TAKAHASHI Y, 1986, GENE, V50, P353; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang GY, 2004, ENDOCRINOLOGY, V145, P1342, DOI 10.1210/en.2003-1116; Wei W, 2005, ENDOCRINOLOGY, V146, P1611, DOI 10.1210/en.2004-1306; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030	60	27	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2639	+		10.1096/fj.06-6315fje	http://dx.doi.org/10.1096/fj.06-6315fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060400				2022-12-25	WOS:000242490700050
J	Yaddanapudi, K; Palacios, G; Towner, JS; Chen, I; Sariol, CA; Nichol, ST; Lipkin, WI				Yaddanapudi, Kavitha; Palacios, Gustavo; Towner, Jonathan S.; Chen, Ivy; Sariol, Carlos A.; Nichol, Stuart T.; Lipkin, W. Ian			Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses	FASEB JOURNAL			English	Article						filovirus; immunosuppression; lymphocyte depletion; apoptosis; cytokine	BLOOD MONONUCLEAR-CELLS; PROTEIN-KINASE-C; DENDRITIC CELLS; T-CELLS; LYMPHOCYTE-PROLIFERATION; STIMULATORY FACTOR; HEMORRHAGIC-FEVER; ENVELOPE PROTEINS; INFECTED PATIENTS; UP-REGULATION	Ebola and Marburg viruses can cause hemorrhagic fever (HF) outbreaks with high mortality in primates. Whereas Marburg (MARV), Ebola Zaire (ZEBOV), and Ebola Sudan (SEBOV) viruses are pathogenic in humans, apes, and monkeys, Ebola Reston (REBOV) is pathogenic only in monkeys (1-3). Early immunosuppression may contribute to pathogenesis by facilitating viral replication (4-6). Lymphocyte depletion, intravascular apoptosis, and cytokine dysregulation are prominent in fatal cases (7). Here we functionally characterize a 17 amino acid domain in filoviral glycoproteins that resembles an immunosuppressive motif in retroviral envelope proteins (8, 9). Activated human or rhesus peripheral blood mononuclear cells (PBMC) were exposed to inactivated ZEBOV or a panel of 17mer peptides representing all sequenced strains of filoviruses, then analyzed for CD4+ and CD8+ T cell activation, apoptosis, and cytokine expression. Exposure of human and rhesus PBMC to ZEBOV, SEBOV, or MARV peptides or inactivated ZEBOV resulted in decreased expression of activation markers on CD4 and CD8 cells; CD4 and CD8 cell apoptosis as early as 12 h postexposure; inhibition of CD4 and CD8 cell cycle progression; decreased interleukin (IL)-2, IFN-gamma, and IL12-p40 expression; and increased IL-10 expression. In contrast, only rhesus T cells were sensitive to REBOV peptides. These findings are consistent with the observation that REBOV is not pathogenic in humans and have implications for understanding the pathogenesis of filoviral HF.-Yaddanapudi, K., Palacios, G., Towner, J. S., Chen, I., Sariol, C. A., Nichol, S. T., Lipkin, W. I. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses.	Columbia Univ, Mailman Sch Publ Hlth, Jerome L & Dawn Greene Infect Dis Lab, New York, NY 10032 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Special Pathogens Branch, Atlanta, GA USA; Univ Puerto Rico, Mayaguez, PR USA	Columbia University; Centers for Disease Control & Prevention - USA; University of Puerto Rico; University of Puerto Rico Mayaguez	Lipkin, WI (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Jerome L & Dawn Greene Infect Dis Lab, 722 W 168th St,Rm 1801, New York, NY 10032 USA.	wil2001@columbia.edu	Towner, Jonathan/ABC-3780-2020; Palacios, Gustavo/I-7773-2015; Sariol, Carlos A./W-6360-2019; Lipkin, W. Ian/ABE-6216-2020	Palacios, Gustavo/0000-0001-5062-1938; Sariol, Carlos A./0000-0001-7535-4303; Lipkin, W. Ian/0000-0002-8768-9386	NIAID NIH HHS [AI51292, AI056118, AI55466, U54-AI057158] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051292, R21AI055466, U54AI057158, R21AI056118] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; Baize S, 2002, CLIN EXP IMMUNOL, V128, P163, DOI 10.1046/j.1365-2249.2002.01800.x; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003; Bosio CM, 2003, J INFECT DIS, V188, P1630, DOI 10.1086/379199; BUKREYEV AA, 1993, FEBS LETT, V323, P183, DOI 10.1016/0014-5793(93)81476-G; CIANCIOLO GJ, 1985, SCIENCE, V230, P453, DOI 10.1126/science.2996136; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DENNER J, 1994, AIDS, V8, P1063, DOI 10.1097/00002030-199408000-00005; DING L, 1993, J IMMUNOL, V151, P1224; Feldmann H, 2001, J GEN VIROL, V82, P2839, DOI 10.1099/0022-1317-82-12-2839; Feldmann H, 1996, ADV VIRUS RES, V47, P1, DOI 10.1016/S0065-3527(08)60733-2; Geisbert TW, 2000, LAB INVEST, V80, P171, DOI 10.1038/labinvest.3780021; Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2; GOTTLIEB RA, 1990, J IMMUNOL, V145, P2566; Gupta M, 2001, VIROLOGY, V284, P20, DOI 10.1006/viro.2001.0836; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HARAGUCHI S, 1995, P NATL ACAD SCI USA, V92, P3611, DOI 10.1073/pnas.92.8.3611; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; HARAGUCHI S, 1995, P NATL ACAD SCI USA, V92, P5568, DOI 10.1073/pnas.92.12.5568; Harcourt BH, 1998, VIROLOGY, V252, P179, DOI 10.1006/viro.1998.9446; Hartman AL, 2004, VIROLOGY, V328, P177, DOI 10.1016/j.virol.2004.07.006; Hensley LE, 2002, IMMUNOL LETT, V80, P169, DOI 10.1016/S0165-2478(01)00327-3; JACOBSEN CN, 1993, VET IMMUNOL IMMUNOP, V39, P461, DOI 10.1016/0165-2427(93)90075-F; JAHRLING PB, 1996, ARCH VIROL         S, V11, P115; KADOTA J, 1991, MICROBIOL IMMUNOL, V35, P443, DOI 10.1111/j.1348-0421.1991.tb01575.x; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Mahanty S, 2003, J IMMUNOL, V170, P2797, DOI 10.4049/jimmunol.170.6.2797; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peters CJ, 1999, J INFECT DIS, V179, pIX; REID SLL, 2006, J VIROL, V80, P1; Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004; SANCHO J, 1992, J BIOL CHEM, V267, P7871; Sopper S, 1997, CYTOMETRY, V29, P351; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; VOLCHKOV VE, 1992, FEBS LETT, V305, P181, DOI 10.1016/0014-5793(92)80662-Z; Volchkov VE, 2001, SCIENCE, V291, P1965, DOI 10.1126/science.1057269; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WOLF SF, 1991, J IMMUNOL, V146, P3074; Yang ZY, 2000, NAT MED, V6, P886, DOI 10.1038/78654	42	60	69	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2519	2530		10.1096/fj.06-6151com	http://dx.doi.org/10.1096/fj.06-6151com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17023517	Green Submitted			2022-12-25	WOS:000242490700012
J	Duan, H; Heckman, CA; Boxer, LM				Duan, H.; Heckman, C. A.; Boxer, L. M.			The immunoglobulin heavy-chain gene 3 ' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells	ONCOGENE			English	Article						follicular lymphoma; bcl-2; promoter usage; IgH enhancer	LOCUS-CONTROL REGION; EXPRESSION; CHEMORESISTANCE; TRANSCRIPTION; APOPTOSIS; PROTEIN	In t(14;18) lymphomas, bcl-2 is juxtaposed to the immunoglobulin heavy-chain gene (IgH), resulting in increased bcl-2 transcription and resistance to apoptosis. Regulatory elements of both the bcl-2 promoter and the IgH enhancers are believed to play a role in the increased expression of bcl-2 in t(14;18) lymphoma cells. In addition, transcription of the translocated bcl-2 allele is deregulated with activation of the normally minor bcl-2 P2 promoter. The mechanisms involved in the promoter shift from P1 to P2 are not known. We found that the murine IgH 30 enhancers increased bcl-2 P2 promoter activity in an episomal model of the translocation, and IgH enhancer region HS12 had the greatest effect. Quantitative chromatin immunoprecipitation (ChIP) assays revealed that localized histone H3 hyperacetylation of the P2 promoter was observed on the translocated allele in t(14;18) DHL-4 cells and also on the stably transfected bcl-2 promoter-IgH enhancer episomal construct. Analysis of the HS12 enhancer region revealed that a previously identified nuclear factor-kappa B (NF-kappa B) site and a previously uncharacterized downstream Cdx site, both of which are conserved in the human and murine IgH enhancers, were important for its enhancer activity and promoter activation. ChIP assays showed that C/EBP beta bound to the HS12 Cdx site in vivo, and mutation of this site abrogated the binding of C/EBP beta. Reduced expression of C/EBP beta by transfection of small interfering RNA or interference with NF-kappa B activity decreased transcription from the bcl-2 promoters. These results demonstrate that the IgH 30 enhancers, particularly HS12, are important for the deregulation of bcl-2 promoter usage in t(14;18) lymphomas.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Hematol, CCSR 1155,269 Campus Dr, Stanford, CA 94305 USA.	lboxer@stanford.edu		Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Heckman CA, 2003, CANCER RES, V63, P6666; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Khamlichi AA, 2000, ADV IMMUNOL, V75, P317, DOI 10.1016/S0065-2776(00)75008-5; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	19	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2635	2641		10.1038/sj.onc.1210061	http://dx.doi.org/10.1038/sj.onc.1210061			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043638				2022-12-25	WOS:000245831200010
J	Jo, M; Thomas, KS; Takimoto, S; Gaultier, A; Hsieh, EH; Lester, RD; Gonias, SL				Jo, M.; Thomas, K. S.; Takimoto, S.; Gaultier, A.; Hsieh, E. H.; Lester, R. D.; Gonias, S. L.			Urokinase receptor primes cells to proliferate in response to epidermal growth factor	ONCOGENE			English	Article						urokinase receptor; epidermal growth factor; ERK; c-Src; STAT5b	C-SRC INTERACTIONS; PLASMINOGEN-ACTIVATOR; EGF RECEPTOR; TYROSINE KINASES; BREAST-CANCER; PHOSPHORYLATION; TRANSACTIVATION; BINDING; SIGNAL; INTEGRINS	Epidermal growth factor (EGF) express es mitogenic activity by a mechanism that requires the EGF receptor (EGFR). We report that murine embryonic. broblasts ( MEFs) prolifer ate in response to EGF only when these cells express the urokinase receptor (uPAR). EGFR expression was equivalent in uPAR-/- and uPAR+/+ MEFs. In response to EGF, these cells demonstrated equivalent overall EGFR tyrosine phosphorylation and ERK/MAP kinase activation; however, phosphorylation of Tyr-845 in the EGFR, which has been implicated in cell growth, was substantially decreased in uPAR-/-MEFs. STAT5b activation also was decreased. As Tyr- 845 is a c- Src target, we overexpressed c- Src in uPAR-/- MEFs and rescued EGF mitogenic activity. Rescue also was achieved by expressing murine but not human uPAR, suggesting a role for autocrine uPAR cell- signaling. In MDA-MB 231 breast cancer cells, EGF mitogenic activity was blocked by uPAR gene silencing, with antibodies that block uPA-binding to uPAR, and with a synthetic peptide that disrupts uPAR-dependent cell signaling. Again, c-Src overexpression rescued the mitogenic activity of EGF. We conclude that uPAR-dependent cell-signaling may prime cells to proliferate in response to EGF by promoting Tyr-845 phosphorylation and STAT5b activation. The importance of this pathway depends on the c-Src level in the cell.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of California System; University of California San Diego; University of Virginia	Gonias, SL (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu			NCI NIH HHS [CA-94900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Angelucci A, 2006, ENDOCR-RELAT CANCER, V13, P197, DOI 10.1677/erc.1.01100; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BOLLA M, 1990, BREAST CANCER RES TR, V16, P97, DOI 10.1007/BF01809293; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; KOSHI S, 1997, TAIWAN J MATH, V1, P1; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Ma Z, 2001, J CELL SCI, V114, P3387; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; MAZZIERI R, 2006, ONCOGENE; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Monaghan-Benson E, 2006, J BIOL CHEM, V281, P9450, DOI 10.1074/jbc.M501901200; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; OREILLY DR, 1986, BIOL CELL, V57, P187, DOI 10.1111/j.1768-322X.1986.tb00475.x; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026	42	52	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2585	2594		10.1038/sj.onc.1210066	http://dx.doi.org/10.1038/sj.onc.1210066			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043637				2022-12-25	WOS:000245831200006
J	Baril, P; Gangeswaran, R; Mahon, PC; Caulee, K; Kocher, HM; Harada, T; Zhu, M; Kalthoff, H; Crnogorac-Jurcevic, T; Lemoine, NR				Baril, P.; Gangeswaran, R.; Mahon, P. C.; Caulee, K.; Kocher, H. M.; Harada, T.; Zhu, M.; Kalthoff, H.; Crnogorac-Jurcevic, T.; Lemoine, N. R.			Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta(4) integrin and the PI3k pathway	ONCOGENE			English	Article						pancreatic cancer; periostin; invasion; survival; hypoxia; PI3kinase	GROWTH-FACTOR-BETA; IN-VITRO; EXTRACELLULAR-MATRIX; ADHESION MOLECULE; ALPHA-6-BETA-4 INTEGRIN; PROGNOSTIC MARKER; SEQUENCE-ANALYSIS; SERUM LEVEL; FASCICLIN-I; EXPRESSION	Pancreatic ductal adenocarcinoma is a devastating disease, characterized by a rapid progression and poor treatment response. Using gene expression pro. ling of pancreatic cancer tissues, we previously identified periostin as a potential diagnostic and therapeutic target. In this study, we report the overexpression of periostin in a larger set of pancreatic cancer tissues and show that although the periostin transcript is exclusively expressed in tumour cells, the protein product is only detected in the extracellular matrix adjacent to cancer cells. Using an enzyme-linked immunosorbent assay (ELISA) assay, we show significantly increased levels of periostin in the sera of pancreatic cancer patients compared to non-cancer controls. We demonstrate that periostin promotes the invasiveness of tumour cells by increasing the motility of cells without inducing expression of proteases, and enhances the survival of tumour cells exposed to hypoxic conditions. At the molecular level, we provide evidence that the alpha(6)beta(4) integrin complex acts as the cell receptor of periostin in pancreatic cancer cells and that interaction promotes phosphorylation of focal adhesion kinase (FAK) and protein kinase B (AKT) though activation of the PI3 kinase pathway, but not the RAS/MEK/ERK pathway. These findings suggest an important role of periostin in pancreatic cancer and provide a rationale to study periostin for diagnostic and therapeutic applications.	Ctr Mol Oncol, Inst Canc, Barts & The London, London, England; John Vane Sci Ctr, London Sch Med & Dent, London EC1M 6BQ, England; CR UK Clin Ctr, Barts & The London, London, England; Ctr Tumour Biol, Barts & The London, Inst Canc, London, England; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA; Univ Kiel, Clin Gen Surg & Thorac Surg, D-24098 Kiel, Germany	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Kiel	Lemoine, NR (corresponding author), Ctr Mol Oncol, Inst Canc, Barts & The London, London, England.	nick.lemoine@cancer.org.uk	Kalthoff, Holger/B-1618-2010	Kocher, Hemant M/0000-0001-6771-1905; BARIL, Patrick/0000-0001-8290-9899				Akakura N, 2001, CANCER RES, V61, P6548; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Boukerche H, 2000, CANCER RES, V60, P5848; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Dowen SE, 2005, AM J PATHOL, V166, P81, DOI 10.1016/S0002-9440(10)62234-1; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; Gillan L, 2002, CANCER RES, V62, P5358; Gleason B, 2005, J HISTOCHEM CYTOCHEM, V53, P799, DOI 10.1369/jhc.4B6522.2005; HALL PA, 1991, J PATHOL, V165, P33, DOI 10.1002/path.1711650107; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Hosotani Ryo, 2002, Pancreas, V25, pe30, DOI 10.1097/00006676-200208000-00021; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kii I, 2006, BIOCHEM BIOPH RES CO, V342, P766, DOI 10.1016/j.bbrc.2006.02.016; Kim CJ, 2005, INT J CANCER, V117, P51, DOI 10.1002/ijc.21120; Kim MO, 2003, NEUROSCI LETT, V336, P93, DOI 10.1016/S0304-3940(02)01260-0; Koninger J, 2004, BIOCHEM BIOPH RES CO, V322, P943, DOI 10.1016/j.bbrc.2004.08.008; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Li P, 2004, J APPL PHYSIOL, V97, P1550, DOI 10.1152/japplphysiol.01311.2003; Lindner V, 2005, ARTERIOSCL THROM VAS, V25, P77, DOI 10.1161/01.ATV.0000149141.81230.c6; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Litvin J, 2005, ANAT REC PART A, V287A, P1205, DOI 10.1002/ar.a.20237; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sasaki H, 2003, BREAST CANCER RES TR, V77, P245, DOI 10.1023/A:1021899904332; Sasaki H, 2002, J PEDIATR SURG, V37, P1293, DOI 10.1053/jpsu.2002.34985; Sasaki H, 2001, CANCER-AM CANCER SOC, V92, P843, DOI 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P; Sasaki H, 2001, JPN J CANCER RES, V92, P869, DOI 10.1111/j.1349-7006.2001.tb01174.x; Sasaki H, 2001, CANCER LETT, V172, P37, DOI 10.1016/S0304-3835(01)00633-4; Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992-4003.2004; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Stoll V, 2005, GUT, V54, P109, DOI 10.1136/gut.2004.046706; Tai IT, 2005, CARCINOGENESIS, V26, P908, DOI 10.1093/carcin/bgi034; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	46	227	243	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2082	2094		10.1038/sj.onc.1210009	http://dx.doi.org/10.1038/sj.onc.1210009			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043657				2022-12-25	WOS:000245313400010
J	Frenkiel-Krispin, D; Wolf, SG; Albeck, S; Unger, T; Peleg, Y; Jacobovitch, J; Michael, Y; Daube, S; Sharon, M; Robinson, CV; Svergun, DI; Fass, D; Tzfira, T; Elbaum, M				Frenkiel-Krispin, Daphna; Wolf, Sharon Grayer; Albeck, Shira; Unger, Tamar; Peleg, Yoav; Jacobovitch, Jossef; Michael, Yigal; Daube, Shirley; Sharon, Michal; Robinson, Carol V.; Svergun, Dmitri I.; Fass, Deborah; Tzfira, Tzvi; Elbaum, Michael			Plant transformation by Agrobacterium tumefaciens - Modulation of single-stranded DNA-VirE2 complex assembly by VirE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; NUCLEAR-LOCALIZATION; TRANSPORT; INTERACTS; VIRULENCE; CHAPERONE; TRANSLOCATION; BIOLOGY; SYSTEM; GENOME	Agrobacterium tumefaciens infects plant cells by the transfer of DNA. A key factor in this process is the bacterial virulence protein VirE2, which associates stoichiometrically with the transported single-stranded (ss) DNA molecule (T-strand). As observed in vitro by transmission electron microscopy, VirE2-ssDNA readily forms an extended helical complex with a structure well suited to the tasks of DNA protection and nuclear import. Here we have elucidated the role of the specific molecular chaperone VirE1 in regulating VireE2-VirE2 and VirE2-ssDNA interactions. VirE2 alone formed functional filamentous aggregates capable of ssDNA binding. In contrast, co-expression with VirE1 yielded monodisperse VirE1-VirE2 complexes. Cooperative binding of VirE2 to ssDNA released VirE1, resulting in a controlled formation mechanism for the helical complex that is further promoted by macromolecular crowding. Based on this in vitro evidence, we suggest that the constrained volume of the VirB channel provides a natural site for the exchange of VirE2 binding from VirE1 to the T-strand.	Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Chem Res Support, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Israel Struct Prot Ctr, IL-76100 Rehovot, Israel; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; University of Cambridge; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of Michigan System; University of Michigan	Elbaum, M (corresponding author), Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel.	michael.elbaum@weizmann.ac.il	WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063; robinson, carol/0000-0001-7829-5505; Sharon, Michal/0000-0003-3933-0595; Svergun, Dmitri/0000-0003-0830-5696				Abu-Arish A, 2004, J BIOL CHEM, V279, P25359, DOI 10.1074/jbc.M401804200; Atmakuri K, 2003, MOL MICROBIOL, V49, P1699, DOI 10.1046/j.1365-2958.2003.03669.x; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; Cascales E, 2004, SCIENCE, V304, P1170, DOI 10.1126/science.1095211; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; Citovsky V, 1997, J MOL BIOL, V271, P718, DOI 10.1006/jmbi.1997.1230; CITOVSKY V, 1989, P NATL ACAD SCI USA, V86, P1193, DOI 10.1073/pnas.86.4.1193; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; CITOVSKY V, 1988, SCIENCE, V240, P501, DOI 10.1126/science.240.4851.501; DAS A, 1988, P NATL ACAD SCI USA, V85, P2909, DOI 10.1073/pnas.85.9.2909; Deng WY, 1999, MOL MICROBIOL, V31, P1795, DOI 10.1046/j.1365-2958.1999.01316.x; Duckely M, 2005, MOL MICROBIOL, V58, P1130, DOI 10.1111/j.1365-2958.2005.04894.x; Duckely M, 2003, FEMS MICROBIOL LETT, V223, P1, DOI 10.1016/S0378-1097(03)00246-5; Dumas F, 2001, P NATL ACAD SCI USA, V98, P485, DOI 10.1073/pnas.011477898; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; ENGSTROM P, 1987, J MOL BIOL, V197, P635, DOI 10.1016/0022-2836(87)90470-0; Gelvin SB, 2000, ANNU REV PLANT PHYS, V51, P223, DOI 10.1146/annurev.arplant.51.1.223; Gelvin SB, 2003, MICROBIOL MOL BIOL R, V67, P16, DOI 10.1128/MMBR.67.1.16-37.2003; Gelvin SB, 2003, TRENDS BIOTECHNOL, V21, P95, DOI 10.1016/S0167-7799(03)00005-2; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Lacroix B, 2005, EMBO J, V24, P428, DOI 10.1038/sj.emboj.7600524; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MCBRIDE KE, 1988, J BACTERIOL, V170, P1430, DOI 10.1128/jb.170.4.1430-1437.1988; Munishkina LA, 2004, J MOL RECOGNIT, V17, P456, DOI 10.1002/jmr.699; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; OTTEN L, 1984, MOL GEN GENET, V195, P159, DOI 10.1007/BF00332739; Rossi L, 1996, P NATL ACAD SCI USA, V93, P126, DOI 10.1073/pnas.93.1.126; Salman H, 2001, P NATL ACAD SCI USA, V98, P7247, DOI 10.1073/pnas.121067698; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEN P, 1989, J BACTERIOL, V171, P2573, DOI 10.1128/jb.171.5.2573-2580.1989; Simone M, 2001, MOL MICROBIOL, V41, P1283, DOI 10.1046/j.1365-2958.2001.02582.x; Sundberg C, 1996, J BACTERIOL, V178, P1207, DOI 10.1128/jb.178.4.1207-1212.1996; Sundberg CD, 1999, J BACTERIOL, V181, P6850, DOI 10.1128/JB.181.21.6850-6855.1999; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; SZEGEDI E, 2001, INT J HORTIC SCI, V7, P53; Tzfira T, 2000, ANNU REV MICROBIOL, V54, P187, DOI 10.1146/annurev.micro.54.1.187; Tzfira T, 2001, EMBO J, V20, P3596, DOI 10.1093/emboj/20.13.3596; Tzfira T, 2003, PLANT PHYSIOL, V133, P943, DOI 10.1104/pp.103.032821; Tzfira T, 2002, TRENDS CELL BIOL, V12, P121, DOI 10.1016/S0962-8924(01)02229-2; Tzfira T, 2005, MOL B INT U, P83; Vergunst AC, 2000, SCIENCE, V290, P979, DOI 10.1126/science.290.5493.979; Vergunst AC, 2003, PLANT PHYSIOL, V133, P978, DOI 10.1104/pp.103.029223; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91; Zhao ZM, 2001, J BACTERIOL, V183, P3855, DOI 10.1128/JB.183.13.3855-3865.2001; Zhou XR, 1999, J BACTERIOL, V181, P4342, DOI 10.1128/JB.181.14.4342-4352.1999; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	51	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					3458	3464		10.1074/jbc.M605270200	http://dx.doi.org/10.1074/jbc.M605270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17060320	hybrid			2022-12-25	WOS:000244481900008
J	Ke, JY; Gururajan, M; Kumar, A; Simmons, A; Turcios, L; Chelvarajan, RL; Cohen, DM; Wiest, DL; Monroe, JG; Bondada, S				Ke, Jiyuan; Gururajan, Murali; Kumar, Anupam; Simmons, Alan; Turcios, Lilia; Chelvarajan, Ralph L.; Cohen, David M.; Wiest, David L.; Monroe, John G.; Bondada, Subbarao			The role of MAPKs in B cell receptor-induced down-regulation of Egr-1 in immature B lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MEDIATED GROWTH-INHIBITION; SERUM RESPONSE ELEMENTS; MURINE LYMPHOCYTES-B; FINGER-ENCODING GENE; TRANSCRIPTION FACTORS; UP-REGULATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; EXPRESSION	Cross-linking of the B cell receptor (BCR) on the immature B lymphoma cell line BKS-2 induces growth inhibition and apoptosis accompanied by rapid down-regulation of the immediate-early gene egr- 1. In these lymphoma cells, egr-1 is expressed constitutively and has a prosurvival role, as Egr-1-specific antisense oligonucleotides or expression of a dominant-negative inhibitor of Egr-1 also prevented the growth of BKS-2 cells. Moreover, enhancement of Egr-1 protein with phorbol 12-myristate 13-acetate or an egr-1 expression vector rescued BKS-2 cells from BCR signal-induced growth inhibition. Nuclear run- on and mRNA stability assays indicated that BCR-derived signals act at the transcriptional level to reduce egr-1 expression. Inhibitors of ERK and JNK (but not of p38 MAPK) reduced egr-1 expression at the protein level. Transcriptional regulation appears to have a role because egr-1 promoter-driven luciferase expression was reduced by ERK and JNK inhibitors. Promoter truncation experiments suggested that several serum response elements are required for MAPK-mediated egr-1 expression. Our study suggests that BCR signals reduce egr-1 expression by inhibiting activation of ERK and JNK. Unlike ERK and JNK, p38 MAPK reduces constitutive expression of egr-1. Unlike the immature B lymphoma cells, normal immature B cells did not exhibit constitutive MAPK activation. BCR- induced MAPK activation was modest and transient with a small increase in egr-1 expression in normal immature B cells consistent with their inability to proliferate in response to BCR cross-linking.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97239 USA; Fox Chase Canc Ctr, Div Basic Sci, Immunol Working Grp, Philadelphia, PA 19111 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; Oregon Health & Science University; Fox Chase Cancer Center; University of Pennsylvania	Bondada, S (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Rm 329A, Lexington, KY 40536 USA.	bondada@uky.edu		Wiest, David/0000-0002-0792-3188	NATIONAL CANCER INSTITUTE [P01CA092372] Funding Source: NIH RePORTER; NCI NIH HHS [5P01CA092372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2000, MOL MED TODAY, V6, P72, DOI 10.1016/S1357-4310(99)01638-X; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; BOLEFEYSOT C, 2000, GENOME BIOL; Carleton M, 2002, J IMMUNOL, V168, P1649, DOI 10.4049/jimmunol.168.4.1649; CARMAN JA, 1995, DNA CELL BIOL, V14, P581, DOI 10.1089/dna.1995.14.581; Chelvarajan RL, 1998, J IMMUNOL, V161, P3315; CHUG J, 2003, CURRENT PROTOCOLS BI, P15; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; de Jager T, 2001, J BIOL CHEM, V276, P27873, DOI 10.1074/jbc.M010984200; Eid MA, 1998, CANCER RES, V58, P2461; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; Gleason D F, 1988, NCI Monogr, P15; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Han SS, 1999, INT IMMUNOL, V11, P871, DOI 10.1093/intimm/11.6.871; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; King LB, 1999, J IMMUNOL, V162, P2655; Koncz G, 2002, IMMUNOL LETT, V82, P41, DOI 10.1016/S0165-2478(02)00017-2; Lee JR, 1998, J IMMUNOL, V161, P1637; Li B, 2006, BLOOD, V107, P2814, DOI 10.1182/blood-2005-09-3610; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; MUTHUKKUMAR S, 1993, EUR J IMMUNOL, V23, P2419, DOI 10.1002/eji.1830231007; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Peterson ML, 2002, MOL CELL BIOL, V22, P5606, DOI 10.1128/MCB.22.15.5606-5615.2002; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; SAKAMOTO KM, 1992, ONCOGENE, V7, P2125; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Schaefer A, 2004, CELL SIGNAL, V16, P223, DOI 10.1016/j.cellsig.2003.07.001; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SEYFERT VL, 1990, J IMMUNOL, V145, P3647; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Sun YT, 2001, BIOCHEM BIOPH RES CO, V287, P983, DOI 10.1006/bbrc.2001.5689; Tam RC, 1997, J IMMUNOL, V158, P200; The FO, 2005, BRIT J PHARMACOL, V146, P252, DOI 10.1038/sj.bjp.0706303; UDHAYAKUMAR V, 1991, J IMMUNOL, V146, P4120; UDHAYAKUMAR V, 1989, CLIN IMMUNOL IMMUNOP, V51, P240, DOI 10.1016/0090-1229(89)90023-8; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; WARNER GL, 1988, CELL IMMUNOL, V115, P195, DOI 10.1016/0008-8749(88)90173-6; Wu HJ, 2001, J IMMUNOL, V167, P1263, DOI 10.4049/jimmunol.167.3.1263; Xi HK, 2003, J IMMUNOL, V170, P315, DOI 10.4049/jimmunol.170.1.315; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yu JX, 2004, MOL CELL, V15, P83, DOI 10.1016/j.molcel.2004.06.030	55	22	23	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39806	39818		10.1074/jbc.M604671200	http://dx.doi.org/10.1074/jbc.M604671200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17065146	hybrid, Green Published			2022-12-25	WOS:000243033900008
J	Tan, WF; Martin, D; Gutkind, JS				Tan, Wenfu; Martin, Daniel; Gutkind, J. Silvio			The G alpha(13)-Rho signaling axis is required for SDF-1-induced migration through CXCR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DERIVED FACTOR-1-ALPHA; HETEROTRIMERIC G-PROTEINS; CHEMOKINE RECEPTOR CXCR4; DEPENDENT ACTIVATION; RHO ACTIVITY; FACTOR-I; EXCHANGE; RAC; GTPASES; FAMILY	The CXC chemokine stromal cell-derived factor-1 alpha (SDF-1) binds to CXCR4, a seven-transmembrane G protein-coupled receptor that plays a critical role in many physiological processes that involve cell migration and cell fate decisions, ranging from stem cell homing, angiogenesis, and neuronal development to immune cell trafficking. CXCR4 is also implicated in various pathological conditions, including metastatic spread and human immunodeficiency virus infection. Although SDF-1-induced cell migration in CXCR4-expressing cells is sensitive to pertussis toxin treatment, hence involving heterotrimeric G proteins of the Gi family, whether other G proteins participate in the chemotactic response to SDF-1 is still unknown. In this study, we took advantage of the potent chemotactic activity of SDF-1 in Jurkat T-cells to examine the nature of the heterotrimeric G protein subunits contributing to CXCR4-mediated cell migration. We observed that whereas G(i) and G beta gamma subunits are involved in SDF-1-induced Rac activation and cell migration, CXCR4 can also stimulate Rho potently leading to the phosphorylation of myosin light chain through the Rho effector, Rho kinase, but independently of Gi. Furthermore, we found that G alpha(13) mediates the activation of Rho by CXCR4 and that the functional activity of both G alpha(13) and Rho is required for directional cell migration in response to SDF-1. Collectively, our data indicate that signaling by CXCR4 to Rho through G alpha(13) contributes to cell migration when stimulated by SDF-1, thus identifying the G alpha(13)-Rho signaling axis as a potential pharmacological target in many human diseases that involve the aberrant function of CXCR4.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Dept Hlth & Human Serv, 30 Convent Dr,Bldg 30,Rm 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Martin Izquierdo, Daniel/0000-0002-8880-9087	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Barac A, 2004, J BIOL CHEM, V279, P6182, DOI 10.1074/jbc.M309579200; Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Curnock AP, 2003, J IMMUNOL, V170, P4021, DOI 10.4049/jimmunol.170.8.4021; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Dutt P, 1998, J IMMUNOL, V161, P3652; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fischer AM, 2004, J BIOL CHEM, V279, P29816, DOI 10.1074/jbc.M312848200; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Juarez J, 2004, CURR PHARM DESIGN, V10, P1245, DOI 10.2174/1381612043452640; Juarez J, 2004, HISTOL HISTOPATHOL, V19, P299, DOI 10.14670/HH-19.299; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; Klein RS, 2004, TRENDS IMMUNOL, V25, P306, DOI 10.1016/j.it.2004.04.002; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; NAGASAWA T, 1994, J IMMUNOL, V152, P2788; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Peacock JW, 1999, J IMMUNOL, V162, P215; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; Stantchev TS, 2001, CYTOKINE GROWTH F R, V12, P219, DOI 10.1016/S1359-6101(00)00033-2; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; UI M, 1990, ADV SEC MESS PHOSPH, V24, P63; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Vicente-Manzanares M, 2005, BLOOD, V105, P3026, DOI 10.1182/blood-2004-07-2925; Vicente-Manzanares M, 2002, J IMMUNOL, V168, P400, DOI 10.4049/jimmunol.168.1.400; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Zlotnik A, 2004, SEMIN CANCER BIOL, V14, P181, DOI 10.1016/j.semcancer.2003.10.004; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	54	111	118	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39542	39549		10.1074/jbc.M609062200	http://dx.doi.org/10.1074/jbc.M609062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17056591	hybrid			2022-12-25	WOS:000242898700062
J	Chappell, KJ; Stoermer, MJ; Fairlie, DP; Young, PR				Chappell, Keith J.; Stoermer, Martin J.; Fairlie, David P.; Young, Paul R.			Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SERINE-PROTEASE; DRUG DESIGN; DENGUE; INHIBITORS; DOMAIN; FLAVIVIRUSES; COFACTOR; CLEAVAGE; POTENT	West Nile Virus is becoming a widespread pathogen, infecting people on at least four continents with no effective treatment for these infections or many of their associated pathologies. A key enzyme that is essential for viral replication is the viral protease NS2B-NS3, which is highly conserved among all flaviviruses. Using a combination of molecular fitting of substrates to the active site of the crystal structure of NS3,site-directed enzyme and cofactor mutagenesis, and kinetic studies on proteolytic processing of panels of short peptide substrates, we have identified important enzyme-substrate interactions that define substrate specificity for NS3 protease. In addition to better understanding the involvement of S2, S3, and S4 enzyme residues in substrate binding, a residue within cofactor NS2B has been found to strongly influence the preference of flavivirus proteases for lysine or arginine at P2 in substrates. Optimization of tetrapeptide substrates for enhanced protease affinity and processing efficiency has also provided important clues for developing inhibitors of West Nile Virus infection.	Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Fairlie, DP (corresponding author), Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.	d.fairlie@imb.uq.edu.au; p.young@uq.edu.au	Stoermer, Martin J/E-2317-2012; Fairlie, David P/F-8865-2014; Young, Paul R/A-6176-2010	Stoermer, Martin J/0000-0003-3445-2104; Fairlie, David P/0000-0002-7856-8566; Young, Paul R/0000-0002-2040-5190				Abbenante G, 2000, LETT PEPT SCI, V7, P347, DOI 10.1023/A:1013016323676; Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Chappell KJ, 2005, J BIOL CHEM, V280, P2896, DOI 10.1074/jbc.M409931200; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; D'Arcy A, 2006, ACTA CRYSTALLOGR F, V62, P157, DOI [10.1107/S1744309106001199, 10.1107/S174430910600119]; Erbel P, 2006, NAT STRUCT MOL BIOL, V13, P372, DOI 10.1038/nsmb1073; Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; Hayes CG, 2001, ANN NY ACAD SCI, V951, P25; Ingallinella P, 1998, BIOCHEMISTRY-US, V37, P8906, DOI 10.1021/bi980314n; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; Li J, 2005, J BIOL CHEM, V280, P28766, DOI 10.1074/jbc.M500588200; Llinas-Brunet M, 2004, J MED CHEM, V47, P6584, DOI 10.1021/jm0494523; Loughlin WA, 2004, CHEM REV, V104, P6085, DOI 10.1021/cr040648k; Murthy HMK, 2000, J MOL BIOL, V301, P759, DOI 10.1006/jmbi.2000.3924; Nall TA, 2004, J BIOL CHEM, V279, P48535, DOI 10.1074/jbc.M406810200; Stoermer Martin J, 2006, Med Chem, V2, P89, DOI 10.2174/157340606775197750; Tyndall JDA, 2005, CHEM REV, V105, P973, DOI 10.1021/cr040669e; van der Meulen KM, 2005, ARCH VIROL, V150, P637, DOI 10.1007/s00705-004-0463-z; WENGLER G, 1991, VIROLOGY, V184, P707, DOI 10.1016/0042-6822(91)90440-M	28	80	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38448	38458		10.1074/jbc.M607641200	http://dx.doi.org/10.1074/jbc.M607641200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17052977	hybrid			2022-12-25	WOS:000242709500038
J	Dobo, J; Swanson, R; Salvesen, GS; Olson, ST; Gettins, PGW				Dobo, Jozsef; Swanson, Richard; Salvesen, Guy S.; Olson, Steven T.; Gettins, Peter G. W.			Cytokine response modifier a inhibition of initiator caspases results in covalent complex formation and dissociation of the caspase tetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; SERPIN-PROTEINASE COMPLEX; INCREASED STRUCTURAL FLEXIBILITY; CRYSTAL-STRUCTURE; ALPHA(1)-PROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR; CYSTEINE PROTEASE; CELL-DEATH; CRMA; MECHANISM	Active caspases are generally composed of two catalytic domains, each containing a large (p20) and a small (p10) subunit so that a fully active caspase has the organization (p20-p10)(2). The cowpox serpin crmA suppresses host apoptosis and inflammation by inhibiting endogenous caspases. We report on the mechanism crmA uses to inhibit caspases 1, 6, and 8. Native PAGE showed formation of tight crmA-caspase complexes. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry provided evidence for a covalent crmA-p20 thioester linkage. SDS-PAGE of isolated complexes showed near complete loss of the p10 subunit from initiator caspases 1 and 8 but not from the executioner caspase-6. This was confirmed for caspase-1 by sequencing and Western blotting. Size exclusion chromatography indicated a size of similar to 60 kDa for complexes with caspases 1 and 8, consistent with a crmA center dot p20 species, suggesting that the p20-p10 interface and possibly the p10-p10 interface had been disrupted. In contrast, crmA center dot caspase-6 complex behaved as an equilibrium mixture of crmA(2)center dot(p20-p10)(2) and crmA center dot(p20-p10). Complex deacylation rates were all slow, suggesting effective kinetic trapping of the covalent thioacyl intermediate. These results suggest a novel serpin inhibition mechanism through which crmA down-regulates apoptosis and inflammation. This involves (i) rapid formation of covalent complex with initiator caspases 8 or 1, (ii) very slow deacylation, and (iii) loss of the caspase p10 subunit for initiator but not for executioner caspases, so that any free p20 formed by deacylation of initiator caspases cannot reassociate to active heterotetramer, thus resulting in irreversible inhibition of apoptosis and inflammation.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Burnham Inst, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Sanford Burnham Prebys Medical Discovery Institute	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland,MC 669, Chicago, IL 60607 USA.	pgettins@uic.edu	Dobo, Jozsef/C-7331-2014	Dobo, Jozsef/0000-0001-9187-8502				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Feeney B, 2005, J BIOL CHEM, V280, P39772, DOI 10.1074/jbc.M505834200; FISH WW, 1979, EUR J BIOCHEM, V101, P39, DOI 10.1111/j.1432-1033.1979.tb04213.x; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HERVE M, 1991, ARCH BIOCHEM BIOPHYS, V285, P142, DOI 10.1016/0003-9861(91)90341-F; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kang BH, 2002, BIOCHEM J, V364, P629, DOI 10.1042/BJ20011787; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nathaniel R, 2004, J GEN VIROL, V85, P1267, DOI 10.1099/vir.0.79905-0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Renatus M, 2000, STRUCT FOLD DES, V8, P789, DOI 10.1016/S0969-2126(00)00165-9; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Simonovic M, 2000, ACTA CRYSTALLOGR D, V56, P1440, DOI 10.1107/S0907444900009884; Simonovic M, 2000, PROTEIN SCI, V9, P1423, DOI 10.1110/ps.9.8.1423; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Stromqvist M, 1996, BBA-PROTEIN STRUCT M, V1295, P103, DOI 10.1016/0167-4838(96)00035-0; Talanian RV, 1996, J BIOL CHEM, V271, P21853, DOI 10.1074/jbc.271.36.21853; Tesch LD, 2005, PROTEIN SCI, V14, P533, DOI 10.1110/ps.041104905; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	44	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38781	38790		10.1074/jbc.M605151200	http://dx.doi.org/10.1074/jbc.M605151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17052983	hybrid			2022-12-25	WOS:000242709500076
J	Kuo, CC; Liang, SM; Liang, CM				Kuo, Cheng-Chin; Liang, Shu-Mei; Liang, Chi-Ming			CpG-B oligodeoxynucleotide promotes cell survival via up-regulation of Hsp70 to increase Bcl-x(L) and to decrease apoptosis-inducing factor translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; NEGATIVE REGULATION; APAF-1 APOPTOSOME; LEUKEMIA-CELLS; DNA; HEAT-SHOCK-PROTEIN-70; DEATH; ACTIVATION; OVEREXPRESSION; DOWNSTREAM	Unmethylated CpG oligodeoxynucleotides (ODNs) activate immune responses in a TLR9-dependent manner. In this study, stimulation of mouse macrophages with CpG-B ODN increased cellular Hsp70 expression and prevented apoptosis induced by serum starvation or staurosporine treatment. CpG-B ODN-induced Hsp70 expression depended on TLR9, MyD88, and phosphatidylinositol 3-kinase. Inhibition of Hsp70 synthesis by an inhibitor (quercetin) or antisense hsp70 attenuated not only Hsp70 expression but also the anti-apoptotic capacity of CpG-B ODN. Ectopic expression of Hsp70 rescued the inhibitory effect of quercetin on CpG-B ODN-induced anti-apoptosis. Additional experiments demonstrated that quercetin and antisense hsp70 modulated CpG-B ODN-induced anti-apoptosis via a caspase-3-independent pathway by down-regulating the survival gene bcl-x(L) and by increasing translocation of apoptosis-inducing factor. These findings suggest that CpG-B ODN may up-regulate Hsp70 via a TLR9/MyD88/phosphatidylinositol 3-kinase pathway to increase Bcl-x(L) and to decrease apoptosis-inducing factor nuclear translocation, resulting in anti-apoptosis.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan; Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Chung Hsing University	Liang, SM (corresponding author), Acad Sinica, Inst Biol Chem, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	smyang@gate.sinica.edu.tw; cmliang@gate.sinica.edu.tw	Kuo, Cheng-Chin/B-1064-2010	Liang, Shu-Mei/0000-0001-8926-4747				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Guo F, 2005, BLOOD, V105, P1246, DOI 10.1182/blood-2004-05-2041; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813; Iordanskiy S, 2004, J VIROL, V78, P9697, DOI 10.1128/JVI.78.18.9697-9704.2004; Ito T, 2005, SPRINGER SEMIN IMMUN, V26, P221, DOI 10.1007/s00281-004-0180-4; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Komarova EY, 2004, CELL STRESS CHAPERON, V9, P265, DOI 10.1379/CSC-27R1.1; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Kuo CC, 2005, PROTEOMICS, V5, P894, DOI 10.1002/pmic.200401144; Kuo CC, 2006, J IMMUNOL, V176, P5943, DOI 10.4049/jimmunol.176.10.5943; Lenert P, 2003, DNA CELL BIOL, V22, P621, DOI 10.1089/104454903770238094; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Park KC, 2000, ARCH DERMATOL RES, V292, P482, DOI 10.1007/s004030000173; Park Y, 2002, J IMMUNOL, V168, P5, DOI 10.4049/jimmunol.168.1.5; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Robert J, 2003, DEV COMP IMMUNOL, V27, P449, DOI 10.1016/S0145-305X(02)00160-X; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sohn WJ, 2006, MOL IMMUNOL, V43, P1163, DOI 10.1016/j.molimm.2005.07.020; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; Tsuchiya D, 2003, J CEREBR BLOOD F MET, V23, P718, DOI 10.1097/01.WCB.0000054756.97390.F7; Verthelyi D, 2003, TRENDS IMMUNOL, V24, P519, DOI 10.1016/S1471-4906(03)00243-6; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Yi AK, 1996, J IMMUNOL, V157, P4918; Yi AK, 1998, J IMMUNOL, V160, P5898; YON W, 2006, NEUROBIOL DIS, V21, P328; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	40	34	37	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38200	38207		10.1074/jbc.M605439200	http://dx.doi.org/10.1074/jbc.M605439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046822	hybrid			2022-12-25	WOS:000242709500012
J	Pagler, TA; Golsabahi, S; Doringer, M; Rhode, S; Schutz, GJ; Pavelka, M; Wadsack, C; Gauster, M; Lohninger, A; Laggner, H; Strobl, W; Stangl, H				Pagler, Tamara A.; Golsabahi, Solmaz; Doringer, Marlon; Rhode, Sebastian; Schuetz, Gerhard J.; Pavelka, Margit; Wadsack, Christian; Gauster, Martin; Lohninger, Alfred; Laggner, Hildegard; Strobl, Wolfgang; Stangl, Herbert			A Chinese hamster ovarian cell line imports cholesterol by high density lipoprotein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; RECEPTOR-MEDIATED ENDOCYTOSIS; HDL PARTICLE UPTAKE; SCAVENGER RECEPTOR; SR-BI; HUMAN-FIBROBLASTS; SURFACE RECEPTOR; TANGIER-DISEASE; EXPRESSION CLONING; FATTY-ACIDS	Plasma high density lipoprotein (HDL) is inversely associated with the development of atherosclerosis. HDL exerts its atheroprotective role through involvement in reverse cholesterol transport in which HDL is loaded with cholesterol at the periphery and transports its lipid load back to the liver for disposal. In this pathway, HDL is not completely dismantled but only transfers its lipids to the cell. Here we present evidence that a Chinese hamster ovarian cell line (CHO7) adapted to grow in lipoprotein-deficient media degrades HDL and concomitantly internalizes HDL-derived cholesterol. Delivery of HDL cholesterol to the cell was demonstrated by a down-regulation of cholesterol biosynthesis, an increase in total cellular cholesterol content and by stimulation of cholesterol esterification after HDL treatment. This HDL degradation pathway is distinct from the low density lipoprotein (LDL) receptor pathway but also degrades LDL. 25-Hydroxycholesterol, a potent inhibitor of the LDL receptor pathway, down-regulated LDL degradation in CHO7 cells only in part and did not down-regulate HDL degradation. Dextran sulfate released HDL bound to the cell surface of CHO7 cells, and heparin treatment released protein(s) contributing to HDL degradation. The involvement of heparan sulfate proteoglycans and lipases in this HDL degradation was further tested by two inhibitors genistein and tetrahydrolipstatin. Both blocked HDL degradation significantly. Thus, we demonstrate that CHO7 cells degrade HDL and LDL to supply themselves with cholesterol via a novel degradation pathway. Interestingly, HDL degradation with similar properties was also observed in a human placental cell line.	Med Univ Vienna, Inst Med Chem, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; Johannes Kepler Univ Linz, Inst Biophys, A-4040 Linz, Austria; Med Univ Vienna, Ctr Anat & Cell Biol, Dept Cell Biol & Ultrastruct Res, A-1090 Vienna, Austria; Med Univ Graz, Clin Obstet & Gynecol, A-8036 Graz, Austria	Medical University of Vienna; Johannes Kepler University Linz; Medical University of Vienna; Medical University of Graz	Stangl, H (corresponding author), Med Univ Vienna, Inst Med Chem, Ctr Physiol & Pathophysiol, Wahringerstr 10, A-1090 Vienna, Austria.	Herbert.Stangl@meduniwien.ac.at	Stangl, Herbert/AAT-4379-2021; Stangl, Herbert/R-9441-2019; Gauster, Martin/M-9659-2019; Schuetz, Gerhard/B-1243-2008; Gauster, Martin/K-7221-2019	Stangl, Herbert/0000-0002-7288-7320; Gauster, Martin/0000-0003-0386-6857; Schuetz, Gerhard/0000-0003-1542-1089; 				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Assemat E, 2005, BIOL REPROD, V72, P1079, DOI 10.1095/biolreprod.104.036913; Bansal N, 2005, CURR OPIN LIPIDOL, V16, P400, DOI 10.1097/01.mol.0000174154.61307.16; BIERMAN EL, 1974, CIRC RES, V35, P136, DOI 10.1161/01.RES.35.1.136; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1978, J SUPRAMOL STR CELL, V8, P223, DOI 10.1002/jss.400080302; DELAMATRE JG, 1990, J LIPID RES, V31, P191; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Farkas MH, 2003, J BIOL CHEM, V278, P9412, DOI 10.1074/jbc.M208026200; Fidge NH, 1999, J LIPID RES, V40, P187; FIELDING CJ, 1995, J LIPID RES, V36, P211; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P7854; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; Hammad SM, 2000, J BIOL CHEM, V275, P12003, DOI 10.1074/jbc.275.16.12003; Hammad SM, 1999, P NATL ACAD SCI USA, V96, P10158, DOI 10.1073/pnas.96.18.10158; Heeren J, 2003, J BIOL CHEM, V278, P14370, DOI 10.1074/jbc.M209006200; Hesse J, 2004, ANAL CHEM, V76, P5960, DOI 10.1021/ac049300f; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; Ioka RX, 2003, J BIOL CHEM, V278, P7344, DOI 10.1074/jbc.M211932200; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOVANEN PT, 1979, J BIOL CHEM, V254, P5498; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Kozyraki R, 1998, BLOOD, V91, P3593; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; LOHNINGER A, 1990, ANAL BIOCHEM, V186, P243, DOI 10.1016/0003-2697(90)90074-J; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Maugeais C, 2003, CIRCULATION, V108, P2121, DOI 10.1161/01.CIR.0000092889.24713.DC; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Moestrup SK, 2005, CURR OPIN LIPIDOL, V16, P301, DOI 10.1097/01.mol.0000169350.45944.d4; Nieland TJF, 2004, J LIPID RES, V45, P1256, DOI 10.1194/jlr.M300358-JLR200; Nieland TJF, 2002, P NATL ACAD SCI USA, V99, P15422, DOI 10.1073/pnas.222421399; Oram JF, 1996, J LIPID RES, V37, P2473; Pagler TA, 2006, J BIOL CHEM, V281, P11193, DOI 10.1074/jbc.M510261200; Pavelka M, 1998, HISTOCHEM CELL BIOL, V109, P555, DOI 10.1007/s004180050255; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Rhode S, 2004, CELL BIOCHEM BIOPHYS, V41, P343, DOI 10.1385/CBB:41:3:343; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; Saraswathi V, 2006, J LIPID RES, V47, P1406, DOI 10.1194/jlr.M600159-JLR200; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 1999, J BIOL CHEM, V274, P4140, DOI 10.1074/jbc.274.7.4140; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Strauss JG, 2002, BIOCHEM J, V368, P69, DOI 10.1042/BJ20020306; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1993, J LIPID RES, V34, P1255; Tall ARB, 2001, METABOLIC MOL BASES, P2915; Tribble DL, 1995, J LIPID RES, V36, P2580; Wadsack C, 2003, PLACENTA, V24, P131, DOI 10.1053/plac.2002.0912; Williams K J, 2001, Methods Mol Biol, V171, P457; Woollett LA, 2001, CURR OPIN LIPIDOL, V12, P305, DOI 10.1097/00041433-200106000-00010; Zannis VI, 2006, J MOL MED, V84, P276, DOI 10.1007/s00109-005-0030-4; ZEIHER AM, 1994, CIRCULATION, V89, P2525, DOI 10.1161/01.CIR.89.6.2525	70	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38159	38171		10.1074/jbc.M603334200	http://dx.doi.org/10.1074/jbc.M603334200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17038318	hybrid			2022-12-25	WOS:000242709500008
J	Supnet, C; Grant, J; Kong, H; Westaway, D; Mayne, M				Supnet, Charlene; Grant, Jeff; Kong, Hong; Westaway, David; Mayne, Michael			Amyloid-beta-(1-42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; CALCIUM-RELEASE; ALZHEIMERS-DISEASE; MOLECULAR-MECHANISMS; EXCITOTOXIC NECROSIS; TRANSGENIC MICE; CA2+ STORES; NEURODEGENERATION; ACTIVATION; PLASTICITY	yDisruption of intracellular calcium homeostasis precedes the neurodegeneration that occurs in Alzheimer disease ( AD). Of the many neuronal calcium-regulating proteins, we focused on endoplasmic reticulum (ER)-resident ryanodine receptors (RyRs) because they are increased in the hippocampus of mice expressing mutant presenilin-1 and are associated with neurotoxicity. Others have observed that ryanodine binding is elevated in human postmortem hippocampal regions suggesting that RyR(s) are involved in AD pathogenesis. Here we report that extracellular amyloid-beta(A beta)-(1-42) specifically increased RyR-3, but not RyR-1 or RyR-2, gene expression in cortical neurons from C57Bl6 mice. Furthermore, endogenously produced A beta-(1-42) increased RyR-3 mRNA and protein in cortical neurons from transgenic (Tg) CRND8 mice, a mouse model of AD. Increased RyR-3 mRNA and protein was also observed in brain tissue from 4- to 4.5-month-old Tg animals compared with non-Tg littermate controls. In experiments performed in nominal extracellular calcium, neurons from Tg mice had significant increases in intracellular calcium following ryanodine or glutamate treatment compared with littermate controls, which was abolished by treatment with small interfering RNA directed to RyR-3, indicating that the higher levels of calcium originated from RyR-3-regulated stores. Taken together, these observations suggest that A beta-(1-42)-mediated changes in intracellular calcium homeostasis is regulated in part through a direct increase of RyR-3 expression and function.	Natl Res Council Canada, Inst Nutrisci & Hlth, Charlottetown, PE C1A 5T1, Canada; Univ Prince Edward Isl, Atlantic Vet Coll, Dept Biomed Sci, Charlottetown, PE C1A 4P3, Canada; Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0T6, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Div Neurodegenerat Disorders, Winnipeg, MB R2H 2A6, Canada	National Research Council Canada; University of Prince Edward Island; University of Manitoba; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba	Mayne, M (corresponding author), Natl Res Council Canada, Inst Nutrisci & Hlth, Rm MO-02,93 Mt Edward Rd, Charlottetown, PE C1A 5T1, Canada.	michael.mayne@nrc.gc.ca		Supnet, Charlene/0000-0001-6917-770X				Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Balschun D, 1999, EMBO J, V18, P5264, DOI 10.1093/emboj/18.19.5264; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Bouchard R, 2003, PROG NEUROBIOL, V69, P391, DOI 10.1016/S0301-0082(03)00053-4; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Clodfelter GV, 2002, EUR J PHARMACOL, V447, P189, DOI 10.1016/S0014-2999(02)01843-5; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; Futatsugi A, 1999, NEURON, V24, P701, DOI 10.1016/S0896-6273(00)81123-X; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Glazner GW, 2000, J NEUROSCI, V20, P3641, DOI 10.1523/JNEUROSCI.20-10-03641.2000; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hyde LA, 2005, BEHAV BRAIN RES, V160, P344, DOI 10.1016/j.bbr.2004.12.017; Jarvis CR, 1999, NEUROIMAGE, V10, P357, DOI 10.1006/nimg.1999.0473; Jennings AM, 2006, FASEB J, V20, pA1158; Kelliher M, 1999, NEUROSCIENCE, V92, P499, DOI 10.1016/S0306-4522(99)00042-1; Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Linn CL, 2001, J PHYSIOL-LONDON, V535, P47, DOI 10.1111/j.1469-7793.2001.00047.x; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Mattson MP, 2001, BIOCHEM SOC SYMP, V67, P151, DOI 10.1042/bss0670151; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; Mori F, 2005, EPILEPSY RES, V65, P59, DOI 10.1016/j.eplepsyres.2005.04.006; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; O'Neill C, 2001, BIOCHEM SOC SYMP, V67, P177; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Reyes M, 1996, J NEUROSCI, V16, P5951; Rogawski MA, 2003, CNS DRUG REV, V9, P275, DOI 10.1111/j.1527-3458.2003.tb00254.x; Rossi D, 2002, J CELL SCI, V115, P2497; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; SHMIGOL A, 1994, PFLUG ARCH EUR J PHY, V426, P174, DOI 10.1007/BF00374686; Smith IF, 2005, J NEUROCHEM, V94, P1711, DOI 10.1111/j.1471-4159.2005.03332.x; Sorrentino V, 2001, TRENDS PHARMACOL SCI, V22, P459, DOI 10.1016/S0165-6147(00)01760-0; Stutzmann GE, 2005, NEUROSCIENTIST, V11, P110, DOI 10.1177/1073858404270899; Stutzmann GE, 2006, J NEUROSCI, V26, P5180, DOI 10.1523/JNEUROSCI.0739-06.2006; Unni VK, 2004, J NEUROSCI, V24, P9612, DOI 10.1523/JNEUROSCI.5583-03.2004; Vanterpool CK, 2006, J APPL PHYSIOL, V101, P392, DOI 10.1152/japplphysiol.00167.2006; Verkhratsky A, 2002, CELL CALCIUM, V32, P393, DOI 10.1016/S0143416002001896; Ye CP, 2004, NEUROSCI LETT, V366, P320, DOI 10.1016/j.neulet.2004.05.060	43	79	81	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38440	38447		10.1074/jbc.M606736200	http://dx.doi.org/10.1074/jbc.M606736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050533	hybrid, Green Published			2022-12-25	WOS:000242709500037
J	DeBerardinis, RJ; Lum, JJ; Thompson, CB				DeBerardinis, Ralph J.; Lum, Julian J.; Thompson, Craig B.			Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ACETYL-COA CARBOXYLASE-2; ACTIVATED PROTEIN-KINASE; AEROBIC GLYCOLYSIS; MALONYL-COA; GLUCOSE-METABOLISM; MOLECULAR-CLONING; HIGH-FREQUENCY; CANCER-CELLS; PIK3CA GENE	An abundant supply of extracellular nutrients is believed to be sufficient to suppress catabolism of cellular macromolecules. Here we show that, despite abundant extracellular nutrients, interleukin-3-deprived hematopoietic cells begin to catabolize intracellular lipids. Constitutive Akt activation blunts the increased beta-oxidation that accompanies growth factor withdrawal, and in growth factor-replete cells, phosphatidylinositol 3-kinase (PI3K) signaling is required to suppress lipid catabolism. Surprisingly, PI3K and Akt exert these effects by suppressing expression of the beta-oxidation enzyme carnitine palmitoyltransferase 1A (CPT1A). Cells expressing a short hairpin RNA against CPT1A fail to induce beta-oxidation in response to growth factor withdrawal and are unable to survive glucose deprivation. When CPT1A is constitutively expressed, growth factor stimulation fails to repress beta-oxidation. As a result, both net lipid synthesis and cell proliferation are diminished. Together, these results demonstrate that modulation of CPT1A expression by PI3K-dependent signaling is the major mechanism by which cells suppress beta-oxidation during anabolic growth.	Univ Penn, Sch Med, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Div Child Dev Rehabil Med & Metab Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Thompson, CB (corresponding author), Univ Penn, Sch Med, Dept Canc Biol, Abramson Family Canc Res Inst, 4th Floor BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu		Lum, Julian/0000-0002-5624-3541				Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; AbuElheiga L, 1997, J BIOL CHEM, V272, P10669; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brachat A, 2000, ONCOGENE, V19, P5073, DOI 10.1038/sj.onc.1203882; BRIVET M, 1995, ANN CLIN BIOCHEM, V32, P154, DOI 10.1177/000456329503200204; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantrell DA, 2003, CURR OPIN IMMUNOL, V15, P294, DOI 10.1016/S0952-7915(03)00052-9; COOPER EH, 1963, BRIT J HAEMATOL, V9, P101, DOI 10.1111/j.1365-2141.1963.tb05446.x; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Foster DW, 2004, ANN NY ACAD SCI, V1033, P1, DOI 10.1196/annals.1320.001; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Frauwirth KA, 2004, J IMMUNOL, V172, P4661, DOI 10.4049/jimmunol.172.8.4661; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064; HEDESKOV CJ, 1968, BIOCHEM J, V110, P373, DOI 10.1042/bj1100373; HUME DA, 1978, BIOCHEM J, V174, P703, DOI 10.1042/bj1740703; KANNY JJ, 1979, J IMMUNOL, V122, P1278; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Pizer ES, 1996, CANCER RES, V56, P1189; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Ramsay Rona R., 2004, Molecular Aspects of Medicine, V25, P475, DOI 10.1016/j.mam.2004.06.002; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Van de Sande T, 2002, CANCER RES, V62, P642; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vats D, 2006, CELL METAB, V4, P13, DOI 10.1016/j.cmet.2006.05.011; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; Warburg O, 1925, KLIN WOCHENSCHR, V4, P534, DOI DOI 10.1007/BF01726151; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x	52	177	187	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37372	37380		10.1074/jbc.M608372200	http://dx.doi.org/10.1074/jbc.M608372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17030509	hybrid			2022-12-25	WOS:000242477100014
J	Draper, O; Middleton, R; Doucleff, M; Zambryski, PC				Draper, Olga; Middleton, Rebecca; Doucleff, Michaeleen; Zambryski, Patricia C.			Topology of the VirB4 C terminus in the Agrobacterium tumefaciens VirB/D4 type IV secretion system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MEMBRANE; PROTEINS; ATPASE; MACHINERY; SUBUNITS; PRODUCT	Gram-negative type IV secretion systems (T4SSs) transfer proteins and DNA to eukaryotic and/or prokaryotic recipients resulting in pathogenesis or conjugative DNA transfer. VirB4, one of the most conserved proteins in these systems, has both energetic and structural roles in substrate translocation. We previously predicted a structural model for the large C-terminal domain ( residues 425-789) of VirB4 of Agrobacterium tumefaciens. Here we have defined a homology-based structural model for Agrobacterium VirB11. Both VirB4 and VirB11 models predict hexameric oligomers. Yeast two-hybrid interactions define peptides in the C terminus of VirB4 and the N terminus of VirB11 that interact with each other. These interactions were mapped onto the homology models to predict direct interactions between the hexameric interfaces of VirB4 and VirB11 such that the VirB4 C terminus stacks above VirB11 in the periplasm. In support of this, fractionation and Western blotting show that the VirB4 C terminus is localized to the membrane and periplasm rather than the cytoplasm of cells. Additional high resolution yeast two- hybrid results demonstrate interactions between the C terminus of VirB4 and the periplasmic portions of VirB1, VirB8, and VirB10. Genetic studies reveal dominant negative interactions and thus function of the VirB4C terminus in vivo. The above data are integrated with the existing body of literature to propose a structural, periplasmic role for the C-terminal half of the Agrobacterium VirB4 protein.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Zambryski, PC (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	zambrysk@nature.berkeley.edu						Atmakuri K, 2004, MOL MICROBIOL, V54, P1199, DOI 10.1111/j.1365-2958.2004.04345.x; Bailey S, 2006, P NATL ACAD SCI USA, V103, P2582, DOI 10.1073/pnas.0511216103; Baron C, 1997, J BACTERIOL, V179, P1203, DOI 10.1128/jb.179.4.1203-1210.1997; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BEIJERSBERGEN A, 1994, PLASMID, V32, P212, DOI 10.1006/plas.1994.1057; BERGER BR, 1993, J BACTERIOL, V175, P1723, DOI 10.1128/JB.175.6.1723-1734.1993; Burns DL, 2003, CURR OPIN MICROBIOL, V6, P29, DOI 10.1016/S1369-5274(02)00006-1; Cao TB, 2001, MICROBIOL-SGM, V147, P3201, DOI 10.1099/00221287-147-12-3201; Cascales E, 2004, P NATL ACAD SCI USA, V101, P17228, DOI 10.1073/pnas.0405843101; Cascales E, 2004, SCIENCE, V304, P1170, DOI 10.1126/science.1095211; Christie PJ, 2005, MOL MEMBR BIOL, V22, P51, DOI 10.1080/09687860500063316; Christie PJ, 2005, ANNU REV MICROBIOL, V59, P451, DOI 10.1146/annurev.micro.58.030603.123630; Dang TA, 1999, MOL MICROBIOL, V32, P1239, DOI 10.1046/j.1365-2958.1999.01436.x; Dang TAT, 1997, J BACTERIOL, V179, P453, DOI 10.1128/jb.179.2.453-462.1997; Das A, 2000, J BACTERIOL, V182, P758, DOI 10.1128/JB.182.3.758-763.2000; Das A, 1998, MOL MICROBIOL, V27, P405, DOI 10.1046/j.1365-2958.1998.00688.x; DEMAAGD RA, 1986, J BACTERIOL, V167, P1083, DOI 10.1128/jb.167.3.1083-1085.1986; Durfee T, 1999, YEAST, V15, P1761, DOI 10.1002/(SICI)1097-0061(199912)15:16<1761::AID-YEA494>3.0.CO;2-C; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; Gribun A, 2005, J BIOL CHEM, V280, P16185, DOI 10.1074/jbc.M414124200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Iyer LM, 2004, J STRUCT BIOL, V146, P11, DOI 10.1016/j.jsb.2003.10.010; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KULDAU GA, 1991, THESIS U CALIFORNIA; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Llosa M, 2000, J BACTERIOL, V182, P3437, DOI 10.1128/JB.182.12.3437-3445.2000; Middleton R, 2005, P NATL ACAD SCI USA, V102, P1685, DOI 10.1073/pnas.0409399102; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P7321, DOI 10.1073/pnas.93.14.7321; Nagai H, 2003, CELL MICROBIOL, V5, P373, DOI 10.1046/j.1462-5822.2003.00285.x; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rashkova S, 1997, J BACTERIOL, V179, P583, DOI 10.1128/jb.179.3.583-591.1997; Sagulenko E, 2001, J BACTERIOL, V183, P5813, DOI 10.1128/JB.183.20.5813-5825.2001; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J, 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schroder G, 2005, PLASMID, V54, P1, DOI 10.1016/j.plasmid.2005.02.001; Tai TH, 1999, P NATL ACAD SCI USA, V96, P14153, DOI 10.1073/pnas.96.24.14153; Terradot L, 2005, P NATL ACAD SCI USA, V102, P4596, DOI 10.1073/pnas.0408927102; THORSTENSON YR, 1994, J BACTERIOL, V176, P1711, DOI 10.1128/jb.176.6.1711-1717.1994; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Ward DV, 2002, P NATL ACAD SCI USA, V99, P11493, DOI 10.1073/pnas.172390299; Yeo HJ, 2000, MOL CELL, V6, P1461, DOI 10.1016/S1097-2765(00)00142-8; Yuan Q, 2005, J BIOL CHEM, V280, P26349, DOI 10.1074/jbc.M502347200; Zahrl D, 2005, MICROBIOL-SGM, V151, P3455, DOI 10.1099/mic.0.28141-0	44	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37628	37635		10.1074/jbc.M606403200	http://dx.doi.org/10.1074/jbc.M606403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17038312	hybrid			2022-12-25	WOS:000242477100039
J	Curnis, F; Longhi, R; Crippa, L; Cattaneo, A; Dondossola, E; Bachi, A; Corti, A				Curnis, Flavio; Longhi, Renato; Crippa, Luca; Cattaneo, Angela; Dondossola, Eleonora; Bachi, Angela; Corti, Angelo			Spontaneous formation of L-isoaspartate and gain of function in fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN CARBOXYL METHYLTRANSFERASE; ASPARTYL RESIDUES; INTEGRIN ALPHA(V)BETA(3); ASPARAGINE RESIDUES; TARGETED DELIVERY; CYCLIC-PEPTIDES; BLOOD-VESSELS; HOMING MOTIF; FACTOR-ALPHA	Isoaspartate formation in extracellular matrix proteins, by aspartate isomerization or asparagine deamidation, is generally viewed as a degradation reaction occurring in vivo during tissue aging. For instance, non-enzymatic isoaspartate formation at RGD-integrin binding sites causes loss of cell adhesion sites, which in turn can be enzymatically "repaired" to RGD by protein-L-isoAsp-O- methyltransferase. We show here that isoaspartate formation is also a mechanism for extracellular matrix activation. In particular, we show that deamidation of Asn(263) at the Asn-Gly-Arg (NGR) site in fibronectin N-terminal region generates an alpha(v)beta(3)-integrin binding site containing the L-isoDGR sequence, which is enzymatically "deactivated" to DGR by protein-L-isoAsp-O-methyltransferase. Furthermore, rapid NGR-to-isoDGR sequence transition in fibronectin fragments generates alpha(v)beta(3) antagonists ( named "isonectins") that competitively bind RGD binding sites and inhibit endothelial cell adhesion, proliferation, and tumor growth. Time-dependent generation of isoDGR may represent a sort of molecular clock for activating latent integrin binding sites in proteins.	Ist Sci San Raffaele, Dept Oncol, Canc Immunotherapy & Gene Therapy Program, I-20132 Milan, Italy; Ist Sci San Raffaele, Italian Inst Technol, Network Res Unit Mol Neurosci, I-20132 Milan, Italy; Conziglio Nazl Ric, Ist Chim Riconoscimento Mol, I-20131 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto Italiano di Tecnologia - IIT; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Corti, A (corresponding author), Ist Sci San Raffaele, Dept Oncol, Canc Immunotherapy & Gene Therapy Program, Via Olgettina 58, I-20132 Milan, Italy.	corti.angelo@hsr.it	Corti, Angelo/F-7046-2012; bachi, angela/B-3527-2015; Curnis, Flavio/AAK-3542-2020	Corti, Angelo/0000-0002-0893-6191; bachi, angela/0000-0003-4842-6556; Curnis, Flavio/0000-0002-7231-9569; Subba, Rajkrishna/0000-0003-0051-0062				AKIYAMA SK, 1995, EXTRACELLULAR MATRIX, P175; ASWAD DW, 1984, J BIOL CHEM, V259, P714; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Colombo G, 2002, J BIOL CHEM, V277, P47891, DOI 10.1074/jbc.M207500200; CORTI A, 1994, J IMMUNOL METHODS, V177, P191, DOI 10.1016/0022-1759(94)90156-2; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; Curnis F, 2005, CANCER RES, V65, P2906, DOI 10.1158/0008-5472.CAN-04-4282; Curnis F, 2004, CANCER RES, V64, P565, DOI 10.1158/0008-5472.CAN-03-1753; Di Matteo P, 2006, MOL IMMUNOL, V43, P1509, DOI 10.1016/j.molimm.2005.10.009; Fuzery AK, 2005, J PEPT SCI, V11, P53, DOI 10.1002/psc.588; GALLETTI P, 1988, EUR J BIOCHEM, V177, P233, DOI 10.1111/j.1432-1033.1988.tb14367.x; Gasparri A, 1999, CANCER RES, V59, P2917; GEIGER T, 1987, J BIOL CHEM, V262, P785; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; HUMPHRIES MJ, 1989, CANCER INVEST, V7, P373, DOI 10.3109/07357908909039866; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Johansson S, 1997, FRONT BIOSCI, V2, P126; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Lanthier J, 2004, EXP CELL RES, V293, P96, DOI 10.1016/j.yexcr.2003.10.003; Lindner H, 2001, EXP GERONTOL, V36, P1551, DOI 10.1016/S0531-5565(01)00140-1; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; Mohri H, 1997, PEPTIDES, V18, P899, DOI 10.1016/S0196-9781(97)00027-2; MURRAY ED, 1984, J BIOL CHEM, V259, P722; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; Pepperkok R, 2000, J CELL BIOL, V148, P715, DOI 10.1083/jcb.148.4.715; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PUSSELL BA, 1985, J CLIN INVEST, V76, P143, DOI 10.1172/JCI111937; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Reissner KJ, 2003, CELL MOL LIFE SCI, V60, P1281, DOI 10.1007/s00018-003-2287-5; ROBINSON AB, 1970, P NATL ACAD SCI USA, V66, P753, DOI 10.1073/pnas.66.3.753; Robinson NE, 2004, J PEPT RES, V63, P426, DOI 10.1111/j.1399-3011.2004.00151.x; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P944, DOI 10.1073/pnas.98.3.944; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Tanzarella S, 1999, CANCER RES, V59, P2668; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; Weber DJ, 1997, J PROTEIN CHEM, V16, P257, DOI 10.1023/A:1026300924908; Weber DJ, 1997, J PROTEIN CHEM, V16, P269, DOI 10.1023/A:1026352908978; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3	48	155	161	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36466	36476		10.1074/jbc.M604812200	http://dx.doi.org/10.1074/jbc.M604812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17015452	hybrid			2022-12-25	WOS:000242100500097
J	Mao, XR; Moerman-Herzog, AM; Wang, W; Barger, SW				Mao, Xianrong; Moerman-Herzog, Andrea M.; Wang, Wei; Barger, Steven W.			Differential transcriptional control of the superoxide dismutase-2 kappa B element in neurons and astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; EMBRYONAL CARCINOMA-CELLS; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; BINDING FACTOR; FACTOR SP3; ACTIVATION; INDUCTION; FAMILY; INTERLEUKIN-1-BETA	In addition to their conventional G-C/T target sequences, Sp1 family transcription factors (Sp-factors)can interact with a subset of the target sequences for NF kappa B. Due to the low level of bona fide NF kappa B activity in most resting cells, this interaction between Sp-factors and kappa B-sites could play important roles in cell function. Here we used mutagenesis of a canonical kappa B element from the immunoglobulin and HIV promoters to identify the GC-rich sequences at each end required for Sp-factor targeting. Through screening of multiple kappa B elements, a sequence element located in the second intron of superoxide dismutase-2 (SOD2) was identified as a good candidate for both NF kappa B and Sp-factor binding. In neurons, the prominent proteins interacting with this site were Sp3 and Sp4, whereas Sp1, Sp3, and NF kappa B were associated with this site in astroglia. The neuronal Sp-factors repressed transcriptional activity through this kappa B-site. In contrast, astroglial Sp-factors activated promoter activity through the same element. NF kappa B contributed to control of the SOD2 kappa B element only in astrocytes. These findings imply that cell-type specificity of transcription in the central nervous system, particularly with regard to kappa B elements, may include two unique aspects of neurons: 1) a recalcitrant NF kappa B and 2) the substitution of Sp4 for Sp1.	Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Neurobiol & Dev Sci, Little Rock, AR 72205 USA; Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Barger, SW (corresponding author), Reynolds Inst Aging, 629 Jack Stephens Dr,807, Little Rock, AR 72205 USA.	bargerstevenw@uams.edu		Moerman-Herzog, Andrea/0000-0002-5969-8939; Barger, Steven/0000-0001-6049-6480	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012411] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG012411, P01 AG012411-060003] Funding Source: Medline; NINDS NIH HHS [R01 NS046439-03, R01NS046439, R01 NS046439] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; Bai LQ, 2001, AM J PHYSIOL-CELL PH, V280, pC1168, DOI 10.1152/ajpcell.2001.280.5.C1168; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Barger SW, 2005, CURR PHARM DESIGN, V11, P985, DOI 10.2174/1381612053381594; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cheung WMW, 1999, BIOTECHNIQUES, V26, P946, DOI 10.2144/99265rr04; Choi HS, 2005, MOL PHARMACOL, V67, P1674, DOI 10.1124/mol.104.008284; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Duttaroy A, 2003, GENETICS, V165, P2295; Ebralidze A, 2004, SCIENCE, V303, P383, DOI 10.1126/science.1088679; Fujimura M, 1999, J NEUROSCI, V19, P3414; Grilli M, 1996, J BIOL CHEM, V271, P15002, DOI 10.1074/jbc.271.25.15002; GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Jarosinski KW, 2001, LAB INVEST, V81, P1275, DOI 10.1038/labinvest.3780341; Jonas EA, 2003, J NEUROSCI, V23, P8423; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Juttler E, 2004, NEUROPHARMACOLOGY, V47, P580, DOI 10.1016/j.neuropharm.2004.05.009; Kaltschmidt B, 2002, BMC MOL BIOL, V3, DOI 10.1186/1471-2199-3-16; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee JA, 2005, J BIOL CHEM, V280, P28061, DOI 10.1074/jbc.M414134200; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Li YK, 2000, J NEUROCHEM, V74, P143; Liu AG, 2004, J BIOL CHEM, V279, P17449, DOI 10.1074/jbc.M311267200; Lukiw WJ, 1998, J NEUROSCI RES, V53, P583, DOI 10.1002/(SICI)1097-4547(19980901)53:5<583::AID-JNR8>3.3.CO;2-B; MAO X, 2006, IN PRESS J NEUROCHEM; Mao XR, 1999, J NEUROCHEM, V73, P1851; Mao XR, 2002, J BIOL CHEM, V277, P44911, DOI 10.1074/jbc.M204292200; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Massa PT, 2006, J NEUROCHEM, V97, P607, DOI 10.1111/j.1471-4159.2006.03810.x; Moerman AM, 1999, MOL BRAIN RES, V67, P303, DOI 10.1016/S0169-328X(99)00091-1; Neumann H, 1997, J EXP MED, V185, P305, DOI 10.1084/jem.185.2.305; Pan XL, 2000, J LAB CLIN MED, V136, P157, DOI 10.1067/mlc.2000.108149; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Saha RN, 2005, J NEUROCHEM, V94, P127; Saito T, 2001, J BIOL CHEM, V276, P38010; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Zhou X, 2005, MOL PSYCHIATR, V10, P393, DOI 10.1038/sj.mp.4001621	51	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35863	35872		10.1074/jbc.M604166200	http://dx.doi.org/10.1074/jbc.M604166200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17023425	hybrid, Green Accepted			2022-12-25	WOS:000242100500033
J	He, DY; Ron, D				He, Dao-Yao; Ron, Dorit			Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine	FASEB JOURNAL			English	Article						growth factor; SHSY5Y; gene expression	NUCLEUS-ACCUMBENS; PURKINJE-CELLS; GDNF; MORPHINE; RATS; DEGENERATION; ATTENUATION; ACQUISITION; WITHDRAWAL; MELATONIN	We recently showed that the up-regulation of the glial cell line-derived neurotrophic factor (GDNF) pathway in the midbrain, is the molecular mechanism by which the putative anti-addiction drug Ibogaine mediates its desirable action of reducing alcohol consumption (1). Human reports and studies in rodents have shown that a single administration of Ibogaine results in a long-lasting reduction of drug craving (humans) and drug and alcohol intake ( rodents). Here we determine whether, and how, Ibogaine exerts its long-lasting actions on GDNF expression and signaling. Using the dopaminergic-like SHSY5Y cell line as a culture model, we observed that short-term Ibogaine exposure results in a sustained increase in GDNF expression that is mediated via the induction of a long-lasting autoregulatory cycle by which GDNF positively regulates its own expression. We show that the initial exposure of cells to Ibogaine or GDNF results in an increase in GDNF mRNA, leading to protein expression and to the corresponding activation of the GDNF signaling pathway. This, in turn, leads to a further increase in the mRNA level of the growth factor. The identification of a GDNF-mediated, autoregulatory long-lasting feedback loop could have important implications for GDNF's potential value as a treatment for addiction and neurodegenerative diseases.	Univ Calif San Francisco, Ernest Gallo Res Ctr, Emeryville, CA USA; Univ Calif San Francisco, Dept Neurol, Emeryville, CA USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Ron, D (corresponding author), 5858 Horton St,Ste 200, Emeryville, CA 94608 USA.	dorit.ron@ucsf.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA014366] Funding Source: NIH RePORTER; NIAAA NIH HHS [5 R01 AA014366-02] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Alper KR, 1999, AM J ADDICTION, V8, P234; Armstrong KJ, 2002, NEUROREPORT, V13, P473, DOI 10.1097/00001756-200203250-00023; Baecker PA, 1999, MOL BRAIN RES, V69, P209, DOI 10.1016/S0169-328X(99)00106-0; Beck KD, 1996, NEURON, V16, P665, DOI 10.1016/S0896-6273(00)80085-9; Bourque MJ, 2000, EUR J NEUROSCI, V12, P3172, DOI 10.1046/j.1460-9568.2000.00219.x; Canossa M, 1997, P NATL ACAD SCI USA, V94, P13279, DOI 10.1073/pnas.94.24.13279; CAPPENDIJK SLT, 1993, EUR J PHARMACOL, V241, P261, DOI 10.1016/0014-2999(93)90212-Z; Castro LMR, 2005, J NEUROCHEM, V95, P1227, DOI 10.1111/j.1471-4159.2005.03457.x; Gerlai R, 2001, EUR J NEUROSCI, V14, P1153, DOI 10.1046/j.0953-816x.2001.01724.x; GLICK SD, 1992, NEUROPHARMACOLOGY, V31, P497, DOI 10.1016/0028-3908(92)90089-8; GLICK SD, 1994, BRAIN RES, V657, P14, DOI 10.1016/0006-8993(94)90948-2; GLICK SD, 1991, EUR J PHARMACOL, V195, P341, DOI 10.1016/0014-2999(91)90474-5; Glick SD, 2000, ANN NY ACAD SCI, V909, P88; Green-Sadan T, 2005, EXP NEUROL, V194, P97, DOI 10.1016/j.expneurol.2005.01.020; Green-Sadan T, 2003, EUR J NEUROSCI, V18, P2093, DOI 10.1046/j.1460-9568.2003.02943.x; He DY, 2005, J NEUROSCI, V25, P619, DOI 10.1523/JNEUROSCI.3959-04.2005; Kelleher RJ, 2004, CELL, V116, P467, DOI 10.1016/S0092-8674(04)00115-1; Kobori N, 2004, J BIOL CHEM, V279, P2182, DOI 10.1074/jbc.M310734200; Mash DC, 1998, ANN NY ACAD SCI, V844, P274, DOI 10.1111/j.1749-6632.1998.tb08242.x; Mash DC, 2000, ANN NY ACAD SCI, V914, P394, DOI 10.1111/j.1749-6632.2000.tb05213.x; Messer CJ, 2000, NEURON, V26, P247, DOI 10.1016/S0896-6273(00)81154-X; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; OHearn E, 1997, J NEUROSCI, V17, P8828; OHEARN E, 1993, NEUROSCIENCE, V55, P303, DOI 10.1016/0306-4522(93)90500-F; REZVANI AH, 1995, PHARMACOL BIOCHEM BE, V52, P615, DOI 10.1016/0091-3057(95)00152-M; Rezvani AH, 1997, PHARMACOL BIOCHEM BE, V58, P615, DOI 10.1016/S0091-3057(97)10003-X; Righi M, 2000, J NEUROSCI, V20, P3165, DOI 10.1523/JNEUROSCI.20-09-03165.2000; SHEPPARD SG, 1994, J SUBST ABUSE TREAT, V11, P379, DOI 10.1016/0740-5472(94)90049-3; Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346; Verity AN, 1999, J NEUROSCI RES, V55, P187, DOI 10.1002/(SICI)1097-4547(19990115)55:2<187::AID-JNR6>3.0.CO;2-T; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Xiong H, 2002, NEUROPHARMACOLOGY, V42, P903, DOI 10.1016/S0028-3908(02)00043-6; Yang F, 2001, NAT NEUROSCI, V4, P1071, DOI 10.1038/nn734	35	41	58	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2420	+		10.1096/fj.06-6394fje	http://dx.doi.org/10.1096/fj.06-6394fje			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023388				2022-12-25	WOS:000241702600040
J	Tavner, F; Frampton, J; Watson, RJ				Tavner, F.; Frampton, J.; Watson, R. J.			Targeting an E2F site in the mouse genome prevents promoter silencing in quiescent and post-mitotic cells	ONCOGENE			English	Article						B-myb promoter; cell cycle; E2F; gene silencing	B-MYB TRANSCRIPTION; IN-VIVO; CYCLE REGULATION; REGULATED EXPRESSION; REPRESSION; ACTIVATION; PRB; PHOSPHORYLATION; SENESCENCE; OCCUPATION	Previous studies have shown that the cell cycle-regulated B-myb promoter contains a conserved E2F binding site that is critical for repressing transcription in quiescent cells. To investigate its significance for permanent promoter silencing, we have inactivated this binding site in the mouse genome. Mice homozygous for the mutant B-myb(mE2F) allele were fully viable, however, B-myb transcription was derepressed during quiescence in mouse embryo fibroblasts (MEFs) derived from mutant animals. Moreover, it was found that mutation of the E2F site resulted in abnormal maintenance of B-myb expression in senescent MEFs and in differentiated brain tissue. These findings therefore reveal a direct and primary role for repressive E2F complexes in silencing gene expression in post-mitotic cells. Analysis of histone modifications at the promoter showed that histone H3 lysine 9 was constitutively acetylated throughout the cell cycle in homozygous mutant MEFs. This mouse system is the first description of an E2F site mutation in situ and will facilitate the study of E2F function in vivo.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; Univ Birmingham, Sch Med, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England	Imperial College London; University of Birmingham	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	r.watson@imperial.ac.uk						Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bennett JD, 1996, ONCOGENE, V13, P1073; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Maehara K, 2005, J CELL BIOL, V168, P553, DOI 10.1083/jcb.200411093; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagy AG, 2003, MANIPULATING MOUSE G; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Robinson C, 1996, ONCOGENE, V12, P1855; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sitzmann J, 1996, ONCOGENE, V12, P1889; Takahashi Y, 2000, GENE DEV, V14, P804; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	27	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2727	2735		10.1038/sj.onc.1210087	http://dx.doi.org/10.1038/sj.onc.1210087			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072340				2022-12-25	WOS:000246210600007
J	Clark, J; Merson, S; Jhavar, S; Flohr, P; Edwards, S; Foster, CS; Eeles, R; Martin, FL; Phillips, DH; Crundwell, M; Christmas, T; Thompson, A; Fisher, C; Kovacs, G; Cooper, CS				Clark, J.; Merson, S.; Jhavar, S.; Flohr, P.; Edwards, S.; Foster, C. S.; Eeles, R.; Martin, F. L.; Phillips, D. H.; Crundwell, M.; Christmas, T.; Thompson, A.; Fisher, C.; Kovacs, G.; Cooper, C. S.			Diversity of TMPRSS2-ERG fusion transcripts in the human prostate	ONCOGENE			English	Article						prostate cancer; ERG gene; TMPRSS2 gene; ERG fusion transcripts	EWINGS-SARCOMA; MYELOID-LEUKEMIA; CANCER; IDENTIFICATION; GENES; TRANSLOCATION; TLS/FUS; RNA; ERG	TMPRSS2-ERG gene fusions have recently been reported to be present in a high proportion of human prostate cancers. In the current study, we show that great diversity exists in the precise structure of TMPRSS2-ERG hybrid transcripts found in human prostates. Fourteen distinct hybrid transcripts are characterized, each containing different combinations of sequences from the TMPRSS2 and ERG genes. The transcripts include two that are predicted to encode a normal full-length ERG protein, six that encode N-terminal truncated ERG proteins and one that encodes a TMPRSS2-ERG fusion protein. Interestingly, distinct patterns of hybrid transcripts were found in samples taken from separate regions of individual cancer-containing prostates, suggesting that TMPRSS2-ERG gene fusions may be arising independently in different regions of a single prostate.	Inst Canc Res, Male Urol Canc Res Ctr, Sutton SM2 5NG, Surrey, England; Univ Liverpool, Royal Liverpool Univ Hosp, Dept Pathol, Liverpool L69 3BX, Merseyside, England; Royal Marsden NHS Trust Fdn Hosp, Surrey, England; Univ Lancaster, Dept Biol Sci, Biomed Sci Unit, Lancaster LA1 4YW, England; Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; Royal Marsden NHS Fdn Trust Hosp, Dept Urol, London, England; Univ Heidelberg, Fac Med, Oncol Mol Lab, Heidelberg, Germany	University of London; Institute of Cancer Research - UK; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Marsden NHS Foundation Trust; Lancaster University; University of Exeter; Royal Marsden NHS Foundation Trust; Ruprecht Karls University Heidelberg	Clark, J (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	jeremy.clark@icr.ac.uk	Martin, Francis L/J-4585-2019	Martin, Francis L/0000-0001-8562-4944; Eeles, Rosalind/0000-0002-3698-6241; Phillips, David/0000-0001-8509-3485	Medical Research Council [G0501019] Funding Source: Medline; MRC [G0501019] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		CARNEY DN, 1985, CANCER RES, V45, P2913; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; COOPER CS, 2001, TRANSLOCATIONS SOLID; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 2002, CHROMOSOMES TRANSLOC; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Jhavar SG, 2005, J CLIN PATHOL, V58, P504, DOI 10.1136/jcp.2004.021808; Kojima T, 2002, BIOL PHARM BULL, V25, P991, DOI 10.1248/bpb.25.991; Kong XT, 1997, BLOOD, V90, P1192; Lin PP, 1999, CANCER RES, V59, P1428; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Soller MJ, 2006, GENE CHROMOSOME CANC, V45, P717, DOI 10.1002/gcc.20329; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679	16	185	205	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2667	2673		10.1038/sj.onc.1210070	http://dx.doi.org/10.1038/sj.onc.1210070			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043636				2022-12-25	WOS:000245831200014
J	Shao, RX; Kato, N; Lin, LJ; Muroyama, R; Moriyama, M; Ikenoue, T; Watabe, H; Otsuka, M; Guleng, B; Ohta, M; Tanaka, Y; Kondo, S; Dharel, N; Chang, JH; Yoshida, H; Kawabe, T; Omata, M				Shao, R-X; Kato, N.; Lin, L-J; Muroyama, R.; Moriyama, M.; Ikenoue, T.; Watabe, H.; Otsuka, M.; Guleng, B.; Ohta, M.; Tanaka, Y.; Kondo, S.; Dharel, N.; Chang, J-H; Yoshida, H.; Kawabe, T.; Omata, M.			Absence of tyrosine kinase mutations in Japanese colorectal cancer patients	ONCOGENE			English	Article						tyrosine kinase; mutation; colorectal cancer	GENE	Tyrosine kinases, which are important regulators of intracellular signal-transduction pathways, have mutated forms that are often associated with oncogenesis and are attractive targets for therapeutic intervention. Recently, systematic mutational analyses of tyrosine kinases revealed that a minimum of 30% of colorectal cancer contain at least one mutation in the tyrosine kinases. To further explore these mutations, we examined all reported mutations of NTRK3, FES, KDR, EPHA3, NTRK2, JAK1, PDGFRA, EPHA7, EPHA8, ERBB4, FGFR1, MLK4 and GUCY2F genes in the 24 colorectal cancer cell lines. Unexpectedly, among 24 colorectal cancer cell lines, only two cell lines (LoVo and CaR1) harbored mutation C1408T (R470C) in MLK4 gene. The mutation rate was extremely low compared to that previously reported. Therefore, we analyzed mutations in 46 colorectal cancer samples resected from the same number of Japanese patients. Surprisingly, none of the 46 samples contained any of the mutations reported. Based on our study, we advise that a more comprehensive tyrosine kinase gene mutation assay is necessary in the future.	Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan; Jilin Univ, China Japan Union Hosp, Dept Gastroenterol, Changchun 130023, Jilin Province, Peoples R China; China Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Shenyang, Peoples R China	University of Tokyo; Jilin University; China Medical University	Kato, N (corresponding author), Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kato-2im@h.u-tokyo.ac.jp	Otsuka, Motoyuki/H-9067-2019	Otsuka, Motoyuki/0000-0003-2869-2881; Tanaka, Yasuo/0000-0002-2917-3365				Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shao RX, 2005, J GASTROENTEROL, V40, P918, DOI 10.1007/s00535-005-1661-5; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022	7	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2133	2135		10.1038/sj.onc.1210007	http://dx.doi.org/10.1038/sj.onc.1210007			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016444				2022-12-25	WOS:000245313400015
J	Ma, L; Kaserer, W; Annamalai, R; Scott, DC; Jin, B; Jiang, XX; Xiao, QB; Maymani, H; Massis, LM; Ferreira, LCS; Newton, SMC; Klebba, PE				Ma, Li; Kaserer, Wallace; Annamalai, Rajasekeran; Scott, Daniel C.; Jin, Bo; Jiang, Xiaoxu; Xiao, Qiaobin; Maymani, Hossein; Massis, Liliana Moura; Ferreira, Luiz C. S.; Newton, Salete M. C.; Klebba, Phillip E.			Evidence of ball-and-chain transport of ferric enterobactin through FepA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; BACTERIAL OUTER-MEMBRANE; CRYSTAL-STRUCTURE; IRON TRANSPORT; CELL-ENVELOPE; SALMONELLA-TYPHIMURIUM; MOLECULAR-BASIS; PORIN CHANNELS; RECEPTOR; PROTEIN	The Escherichia coli iron transporter, FepA, has a globular N terminus that resides within a transmembrane beta-barrel formed by its C terminus. We engineered 25 cysteine substitution mutations at different locations in FepA and modified their sulfhydryl side chains with fluorescein maleimide in live cells. The reactivity of the Cys residues changed, sometimes dramatically, during the transport of ferric enterobactin, the natural ligand of FepA. Patterns of Cys susceptibility reflected energy- and TonB-dependent motion in the receptor protein. During transport, a residue on the normally buried surface of the N-domain was labeled by fluorescein maleimide in the periplasm, providing evidence that the transport process involves expulsion of the globular domain from the beta-barrel. Porin deficiency much reduced the fluoresceination of this site, confirming the periplasmic labeling route. These data support the previously proposed, but never demonstrated, ball-and-chain theory of membrane transport. Functional complementation between a separately expressed N terminus and C-terminal beta-barrel domain confirmed the feasibility of this mechanism.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Univ Sao Paulo, Dept Microbiol, BR-05508900 Sao Paulo, Brazil	University of Oklahoma System; University of Oklahoma - Norman; Universidade de Sao Paulo	Klebba, PE (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval, Norman, OK 73019 USA.	peklebba@ou.edu	Ferreira, Luis Carlos S/M-3954-2014; Jiang, xiaoxu/B-6996-2012; Massis, Liliana Moura/G-3660-2013	Ferreira, Luis Carlos S/0000-0002-4883-1693; Massis, Liliana Moura/0000-0001-8938-9507	NIGMS NIH HHS [R01 GM053836, R01 GM053836-11, GM53836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1974, J BIOL CHEM, V249, P634; Annamalai R, 2004, J BACTERIOL, V186, P3578, DOI 10.1128/JB.186.11.3578-3589.2004; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BRADBEER C, 1978, J BIOL CHEM, V253, P1347; BRADBEER C, 1976, J BACTERIOL, V125, P1032, DOI 10.1128/JB.125.3.1032-1039.1976; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; Braun M, 2003, J BACTERIOL, V185, P5508, DOI 10.1128/JB.185.18.5508-5518.2003; BRAUN V, 1973, FEBS LETT, V34, P77, DOI 10.1016/0014-5793(73)80707-0; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 2003, P NATL ACAD SCI USA, V100, P10688, DOI 10.1073/pnas.1932538100; Cao ZH, 2000, MOL MICROBIOL, V37, P1306, DOI 10.1046/j.1365-2958.2000.02093.x; Cao ZH, 2003, J BIOL CHEM, V278, P1022, DOI 10.1074/jbc.M210360200; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; Cobessi D, 2005, J MOL BIOL, V347, P121, DOI 10.1016/j.jmb.2005.01.021; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DIMASI DR, 1973, J BACTERIOL, V115, P506, DOI 10.1128/JB.115.2.506-513.1973; Eisenhauer HA, 2005, J BIOL CHEM, V280, P30574, DOI 10.1074/jbc.M506708200; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; GUTERMAN SK, 1973, J BACTERIOL, V114, P1225, DOI 10.1128/JB.114.3.1225-1230.1973; HASHIMOTOGOTOH T, 1981, GENE, V16, P227, DOI 10.1016/0378-1119(81)90079-2; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; KLEBBA PE, 1982, J BACTERIOL, V149, P880, DOI 10.1128/JB.149.3.880-888.1982; Klebba PE, 2003, FRONT BIOSCI, V8, pS1422, DOI 10.2741/1233; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LUCKEY M, 1972, Journal of Bacteriology, V111, P731; LUCKEY M, 1976, J BACTERIOL, V127, P1036, DOI 10.1128/JB.127.2.1036-1037.1976; Merianos HJ, 2000, NAT STRUCT BIOL, V7, P205; MILELR JH, 1972, EXPT MOL GENETICS; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Newton SMC, 1999, MOL MICROBIOL, V32, P1153, DOI 10.1046/j.1365-2958.1999.01424.x; Newton SMC, 1997, P NATL ACAD SCI USA, V94, P4560, DOI 10.1073/pnas.94.9.4560; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Pawelek PD, 2006, SCIENCE, V312, P1399, DOI 10.1126/science.1128057; Payne MA, 1997, J BIOL CHEM, V272, P21950, DOI 10.1074/jbc.272.35.21950; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; PUGSLEY AP, 1976, J BACTERIOL, V126, P1052, DOI 10.1128/JB.126.3.1052-1062.1976; PUGSLEY AP, 1977, J BACTERIOL, V130, P26, DOI 10.1128/JB.130.1.26-36.1977; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; RUTZ JM, 1991, J BACTERIOL, V173, P5964, DOI 10.1128/jb.173.19.5964-5974.1991; Saier MH, 2000, J MEMBRANE BIOL, V175, P165, DOI 10.1007/s00232001065; Scott DC, 2002, J BACTERIOL, V184, P4906, DOI 10.1128/JB.184.17.4906-4911.2002; Scott DC, 2001, J BIOL CHEM, V276, P13025, DOI 10.1074/jbc.M011282200; Shultis DD, 2006, SCIENCE, V312, P1396, DOI 10.1126/science.1127694; SMIT J, 1975, J BACTERIOL, V124, P942, DOI 10.1128/JB.124.2.942-958.1975; Sprencel C, 2000, J BACTERIOL, V182, P5359, DOI 10.1128/JB.182.19.5359-5364.2000; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; Usher KC, 2001, P NATL ACAD SCI USA, V98, P10676, DOI 10.1073/pnas.181353398; Vakharia HL, 2002, J BACTERIOL, V184, P5508, DOI 10.1128/JB.184.19.5508-5512.2002; WANG CC, 1971, J BIOL CHEM, V246, P2147; WANG CC, 1969, J BACTERIOL, V98, P1142, DOI 10.1128/JB.98.3.1142-1150.1969; WAYNE R, 1976, J BACTERIOL, V126, P7, DOI 10.1128/JB.126.1.7-12.1976	56	60	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					397	406		10.1074/jbc.M605333200	http://dx.doi.org/10.1074/jbc.M605333200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17056600	Green Accepted, hybrid			2022-12-25	WOS:000243166500045
J	Ohnishi, T; Ohba, H; Seo, KC; Im, J; Sato, Y; Iwayama, Y; Furuichi, T; Chung, SK; Yoshikawa, T				Ohnishi, Tetsuo; Ohba, Hisako; Seo, Kyung-Chang; Im, Jungkyun; Sato, Yumi; Iwayama, Yoshimi; Furuichi, Tefichi; Chung, Sung-Kee; Yoshikawa, Takeo			Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL MONOPHOSPHATASE; BOVINE BRAIN; BIPOLAR DISORDER; PUTATIVE TARGET; PROTEIN-KINASE; RAT-BRAIN; LITHIUM; PURIFICATION; MYO-INOSITOL-1-PHOSPHATASE; PHOSPHORYLATION	Lithium is used in the clinical treatment of bipolar disorder, a disease where patients suffer mood swings between mania and depression. Although the mode of action of lithium remains elusive, a putative primary target is thought to be inositol monophosphatase (IMPase) activity. Two IMPase genes have been identified in mammals, the well characterized myo-inositol monophosphatase 1 (IMPA1) and myo-inositol monophosphatase 2 (IMPA2). Several lines of genetic evidence have implicated IMPA2 in the pathogenesis of not only bipolar disorder but also schizophrenia and febrile seizures. However, little is known about the protein, although it is predicted to have lithium-inhibitable IMPase activity based on its homology to IMPA1. Here we present the first biochemical study comparing the enzyme activity of IMPA2 to that of IMPA1. We demonstrate that in vivo, IMPA2 forms homodimers but no heterodimers with IMPA1. Recombinant IMPA2 exhibits IMPase activity, although maximal activity requires higher concentrations of magnesium and a higher pH. IMPA2 shows significantly lower activity toward myo-inositol monophosphate than IMPA1. We therefore screened for additional substrates that could be more efficiently dephosphorylated by IMPA2, but failed to find any. Importantly, when using myo-inositol monophosphate as a substrate, the IMPase activity of IMPA2 was inhibited at high lithium and restricted magnesium concentrations. This kinetics distinguishes it from IMPA1. We also observed a characteristic pattern of differential expression between IMPA1 and IMPA2 in a selection of tissues including the brain, small intestine, and kidney. These data suggest that IMPA2 has a separate function in vivo from that of IMPA1.	RIKEN, Brain Sci Inst, Lab Mol Psychiat, Wako, Saitama 3510198, Japan; Pohang Univ Sci & Technol, Div Mol & Life Sci, Dept Chem, Pohang 790784, South Korea; RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan	RIKEN; Pohang University of Science & Technology (POSTECH); RIKEN	Ohnishi, T (corresponding author), RIKEN, Brain Sci Inst, Lab Mol Psychiat, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	tohnishi@brain.riken.jp	Furuichi, Teiichi/B-5086-2014; Yoshikawa, Takeo/F-9599-2019; Ohnishi, Tetsuo/D-3791-2018; Ohnishi, Tetsuo/AAC-2767-2022; Ohnishi, Tetsuo/AAC-5694-2019	Furuichi, Teiichi/0000-0002-9676-1888; Ohnishi, Tetsuo/0000-0002-6696-9725; Ohnishi, Tetsuo/0000-0002-6696-9725				Agranoff B W, 2001, Psychopharmacol Bull, V35, P5; ARAI R, 2007, IN PRESS PROTEINS ST; Atack JR, 1996, BRAIN RES REV, V22, P183; ATACK JR, 1995, TRENDS NEUROSCI, V18, P343, DOI 10.1016/0166-2236(95)93926-O; ATTWOOD PV, 1988, BIOCHEM J, V253, P387, DOI 10.1042/bj2530387; Berggard T, 2002, J BIOL CHEM, V277, P41954, DOI 10.1074/jbc.M203492200; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; Chung S. K., 1996, KOR J MED CHEM, V6, P162; Chung SK, 1999, BIOORGAN MED CHEM, V7, P2577, DOI 10.1016/S0968-0896(99)00183-2; DIEHL RE, 1990, J BIOL CHEM, V265, P5946; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; GEE NS, 1988, BIOCHEM J, V249, P883, DOI 10.1042/bj2490883; Gould TD, 2005, NEUROPSYCHOPHARMACOL, V30, P1223, DOI 10.1038/sj.npp.1300731; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; Harwood AJ, 2005, MOL PSYCHIATR, V10, P117, DOI 10.1038/sj.mp.4001618; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; KENNEDY SP, 1988, BIOCHEM BIOPH RES CO, V155, P189, DOI 10.1016/S0006-291X(88)81067-2; MCALLISTER G, 1992, BIOCHEM J, V284, P749, DOI 10.1042/bj2840749; MEEK JL, 1988, BIOCHEM BIOPH RES CO, V156, P143, DOI 10.1016/S0006-291X(88)80816-7; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; Nakayama J, 2004, NEUROLOGY, V63, P1803, DOI 10.1212/01.WNL.0000144499.34164.E0; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; Quiroz JA, 2004, MOL INTERV, V4, P259, DOI 10.1124/mi.4.5.6; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035; Schmidt H, 2005, P NATL ACAD SCI USA, V102, P5850, DOI 10.1073/pnas.0407855102; SEO KC, 2006, IN PRESS J CARBOHYDR; Sjoholt G, 2004, MOL PSYCHIATR, V9, P621, DOI 10.1038/sj.mp.4001460; Stolovich M, 2005, J BIOL CHEM, V280, P5336, DOI 10.1074/jbc.M412434200; TAKIMOTO K, 1985, J BIOCHEM-TOKYO, V98, P363, DOI 10.1093/oxfordjournals.jbchem.a135290; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Yoshikawa T, 2000, MOL PSYCHIATR, V5, P165, DOI 10.1038/sj.mp.4000688; Yoshikawa T, 1997, MOL PSYCHIATR, V2, P393, DOI 10.1038/sj.mp.4000325; Yoshikawa T, 2001, MOL PSYCHIATR, V6, P202, DOI 10.1038/sj.mp.4000835; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; ZUBILETE MZ, 2003, VERTEX, V14, P45	41	52	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					637	646		10.1074/jbc.M604474200	http://dx.doi.org/10.1074/jbc.M604474200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17068342	hybrid			2022-12-25	WOS:000243166500069
J	Suen, DF; Huang, AHC				Suen, Der Fen; Huang, Anthony H. C.			Maize pollen coat xylanase facilitates pollen tube penetration into silk during sexual reproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; STIGMA; PURIFICATION; GROWTH	Cell wall hydrolases are well documented to be present on pollen, but their roles on the stigma during sexual reproduction have not been previously demonstrated. We explored the function of the tapetum-synthesized xylanase, ZmXYN1, on maize (Zea mays L.) pollen. Transgenic lines (xyl-less) containing little or no xylanase in the pollen coat were generated with use of an antisense construct of the xylanase gene-coding region driven by the XYN1 gene promoter. Xyl-less and wild-type plants had similar vegetative growth. Electron microscopy revealed no appreciable morphological difference in anther cells and pollen between xyl-less lines and the wild type, whereas immunofluorescence microscopy and biochemical analyses indicated an absence of xylanase on xyl-less pollen. Xyl-less pollen germinated as efficiently as wild-type pollen in vitro in a liquid medium but less so on gel media of increasing solidity or on silk, which is indicative of partial impaired water uptake. Once germinated in vitro or on silk, the xyl-less and wild-type pollen tubes elongated at comparable rates. Tubes of germinated xyl-less pollen on silk did not penetrate into the silk as efficiently as tubes of wild-type pollen, and this lower efficiency could be overcome by the addition of xylanase to the silk. For wild-type pollen, coat xylanase activity on oat spelled xylan in vitro and tube penetration into silk were inhibited by xylose but not glucose. The overall findings indicate that maize pollen coat xylanase facilitates pollen tube penetration into silk via enzymatic xylan hydrolysis.	Univ Calif Riverside, Ctr Cell Biol, Dept Bot & Plant Sci, Riverside, CA 92521 USA	University of California System; University of California Riverside	Huang, AHC (corresponding author), Univ Calif Riverside, Ctr Cell Biol, Dept Bot & Plant Sci, Riverside, CA 92521 USA.	Anthony.Huang@ucr.edu	Suen, Der-Fen/ACF-7547-2022					ALLEN RL, 1993, PLANT J, V3, P261, DOI 10.1046/j.1365-313X.1993.t01-14-00999.x; Aylor DE, 2003, J EXP BOT, V54, P2307, DOI 10.1093/jxb/erg242; Bewley JD, 2000, BIOCH MOL BIOL PLANT, P988; Bih FY, 1999, J BIOL CHEM, V274, P22884, DOI 10.1074/jbc.274.32.22884; Bosch M, 2005, PLANT CELL, V17, P3219, DOI 10.1105/tpc.105.037473; Bosch M, 2005, PLANT PHYSIOL, V138, P1334, DOI 10.1104/pp.105.059865; Carpita N., 2000, BIOCH MOL BIOL PLANT, P52; CHAY CH, 1992, PLANT PHYSIOL, V100, P756, DOI 10.1104/pp.100.2.756; Edlund AF, 2004, PLANT CELL, V16, pS84, DOI 10.1105/tpc.015800; GORDONKAMM WJ, 1990, PLANT CELL, V2, P603, DOI 10.1105/tpc.2.7.603; Hadfield KA, 1998, PLANT PHYSIOL, V117, P337, DOI 10.1104/pp.117.2.337; HESLOPHARRISON Y, 1984, ACTA BOT NEERL, V33, P205, DOI 10.1111/j.1438-8677.1984.tb01799.x; HESSE M, 1993, CYTOLOGY FUNCTION BI; Kachroo A, 2002, PLANT CELL, V14, pS227, DOI 10.1105/tpc.010440; KATO TH, 2004, PLANT CELL, V16, pS72; Kim HU, 2002, J BIOL CHEM, V277, P22677, DOI 10.1074/jbc.M109298200; Knox RB, 1984, EMBRYOLOGY ANGIOSPER, P197, DOI DOI 10.1007/978-3-642-69302-1_5; Li LC, 2003, PLANT PHYSIOL, V132, P2073, DOI 10.1104/pp.103.020024; Luna S, 2001, CROP SCI, V41, P1551, DOI 10.2135/cropsci2001.4151551x; MALKIN AY, 1983, EXPT METHODS POLYM P, P256; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Mayfield JA, 2000, NAT CELL BIOL, V2, P128, DOI 10.1038/35000084; McCormick S, 2004, PLANT CELL, V16, pS142, DOI 10.1105/tpc.016659; Platt KA, 1998, INT J PLANT SCI, V159, P724, DOI 10.1086/297590; RUBINSTEIN AL, 1995, P NATL ACAD SCI USA, V92, P3086, DOI 10.1073/pnas.92.8.3086; SAINI JP, 1986, MAYDICA, V31, P227; SKVARLA JJ, 1966, AM J BOT, V53, P1112, DOI 10.2307/2440692; Suen DF, 2003, J BIOL CHEM, V278, P43672, DOI 10.1074/jbc.M307843200; Suen DF, 1997, THEOR APPL GENET, V94, P331, DOI 10.1007/s001220050420; TOBIAS RB, 1991, BIOCHEM PHYSIOL PFL, V187, P243, DOI 10.1016/S0015-3796(11)80104-6; Vaucheret H, 2001, TRENDS GENET, V17, P29, DOI 10.1016/S0168-9525(00)02166-1; Walden D. B., 1994, P723; Wu SSH, 2002, J BIOL CHEM, V277, P49055, DOI 10.1074/jbc.M208804200; Wu YJ, 2001, PLANT PHYSIOL, V126, P222, DOI 10.1104/pp.126.1.222	35	28	35	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					625	636		10.1074/jbc.M608567200	http://dx.doi.org/10.1074/jbc.M608567200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17062571	hybrid			2022-12-25	WOS:000243166500068
J	Kuan, YH; Gruebl, T; Soba, P; Eggert, S; Nesic, I; Back, S; Kirsch, J; Beyreuther, K; Kins, S				Kuan, Yung-Hui; Gruebl, Tomas; Soba, Peter; Eggert, Simone; Nesic, Iva; Back, Simone; Kirsch, Joachim; Beyreuther, Konrad; Kins, Stefan			PAT1a modulates intracellular transport and processing of amyloid precursor protein (APP), APLP1, and APLP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SECRETASE CLEAVAGE; TERMINAL FRAGMENT-GAMMA; BETA-PROTEIN; ALZHEIMERS-DISEASE; CELL-SURFACE; TRANSMEMBRANE DOMAIN; DISTINCT MECHANISMS; TRANSGENIC MICE; ZETA-CLEAVAGE; FAMILY	Understanding the intracellular transport of the beta-amyloid precursor protein (APP) is a major key to elucidate the regulation of APP processing and thus beta-amyloid peptide generation in Alzheimer disease pathogenesis. APP and its two paralogues, APLP1 and APLP2 (APLPs), are processed in a very similar manner by the same protease activities. A putative candidate involved in APP transport is protein interacting with APP tail 1 (PAT1), which was reported to interact with the APP intracellular domain. We show that PAT1a, which is 99.0% identical to PAT1, binds to APP, APLP1, and APLP2 in vivo and describe their co-localization in trans-Golgi network vesicles or endosomes in primary neurons. We further demonstrate a direct interaction of PAT1a with the basolateral sorting signal of APP/APLPs. Moreover, we provide evidence for a direct role of PAT1a in APP/APLP transport as overexpression or RNA interference-mediated knockdown of PAT1a modulates APP/APLPs levels at the cell surface. Finally, we show that PAT1a promotes APP/APLPs processing, resulting in increased secretion of beta-amyloid peptide. Taken together, our data establish PAT1a as a functional link between APP/APLPs transport and their processing.	Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Anat & Cell Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kins, S (corresponding author), Univ Heidelberg, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	s.kins@zmbh.uni-heidelberg.de	Soba, Peter/AAC-8143-2020; Soba, Peter/AAK-1134-2021	Soba, Peter/0000-0002-6163-4686; Soba, Peter/0000-0002-6163-4686				Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chang Y, 2003, J BIOL CHEM, V278, P51100, DOI 10.1074/jbc.M309561200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Coulson EJ, 2000, NEUROCHEM INT, V36, P175, DOI 10.1016/S0197-0186(99)00125-4; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Duering M, 2005, NEUROBIOL AGING, V26, P785, DOI 10.1016/j.neurobiolaging.2004.08.002; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lai A, 1998, J BIOL CHEM, V273, P3732, DOI 10.1074/jbc.273.6.3732; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lazarov O, 2005, J NEUROSCI, V25, P2386, DOI 10.1523/JNEUROSCI.3089-04.2005; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; LO ACY, 1995, J BIOL CHEM, V270, P12641, DOI 10.1074/jbc.270.21.12641; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Santiard-Baron D, 2005, J NEUROCHEM, V93, P330, DOI 10.1111/j.1471-4159.2005.03026.x; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Xie ZC, 2005, J BIOL CHEM, V280, P15413, DOI 10.1074/jbc.M414353200; Yamazaki T, 1996, J CELL SCI, V109, P999; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhang YQ, 2004, MOL CELL BIOL, V24, P1044, DOI 10.1128/MCB.24.3.1044-1057.2004; Zhao GJ, 2005, J BIOL CHEM, V280, P37689, DOI 10.1074/jbc.M507993200; Zhao GJ, 2004, J BIOL CHEM, V279, P50647, DOI 10.1074/jbc.C400473200; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	52	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40114	40123		10.1074/jbc.M605407200	http://dx.doi.org/10.1074/jbc.M605407200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17050537	hybrid			2022-12-25	WOS:000243033900041
J	Simonsson, M; Kanduri, M; Gronroos, E; Heldin, CH; Ericsson, J				Simonsson, Maria; Kanduri, Meena; Gronroos, Eva; Heldin, Carl-Henrik; Ericsson, Johan			The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; C-TERMINAL DOMAIN; TGF-BETA; HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL COACTIVATOR; SIGNAL-TRANSDUCTION; FACTOR YY1; L3 LOOP; PROTEIN; ACTIVATION	Phosphorylation-dependent activation of the transcription factors Smad2 and Smad3 plays an important role in TGF beta-dependent signal transduction. Following phosphorylation of Smad2 and Smad3, these molecules are translocated to the nucleus where they interact with coactivators and/or corepressors, including p300, CBP, and P/CAF, and regulate the expression of TGF beta target genes. In the current study, we demonstrate that both Smad2 and Smad3 are acetylated by the coactivators p300 and CBP in a TGF beta-dependent manner. Smad2 is also acetylated by P/CAF. The acetylation of Smad2 was significantly higher than that of Smad3. Lys19 in the MH1 domain was identified as the major acetylated residue in both the long and short isoform of Smad2. Mutation of Lys(19) also reduced the p300-mediated acetylation of Smad3. By generating acetyl-Lys(19)-specific antibodies, we demonstrate that endogenous Smad2 is acetylated on this residue in response to TGF beta signaling. Acetylation of the short isoform of Smad2 improves itsDNAbinding activity in vitro and enhances its association with target promoters in vivo, thereby augmenting its transcriptional activity. Acetylation of Lys(19) also enhanced the DNA binding activity of Smad3. Our data indicate that acetylation of Lys(19) induces a conformational change in the MH1 domain of the short isoform of Smad2, thereby making its DNA binding domain accessible for interactions with DNA. Thus, coactivator-mediated acetylation of receptor-activated Smad molecules could represent a novel way to regulate TGF beta signaling.	Uppsala Univ, Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University	Ericsson, J (corresponding author), Uppsala Univ, Ludwig Inst Canc Res, Biomed Ctr, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.	johan.ericsson@licr.uu.se	kanduri, meena/AAG-1813-2019; Gronroos, Eva/E-9351-2013; KANDURI, MEENA/AAI-6169-2021; Ericsson, Johan/AAA-6664-2020; Gronroos, Eva/P-6951-2015	KANDURI, MEENA/0000-0003-2781-4779; Ericsson, Johan/0000-0003-1186-6574; Gronroos, Eva/0000-0001-8303-5409				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Dunn NR, 2005, GENE DEV, V19, P152, DOI 10.1101/gad.1243205; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Friedler A, 2005, STRUCTURE, V13, P629, DOI 10.1016/j.str.2005.01.020; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; INOUE Y, 2006, IN PRESS ONCOGENE; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kahata K, 2004, GENES CELLS, V9, P143, DOI 10.1111/j.1365-2443.2004.00706.x; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Ogryzko VV, 2001, CELL MOL LIFE SCI, V58, P683, DOI 10.1007/PL00000892; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Simonsson M, 2005, J BIOL CHEM, V280, P21797, DOI 10.1074/jbc.M503134200; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhao Q, 2004, J BIOL CHEM, V279, P41477, DOI 10.1074/jbc.M405129200	52	87	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39870	39880		10.1074/jbc.M607868200	http://dx.doi.org/10.1074/jbc.M607868200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074756	hybrid			2022-12-25	WOS:000243033900014
J	Bartoli, M; Bourg, N; Stockholm, D; Raynaud, F; Delevacque, A; Han, Y; Borel, P; Seddik, K; Armande, N; Richard, I				Bartoli, Marc; Bourg, Nathalie; Stockholm, Daniel; Raynaud, Fabrice; Delevacque, Antony; Han, Yang; Borel, Perrine; Seddik, Kenza; Armande, Nasser; Richard, Isabelle			A mouse model for monitoring calpain activity under physiological and pathological conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; RAT SKELETAL-MUSCLE; ECCENTRIC EXERCISE; MU-CALPAIN; CALCIUM; ACTIVATION; CALPASTATIN; DEGRADATION; PROTEOLYSIS; DENERVATION	Calpains are Ca2+-dependent cysteine proteases known to be important for the regulation of cell functions and which aberrant activation causes cell death in a number of degenerative disorders. To provide a tool for monitoring the status of calpain activity in vivo under physiological and pathological conditions, we created a mouse model that expresses ubiquitously a fluorescent reporter consisting of eCFP and eYFP separated by a linker cleavable by the ubiquitous calpains. We named this mouse CAFI for calpain activity monitored by FRET imaging. Our validation studies demonstrated that the level of calpain activity correlates with a decrease in FRET (fluorescence resonance energy transfer) between the two fluorescent proteins. Using this model, we observed a small level of activity after denervation and fasting, a high level of activity during muscle regeneration and ischemia, and local activity in damaged myofibers after exercise. Finally, we crossed the CAFI mouse with the alpha-sarcoglycandeficient model, demonstrating an increase of calpain activity at the steady state. Altogether, our results present evidence that CAFI mice could be a valuable tool in which to follow calpain activity at physiological levels and in disease states.	Genethon, CNRS UMR8115, F-91000 Evry, France; Univ Montpellier, CNRS UMR5539, F-34000 Montpellier, France	Universite de Montpellier	Richard, I (corresponding author), Genethon, CNRS UMR8115, 1 Rue Int, F-91000 Evry, France.	richard@genethon.fr	Stockholm, Daniel/J-7912-2013; Bartoli, Marc/O-8893-2016; Richard, isabelle/J-8298-2013; Bartoli, Marc/Q-5979-2017; Borel, Patrick/A-4057-2015	Bartoli, Marc/0000-0003-3339-9858; Bartoli, Marc/0000-0003-3339-9858; Borel, Patrick/0000-0001-9977-3238; Raynaud, Fabrice/0000-0003-3055-0524				Allen DG, 2005, J PHYSIOL-LONDON, V567, P723, DOI 10.1113/jphysiol.2005.091694; Arthur GD, 1999, CAN J PHYSIOL PHARM, V77, P42, DOI 10.1139/cjpp-77-1-42; BAKER JH, 1987, MUSCLE NERVE, V10, P34, DOI 10.1002/mus.880100107; Barnoy S, 1998, BBA-MOL CELL RES, V1402, P52, DOI 10.1016/S0167-4889(97)00144-4; Barnoy S, 2005, BIOCHEM BIOPH RES CO, V332, P697, DOI 10.1016/j.bbrc.2005.05.010; Bartoli M, 2005, INT J BIOCHEM CELL B, V37, P2115, DOI 10.1016/j.biocel.2004.12.012; Belcastro A N, 1996, Can J Appl Physiol, V21, P328; BELCASTRO AN, 1993, J APPL PHYSIOL, V74, P1381, DOI 10.1152/jappl.1993.74.3.1381; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; ELCE JS, 1983, EXP NEUROL, V81, P320, DOI 10.1016/0014-4886(83)90266-2; Ertbjerg P, 1999, J ANIM SCI, V77, P2428; Faddis BT, 1997, J NEUROSCI, V17, P951; Feasson L, 2002, J PHYSIOL-LONDON, V543, P297, DOI 10.1113/jphysiol.2002.018689; French JP, 2006, AM J PHYSIOL-HEART C, V290, pH128, DOI 10.1152/ajpheart.00739.2005; FURUNO K, 1990, J BIOL CHEM, V265, P8550; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; Gil-Parrado S, 2003, BIOL CHEM, V384, P395, DOI 10.1515/BC.2003.045; Gillis JM, 1999, J MUSCLE RES CELL M, V20, P605, DOI 10.1023/A:1005545325254; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; HARRIS JB, 1978, CLIN EXP PHARMACOL P, V5, P587, DOI 10.1111/j.1440-1681.1978.tb00714.x; Hayes RL, 1998, DRUG NEWS PERSPECT, V11, P215; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; IKAWA M, 1995, DEV GROWTH DIFFER, V37, P455, DOI 10.1046/j.1440-169X.1995.t01-2-00012.x; ILIAN MA, 1992, BIOCHEM J, V287, P163, DOI 10.1042/bj2870163; Iwata Y, 2005, BIOCHEM PHARMACOL, V70, P740, DOI 10.1016/j.bcp.2005.05.034; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; KUMAMOTO T, 1992, ANAT REC, V232, P60, DOI 10.1002/ar.1092320108; KUMAR A, 1992, CELL MOL BIOL, V38, P477; Kunimatsu M, 1999, CARDIOVASC PATHOL, V8, P7, DOI 10.1016/S1054-8807(98)00018-0; KWAK KB, 1993, BIOCHIM BIOPHYS ACTA, V1175, P243, DOI 10.1016/0167-4889(93)90212-8; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; McHugh MP, 2003, SCAND J MED SCI SPOR, V13, P88, DOI 10.1034/j.1600-0838.2003.02477.x; Moraczewski J, 1996, CR ACAD SCI III-VIE, V319, P681; Moraczewski J, 1996, ACTA BIOCHIM POL, V43, P693; Murphy RM, 2006, AM J PHYSIOL-CELL PH, V290, pC116, DOI 10.1152/ajpcell.00291.2005; Nakashima K, 2005, J NUTR SCI VITAMINOL, V51, P248, DOI 10.3177/jnsv.51.248; Nixon RA, 2003, AGEING RES REV, V2, P407, DOI 10.1016/S1568-1637(03)00029-1; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Raynaud F, 2004, EXP CELL RES, V298, P48, DOI 10.1016/j.yexcr.2004.03.053; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; Stockholm D, 2005, J MOL BIOL, V346, P215, DOI 10.1016/j.jmb.2004.11.039; Stockholm D, 2001, AM J PHYSIOL-CELL PH, V280, pC1561, DOI 10.1152/ajpcell.2001.280.6.C1561; Stupka N, 2001, J APPL PHYSIOL, V91, P1669, DOI 10.1152/jappl.2001.91.4.1669; Sultan KR, 2000, AM J PHYSIOL-CELL PH, V279, pC639, DOI 10.1152/ajpcell.2000.279.3.C639; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; TISCHLER ME, 1990, METABOLISM, V39, P756, DOI 10.1016/0026-0495(90)90113-Q; Tsuji T, 2001, AM J PHYSIOL-HEART C, V281, pH1286, DOI 10.1152/ajpheart.2001.281.3.H1286; TURNER PR, 1993, J MEMBRANE BIOL, V133, P243; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Zalewska T, 1996, FOLIA NEUROPATHOL, V34, P121; Zimowska M, 2005, J CELL PHYSIOL, V205, P237, DOI 10.1002/jcp.20403	57	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39672	39680		10.1074/jbc.M608803200	http://dx.doi.org/10.1074/jbc.M608803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17056592	Green Published, hybrid			2022-12-25	WOS:000242898700074
J	Dong, CM; Wu, GY				Dong, Chunmin; Wu, Guangyu			Regulation of anterograde transport of alpha(2)-adrenergic receptors by the N termini at multiple intracellular compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; PROTEIN-COUPLED RECEPTORS; TO-GOLGI TRANSPORT; ENDOPLASMIC-RETICULUM; MEMBRANE TRAFFICKING; ANGIOTENSIN-II; EXPORT; MOTIF; INTERNALIZATION; SEQUENCE	The studies on the intrinsic structural determinants for export trafficking of G protein-coupled receptors (GPCRs) have been mainly focused on the C termini of the receptors. In this report we determined the role of the extracellular N termini of alpha(2)-adrenergic receptors (alpha(2)-ARs) in the anterograde transport from the endoplasmic reticulum ( ER) through the Golgi to the cell surface. The N-terminal-truncated alpha(2B)-AR mutant is completely unable to target to the cell surface. A single Met-6 residue is essential for the export of alpha(2B)-AR from the ER, likely through modulating correct alpha(2B)-AR folding in the ER. The Tyr-Ser motif, highly conserved in the membrane-proximal N termini of all alpha(2)-AR subtypes, is required for the exit of alpha(2A)-AR and alpha(2B)-AR from the Golgi apparatus, thus representing a novel Tyr-based motif modulating GPCR transport at the Golgi level. These data provide the first evidence indicating an essential role of the N termini of GPCRs in the export from distinct intracellular compartments along the secretory pathway.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Wu, GY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	gwu@lsuhsc.edu			NCRR NIH HHS [P20 RR018766, P20 RR 018766] Funding Source: Medline; NIGMS NIH HHS [R01 GM 076167, R01 GM076167-02, R01 GM076167] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076167] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson H, 2003, MOL PHARMACOL, V64, P570, DOI 10.1124/mol.64.3.570; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bouley R, 2003, AM J PHYSIOL-CELL PH, V285, pC750, DOI 10.1152/ajpcell.00477.2002; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; Duvernay MT, 2005, CELL SIGNAL, V17, P1457, DOI 10.1016/j.cellsig.2005.05.020; Duvernay MT, 2004, J BIOL CHEM, V279, P30741, DOI 10.1074/jbc.M313881200; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Filipeanu CM, 2006, MOL PHARMACOL, V69, P1571, DOI 10.1124/mol.105.019984; Filipeanu CM, 2004, J BIOL CHEM, V279, P41077, DOI 10.1074/jbc.M405988200; Gimelbrant AA, 2001, J BIOL CHEM, V276, P7285, DOI 10.1074/jbc.M005433200; Grantcharova E, 2002, J BIOL CHEM, V277, P43933, DOI 10.1074/jbc.M208407200; Hague C, 2004, J BIOL CHEM, V279, P15541, DOI 10.1074/jbc.M314014200; Hague C, 2004, J PHARMACOL EXP THER, V309, P388, DOI 10.1124/jpet.103.060509; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kalatskaya I, 2004, J BIOL CHEM, V279, P31268, DOI 10.1074/jbc.M401796200; Lee TH, 2000, MOL BIOL CELL, V11, P2577, DOI 10.1091/mbc.11.8.2577; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Morello JP, 2001, ANNU REV PHYSIOL, V63, P607, DOI 10.1146/annurev.physiol.63.1.607; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2002, J CELL SCI, V115, P619; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; Robert J, 2005, J BIOL CHEM, V280, P2300, DOI 10.1074/jbc.M410655200; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Stockklausner C, 2003, J BIOL CHEM, V278, P17000, DOI 10.1074/jbc.M212243200; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tan CM, 2004, ANNU REV PHARMACOL, V44, P559, DOI 10.1146/annurev.pharmtox.44.101802.121558; Themmen APN, 1996, EUR J ENDOCRINOL, V134, P533, DOI 10.1530/eje.0.1340533; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Venkatesan S, 2002, J BIOL CHEM, V277, P2287, DOI 10.1074/jbc.M108321200; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; Wang W, 2003, J BIOL CHEM, V278, P36848, DOI 10.1074/jbc.M301540200; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 2003, J BIOL CHEM, V278, P47062, DOI 10.1074/jbc.M305707200; Zhou FG, 2006, CELL SIGNAL, V18, P318, DOI 10.1016/j.cellsig.2005.05.014	51	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38543	38554		10.1074/jbc.M605734200	http://dx.doi.org/10.1074/jbc.M605734200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17038316	Green Accepted, hybrid			2022-12-25	WOS:000242709500049
J	Nakagami, H; Soukupova, H; Schikora, A; Zarsky, V; Hirt, H				Nakagami, Hirofumi; Soukupova, Hanka; Schikora, Adam; Zarsky, Viktor; Hirt, Heribert			A mitogen-activated protein kinase kinase kinase mediates reactive oxygen species homeostasis in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; MAP; PATHWAYS; CASCADE; PLANTS; RESISTANCE; THALIANA; BURST; COLD	Mitogen-activated protein kinase kinase kinases (MAPKKKs) play key roles in intra- and extracellular signaling in eukaryotes. Here we report that the MAPKKK MEKK1 regulates redox homeostasis in Arabidopsis. We show that MEKK1-deficient plants are misregulated in the expression of a number of genes involved in cellular redox control and accumulate reactive oxygen species (ROS). Most strikingly, homozygous mekk1 mutant plants exhibit a lethal phenotype when developing true leaves. MEKK1 kinase activity and protein stability was regulated by H2O2 in a proteasome-dependent manner and mekk1 plants were compromised in ROS-induced MAPK MPK4 activation. Whereas mpk3 and mpk6 knock out plants showed no defects in development or changes in redox control genes, mpk4 null mutant shared several phenotypic and transcript profile features with mekk1 plants. In agreement with the concept that ROS negatively regulates auxin responses in plants, mekk1 and mpk4 mutants show reduced expression of several auxin-inducible marker genes. Overall, our data defines MPK4 as downstream target of MEKK1 and show that MEKK1 functions in integrating ROS homeostasis with plant development and hormone signaling.	Univ Vienna, Dept Plant Mol Biol, Max F Perutz Labs, A-1030 Vienna, Austria; Acad Sci Czech Republ, Cell Biol Lab, Inst Expt Bot, CR-16502 Prague 6, Czech Republic	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences	Hirt, H (corresponding author), Univ Vienna, Dept Plant Mol Biol, Max F Perutz Labs, Dr Bohrgasse 9, A-1030 Vienna, Austria.	heribert.hirt@univie.ac.at	Žárský, Viktor/P-3673-2018; Schikora, Adam/B-4842-2014; Zarsky, Viktor/G-7352-2014; Nakagami, Hirofumi/A-4122-2011; Hirt, Heribert/A-2061-2013; Soukupova, Hana/H-3071-2014	Žárský, Viktor/0000-0002-5301-0339; Schikora, Adam/0000-0002-0869-6423; Zarsky, Viktor/0000-0002-5301-0339; Nakagami, Hirofumi/0000-0003-2569-7062; Soukupova, Hana/0000-0001-8728-5018				Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Cardinale F, 2000, J BIOL CHEM, V275, P36734, DOI 10.1074/jbc.M007418200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Desikan R, 2001, PLANT PHYSIOL, V126, P1579, DOI 10.1104/pp.126.4.1579; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Grant JJ, 2000, PLANT J, V24, P569, DOI 10.1046/j.1365-313x.2000.00902.x; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Ichimura K, 1998, BIOCHEM BIOPH RES CO, V253, P532, DOI 10.1006/bbrc.1998.9796; Jonak C, 2002, CURR OPIN PLANT BIOL, V5, P415, DOI 10.1016/S1369-5266(02)00285-6; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murgia I, 2004, PLANT J, V38, P940, DOI 10.1111/j.1365-313X.2004.02092.x; Nakagami H, 2005, TRENDS PLANT SCI, V10, P339, DOI 10.1016/j.tplants.2005.05.009; Nakagami H, 2004, J BIOL CHEM, V279, P26959, DOI 10.1074/jbc.M312662200; Petersen M, 2000, CELL, V103, P1111, DOI 10.1016/S0092-8674(00)00213-0; Rentel MC, 2004, NATURE, V427, P858, DOI 10.1038/nature02353; Rizhsky L, 2004, J BIOL CHEM, V279, P11736, DOI 10.1074/jbc.M313350200; Teige M, 2004, MOL CELL, V15, P141, DOI 10.1016/j.molcel.2004.06.023; Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499	21	256	278	1	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38697	38704		10.1074/jbc.M605293200	http://dx.doi.org/10.1074/jbc.M605293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17043356	hybrid, Green Published			2022-12-25	WOS:000242709500067
J	Tang, GM; Xu, ZH; Goldman, JE				Tang, Guomei; Xu, Zhiheng; Goldman, James E.			Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; N-TERMINAL KINASE; INDUCED APOPTOSIS; ROSENTHAL FIBERS; TRANSGENIC MICE; STRESS-PROTEINS; ACTIVATION; GENE; AGGREGATION; MUTATIONS	Protein aggregates in astrocytes that contain glial fibrillary acidic protein (GFAP), small heat shock proteins, and ubiquitinated proteins are termed Rosenthal fibers and characterize Alexander disease, a leukodystrophy caused by heterozygous mutations in GFAP. The mechanisms responsible for the massive accumulation of GFAP in Alexander disease remain unclear. In this study, we show that overexpression of both wild type and R239C mutant human GFAP led to cytoplasmic inclusions. GFAP accumulation also led to a decrease of proteasome activity and an activation of the MLK2-JNK pathway. In turn, the expression of activated mixed lineage kinases (MLKs) induced JNK activation and increased GFAP accumulation, whereas blocking the JNK pathway decreased GFAP accumulation. Activated MLK also inhibited proteasome function. A direct inhibition of proteasome function pharmacologically further activated JNK. Our data suggest a synergistic interplay between the proteasome and the SAPK/JNK pathway in the context of GFAP accumulation. Feedback interactions among GFAP accumulation, SAPK/JNK activation, and proteasomal hypofunction cooperate to produce further protein accumulation and cellular stress responses.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University	Goldman, JE (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, P&S Rm 15-420,630 W 168th St, New York, NY 10032 USA.	jeg5@columbia.edu		Xu, Zhiheng/0000-0002-4809-2851	NINDS NIH HHS [P01 NS 42803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS042803] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriaga MA, 1998, AM J OTOL, V19, P26; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; Eng LF, 1998, J NEUROSCI RES, V53, P353, DOI 10.1002/(SICI)1097-4547(19980801)53:3<353::AID-JNR9>3.0.CO;2-9; Hagemann TL, 2005, HUM MOL GENET, V14, P2443, DOI 10.1093/hmg/ddi248; HEAD MW, 1993, AM J PATHOL, V143, P1743; Head MW, 2000, NEUROREPORT, V11, P361, DOI 10.1097/00001756-200002070-00028; Hsiao VC, 2005, J CELL SCI, V118, P2057, DOI 10.1242/jcs.02339; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; Johnson AB, 2002, INT J DEV NEUROSCI, V20, P391, DOI 10.1016/S0736-5748(02)00045-X; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Koyama Y, 1999, AM J PATHOL, V154, P1563, DOI 10.1016/S0002-9440(10)65409-0; Li R, 2002, INT J DEV NEUROSCI, V20, P259, DOI 10.1016/S0736-5748(02)00019-9; Li R, 2005, ANN NEUROL, V57, P310, DOI 10.1002/ana.20406; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Merienne K, 2003, J BIOL CHEM, V278, P16957, DOI 10.1074/jbc.M212049200; Meriin AB, 2001, J CELL BIOL, V153, P851, DOI 10.1083/jcb.153.4.851; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Messing A, 1998, AM J PATHOL, V152, P391; Richter-Landsberg C, 2004, INT J DEV NEUROSCI, V22, P443, DOI 10.1016/j.ijdevneu.2004.07.003; Savage MJ, 2002, J NEUROSCI, V22, P3376; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001	26	78	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38634	38643		10.1074/jbc.M604942200	http://dx.doi.org/10.1074/jbc.M604942200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17038307	hybrid			2022-12-25	WOS:000242709500059
J	Rizos, H; McKenzie, HA; Ayub, AL; Woodruff, S; Becker, TM; Scurr, LL; Stahl, J; Kefford, RF				Rizos, Helen; McKenzie, Heather A.; Ayub, Ana Luisa; Woodruff, Sarah; Becker, Therese M.; Scurr, Lyndee L.; Stahl, Joachim; Kefford, Richard F.			Physical and functional interaction of the p14(ARF) tumor suppressor with ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-DAMAGE; PROTEIN; P53; ARF; NUCLEOLAR; RNA; TRANSLATION; MDM2; MELANOMA	Alterations in the p14(ARF) tumor suppressor are frequent in many human cancers and are associated with susceptibility to melanoma, pancreatic cancer, and nervous system tumors. In addition to its p53-regulatory functions, p14(ARF) has been shown to influence ribosome biogenesis and to regulate the endoribonuclease B23, but there remains considerable controversy about its nucleolar role. We sought to clarify the activities of p14(ARF) by studying its interaction with ribosomes. We show that p14(ARF) and B23 interact within the nucleolar 60 S preribosomal particle and that this interaction does not require rRNA. In contrast to previous reports, we found that expression of p14(ARF) does not significantly alter ribosome biogenesis but inhibits polysome formation and protein translation in vivo. These results suggest a ribosome- dependent p14(ARF) pathwaythat regulates cellgrowthandthuscomplementsp53-dependent p14(ARF) functions.	Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	University of Sydney; Westmead Institute for Medical Research; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Rizos, H (corresponding author), Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia.	helen_rizos@wmi.usyd.edu.au	Rizos, Helen/AAE-5010-2020	Rizos, Helen/0000-0002-2094-9198; Kefford, Richard/0000-0001-9251-9229; Becker, Therese/0000-0002-5636-9902; Ayub, Ana Luisa/0000-0002-1848-6999				Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Ausserlechner MJ, 2005, LEUKEMIA, V19, P1051, DOI 10.1038/sj.leu.2403729; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Becker TM, 2001, CLIN CANCER RES, V7, P3282; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; DEBENEDETTI A, 1985, J VIROL, V55, P588, DOI 10.1128/JVI.55.3.588-593.1985; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DURO D, 1995, ONCOGENE, V11, P21; FREEDBERG DE, 2004, 2 MELANOMA RES C; Gallagher S, 2005, CELL CYCLE, V4, P465, DOI 10.4161/cc.4.3.1526; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Harland M, 2005, ONCOGENE, V24, P4604, DOI 10.1038/sj.onc.1208678; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Huang N, 2005, J BIOL CHEM, V280, P5496, DOI 10.1074/jbc.M407856200; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kefford R, 2002, LANCET ONCOL, V3, P653, DOI 10.1016/S1470-2045(02)00894-X; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Laud K, 2006, J MED GENET, V43, P39, DOI 10.1136/jmg.2005.033498; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MAO XH, 1992, J BIOL CHEM, V267, P20444; Marissen WE, 2000, J BIOL CHEM, V275, P9314, DOI 10.1074/jbc.275.13.9314; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Yin X, 2003, J CELL PHYSIOL, V196, P474, DOI 10.1002/jcp.10329; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38080	38088		10.1074/jbc.M609405200	http://dx.doi.org/10.1074/jbc.M609405200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035234	hybrid			2022-12-25	WOS:000242477100086
J	Gueorguieva, D; Li, SH; Walsh, N; Mukerji, A; Tanha, J; Pandey, S				Gueorguieva, Deyzi; Li, Shenghua; Walsh, Nicole; Mukerji, Amit; Tanha, Jamshid; Pandey, Siyaram			Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis	FASEB JOURNAL			English	Article						VHH; phage display library; mitochondria; neurodegenerative diseases	INTRACELLULAR ANTIBODY; PHAGE DISPLAY; CYTOCHROME-C; SELECTION; PROTEIN; ANTIGEN; MITOCHONDRIA; PEROXIDATION; TECHNOLOGY; HUNTINGTIN	Bax is a proapoptotic protein implicated in cell death involved in several neurodegenerative diseases. Intracellularly expressed antibody (Ab) fragments (intrabodies) inhibiting Bax function would have potential for developing therapeutics for the aforementioned diseases and can serve as research tools. We report identification, cloning, and functional characterization of several Bax-specific single-domain antibodies (sdAbs). These minimal size Ab fragments, which were isolated from a llama VHH phage display library by panning, inhibited Bax function in in vitro assays. Importantly, as intrabodies, these sdAbs, which were stably expressed in mammalian cells, were nontoxic to their host cells and rendered them highly resistant to oxidative-stress-induced apoptosis. The intrabodies prevented mitochondrial membrane potential collapse and apoptosis after oxidative stress in the host cells. These anti-Bax V(H)Hs could be used as tools for studying the role of Bax in oxidative-stress-induced apoptosis and for developing novel therapeutics for the degenerative diseases involving oxidative stress.	Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON, Canada	University of Windsor; National Research Council Canada	Pandey, S (corresponding author), Univ Windsor, Dept Chem & Biochem, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	spandey@uwindsor.ca	Pandey, Siyaram/AAI-5491-2020; Mukerji, Amit/AAS-5922-2021	Mukerji, Amit/0000-0003-2609-9240				Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; ADHIHETTY PJ, 2003, BASIC APPL MYOL, V13, P171; Battistutta R, 2000, PROTEINS, V41, P429, DOI 10.1002/1097-0134(20001201)41:4<429::AID-PROT10>3.0.CO;2-D; Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025; Colby DW, 2004, J MOL BIOL, V342, P901, DOI 10.1016/j.jmb.2004.07.054; Colby DW, 2004, P NATL ACAD SCI USA, V101, P17616, DOI 10.1073/pnas.0408134101; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; da Silva FA, 2004, J MOL BIOL, V340, P525, DOI 10.1016/j.jmb.2004.04.062; Dekker S, 2003, J VIROL, V77, P12132, DOI 10.1128/JVI.77.22.12132-12139.2003; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Jespers L, 2004, NAT BIOTECHNOL, V22, P1161, DOI 10.1038/nbt1000; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Kabat EA, 1991, SEQUENCES PROTEINS I; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Miller TW, 2005, MOL THER, V12, P394, DOI 10.1016/j.ymthe.2005.04.003; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Rajpal A, 2001, J BIOL CHEM, V276, P33139, DOI 10.1074/jbc.M101332200; Somayajulu M, 2005, NEUROBIOL DIS, V18, P618, DOI 10.1016/j.nbd.2004.10.021; SUNDERMAN FW, 1985, ANN CLIN LAB SCI, V15, P229; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tanaka T, 2003, J MOL BIOL, V331, P1109, DOI 10.1016/S0022-2836(03)00836-2; Tanha J, 2002, J IMMUNOL METHODS, V263, P97, DOI 10.1016/S0022-1759(02)00027-3; Tanha Jamshid, 2003, Methods Mol Med, V89, P435; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; Warner HR, 1999, ANTICANCER RES, V19, P2837; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Yau KYF, 2005, J IMMUNOL METHODS, V297, P213, DOI 10.1016/j.jim.2004.12.005; Yau KYF, 2003, J IMMUNOL METHODS, V281, P161, DOI 10.1016/j.jim.2003.07.011; Zhu QA, 1999, J IMMUNOL METHODS, V231, P207, DOI 10.1016/S0022-1759(99)00158-1	33	43	52	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2636	+		10.1096/fj.06-6306fje	http://dx.doi.org/10.1096/fj.06-6306fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060401				2022-12-25	WOS:000242490700049
J	Mall, S; Broadbridge, R; Harrison, SL; Gore, MG; Lee, AG; East, JM				Mall, Sanjay; Broadbridge, Robert; Harrison, Steven L.; Gore, Michael G.; Lee, Anthony G.; East, J. Malcolm			The presence of sarcolipin results in increased heat production by Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; SKELETAL-MUSCLE; CALCIUM-PUMP; RECONSTITUTED VESICLES; CA2+; PHOSPHOLAMBAN; ATPASE; MECHANISM; (CA-2++MG-2+)-ATPASE; ACCUMULATION	Skeletal muscle sarcoplasmic reticulum of large mammals such as rabbit contains sarcolipin (SLN), a small peptide with a single transmembrane alpha-helix. When reconstituted with the Ca2+-ATPase from skeletal muscle sarcoplasmic reticulum into sealed vesicles, the presence of SLN leads to a reduced level of accumulation of Ca2+. Heats of reaction of the reconstituted Ca2+-ATPase with ATP were measured using isothermal calorimetry. The heat released increased linearly with time over 30 min and increased with increasing SLN content. Rates of ATP hydrolysis by the reconstituted Ca2+-ATPase were constant over a 30-min time period and were the same when measured in the presence or absence of an ATP-regenerating system. The calculated values of heat released per mol of ATP hydrolyzed increased with increasing SLN content and fitted to a simple binding equation with a dissociation constant for the SLN center dot ATPase complex of 6.9 x 10(-4) +/- 2.9 x 10(-4) in units of mol fraction per monolayer. It is suggested that the interaction between Ca2+-ATPase and SLN in the sarcoplasmic reticulum could be important in thermogenesis by the sarcoplasmic reticulum.	Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England; Peptide & Prot Res Ltd, Wickham PO17 5DY, England	University of Southampton	East, JM (corresponding author), Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England.	jme1@soton.ac.uk						Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Asahi M, 2003, P NATL ACAD SCI USA, V100, P5040, DOI 10.1073/pnas.0330962100; Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; Buffy JJ, 2006, J MOL BIOL, V358, P420, DOI 10.1016/j.jmb.2006.02.005; Dalton KA, 1999, BIOCHEM J, V342, P431, DOI 10.1042/0264-6021:3420431; de Meis L, 2002, J MEMBRANE BIOL, V188, P1, DOI 10.1007/s00232-001-0171-5; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DEMEIS L, 1981, SACROPLASMIC RETICUL; GODT RE, 1974, J GEN PHYSIOL, V63, P722, DOI 10.1085/jgp.63.6.722; GOULD GW, 1987, BIOCHEM J, V245, P751, DOI 10.1042/bj2450751; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P36, DOI 10.1016/0005-2736(87)90084-8; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P45, DOI 10.1016/0005-2736(87)90085-X; Hughes G, 1996, BIOCHEM J, V318, P973, DOI 10.1042/bj3180973; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1983, J BIOL CHEM, V258, P4804; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; Lee AG, 2003, FEBS LETT, V551, P37, DOI 10.1016/S0014-5793(03)00869-X; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; Logan-Smith MJ, 2001, J BIOL CHEM, V276, P46905, DOI 10.1074/jbc.M108778200; MCWHIRTER JM, 1987, BIOCHEM J, V245, P731, DOI 10.1042/bj2450731; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Smith WS, 2002, BIOCHEM J, V361, P277, DOI 10.1042/0264-6021:3610277; TADA M, 1979, J BIOL CHEM, V254, P319; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; Vangheluwe P, 2005, BIOCHEM J, V389, P151, DOI 10.1042/BJ20050068; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	33	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36597	36602		10.1074/jbc.M606869200	http://dx.doi.org/10.1074/jbc.M606869200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17018526	hybrid			2022-12-25	WOS:000242220800016
J	Iwamaru, A; Szymanski, S; Iwado, E; Aoki, H; Yokoyama, T; Fokt, I; Hess, K; Conrad, C; Madden, T; Sawaya, R; Kondo, S; Priebe, W; Kondo, Y				Iwamaru, A.; Szymanski, S.; Iwado, E.; Aoki, H.; Yokoyama, T.; Fokt, I.; Hess, K.; Conrad, C.; Madden, T.; Sawaya, R.; Kondo, S.; Priebe, W.; Kondo, Y.			A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo	ONCOGENE			English	Article						STAT3; apoptosis; malignant glioma	ACTIVATION; CANCER; GLIOBLASTOMA; KINASE; TUMORS; INTERLEUKIN-6; EXPRESSION; PROTEINS; MCL-1	Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in a variety of cancer types, including malignant gliomas. STAT3 is activated by phosphorylation of a tyrosine residue, after which it dimerizes and translocates into the nucleus. There it regulates the expression of several genes responsible for proliferation and survival at the transcriptional level. A selective inhibitor of STAT3 phosphorylation, AG490, has been shown to inhibit growth and induce apoptosis in some cancer cell types. However, although AG490 routinely shows in vitro anticancer activity, it has not consistently demonstrated an in vivo anticancer effect in animal models. Here, we have tested WP1066, a novel inhibitor structurally related to AG490 but significantly more potent and active, against human malignant glioma U87MG and U373-MG cells in vitro and in vivo. IC50 values for WP1066 were 5.6 mu M in U87-MG cells and 3.7 mu M in U373-MG cells, which represents 18-fold and eightfold increases in potency, respectively, over that of AG490. WP1066 activated Bax, suppressed the expression of c-myc, Bcl-X-L and Mcl-1, and induced apoptosis. Systemic intraperitoneal administration of WP1066 in mice significantly (P < 0.001) inhibited the growth of subcutaneous malignant glioma xenografts during the 30-day follow-up period. Immunohistochemical analysis of the excised tumors revealed that phosphorylated STAT3 levels in the WP1066 treatment group remained inhibited at 3 weeks after the final WP1066 injection, whereas tumors from the control group expressed high levels of phosphorylated STAT3. We conclude that WP1066 holds promise as a therapeutic agent against malignant gliomas.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci Houston, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System	Kondo, Y (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit BSRB1004,1515 Holcombe Blvd, Houston, TX 77030 USA.	yaskondo@mdanderson.org	Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070	NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Bogler O, 2002, FRONT BIOSCI, V7, pE339, DOI 10.2741/bogler; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Kanzawa T, 2006, ONCOGENE, V25, P3638, DOI 10.1038/sj.onc.1209414; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kapoor GS, 2003, NEUROSURGERY, V52, P1425, DOI 10.1227/01.NEU.0000065135.28143.39; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kondo Y, 2004, INT J ONCOL, V24, P1101; Konnikova L, 2005, CANCER RES, V65, P6516, DOI 10.1158/0008-5472.CAN-05-0924; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LICHTOR T, 1994, NEUROSURGERY, V34, P669, DOI 10.1227/00006123-199404000-00015; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Reardon DA, 2006, J CLIN ONCOL, V24, P1253, DOI 10.1200/JCO.2005.04.5302; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Sonoda Y, 2001, CANCER RES, V61, P4956; Sun JZ, 2005, ONCOGENE, V24, P3236, DOI 10.1038/sj.onc.1208470; Turkson J, 2004, MOL CANCER THER, V3, P1533; VAN MEIR E, 1990, CANCER RES, V50, P6683; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940	36	295	323	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2435	2444		10.1038/sj.onc.1210031	http://dx.doi.org/10.1038/sj.onc.1210031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043651				2022-12-25	WOS:000245831000004
J	Das, R; Melacini, G				Das, Rahul; Melacini, Giuseppe			A model for agonism and antagonism in an ancient and ubiquitous cAMP-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CAP-DNA COMPLEX; PRIMARY-KINK SITE; CHEMICAL-SHIFT ANISOTROPY; I REGULATORY SUBUNIT; CYCLIC-AMP; INDIRECT READOUT; NMR RELAXATION; ACTIVATOR PROTEIN; CRYSTAL-STRUCTURE	The cAMP-binding domain (CBD) is an ancient and conserved regulatory motif that allosterically modulates the function of a group of diverse proteins, thereby translating the cAMP signal into a controlled biological response. The main receptor for cAMP in mammals is the ubiquitous regulatory (R) subunit of protein kinase A. Despite the recognized significant potential for pharmacological applications of CBDs, currently only one group of competitive inhibitor antagonists is known: the (R-p)-cAMPS family of phosphorothioate cAMP analogs, in which the equatorial exocyclic oxygen of cAMP is replaced by sulfur. It is also known that the diastereoisomer (S-p)-cAMPS with opposite phosphorous chirality is a cAMP agonist, but the molecular mechanism of action of these analogs is currently not fully understood. Previous crystallographic and unfolding investigations point to the enhanced CBD dynamics as a key determinant of antagonism. Here, we investigate the (R-p)- and (S-p)-cAMPS-bound states of R(CBD-A) using a comparative NMR approach that reveals a clear chemical shift and dynamic NMR signature, differentiating the (Sp)-cAMPS agonist from the (Rp)-cAMPS antagonist. Based on these data, we have proposed a model for the (R-p/S-p)-cAMPS antagonism and agonism in terms of steric and electronic effects on two main allosteric relay sites, Ile(163) and Asp(170), respectively, affecting the stability of a ternary inhibitory complex formed by the effector ligand, the regulatory and the catalytic subunits of protein kinase A. The proposed model not only rationalizes the existing data on the phosphorothioate analogs, but it will also facilitate the design of novel cAMP antagonists and agonists.	McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8S 4M1, Canada; McMaster Univ, Dept Biomed Sci, Hamilton, ON L8S 4M1, Canada	McMaster University; McMaster University; McMaster University	Das, R (corresponding author), McMaster Univ, Dept Chem, 1280 Main St W, Hamilton, ON L8S 4M1, Canada.		Das, Rahul/AAU-5123-2020	Das, Rahul/0000-0001-7841-8229				Anand GS, 2002, J MOL BIOL, V323, P377, DOI 10.1016/S0022-2836(02)00919-1; Arnsten AFT, 2005, TRENDS MOL MED, V11, P121, DOI 10.1016/j.molmed.2005.01.006; Atkinson RA, 2004, PROG NUCL MAG RES SP, V44, P141, DOI 10.1016/j.pnmrs.2004.01.001; Beach H, 2005, J AM CHEM SOC, V127, P9167, DOI 10.1021/ja0514949; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Bernado P, 2002, J BIOMOL NMR, V23, P139, DOI 10.1023/A:1016359412284; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Canaves JM, 2000, BIOCHEMISTRY-US, V39, P15022, DOI 10.1021/bi001563q; CAVANAGH J, 1996, PROTEIN NMR PRINCIPL, P63405; Chen SF, 2001, J MOL BIOL, V314, P63, DOI 10.1006/jmbi.2001.5089; Chen SF, 2001, J MOL BIOL, V314, P75, DOI 10.1006/jmbi.2001.5090; Dai JY, 2004, BIOCHEMISTRY-US, V43, P8901, DOI 10.1021/bi0499359; Dao KK, 2006, J BIOL CHEM, V281, P21500, DOI 10.1074/jbc.M603116200; Das R, 2006, J AM CHEM SOC, V128, P8406, DOI 10.1021/ja060046d; DAYIE KT, 1994, J MAGN RESON SER A, V111, P121, DOI 10.1006/jmra.1994.1236; de la Torre JG, 2001, BIOPHYS CHEM, V93, P159, DOI 10.1016/S0301-4622(01)00218-6; DELAGLIO F, 1991, Journal of Biomolecular NMR, V1, P439, DOI 10.1007/BF02192865; Ding ZF, 2005, BIOCHEMISTRY-US, V44, P10119, DOI 10.1021/bi050414a; DOSTMANN WRG, 1995, FEBS LETT, V375, P231, DOI 10.1016/0014-5793(95)01201-O; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; Eghbalnia HR, 2005, J BIOMOL NMR, V32, P219, DOI 10.1007/s10858-005-7944-6; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Fayos R, 2003, J BIOL CHEM, V278, P18581, DOI 10.1074/jbc.M300866200; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Fischer MWF, 1998, PROG NUCL MAG RES SP, V33, P207, DOI 10.1016/S0079-6565(98)00023-5; FREY PA, 1985, SCIENCE, V228, P541, DOI 10.1126/science.2984773; Gekko K, 2004, BIOCHEMISTRY-US, V43, P3844, DOI 10.1021/bi036271e; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Goddard T. D., 2006, SPARKY 3; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Gullingsrud J, 2006, STRUCTURE, V14, P141, DOI 10.1016/j.str.2005.09.019; Hamuro Y, 2004, J MOL BIOL, V340, P1185, DOI 10.1016/j.jmb.2004.05.042; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; Houben K, 2005, J MOL BIOL, V349, P621, DOI 10.1016/j.jmb.2005.04.007; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Kneller JM, 2002, J AM CHEM SOC, V124, P1852, DOI 10.1021/ja017461k; Kopperud R, 2002, J BIOL CHEM, V277, P13443, DOI 10.1074/jbc.M109869200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kroenke CD, 1999, J AM CHEM SOC, V121, P10119, DOI 10.1021/ja9909273; Lawson CL, 2004, CURR OPIN STRUC BIOL, V14, P10, DOI 10.1016/j.sbi.2004.01.012; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; Leon DA, 2000, BIOCHEMISTRY-US, V39, P5662, DOI 10.1021/bi992819z; Li JQ, 2002, BIOCHEMISTRY-US, V41, P14771, DOI 10.1021/bi026383q; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; Matulef K, 2003, ANNU REV CELL DEV BI, V19, P23, DOI 10.1146/annurev.cellbio.19.110701.154854; Mei FC, 2005, MOL BIOSYST, V1, P325, DOI 10.1039/b511267b; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; Mulder FAA, 2004, BIOCHEMISTRY-US, V43, P5930, DOI 10.1021/bi0495331; Mulder FAA, 2001, J AM CHEM SOC, V123, P967, DOI 10.1021/ja003447g; Napoli AA, 2006, J MOL BIOL, V357, P173, DOI 10.1016/j.jmb.2005.12.051; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; Qiao JB, 2002, J BIOL CHEM, V277, P26581, DOI 10.1074/jbc.M203571200; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Renner C, 2002, J BIOMOL NMR, V23, P23, DOI 10.1023/A:1015385910220; Rodriguez JC, 2004, J BIOMOL NMR, V30, P155, DOI 10.1023/B:JNMR.0000048857.44219.c3; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; TAYLOR SS, 2005, BIOCHIM BIOPHYS ACTA, V175, P25; Tollinger M, 2001, J AM CHEM SOC, V123, P11341, DOI 10.1021/ja011300z; TORRORA G, 2002, ANN NY ACAD SCI, V968, P139; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; Vialle-Printems C, 2000, J MAGN RESON, V142, P276, DOI 10.1006/jmre.1999.1954; Vigil D, 2006, PROTEIN SCI, V15, P113, DOI 10.1110/ps.051723606; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Wu J, 2004, BIOCHEMISTRY-US, V43, P6620, DOI 10.1021/bi0302503; Yip GNB, 2004, J MAGN RESON, V171, P25, DOI 10.1016/j.jmr.2004.06.021; ZORN M, 1995, FEBS LETT, V362, P291, DOI 10.1016/0014-5793(95)00261-7	78	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					581	593		10.1074/jbc.M607706200	http://dx.doi.org/10.1074/jbc.M607706200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17074757	hybrid			2022-12-25	WOS:000243166500064
J	O'Malley, Y; Fink, BD; Ross, NC; Prisinzano, TE; Sivitz, WI				O'Malley, Yunxia; Fink, Brian D.; Ross, Nicolette C.; Prisinzano, Thomas E.; Sivitz, William I.			Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON LEAK; SUPEROXIDE-PRODUCTION; RESPIRATORY-CHAIN; UNCOUPLING PROTEIN-2; OXIDATIVE STRESS; FLOW RESERVE; GENERATION; DAMAGE; FIBROBLASTS; UBIQUINONE	We used fluorescent probes and EPR to study the mechanism(s) underlying reactive oxygen species (ROS) production by endothelial cell mitochondria and the action of mitoquinol, a mitochondria-targeted antioxidant. ROS measured by fluorescence resulted from complex I superoxide released to the matrix and converted to H2O2. In contrast, EPR largely detected superoxide generated at complex III and effluxed outward. ROS fluorescence by mitochondria fueled by the complex II substrate, succinate, was substantial but markedly inhibited by rotenone. Superoxide, detected by EPR, in succinate-fueled mitochondria was not inhibited by rotenone and likely derived from semiquinone formation at complex III. Mitoquinol decreased H2O2 fluorescence by succinate-fueled mitochondria but had little effect on the EPR signal for superoxide. This was not associated with a detectable decrease in membrane potential. Mitoquinol markedly enhanced ROS fluorescence in mitochondria fueled by the complex I substrates, glutamate and malate. Inhibitor studies suggested that this occurred in complex I, at one or more Q binding pockets. The above effects of mitoquinol were determined in mitochondria isolated and subsequently exposed to the targeted antioxidant. However, similar effects were observed in mitochondria after antecedent exposure to mitoquinol/mitoquinone in culture, suggesting that the agent is retained after isolation of the organelles. In conclusion, ROS production in bovine aortic endothelial cell mitochondria results largely from reverse transport to complex I and through the Q cycle in complex III. Mitoquinol blocks ROS from reverse electron transport but increases superoxide production derived from forward transport. These effects likely occur at one or more Q binding sites in complex I.	Iowa City Vet Affairs Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Iowa City, IA 52242 USA; Iowa City Vet Affairs Med Ctr, Coll Pharm, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa	Sivitz, WI (corresponding author), Univ Iowa Hosp & Clin, Dept Internal Med, Div Endocrinol & Metab, 422GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	william-sivitz@uiowa.edu	Prisinzano, Thomas E/B-7877-2010	Prisinzano, Thomas/0000-0002-0649-8052; Sivitz, William/0000-0002-7829-0189; Fink, Brian/0000-0002-1149-7935	NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asin-Cayuela J, 2004, FEBS LETT, V571, P9, DOI 10.1016/j.febslet.2004.06.045; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Brand MD, 2004, BIOCHEM SOC SYMP, V71, P203; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BROWN GC, 1988, BIOCHEM J, V252, P473, DOI 10.1042/bj2520473; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; Fink BD, 2005, AM J PHYSIOL-ENDOC M, V288, pE71, DOI 10.1152/ajpendo.00332.2004; Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; James AM, 2004, ARCH BIOCHEM BIOPHYS, V423, P47, DOI 10.1016/j.abb.2003.12.025; James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1007/BF02254975; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lionetti L, 1998, ARCH BIOCHEM BIOPHYS, V352, P240, DOI 10.1006/abbi.1998.0579; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; Miwa S, 2003, BIOCHEM SOC T, V31, P1300; MOSER DR, 1992, MOL ENDOCRINOL, V6, P1805, DOI 10.1210/me.6.11.1805; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Nicholls DG, 1997, BIOSCIENCE REP, V17, P251, DOI 10.1023/A:1027376426860; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NITENBERG A, 1993, DIABETES, V42, P1017, DOI 10.2337/diabetes.42.7.1017; Ogita H, 2004, ENDOTHELIUM-J ENDOTH, V11, P123, DOI 10.1080/10623320490482664; Ohnishi ST, 2005, J BIOENERG BIOMEMBR, V37, P1, DOI 10.1007/s10863-005-4117-y; Pitkanen OP, 1998, DIABETES, V47, P248, DOI 10.2337/diabetes.47.2.248; Porter RK, 1999, INT J OBESITY, V23, pS12, DOI 10.1038/sj.ijo.0800937; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Saretzki G, 2003, AGING CELL, V2, P141, DOI 10.1046/j.1474-9728.2003.00040.x; Schafer M, 2003, CIRC RES, V92, P1010, DOI 10.1161/01.RES.0000070882.81508.FC; SHULACHEV VP, 1998, BIOCHIM BIOPHYS ACTA, V1363, P100; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Yokoyama I, 1997, J AM COLL CARDIOL, V30, P1472, DOI 10.1016/S0735-1097(97)00327-6; Yorek MA, 2003, FREE RADICAL RES, V37, P471, DOI 10.1080/1071576031000083161; Zwicker K, 1998, ARZNEIMITTEL-FORSCH, V48, P629	49	87	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39766	39775		10.1074/jbc.M608268200	http://dx.doi.org/10.1074/jbc.M608268200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17060316	hybrid			2022-12-25	WOS:000243033900004
J	Aeling, KA; Opel, ML; Steffen, NR; Tretyachenko-Ladokhina, V; Hatfield, GW; Lathrop, RH; Senear, DF				Aeling, Kimberly A.; Opel, Michael L.; Steffen, Nicholas R.; Tretyachenko-Ladokhina, Vira; Hatfield, G. Wesley; Lathrop, Richard H.; Senear, Donald F.			Indirect recognition in sequence-specific DNA binding by Escherichia coli integration host factor - The role of DNA deformation energy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL TRANSMISSION MECHANISM; PROMOTER-REGULATORY REGION; SURFACE SALT-BRIDGES; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; OPERON EXPRESSION; GENE-EXPRESSION; PROTEIN INTERACTIONS; TYPE-1 FIMBRIAE; PHASE VARIATION	Integration host factor (IHF) is a bacterial histone-like protein whose primary biological role is to condense the bacterial nucleoid and to constrain DNA supercoils. It does so by binding in a sequence-independent manner throughout the genome. However, unlike other structurally related bacterial histone-like proteins, IHF has evolved a sequence-dependent, high affinity DNA-binding motif. The high affinity binding sites are important for the regulation of a wide range of cellular processes. A remarkable feature of IHF is that it employs an indirect readoutmechanism to bind and wrap DNA at both the nonspecific and high affinity (sequence-dependent) DNA sites. In this study we assessed the contributions of pre-formed and protein-induced DNA conformations to the energetics of IHF binding. Binding energies determined experimentally were compared with energies predicted for the IHF-induced deformation of the DNA helix ( DNA deformation energy) in the IHF-DNA complex. Combinatorial sets of de novo DNA sequences were designed to systematically evaluate the influence of sequence-dependent structural characteristics of the conserved IHF recognition elements of the consensus DNA sequence. We show that IHF recognizes pre-formed conformational characteristics of the consensus DNA sequence at high affinity sites, whereas at all other sites relative affinity is determined by the deformational energy required for nearest-neighbor base pairs to adopt the DNA structure of the bound DNA-IHF complex.	Univ Calif Irvine, Sch Med, Inst Genom & Bioinformat, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Informat & Comp Sci, Dept Comp Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Biol Sci, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Senear, DF (corresponding author), Univ Calif Irvine, Sch Med, Inst Genom & Bioinformat, Irvine, CA 92697 USA.	dfsenear@uci.edu			PHS HHS [NIH68903] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AELING KA, 2006, IEEE ACM T COMPUTATI; Ali BMJ, 2001, P NATL ACAD SCI USA, V98, P10658, DOI 10.1073/pnas.181029198; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Arauzo-Bravo MJ, 2005, J AM CHEM SOC, V127, P16074, DOI 10.1021/ja053241l; Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105; Blomfield IC, 1997, MOL MICROBIOL, V23, P705, DOI 10.1046/j.1365-2958.1997.2241615.x; BONGAERTS J, 1995, MOL MICROBIOL, V16, P521, DOI 10.1111/j.1365-2958.1995.tb02416.x; Bosch D, 2003, J COMPUT CHEM, V24, P682, DOI 10.1002/jcc.10200; BOX GEP, 1960, ANN NY ACAD SCI, V86, P792, DOI 10.1111/j.1749-6632.1960.tb42843.x; Browning DF, 2002, MOL MICROBIOL, V43, P687, DOI 10.1046/j.1365-2958.2002.02776.x; Bykowski T, 1998, BIOCHIMIE, V80, P987, DOI 10.1016/S0300-9084(99)80004-2; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; Dworkin J, 1998, GENE DEV, V12, P894, DOI 10.1101/gad.12.6.894; ENGELHORN N, 1995, NUCLEIC ACIDS RES, V23, P2959, DOI 10.1093/nar/23.15.2959; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; FREUNDLICH M, 1992, MOL MICROBIOL, V6, P2557, DOI 10.1111/j.1365-2958.1992.tb01432.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GARDNER JF, 1986, J MOL BIOL, V191, P181, DOI 10.1016/0022-2836(86)90255-X; Goodman SD, 1999, J BACTERIOL, V181, P3246, DOI 10.1128/JB.181.10.3246-3255.1999; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; Green J, 1997, MICROBIOL-SGM, V143, P2865, DOI 10.1099/00221287-143-9-2865; Gromiha MM, 2004, J MOL BIOL, V337, P285, DOI 10.1016/j.jmb.2004.01.033; Gromiha MM, 2005, GENE, V364, P108, DOI 10.1016/j.gene.2005.07.022; HALES LM, 1994, J BACTERIOL, V176, P2999, DOI 10.1128/JB.176.10.2999-3006.1994; Hales LM, 1996, NUCLEIC ACIDS RES, V24, P1780, DOI 10.1093/nar/24.9.1780; Hatfield GW, 2002, ANNU REV GENET, V36, P175, DOI 10.1146/annurev.genet.36.032902.111815; Holbrook JA, 2001, J MOL BIOL, V310, P379, DOI 10.1006/jmbi.2001.4768; HOPPER S, 1994, J BIOL CHEM, V269, P19597; HUANG L, 1990, J BACTERIOL, V172, P5293, DOI 10.1128/jb.172.9.5293-5298.1990; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Jovanovic G, 1997, MOL MICROBIOL, V25, P473, DOI 10.1046/j.1365-2958.1997.4791844.x; Kulasekara HD, 1999, MOL MICROBIOL, V31, P1171, DOI 10.1046/j.1365-2958.1999.01257.x; Lynch TW, 2003, J MOL BIOL, V330, P493, DOI 10.1016/S0022-2836(03)00529-1; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; McNicholas PM, 1998, MOL MICROBIOL, V27, P197, DOI 10.1046/j.1365-2958.1998.00675.x; MENGERITSKY G, 1993, J MOL BIOL, V231, P646, DOI 10.1006/jmbi.1993.1316; Morozov AV, 2005, NUCLEIC ACIDS RES, V33, P5781, DOI 10.1093/nar/gki875; Murtin C, 1998, J MOL BIOL, V284, P949, DOI 10.1006/jmbi.1998.2256; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; Opel ML, 2004, MOL MICROBIOL, V53, P665, DOI 10.1111/j.1365-2958.2004.04147.x; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; Paul L, 2001, J BACTERIOL, V183, P3910, DOI 10.1128/JB.183.13.3910-3918.2001; Pratt TS, 1997, J BACTERIOL, V179, P6367, DOI 10.1128/jb.179.20.6367-6377.1997; RABIN RS, 1992, P NATL ACAD SCI USA, V89, P8701, DOI 10.1073/pnas.89.18.8701; RAMANI N, 1992, MOL GEN GENET, V231, P248, DOI 10.1007/BF00279798; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rice PA, 1997, CURR OPIN STRUC BIOL, V7, P86, DOI 10.1016/S0959-440X(97)80011-5; Saecker RM, 2002, CURR OPIN STRUC BIOL, V12, P311, DOI 10.1016/S0959-440X(02)00326-3; Sewitz S, 2003, NUCLEIC ACIDS RES, V31, P5868, DOI 10.1093/nar/gkg797; Sheridan SD, 1998, J BIOL CHEM, V273, P21298, DOI 10.1074/jbc.273.33.21298; Sheridan SD, 1999, J BIOL CHEM, V274, P8169, DOI 10.1074/jbc.274.12.8169; SIRKO A, 1993, J BACTERIOL, V175, P5769, DOI 10.1128/JB.175.18.5769-5777.1993; Sirko A, 1998, MOL GEN GENET, V258, P174, DOI 10.1007/s004380050720; Spira B, 1999, CURR MICROBIOL, V38, P80, DOI 10.1007/s002849900407; Steffen Nicholas R, 2002, Genome Inform, V13, P153; Steffen NR, 2002, BIOINFORMATICS, V18, P22; TEFFEN NR, 2003, THESIS U CALIFORNIA; TOLLERI L, 2002, THESIS U STUDI PAVIA; Travers A, 1997, CURR BIOL, V7, pR252, DOI 10.1016/S0960-9822(06)00114-X; Tsodikov OV, 2001, BIOPHYS J, V81, P1960, DOI 10.1016/S0006-3495(01)75847-X; TSUI P, 1991, J BACTERIOL, V173, P5800, DOI 10.1128/jb.173.18.5800-5807.1991; TSUI P, 1988, J MOL BIOL, V203, P817, DOI 10.1016/0022-2836(88)90212-4; Ussery D, 2001, BIOCHIMIE, V83, P201, DOI 10.1016/S0300-9084(00)01225-6; van der Ploeg JR, 1999, J BIOL CHEM, V274, P29358, DOI 10.1074/jbc.274.41.29358; Wackwitz B, 1999, MOL GEN GENET, V262, P876, DOI 10.1007/s004380051153; WANG SQ, 1995, BIOCHEMISTRY-US, V34, P13082, DOI 10.1021/bi00040a020; WEINER L, 1995, NUCLEIC ACIDS RES, V23, P2030, DOI 10.1093/nar/23.11.2030; WU YF, 1992, J BACTERIOL, V174, P6918, DOI 10.1128/JB.174.21.6918-6927.1992; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x; Zhang X, 1996, J BACTERIOL, V178, P3971, DOI 10.1128/jb.178.13.3971-3973.1996	72	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39236	39248		10.1074/jbc.M606363200	http://dx.doi.org/10.1074/jbc.M606363200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17035240	hybrid, Green Submitted			2022-12-25	WOS:000242898700031
J	Kim, YS; Cho, KO; Lee, HJ; Kim, SY; Sato, Y; Cho, YJ				Kim, Young Sun; Cho, Kyung-Ok; Lee, Hong Joon; Kim, Seong Yun; Sato, Yasufumi; Cho, Young-Jin			Down syndrome candidate region 1 increases the stability of the I kappa B alpha protein - Implications for its anti-inflammatory effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; FOCAL CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; ENDOTHELIAL-CELLS; CONSTITUTIVE PHOSPHORYLATION; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DSCR1 ADAPT78; CALCINEURIN	Down syndrome candidate region 1 (DSCR1), an endogenous inhibitor of calcineurin, inhibits the expression of genes involved in the inflammatory response. To elucidate the molecular basis of these anti-inflammatory effects, we analyzed the role of DSCR1 in the regulation of NF-kappa B transactivation using glioblastoma cells stably transfected with DSCR1.4 or its truncation mutants (DSCR1.4-(1-133) and DSCR1.4-(134-197)). Overexpression of DSCR1.4 significantly attenuated the induction of cyclooxygenase-2 (COX-2) expression by phorbol 12-myristate 13-acetate (PMA) via a calcineurin-independent mechanism. Experiments using inhibitors of the signaling molecules for NF-kappa B activation showed that NF-kappa B is responsible for the induction of COX-2. Full-length and truncated DSCR1.4 decreased the steady-state activity of NF-kappa B as well as PMA-induced activation of NF-kappa B, which correlated with attenuation of COX-2 induction. DSCR1.4 did not affect the PMA-stimulated phosphorylation or degradation kinetics of I kappa B alpha; however, DSCR1.4 significantly decreased the basal turnover rate of I kappa B alpha and consequently up-regulated its steady-state level. In the same context, knockdown of endogenous DSCR1.4 increased the turnover rate of I kappa B alpha as well as COX-2 induction. These results suggest that DSCR1 attenuates NF-kappa B-mediated transcriptional activation by stabilizing its inhibitory protein, I kappa B alpha.	Catholic Univ Korea, Dept Pharmacol, Coll Med, Seoul 137701, South Korea; Catholic Univ Korea, Cell Death Ctr, MRC, Coll Med, Seoul 137701, South Korea; Tohoku Univ, Dept Vasc Biol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan	Catholic University of Korea; Catholic University of Korea; Tohoku University	Cho, YJ (corresponding author), Catholic Univ Korea, Dept Pharmacol, Coll Med, Banpo Dong 505, Seoul 137701, South Korea.	haechee@catholic.ac.kr	Sato, Yasufumi/AAF-3367-2019; Cho, Kyungok/R-5359-2019	Cho, Kyungok/0000-0002-1314-7584				Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Barker KS, 2005, J INFECT DIS, V192, P901, DOI 10.1086/432487; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cano E, 2005, J BIOL CHEM, V280, P29435, DOI 10.1074/jbc.M506205200; Cavin LG, 2003, HEPATOLOGY, V38, P1540, DOI 10.1016/j.hep.2003.09.019; Chan B, 2005, P NATL ACAD SCI USA, V102, P13075, DOI 10.1073/pnas.0503846102; Chang MS, 2005, CELL SIGNAL, V17, P299, DOI 10.1016/j.cellsig.2004.07.008; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Cho YJ, 2005, ARCH BIOCHEM BIOPHYS, V439, P121, DOI 10.1016/j.abb.2005.05.002; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Cook CN, 2005, J ALZHEIMERS DIS, V8, P63; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; Ferrer I, 1998, NEUROPATH APPL NEURO, V24, P271; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Harris CD, 2005, CELL MOL LIFE SCI, V62, P2477, DOI 10.1007/s00018-005-5085-4; Hesser BA, 2004, BLOOD, V104, P149, DOI 10.1182/blood-2004-01-0273; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Iizuka M, 2004, J VASC RES, V41, P334, DOI 10.1159/000079832; Kanno T, 1996, J IMMUNOL, V157, P5277; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee NK, 2002, J BIOCHEM MOL BIOL, V35, P61; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Minami T, 2004, J BIOL CHEM, V279, P50537, DOI 10.1074/jbc.M406454200; Minami T, 2006, J BIOL CHEM, V281, P20503, DOI 10.1074/jbc.M513112200; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Rothermel BA, 2003, TRENDS CARDIOVAS MED, V13, P15, DOI 10.1016/S1050-1738(02)00188-3; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schuette R, 2000, AM J PHYSIOL-HEART C, V279, pH719, DOI 10.1152/ajpheart.2000.279.2.H719; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Seegers H, 2000, NEUROSCI LETT, V288, P241, DOI 10.1016/S0304-3940(00)01245-3; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Uzonyi B, 2006, P NATL ACAD SCI USA, V103, P6326, DOI 10.1073/pnas.0601223103; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Viviani B, 2004, TOXICOL LETT, V149, P85, DOI 10.1016/j.toxlet.2003.12.022; Yao YG, 2004, BIOCHEM BIOPH RES CO, V321, P648, DOI 10.1016/j.bbrc.2004.06.176; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004	52	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39051	39061		10.1074/jbc.M604659200	http://dx.doi.org/10.1074/jbc.M604659200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17062574	hybrid			2022-12-25	WOS:000242898700011
J	Lechner, AM; Assfalg-Machleidt, I; Zahler, S; Stoeckelhuber, M; Machleidt, W; Jochum, M; Nagler, DK				Lechner, Annette M.; Assfalg-Machleidt, Irmgard; Zahler, Stefan; Stoeckelhuber, Mechthild; Machleidt, Werner; Jochum, Marianne; Naegler, Dorit K.			RGD-dependent binding of procathepsin X to integrin alpha(v)beta(3) mediates cell-adhesive properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATHEPSIN-X; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; CYSTEINE PROTEASE; PROSTATE-CANCER; UP-REGULATION; THROMBIN; ALPHA-V-BETA-3; PROTEOGLYCAN; MECHANISM	Secreted lysosomal cysteine proteases (cathepsins) are involved in degradation and remodeling of the extracellular matrix, thus contributing to cell adhesion and migration. Among the eleven human lysosomal cysteine proteases, only procathepsin X contains an RGD motif located in a highly exposed region of the propeptide, which may allow binding of the proenzyme to RGD-recognizing integrins. Here, we have tested procathepsin X for cell-adhesive properties and found that it supports integrin alpha(v)beta(3)-dependent attachment and spreading of human umbilical vein endothelial cells. Using site-directed mutants of procathepsin X, we proved that this effect is mediated by the RGD sequence within the proregion of the protease. Endogenous procathepsin X is transported to the plasma membrane, accumulates in vesicles at lamellipodia of the human umbilical vein endothelial cell, and is partly associated with the cell surface, as shown by immunofluorescence. In addition, procathepsin X is partly co-localized with integrin beta(3), as detected by immunogold electron microscopy. A direct interaction etween endogenous procathepsin X and alpha(v)beta(3) was demonstrated by co-immunoprecipitation. Moreover, surface plasmon resonance analysis revealed significant and RGD-dependent binding of procathepsin X to integrin alpha(v)beta(3). Our results provide for the first time evidence that the extracellular function of cathepsin X may include binding to integrins thereby modulating the attachment of migrating cells to ECM components.	Univ Munich, Dept Surg, Div Clin Chem & Clin Biochem, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Univ Munich, Dept Pharm Pharmaceut Biol, D-81377 Munich, Germany; Univ Munich, Inst Anat, D-80336 Munich, Germany	University of Munich; University of Munich; University of Munich; University of Munich	Nagler, DK (corresponding author), Univ Munich, Dept Surg, Div Clin Chem & Clin Biochem, Nussbaumstr 20, D-80336 Munich, Germany.	dorit.naegler@med.uni-muenchen.de		Zahler, Stefan/0000-0002-5140-7287				ALBELDA SM, 1990, CANCER RES, V50, P6757; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BODE W, 1992, PROTEIN SCI, V1, P426; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; Buth H, 2004, EUR J CELL BIOL, V83, P781, DOI 10.1078/0171-9335-00428; Byzova TV, 1997, J BIOL CHEM, V272, P27183, DOI 10.1074/jbc.272.43.27183; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Chapman HA, 2001, THROMB HAEMOSTASIS, V86, P124; Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224; DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002-9440(10)63200-2; Geho DH, 2005, PHYSIOLOGY, V20, P194, DOI 10.1152/physiol.00009.2005; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Gonscherowski V, 2006, AM J PHYSIOL-HEART C, V290, pH2035, DOI 10.1152/ajpheart.00772.2004; Groves MR, 1998, PROTEINS, V32, P504, DOI 10.1002/(SICI)1097-0134(19980901)32:4<504::AID-PROT8>3.0.CO;2-F; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hook V, 2005, BIOL CHEM, V386, P931, DOI 10.1515/BC.2005.108; Hook V, 2004, BIOL CHEM, V385, P473, DOI 10.1515/BC.2004.055; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Kos J, 2005, EXP CELL RES, V306, P103, DOI 10.1016/j.yexcr.2004.12.006; Krueger S, 2005, J PATHOL, V207, P32, DOI 10.1002/path.1820; Kumar CC, 2003, CURR DRUG TARGETS, V4, P123, DOI 10.2174/1389450033346830; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mondino A, 2004, TRENDS IMMUNOL, V25, P450, DOI 10.1016/j.it.2004.06.004; Nagler DK, 1999, BIOCHEMISTRY-US, V38, P12648, DOI 10.1021/bi991371z; Nagler DK, 2004, PROSTATE, V60, P109, DOI 10.1002/pros.20046; Nagler DK, 2006, J IMMUNOL METHODS, V308, P241, DOI 10.1016/j.jim.2005.11.002; Nascimento FD, 2005, ARCH BIOCHEM BIOPHYS, V436, P323, DOI 10.1016/j.abb.2005.01.013; Papaconstantinou ME, 2005, J BIOL CHEM, V280, P29393, DOI 10.1074/jbc.C500248200; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Sajid M, 2003, AM J PHYSIOL-CELL PH, V285, pC1330, DOI 10.1152/ajpcell.00475.2002; Sivaraman J, 2000, J MOL BIOL, V295, P939, DOI 10.1006/jmbi.1999.3410; SMITH JW, 1994, J BIOL CHEM, V269, P960; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Stoeckelhuber M, 2002, HISTOCHEM CELL BIOL, V118, P221, DOI 10.1007/s00418-002-0438-7; Stouffer GA, 2003, ARTERIOSCL THROM VAS, V23, P1971, DOI 10.1161/01.ATV.0000093470.51580.0F; Tanaka Y, 1998, ARTHRITIS RHEUM-US, V41, P1365, DOI 10.1002/1529-0131(199808)41:8<1365::AID-ART5>3.0.CO;2-W; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	44	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39588	39597		10.1074/jbc.M513439200	http://dx.doi.org/10.1074/jbc.M513439200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17065156	hybrid			2022-12-25	WOS:000242898700066
J	Lee, FA; van Lier, M; Relou, IAM; Foley, L; Akkerman, JWN; Heijnen, HFG; Farndale, RW				Lee, Fiona A.; van Lier, Marjolijn; Relou, Ingrid A. M.; Foley, Loraine; Akkerman, Jan-Willem N.; Heijnen, Harry F. G.; Farndale, Richard W.			Lipid rafts facilitate the interaction of PECAM-1 with the glycoprotein VI-FcR gamma-chain complex in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; PROTEIN-TYROSINE-PHOSPHATASE; SRC FAMILY KINASES; COLLAGEN RECEPTOR; FUNCTIONAL ASSOCIATION; ACTIN CYTOSKELETON; MURINE PLATELETS; MEMBRANE DOMAINS; PLASMA-MEMBRANE; ACTIVATION	Glycoprotein ( GP) VI, the main signaling receptor for collagen on platelets, is expressed in complex with the FcR gamma-chain. The latter contains an immunoreceptor tyrosine-based activation motif, which becomes phosphorylated, initiating a signaling cascade leading to the rapid activation and aggregation of platelets. Previous studies have shown that signaling by immunoreceptor tyrosine-based activation motif-containing receptors is counteracted by signals from receptors with immunoreceptor tyrosine-based inhibitory motifs. Here we show, by immunoprecipitation, that the GPVI-FcR gamma-chain complex associates with the immunoreceptor tyrosine-based inhibitory motif-containing receptor, PECAM-1. In platelets stimulated with collagen-related peptide (CRP-XL), tyrosine phosphorylation of PECAM-1 precedes that of the FcR gamma-chain, implying direct regulation of the former. The GPVI-FcR gamma-chain complex and PECAM-1 were present in both lipid raft and soluble fractions in human platelets; this distribution was unaltered by activation with CRP-XL. Their association occurred in lipid rafts and was lost after lipid raft depletion using methyl-beta-cyclodextrin. We propose that lipid raft clustering facilitates the interaction of PECAM-1 with the GPVI- FcR gamma-chain complex, leading to the down-regulation of the latter.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Cell Microscopy Ctr, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	University of Cambridge; Utrecht University; Utrecht University; Utrecht University	Farndale, RW (corresponding author), Univ Cambridge, Dept Biochem, Downing Site, Cambridge CB2 1QW, England.	rwf10@cam.ac.uk			MRC [G0400701] Funding Source: UKRI; Medical Research Council [G0400701] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Barrow AD, 2004, J IMMUNOL, V172, P5838, DOI 10.4049/jimmunol.172.10.5838; Bodin S, 2005, J CELL SCI, V118, P759, DOI 10.1242/jcs.01648; BODIN S, 2005, J CELL SCI, V25, P25; Cicmil M, 2002, BLOOD, V99, P137, DOI 10.1182/blood.V99.1.137; Cicmil M, 2000, J BIOL CHEM, V275, P27339; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Ezumi Y, 2002, BLOOD, V99, P3250, DOI 10.1182/blood.V99.9.3250; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Heijnen HFG, 2003, J THROMB HAEMOST, V1, P1161, DOI 10.1046/j.1538-7836.2003.00316.x; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Jones KL, 2001, BLOOD, V98, P1456, DOI 10.1182/blood.V98.5.1456; LIER M, 2005, J THROMB HAEMOST, V3, P2514; Locke D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/jbc.M111520200; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Pasquet JM, 2000, J BIOL CHEM, V275, P28526, DOI 10.1074/jbc.M001531200; Patil S, 2001, BLOOD, V97, P1727, DOI 10.1182/blood.V97.6.1727; Quek LS, 2000, BLOOD, V96, P4246; Quinton TM, 2005, J THROMB HAEMOST, V3, P1036, DOI 10.1111/j.1538-7836.2005.01325.x; Rathore V, 2003, BLOOD, V102, P3658, DOI 10.1182/blood-2003-06-1888; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Thai LM, 2003, BLOOD, V102, P3637, DOI 10.1182/blood-2003-02-0496; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Valensin S, 2002, EUR J IMMUNOL, V32, P435, DOI 10.1002/1521-4141(200202)32:2<435::AID-IMMU435>3.0.CO;2-H; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Wonerow P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128; Wu XW, 1997, ARTERIOSCL THROM VAS, V17, P3154, DOI 10.1161/01.ATV.17.11.3154; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	39	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39330	39338		10.1074/jbc.M607930200	http://dx.doi.org/10.1074/jbc.M607930200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17068334	hybrid			2022-12-25	WOS:000242898700040
J	Simanshu, DK; Savithri, HS; Murthy, MRN				Simanshu, Dhirendra K.; Savithri, Handanahal S.; Murthy, Mathur R. N.			Crystal structures of Salmonella typhimurium biodegradative threonine deaminase and its complex with CMP provide structural insights into ligand-induced oligomerization and enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ALLOSTERIC INHIBITION; DEHYDRATASE; MECHANISM; PROGRAM; SYNTHASE; AMP	Two different pyridoxal 5'-phosphate-containing L-threonine deaminases (EC 4.3.1.19), biosynthetic and biodegradative, which catalyze the deamination of L-threonine to alpha-ketobutyrate, are present in Escherichia coli and Salmonella typhimurium. Biodegradative threonine deaminase (TdcB) catalyzes the first reaction in the anaerobic breakdown of L-threonine to propionate. TdcB, unlike the biosynthetic threonine deaminase, is insensitive to L-isoleucine and is activated by AMP. In the present study, TdcB from S. typhimurium was cloned and over-expressed in E. coli. In the presence of AMP or CMP, the recombinant enzyme was converted to the tetrameric form accompanied by significant enzyme activation. To provide insights into ligand-mediated oligomerization and enzyme activation, crystal structures of S. typhimurium TdcB and its complex with CMP were determined. In the native structure, TdcB is in a dimeric form, whereas in the TdcB(.)CMP complex, it exists in a tetrameric form with 222 symmetry and appears as a dimer of dimers. Tetrameric TdcB binds to four molecules of CMP, two at each of the dimer interfaces. Comparison of the dimer structure in the ligand (CMP)-free and -bound forms suggests that the changes induced by ligand binding at the dimer interface are essential for tetramerization. The differences observed in the tertiary and quaternary structures of TdcB in the absence and presence of CMP appear to account for enzyme activation and increased binding affinity for L-threonine. Comparison of TdcB with related pyridoxal 5'-phosphate-dependent enzymes points to structural and mechanistic similarities.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Murthy, MRN (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	mm@mbu.iisc.ernet.in	Simanshu, Dhirendra/B-3361-2008	Simanshu, Dhirendra/0000-0002-9717-4618				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHADRA R, 1978, BIOCHEMISTRY-US, V17, P1691, DOI 10.1021/bi00602a017; Blankenhorn D, 1999, J BACTERIOL, V181, P2209, DOI 10.1128/JB.181.7.2209-2216.1999; Bond CS, 2003, BIOINFORMATICS, V19, P311, DOI 10.1093/bioinformatics/19.2.311; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Dunne C P, 1975, Curr Top Cell Regul, V9, P65; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FISHER KE, 1993, J BACTERIOL, V175, P6605, DOI 10.1128/jb.175.20.6605-6613.1993; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GERLT JA, 1973, J BIOL CHEM, V248, P8200; Guillouet S, 1999, APPL ENVIRON MICROB, V65, P3100; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUGINBUHL GH, 1974, J BACTERIOL, V120, P559, DOI 10.1128/JB.120.1.559-561.1974; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; NAKAZAWA A, 1967, J BIOL CHEM, V242, P3868; NAWAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEDERMAN RA, 1969, BIOCHEM BIOPH RES CO, V36, P951, DOI 10.1016/0006-291X(69)90296-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK LS, 1979, J BACTERIOL, V138, P1026, DOI 10.1128/JB.138.3.1026-1028.1979; PATIL RV, 1988, EUR J BIOCHEM, V177, P569, DOI 10.1111/j.1432-1033.1988.tb14408.x; RABINOWITZ KW, 1968, J BIOL CHEM, V243, P3214; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SHIZUTA Y, 1976, CURR TOP CELL REGUL, V11, P99; SHIZUTA Y, 1973, J BIOL CHEM, V248, P512; Simanshu DK, 2006, ACTA CRYSTALLOGR F, V62, P275, DOI 10.1107/S1744309106005707; Thomazeau K, 2001, PROTEIN SCI, V10, P638, DOI 10.1110/ps.44301; TOKUSHIGE M, 1963, BIOCHEM BIOPH RES CO, V13, P380, DOI 10.1016/0006-291X(63)90351-6; UMBARGER HE, 1956, SCIENCE, V123, P848, DOI 10.1126/science.123.3202.848; UMBARGER HE, 1957, J BACTERIOL, V73, P105, DOI 10.1128/JB.73.1.105-112.1957; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WHANGER PD, 1968, J BIOL CHEM, V243, P167; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu Qian Steven, 2005, Journal of Structural and Functional Genomics, V6, P269, DOI 10.1007/s10969-005-9001-9; Yamada T, 2003, BIOCHEMISTRY-US, V42, P12854, DOI 10.1021/bi035324p; Yao M, 2000, J BIOL CHEM, V275, P34557, DOI 10.1074/jbc.M004681200	47	36	38	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39630	39641		10.1074/jbc.M605721200	http://dx.doi.org/10.1074/jbc.M605721200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17046821	hybrid			2022-12-25	WOS:000242898700070
J	Wang, YL; Liu, L; Wei, ZY; Cheng, ZJ; Lin, YJ; Gong, WM				Wang, Yanli; Liu, Lin; Wei, Zhiyi; Cheng, Zhongjun; Lin, Yajing; Gong, Weimin			Seeing the process of histidine phosphorylation in human bisphosphoglycerate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PHOSPHOGLYCERATE MUTASE; RAY CRYSTAL-STRUCTURE; BACILLUS-STEAROTHERMOPHILUS; ACTIVE-SITE; INTERMEDIATE; MECHANISM; SYSTEM; EXPRESSION; SYNTHASE; COMPLEX	Bisphosphoglycerate mutase is an erythrocyte-specific enzyme catalyzing a series of intermolecular phosphoryl group transfer reactions. Its main function is to synthesize 2,3-bisphosphoglycerate, the allosteric effector of hemoglobin. In this paper, we directly observed real-time motion of the enzyme active site and the substrate during phosphoryl transfer. A series of high resolution crystal structures of human bisphosphoglycerate mutase co-crystallized with 2,3-bisphosphoglycerate, representing different time points in the phosphoryl transfer reaction, were solved. These structures not only clarify the argument concerning the substrate binding mode for this enzyme family but also depict the entire process of the key histidine phosphorylation as a "slow movie". It was observed that the enzyme conformation continuously changed during the different states of the reaction. These results provide direct evidence for an "in line" phosphoryl transfer mechanism, and the roles of some key residues in the phosphoryl transfer process are identified.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Gong, WM (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	wgong@ibp.ac.cn	Cheng, zhongjun/D-6929-2011; Wei, Zhiyi/C-4315-2014; Wei, Zhiyi/B-5001-2010; Wei, Zhiyi/N-9995-2019; wang, yanli/G-3306-2010	Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; Wei, Zhiyi/0000-0002-4446-6502; Wang, Yanli/0000-0002-5969-1745				Bahnson BJ, 2004, P NATL ACAD SCI USA, V101, P16399, DOI 10.1073/pnas.0407418101; Blackburn GM, 2003, SCIENCE, V301; Bond CS, 2001, J BIOL CHEM, V276, P3247, DOI 10.1074/jbc.M007318200; Bond CS, 2002, J MOL BIOL, V316, P1071, DOI 10.1006/jmbi.2002.5418; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMPBELL JW, 1974, NATURE, V250, P301, DOI 10.1038/250301a0; Crowhurst GS, 1999, ACTA CRYSTALLOGR D, V55, P1822, DOI 10.1107/S0907444999009944; FOTHERGILLGILMORE LA, 1989, ADV ENZYMOL RAMB, V62, P227; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE G, 1981, PHILOS T ROY SOC B, V293, P75, DOI 10.1098/rstb.1981.0062; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Muller P, 2005, ACTA CRYSTALLOGR D, V61, P309, DOI 10.1107/S0907444904033190; Nairn J, 1996, BBA-PROTEIN STRUCT M, V1296, P69, DOI 10.1016/0167-4838(96)00046-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rigden DJ, 2003, FEBS LETT, V536, P77, DOI 10.1016/S0014-5793(03)00014-0; Rigden DJ, 2002, J MOL BIOL, V315, P1129, DOI 10.1006/jmbi.2001.5290; Rigden DJ, 2003, J MOL BIOL, V325, P411, DOI 10.1016/S0022-2836(02)01229-9; Rigden DJ, 1999, J MOL BIOL, V289, P691, DOI 10.1006/jmbi.1999.2848; Rigden DJ, 1998, J MOL BIOL, V276, P449, DOI 10.1006/jmbi.1997.1554; Rigden DJ, 1999, J MOL BIOL, V286, P1507, DOI 10.1006/jmbi.1999.2566; Rose Z B, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P211; Theisen MJ, 2004, P NATL ACAD SCI USA, V101, P16442, DOI 10.1073/pnas.0405809101; VANWAZER JR, 1964, J DENT RES, V43, P1052, DOI 10.1177/00220345640430060901; Walter RA, 1999, BIOCHEM J, V337, P89, DOI 10.1042/0264-6021:3370089; Wang YL, 2005, BIOCHEM BIOPH RES CO, V331, P1207, DOI 10.1016/j.bbrc.2005.03.243; Wang YL, 2004, J BIOL CHEM, V279, P39132, DOI 10.1074/jbc.M405982200; Webster CE, 2004, J AM CHEM SOC, V126, P6840, DOI 10.1021/ja049232e; WHITE MF, 1992, EUR J BIOCHEM, V207, P709, DOI 10.1111/j.1432-1033.1992.tb17099.x; WHITE MF, 1993, BIOCHEM J, V291, P479, DOI 10.1042/bj2910479; WINN SI, 1981, PHILOS T ROY SOC B, V293, P121, DOI 10.1098/rstb.1981.0066; Wolf-Watz M, 2004, NAT STRUCT MOL BIOL, V11, P945, DOI 10.1038/nsmb821	34	23	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39642	39648		10.1074/jbc.M606421200	http://dx.doi.org/10.1074/jbc.M606421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17052986	hybrid			2022-12-25	WOS:000242898700071
J	Dugan, TA; Yang, VWC; McQuillan, DJ; Hook, M				Dugan, Tracey A.; Yang, Vivian W. -C.; McQuillan, David J.; Hook, Magnus			Decorin modulates fibrin assembly and structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; HUMAN CORONARY-ARTERIES; VASCULAR SMOOTH-MUSCLE; HEPARIN-COFACTOR-II; GROWTH-FACTOR-BETA; COLLAGEN TYPE-I; PROTEOGLYCAN DECORIN; GAMMA-CHAIN; RECOMBINANT FIBRINOGEN; EXTRACELLULAR-MATRIX	Emerging evidence indicates that fibrin clotting is regulated by different external factors. We demonstrated recently that decorin, a regulator of collagen fibrillogenesis and transforming growth factor-beta activity, binds to the D regions of fibrinogen (Dugan, T.A., Yang, V.W.-C., McQuillan, D.J., and Hook, M. (2003) J. Biol. Chem. 278, 13655-13662). We now report that the decorin-fibrinogen interaction alters the assembly, structure, and clearance of fibrin fibers. Relative to fibrinogen, substoichiometric amounts of decorin core protein modulated clotting, whereas an excess of an active decorin peptide was necessary for similar activity. These concentration-dependent effects suggest that decorin bound to the D regions sterically modulates fibrin assembly. Scanning electron microscopy images of fibrin clotted in the presence of increasing concentrations of decorin core protein showed progressively decreasing fiber diameter. The sequestration of Zn2+ ions from the N-terminal fibrinogen-binding region abrogated decorin incorporation into the fibrin network. Compared with linear thicker fibrin fibers, the curving thin fibers formed with decorin underwent accelerated tissue-type plasminogen activator-dependent fibrinolysis. Collectively, these data demonstrate that decorin can regulate fibrin organization and reveal a novel mechanism by which extracellular matrix components can participate in hemostasis, thrombosis, and wound repair.	Texas A&M Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA; Taipei Med Univ, Grad Inst Biomed Mat, Taipei 110, Taiwan; LifeCell Corp, Branchburg, NJ 08876 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Taipei Medical University	Hook, M (corresponding author), Texas A&M Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mhook@ibt.tamhsc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 020624] Funding Source: Medline; NIAMS NIH HHS [AR 042919] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Armani DL, 2001, ANN NY ACAD SCI, V936, P566; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BOYER MH, 1972, BLOOD-J HEMATOL, V39, P382, DOI 10.1182/blood.V39.3.382.382; BROWNLEE M, 1983, DIABETES, V32, P680, DOI 10.2337/diabetes.32.7.680; CARR ME, 1995, BLOOD COAGUL FIBRIN, V6, P567, DOI 10.1097/00001721-199509000-00011; Carr ME, 1996, J LAB CLIN MED, V128, P83, DOI 10.1016/S0022-2143(96)90116-X; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CIANO PS, 1986, LAB INVEST, V54, P62; Clark RAF, 2001, ANN NY ACAD SCI, V936, P355; Collet JP, 2004, ARTERIOSCL THROM VAS, V24, P382, DOI 10.1161/01.ATV.0000109748.77727.3e; Collet JP, 1999, THROMB HAEMOSTASIS, V82, P1482; Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Cote HCF, 1998, BLOOD, V92, P2195, DOI 10.1182/blood.V92.7.2195.2195_2195_2212; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Delorme MA, 1998, THROMB RES, V90, P147, DOI 10.1016/S0049-3848(98)00035-8; Doolittle RF, 2001, ANN NY ACAD SCI, V936, P31; Dugan TA, 2003, J BIOL CHEM, V278, P13655, DOI 10.1074/jbc.M300171200; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Evanko SP, 1998, AM J PATHOL, V152, P533; Fatah K, 1996, THROMB HAEMOSTASIS, V76, P535; Fischer JW, 2004, ARTERIOSCL THROM VAS, V24, P2391, DOI 10.1161/01.ATV.0000147029.63303.28; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOWLER WE, 1981, P NATL ACAD SCI-BIOL, V78, P4872, DOI 10.1073/pnas.78.8.4872; Greiling D, 1997, J CELL SCI, V110, P861; Gutierrez P, 1997, CARDIOVASC PATHOL, V6, P271, DOI 10.1016/S1054-8807(97)00001-X; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hogan KA, 2000, J BIOL CHEM, V275, P17778, DOI 10.1074/jbc.M001618200; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Jarrold BB, 1999, ATHEROSCLEROSIS, V146, P299, DOI 10.1016/S0021-9150(99)00154-9; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; Kaji T, 2004, BIOL PHARM BULL, V27, P1763, DOI 10.1248/bpb.27.1763; KANAIDE H, 1975, J LAB CLIN MED, V85, P574; Keller MA, 2005, BLOOD, V105, P3162, DOI 10.1182/blood-2004-04-1621; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Kolodgie FD, 2002, ARTERIOSCL THROM VAS, V22, P1642, DOI 10.1161/01.ATV.0000034021.92658.4C; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Lin H, 1996, J HEART LUNG TRANSPL, V15, P1233; LIU J, 1994, J BIOL CHEM, V269, P28366; Marchi R, 2004, J THROMB HAEMOST, V2, P940, DOI 10.1111/j.1538-7836.2004.00730.x; MARX G, 1986, AM J HEMATOL, V22, P347, DOI 10.1002/ajh.2830220403; Merrilees MJ, 2001, CORONARY ARTERY DIS, V12, P7, DOI 10.1097/00019501-200102000-00002; MOSESSON MW, 1995, J CLIN INVEST, V96, P1053, DOI 10.1172/JCI118091; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; MOSESSON MW, 2001, ANN NY ACAD SCI, V270, P11; Mullin JL, 2000, J BIOL CHEM, V275, P25239, DOI 10.1074/jbc.M004142200; Mullin JL, 2001, ANN NY ACAD SCI, V936, P331; Nili N, 2003, AM J PATHOL, V163, P869, DOI 10.1016/S0002-9440(10)63447-5; Okumura N, 2004, BLOOD, V103, P4157, DOI 10.1182/blood-2003-12-4296; Okumura N, 1997, J BIOL CHEM, V272, P29596, DOI 10.1074/jbc.272.47.29596; Radhakrishnamurthy B, 1998, EXP MOL PATHOL, V65, P1, DOI 10.1006/exmp.1998.2222; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; RIESSEN R, 1994, AM J PATHOL, V144, P962; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; SCULLY MF, 1983, THROMB RES, V30, P297, DOI 10.1016/0049-3848(83)90083-X; Shirk RA, 2000, J BIOL CHEM, V275, P18085, DOI 10.1074/jbc.M001659200; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Strom A, 2004, HISTOL HISTOPATHOL, V19, P337, DOI 10.14670/HH-19.337; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOSKUILEN M, 1987, J BIOL CHEM, V262, P5944; WADA Y, 1994, BLOOD, V84, P3709, DOI 10.1182/blood.V84.11.3709.bloodjournal84113709; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Weis SM, 2005, MATRIX BIOL, V24, P313, DOI 10.1016/j.matbio.2005.05.003; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; Yamazumi K, 1990, Blood Coagul Fibrinolysis, V1, P557, DOI 10.1097/00001721-199010000-00039; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454; YONEKAWA O, 1992, BIOCHEM J, V283, P187, DOI 10.1042/bj2830187	84	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38208	38216		10.1074/jbc.M607244200	http://dx.doi.org/10.1074/jbc.M607244200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046817	hybrid			2022-12-25	WOS:000242709500013
J	Oganesian, A; Au, S; Horst, JA; Holzhausen, LC; Macy, AJ; Pace, JM; Bornstein, P				Oganesian, Anush; Au, Sandra; Horst, Jeremy A.; Holzhausen, Lars C.; Macy, Athena J.; Pace, James M.; Bornstein, Paul			The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; FYVE DOMAIN PROTEIN; TGF-BETA; EXTRACELLULAR-MATRIX; OSTEOGENESIS IMPERFECTA; MOLECULAR RECOGNITION; COLLAGEN-SYNTHESIS; MESANGIAL CELLS; N-PROTEINASE; OIM MICE	The function of the NH2-terminal propeptide of type I procollagen (N-propeptide) is poorly understood. We now show that a recombinant trimeric N-propeptide interacts with transforming growth factor-beta 1 and BMP2 and exhibits functional effects in stably transfected cells. The synthesis of N-propeptide by COS-7 cells results in an increase in phosphorylation of Akt and Smad3 and is associated with a marked reduction in type I procollagen synthesis and impairment in adhesion. In C2C12 cells, N-propeptide inhibits the osteoblastic differentiation induced by BMP2. Our data suggest that these effects are mediated by the interaction of N-propeptide with an intracellular receptor in the secretory pathway, because they are not observed when recombinant N-propeptide is added to the culture medium of either COS-7 or C2C12 cells. Both the binding of N-propeptide to cytokines and its functional properties are entirely dependent on the exon 2-encoded globular domain, and a mutation that substitutes a serine for a highly conserved cysteine in exon 2 abolishes its function. Our findings suggest that N-propeptide performs an important feedback regulatory function and provides a rationale for the prominence of a homotrimeric form of type I procollagen (alpha 1 trimer) during vertebrate development.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bornstein, P (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	bornsten@u.washington.edu			NIAMS NIH HHS [R01 AR011248, R01 AR 11248] Funding Source: Medline; NIDCR NIH HHS [F30 DE017522, F30 DE017522-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR011248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F30DE017522] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bornstein P, 2002, MATRIX BIOL, V21, P217, DOI 10.1016/S0945-053X(02)00008-2; Bornstein P, 2002, J BIOL CHEM, V277, P2605, DOI 10.1074/jbc.m106181200; BORNSTEIN P, 1974, ANNU REV BIOCHEM, V43, P567, DOI 10.1146/annurev.bi.43.070174.003031; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BRUCKNER P, 1978, EUR J BIOCHEM, V90, P595, DOI 10.1111/j.1432-1033.1978.tb12640.x; Camacho NP, 1999, J BONE MINER RES, V14, P264, DOI 10.1359/jbmr.1999.14.2.264; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Canty EG, 2004, J CELL BIOL, V165, P553, DOI 10.1083/jcb.200312071; Cheah KSE, 2005, MECH DEVELOP, V122, pS25; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; CROUCH E, 1978, BIOCHEMISTRY-US, V17, P5499, DOI 10.1021/bi00618a027; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; ENGEL J, 1977, BIOCHEMISTRY-US, V16, P4026, DOI 10.1021/bi00637a014; Frank S, 2001, J MOL BIOL, V308, P1081, DOI 10.1006/jmbi.2001.4644; Goto D, 2001, BIOCHEM BIOPH RES CO, V281, P1100, DOI 10.1006/bbrc.2001.4489; HARALSON MA, 1987, LAB INVEST, V57, P513; Hernandez-Canaveral, 2004, J GASTROEN HEPATOL, V19, P380, DOI 10.1111/j.1440-1746.2003.03292.x; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; HORLEIN D, 1981, P NATL ACAD SCI-BIOL, V78, P6163, DOI 10.1073/pnas.78.10.6163; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JIMENEZ SA, 1977, BIOCHEM BIOPH RES CO, V78, P1354, DOI 10.1016/0006-291X(77)91441-3; KATAYAMA K, 1993, J BIOL CHEM, V268, P9941; Larrain J, 2000, DEVELOPMENT, V127, P821; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MARTIN GR, 1975, ADV ENZYMOL RAMB, V42, P167; Mauviel A, 2005, METH MOLEC MED, V117, P69; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; NAKAMURA T, 1980, J BIOCHEM, V87, P629, DOI 10.1093/oxfordjournals.jbchem.a132787; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; O'Leary JM, 2004, J BIOL CHEM, V279, P53857, DOI 10.1074/jbc.M409225200; PAGLIA L, 1979, BIOCHEMISTRY-US, V18, P5030, DOI 10.1021/bi00589a034; Palamakumbura AH, 2004, J BIOL CHEM, V279, P40593, DOI 10.1074/jbc.M406639200; Palmieri D, 2000, J BIOL CHEM, V275, P32658, DOI 10.1074/jbc.M002698200; Palmieri D, 2003, J BIOL CHEM, V278, P3639, DOI 10.1074/jbc.M207483200; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Pfeiffer BJ, 2005, MATRIX BIOL, V24, P451, DOI 10.1016/j.matbio.2005.07.001; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Sanchez-Capelo A, 2005, CYTOKINE GROWTH F R, V16, P15, DOI 10.1016/j.cytogfr.2004.11.002; SHUPPBYRNE DE, 1982, COLLAGEN REL RES, V2, P481; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Weis SM, 2000, CIRC RES, V87, P663, DOI 10.1161/01.RES.87.8.663; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIESTNER M, 1979, J BIOL CHEM, V254, P7016; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	56	19	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38507	38518		10.1074/jbc.M607536200	http://dx.doi.org/10.1074/jbc.M607536200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17018525	hybrid, Green Accepted			2022-12-25	WOS:000242709500045
J	Yamazaki, D; Aoyama, M; Ohya, S; Muraki, K; Asai, K; Imaizumi, Y				Yamazaki, Daiju; Aoyama, Mineyoshi; Ohya, Susumu; Muraki, Katsuhiko; Asai, Kiyofumi; Imaizumi, Yuji			Novel functions of small conductance Ca2+-activated K+ channel in enhanced cell proliferation by ATP in brain endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; ION CHANNELS; MOLECULAR-CLONING; POTASSIUM CHANNEL; CALCIUM; EXPRESSION; ASTROCYTE; ACTIVATION; RECEPTOR; GROWTH	Brain capillary endothelial cells (BCECs) form the blood-brain barrier (BBB), which is essential for maintaining homeostasis of the brain. Net cellular turnover, which results from the balance between cell death and proliferation, is important in maintaining BBB homeostasis. Here we report a novel mechanism that underlies ATP-induced cell proliferation in t-BBEC 117, a cell line derived from bovine brain endothelial cells. Application of 0.1-30 mu M ATP to t-BBEC 117 concentration-dependently increased intracellular Ca2+ concentration ([Ca2+](i)) in two phases: an initial transient phase and a later and smaller sustained one. These two phases of [Ca2+](i) rise were mainly due to Ca2+ release and sustained Ca2+ influx, respectively. The pretreatment with apamin, a selective blocker of small conductance Ca2+-activated K+ channels (SK), significantly reduced both the [Ca2+](i) increase and K+ current induced by ATP. Transcripts corresponding to P2Yx, SK2, and transient receptor potential channels were detected in t-BBEC 117. Knock down of SK2 protein, which was the predominant Ca2+-activated K+ channel expressed in t-BBEC 117, by siRNA significantly reduced both the sustained phase of the [Ca2+](i) rise and the K+ current induced by ATP. Cell proliferation was increased significantly by the presence of the stable ATP analogue ATP gamma S. This effect was blunted by UCL1684, a synthesized SK blocker. In conclusion, in brain endothelial cells ATP-induced [Ca2+](i) rise activates SK2 current, and the subsequent membrane hyperpolarization enhances Ca2+ entry presumably through transient receptor potential channels. This positive feedback mechanism can account for the augmented cell proliferation by ATP.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol & Cellular Pharmacol, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Neurobiol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Aichi Gakuin Univ, Sch Pharm, Cell Signaling & Ion Channel Res Grp, Chikusa Ku, Nagoya, Aichi 4648650, Japan	Nagoya City University; Nagoya City University; Aichi Gakuin University	Imaizumi, Y (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol & Cellular Pharmacol, Mizuho Ku, 3-1 Tanabedori, Nagoya, Aichi 4678603, Japan.	yimaizum@phar.nagoya-cu.ac.jp	Ohya, Susumu/AAB-3618-2020; Imaizumi, Yuji/AAF-6585-2020; Asai, Kiyofumi/H-2356-2014	Ohya, Susumu/0000-0002-5765-0667; Asai, Kiyofumi/0000-0001-7015-2251				Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Antoniotti S, 2002, FEBS LETT, V510, P189, DOI 10.1016/S0014-5793(01)03256-2; Bahra P, 2004, BRIT J PHARMACOL, V143, P91, DOI 10.1038/sj.bjp.0705913; Beech DJ, 2004, J PHYSIOL-LONDON, V559, P685, DOI 10.1113/jphysiol.2004.068734; Beech DJ, 2005, PFLUG ARCH EUR J PHY, V451, P53, DOI 10.1007/s00424-005-1441-3; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Braet K, 2001, EUR J NEUROSCI, V13, P79, DOI 10.1046/j.1460-9568.2001.01372.x; Cheong A, 2005, MOL CELL, V20, P45, DOI 10.1016/j.molcel.2005.08.030; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Flemming R, 2003, BRIT J PHARMACOL, V139, P955, DOI 10.1038/sj.bjp.0705327; Forsyth SE, 1997, FEBS LETT, V409, P277, DOI 10.1016/S0014-5793(97)00514-0; Franke H, 2006, PHARMACOL THERAPEUT, V109, P297, DOI 10.1016/j.pharmthera.2005.06.002; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hosoya K, 2002, INT J PHARMACEUT, V248, P15, DOI 10.1016/S0378-5173(02)00457-X; IMAIZUMI Y, 1989, J PHYSIOL-LONDON, V411, P131, DOI 10.1113/jphysiol.1989.sp017565; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1; Lang F, 2005, J MEMBRANE BIOL, V205, P147, DOI 10.1007/s00232-005-0780-5; Lee WK, 2001, J DERMATOL SCI, V25, P97, DOI 10.1016/S0923-1811(00)00117-1; Malik-Hall M, 2000, BRIT J PHARMACOL, V129, P1431, DOI 10.1038/sj.bjp.0703233; Muraki K, 1997, BIOCHEM BIOPH RES CO, V236, P340, DOI 10.1006/bbrc.1997.6949; Muraki K, 2001, J PHYSIOL-LONDON, V537, P431, DOI 10.1111/j.1469-7793.2001.00431.x; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Nilius B, 1997, ANNU REV PHYSIOL, V59, P145, DOI 10.1146/annurev.physiol.59.1.145; Ningaraj NS, 2002, J PHARMACOL EXP THER, V301, P838, DOI 10.1124/jpet.301.3.838; Paemeleire K, 2000, J NEUROTRAUM, V17, P345, DOI 10.1089/neu.2000.17.345; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Rojas S, 2003, EXP PHYSIOL, V88, P209, DOI 10.1113/eph8802515; Sailer CA, 2002, J NEUROSCI, V22, P9698; Sobue K, 1999, NEUROSCI RES, V35, P155, DOI 10.1016/S0168-0102(99)00079-6; Sollini M, 2002, BRIT J PHARMACOL, V136, P1201, DOI 10.1038/sj.bjp.0704819; Srivastava S, 2005, MOL CELL BIOL, V25, P3630, DOI 10.1128/MCB.25.9.3630-3638.2005; Takasaki J, 2001, MOL PHARMACOL, V60, P432; Tu MT, 2000, BRIT J PHARMACOL, V129, P1481, DOI 10.1038/sj.bjp.0703182; Xu SZ, 2005, BRIT J PHARMACOL, V145, P405, DOI 10.1038/sj.bjp.0706197; Yamada A, 2001, JPN J PHARMACOL, V86, P342, DOI 10.1254/jjp.86.342; Yang DL, 2003, INVEST OPHTH VIS SCI, V44, P3511, DOI 10.1167/iovs.02-1306; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	45	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38430	38439		10.1074/jbc.M603917200	http://dx.doi.org/10.1074/jbc.M603917200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17062575	hybrid			2022-12-25	WOS:000242709500036
J	Ala, PJ; Gonneville, L; Hillman, M; Becker-Pasha, M; Yue, EW; Douty, B; Wayland, B; Polam, P; Crawley, ML; McLaughlin, E; Sparks, RB; Glass, B; Takvorian, A; Combs, AP; Burn, TC; Hollis, GF; Wynn, R				Ala, Paul J.; Gonneville, Lucie; Hillman, Milton; Becker-Pasha, Mary; Yue, Eddy W.; Douty, Brent; Wayland, Brian; Polam, Padmaja; Crawley, Matthew L.; McLaughlin, Erin; Sparks, Richard B.; Glass, Brian; Takvorian, Amy; Combs, Andrew P.; Burn, Timothy C.; Hollis, Gregory F.; Wynn, Richard			Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; INSULIN SENSITIVITY; NEGATIVE REGULATOR; PROTEIN; POTENT; DISCOVERY; MICE; NONPHOSPHORUS; MIMETICS; GLUCOSE	Structural analyses of the protein-tyrosine phosphatase 1B (PTP1B) active site and inhibitor complexes have aided in optimization of a peptide inhibitor containing the novel (S)-isothiazolidinone (IZD) phosphonate mimetic. Potency and permeability were simultaneously improved by replacing the polar peptidic backbone of the inhibitor with nonpeptidic moieties. The C-terminal primary amide was replaced with a benzimidazole ring, which hydrogen bonds to the carboxylate of Asp(48), and the N terminus of the peptide was replaced with an aryl sulfonamide, which hydrogen bonds to Asp48 and the backbone NH of Arg(47) via a water molecule. Although both substituents retain the favorable hydrogen bonding network of the peptide scaffold, their aryl rings interact weakly with the protein. The aryl ring of benzimidazole is partially solvent exposed and only participates in van der Waals interactions with Phe182 of the flap. The aryl ring of aryl sulfonamide adopts an unexpected conformation and only participates in intramolecular pi-stacking interactions with the benzimidazole ring. These results explain the flat SAR for substitutions on both rings and the reason why unsubstituted moieties were selected as candidates. Finally, substituents ortho to the IZD heterocycle on the aryl ring of the IZD-phenyl moiety bind in a small narrow site adjacent to the primary phosphate binding pocket. The crystal structure of an o-chloro derivative reveals that chlorine interacts extensively with residues in the small site. The structural insights that have led to the discovery of potent benzimidazole aryl sulfonamide o-substituted derivatives are discussed in detail.	Incyte Corp, Wilmington, DE 19880 USA	Incyte	Ala, PJ (corresponding author), Expt Stn, Route 141 & Henry Clay Rd, Wilmington, DE 19880 USA.	pauljala@gmail.com		Burn, Timothy/0000-0001-6648-4333				Ala PJ, 2006, J BIOL CHEM, V281, P32784, DOI 10.1074/jbc.M606873200; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bialy L, 2005, ANGEW CHEM INT EDIT, V44, P3814, DOI 10.1002/anie.200461517; Blaskovich MA, 2002, EXPERT OPIN THER PAT, V12, P871; Burke TR, 1998, TETRAHEDRON, V54, P9981, DOI 10.1016/S0040-4020(98)00590-0; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Combs AP, 2006, J MED CHEM, V49, P3774, DOI 10.1021/jm0600904; Combs AP, 2005, J MED CHEM, V48, P6544, DOI 10.1021/jm0504555; Costantino L, 2004, CURR MED CHEM, V11, P2725, DOI 10.2174/0929867043364315; Dufresne C, 2004, BIOORG MED CHEM LETT, V14, P1039, DOI 10.1016/j.bmcl.2003.11.048; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; HANSEN TK, 2002, POTENT NONPEPTIDE PR; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Johnson TO, 2002, NAT REV DRUG DISCOV, V1, P696, DOI 10.1038/nrd895; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Liu G, 2003, CURR MED CHEM, V10, P1407, DOI 10.2174/0929867033457296; Liu G, 2003, J MED CHEM, V46, P3437, DOI 10.1021/jm034088d; Pei ZH, 2004, CURR PHARM DESIGN, V10, P3481, DOI 10.2174/1381612043382954; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Szczepankiewicz BG, 2003, J AM CHEM SOC, V125, P4087, DOI 10.1021/ja0296733; Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/eoid.13.3.199.27347; Yao ZJ, 1998, BIOORGAN MED CHEM, V6, P1799, DOI 10.1016/S0968-0896(98)00140-0; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	29	53	56	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38013	38021		10.1074/jbc.M607913200	http://dx.doi.org/10.1074/jbc.M607913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17028182	hybrid			2022-12-25	WOS:000242477100080
J	Courel, M; Rodemer, C; Nguyen, ST; Pance, A; Jackson, AP; O'Connor, DT; Taupenot, L				Courel, Maite; Rodemer, Carrie; Nguyen, Susan T.; Pance, Alena; Jackson, Antony P.; O'Connor, Daniel T.; Taupenot, Laurent			Secretory granule biogenesis in sympathoadrenal cells - Identification of a granulogenic determinant in the secretory prohormone chromogranin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CHROMAFFIN CELLS; SECRETOGRANIN-III; TARGETED ABLATION; HORMONE STORAGE; GROWTH-HORMONE; PC12 CELLS; EXPRESSION; NEUROENDOCRINE; MEMBRANE	Chromogranin A (CgA) may be critical for secretory granule biogenesis in sympathoadrenal cells. We found that silencing the expression of CgA reduced the number of secretory granules in normal sympathoadrenal cells (PC12), and we therefore questioned whether a discrete domain of CgA might promote the formation of a regulated secretory pathway in variant sympathoadrenal cells (A35C) devoid of such a phenotype. The secretory granule-forming activity of a series of human CgA domains labeled with a hemagglutinin epitope, green fluorescent protein, or embryonic alkaline phosphatase was assessed in A35C cells by deconvolution and electron microscopy and by secretagogue-stimulated release assays. Expression of CgA in A35C cells induced the formation of vesicular organelles throughout the cytoplasm, whereas two constitutive secretory pathway markers accumulated in the Golgi complex. The lysosome-associated membrane protein LGP110 did not co-localize with CgA, consistent with non-lysosomal targeting of the granin in A35C cells. Thus, CgA-expressing A35C cells showed electron-dense granules similar to 180-220 nm in diameter, and secretagogue-stimulated exocytosis of CgA from A35C cells suggested that expression of the granin may be sufficient to restore a regulated secretory pathway and thereby rescue the sorting of other secretory proteins. We show that the formation of vesicular structures destined for regulated exocytosis may be mediated by a determinant located within the CgA N-terminal region (CgA-(1-115), with a necessary contribution of CgA-(40-115)), but not the C-terminal region (CgA-(233-439)) of the protein. We propose that CgA promotes the biogenesis of secretory granules by a mechanism involving a granulogenic determinant located within CgA-(40-115) of the mature protein.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92161 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Cambridge	Taupenot, L (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr,0838, La Jolla, CA 92093 USA.	ltaupenot@ucsd.edu	Pance, Alena/AAH-2878-2021	Pance, Alena/0000-0002-9017-2644; Taupenot, Laurent/0000-0003-2316-3825; Jackson, Antony Philip/0000-0002-2895-7387	NHLBI NIH HHS [HL58120] Funding Source: Medline; NIDDK NIH HHS [DK60702, DK59628] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059628, R01DK060702] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Beuret N, 2004, J BIOL CHEM, V279, P20242, DOI 10.1074/jbc.M310613200; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; CLEMENTI E, 1992, EUR J NEUROSCI, V4, P944, DOI 10.1111/j.1460-9568.1992.tb00121.x; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Corradi N, 1996, J BIOL CHEM, V271, P27116, DOI 10.1074/jbc.271.43.27116; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Crivellato E, 2006, ANAT EMBRYOL, V211, P79, DOI 10.1007/s00429-005-0059-8; Dannies PS, 2002, MOL GENET METAB, V76, P6, DOI 10.1016/S1096-7192(02)00011-2; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Dannies PS, 2001, MOL CELL ENDOCRINOL, V177, P87, DOI 10.1016/S0303-7207(01)00437-3; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; Grabner CP, 2005, J NEUROPHYSIOL, V94, P2093, DOI 10.1152/jn.00316.2005; HELDMAN E, 1989, J BIOL CHEM, V264, P7914; Hendy GN, 2006, MOL ENDOCRINOL, V20, P1935, DOI 10.1210/me.2005-0398; Hosaka M, 2004, J BIOL CHEM, V279, P3627, DOI 10.1074/jbc.M310104200; Hosaka M, 2002, MOL BIOL CELL, V13, P3388, DOI 10.1091/mbc.02-03-0040; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; Kim T, 2006, MOL BIOL CELL, V17, P789, DOI 10.1091/mbc.E05-08-0755; Kim T, 2005, J NEUROSCI, V25, P6958, DOI 10.1523/JNEUROSCI.1058-05.2005; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; Lacombe MJ, 2005, J BIOL CHEM, V280, P4803, DOI 10.1074/jbc.M408658200; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; Lee MS, 2001, J BIOL CHEM, V276, P715, DOI 10.1074/jbc.M008530200; Leoni C, 1999, MOL BIOL CELL, V10, P2919, DOI 10.1091/mbc.10.9.2919; Lochner JE, 1998, MOL BIOL CELL, V9, P2463, DOI 10.1091/mbc.9.9.2463; Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354; Malosio ML, 2004, J CELL SCI, V117, P743, DOI 10.1242/jcs.00934; Martin P, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-4; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Pance A, 1999, J NEUROCHEM, V73, P21, DOI 10.1046/j.1471-4159.1999.0730021.x; Reaves BJ, 1996, J CELL SCI, V109, P749; Taupenot L, 2005, J BIOL CHEM, V280, P3885, DOI 10.1074/jbc.M408197200; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; Taupenot L, 2002, ANN NY ACAD SCI, V971, P262, DOI 10.1111/j.1749-6632.2002.tb04473.x; TAUPENOT L, 1995, REGUL PEPTIDES, V56, P71, DOI 10.1016/0167-0115(95)00008-Y; Taylor CV, 2000, J BIOL CHEM, V275, P22905, DOI 10.1074/jbc.M001232200; Thiele C, 1998, J BIOL CHEM, V273, P1223, DOI 10.1074/jbc.273.2.1223; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; Wang YZ, 2000, TRAFFIC, V1, P952, DOI 10.1034/j.1600-0854.2000.011205.x; WICK PF, 1993, J BIOL CHEM, V268, P10983; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1991, J BIOL CHEM, V266, P7740	52	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38038	38051		10.1074/jbc.M604037200	http://dx.doi.org/10.1074/jbc.M604037200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17032650	hybrid			2022-12-25	WOS:000242477100082
J	Hoffmann, KM; Tapia, JA; Berna, MJ; Thill, M; Braunschweig, T; Mantey, SA; Moody, TW; Jensen, RT				Hoffmann, K. Martin; Tapia, Jose A.; Berna, Marc J.; Thill, Michelle; Braunschweig, Till; Mantey, Samuel A.; Moody, Terry W.; Jensen, Robert T.			Gastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; PANCREATIC ACINAR-CELLS; PROTEIN-KINASE-C; STIMULATED TYROSINE PHOSPHORYLATION; CHOLECYSTOKININ RECEPTORS; FEEDBACK-REGULATION; ACTIN CYTOSKELETON; COUPLED RECEPTORS; MET/HGF RECEPTOR; AMYLASE RELEASE	The activated c-Met receptor has potent effects on normal tissues and tumors. c-Met levels are regulated by hepatocyte growth factor (HGF); however, it is unknown if they can be regulated by gastrointestinal (GI) hormones. c-Met is found in many GI tissues/tumors that possess GI hormone receptors. We studied the effect of GI hormones on c-Met in rat pancreatic acini, which possess both receptors. CCK-8, carbachol, and bombesin, but not VIP/secretin, decreased c-Met. CCK-8 caused rapid and potent c-Met down-regulation and abolished HGF-induced c-Met and Gab1 tyrosine phosphorylation, while stimulating c-Met serine phosphorylation. The effect of cholecystokinin (CCK) was also seen in intact acini using immunofluorescence, in a biotinylated fraction representing membrane proteins, in single acinar cells, in Panc-1 tumor cells, and in vivo in rats injected with CCK. CCK-8 did not decrease cell viability or overall responsiveness. GF109203X, thapsigargin, or their combination partially reversed the effect of CCK-8. In contrast to HGF-induced c-Met down-regulation, the effect of CCK was decreased by a lysosome inhibitor (concanamycin) but not the proteasome inhibitor lactacystin. Inhibitors of clathrin-mediated endocytosis blocked the effect of CCK. HGF but not CCK-8 caused c-Met ubiquitination. These results show CCK and other GI hormones can cause rapid c-Met down-regulation, which occurs by a novel mechanism. These results could be important for c-Met regulation in normal as well as in neoplastic tissue in the GI tract.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Extremadura, Dept Fisiol, Badajoz 10071, Spain; NEI, Natl Inst Hlth, Bethesda, MD 20892 USA; NCI, Tissue Array Res Program, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Universidad de Extremadura; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jensen, RT (corresponding author), NIDDK, Digest Dis Branch, NIH, Bldg 10,Rm 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov	Braunschweig, Till/AAO-5725-2020; Tapia, Jose A./C-5181-2008	Braunschweig, Till/0000-0001-9166-2912; Tapia, Jose A./0000-0002-3614-6867	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK053101, ZIADK053101] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Aparicio IM, 2003, BBA-MOL CELL RES, V1643, P37, DOI 10.1016/j.bbamcr.2003.08.007; Baig AH, 2002, ENDOCR RES, V28, P281, DOI 10.1081/ERC-120016798; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Calvo EL, 1996, BIOCHEM BIOPH RES CO, V229, P257, DOI 10.1006/bbrc.1996.1789; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DOUGHNEY C, 1987, BIOCHIM BIOPHYS ACTA, V928, P341, DOI 10.1016/0167-4889(87)90194-7; EBERT M, 1994, CANCER RES, V54, P5775; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; Furukawa M, 2005, CLIN CANCER RES, V11, P3233, DOI 10.1158/1078-0432.CCR-04-1915; FURUKAWA T, 1995, AM J PATHOL, V147, P889; Gahr S, 2002, J MOL ENDOCRINOL, V28, P99, DOI 10.1677/jme.0.0280099; GALVANI AP, 1995, BIOCHEM PHARMACOL, V50, P959, DOI 10.1016/0006-2952(95)00219-P; Garcia LJ, 1999, ADV MOL CELL ENDOCR, V3, P119; Garcia LJ, 1997, BIOCHEM J, V327, P461; GARDNER JD, 1977, J PHYSIOL-LONDON, V270, P439, DOI 10.1113/jphysiol.1977.sp011961; GIBSON AE, 1989, AM J PHYSIOL, V257, pC182, DOI 10.1152/ajpcell.1989.257.2.C182; Gicquiaux H, 2002, J BIOL CHEM, V277, P6645, DOI 10.1074/jbc.M107224200; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hammond DE, 2004, CURR TOP MICROBIOL, V286, P21; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; Herynk MH, 2003, CANCER RES, V63, P2990; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; Hoffmann KM, 2005, GASTROENTEROLOGY, V128, pA631; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jensen Robert T., 1994, P1377; JENSEN RT, 1981, FED PROC, V40, P2486; Jensen RT, 2002, PHARMACOL TOXICOL, V91, P333, DOI 10.1034/j.1600-0773.2002.910611.x; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Kiehne K, 1997, PANCREAS, V15, P35, DOI 10.1097/00006676-199707000-00005; Kim J, 2003, BIOCHEMISTRY-US, V42, P2887, DOI 10.1021/bi026942t; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Komada M, 2005, J BIOCHEM, V137, P1, DOI 10.1093/jb/mvi001; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Lankisch TO, 1999, EUR J CELL BIOL, V78, P632, DOI 10.1016/S0171-9335(99)80048-X; Lefebvre VH, 1998, DIABETES, V47, P134, DOI 10.2337/diabetes.47.1.134; Liang HY, 2004, INT J ONCOL, V24, P1057; Liddle RA., 1994, GUT PEPTIDES BIOCH P; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MATOZAKI T, 1991, AM J PHYSIOL, V260, pG858, DOI 10.1152/ajpgi.1991.260.6.G858; Menke A, 1999, PANCREAS, V18, P28, DOI 10.1097/00006676-199901000-00004; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; Mizuguchi T, 2001, J SURG RES, V99, P385, DOI 10.1006/jsre.2001.6216; Nath D, 2001, J CELL SCI, V114, P1213; Oh MC, 2006, J BIOL CHEM, V281, P752, DOI 10.1074/jbc.M509677200; OKABAYASHI Y, 1990, AM J PHYSIOL, V258, pE562, DOI 10.1152/ajpendo.1990.258.4.E562; Otte JM, 2000, SCAND J GASTROENTERO, V35, P90; Otte JM, 2001, EUR J CLIN INVEST, V31, P865, DOI 10.1046/j.1365-2362.2001.00894.x; Pace A, 2003, J BIOL CHEM, V278, P19008, DOI 10.1074/jbc.M300832200; Paciucci R, 1998, AM J PATHOL, V153, P201, DOI 10.1016/S0002-9440(10)65561-7; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; RAUFMAN JP, 1987, J BIOL CHEM, V262, P5957; Resnick MB, 2004, CLIN CANCER RES, V10, P3069, DOI 10.1158/1078-0432.CCR-03-0462; RIVARD N, 1994, AM J PHYSIOL, V266, pG62, DOI 10.1152/ajpgi.1994.266.1.G62; ROBBERECHT P, 1977, GASTROEN CLIN BIOL, V1, P519; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Rubin C, 2005, CELL RES, V15, P66, DOI 10.1038/sj.cr.7290268; SANKARAN H, 1980, J BIOL CHEM, V255, P1849; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; Tapia JA, 2003, J BIOL CHEM, V278, P35220, DOI 10.1074/jbc.M303119200; Tapia JA, 2002, BBA-MOL CELL RES, V1593, P99, DOI 10.1016/S0167-4889(02)00346-4; Tapia JA, 1999, BBA-MOL CELL RES, V1448, P486, DOI 10.1016/S0167-4889(98)00157-8; TSUNODA Y, 1996, AM J PHYSIOL, V271, pB8; VILA MR, 1995, LAB INVEST, V73, P409; WANK SA, 1988, AM J PHYSIOL, V255, pG106, DOI 10.1152/ajpgi.1988.255.1.G106; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; YOUNES M, 1989, AM J PHYSIOL, V256, pG291, DOI 10.1152/ajpgi.1989.256.2.G291; Yule David I., 1994, P1447; Zhang XH, 2005, AM J PHYSIOL-RENAL, V288, pF16, DOI 10.1152/ajprenal.00318.2003; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF1216, DOI 10.1152/ajprenal.00426.2002; ZHU H, 1994, J BIOL CHEM, V269, P29943; [No title captured]	86	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37705	37719		10.1074/jbc.M602583200	http://dx.doi.org/10.1074/jbc.M602583200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035232	hybrid			2022-12-25	WOS:000242477100048
J	Kerr, LE; Birse-Archbold, JLA; Short, DM; McGregor, AL; Heron, I; MacDonald, DC; Thompson, J; Carlson, GJ; Kelly, JS; McCulloch, J; Sharkey, J				Kerr, L. E.; Birse-Archbold, J-L A.; Short, D. M.; McGregor, A. L.; Heron, I.; MacDonald, D. C.; Thompson, J.; Carlson, G. J.; Kelly, J. S.; McCulloch, J.; Sharkey, J.			Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death	ONCOGENE			English	Article						bcl-2 family; translocation; apoptosis; focal cerebral ischaemia; protein-protein interaction	FOCAL CEREBRAL-ISCHEMIA; MITOCHONDRIAL APOPTOSIS; BCL-2 FAMILY; CYTOSOLIC HEAT-SHOCK-PROTEIN-60; CONFORMATIONAL-CHANGE; SIGNALING PATHWAY; NEURONAL DEATH; PROTEIN B23; C-TERMINUS; P53	The proapoptotic B-cell lymphoma-2 family protein Bax is a key regulatory point in the intrinsic apoptotic pathway. However, the factors controlling the process of Bax activation and translocation to mitochondria have yet to be fully identified and characterized. We performed affinity chromatography using peptides corresponding to the mitochondrial-targeting region of Bax, which is normally sequestered within the inactive structure. The molecular chaperone nucleophosmin was identified. ed as a novel Bax-binding protein by matrix- assisted laser desorption/ionization time-of-flight mass spectrometry. Reciprocal co-immunoprecipitation and proximity assays con. confirmed the Bax-nucleophosmin protein-protein interaction and verified that nucleophosmin only bound to activated conformationally altered Bax. Confocal microscopy in a cell-based apoptosis model, demonstrated that nucleophosmin translocation from nucleolus to cytosol preceded Bax movement. Specific. c knockdown of nucleophosmin expression using RNAi attenuated apoptosis as measured by mitochondrial cytochrome c release and activation of the caspase cascade. In a mouse model of ischaemic stroke, subcellular fractionation studies veri. ed that nucleophosmin translocation occurred within 3 h, at a time before Bax translocation but after Bax conformational changes have occurred. Thus, we have elucidated a novel molecular mechanism whereby Bax becomes activated and translocates to the mitochondria to orchestrate mitochondrial dysfunction and apoptotic cell death, which opens new avenues for therapeutic intervention.	Univ Edinburgh, Astellas CNS Res Edinburgh, Edinburgh EH16 4SB, Midlothian, Scotland	University of Edinburgh	Kerr, LE (corresponding author), Univ Edinburgh, Astellas CNS Res Edinburgh, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	Lorraine.Kerr@ed.ac.uk		McGregor, Ailsa/0000-0002-8598-1535; Sharkey, John/0000-0001-8288-1857				Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Akhtar RS, 2004, BBA-MOL CELL RES, V1644, P189, DOI 10.1016/j.bbamcr.2003.10.013; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Birse-Archbold JLA, 2005, J CEREBR BLOOD F MET, V25, P1356, DOI 10.1038/sj.jcbfm.9600133; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; Gleave M, 2003, ANN NY ACAD SCI, V1002, P95, DOI 10.1196/annals.1281.020; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Gustafsson AB, 2004, J BIOL CHEM, V279, P21233, DOI 10.1074/jbc.M400695200; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kerr LE, 2004, APOPTOSIS, V9, P739, DOI 10.1023/B:APPT.0000045787.50848.e1; Kerr LE, 2004, CELL DEATH DIFFER, V11, P1102, DOI 10.1038/sj.cdd.4401449; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Li J, 2005, LEUKEMIA RES, V29, P1415, DOI 10.1016/j.leukres.2005.05.005; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Lu YY, 1996, BIOCHEM J, V317, P321, DOI 10.1042/bj3170321; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; MAR MSM, 2001, BIOCHEMISTRY-US, V40, P9983; Matsushita K, 1998, NEUROSCIENCE, V83, P439, DOI 10.1016/S0306-4522(97)00391-6; Nam YJ, 2004, MOL CELL, V15, P901, DOI 10.1016/j.molcel.2004.08.020; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takemura M, 2002, EXP CELL RES, V276, P233, DOI 10.1006/excr.2002.5523; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; White FA, 1998, J NEUROSCI, V18, P1428; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291	46	66	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2554	2562		10.1038/sj.onc.1210044	http://dx.doi.org/10.1038/sj.onc.1210044			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072349				2022-12-25	WOS:000245831200003
J	Carvalho, G; Fabre, C; Braun, T; Grosjean, J; Ades, L; Agou, F; Tasdemir, E; Boehrer, S; Israel, A; Veron, M; Fenaux, P; Kroemer, G				Carvalho, G.; Fabre, C.; Braun, T.; Grosjean, J.; Ades, L.; Agou, F.; Tasdemir, E.; Boehrer, S.; Israel, A.; Veron, M.; Fenaux, P.; Kroemer, G.			Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; NF-kappa B; mitochondria	NF-KAPPA-B; MITOCHONDRIAL ALTERATIONS; PROTEIN INTERACTIONS; CELL-LINE; ACTIVATION; SYSTEM	In high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), blasts constitutively activate the antiapoptotic transcription factor nuclear factor-kappa B (NF-kappa B). Here, we show that this NF-kappa B activation relies on the constitutive activation of the I kappa B kinase (IKK) complex, which is formed by the IKK alpha, IKK beta and IKK gamma/NF-kappa B essential modulator (NEMO) subunits. A cell-permeable peptide that mimics the leucine zipper subdomain of IKK gamma, thus preventing its oligomerization, inhibited the constitutive NF-kappa B activation and induced apoptotic cell death in a panel of human MDS and AML cell lines (P39, MOLM13, THP1 and MV4-11). Small interfering RNA-mediated knockdown of the p65 NF-kappa B subunit or the three IKK subunits including IKK gamma/NEMO also induced apoptotic cell death in P39 cells. Cell death induced by the IKK gamma/NEMO-antagonistic peptide involved the caspase-independent loss of the mitochondrial transmembrane potential as well as signs of outer mitochondrial membrane permeabilization with the consequent release of cytochrome c, apoptosis-inducing factor and endonuclease G. Primary bone marrow CD34(+) cells from high-risk MDS and AML patients also succumbed to the IKK gamma/NEMO-antagonistic peptide, but not to a mutated control peptide. Altogether, these data indicate that malignant cells in high-risk MDS and AML cells critically depend on IKK gamma/NEMO to survive. Moreover, our data delineate a novel procedure for their therapeutic removal, through inhibition of IKK gamma/NEMO oligomerization.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; INSERM, Unit Apoptosis Canc & Immun, Villejuif, France; Univ Paris 11, Fac Med Paris Sud, Villejuif, France; Univ Paris 13, AP HP, Hop Avicenne, Hematol Unit, Bobigny, France; Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Activities Cellulaires, Paris, France; Inst Pasteur, CNRS, URA 2582, SMAC, Paris, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, Rue Camille Desmoulins,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	, AGOU/GXA-2760-2022; KROEMER, Guido/B-4263-2013; Ades, lionel/T-6882-2019; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; 				Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Dombret H, 2002, SEMIN HEMATOL, V39, P8, DOI 10.1053/shem.2002.33608; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; Fenaux P, 2005, SEMIN ONCOL, V32, pS11, DOI 10.1053/j.seminoncol.2005.06.016; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GLOIRE G, 2006, BIOCH PHARM; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Lindberg EH, 2005, CURR DRUG TARGETS, V6, P713, DOI 10.2174/1389450054863707; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; NAGAI M, 1984, GANN, V75, P1100; Nakamori Y, 2006, J CELL BIOL, V173, P665, DOI 10.1083/jcb.200601065; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Steensma DP, 2006, MAYO CLIN PROC, V81, P104, DOI 10.4065/81.1.104; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; ZAMZAMI N, 2003, METH MOL B, V282, P103	30	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2299	2307		10.1038/sj.onc.1210043	http://dx.doi.org/10.1038/sj.onc.1210043			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043643				2022-12-25	WOS:000245466000006
J	Crosby, ME; Jacobberger, J; Gupta, D; Macklis, RM; Almasan, A				Crosby, M. E.; Jacobberger, J.; Gupta, D.; Macklis, R. M.; Almasan, A.			E2F4 regulates a stable G(2) arrest response to genotoxic stress in prostate carcinoma	ONCOGENE			English	Article						E2F4 knockdown; G(2) cell cycle arrest; apoptosis; ionizing radiation	CELL-CYCLE EXIT; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; GENETIC INSTABILITY; DOWN-REGULATION; IN-VIVO; EXPRESSION; P53; REPLICATION; CHECKPOINT	The retinoblastoma (pRB) family proteins regulate the E2F transcription factors; their complexes regulate critical transitions through the cell cycle. The function of these pRBfamily/E2F complexes, which includes p130/E2F4, in response to genotoxic agents, is not well understood. We investigated the role of E2F4 in the genotoxic stress response. Following radiation treatment, E2F4 colocalized with p130 in the nucleus during a radiation-induced stable G2-phase arrest. Arrested cells had significantly decreased expression of Cyclins A2 and B1 and decreased phosphorylation of mitotic protein monoclonal-2 (MPM-2) mitotic proteins. Small interference RNA (siRNA)-mediated knockdown of E2F4 sensitized cells to subsequent irradiation, resulting in enhanced cellular DNA damage and cell death, as determined by caspase activation and decreased clonogenic cell survival. Downstream E2F4 targets potentially involved in the progression from G2 into M phase were identified by oligonucleotide microarray expression pro. ling. Chromatin immunoprecipitation localized E2F4 at promoter regions of the Bub3 and Pttg1 mitotic genes following irradiation, which were among the downregulated genes identified by the microarray. These data suggest that in response to radiation, E2F4 becomes active in the nucleus, enforces a stable G2 arrest by target gene repression, and thus provides increased cell survival ability by minimizing propagation of cells that have irreparable DNA damage.	Cleveland Clin, Dept Canc Biol & Radiat Oncol, Cleveland, OH 44195 USA; Lerner Res Inst, Dept Canc Biol, Cleveland, OH USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Almasan, A (corresponding author), Cleveland Clin, Dept Canc Biol & Radiat Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	almasaa@ccf.org	Almasan, Alex/C-2715-2008; Jacobberger, James/P-9183-2014	Almasan, Alex/0000-0002-8916-6650; Jacobberger, James/0000-0002-3092-5157; Crosby, Meredith/0000-0002-3626-9445	NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081504-08, R01 CA081504-09, R01 CA081504-07, CA82858, R01 CA082858, CA81504, R01 CA081504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bindra RS, 2005, MUTAT RES-FUND MOL M, V569, P75, DOI 10.1016/j.mrfmmm.2004.03.013; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 2000, GENE DEV, V14, P1584; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Crosby ME, 2004, J ENVIRON PATHOL TOX, V23, P67, DOI 10.1615/JEnvPathToxOncol.v23.i1.70; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DuPree EL, 2004, CANCER RES, V64, P4390, DOI 10.1158/0008-5472.CAN-03-3695; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Ray S, 2003, CANCER RES, V63, P4713; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takahashi Y, 2000, GENE DEV, V14, P804; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Waghray A, 2001, CANCER RES, V61, P4283; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yan T, 2004, MOL CANCER THER, V3, P1147; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	46	36	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1897	1909		10.1038/sj.onc.1209998	http://dx.doi.org/10.1038/sj.onc.1209998			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043659	Green Accepted			2022-12-25	WOS:000245117700007
J	Fu, XR; Choi, YK; Qu, DN; Yu, Y; Cheung, NS; Qi, RZ				Fu, Xinrong; Choi, Yuk-Kwan; Qu, Dianbo; Yu, Yan; Cheung, Nam Sang; Qi, Robert Z.			Identification of nuclear import mechanisms for the neuronal Cdk5 activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; BRAIN-SPECIFIC ACTIVATOR; PROTEIN IMPORT; NUCLEOCYTOPLASMIC TRANSPORT; MAMMALIAN-CELLS; PORE COMPLEX; BETA; P35; PATHWAY; EXPORT	The activation of Cdk5 by p35 plays a pivotal role in a multitude of nervous system activities ranging from neuronal differentiation to degeneration. A fraction of Cdk5 and p35 localizes in the nucleus where Cdk5-p35 exerts its functions via protein phosphorylation, and p35 displays a dynamic localization between the cytoplasm and the nucleus. Here, we examined the nuclear import properties of p35. In nuclear import assays, p35 was actively transported into the nuclei of digitonin-permeabilized HeLa cells and cortical neurons by cytoplasmic carrier-mediated mechanisms. Importin-beta, importin-5, and importin-7 were identified to import p35 into the nuclei via a direct interaction with it. An N-terminal region of p35 was defined to interact with the above importins, serving as a nuclear localization signal. Finally, we show that the nuclear localization of p35 does not require the association of Cdk5. Furthermore, Cdk5 and importin-beta/5/7 are mutually exclusive in binding to p35. These results suggest that p35 employs pathways distinct from that used by Cdk5 for transport to the nucleus.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Qi, RZ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	qirz@ust.hk	Qu, Dianbo/C-5121-2011; , Dianbo/AAU-8480-2021	, Dianbo/0000-0002-0435-9585; Qi, Robert Zhong/0000-0001-5596-8172				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hanz S, 2003, NEURON, V40, P1095, DOI 10.1016/S0896-6273(03)00770-0; Ino H, 1996, BRAIN RES, V732, P179, DOI 10.1016/0006-8993(96)00523-9; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lim ACB, 2004, J BIOL CHEM, V279, P46668, DOI 10.1074/jbc.M404760200; Lim ACB, 2003, NEUROSIGNALS, V12, P230, DOI 10.1159/000074625; Mingot JM, 2004, EMBO J, V23, P3227, DOI 10.1038/sj.emboj.7600338; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Namgung U, 2004, MOL CELL NEUROSCI, V25, P422, DOI 10.1016/j.mcn.2003.11.005; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; NISHI K, 1994, J BIOL CHEM, V269, P6320; Paglini G, 2001, EMBO REP, V2, P1139, DOI 10.1093/embo-reports/kve250; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Rosorius O, 1999, BIOTECHNIQUES, V27, P350, DOI 10.2144/99272rr02; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; Thompson KR, 2004, NEURON, V44, P997, DOI 10.1016/j.neuron.2004.11.025; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451	43	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39014	39021		10.1074/jbc.M512663200	http://dx.doi.org/10.1074/jbc.M512663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17060323	hybrid, Green Published			2022-12-25	WOS:000242898700007
J	Hatanaka, T; Hatanaka, Y; Tsuchida, J; Ganapathy, V; Setou, M				Hatanaka, Takahiro; Hatanaka, Yasue; Tsuchida, Jun-ichi; Ganapathy, Vadivel; Setou, Mitsutoshi			Amino acid transporter ATA2 is stored at the trans-Golgi network and released by insulin stimulus in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE EXPRESSION PATTERN; UP-REGULATION; BREFELDIN-A; SYSTEM-A; FUNCTIONAL-CHARACTERISTICS; 3T3-L1 ADIPOCYTES; MEMBRANE-PROTEIN; RAT ADIPOCYTES; GLUCOSE; GLUT4	Recently, we cloned the ATA/SNAT transporters responsible for amino acid transport system A. System A is one of the major transport systems for small neutral and glucogenic amino acids represented by alanine and is involved in the metabolism of glucose and fat. Here, we describe the cellular mechanisms that participate in the acute translocation of ATA2 by insulin stimulus in 3T3-L1 adipocytes. We monitored this insulin-stimulated translocation of ATA2 using an expression system of enhanced green fluorescent protein-tagged ATA2. Studies in living cells revealed that ATA2 is stored in a discrete perinuclear site and that the transporter is released in vesicles from this site toward the plasma membrane. In immunofluorescent analysis, the storage site of ATA2 overlapped with the location of syntaxin 6, a marker of the trans-Golgi network (TGN), but not with that of EEA1, a marker of the early endosomes. The ATA2-containing vesicles on or near the plasma membrane were distinct from GLUT4-containing vesicles. Brefeldin A, an inhibitor of vesicular exit from the TGN, caused morphological changes in the ATA2 storage site along with the similar changes in the TGN. In non-transfected adipocytes, brefeldin A inhibited insulin-stimulated uptake of alpha-(methylamino) isobutyric acid more profoundly than insulin-stimulated uptake of 2-deoxy-D-glucose. These data demonstrate that the ATA2 storage site is specifically associated with the TGN and not with the general endosomal recycling system. Thus, the insulin-stimulated translocation pathways for ATA2 and GLUT4 in adipocytes are distinct, involving different storage sites.	Mitsubishi Kagaku Inst Life Sci, MITILS, Machida, Tokyo 1948511, Japan; Mitsubishi Pharma Corp, Aoba Ku, Yokohama, Kanagawa 2270033, Japan; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Natl Inst Physiol Sci, Okazaki, Aichi 4448787, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); Mitsubishi Tanabe Pharma Corporation; University System of Georgia; Augusta University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Setou, M (corresponding author), Mitsubishi Kagaku Inst Life Sci, MITILS, 11 Minamiooya, Machida, Tokyo 1948511, Japan.	setou@nips.ac.jp						Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Brosnan JT, 2003, J NUTR, V133, p2068S, DOI 10.1093/jn/133.6.2068S; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dubois L, 2001, CELL, V105, P613, DOI 10.1016/S0092-8674(01)00375-0; Dugani CB, 2005, EMBO REP, V6, P1137, DOI 10.1038/sj.embor.7400584; EGAN JM, 1995, AM J PHYSIOL-ENDOC M, V269, pE61, DOI 10.1152/ajpendo.1995.269.1.E61; Ewart MA, 2005, J BIOL CHEM, V280, P3812, DOI 10.1074/jbc.M409928200; GRUNFELD C, 1983, ENDOCRINOLOGY, V113, P1763, DOI 10.1210/endo-113-5-1763; Hanson RW, 2003, BIOCHIMIE, V85, P1199, DOI 10.1016/j.biochi.2003.10.022; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; Hatanaka T, 2001, BBA-BIOMEMBRANES, V1510, P10, DOI 10.1016/S0005-2736(00)00390-4; Hatanaka T, 2000, BBA-BIOMEMBRANES, V1467, P1, DOI 10.1016/S0005-2736(00)00252-2; Hatanaka T, 2001, J CLIN INVEST, V107, P1035, DOI 10.1172/JCI12060; Hatanaka T, 2006, J BIOL CHEM, V281, P35922, DOI 10.1074/jbc.M606577200; HAUSSINGER D, 1992, MAMMALIAN AMINO ACID TRANSPORT, P113; Hyde R, 2002, J BIOL CHEM, V277, P13628, DOI 10.1074/jbc.M108609200; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; Ishiki M, 2005, ENDOCRINOLOGY, V146, P5071, DOI 10.1210/en.2005-0850; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; Kasai K, 2001, J CELL SCI, V114, P3115; KILBERG MS, 1986, FED PROC, V45, P2438; Kurz DJ, 2000, J CELL SCI, V113, P3613; Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Martin S, 2000, TRAFFIC, V1, P652, DOI 10.1034/j.1600-0854.2000.010809.x; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; PALACIN M, 1988, J LIPID RES, V29, P26; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; Ritchie JWA, 2001, CELL PHYSIOL BIOCHEM, V11, P259, DOI 10.1159/000047812; ROMANEK R, 1993, BIOCHEM J, V296, P321, DOI 10.1042/bj2960321; Rotmann A, 2004, J BIOL CHEM, V279, P54185, DOI 10.1074/jbc.M409556200; Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Shiraishi S, 2003, BRAIN RES, V966, P175, DOI 10.1016/S0006-8993(02)04152-5; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; Su TZ, 1998, J BIOL CHEM, V273, P3173, DOI 10.1074/jbc.273.6.3173; Sugawara M, 2000, BBA-BIOMEMBRANES, V1509, P7, DOI 10.1016/S0005-2736(00)00349-7; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Wang HP, 2000, BIOCHEM BIOPH RES CO, V273, P1175, DOI 10.1006/bbrc.2000.3061; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200	58	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39273	39284		10.1074/jbc.M604534200	http://dx.doi.org/10.1074/jbc.M604534200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17050538	hybrid			2022-12-25	WOS:000242898700034
J	Nair, VD; McNaught, KS; Gonzalez-Maeso, J; Sealfon, SC; Olanow, CW				Nair, Venugopalan D.; McNaught, Kevin St. P.; Gonzalez-Maeso, Javier; Sealfon, Stuart C.; Olanow, C. Warren			p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS; SUBSTANTIA-NIGRA; PIFITHRIN-ALPHA; MODEL; APOPTOSIS; ACTIVATION; NEURONS	Proteasome dysfunction has been demonstrated in Parkinson disease (PD), and proteasome inhibitors have been shown to induce degeneration of dopaminergic neurons in vitro and in vivo. The mechanism whereby proteasome dysfunction leads to dopaminergic cell death, however, is unknown. In this study, we show that proteasome inhibition in both PC12 cells and dopaminergic neurons derived from embryonic stem cells is associated with mitochondrial membrane permeabilization, activation of caspase-3, and nuclear changes consistent with apoptosis. Prior to the emergence of apoptotic features, we found that proteasome inhibition induced increased levels of phosphorylated p53. Inhibition of p53 by pifithrin-alpha or by RNA interference prevented mitochondrial membrane permeabilization and cytotoxicity. There was no increase in p53 mRNA in proteasome-inhibited cells, suggesting that p53 was increased in a transcription-independent manner. Further, there was no increase in Puma or Bax mRNA and p53 co-immunoprecipitated with Bcl-xL and Mdm2. These findings suggest that p53 mediates cell death by way of a direct mitochondrial effect in this model. We also observed increased levels of phosphorylated p53 in dopamine neurons of the substantia nigra pars compacta of mice following systemic administration of a proteasome inhibitor. These changes preceded degeneration of dopaminergic neurons. Increased phosphorylated p53 was also demonstrated in the substantia nigra pars compacta of post-mortem PD brains. These results suggest that abnormalities in p53 signaling play a role in dopaminergic cell death induced by proteasome inhibition and may be relevant to neurodegeneration in PD.	Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Nair, VD (corresponding author), Mt Sinai Sch Med, Dept Neurol, Annenberg 14-72,Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	Venugopalan.Nair@mssm.edu		Nair, Venugopalan/0000-0002-0299-0998; Nair, Venugopalan/0000-0002-8231-6230; SEALFON, Stuart/0000-0001-5791-1217	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045999] Funding Source: NIH RePORTER; NINDS NIH HHS [1 R01 NS045999-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Biasini E, 2004, J NEUROCHEM, V88, P545, DOI 10.1046/j.1471-4159.2003.02152.x; Biswas SC, 2005, NEUROCHEM RES, V30, P839, DOI 10.1007/s11064-005-6877-5; Bove J, 2006, ANN NEUROL, V60, P260, DOI 10.1002/ana.20937; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Kordower JH, 2006, ANN NEUROL, V60, P264, DOI 10.1002/ana.20935; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Manning-Bog AB, 2006, ANN NEUROL, V60, P256, DOI 10.1002/ana.20938; Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006; McNaught KS, 2006, ANN NEUROL, V60, P243, DOI 10.1002/ana.20936; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; McNaught KSP, 2004, ANN NEUROL, V56, P149, DOI 10.1002/ana.20186; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; McNaught KSP, 2006, NEUROBIOL AGING, V27, P530, DOI 10.1016/j.neurobiolaging.2005.08.012; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Murphy PJM, 2004, J BIOL CHEM, V279, P30195, DOI 10.1074/jbc.M403539200; Nair VD, 2006, APOPTOSIS, V11, P955, DOI 10.1007/s10495-006-6316-3; Nair VD, 2004, J BIOL CHEM, V279, P27494, DOI 10.1074/jbc.M312135200; Nair VD, 2003, BIOCHEM J, V373, P25, DOI 10.1042/BJ20030017; Nair VD, 2003, J BIOL CHEM, V278, P47053, DOI 10.1074/jbc.M303364200; Onyango IG, 2005, NEUROBIOL DIS, V20, P141, DOI 10.1016/j.nbd.2005.02.009; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Rideout HJ, 2005, J NEUROCHEM, V93, P1304, DOI 10.1111/j.1471-4159.2005.03124.x; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Schapira AHV, 2006, ANN NEUROL, V60, P253, DOI 10.1002/ana.20934; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zeng BY, 2006, ANN NEUROL, V60, P248, DOI 10.1002/ana.20932	47	86	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39550	39560		10.1074/jbc.M603950200	http://dx.doi.org/10.1074/jbc.M603950200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17060322	hybrid			2022-12-25	WOS:000242898700063
J	Zhang, J; Li, FY; Liu, XP; Shen, L; Liu, JY; Su, J; Zhang, W; Deng, YC; Wang, LF; Liu, N; Han, W; Zhang, J; Ji, SP; Yang, AG; Han, H; Yao, LB				Zhang, Jian; Li, Fuyang; Liu, Xinping; Shen, Lan; Liu, Junye; Su, Jin; Zhang, Wei; Deng, Yanchun; Wang, Lifeng; Liu, Na; Han, Wei; Zhang, Jing; Ji, Shaoping; Yang, Angang; Han, Hua; Yao, Libo			The repression of human differentiation-related gene NDRG2 expression by Myc via miz-1-dependent interaction with the NDRG2 core promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWNSTREAM-REGULATED GENE-2; TATA-BINDING PROTEIN; CELL-CYCLE ARREST; N-MYC; C-MYC; DNA-DAMAGE; EMBRYONIC LETHALITY; TUMOR-METASTASIS; IN-VIVO; CANCER	The N-myc downstream-regulated gene 1 (ndrg1) is highly expressed in N-myc knock-out mice through an unknown regulatory mechanism. As one member of the human NDRG gene family, NDRG2 encodes a protein highly homologous to Ndrg1. However, it is uncertain whether the expression of human NDRG2 is regulated by Myc because mouse ndrg2 and -3 are not affected by Myc. In this study, we provide the novel evidence that the expression of human NDRG2 is down-regulated by Myc via transcriptional repression. A high level of NDRG2 was observed as Myc expression was reduced in differentiated cells, whereas a low level of NDRG2 was shown following increased Myc expression upon serum stimulation. The ectopic expression of c-Myc dramatically reduces the cellular Ndrg2 protein and mRNA level. We further identified the core promoter region of NDRG2 that is required for Myc repression on NDRG2 transcription, and we verified the interaction of Myc with the core promoter region both in vitro and in vivo. Moreover, the c-Myc-mediated repression of NDRG2 requires association with Miz-1, and possibly the recruitment of other epigenetic factors, such as histone deacetylases, to the promoter. The regulatory function of Myc on NDRG2 gene expression implicated the role of the Ndrg2 in regulating cell differentiation.	Fourth Mil Med Univ, Dept Biochem & Mol Biol, Inst Mol Biol, Xian 710032, Peoples R China; Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Yao, LB (corresponding author), Fourth Mil Med Univ, Dept Biochem & Mol Biol, Inst Mol Biol, 17 Changle Western Rd, Xian 710032, Peoples R China.	bioyao@fmmu.edu.cn		han, hua/0000-0002-1872-9700				ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bandyopadhyay S, 2004, ONCOGENE, V23, P5675, DOI 10.1038/sj.onc.1207734; Bandyopadhyay S, 2003, CANCER RES, V63, P1731; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BISHOP JM, 1982, ADV CANCER RES, V37, P1, DOI 10.1016/S0065-230X(08)60880-5; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; Cangul H, 2002, ENVIRON HEALTH PERSP, V110, P783, DOI 10.1289/ehp.02110s5783; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen L, 2004, NUCLEIC ACIDS RES, V32, P1251, DOI 10.1093/nar/gkh297; Choi SC, 2003, FEBS LETT, V553, P413, DOI 10.1016/S0014-5793(03)01030-5; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Dang CV, 1999, MOL CELL BIOL, V19, P1; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hirata K, 2004, GLIA, V47, P325, DOI 10.1002/glia.20037; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lachat P, 2002, HISTOCHEM CELL BIOL, V118, P399, DOI 10.1007/s00418-002-0460-9; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MALAGOLINI N, 1994, ALCOHOL CLIN EXP RES, V18, P1386, DOI 10.1111/j.1530-0277.1994.tb01440.x; Mitchelmore C, 2004, NEUROBIOL DIS, V16, P48, DOI 10.1016/j.nbd.2004.01.003; Ohki T, 2002, DEV BRAIN RES, V135, P55; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Okuda T, 2004, MOL CELL BIOL, V24, P3949, DOI 10.1128/MCB.24.9.3949-3956.2004; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; SALNIKOW KDT, 2002, ENV HLTH PERSPECT, V5, P831; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shimono A, 1999, MECH DEVELOP, V83, P39, DOI 10.1016/S0925-4773(99)00025-8; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Takahashi K, 2005, NEUROSCI LETT, V388, P157, DOI 10.1016/j.neulet.2005.06.055; vanBelzen N, 1997, LAB INVEST, V77, P85; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WICE BM, 1995, J BIOL CHEM, V270, P21907, DOI 10.1074/jbc.270.37.21907; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zhou DJ, 1998, CANCER RES, V58, P2182; Zhou RH, 2001, GENOMICS, V73, P86, DOI 10.1006/geno.2000.6496; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6	56	79	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39159	39168		10.1074/jbc.M605820200	http://dx.doi.org/10.1074/jbc.M605820200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17050536	hybrid			2022-12-25	WOS:000242898700024
J	Canty, EG; Starborg, T; Lu, YH; Humphries, SM; Holmes, DF; Meadows, RS; Huffman, A; O'Toole, ET; Kadler, KE				Canty, Elizabeth G.; Starborg, Tobias; Lu, Yinhui; Humphries, Sally M.; Holmes, David F.; Meadows, Roger S.; Huffman, Adam; O'Toole, Eileen T.; Kadler, Karl E.			Actin filaments are required for fibripositor-mediated collagen fibril alignment in tendon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIODONTAL-LIGAMENT FIBROBLASTS; GOLGI-COMPLEX; ANTIMICROTUBULAR AGENTS; LIVING CELLS; SECRETION; PROCOLLAGEN; MICROTUBULES; COLCHICINE; FIBRILLOGENESIS; COMPARTMENTS	Cells in tendon deposit parallel arrays of collagen fibrils to form a functional tissue, but how this is achieved is unknown. The cellular mechanism is thought to involve the formation of intracellular collagen fibrils within Golgi to plasma membrane carriers. This is facilitated by the intracellular processing of procollagen to collagen by members of the tolloid and ADAMTS families of enzymes. The carriers subsequently connect to the extracellular matrix via finger-like projections of the plasma membrane, known as fibripositors. In this study we have shown, using three-dimensional electron microscopy, the alignment of fibripositors with intracellular fibrils as well as an orientated cable of actin filaments lining the cytosolic face of a fibripositor. To demonstrate a specific role for the cytoskeleton in coordinating extracellular matrix assembly, cytochalasin was used to disassemble actin filaments and nocodazole or colchicine were used to disrupt microtubules. Microtubule disruption delayed procollagen transport through the secretory pathway, but fibripositor numbers were unaffected. Actin filament disassembly resulted in rapid loss of fibripositors and a subsequent disappearance of intracellular fibrils. Procollagen secretion or processing was not affected by cytochalasin treatment, but the parallelism of extracellular collagen fibrils was altered. In this case a significant proportion of collagen fibrils were found to no longer be orientated with the long axis of the tendon. The results suggest an important role for the actin cytoskeleton in the alignment and organization of the collagenous extracellular matrix in embryonic tendon.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Colorado, Boulder Lab Electron Microscopy Cells Dimens 3, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Manchester; University of Colorado System; University of Colorado Boulder	Kadler, KE (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	karl.kadler@manchester.ac.uk	Laird, Elizabeth/AAX-7280-2020; KADLER, KARL/ABI-2403-2020	Laird, Elizabeth/0000-0001-5041-1316; KADLER, KARL/0000-0003-4977-4683; Starborg, Tobias/0000-0002-1091-1487	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000592] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00592] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Wellcome Trust(Wellcome TrustEuropean Commission)		Banes AJ, 1995, BIOCHEM CELL BIOL, V73, P349, DOI 10.1139/o95-043; BELLAMY G, 1971, P NATL ACAD SCI USA, V68, P1138, DOI 10.1073/pnas.68.6.1138; BIRK DE, 1986, J CELL BIOL, V103, P231, DOI 10.1083/jcb.103.1.231; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Canty EG, 2004, J CELL BIOL, V165, P553, DOI 10.1083/jcb.200312071; CHAPMAN JA, 1990, ELECTRON MICROSC REV, V3, P143, DOI 10.1016/0892-0354(90)90018-N; CHO MI, 1981, ANAT REC, V201, P587, DOI 10.1002/ar.1092010403; CHO MI, 1981, ANAT REC, V201, P577, DOI 10.1002/ar.1092010402; CHO MI, 1981, ANAT RECORD, V199, P459, DOI 10.1002/ar.1091990403; DEHM P, 1972, BIOCHIM BIOPHYS ACTA, V264, P375, DOI 10.1016/0304-4165(72)90302-9; DIEGELMA.RF, 1972, P NATL ACAD SCI USA, V69, P892, DOI 10.1073/pnas.69.4.892; EHRLICH HP, 1972, NATURE-NEW BIOL, V238, P257, DOI 10.1038/newbio238257a0; EHRLICH HP, 1974, J CELL BIOL, V62, P390, DOI 10.1083/jcb.62.2.390; Ellis S, 2000, CURR BIOL, V10, P1387, DOI 10.1016/S0960-9822(00)00777-6; EVERTS V, 1987, COLLAGEN REL RES, V7, P1; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002; FERNANDEZMADRID F, 1980, J ANAT, V130, P229; FERNANDEZMADRID F, 1981, J ANAT, V132, P157; FLEISCHMAJER R, 1988, J HISTOCHEM CYTOCHEM, V36, P1425, DOI 10.1177/36.11.3049791; Guild GM, 2005, MOL BIOL CELL, V16, P3620, DOI 10.1091/mbc.E05-03-0185; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; ISHIZEKI K, 1989, ACTA ANAT, V134, P133; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013; Lane J, 1998, BBA-REV BIOMEMBRANES, V1376, P27, DOI 10.1016/S0304-4157(97)00010-5; LEBLOND CP, 1989, ANAT REC, V224, P123, DOI 10.1002/ar.1092240204; MARCHI F, 1984, J CELL BIOL, V98, P1705, DOI 10.1083/jcb.98.5.1705; Marx J, 2006, SCIENCE, V312, P1868, DOI 10.1126/science.312.5782.1868; Mastronarde DN, 1997, J STRUCT BIOL, V120, P343, DOI 10.1006/jsbi.1997.3919; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSEN BR, 2004, MATRIX BIOL, V23, P73; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; SCHERFT JP, 1975, CELL TISSUE RES, V157, P353; SCHOFIELD JD, CLIN ORTHOP RELAT RE, V97, P175; THYBERG J, 1978, CELL TISSUE RES, V193, P247; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Tickle C, 2003, DEV CELL, V4, P449, DOI 10.1016/S1534-5807(03)00095-9; Tilney LG, 2005, P NATL ACAD SCI USA, V102, P18785, DOI 10.1073/pnas.0509437102; Toomre D, 1999, J CELL SCI, V112, P21; TRELSTAD RL, 1971, J CELL BIOL, V48, P689, DOI 10.1083/jcb.48.3.689; TRELSTAD RL, 1971, J CELL BIOL, V50, P840, DOI 10.1083/jcb.50.3.840; TRELSTAD RL, 1979, DEV BIOL, V71, P228, DOI 10.1016/0012-1606(79)90166-0; Vaughan KT, 2005, BBA-MOL CELL RES, V1744, P316, DOI 10.1016/j.bbamcr.2005.05.001; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; WEINSTOCK M, 1974, J CELL BIOL, V60, P92, DOI 10.1083/jcb.60.1.92; YANG GCH, 1986, J ULTRA MOL STRUCT R, V97, P238, DOI 10.1016/S0889-1605(86)80023-4; Young BB, 2000, DEV DYNAM, V217, P430, DOI 10.1002/(SICI)1097-0177(200004)217:4<430::AID-DVDY10>3.0.CO;2-5	51	93	96	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38592	38598		10.1074/jbc.M607581200	http://dx.doi.org/10.1074/jbc.M607581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17020878	hybrid			2022-12-25	WOS:000242709500054
J	Gomez, D; Wenner, T; Brassart, B; Douarre, C; O'Donohue, MF; El Khoury, V; Shin-Ya, K; Morjani, H; Trentesaux, C; Riou, JF				Gomez, Dennis; Wenner, Thomas; Brassart, Bertrand; Douarre, Celine; O'Donohue, Marie-Francois; El Khoury, Victoria; Shin-ya, Kazuo; Morjani, Hamid; Trentesaux, Chantal; Riou, Jean-Francois			Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-QUADRUPLEX LIGAND-12459; IN-VITRO; HUMAN-CHROMOSOMES; DAMAGE RESPONSE; INHIBITOR; TRF2; SENESCENCE; RESISTANCE; BINDING; PROTEIN	Telomestatin is a potent G-quadruplex ligand that interacts with the 3' telomeric overhang, leading to its degradation, and induces a delayed senescence and apoptosis of cancer cells. POT1 and TRF2 were recently identified as specific telomere-binding proteins involved in telomere capping and t-loop maintenance and whose interaction with telomeres is modulated by telomestatin. We show here that the treatment of HT1080 human tumor cells by telomestatin induces a rapid decrease of the telomeric G-overhang and of the double-stranded telomeric repeats. Telomestatin treatment also provokes a strong decrease of POT1 and TRF2 from their telomere sites, suggesting that the ligand triggers the uncapping of the telomere ends. The effect of the ligand is associated with an increase of the lambda-H2AX foci, one part of them colocalizing at telomeres, thus indicating the occurrence of a DNA damage response at the telomere, but also the presence of additional DNA targets for telomestatin. Interestingly, the expression of GFP-POT1 in HT1080 cells increases both telomere and G-overhang length. As compared with HT1080 cells, HT1080GFP-POT1 cells presented a resistance to telomestatin treatment characterized by a protection to the telomestatin-induced growth inhibition and the G-overhang shortening. This protection is related to the initial G-overhang length rather than to its degradation rate and is overcome by increased telomestatin concentration. Altogether these results suggest that telomestatin induced a telomere dysfunction in which G-overhang length and POT1 level are important factors but also suggest the presence of additional DNA sites of action for the ligand.	Univ Reims, Lab Oncopharmacol, JE 2428, UFR Pharm, F-51096 Reims, France; CNRS, UMR 6142, Reims, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); University of Tokyo	Riou, JF (corresponding author), Univ Reims, Lab Oncopharmacol, JE 2428, UFR Pharm, 51 Rue Cognacq Jay, F-51096 Reims, France.	jean-francois.riou@univ-reims.fr	Gomez Zamorano, Dennis Gomez/AAX-5182-2021; Morjani, Hamid/AAJ-1260-2020	Gomez Zamorano, Dennis Gomez/0000-0001-9942-1451; O'Donohue, Marie-Francoise/0000-0002-1204-8285; riou, jean-francois/0000-0002-0055-6506				Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2000, COLD SPRING HARB SYM, V65, P253, DOI 10.1101/sqb.2000.65.253; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Douarre C, 2005, NUCLEIC ACIDS RES, V33, P2192, DOI 10.1093/nar/gki514; Duan WH, 2001, MOL CANCER THER, V1, P103; Gomez D, 2004, J BIOL CHEM, V279, P41487, DOI 10.1074/jbc.M406123200; Gomez D, 2003, J BIOL CHEM, V278, P50554, DOI 10.1074/jbc.M308440200; Gomez D, 2003, CANCER RES, V63, P6149; Gomez D, 2006, CANCER RES, V66, P6908, DOI 10.1158/0008-5472.CAN-06-1581; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MY, 2003, CANCER RES, V63, P3247; Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q; Koeppel F, 2001, NUCLEIC ACIDS RES, V29, P1087, DOI 10.1093/nar/29.5.1087; Lemarteleur T, 2004, BIOCHEM BIOPH RES CO, V323, P802, DOI 10.1016/j.bbrc.2004.08.150; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Li JL, 2001, BIOCHEMISTRY-US, V40, P15194, DOI 10.1021/bi011067h; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Mergny JL, 2001, P NATL ACAD SCI USA, V98, P3062, DOI 10.1073/pnas.051620698; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Pennarun G, 2005, ONCOGENE, V24, P2917, DOI 10.1038/sj.onc.1208468; Perry PJ, 1999, J MED CHEM, V42, P2679, DOI 10.1021/jm990084q; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Rosu F, 2003, CHEM COMMUN, P2702, DOI 10.1039/b309394h; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Stansel RM, 2001, EMBO J, V20, P5532; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; Tahara H, 2006, ONCOGENE, V25, P1955, DOI 10.1038/sj.onc.1209217; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; Todd AK, 2005, NUCLEIC ACIDS RES, V33, P2901, DOI 10.1093/nar/gki553; Veldman T, 2004, CURR BIOL, V14, P2264, DOI 10.1016/j.cub.2004.12.031; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zaug AJ, 2005, P NATL ACAD SCI USA, V102, P10864, DOI 10.1073/pnas.0504744102	48	175	183	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38721	38729		10.1074/jbc.M605828200	http://dx.doi.org/10.1074/jbc.M605828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050546	hybrid			2022-12-25	WOS:000242709500070
J	Rey, A; Manen, D; Rizzoli, R; Caverzasio, J; Ferrari, SL				Rey, Alexandre; Manen, Danielle; Rizzoli, Rene; Caverzasio, Joseph; Ferrari, Serge L.			Proline-rich motifs in the parathyroid hormone (PTH)/PTH-related protein receptor C terminus mediate scaffolding of c-Src with beta-arrestin2 for ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; RAT OSTEOBLASTIC CELLS; BETA-ARRESTIN; COUPLED RECEPTOR; TYROSINE KINASE; CYCLIC-AMP; PTH; PHOSPHORYLATION; PEPTIDE; PROLIFERATION	Parathyroid hormone (PTH) stimulates ERK1/2 through both G-protein signaling and beta-arrestin2-mediated internalization. beta-Arrestin may serve as a scaffold for c-Src. However, the molecular mechanisms for ERK1/2 activation by PTH remain unclear. By using a targeted mutagenesis approach, we investigated the PTH/PTH-related protein receptor (PTH1R) structural determinants for ERK1/2 activation and transcriptional activity in HEK-293 cells. First, ERK1/2 activation was inhibited by PTH1R mutations that specifically abrogate Gq-protein kinase C signaling without a decrease in cAMP-protein kinase A. Second, PTH1R C-terminal mutations and/or deletions that prevent interaction with beta-arrestin inhibited ERK1/2 activation. Similar results were obtained in HEK-293 cells co-expressing wild-type PTH1R and a dominant negative beta-arrestin2. Third, the c-Src inhibitor PP2 and a kinase-dead c- SrcK295M mutant co-expressed with wild-type PTH1R both inhibited ERK1/2 activation. Furthermore, c-Src co-precipitated with both PTH1R and beta-arrestin2 in response to PTH. Deleting the PTH1R- proximal C terminus abolished these interactions. However, the need for receptor interaction with beta-arrestin to co-precipitate Src and activate ERK1/2 was obviated by expressing a constitutively active c-SrcY527A mutant, suggesting direct binding of activated Src to PTH1R. Subsequently, we identified and mutated to alanine four proline-rich motifs in the PTH1R distal C terminus, which resulted in loss of both c-Src and arrestin co-precipitation and significantly decreased ERK1/2 activation. These data delineate the multiple PTH1R structural determinants for ERK1/2 activation and newly identify a unique mechanism involving proline-rich motifs in the receptor C terminus for reciprocal scaffolding of c-Src and beta-arrestin2 with a class II G-protein-coupled receptor.	Univ Hosp Geneva, Serv Bone Dis, Dept Rehabil & Geriatr, CH-1211 Geneva 14, Switzerland	University of Geneva	Ferrari, SL (corresponding author), Univ Hosp Geneva, Serv Bone Dis, Dept Rehabil & Geriatr, CH-1211 Geneva 14, Switzerland.	Serge.Ferrari@medecine.unige.ch	Ferrari, Serge/ABD-2730-2020	Ferrari, Serge/0000-0002-1372-4417				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Bisello A, 2004, MOL ENDOCRINOL, V18, P1486, DOI 10.1210/me.2003-0487; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; Blind E, 1996, J BONE MINER RES, V11, P578; BLIND E, 1995, ENDOCRINOLOGY, V136, P4271, DOI 10.1210/en.136.10.4271; Bradaia A, 2005, P NATL ACAD SCI USA, V102, P3034, DOI 10.1073/pnas.0406632102; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002-0049; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Doggett TA, 2002, ENDOCRINOLOGY, V143, P1880, DOI 10.1210/en.143.5.1880; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Fitzpatrick Lorraine A., 1996, P339; Fujita T, 2002, J BIOL CHEM, V277, P22191, DOI 10.1074/jbc.M110364200; Gesty-Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; Jeanneteau F, 2004, MOL BIOL CELL, V15, P4926, DOI 10.1091/mbc.E04-04-0285; Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756-3282(97)00147-6; Jiang D, 2004, J BIOL CHEM, V279, P5329, DOI 10.1074/jbc.M311547200; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2002, CAN J PHYSIOL PHARM, V80, P375, DOI 10.1139/Y02-045; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mahon MJ, 2006, MOL ENDOCRINOL, V20, P136, DOI 10.1210/me.2005-0169; Malbon CC, 2004, BIOCHEM SOC T, V32, P861, DOI 10.1042/BST0320861; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Oldenhof J, 2001, CELL SIGNAL, V13, P411, DOI 10.1016/S0898-6568(01)00157-7; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Pines M, 1996, BONE, V18, P381, DOI 10.1016/8756-3282(96)00008-7; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Syme CA, 2005, J BIOL CHEM, V280, P11281, DOI 10.1074/jbc.M413393200; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tawfeek HAW, 2002, MOL ENDOCRINOL, V16, P1, DOI 10.1210/me.16.1.1; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; UZAWA T, 1995, BONE, V16, P477; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100	54	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38181	38188		10.1074/jbc.M606762200	http://dx.doi.org/10.1074/jbc.M606762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17038311	hybrid			2022-12-25	WOS:000242709500010
J	Jonczyk, R; Genschel, U				Jonczyk, Rafal; Genschel, Ulrich			Molecular adaptation and allostery in plant pantothenate synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; COENZYME-A BIOSYNTHESIS; MYCOBACTERIUM-TUBERCULOSIS; NEGATIVE COOPERATIVITY; COMPARATIVE GENOMICS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ENZYME; INTERMEDIATE; NUCLEOTIDE	Pantothenate synthetase catalyzes the ATP-dependent condensation of pantoate and beta-alanine to yield pantothenate, the essential precursor to coenzyme A. Bacterial and plant pantothenate synthetases are dimeric enzymes that share significant sequence identity. Here we show that the two-step reaction mechanism of pantothenate synthetase is conserved between the enzymes from Arabidopsis thaliana and Escherichia coli. Strikingly, though, the Arabidopsis enzyme exhibits large allosteric effects, whereas the Escherichia coli enzyme displays essentially non-allosteric behavior. Our data suggest that specific subunit contacts were selected and maintained in the plant lineage of the pantothenate synthetase protein family and that the resulting allosteric interactions are balanced for efficient catalysis at low pantoate levels. This is supported by mutations in the putative subunit interface of Arabidopsis pantothenate synthetase, which strongly attenuated or otherwise modified its allosteric properties but did not affect the dimeric state of the enzyme. At the molecular level, plant pantothenate synthetases exemplify functional adaptation through allostery and without alterations to the active site architecture. We propose that the allosteric behavior confers a selective advantage in the context of the subcellular compartmentation of pantothenate biosynthesis in plants.	Tech Univ Munich, Lehrstuhl Genet, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Genschel, U (corresponding author), Tech Univ Munich, Lehrstuhl Genet, D-85350 Freising Weihenstephan, Germany.	genschel@wzw.tum.de						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 2002, PROTEINS, V48, P1, DOI 10.1002/prot.10064; Begley TP, 2001, VITAM HORM, V61, P157; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CONWAY A, 1968, BIOCHEMISTRY-US, V7, P4011, DOI 10.1021/bi00851a031; CORNISHBOWDEN A, 1987, J THEOR BIOL, V124, P1, DOI 10.1016/S0022-5193(87)80248-5; CORNISHBOWDEN A, 1975, BIOCHEM J, V149, P305, DOI 10.1042/bj1490305; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P5, DOI 10.1021/bi00672a002; FERSHT AR, 1985, BIOCHEMISTRY-US, V24, P5858, DOI 10.1021/bi00342a025; Genschel U, 2004, MOL BIOL EVOL, V21, P1242, DOI 10.1093/molbev/msh119; Genschel U, 1999, BIOCHEM J, V341, P669, DOI 10.1042/0264-6021:3410669; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; KING HL, 1974, J BIOL CHEM, V249, P4689; Koshland DE, 2002, J BIOL CHEM, V277, P46841, DOI 10.1074/jbc.R200014200; Maas W.K., 1960, P INT C BIOCH, V11, P161; MacRae IJ, 1999, ARCH BIOCHEM BIOPHYS, V361, P277, DOI 10.1006/abbi.1998.0993; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; Miyatake K, 1979, Methods Enzymol, V62, P215; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Nishiyama T, 2003, P NATL ACAD SCI USA, V100, P8007, DOI 10.1073/pnas.0932694100; Ottenhof HH, 2004, PLANT J, V37, P61, DOI 10.1046/j.1365-313X.2003.01940.x; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; SCHULZ AR, 1994, ENZYME KINETICS DIST, P133; Segel I.H., 1975, ENZYME KINETICS; von Delft F, 2001, STRUCTURE, V9, P439, DOI 10.1016/S0969-2126(01)00604-9; Wang SS, 2006, BIOCHEMISTRY-US, V45, P1554, DOI 10.1021/bi051873e; Wang SS, 2003, PROTEIN SCI, V12, P1097, DOI 10.1110/ps.0241803; WIELAND T, 1963, BIOCHEM Z, V339, P1; Zheng RJ, 2004, BIOCHEMISTRY-US, V43, P7171, DOI 10.1021/bi049676n; Zheng RJ, 2001, BIOCHEMISTRY-US, V40, P12904, DOI 10.1021/bi011522+	33	9	12	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37435	37446		10.1074/jbc.M607895200	http://dx.doi.org/10.1074/jbc.M607895200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17040917	hybrid			2022-12-25	WOS:000242477100020
J	Sano, Y; Syuzo-Takabatake, A; Nakaya, T; Saito, Y; Tomita, S; Itohara, S; Suzuki, T				Sano, Yoshitake; Syuzo-Takabatake, Aiko; Nakaya, Tadashi; Saito, Yuhki; Tomita, Susumu; Itohara, Shigeyoshi; Suzuki, Toshiharu			Enhanced amyloidogenic metabolism of the amyloid beta-protein precursor in the X11L-deficient mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE65-DEPENDENT GENE TRANSACTIVATION; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; SCAFFOLD PROTEINS; X11-LIKE PROTEIN; TRANSGENIC MICE; KNOCKOUT MICE; FE65 PROTEIN; PHOSPHORYLATION	X11L, a neuronal adaptor protein, associates with the cytoplasmic domain of APP and suppresses APP cellular metabolism. APP is the precursor of A beta, whose metabolism is strongly implicated in Alzheimer disease pathogenesis. To examine the roles of X11L function in APP metabolism, including the generation of A beta in the brain, we produced X11L-deficient mutant mice on the C57BL/6 background. The mutant mice did not exhibit histopathological alterations or compensatory changes in the expression of other X11 family proteins, X11 and X11L2. The expression level and distribution of APP in the brain of mutant mice were also identical to those in wild-type mice. However, in the hippocampus, where substantial levels of X11L and APP are expressed, the mutant mice exhibited a significant increase in the level of the C-terminal fragments of APP produced by cleavage with beta-secretase but not beta-secretase. The levels of A beta were increased in the hippocampus of aged mutant mice as compared with age-matched controls. These observations clearly indicate that X11L suppresses the amyloidogenic but not amyloidolytic processing of APP in regions of the brain such as the hippocampus, which express significant levels of X11L.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Sapporo, Hokkaido 0600812, Japan; RIKEN, Brain Sci Inst, Lab Behav Genet, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan	Hokkaido University; RIKEN; University of Tokyo	Suzuki, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Neurosci Lab, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tsuzuki@pharm.hokudai.ac.jp	Itohara, Shigeyoshi/I-8769-2012; Suzuki, Toshiharu/B-5342-2013	Itohara, Shigeyoshi/0000-0002-2410-9989; Sano, Yoshitake/0000-0001-5188-3104				Araki Y, 2004, J BIOL CHEM, V279, P24343, DOI 10.1074/jbc.M401925200; Araki Y, 2003, J BIOL CHEM, V278, P49448, DOI 10.1074/jbc.M306024200; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Ciufo LF, 2005, MOL BIOL CELL, V16, P470, DOI 10.1091/mbc.E04-08-0685; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hill K, 2003, J BIOL CHEM, V278, P36032, DOI 10.1074/jbc.M301632200; Ho A, 2003, P NATL ACAD SCI USA, V100, P1409, DOI 10.1073/pnas.252774899; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; KAWASE E, 1994, INT J DEV BIOL, V38, P385; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Lee JH, 2004, J BIOL CHEM, V279, P49099, DOI 10.1074/jbc.M405602200; Lee JH, 2003, J BIOL CHEM, V278, P47025, DOI 10.1074/jbc.M300503200; Lee MS, 2003, J CELL BIOL, V163, P83, DOI 10.1083/jcb.200301115; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; LOPEZ LA, 1986, BRAIN RES, V382, P46, DOI 10.1016/0006-8993(86)90109-5; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; Mori A, 2002, NEUROSCI RES, V43, P251, DOI 10.1016/S0168-0102(02)00041-X; Nakajima Y, 2001, MOL BRAIN RES, V92, P27, DOI 10.1016/S0169-328X(01)00126-7; Nakaya T, 2006, GENES CELLS, V11, P633, DOI 10.1111/j.1365-2443.2006.00968.x; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sumioka A, 2003, BIOCHEM J, V374, P261, DOI 10.1042/BJ20030489; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Taru H, 2004, J BIOL CHEM, V279, P21628, DOI 10.1074/jbc.M312007200; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Xie ZC, 2005, J BIOL CHEM, V280, P15413, DOI 10.1074/jbc.M414353200	42	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37853	37860		10.1074/jbc.M609312200	http://dx.doi.org/10.1074/jbc.M609312200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17032642	hybrid			2022-12-25	WOS:000242477100063
J	Khwaja, FW; Svoboda, P; Reed, M; Pohl, J; Pyrzynska, B; Van Meir, EG				Khwaja, F. W.; Svoboda, P.; Reed, M.; Pohl, J.; Pyrzynska, B.; Van Meir, E. G.			Proteomic identification of the wt-p53-regulated tumor cell secretome	ONCOGENE			English	Article						p53; proteomics; secretion; glioma; brain cancer; two-dimensional electrophoresis	GLIOBLASTOMA CELLS; WILD-TYPE; STROMA INTERACTIONS; P53 ALLELES; TGF-BETA; ANGIOGENESIS; EXPRESSION; CANCER; PROTEINS; PATHWAY	Tumor-stroma interactions play a major role in tumor development, maintenance and progression. Yet little is known on how the genetic alterations that underlie cell transformation elicit cell extrinsic changes modulating heterotypic cell interactions. We hypothesized that these events involve a modi. cation in the complement of secreted proteins by the cell, acting as mediators of intercellular communication. To test this hypothesis, we examined the role of wt-p53, a major tumor suppressor, on the tumor microenvironment through its regulation of secreted factors. Using a combination of 2-DE and cICAT proteomic techniques, we found a total of 111 secreted proteins, 39 of which showed enhanced and 21 inhibited secretion in response to wt-p53 expression. The majority of these were not direct targets of p53 transcription factor activity, suggesting a novel role for wt-p53 in the control of intracellular protein trafficking and/or secreted protein stability. Evidence for p53-controlled post-translational modi. cations on nine secreted proteins was also found. These findings will enhance our understanding of wt-p53 modulated interactions of the tumor with its environment.	Emory Univ, Lab Mol NeuroOncol, Dept Neurosurg, Winship Canc Inst,Sch Med, Atlanta, GA 30322 USA; Emory Univ, Dept Hematol Oncol, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Microchem & Proteom Facil, Sch Med, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Lab Mol NeuroOncol, Dept Neurosurg, Winship Canc Inst,Sch Med, 1365C Clifton Rd,NE,C5078, Atlanta, GA 30322 USA.	evanmei@emory.edu	Pyrzyńska, Beata/T-2187-2018	Pyrzyńska, Beata/0000-0002-0490-618X; Van Meir, Erwin G./0000-0003-2444-7707	NCI NIH HHS [CA 86335] Funding Source: Medline; NCRR NIH HHS [RR 02878, RR 12878, RR 13948] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086335] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012878, S10RR002878, S10RR013948] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Bueter M, 2006, INT J ONCOL, V28, P519; Chiarugi V, 1998, INT J MOL MED, V2, P715; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Fulci G, 1999, MOL NEUROBIOL, V19, P61, DOI 10.1007/BF02741378; GOLDMAN D, 1980, CLIN CHEM, V26, P1317; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; Gygi SP, 2002, J PROTEOME RES, V1, P47, DOI 10.1021/pr015509n; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; KHWAJA FW, 2006, IN PRESS CLIN CANC R; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Mazzocca A, 2005, CANCER RES, V65, P4728, DOI 10.1158/0008-5472.CAN-04-4449; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Pietras K, 2002, CANCER RES, V62, P5476; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Steer M, 2005, IEEE T MICROW THEORY, V53, P3, DOI 10.1109/TMTT.2004.839957; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Tsai MS, 2000, CANCER RES, V60, P5603; Tsuzuki T, 1998, J CLIN PATHOL, V51, P13, DOI 10.1136/jcp.51.1.13; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Volmer MW, 2005, PROTEOMICS, V5, P2587, DOI 10.1002/pmic.200401188; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Zigrino P, 2005, BIOCHIMIE, V87, P321, DOI 10.1016/j.biochi.2004.10.025	37	57	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7650	7661		10.1038/sj.onc.1209969	http://dx.doi.org/10.1038/sj.onc.1209969			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	17043663				2022-12-25	WOS:000242655500010
J	D'Argenio, G; Calvani, M; Casamassimi, A; Petillo, O; Margarucci, S; Rienzo, M; Peluso, I; Calvani, R; Ciccodicola, A; Caporaso, N; Peluso, G				D'Argenio, Giuseppe; Calvani, Menotti; Casamassimi, Amelia; Petillo, Orsolina; Margarucci, Sabrina; Rienzo, Monica; Peluso, Ivana; Calvani, Riccardo; Ciccodicola, Alfredo; Caporaso, Nicola; Peluso, Gianfranco			Experimental colitis: decreased Octn2 and Atb0+expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes	FASEB JOURNAL			English	Article						butyrate; acetyl-CoA; mitochondria	CHAIN FATTY-ACID; SKELETAL-MUSCLE; TRANSPORTER; METABOLISM; EXPRESSION; CELLS; BUTYRATE; PROFILE; COLON	Carnitine transporters have recently been implicated in susceptibility to inflammatory bowel disease (IBD). Because carnitine is required for beta-oxidation, it was suggested that decreased carnitine transporters, and hence reduced carnitine uptake, could lead to impaired fatty acid oxidation in intestinal epithelial cells, and to cell injury. We investigated this issue by examining the expression of the carnitine transporters OCTN2 and ATB0+, and butyrate metabolism in colonocytes in a rat model of IBD induced by trinitrobenzene sulfonic acid (TNBS). We found that Octn2 and Atb0+ expression was decreased in inflammatory samples at translational and functional level. Butyrate oxidation, evaluated based on CO2 production and acetyl-coenzyme A synthesis, was deranged in colonocytes from TNBS-treated rats. Treatment with carnitine-loaded liposomes corrected the butyrate metabolic alterations in vitro and reduced the severity of colitis in vivo. These results suggest that carnitine depletion in colonocytes is associated with the inability of mitochondria to maintain normal butyrate beta-oxidation. Our data indicate that carnitine is a rate-limiting factor for the maintenance of physiological butyrate oxidation in colonic cells. This hypothesis could also explain the contradictory therapeutic efficacy of butyrate supplementation observed in clinical trials of IBD.-D'Argenio, G., Calvani, M., Casamassimi, A., Petillo, O., Margarucci, S., Rienzo, M., Peluso, I., Calvani, R., Ciccodicola, A., Caporaso, N., and Peluso, G. Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by carnitine-loaded liposomes.	Univ Naples Federico II, Dept Clin & Expt Med, Gastroenterol Unit, Naples, Italy; Sigma Tau Pharmaceut Co, Dept Sci, Rome, Italy; CNR, IGB, Inst Genet & Biophys A Buzzati Traverso, I-80125 Naples, Italy; CNR, IBP, Inst Prot Biochem, I-80125 Naples, Italy; Telethon Inst Genet & Med, Naples, Italy	University of Naples Federico II; Italfarmaco; Leadiant Biosciences; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM)	Peluso, G (corresponding author), CNR, IBP, Inst Prot Biochem, Via P Castellino 111, I-80125 Naples, Italy.	g.peluso@ibp.cnr.it	Casamassimi, Amelia/AAD-2816-2020; Calvani, Riccardo/K-2011-2018	Casamassimi, Amelia/0000-0002-6010-4261; Calvani, Riccardo/0000-0001-5472-2365; Rienzo, Monica/0000-0002-4496-4894; MARGARUCCI, SABRINA/0000-0001-5361-1241; Ciccodicola, Alfredo/0000-0002-9924-1482	Telethon [TGM06S01, TGM03Z04] Funding Source: Medline	Telethon(Fondazione Telethon)		Bene J, 2006, WORLD J GASTROENTERO, V12, P110, DOI 10.3748/wjg.v12.i1.110; Boren J, 2003, J BIOL CHEM, V278, P28395, DOI 10.1074/jbc.M302932200; BREMER J, 1977, TRENDS BIOCHEM SCI, V2, P207; CARTER AL, 1995, J CHILD NEUROL, V10, pS2; D'Argenio G, 1999, ADV EXP MED BIOL, V472, P149; DARGENIO G, 1994, GASTROENTEROLOGY, V106, P399, DOI 10.1016/0016-5085(94)90598-3; Domazou AS, 2002, J LIPOSOME RES, V12, P205, DOI 10.1081/LPR-120014758; Evans AM, 2003, CLIN PHARMACOKINET, V42, P941, DOI 10.2165/00003088-200342110-00002; FLEMING SE, 1994, CAN J PHYSIOL PHARM, V72, P266, DOI 10.1139/y94-041; Foster DW, 2004, ANN NY ACAD SCI, V1033, P1, DOI 10.1196/annals.1320.001; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; Jorgensen JR, 1997, GUT, V40, P400, DOI 10.1136/gut.40.3.400; Kerner J, 1998, ANNU REV NUTR, V18, P179, DOI 10.1146/annurev.nutr.18.1.179; Lahjouji K, 2001, MOL GENET METAB, V73, P287, DOI 10.1006/mgme.2001.3207; Loguercio C, 1996, DIGEST DIS SCI, V41, P1204, DOI 10.1007/BF02088238; Matern D, 2001, J NUTR, V131, p1615S, DOI 10.1093/jn/131.5.1615S; Matsuda K, 1998, BIOL PHARM BULL, V21, P752, DOI 10.1248/bpb.21.752; Michno A, 2005, CLIN CHEM, V51, P1673, DOI 10.1373/clinchem.2005.050328; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Nakanishi T, 2001, J PHYSIOL-LONDON, V532, P297, DOI 10.1111/j.1469-7793.2001.0297f.x; Newman B, 2005, GASTROENTEROLOGY, V128, P260, DOI 10.1053/j.gastro.2004.11.056; Ohashi R, 2001, MOL PHARMACOL, V59, P358, DOI 10.1124/mol.59.2.358; Ohashi R, 1999, J PHARMACOL EXP THER, V291, P778; Peluso G, 2005, J CELL PHYSIOL, V203, P439, DOI 10.1002/jcp.20239; Peluso G, 2002, FRONT BIOSCI, V7, pA109, DOI 10.2741/peluso; Peluso G, 2000, J CELL PHYSIOL, V182, P339, DOI 10.1002/(SICI)1097-4652(200003)182:3<339::AID-JCP4>3.3.CO;2-2; Pizarro TT, 2003, TRENDS MOL MED, V9, P218, DOI 10.1016/S1471-4914(03)00052-2; REBOUCHE CJ, 1992, FASEB J, V6, P3379, DOI 10.1096/fasebj.6.15.1464372; Rebouche CJ, 1998, ANNU REV NUTR, V18, P39, DOI 10.1146/annurev.nutr.18.1.39; ROEDIGER WEW, 1979, GUT, V20, P484, DOI 10.1136/gut.20.6.484; ROEDIGER WEW, 1988, DIS COLON RECTUM, V31, P482, DOI 10.1007/BF02552623; ROEDIGER WEW, 1980, LANCET, V2, P712; Rytting E, 2005, J PHARMACOL EXP THER, V312, P192, DOI 10.1124/jpet.104.072363; Sekine T, 1998, BIOCHEM BIOPH RES CO, V251, P586, DOI 10.1006/bbrc.1998.9521; Sloan JL, 2003, AM J PHYSIOL-LUNG C, V284, pL39, DOI 10.1152/ajplung.00164.2002; Spinozzi F, 1998, FASEB J, V12, P1747, DOI 10.1096/fasebj.12.15.1747; Stano P, 2004, J LIPOSOME RES, V14, P87, DOI 10.1081/LPR-120039794; SZUTOWICZ A, 1987, ANAL BIOCHEM, V164, P292, DOI 10.1016/0003-2697(87)90495-7; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Waller S, 2006, GUT, V55, P809, DOI 10.1136/gut.2005.084574; WILEMAN T, 1984, BIOCHEM J, V198, P665; WU GY, 1988, BIOCHEM J, V255, P139, DOI 10.1042/bj2550139; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	43	37	38	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2544	+		10.1096/fj.06-5950fje	http://dx.doi.org/10.1096/fj.06-5950fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065219				2022-12-25	WOS:000242490700018
J	Kwakkenbos, MJ; Matmati, M; Madsen, O; Pouwels, W; Wang, YY; Bontrop, RE; Heidt, PJ; Hoek, RM; Hamann, J				Kwakkenbos, Mark J.; Matmati, Mourad; Madsen, Ole; Pouwels, Walter; Wang, YongYi; Bontrop, Ronald E.; Heidt, Peter J.; Hoek, Robert M.; Hamann, Jorg			An unusual mode of concerted evolution of the EGF-TM7 receptor chimera EMR2	FASEB JOURNAL			English	Article						adhesion class; gene conversion; ligand specificity; mammals	CHONDROITIN SULFATE; CELLULAR LIGAND; FAMILY; CD97; EXPRESSION; MOLECULE; MEMBER; GENE; 7-TRANSMEMBRANE; MACROPHAGES	The epidermal growth factor (EGF)-TM7 receptors CD97, EMR1, EMR2, EMR3, and EMR4 form a group of adhesion class heptahelical molecules predominantly expressed by cells of the immune system. These receptors bind cellular ligands through EGF-like domains, localized N-terminal to a large extracellular region. Remarkably, EMR2 possesses a chimeric structure with a seven-span transmembrane (TM7) region most related to EMR3 and an EGF domain region nearly identical to CD97. By comparing EGF-TM7 receptors in primates and dogs, we identified an intriguing pattern of concerted evolution, apparently mediated by gene conversion, among EMR2 and the oppositely orientated and physically adjacent genes CD97 and EMR3. This concerted evolution has continuously maintained the chimeric structure of EMR2 since early mammal radiation. Most highly conserved between EMR2 and CD97 is the fourth EGF domain, which mediates binding to chondroitin sulfate, a ligand specificity shared by both receptors. Another ligand, CD55, is bound effectively only by CD97. We show that different molecular mechanisms (mutations vs. alternative splicing) prevent CD55 binding by EMR2 in hominoids. Our findings illustrate how various and partially opposing evolutionary events have shaped the structure and ligand specificity of a modern mammalian gene family.	Univ Amsterdam, Dept Expt Immunol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; Radboud Univ Nijmegen, Dept Biochem, Nijmegen, Netherlands; Biomed Primate Res Ctr, Dept Comparat Genet & Refinement, Rijswijk, Netherlands; Biomed Primate Res Ctr, Dept Anim Sci, Rijswijk, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Radboud University Nijmegen	Hamann, J (corresponding author), Univ Amsterdam, Dept Expt Immunol, Acad Med Ctr, K1-144,POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.hamann@amc.uva.nl	Bontrop, Ronald E./D-4844-2011; Madsen, Ole/E-3730-2012; Heidt, Peter/GQQ-8459-2022; Bontrop, Ronald E/J-3628-2012	Madsen, Ole/0000-0001-8082-7881; Bontrop, Ronald E/0000-0003-0874-6467; Kwakkenbos, Mark/0000-0003-0340-5655; Hamann, Jorg/0000-0002-9448-1727				BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Benedict MQ, 1996, INSECT MOL BIOL, V5, P73, DOI 10.1111/j.1365-2583.1996.tb00042.x; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Eichler EE, 2001, TRENDS GENET, V17, P661, DOI 10.1016/S0168-9525(01)02492-1; Eichler W, 2000, J LEUKOCYTE BIOL, V68, P561; ESKO JD, 1987, J BIOL CHEM, V262, P12189; Gagneux P, 2001, MOL PHYLOGENET EVOL, V18, P2, DOI 10.1006/mpev.2000.0799; Gray JX, 1996, J IMMUNOL, V157, P5438; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 2004, IMMUNOGENETICS, V56, P679, DOI 10.1007/s00251-004-0729-3; Hamann J, 2003, EUR J IMMUNOL, V33, P1365, DOI 10.1002/eji.200323881; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Hamann J, 2000, INT IMMUNOL, V12, P439, DOI 10.1093/intimm/12.4.439; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Kop EN, 2005, ARTHRITIS RHEUM-US, V52, P442, DOI 10.1002/art.20788; Kwakkenbos MJ, 2005, J LEUKOCYTE BIOL, V77, P112, DOI 10.1189/jlb.0704402; Kwakkenbos MJ, 2004, IMMUNOGENETICS, V55, P655, DOI 10.1007/s00251-003-0625-2; Kwakkenbos MJ, 2002, J LEUKOCYTE BIOL, V71, P854; Kwakkenbos MJ, 2001, LEUCOCYTE TYPING, P381; Leemans JC, 2004, J IMMUNOL, V172, P1125, DOI 10.4049/jimmunol.172.2.1125; Li W. H, 1997, MOL EVOLUTION; Liao DQ, 1999, AM J HUM GENET, V64, P24, DOI 10.1086/302221; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; LUBLIN DM, 1989, ANNU REV IMMUNOL, V7, P35, DOI 10.1146/annurev.immunol.7.1.35; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; Olson MV, 2003, NAT REV GENET, V4, P20, DOI 10.1038/nrg981; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Schimenti JC, 1999, AM J HUM GENET, V64, P40, DOI 10.1086/302220; Shimodaira H, 1999, MOL BIOL EVOL, V16, P1114, DOI 10.1093/oxfordjournals.molbev.a026201; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Stacey M, 2003, BLOOD, V102, P2916, DOI 10.1182/blood-2002-11-3540; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Swofford D. L., 2003, PAUP PHYLOGENTIC ANA; Thornton JW, 2000, ANNU REV GENOM HUM G, V1, P41, DOI 10.1146/annurev.genom.1.1.41; Wang T, 2005, BLOOD, V105, P2836, DOI 10.1182/blood-2004-07-2878	44	38	38	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2582	+		10.1096/fj.06-6500fje	http://dx.doi.org/10.1096/fj.06-6500fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068111				2022-12-25	WOS:000242490700031
J	Nahmias, Y; Kramvis, Y; Barbe, L; Casali, M; Berthiaume, F; Yarmush, ML				Nahmias, Yaakov; Kramvis, Yiannos; Barbe, Laurent; Casali, Monica; Berthiaume, Francois; Yarmush, Martin L.			A novel formulation of oxygen-carrying matrix enhances liver-specific function of cultured hepatocytes	FASEB JOURNAL			English	Article						cytochrome P450; fluorocarbon	LONG-TERM CULTURE; BLOOD SUBSTITUTES; RAT HEPATOCYTES; IN-VITRO; PERFLUOROCARBON; HEMOGLOBIN; GRADIENTS; GROWTH; CELLS; PERFLUOROCHEMICALS	Oxygen is an important component of the cellular microenvironment, mediating cell survival, differentiation, and function. Oxygen supply is a limiting factor during culture of highly metabolic cells such as hepatocytes. Here we present a simple formulation of a fluorocarbon-based oxygen carrier embedded in collagen gel that increases oxygen concentration in culture 6-fold. Rat hepatocytes cultured on oxygen carrier-collagen showed a significant increase in viability and function. Cytochrome P450IA1 activity was increased by 140% in serum-free cultures and by 820% in serum-containing cultures. The significantly higher hepatocellular function on oxygen carrier-collagen matrix persisted and increased during long-term culture. Long-term albumin secretion was increased by 350% in serum-free cultures and by 166% in serum-containing culture. Long-term urea secretion was increased by 79% in serum-free cultures and by 76% in serum-containing cultures. We conclude that oxygen supply may limit hepatocyte function in vitro. This limitation can be overcome by addition of an oxygen carrier to the extracellular matrix. Culture of hepatocytes on oxygen-carrying matrix mimics the oxygen-rich environment of the liver and provides a simple method for enhanced long-term function.-Nahmias, Y., Kramvis, Y., Barbe, L., Casali, M., Berthiaume, F., Yarmush, M. L. A novel formulation of oxygen-carrying matrix enhances liver-specific function of cultured hepatocytes.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Burns Hosp,Dept Surg,Ctr Engn Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Yarmush, ML (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Burns Hosp,Dept Surg,Ctr Engn Med, Boston, MA 02114 USA.	ireis@sbi.org	Barbe, Laurent/G-3676-2019; Berthiaume, Francois/ABD-2139-2020; Nahmias, Yaakov/AAM-3872-2020; Nahmias, Yaakov/H-4725-2013	Barbe, Laurent/0000-0003-4475-6478; Nahmias, Yaakov/0000-0002-6051-616X; Nahmias, Yaakov/0000-0002-6051-616X; Yarmush, Martin/0000-0003-4986-8444				Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307; Alayash AI, 1999, NAT BIOTECHNOL, V17, P545, DOI 10.1038/9849; Allen JW, 2003, BIOTECHNOL BIOENG, V82, P253, DOI 10.1002/bit.10569; Arendt E, 2005, CELL PROLIFERAT, V38, P287, DOI 10.1111/j.1365-2184.2005.00350.x; Balis UJ, 1999, METAB ENG, V1, P49, DOI 10.1006/mben.1998.0105; Behnia K, 2000, TISSUE ENG, V6, P467, DOI 10.1089/107632700750022125; Bertilla SM, 2004, LANGMUIR, V20, P3920, DOI 10.1021/la036381m; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; BURKE MD, 1994, BIOCHEM PHARMACOL, V48, P923, DOI 10.1016/0006-2952(94)90363-8; Cain K, 2001, TOXICOL LETT, V120, P307, DOI 10.1016/S0378-4274(01)00283-1; Dieryck W, 1997, NATURE, V386, P29, DOI 10.1038/386029b0; DROCHMANS P, 1975, J CELL BIOL, V66, P1, DOI 10.1083/jcb.66.1.1; Dudich E, 1998, TUMOR BIOL, V19, P30, DOI 10.1159/000029972; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; Eguchi H, 1987, Alcohol Alcohol Suppl, V1, P519; FARISS MW, 1990, FREE RADICAL BIO MED, V9, P333, DOI 10.1016/0891-5849(90)90008-7; FOY BD, 1994, CELL TRANSPLANT, V3, P515, DOI 10.1177/096368979400300609; GIAEVER I, 1983, P NATL ACAD SCI-BIOL, V80, P219, DOI 10.1073/pnas.80.1.219; KEESE CR, 1983, SCIENCE, V219, P1448, DOI 10.1126/science.6828872; KING AT, 1989, BIO-TECHNOL, V7, P1037; Krafft MP, 1998, BIOCHIMIE, V80, P489, DOI 10.1016/S0300-9084(00)80016-4; LEMASTERS JJ, 1981, SCIENCE, V213, P661, DOI 10.1126/science.7256265; Lemasters JJ., 2001, LIVER BIOL PATHOBIOL, P257; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; Lowe KC, 2003, TISSUE ENG, V9, P389, DOI 10.1089/107632703322066570; Lowe KC, 1998, TRENDS BIOTECHNOL, V16, P272, DOI 10.1016/S0167-7799(98)01205-0; MAGDASSI S, 1992, INT J PHARMACEUT, V88, P171, DOI 10.1016/0378-5173(92)90314-R; Martin H, 2002, CELL BIOL TOXICOL, V18, P73, DOI 10.1023/A:1015379815897; Matsumoto S, 2002, TRANSPLANTATION, V74, P1804, DOI 10.1097/01.TP.0000038315.74633.DE; McCuskey RS, 2003, ANAT REC PART A, V275A, P1019, DOI 10.1002/ar.a.10117; NI Y, 1994, ARTIF CELL BLOOD SUB, V22, P1307, DOI 10.3109/10731199409138831; Radisic M, 2006, BIOTECHNOL BIOENG, V93, P332, DOI 10.1002/bit.20722; Rappaport C, 2002, BIOTECHNIQUES, V32, P142, DOI 10.2144/02321rr03; Riess JG, 2005, ARTIF CELL BLOOD SUB, V33, P47, DOI 10.1081/BIO-200046659; Riess JG, 2001, CHEM REV, V101, P2797, DOI 10.1021/cr970143c; Riess JG, 1998, BIOMATERIALS, V19, P1529, DOI 10.1016/S0142-9612(98)00071-4; ROTEM A, 1994, BIOTECHNOL BIOENG, V43, P654, DOI 10.1002/bit.260430715; STEVENS KM, 1965, NATURE, V206, P199, DOI 10.1038/206199a0; Strain AJ, 2002, SCIENCE, V295, P1005, DOI 10.1126/science.1068660; Tilles AW, 2001, BIOTECHNOL BIOENG, V73, P379, DOI 10.1002/bit.1071; Wang WJ, 2005, J ENDOCRINOL, V185, P445, DOI 10.1677/joe.1.06092; Wu FJ, 1999, CELL TRANSPLANT, V8, P233, DOI 10.1177/096368979900800304; YARMUSH ML, 1992, ANN NY ACAD SCI, V665, P238, DOI 10.1111/j.1749-6632.1992.tb42588.x; ZHANG JX, 1994, AM J PHYSIOL, V266, pG624, DOI 10.1152/ajpgi.1994.266.4.G624	45	68	72	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2531	+		10.1096/fj.06-6192fje	http://dx.doi.org/10.1096/fj.06-6192fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077286				2022-12-25	WOS:000242490700013
J	Porto, A; Palumbo, R; Pieroni, M; Aprigliano, G; Chiesa, R; Sanvito, F; Maseri, A; Bianchi, ME				Porto, Annalisa; Palumbo, Roberta; Pieroni, Maurizio; Aprigliano, Gianfranco; Chiesa, Roberto; Sanvito, Francesca; Maseri, Attilio; Bianchi, Marco E.			Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein	FASEB JOURNAL			English	Article						atherosclerosis; cholesterol; cytokine; inflammation	CHROMATIN PROTEIN; DOWN-REGULATION; HMGB1; INFLAMMATION; EXPRESSION; MEDIATOR; HMG-1; MONOCYTES; MIGRATION; LESIONS	High mobility group box 1 protein (HMGB1) is a chromatin component leaked out by necrotic cells and actively secreted by activated myeloid cells. The extracellular protein is a potent mediator of tissue remodeling. We show here that human atherosclerotic plaques, but not normal arteries, produce extracellular HMGB1. Secreted HMGB1 originates from endothelial cells, by neointimal foam cells, and also smooth muscle cells (SMCs). SMCs are an unexpected source for secreted HMGB1, since they normally express much lower amounts of HMGB1 than other cells types, and they do not secrete it. However, cultured SMCs actively secrete HMGB1 after cholesterol loading. In turn, in response to HMGB1, SMCs proliferate, migrate, and secrete more HMGB1. Thus, SMCs are both a source and a target of HMGB1; blocking HMGB1 secretion by SMCs can be an important strategy for treatment of atherosclerotic disease and in particular restenosis.-Porto, A., Palumbo, R., Pieroni, M., Aprigliano, G., Chiesa, R., Sanvito, F., Maseri, A., Bianchi, M. E. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility protein box 1.	San Raffaele Univ, I-20132 Milan, Italy; San Raffaele Sci Inst, I-20132 Milan, Italy; Catholic Univ, Inst Cardiol, Rome, Italy	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Bianchi, ME (corresponding author), San Raffaele Univ, Via Olgettina 58, I-20132 Milan, Italy.	bianchi.marco@hsr.it	Roberto, Chiesa/AAV-6476-2021; Bianchi, Marco Emilio/K-3417-2018; Pieroni, Maurizio/K-8488-2019	Bianchi, Marco Emilio/0000-0002-5329-6445; Pieroni, Maurizio/0000-0002-6830-4292				Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Andersson U, 2004, J INTERN MED, V255, P344, DOI 10.1111/j.1365-2796.2003.01303.x; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Bianchi ME, 2004, BBA-GENE STRUCT EXPR, V1677, P181, DOI 10.1016/j.bbaexp.2003.10.017; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Brunelli S, 2004, CIRC RES, V94, P1571, DOI 10.1161/01.RES.0000132747.12860.10; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Duran MC, 2003, PROTEOMICS, V3, P973, DOI 10.1002/pmic.200300389; Fiuza C, 2002, BLOOD, V27, P2652; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; JAULMES A, 2006, IN PRESS FASEB J; Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P2320, DOI 10.1161/01.ATV.0000145573.36113.8a; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135; Palumbo R, 2000, CIRCULATION, V102, P225, DOI 10.1161/01.CIR.102.2.225; Rong JX, 2003, P NATL ACAD SCI USA, V100, P13531, DOI 10.1073/pnas.1735526100; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sappington PL, 2002, GASTROENTEROLOGY, V123, P790, DOI 10.1053/gast.2002.35391; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schwartz S M, 2000, Curr Atheroscler Rep, V2, P422, DOI 10.1007/s11883-000-0081-5; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Ulfgren AK, 2004, ARTHRITIS RHEUM, V50, P1586, DOI 10.1002/art.20220; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yan SF, 2003, CIRC RES, V93, P1159, DOI 10.1161/01.RES.0000103862.26506.3D	32	148	159	2	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2565	+		10.1096/fj.06-5867fje	http://dx.doi.org/10.1096/fj.06-5867fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060403				2022-12-25	WOS:000242490700025
J	He, J; Sheng, T; Stelter, AA; Li, CX; Zhang, XL; Sinha, M; Luxon, BA; Xie, JW				He, Jing; Sheng, Tao; Stelter, Arwen A.; Li, Chengxin; Zhang, Xiaoli; Sinha, Mala; Luxon, Bruce A.; Xie, Jingwu			Suppressing Wnt signaling by the hedgehog pathway through sFRP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; BETA-CATENIN; CANCER; ACTIVATION; PROTEIN; IDENTIFICATION; TUMORIGENESIS; ASSOCIATION; ANTAGONIST; CARCINOMA	The hedgehog (Hh) signaling pathway is essential for embryonic development and carcinogenesis. Activation of Hh signaling has been identified in several types of gastrointestinal cancers, including esophageal, gastric, pancreatic, and liver cancers. Several recent studies suggest that Hh signaling activation can inhibit Wnt signaling. However, the molecular basis underlying this inhibition remains unclear. As transcription factors in the Hh signaling pathway, Gli molecules transform cells in culture, and their expression are associated with cancer development. Here we report that expression of a secreted frizzled-related protein-sFRP-1 in mouse embryonic fibroblasts is dependent on Gli1 and Gli2. In human gastric cancer cells, inhibition of Hh signaling reduces the level of sFRP-1 transcript, whereas ectopic expression of Gli1 increases the level of sFRP-1 transcript. Results from chromatin immunoprecipitation indicate that Gli1 is involved in transcriptional regulation of sFRP-1. In 293 cells with Gli1 expression, Wnt-1-mediated beta-catenin accumulation in the cytosol and DKK1 expression are all abrogated, which can be reversed by inhibiting sFRP-1 expression. Furthermore, while SIIA cells do not respond to Wnt-1-conditioned medium, inhibition of Hh signaling by smoothened (SMO) antagonist KAAD-cyclopamine (keto-N-aminoethylaminocaproyldihydrocinnamoylcyclopamine) leads to Wnt1-mediated beta-catenin accumulation in the cytosol. These data indicate that sFRP-1, a target gene of the hedgehog pathway, is involved in cross-talk between the hedgehog pathway and the Wnt pathway.	Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Xie, JW (corresponding author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, MRB 9-104,301 Univ Blvd, Galveston, TX 77555 USA.	jinxie@utmb.edu	Luxon, Bruce A/C-9140-2012		NCI NIH HHS [R01-CA94160] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094160] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi T, 2006, GUT, V55, P991, DOI 10.1136/gut.2005.080333; BARRANCO SC, 1991, INVEST NEW DRUG, V9, P29; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chuman Y, 2004, PEPTIDES, V25, P1831, DOI 10.1016/j.peptides.2004.07.010; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huang SH, 2006, CARCINOGENESIS, V27, P1334, DOI 10.1093/carcin/bgi378; Jia JH, 2003, GENE DEV, V17, P2709, DOI 10.1101/gad.1136603; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200; Lum L, 2003, MOL CELL, V12, P1261, DOI 10.1016/S1097-2765(03)00426-X; Ma XL, 2005, CARCINOGENESIS, V26, P1698, DOI 10.1093/carcin/bgi130; Moon Randall T, 2005, Sci STKE, V2005, pcm1; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Patil MA, 2006, CANCER BIOL THER, V5, P111, DOI 10.4161/cbt.5.1.2379; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Sicklick JK, 2006, CARCINOGENESIS, V27, P748, DOI 10.1093/carcin/bgi292; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304	30	109	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35598	35602		10.1074/jbc.C600200200	http://dx.doi.org/10.1074/jbc.C600200200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17035233	hybrid			2022-12-25	WOS:000242100500003
J	Weiss, TW; Samson, AL; Niego, B; Daniel, PB; Medcalf, RL				Weiss, Thomas W.; Samson, Andre L.; Niego, Be'eri; Daniel, Philip B.; Medcalf, Robert L.			Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo	FASEB JOURNAL			English	Article						inflammation; glycoprotein 130; glutamate; stroke	NMDA RECEPTOR; PLASMINOGEN-ACTIVATOR; CEREBRAL INFARCT; GROWTH-FACTOR; EXPRESSION; GLUTAMATE; INTERLEUKIN-6; CELLS; NEUROTOXICITY; NEURODEGENERATION	Oncostatin M (OsM) is a member of the interleukin (IL)-6 family of cytokines and is well known for its role in inflammation, cell proliferation, and hematopoiesis. OsM, together with its glycoprotein 130 containing receptor complex, is expressed and regulated in most cells of the central nervous system (CNS), yet the function of OsM within this compartment is poorly understood. Here we have investigated the effect of OsM using in vitro and in vivo models of excitotoxic injury. Using primary cultures of mouse cortical neurons, OsM was shown to reduce N-methyl-D- aspartate (NMDA) - induced neuronal death by 50% when added simultaneously with NMDA while pretreatment of neurons with OsM fully prevented NMDA toxicity indicating a profound protective effect of this cytokine. OsM was also shown to inhibit NMDA-mediated increase in levels of free intracellular calcium and to selectively reduce neuronal expression of the NR2C subunit of the NMDA receptor. Finally, using an in vivo model of excitotoxic injury, OsM significantly reduced the NMDA-induced lesion volume when coinjected with NMDA into the mouse striatum. Taken together, these results identify OsM as a powerful neuroprotective cytokine and provide a rational foundation to explore the therapeutic potential for OsM in diseases of the CNS.	Monash Univ, Australian Ctr Blood Dis, Prahran, Vic 3181, Australia	Monash University	Medcalf, RL (corresponding author), Monash Univ, Australian Ctr Blood Dis, 89 Commercial Rd,Alfred Med Res & Educ Precinct, Prahran, Vic 3181, Australia.	robert.medcalf@med.monash.edu.au	Medcalf, Robert L/E-9632-2011; Samson, Andre L/I-3432-2012; Niego, Beeri/AAG-5534-2019	Samson, Andre L/0000-0003-4825-1645; Niego, Beeri/0000-0001-6714-9131; Samson, Andre/0000-0002-0637-2716				Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Brandoli C, 1998, J NEUROSCI, V18, P7953; Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308; Callaway JK, 2000, J NEUROSCI METH, V102, P53, DOI 10.1016/S0165-0270(00)00278-8; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chen SH, 2006, GLIA, V53, P191, DOI 10.1002/glia.20264; Chen SH, 2004, CYTOKINE GROWTH F R, V15, P379, DOI 10.1016/j.cytogfr.2004.06.002; Choi JS, 2003, GLIA, V41, P237, DOI 10.1002/glia.10186; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; D'Arcangelo G, 2000, EUR J NEUROSCI, V12, P1241, DOI 10.1046/j.1460-9568.2000.00011.x; Ensoli F, 1999, J IMMUNOL, V162, P6268; Fernandez-Monreal M, 2004, MOL CELL NEUROSCI, V25, P594, DOI 10.1016/j.mcn.2003.11.002; Gomez-Lechon MJ, 1999, LIFE SCI, V65, P2019, DOI 10.1016/S0024-3205(99)00296-9; Igaz P, 2006, ENDOCRINOLOGY, V147, P1037, DOI 10.1210/en.2005-0729; Jankowsky JL, 1999, EXP NEUROL, V159, P333, DOI 10.1006/exnr.1999.7137; Jensen JB, 1999, J NEUROSCI RES, V55, P208, DOI 10.1002/(SICI)1097-4547(19990115)55:2<208::AID-JNR8>3.0.CO;2-P; Kadotani H, 1998, NEUROREPORT, V9, P471, DOI 10.1097/00001756-199802160-00021; Kasza A, 2002, J NEUROCHEM, V83, P696, DOI 10.1046/j.1471-4159.2002.01163.x; Leuchtmann EA, 2003, NEUROBIOL DIS, V14, P336, DOI 10.1016/j.nbd.2003.07.004; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Petzold GC, 2005, BRAIN RES, V1063, P9, DOI 10.1016/j.brainres.2005.09.048; Pizzi M, 1999, EUR J NEUROSCI, V11, P2489, DOI 10.1046/j.1460-9568.1999.00669.x; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Qiu ZH, 1998, J NEUROSCI, V18, P10445; Reddrop C, 2005, STROKE, V36, P1241, DOI 10.1161/01.STR.0000166050.84056.48; ROMANO C, 1995, J NEUROCHEM, V65, P59; Rosenberg PA, 2003, J NEUROSCI RES, V71, P237, DOI 10.1002/jnr.10472; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Ruprecht K, 2001, J NEUROPATH EXP NEUR, V60, P1087, DOI 10.1093/jnen/60.11.1087; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Tanaka M, 2003, BLOOD, V102, P3154, DOI 10.1182/blood-2003-02-0367; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Wallace PM, 1999, J IMMUNOL, V162, P5547; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Weiss TW, 2005, J MOL CELL CARDIOL, V39, P545, DOI 10.1016/j.yjmcc.2005.03.015; Weiss TW, 2003, CARDIOVASC RES, V59, P628, DOI 10.1016/S0008-6363(03)00463-2; Yepes M, 2000, BLOOD, V96, P569	41	37	39	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2369	+		10.1096/fj.06-5850fje	http://dx.doi.org/10.1096/fj.06-5850fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023520				2022-12-25	WOS:000241702600023
J	Saintigny, Y; Delacote, F; Boucher, D; Averbeck, D; Lopez, BS				Saintigny, Y.; Delacote, F.; Boucher, D.; Averbeck, D.; Lopez, B. S.			XRCC4 in G1 suppresses homologous recombination in S/G2, in G1 checkpoint-defective cells	ONCOGENE			English	Article						double strand break; non homologous end joining; homologous recombination; cell cycle; mammalian cell	DOUBLE-STRAND BREAKS; DNA-LIGASE-IV; MAMMALIAN RAD51; V(D)J RECOMBINATION; INDUCED REPLICATION; GENOMIC STABILITY; REPAIR PATHWAYS; BACKUP PATHWAYS; NUCLEAR FOCI; S-PHASE	Non-homologous end joining (NHEJ) and homologous recombination (HR) are two pathways that can compete or cooperate for DNA double-strand break (DSB) repair. NHEJ was previously shown to act throughout the cell cycle whereas HR is restricted to late S/G2. Paradoxically, we show here that defect in XRCC4 (NHEJ) leads to over-stimulation of HR when cells were irradiated in G1, not in G2. However, XRCC4 defect did not modify the strict cell cycle regulation for HR (i.e. in S/G2) as attested by (i) the formation of Rad51 foci in late S/G2 whatever the XRCC4 status, and (ii) the fact that neither Rad51 foci nor HR (gene conversion plus single-strand annealing) events induced by ionizing radiation were detected when cells were maintained blocked in G1. Finally, both gamma-H2AX analysis and pulse field gel electrophoresis showed that following irradiation in G1, some DSBs reached S/G2 in NHEJ-defective cells. Taken together, our results show that when cells are defective in G1/S arrest, DSB produced in G1 and left unrepaired by XRCC4 can be processed by HR but in late S/G2.	CEA, CNRS, UMR 217, F-92265 Fontenay Aux Roses, France; Ctr Univ, Inst Curie, CNRS, UMR 2027,Sect Rech, F-91405 Orsay, France	CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, 18 Route Panorama,BP6, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Saintigny, Yannick/C-2697-2008; Lopez, Bernard S/O-7308-2017	Saintigny, Yannick/0000-0002-3839-3562; Lopez, Bernard S/0000-0001-5088-0155; Boucher, Didier/0000-0002-7964-0881				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Ausubel F., 1999, CURRENT PROTOCOLS MO; BELMAAZA A, 1990, NUCLEIC ACIDS RES, V18, P6385, DOI 10.1093/nar/18.21.6385; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; Boucher D, 2004, CAN J PHYSIOL PHARM, V82, P125, DOI 10.1139/Y04-006; BROUILLETTE S, 1987, MOL CELL BIOL, V7, P2248, DOI 10.1128/MCB.7.6.2248; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferguson DO, 2000, COLD SPRING HARB SYM, V65, P395, DOI 10.1101/sqb.2000.65.395; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hinz JM, 2005, DNA REPAIR, V4, P782, DOI 10.1016/j.dnarep.2005.03.005; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; KADYK LC, 1992, GENETICS, V132, P387; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Malkova A, 2005, MOL CELL BIOL, V25, P933, DOI 10.1128/MCB.25.3.933-944.2005; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Rothstein R, 2000, GENE DEV, V14, P1; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Saleh-Gohari N, 2004, NUCLEIC ACIDS RES, V32, P3683, DOI 10.1093/nar/gkh703; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STAMATO TD, 1988, RADIAT RES, V115, P325, DOI 10.2307/3577168; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; Wang HC, 2003, NUCLEIC ACIDS RES, V31, P5377, DOI 10.1093/nar/gkg728; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	63	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2769	2780		10.1038/sj.onc.1210075	http://dx.doi.org/10.1038/sj.onc.1210075			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057732	Green Published			2022-12-25	WOS:000246210600011
J	Sharif, A; Legendre, P; Prevot, V; Allet, C; Romao, L; Studler, JM; Chneiweiss, H; Junier, MP				Sharif, A.; Legendre, P.; Prevot, V.; Allet, C.; Romao, L.; Studler, J.-M.; Chneiweiss, H.; Junier, M.-P.			Transforming growth factor a promotes sequential conversion of mature astrocytes into neural progenitors and stem cells	ONCOGENE			English	Article						erbB1; differentiation; radial glia; gliogenesis; oncogenesis; EGFR	RADIAL GLIAL-CELLS; FACTOR-ALPHA; TGF-ALPHA; MOUSE; DIFFERENTIATION; EXPRESSION; PROTEIN; RECEPTOR; NEURONS; NESTIN	An instability of the mature cell phenotype is thought to participate to the formation of gliomas, primary brain tumors deriving from astrocytes and/or neural stem cells. Transforming growth factor alpha (TGF alpha) is an erbB1 ligand overexpressed in the earliest stages of gliomas, and exerts trophic effects on gliomal cells and astrocytes. Here, we questioned whether prolonged TGF alpha exposure affects the stability of the normal mature astrocyte phenotype. We first developed astrocyte cultures devoid of residual neural stem cells or progenitors. We demonstrate that days of TGF alpha treatment result in the functional conversion of a population of mature astrocytes into radial glial cells, a population of neural progenitors. TGF alpha-generated radial glial cells support embryonic neurons migration, and give birth to cells of the neuronal lineage, expressing neuronal markers and the electrophysiological properties of neuroblasts. Lengthening TGF alpha treatment to months results in the delayed appearance of cells with neural stem cells properties: they form floating cellular spheres that are self-renewing, can be clonally derived from a single cell and differentiated into cells of the neuronal lineage. This study uncovers a novel population of mature astrocytes capable, in response to a single epigenetic factor, to regress progressively into a neural stem-like cell stage via an intermediate progenitor stage.	INSERM, U752, Coll France, F-75005 Paris, France; INSERM, U114, F-75005 Paris, France; Univ Paris 05, Paris, France; Univ Paris 06, CNRS, UMR 7102, Paris, France; INSERM, U816, F-59045 Lille, France; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, Rio De Janeiro, Brazil	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade Federal do Rio de Janeiro	Junier, MP (corresponding author), INSERM, U752, Coll France, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	marie-pierre.junier@college-de-france.fr	Romao, Luciana/I-4291-2015; Prevot, Vincent/E-5720-2016; Sharif, Ariane/AGW-8363-2022; herve, chneiweiss/Q-6818-2019	Prevot, Vincent/0000-0001-7185-3615; herve, chneiweiss/0000-0001-7675-5061; Sharif, Ariane/0000-0003-0810-400X; ALLET, Cecile/0000-0003-1294-9064				Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bahrey HLP, 2003, CEREB CORTEX, V13, P239, DOI 10.1093/cercor/13.3.239; BIGNAMI A, 1974, NATURE, V252, P55, DOI 10.1038/252055a0; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Chanas-Sacre G, 2000, DEV DYNAM, V219, P514, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1078>3.0.CO;2-0; Dai C, 2003, CANCER J, V9, P72, DOI 10.1097/00130404-200303000-00002; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Feldman DH, 1996, EXP NEUROL, V140, P206, DOI 10.1006/exnr.1996.0130; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Fukuda S, 2003, J NEUROSCI, V23, P9357; Fukuda S, 2004, CELL DEATH DIFFER, V11, P196, DOI 10.1038/sj.cdd.4401332; Gregg C, 2003, J NEUROSCI, V23, P11587; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harris H, 2004, NATURE, V427, P201, DOI 10.1038/427201a; Imura T, 2006, GLIA, V53, P277, DOI 10.1002/glia.20281; Imura T, 2003, J NEUROSCI, V23, P2824; Jung M, 1998, EUR J NEUROSCI, V10, P3246, DOI 10.1046/j.1460-9568.1998.00344.x; Junier MP, 2000, PROG NEUROBIOL, V62, P443, DOI 10.1016/S0301-0082(00)00017-4; KRESSIN K, 1995, GLIA, V15, P173, DOI 10.1002/glia.440150210; Kriegstein AR, 2003, GLIA, V43, P37, DOI 10.1002/glia.10250; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982; LEE DC, 1995, PHARMACOL REV, V47, P51; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; Liu B, 2004, DEV BIOL, V273, P297, DOI 10.1016/j.ydbio.2004.06.006; Marshall CAG, 2005, J NEUROSCI, V25, P7289, DOI 10.1523/JNEUROSCI.1924-05.2005; Miller S, 1996, J NEUROCHEM, V67, P1435; Muroyama Y, 2005, NATURE, V438, P360, DOI 10.1038/nature04139; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Prevot V, 2005, ENDOCRINOLOGY, V146, P1465, DOI 10.1210/en.2004-1146; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; Rakic P, 2003, GLIA, V43, P19, DOI 10.1002/glia.10244; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Scherer SS, 1997, CURR OPIN NEUROL, V10, P386, DOI 10.1097/00019052-199710000-00006; Seaberg RM, 2005, DEV BIOL, V278, P71, DOI 10.1016/j.ydbio.2004.10.017; Sharif A, 2006, ONCOGENE, V25, P4076, DOI 10.1038/sj.onc.1209443; Sharif A, 2004, NEUROSCIENCE, V126, P263, DOI 10.1016/j.neuroscience.2004.02.039; SHARIF A, 2006, M SOC NEUR ATL US OC; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Sun Y, 2005, NEURON, V45, P873, DOI 10.1016/j.neuron.2005.01.045; Sutherland ML, 1996, J NEUROSCI, V16, P2191; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Verkhratsky A, 2000, BRAIN RES REV, V32, P380, DOI 10.1016/S0165-0173(99)00093-4; Wagner B, 2006, EMBO J, V25, P752, DOI 10.1038/sj.emboj.7600988; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Zhou RX, 2001, BRAIN RES BULL, V56, P37, DOI 10.1016/S0361-9230(01)00591-3	54	63	70	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2695	2706		10.1038/sj.onc.1210071	http://dx.doi.org/10.1038/sj.onc.1210071			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057735				2022-12-25	WOS:000246210600004
J	Huh, JR; Foe, I; Muro, I; Chen, CH; Seol, JH; Yoo, SJ; Guo, M; Park, JM; Hay, BA				Huh, Jun R.; Foe, Ian; Muro, Israel; Chen, Chun Hong; Seol, Jae Hong; Yoo, Soon Ji; Guo, Ming; Park, Jin Mo; Hay, Bruce A.			The Drosophila inhibitor of apoptosis (IAP) DIAP2 is dispensable for cell survival, required for the innate immune response to gram-negative bacterial infection, and can be negatively regulated by the Reaper/Hid/Grim family of IAP-binding apoptosis inducers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNALING PATHWAYS; EFFECTOR CASPASES; DEATH; PROTEIN; ACTIVATION; REAPER; GRIM; HID; RECOGNITION	Many inhibitor of apoptosis ( IAP) family proteins inhibit apoptosis. IAPs contain N-terminal baculovirus IAP repeat domains and a C-terminal RING ubiquitin ligase domain. Drosophila IAP DIAP1 is essential for the survival of many cells, protecting them from apoptosis by inhibiting active caspases. Apoptosis initiates when proteins such as Reaper, Hid, and Grim bind a surface groove in DIAP1 baculovirus IAP repeat domains via an N-terminal IAP-binding motif. This evolutionarily conserved interaction disrupts DIAP1-caspase interactions, unleashing apoptosis- inducing caspase activity. A second Drosophila IAP, DIAP2, also binds Rpr and Hid and inhibits apoptosis in multiple contexts when overexpressed. However, due to a lack of mutants, little is known about the normal functions of DIAP2. We report the generation of diap2 null mutants. These flies are viable and show no defects in developmental or stress-induced apoptosis. Instead, DIAP2 is required for the innate immune response to Gram-negative bacterial infection. DIAP2 promotes cytoplasmic cleavage and nuclear translocation of the NF-kappa B homolog Relish, and this requires the DIAP2 RING domain. Increasing the genetic dose of diap2 results in an increased immune response, whereas expression of Rpr or Hid results in down-regulation of DIAP2 protein levels. Together these observations suggest that DIAP2 can regulate immune signaling in a dose-dependent manner, and this can be regulated by IBM-containing proteins. Therefore, diap2 may identify a point of convergence between apoptosis and immune signaling pathways.	CALTECH, Med Ctr, Div Biol, Pasadena, CA 91125 USA; Seoul Natl Univ, Dept Biochem, Seoul 151, South Korea; Kyung Hee Univ, Coll Sci, Dept Biol, Seoul 130701, South Korea; Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Dept Neurol, Los Angeles, CA 90095 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	California Institute of Technology; Seoul National University (SNU); Kyung Hee University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Massachusetts General Hospital	Huh, JR (corresponding author), CALTECH, Med Ctr, Div Biol, 156-29,1200 E Calif Blvd, Pasadena, CA 91125 USA.	haybruce@caltech.edu	Chen, Chun-Hong/E-3990-2010	CHEN, CHUN-HONG/0000-0002-3028-5508				Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; Chai JJ, 2003, NAT STRUCT BIOL, V10, P892, DOI 10.1038/nsb989; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; Creagh EM, 2004, J BIOL CHEM, V279, P26906, DOI 10.1074/jbc.M313859200; Daish TJ, 2004, DEV CELL, V7, P909, DOI 10.1016/j.devcel.2004.09.018; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Fedorov Y, 2006, RNA, V12, P1188, DOI 10.1261/rna.28106; Foley E, 2004, PLOS BIOL, V2, P1091, DOI 10.1371/journal.pbio.0020203; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gesellchen V, 2005, EMBO REP, V6, P979, DOI 10.1038/sj.embor.7400530; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hay BA, 2004, NAT REV GENET, V5, P911, DOI 10.1038/nrg1491; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hay BA, 2006, ANNU REV CELL DEV BI, V22, P623, DOI 10.1146/annurev.cellbio.21.012804.093845; Hell K, 2003, CELL DEATH DIFFER, V10, P1234, DOI 10.1038/sj.cdd.4401298; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kaneko T, 2005, CELL MICROBIOL, V7, P461, DOI 10.1111/j.1462-5822.2005.00504.x; Kim T, 2005, NAT IMMUNOL, V6, P211, DOI 10.1038/ni1159; Kleino A, 2005, EMBO J, V24, P3423, DOI 10.1038/sj.emboj.7600807; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; LEULIER F, 2006, CELL DEATH DIFFER, V26, P7821; Leulier F, 2006, MOL CELL BIOL, V26, P7821, DOI 10.1128/MCB.00548-06; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Mahoney JA, 2005, CURR OPIN IMMUNOL, V17, P583, DOI 10.1016/j.coi.2005.09.018; Mukae N, 2002, GENE DEV, V16, P2662, DOI 10.1101/gad.1022802; Muro I, 2006, DEVELOPMENT, V133, P3305, DOI 10.1242/dev.02495; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; Park JM, 2004, GENE DEV, V18, P584, DOI 10.1101/gad.1168104; Roman G, 2001, P NATL ACAD SCI USA, V98, P12602, DOI 10.1073/pnas.221303998; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Schmid-Hempel P, 2005, ANNU REV ENTOMOL, V50, P529, DOI 10.1146/annurev.ento.50.071803.130420; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Silverman N, 2003, J BIOL CHEM, V278, P48928, DOI 10.1074/jbc.M304802200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Sun EW, 2001, PHARMACOL THERAPEUT, V92, P135, DOI 10.1016/S0163-7258(01)00164-4; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Tenev T, 2005, NAT CELL BIOL, V7, P70, DOI 10.1038/ncb1204; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Xu D, 2006, CELL DEATH DIFFER, V13, P1697, DOI 10.1038/sj.cdd.4401920; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; XU X, 2005, DEVELOPMENT CAMB, V132, P2125; Yan N, 2005, ANNU REV CELL DEV BI, V21, P35, DOI 10.1146/annurev.cellbio.21.012704.131040; Yin VP, 2004, P NATL ACAD SCI USA, V101, P8022, DOI 10.1073/pnas.0402647101; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zhou R, 2005, J BIOL CHEM, V280, P34048, DOI 10.1074/jbc.M506655200; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	75	74	78	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2056	2068		10.1074/jbc.M608051200	http://dx.doi.org/10.1074/jbc.M608051200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17068333	hybrid, Green Accepted			2022-12-25	WOS:000243451300057
J	Odaert, B; Saida, F; Aliprandi, P; Durand, S; Crechet, JB; Guerois, R; Laalami, S; Uzan, M; Bontems, F				Odaert, Benoit; Saida, Fakhri; Aliprandi, Pascale; Durand, Sylvain; Crechet, Jean-Bernard; Guerois, Raphael; Laalami, Soumaya; Uzan, Marc; Bontems, Francois			Structural and functional studies of RegB, a new member of a family of sequence-specific ribonucleases involved in mRNA inactivation on the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENDORIBONUCLEASE REGB; CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; YOEB TOXIN; PROTEIN; BACTERIOPHAGE-T4; ANTITOXIN; TRANSLATION; BACTERIA	The RegB endoribonuclease participates in the bacteriophage T4 life cycle by favoring early messenger RNA breakdown. RegB specifically cleaves GGAG sequences found in intergenic regions, mainly in translation initiation sites. Its activity is very low but can be enhanced up to 100-fold by the ribosomal 30 S subunit or by ribosomal protein S1. RegB has no significant sequence homology to any known protein. Here we used NMR to solve the structure of RegB and map its interactions with two RNA substrates. We also generated a collection of mutants affected in RegB function. Our results show that, despite the absence of any sequence homology, RegB has structural similarities with two Escherichia coli ribonucleases involved in mRNA inactivation on translating ribosomes: YoeB and Re1E. Although these ribonucleases have different catalytic sites, we propose that RegB is a new member of the Re1E/YoeB structural and functional family of ribonucleases specialized in mRNA inactivation within the ribosome.	CNRS, Inst Chim Substances Nat, ICSN RMN, F-91190 Gif Sur Yvette, France; Ecole Polytech, F-91128 Palaiseau, France; Univ Paris 06, F-75005 Paris, France; Univ Paris 07, F-75005 Paris, France; CNRS, Inst Jacques Monod, F-75005 Paris, France; Ctr Etud Atom Saclay, Dept Biol Joliot Curie, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut Polytechnique de Paris; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Bontems, F (corresponding author), CNRS, Inst Chim Substances Nat, ICSN RMN, F-91190 Gif Sur Yvette, France.	francois.bontems@polytechnique.fr	, raph/AAF-4380-2019	DURAND, Sylvain/0000-0003-3509-6463				Audic Y, 2004, BIOL CELL, V96, P479, DOI 10.1016/j.biolcel.2004.05.002; BARRICK D, 1994, NUCLEIC ACIDS RES, V22, P1287, DOI 10.1093/nar/22.7.1287; Christensen SK, 2004, MOL MICROBIOL, V51, P1705, DOI 10.1046/j.1365-2958.2003.03941.x; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cuchillo C. M., 1997, RIBONUCLEASES STRUCT, P271; Deutscher MP, 2006, NUCLEIC ACIDS RES, V34, P659, DOI 10.1093/nar/gkj472; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; Gaur D, 2005, MOL CELL BIOCHEM, V275, P95, DOI 10.1007/s11010-005-0997-8; Gerdes K, 2005, NAT REV MICROBIOL, V3, P371, DOI 10.1038/nrmicro1147; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; GRUNERT HP, 1991, EUR J BIOCHEM, V197, P203, DOI 10.1111/j.1432-1033.1991.tb15900.x; Hargreaves D, 2002, STRUCTURE, V10, P1425, DOI 10.1016/S0969-2126(02)00856-0; HARTZ D, 1991, J MOL BIOL, V218, P99, DOI 10.1016/0022-2836(91)90876-8; Irie M, 2001, METHOD ENZYMOL, V341, P42, DOI 10.1016/S0076-6879(01)41144-X; Kamada K, 2005, MOL CELL, V19, P497, DOI 10.1016/j.molcel.2005.07.004; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; Lebars I, 2001, J BIOL CHEM, V276, P13264, DOI 10.1074/jbc.M010680200; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1999, EMBO J, V18, P2878, DOI 10.1093/emboj/18.10.2878; Nayak SK, 2001, BIOCHEMISTRY-US, V40, P9115, DOI 10.1021/bi010923m; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Piesiniene L, 2004, NUCLEIC ACIDS RES, V32, P5582, DOI 10.1093/nar/gkh892; RUCKMAN J, 1989, New Biologist, V1, P54; RUCKMAN J, 1994, J BIOL CHEM, V269, P26655; Saida F, 2004, PROTEIN EXPRES PURIF, V34, P158, DOI 10.1016/j.pep.2003.11.002; Saida F, 2003, BIOTECHNOL PROGR, V19, P727, DOI 10.1021/bp0257224; Saida F, 2003, NUCLEIC ACIDS RES, V31, P2751, DOI 10.1093/nar/gkg377; Sanson B, 2000, J MOL BIOL, V297, P1063, DOI 10.1006/jmbi.2000.3626; SANSON B, 1993, J MOL BIOL, V233, P429, DOI 10.1006/jmbi.1993.1522; SANSON B, 1995, FEMS MICROBIOL REV, V17, P141; Savarin P, 2001, J BIOMOL NMR, V19, P49, DOI 10.1023/A:1008311110174; Snoussi K, 2001, J MOL BIOL, V309, P139, DOI 10.1006/jmbi.2001.4618; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; Takagi H, 2005, NAT STRUCT MOL BIOL, V12, P327, DOI 10.1038/nsmb911; Uzan M, 2001, METHOD ENZYMOL, V342, P467, DOI 10.1016/S0076-6879(01)42567-5; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8885; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Yoshida H, 2001, METHOD ENZYMOL, V341, P28, DOI 10.1016/S0076-6879(01)41143-8; Zhang YL, 2005, J BIOL CHEM, V280, P26080, DOI 10.1074/jbc.M502050200	43	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2007	282	3					2019	2028		10.1074/jbc.M608271200	http://dx.doi.org/10.1074/jbc.M608271200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	125OK	17046813	hybrid			2022-12-25	WOS:000243451300053
J	Dose, AC; Ananthanarayanan, S; Moore, JE; Burnside, B; Yengo, CM				Dose, Andra C.; Ananthanarayanan, Shobana; Moore, Judy E.; Burnside, Beth; Yengo, Christopher M.			Kinetic mechanism of human myosin IIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE MYOSIN; ACTOMYOSIN SUBFRAGMENT-1; NUCLEOTIDE-BINDING; FLUORESCENT-PROBE; MOTOR PROTEIN; LIGHT-CHAIN; ADP; ACTIN; LOCALIZATION	Myosin IIIA is specifically expressed in photoreceptors and cochlea and is important for the phototransduction and hearing processes. In addition, myosin IIIA contains a unique N-terminal kinase domain and C-terminal tail actin-binding motif. We examined the kinetic properties of baculovirus expressed human myosin IIIA containing the kinase, motor, and two IQ domains. The maximum actin-activated ATPase rate is relatively slow (k(cat) = 0.77 +/- 0.08 s(-1)), and high actin concentrations are required to fully activate the ATPase rate (K-ATPase = 34 +/- 11 mu m). However, actin co-sedimentation assays suggest that myosin III has a relatively high steady-state affinity for actin in the presence of ATP (K-actin similar to 7 mu m). The rate of ATP binding to the motor domain is quite slow both in the presence and absence of actin (K(1)k(+2) = 0.020 and 0.001 mu m(-1.)s(-1), respectively). The rate of actin-activated phosphate release is more than 100-fold faster (85 s(-1)) than the k(cat), whereas ADP release in the presence of actin follows a two-step mechanism (7.0 and 0.6 s(-1)). Thus, our data suggest a transition between two actomyosin-ADP states is the rate-limiting step in the actomyosin III ATPase cycle. Our data also suggest the myosin III motor spends a large fraction of its cycle in an actomyosin ADP state that has an intermediate affinity for actin (K-d similar to 5 mu m). The long lived actomyosin-ADP state may be important for the ability of myosin III to function as a cellular transporter and actin crosslinker in the actin bundles of sensory cells.	Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of North Carolina; University of North Carolina Charlotte; University of California System; University of California Berkeley	Yengo, CM (corresponding author), Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA.	cmyengo@email.uncc.edu			NATIONAL EYE INSTITUTE [R03EY016419, R01EY003575, R37EY003575] Funding Source: NIH RePORTER; NEI NIH HHS [EY03575, R03EY016419] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Battelle BA, 1998, J NEUROSCI, V18, P4548; Brown ME, 2004, J NEUROBIOL, V58, P118, DOI 10.1002/neu.10285; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Cronin MA, 2004, J CELL SCI, V117, P4797, DOI 10.1242/jcs.01371; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dose AC, 2003, MOL BIOL CELL, V14, P1058, DOI 10.1091/mbc.E02-06-0317; Dose AC, 2002, GENOMICS, V79, P621, DOI 10.1006/geno.2002.6749; Dose AC, 2000, GENOMICS, V67, P333, DOI 10.1006/geno.2000.6256; Erickson FL, 2003, MOL BIOL CELL, V14, P4173, DOI 10.1091/mbc.e02-10-0656; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; Henn A, 2005, J BIOL CHEM, V280, P39665, DOI 10.1074/jbc.M507667200; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; Kambara T, 2006, J BIOL CHEM, V281, P37291, DOI 10.1074/jbc.M603823200; Komaba S, 2003, J BIOL CHEM, V278, P21352, DOI 10.1074/jbc.M300757200; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Lee SJ, 2004, NEURON, V43, P95, DOI 10.1016/j.neuron.2004.06.014; Lin-Jones J, 2004, J CELL SCI, V117, P5825, DOI 10.1242/jcs.01512; Mehta A, 2001, J CELL SCI, V114, P1981; Menetrey J, 2005, NATURE, V435, P779, DOI 10.1038/nature03592; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; NVITRAI M, 2004, PHILOS T R SOC LON B, V359, P1867; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Robblee JP, 2004, J BIOL CHEM, V279, P38608, DOI 10.1074/jbc.M403504200; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; Schneider ME, 2006, J NEUROSCI, V26, P10243, DOI 10.1523/JNEUROSCI.2812-06.2006; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sun MX, 2006, J BIOL CHEM, V281, P5711, DOI 10.1074/jbc.M508103200; Sweeney HL, 2004, PHILOS T R SOC B, V359, P1829, DOI 10.1098/rstb.2004.1576; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Walsh T, 2002, P NATL ACAD SCI USA, V99, P7518, DOI 10.1073/pnas.102091699; Watanabe S, 2006, BIOCHEMISTRY-US, V45, P2729, DOI 10.1021/bi051682b; WHITE HD, 1993, BIOCHEMISTRY-US, V32, P9859, DOI 10.1021/bi00088a042; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Wu H, 2003, BIOCHEMISTRY-US, V42, P1129, DOI 10.1021/bi026857l; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u	54	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					216	231		10.1074/jbc.M605964200	http://dx.doi.org/10.1074/jbc.M605964200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17074769	hybrid			2022-12-25	WOS:000243166500026
J	Thakur, M; Chakraborti, PK				Thakur, Meghna; Chakraborti, Pradip K.			GTPase activity of mycobacterial FtsZ is impaired due to its transphosphorylation by the eukaryotic-type Ser/Thr kinase, PknA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; BACTERIAL-CELL DIVISION; TUBERCULOSIS-FTSZ; ESCHERICHIA-COLI; PROTEIN; RING; TUBULIN; PHOSPHORYLATION; POLYMERIZATION; MUTATIONS	FtsZ, a homolog of eukaryotic tubulin, is involved in the process of cell division, particularly in septum formation in bacteria. The primary amino acid sequences of this protein are fairly conserved in prokaryotes. We observed that a eukaryotic-type Ser/Thr protein kinase, PknA from Mycobacterium tuberculosis, when expressed in Escherichia coli exhibited cell elongation due to a defect in septum formation. We found that FtsZ either from Escherichia coli (eFtsZ) or from M. tuberculosis (mFtsZ) was phosphorylated on co-expression with PknA. Consistent with these observations, solid phase binding and in vitro kinase assays revealed the ability of PknA to interact with mFtsZ protein and also to phosphorylate it. We, therefore, ascertained mFtsZ as a substrate of PknA. Furthermore, the phosphorylated mFtsZ exhibited impairment in its GTP hydrolysis and polymerization abilities. Thus, our results highlighted the ability of PknA to phosphorylate as well as to regulate the functionality of FtsZ, the protein central to cell division throughout the bacterial lineage.	Inst Microbial Technol, Sector 39A, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Chakraborti, PK (corresponding author), Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.	pradip@imtech.res.in	Thakur, Meghna/J-4011-2019	Thakur, Meghna/0000-0001-7952-6029				Addinall SG, 1996, J BACTERIOL, V178, P3877, DOI 10.1128/jb.178.13.3877-3884.1996; Beilina A, 2005, P NATL ACAD SCI USA, V102, P5703, DOI 10.1073/pnas.0500617102; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boitel B, 2003, MOL MICROBIOL, V49, P1493, DOI 10.1046/j.1365-2958.2003.03657.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaba R, 2002, EUR J BIOCHEM, V269, P1078, DOI 10.1046/j.1432-1033.2002.02778.x; Chopra P, 2003, BIOCHEM BIOPH RES CO, V311, P112, DOI 10.1016/j.bbrc.2003.09.173; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cordell SC, 2003, P NATL ACAD SCI USA, V100, P7889, DOI 10.1073/pnas.1330742100; Datta P, 2002, J BIOL CHEM, V277, P24983, DOI 10.1074/jbc.M203847200; Dziadek J, 2002, MICROBIOL-SGM, V148, P961, DOI 10.1099/00221287-148-4-961; Dziadek J, 2003, MICROBIOL-SGM, V149, P1593, DOI 10.1099/mic.0.26023-0; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; Fourest-Lieuvin A, 2006, MOL BIOL CELL, V17, P1041, DOI 10.1091/mbc.E05-07-0621; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; Hu ZL, 2000, J BACTERIOL, V182, P3965, DOI 10.1128/JB.182.14.3965-3971.2000; Ishikawa S, 2006, MOL MICROBIOL, V60, P1364, DOI 10.1111/j.1365-2958.2006.05184.x; Kang CM, 2005, GENE DEV, V19, P1692, DOI 10.1101/gad.1311105; Leung AKW, 2004, J MOL BIOL, V342, P953, DOI 10.1016/j.jmb.2004.07.061; Leung AKW, 2000, ACTA CRYSTALLOGR D, V56, P1634, DOI 10.1107/S0907444900011835; Liu Z, 1999, MOL MICROBIOL, V31, P1853, DOI 10.1046/j.1365-2958.1999.01322.x; Margalit DN, 2004, P NATL ACAD SCI USA, V101, P11821, DOI 10.1073/pnas.0404439101; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Rajagopalan M, 2005, BIOCHEM BIOPH RES CO, V331, P1171, DOI 10.1016/j.bbrc.2005.03.239; Rajagopalan M, 2005, FEMS MICROBIOL LETT, V250, P9, DOI 10.1016/j.femsle.2005.06.043; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarin J, 2001, J BIOL CHEM, V276, P44590, DOI 10.1074/jbc.M105401200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vicente M, 2006, J BACTERIOL, V188, P19, DOI 10.1128/JB.188.1.19-27.2006; Weiss DS, 2004, MOL MICROBIOL, V54, P588, DOI 10.1111/j.1365-2958.2004.04283.x; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Yang W, 2001, PROTEIN EXPRES PURIF, V22, P472, DOI 10.1006/prep.2001.1453; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	39	91	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40107	40113		10.1074/jbc.M607216200	http://dx.doi.org/10.1074/jbc.M607216200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17068335	hybrid			2022-12-25	WOS:000243033900040
J	Moncalian, G; Cardenes, N; Deribe, YL; Spinola-Amilibia, M; Dikic, I; Bravo, J				Moncalian, Gabriel; Cardenes, Nayra; Deribe, Yonathan Lissanu; Spinola-Amilibia, Mercedes; Dikic, Ivan; Bravo, Jeronimo			Atypical polyproline recognition by the CMS N-terminal SRC homology 3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; SH3 DOMAINS; BETA-PIX; PEPTIDE; CBL; IDENTIFICATION; SPECIFICITY; ENDOCYTOSIS; COMPLEX; BINDING	The CIN85/CMS (human homologs of mouse SH3KBP1/CD2AP) family of endocytic adaptor proteins has the ability to engage multiple effectors and couple cargo trafficking with the cytoskeleton. CIN85 and CMS (Cas ligand with multiple Src homology 3 (SH3) domains) facilitate the formation of large multiprotein complexes required for an efficient internalization of cell surface receptors. It has recently been shown that c-Cbl/Cbl-b could mediate the formation of a ternary complex between one c-Cbl/Cbl-b molecule and two SH3 domains of CIN85, important for the ability of Cbl to promote epidermal growth factor receptor down-regulation. To further investigate whether multimerization is conserved within the family of adaptor proteins, we have solved the crystal structures of the CMS N-terminal SH3 domain-forming complexes with Cbl-b-and CD2-derived peptides. Together with biochemical evidence, the structures support the notion that, despite clear differences in the interaction surface, both Cbl-b and CD2 can mediate multimerization of N-terminal CMS SH3 domains. Detailed analyses on the interacting surfaces also provide the basis for a differential Cbl-b molecular recognition of CMS and CIN85.	Ctr Nacl Invest Oncol, Signal Transduct Grp, Struct Biol & Biocomp Programme, E-28029 Madrid, Spain; Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Bravo, J (corresponding author), Ctr Nacl Invest Oncol, Signal Transduct Grp, Struct Biol & Biocomp Programme, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	jbravo@cnio.es	Moncalian, Gabriel/K-3493-2014; Dikic, Ivan/O-4650-2015; Bravo, Jeronimo/K-9103-2014	Moncalian, Gabriel/0000-0002-3007-6490; Dikic, Ivan/0000-0001-8156-9511; Bravo, Jeronimo/0000-0001-6695-2846				ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Ferreon JC, 2004, BIOCHEMISTRY-US, V43, P7787, DOI 10.1021/bi049752m; Hoelz A, 2006, J MOL BIOL, V358, P509, DOI 10.1016/j.jmb.2006.02.027; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Kurakin AV, 2003, J BIOL CHEM, V278, P34102, DOI 10.1074/jbc.M305264200; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Mayer BJ, 2001, J CELL SCI, V114, P1253; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mott HR, 2005, BIOCHEMISTRY-US, V44, P10977, DOI 10.1021/bi050374a; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2004, BIOCHEM J, V383, P1, DOI 10.1042/BJ20040913; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Tibaldi EV, 2003, INT IMMUNOL, V15, P313, DOI 10.1093/intimm/dxg032; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	32	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38845	38853		10.1074/jbc.M606411200	http://dx.doi.org/10.1074/jbc.M606411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17020880	hybrid			2022-12-25	WOS:000242709500082
J	Mutsuda, M; Sugiura, M				Mutsuda, Michinori; Sugiura, Masahiro			Translation initiation of cyanobacterial rbcS mRNAs requires the 38-kDa ribosomal protein S1 but not the Shine-Dalgarno sequence - Development of a cyanobacterial in vitro translation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REINHARDTII CHLOROPLAST RIBOSOME; ANABAENA-VARIABILIS M3; SP STRAIN PCC-6301; BINDING PROTEIN; PROTEOMIC CHARACTERIZATION; SYNECHOCOCCUS PCC-7942; ANACYSTIS-NIDULANS; ESCHERICHIA-COLI; SMALL-SUBUNIT; GENE	Little is known about the biochemical mechanism of translation in cyanobacteria though substantial studies have been made on photosynthesis, nitrogen fixation, circadian rhythm, and genome structure. To analyze the mechanism of cyanobacterial translation, we have developed an in vitro translation system from Synechococcus cells using a psbAI-lacZ fusion mRNA as a model template. This in vitro system supports accurate translation from the authentic initiation site of a variety of Synechococcus mRNAs. In Synechococcus cells, rbcL and rbcS encoding the large and small subunits, respectively, of ribulose-1,5- bisphosphate carboxylase/oxygenase are co-transcribed as a dicistronic mRNA, and the downstream rbcS mRNA possesses two possible initiation codons separated by three nucleotides. Using this in vitro system and mutated mRNAs, we demonstrated that translation starts exclusively from the upstream AUG codon. Although there are Shine-Dalgarno-like sequences in positions similar to those of the functional Shine-Dalgarno elements in Escherichia coli, mutation analysis indicated that these sequences are not required for translation. Assays with deletions within the 5'-untranslated region showed that a pyrimidine-rich sequence in the -46 to -15 region is necessary for efficient translation. Synechococcus cells contain two ribosomal protein S1 homologues of 38 and 33 kDa in size. UV cross-linking and immunoprecipitation experiments suggested that the 38-kDa S1 is involved in efficient translation via associating with the pyrimidine-rich sequence. The present in vitro translation system will be a powerful tool to analyze the basic mechanism of translation in cyanobacteria.	Nagoya Univ, Ctr Gene Res, Nagoya, Aichi 4648602, Japan; Nagoya City Univ, Grad Sch Nat Sci, Nagoya, Aichi 4678501, Japan	Nagoya University; Nagoya City University	Sugiura, M (corresponding author), Sugiyama Jogakuen Univ, Sugiyama Human Res Ctr, Nagoya, Aichi 4648662, Japan.	sugiura@nsc.nagoya-cu.ac.jp						BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; Boni IV, 2001, EMBO J, V20, P4222, DOI 10.1093/emboj/20.15.4222; Choquet Y, 2002, FEBS LETT, V529, P39, DOI 10.1016/S0014-5793(02)03260-X; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Gruber TM, 2003, ANNU REV MICROBIOL, V57, P441, DOI 10.1146/annurev.micro.57.030502.090913; Hirosawa M, 1997, DNA Res, V4, P179, DOI 10.1093/dnares/4.3.179; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; Hirose T, 2004, NUCLEIC ACIDS RES, V32, P3503, DOI 10.1093/nar/gkh682; Komarova AV, 2002, RNA, V8, P1137, DOI 10.1017/S1355838202029990; Ma J, 2002, J BACTERIOL, V184, P5733, DOI 10.1128/JB.184.20.5733-5745.2002; MCCARTHY JEG, 1994, TRENDS GENET, V10, P402, DOI 10.1016/0168-9525(94)90057-4; McFadden GI, 1999, CURR OPIN PLANT BIOL, V2, P513, DOI 10.1016/S1369-5266(99)00025-4; Michel KP, 2004, PHYSIOL PLANTARUM, V120, P36, DOI 10.1111/j.0031-9317.2004.0229.x; Mutsuda M, 1999, PLANT CELL PHYSIOL, V40, P1203, DOI 10.1093/oxfordjournals.pcp.a029508; Ogawa T, 2002, J BIOL CHEM, V277, P28981, DOI 10.1074/jbc.M204175200; OMATA T, 1991, PLANT CELL PHYSIOL, V32, P151, DOI 10.1093/oxfordjournals.pcp.a078059; Plader W, 2003, PLANT J, V34, P377, DOI 10.1046/j.1365-313X.2003.01732.x; Raven JA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-209; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SAMBOROOK J, 1989, MOL CLONING LAB MANU; Sato N, 1998, PLANT CELL PHYSIOL, V39, P1367, DOI 10.1093/oxfordjournals.pcp.a029343; Sato N, 1997, J BACTERIOL, V179, P7063, DOI 10.1128/jb.179.22.7063-7071.1997; Sato N, 1996, PLANT CELL PHYSIOL, V37, P1150, DOI 10.1093/oxfordjournals.pcp.a029066; SATO N, 1995, NUCLEIC ACIDS RES, V23, P2161; Sato Naoki, 2002, Genome Inform, V13, P173; Sauer J, 2001, PLANT PHYSIOL, V126, P233, DOI 10.1104/pp.126.1.233; SCANLAN DJ, 1992, PLANT MOL BIOL, V19, P877, DOI 10.1007/BF00027085; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; SHINOZAKI K, 1985, MOL GEN GENET, V200, P27, DOI 10.1007/BF00383308; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; Sugita C, 2000, MOL GEN GENET, V263, P655, DOI 10.1007/s004380051214; SUGITA M, 1994, NUCLEIC ACIDS RES, V22, P25, DOI 10.1093/nar/22.1.25; Sugita M, 1997, GENE, V195, P73, DOI 10.1016/S0378-1119(97)00169-8; SUGITA M, 1995, MOL GEN GENET, V246, P142, DOI 10.1007/BF00294676; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; Thornton LE, 2004, PLANT CELL, V16, P2164, DOI 10.1105/tpc.104.023515; TOMIOKA N, 1983, MOL GEN GENET, V191, P46, DOI 10.1007/BF00330888; Wang T, 2004, J BACTERIOL, V186, P956, DOI 10.1128/JB.186.4.956-967.2004; Watanabe T, 1998, BBA-GENE STRUCT EXPR, V1396, P97, DOI 10.1016/S0167-4781(97)00180-2; Yamaguchi K, 2000, J BIOL CHEM, V275, P28455, DOI 10.1074/jbc.M004350200; Yamaguchi K, 2000, J BIOL CHEM, V275, P28466, DOI 10.1074/jbc.M005012200; Yamaguchi K, 2003, J BIOL CHEM, V278, P33774, DOI 10.1074/jbc.M301934200; Yamaguchi K, 2003, EUR J BIOCHEM, V270, P190, DOI 10.1046/j.1432-1033.2003.03359.x; Yamaguchi K, 2002, PLANT CELL, V14, P2957, DOI 10.1105/tpc.004341; ZHANG JR, 1992, P NATL ACAD SCI USA, V89, P2605, DOI 10.1073/pnas.89.7.2605	49	18	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38314	38321		10.1074/jbc.M604647200	http://dx.doi.org/10.1074/jbc.M604647200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046824	hybrid			2022-12-25	WOS:000242709500024
J	Schwem, BE; Fillingame, RH				Schwem, Brian E.; Fillingame, Robert H.			Cross-linking between helices within subunit a of Escherichia coli ATP synthase defines the transmembrane packing of a four-helix bundle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING PROTON MOVEMENTS; AQUEOUS ACCESS CHANNELS; C-RING ROTATION; ALPHA-SUBUNIT; ROTARY MOTOR; A-SUBUNIT; MUTAGENIC ANALYSIS; MECHANISM; MEMBRANE; OLIGOMER	Subunit a of F1F0 ATP synthase is required in the H+ transport driven rotation of the c-ring of F-0, the rotation of which is coupled to ATP synthesis in F-1. The three-dimensional structure of subunit a is unknown. In this study, Cys substitutions were introduced into two different transmembrane helices (TMHs) of subunit a, and the proximity of the thiol side chains was tested via attempted oxidative cross-linking to form the disulfide bond. Pairs of Cys substitutions were made in TMHs 2/3, 2/4, 2/5, 3/4, 3/5, and 4/5. Cu+2-catalyzed oxidation led to cross-link formation between Cys pairs L120C(TMH2) and S144C(TMH3), L120C(TMH2) and G218C(TMH4), L120C(TMH2) and H245C(TMH5), L120C(TMH2) and I246C(TMH5), N148C(TMH3) and E219C(TMH4), N148C(TMH3) and H245C(TMH5), and G218C(TMH4) and I248C(TMH5). Iodine, but not Cu+2, was found to catalyze cross-link formation between D119C(TMH2) and G218C(TMH4). The results suggest that TMHs 2, 3, 4, and 5 form a four-helix bundle with one set of key functional residues in TMH4(Ser-206, Arg-210, and Asn-214) located at the periphery facing subunit c. Other key residues in TMHs 2, 4, and 5, which were concluded previously to compose a possible aqueous access pathway from the periplasm, were found to locate to the inside of the four-helix bundle.	Univ Wisconsin, Dept Biomol Chem, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Dept Biomol Chem, Sch Med & Publ Hlth, 1300 Univ Ave, Madison, WI 53706 USA.	rhfillin@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aksimentiev A, 2004, BIOPHYS J, V86, P1332, DOI 10.1016/S0006-3495(04)74205-8; Angevine CM, 2003, P NATL ACAD SCI USA, V100, P13179, DOI 10.1073/pnas.2234364100; Angevine CM, 2003, J BIOL CHEM, V278, P6066, DOI 10.1074/jbc.M210199200; [Anonymous], 1973, CHEM BIOCH SULFHYDRY; Barik S, 1996, Methods Mol Biol, V57, P203; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Capozzi G, 1974, CHEM THIOL GROUP, P785; Dimroth P, 2006, EMBO REP, V7, P276, DOI 10.1038/sj.embor.7400646; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 2000, J EXP BIOL, V203, P9; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P2187, DOI 10.1093/nar/9.9.2187; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HERMOLIN J, 1995, J BIOL CHEM, V270, P2815, DOI 10.1074/jbc.270.6.2815; HOWITT SM, 1990, BIOCHIM BIOPHYS ACTA, V1015, P264, DOI 10.1016/0005-2728(90)90030-8; HOWITT SM, 1992, P NATL ACAD SCI USA, V89, P9799, DOI 10.1073/pnas.89.20.9799; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kinosita K, 2000, PHILOS T R SOC B, V355, P473, DOI 10.1098/rstb.2000.0589; Kuo PH, 2000, BIOCHEM J, V347, P797, DOI 10.1042/0264-6021:3470797; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GF, 1994, J BIOL CHEM, V269, P29920; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Mitome N, 2004, P NATL ACAD SCI USA, V101, P12159, DOI 10.1073/pnas.0403545101; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zhang D, 2003, J BIOL CHEM, V278, P12319, DOI 10.1074/jbc.M212413200; Zhang D, 2003, BIOCHEMISTRY-US, V42, P331, DOI 10.1021/bi026649t	57	40	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37861	37867		10.1074/jbc.M607453200	http://dx.doi.org/10.1074/jbc.M607453200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035244	hybrid			2022-12-25	WOS:000242477100064
J	Sekine, H; Mimura, J; Yamamoto, M; Fujii-Kuriyama, Y				Sekine, Hiroki; Mimura, Junsei; Yamamoto, Masayuki; Fujii-Kuriyama, Yoshiaki			Unique and overlapping transcriptional roles of arylhydrocarbon receptor nuclear translocator (Arnt) and Arnt2 in xenobiotic and hypoxic responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSE SEQUENCE SIMILARITY; INDUCIBLE FACTOR 1-ALPHA; MINDED GENE ENCODES; AH DIOXIN RECEPTOR; PAS DOMAIN; STRUCTURAL BASIS; IN-VIVO; EXPRESSION; PROTEIN; DEFINITION	Arnt and the homologous Arnt2 share a high degree of sequence similarity and are believed to function as obligate common partners for a number of basic helix-loop-helix (bHLH)-PAS transcription factors including arylhydrocarbon receptor (AhR) and HIF alpha. Genetic disruption of both Arnt and Arnt2 demonstrated both unique and overlapping functions in response to environmental stimuli and during mouse development. Either stably or transiently expressed Arnt/Arnt2 wild type and various mutants or chimeric constructs in Hepa1-c4 cells exhibit similar levels of hypoxic response element-driven reporter gene expression and the induction of endogenous Glut-1 through binding with HIF alpha in response to hypoxia. In contrast, we observed clear functional differences in the ability of Arnt and Arnt2 to induce xenobiotic response element-driven reporter and endogenous CYP1A1 gene expression. In contrast with Arnt, Arnt2 was practically incapable of interacting with ligand-activated AhR to induce the expression of target genes for xenobiotic-metabolizing enzymes in response to xenobiotics. The differential binding of AhR by Arnt and Arnt2 can be ascribed to a single His/Pro amino acid difference in the PASB region of Arnt and Arnt2, suggesting that the PASB/PASB interaction between bHLH-PAS transcription factors plays a selective role for their specific partner molecule.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Japan Sci & Technol Agcy, SORST, Kawaguchi 3320012, Japan	University of Tsukuba; University of Tsukuba; Japan Science & Technology Agency (JST)	Fujii-Kuriyama, Y (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058577, Japan.	ykfujii@tara.tsukuba.ac.jp	Mimura, Junsei/E-7893-2013; Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Sekine, Hiroki/0000-0002-0929-6456				Abbott BD, 2000, DEV DYNAM, V219, P526, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1080>3.0.CO;2-N; Adelman DM, 2000, GENE DEV, V14, P3191, DOI 10.1101/gad.853700; Aitola MH, 2003, J HISTOCHEM CYTOCHEM, V51, P41, DOI 10.1177/002215540305100106; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; Baba T, 2005, MOL CELL BIOL, V25, P10040, DOI 10.1128/MCB.25.22.10040-10051.2005; Card PB, 2005, J MOL BIOL, V353, P664, DOI 10.1016/j.jmb.2005.08.043; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Drutel G, 1996, BIOCHEM BIOPH RES CO, V225, P333, DOI 10.1006/bbrc.1996.1176; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hosoya T, 2001, GENES CELLS, V6, P361, DOI 10.1046/j.1365-2443.2001.00421.x; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Huffman JL, 2001, J BIOL CHEM, V276, P40537, DOI 10.1074/jbc.M105675200; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Prasch AL, 2004, TOXICOL SCI, V82, P250, DOI 10.1093/toxsci/kfh235; REDDY P, 1986, CELL, V46, P53, DOI 10.1016/0092-8674(86)90859-7; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yang JS, 2005, J BIOL CHEM, V280, P36047, DOI 10.1074/jbc.M501755200	42	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37507	37516		10.1074/jbc.M606910200	http://dx.doi.org/10.1074/jbc.M606910200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17023418	hybrid			2022-12-25	WOS:000242477100027
J	Stoica, C; Carmichael, JB; Parker, H; Pare, J; Hobman, TC				Stoica, Cezar; Carmichael, Jon B.; Parker, Henry; Pare, Justin; Hobman, Tom C.			Interactions between the RNA interference effector protein Ago1 and 14-3-3 proteins - Consequences for cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; FISSION YEAST; NUCLEAR EXPORT; LOCALIZATION; PATHWAY; CDC25; CHK1	The Argonaute family member Ago1 is required for formation of pericentric heterochromatin and small interfering RNA (siRNA)-mediated post-transcriptional gene silencing in the fission yeast Schizosaccharomyces pombe. In addition, we have recently demonstrated that Ago1 function is required for enactment of cell cycle checkpoints (Carmichael, J. B., Provost, P., Ekwall, K., and Hobman, T. C. (2004) Mol. Biol. Cell 15, 1425 1435). Here, we provide evidence that the amino terminus of Ago1 binds to proteins that function in cell cycle regulation including 14-3-3 proteins. Interestingly, the amino terminus of human Ago2, the endonuclease that cleaves siRNA-targeted mRNAs, was also demonstrated to bind 14-3-3 proteins. Overexpression of the Ago1 amino terminus in yeast resulted in cell cycle delay at the G(2)/M boundary. Further investigation revealed that nuclear import of the mitosis-inducing phosphatase Cdc25 is inhibited by overexpression of the Ago1 amino terminus. Under these conditions, we found that the cyclin-dependent kinase Cdc2 is constitutively phosphorylated on tyrosine 15, thereby reducing the activity of this kinase, a situation that delays entry into mitosis. We hypothesize that 14-3-3 proteins are required for Argonaute protein functions in cell cycle and/or gene-silencing pathways.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Hobman, TC (corresponding author), Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada.	tom.hobman@ualberta.ca						ALFA C, 1993, EXPT FISSION YEASTS; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Carmichael JB, 2004, MOL BIOL CELL, V15, P1425, DOI 10.1091/mbc.E03-06-0433; Carmichael JB, 2006, TRAFFIC, V7, P1032, DOI 10.1111/j.1600-0854.2006.00441.x; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Chua G, 2002, GENETICS, V162, P689; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Dunaway S, 2004, METHODS, V33, P260, DOI 10.1016/j.ymeth.2003.11.022; Fantes P, 1989, CURR OPIN CELL BIOL, V1, P250, DOI 10.1016/0955-0674(89)90096-3; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hansen KR, 2005, MOL CELL BIOL, V25, P590, DOI 10.1128/MCB.25.2.590-601.2005; Jaronczyk K, 2005, BIOCHEM J, V387, P561, DOI 10.1042/BJ20041822; Kino T, 2005, J VIROL, V79, P2780, DOI 10.1128/JVI.79.5.2780-2787.2005; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Ozoe F, 2002, MOL CELL BIOL, V22, P7105, DOI 10.1128/MCB.22.20.7105-7119.2002; Provost P, 2002, P NATL ACAD SCI USA, V99, P16648, DOI 10.1073/pnas.212633199; Sigova A, 2004, GENE DEV, V18, P2359, DOI 10.1101/gad.1218004; Tahbaz N, 2001, J BIOL CHEM, V276, P43294, DOI 10.1074/jbc.M107808200; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; XU HP, 1992, MOL BIOL CELL, V3, P721, DOI 10.1091/mbc.3.7.721; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	37	19	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37646	37651		10.1074/jbc.M604476200	http://dx.doi.org/10.1074/jbc.M604476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17043360	hybrid			2022-12-25	WOS:000242477100041
J	Jiang, ZL; Clemens, PR				Jiang, Zhilong; Clemens, Paula R.			Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells	FASEB JOURNAL			English	Article						cachexia; NF-kappa B; apoptosis	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; MYOGENIC DIFFERENTIATION; INDUCED APOPTOSIS; MESSENGER-RNA; FACTOR-ALPHA; ACTIVATION; DEATH; EXPRESSION; CACHEXIA	Cachexia is a frequent complication of cancer or other chronic diseases. To investigate the pathophysiology of cancer cachexia and pursue treatment options, we developed an in vitro assay of the effects of cancer cell-produced cytokines on primary muscle cells derived from murine skeletal muscle. These studies led to the novel observation that factors secreted by cell lines from prostate cancer and melanoma significantly inhibit differentiation of primary mouse muscle cells. The expression of interleukin (IL) -1 beta, TNF-alpha, and proteolysis-inducing factor (PIF) by cancer cells used in this study suggested their role in preventing myogenic differentiation. Both NF-kappa B binding and transcriptional activity were enhanced in muscle cells treated with conditioned media from cancer cells or with proinflammatory cytokines. Stable expression of IKBSR, a known repressor of NF-kappa B activation, and cellular caspase-8-like inhibitory protein (cFLIP) inhibited activation of NF-kappa B in cancer cell media-treated muscle cells with an accompanying enhancement of myogenic protein expression and differentiation. In contrast, overexpression of antiapoptotic protein Bcl-xL did not protect myoblast cells exposed to the same treatment. Instead, we observed enhanced activation of NF-kappa B in Bcl-xL overexpressing cells. These studies show that the in vitro system recapitulates some of the molecular events causing muscle cachexia and provides the basis for new treatment approaches.-Jiang, Z., Clemens, P. R. Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells.	Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15213 USA; Dept Vet Affairs Med Ctr, Neurol Serv, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Clemens, PR (corresponding author), Univ Pittsburgh, Dept Neurol, Sch Med, Biomed Sci Tower,S Wing,Rm 250,203 Lothrop St, Pittsburgh, PA 15213 USA.	pclemens@pitt.edu						Anker SD, 1999, CURR OPIN CARDIOL, V14, P211, DOI 10.1097/00001573-199905000-00004; Bannerman DD, 2004, AM J PATHOL, V165, P1423, DOI 10.1016/S0002-9440(10)63400-1; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chen GG, 2004, APOPTOSIS, V9, P619, DOI 10.1023/B:APPT.0000038041.57782.84; Crawford MJ, 2001, BIOCHEM BIOPH RES CO, V281, P1304, DOI 10.1006/bbrc.2001.4501; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; FONG Y, 1989, AM J PHYSIOL, V256, pR659, DOI 10.1152/ajpregu.1989.256.3.R659; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Huang YT, 1999, CANCER RES, V59, P1599; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong CW, 2003, CLIN EXP ALLERGY, V33, P1717, DOI 10.1111/j.1365-2222.2003.01782.x; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; NAKASHIMA J, 1995, CANCER RES, V55, P4881; Okano H, 2003, LAB INVEST, V83, P1033, DOI 10.1097/01.LAB.0000079328.76631.28; Pfitzenmaier J, 2003, CANCER, V97, P1211, DOI 10.1002/cncr.11178; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Song YS, 2004, NEUROSCI RES, V49, P69, DOI 10.1016/j.neures.2004.01.010; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; Todorov PT, 1996, CANCER RES, V56, P1256; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Wang ZJ, 2003, INT J CANCER, V105, P123, DOI 10.1002/ijc.11035; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	34	15	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2570	+		10.1096/fj.06-6347fje	http://dx.doi.org/10.1096/fj.06-6347fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060399				2022-12-25	WOS:000242490700027
J	Reijerkerk, A; Kooij, G; van der Pol, SMA; Khazen, S; Dijkstra, CD; de Vries, HE				Reijerkerk, Arie; Kooij, Gijs; van der Pol, Susanne M. A.; Khazen, Shadi; Dijkstra, Christine D.; de Vries, Helga E.			Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells	FASEB JOURNAL			English	Article						tight junction; occludin; blood-brain barrier; matrix metalloproteinase; diapedesis	TIGHT JUNCTION PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MATRIX-METALLOPROTEINASE EXPRESSION; INTEGRAL MEMBRANE-PROTEIN; BLOOD-BRAIN; LEUKOCYTE TRANSMIGRATION; BARRIER PERMEABILITY; ZONULA OCCLUDENS-1; CADHERIN COMPLEX; WHITE-MATTER	The blood-brain barrier (BBB), a selective barrier formed by endothelial cells and dependent on the presence of tight junctions, is compromised during neuroinflammation. A detailed study of tight junction dynamics during transendothelial migration of leukocytes has been lacking. Therefore, we retrovirally expressed green fluorescent protein (GFP) fused to the N-terminus of the tight junction protein occludin in the rat brain endothelial cell line GP8/3.9. Confocal microscopy analyses revealed that GFP-occludin colocalized with the intracellular tight junction protein, ZO-1, localized at intercellular connections, and was absent at cell borders lacking apposing cells. Using live cell imaging we found that monocytes scroll over the brain endothelial cell surface toward cell-cell contacts, induce gap formation, which is associated with local disappearance of GFP-occludin, and subsequently traverse the endothelium paracellularly. Immunoblot analyses indicated that loss of occludin was due to protein degradation. The broad spectrum matrix metalloproteinase (MMP) inhibitor BB-3103 significantly inhibited endothelial gap formation, occludin loss, and the ability of monocytes to pass the endothelium. Our results provide a novel insight into the mechanism by which leukocytes traverse the BBB and illustrate that therapeutics aimed at the stabilization of the tight junction may be beneficial to resist a neuroinflammatory attack.-Reijerkerk, A., Kooij, G., van der Pol, S. M. A., Khazen, S., Dijkstra, C. D., de Vries, H. E. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells.	Vrije Univ Amsterdam, Med Ctr, Neuroimmunol Res Grp, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Reijerkerk, A (corresponding author), Vrije Univ Amsterdam, Med Ctr, Neuroimmunol Res Grp, POB 7057, NL-1007 MB Amsterdam, Netherlands.	a.reijerkerk@vumc.nl	Kooij, Gijs/AAA-4268-2020	Kooij, Gijs/0000-0002-9488-2918; de Vries, Helga/0000-0001-7904-7124				Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; Allport JR, 2000, J CELL BIOL, V148, P203, DOI 10.1083/jcb.148.1.203; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Balda MS, 2000, J CELL BIOCHEM, V78, P85, DOI 10.1002/(SICI)1097-4644(20000701)78:1<85::AID-JCB8>3.3.CO;2-6; Basuroy S, 2006, BIOCHEM J, V393, P69, DOI 10.1042/BJ20050959; Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853; Bojarski C, 2004, J CELL SCI, V117, P2097, DOI 10.1242/jcs.01071; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Boven LA, 2000, NEUROPATH APPL NEURO, V26, P356, DOI 10.1046/j.1365-2990.2000.00255.x; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Caron A, 2005, EXP CELL RES, V310, P105, DOI 10.1016/j.yexcr.2005.07.004; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; Del Maschio A, 1999, J EXP MED, V190, P1351, DOI 10.1084/jem.190.9.1351; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Floris S, 2004, BRAIN, V127, P616, DOI 10.1093/brain/awh068; Floris S, 2002, J NEUROIMMUNOL, V127, P69, DOI 10.1016/S0165-5728(02)00098-X; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1996, J CELL SCI, V109, P429; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hirase T, 1997, J CELL SCI, V110, P1603; Huber JD, 2002, AM J PHYSIOL-HEART C, V283, pH1531, DOI 10.1152/ajpheart.00027.2002; Huber JD, 2001, AM J PHYSIOL-HEART C, V280, pH1241, DOI 10.1152/ajpheart.2001.280.3.H1241; Kago T, 2006, BIOCHEM BIOPH RES CO, V339, P1197, DOI 10.1016/j.bbrc.2005.11.133; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kirk J, 2003, J PATHOL, V201, P319, DOI 10.1002/path.1434; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lohmann C, 2004, BRAIN RES, V995, P184, DOI 10.1016/j.brainres.2003.10.002; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Moll T, 1998, J CELL BIOL, V140, P403, DOI 10.1083/jcb.140.2.403; Pflugfelder SC, 2005, AM J PATHOL, V166, P61, DOI 10.1016/S0002-9440(10)62232-8; Plumb J, 2002, BRAIN PATHOL, V12, P154; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; SCHNEEBERGER EE, 1976, CIRC RES, V38, P404, DOI 10.1161/01.RES.38.5.404; Seguin R, 2003, J NEUROPATH EXP NEUR, V62, P412, DOI 10.1093/jnen/62.4.412; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; Sheth P, 2003, J BIOL CHEM, V278, P49239, DOI 10.1074/jbc.M305654200; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; van der Goes A, 2001, FASEB J, V15, P1852, DOI 10.1096/fj.00-0881fje; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wachtel M, 1999, J CELL SCI, V112, P4347; Wolburg H, 2003, ACTA NEUROPATHOL, V105, P586, DOI 10.1007/s00401-003-0688-z; Wolburg H, 2005, ACTA NEUROPATHOL, V109, P181, DOI 10.1007/s00401-004-0928-x; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859; Xu HP, 2005, INVEST OPHTH VIS SCI, V46, P2487, DOI 10.1167/iovs.04-1333; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	59	103	107	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2550	+		10.1096/fj.06-6099fje	http://dx.doi.org/10.1096/fj.06-6099fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065217				2022-12-25	WOS:000242490700020
J	Reiter, TA; Pang, B; Dedon, P; Demple, B				Reiter, Tiffany A.; Pang, Bo; Dedon, Peter; Demple, Bruce			Resistance to nitric oxide-induced necrosis in heme oxygenase-1 overexpressing pulmonary epithelial cells associated with decreased lipid peroxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CARBON-MONOXIDE; MOTOR-NEURONS; PEROXYNITRITE; BILIRUBIN; DNA; DEGRADATION; DEAMINATION; PATHWAYS; DAMAGE	Increased expression of heme oxygenase-1 (HO-1) increases NO resistance in several cell types, although the biochemical mechanism for this protection is unknown. To address this issue, we have measured different molecular markers of nitrosative stress in three stably transfected cell lines derived from the human lung epithelial line A549: two lines that overexpress rat HO-1 (L1 and A4), and a control line with the empty vector (Neo). Compared with the control Neo cells, L1 and A4 cells had, respectively, 5.8- and 3.8- fold greater HO activity accompanied by increased resistance to NO-induced necrosis. Compared with the Neo control, the HO-1-overexpressing cells also showed significantly less lipid peroxide formation and decreased perturbation of transition metal oxidation and coordination states following a cytotoxic NO exposure. These effects were blocked by the HO-1 inhibitors Zn- and Sn-protoporphyrin IX. In contrast, HO-1 overexpression did not significantly affect total reactive oxygen or nitrogen species, the levels of the nucleobase deamination products in DNA ( xanthine, inosine, and uracil) following NO exposure, or NO-induced protein nitration. While increased HO-1 activity prevented NO-induced fluctuations in transition metal homeostasis, addition of an iron chelator decreased NO toxicity only slightly. Our results indicate that lipid peroxidation is a significant cause of NO-induced necrosis in human lung epithelial cells, and that the increased NO survival of L1 cells is due at least in part to decreased lipid peroxidation mediated by HO-1-generated biliverdin or bilirubin.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA	Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT)	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.havard.edu		Dedon, Peter/0000-0003-0011-3067	NCI NIH HHS [T32 CA09078, CA82737, CA26735] Funding Source: Medline; NIEHS NIH HHS [ES002109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082737, T32CA009078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; AWASTHI YC, 2003, MOL ASPECTS MED, V24, P219; Bakan E, 2002, JPN J CLIN ONCOL, V32, P162, DOI 10.1093/jjco/hyf035; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Bishop A, 2004, BIOCHEM BIOPH RES CO, V325, P3, DOI 10.1016/j.bbrc.2004.10.010; Bishop A, 1999, FREE RADICAL BIO MED, V26, P978, DOI 10.1016/S0891-5849(98)00284-6; BLOOMER JR, 1971, J AMER MED ASSOC, V218, P216, DOI 10.1001/jama.218.2.216; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BOUTON C, 2003, SCI STKE, V182, pPE17; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Choi BM, 2003, FREE RADICAL BIO MED, V34, P1136, DOI 10.1016/S0891-5849(03)00064-9; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; DEROJASWALKER T, 1995, CHEM RES TOXICOL, V8, P473, DOI 10.1021/tx00045a020; Dong M, 2006, CHEM RES TOXICOL, V19, P50, DOI 10.1021/tx050252j; Dong M, 2003, CHEM RES TOXICOL, V16, P1044, DOI 10.1021/tx034046s; Duncan Andrew J., 2005, Molecular Aspects of Medicine, V26, P67, DOI 10.1016/j.mam.2004.09.004; El-Remessy AB, 2003, AM J PATHOL, V163, P1997, DOI 10.1016/S0002-9440(10)63558-4; Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Glaser R, 2005, J AM CHEM SOC, V127, P7346, DOI 10.1021/ja0501159; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; Hofseth LJ, 2003, FREE RADICAL BIO MED, V34, P955, DOI 10.1016/S0891-5849(02)01363-1; Jung M, 2000, J HEPATOL, V33, P387, DOI 10.1016/S0168-8278(00)80274-3; Kapitulnik J, 2004, MOL PHARMACOL, V66, P773, DOI 10.1124/mol.104.002832; Kaur H, 2003, FEBS LETT, V543, P113, DOI 10.1016/S0014-5793(03)00420-4; KIM YM, 1995, FEBS LETT, V374, P228, DOI 10.1016/0014-5793(95)01115-U; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Mancuso C, 2003, BIOCHEM PHARMACOL, V66, P2355, DOI 10.1016/j.bcp.2003.08.022; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; O'Hara KA, 2006, J CELL PHYSIOL, V209, P113, DOI 10.1002/jcp.20710; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Reiter TA, 2005, FREE RADICAL BIO MED, V39, P1075, DOI 10.1016/j.freeradbiomed.2005.05.023; Rubbo H, 2005, TOXICOLOGY, V208, P305, DOI 10.1016/j.tox.2004.11.019; Rubbo H, 2000, BIOL RES, V33, P167; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Ryter SW, 2000, METH MOL B, V99, P369; Ryter SW, 2002, ANTIOXID REDOX SIGN, V4, P625, DOI 10.1089/15230860260220120; Schopfer FJ, 2003, TRENDS BIOCHEM SCI, V28, P646, DOI 10.1016/j.tibs.2003.10.006; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Thomas DD, 2003, ANTIOXID REDOX SIGN, V5, P307, DOI 10.1089/152308603322110887; Tretyakova NY, 2000, MUTAT RES-FUND MOL M, V447, P287, DOI 10.1016/S0027-5107(99)00221-3; Ueno T, 2000, JPN J PHARMACOL, V82, P95, DOI 10.1254/jjp.82.95; van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365-2567.2001.01261.x; Yang YS, 2003, ACTA BIOCHIM POL, V50, P319; Yoshida T, 2000, J INORG BIOCHEM, V82, P33, DOI 10.1016/S0162-0134(00)00156-2	52	19	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36603	36612		10.1074/jbc.M602634200	http://dx.doi.org/10.1074/jbc.M602634200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17020887	hybrid			2022-12-25	WOS:000242220800017
J	Brauweiler, A; Lorick, KL; Lee, JP; Tsai, YC; Chan, D; Weissman, AM; Drabkin, HA; Gemmill, RM				Brauweiler, A.; Lorick, K. L.; Lee, J. P.; Tsai, Y. C.; Chan, D.; Weissman, A. M.; Drabkin, H. A.; Gemmill, R. M.			RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene	ONCOGENE			English	Article						ubiquitin ligase; SREBP; clear-cell renal carcinoma; RING-H2	RENAL-CELL CARCINOMA; ELEMENT-BINDING PROTEIN; CHOLESTEROL; EXPRESSION; GROWTH; TRANSLOCATION; ACTIVATION; MECHANISMS; COMPLEX; DOMAIN	TRC8/RNF139 and von Hippel-Lindau (VHL) both encode E3 ubiquitin (Ub) ligases mutated in clear-cell renal carcinomas (ccRCC). VHL, inactivated in nearly 70% of ccRCCs, is a tumor suppressor encoding the targeting subunit for a Ub ligase complex that down-regulates hypoxia-inducible factor-alpha. TRC8/RNF139 is a putative tumor suppressor containing a sterol-sensing domain and a RING-H2 motif essential for Ub ligase activity. Here we report that human kidney cells are growth inhibited by TRC8. Inhibition is manifested by G2/M arrest, decreased DNA synthesis and increased apoptosis and is dependent upon the Ub ligase activity of the RING domain. Tumor formation in a nude mouse model is inhibited by TRC8 in a RING-dependent manner. Expression of TRC8 represses genes involved in cholesterol and fatty acid biosynthesis that are transcriptionally regulated by the sterol response element binding proteins (SREBPs). Expression of activated SREBP-1a partially restores the growth of TRC8-inhibited cells. These data suggest that TRC8 modulation of SREBP activity comprises a novel regulatory link between growth control and the cholesterol/lipid homeostasis pathway.	Univ Colorado Denver & Hlth Sci Ctr, Div Med Oncol, Dept Med, Aurora, CO 80045 USA; Univ Colorado, Ctr Canc, Aurora, CO 80045 USA; NCI, Lab Prot Dynam & Signaling, Frederick, MD 21701 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gemmill, RM (corresponding author), Univ Colorado Denver & Hlth Sci Ctr, Div Med Oncol, Dept Med, 12801 E 17th Ave,Mail Stop 8117,POB 6511, Aurora, CO 80045 USA.	robert.gemmill@uchsc.edu		Tsai, Yien Che/0000-0001-9624-1092	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA076035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076035, Z01BC009392] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; CLAYMAN RV, 1986, CANCER RES, V46, P2958; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; GEBHARD RL, 1987, J LIPID RES, V28, P1177; Gemmill RM, 2002, ONCOGENE, V21, P3507, DOI 10.1038/sj.onc.1205437; Gemmill RM, 2005, ONCOGENE, V24, P3503, DOI 10.1038/sj.onc.1208509; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kaelin WG, 2004, CLIN CANCER RES, V10, p6290S, DOI 10.1158/1078-0432.CCR-sup-040025; Katoh S, 2003, J BIOL CHEM, V278, P15341, DOI 10.1074/jbc.M210531200; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ma DQ, 2005, CANCER RES, V65, P5523, DOI 10.1158/0008-5472.CAN-04-2582; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	28	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2263	2271		10.1038/sj.onc.1210017	http://dx.doi.org/10.1038/sj.onc.1210017			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016439	Bronze			2022-12-25	WOS:000245466000002
J	Lauer, ME; Hascall, VC; Wang, AM				Lauer, Mark E.; Hascall, Vincent C.; Wang, Aimin			Heparan sulfate analysis from diabetic rat glomeruli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE GLYCOSAMINOGLYCANS; GLUCOSAMINYL N-DEACETYLASE; INCREASED PERMEABILITY; SELECTIVE PROTEINURIA; METABOLISM; PROTEOGLYCAN; NEPHROPATHY; HEPARAN-(SO4)-S-35; INHIBITION; MELLITUS	One of the major complicating factors in insulin-dependent diabetes mellitus is nephropathy. Several investigators have linked heparan sulfate (HS) alterations in the glomerular basement membrane (GBM) with albuminuria as a marker of abnormal blood filtration and the subsequent progression to renal failure. In this study, we examined the fine structure of HS in the glomerulus and the GBM isolated from the kidneys of rats injected with streptozotocin. Using fluorophore-assisted carbohydrate electrophoresis, we obtained disaccharide composition analyses for HS. In a time course study, we observed that normal rat HS isolated from the GBM becomes more N-sulfated as the glomeruli mature over a period of 8 weeks. Diabetic rats injected with streptozotocin at the beginning of this period showed a reversal of this trend. Using a graded sieve technique, we found that two different sizes of glomeruli could be isolated from the rat kidneys and that there was a significant difference in the HS disaccharide content between these two pools of glomeruli. Only the larger sized glomeruli had less N-sulfation of HS as a result of insulin-dependent diabetes mellitus. This change in the fine structure of HS was localized to the GBM and was not associated with cell surface HS. We also generated oligosaccharides of HS that portray fine structural alterations in the diabetic rats indicative of a loss of the sulfation of N-acetylglucosamine.	Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Wang, AM (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, Lerner Res Inst, 9500 Euclid Ave,ND20, Cleveland, OH 44195 USA.	wanga@ccf.org			NIDDK NIH HHS [K01 DK02847, R01 DK62934] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062934, K01DK002847] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calabro A, 2001, OSTEOARTHR CARTILAGE, V9, pS16, DOI 10.1053/joca.2001.0439; CASTILLO GM, 1992, BIOCHIM BIOPHYS ACTA, V1136, P119, DOI 10.1016/0167-4889(92)90246-8; COHEN MP, 1981, J LAB CLIN MED, V98, P715; COHEN MP, 1988, DIABETES, V37, P1324, DOI 10.2337/diabetes.37.10.1324; COHEN MP, 1984, DIABETES, V33, P8, DOI 10.2337/diabetes.33.1.8; COHEN MP, 1979, J EXP MED, V149, P623, DOI 10.1084/jem.149.3.623; DAVIDSON JK, 2000, CLIN DIABETES MELLIT, P37; FAN MY, 1992, DIABETES METAB, V18, P98; Farquhar M. G., 1991, CELL BIOL EXTRACELLU, P365; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; KLEIN DJ, 1986, DIABETES, V35, P1130, DOI 10.2337/diabetes.35.10.1130; KLEIN DJ, 1989, DIABETES, V38, P130, DOI 10.2337/diabetes.38.1.130; KOFOEDENEVOLDSEN A, 1992, KIDNEY INT, V41, P763, DOI 10.1038/ki.1992.119; KOFOEDENEVOLDSEN A, 1993, DIABETOLOGIA, V36, P310, DOI 10.1007/BF00400233; MAUER SM, 1994, KIDNEY INT, V45, P612, DOI 10.1038/ki.1994.80; McCarthy KJ, 1997, MICROSC RES TECHNIQ, V39, P233, DOI 10.1002/(SICI)1097-0029(19971101)39:3<233::AID-JEMT4>3.0.CO;2-L; MISRA RP, 1972, AM J CLIN PATHOL, V58, P135; ODONNELL MP, 1988, FASEB J, V2, P2339, DOI 10.1096/fasebj.2.8.3282959; OSTERBY R, 1990, DIABETES, V39, P1057, DOI 10.2337/diabetes.39.9.1057; OSTERBY R, 1992, DIABETOLOGIA, V35, P803, DOI 10.1007/BF00399925; Rees DA, 2005, DIABETIC MED, V22, P359, DOI 10.1111/j.1464-5491.2005.01499.x; ROSENZWEIG LJ, 1982, LAB INVEST, V47, P177; TAMSMA JT, 1994, DIABETOLOGIA, V37, P313, DOI 10.1007/BF00398060; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VANDENBORN J, 1995, DIABETOLOGIA, V38, P161, DOI 10.1007/s001250050266; VARKI RC, 1999, ESSENTIALS GLYCOBIOL, P153; WALKER JD, 1992, KIDNEY INT, V41, P741, DOI 10.1038/ki.1992.116; Wang A, 1999, METABOLISM, V48, P1220, DOI 10.1016/S0026-0495(99)90259-7; WANG AM, 1994, J CELL PHYSIOL, V159, P295, DOI 10.1002/jcp.1041590213; WHITESIDE C, 1992, CAN J PHYSIOL PHARM, V70, P1096, DOI 10.1139/y92-152; WU VY, 1987, DIABETES, V36, P679, DOI 10.2337/diabetes.36.6.679	32	21	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					843	852		10.1074/jbc.M608823200	http://dx.doi.org/10.1074/jbc.M608823200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17038308	hybrid			2022-12-25	WOS:000243295200006
J	Schweiger, M; Schreiber, R; Haemmerle, G; Lass, A; Fledelius, C; Jacobsen, P; Tornqvist, H; Zechner, R; Zimmermann, R				Schweiger, Martina; Schreiber, Renate; Haemmerle, Guenter; Lass, Achim; Fledelius, Christian; Jacobsen, Poul; Tornqvist, Hans; Zechner, Rudolf; Zimmermann, Robert			Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANARIN-DORFMAN-SYNDROME; LIPID STORAGE DISEASE; A-MEDIATED LIPOLYSIS; PERILIPIN-A; MICE; PROTEIN; OBESITY; CGI-58; IDENTIFICATION; TRANSLOCATION	The mobilization of free fatty acids from adipose triacylglycerol (TG) stores requires the activities of triacylglycerol lipases. In this study, we demonstrate that adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) are the major enzymes contributing to TG breakdown in in vitro assays and in organ cultures of murine white adipose tissue (WAT). To differentiate between ATGL- and HSL-specific activities in cytosolic preparations of WAT and to determine the relative contribution of these TG hydrolases to the lipolytic catabolism of fat, mutant mouse models lacking ATGL or HSL and a mono-specific, small molecule inhibitor for HSL (76-0079) were used. We show that 76-0079 had no effect on TG catabolism in HSL-deficient WAT but, in contrast, essentially abolished free fatty acid mobilization in ATGL- deficient fat. CGI-58, a recently identified coactivator of ATGL, stimulates TG hydrolase activity in wild-type and HSL-deficient WAT but not in ATGL- deficient WAT, suggesting that ATGL is the sole target for CGI-58-mediated activation of adipose lipolysis. Together, ATGL and HSL are responsible for more than 95% of the TG hydrolase activity present in murine WAT. Additional known or unknown lipases appear to play only a quantitatively minor role in fat cell lipolysis.	Graz Univ, Inst Mol Biosci, A-8010 Graz, Austria; Novo Nordisk AS, Diabet Res Unit, DK-2706 Malov, Denmark; Lund Univ, Malmo Univ Hosp, Dept Clin Sci Diabet & Endocrinol, S-22100 Lund, Sweden	University of Graz; Novo Nordisk; Lund University; Skane University Hospital	Zimmermann, R (corresponding author), Graz Univ, Inst Mol Biosci, Heinrichstr 31A, A-8010 Graz, Austria.	robert.zimmermann@uni-graz.at	Lass, Achim/C-3332-2008	Lass, Achim/0000-0002-8190-7151; Schweiger, Martina/0000-0002-3419-1007; Zimmermann, Robert/0000-0002-7354-870X; Haemmerle, Guenter/0000-0001-9900-5896; Schreiber, Renate/0000-0002-3475-157X; Zechner, Rudolf/0000-0001-5483-1182	Austrian Science Fund FWF [W 901, P 18434] Funding Source: Medline; Austrian Science Fund (FWF) [W 901] Funding Source: researchfish	Austrian Science Fund FWF(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))		Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; DORFMAN ML, 1974, ARCH DERMATOL, V110, P261, DOI 10.1001/archderm.110.2.261; Gao J, 2005, J INVEST DERMATOL, V124, P1259, DOI 10.1111/j.0022-202X.2005.23761.x; Haemmerle G, 2002, J BIOL CHEM, V277, P12946, DOI 10.1074/jbc.M108640200; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Harada K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1182, DOI 10.1152/ajpendo.00259.2003; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Igal RA, 1998, J LIPID RES, V39, P31; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Kershaw EE, 2006, DIABETES, V55, P148, DOI 10.2337/diabetes.55.01.06.db05-0982; Langin D, 2005, DIABETES, V54, P3190, DOI 10.2337/diabetes.54.11.3190; Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Okazaki H, 2006, DIABETES, V55, P2091, DOI 10.2337/db05-0585; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Soni KG, 2004, J BIOL CHEM, V279, P40683, DOI 10.1074/jbc.M400541200; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Su CL, 2003, J BIOL CHEM, V278, P43615, DOI 10.1074/jbc.M301809200; Subramanian V, 2004, J BIOL CHEM, V279, P42062, DOI 10.1074/jbc.M407462200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747; Zimmermann R, 2003, J LIPID RES, V44, P2089, DOI 10.1194/jlr.M300190-JLR200	32	484	521	4	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40236	40241		10.1074/jbc.M608048200	http://dx.doi.org/10.1074/jbc.M608048200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074755	hybrid			2022-12-25	WOS:000243033900054
J	Case, CL; Concar, EM; Boswell, KL; Mukhopadhyay, B				Case, Christopher L.; Concar, Edward M.; Boswell, Kristin L.; Mukhopadhyay, Biswarup			Roles of Asp(75), Asp(78), and Glu(83) of GTP-dependent phosphoenolpyruvate carboxykinase from Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; CIRCULAR-DICHROISM SPECTRA; SECONDARY STRUCTURE; ESCHERICHIA-COLI; PURIFICATION; GENE; LOCALIZATION; MECHANISM; DECARBOXYLATION; TRANSFORMATION	The roles of Asp(75), Asp(78), and Glu(83) of the (75)DPSDVARVE(83) element of Mycobacterium smegmatis GTP-dependent phosphoenolpyruvate ( PEP) carboxykinase (GTP-PEPCK) were investigated. Asp(78) and Glu(83) are fully conserved in GTP-PEPCKs. The human PEPCK crystal structure suggests that Asp(78) influences Tyr(220); Tyr(220) helps to position bound PEP, and Glu(83) interacts with Arg(81). Experimental data on other PEPCKs indicate that Arg(81) binds PEP, and the phosphate of PEP interacts with Mn2+ of metal site 1 for catalysis. We found that D78A and E83A replacements severely reduced activity. E83A substitution raised the apparent K-m value for Mn2+ 170- fold. In contrast, Asp75 is highly but not fully conserved; natural substitutions are Ala, Asn, Gln, or Ser. Such substitutions, when engineered, in M. smegmatis enzyme caused the following. 1) For oxaloacetate synthesis, V-max decreased 1.4-4-fold. K-m values for PEP and Mn2+ increased 3-9- and 1.2-10-fold, respectively. K-m values for GDP and bicarbonate changed little. 2) For PEP formation, V-max increased 1.5-2.7-fold. K-m values for oxaloacetate increased 2-2.8-fold. The substitutions did not change the secondary structure of protein significantly. The kinetic effects are rationalized as follows. In E83A the loss of Glu(83) Arg(81) interaction affected Arg81-PEP association. D78A change altered the Tyr(220)-PEP interaction. These events perturbed PEP-Mn2+ interaction and consequently affected catalysis severely. In contrast, substitutions at Asp(75), a site far from bound PEP, brought subtle effects, lowering oxaloacetate formation rate but enhancing PEP formation rate. It is likely that Asp(75) substitutions affected PEP-Mn2+ interaction by changing the positions of Asp(78), Arg(81), and Glu(83), which translated to differential effects on two directions.	Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; University of Illinois System; University of Illinois Urbana-Champaign	Mukhopadhyay, B (corresponding author), Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Washington St 0477, Blacksburg, VA 24061 USA.	biswarup@vt.edu		Mukhopadhyay, Biswarup/0000-0003-0736-0298				ASH DE, 1990, J BIOL CHEM, V265, P7377; Barbe V, 2004, NUCLEIC ACIDS RES, V32, P5766, DOI 10.1093/nar/gkh910; BARBIERI JT, 1981, INFECT IMMUN, V31, P1071, DOI 10.1128/IAI.31.3.1071-1077.1981; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cano N, 2002, CRIT CARE, V6, P317; CHANG HC, 1966, J BIOL CHEM, V241, P2413; Cleland W W, 1979, Methods Enzymol, V63, P103; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; COOK JS, 1986, P NATL ACAD SCI USA, V83, P7583, DOI 10.1073/pnas.83.20.7583; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Dunten P, 2002, J MOL BIOL, V316, P257, DOI 10.1006/jmbi.2001.5364; Eisen JA, 2002, P NATL ACAD SCI USA, V99, P9509, DOI 10.1073/pnas.132181499; ELANO WL, 2002, PYMOL MOL GRAPHICS S; FERSHT A, 1998, STRUCTURE MECH PROTE, P180; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUNDELFINGER ED, 1987, NUCLEIC ACIDS RES, V15, P6745, DOI 10.1093/nar/15.16.6745; Gutteridge Ian F, 1999, Clin Exp Optom, V82, P102; Haldane J. B. S., 1930, ENZYMES, P80; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANSON RW, 1993, ADV ENZYMOL RAMB, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HEBDA CA, 1982, J BIOL CHEM, V257, P5503; HEBDA CA, 1982, J BIOL CHEM, V257, P5515; Hlavaty JJ, 2000, BIOCHEMISTRY-US, V39, P1373, DOI 10.1021/bi991692a; Holyoak T, 2006, BIOCHEMISTRY-US, V45, P8254, DOI 10.1021/bi060269g; Jackson LK, 2004, BIOCHEMISTRY-US, V43, P12990, DOI 10.1021/bi048933l; JOMAINBAUM M, 1978, J BIOL CHEM, V253, P3648; Kawashima T, 2000, P NATL ACAD SCI USA, V97, P14257, DOI 10.1073/pnas.97.26.14257; Kim D, 2004, BIOCHEMISTRY-US, V43, P981, DOI 10.1021/bi035593f; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1981, J BIOL CHEM, V256, P2793; LEE MH, 1985, BIOCHEMISTRY-US, V24, P7594, DOI 10.1021/bi00347a014; Matte A, 1997, J BIOL CHEM, V272, P8105, DOI 10.1074/jbc.272.13.8105; MEYUHAS O, 1971, BIOCHIM BIOPHYS ACTA, V250, P224, DOI 10.1016/0005-2744(71)90138-0; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Modaressi S, 1998, BIOCHEM J, V333, P359, DOI 10.1042/bj3330359; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Mukhopadhyay B, 2001, J BIOL CHEM, V276, P16137, DOI 10.1074/jbc.M008960200; Nishio Y, 2003, GENOME RES, V13, P1572, DOI 10.1101/gr.1285603; NOCE PS, 1975, J BIOL CHEM, V250, P9099; Ravanal MC, 2004, BIOCHIMIE, V86, P357, DOI 10.1016/j.biochi.2004.06.001; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; Riedel C, 2001, J MOL MICROB BIOTECH, V3, P573; Rod TH, 2003, P NATL ACAD SCI USA, V100, P6980, DOI 10.1073/pnas.1230801100; ROHRER SP, 1986, J BIOL CHEM, V261, P3049; Sambrook J., MOL CLONING LAB MANU; Schocke L, 1997, ARCH MICROBIOL, V167, P289, DOI 10.1007/s002030050446; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STOFFEL M, 1993, HUM MOL GENET, V2, P1, DOI 10.1093/hmg/2.1.1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TING CN, 1993, GENOMICS, V16, P698, DOI 10.1006/geno.1993.1250; UTTER MF, 1954, J BIOL CHEM, V207, P803; WELDON SL, 1990, J BIOL CHEM, V265, P7308; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371	57	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39262	39272		10.1074/jbc.M602591200	http://dx.doi.org/10.1074/jbc.M602591200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17015450	hybrid			2022-12-25	WOS:000242898700033
J	Chen, LG; Durkin, KA; Casida, JE				Chen, Ligong; Durkin, Kathleen A.; Casida, John E.			Spontaneous mobility of GABA(A) receptor M2 extracellular half relative to noncompetitive antagonist action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; MEMBRANE-SPANNING SEGMENT; BINDING-SITE CREVICE; DOPAMINE D2 RECEPTOR; CHANNEL-LINING SEGMENTS; GATED CHLORIDE CHANNEL; ACETYLCHOLINE-RECEPTOR; PROTEIN MOBILITY; ION-CHANNEL; SUBUNIT	The gamma-aminobutyric acid type A receptor beta(3) homopentamer is spontaneously open and highly sensitive to many noncompetitive antagonists(NCAs) and Zn2+. OurearlierstudyoftheM2cytoplasmic half (-1' to 10') established a model in which NCAs bind at pore-lining residues Ala(2)', Thr(6)', and Leu(9)'. To further define transmembrane 2 (M2) structure relative to NCA action, we extended the Cys scanning to the extra cellular half of the beta 3 homopentamer (11' to 20'). Spontaneous disulfides formed with T13'C, L18'C, and E20'C from M2/M2 cross-linking and with I14'C (weak), H17'C, and R19'C on bridging M2/M3 intersubunits, based on single (M2 Cys only) and dual (M2 Cys plus M3 C289S) mutations. Induced disulfides also formed with T16'C, but there were few or none with M11'C, T12'C, and N15'C. These findings show conformational flexibility/ mobility in the M2 extracellular half 17' to 20' region interpreted as a deformed beta-like conformation in the open channel. The NCA radioligands used were [H-3]1-(4-ethynylphenyl)-4- n-propyl-2,6,7-trioxabicyclo[2.2.2] octane ([H-3]EBOB) and [H-3] 3,3-bis-trifluoromethylbicyclo[2.2.1] heptane-2,2-di-carbonitrile with essentially the same results. NCA binding was disrupted by individual Cys substitutions at 13', 14', 16', 17', and 19'. The inactivity of T13'C/T13'S may have been due to disturbance of the channel gate; I14'S and T16'S showed much better binding activity than their Cys counterparts, and the low activities of H17'C and R19'C were reversed by dithiothreitol. Zn2+ potency for inhibition of [H-3] EBOB binding was lowered 346-fold by the mutation H17'A. We propose that NCAs enter their binding site both directly, through the channel pore, and indirectly, through the water cavity of adjacent subunits.	Univ Calif Berkeley, Environm Chem & Toxicol Lab, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; Univ Calif Berkeley, Coll Chem, Mol Graph Facil, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Casida, JE (corresponding author), Univ Calif Berkeley, Environm Chem & Toxicol Lab, Dept Environm Sci Policy & Management, 114 Wellman Hall, Berkeley, CA 94720 USA.	ectl@nature.berkeley.edu	Chen, Ligong/AAE-8536-2020; Chen, Ligong/F-7492-2016	Chen, Ligong/0000-0002-7893-7173; Durkin, Kathleen/0000-0003-1282-6101	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008419] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 08419] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Absalom NL, 2004, EXP PHYSIOL, V89, P145, DOI 10.1113/expphysiol.2003.026815; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Bera AK, 2005, J BIOL CHEM, V280, P35506, DOI 10.1074/jbc.M504645200; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CASIDA JE, 1993, ARCH INSECT BIOCHEM, V22, P13, DOI 10.1002/arch.940220104; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Chen LG, 2006, P NATL ACAD SCI USA, V103, P5185, DOI 10.1073/pnas.0600370103; COLE LM, 1992, PESTIC BIOCHEM PHYS, V44, P1, DOI 10.1016/0048-3575(92)90002-H; Cymes GD, 2002, BIOCHEMISTRY-US, V41, P5548, DOI 10.1021/bi011864f; Dalziel JE, 1999, EUR J PHARMACOL, V370, P345, DOI 10.1016/S0014-2999(99)00138-7; England PM, 1999, CELL, V96, P89, DOI 10.1016/S0092-8674(00)80962-9; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; Gingrich KJ, 1998, J PHYSIOL-LONDON, V506, P609, DOI 10.1111/j.1469-7793.1998.609bv.x; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; HAWKINSON JE, 1992, MOL PHARMACOL, V42, P1069; Hemmings HC, 2005, TRENDS PHARMACOL SCI, V26, P503, DOI 10.1016/j.tips.2005.08.006; Horenstein J, 2005, J BIOL CHEM, V280, P1573, DOI 10.1074/jbc.M410881200; Horenstein J, 1998, MOL PHARMACOL, V53, P870; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; Jansen M, 2006, J NEUROSCI, V26, P4492, DOI 10.1523/JNEUROSCI.0224-06.2006; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; Jensen ML, 2002, J BIOL CHEM, V277, P41438, DOI 10.1074/jbc.M205645200; Jung SW, 2005, J BIOL CHEM, V280, P308, DOI 10.1074/jbc.M409871200; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; O'Mara M, 2005, BIOPHYS J, V88, P3286, DOI 10.1529/biophysj.104.051664; Olsen RW, 2004, BIOCHEM PHARMACOL, V68, P1675, DOI 10.1016/j.bcp.2004.07.026; Panicker S, 2004, J BIOL CHEM, V279, P28149, DOI 10.1074/jbc.M403545200; Perret P, 1999, J BIOL CHEM, V274, P25350, DOI 10.1074/jbc.274.36.25350; Ratra GS, 2001, TOXICOL APPL PHARM, V172, P233, DOI 10.1006/taap.2001.9154; Rauh JJ, 1997, BRIT J PHARMACOL, V121, P1496, DOI 10.1038/sj.bjp.0701215; Riby JE, 2006, MOL PHARMACOL, V69, P430, DOI 10.1124/mol.105.017053; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x; Wooltorton JRA, 1997, J PHYSIOL-LONDON, V505, P633, DOI 10.1111/j.1469-7793.1997.633ba.x; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643	43	14	15	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38871	38878		10.1074/jbc.M608301200	http://dx.doi.org/10.1074/jbc.M608301200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050528	hybrid			2022-12-25	WOS:000242709500085
J	Huang, YM; Feng, XR; Sando, JJ; Zuo, ZY				Huang, Yueming; Feng, Xiaorong; Sando, Julianne J.; Zuo, Zhiyi			Critical role of serine 465 in isoflurane-induced increase of cell-surface redistribution and activity of glutamate transporter type 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-BRAIN; REENTRANT LOOP; SEROTONIN TRANSPORTERS; VOLATILE ANESTHETICS; SYNAPTIC PLASTICITY; INHALED ANESTHETICS; EXPRESSION; SUBSTRATE; GLT-1	Glutamate transporters (also called excitatory amino acid transporters, EAATs) bind extracellular glutamate and transport it to intracellular space to regulate glutamate neurotransmission and to maintain extracellular glutamate concentrations below neurotoxic levels. We previously showed that isoflurane, a commonly used anesthetic, enhanced the activity of EAAT3, a major neuronal EAAT. This effect required a protein kinase C (PKC) alpha-dependent EAAT3 redistribution to the plasma membrane. In this study, we prepared COS7 cells stably expressing EAAT3 with or without mutations of potential PKC phosphorylation sites in the putative intracellular domains. Here we report that mutation of threonine 5 or threonine 498 to alanine did not affect the isoflurane effects on EAAT3. However, the mutation of serine 465 to alanine abolished isoflurane-induced increase of EAAT3 activity and redistribution to the plasma membrane. The mutation of serine 465 to aspartic acid increased the expression of EAAT3 in the plasma membrane and also abolished the isoflurane effects on EAAT3. These results suggest an essential role of serine 465 in the isoflurane-increased EAAT3 activity and redistribution and a direct effect of PKC on EAAT3. Consistent with these results, isoflurane induced an increase in phosphorylation of wild type, T5A, and T498A EAAT3, and this increase was absent in S465A and S465D. Our current results, together with our previous data that showed the involvement of PKC alpha in the isoflurane effects on EAAT3, suggest that the phosphorylation of serine 465 in EAAT3 by PKC alpha mediates the increased EAAT3 activity and redistribution to plasma membrane after isoflurane exposure.	Univ Virginia, Hlth Syst, Dept Anesthesiol, Charlottesville, VA 22908 USA	University of Virginia	Zuo, ZY (corresponding author), Univ Virginia, Hlth Syst, Dept Anesthesiol, POB 800710,1 Hosp Dr, Charlottesville, VA 22908 USA.	zz3c@virginia.edu	feng, xiaorong/G-4811-2010; Zuo, Zhiyi/F-3950-2010	feng, xiaorong/0000-0001-8410-3020; Zuo, Zhiyi/0000-0002-3542-5047	NIGMS NIH HHS [R01 GM 065211] Funding Source: Medline; NINDS NIH HHS [R01 NS 45983] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Billups B, 1998, PROG BRAIN RES, V116, P45, DOI 10.1016/S0079-6123(08)60429-X; Borre L, 2004, J BIOL CHEM, V279, P2513, DOI 10.1074/jbc.M311446200; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Cechova S, 2006, BRIT J ANAESTH, V97, P192, DOI 10.1093/bja/ael152; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Danbolt NC, 1998, PROG BRAIN RES, V116, P23, DOI 10.1016/S0079-6123(08)60428-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Deken SL, 2003, J NEUROSCI, V23, P1563; Do SH, 2002, ANESTHESIOLOGY, V96, P1492, DOI 10.1097/00000542-200206000-00032; Fang HY, 2006, AM J PHYSIOL-CELL PH, V290, pC1334, DOI 10.1152/ajpcell.00443.2005; Fang HY, 2002, BRAIN RES, V953, P255, DOI 10.1016/S0006-8993(02)03299-7; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Hodge CW, 1999, NAT NEUROSCI, V2, P997, DOI 10.1038/14795; Horton N, 2001, MOL MEMBR BIOL, V18, P39; Huang YM, 2005, MOL PHARMACOL, V67, P1522, DOI 10.1124/mol.104.007443; Huang YM, 2003, ANESTHESIOLOGY, V99, P1346, DOI 10.1097/00000542-200312000-00016; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANAI Y, 1996, EXCITATORY AMINO ACI, P102; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; Levenson J, 2002, NAT NEUROSCI, V5, P155, DOI 10.1038/nn791; Lin CLG, 1998, MOL BRAIN RES, V63, P174, DOI 10.1016/S0169-328X(98)00256-3; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Paillart C, 2003, J NEUROSCI, V23, P4092; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Sheldon AL, 2006, J BIOL CHEM, V281, P4876, DOI 10.1074/jbc.M504983200; Simon W, 2001, ANESTHESIOLOGY, V94, P1058, DOI 10.1097/00000542-200106000-00021; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Sonner JM, 2003, ANESTH ANALG, V97, P718, DOI 10.1213/01.ANE.0000081063.76651.33; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751; Zuo ZY, 1997, MOL PHARMACOL, V52, P606, DOI 10.1124/mol.52.4.606; Zuo ZY, 2001, NEUROREPORT, V12, P1077, DOI 10.1097/00001756-200104170-00042	50	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38133	38138		10.1074/jbc.M603885200	http://dx.doi.org/10.1074/jbc.M603885200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17062570	hybrid			2022-12-25	WOS:000242709500005
J	Anthony, RG; Khan, S; Costa, J; Pais, MS; Bogre, L				Anthony, Richard G.; Khan, Safina; Costa, Joana; Pais, Maria S.; Bogre, Laszlo			The Arabidopsis protein kinase PTI1-2 is activated by convergent phosphatidic acid and oxidative stress signaling pathways downstream of PDK1 and OXI1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D; CELL-DEATH; DISEASE-RESISTANCE; SUSPENSION-CULTURES; PLANT-CELLS; THALIANA; TOMATO; EXPRESSION; RESPONSES; PHOSPHORYLATION	Arabidopsis PDK1 activity is regulated by binding to the lipid phosphatidic acid (PA) resulting in activation of the oxidative stress-response protein kinase OXI1/AGC2-1. Thus there is an inferred link between lipid signaling and oxidative stress signaling modules. Among a panel of hormones and stresses tested, we found that, in addition to PA, the fungal elicitor xylanase activated PDK1, suggesting that PDK1 has a role in plant pathogen defense mechanisms. The downstream OXI1 was activated by additional stress factors, including PA, H2O2, and partially by xylanase. We have isolated an interacting partner of OXI1, a Ser/Thr kinase (PTI1-2), which is downstream of OXI1. Its sequence closely resembles the tomato Pti kinase, which has been implicated in the hypersensitive response, a localized programmed cell death that occurs at the site of pathogen infection. PTI1-2 is activated by the same stresses/elicitors as OXI1 and additionally flagellin. We have used RNA interference to knock out the expression of PDK1 and OXI1 and to study the effects on PTI1-2 activity. We show that specific lipid signaling pathways converge on PTI1-2 via the PDK1-OXI1 axis, whereas H2O2 and flagellin signals to OXI1-PTI1-2 via a PDK1-independent pathway. PTI1-2 represents a new downstream component that integrates diverse lipid and reactive oxygen stress signals and functions closely with OXI1.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Univ Leeds, Sch Biol, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Lisbon, Fac Ciencias, Inst Ciencia Aplicada & Tecnol, Lab Plant Biotechnol, P-1749016 Lisbon, Portugal	University of London; Royal Holloway University London; University of Leeds; Universidade de Lisboa	Anthony, RG (corresponding author), Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham Hill, Egham TW20 0EX, Surrey, England.	r.g.anthony@rhul.ac.uk		Pais, Maria Salome/0000-0002-3068-5851; Costa, Joana/0000-0001-7046-2284	Biotechnology and Biological Sciences Research Council [C18199] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allwood EG, 2002, PLANT CELL, V14, P2915, DOI 10.1105/tpc.005363; Anthony RG, 2004, EMBO J, V23, P572, DOI 10.1038/sj.emboj.7600068; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; Davies DR, 2006, J EXP BOT, V57, P1817, DOI 10.1093/jxb/erj216; de Jong CF, 2004, PLANT J, V39, P1, DOI 10.1111/j.1365-313X.2004.02110.x; Desikan R, 1998, BIOCHEM J, V330, P115, DOI 10.1042/bj3300115; Devarenne TP, 2006, EMBO J, V25, P255, DOI 10.1038/sj.emboj.7600910; DEZABELAQQ T, 2002, MOL PLANT MICROBE IN, V15, P808; Dhonukshe P, 2003, PLANT CELL, V15, P2666, DOI 10.1105/tpc.014977; Fujita M, 2006, CURR OPIN PLANT BIOL, V9, P436, DOI 10.1016/j.pbi.2006.05.014; Gardiner J, 2003, PLANT CELL PHYSIOL, V44, P687, DOI 10.1093/pcp/pcg095; Gardiner JC, 2001, PLANT CELL, V13, P2143, DOI 10.1105/tpc.13.9.2143; Ishitani M, 1997, PLANT CELL, V9, P1935, DOI 10.1105/tpc.9.11.1935; Karimi M, 2005, TRENDS PLANT SCI, V10, P103, DOI 10.1016/j.tplants.2005.01.008; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Laxalt AM, 2001, PLANT J, V26, P237, DOI 10.1046/j.1365-313X.2001.01023.x; LOH YT, 1995, P NATL ACAD SCI USA, V92, P4181, DOI 10.1073/pnas.92.10.4181; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MELIN PM, 1992, BIOCHIM BIOPHYS ACTA, V1123, P163, DOI 10.1016/0005-2760(92)90107-7; Menke FLH, 2004, PLANT CELL, V16, P897, DOI 10.1105/tpc.015552; Meskiene I, 2003, J BIOL CHEM, V278, P18945, DOI 10.1074/jbc.M300878200; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; Munnik T, 1999, PLANT J, V20, P381, DOI 10.1046/j.1365-313x.1999.00610.x; Nakagami H, 2005, TRENDS PLANT SCI, V10, P339, DOI 10.1016/j.tplants.2005.05.009; Nemeth K, 1998, GENE DEV, V12, P3059, DOI 10.1101/gad.12.19.3059; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; Regier DS, 1999, J BIOL CHEM, V274, P36601, DOI 10.1074/jbc.274.51.36601; Rentel MC, 2004, NATURE, V427, P858, DOI 10.1038/nature02353; Sang YM, 2001, PLANT PHYSIOL, V126, P1449, DOI 10.1104/pp.126.4.1449; Schneider S, 1996, BIOTECHNIQUES, V20, P960; TAKAHASHI T, 1989, MOL GEN GENET, V219, P365, DOI 10.1007/BF00259608; Testerink C, 2004, PLANT J, V39, P527, DOI 10.1111/j.1365-313X.2004.02152.x; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; Torres MA, 2005, NAT GENET, V37, P1130, DOI 10.1038/ng1639; van der Luit AH, 2000, PLANT PHYSIOL, V123, P1507, DOI 10.1104/pp.123.4.1507; Wang XM, 2006, PROG LIPID RES, V45, P250, DOI 10.1016/j.plipres.2006.01.005; Yamaguchi T, 2005, PLANT CELL PHYSIOL, V46, P579, DOI 10.1093/pcp/pci065; Yoshioka H, 2003, PLANT CELL, V15, P706, DOI 10.1105/tpc.008680; Zegzouti H, 2006, P NATL ACAD SCI USA, V103, P6404, DOI 10.1073/pnas.0510283103; Zhang WH, 2003, PLANT CELL, V15, P2285, DOI 10.1105/tpc.013961; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	45	87	96	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37536	37546		10.1074/jbc.M607341200	http://dx.doi.org/10.1074/jbc.M607341200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17040918	hybrid			2022-12-25	WOS:000242477100030
J	Mukai, S; Fujiki, Y				Mukai, Satoru; Fujiki, Yukio			Molecular mechanisms of import of peroxisome-targeting signal type 2 (PTS2) proteins by PTS2 receptor pex7p and PTS1 receptor Pex5pL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOMELIC CHONDRODYSPLASIA PUNCTATA; OVARY CELL MUTANTS; 3-KETOACYL-COA THIOLASE; FUNCTIONAL COMPLEMENTATION; MUTATION ANALYSIS; LONGER ISOFORM; AMINO-TERMINUS; CDNA CLONING; LOCALIZATION; BIOGENESIS	In the present study, we investigated molecular mechanisms underlying the import of peroxisome-targeting signal type 2 (PTS2) proteins into peroxisomes. Purified Chinese hamster Pex7p that had been expressed in an Sf9/baculovirus system was biologically active in several assays such as those for PTS2 binding and assessing the restoration of the impaired PTS2 protein import in Chinese hamster ovary (CHO) pex7 mutant ZPG207. Pex7p was eluted as a monomer in gel filtration chromatography. Moreover, the mutation of the highly conserved cysteine residue suggested to be involved in the dimer formation did not affect the complementing activity in ZPG207 cells. Together, Pex7p more likely functions as a monomer. Together with PTS1 protein, the Pex7p-PTS2 protein complex was bound to Pex5pL, the longer form of Pex5p, which was prerequisite for the translocation of Pex7p-PTS2 protein complexes. Pex5pL-(Pex7p-PTS2 protein) complexes were detectable in wild-type CHO-K1 cells and were apparently more stable in pex14 CHO cells deficient in the entry site of the matrix proteins, whereas only the Pex7p-PTS2 protein complex was discernible in a Pex5pL- defective pex5 CHO mutant. Pex7p-PTS2 proteins bound to Pex14p via Pex5pL. In contrast, PTS2 protein-bound Pex7p as well as Pex7p directly and equally interacted with Pex13p, implying that the PTS2 cargo may be released at Pex13p. Furthermore, we detected the Pex13p complexes likewise formed with Pex5pL- bound Pex7p-PTS2 proteins. Thus, the Pex7p-mediated PTS2 protein import shares most of the steps with the Pex5p-dependent PTS1 import machinery but is likely distinct at the cargo-releasing stage.	Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci, Dept Biol,Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	yfujiscb@mbox.nc.kyushu-u.ac.jp						Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; Braverman N, 2002, HUM MUTAT, V20, P284, DOI 10.1002/humu.10124; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; FUJIKI Y, 2006, IN PRESS BIOCH BIOPH; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; Ghys K, 2002, BIOCHEM J, V365, P41, DOI 10.1042/BJ20011432; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; Itoh R, 2006, J BIOL CHEM, V281, P10196, DOI 10.1074/jbc.M600158200; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Leon S, 2006, J CELL BIOL, V172, P67, DOI 10.1083/jcb.200508096; Matsumoto N, 2003, NAT CELL BIOL, V5, P454, DOI 10.1038/ncb982; Matsumura T, 2000, J BIOL CHEM, V275, P21715, DOI 10.1074/jbc.M000721200; MIURA S, 1992, J BIOL CHEM, V267, P14405; Miyata N, 2005, MOL CELL BIOL, V25, P10822, DOI 10.1128/MCB.25.24.10822-10832.2005; Motley AM, 1997, NAT GENET, V15, P377, DOI 10.1038/ng0497-377; Mukai S, 2002, J BIOL CHEM, V277, P9548, DOI 10.1074/jbc.M108635200; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 1997, NAT GENET, V15, P381, DOI 10.1038/ng0497-381; Purdue PE, 1998, J CELL BIOL, V143, P1859; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Siegers K, 2003, EMBO J, V22, P5230, DOI 10.1093/emboj/cdg483; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; Stein K, 2002, MOL CELL BIOL, V22, P6056, DOI 10.1128/MCB.22.17.6056-6069.2002; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	37	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37311	37320		10.1074/jbc.M607178200	http://dx.doi.org/10.1074/jbc.M607178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17040904	hybrid			2022-12-25	WOS:000242477100008
J	Yang, W; Carman, CV; Kim, M; Salas, A; Shimaoka, M; Springer, TA				Yang, Wei; Carman, Christopher V.; Kim, Minsoo; Salas, Azucena; Shimaoka, Motomu; Springer, Timothy A.			A small molecule agonist of an integrin, alpha(L)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-LIKE DOMAIN; ADHESION MOLECULE-1; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CELL-MIGRATION; HIGH-AFFINITY; BINDING-SITE; SUBUNIT; ANTAGONISTS; INHIBITION	The binding of integrin alpha(L)beta(2) to its ligand intercellular adhesion molecule-1 is required for immune responses and leukocyte trafficking. Small molecule antagonists of alpha(L)beta(2) are under intense investigation as potential anti-inflammatory drugs. We describe for the first time a small molecule integrin agonist. A previously described alpha/beta I allosteric inhibitor, compound 4, functions as an agonist of alpha(L)beta(2) in Ca2+ and Mg2+ and as an antagonist in Mn2+. We have characterized the mechanism of activation and its competitive and noncompetitive inhibition by different compounds. Although it stimulates ligand binding, compound 4 nonetheless inhibits lymphocyte transendothelial migration. Agonism by compound 4 results in accumulation of alpha(L)beta(2) in the uropod, extreme uropod elongation, and defective de-adhesion. Small molecule integrin agonists open up novel therapeutic possibilities.	Harvard Univ, Sch Med, CRB Inst Biomed Res, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, CRB Inst Biomed Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, CRB Inst Biomed Res, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu	Carman, Christopher V./AAX-8995-2020; Salas, Azucena/AAN-7035-2020; Yang, Wei/U-6557-2017; Carman, Christopher/L-8108-2016	Carman, Christopher V./0000-0001-7358-2548; Carman, Christopher/0000-0001-7358-2548; Salas, Azucena/0000-0003-4572-2907; Yang, Wei/0000-0002-7634-6601	NCI NIH HHS [R01 CA031798, R37 CA031798, CA31798] Funding Source: Medline; NIAID NIH HHS [R01 AI063421, AI63421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; ANDERSON DC, 1989, METABOLIC BASIS INHE, P2751; BURDICK DJ, 1999, Patent No. 9949856; BURDICK DJ, 2001, Patent No. 02059114; Carman CV, 2004, J CELL BIOL, V167, P377, DOI 10.1083/jcb.200404129; Cather JC, 2003, EXPERT OPIN BIOL TH, V3, P361, DOI 10.1517/14712598.3.2.361; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; FOTOUHI N, 1999, Patent No. 0021920; Gadek TR, 2002, SCIENCE, V295, P1086, DOI 10.1126/science.295.5557.1086; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Giblin PA, 2001, ANNU REP MED CHEM, V36, P181, DOI 10.1016/S0065-7743(01)36058-X; Gottlieb A, 2000, J AM ACAD DERMATOL, V42, P428, DOI 10.1016/S0190-9622(00)90214-7; Gottlieb AB, 2002, CLIN IMMUNOL, V105, P105, DOI 10.1006/clim.2002.5289; Gottlieb AB, 2002, ARCH DERMATOL, V138, P591, DOI 10.1001/archderm.138.5.591; HARLAN JM, 1992, ADHESION ITS ROLE IN, P117; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Keating SM, 2006, PROTEIN SCI, V15, P290, DOI 10.1110/ps.051583406; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; Last-Barney K, 2001, J AM CHEM SOC, V123, P5643, DOI 10.1021/ja0104249; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Liu G, 2001, J MED CHEM, V44, P1202, DOI 10.1021/jm000503f; Lu CF, 2004, J IMMUNOL, V173, P3972, DOI 10.4049/jimmunol.173.6.3972; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Semmrich M, 2005, J EXP MED, V201, P1987, DOI 10.1084/jem.20041850; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; Smith A, 2003, J CELL SCI, V116, P3123, DOI 10.1242/jcs.00606; Song G, 2005, P NATL ACAD SCI USA, V102, P3366, DOI 10.1073/pnas.0500200102; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1986, CIBA F SYMP, V118, P102, DOI 10.1002/9780470720998.ch8; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Weber C, 1997, J IMMUNOL, V159, P3968; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Welzenbach K, 2002, J BIOL CHEM, V277, P10590, DOI 10.1074/jbc.M110521200; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101; Yang W, 2004, P NATL ACAD SCI USA, V101, P2333, DOI 10.1073/pnas.0307291101; Yusuf-Makagiansar H, 2002, MED RES REV, V22, P146, DOI 10.1002/med.10001	54	28	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37904	37912		10.1074/jbc.M606888200	http://dx.doi.org/10.1074/jbc.M606888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17023419	Green Accepted, hybrid			2022-12-25	WOS:000242477100069
J	Cyr, M; Sotnikova, TD; Gainetdinov, RR; Caron, MG				Cyr, Michel; Sotnikova, Tatyana D.; Gainetdinov, Raul R.; Caron, Marc G.			Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin	FASEB JOURNAL			English	Article						polyglutamine disease; basal ganglia; chorea; hyperkinetic disorders; Huntington's disease; medium spiny neurons	NEURONAL INTRANUCLEAR INCLUSIONS; HD TRANSGENIC MICE; STRIATAL NEURONS; MOUSE MODEL; BEHAVIORAL ABNORMALITIES; TETRABENAZINE TREATMENT; DIFFERENTIAL REGULATION; MORPHOLOGICAL-CHANGES; FUNCTIONAL-ANATOMY; MUTANT HUNTINGTIN	An expansion in the CAG repeat of the IT15 ( huntingtin) gene underlies the development of Huntington's disease (HD), but the basis for the specific vulnerability of dopamine-receptive striatal neurons remains unclear. To examine the potential role of the dopamine system in the emergence of pathological conditions in HD, we generated a double mutant mouse strain with both enhanced dopamine transmission and endogenous expression of a mutant huntingtin gene. This strain was generated by crossing the dopamine transporter knock-out mouse, which exhibits a 5-fold elevation in extracellular dopamine levels in the striatum and locomotor hyperactivity, to a knock-in mouse model of HD containing 92 CAG repeats. These double mutant mice exhibited an increased stereotypic activity at 6 months of age, followed by a progressive decline of their locomotor hyperactivity. Expression of the mutated huntingtin did not alter dopamine or its metabolite levels in normal or dopamine transporter knock-out mice. However, the mutant huntingtin protein aggregated much earlier and to a greater extent in the striatum and other dopaminergic brain regions in the hyperdopaminergic mouse model of HD. Furthermore, the formation of neuropil aggregates in the striatum and other regions of hyperdopaminergic HD mice was observed at 4 months of age, well before similar events occurred in normal HD mice ( 12 months). These findings indicate that dopamine contributes to the deleterious effects of mutated huntingtin on striatal function, and this is accompanied by enhanced formation of huntingtin aggregates.-Cyr, M., Sotnikova, T. D., Gainetdinov, R. R., Caron, M. G. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.	Duke Univ, Ctr Models Human Dis, Dept Cell Biol, IGSP, Durham, NC 27710 USA; Univ Quebec Trois Rivieres, Neurosci Res Grp, Trois Rivieres, PQ GA9 5H7, Canada	Duke University; University of Quebec; University of Quebec Trois Rivieres	Caron, MG (corresponding author), Duke Univ, Ctr Models Human Dis, Dept Cell Biol, IGSP, Box 3287, Durham, NC 27710 USA.	cyrmi@uqtr.ca	Sotnikova, Tatyana D/T-9992-2017; Gainetdinov, Raul R/G-5875-2011	Gainetdinov, Raul R/0000-0003-2951-6038	NINDS NIH HHS [NS19576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALBIN RL, 1990, ANN NEUROL, V27, P357, DOI 10.1002/ana.410270403; Andrews TC, 1999, BRAIN, V122, P2353, DOI 10.1093/brain/122.12.2353; Antonini A, 1996, BRAIN, V119, P2085, DOI 10.1093/brain/119.6.2085; Ariano MA, 2002, J NEUROSCI RES, V68, P716, DOI 10.1002/jnr.10272; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Beaulieu JM, 2004, P NATL ACAD SCI USA, V101, P5099, DOI 10.1073/pnas.0307921101; Cepeda C, 2001, J NEUROSCI RES, V66, P525, DOI 10.1002/jnr.1244; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Charvin D, 2005, P NATL ACAD SCI USA, V102, P12218, DOI 10.1073/pnas.0502698102; Cyr M, 2005, NEUROIMAGE, V26, P83, DOI 10.1016/j.neuroimage.2005.01.039; Cyr M, 2003, P NATL ACAD SCI USA, V100, P11035, DOI 10.1073/pnas.1831768100; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Fauchey V, 2000, EUR J NEUROSCI, V12, P19, DOI 10.1046/j.1460-9568.2000.00876.x; FEIGIN A, 1995, MOVEMENT DISORD, V10, P211, DOI 10.1002/mds.870100213; Fernagut PO, 2003, NEUROSCIENCE, V116, P1123, DOI 10.1016/S0306-4522(02)00778-9; Fernagut PO, 2002, EUR J NEUROSCI, V15, P2053, DOI 10.1046/j.1460-9568.2002.02047.x; FERRANTE RJ, 1987, BRAIN RES, V411, P162, DOI 10.1016/0006-8993(87)90694-9; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; Folstein S.E., 1989, HUNTINGTONS DIS DISO; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.neuro.15.1.285; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Harper PS, 1991, HUNTINGTONS DIS; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; Hersch SM, 2003, CURR OPIN NEUROL, V16, P501, DOI 10.1097/01.wco.0000084229.82329.03; Higgins Donald S Jr, 2006, Curr Treat Options Neurol, V8, P236, DOI 10.1007/s11940-006-0014-x; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Jaber M, 1999, EUR J NEUROSCI, V11, P3499, DOI 10.1046/j.1460-9568.1999.00764.x; Jakel RJ, 2000, TRENDS NEUROSCI, V23, P239, DOI 10.1016/S0166-2236(00)01568-X; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Kennedy L, 2005, BRAIN RES, V1039, P14, DOI 10.1016/j.brainres.2005.01.029; Kenney Christopher, 2006, Expert Rev Neurother, V6, P7, DOI 10.1586/14737175.6.1.7; Klapstein GJ, 2001, J NEUROPHYSIOL, V86, P2667, DOI 10.1152/jn.2001.86.6.2667; KLAWANS HC, 1970, LANCET, V2, P1185; Laforet GA, 2001, J NEUROSCI, V21, P9112, DOI 10.1523/JNEUROSCI.21-23-09112.2001; Levine MS, 1999, J NEUROSCI RES, V58, P515, DOI 10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F; Levine MS, 2004, TRENDS NEUROSCI, V27, P691, DOI 10.1016/j.tins.2004.08.008; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Lindvall O, 1978, Adv Biochem Psychopharmacol, V19, P1; Luesse HG, 2001, BEHAV BRAIN RES, V126, P185, DOI 10.1016/S0166-4328(01)00261-3; Luo SQ, 2005, J CELL BIOL, V169, P647, DOI 10.1083/jcb.200412071; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Marshall FJ, 2006, NEUROLOGY, V66, P366, DOI 10.1212/01.wnl.0000198586.85250.13; MCCORMACK MK, 1982, NEW ENGL J MED, V307, P1406; Menalled LB, 2003, J COMP NEUROL, V465, P11, DOI 10.1002/cne.10776; Menalled LB, 2002, J NEUROSCI, V22, P8266; MYERS RH, 1991, ARCH NEUROL-CHICAGO, V48, P800, DOI 10.1001/archneur.1991.00530200036015; Ondo WG, 2002, CLIN NEUROPHARMACOL, V25, P300, DOI 10.1097/00002826-200211000-00003; Paleacu D, 2004, CLIN NEUROPHARMACOL, V27, P230, DOI 10.1097/01.wnf.0000136892.24629.96; Paulsen JS, 2001, J NEUROL NEUROSUR PS, V71, P310, DOI 10.1136/jnnp.71.3.310; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; RICHFIELD EK, 1995, ANN NEUROL, V37, P335, DOI 10.1002/ana.410370309; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; SAPP E, 1995, NEUROSCIENCE, V64, P397, DOI 10.1016/0306-4522(94)00427-7; Slow EJ, 2005, P NATL ACAD SCI USA, V102, P11402, DOI 10.1073/pnas.0503634102; Slow EJ, 2003, HUM MOL GENET, V12, P1555, DOI 10.1093/hmg/ddg169; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Sotnikova TD, 2005, PLOS BIOL, V3, P1488, DOI 10.1371/journal.pbio.0030271; Spektor BS, 2002, MOL BRAIN RES, V102, P118, DOI 10.1016/S0169-328X(02)00216-4; Stevanin G, 1996, HUM MOL GENET, V5, P1887, DOI 10.1093/hmg/5.12.1887; Tallaksen-Greene SJ, 2005, NEUROSCIENCE, V131, P843, DOI 10.1016/j.neuroscience.2004.10.037; Tang TS, 2005, P NATL ACAD SCI USA, V102, P2602, DOI 10.1073/pnas.0409402102; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P1; von Horsten S, 2003, HUM MOL GENET, V12, P617, DOI 10.1093/hmg/ddg075; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Warby SC, 2005, HUM MOL GENET, V14, P1569, DOI 10.1093/hmg/ddi165; Weeks RA, 1996, ANN NEUROL, V40, P49, DOI 10.1002/ana.410400110; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503	80	52	52	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2541	+		10.1096/fj.06-6533fje	http://dx.doi.org/10.1096/fj.06-6533fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065224				2022-12-25	WOS:000242490700017
J	Hurley, RL; Barre, LK; Wood, SD; Anderson, KA; Kemp, BE; Means, AR; Witters, LA				Hurley, Rebecca L.; Barre, Laura K.; Wood, Sumintra D.; Anderson, Kristin A.; Kemp, Bruce E.; Means, Anthony R.; Witters, Lee A.			Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; DEPENDENT INSULINOTROPIC POLYPEPTIDE; PANCREATIC BETA-CELLS; GLYCOGEN-SYNTHASE; CYCLIC-AMP; POSTTRANSLATIONAL MODIFICATIONS; TUMOR-SUPPRESSOR; UPSTREAM KINASE; SKELETAL-MUSCLE; GENE-EXPRESSION	The AMP-activated protein kinase ( AMPK) and cAMP signaling systems are both key regulators of cellular metabolism. In this study, we show that AMPK activity is attenuated in response to cAMP-elevating agents through modulation of at least two of its alpha subunit phosphorylation sites, viz. alpha-Thr(172) and alpha 1-Ser(485)/alpha 2-Ser(491), in the clonal ss-cell line INS-1 as well as in mouse embryonic fibroblasts and COS cells. Forskolin, isobutylmethylxanthine, and the glucose-dependent insulinotropic peptide inhibited AMPK activity and reduced phosphorylation of the activation loop alpha-Thr(172) via inhibition of calcium/calmodulindependent protein kinase kinase-alpha and -ss, but not LKB1. These agents also enhanced phosphorylation of alpha-Ser(485/491) by the cAMP-dependent protein kinase. AMPK alpha-Ser(485/491) phosphorylation was necessary but not sufficient for inhibition of AMPK activity in response to forskolin/isobutylmethylxanthine. We show that AMPK alpha-Ser(485/491) can be a site for autophosphorylation, which may play a role inlimiting AMPK activation in response to energy depletion or other regulators. Thus, our findings not only demonstrate cross-talk between the cAMP/cAMP-dependent protein kinase and AMPK signaling modules, but also describe a novel mechanism by which multisite phosphorylation of AMPK contributes to regulation of its enzyme activity.	Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Dept Sci Biol, Hanover, NH 03755 USA; St Vincents Inst & Commonwealth Sci, Fitzroy, Vic 3065, Australia; Ind Res Org Mol & Hlth Technol, Fitzroy, Vic 3065, Australia; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Dartmouth College; Dartmouth College; Dartmouth College; Duke University	Witters, LA (corresponding author), Dartmouth Coll Sch Med, Dept Med, Remsen 322,N Coll St, Hanover, NH 03755 USA.	lee.a.witters@dartmouth.edu	Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Niles, Rebecca/0000-0001-8568-3047	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712, R01DK074701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK074701, DK35712] Funding Source: Medline; NIGMS NIH HHS [GM33976] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; Boone AN, 1999, BIOCHEM J, V341, P347, DOI 10.1042/0264-6021:3410347; COHEN P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P292, DOI 10.1016/0167-4889(91)90089-G; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Davare MA, 2004, J BIOL CHEM, V279, P52191, DOI 10.1074/jbc.M409873200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Hutchinson DS, 2005, DIABETOLOGIA, V48, P2386, DOI 10.1007/s00125-005-1936-7; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim SJ, 2005, J BIOL CHEM, V280, P22297, DOI 10.1074/jbc.M500540200; Kimball SR, 2004, J BIOL CHEM, V279, P54103, DOI 10.1074/jbc.M410755200; Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Leclerc I, 2004, DIABETES, V53, pS67, DOI 10.2337/diabetes.53.suppl_3.S67; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Matsushita M, 1999, J BIOL CHEM, V274, P10086, DOI 10.1074/jbc.274.15.10086; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Misra UK, 2005, J BIOL CHEM, V280, P38276, DOI 10.1074/jbc.M507332200; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Mulder H, 2004, DIABETES, V53, P122, DOI 10.2337/diabetes.53.1.122; Nielsen JN, 2003, ACTA PHYSIOL SCAND, V178, P309, DOI 10.1046/j.1365-201X.2003.01165.x; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Richards SK, 2005, J ENDOCRINOL, V187, P225, DOI 10.1677/joe.1.06413; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P104; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Soltys CLM, 2006, AM J PHYSIOL-HEART C, V290, pH2472, DOI 10.1152/ajpheart.01206.2005; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Trumper A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740233; Wang Q, 2004, DIABETOLOGIA, V47, P478, DOI 10.1007/s00125-004-1327-5; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Watt MJ, 2006, AM J PHYSIOL-ENDOC M, V290, pE500, DOI 10.1152/ajpendo.00361.2005; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Winder WW, 1997, J APPL PHYSIOL, V82, P219, DOI 10.1152/jappl.1997.82.1.219; Winzell MS, 2006, NUTR METAB CARDIOVAS, V16, pS11, DOI 10.1016/j.numecd.2005.11.006; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Witters LA, 2006, TRENDS BIOCHEM SCI, V31, P13, DOI 10.1016/j.tibs.2005.11.009; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xavier GD, 2003, BIOCHEM J, V371, P761; Yaney GC, 2003, DIABETOLOGIA, V46, P1297, DOI 10.1007/s00125-003-1207-4; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Zhang YJ, 2006, ARTERIOSCL THROM VAS, V26, P1281, DOI 10.1161/01.ATV.0000221230.08596.98	63	218	219	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36662	36672		10.1074/jbc.M606676200	http://dx.doi.org/10.1074/jbc.M606676200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023420	hybrid			2022-12-25	WOS:000242220800023
J	Moghimi, SM; Hamad, I; Andresen, TL; Jorgensen, K; Szebeni, J				Moghimi, S. Moein; Hamad, Islam; Andresen, Thomas L.; Jorgensen, Kent; Szebeni, Janos			Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production	FASEB JOURNAL			English	Article						stealth liposomes; anaphylactic reactions; complement system; steric stabilization; SC5b-9; C3a-desarg	ENCAPSULATED HEMOGLOBIN; SURFACE-CHARGE; POLY(ETHYLENE GLYCOL); GLOBULAR HEAD; IN-VITRO; BINDING; PATHWAY; DOXORUBICIN; C1Q; PHARMACOKINETICS	Methoxy(polyethylene glycol), mPEG, -grafted liposomes are known to exhibit prolonged circulation time in the blood, but their infusion into a substantial percentage of human subjects triggers immediate non-IgE-mediated hypersensitivity reactions. These reactions are strongly believed to arise from anaphylatoxin production through complement activation. Despite the general view that vesicle surface camouflaging with mPEG should dramatically suppress complement activation, here we show that bilayer enrichment of noncomplement activating liposomes [di-palmitoylphosphatidylcholine (DPPC) vesicles] with phospholipid-mPEG conjugate induces complement activation resulting in vesicle recognition by macrophage complement receptors. The extent of vesicle uptake, however, is dependent on surface mPEG density. We have delineated the likely structural features of phospholipid-mPEG conjugate responsible for PEGylated liposome-induced complement activation in normal as well as C1q-deficient human sera, using DPPC vesicles bearing the classical as well as newly synthesized lipid-mPEG conjugates. With PEGylated DPPC vesicles, the net anionic charge on the phosphate moiety of phospholipid-mPEG conjugate played a key role in activation of both classical and alternative pathways of complement and anaphylatoxin production (reflected in significant rises in SC5b-9, C4d, and C3a-desarg levels in normal human sera as well as SC5b-9 in EGTA-chelated/Mg2+ supplemented serum), since methylation of the phosphate oxygen of phospholipid-mPEG conjugate, and hence the removal of the negative charge, totally prevented complement activation. To further corroborate on the role of the negative charge in complement activation, vesicles bearing anionic phospholipid-mPEG conjugates, but not the methylated phospholipid-mPEG, were shown to significantly decrease serum hemolytic activity and increase plasma thromboxane B2 levels in rats. In contrast to liposomes, phospholipid-mPEG micelles had no effect on complement activation, thus suggesting a possible role for vesicular zwitterionic phospholipid head-groups as an additional factor contributing to PEGylated liposome-mediated complement activation. Our findings provide a rational conceptual basis for development of safer vesicles for site-specific drug delivery and controlled release at pathological sites.	Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Brighton BN2 4GJ, E Sussex, England; Tech Univ Denmark, LiPlasome Pharm AS, DK-2800 Lyngby, Denmark; Hungarian Acad Sci, Nephrol Res Grp, Budapest, Hungary; Semmelweis Univ, Inst Pathophysiol, Budapest, Hungary	University of Brighton; Technical University of Denmark; Hungarian Academy of Sciences; Semmelweis University	Moghimi, SM (corresponding author), Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Cockcroft Bldg,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.	s.m.moghimi@brighton.ac.uk	Hamad, Islam/AAY-2540-2020; Andresen, Thomas L/B-5324-2012	Moghimi, Seyed Moein/0000-0003-0836-926X; Andresen, Thomas Lars/0000-0002-1048-127X				Alberts DS, 1997, DRUGS, V54, P30, DOI 10.2165/00003495-199700544-00007; Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; ALVING CR, 1991, CRIT REV IMMUNOL, V10, P441; Andresen Thomas L., 2005, Current Drug Delivery, V2, P353, DOI 10.2174/156720105774370203; Andresen TL, 2004, J MED CHEM, V47, P1694, DOI 10.1021/jm031029r; Andresen TL, 2005, PROG LIPID RES, V44, P68, DOI 10.1016/j.plipres.2004.12.001; Bradley AJ, 1999, BBA-BIOMEMBRANES, V1418, P19, DOI 10.1016/S0005-2736(99)00013-9; Bradley AJ, 1998, ARCH BIOCHEM BIOPHYS, V357, P185, DOI 10.1006/abbi.1998.0798; Bradley AJ, 1999, BIOCHEMISTRY-US, V38, P8112, DOI 10.1021/bi990480a; Chanan-Khan A, 2003, ANN ONCOL, V14, P1430, DOI 10.1093/annonc/mdg374; Chiu GNC, 2001, BBA-BIOMEMBRANES, V1510, P56, DOI 10.1016/S0005-2736(00)00335-7; CHONN A, 1991, J IMMUNOL, V146, P4234; DEVINE DV, 1994, BBA-BIOMEMBRANES, V1191, P43, DOI 10.1016/0005-2736(94)90231-3; FRIES LF, 1984, J EXP MED, V160, P1640, DOI 10.1084/jem.160.6.1640; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; Garbuzenko O, 2005, LANGMUIR, V21, P2560, DOI 10.1021/la0479105; Gbadamosi JK, 2002, FEBS LETT, V532, P338, DOI 10.1016/S0014-5793(02)03710-9; Gulati S, 2002, J IMMUNOL, V168, P4078, DOI 10.4049/jimmunol.168.8.4078; KENWORTHY AK, 1995, BIOPHYS J, V68, P1921, DOI 10.1016/S0006-3495(95)80369-3; Kishore U, 2003, J IMMUNOL, V171, P812, DOI 10.4049/jimmunol.171.2.812; Klint C, 2000, SCAND J IMMUNOL, V52, P103; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; Moghimi SM, 2006, BIOMATERIALS, V27, P136, DOI 10.1016/j.biomaterials.2005.05.082; Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Moghimi SM, 2002, J CONTROL RELEASE, V78, P55, DOI 10.1016/S0168-3659(01)00481-3; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; Moghimi SM, 2001, PHARM RES-DORDR, V18, P1, DOI 10.1023/A:1011054123304; MOORE FD, 1982, J IMMUNOL, V128, P1302; Price ME, 2001, BBA-BIOMEMBRANES, V1512, P191, DOI 10.1016/S0005-2736(01)00330-3; SAVAY S, 2002, BIOCHIM BIOPHYS ACTA, V1559, P29; Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814; SZEBENI J, 1994, BIOCHEM BIOPH RES CO, V205, P255, DOI 10.1006/bbrc.1994.2658; Szebeni J, 2006, AM J PHYSIOL-HEART C, V290, pH1050, DOI 10.1152/ajpheart.00622.2005; Szebeni J, 2002, J LIPOSOME RES, V12, P165, DOI 10.1081/LPR-120004790; Szebeni J, 1996, BBA-BIOMEMBRANES, V1285, P127, DOI 10.1016/S0005-2736(96)00201-5; Szebeni J, 2000, J LIPOSOME RES, V10, P467, DOI 10.3109/08982100009031112; Szebeni J, 1997, TRANSFUSION, V37, P150, DOI 10.1046/j.1537-2995.1997.37297203517.x; Szebeni J, 2000, AM J PHYSIOL-HEART C, V279, pH1319, DOI 10.1152/ajpheart.2000.279.3.H1319; Szebeni J, 2003, METHOD ENZYMOL, V373, P136; Tirosh O, 1998, BIOPHYS J, V74, P1371, DOI 10.1016/S0006-3495(98)77849-X; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; Webb MS, 1998, BBA-BIOMEMBRANES, V1372, P272, DOI 10.1016/S0005-2736(98)00077-7; Zalipsky S., 2004, PCT Patent Application, Patent No. [WO 2004/078121, 2004078121]	45	156	161	1	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2591	+		10.1096/fj.06-6186fje	http://dx.doi.org/10.1096/fj.06-6186fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065229				2022-12-25	WOS:000242490700034
J	Chang, WC; Nelson, C; Parekh, AB				Chang, Wei-Chiao; Nelson, Charmaine; Parekh, Anant B.			Ca2+ influx through CRAC channels activates cytosolic phospholipase A(2), leukotriene C-4 secretion, and expression of c-fos through ERK-dependent and -independent pathways in mast cells	FASEB JOURNAL			English	Article						store-operated influx; 5-lipoxygenase; protein kinase	PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; BASOPHILIC LEUKEMIA-CELLS; SIGNAL-REGULATED KINASES; CURRENT I-CRAC; PHOSPHORYLATION SITES; MAP KINASE; HUMAN EOSINOPHILS; CALCIUM-RELEASE; HUMAN PLATELETS	Cytosolic phospholipase A(2) (cPLA(2)) is a Ca2+-dependent enzyme that mediates agonist-dependent arachidonic acid release in most cell types. Arachidonic acid can then be metabolized by the 5-lipoxygenase enzyme to generate the proinflammatory signal leukotriene C-4 (LTC4). Here we report that Ca2+ entry through store-operated CRAC (Ca2+ release-activated Ca2+) channels activates the extracellular signal-regulated kinases (ERKs), members of the mitogen-activated protein kinase family, within minutes and this is necessary for stimulation of cPLA(2). Ca2+ entry activates ERK indirectly, via recruitment of Ca2+-dependent protein kinase C alpha and beta I. Ca2+ influx also promotes translocation of cytosolic 5-lipoxygenase to the nuclear membrane, a key step in the activation of this enzyme. Translocation is dependent on ERK activation. A role for gene activation is shown by the finding that CRAC channel opening results in increased transcription and translation of c-fos. Inhibition of ERK activation failed to prevent c-fos expression. Our results show that CRAC channel activation elicits short-term effects through the co-coordinated regulation of two metabolic pathways (cPLA(2) and 5-lipoxygenase), which results in the generation of both intra- and intercellular messengers within minutes, as well as longer term changes involving gene activation. These short-term effects are mediated via ERK, whereas, paradoxically, c-fos expression is not. Ca2+ influx through CRAC channels can therefore activate different signaling pathways at the same time, culminating in a range of temporally diverse responses.	Univ Oxford, Dept Physiol, Oxford OX1 3PT, England	University of Oxford	Parekh, AB (corresponding author), Univ Oxford, Dept Physiol, Parks Rd, Oxford OX1 3PT, England.	anant.parekh@physiol.ox.ac.uk		Chang, Wei-Chiao/0000-0002-8573-5924	Medical Research Council [G0200218] Funding Source: Medline; MRC [G0200218] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahamed J, 2002, J BIOL CHEM, V277, P22685, DOI 10.1074/jbc.M110210200; AMBS P, 1995, BIOCHEM J, V311, P189, DOI 10.1042/bj3110189; Atherfold PA, 1999, MOL IMMUNOL, V36, P543, DOI 10.1016/S0161-5890(99)00076-0; Bates ME, 2000, J BIOL CHEM, V275, P10968, DOI 10.1074/jbc.275.15.10968; Boden SE, 2000, INT J BIOCHEM CELL B, V32, P1069, DOI 10.1016/S1357-2725(00)00049-2; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; BUERKERT E, 2002, BIOCHEM BIOPH RES CO, P985; Chang WC, 2004, J BIOL CHEM, V279, P29994, DOI 10.1074/jbc.M403969200; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Das S, 2003, J BIOL CHEM, V278, P41431, DOI 10.1074/jbc.M304897200; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dellis O, 2002, J BIOL CHEM, V277, P6044, DOI 10.1074/jbc.M111831200; Denys A, 2004, FEBS LETT, V564, P177, DOI 10.1016/S0014-5793(04)00361-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fierro AF, 2004, J BIOL CHEM, V279, P25646, DOI 10.1074/jbc.M400296200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ20041501; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Oliver D, 2004, SCIENCE, V304, P265, DOI 10.1126/science.1094113; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1994, J BIOL CHEM, V269, P19480; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Rosado JA, 2001, J BIOL CHEM, V276, P15659, DOI 10.1074/jbc.M009218200; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shuttleworth TJ, 2004, PHYSIOLOGY, V19, P355, DOI 10.1152/physiol.00018.2004; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1141; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TAYLOR GW, 1989, LANCET, V1, P584; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	66	77	79	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2381	+		10.1096/fj.06-6016fje	http://dx.doi.org/10.1096/fj.06-6016fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17023391				2022-12-25	WOS:000241702600027
J	Ekici, OD; Karla, A; Paetzel, M; Lively, MO; Pei, DH; Dalbey, RE				Ekici, Ozlem Dogan; Karla, Andrew; Paetzel, Mark; Lively, Mark O.; Pei, Dehua; Dalbey, Ross E.			Altered-3 substrate specificity of Escherichia coli signal peptidase 1 mutants as revealed by screening a combinatorial peptide library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER PEPTIDASE; CRYSTAL-STRUCTURE; CLEAVAGE SITES; MEMBRANE; SEQUENCE; PROTEIN; IDENTIFICATION; BINDING; DOMAIN; LYSINE	Signal peptidase functions to cleave signal peptides from preproteins at the cell membrane. It has a substrate specificity for small uncharged residues at -1 (P1) and aliphatic residues at the -3 (P3) position. Previously, we have reported that certain alterations of the Ile-144 and Ile-86 residues in Escherichia coli signal peptidase I (SPase) can change the specificity such that signal peptidase is able to cleave pro-OmpA nuclease A in vitro after phenylalanine or asparagine residues at the - 1 position (Karla, A., Lively, M. O., Paetzel, M. and Dalbey, R. (2005) J. Biol Chem. 280, 6731 6741). In this study, screening of a fluorescence resonance energy transfer-based peptide library revealed that the I144A, I144C, and I144C/I86T SPase mutants have a more relaxed substrate specificity at the -3 position, in comparison to the wild-type SPase. The double mutant tolerated arginine, glutamine, and tyrosine residues at the -3 position of the substrate. The altered specificity of the I144C/I86T mutant was confirmed by in vivo processing of pre-beta-lactamase containing non-canonical arginine and glutamine residues at the -3 position. This work establishes Ile-144 and Ile-86 as key P3 substrate specificity determinants for signal peptidase I and demonstrates the power of the fluorescence resonance energy transfer-based peptide library approach in defining the substrate specificity of proteases.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	University System of Ohio; Ohio State University; Wake Forest University; Simon Fraser University	Dalbey, RE (corresponding author), 100 W 18th Ave, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu	Pei, Dehua/P-4594-2016	Pei, Dehua/0000-0002-2057-6934; Paetzel, Mark/0000-0002-7408-5487	NIGMS NIH HHS [GM062820] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062820] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen XM, 1999, J BIOL CHEM, V274, P37750, DOI 10.1074/jbc.274.53.37750; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; DeLano W, 2002, PYMOL 0 99; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; Karla A, 2005, J BIOL CHEM, V280, P6731, DOI 10.1074/jbc.M413019200; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Liu RW, 2002, J AM CHEM SOC, V124, P7678, DOI 10.1021/ja026421t; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MELDAL M, 1994, P NATL ACAD SCI USA, V91, P3314, DOI 10.1073/pnas.91.8.3314; MOORE KE, 1987, J BIOL CHEM, V262, P8806; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 2004, J BIOL CHEM, V279, P30781, DOI 10.1074/jbc.M401686200; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; Rosse G, 2000, J COMB CHEM, V2, P461, DOI 10.1021/cc000019y; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stein RL, 2000, BIOCHEMISTRY-US, V39, P7973, DOI 10.1021/bi000352i; Sweeney MC, 2003, J COMB CHEM, V5, P218, DOI 10.1021/cc020113+; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; van Klompenburg W, 1998, FEBS LETT, V431, P75, DOI 10.1016/S0014-5793(98)00733-9; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WHITLEY P, 1993, BIOCHEMISTRY-US, V32, P8534, DOI 10.1021/bi00084a020; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1982, J BIOL CHEM, V257, P7898	42	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					417	425		10.1074/jbc.M608779200	http://dx.doi.org/10.1074/jbc.M608779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17077081	hybrid			2022-12-25	WOS:000243166500047
J	Chen, H; Hewison, M; Adams, JS				Chen, Hong; Hewison, Martin; Adams, John S.			Functional characterization of heterogeneous nuclear ribonuclear protein C1/C2 in vitamin D resistance - A novel response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; PROXIMAL TUBULE; HNRNP-C; RECEPTOR; ALBUMIN; RIBONUCLEOPROTEINS; CELLS; COACTIVATOR; REGULATORS; COMPLEXES	Clinically apparent hereditary vitamin D-resistant rickets (HVDRR) usually results from a loss of function mutation in the vitamin D receptor (VDR). We recently described a human with the classical HVDRR phenotype but normal VDR function. Hormone resistance resulted from constitutive overexpression of heterogeneous nuclear ribonucleoprotein (hnRNP) that competed with a normally functioning VDR-retinoid X receptor (RXR) dimer for binding to the vitamin D response element (VDRE). Here we describe the purification, molecular cloning, and expression of this vitamin D resistance- causing, competitive response element-binding protein (REBiP) hnRNP C1/C2. When overexpressed in vitamin D-responsive cells, cDNAs for both hnRNPC1 and hnRNPC2 inhibited VDR-VDRE-directed transactivation (28 and 43%, respectively; both p < 0.005). By contrast, transient expression of an hnRNP C1/C2 small interfering RNA increased VDR transactivation by 39% (p < 0.005). Chromatin immunoprecipitation of nucleoproteins bound to the transcriptionally active 1,25-dihydroxy vitamin D-driven CYP24 promoter revealed the presence of REBiP in vitamin D-responsive human cells and indicated that the normal pattern of 1,25-dihydroxy vitamin D-initiated cyclical movement of the VDR on and off the VDRE is legislated by competitive, reciprocal occupancy of the VDRE by hnRNP C1/C2. The temporal and reciprocal pattern of VDR and hnRNPC1/C2 interaction with the VDRE was lost in HVDRR cells overexpressing the hnRNP C1/C2 REBiP. These observations provide further evidence for the functional importance of REBiP as a component of the multiprotein complex involved in the regulation of vitamin D-mediated transcription. In particular, chromatin immunoprecipitation data suggest that, in addition to its RNA-processing functions, hnRNP C1/C2 may be a key determinant of the temporal patterns of VDRE occupancy.	Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Burns & Allen Res Inst, Cedars Sinai Med Ctr,Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Adams, JS (corresponding author), Univ Calif Los Angeles, Div Endocrinol Diabet & Metab, Burns & Allen Res Inst, Cedars Sinai Med Ctr,Sch Med, 8700 Beverly Blvd,Rm B-131, Los Angeles, CA 90048 USA.	adamsj@cshs.or	Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037399] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR37399] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams JS, 2004, J STEROID BIOCHEM, V89-90, P461, DOI 10.1016/j.jsbmb.2004.03.016; Adams JS, 2003, J CELL BIOCHEM, V88, P308, DOI 10.1002/jcb.10333; Arbelle JE, 1996, ENDOCRINOLOGY, V137, P786, DOI 10.1210/en.137.2.786; Arbour NC, 1998, ANAL BIOCHEM, V255, P148, DOI 10.1006/abio.1997.2439; BARNETT SF, 1991, MOL CELL BIOL, V11, P864, DOI 10.1128/MCB.11.2.864; Birn H, 2000, J CLIN INVEST, V105, P1353, DOI 10.1172/JCI8862; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chen H, 2005, ENDOCRINOLOGY, V146, P4266, DOI 10.1210/en.2005-0160; Chen H, 1997, J CLIN INVEST, V99, P669, DOI 10.1172/JCI119210; Chen H, 1998, J BIOL CHEM, V273, P31352, DOI 10.1074/jbc.273.47.31352; Chen H, 2003, P NATL ACAD SCI USA, V100, P6109, DOI 10.1073/pnas.1031395100; Chen H, 2000, J BIOL CHEM, V275, P35557, DOI 10.1074/jbc.M007117200; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; Christensen EI, 1999, J AM SOC NEPHROL, V10, P2224; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900, DOI 10.1152/ajprenal.1996.271.4.F900; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; DREYFUSS G, 1999, ANNU REV BIOCHEM, V62, P289; Enokizono Y, 2005, J BIOL CHEM, V280, P18862, DOI 10.1074/jbc.M411822200; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Herdick M, 2000, J MOL BIOL, V304, P793, DOI 10.1006/jmbi.2000.4267; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Jimenez-Lara AM, 2000, HORM RES, V54, P301, DOI 10.1159/000053276; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lee HH, 2004, J CELL SCI, V117, P5579, DOI 10.1242/jcs.01482; Lutz W, 2001, BIOCHEM BIOPH RES CO, V282, P1211, DOI 10.1006/bbrc.2001.4711; Mahajan MC, 2005, P NATL ACAD SCI USA, V102, P15012, DOI 10.1073/pnas.0507596102; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MCLEOD JF, 1989, J BIOL CHEM, V264, P21760; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; RECH JE, 1995, J STRUCT BIOL, V114, P77, DOI 10.1006/jsbi.1995.1007; Vaisanen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/j.jmb.2005.04.057; VANEEKELEN CAG, 1981, EUR J BIOCHEM, V119, P461; White P, 2000, TRENDS ENDOCRIN MET, V11, P320, DOI 10.1016/S1043-2760(00)00317-9; Whitson SR, 2005, J MOL BIOL, V350, P319, DOI 10.1016/j.jmb.2005.05.002; Zhai XY, 2000, KIDNEY INT, V58, P1523, DOI 10.1046/j.1523-1755.2000.00314.x; Zhang C, 2003, J BIOL CHEM, V278, P35325, DOI 10.1074/jbc.M305191200; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	43	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39114	39120		10.1074/jbc.M608006200	http://dx.doi.org/10.1074/jbc.M608006200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17071612	hybrid			2022-12-25	WOS:000242898700018
J	Lu, YC; Song, J; Cho, HY; Fan, GP; Yokoyama, KK; Chiu, R				Lu, Ying-Chun; Song, Jun; Cho, Hee-Yeon; Fan, Guoping; Yokoyama, Kazunari K.; Chiu, Robert			Cyclophilin A protects Peg3 from hypermethylation and inactive histone modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; IMPRINTED GENE; CELL-LINES; MAMMALIAN DEVELOPMENT; DEACETYLASE COMPLEX; CANCER; EXPRESSION; MECP2; RNA; METHYLTRANSFERASES	Imprinted genes are expressed from only one of the parental alleles and are marked epigenetically by DNA methylation and histone modifications. Disruption of normal imprinting leads to abnormal embryogenesis, certain inherited diseases, and is associated with various cancers. In the context of screening for the gene(s) responsible for the alteration of phenotype in cyclophilin A knockdown (CypA-KD) P19 cells, we observed a silent paternally expressed gene, Peg3. Treatment of CypA-KD P19 cells with the DNA demethylating agent 5-aza-dC reversed the silencing of Peg3 biallelically. Genomic bisulfite sequencing and methylation-specific PCR revealed DNA hypermethylation in CypA-KD P19 cells, as the normally unmethylated paternal allele acquired methylation that resulted in biallelic methylation of Peg3. Chromatin immunoprecipitation assays indicated a loss of acetylation and a gain of lysine 9 trimethylation in histone 3, as well as enhanced DNA methyltransferase 1 and MBD2 binding on the cytosine-guanine dinucleotide (CpG) islands of Peg3. Our results indicate that DNA hypermethylation on the paternal allele and allele-specific acquisition of histone methylation leads to silencing of Peg3 in CypA-KD P19 cells. This study is the first demonstration of the epigenetic function of CypA in protecting the paternal allele of Peg3 from DNA methylation and inactive histone modifications.	Univ Calif Los Angeles, Dent Res Inst, Sch Dent, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; RIKEN, Gene Engn Div, Bioresource Ctr, Tsukuba, Ibaraki 305, Japan; Univ Calif Los Angeles, Dept Surg Oncol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; RIKEN; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Chiu, R (corresponding author), Univ Calif Los Angeles, Dent Res Inst, Sch Dent, Los Angeles, CA 90095 USA.	rchiu@dent.ucla.edu		Fan, Guoping/0000-0001-5235-6410	NATIONAL CANCER INSTITUTE [R01CA066746] Funding Source: NIH RePORTER; NCI NIH HHS [CA66746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ansari H, 2002, MOL CELL BIOL, V22, P6993, DOI 10.1128/MCB.22.20.6993-7003.2002; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Dowdy SC, 2005, GYNECOL ONCOL, V99, P126, DOI 10.1016/j.ygyno.2005.05.036; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Hiby SE, 2001, HUM MOL GENET, V10, P1093, DOI 10.1093/hmg/10.10.1093; Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kim J, 1997, GENOME RES, V7, P532, DOI 10.1101/gr.7.5.532; Kohda T, 2001, GENES CELLS, V6, P237, DOI 10.1046/j.1365-2443.2001.00412.x; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; Li T, 2005, MOL HUM REPROD, V11, P631, DOI 10.1093/molehr/gah230; Liu K, 2003, MOL CELL BIOL, V23, P2709, DOI 10.1128/MCB.23.8.2709-2719.2003; Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Razin A, 2005, PROG MOLEC, V38, P151; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Ruden DM, 2005, HUM MOL GENET, V14, pR149, DOI 10.1093/hmg/ddi103; SOLDARS V, 2005, NAT GENET, V33, P70; Song J, 2004, J BIOL CHEM, V279, P24414, DOI 10.1074/jbc.M311406200; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; TURKER MS, 1989, J BIOL CHEM, V264, P11632	34	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39081	39087		10.1074/jbc.M606687200	http://dx.doi.org/10.1074/jbc.M606687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17071620	hybrid			2022-12-25	WOS:000242898700014
J	Sarfaraz, S; Afaq, F; Adhami, VM; Malik, A; Mukhtar, H				Sarfaraz, Sami; Afaq, Farrukh; Adhami, Vaqar M.; Malik, Arshi; Mukhtar, Hasan			Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G(1) cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITORS; IN-VIVO; GROWTH; PROGRESSION; SYSTEM; CHECKPOINTS; CERAMIDE; PROTEINS; PATHWAY; FAMILY	We have recently shown that the expression levels of both cannabinoid receptors CB1 and CB2 are higher in human prostate cancer cells than in normal prostate epithelial cells, and treatment of LNCaP cells with WIN-55,212-2 (a mixed CB1/CB2 agonist) resulted in inhibition of cell growth and induction of apoptosis (Sarfaraz, S., Afaq, F., Adhami, V. M., and Mukhtar, H. ( 2005) Cancer Res. 65, 1635-1641). This study was conducted to understand the mechanistic basis of these effects. Treatment of LNCaP cells with WIN-55,212-2 (1-10 mu M; 24 h) resulted in: (i) an arrest of the cells in the G(0)/G(1) phase of the cell cycle; (ii) an induction of p53 and p27/KIP1; (iii) down-regulation of cyclins D1, D2, E; (iii) decrease in the expression of cdk-2, -4, and -6; (iv) decrease in protein expression of pRb; (v) down-regulation of E2F (1-4); and (vi) decrease in the protein expression of DP1 and DP2. Similar effects were also observed when androgen-independent PC3 cells were treated with WIN-55,212-2 (5-30 mu M). We further observed sustained up-regulation of ERK1/2 and inhibition of PI3k/Akt pathways in WIN-55,212-2-treated cells. Inhibition of ERK1/2 abrogated WIN-55,212-2-indued cell death suggesting that sustained activation of ERK1/2 leads to cell cycle dysregulation and arrest of cells in G0/G1 phase subsequently leading to an induction of apoptosis. Further, WIN-55,212-2 treatment of cells resulted in a dose-dependent increase in Bax/Bcl-2 ratio in such a way that favors apoptosis. The induction of apoptosis proceeded through down-regulation of caspases 3, 6, 7, and 9 and cleavage of poly (ADP-ribose) polymerases. Based on these data we suggest that cannabinoid receptor agonists should be considered as novel agents for the management of prostate cancer.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Rm B-25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Adhami, Vaqar/AAY-2837-2020	Adhami, Vaqar/0000-0002-2048-4570				Atallah D, 2004, INT J HYPERTHER, V20, P405, DOI 10.1080/02656730310001637325; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Bisogno T, 2005, PHARMACOL BIOCHEM BE, V81, P224, DOI 10.1016/j.pbb.2005.01.027; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; Denmeade SR, 1996, PROSTATE, V28, P251; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; Masciullo V, 2000, INT J ONCOL, V17, P897; McDonald ER, 2000, INT J ONCOL, V16, P871; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nithipatikom K, 2004, CANCER RES, V64, P8826, DOI 10.1158/0008-5472.CAN-04-3136; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007; Sandhu C, 2000, CANCER DETECT PREV, V24, P107; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Sarfaraz S, 2005, CANCER RES, V65, P1635, DOI 10.1158/0008-5472.CAN-04-3410; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tang DG, 1997, PROSTATE, V32, P284; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Vermeulen K, 2003, CELL PROLIFERAT, V36, P165, DOI 10.1046/j.1365-2184.2003.00267.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	48	138	143	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39480	39491		10.1074/jbc.M603495200	http://dx.doi.org/10.1074/jbc.M603495200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17068343	hybrid			2022-12-25	WOS:000242898700056
J	Yevenes, GE; Moraga-Cid, G; Guzman, L; Haeger, S; Oliveira, L; Olate, J; Schmalzing, G; Aguayo, LG				Yevenes, Gonzalo E.; Moraga-Cid, Gustavo; Guzman, Leonardo; Haeger, Svenja; Oliveira, Laerte; Olate, Juan; Schmalzing, Gunther; Aguayo, Luis G.			Molecular determinants for G protein beta gamma modulation of ionotropic glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; RECTIFYING K+ CHANNEL; ALPHA-1 SUBUNIT; ION CHANNELS; N-TERMINUS; KINASE-C; BINDING; PHOSPHORYLATION; IDENTIFICATION; RESIDUES	The ligand-gated ion channel superfamily plays a critical role in neuronal excitability. The functions of glycine receptor ( GlyR) and nicotinic acetylcholine receptor are modulated by G protein beta gamma subunits. The molecular determinants for this functional modulation, however, are still unknown. Studying mutant receptors, we identified two basic amino acid motifs within the large intracellular loop of the GlyR alpha(1) subunit that are critical for binding and functional modulation by G beta gamma. Mutations within these sequences demonstrated that all of the residues detected are important for G beta gamma modulation, although both motifs are necessary for full binding. Molecular modeling predicts that these sites are alpha-helixes near transmembrane domains 3 and 4, near to the lipid bilayer and highly electropositive. Our results demonstrate for the first time the sites for G protein beta gamma subunit modulation on GlyRs and provide a new framework regarding the ligand-gated ion channel superfamily regulation by intracellular signaling.	Univ Concepcion, Dept Physiol, Neurophysiol Lab, Concepcion, Chile; Rhein Westfal TH Aachen, Dept Mol Pharmacol, Aachen, Germany; Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil; Univ Concepcion, Dept Biochem & Mol Biol, Genet Mol Lab, Concepcion, Chile	Universidad de Concepcion; RWTH Aachen University; Universidade Federal de Sao Paulo (UNIFESP); Universidad de Concepcion	Aguayo, LG (corresponding author), Univ Concepcion, Dept Physiol, Neurophysiol Lab, POB 160-C, Concepcion, Chile.	laguayo@udec.cl	Guzman, Jose/AAM-7649-2020; Moraga-Cid, Gustavo/AAC-3314-2021	Guzman, Jose/0000-0001-9596-5494; Yevenes, Gonzalo/0000-0003-0294-4075	NIAAA NIH HHS [R01 AA15150-01] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA015150] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Absalom NL, 2003, J BIOL CHEM, V278, P50151, DOI 10.1074/jbc.M305357200; Agnati LF, 2005, J HISTOCHEM CYTOCHEM, V53, P941, DOI 10.1369/jhc.4A6355.2005; Aguayo LG, 2004, BRAIN RES REV, V47, P33, DOI 10.1016/j.brainresrev.2004.06.007; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Cascio M, 2004, J BIOL CHEM, V279, P19383, DOI 10.1074/jbc.R300035200; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DE WM, 1997, NATURE, V385, P446; DELANO WL, 2002, MYMOL MOL GRAPHICS S; Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381; Dolphin AC, 2003, PHARMACOL REV, V55, P607, DOI 10.1124/pr.55.4.3; Fischer H, 2005, J NEUROSCI, V25, P3571, DOI 10.1523/JNEUROSCI.4971-04.2005; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Guo X, 2002, J NEUROCHEM, V82, P439, DOI 10.1046/j.1471-4159.2002.01027.x; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Harris RA, 1999, ALCOHOL CLIN EXP RES, V23, P1563, DOI 10.1097/00000374-199910000-00001; Harvey RJ, 2004, SCIENCE, V304, P884, DOI 10.1126/science.1094925; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; IKEDA SR, 1996, NATURE, V380, P258; Inoue K, 2005, BIOCHEM BIOPH RES CO, V327, P300, DOI 10.1016/j.bbrc.2004.12.010; Kandel ER., 2000, PRINCIPLES NEURAL SC, P207; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; RUIZGOMEZ A, 1991, J BIOL CHEM, V266, P559; Sadtler S, 2003, J BIOL CHEM, V278, P16782, DOI 10.1074/jbc.M213077200; Sebe JY, 2006, J NEUROPHYSIOL, V96, P391, DOI 10.1152/jn.00086.2006; Sine SM, 2006, NATURE, V440, P448, DOI 10.1038/nature04708; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Smart TG, 2004, NEUROSCIENTIST, V10, P432, DOI 10.1177/1073858404263463; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; VAELLO ML, 1994, J BIOL CHEM, V269, P2002; van Zundert B, 2004, J NEUROPHYSIOL, V91, P1036, DOI 10.1152/jn.00364.2003; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Yevenes GE, 2003, NAT NEUROSCI, V6, P819, DOI 10.1038/nn1095	43	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39300	39307		10.1074/jbc.M608272200	http://dx.doi.org/10.1074/jbc.M608272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17040914	hybrid			2022-12-25	WOS:000242898700037
J	Honda, T; Nakajima, K				Honda, Takao; Nakajima, Kazunori			Mouse Disabled1 (DAB1) is a nucleocytoplasmic shuttling protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; REELER-LIKE PHENOTYPE; APOE RECEPTOR 2; NEURONAL MIGRATION; BRAIN-DEVELOPMENT; TYROSINE PHOSPHORYLATION; LAMINAR ORGANIZATION; STIMULATED NEURONS; BINDING DOMAIN; VLDL RECEPTOR	Disabled1 (DAB1) is an intracellular mediator of the Reelinsignaling pathway and essential for correct neuronal positioning during brain development. So far, DAB1 has been considered a cytoplasmic protein. Here, we show that DAB1 is subject to nucleocytoplasmic shuttling. In its steady state, DAB1 is mainly located in the cytoplasm. However, treatment with leptomycine B, a specific inhibitor of the CRM1 (chromosomal region maintenance 1)-RanGTP-dependent nuclear export, resulted in nuclear accumulation of DAB1. By using deletion or substitutional mutants of DAB1 fused with enhanced green fluorescent protein, we have mapped a bipartite nuclear localization signal and two CRM1-dependent nuclear export signals. These targeting signals were functional in both Neuro2a cells and primary cerebral cortical neurons. Using purified recombinant proteins, we have shown that CRM1 binds to DAB1 directly in a RanGTP-dependent manner. We also show that tyrosine phosphorylation of DAB1, which is indispensable for the layer formation of the brain, by Fyn tyrosine kinase or Reelin stimulation did not affect the subcellular localization of DAB1 in vitro. These results suggest that DAB1 is a nucleocytoplasmic shuttling protein and raise the possibility that DAB1 plays a role in the nucleus as well as in the cytoplasm.	Keio Univ, Sch Med, Dept Anat, Shinjuku Ku, Tokyo 1608582, Japan; Jikei Univ, Dept Mol Neurobiol, Sch Med, Inst DNA Med,Minato Ku, Tokyo 1058561, Japan	Keio University; Jikei University	Nakajima, K (corresponding author), Keio Univ, Sch Med, Dept Anat, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kazunori@sc.itc.keio.ac.jp	Nakajima, Kazunori/L-3396-2013; Honda, Takao/B-2851-2013	Nakajima, Kazunori/0000-0003-1864-9425; Honda, Takao/0000-0002-4425-9095				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Ballif BA, 2004, CURR BIOL, V14, P606, DOI 10.1016/j.cub.2004.03.038; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bielas S, 2004, ANNU REV CELL DEV BI, V20, P593, DOI 10.1146/annurev.cellbio.20.082503.103047; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Chen KL, 2004, J CELL SCI, V117, P4527, DOI 10.1242/jcs.01320; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DARCANGELO G, 1996, BRAIN RES MOL BRAIN, V39, P234; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Goslin K., 1998, CULTURING NERVE CELL, P339; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; Herrick TM, 2002, DEVELOPMENT, V129, P787; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Homayouni R, 2001, BIOCHEM BIOPH RES CO, V289, P539, DOI 10.1006/bbrc.2001.5998; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huang YC, 2004, BIOCHEM BIOPH RES CO, V318, P204, DOI 10.1016/j.bbrc.2004.04.023; IMAMOTO N, 1995, FEBS LETT, V368, P415; Jossin Y, 2003, J NEUROSCI, V23, P9953; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kojima T, 2000, MOL BRAIN RES, V75, P121, DOI 10.1016/S0169-328X(99)00313-7; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kuo G, 2005, J NEUROSCI, V25, P8578, DOI 10.1523/JNEUROSCI.1656-05.2005; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Nakajima K, 1997, P NATL ACAD SCI USA, V94, P8196, DOI 10.1073/pnas.94.15.8196; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Pramatarova A, 2003, MOL CELL BIOL, V23, P7210, DOI 10.1128/MCB.23.20.7210-7221.2003; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 1998, DEVELOPMENT, V125, P3719; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5469; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stolt PC, 2005, J BIOL CHEM, V280, P9671, DOI 10.1074/jbc.M413356200; Suetsugu S, 2004, BIOCHEM J, V384, P1, DOI 10.1042/BJ20041103; Tabata H, 2003, J NEUROSCI, V23, P9996; Tabata H, 2001, NEUROSCIENCE, V103, P865, DOI 10.1016/S0306-4522(01)00016-1; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Yoneshima H, 1997, NEUROSCI RES, V29, P217, DOI 10.1016/S0168-0102(97)00088-6; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110	77	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38951	38965		10.1074/jbc.M609061200	http://dx.doi.org/10.1074/jbc.M609061200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17062576	hybrid			2022-12-25	WOS:000242709500092
J	Lu, TJ; Lai, WY; Huang, CYF; Hsieh, WJ; Yu, JS; Hsieh, YJ; Chang, WT; Leu, TH; Chang, WC; Chuang, WJ; Tang, MJ; Chen, TY; Lu, TL; Lai, MD				Lu, Te-Jung; Lai, Wen-Yang; Huang, Chi-Ying F.; Hsieh, Wan-Jung; Yu, Jau-Song; Hsieh, Ya-Ju; Chang, Wen-Tsan; Leu, Tzeng-Horng; Chang, Wen-Chang; Chuang, Woei-Jer; Tang, Ming-Jer; Chen, Tzong-Yueh; Lu, Te-Ling; Lai, Ming-Derg			Inhibition of cell migration by autophosphorylated mammalian sterile 20-like kinase 3 (MST3) involves paxillin and protein-tyrosine phosphatase-PEST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-PEST; STE20-LIKE KINASE; RNA INTERFERENCE; PHOSPHORYLATION; GROWTH; ADHESION; ACTIVATION; MOTILITY; MUSCLE; SITES	MST3 is a member of the sterile-20 protein kinase family with a unique preference for manganese ion as a cofactor in vitro; however, its biological function is largely unknown. Suppression of endogenous MST3 by small interference RNA enhanced cellular migration in MCF-7 cells with reduced expression of E-cadherin at the edge of migrating cells. The alteration of cellular migration and protruding can be rescued by RNA interference-resistant MST3. The expression of surface integrin and Golgi apparatus was not altered, but phosphorylation on tyrosine 118 and tyrosine 31 of paxillin was attenuated by MST3 small interfering RNA ( siRNA). Threonine 178 was determined to be one of the two main autophosphorylation sites of MST3 in vitro. Mutant T178A MST3, containing alanine instead of threonine at codon 178, lost autophosphorylation and kinase activities. Overexpression of wild type MST3, but not the T178A mutant MST3, inhibited migration and spreading in Madin-Darby canine kidney cells. MST3 could phosphorylate the protein-tyrosine phosphatase (PTP)-PEST and inhibit the tyrosine phosphatase activity of PTP-PEST. We conclude that MST3 inhibits cell migration in a fashion dependent on autophosphorylation and may regulate paxillin phosphorylation through tyrosine phosphatase PTP-PEST.	Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Ctr Gene Regulat & Signal Transduct Res, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Biotechnol, Tainan 70101, Taiwan; Chung Hwa Coll Med Technol, Dept Med Technol, Tainan 717, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Chang Gung Univ, Coll Med, Inst Basic Med Sci, Dept Cell & Mol Biol, Tao Yuan 333, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Health Research Institutes - Taiwan; Chang Gung University; National Tsing Hua University	Lai, MD (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 70101, Taiwan.	a1211207@mail.ncku.edu.tw	Huang, Chi-Ying/AAG-7672-2022; Huang, Chi-Ying/AFL-7729-2022; Lai, Ming-Derg/M-8028-2014	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937; Hsieh, Ya-Ju/0000-0003-3853-4342; Yu, Jau-Song/0000-0002-4295-983X; Tang, Ming-Jer/0000-0002-0883-4363				Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Ceacareanu AC, 2006, AM J PHYSIOL-CELL PH, V290, pC1263, DOI 10.1152/ajpcell.00241.2005; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Chang YZ, 2004, AM J PHYSIOL-HEART C, V287, pH2201, DOI 10.1152/ajpheart.00520.2004; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Cheng TL, 2005, BIOCHEM BIOPH RES CO, V336, P820, DOI 10.1016/j.bbrc.2005.08.173; Deng Y, 2003, J BIOL CHEM, V278, P11760, DOI 10.1074/jbc.M211085200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200; Goldfinger LE, 2003, J CELL BIOL, V162, P731, DOI 10.1083/jcb.200304031; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Horwitz R, 2003, CURR BIOL, V13, pR756, DOI 10.1016/j.cub.2003.09.014; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; Iwasaki T, 2002, INT J CANCER, V97, P330, DOI 10.1002/ijc.1609; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jamieson JS, 2005, J CELL SCI, V118, P5835, DOI 10.1242/jcs.02693; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee WS, 2004, FEBS LETT, V572, P41, DOI 10.1016/j.febslet.2004.07.007; Lin JL, 2001, ONCOGENE, V20, P6559, DOI 10.1038/sj.onc.1204818; Lu TJ, 2005, J INORG BIOCHEM, V99, P1306, DOI 10.1016/j.jinorgbio.2005.03.003; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Schaller MD, 2004, J CELL BIOL, V166, P157, DOI 10.1083/jcb.200406151; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Sung V, 2003, CANCER RES, V63, P3356; Takino T, 2003, J CELL SCI, V116, P3145, DOI 10.1242/jcs.00632; Tetreault MP, 2005, EXP CELL RES, V306, P285, DOI 10.1016/j.yexcr.2005.02.019; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wu MT, 2005, BIOCHEM BIOPH RES CO, V330, P53, DOI 10.1016/j.bbrc.2005.02.129; Yang HL, 2006, J IMMUNOL, V176, P5898, DOI 10.4049/jimmunol.176.10.5898; YANG SD, 1994, J NEUROCHEM, V63, P1416; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yano H, 2004, J CELL BIOL, V166, P283, DOI 10.1083/jcb.200312013; Yu JS, 1998, BIOCHEM J, V334, P121, DOI 10.1042/bj3340121; Zhan Q, 2003, J IMMUNOL, V171, P3785, DOI 10.4049/jimmunol.171.7.3785; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638	56	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38405	38417		10.1074/jbc.M605035200	http://dx.doi.org/10.1074/jbc.M605035200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046825	hybrid			2022-12-25	WOS:000242709500034
J	Ochiai, K; Katoh, Y; Ikura, T; Hoshikawa, Y; Noda, T; Karasuyama, H; Tashiro, S; Muto, A; Igarashi, K				Ochiai, Kyoko; Katoh, Yasutake; Ikura, Tsuyoshi; Hoshikawa, Yutaka; Noda, Tetsuo; Karasuyama, Hajime; Tashiro, Satoshi; Muto, Akihiko; Igarashi, Kazuhiko			Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE TERMINAL DIFFERENTIATION; SMALL MAF PROTEINS; LEUCINE-ZIPPER; CLASS-SWITCH; EXPRESSION; FAMILY; BCL-6; NF-E2; RECOGNITION; ACTIVATION	Bach2 is a B cell-specific transcription repressor whose deficiency in mice causes a reduced class switch recombination and a reduced somatic hypermutation of immunoglobulin genes. Little is known about the direct target genes of Bach2 in B cells. By analyzing various B cell and plasma cell lines, we showed that the expression patterns of Bach2 and Blimp-1 (B lymphocyte-induced maturation protein 1), a master regulator of plasma cell differentiation, are mutually exclusive. The reporter gene of the Blimp-1 gene (Prdm1) was repressed by the overexpression of Bach2 in B cell lines. The heterodimer of Bach2/MafK bound to the Maf recognition element located upstream of the Prdm1 promoter in an electrophoretic mobility shift assay. The binding of MafK in B cells to the Prdm1 Maf recognition element was confirmed by chromatin immunoprecipitation assays. When MafK was purified from the BAL17 B cell line, a significant portion of it was present as a heterodimer with Bach2, with no apparent formation of MafK homodimer. These results strongly suggest that Bach2 represses the expression of Blimp-1 together with MafK in B cells prior to plasma cell differentiation. Accordingly, the knockdown of Bach2 mRNA using short hairpin RNA in BAL17 cells resulted in higher levels of Prdm1 expression after the stimulation of B cell receptor by surface IgM cross-linking. Induction of Prdm1 was more robust and faster in primary Bach2-deficient B cells than in wild-type control B cells upon lipopolysaccharide stimulation. Therefore, the Prdm1 regulation in B cells involves the repression by Bach2, which may be cancelled upon terminal plasma cell differentiation.	Tohoku Univ, Sch Med, Dept Biochem, Sendai, Miyagi 9808575, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima 7348551, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 1358550, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Immune Regulat, Bunkyo Ku, Tokyo 1138519, Japan	Tohoku University; Hiroshima University; Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU)	Igarashi, K (corresponding author), Tohoku Univ, Sch Med, Dept Biochem, Seiryo Machi 2-1, Sendai, Miyagi 9808575, Japan.	igarak@mail.tains.tohoku.ac.jp	Noda, Tetsuo/B-1667-2016; Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836; Igarashi, Kazuhiko/0000-0002-2470-2475				Angelin-Duclos C, 2000, J IMMUNOL, V165, P5462, DOI 10.4049/jimmunol.165.10.5462; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Chang DH, 2000, NAT IMMUNOL, V1, P169, DOI 10.1038/77861; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Jugloff LS, 1997, J IMMUNOL, V159, P1096; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; MATSUI K, 1989, J IMMUNOL, V142, P2918; Matthias P, 2005, NAT REV IMMUNOL, V5, P497, DOI 10.1038/nri1633; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Muto A, 2004, NATURE, V429, P566, DOI 10.1038/nature02596; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Nakayama Y, 2006, J CELL BIOCHEM, V99, P1308, DOI 10.1002/jcb.20952; Ohkubo Y, 2005, J IMMUNOL, V174, P7703, DOI 10.4049/jimmunol.174.12.7703; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Schliephake DE, 1996, EUR J IMMUNOL, V26, P268, DOI 10.1002/eji.1830260142; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Shapiro-Shelef M, 2004, CURR OPIN IMMUNOL, V16, P226, DOI 10.1016/j.coi.2004.02.001; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Tashiro S, 2004, MOL CELL BIOL, V24, P3473, DOI 10.1128/MCB.24.8.3473-3484.2004; Tunyaplin C, 2004, J IMMUNOL, V173, P1158, DOI 10.4049/jimmunol.173.2.1158; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Yamasaki C, 2005, J BIOCHEM, V137, P287, DOI 10.1093/jb/mvi031	45	119	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38226	38234		10.1074/jbc.M607592200	http://dx.doi.org/10.1074/jbc.M607592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046816	hybrid			2022-12-25	WOS:000242709500015
J	Uyama, T; Ishida, M; Izumikawa, T; Trybala, E; Tufaro, F; Bergstrom, T; Sugahara, K; Kitagawa, H				Uyama, Toru; Ishida, Miho; Izumikawa, Tomomi; Trybala, Edward; Tufaro, Frank; Bergstrom, Tomas; Sugahara, Kazuyuki; Kitagawa, Hiroshi			Chondroitin 4-O-sulfotransferase-1 regulates E disaccharide expression of chondroitin sulfate required for herpes simplex virus infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSORS EXT1; PROTEIN LINKAGE REGION; TYPE-1 GLYCOPROTEIN-C; HEPARAN-SULFATE; MOLECULAR-CLONING; CAENORHABDITIS-ELEGANS; DERMATAN SULFATE; BINDING-SITES; GRO2C CELLS; PROTEOGLYCANS	We have demonstrated a defect in expression of chondroitin 4-O-sulfotransferase-1 (C4ST-1) in murine sog9 cells, which are poorly sensitive to infection by herpes simplex virus type 1 (HSV-1). Sog9 cells were previously isolated as CS-deficient cells from gro2C cells, which were partially resistant to HSV-1 infection and defective in the expression of heparan sulfate (HS) because of a splice site mutation in the EXT1 gene encoding the HS-synthesizing enzyme. Here we detected a small amount of CS chains in sog9 cells with a drastic decrease in 4-O-sulfation compared with the parental gro2C cells. RT-PCR revealed that sog9 cells had a defect intheexpression of C4ST-1 in additionto EXT1. Gel filtration analysis showed that the decrease in the amount of CS in sog9 cells was the result of a reduction in the length of CS chains. Transfer of C4ST-1 cDNA into sog9 cells (sog9-C4ST-1) restored 4-O-sulfation and amount of CS, verifying that sog9 cells had a specific defect in C4ST-1. Furthermore, the expression of C4ST-1 rendered sog9 cells significantly more susceptible to HSV-1 infection, suggesting that CS modified by C4ST-1 is sufficient for the binding and infectivity of HSV-1. Analysis of CS chains of gro2C and sog9-C4ST-1 cells revealed a considerable proportion of the E disaccharide unit, consistent with our recent finding that this unit is an essential component of the HSV receptor. These results suggest that C4ST-1 regulates the expression of the E disaccharide unit and the length of CS chains, the features that facilitate infection of cells by HSV-1.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Gothenburg Univ, Dept Clin Virol, S-41346 Gothenburg, Sweden; Allera Hlth Prod Inc, St Petersburg, FL 33701 USA	Kobe Pharmaceutical University; University of Gothenburg	Kitagawa, H (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	kitagawa@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079; Bergstrom, Tomas/0000-0002-9257-6757; Trybala, Edward/0000-0003-2384-2123				BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Bergefall K, 2005, J BIOL CHEM, V280, P32193, DOI 10.1074/jbc.M503645200; Bomsel M, 2003, NAT REV MOL CELL BIO, V4, P57, DOI 10.1038/nrm1005; Busse M, 2003, J BIOL CHEM, V278, P41333, DOI 10.1074/jbc.M308314200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GRUENHEID S, 1993, J VIROL, V67, P93, DOI 10.1128/JVI.67.1.93-100.1993; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; HOLLAND TC, 1983, J VIROL, V45, P672, DOI 10.1128/JVI.45.2.672-682.1983; HOLLAND TC, 1984, J VIROL, V52, P566, DOI 10.1128/JVI.52.2.566-574.1984; Kim BT, 2003, J BIOL CHEM, V278, P41618, DOI 10.1074/jbc.M304831200; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kluppel M, 2005, DEVELOPMENT, V132, P3989, DOI 10.1242/dev.01948; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Mardberg K, 2002, J GEN VIROL, V83, P291, DOI 10.1099/0022-1317-83-2-291; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Prydz K, 2000, J CELL SCI, V113, P193; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Trybala E, 2000, J VIROL, V74, P9106, DOI 10.1128/JVI.74.19.9106-9114.2000; Tsutsumi K, 1998, FEBS LETT, V441, P235, DOI 10.1016/S0014-5793(98)01532-4; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975	37	83	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38668	38674		10.1074/jbc.M609320200	http://dx.doi.org/10.1074/jbc.M609320200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17040900	hybrid			2022-12-25	WOS:000242709500063
J	Hentges, P; Ahnesorg, P; Pitcher, RS; Bruce, CK; Kysela, B; Green, AJ; Bianchi, J; Wilson, TE; Jackson, SP; Doherty, AJ				Hentges, Pierre; Ahnesorg, Peter; Pitcher, Robert S.; Bruce, Chris K.; Kysela, Boris; Green, Andrew J.; Bianchi, Julie; Wilson, Thomas E.; Jackson, Stephen P.; Doherty, Aidan J.			Evolutionary and functional conservation of the DNA non-homologous end-joining protein, XLF/cernunnos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; KINASE CATALYTIC SUBUNIT; LIGASE-IV COMPLEX; V(D)J RECOMBINATION; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; POLYNUCLEOTIDE KINASE; PHOSPHORYLATION SITES; CRYSTAL-STRUCTURE; XRCC4 PROTEIN	Non-homologous end-joining is a major pathway of DNA double-strand break repair in mammalian cells, deficiency in which confers radiosensitivity and immune deficiency at the whole organism level. A core protein complex comprising the Ku70/80 heterodimer together with a complex between DNA ligase IV and XRCC4 is conserved throughout eukaryotes and assembles at double-strand breaks to mediate ligation of broken DNA ends. In Saccharomyces cerevisiae an additional NHEJ protein, Nej1p, physically interacts with the ligase IV complex and is required in vivo for ligation of DNA double-strand breaks. Recent studies with cells derived from radiosensitive and immune-deficient patients have identified the human protein, XLF(also named Cernunnos), as a crucial NHEJ protein. Here we show that XLF and Nej1p are members of the same protein superfamily and that this family has members in diverse eukaryotes. Indeed, we show that a member of this family encoded by a previously uncharacterized open-reading frame in the Schizosaccharomyces pombe genome is required for NHEJ in this organism. Furthermore, our data reveal that XLF family proteins can bind to DNA and directly interact with the ligase IV-XRCC4 complex to promote DSB ligation. We therefore conclude that XLF family proteins interact with the ligase IV-XRCC4 complex to constitute the evolutionarily conserved enzymatic core of the NHEJ machinery.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Univ Cambridge, Gurdon Inst, Cambridge CB2 1QN, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QN, England; Univ Birmingham, Sch Med, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Sussex; University of Cambridge; University of Cambridge; University of Birmingham; University of Michigan System; University of Michigan	Doherty, AJ (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	AJD21@sussex.ac.uk	Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; bianchi, julie/0000-0001-7958-4261; Doherty, Aidan/0000-0002-6370-1109; Green, Andrew/0000-0002-1077-7417	NATIONAL CANCER INSTITUTE [R01CA102563] Funding Source: NIH RePORTER; Medical Research Council [G0300662B] Funding Source: researchfish; Biotechnology and Biological Sciences Research Council [BB/D522746/1, BB/C516036/1] Funding Source: Medline; NCI NIH HHS [R01 CA102563-03, R01 CA102563] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; AHNESORG P, 2006, IN PRESS DNA REPAIR; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Callebaut I, 2006, J BIOL CHEM, V281, P13857, DOI 10.1074/jbc.C500473200; Calsou P, 2003, J MOL BIOL, V326, P93, DOI 10.1016/S0022-2836(02)01328-1; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Chibana H, 2005, GENETICS, V170, P1525, DOI 10.1534/genetics.104.034652; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dai Y, 2003, P NATL ACAD SCI USA, V100, P2462, DOI 10.1073/pnas.0437964100; Daley JM, 2005, J BIOL CHEM, V280, P29030, DOI 10.1074/jbc.M505277200; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Dore AS, 2006, DNA REPAIR, V5, P362, DOI 10.1016/j.dnarep.2005.11.004; Drouet J, 2006, J BIOL CHEM, V281, P27784, DOI 10.1074/jbc.M603047200; Dujon B, 2005, CURR OPIN GENET DEV, V15, P614, DOI 10.1016/j.gde.2005.09.005; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Ferreira MG, 2004, GENE DEV, V18, P2249, DOI 10.1101/gad.315804; Fischer G, 2006, PLOS GENET, V2, P253, DOI 10.1371/journal.pgen.0020032; Frank-Vaillant M, 2001, GENE DEV, V15, P3005, DOI 10.1101/gad.206801; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Hefferin ML, 2005, DNA REPAIR, V4, P639, DOI 10.1016/j.dnarep.2004.12.005; Hentges P, 2005, YEAST, V22, P1013, DOI 10.1002/yea.1291; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kegel A, 2001, CURR BIOL, V11, P1611, DOI 10.1016/S0960-9822(01)00488-2; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Koch CA, 2004, EMBO J, V23, P3874, DOI 10.1038/sj.emboj.7600375; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Lee KJ, 2004, DNA REPAIR, V3, P267, DOI 10.1016/j.dnarep.2003.11.005; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liti G, 2003, MOL CELL, V11, P1373, DOI 10.1016/S1097-2765(03)00177-1; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Ma YM, 2005, CELL CYCLE, V4, P1193, DOI 10.4161/cc.4.9.1977; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Manolis KG, 2001, EMBO J, V20, P210, DOI 10.1093/emboj/20.1.210; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Modesti M, 2003, J MOL BIOL, V334, P215, DOI 10.1016/j.jmb.2003.09.031; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; Revy P, 2005, ADV IMMUNOL, V87, P237, DOI 10.1016/S0065-2776(05)87007-5; Rivera-Calzada A, 2005, STRUCTURE, V13, P243, DOI 10.1016/j.str.2004.12.006; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Schatz DG, 2005, CURR TOP MICROBIOL, V290, P49; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; Yu YP, 2003, DNA REPAIR, V2, P1239, DOI 10.1016/S1568-7864(03)00143-5	61	65	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37517	37526		10.1074/jbc.M608727200	http://dx.doi.org/10.1074/jbc.M608727200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17038309	hybrid			2022-12-25	WOS:000242477100028
J	Jiao, W; Datta, J; Lin, HM; Dundr, M; Rane, SG				Jiao, Wan; Datta, Jashodeep; Lin, Huei-Min; Dundr, Miroslav; Rane, Sushil G.			Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation-dependent nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; GENE-PRODUCT; CELL-CYCLE; CANCER; E2F; P53; LOCALIZATION; PHO80-PHO85; EXPRESSION; PROLIFERATION	The retinoblastoma (RB) tumor suppressor protein is a negative regulator of cell proliferation that is functionally inactivated in the majority of human tumors. Elevated Cdk activity via RB pathway mutations is observed in virtually every human cancer. Thus, Cdk inhibitors have tremendous promise as anticancer agents although detailed mechanistic knowledge of their effects on RB function is needed to harness their full potential. Here, we illustrate a novel function for Cdks in regulating the subcellular localization of RB. We present evidence of significant cytoplasmic mislocalization of ordinarily nuclear RB in cells harboring Cdk4 mutations. Ourfindings uncover a novel mechanism to circumvent RB-mediated growth suppression by altered nucleocytoplasmic trafficking via the Exportin1 pathway. Cytoplasmically mislocalized RB could be efficiently confined to the nucleus by inhibiting the Exportin1 pathway, reducing Cdk activity, or mutating the Cdk-dependent phosphorylation sites in RB that result in loss of RB-Exportin1 association. Thus RB-mediated tumor suppression can be subverted by phosphorylation-dependent enhancement of nuclear export. These results support the notion that tumor cells can modulate the protein transport machinery thereby making the protein transport process a viable therapeutic target.	NIDDK, Cell Cycle & Human Dis Grp, Diabet Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Rosalind Franklin Univ Med & Sci, Dept Cell Biol, N Chicago, IL 60064 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rosalind Franklin University Medical & Science	Rane, SG (corresponding author), NIDDK, Cell Cycle & Human Dis Grp, Diabet Branch, NIH, Bethesda, MD 20892 USA.	ranes@mail.nih.gov		Datta, Jashodeep/0000-0003-2869-1571				Angus SP, 2003, MOL CELL BIOL, V23, P8172, DOI 10.1128/MCB.23.22.8172-8188.2003; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; STOKKE T, 1993, EXP CELL RES, V204, P147, DOI 10.1006/excr.1993.1019; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yang H, 2002, MOL CELL BIOL, V22, P3103, DOI 10.1128/MCB.22.9.3103-3110.2002; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; Ziegler E. C., 2005, SCI STKE, pre6, DOI DOI 10.1126/STKE.2842005RE6; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	43	53	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38098	38108		10.1074/jbc.M605271200	http://dx.doi.org/10.1074/jbc.M605271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17043357	hybrid			2022-12-25	WOS:000242477100088
J	Nardini, M; Pesce, A; Labarre, M; Richard, C; Bolli, A; Ascenzi, P; Guertin, M; Bolognesi, M				Nardini, Marco; Pesce, Alessandra; Labarre, Marie; Richard, Christian; Bolli, Alessandro; Ascenzi, Paolo; Guertin, Michel; Bolognesi, Martino			Structural determinants in the group III truncated hemoglobin from Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS HEMOGLOBIN; X-RAY; OXYGEN-METABOLISM; CYANIDE BINDING; LIGAND-BINDING; PROGRAM; MYOGLOBIN; GLOBIN; BASES; HBN	Truncated hemoglobins (trHbs) constitute a distinct lineage in the globin superfamily, distantly related in size and fold to myoglobin and monomeric hemoglobins. Their phylogenetic analyses revealed that three groups (I, II, and III) compose the trHb family. Group I and II trHbs adopt a simplified globin fold, essentially composed of a 2-on-2 alpha-helical sandwich, wrapped around the heme group. So far no structural data have been reported for group III trHbs. Here we report the three-dimensional structure of the group III trHbP from the eubacterium Campylobacter jejuni. The 2.15-angstrom resolution crystal structure of C. jejuni trHbP (cyano-met form) shows that the 2-on-2 trHb fold is substantially conserved in the trHb group III, despite the absence of the Gly-based sequence motifs that were considered necessary for the attainment of the trHb specific fold. The heme crevice presents important structural modifications in the C-E region and in the FG helical hinge, with novel surface clefts at the proximal heme site. Contrary to what has been observed for group I and II trHbs, no protein matrix tunnel/cavity system is evident in C. jejuni trHbP. A gating movement of His(E7) side chain (found in two alternate conformations in the crystal structure) may be instrumental for ligand entry to the heme distal site. Sequence conservation allows extrapolating part of the structural results here reported to the whole trHb group III.	Univ Milan, Dept Biomol Sci & Biotechnol, I-20131 Milan, Italy; Univ Milan, CNR, INFM, I-20131 Milan, Italy; Univ Genoa, Dept Phys, CNR, INFM, I-16146 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16146 Genoa, Italy; Univ Laval, Fac Sci & Genie, Dept Biochim & Microbiol, Ste Foy, PQ G1K 7P4, Canada; Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Roma Tre, Interdept Lab Elect Microscopy, I-00146 Rome, Italy; Natl Inst Infect Dis, IRCCS Lazzaro Spallanzani, I-00149 Rome, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Genoa; University of Genoa; Laval University; Roma Tre University; Roma Tre University; IRCCS Lazzaro Spallanzani	Bolognesi, M (corresponding author), Via Celoria 26, I-20131 Milan, Italy.	martino.bolognesi@unimi.it	Pesce, Alessandra/A-3660-2015; Bolognesi, Martino/B-7924-2017; Nardini, Marco/B-7842-2017	Bolognesi, Martino/0000-0002-9253-5170; Nardini, Marco/0000-0002-3718-2165; Bolli, Alessandro/0000-0001-7259-5785	NIAID NIH HHS [1-R01-AI052258] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052258] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; Bolognesi M, 1999, BIOPHYS J, V77, P1093, DOI 10.1016/S0006-3495(99)76959-6; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Falzone CJ, 2002, J MOL BIOL, V324, P1015, DOI 10.1016/S0022-2836(02)01093-8; Giangiacomo L, 2005, J BIOL CHEM, V280, P9192, DOI 10.1074/jbc.M407267200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGM, 2003, MOSFLM USER GUIDE; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Milani M, 2005, J INORG BIOCHEM, V99, P97, DOI 10.1016/j.jinorgbio.2004.10.035; Milani M, 2004, BIOCHEMISTRY-US, V43, P5213, DOI 10.1021/bi049870+; Milani M, 2004, J BIOL CHEM, V279, P21520, DOI 10.1074/jbc.M401320200; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pathania R, 2002, MOL MICROBIOL, V45, P1303, DOI 10.1046/j.1365-2958.2002.03095.x; PERUTZ MF, 1989, TRENDS BIOCHEM SCI, V14, P42, DOI 10.1016/0968-0004(89)90039-X; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Trent JT, 2004, J MOL BIOL, V341, P1097, DOI 10.1016/j.jmb.2004.05.070; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vinogradov SN, 2005, P NATL ACAD SCI USA, V102, P11385, DOI 10.1073/pnas.0502103102; Vuletich DA, 2006, J MOL EVOL, V62, P196, DOI 10.1007/s00239-005-0077-4; Wainwright LM, 2006, BIOCHEMISTRY-US, V45, P6003, DOI 10.1021/bi052247k; Wainwright LM, 2005, MICROBIOL-SGM, V151, P4079, DOI 10.1099/mic.0.28266-0; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200	33	49	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37803	37812		10.1074/jbc.M607254200	http://dx.doi.org/10.1074/jbc.M607254200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17023416	hybrid			2022-12-25	WOS:000242477100057
J	Lu, Y; Fukuyama, S; Yoshida, R; Kobayashi, T; Saeki, K; Shiraishi, H; Yoshimura, A; Takaesu, G				Lu, Yang; Fukuyama, Satoru; Yoshida, Ryoko; Kobayashi, Takashi; Saeki, Kazuko; Shiraishi, Hiroshi; Yoshimura, Akihiko; Takaesu, Giichi			Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSIOLOGICAL NEGATIVE REGULATOR; DIET-INDUCED OBESITY; M1 LEUKEMIA-CELLS; CYTOKINE SIGNALING-3; LEPTIN SENSITIVITY; MAMMARY-GLAND; DIFFERENTIATION; ACTIVATION; IL-6; GROWTH	The transcription factor STAT3 is activated by interleukin-6-related cytokines and has been implicated as an oncogene; it promotes cell proliferation and is anti-apoptotic. However, in some cases, STAT3 has been shown to be pro-apoptotic, especially in mammary epithelial cells. In this report, we generated SOCS3-deficient murine embryonic fibroblasts (MEFs), in which STAT3 activation is extremely enhanced and prolonged. We found that LIF induces caspase-3 activation and apoptosis of SOCS3(-/-) MEFs. Exogenous expression of the dominant negative form of STAT3 but not STAT1 suppressed LIF-induced apoptosis of SOCS3(-/-) MEFs, indicating that STAT3 plays a critical role in apoptosis induction. As shown in mammary gland epithelial cells, expression of the phosphatidylinositol 3-kinase regulatory subunits p50 alpha and p55 alpha was induced in response to LIF in SOCS3(-/-) MEFs but not in wild-type MEFs, and Akt/protein kinase B activity was substantially reduced in SOCS3(-/-) MEFs. Furthermore, we found that some of the STAT3 target genes related to apoptosis and proliferation, such as Bcl-2 and cyclin D1, were repressed upon LIF treatment in SOCS3(-/-) cells. Not only the up-regulation of p50 alpha and p55 alpha but also the repression of cyclin D1 and Bcl- 2 in SOCS3(-/-) MEFs was inhibited by dominant negative STAT3. These data suggest that prolonged activation of STAT3 could induce apoptosis/growth arrest rather than anti-apoptosis and proliferation in certain cases, and SOCS3 is a critical regulator of this balance.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Takaesu, G (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	takaesug@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Takaesu, Giichi/0000-0002-1581-1055				Abell K, 2005, NAT CELL BIOL, V7, P392, DOI 10.1038/ncb1242; Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Clarkson RWE, 2006, MOL ENDOCRINOL, V20, P675, DOI 10.1210/me.2005-0392; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; Kinjyo I, 2006, J EXP MED, V203, P1021, DOI 10.1084/jem.20052333; Kritikou EA, 2003, DEVELOPMENT, V130, P3459, DOI 10.1242/dev.00578; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Niemand C, 2003, J IMMUNOL, V170, P3263, DOI 10.4049/jimmunol.170.6.3263; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yang E, 2003, J BIOL CHEM, V278, P15794, DOI 10.1074/jbc.M213073200; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	40	75	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36683	36690		10.1074/jbc.M607374200	http://dx.doi.org/10.1074/jbc.M607374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028185	hybrid			2022-12-25	WOS:000242220800025
J	Mentaverri, R; Yano, S; Chattopadhyay, N; Petit, L; Kifor, O; Kamel, S; Terwilliger, EF; Brazier, M; Brown, EM				Mentaverri, R.; Yano, S.; Chattopadhyay, N.; Petit, L.; Kifor, O.; Kamel, S.; Terwilliger, E. F.; Brazier, M.; Brown, E. M.			The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis	FASEB JOURNAL			English	Article						phospholipase C; NF-kappa B; caspases	HIGH EXTRACELLULAR CALCIUM; FACTOR-KAPPA-B; OSTEOPROTEGERIN LIGAND; CHICKEN OSTEOCLASTS; MATURE OSTEOCLASTS; BONE-RESORPTION; NITRIC-OXIDE; IN-VITRO; CA2+; ACTIVATION	Intracellular transduction pathways that are dependent on activation of the CaR by Ca-o(2+) have been studied extensively in parathyroid and other cell types, and include cytosolic calcium, phospholipases C, A(2), and D, protein kinase C isoforms and the cAMP/protein kinase A system. In this study, using bone marrow cells isolated from CaR-/- mice as well as DN-CaR-transfected RAW 264.7 cells, we provide evidence that expression of the CaR plays an important role in osteoclast differentiation. We also establish that activation of the CaR and resultant stimulation of PLC are involved in high Ca-o(2+)-induced apoptosis of mature rabbit osteoclasts. Similar to RANKL, Ca-o(2+) (20 mM) appeared to trigger rapid and significant nuclear translocation of NF-kappa B in a CaR- and PLC-dependent manner. In summary, our data suggest that stimulation of the CaR may play a pivotal role in the control of both osteoclast differentiation and apoptosis in the systems studied here through a signaling pathway involving activation of the CaR, phospholipase C, and NF-kappa B. Mentaverri, R., Yano, S., Chattopadhyay, N., Petit, L., Kifor, O., Kamel, S., Terwilliger, E. F., Brazier, M., Brown, E. M. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis.	Univ Picardie, Unite Rech Mecan Resorpt Osseuse, F-80037 Amiens, France; Harvard Univ, Sch Med, Div Endocrinol Diabet & Hypertens, Brigham & Womens Hosp, Boston, MA 02115 USA; INSERM, ERI12, Amiens, France; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Picardie Universites; Universite de Picardie Jules Verne (UPJV); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Beth Israel Deaconess Medical Center	Mentaverri, R (corresponding author), Univ Picardie, Unite Rech Mecan Resorpt Osseuse, ERI-12,1 Rue Louvels, F-80037 Amiens, France.	romuald.mentaverri@sa.u-picardie.fr	Chattopadhyay, Naibedya/AAF-2058-2019; Kamel, Said/HGA-7781-2022; Chattopadhyay, Naibedya/AAQ-3213-2021	Chattopadhyay, Naibedya/0000-0003-2473-0246				Anderson HC, 1997, J CLIN INVEST, V99, P2059, DOI 10.1172/JCI119375; Anderson JJB, 1998, BAILLIERE CLIN ENDOC, V12, P543, DOI 10.1016/S0950-351X(98)80003-7; Bennett BD, 2001, ENDOCRINOLOGY, V142, P1968, DOI 10.1210/en.142.5.1968; Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523-1755.63.s85.2.x; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chattopadhyay N, 2004, ENDOCRINOLOGY, V145, P3451, DOI 10.1210/en.2003-1127; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122; Chen XF, 2003, CANCER RES, V63, P1059; Collin-Osdoby P, 2003, METH MOLEC MED, V80, P65; Foged NT, 1996, J BONE MINER RES, V11, P226; Garner SC, 2001, ENDOCRINOLOGY, V142, P3996, DOI 10.1210/en.142.9.3996; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; Hofer AM, 2005, J CELL SCI, V118, P855, DOI 10.1242/jcs.01705; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; KAMEDA T, 1995, BIOCHEM BIOPH RES CO, V207, P753, DOI 10.1006/bbrc.1995.1251; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; Kanaoka K, 2000, ENDOCRINOLOGY, V141, P2995, DOI 10.1210/en.141.8.2995; Kanatani N, 1999, BIOCHEM BIOPH RES CO, V261, P144, DOI 10.1006/bbrc.1999.0932; Kifor O, 2003, J BIOL CHEM, V278, P31167, DOI 10.1074/jbc.M303377200; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; LA RF, 1994, MOL CELL BIOL, V14, P1039; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lorget F, 2000, BIOCHEM BIOPH RES CO, V268, P899, DOI 10.1006/bbrc.2000.2229; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; Mentaverri R, 2003, J CELL BIOCHEM, V88, P1145, DOI 10.1002/jcb.10463; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; Pi M, 2005, J BIOL CHEM, V280, P40201, DOI 10.1074/jbc.M505186200; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Saunders R, 1998, NEUROPHARMACOLOGY, V37, P273, DOI 10.1016/S0028-3908(98)00027-6; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Spurr NK, 2003, CURR OPIN PHARMACOL, V3, P291, DOI 10.1016/S1471-4892(03)00034-1; Takayashiki T, 2002, HEPATO-GASTROENTEROL, V49, P109; Tfelt-Hansen J, 2003, AM J PHYSIOL-ENDOC M, V285, pE329, DOI 10.1152/ajpendo.00489.2002; WU HY, 1994, J BIOL CHEM, V269, P20067; Xu JK, 2005, J CELL PHYSIOL, V202, P554, DOI 10.1002/jcp.20159; Yamaguchi T, 1998, BIOCHEM BIOPH RES CO, V243, P753, DOI 10.1006/bbrc.1998.8178; Yano S, 2005, ENDOCRINOLOGY, V146, P2324, DOI 10.1210/en.2005-0065; Zaidi M, 1999, J BONE MINER RES, V14, P669, DOI 10.1359/jbmr.1999.14.5.669; Zaidi M, 1999, P ASSOC AM PHYSICIAN, V111, P319, DOI 10.1046/j.1525-1381.1999.99233.x; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197; Ziegelstein RC, 2006, BIOCHEM BIOPH RES CO, V342, P153, DOI 10.1016/j.bbrc.2006.01.135	50	151	157	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2562	+		10.1096/fj.06-6304fje	http://dx.doi.org/10.1096/fj.06-6304fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077282				2022-12-25	WOS:000242490700024
J	Stitham, J; Gleim, SR; Douville, K; Arehart, E; Hwa, J				Stitham, Jeremiah; Gleim, Scott R.; Douville, Karen; Arehart, Eric; Hwa, John			Versatility and differential roles of cysteine residues in human prostacyclin receptor structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED EXTRACELLULAR CYSTEINES; SITE-DIRECTED MUTAGENESIS; DISULFIDE BOND; LIGAND-BINDING; RETINITIS-PIGMENTOSA; OXIDATIVE STRESS; HORMONE RECEPTOR; RHODOPSIN; LOOP; ISOPRENYLATION	Prostacyclin plays important roles in vascular homeostasis, promoting vasodilatation and inhibiting platelet thrombus formation. Previous studies have shown that three of six cytoplasmic cysteines, particularly those within the C-terminal tail, serve as important lipidation sites and are differentially conjugated to palmitoyl and isoprenyl groups (Miggin, S. M., Lawler, O. A., and Kinsella, B. T. (2003) J. Biol. Chem. 278, 6947-6958). Here we report distinctive roles for extracellular- and trans-membrane-located cysteine residues in human prostacyclin receptor structure-function. Within the extracellular domain, all cysteines (4 of 4) appear to be involved in disulfide bonding interactions (i.e. a highly conserved Cys-92-Cys-170 bond and a putative non-conserved Cys-5-Cys-165 bond), and within the transmembrane (TM) region there are several cysteines (3 of 8) that maintain critical hydrogen bonding interactions (Cys-118 (TMIII), Cys-251 (TMVI), and Cys-202 (TMV)). This study highlights the necessity of sulfhydryl (SH) groups in maintaining the structural integrity of the human prostacyclin receptor, as 7 of 12 extracellular and transmembrane cysteines studied were found to be differentially indispensable for receptor binding, activation, and/or trafficking. Moreover, these results also demonstrate the versatility and reactivity of these cysteine residues within different receptor environments, that is, extracellular (disulfide bonds), transmembrane (H-bonds), and cytoplasmic (lipid conjugation).	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Med Cardiol, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Hwa, J (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	John.Hwa@Dartmouth.edu						Audoly L, 1997, J BIOL CHEM, V272, P13475, DOI 10.1074/jbc.272.21.13475; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Fay JF, 2005, BIOCHEMISTRY-US, V44, P8757, DOI 10.1021/bi0472651; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Fotiadis D, 2006, CURR OPIN STRUC BIOL, V16, P252, DOI 10.1016/j.sbi.2006.03.013; Giguere V, 2004, EUR J PHARMACOL, V494, P11, DOI 10.1016/j.ejphar.2004.04.041; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hayes JS, 1999, J BIOL CHEM, V274, P23707, DOI 10.1074/jbc.274.34.23707; Heitzer T, 2001, CIRCULATION, V104, P2673, DOI 10.1161/hc4601.099485; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Jones RL, 1997, CLIN EXP PHARMACOL P, V24, P969, DOI 10.1111/j.1440-1681.1997.tb02730.x; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; Keith RL, 2002, CANCER RES, V62, P734; Lisenbee CS, 2005, J BIOL CHEM, V280, P12330, DOI 10.1074/jbc.M414016200; Miggin SM, 2003, J BIOL CHEM, V278, P6947, DOI 10.1074/jbc.M210637200; Miggin SM, 2002, EUR J BIOCHEM, V269, P1714, DOI 10.1046/j.1432-1327.2002.02817.x; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nagaya N, 1999, J AM COLL CARDIOL, V34, P1188, DOI 10.1016/S0735-1097(99)00312-5; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NODA K, 1994, J BIOL CHEM, V269, P6743; Olschewski H, 2000, ANN INTERN MED, V132, P435, DOI 10.7326/0003-4819-132-6-200003210-00003; PERLMAN JH, 1995, J BIOL CHEM, V270, P24682, DOI 10.1074/jbc.270.42.24682; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Schiffrin EL, 1998, J CARDIOVASC PHARM, V32, pS2; Schneider MR, 1996, BREAST CANCER RES TR, V38, P133, DOI 10.1007/BF01803791; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Stitham J, 2004, BIOCHEMISTRY-US, V43, P8974, DOI 10.1021/bi0496788; Stitham J, 2003, J BIOL CHEM, V278, P4250, DOI 10.1074/jbc.M207420200; Stitham J, 2002, J BIOL CHEM, V277, P15439, DOI 10.1074/jbc.M201187200; Stitham J, 2002, MOL PHARMACOL, V61, P1202, DOI 10.1124/mol.61.5.1202; Stojanovic A, 2004, J BIOL CHEM, V279, P35932, DOI 10.1074/jbc.M403821200; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; Tarnow P, 2003, J BIOL CHEM, V278, P48666, DOI 10.1074/jbc.M309941200; Watanabe K, 1999, CANCER RES, V59, P5093; Wilson SJ, 2004, J BIOL CHEM, V279, P53036, DOI 10.1074/jbc.M405002200; Zhang PS, 1999, MOL BRAIN RES, V72, P195, DOI 10.1016/S0169-328X(99)00241-7	45	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37227	37236		10.1074/jbc.M604042200	http://dx.doi.org/10.1074/jbc.M604042200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17015447	hybrid			2022-12-25	WOS:000242220800083
J	He, H; Sun, Y				He, H.; Sun, Y.			Ribosomal protein S27L is a direct p53 target that regulates apoptosis	ONCOGENE			English	Article						RPS27L; p53; apoptosis; ribosomal protein; gene expression and siRNA silencing	BREAST-CANCER; TUMOR-MARKER; DNA-DAMAGE; GROWTH; CARCINOMA; ACTIVATION; METALLOPANSTIMULIN; INHIBITION; EXPRESSION; CELLS	Ribosomal proteins were recently shown to regulate p53 activity by abrogating Mdm2-induced p53 degradation (L23, L11, L5) or by enhancing p53 translation (L26). Here, we report that a novel ribosomal protein, RPS27L (S27-like protein), is a direct p53 target. RPS27L, but not its family member RPS27, was identified as a p53 inducible gene in a genome-wide chip-profiling study. Further characterization revealed a p53-dependent induction of RPS27L in multiple cancer cell models. Indeed, a consensus p53-binding site was identified in the first intron of the RPS27L gene and a direct binding of p53 to this site was demonstrated both in vitro and in vivo. Characterization of a luciferase reporter driven by the RPS27L intron fragment revealed a p53-binding site-dependent transaction by wild-type p53, but not by several transactivating-deficient p53 mutants. This transactivation was enhanced by etoposide, a DNA damaging agent that activates p53 and was completely blocked by a dominant-negative p53 mutant. Functionally, overexpression of RPS27L within the physiological inducible levels promoted, whereas siRNA silencing of RPS27L inhibited, apoptosis induced by etoposide. This is the first report, to our knowledge, that p53 directly induces the expression of a ribosomal protein, RPS27L, which in turn promotes apoptosis.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, 4304 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287	NATIONAL CANCER INSTITUTE [R01CA111554] Funding Source: NIH RePORTER; NCI NIH HHS [1R01-CA111554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atsuta Y, 2002, CANCER LETT, V182, P101, DOI 10.1016/S0304-3835(02)00068-X; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FernandezPol JA, 1997, ANTICANCER RES, V17, P1519; FERNANDEZPOL JA, 1993, J BIOL CHEM, V268, P21198; FERNANDEZPOL JA, 1994, CELL GROWTH DIFFER, V5, P811; FernandezPol JA, 1996, ANTICANCER RES, V16, P2177; Ganger DR, 1997, ANTICANCER RES, V17, P1993; Ganger DR, 2001, CANCER DETECT PREV, V25, P231; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Lee WJ, 2004, OTOLARYNG HEAD NECK, V131, P466, DOI 10.1016/j.otohns.2004.03.011; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 2005, NEOPLASIA, V7, P312, DOI 10.1593/neo.04325; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Robinson M, 2003, CANCER BIOL THER, V2, P406, DOI 10.4161/cbt.2.4.437; Stack Brendan C Jr, 2004, World J Surg Oncol, V2, P45, DOI 10.1186/1477-7819-2-45; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; Sun YJ, 2006, IEEE T CIRCUITS-II, V53, P409, DOI 10.1109/TCSII.2006.869913; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; WONG JM, 1993, CANCER RES, V53, P1916; Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005	38	72	77	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2707	2716		10.1038/sj.onc.1210073	http://dx.doi.org/10.1038/sj.onc.1210073			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057733				2022-12-25	WOS:000246210600005
J	Nanjundan, M; Zhang, F; Schmandt, R; Smith-McCune, K; Mills, GB				Nanjundan, M.; Zhang, F.; Schmandt, R.; Smith-McCune, K.; Mills, G. B.			Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions	ONCOGENE			English	Article						AML1; splicing; ovarian cancers	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; E-CADHERIN; NUCLEAR-MATRIX; CELL-MIGRATION; BETA-CATENIN; EXPRESSION; GENE; TRANSACTIVATION; ASSOCIATION	Acute myeloid leukemia (AML) 1 is often disrupted by chromosomal translocations generating oncogenic fusions in human leukemias. However, its role in epithelial cancers has not been extensively investigated. Herein, we show a marked accumulation of AML1 transcripts including a high frequency of a novel alternatively spliced AML1b transcript lacking exon 6 (AML1b(Del179-242)) in ovarian cancer patients. The increases in RNA transcripts for total wild-type AML1 and AML1b(Del179-242) are associated with poor patient outcomes. We have shown that although both wild-type AML1b and AML1b(Del179-242) are localized to nuclear speckles, AML1b(Del179-242) was observed to have dramatically reduced transactivation potential with the plasminogen activator inhibitor-1 promoters and behaved as a weak dominant negative of wild-type AML1b. Wild-type AML1b was found to inhibit the growth of immortalized ovarian epithelial cells (T29) decreasing colony-forming ability. Moreover, we have identified a novel function of AML1b where it inhibits ovarian cell migration. In contrast, AML1b(Del179-242) has lost the ability to inhibit both ovarian cell proliferation and migration indicating that the functional effects observed with wild-type AML1b are dependent on amino acids 179-242. Collectively, these studies suggest that deregulated alternative splicing of AML1b transcripts may potentially contribute to the pathophysiology of ovarian cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77054 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77054 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco	Nanjundan, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, 7435 Fannin St, Houston, TX 77054 USA.	mnanjund@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, P50CA083639, P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16672, P50 CA083639, P01 CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Berger R, 1997, CANCER GENET CYTOGEN, V94, P8, DOI 10.1016/S0165-4608(96)00351-2; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47; Faleiro-Rodrigues C, 2004, HUM PATHOL, V35, P663, DOI 10.1016/j.humpath.2004.01.024; Fowler M, 2006, J CELL BIOCHEM, V97, P1, DOI 10.1002/jcb.20664; Fujioka T, 2001, ONCOL REP, V8, P249; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Harrison S., 2002, SMALL SCALE EC MANAG, V1, P1, DOI [DOI 10.1007/S11842-002-0001-3, 10.1007/s11842-002-0001-3]; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; INOUE M, 1992, AM J CLIN PATHOL, V98, P76, DOI 10.1093/ajcp/98.1.76; Kirschnerova G, 2006, NEOPLASMA, V53, P150; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Orban TI, 2003, J CLIN PATHOL-MOL PA, V56, P191, DOI 10.1136/mp.56.4.191; Robinson HM, 2003, LEUKEMIA, V17, P2249, DOI 10.1038/sj.leu.2403140; Sun LX, 2001, CANCER RES, V61, P4994; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Whitley BR, 2004, EXP CELL RES, V296, P151, DOI 10.1016/j.yexer.2004.02.022; Yamagata T, 2005, INT J HEMATOL, V82, P1, DOI 10.1532/IJH97.05075; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	28	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2574	2584		10.1038/sj.onc.1210067	http://dx.doi.org/10.1038/sj.onc.1210067			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072347				2022-12-25	WOS:000245831200005
J	Dow, LE; Kauffman, JS; Caddy, J; Peterson, AS; Jane, SM; Russell, SM; Humbert, PO				Dow, L. E.; Kauffman, J. S.; Caddy, J.; Peterson, A. S.; Jane, S. M.; Russell, S. M.; Humbert, P. O.			The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge	ONCOGENE			English	Article						scribble; polarity; migration; wound healing; epithelium	DISCS LARGE; DIFFERENTIAL EXPRESSION; CDC42 CONTROLS; HUMAN HOMOLOG; PROTEIN; DROSOPHILA; ACTIVATION; COMPLEX; ACTIN; MOUSE	Altered expression of human Scribble is associated with invasive epithelial cancers, however, its role in tumour development remains unclear. Mutations in Drosophila Scribble result in loss of polarity, overproliferation and 3D-tumourous overgrowth of epithelial cells. Using complementation studies in Drosophila we recently demonstrated that expression of human Scribble can also regulate polarity and restrict tissue overgrowth. Here, we have undertaken a detailed study of human Scribble function in the polarized mammary cell line, MCF10A. We show that although Scribble does not seem to be required for apical-basal polarity or proliferation control in MCF10A cells, Scribble is essential for the control of polarity associated with directed epithelial cell migration. Scribble-depleted MCF10A cells show defective in vitro wound closure and chemotactic movement. The cells at the wound edge fail to polarize, show reduced lamellipodia formation and impaired recruitment of Cdc42 and Rac1 to the leading edge. Furthermore, we show that this function is relevant in vivo as Scribble mutant mice show defective epidermal wound healing. This data identifies an essential role for mammalian Scribble in the regulation of the polarity specifically involved in directed epithelial migration.	Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic 8006, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic, Australia; Rotary Bone Marrow Res Labs, Parkville, Vic, Australia; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Peter MacCallum Canc Ctr, Immune Signalling Lab, Melbourne, Vic, Australia; Swinburne Univ Technol, Fac Engn & Ind Sci, Ctr Microphoton, Cell Biol Lab, Hawthorn, Vic 3122, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; University of Melbourne; Roche Holding; Genentech; Peter Maccallum Cancer Center; Swinburne University of Technology; University of Melbourne	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.	patrick.humbert@petermac.org	Humbert, Patrick O/L-4264-2016; Russell, Sarah M/B-9341-2009; Jane, Stephen/D-6659-2011	Humbert, Patrick O/0000-0002-1366-6691; Russell, Sarah M/0000-0001-5826-9641; Dow, Lukas/0000-0001-7048-1418; Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL53749-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Berkowitz EA, 1996, CELL GROWTH DIFFER, V7, P1271; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Boussioutas A, 2003, CANCER RES, V63, P2569; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cau JL, 2005, J CELL SCI, V118, P2579, DOI 10.1242/jcs.02385; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; HUMBERT PO, 2006, IN PRESS TRENDS CELL; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; MCCLUSKEY J, 1993, TISSUE CELL, V25, P173, DOI 10.1016/0040-8166(93)90017-F; Mine N, 2005, DEVELOPMENT, V132, P4317, DOI 10.1242/dev.02030; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pinheiro EM, 2004, DEVELOPMENT, V131, P5243, DOI 10.1242/dev.01412; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Redvers RP, 2004, METH MOL B, V289, P15; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	48	138	140	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2272	2282		10.1038/sj.onc.1210016	http://dx.doi.org/10.1038/sj.onc.1210016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043654				2022-12-25	WOS:000245466000003
J	Faraonio, R; Vergara, P; Di Marzo, D; Pierantoni, MG; Napolitano, M; Russo, T; Cimino, F				Faraonio, Raffaella; Vergara, Paola; Di Marzo, Domenico; Pierantoni, Maria Giovanna; Napolitano, Maria; Russo, Tommaso; Cimino, Filiberto			p53 suppresses the Nrf2-dependent transcription of antioxidant response genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-MEDIATED EXPRESSION; OXIDATIVE STRESS; NF-Y; TUMOR-SUPPRESSOR; SUBUNIT GENE; FACTOR NRF2; KEAP1; PROTEIN; INDUCTION; APOPTOSIS	Cells respond to the shift of intracellular environment toward pro-oxidant conditions by activating the transcription of numerous "antioxidant" genes. This response is based on the activation of the Nrf2 transcription factor, which transactivates the genes containing in their promoters the antioxidant response cis- elements (AREs). If the oxidative stress provokes DNA damage, a second response of the cell takes place, based on the activation of p53, which induces cell cycle arrest and/or apoptosis. Here we have explored the cross-talk between these two regulatory mechanisms. The results show that p53 counteracts the Nrf2-induced transcription of three ARE-containing promoters of the x-CT, NQO1, and GST-alpha 1 genes. Endogenous transcripts of these antioxidant genes accumulate as a consequence of Nrf2 overexpression or exposure to electrophile diethylmaleate, but these effects are again blocked by p53 overexpression or endogenous p53 activation. Chromatin immuno-precipitation experiments support the hypothesis that this p53-dependent trans-repression is due to the direct interaction of p53 with the ARE-containing promoters. Considering that p53-induced apoptosis requires an accumulation of reactive oxygen species, this negative control on the Nrf2 transactivation appears to be aimed to prevent the generation of a strong antioxidant intracellular environment that could hinder the induction of apoptosis.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, CEINGE Biotecnol Avanzate, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Nazl Tumori, Fdn Pascale, I-80131 Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Naples Federico II; IRCCS Fondazione Pascale	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, CEINGE Biotecnol Avanzate, I-80131 Naples, Italy.	russot@dbbm.unina.it	faraonio, raffaella/K-3802-2018; Vergara, Paola/K-9145-2013; Russo, Tommaso/K-1331-2016; napolitano, maria/K-1615-2016	Russo, Tommaso/0000-0003-4426-0106; napolitano, maria/0000-0002-8996-3297; Faraonio, Raffaella/0000-0002-7040-6781; Pierantoni, Giovanna Maria/0000-0003-4078-8528				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CAAMANO J, 1991, AM J PATHOL, V139, P839; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Faraonio R, 2006, ANTIOXID REDOX SIGN, V8, P365, DOI 10.1089/ars.2006.8.365; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kaeser MD, 2004, ONCOGENE, V23, P4007, DOI 10.1038/sj.onc.1207536; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004	35	241	248	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39776	39784		10.1074/jbc.M605707200	http://dx.doi.org/10.1074/jbc.M605707200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17077087	hybrid			2022-12-25	WOS:000243033900005
J	Quintana, A; Schwarz, EC; Schwindling, C; Lipp, P; Kaestner, L; Hoth, M				Quintana, Ariel; Schwarz, Eva C.; Schwindling, Christian; Lipp, Peter; Kaestner, Lars; Hoth, Markus			Sustained activity of calcium release-activated calcium channels requires translocation of mitochondria to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED CA2+ ENTRY; T-LYMPHOCYTES; CRAC CHANNELS; STORE; CELLS; TRANSPORT; MICROTUBULES; MECHANISMS; DYNAMICS; MOTILITY	A rise of the intracellular Ca2+ concentration has multiple signaling functions. Sustained Ca2+ influx across plasma membrane through calcium release-activated calcium ( CRAC) channels is required for T-cell development in the thymus, gene transcription, and proliferation and differentiation of naive T-cells into armed effectors cells. Intracellular Ca2+ signals are shaped by mitochondria, which function as a highly dynamic Ca2+ buffer. However, the precise role of mitochondria for Ca2+-dependent T-cell activation is unknown. Here we have shown that mitochondria are translocated to the plasma membrane as a consequence of Ca2+ influx and that this directed movement is essential to sustain Ca2+ influx through CRAC channels. The decreased distance between mitochondria and the plasma membrane enabled mitochondria to take up large amounts of inflowing Ca2+ at the plasma membrane, thereby preventing Ca2+-dependent inactivation of CRAC channels and sustaining Ca2+ signals. Inhibition of kinesin-dependent mitochondrial movement along microtubules abolished mitochondrial translocation and reduced sustained Ca2+ signals. Our results show how a directed movement of mitochondria is used to control important cellular functions such as Ca2+-dependent T-cell activation.	Univ Saarland, Inst Physiol, Dept Physiol, D-66421 Homburg, Saar, Germany; Univ Saarland, Inst Mol Cell Biol, D-66421 Homburg, Saar, Germany	Saarland University; Saarland University	Quintana, A (corresponding author), Univ Saarland, Inst Physiol, Dept Physiol, Gebaude 58, D-66421 Homburg, Saar, Germany.	ptaqgo@uniklinikum-saarland.de	Kaestner, Lars/P-6988-2016	Kaestner, Lars/0000-0001-6796-9535; Schwarz, Eva C./0000-0002-6503-4864; Hoth, Markus/0000-0001-7080-4643				BALL EH, 1982, P NATL ACAD SCI-BIOL, V79, P123, DOI 10.1073/pnas.79.1.123; Bautista DM, 2002, J PHYSIOL-LONDON, V541, P877, DOI 10.1113/jphysiol.2001.016154; Bhakta NR, 2005, NAT IMMUNOL, V6, P143, DOI 10.1038/ni1161; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2005, J EXP MED, V202, P651, DOI 10.1084/jem.20050687; Gallo EM, 2006, NAT IMMUNOL, V7, P25, DOI 10.1038/ni1295; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Knowles MK, 2002, P NATL ACAD SCI USA, V99, P14772, DOI 10.1073/pnas.232346999; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nolz JC, 2006, CURR BIOL, V16, P24, DOI 10.1016/j.cub.2005.11.036; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Philipp S, 2003, J BIOL CHEM, V278, P26629, DOI 10.1074/jbc.M304044200; Quintana A, 2005, PFLUG ARCH EUR J PHY, V450, P1, DOI 10.1007/s00424-004-1364-4; Quintana A, 2004, CELL CALCIUM, V36, P99, DOI 10.1016/j.ceca.2004.01.003; Schwarz A, 2004, J BIOL CHEM, V279, P5641, DOI 10.1074/jbc.M309317200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Tutsch E, 2004, EUR J IMMUNOL, V34, P3477, DOI 10.1002/eji.200425265; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Varadi A, 2004, CELL CALCIUM, V36, P499, DOI 10.1016/j.ceca.2004.05.003; Varadi A, 2004, J CELL SCI, V117, P4389, DOI 10.1242/jcs.01299; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Yi MQ, 2004, J CELL BIOL, V167, P661, DOI 10.1083/jcb.200406038; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; YOON Y, 2005, SCI STKE, pPE18; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zitt C, 2004, J BIOL CHEM, V279, P12427, DOI 10.1074/jbc.M309297200; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	36	113	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40302	40309		10.1074/jbc.M607896200	http://dx.doi.org/10.1074/jbc.M607896200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17056596	hybrid			2022-12-25	WOS:000243033900061
J	Robert, R; Jacobin-Valat, MJ; Daret, D; Miraux, S; Nurden, AT; Franconi, JM; Clofent-Sanchez, G				Robert, Remy; Jacobin-Valat, Marie-Josee; Daret, Daniele; Miraux, Sylvain; Nurden, Alan T.; Franconi, Jean-Michel; Clofent-Sanchez, Gisele			Identification of human scFvs targeting atherosclerotic lesions - Selection by single round in vivo phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBODY FRAGMENTS; HETEROGENEITY; VITRONECTIN; ACTIVATION; MECHANISMS; EXPRESSION; DISEASE; CELLS	Our aim was to investigate by in vivo biopanning the lesions developed early in atherosclerosis and identify human antibodies that home to diseased regions. We have designed a two-step approach for a rapid isolation of human Monoclonal phage-display single-chain antibodies (MoPhabs) reactive with proteins found in lesions developed in an animal model of atherosclerosis. After a single round of in vivo biopanning, the MoPhabs were eluted from diseased sections of rabbit aorta identified by histology and NMR microscopy. MoPhabs expressed in situ were selected by subtractive colony filter screening for their capacity to recognize atherosclerotic but not normal aorta. MoPhabs selected by our method predominantly bind atherosclerotic lesions. Two of them, B3.3G and B3.GER, produced as scFv fragments, recognized an epitope present on the surface in early atherosclerotic lesions and within the intimal thickness in more complex plaques. These human MoPhabs homed to atherosclerotic lesions in ApoE(-/-) mice after in vivo injection. A protein of similar to 56 kDa recognized by B3.3G was affinity-purified and identified by mass spectrometry analysis as vitronectin. This is the first time that single round in vivo biopanning has been used to select human antibodies as candidates for diagnostic imaging and for obtaining insight into targets displayed in atherosclerotic plaques.	INSERM, U441, F-33600 Pessac, France; CHU Bordeaux, Inst Fed Rech 4, F-33600 Pessac, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux	Robert, R (corresponding author), Univ Bordeaux 2, CNRS, UMR 5536, RMSB, Bat 4A,146 Rue Leo Saignat, F-33076 Bordeaux, France.	remy.robert@etud.u-bordeaux2.fr	Miraux, Sylvain/AAF-1023-2019; Robert, Remy/O-3602-2019; Clofent-Sanchez, Gisèle/AAL-4545-2020; robert, remy/E-6881-2012	Robert, Remy/0000-0003-2416-9268; robert, remy/0000-0003-2416-9268; Miraux, Sylvain/0000-0002-3642-2390				Botnar RM, 2004, CIRCULATION, V109, P2023, DOI 10.1161/01.CIR.0000127034.50006.C0; de Wildt RMT, 2000, NAT BIOTECHNOL, V18, P989, DOI 10.1038/79494; DREHER ML, 1991, J IMMUNOL METHODS, V139, P197, DOI 10.1016/0022-1759(91)90189-M; Dufourcq P, 2002, CARDIOVASC RES, V53, P952, DOI 10.1016/S0008-6363(01)00547-8; Dufourcq P, 1998, ARTERIOSCL THROM VAS, V18, P168, DOI 10.1161/01.ATV.18.2.168; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Giovannoni L, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e27; Goncalves I, 2005, J BIOL CHEM, V280, P15430, DOI 10.1074/jbc.M410235200; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Houston P, 2001, FEBS LETT, V492, P73, DOI 10.1016/S0014-5793(01)02191-3; Kelly KA, 2005, CIRC RES, V96, P327, DOI 10.1161/01.RES.0000155722.17881.dd; Kuhne SA, 2004, J CLIN MICROBIOL, V42, P2966, DOI 10.1128/JCM.42.7.2966-2976.2004; Lasserre JP, 2006, ELECTROPHORESIS, V27, P3306, DOI 10.1002/elps.200500912; Liu C, 2003, AM J PATHOL, V163, P1859, DOI 10.1016/S0002-9440(10)63545-6; Mori M, 1996, J Atheroscler Thromb, V3, P25; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Paulhe F, 2001, J BIOL CHEM, V276, P41832, DOI 10.1074/jbc.M105459200; Pini A, 2002, COMB CHEM HIGH T SCR, V5, P503, DOI 10.2174/1386207023330039; POUL MA, 1995, EUR J IMMUNOL, V25, P2005, DOI 10.1002/eji.1830250731; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Robert R, 2005, J CHROMATOGR B, V818, P43, DOI 10.1016/j.jchromb.2004.10.038; Rodenburg CM, 1998, HYBRIDOMA, V17, P1, DOI 10.1089/hyb.1998.17.1; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SATO R, 1990, J BIOL CHEM, V265, P21232; Takahashi T, 2001, CIRC RES, V88, P422; Trepel M, 2002, CURR OPIN CHEM BIOL, V6, P399, DOI 10.1016/S1367-5931(02)00336-8; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601	28	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40135	40143		10.1074/jbc.M609344200	http://dx.doi.org/10.1074/jbc.M609344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17068330	hybrid			2022-12-25	WOS:000243033900043
J	Das, A; Fernandez-Zapico, ME; Cao, S; Yao, J; Fiorucci, S; Hebbel, RP; Urrutia, R; Shah, VH				Das, Amitava; Fernandez-Zapico, Martin E.; Cao, Sheng; Yao, Janet; Fiorucci, Stefano; Hebbel, Robert P.; Urrutia, Raul; Shah, Vijay H.			Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; HEPATIC STELLATE CELLS; BILE-ACIDS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; GROWTH-REGULATION; BINDING-PROTEIN; IV COLLAGENASE; LIVER FIBROSIS; ACTIVATION	The farnesoid X receptor (FXR) signaling pathway regulates bile acid and cholesterol homeostasis. Here, we demonstrate, using a variety of gain-and loss-of-function approaches, a role of FXR in the process of cell motility, which involves the small heterodimeric partner (SHP)-dependent up-regulation of matrix metalloproteinase-9. We use this observation to reveal a transcriptional regulatory mechanism involving the SP/KLF transcription factors, SP2 and KLF6. Small interference RNA-based silencing studies in combination with promoter, gel shift, and chromatin immunoprecipitation assays indicate that SP2 and KLF6 bind to the matrix metalloproteinase-9 promoter and together function to maintain this gene in a silenced state. However, upon activation of FXR, SHP interacts with SP2 and KLF6, disrupting the SP2/KLF6 repressor complex. Thus, together, these studies identify a mechanism for antagonizing Sp/KLF protein repression function via SHP, with this process regulating endothelial cell motility.	Mayo Clin, GI Res Unit, Gastroenterol Res Unit, Dept Physiol, Rochester, MN 55905 USA; Mayo Clin, Canc Biol Program, Rochester, MN 55905 USA; Univ Perugia, Dipartimento Med Clin & Sperimentale, Clin Gastroenterol & Endoscopia Digest, I-06122 Perugia, Italy; Univ Minnesota, Sch Med, Vasc Biol Ctr, Div Hematol Oncol & Transplantat, Minneapolis, MN 55454 USA	Mayo Clinic; Mayo Clinic; University of Perugia; University of Minnesota System; University of Minnesota Twin Cities	Das, A (corresponding author), Mayo Clin, GI Res Unit, Gastroenterol Res Unit, Dept Physiol, Alfred 2-435,200 1st St SW, Rochester, MN 55905 USA.	das.amitava@mayo.edu; shah.vijay@mayo.edu	Das, Amitava/AAJ-5682-2020; Fiorucci, Stefano/I-1251-2012	Das, Amitava/0000-0002-7510-1805	NATIONAL CANCER INSTITUTE [P50CA102701] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055552, P01HL076540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, R01DK059615, R56DK052913] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA102701] Funding Source: Medline; NHLBI NIH HHS [P01 HL055552, P01-HL076540] Funding Source: Medline; NIDDK NIH HHS [R01 DK059615, R01 DK052913-08, DK 52913, R01 DK052913-09, R01 DK052913] Funding Source: Medline; PHS HHS [R01-59615, R01-59388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bishop-Bailey D, 2004, P NATL ACAD SCI USA, V101, P3668, DOI 10.1073/pnas.0400046101; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Boulias K, 2004, NUCLEIC ACIDS RES, V32, P6096, DOI 10.1093/nar/gkh947; Boulias K, 2005, EMBO J, V24, P2624, DOI 10.1038/sj.emboj.7600728; Cao S, 2005, J BIOL CHEM, V280, P1901, DOI 10.1074/jbc.M407941200; Claudel T, 2002, J CLIN INVEST, V109, P961; Davis RA, 2002, J LIPID RES, V43, P533; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Fernandez-Zapico ME, 2003, EMBO J, V22, P4748, DOI 10.1093/emboj/cdg470; Fiorucci S, 2005, J PHARMACOL EXP THER, V314, P584, DOI 10.1124/jpet.105.084905; Fiorucci S, 2004, GASTROENTEROLOGY, V127, P1497, DOI 10.1053/j.gastro.2004.08.001; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Gobinet J, 2005, BIOCHEMISTRY-US, V44, P6312, DOI 10.1021/bi047308d; Gulati R, 2004, AM J PHYSIOL-HEART C, V287, pH512, DOI 10.1152/ajpheart.00063.2004; He FT, 2006, CIRC RES, V98, P192, DOI 10.1161/01.RES.0000200400.55539.85; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Huang WD, 2006, SCIENCE, V312, P233, DOI 10.1126/science.1121435; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Hwang ST, 2002, GASTROENTEROLOGY, V122, P1483, DOI 10.1053/gast.2002.32982; Inagaki T, 2006, P NATL ACAD SCI USA, V103, P3920, DOI 10.1073/pnas.0509592103; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kemper JK, 2004, MOL CELL BIOL, V24, P7707, DOI 10.1128/MCB.24.17.7707-7719.2004; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Lee JS, 2005, AM J PATHOL, V166, P1861, DOI 10.1016/S0002-9440(10)62495-9; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pellicciari R, 2002, J MED CHEM, V45, P3569, DOI 10.1021/jm025529g; Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724; SATO H, 1993, ONCOGENE, V8, P395; Sirvent A, 2004, FEBS LETT, V566, P173, DOI 10.1016/j.febslet.2004.04.026; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Torra IP, 2003, MOL ENDOCRINOL, V17, P259, DOI 10.1210/me.2002-0120; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zhao A, 2003, J BIOL CHEM, V278, P28765, DOI 10.1074/jbc.M304568200	39	64	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39105	39113		10.1074/jbc.M607720200	http://dx.doi.org/10.1074/jbc.M607720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17071613	hybrid			2022-12-25	WOS:000242898700017
J	Eyster, CA; Duggins, QS; Gorbsky, GJ; Olson, AL				Eyster, Craig A.; Duggins, Quwanza S.; Gorbsky, Gary J.; Olson, Ann Louise			Microtubule network is required for insulin signaling through activation of Akt/protein kinase B - Evidence that insulin stimulates vesicle docking/fusion but not intracellular mobility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; REGULATED TRANSPORT; LIVING CELLS; TRANSLOCATION; MECHANISM; FUSION; TRAFFICKING	The microtubule network has been shown to be required for insulin-dependent GLUT4 redistribution; however, the precise molecular function has not been elucidated. In this article, we used fluorescence recovery after photobleaching (FRAP) to evaluate the role of microtubules in intracellular GLUT4 vesicle mobility. A comparison of the rate of fluorescence recovery (t1/2), and the maximum fluorescence recovered (F-max) was made between basal and insulin-treated cells with or without nocodazole treatment to disrupt microtubules. We found that intracellular mobility of fluorescently tagged GLUT4 (HA-GLUT4-GFP) was high in basal cells. Mobility was not increased by insulin treatment. Basal mobility was dependent upon an intact microtubule network. Using a constitutively active Akt to signal GLUT4 redistribution, we found that microtubule-based GLUT4 vesicle mobility was not obligatory for GLUT4 plasma membrane insertion. Our findings suggest that microtubules organize the insulin-signaling complex and provide a surface for basal mobility of GLUT4 vesicles. Our data do not support an obligatory requirement for long range microtubule-based movement of GLUT4 vesicles for insulin-mediated GLUT4 redistribution to the cell surface. Taken together, these findings suggest a model in which insulin signaling targets membrane docking and/or fusion rather than GLUT4 trafficking to the cell surface.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Med Res Fdn, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Olson, AL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.	ann-olson@ouhsc.edu		Gorbsky, Gary/0000-0003-3076-4725	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068438, R01DK062341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050412] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK62341, DK68438, R01 DK068438] Funding Source: Medline; NIGMS NIH HHS [R01 GM050412-16, GM50412, R01 GM050412] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Bogan JS, 2003, NATURE, V425, P727, DOI 10.1038/nature01989; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Day RN, 2005, MOL ENDOCRINOL, V19, P1675, DOI 10.1210/me.2005-0028; El-Jack AK, 1999, MOL BIOL CELL, V10, P1581, DOI 10.1091/mbc.10.5.1581; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; Eyster CA, 2005, J BIOL CHEM, V280, P17978, DOI 10.1074/jbc.M409806200; Fletcher LM, 2000, BIOCHEM J, V352, P267, DOI 10.1042/0264-6021:3520267; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Govers R, 2004, MOL CELL BIOL, V24, P6456, DOI 10.1128/MCB.24.14.6456-6466.2004; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; Huang J, 2005, J BIOL CHEM, V280, P42300, DOI 10.1074/jbc.M510920200; Ishiki M, 2005, J BIOL CHEM, V280, P28792, DOI 10.1074/jbc.M500501200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Karylowski O, 2004, MOL BIOL CELL, V15, P870, DOI 10.1091/mbc.E03-07-0517; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONO T, 1981, J BIOL CHEM, V256, P6400; Koumanov F, 2005, CELL METAB, V2, P179, DOI 10.1016/j.cmet.2005.08.007; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Martin OJ, 2006, J BIOL CHEM, V281, P484, DOI 10.1074/jbc.M505944200; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; Olson AL, 2003, ENDOCRINOLOGY, V144, P5030, DOI 10.1210/en.2003-0609; Olson AL, 2001, J BIOL CHEM, V276, P10706, DOI 10.1074/jbc.M007610200; Parton RG, 2002, J BIOL CHEM, V277, P46769, DOI 10.1074/jbc.M205683200; Patki V, 2001, MOL BIOL CELL, V12, P129, DOI 10.1091/mbc.12.1.129; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; Semiz S, 2003, EMBO J, V22, P2387, DOI 10.1093/emboj/cdg237; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Xu Z, 2002, J BIOL CHEM, V277, P47972, DOI 10.1074/jbc.C200486200; YANG J, 1992, J BIOL CHEM, V267, P10393; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zeigerer A, 2004, MOL BIOL CELL, V15, P4406, DOI 10.1091/mbc.e04-04-0333	47	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39719	39727		10.1074/jbc.M607101200	http://dx.doi.org/10.1074/jbc.M607101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17068336	hybrid			2022-12-25	WOS:000242898700079
J	Baird, NA; Turnbull, DW; Johnson, EA				Baird, Nathan A.; Turnbull, Douglas W.; Johnson, Eric A.			Induction of the heat shock pathway during hypoxia requires regulation of heat shock factor by hypoxia-inducible factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIF-ALPHA; DROSOPHILA-MELANOGASTER; CANCER; TRANSCRIPTION; GENES; CELLS; IDENTIFICATION; REOXYGENATION; ACCLIMATION; ACTIVATION	Activation of heat shock proteins (Hsps) is critical to adaptation to low oxygen levels (hypoxia) and for enduring the oxidative stress of reoxygenation. Hsps are known to be regulated by heat shock factor (Hsf), but our results demonstrate an unexpected regulatory link between the oxygen-sensing and heat shock pathways. Hsf transcription is up-regulated during hypoxia due to direct binding by hypoxia-inducible factor-1 (HIF-1) to HIF-1 response elements in an Hsf intron. This increase in Hsf transcripts is necessary for full Hsp induction during hypoxia and reoxygenation. The HIF-1-dependent increase in Hsps has a functional impact, as reduced production of Hsps decreases viability of adult flies exposed to hypoxia and reoxygenation. Thus, HIF-1 control of Hsf transcriptional levels is a regulatory mechanism for sensitizing heat shock pathway activity in order to maximize production of protective Hsps. This cross-regulation represents a mechanism by which the low oxygen response pathway has assimilated complex new functions by regulating the key transcriptional activator of the heat shock pathway.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Johnson, EA (corresponding author), Univ Oregon, Inst Mol Biol, 297 Klamath Hall, Eugene, OR 97403 USA.	eric-johnson@molbio.uoregon.edu			NICHD NIH HHS [T32 HD007348] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; Bray N, 2004, GENOME RES, V14, P693, DOI 10.1101/gr.1960404; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DONNELLY TJ, 1992, CIRCULATION, V85, P769, DOI 10.1161/01.CIR.85.2.769; Gorr TA, 2004, J BIOL CHEM, V279, P36048, DOI 10.1074/jbc.M405077200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; Kabakov AE, 2003, CELL STRESS CHAPERON, V8, P335, DOI 10.1379/1466-1268(2003)008<0335:HSPOHS>2.0.CO;2; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Liu GW, 2006, PHYSIOL GENOMICS, V25, P134, DOI 10.1152/physiolgenomics.00262.2005; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Nakano M, 1997, CIRCULATION, V95, P1523; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Orosz A, 1996, MOL CELL BIOL, V16, P7018; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shen C, 2005, J BIOL CHEM, V280, P20580, DOI 10.1074/jbc.M501894200; Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WELCH WJ, 1993, PHILOS T ROY SOC B, V339, P327, DOI 10.1098/rstb.1993.0031; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	39	97	99	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38675	38681		10.1074/jbc.M608013200	http://dx.doi.org/10.1074/jbc.M608013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17040902	hybrid			2022-12-25	WOS:000242709500064
J	Geslain, R; Aeby, E; Guitart, T; Jones, TE; de Moura, MC; Charriere, F; Schneider, A; de Pouplana, LR				Geslain, Renaud; Aeby, Eric; Guitart, Tanit; Jones, Thomas E.; de Moura, Manuel Castro; Charriere, Fabien; Schneider, Andre; Ribas de Pouplana, Lluis			Trypanosoma seryl-tRNA synthetase is a metazoan-like enzyme with high affinity for tRNA(Sec)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTING COILED COILS; ESCHERICHIA-COLI; TRANSFER RNA(SER); ACCEPTOR STEM; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; RECOGNITION; IDENTITY; TRNA(LEU); SERINE	Trypanosomatids are important human pathogens that form a basal branch of eukaryotes. Their evolutionary history is still unclear as are many aspects of their molecular biology. Here we characterize essential components required for the incorporation of serine and selenocysteine into the proteome of Trypanosoma. First, the biological function of a putative Trypanosoma seryl-tRNA synthetase was characterized in vivo. Secondly, the molecular recognition by Trypanosoma seryl-tRNA synthetase of its cognate tRNAs was dissected in vitro. The cellular distribution of tRNA(Sec) was studied, and the catalytic constants of its aminoacylation were determined. These were found to be markedly different from those reported in other organisms, indicating that this reaction is particularly efficient in trypanosomatids. Our functional data were analyzed in the context of a new phylogenetic analysis of eukaryotic seryl-tRNA synthetases that includes Trypanosoma and Leishmania sequences. Our results show that trypanosomatid seryl-tRNA synthetases are functionally and evolutionarily more closely related to their metazoan homologous enzymes than to other eukaryotic enzymes. This conclusion is supported by sequence synapomorphies that clearly connect metazoan and trypanosomatid seryl-tRNA synthetases.	Inst Res Biomed, Barcelona 08015, Catalonia, Spain; ICREA, Barcelona 08015, Catalonia, Spain; Univ Fribourg, Dept Biol Cell & Dev Biol, CH-1700 Fribourg, Switzerland	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; University of Fribourg	de Pouplana, LR (corresponding author), Inst Res Biomed, C Samitier 1-5,Barcelona Sci Pk, Barcelona 08015, Catalonia, Spain.	lluisribas@pcb.ub.es	Aeby, Eric/A-4819-2017; Guitart, Tanit/G-9772-2015; de Pouplana, Lluis Ribas/AAA-4738-2019; Castro, Manuel/AAF-5985-2019	Aeby, Eric/0000-0002-0463-4444; Guitart, Tanit/0000-0003-2992-9895; de Pouplana, Lluis Ribas/0000-0002-2087-0359; Castro, Manuel/0000-0002-8488-5306	ICREA Funding Source: Custom	ICREA(ICREA)		ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; Amberg R, 1996, J MOL BIOL, V263, P8, DOI 10.1006/jmbi.1996.0552; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BARON C, 1991, J BIOL CHEM, V266, P20375; Benson Dennis A, 2005, Nucleic Acids Res, V33, pD34; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bilokapic S, 2004, EUR J BIOCHEM, V271, P694, DOI 10.1111/j.1432-1033.2003.03971.x; BILOKAPIC S, 2006, EMBO J, V4, P4; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; BOREL F, 1994, NUCLEIC ACIDS RES, V22, P2963, DOI 10.1093/nar/22.15.2963; Breitschopf K, 1996, NUCLEIC ACIDS RES, V24, P405, DOI 10.1093/nar/24.3.405; CASSAGO A, 2006, MOL BIOCHEM PARASIT, V23, P23; CHIMNARONK S, 2006, EMBO J, V15, P15; CHOI IS, 1994, BIOCHEMISTRY-US, V33, P601, DOI 10.1021/bi00168a027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; de Pouplana LR, 2001, CELL, V104, P191, DOI 10.1016/S0092-8674(01)00204-5; Drabkin HJ, 1998, MOL CELL BIOL, V18, P1459, DOI 10.1128/MCB.18.3.1459; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Esseiva AC, 2004, MOL BIOL CELL, V15, P2750, DOI 10.1091/mbc.E03-11-0821; Gabriel K, 1996, SCIENCE, V271, P195, DOI 10.1126/science.271.5246.195; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Heckl M, 1998, FEBS LETT, V427, P315, DOI 10.1016/S0014-5793(98)00435-9; Himeno H, 1997, J MOL BIOL, V268, P704, DOI 10.1006/jmbi.1997.0991; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; Kim HS, 1998, J BACTERIOL, V180, P6446, DOI 10.1128/JB.180.24.6446-6449.1998; Korencic D, 2004, J BIOL CHEM, V279, P48780, DOI 10.1074/jbc.M408753200; Lenhard B, 1999, NUCLEIC ACIDS RES, V27, P721, DOI 10.1093/nar/27.3.721; Lenhard B, 1997, J BIOL CHEM, V272, P1136, DOI 10.1074/jbc.272.2.1136; Lenhard B, 1998, FEBS LETT, V439, P235, DOI 10.1016/S0014-5793(98)01376-3; Lobanov AV, 2006, NUCLEIC ACIDS RES, V34, P4012, DOI 10.1093/nar/gkl541; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; McCulloch Richard, 2004, Methods Mol Biol, V262, P53; Metzger AU, 1997, NUCLEIC ACIDS RES, V25, P4551, DOI 10.1093/nar/25.22.4551; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; Tan THP, 2002, MOL CELL BIOL, V22, P3707, DOI 10.1128/MCB.22.11.3707-3716.2002; Taupin CMJ, 1999, J MOL EVOL, V48, P408, DOI 10.1007/PL00006485; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Vella F, 2005, IUBMB LIFE, V57, P523, DOI 10.1080/15216540500167302; WeygandDurasevic I, 1996, J BIOL CHEM, V271, P2455, DOI 10.1074/jbc.271.5.2455; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wolf YI, 1999, GENOME RES, V9, P689; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589	49	21	21	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38217	38225		10.1074/jbc.M607862200	http://dx.doi.org/10.1074/jbc.M607862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17040903	Green Submitted, hybrid			2022-12-25	WOS:000242709500014
J	Vogel, M; Mayer, MP; Bukau, B				Vogel, Markus; Mayer, Matthias P.; Bukau, Bernd			Allosteric regulation of Hsp70 chaperones involves a conserved interdomain linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; SUBSTRATE-BINDING; DNAK CHAPERONE; CONFORMATIONAL-CHANGES; PROTEIN; MECHANISM; DOMAIN; MUTATIONS; ATPASE; COMMUNICATION	The 70-kDa heat shock proteins (Hsp70) are essential members of the cellular chaperone machinery that assists protein-folding processes. To perform their functions Hsp70 chaperones toggle between two nucleotide-controlled conformational states. ATP binding to the ATPase domain triggers the transition to the low affinity state of the substrate-binding domain, while substrate binding to the substrate-binding domain in synergism with the action of a J-domain-containing cochaperone stimulates ATP hydrolysis and thereby transition to the high affinity state. Thus, ATPase and substrate-binding domains mutually affect each other through an allosteric control mechanism, the basis of which is largely unknown. In this study we identified two positively charged, surface-exposed residues in the ATPase domain and a negatively charged residue in the linker connecting both domains that are important for interdomain communication. Furthermore, we demonstrate that the linker alone is sufficient to stimulate the ATPase activity, an ability that is lost upon amino acid replacement. The linker therefore is most likely the lever that is wielded by the substrate-binding domain and the cochaperone onto the ATPase domain to induce a conformation favorable for ATP hydrolysis. Based on our results we propose a mechanism of interdomain communication.	Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Mayer, MP (corresponding author), Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	M.Mayer@zmbh.uni-heidelberg.de; Bukau@zmbh.uni-heidelberg.de	Gimenez, Luis E Diaz/D-9291-2011; Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Bukau, Bernd/0000-0003-0521-7199				BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Han WJ, 2001, FEBS LETT, V497, P55, DOI 10.1016/S0014-5793(01)02435-8; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Jiang JW, 2005, MOL CELL, V20, P513, DOI 10.1016/j.molcel.2005.09.028; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Moro F, 2003, FEBS LETT, V533, P119, DOI 10.1016/S0014-5793(02)03752-3; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; Revington M, 2004, J BIOL CHEM, V279, P33958, DOI 10.1074/jbc.M313967200; Rist W, 2006, J BIOL CHEM, V281, P16493, DOI 10.1074/jbc.M600847200; Ryan MT, 2002, ADV PROTEIN CHEM, V59, P223; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Sousa MC, 1998, BIOCHEMISTRY-US, V37, P15392, DOI 10.1021/bi981510x; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Vogel M, 2006, MOL CELL, V21, P359, DOI 10.1016/j.molcel.2005.12.017; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	30	163	164	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38705	38711		10.1074/jbc.M609020200	http://dx.doi.org/10.1074/jbc.M609020200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17052976	hybrid			2022-12-25	WOS:000242709500068
J	Wrighton, KH; Willis, D; Long, JY; Liu, F; Lin, X; Feng, XH				Wrighton, Katharine H.; Willis, Danielle; Long, Jianyin; Liu, Fang; Lin, Xia; Feng, Xin-Hua			Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; CONSERVED GENE; TRANSCRIPTION; KINASE; PHOSPHORYLATION; PATHWAY; CELLS; IDENTIFICATION; MODULATION; ACTIVATION	Transforming growth factor-beta(TGF-beta) controls a diverse set of cellular processes, and its canonical signaling is mediated via TGF-beta-induced phosphorylation of receptor-activated Smads ( 2 and 3) at the C-terminal SXS motif. We recently discovered that PPM1A can dephosphorylate Smad2/3 at the C-terminal SXS motif, implicating a critical role for phosphatases in regulating TGF-beta signaling. Smad2/3 activity is also regulated by phosphorylation in the linker region (and N terminus) by a variety of intracellular kinases, making it a critical platform for cross-talk between TGF-beta and other signaling pathways. Using a functional genomic approach, we identified the small C-terminal domain phosphatase 1 (SCP1) as a specific phosphatase for Smad2/3 dephosphorylation in the linker and N terminus. A catalytically inactive SCP1 mutant (dnSCP1) had no effect on Smad2/3 phosphorylation in vitro or in vivo. Of the other FCP/SCP family members SCP2 and SCP3, but not FCP1, could also dephosphorylate Smad2/3 in the linker/N terminus. Depletion of SCP1/2/3 enhanced Smad2/3 linker phosphorylation. SCP1 increased TGF-beta-induced transcriptional activity in agreement with the idea that phosphorylation in the Smad2/3 linker must be removed for a full transcriptional response. SCP1 overexpression also counteracts the inhibitory effect of epidermal growth factor on TGF-beta-induced p15 expression. Taken together, this work identifies the first example of a Smad2/3 linker phosphatase(s) and reveals an important new substrate for SCPs.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; Baylor Coll Med, Interdept Grad Program Cell & Mol Biol, Houston, TX 77030 USA; Rutgers State Univ, Canc Inst New Jersey, Ernest Mario Sch Pharm, Ctr Adv Biotechnol & Med,Susan Lehman Cullman Lab, Piscataway, NJ 08854 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Feng, XH (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,Rm 137D, Houston, TX 77030 USA.	xfeng@bcm.edu	Long, Jianyin/H-8261-2013	Wrighton, Katharine/0000-0001-7075-3399	NCI NIH HHS [R01 CA 108454, R21 CA 11293, R01 CA 93771] Funding Source: Medline; NIDDK NIH HHS [R01 DK 073932] Funding Source: Medline; NIGMS NIH HHS [R01 GM 63773, R25 GM069234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093771, R01CA108454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Duan XY, 2006, J BIOL CHEM, V281, P36526, DOI 10.1074/jbc.M605169200; Dunfield LD, 2003, ONCOGENE, V22, P4745, DOI 10.1038/sj.onc.1206617; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FENG XH, 2006, SMAD SIGNAL TRANSDUC, P258; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Kamenski T, 2004, MOL CELL, V15, P399, DOI 10.1016/j.molcel.2004.06.035; Kimura K, 2006, GENOME RES, V16, P55, DOI 10.1101/gr.4039406; Knockaert M, 2006, P NATL ACAD SCI USA, V103, P11940, DOI 10.1073/pnas.0605133103; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Liang M, 2004, J BIOL CHEM, V279, P22857, DOI 10.1074/jbc.M401554200; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Matsuura I, 2005, BIOCHEMISTRY-US, V44, P12546, DOI 10.1021/bi050560g; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Su YA, 1997, ONCOGENE, V15, P1289, DOI 10.1038/sj.onc.1201294; Thompson J, 2006, EMBO J, V25, P2757, DOI 10.1038/sj.emboj.7601161; Waddell DS, 2004, J BIOL CHEM, V279, P29236, DOI 10.1074/jbc.M400880200; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Yakmovych I, 2001, FASEB J, V15, P553; Yamagata H, 2005, CANCER RES, V65, P157; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yeo M, 2005, SCIENCE, V307, P596, DOI 10.1126/science.1100801; Zohn IE, 2001, DEV BIOL, V239, P118, DOI 10.1006/dbio.2001.0420	44	83	88	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38365	38375		10.1074/jbc.M607246200	http://dx.doi.org/10.1074/jbc.M607246200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17035229	hybrid			2022-12-25	WOS:000242709500030
J	Agarwal, M; Hao, YJ; Kapoor, A; Dong, CH; Fujii, H; Zheng, XW; Zhu, JK				Agarwal, Manu; Hao, Yujin; Kapoor, Avnish; Dong, Chun-Hai; Fujii, Hiroaki; Zheng, Xianwu; Zhu, Jian-Kang			A R2R3 type MYB transcription factor is involved in the cold regulation of CBF genes and in acquired freezing tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENT; LOW-TEMPERATURE; ARABIDOPSIS-THALIANA; SALT-STRESS; SIGNAL-TRANSDUCTION; DROSOPHILA EMBRYO; RESPONSE PATHWAY; MEDIATES COLD; ACCLIMATION; EXPRESSION	Cold temperatures trigger the expression of the CBF family of transcription factors, which in turn activate many downstream genes that confer freezing tolerance to plants. It has been shown previously that the cold regulation of CBF3 involves an upstream bHLH-type transcription factor, ICE1. ICE1 binds to the Myc recognition sequences in the CBF3 promoter. Apart from Myc recognition sequences, CBF promoters also have Myb recognition sequences. We report here that the Arabidopsis MYB15 is involved in cold-regulation of CBF genes and in the development of freezing tolerance. The MYB15 gene transcript is up-regulated by cold stress. The MYB15 protein interacts with ICE1 and binds to Myb recognition sequences in the promoters of CBF genes. Overexpression of MYB15 results in reduced expression of CBF genes whereas its loss-of-function leads to increased expression of CBF genes in the cold. The myb15 mutant plants show increased tolerance to freezing stress whereas its overexpression reduces freezing tolerance. Our results suggest that MYB15 is part of a complex network of transcription factors controlling the expression of CBFs and other genes in response to cold stress.	Univ Calif Riverside, Dept Bot & Plant Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Zhu, JK (corresponding author), Univ Calif Riverside, Dept Bot & Plant Sci, 2150 Batchelor Hall, Riverside, CA 92521 USA.	jian-kang.zhu@ucr.edu	Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X; AGARWAL, MANU/0000-0003-4241-5055; Fujii, Hiroaki/0000-0002-0013-5891	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059138] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059138] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bechtold N, 1998, METH MOL B, V82, P259; Browse J, 2001, CURR OPIN PLANT BIOL, V4, P241, DOI 10.1016/S1369-5266(00)00167-9; Chinnusamy V, 2003, GENE DEV, V17, P1043, DOI 10.1101/gad.1077503; Cook D, 2004, P NATL ACAD SCI USA, V101, P15243, DOI 10.1073/pnas.0406069101; COUREY AJ, 1995, BBA-GENE STRUCT EXPR, V1261, P1, DOI 10.1016/0167-4781(94)00234-T; Cutler SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/pnas.97.7.3718; Flores-Saaib RD, 2000, CELL BIOCHEM BIOPHYS, V33, P1, DOI 10.1385/CBB:33:1:1; Fowler S, 2002, PLANT CELL, V14, P1675, DOI 10.1105/tpc.003483; Gilmour SJ, 2004, PLANT MOL BIOL, V54, P767, DOI 10.1023/B:PLAN.0000040902.06881.d4; Gong ZZ, 2002, P NATL ACAD SCI USA, V99, P11507, DOI 10.1073/pnas.172399299; Grotewold E, 2000, P NATL ACAD SCI USA, V97, P13579, DOI 10.1073/pnas.250379897; Guo Y, 2002, P NATL ACAD SCI USA, V99, P7786, DOI 10.1073/pnas.112040099; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; Hsieh TH, 2002, PLANT PHYSIOL, V129, P1086, DOI 10.1104/pp.003442; Hughes MA, 1996, J EXP BOT, V47, P291, DOI 10.1093/jxb/47.3.291; Ishitani M, 1998, PLANT CELL, V10, P1151, DOI 10.1105/tpc.10.7.1151; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Kaplan F, 2004, PLANT PHYSIOL, V136, P4159, DOI 10.1104/pp.104.052142; Kasuga M, 1999, NAT BIOTECHNOL, V17, P287, DOI 10.1038/7036; Knight H, 1999, PLANT CELL, V11, P875, DOI 10.1105/tpc.11.5.875; Kreps JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532; Lee BH, 2005, PLANT CELL, V17, P3155, DOI 10.1105/tpc.105.035568; Lee HJ, 2001, GENE DEV, V15, P912, DOI 10.1101/gad.866801; Liu JP, 1997, PLANT PHYSIOL, V114, P591, DOI 10.1104/pp.114.2.591; Liu Q, 1998, PLANT CELL, V10, P1391, DOI 10.1105/tpc.10.8.1391; MOHAPATRA SS, 1989, PLANT PHYSIOL, V89, P375, DOI 10.1104/pp.89.1.375; Novillo F, 2004, P NATL ACAD SCI USA, V101, P3985, DOI 10.1073/pnas.0303029101; Ohta M, 2000, PLANT J, V22, P29, DOI 10.1046/j.1365-313x.2000.00709.x; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; Romero I, 1998, PLANT J, V14, P273, DOI 10.1046/j.1365-313X.1998.00113.x; Seki M, 2001, PLANT CELL, V13, P61, DOI 10.1105/tpc.13.1.61; Shinwari ZK, 1998, BIOCHEM BIOPH RES CO, V250, P161, DOI 10.1006/bbrc.1998.9267; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Spelt C, 2000, PLANT CELL, V12, P1619, DOI 10.1105/tpc.12.9.1619; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; Tahtiharju S, 2001, PLANT J, V26, P461, DOI 10.1046/j.1365-313X.2001.01048.x; Teige M, 2004, MOL CELL, V15, P141, DOI 10.1016/j.molcel.2004.06.023; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; van den Heuvel M, 2001, NAT CELL BIOL, V3, pE155, DOI 10.1038/35083101; Walker AR, 1999, PLANT CELL, V11, P1337, DOI 10.1105/tpc.11.7.1337; Xin ZG, 1998, P NATL ACAD SCI USA, V95, P7799, DOI 10.1073/pnas.95.13.7799; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251; Zhu JH, 2005, P NATL ACAD SCI USA, V102, P9966, DOI 10.1073/pnas.0503960102; Zhu JH, 2004, P NATL ACAD SCI USA, V101, P9873, DOI 10.1073/pnas.0403166101; Zimmermann IM, 2004, PLANT J, V40, P22, DOI 10.1111/j.1365-313X.2004.02183.x	47	565	679	21	233	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37636	37645		10.1074/jbc.M605895200	http://dx.doi.org/10.1074/jbc.M605895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17015446	hybrid			2022-12-25	WOS:000242477100040
J	Breit, A; Wolff, K; Kalwa, H; Jarry, H; Buch, T; Gudermann, T				Breit, Andreas; Wolff, Katharina; Kalwa, Hermann; Jarry, Hubertus; Buech, Thomas; Gudermann, Thomas			The natural inverse agonist agouti-related protein induces arrestin-mediated endocytosis of melanocortin-3 and-4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; IN-VITRO; DIFFERENTIAL REGULATION; HETERO-OLIGOMERIZATION; HORMONE RECEPTOR; DOWN-REGULATION; LIVING CELLS; INTERNALIZATION; DESENSITIZATION; ACTIVATION	Agouti-related protein (Agrp), one of the two naturally occurring inverse agonists known to inhibit G protein-coupled receptor activity, regulates energy expenditure by decreasing basal and blocking agonist-promoted melanocortin receptor (MCR) signaling. Here we report that, in addition to its inverse agonistic activities, Agrp exhibits agonistic properties on the endocytosis pathway of melanocortin receptors. Sustained exposure of human embryonic kidney 293 cells to Agrp induced endocytosis of the MC3R or the MC4R. The extent and kinetics of Agrp-promoted MCR endocytosis were similar to the endocytosis induced by melanocortins. Using the bioluminescence resonance energy transfer technique, we further showed that after binding of Agrp both MCRs interacted with beta-arrestins. In line with this observation, in COS-7 cells co-expression of beta-arrestins enhanced Agrp-induced MCR endocytosis, whereas in human embryonic kidney 293 cells co-transfection of beta-arrestin-specific small interference RNAs diminished Agrp-promoted endocytosis. This new regulatory mechanism was likewise detectable in a cell line derived from murine hypothalamic neurons endogenously expressing MC4R, pointing to the physiological relevance of Agrp-promoted receptor endocytosis. In conclusion, we demonstrated that Agrp does not solely act by directly blocking MCR signaling but also by reducing the amount of MCR molecules accessible to melanocortins at the cell surface. This beta-arrestin-dependent mechanism reveals a new aspect of MCR signaling in particular and refines the concept of G protein-coupled receptor antagonism in general.	Univ Marburg, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany; Univ Gottingen, Zentrum Frauenheilkunde, Abt Klin & Expt Endokrinol, D-37075 Gottingen, Germany	Philipps University Marburg; University of Gottingen	Gudermann, T (corresponding author), Univ Marburg, Inst Pharmakol & Toxikol, D-35033 Marburg, Germany.	guderman@staff.uni-marburg.de	Kalwa, Hermann/ABG-2323-2021					Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Baig AH, 2002, ENDOCR RES, V28, P281, DOI 10.1081/ERC-120016798; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Bhowmick N, 1998, ENDOCRINOLOGY, V139, P3185, DOI 10.1210/en.139.7.3185; Blondet A, 2004, J BIOCHEM, V135, P541, DOI 10.1093/jb/mvh064; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Butler AA, 2006, PEPTIDES, V27, P281, DOI 10.1016/j.peptides.2005.02.029; Chai BX, 2003, PEPTIDES, V24, P603, DOI 10.1016/S0196-9781(03)00104-9; Charest PG, 2003, J BIOL CHEM, V278, P41541, DOI 10.1074/jbc.M306589200; Clark AJL, 2003, ANN NY ACAD SCI, V994, P111, DOI 10.1111/j.1749-6632.2003.tb03169.x; COLLINS S, 1990, BIOCHEM SOC T, V18, P541, DOI 10.1042/bst0180541; Creemers JWM, 2006, ENDOCRINOLOGY, V147, P1621, DOI 10.1210/en.2005-1373; Daniels D, 2003, BRAIN RES, V986, P1, DOI 10.1016/S0006-8993(03)03162-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gao ZH, 2003, J PHARMACOL EXP THER, V307, P870, DOI 10.1124/jpet.103.055525; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; GRIER CE, 1989, J BIOL CHEM, V264, P5384; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; HERTEL C, 1983, J CYCLIC NUCL PROT, V9, P119; Jequier E, 2002, ANN NY ACAD SCI, V967, P379, DOI 10.1111/j.1749-6632.2002.tb04293.x; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Khong K, 2001, NEUROENDOCRINOLOGY, V74, P193, DOI 10.1159/000054686; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; NANTEL F, 1993, MOL PHARMACOL, V43, P548; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; Ollmann MM, 1999, J BIOL CHEM, V274, P15837, DOI 10.1074/jbc.274.22.15837; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ollmann MM, 1998, GENE DEV, V12, P316, DOI 10.1101/gad.12.3.316; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Ponimaskin E, 2005, MOL PHARMACOL, V67, P1434, DOI 10.1124/mol.104.008748; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Shinyama H, 2003, ENDOCRINOLOGY, V144, P1301, DOI 10.1210/en.2002-220931; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Villemure JF, 2005, BIOCHEM J, V388, P47, DOI 10.1042/BJ20041435; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; von Zastrow M, 2001, BIOCHEM SOC T, V29, P500, DOI 10.1042/BST0290500; VON ZM, 1992, J BIOL CHEM, V267, P3530; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Wortley KE, 2005, CELL METAB, V2, P421, DOI 10.1016/j.cmet.2005.11.004; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	54	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37447	37456		10.1074/jbc.M605982200	http://dx.doi.org/10.1074/jbc.M605982200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17041250	hybrid			2022-12-25	WOS:000242477100021
J	Du, JA; Daniels, DH; Asbury, C; Venkataraman, S; Liu, JR; Spitz, DR; Oberley, LW; Cullen, JJ				Du, Juan; Daniels, David H.; Asbury, Carla; Venkataraman, Sujatha; Liu, Jingru; Spitz, Douglas R.; Oberley, Larry W.; Cullen, Joseph J.			Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLUCOSE DEPRIVATION; PANCREATIC-CANCER; OXIDATIVE STRESS; ANTITUMOR-ACTIVITY; SUPEROXIDE; COUMARIN; GROWTH; INHIBITORS; NAD(P)H	Dicumarol is a naturally occurring anticoagulant derived from coumarin that induces cytotoxicity and oxidative stress in human pancreatic cancer cells (Cullen, J. J., Hinkhouse, M. M., Grady, M., Gaut, A. W., Liu, J., Zhang, Y., Weydert, C. J. D., Domann, F. E., and Oberley, L. W. (2003) Cancer Res. 63, 5513 5520). Although dicumarol has been used as an inhibitor of the two-electron reductase NAD(P)H:quinone oxidoreductase (NQO1), dicumarol is also thought to affect quinone-mediated electron transfer reactions in the mitochondria, leading to the production of superoxide (O-2((center dot) over bar)) and hydrogen peroxide (H2O2). We hypothesized that mitochondrial production of reactive oxygen species mediates the increased susceptibility of pancreatic cancer cells to dicumarol-induced metabolic oxidative stress. Dicumarol decreased clonogenic survival equally in both MDA-MB-468 NQO1(-) and MDA-MB-468 NQO1(-) breast cancer cells. Dicumarol decreased clonogenic survival in the transformed fibroblast cell line IMRSV-90 compared with the IMR-90 cell line. Dicumarol, with the addition of mitochondrial electron transport chain blockers, decreased clonogenic cell survival in human pancreatic cancer cells and increased superoxide levels. Dicumarol with the mitochondrial electron transport chain blocker antimycin A decreased clonogenic survival and increased superoxide levels in cells with functional mitochondria but had little effect on cancer cells without functional mitochondria. Overexpression of manganese superoxide dismutase and mitochondrial-targeted catalase with adenoviral vectors reversed the dicumarol-induced cytotoxicity and reversed fluorescence of the oxidation-sensitive probe. We conclude mitochondrial production of reactive oxygen species mediates the increased susceptibility of cancer cells to dicumarol-induced cytotoxicity.	Univ Iowa, Coll Med, Iowa City, IA 52242 USA; Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Dept Surg, Iowa City, IA 52242 USA; Dept Radiat Oncol, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Cullen, JJ (corresponding author), Univ Iowa Hosp & Clin, 4605 JCP, Iowa City, IA 52242 USA.	joseph-cullen@uiowa.edu		Cullen, Joseph/0000-0002-2222-1328; Spitz, Douglas/0000-0002-1254-8765	NATIONAL CANCER INSTITUTE [P01CA066081, R01CA100045, R21CA115785] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007485] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; BEERS RF, 1952, J BIOL CHEM, V195, P133; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Brar SS, 2001, AM J PHYSIOL-CELL PH, V280, pC659, DOI 10.1152/ajpcell.2001.280.3.C659; Collier AC, 2003, BIOCHEM PHARMACOL, V66, P281, DOI 10.1016/S0006-2952(03)00240-5; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Cullen JJ, 2003, CANCER RES, V63, P1297; Cullen JJ, 2003, CANCER RES, V63, P5513; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; FEUER G, 1976, ONCOLOGY, V33, P35, DOI 10.1159/000225098; HOLLANDER PM, 1975, ARCH BIOCHEM BIOPHYS, V169, P560, DOI 10.1016/0003-9861(75)90200-3; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; JOSODA S, 1974, J BIOL CHEM, V249, P6416; Keating G., 1997, COUMARINS BIOL APPL, P23; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Lewis A, 2004, CLIN CANCER RES, V10, P4550, DOI 10.1158/1078-0432.CCR-03-0667; Lewis AM, 2005, MOL CARCINOGEN, V43, P215, DOI 10.1002/mc.20107; Li NY, 2003, FREE RADICAL BIO MED, V34, P465, DOI 10.1016/S0891-5849(02)01325-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Madari H, 2003, CANCER RES, V63, P1214; MARSHALL ME, 1994, J CANCER RES CLIN, V120, pS39, DOI 10.1007/BF01377124; MAUCHER A, 1994, J CANCER RES CLIN, V120, P502, DOI 10.1007/BF01191806; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; OBERLEY LW, 1981, MED HYPOTHESES, V7, P21, DOI 10.1016/0306-9877(81)90018-9; OMARBASHA B, 1989, CANCER RES, V49, P3045; Pink JJ, 2000, J BIOL CHEM, V275, P5416, DOI 10.1074/jbc.275.8.5416; RAEV LD, 1990, PHARMAZIE, V45, P696; Siegel D, 2004, MOL PHARMACOL, V65, P1238, DOI 10.1124/mol.65.5.1238; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Winski SL, 2002, CANCER RES, V62, P1420; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381	37	62	63	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37416	37426		10.1074/jbc.M605063200	http://dx.doi.org/10.1074/jbc.M605063200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17040906	hybrid			2022-12-25	WOS:000242477100018
J	Li, RS; Luo, C; Mines, M; Zhang, JW; Fan, GH				Li, Runsheng; Luo, Cherry; Mines, Marjelo; Zhang, Jingwu; Fan, Guo-Huang			Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL EPITHELIAL-CELLS; RHEUMATOID-ARTHRITIS; REACTIVE OXYGEN; T-LYMPHOCYTES; UP-REGULATION; LUNG-CANCER; PROTEIN; MIGRATION; DISEASE; SDF-1	Chemokine receptor-initiated signaling plays critical roles in cell differentiation, proliferation, and migration. However, the regulation of chemokine receptor signaling under physiological and pathological conditions is not fully understood. In the present study, we demonstrate that the CXC chemokine receptor 4 (CXCR4) formed a complex with ferritin heavy chain (FHC) in a ligand-dependent manner. Our in vitro binding assays revealed that purified FHC associated with both the glutathione S-transferase-conjugated N-terminal and C-terminal domains of CXCR4, thereby suggesting the presence of more than one FHC binding site in the protein sequence of CXCR4. Using confocal microscopy, we observed that stimulation with CXCL12, the receptor ligand, induced colocalization of the internalized CXCR4 with FHC into internal vesicles. Furthermore, after CXCL12 treatment, FHC underwent time-dependent nuclear translocation and phosphorylation at serine residues. By contrast, a mutant form of FHC in which serine 178 was replaced by alanine(S178A) failed to undergo phosphorylation, suggesting that serine 178 is the major phosphorylation site. Compared with the wild type FHC, the FHC-S178A mutant exhibited reduced association with CXCR4 and constitutive nuclear translocation. We also found that CXCR4-mediated extracellular signal-regulated kinase 1/2 (ERK1/2) activation and chemotaxis were inhibited by overexpression of wild type FHC but not FHC-S178A mutant, and were prolonged by FHC knockdown. In addition to CXCR4, other chemokine receptor-initiated signaling appeared to be similarly regulated by FHC, because CXCR2 mediated ERK1/2 activation was also inhibited by FHC overexpression and prolonged by FHC knockdown. Altogether, our data provide strong evidence for an important role of FHC in chemokine receptor signaling and receptor-mediated cell migration.	Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA; Meharry Med Coll, Dept Biomed Sci, Nashville, TN 37208 USA; Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200025, Peoples R China	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Meharry Medical College; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Fan, GH (corresponding author), Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA.	gfan@mmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS041071] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03032-19] Funding Source: Medline; NINDS NIH HHS [U54NS41071] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; AROSIO P, 1976, CANCER RES, V36, P1735; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; BIEMOND P, 1986, ARTHRITIS RHEUM, V29, P1187, DOI 10.1002/art.1780291002; Bodner A, 2003, J NEUROIMMUNOL, V140, P1, DOI 10.1016/S0165-5728(03)00162-0; Broyles RH, 2001, P NATL ACAD SCI USA, V98, P9145, DOI 10.1073/pnas.151147098; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BYRD TF, 1993, J CLIN INVEST, V91, P969, DOI 10.1172/JCI116318; Cai CX, 2001, J CELL SCI, V114, P2327; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; Cheepsunthorn P, 1998, J COMP NEUROL, V400, P73; Cozzi A, 2004, BLOOD, V103, P2377, DOI 10.1182/blood-2003-06-1842; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; Ding Y, 2006, MOL PHARMACOL, V69, P1269, DOI 10.1124/mol.105.020271; Dragic T, 2001, J GEN VIROL, V82, P1807, DOI 10.1099/0022-1317-82-8-1807; Fan GH, 2002, J BIOL CHEM, V277, P6590, DOI 10.1074/jbc.M110588200; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Floridi F, 2003, J NEUROIMMUNOL, V135, P38, DOI 10.1016/S0165-5728(02)00432-0; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Hartmann TN, 2004, J BIOL REG HOMEOS AG, V18, P126; HURTA RAR, 1991, BIOCHEM CELL BIOL, V69, P635, DOI 10.1139/o91-094; Jaleel MA, 2004, MOL HUM REPROD, V10, P901, DOI 10.1093/molehr/gah118; Kondo T, 1996, NEUROSCI LETT, V209, P157, DOI 10.1016/0304-3940(96)12618-5; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Linert W, 2000, J INORG BIOCHEM, V79, P319, DOI 10.1016/S0162-0134(99)00238-X; Luo YQ, 2005, J NEUROCHEM, V93, P452, DOI 10.1111/j.1471-4159.2005.03049.x; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Millholland JM, 2003, J BIOL CHEM, V278, P23963, DOI 10.1074/jbc.M210050200; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Pang JHS, 1996, J CLIN INVEST, V97, P2204, DOI 10.1172/JCI118661; Peng SB, 2005, MOL CANCER RES, V3, P227; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Ryan TP, 1997, FREE RADICAL BIO MED, V22, P901, DOI 10.1016/S0891-5849(96)00483-2; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Surguladze N, 2004, J BIOL CHEM, V279, P14694, DOI 10.1074/jbc.M313348200; Thompson KJ, 2002, J CELL SCI, V115, P2165; TORTI SV, 1988, J BIOL CHEM, V263, P12638; Tran PB, 2003, NAT REV NEUROSCI, V4, P444, DOI 10.1038/nrn1116; Tsai HR, 2004, EUR J PHARMACOL, V498, P45, DOI 10.1016/j.ejphar.2004.07.077; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; Wysoczynski M, 2005, BLOOD, V105, P40, DOI 10.1182/blood-2004-04-1430; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; YOKOMORI N, 1991, ENDOCRINOLOGY, V128, P1474, DOI 10.1210/endo-128-3-1474; Zhang XY, 2005, ARTHRITIS RHEUM-US, V52, P3839, DOI 10.1002/art.21482; Zhao M, 2006, MOL PHARMACOL, V69, P66, DOI 10.1124/mol.105.016923; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	59	88	90	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37616	37627		10.1074/jbc.M607266200	http://dx.doi.org/10.1074/jbc.M607266200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17056593	hybrid			2022-12-25	WOS:000242477100038
J	Budas, GR; Sukhodub, A; Alessi, DR; Jovanovic, A				Budas, Grant R.; Sukhodub, Andrey; Alessi, Dario R.; Jovanovic, Aleksandar			3 ' phosphoinositide-dependent kinase-1 is essential for ischemic preconditioning of the myocardium	FASEB JOURNAL			English	Article						GSK-3; hypoxia; ischemia; mitochondria; cardioprotection	K-ATP CHANNELS; GLYCOGEN-SYNTHASE KINASE-3-BETA; SIGNALING PATHWAYS; INSULIN; PDK1; ACTIVATION; PHOSPHORYLATION; PHYSIOLOGY; MECHANISM; RABBIT	Brief periods of ischemia and reperfusion that precede sustained ischemia lead to a reduction in myocardial infarct size. This phenomenon, known as ischemic preconditioning, is mediated by signaling pathway(s) that are yet to be fully defined. 3'-phosphoinositide- dependent kinase-1 (PDK1) has been implicated in numerous cellular processes. However, the involvement of PDK1 in preconditioning has yet to be elucidated. Studying PDK1 is not as straightforward as it is for the majority of kinases, due to the lack of a specific inhibitor of PDK1. Therefore, we have taken advantage of PDK1 hypomorphic mutant mice with reduced expression of PDK1 to study the role of PDK1 in preconditioning. Whole heart and single cell models of preconditioning demonstrated that the hearts and cardiac cells from PDK1 hypomorphic mice could not be preconditioned. The cardioprotective effect of PDK1 was not related to the effect that preconditioning has on sarcolemmal membrane action potential as revealed by di-8-ANEPPS, a sarcolemmalpotential sensitive dye, and laser confocal microscopy. In contrast, experiments with JC-1, a mitochondrial membrane potential-sensitive dye, has demonstrated that intact PDK1 levels were required for preconditioningmediated regulation of mitochondrial membrane potential. Western blotting combined with functional experiments have shown that intact PDK1 levels were required for preconditioning-induced phosphorylation of protein kinase B (PKB), glycogen synthase kinase-3 beta (GSK-3 beta), and cardioprotection. We conclude that PDK1 mediates preconditioning in the heart by regulating activating PKB-GSK-3 beta to regulate mitochondrial but not sarcolemmal membrane potential. 3'phosphoinositidedependent kinase-1 (PDK1) is essential for ischemic preconditioning of the myocardium.-Budas, G. R., Sukhodub, A., Alessi, D. R., Jovanovic, A. 3'phosphoinositidedependent kinase-1 is essential for ischemic preconditioning of the myocardium.	Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Dundee, MRC, Prot Phosphorylat Unit, Sch Life Sci, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Jovanovic, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	a.jovanovic@dundee.ac.uk	Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318; Alessi, Dario/0000-0002-2140-9185	MRC [G0400608, MC_U127015387] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [S18744] Funding Source: Medline; British Heart Foundation [PG/04/096/17627, PG/02/117/14488, PG/04/086/17410] Funding Source: Medline; Medical Research Council [MC_U127015387, G0400608(71317), G0400608] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; BILLMAN GE, 1994, CARDIOVASC RES, V28, P762, DOI 10.1093/cvr/28.6.762; Budas GR, 2004, FASEB J, V18, P1046, DOI 10.1096/fj.04-1602fje; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Du QY, 2006, FASEB J, V20, P1131, DOI 10.1096/fj.05-5483com; Farese RV, 2005, EXP BIOL MED, V230, P593; Gross GJ, 2003, AM J PHYSIOL-HEART C, V285, pH921, DOI 10.1152/ajpheart.00421.2003; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hanley PJ, 2005, J MOL CELL CARDIOL, V39, P17, DOI 10.1016/j.yjmcc.2005.04.002; Hausenloy DJ, 2002, CARDIOVASC RES, V55, P534, DOI 10.1016/S0008-6363(02)00455-8; Javadov SA, 2003, J PHYSIOL-LONDON, V549, P513, DOI 10.1113/jphysiol.2003.034231; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kane GC, 2005, J MOL CELL CARDIOL, V38, P937, DOI 10.1016/j.yjmcc.2005.02.026; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; LIU YG, 1994, J MOL CELL CARDIOL, V26, P661, DOI 10.1006/jmcc.1994.1078; Minners J, 2001, CIRC RES, V89, P787, DOI 10.1161/hh2101.098372; Mirshamsi S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-54; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; O'Rourke B, 2005, PHYSIOLOGY, V20, P303, DOI 10.1152/physiol.00020.2005; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SPEECHLYDICK ME, 1994, CIRC RES, V75, P586, DOI 10.1161/01.RES.75.3.586; Sugden PH, 2001, ANN MED, V33, P611; SUKHODUB A, 2006, IN PRESS J CELL PHYS; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309; Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55; Uchiyama T, 2004, CIRCULATION, V109, P3042, DOI 10.1161/01.CIR.0000130647.29030.90; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verkerk AO, 1996, J MOL CELL CARDIOL, V28, P2443, DOI 10.1006/jmcc.1996.0237; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Yellon DM, 2003, PHYSIOL REV, V83, P1113, DOI 10.1152/physrev.00009.2003; Zhuo ML, 2005, INT J BIOCHEM CELL B, V37, P751, DOI 10.1016/j.biocel.2004.10.008	41	38	38	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2556	+		10.1096/fj.06-6252fje	http://dx.doi.org/10.1096/fj.06-6252fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077284	Green Accepted			2022-12-25	WOS:000242490700022
J	Rieken, S; Herroeder, S; Sassmann, A; Wallenwein, B; Moers, A; Offermanns, S; Wettschureck, N				Rieken, Stefan; Herroeder, Susanne; Sassmann, Antonia; Wallenwein, Barbara; Moers, Alexandra; Offermanns, Stefan; Wettschureck, Nina			Lysophospholipids control integrin-dependent adhesion in splenic B cells through G(i) and G(12)/G(13) family g-proteins but not through G(q)/G(11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-ALPHA-Q; SPHINGOSINE 1-PHOSPHATE; LYMPHOCYTE TRAFFICKING; LYSOPHOSPHATIDIC ACID; LEUKOCYTE ADHESION; COUPLED RECEPTORS; ACTIVATION; RHOA; MIGRATION; PLATELETS	Integrin-mediated adhesion is a crucial step in lymphocyte extravasation and homing. We show here that not only the chemokines CXCL12 and CXCL13 but also the lysophospholipids sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) enhance adhesion of murine follicular and marginal zone B cells to ICAM-1 in vitro. This process involves clustering of integrin LFA-1 and is blocked by pertussis toxin, suggesting that Gi family G-proteins are involved. In addition, lysophospho-lipid-induced adhesion on ICAM-1 depends on Rho and Rhokinase, indicative of an involvement of G(12)/G(13), possibly also G(q)/G(11) family G-proteins. We used G(12)/G(13)-or G(q)/G(11)-deficient B cells to study the role of these G-protein families in lysophospholipid-induced adhesion and found that the pro-adhesive effects of LPA and S1P are completely abrogated in G(12)/G(13)-deficient marginal zone B cells, reduced in G(12)/G(13)-deficient follicular B cells, and normal in G(q)/G(11)-deficient B cells. We also show that loss of lysophospholipid-induced adhesion results in disinhibition of migration in response to the follicular chemokine CXCL13, which might contribute to the abnormal localization of splenic B cell populations observed in B cell-specific G(12)/G(13)-deficient mice in vivo. Taken together, this study shows that lysophospholipids regulate integrin-mediated adhesion of splenic B cells to ICAM-1 through Gi and G(12)/G(13) family G-proteins but not through G(q)/G(11).	Heidelberg Univ, Inst Pharmacol, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Anesthesiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Wettschureck, N (corresponding author), Heidelberg Univ, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	Nina.Wettschureck@urz.uni-heidelberg.de	Wettschureck, Nina/L-3651-2017; Offermanns, Stefan/L-3313-2017	Wettschureck, Nina/0000-0001-6858-1460; Offermanns, Stefan/0000-0001-8676-6805				Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; ARNAOUT MA, 1990, BLOOD, V75, P1037; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P581; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; Croker BA, 2002, IMMUNOL CELL BIOL, V80, P231, DOI 10.1046/j.1440-1711.2002.01077.x; Dalwadi H, 2003, J IMMUNOL, V170, P1707, DOI 10.4049/jimmunol.170.4.1707; Dorsam RT, 2002, J BIOL CHEM, V277, P47588, DOI 10.1074/jbc.M208778200; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Giagulli C, 2004, IMMUNITY, V20, P25, DOI 10.1016/S1074-7613(03)00350-9; Girkontaite I, 2001, NAT IMMUNOL, V2, P855, DOI 10.1038/ni0901-855; Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Halin C, 2005, BLOOD, V106, P1314, DOI 10.1182/blood-2004-09-3687; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Huang JS, 2004, CELL SIGNAL, V16, P521, DOI 10.1016/j.cellsig.2003.10.008; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lo CG, 2003, J EXP MED, V197, P353, DOI 10.1084/jem.20021569; Lu TT, 2002, SCIENCE, V297, P409, DOI 10.1126/science.1071632; Martin D, 2002, BRILLS TIBET STU LIB, V2, P335; Moers A, 2004, J BIOL CHEM, V279, P45354, DOI 10.1074/jbc.M408962200; Moers A, 2003, NAT MED, V9, P1418, DOI 10.1038/nm943; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Pillai S, 2005, ANNU REV IMMUNOL, V23, P161, DOI 10.1146/annurev.immunol.23.021704.115728; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Rieken S, 2006, J IMMUNOL, V177, P2985, DOI 10.4049/jimmunol.177.5.2985; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stein JV, 2005, IMMUNOLOGY, V116, P1, DOI 10.1111/j.1365-2567.2005.02183.x; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stouffer GA, 2003, ARTERIOSCL THROM VAS, V23, P1971, DOI 10.1161/01.ATV.0000093470.51580.0F; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vielkind S, 2005, J IMMUNOL, V175, P350, DOI 10.4049/jimmunol.175.1.350; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Vora KA, 2005, J LEUKOCYTE BIOL, V78, P471, DOI 10.1189/jlb.0904487; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Yamamura S, 2000, ANN NY ACAD SCI, V905, P301; Yopp AC, 2005, J IMMUNOL, V175, P2913, DOI 10.4049/jimmunol.175.5.2913	52	27	30	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36985	36992		10.1074/jbc.M605287200	http://dx.doi.org/10.1074/jbc.M605287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023430	hybrid			2022-12-25	WOS:000242220800059
J	Chung, KM; Hsu, HH; Yeh, HY; Chang, BY				Chung, Kuei-Min; Hsu, Hsin-Hsien; Yeh, Hsin-Yi; Chang, Ban-Yang			Mechanism of regulation of prokaryotic tubulin-like GTPase FtsZ by membrane protein EzrA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION PROTEIN; ALPHA-BETA-TUBULIN; INHIBITS POLYMERIZATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; LOCALIZATION; HYDROLYSIS; HOMOLOG; RING; SULA	At initiation of cell division, FtsZ, a tubulin-like GTPase, assembles into a so-called Z-ring structure at the site of division. The formation of Z ring is negatively regulated by EzrA, which ensures only one ring at the midcell per cell cycle. The mechanism leading to the negative regulation of Z-ring formation by EzrA has been analyzed. Our data reveal that the interaction between EzrA and FtsZ not only reduces the GTP-binding ability of FtsZ but also accelerates the rate of GTP hydrolysis, both of which are unfavorable for the polymerization of FtsZ. Moreover, the acceleration in rate of GTP hydrolysis by EzrA is attributed to stabilization of the transition state for GTP hydrolysis and reduction in the affinity of GDP for FtsZ. Clearly, EzrA is able to modify the GTP hydrolysis cycle of FtsZ. On the basis of these results, a model for how EzrA acts to negatively regulate Z-ring formation is proposed.	Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan	National Chung Hsing University	Chang, BY (corresponding author), Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan.	bychang@mail.nchu.edu.tw						BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Chen JC, 1999, J BACTERIOL, V181, P521, DOI 10.1128/JB.181.2.521-530.1999; Chung KM, 2004, J BACTERIOL, V186, P5926, DOI 10.1128/JB.186.17.5926-5932.2004; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Cordell SC, 2003, P NATL ACAD SCI USA, V100, P7889, DOI 10.1073/pnas.1330742100; Daniel RA, 1998, MOL MICROBIOL, V29, P593, DOI 10.1046/j.1365-2958.1998.00954.x; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Haeusser DP, 2004, MOL MICROBIOL, V52, P801, DOI 10.1111/j.1365-2958.2004.04016.x; KIMPLE RJ, 2003, COMB CHEM HIGH T SCR, V6, P1; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lappchen T, 2005, BIOCHEMISTRY-US, V44, P7879, DOI 10.1021/bi047297o; Leung AKW, 2004, J MOL BIOL, V342, P953, DOI 10.1016/j.jmb.2004.07.061; Levin PA, 1999, P NATL ACAD SCI USA, V96, P9642, DOI 10.1073/pnas.96.17.9642; Levin PA, 2001, J BACTERIOL, V183, P5449, DOI 10.1128/JB.183.18.5449-5452.2001; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Lu C, 2001, BMC Microbiol, V1, P7, DOI 10.1186/1471-2180-1-7; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Mukherjee A, 1998, P NATL ACAD SCI USA, V95, P2885, DOI 10.1073/pnas.95.6.2885; Mukherjee A, 1998, METHOD ENZYMOL, V298, P296, DOI 10.1016/S0076-6879(98)98026-0; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; ROMERG L, 2003, ANNU REV MICROBIOL, V57, P125; Rothfield L, 1999, ANNU REV GENET, V33, P423, DOI 10.1146/annurev.genet.33.1.423; Scheffers DJ, 2002, BIOCHEMISTRY-US, V41, P521, DOI 10.1021/bi011370i; Scheffers DJ, 2000, MOL MICROBIOL, V35, P1211, DOI 10.1046/j.1365-2958.2000.01791.x; Scheffers DJ, 2002, MOL MICROBIOL, V43, P1517, DOI 10.1046/j.1365-2958.2002.02828.x; Sonenshein AL, 2000, CURR OPIN MICROBIOL, V3, P561, DOI 10.1016/S1369-5274(00)00141-7; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Trusca D, 1998, J BACTERIOL, V180, P3946, DOI 10.1128/JB.180.15.3946-3953.1998; Wang XD, 1997, J BACTERIOL, V179, P5551, DOI 10.1128/jb.179.17.5551-5559.1997; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455	41	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14891	14897		10.1074/jbc.M605177200	http://dx.doi.org/10.1074/jbc.M605177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17043359	hybrid			2022-12-25	WOS:000246589000026
J	Ghaleb, AM; Katz, JP; Kaestner, KH; Du, JX; Yang, VW				Ghaleb, A. M.; Katz, J. P.; Kaestner, K. H.; Du, J. X.; Yang, V. W.			Kruppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage	ONCOGENE			English	Article						apoptosis; cell cycle; KLF4; p53; BAX; p21(WAF1/CIP1)	P53 TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; APOPTOSIS; GENE; KLF4; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; EXPRESSION; PROGRESSION	In response to gamma-radiation- induced DNA damage, organisms either activate cell cycle checkpoint and repair machinery or undergo apoptosis to eliminate damaged cells. Although previous studies indicated that the tumor suppressor p53 is critically involved in mediating both responses, how a cell decides which pathway to take is not well established. The zinc-finger-containing transcription factor, Kruppel-like factor 4 (KLF4), is a crucial mediator for the checkpoint functions of p53 after gamma-irradiation and does so by inhibiting the transition from the G1 to S and G(2) to M phases of the cell cycle. Here, we determined the role of KLF4 in modulating the apoptotic response following c-irradiation. In three independent cell systems including colorectal cancer cells and mouse embryo fibroblasts in which expression of KLF4 could be manipulated, we observed that gamma-irradiated cells underwent apoptosis if KLF4 was absent. In the presence of KLF4, the degree of apoptosis was significantly reduced and cells resorted to checkpoint arrest. The mechanism by which KLF4 accomplished this antiapoptotic effect is by activating expression of the cell cycle arrest gene, p21(WAF1/CIP1), and by inhibiting the ability of p53 to transactivate expression of the proapoptotic gene, BAX. Results of our study illustrate an unexpected antiapoptotic function of KLF4, heretofore considered a tumor suppressor in colorectal cancer, and suggest that KLF4 may be an important determinant of cell fate following gamma-radiation- induced DNA damage.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA	Emory University; University of Pennsylvania; University of Pennsylvania; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu			NCI NIH HHS [R01 CA084197-07, R01 CA084197-09, R01 CA084197-08, R01 CA084197, CA84197] Funding Source: Medline; NIDDK NIH HHS [R24 DK064399-03, R01 DK052230-11, R01 DK052230, R01 DK052230-09, DK52230, DK64399, R24 DK064399, R24 DK064399-05, R24 DK064399-04, R01 DK052230-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, R24DK064399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chan TA, 2000, GENE DEV, V14, P1584; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; Lewanski CR, 2001, LANCET ONCOL, V2, P455; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yu J, 2003, CANCER BIOL THER, V2, P694; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	42	83	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2365	2373		10.1038/sj.onc.1210022	http://dx.doi.org/10.1038/sj.onc.1210022			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016435	Green Accepted			2022-12-25	WOS:000245466000012
J	Serrano, SMT; Kim, J; Wang, DY; Dragulev, B; Shannon, JD; Mann, HH; Veit, G; Wagener, R; Koch, M; Fox, JW				Serrano, Solange M. T.; Kim, Junho; Wang, Deyu; Dragulev, Bojan; Shannon, John D.; Mann, Henning H.; Veit, Guido; Wagener, Raimund; Koch, Manuel; Fox, Jay W.			The cysteine-rich domain of snake venom metalloproteinases is a ligand for von Willebrand factor A domains - Role in substrate targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEINS; CROTALUS-ATROX VENOM; PLATELET-AGGREGATION; COLLAGEN-XII; COBRA VENOM; BINDING; INHIBITION; ADAMTS-13; ATROLYSIN; ADHESION	Snake venom metalloproteinases (SVMPs) are members of the Reprolysin family of metalloproteinases to which the ADAM (a disintegrin and metalloproteinase) proteins also belong. The disintegrin-like/cysteine-rich domains of the ADAM shave been implicated in their function. In the case of the SVMPs, we hypothesized that these domains could function to target the metalloproteinases to key extracellular matrix proteins or cell surface proteins. Initially we detected interaction of collagen XIV, a fibril-associated collagen with interrupted triple helices containing von Willebrand factor A (VWA) domains, with the PIII SVMP catrocollastatin. Next we investigated whether other VWA domain-containing matrix proteins could support the binding of PIII SVMPs. Using surface plasmon resonance, the PIII SVMP jararhagin and a recombinant cysteine-rich domain from a PIII SVMP were demonstrated to bind to collagen XIV, collagen XII, and matrilins 1, 3, and 4. Jararhagin was shown to cleave these proteins predominantly at sites localized at or near the VWA domains suggesting that it is the VWA domains to which the PIII SVMPs are binding via their cysteine-rich domain. In light of the fact that these extracellular matrix proteins function to stabilize matrix, targeting the SVMPs to these proteins followed by their specific cleavage could promote the destabilization of extracellular matrix and cell-matrix interactions and in the case of capillaries could contribute to their disruption and hemorrhage. Although there is only limited structural homology shared by the cysteine-rich domains of the PIII SVMPs and the ADAMs our results suggest an analogous function for the cysteine-rich domains in certain members of the expanded ADAM family of proteins to target them to VWA domain-containing proteins.	Univ Virginia, Biomol Res Facil, Charlottesville, VA 22908 USA; Inst Butanton, Ctr Appl Toxinol, Lab Especial Toxinol Aplicada, BR-05503900 Sao Paulo, Brazil; Sangji Univ, Dept Chem, Wonju 220702, Kangwon, South Korea; Univ Cologne, Ctr Biochem, Fac Med, D-50931 Cologne, Germany; Univ Cologne, Dept Dermatol, D-50931 Cologne, Germany	University of Virginia; Instituto Butantan; Sangji University; University of Cologne; University of Cologne	Fox, JW (corresponding author), Univ Virginia, Dept Microbiol, POB 800734, Charlottesville, VA 22908 USA.	jwf8x@virginia.edu	Koch, Manuel/AAG-9914-2021; Veit, Guido/C-9596-2009; Serrano, Solange/ABB-7569-2021; Serrano, Solange M. T./A-7132-2008	Koch, Manuel/0000-0002-2962-7814; Veit, Guido/0000-0002-6758-2696; Serrano, Solange/0000-0001-8994-1904; Serrano, Solange M. T./0000-0001-8994-1904				BARAMOVA EN, 1989, ARCH BIOCHEM BIOPHYS, V275, P63, DOI 10.1016/0003-9861(89)90350-0; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; BOHME K, 1995, DEV DYNAM, V204, P432; Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401; Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380; Fox JW, 2005, TOXICON, V45, P969, DOI 10.1016/j.toxicon.2005.02.012; FURLAN M, 1996, BLOOD, V96, P1808; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; Gerecke DR, 2003, MATRIX BIOL, V22, P209, DOI 10.1016/S0945-053X(03)00021-0; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; Hamako J, 1998, THROMB HAEMOSTASIS, V80, P499, DOI 10.1055/s-0037-1615236; HANNA SL, 2000, MICROBIOLOGY, V146, P95; Jia LG, 2000, ARCH BIOCHEM BIOPHYS, V373, P281, DOI 10.1006/abbi.1999.1517; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; Kamiguti AS, 1996, TOXICON, V34, P627, DOI 10.1016/0041-0101(96)00017-7; Kamiguti AS, 2003, FEBS LETT, V549, P129, DOI 10.1016/S0014-5793(03)00799-3; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Majerus EM, 2005, J BIOL CHEM, V280, P21773, DOI 10.1074/jbc.M502529200; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; OHSAKA A, 1960, BRIT J EXP PATHOL, V41, P478; OWNBY CL, 1978, AM J PATHOL, V93, P201; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; Serrano SMT, 2005, BIOCHEM J, V391, P69, DOI 10.1042/BJ20050483; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; Shoibonov BB, 2005, MOL IMMUNOL, V42, P1141, DOI 10.1016/j.molimm.2004.11.009; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; Takeda S, 2006, EMBO J, V25, P2388, DOI 10.1038/sj.emboj.7601131; Veit G, 2006, J BIOL CHEM, V281, P27461, DOI 10.1074/jbc.M603147200; Wagener R, 2005, FEBS LETT, V579, P3323, DOI 10.1016/j.febslet.2005.03.018; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Zanardelli S, 2006, J BIOL CHEM, V281, P1555, DOI 10.1074/jbc.M508316200; Zhang ZG, 2006, J CELL SCI, V119, P1886, DOI 10.1242/jcs.02921; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200	40	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39746	39756		10.1074/jbc.M604855200	http://dx.doi.org/10.1074/jbc.M604855200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17040908	hybrid			2022-12-25	WOS:000243033900002
J	Degenhardt, T; Matilainen, M; Herzig, KH; Dunlop, TW; Carlberg, C				Degenhardt, Tatjana; Matilainen, Merja; Herzig, Karl-Heinz; Dunlop, Thomas W.; Carlberg, Carsten			The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENT RECOGNITION; RETINOID-X RECEPTORS; NUCLEAR RECEPTOR; TRANSCRIPTION FACTOR; THYROID-HORMONE; PPAR-GAMMA; FUNCTIONAL-CHARACTERIZATION; HETERODIMER FORMATION; LIPID-METABOLISM; FATTY-ACIDS	Insulin-like growth factor-binding protein 1 (IGFBP-1) is a biomarker for metabolic and hyperproliferative diseases. At the same time, the nuclear receptors peroxisome proliferator-activated receptors (PPARs) are known for their critical role in the development of both the metabolic syndrome and various cancers. Here we demonstrate, in human hepatocellular carcinoma cells and in normal mouse liver, that IGFBP-1 mRNA expression is under the primary control of PPAR ligands. We applied an improved in silico screening approach for PPAR response elements (PPREs) and identified five candidate PPREs located within 10 kb of the transcription start site (TSS) of the IGFBP-1 gene. Chromatin immunoprecipitation assays showed that, in living cells, the genomic region containing the most proximal PPRE, at position -1200 (relative to the TSS), preferentially associates with multiple PPAR subtypes and various other components of the transcriptional apparatus, which include their heterodimerizing partner, retinoid X receptor, as well as phosphorylated RNA polymerase II, co-repressor, co-activator, and mediator proteins. Moreover, further chromatin immunoprecipitation assays demonstrated that the TSS regions of the IGFBP-1 gene and those of the related IGFBP-2, -5, and -6, but not of IGFBP-3 and -4 genes, bind PPARs as well. We also show that these additional PPAR binding genes contain a number of candidate PPREs and that their mRNA levels respond quickly to the presence of PPAR ligands, indicating that they are also primary PPAR target genes.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Univ Luxembourg, Life Sci Res Unit, L-1511 Luxembourg, Luxembourg	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; University of Luxembourg	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Carlberg, Carsten/C-9075-2011; Heinäniemi, Merja/C-5051-2014; Heinaniemi, Merja/AAS-4530-2020	Carlberg, Carsten/0000-0003-2633-0684; Heinäniemi, Merja/0000-0001-6190-3439; Heinaniemi, Merja/0000-0001-6190-3439				Baumann CA, 2000, J BIOL CHEM, V275, P9131, DOI 10.1074/jbc.275.13.9131; Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003; Carlberg C, 2006, CRIT REV EUKAR GENE, V16, P1; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Dunlop TW, 2005, J MOL BIOL, V349, P248, DOI 10.1016/j.jmb.2005.03.060; Fang HL, 2005, MOL PHARMACOL, V67, P1257, DOI 10.1124/mol.104.005389; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Frederiksen KS, 2004, J LIPID RES, V45, P592, DOI 10.1194/jlr.M300239-JLR200; Hansmannel F, 2003, BIOCHEM BIOPH RES CO, V311, P149, DOI 10.1016/j.bbrc.2003.09.185; Heuvel JPV, 2003, TOXICOL APPL PHARM, V188, P185, DOI 10.1016/S0041-008X(03)00015-2; Hilding A, 2003, BIOCHEM BIOPH RES CO, V303, P693, DOI 10.1016/S0006-291X(03)00403-0; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; Krogsdam AM, 2002, BIOCHEM J, V363, P157, DOI 10.1042/0264-6021:3630157; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; Lenhard Boris, 2003, J Biol, V2, P13, DOI 10.1186/1475-4924-2-13; Leu JI, 2003, J CLIN INVEST, V111, P129, DOI 10.1172/JCI200316712; LEWITT MS, 1994, DIABETES RES CLIN PR, V23, P3, DOI 10.1016/0168-8227(94)90121-X; Lu SY, 2003, MOL CARCINOGEN, V36, P142, DOI 10.1002/mc.10105; MADER S, 1993, J BIOL CHEM, V268, P591; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Matilainen M, 2005, NUCLEIC ACIDS RES, V33, P5521, DOI 10.1093/nar/gki872; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Molnar F, 2005, J BIOL CHEM, V280, P26543, DOI 10.1074/jbc.M502463200; Molnar F, 2006, J BIOL CHEM, V281, P10516, DOI 10.1074/jbc.M513609200; Mortensen DL, 1997, ENDOCRINOLOGY, V138, P2073, DOI 10.1210/en.138.5.2073; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; Seto-Young D, 2005, J CLIN ENDOCR METAB, V90, P6099, DOI 10.1210/jc.2005-0469; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torra IP, 2002, MOL ENDOCRINOL, V16, P1013; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Walczak R, 2002, J LIPID RES, V43, P177; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yamazaki K, 2002, BIOCHEM BIOPH RES CO, V290, P1114, DOI 10.1006/bbrc.2001.6319; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939	51	52	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39607	39619		10.1074/jbc.M605623200	http://dx.doi.org/10.1074/jbc.M605623200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17062566	hybrid			2022-12-25	WOS:000242898700068
J	Huang, HT; Brand, OM; Mathew, M; Ignatiou, C; Ewen, EP; McCalmon, SA; Naya, FJ				Huang, Hsuan-Ting; Brand, Ondra M.; Mathew, Matthen; Ignatiou, Christos; Ewen, Elizabeth P.; McCalmon, Sarah A.; Naya, Francisco J.			Myomaxin is a novel transcriptional target of MEF2A that encodes a Xin-related alpha-actinin-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-2 MEF2; DEVELOPMENT IN-VIVO; MUSCLE DEVELOPMENT; CARDIAC-HYPERTROPHY; SIGNALING PATHWAYS; STRIATED-MUSCLE; MICE LACKING; SKELETAL; DIFFERENTIATION; GENE	The physiological targets regulated by MEF2 in striated muscle are not completely known. Several recent studies have identified novel downstream target genes and shed light on the global transcriptional network regulated by MEF2 in muscle. In our continuing effort to identify novel, downstream pathways controlled by MEF2, we have used mef2a knock-out mice to find those genes dependent on MEF2A transcriptional activity. Here, we describe the characterization of a direct, downstream target gene for the MEF2A transcription factor encoding a large, muscle-specific protein that localizes to the Z-disc/costameric region in striated muscle. This gene, called myomaxin, was identified as a gene markedly down-regulated in MEF2A knock-out hearts. Myomaxin is the mouse ortholog of a partial human cDNA of unknown function named cardiomyopathy associated gene 3 (CMYA3). Myomaxin is expressed as a single, large transcript of similar to 11 kilobases in adult heart and skeletal muscle with an open reading frame of 3,283 amino acids. The protein encoded by the myomaxin gene is related to the actin-binding protein Xin and interacts with the sarcomeric Z-disc protein, alpha-actinin-2. Our findings demonstrate that Myomaxin functions directly downstream of MEF2A at the peripheral Z-disc complex in striated muscle potentially playing a role in regulating cytoarchitectural integrity.	Boston Univ, Dept Biol, Cell & Mol Biol Program, Boston, MA 02215 USA	Boston University	Naya, FJ (corresponding author), Boston Univ, Dept Biol, Cell & Mol Biol Program, 5 Cummington St, Boston, MA 02215 USA.	fnaya@bu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073304] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 73304] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson JP, 2004, MOL CELL BIOL, V24, P3757, DOI 10.1128/MCB.24.9.3757-3768.2004; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Benson MA, 2004, J BIOL CHEM, V279, P10450, DOI 10.1074/jbc.M312664200; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Czubryt MP, 2004, RECENT PROG HORM RES, V59, P105, DOI 10.1210/rp.59.1.105; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; Duka A, 2006, AM J HYPERTENS, V19, P275, DOI 10.1016/j.amjhyper.2005.08.017; Durham JT, 2006, J BIOL CHEM, V281, P6841, DOI 10.1074/jbc.M510499200; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Hoppe T, 2004, CELL, V118, P337, DOI 10.1016/j.cell.2004.07.014; Liu ZP, 2001, DEV BIOL, V234, P497, DOI 10.1006/dbio.2001.0277; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Nakagawa O, 2005, GENE DEV, V19, P2066, DOI 10.1101/gad.1338705; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Pacholsky D, 2004, J CELL SCI, V117, P5257, DOI 10.1242/jcs.01406; Paris J, 2004, PHYSIOL GENOMICS, V20, P143, DOI 10.1152/physiolgenomics.00149.2004; Phan D, 2005, DEVELOPMENT, V132, P2669, DOI 10.1242/dev.01849; Price MG, 2002, J CELL SCI, V115, P4013, DOI 10.1242/jcs.00108; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Wang DZ, 1999, DEVELOPMENT, V126, P1281; Xu J, 2006, J BIOL CHEM, V281, P9152, DOI 10.1074/jbc.M510217200	30	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39370	39379		10.1074/jbc.M603244200	http://dx.doi.org/10.1074/jbc.M603244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17046827	hybrid			2022-12-25	WOS:000242898700044
J	Hussain, SA; Piper, M; Fukuhara, N; Strochlic, L; Cho, G; Howitt, JA; Ahmed, Y; Powell, AK; Turnbull, JE; Holt, CE; Hohenester, E				Hussain, Sadaf-Ahmahni; Piper, Michael; Fukuhara, Noemi; Strochlic, Laure; Cho, Gian; Howitt, Jason A.; Ahmed, Yassir; Powell, Andrew K.; Turnbull, Jeremy E.; Holt, Christine E.; Hohenester, Erhard			A molecular mechanism for the heparan sulfate dependence of Slit-Robo signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MIDLINE AXON GUIDANCE; CELL-SURFACE; CRYSTAL-STRUCTURE; BINDING; RECEPTOR; MIGRATION; MORPHOGENESIS; DIMERIZATION; REGULATORS	Slit is a large secreted protein that provides important guidance cues in the developing nervous system and in other organs. Signaling by Slit requires two receptors, Robo transmembrane proteins and heparan sulfate (HS) proteoglycans. How HS controls Slit-Robo signaling is unclear. Here we show that the second leucine-rich repeat domain (D2) of Slit, which mediates binding to Robo receptors, also contains a functionally important binding site for heparin, a highly sulfated variant of HS. Heparin markedly enhances the affinity of the Slit-Robo interaction in a solid-phase binding assay. Analytical gel filtration chromatography demonstrates that Slit D2 associates with a soluble Robo fragment and a heparin-derived oligosaccharide to form a ternary complex. Retinal growth cone collapse triggered by Slit D2 requires cell surface HS or exogenously added heparin. Mutation of conserved basic residues in the C-terminal cap region of Slit D2 reduces heparin binding and abolishes biological activity. We conclude that heparin/HS is an integral component of the minimal Slit-Robo signaling complex and serves to stabilize the relatively weak Slit-Robo interaction.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Div Mol & Cell Biol, London SW7 2AZ, England; Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3DY, England; Univ Liverpool, Sch Biol Sci, Mol Glycobiol Grp, Liverpool L69 7ZB, Merseyside, England	Imperial College London; University of Cambridge; University of Liverpool	Hohenester, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Div Mol & Cell Biol, Prince Consort Rd, London SW7 2AZ, England.	e.hohenester@imperial.ac.uk	Powell, Andrew/E-4491-2010; Piper, Michael J/B-2805-2010; Strochlic, Laure/J-3610-2017	Piper, Michael J/0000-0002-6759-2560; Strochlic, Laure/0000-0001-5373-4284; Howitt, Jason/0000-0001-9922-7931; Holt, Christine Elizabeth/0000-0003-2829-121X	MRC [G117/423] Funding Source: UKRI; Medical Research Council [G117/423] Funding Source: Medline; Wellcome Trust [070568, 054334, 067203] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Guan KL, 2003, NAT REV NEUROSCI, V4, P941, DOI 10.1038/nrn1254; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Hinck L, 2004, DEV CELL, V7, P783, DOI 10.1016/j.devcel.2004.11.002; Hivert B, 2002, MOL CELL NEUROSCI, V21, P534, DOI 10.1006/mcne.2002.1193; Howitt JA, 2004, EMBO J, V23, P4406, DOI 10.1038/sj.emboj.7600446; Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; Irie A, 2002, DEVELOPMENT, V129, P61; Johnson KG, 2004, CURR BIOL, V14, P499, DOI 10.1016/j.cub.2004.02.005; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kaus S, 2006, J BIOL CHEM, V281, P11347, DOI 10.1074/jbc.M508853200; Lee JS, 2004, NEURON, V44, P947, DOI 10.1016/j.neuron.2004.11.029; Liu Z, 2004, MOL CELL NEUROSCI, V26, P232, DOI 10.1016/j.mcn.2004.01.002; Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Piper M, 2006, NEURON, V49, P215, DOI 10.1016/j.neuron.2005.12.008; Pratt T, 2006, J NEUROSCI, V26, P6911, DOI 10.1523/JNEUROSCI.0505-06.2006; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rhiner C, 2005, DEVELOPMENT, V132, P4621, DOI 10.1242/dev.02042; Robinson CJ, 2005, J BIOL CHEM, V280, P42274, DOI 10.1074/jbc.M505720200; Ronca F, 2001, J BIOL CHEM, V276, P29141, DOI 10.1074/jbc.M100240200; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SKIDMORE MA, 2005, CHEM BIOL HEPARIN HE, P181; Steigemann P, 2004, CURR BIOL, V14, P225, DOI 10.1016/j.cub.2004.01.006; Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	31	86	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39693	39698		10.1074/jbc.M609384200	http://dx.doi.org/10.1074/jbc.M609384200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17062560	hybrid, Green Accepted			2022-12-25	WOS:000242898700076
J	Rasar, M; DeFranco, DB; Hammes, SR				Rasar, Melissa; DeFranco, Donald B.; Hammes, Stephen R.			Paxillin regulates steroid-triggered meiotic resumption in oocytes by enhancing an all-or-none positive feedback kinase loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION LOCALIZATION; MOS MESSENGER-RNA; CYTOPLASMIC POLYADENYLATION; ANDROGEN RECEPTOR; PROTEIN PAXILLIN; MAP KINASE; CELL-CYCLE; PHOSPHORYLATION SITES; XENOPUS; MATURATION	Oocyte maturation is triggered by steroids in a transcription-independent fashion that involves an unusual positive feedback loop whereby MOS ( a germ cell-specific Raf) activates MEK1, which in turn activates ERK2. ERK2 then acts back on MOS to enhance its expression and amplify the kinase signaling cascade. To date, little is known regarding other factors that regulate this powerful positive feedback kinase cascade. Here we present the scaffold molecule Paxillin as a newly recognized essential regulator of meiosis in Xenopus laevis oocytes. Reduction of Paxillin expression using RNA interference or antisense oligonucleotides completely abrogates steroid-triggered meiotic resumption. Detailed signaling studies reveal that Paxillin is acting early in the kinase cascade, because it is required for accumulation of MOS protein and complete activation of downstream kinase signaling in response to steroids. Surprisingly, full Paxillin activity also requires serine phosphorylation by a kinase downstream of MOS and MEK1, possibly ERK2. Together, these data suggest that Paxillin is an important regulator of the positive feedback effects of MEK/ERK signaling on MOS protein expression. These experiments reveal a novel and critical function for Paxillin in meiosis and support the notion that Paxillin may be a general modulator of mitogen-activated protein kinase signaling.	Univ Texas, SW Med Ctr, Div Endocrinol & Metab, Dept Internal Med,Dept Pharmacol, Dallas, TX 75390 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hammes, SR (corresponding author), Univ Texas, SW Med Ctr, Div Endocrinol, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	stephen.hammes@utsouthwestern.edu		Young, Melissa/0000-0002-6519-4999	NCI NIH HHS [CA43037] Funding Source: Medline; NIDDK NIH HHS [DK59913] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059913] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albertini DF, 1998, J MOL MED, V76, P795, DOI 10.1007/s001090050283; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anantharam A, 2003, J BIOL CHEM, V278, P11739, DOI 10.1074/jbc.M212751200; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Cai XM, 2006, MOL CELL BIOL, V26, P2857, DOI 10.1128/MCB.26.7.2857-2868.2006; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Conti M, 2002, MOL CELL ENDOCRINOL, V187, P153, DOI 10.1016/S0303-7207(01)00686-4; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; GALLO CJ, 1995, J CELL BIOL, V130, P275, DOI 10.1083/jcb.130.2.275; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; Gill A, 2004, MOL ENDOCRINOL, V18, P97, DOI 10.1210/me.2003-0326; Gordon E, 2006, BIOPHYS J, V90, P1223, DOI 10.1529/biophysj.105.072504; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Haas D, 2005, MOL ENDOCRINOL, V19, P2035, DOI 10.1210/me.2004-0531; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Howard EL, 1999, MOL CELL BIOL, V19, P1990; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; ISHIDA N, 1993, FEBS LETT, V324, P345, DOI 10.1016/0014-5793(93)80148-N; Jamnongjit M, 2005, P NATL ACAD SCI USA, V102, P16257, DOI 10.1073/pnas.0508521102; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Lutz LB, 2001, P NATL ACAD SCI USA, V98, P13728, DOI 10.1073/pnas.241471598; Lutz LB, 2003, MOL ENDOCRINOL, V17, P1106, DOI 10.1210/me.2003-0032; Lutz LB, 2000, J BIOL CHEM, V275, P41512, DOI 10.1074/jbc.M006757200; Maller J L, 1980, Curr Top Cell Regul, V16, P271; Martinez SE, 2005, MOL BIOL CELL, V16, P1152, DOI 10.1091/mbc.E04-07-0585; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; Mehlmann LM, 2005, DEV BIOL, V288, P397, DOI 10.1016/j.ydbio.2005.09.030; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; MORRILL GA, 1977, DIFFERENTIATION, V8, P97, DOI 10.1111/j.1432-0436.1977.tb00925.x; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; Ogawa M, 2001, BBA-GENE STRUCT EXPR, V1519, P235, DOI 10.1016/S0167-4781(01)00230-5; Ogawa M, 2003, BIOCHEM BIOPH RES CO, V304, P676, DOI 10.1016/S0006-291X(03)00640-5; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; Roy LM, 1996, ONCOGENE, V12, P2203; SADLER SE, 1981, J BIOL CHEM, V256, P6368; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Sheng J, 2002, EMBO J, V21, P6061, DOI 10.1093/emboj/cdf626; Sheng YL, 2001, CURR BIOL, V11, P405, DOI 10.1016/S0960-9822(01)00123-3; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Stein P, 2005, DEV BIOL, V286, P464, DOI 10.1016/j.ydbio.2005.08.015; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Terfera DR, 2002, J CELL PHYSIOL, V191, P82, DOI 10.1002/jcp.10082; TORPEY N, 1992, NATURE, V357, P413, DOI 10.1038/357413a0; Tumbarello DA, 2002, FEBS LETT, V513, P114, DOI 10.1016/S0014-5793(01)03244-6; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Webb DJ, 2005, J CELL SCI, V118, P4925, DOI 10.1242/jcs.02563; Woodrow MA, 2003, EXP CELL RES, V287, P325, DOI 10.1016/S0014-4827(03)00122-8; Woods AJ, 2005, MOL CELL BIOL, V25, P3763, DOI 10.1128/MCB.25.9.3763-3773.2005	57	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39455	39464		10.1074/jbc.M608959200	http://dx.doi.org/10.1074/jbc.M608959200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17065147	hybrid			2022-12-25	WOS:000242898700053
J	Seward, HE; Roujeinikova, A; McLean, KJ; Munro, AW; Leys, D				Seward, Harriet E.; Roujeinikova, Anna; McLean, Kirsty J.; Munro, Andrew W.; Leys, David			Crystal structure of the Mycobacterium tuberculosis P450CYP121-fluconazole complex reveals new azole drug-P450 binding mode	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; CYTOCHROME-P450; ANTIFUNGALS; IDENTIFICATION; INHIBITORS; AGENTS	Azole and triazole drugs are cytochrome P450 inhibitors widely used as fungal antibiotics and possessing potent antimy-cobacterial activity. We present here the crystal structure of Mycobacterium tuberculosis cytochrome P450 CYP121 in complex with the triazole drug fluconazole, revealing a new azole heme ligation mode. In contrast to other structurally characterized cytochrome P450 azole complexes, where the azole nitrogen directly coordinates the heme iron, in CYP121 fluconazole does not displace the aqua sixth heme ligand but occupies a position that allows formation of a direct hydrogen bond to the aqua sixth heme ligand. Direct ligation of fluconazole to the heme iron is observed in a minority of CYP121 molecules, albeit with severe deviations from ideal geometry due to close contacts with active site residues. Analysis of both ligand-on and -off structures reveals the relative position of active site residues derived from the I-helix is a key determinant in the relative ratio of on and off states. Regardless, both ligand- bound states lead to P450 inactivation by active site occlusion. This previously unrecognized means of P450 inactivation is consistent with spectroscopic analyses in both solution and in the crystalline form and raises important questions relating to interaction of azoles with both pathogen and human P450s.	Univ Leicester, Dept Biochem, Leicester LE6 0HQ, Leics, England; Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England; Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester Interdisciplinary Bioctr, Manchester M1 7DN, Lancs, England	University of Leicester; University of Manchester; University of Manchester	Munro, AW (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE6 0HQ, Leics, England.	Andrew.Munro@Manchester.ac.uk; David.Leys@Manchester.ac.uk	Munro, Andrew/G-5639-2019; McLean, Kirsty J/GXI-2853-2022	Munro, Andrew/0000-0002-4642-180X; McLean, Kirsty/0000-0002-7193-5044; Roujeinikova, Anna/0000-0001-8478-4751	Biotechnology and Biological Sciences Research Council [C19757/2] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Ahmad Z, 2006, FEMS MICROBIOL LETT, V258, P200, DOI 10.1111/j.1574-6968.2006.00224.x; Ahmad Z, 2006, FEMS MICROBIOL LETT, V261, P181, DOI 10.1111/j.1574-6968.2006.00350.x; Akins RA, 2005, MED MYCOL, V43, P285, DOI 10.1080/13693780500138971; Cupp-Vickery JR, 2001, J MOL BIOL, V311, P101, DOI 10.1006/jmbi.2001.4803; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; GADSBY PMA, 1990, J AM CHEM SOC, V112, P5003, DOI 10.1021/ja00169a002; Girvan HM, 2004, J BIOL CHEM, V279, P23274, DOI 10.1074/jbc.M401716200; Kale P, 2005, DRUG TODAY, V41, P91, DOI 10.1358/dot.2005.41.2.882661; Leys D, 2003, J BIOL CHEM, V278, P5141, DOI 10.1074/jbc.M209928200; MCKNIGHT J, 1993, EUR J BIOCHEM, V213, P683, DOI 10.1111/j.1432-1033.1993.tb17808.x; McLean KJ, 2006, TRENDS MICROBIOL, V14, P220, DOI 10.1016/j.tim.2006.03.002; McLean KJ, 2002, MICROBIOL-SGM, V148, P2937, DOI 10.1099/00221287-148-10-2937; McLean KJ, 2005, BIOCHEM SOC T, V33, P796, DOI 10.1042/BST0330796; McLean KJ, 2002, J INORG BIOCHEM, V91, P527, DOI 10.1016/S0162-0134(02)00479-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Podust LM, 2004, STRUCTURE, V12, P1937, DOI 10.1016/j.str.2004.08.009; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; Walker FA, 2004, CHEM REV, V104, P589, DOI 10.1021/cr020634j; Zhao YH, 2006, J BIOL CHEM, V281, P5973, DOI 10.1074/jbc.M511464200	23	97	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39437	39443		10.1074/jbc.M607665200	http://dx.doi.org/10.1074/jbc.M607665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17028183	hybrid			2022-12-25	WOS:000242898700051
J	Shin, SW; Bian, GW; Raikhel, AS				Shin, Sang Woon; Bian, Guowu; Raikhel, Alexander S.			A toll receptor and a cytokine, Toll5A and Spz1C, are involved in toll antifungal immune signaling in the mosquito Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-VENTRAL POLARITY; ANOPHELES-GAMBIAE; DROSOPHILA EMBRYO; GENE-PRODUCT; SPATZLE; PATHWAY; ESTABLISHMENT; RELISH	The fungal-specific immune response in the mosquito Aedes aegypti involves the Toll immune pathway transduced through REL1, a homologue of the NF-kappa B transcription factor Drosophila Dorsal. The Toll receptor and its ligand, Spatzle (Spz), link extracellular immune signals to the Toll intracellular transduction pathway. Five homologues to the Drosophila Toll (Toll1) receptor (Toll1A, Toll1B, Toll5A, Toll5B, and Toll4) and three homologues to the Drosophila cytokine Spatzle (Spz1A, 1B, and 1C) were identified from genomic and cDNA sequence data bases. Toll1A, Toll5A, Toll5B, and Spz1A were specifically induced in the mosquito fat body following fungal challenge. This transcriptional up-regulation was mediated by REL1. Spz1C was constitutively expressed in the mosquito fat body, whereas Spz1B and Toll4 were primarily expressed in ovarian tissues of female mosquitoes. The transcripts of Toll1B were only detected in early stages of mosquito embryos. RNA interference knock down of Toll5A and Spz1C resulted in two phenotypes of Aedes Toll/REL1 pathway deficiency: decreased induction of Aedes Serpin-27A following fungal challenge and increased susceptibility to the entomopathogenic fungus Beauveria bassiana. These data suggest that Toll5A and Spz1C function as cytokine receptor systems specific to the Toll receptor-mediated immune response following fungal challenge in the mosquito fat body.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Bian, Guowu/B-1572-2010	Shin, Sang Woon/0000-0001-9467-0803	NCI NIH HHS [1 R01 CA1059492] Funding Source: Medline; NIAID NIH HHS [R01 AI059492] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; Beaty BJ, 2000, P NATL ACAD SCI USA, V97, P10295, DOI 10.1073/pnas.97.19.10295; Beier JC, 1998, ANNU REV ENTOMOL, V43, P519, DOI 10.1146/annurev.ento.43.1.519; Bian G, 2005, P NATL ACAD SCI USA, V102, P13568, DOI 10.1073/pnas.0502815102; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; Brudno M, 2004, GENOME RES, V14, P685, DOI 10.1101/gr.2067704; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Enserink M, 2002, SCIENCE, V297, P1988, DOI 10.1126/science.297.5589.1988; HAGEDORN HH, 1977, J INSECT PHYSIOL, V23, P203, DOI 10.1016/0022-1910(77)90030-0; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hu XD, 2004, P NATL ACAD SCI USA, V101, P9369, DOI 10.1073/pnas.0307062101; Imler JL, 2004, J LEUKOCYTE BIOL, V75, P18, DOI 10.1189/jlb.0403160; Kambris Zakaria, 2002, Gene Expression Patterns, V2, P311, DOI 10.1016/S1567-133X(02)00020-0; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Luna C, 2003, INSECT MOL BIOL, V12, P67, DOI 10.1046/j.1365-2583.2003.00388.x; Luna C, 2002, INSECT BIOCHEM MOLEC, V32, P1171, DOI 10.1016/S0965-1748(02)00053-X; Luo C, 2001, INSECT MOL BIOL, V10, P457, DOI 10.1046/j.0962-1075.2001.00284.x; Michel K, 2005, EMBO REP, V6, P891, DOI 10.1038/sj.embor.7400478; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; Ooi JY, 2002, EMBO REP, V3, P82, DOI 10.1093/embo-reports/kvf004; Parker JS, 2001, PROTEINS, V45, P71, DOI 10.1002/prot.1125; Shin SW, 2005, J BIOL CHEM, V280, P16499, DOI 10.1074/jbc.M500711200; Shin SW, 2002, P NATL ACAD SCI USA, V99, P9978, DOI 10.1073/pnas.162345999; Shin SW, 2003, P NATL ACAD SCI USA, V100, P2616, DOI 10.1073/pnas.0537347100; Smith PL, 2005, MOL IMMUNOL, V42, P869, DOI 10.1016/j.molimm.2004.11.008; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; WATTAM AR, 1992, P NATL ACAD SCI USA, V89, P6502, DOI 10.1073/pnas.89.14.6502; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955	34	69	74	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39388	39395		10.1074/jbc.M608912200	http://dx.doi.org/10.1074/jbc.M608912200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17068331	hybrid			2022-12-25	WOS:000242898700046
J	Bentley, M; Liang, YJ; Mullen, K; Xu, DL; Sztul, E; Hay, JC				Bentley, Marvin; Liang, Yingjian; Mullen, Karl; Xu, Dalu; Sztul, Elizabeth; Hay, Jesse C.			SNARE status regulates tether recruitment and function in homotypic COPII vesicle fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-GOLGI TRANSPORT; ENDOPLASMIC-RETICULUM; COMPLEX; ER; PROTEINS; REVEALS; DOCKING; TRAFFICKING; GM130; DYNAMICS	In mammals, coat complex II (COPII)-coated transport vesicles deliver secretory cargo to vesicular tubular clusters (VTCs) that facilitate cargo sorting and transport to the Golgi. We documented in vitro tethering and SNARE-dependent homotypic fusion of endoplasmic reticulum-derived COPII transport vesicles to form larger cargo containers characteristic of VTCs (Xu, D., and Hay, J. C. (2004) J. Cell Biol. 167, 997-1003). COPII vesicles thus appear to contain all necessary components for homotypic tethering and fusion, providing a pathway for de novo VTC biogenesis. Here we demonstrate that antibodies against the endoplasmic reticulum/Golgi SNARE Syntaxin 5 inhibit COPII vesicle homotypic tethering as well as fusion, implying an unanticipated role for SNAREs upstream of fusion. Inhibition of SNARE complex access and/or disassembly with dominant-negative alpha-soluble NSF attachment protein (SNAP) also inhibited tethering, implicating SNARE status as a critical determinant in COPII vesicle tethering. The tethering-defective vesicles generated in the presence of dominant-negative alpha-SNAP specifically lacked the Rab1 effectors p115 and GM130 but not other peripheral membrane proteins. Furthermore, Rab effectors, including p115, were shown to be required for homotypic COPII vesicle tethering. Thus, our results demonstrate a requirement for SNARE-dependent tether recruitment and function in COPII vesicle fusion. We anticipate that recruitment of tether molecules by an upstream SNARE signal ensures that tethering events are initiated only at focal sites containing appropriately poised fusion machinery.	Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Montana System; University of Montana; University of Alabama System; University of Alabama Birmingham	Hay, JC (corresponding author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.	jesse.hay@umontana.edu		Bentley, Marvin/0000-0002-1754-0332	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH066179] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 015583] Funding Source: Medline; NIGMS NIH HHS [R01 GM 59378] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Ben-Tekaya H, 2005, J CELL SCI, V118, P357, DOI 10.1242/jcs.01615; Brandhorst D, 2006, P NATL ACAD SCI USA, V103, P2701, DOI 10.1073/pnas.0511138103; Brandon E, 2006, MOL BIOL CELL, V17, P2996, DOI 10.1091/mbc.e05-09-0862; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Collins KM, 2005, EMBO J, V24, P1775, DOI 10.1038/sj.emboj.7600658; Conibear E, 2003, MOL BIOL CELL, V14, P1610, DOI 10.1091/mbc.E02-10-0654; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Joglekar AP, 2003, J BIOL CHEM, V278, P14121, DOI 10.1074/jbc.M300659200; Laage R, 2001, MOL BIOL CELL, V12, P3375, DOI 10.1091/mbc.12.11.3375; Loh E, 2005, J CELL SCI, V118, P1209, DOI 10.1242/jcs.01723; Marra P, 2001, NAT CELL BIOL, V3, P1101, DOI 10.1038/ncb1201-1101; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Puthenveedu MA, 2004, P NATL ACAD SCI USA, V101, P1253, DOI 10.1073/pnas.0306373101; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; Siniossoglou S, 2002, J BIOL CHEM, V277, P48318, DOI 10.1074/jbc.M209428200; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Stroupe C, 2006, EMBO J, V25, P1579, DOI 10.1038/sj.emboj.7601051; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Ungermann C, 2000, P NATL ACAD SCI USA, V97, P8889, DOI 10.1073/pnas.160269997; Vasile E, 2003, TRAFFIC, V4, P254, DOI 10.1034/j.1600-0854.2003.00080.x; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; Wang W, 2000, J CELL BIOL, V151, P289, DOI 10.1083/jcb.151.2.289; Williams AL, 2004, MOL BIOL CELL, V15, P162, DOI 10.1091/mbc.E03-07-0535; XU D, 2006, IN PRESS INTRACELLUL; Xu DL, 2004, J CELL BIOL, V167, P997, DOI 10.1083/jcb.200408135; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Yu S, 2006, J CELL BIOL, V174, P359, DOI 10.1083/jcb.200603044; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zeuschner D, 2006, NAT CELL BIOL, V8, P377, DOI 10.1038/ncb1371	46	42	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38825	38833		10.1074/jbc.M606044200	http://dx.doi.org/10.1074/jbc.M606044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17038314	hybrid			2022-12-25	WOS:000242709500080
J	Shalbuyeva, N; Brustovetsky, T; Bolshakov, A; Brustovetsky, N				Shalbuyeva, Natalia; Brustovetsky, Tatiana; Bolshakov, Alexey; Brustovetsky, Nickolay			Calcium-dependent spontaneously reversible remodeling of brain mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CEREBELLAR GRANULE CELLS; CYTOCHROME-C RELEASE; CULTURED HIPPOCAMPAL-NEURONS; CYCLOSPORINE-A; HEART-MITOCHONDRIA; CORTICAL-NEURONS; GLUTAMATE EXCITOTOXICITY; CNS MITOCHONDRIA; RAT-BRAIN	An exposure of cultured hippocampal neurons expressing mitochondrially targeted enhanced yellow fluorescent protein to excitotoxic glutamate resulted in reversible mitochondrial remodeling that in many instances could be interpreted as swelling. Remodeling was not evident if glutamate receptors were blocked with MK801, if Ca2+ was omitted or substituted for Sr2+ in the bath solution, if neurons were treated with carbonylcyanide p-trifluoromethoxyphenylhydrazone to depolarize mitochondria, or if neurons were pretreated with cyclosporin A or N-methyl-4-isoleucine-cyclosporin (NIM811) to inhibit the mitochondrial permeability transition. In the experiments with isolated brain synaptic or nonsynaptic mitochondria, Ca2+ triggered transient, spontaneously reversible cyclosporin A-sensitive swelling closely resembling remodeling of organelles in cultured neurons. The swelling was accompanied by the release of cytochrome c, Smac/DIABLO, Omi/HtrA2, and AIF but not endonuclease G. Depolarization with carbonylcyanide p-trifluoromethoxyphenylhydrazone or inhibition of the Ca2+ uniporter with Ru360 prevented rapid onset of the swelling. Sr2+ depolarized mitochondria but failed to induce swelling. Neither inhibitors of the large conductance Ca2+-activated K+ channel ( charybdotoxin, iberiotoxin, quinine, and Ba2+)nor inhibitors of the mitochondrial ATP-sensitive K+ channel (5-hydroxydecanoate and glibenclamide) suppressed swelling. Quinine, dicyclohexylcarbodiimide, and Mg2+, inhibitors of the mitochondrial K+/H+ exchanger, as well as external alkalization inhibited a recovery phase of the reversible swelling. In contrast to brain mitochondria, liver and heart mitochondria challenged with Ca2+ experienced sustained swelling without spontaneous recovery. The proposed model suggests an involvement of the Ca2+-dependent transient K+ influx into the matrix causing mitochondrial swelling followed by activation of the K+/H+ exchanger leading to spontaneous mitochondrial contraction both in situ and in vitro.	Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Brustovetsky, N (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, 635 Barnhill Dr,Med Sci Bldg,Rm 549, Indianapolis, IN 46202 USA.	nbrous@iupui.edu	Bolshakov, Alexey P/K-4173-2013		NINDS NIH HHS [R01 NS 050131] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050131] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1982, J BIOENERG BIOMEMBR, V14, P387, DOI 10.1007/BF00743066; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; Borutaite V, 1999, BBA-MOL BASIS DIS, V1453, P41, DOI 10.1016/S0925-4439(98)00082-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brand M. D., 1995, BIOENERGETICS, V154, P62; BRIERLEY GP, 1970, BIOCHEMISTRY-US, V9, P697, DOI 10.1021/bi00806a001; BRIERLEY GP, 1990, BIOCHEMISTRY-US, V29, P408, DOI 10.1021/bi00454a015; BRIERLEY GP, 1988, J BIOENERG BIOMEMBR, V20, P193, DOI 10.1007/BF00768394; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Broekemeier KM, 1998, BIOCHEMISTRY-US, V37, P13059, DOI 10.1021/bi980820c; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Brustovetsky T, 2005, J NEUROCHEM, V94, P980, DOI 10.1111/j.1471-4159.2005.03248.x; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Castilho RF, 1998, J NEUROSCI, V18, P10277; Catisti R, 1999, J BIOENERG BIOMEMBR, V31, P153, DOI 10.1023/A:1005455912711; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chinopoulos C, 2004, J NEUROCHEM, V91, P471, DOI 10.1111/j.1471-4159.2004.02732.x; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; Douglas RM, 2006, NEUROSCIENCE, V139, P1249, DOI 10.1016/j.neuroscience.2006.01.061; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1986, BIOCHEM J, V236, P779, DOI 10.1042/bj2360779; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; Isaev NK, 1996, FEBS LETT, V392, P143, DOI 10.1016/0014-5793(96)00804-6; JUNG DW, 1989, ANAL BIOCHEM, V178, P348, DOI 10.1016/0003-2697(89)90651-9; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; KIEDROWSKI L, 1994, MOL PHARMACOL, V45, P1050; KIEDROWSKI L, 1994, NEURON, V12, P295, DOI 10.1016/0896-6273(94)90272-0; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Kushnareva YE, 2005, J BIOL CHEM, V280, P28894, DOI 10.1074/jbc.M503090200; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Novgorodov SA, 1996, J BIOENERG BIOMEMBR, V28, P139, DOI 10.1007/BF02110644; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; PINELIS VG, 1994, BIOCHEM MOL BIOL INT, V32, P475; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Ruiz F, 2000, EUR J PHARMACOL, V404, P29, DOI 10.1016/S0014-2999(00)00584-7; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schonfeld P, 2003, BBA-BIOENERGETICS, V1604, P125, DOI 10.1016/S0005-2728(03)00043-4; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Siemen D, 1999, BIOCHEM BIOPH RES CO, V257, P549, DOI 10.1006/bbrc.1999.0496; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; TSUZUKI K, 1994, MOL BRAIN RES, V26, P37, DOI 10.1016/0169-328X(94)90071-X; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; WHITE RJ, 1995, J NEUROSCI, V15, P1318; White RJ, 1996, J NEUROSCI, V16, P5688; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zeng YS, 2000, NEUROSCI RES, V37, P113, DOI 10.1016/S0168-0102(00)00107-3; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	84	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37547	37558		10.1074/jbc.M607263200	http://dx.doi.org/10.1074/jbc.M607263200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17056496	hybrid			2022-12-25	WOS:000242477100031
J	Dedja, A; Zaglia, T; Dall'Olmo, L; Chioato, T; Thiene, G; Fabris, L; Ancona, E; Schiaffino, S; Ausoni, S; Cozzi, E				Dedja, Arben; Zaglia, Tania; Dall'Olmo, Luigi; Chioato, Tatiana; Thiene, Gaetano; Fabris, Luca; Ancona, Ermanno; Schiaffino, Stefano; Ausoni, Simonetta; Cozzi, Emanuele			Hybrid cardiomyocytes derived by cell fusion in heterotopic cardiac xenografts	FASEB JOURNAL			English	Article						stem cells; transgenic animals; cardiac transplantation	HEMATOPOIETIC STEM-CELLS; SKELETAL-MUSCLE; TRANSPLANTATION; EXPRESSION; CHIMERISM; MYOCYTES; HEART; XENOTRANSPLANTATION; REGENERATION; MYOCARDIUM	Cardiomyocytes expressing host markers, such as the Y chromosome in sex-mismatched transplants, have been described in human allografts, suggesting that circulating cells can contribute to cardiac regeneration. It has not been established, however, whether host-derived cardiomyocytes result from transdifferentiation of stem cells or cell fusion. To address this issue, we used heterotopic heart xenografts and looked for markers of donor and recipient cells. Golden Syrian hamsters or transgenic mice expressing nuclear beta-galactosidase under the control of the cardiac troponin I promoter served as organ donors, while GFP(+) transgenic rats were used as recipients. GFP(+) cells, including abundant CD-45(+) inflammatory cells and rare undifferentiated cells expressing early cardiac markers (GATA-4 or MEF2C), were found in xenografts harvested two weeks after surgery. In addition, rare GFP(+) mature cardiomyocytes were found in 7 of 8 hamster xenografts and 6 of 6 mouse xenografts. The proportion of these cells was very low (0.0001% to 0.0344% in hamster xenografts) but similar to the one observed in control rat heart allografts. Without exception, all GFP(+) cardiomyocytes also expressed donor markers, i.e., hamster membrane antigens or lacZ, so they must derive from cell fusion, not transdifferentiation. Dedja, A., Zaglia T., Dall'Olmo, L., Chioato, T., Thiene, G., Fabris, L., Ancona, E., Schiaffino, S., Ausoni, S., Cozzi, E. Hybrid cardiomyocytes derived by cell fusion in heterotopic cardiac xenografts.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Med & Surg Sci, I-35121 Padua, Italy; CORIT, Padua, Italy; CNR, Inst Neurosci, Padua, Italy; Univ Padua, Inst Pathol Anat, I-35100 Padua, Italy; Padova Gen Hosp, Clin Chirurg 3, Padua, Italy; Venetian Inst Mol Med, Padua, Italy; Direz Sanitaria, Padua, Italy	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Azienda Ospedaliera - Universita di Padova; Veneto Institute Molecular Medicine	Schiaffino, S (corresponding author), Univ Padua, Dept Biomed Sci, Via G Colombo 3, I-35121 Padua, Italy.	stefano.schiaffino@unipd.it; ausoni@bio.unipd.it; emanuele.cozzi@unipd.it	Dedja, Arben/J-2138-2018; Fabris, Luca/J-7565-2018	Dedja, Arben/0000-0003-3535-598X; Fabris, Luca/0000-0001-8538-6317; Cadamuro, Massimiliano/0000-0002-0899-7613; Schiaffino, Stefano/0000-0002-5607-6421; dall'olmo, luigi/0000-0003-1564-2594; Cozzi, Emanuele/0000-0001-7855-5055				Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Anversa P, 2002, CIRCULATION, V106, pE129, DOI 10.1161/01.CIR.0000035926.40150.D0; Ausoni S, 2005, CARDIOVASC RES, V68, P394, DOI 10.1016/j.cardiores.2005.06.014; Bayes-Genis A, 2002, CARDIOVASC RES, V56, P404, DOI 10.1016/S0008-6363(02)00597-7; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Dedja A, 2005, MICROSURG, V25, P227, DOI 10.1002/micr.20101; Di Lisi R, 1998, J BIOL CHEM, V273, P25371, DOI 10.1074/jbc.273.39.25371; Fogt F, 2003, J HEART LUNG TRANSPL, V22, P1314, DOI 10.1016/S1053-2498(03)00035-4; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Ishikawa F, 2006, FASEB J, V20, P950, DOI 10.1096/fj.05-4863fje; Koopmans M, 2005, AM J TRANSPLANT, V5, P1495, DOI 10.1111/j.1600-6143.2005.00858.x; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lapidos KA, 2004, J CLIN INVEST, V114, P1577, DOI 10.1172/JCI200423071; Matsuura K, 2004, J CELL BIOL, V167, P351, DOI 10.1083/jcb.200312111; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Niimi M, 2001, J HEART LUNG TRANSPL, V20, P1123, DOI 10.1016/S1053-2498(01)00309-6; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Pomerantz J, 2004, NAT CELL BIOL, V6, P810, DOI 10.1038/ncb0904-810; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Rubart M, 2004, J CLIN INVEST, V114, P775, DOI 10.1172/JCI200421589; Sacco A, 2005, J CELL BIOL, V171, P483, DOI 10.1083/jcb.200506123; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; SARTORE S, 1981, J CELL BIOL, V88, P226, DOI 10.1083/jcb.88.1.226; Takayama J, 2001, TRANSPLANT P, V33, P749, DOI 10.1016/S0041-1345(00)02236-3; Taylor DA, 2002, CIRCULATION, V106, P2, DOI 10.1161/01.CIR.0000024386.99599.4A; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wu GD, 2001, XENOTRANSPLANTATION, V8, P291, DOI 10.1034/j.1399-3089.2001.00136.x; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326; Zhang S, 2004, CIRCULATION, V110, P3803, DOI 10.1161/01.CIR.0000150796.18473.8E	39	14	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2534	+		10.1096/fj.06-6586fje	http://dx.doi.org/10.1096/fj.06-6586fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077278				2022-12-25	WOS:000242490700014
J	Nishikawa, K; Watanabe, M; Kita, E; Igai, K; Omata, K; Yaffe, MB; Natori, Y				Nishikawa, Kiyotaka; Watanabe, Miho; Kita, Eiji; Igai, Katsura; Omata, Kazumi; Yaffe, Michael B.; Natori, Yasuhiro			A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin	FASEB JOURNAL			English	Article						multivalent interaction; retrograde transport; globotriaosylceramide; Shiga toxin-producing E. coli infection; therapeutic agent	HEMOLYTIC-UREMIC SYNDROME; ESCHERICHIA-COLI; INFECTIONS; AGENT	Infection with Shiga toxin (Stx)-producing Escherichia coli O157:H7 causes bloody diarrhea and hemorrhagic colitis in humans, sometimes resulting in fatal systemic complications. Among the known Stx family members, Stx2 is responsible for the most severe forms of disease. Stx2 binds to target cells via multivalent interactions between its B-subunit pentamer and globotriaosyl ceramide. After binding, it is first retrogradely transported to the Golgi and then to the endoplasmic reticulum (ER). Using a multivalent peptide library approach, we identified a tetravalent peptide that exhibits a high affinity for the Stx2 B-subunit pentamer (K-D = 0.13 mu M) and markedly inhibits Stx2 cytotoxicity. The tetravalent peptide exerted its inhibitory effects by inducing aberrant cellular transport of Stx2. Although the tetravalent peptide/Stx2 complex was incorporated into cells and translocated to the Golgi, this process was followed by the effective degradation of Stx2 in an acidic compartment rather than by its transfer to the ER. This peptide thoroughly protected mice from a fatal dose of E. coli O157:H7 even when administered after an established infection. Thus, the multivalent peptide library approach enabled the identification of a peptide-based Stx2 inhibitor that has remarkable therapeutic potency and appears to function by inducing aberrant cellular transport and degradation of Stx2.	Int Med Ctr Japan, Dept Clin Pharmacol, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan; Nara Med Univ, Dept Bacteriol, Kashihara, Nara 634, Japan; Int Med Ctr Japan, Dept Med Ecol & Informat, Res Inst, Tokyo, Japan; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	National Center for Global Health & Medicine - Japan; Nara Medical University; National Center for Global Health & Medicine - Japan; Massachusetts Institute of Technology (MIT)	Nishikawa, K (corresponding author), Int Med Ctr Japan, Dept Clin Pharmacol, Res Inst, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	knishika@ri.imcj.go.jp						BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Fraser ME, 2004, J BIOL CHEM, V279, P27511, DOI 10.1074/jbc.M401939200; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; Kita E, 2000, INFECT IMMUN, V68, P1207, DOI 10.1128/IAI.68.3.1207-1214.2000; Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095; Kurioka T, 1998, INFECT IMMUN, V66, P1726, DOI 10.1128/IAI.66.4.1726-1734.1998; Ling H, 1998, BIOCHEMISTRY-US, V37, P1777, DOI 10.1021/bi971806n; Matsuoka K, 1999, TETRAHEDRON LETT, V40, P7839, DOI 10.1016/S0040-4039(99)01632-9; Melton-Chelsa A.R., 1998, ESCHERICHIA COLI O15, P121; Miyagawa A, 2004, CARBOHYD POLYM, V57, P441, DOI 10.1016/j.carbpol.2004.06.001; Mulvey GL, 2003, J INFECT DIS, V187, P640, DOI 10.1086/373996; Nishikawa K, 2000, MOL CELL, V6, P969, DOI 10.1016/S1097-2765(05)00085-7; Nishikawa K, 2005, J INFECT DIS, V191, P2097, DOI 10.1086/430388; Nishikawa K, 2002, P NATL ACAD SCI USA, V99, P7669, DOI 10.1073/pnas.112058999; OBRIEN AD, 1987, MICROBIOL REV, V51, P206, DOI 10.1128/MMBR.51.2.206-220.1987; Paton AW, 2000, NAT MED, V6, P265, DOI 10.1038/73111; Paton AW, 2006, NAT REV MICROBIOL, V4, P193, DOI 10.1038/nrmicro1349; Paton JC, 1998, CLIN MICROBIOL REV, V11, P450, DOI 10.1128/CMR.11.3.450; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Watanabe M, 2004, J INFECT DIS, V189, P360, DOI 10.1086/381124; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	27	51	53	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2597	+		10.1096/fj.06-6572fje	http://dx.doi.org/10.1096/fj.06-6572fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065223				2022-12-25	WOS:000242490700036
J	Imamichi, Y; Konig, A; Gress, T; Menke, A				Imamichi, Y.; Koenig, A.; Gress, T.; Menke, A.			Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer	ONCOGENE			English	Article						pancreatic cancer; Smad-interacting protein 1 (SIP1); extracellular matrix (ECM); E-cadherin	TRANSCRIPTION FACTOR SNAIL; GENE-EXPRESSION; SIP1; BINDING; INVASION; FAMILY; TARGET; CELLS; CARCINOMAS; REPRESSION	Pancreatic cancer is a devastating disease with poor prognosis. Production of large quantities of extracellular matrix and early metastasis are characteristics of this disease. One important step in the development of various cancers is the loss of E-cadherin gene expression or inactivation of E-cadherin mediated cell-cell adhesion. It has been shown that collagen type I promotes down-regulation of E-cadherin expression, which correlates with enhanced cell migration and invasiveness. In this context, we elucidated the role of Smad-interacting protein 1 (SIP1), which has been discussed as a negative regulator of E-cadherin gene expression. We demonstrate that SIP1 upregulation shows an inverse relationship with E-cadherin in advanced pancreatic tumour stages. In Panc-1 cells, SIP1 expression can be induced by exposure to collagen type I in a src-dependent manner. In addition, overexpression of SIP1 reduces E-cadherin mRNA and protein levels. Taken together, these results suggest that SIP1 is involved in the progression of pancreatic cancer and plays a role in mediating signal transduction from collagen type I to downregulate E-cadherin expression.	Univ Hosp Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Hosp Giessen & Marburg, Dept Gastroenterol Endocrinol & Metab, Marburg, Germany	Ulm University; University Hospital of Giessen & Marburg	Imamichi, Y (corresponding author), Univ Hosp Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	yukiko.imamichi@uni-ulm.de		Gress, Thomas/0000-0002-9333-5461				Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Erickson AC, 2003, EXPERT OPIN THER TAR, V7, P71, DOI 10.1517/14728222.7.1.71; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Hajra KM, 2002, CANCER RES, V62, P1613; Heidenblut AM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh130; HENNIG G, 1995, ONCOGENE, V11, P475; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Maeda G, 2005, INT J ONCOL, V27, P1535; Menke A, 2001, CANCER RES, V61, P3508; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; MOLLENHAUER J, 1987, Pancreas, V2, P14, DOI 10.1097/00006676-198701000-00003; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	30	94	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2381	2385		10.1038/sj.onc.1210012	http://dx.doi.org/10.1038/sj.onc.1210012			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043655				2022-12-25	WOS:000245466000014
J	Johnson, S; Roversi, P; Espina, M; Olive, A; Deane, JE; Birket, S; Field, T; Picking, WD; Blocker, AJ; Galyov, EE; Picking, WL; Lea, SM				Johnson, Steven; Roversi, Pietro; Espina, Marianela; Olive, Andrew; Deane, Janet E.; Birket, Susan; Field, Terry; Picking, William D.; Blocker, Ariel J.; Galyov, Edouard E.; Picking, Wendy L.; Lea, Susan M.			Self-chaperoning of the type III secretion system needle tip proteins IpaD and BipD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRELIMINARY CRYSTALLOGRAPHIC ANALYSIS; SHIGELLA-FLEXNERI; VINCULIN ACTIVATION; MAXIMUM-LIKELIHOOD; CRYSTAL-STRUCTURE; VIRULENCE FACTOR; YERSINIA-PESTIS; V-ANTIGEN; INVASION; BINDING	Bacteria expressing type III secretion systems (T3SS) have been responsible for the deaths of millions worldwide, acting as key virulence elements in diseases ranging from plague to typhoid fever. The T3SS is composed of a basal body, which traverses both bacterial membranes, and an external needle through which effector proteins are secreted. We report multiple crystal structures of two proteins that sit at the tip of the needle and are essential for virulence: IpaD from Shigella flexneri and BipD from Burkholderia pseudomallei. The structures reveal that the N-terminal domains of the molecules are intramolecular chaperones that prevent premature oligomerization, as well as sharing structural homology with proteins involved in eukaryotic actin rearrangement. Crystal packing has allowed us to construct a model for the tip complex that is supported by mutations designed using the structure.	Univ Oxford, Dept Biochem, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Inst Anim Hlth, Div Microbiol, Compton Lab, Compton RG20 7NN, Berks, England	University of Oxford; University of Oxford; University of Kansas; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Lea, SM (corresponding author), Univ Oxford, Dept Biochem, Mol Biophys Lab, S Parks Rd, Oxford OX1 3QU, England.	susan.lea@path.ox.ac.uk	Johnson, Steven J/F-9182-2016; Roversi, Pietro/AAK-4241-2021; Roversi, Pietro/F-8925-2011; Blocker, Ariel/Q-6617-2016; Lea, Susan M/B-7678-2009	Johnson, Steven J/0000-0002-7877-3543; Roversi, Pietro/0000-0001-9280-9437; Roversi, Pietro/0000-0001-9280-9437; Lea, Susan M/0000-0001-9287-8053; Deane, Janet/0000-0002-4863-0330; Olive, Andrew/0000-0003-3441-3113; Galyov, Edouard/0000-0003-2609-0748	MRC [G0400389, G0401595, G0400775] Funding Source: UKRI; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034428, R01AI034428] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [C20021] Funding Source: Medline; Medical Research Council [G0400775(71657), G0400389, G0400389(70832), G0401595, G0400775] Funding Source: Medline; NCRR NIH HHS [RR017708, P20 RR017708] Funding Source: Medline; NIAID NIH HHS [R01 AI034428, R29 AI034428, AI034428] Funding Source: Medline; Wellcome Trust [077082] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome Trust)		AIZAWA SI, 1990, J MOL BIOL, V211, P673, DOI 10.1016/0022-2836(90)90064-S; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Deane JE, 2006, P NATL ACAD SCI USA, V103, P12529, DOI 10.1073/pnas.0602689103; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Derewenda U, 2004, STRUCTURE, V12, P301, DOI 10.1016/j.str.2004.01.010; Espina M, 2006, BIOCHEMISTRY-US, V45, P9219, DOI 10.1021/bi060625v; Espina M, 2006, INFECT IMMUN, V74, P4391, DOI 10.1128/IAI.00440-06; Evdokimov AG, 2003, NAT STRUCT BIOL, V10, P789, DOI 10.1038/nsb982; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hamiaux C, 2006, EMBO REP, V7, P794, DOI 10.1038/sj.embor.7400753; He SY, 2004, BBA-MOL CELL RES, V1694, P181, DOI 10.1016/j.bbamcr.2004.03.011; Hilsenbeck JL, 2004, MOL MICROBIOL, V51, P711, DOI 10.1111/j.1365-2958.2003.03884.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Jaroszewski L, 2005, NUCLEIC ACIDS RES, V33, pW284, DOI 10.1093/nar/gki418; Johnson S, 2005, CURR OPIN STRUC BIOL, V15, P700, DOI 10.1016/j.sbi.2005.10.007; Johnson S, 2006, ACTA CRYSTALLOGR F, V62, P865, DOI 10.1107/S1744309106027047; Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651; Krissinel E., 2005, LECT NOTES COMPUTER; Lawton DG, 2002, J BIOL CHEM, V277, P38714, DOI 10.1074/jbc.M203632200; Lilic M, 2006, MOL CELL, V21, P653, DOI 10.1016/j.molcel.2006.01.026; Lupas A, 1996, METHOD ENZYMOL, V266, P513; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MENARD R, 1993, J BACTERIOL, V175, P5899; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; Mueller CA, 2005, SCIENCE, V310, P674, DOI 10.1126/science.1118476; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Parsot C, 2003, CURR OPIN MICROBIOL, V6, P7, DOI 10.1016/S1369-5274(02)00002-4; Phan J, 2005, PROTEIN SCI, V14, P2759, DOI 10.1110/ps.051706105; Picking WL, 2005, INFECT IMMUN, V73, P1432, DOI 10.1128/IAI.73.3.1432-1440.2005; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; POPE LM, 1995, INFECT IMMUN, V63, P3642, DOI 10.1128/IAI.63.9.3642-3648.1995; Roversi P, 2006, ACTA CRYSTALLOGR F, V62, P861, DOI 10.1107/S1744309106027035; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Stevens MP, 2004, MICROBIOL-SGM, V150, P2669, DOI 10.1099/mic.0.27146-0; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VENKATESAN MM, 1992, J BACTERIOL, V174, P1990, DOI 10.1128/jb.174.6.1990-2001.1992; VONRHEIN C, 2005, CRYSTALLOGRAPHIC MET; West NP, 2005, SCIENCE, V307, P1313, DOI 10.1126/science.1108472; White NJ, 2003, LANCET, V361, P1715, DOI 10.1016/S0140-6736(03)13374-0; Yip CK, 2005, NAT STRUCT MOL BIOL, V12, P75, DOI 10.1038/nsmb879; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830	50	119	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2007	282	6					4035	4044		10.1074/jbc.M607945200	http://dx.doi.org/10.1074/jbc.M607945200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	140CW	17077085	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000244481900067
J	Li, WJ; Marshall, C; Mei, LJ; Gelfand, J; Seykora, JT				Li, Weijie; Marshall, Christine; Mei, Lijuan; Gelfand, Joel; Seykora, John T.			Srcasm corrects Fyn-induced epidermal hyperplasia by kinase down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; FAMILY KINASES; KERATINOCYTE DIFFERENTIATION; TRANSGENIC MICE; CELL-MIGRATION; CANCER-CELLS; C-CBL; PHOSPHORYLATION	Src family tyrosine kinases (SFKs) are important regulators of epithelial cell growth and differentiation. Characterization of cellular mechanisms that regulate SFK activity will provide insights into the pathogenesis of diseases associated with increased SFK activity. Keratin 14-Fyn (K14) transgenic mice were derived to characterize the effect of Fyn on epidermal growth and differentiation in vivo. The epidermis of K14-Fyn mice is thickened, manifests prominent scale, and exhibits features consistent with hyperproliferation. Increased epidermal Fyn levels correlate with activation of p44/42 MAP kinases, STAT-3, and PDK-1, key signaling molecules that promote epithelial cell growth. The Src-activating and signaling molecule (Srcasm) is a substrate of SFKs that becomes tyrosine-phosphorylated downstream of the EGF receptor. In vitro, increased Srcasm levels promote activation of endogenous Fyn and keratinocyte differentiation. To study the in vivo effect of Srcasm upon Fyn, double transgenic lines were derived. K14-Fyn/Srcasm transgenic mice did not manifest the hyperproliferative phenotype. In contrast, K14-Fyn/Srcasm-P transgenic mice, which express a nonphosphorylatable Srcasm mutant, maintained the hyperproliferative phenotype. Resolution of the hyperproliferative phenotype correlated with reduced Fyn levels in vivo in three experimental systems: transgenic mice, primary keratinocytes, and celllines. Biochemical studies revealed that Srcasm-dependent Fyn down-regulation requires Fyn kinase activity, phosphorylation of Srcasm, and the Srcasm GAT domain. Therefore, Srcasm is a novel regulator of Fyn promoting kinase down-regulation in a phosphorylation-dependent manner. Srcasm may act as a molecular "rheostat" for activated SFKs, and cellular levels of Srcasm may be important for regulating epithelial hyperproliferation associated with increased SFK activity.	Univ Penn, Sch Med, Dept Dermatol, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA	University of Pennsylvania	Seykora, JT (corresponding author), Univ Penn, Sch Med, Dept Dermatol, Cell & Mol Biol Grad Grp, 235A Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	john.seykora@uphs.upenn.edu	li, wj/HGD-7322-2022	Gelfand, Joel/0000-0003-3480-2661	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051380, K08AR047597] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR051380-02, R01 AR051380-01A2, R01-AR051380, K08-AR47597, K08 AR047597, R01 AR051380, K08 AR047597-05] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; AMENTA JS, 1980, J CELL PHYSIOL, V102, P259, DOI 10.1002/jcp.1041020217; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Barnes CJ, 2003, MOL CANCER THER, V2, P345; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Daigo Y, 1999, CANCER RES, V59, P4222; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; Didierlaurent A, 2006, MOL CELL BIOL, V26, P735, DOI 10.1128/MCB.26.3.735-742.2006; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Ghosh AK, 2004, J BIOL CHEM, V279, P36132, DOI 10.1074/jbc.M404189200; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JESSUP W, 1982, BIOCHEM PHARMACOL, V31, P2657, DOI 10.1016/0006-2952(82)90714-6; Kansra S, 2005, MOL PHARMACOL, V67, P1145, DOI 10.1124/mol.104.004689; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Katoh Y, 2004, J BIOL CHEM, V279, P24435, DOI 10.1074/jbc.M400059200; Kokkonen N, 2004, J BIOL CHEM, V279, P39982, DOI 10.1074/jbc.M406698200; KRUEGER JG, 1990, J INVEST DERMATOL, V94, pS135, DOI 10.1111/1523-1747.ep12876121; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li WJ, 2005, J BIOL CHEM, V280, P6036, DOI 10.1074/jbc.M406546200; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; PARK JS, 1993, ONCOGENE, V8, P2627; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Puertollano R, 2005, J BIOL CHEM, V280, P9258, DOI 10.1074/jbc.M412481200; Quadros MRD, 2004, CANCER RES, V64, P3934, DOI 10.1158/0008-5472.CAN-04-0214; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Seykora JT, 2002, J BIOL CHEM, V277, P2812, DOI 10.1074/jbc.M106813200; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	45	24	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1161	1169		10.1074/jbc.M606583200	http://dx.doi.org/10.1074/jbc.M606583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17046829	Green Accepted, hybrid			2022-12-25	WOS:000243295200041
J	Wong, KW; Mohammadi, S; Isberg, RR				Wong, Ka-Wing; Mohammadi, Sina; Isberg, Ralph R.			Disruption of RhoGDI and RhoA regulation by a Rac1 specificity switch mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTORS; YERSINIA-ENTEROCOLITICA INVASIN; N-WASP; ACTIN CYTOSKELETON; INTEGRIN RECEPTORS; APOPTOTIC CELLS; PSEUDOTUBERCULOSIS; DISSOCIATION; BINDING; GTPASES	Rho family GTPases are important regulators of the actin cytoskeleton. Activation of these proteins can be promoted by guanine nucleotide exchange factors containing Dbl and Pleckstrin homology domains resulting in membrane insertion of a Rho family member, whereas the inactive GDP- bound form is sequestered primarily in the cytoplasm, bound to the guanosine dissociation inhibitor RhoGDI. Dominant interfering variants of Rac1, but not Cdc42, inhibit beta 1 integrin- promoted uptake of Yersinia pseudotuberculosis. Unexpectedly, we found that the Rac1( W56F) guanine nucleotide exchange factors specificity switch mutant blocked invasin-promoted uptake as well as Cdc42- dependent uptake of enteropathogenic Escherichia coli. Fluorescence resonance energy transfer experiments demonstrated that Rac1( W56F) retained the ability to be loaded with GTP, bind a downstream effector, and interact with RhoGDI. Mutational analyses of intragenic suppressors and coexpression studies demonstrated that binding of the Rac1( W56F) mutant to RhoGDI appeared to play a role in the inhibition of uptake. As RhoGDI inhibits RhoA, overactivation of RhoA may account for the uptake interference caused by Rac1( W56F). Consistent with this model, a dominant interfering form of RhoA restored significant uptake in the presence of the Rac1( W56F) mutant but had no effect on another interfering Rac1 form. Furthermore, the cellular GTP- RhoA level was elevated by the presence of Rac1( W56F) mutant protein. These data are consistent with the proposition that Rac1( W56F) blocks invasin- promoted uptake by preventing RhoGDI from inactivating RhoA. We conclude that RhoGDI allows cross- talk between Rho family members that promote potentially antagonistic processes, and disruption of this cross- talk can interfere with invasin- promoted uptake.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Howard Hughes Medical Institute; Tufts University	Isberg, RR (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, 150 Harrison Ave, Boston, MA 02111 USA.	Ralph.Isberg@tufts.edu			NIAID NIH HHS [R37AI23538] Funding Source: Medline; NIDDK NIH HHS [P30DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Alberts AS, 2005, J BIOL CHEM, V280, P12152, DOI 10.1074/jbc.M405073200; Alrutz MA, 1998, P NATL ACAD SCI USA, V95, P13658, DOI 10.1073/pnas.95.23.13658; Alrutz MA, 2001, MOL MICROBIOL, V42, P689, DOI 10.1046/j.1365-2958.2001.02676.x; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Campellone KG, 2004, DEV CELL, V7, P217, DOI 10.1016/j.devcel.2004.07.004; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Dransart E, 2005, J BIOL CHEM, V280, P4674, DOI 10.1074/jbc.M409741200; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Gandhi PN, 2004, BIOCHEM J, V378, P409, DOI 10.1042/BJ20030979; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; GEMSKI P, 1980, INFECT IMMUN, V28, P1044; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; Handley SA, 2005, INFECT IMMUN, V73, P8453, DOI 10.1128/IAI.73.12.8453-8455.2005; HEESEMANN J, 1993, APMIS, V101, P417, DOI 10.1111/j.1699-0463.1993.tb00130.x; Hudson KJ, 2005, CELL MICROBIOL, V7, P1474, DOI 10.1111/j.1462-5822.2005.00571.x; Isberg RR, 2000, MICROBES INFECT, V2, P793, DOI 10.1016/S1286-4579(00)90364-2; Jepson MA, 2003, CELL MICROBIOL, V5, P773, DOI 10.1046/j.1462-5822.2003.00315.x; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Kim JS, 2004, J BIOL CHEM, V279, P21589, DOI 10.1074/jbc.M308386200; Lanning CC, 2003, J BIOL CHEM, V278, P12495, DOI 10.1074/jbc.M211286200; Marra A, 1997, INFECT IMMUN, V65, P3412, DOI 10.1128/IAI.65.8.3412-3421.1997; McGee K, 2001, FEBS LETT, V509, P59, DOI 10.1016/S0014-5793(01)03139-8; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Molnar G, 2001, BIOCHEMISTRY-US, V40, P10542, DOI 10.1021/bi011158e; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Ory S, 2000, J CELL SCI, V113, P1177; PEPE JC, 1993, P NATL ACAD SCI USA, V90, P6473, DOI 10.1073/pnas.90.14.6473; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Tosello-Trampont AC, 2003, J BIOL CHEM, V278, P49911, DOI 10.1074/jbc.M306079200; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Weidow CL, 2000, CELL MICROBIOL, V2, P549, DOI 10.1046/j.1462-5822.2000.00079.x; Wong KW, 2005, PLOS PATHOG, V1, P125, DOI 10.1371/journal.ppat.0010016; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014	47	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40379	40388		10.1074/jbc.M605387200	http://dx.doi.org/10.1074/jbc.M605387200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074770	hybrid			2022-12-25	WOS:000243033900068
J	Yun, YS; Lee, W; Shin, S; Oh, BH; Choi, KY				Yun, Young Sung; Lee, Wook; Shin, Sejeong; Oh, Byung-Ha; Choi, Kwan Yong			Arg-158 is critical in both binding the substrate and stabilizing the transition-state oxyanion for the enzymatic reaction of malonamidase E2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID AMIDE HYDROLASE; LYS CATALYTIC TRIAD; ACTIVE-SITE; ASPARTATE-AMINOTRANSFERASE; WATER-MOLECULES; SERINE HYDROXYMETHYLTRANSFERASE; BRADYRHIZOBIUM-JAPONICUM; PROLYL OLIGOPEPTIDASE; LIGAND INTERACTIONS; NITRILE HYDRATASE	Malonamidase E2 (MAE2) from Bradyrhizobium japonicum is an enzyme that hydrolyzes malonamate to malonate and has a Ser-cis-Ser-Lys catalytic triad at the active site. The crystal structures of wild type and mutant MAE2 exhibited that the guanido group of Arg-158 could be involved in the binding of malonamate in which the negative charge of the carboxyl group could destabilize a negatively charged transition-state oxyanion in the enzymatic reaction. In an attempt to elucidate the specific roles of Arg-158, site-directed mutants, R158Q, R158E, and R158K, were prepared (see Table 1). The crystal structure of R158Q determined at 2.2 angstrom resolution showed that the guanido group of Arg-158 was important for the substrate binding with the marginal structural change upon the mutation. The k(cat) value of R158Q significantly decreased by over 1500-fold and the catalytic activity of R158E could not be detected. The kcat value of R158K was similar to that of the wild type with the Km value drastically increased by 100-fold, suggesting that Lys-158 of R158K can stabilize the negative charge of the carboxylate in the substrate to some extent and contribute to the stabilization of the transition-state oxyanion, but a single amine group of Lys-158 in R158K could not precisely anchor the carboxyl group of malonamate compared with the guanido group of Arg-158. Our kinetic and structural evidences demonstrate that Arg-158 in MAE2 should be critical to both binding the substrate and stabilizing the transition-state oxyanion for the catalytic reaction of MAE2.	Pohang Univ Sci & Technol, Program Biomol Funct, Dept Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Natl CRI Ctr Biomol Recognit, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Choi, KY (corresponding author), Pohang Univ Sci & Technol, Program Biomol Funct, Dept Life Sci, Pohang 790784, South Korea.	kchoi@postech.ac.kr	Oh, Byung-Ha/C-2061-2011					ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; Amadasi A, 2006, J MOL BIOL, V358, P289, DOI 10.1016/j.jmb.2006.01.053; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHEBROU H, 1996, BIOCHIM BIOPHYS ACTA, V5, P285; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DANISHEFSKY AT, 1991, BIOCHEMISTRY-US, V30, P1980, DOI 10.1021/bi00221a035; Deutsch DG, 2002, PROSTAG LEUKOTR ESS, V66, P201, DOI 10.1054/plef.2001.0358; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; FERSHT A, 1999, PROTEIN SCI, P349; FRATTE SD, 1994, EUR J BIOCHEM, V225, P395, DOI 10.1111/j.1432-1033.1994.00395.x; GAFFNEY TD, 1990, J BACTERIOL, V172, P5593, DOI 10.1128/jb.172.10.5593-5601.1990; GOMI K, 1991, GENE, V108, P91, DOI 10.1016/0378-1119(91)90491-S; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; Heinz DW, 1999, ANGEW CHEM INT EDIT, V38, P2348, DOI 10.1002/(SICI)1521-3773(19990816)38:16<2348::AID-ANIE2348>3.0.CO;2-O; Hondal RJ, 1997, BIOCHEMISTRY-US, V36, P6633, DOI 10.1021/bi962866g; Jagath JR, 1997, BIOCHEM J, V327, P877, DOI 10.1042/bj3270877; Ji XH, 1999, BIOCHEMISTRY-US, V38, P10231, DOI 10.1021/bi990668u; Juhasz T, 2002, BIOCHEMISTRY-US, V41, P4096, DOI 10.1021/bi016016z; KIM YS, 1994, J BIOL CHEM, V269, P8014; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; Koo HM, 2000, BIOCHEM J, V349, P501, DOI 10.1042/0264-6021:3490501; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Labahn J, 2002, J MOL BIOL, V322, P1053, DOI 10.1016/S0022-2836(02)00886-0; MAYAUX JF, 1991, J BACTERIOL, V173, P6694, DOI 10.1128/jb.173.21.6694-6704.1991; McKinney MK, 2003, J BIOL CHEM, V278, P37393, DOI 10.1074/jbc.M303922200; MURPHY DJ, 1995, BIOCHEMISTRY-US, V34, P4507, DOI 10.1021/bi00014a001; Nicolas A, 1996, BIOCHEMISTRY-US, V35, P398, DOI 10.1021/bi9515578; Omeir RL, 1999, BIOCHEM BIOPH RES CO, V264, P316, DOI 10.1006/bbrc.1999.1524; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pujadas G, 2001, PROTEIN SCI, V10, P1645, DOI 10.1110/ps.8201; Raymer ML, 1997, J MOL BIOL, V265, P445, DOI 10.1006/jmbi.1996.0746; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; Shin S, 2002, EMBO J, V21, P2509, DOI 10.1093/emboj/21.11.2509; Shin S, 2003, J BIOL CHEM, V278, P24937, DOI 10.1074/jbc.M302156200; Szeltner Z, 2002, J BIOL CHEM, V277, P42613, DOI 10.1074/jbc.M208043200; Szeltner Z, 2000, PROTEIN SCI, V9, P353; Vacca RA, 1997, J BIOL CHEM, V272, P21932, DOI 10.1074/jbc.272.35.21932; Xu YY, 2000, J BIOL CHEM, V275, P378, DOI 10.1074/jbc.275.1.378; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391; Zhao B, 2005, J BIOL CHEM, V280, P42188, DOI 10.1074/jbc.M509220200	45	5	5	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40057	40064		10.1074/jbc.M604515200	http://dx.doi.org/10.1074/jbc.M604515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17077089	hybrid			2022-12-25	WOS:000243033900035
J	Ferella, M; Montalvetti, A; Rohloff, P; Miranda, K; Fang, JM; Reina, S; Kawamukai, M; Bua, J; Nilsson, D; Pravia, C; Katzin, A; Cassera, MB; Aslund, L; Andersson, B; Docampo, R; Bontempi, EJ				Ferella, Marcela; Montalvetti, Andrea; Rohloff, Peter; Miranda, Kildare; Fang, Jianmin; Reina, Silvia; Kawamukai, Makoto; Bua, Jacqueline; Nilsson, Daniel; Pravia, Carlos; Katzin, Alejandro; Cassera, Maria B.; Aslund, Lena; Andersson, Bjorn; Docampo, Roberto; Bontempi, Esteban J.			A solanesyl-diphosphate synthase localizes in glycosomes of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL PYROPHOSPHATE SYNTHASE; COENZYME-Q; IN-VITRO; 3-HYDROXY-3-METHYL-GLUTARYL-COA REDUCTASE; MOLECULAR CHARACTERIZATION; SUBCELLULAR-LOCALIZATION; UBIQUINONE BIOSYNTHESIS; MEVALONATE PATHWAY; POTENT INHIBITORS; ESCHERICHIA-COLI	We report the cloning of a Trypanosoma cruzi gene encoding a solanesyl-diphosphate synthase, TcSPPS. The amino acid sequence ( molecular mass similar to 39 kDa) is homologous to polyprenyl-diphosphate synthases from different organisms, showing the seven conserved motifs and the typical hydrophobic profile. TcSPPS preferred geranylgeranyl diphosphate as the allylic substrate. The final product, as determined by TLC, had nine isoprene units. This suggests that the parasite synthesizes mainly ubiquinone-9 (UQ-9), as described for Trypanosoma brucei and Leishmania major. In fact, that was the length of the ubiquinone extracted from epimastigotes, as determined by high-performance liquid chromatography. Expression of TcSPPS was able to complement an Escherichia coli ispB mutant. A punctuated pattern in the cytoplasm of the parasite was detected by immunofluorescence analysis with a specific polyclonal antibody against TcSPPS. An overlapping fluorescence pattern was observed using an antibody directed against the glycosomal marker pyruvate phosphate dikinase, suggesting that this step of the isoprenoid biosynthetic pathway is located in the glycosomes. Co-localization in glycosomes was confirmed by immunogold electron microscopy and subcellular fractionation. Because UQ has a central role in energy production and in reoxidation of reduction equivalents, TcSPPS is promising as a new chemotherapeutic target.	Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; Minist Salud, Inst Nacl Parasitol Dr M Fatala Chaben, Adm Nacl Labs, RA-1063 Buenos Aires, DF, Argentina; Minist Salud, Inst Salud, RA-1063 Buenos Aires, DF, Argentina; Uppsala Univ, Dept Genet & Pathol, SE-75185 Uppsala, Sweden; Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA; Karolinska Inst, Ctr Genom & Bioinformat, SE-17177 Stockholm, Sweden; Shimane Univ, Fac Life & Environm Sci, Dept Appl Biosci & Biotechnol, Matsue, Shimane 6908540, Japan; Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508900 Sao Paulo, Brazil	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Uppsala University; University of Illinois System; University of Illinois Urbana-Champaign; Karolinska Institutet; Shimane University; Universidade de Sao Paulo	Docampo, R (corresponding author), Univ Georgia, Ctr Trop & Emerging Global Dis, 350 Paul D Coverdell Ctr, Athens, GA 30602 USA.	rdocampo@uga.edu; ejbon@yahoo.com	Rohloff, Peter/P-8722-2017; Cassera, Maria/L-1572-2013; Reina, Silvia/ABB-7658-2021; Andersson, Bjorn/G-9832-2013; Kawamukai, Makoto/AET-1038-2022; Nilsson, Daniel/B-8365-2009; Katzin, Alejandro/E-9862-2013	Rohloff, Peter/0000-0001-7274-8315; Reina, Silvia/0000-0003-4599-3563; Andersson, Bjorn/0000-0002-4624-0259; Kawamukai, Makoto/0000-0003-2929-8798; Nilsson, Daniel/0000-0001-5831-385X; Katzin, Alejandro/0000-0002-4782-2162; Bontempi, Esteban/0000-0001-8182-2089	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065307] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI068647-01, R01 AI068647, AI-68647] Funding Source: Medline; NIGMS NIH HHS [GM-65307] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acosta H, 2004, COMP BIOCHEM PHYS B, V138, P347, DOI 10.1016/j.cbpc.2004.04.017; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALVAREZ F, 1994, MOL BIOL EVOL, V11, P790; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; Bouzahzah B, 2005, PARASITOL RES, V96, P184, DOI 10.1007/s00436-005-1331-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Bua J, 1999, MEDICINA-BUENOS AIRE, V59, P11; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; Concepcion JL, 1998, ARCH BIOCHEM BIOPHYS, V352, P114, DOI 10.1006/abbi.1998.0577; DEBURGOS NMG, 1976, ACTA PHYSL LATINOAM, V26, P10; Docampo Roberto, 2001, Current Drug Targets - Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; ELLIS JE, 1994, MOL BIOCHEM PARASIT, V65, P213, DOI 10.1016/0166-6851(94)90073-6; ELLIS JE, 1994, PARASITOL TODAY, V10, P296, DOI 10.1016/0169-4758(94)90079-5; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019; Gelb MH, 2003, MOL BIOCHEM PARASIT, V126, P155, DOI 10.1016/S0166-6851(02)00282-7; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hanke J, 1996, BIOTECHNIQUES, V21, P686; Hirooka K, 2003, BIOCHEM J, V370, P679, DOI 10.1042/BJ20021311; Jun L, 2004, PLANT CELL PHYSIOL, V45, P1882, DOI 10.1093/pcp/pch211; Kawamukai M, 2002, J BIOSCI BIOENG, V94, P511, DOI 10.1016/S1389-1723(02)80188-8; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KOYAMA T, 1985, METHOD ENZYMOL, V110, P153; Koyama T, 1999, BIOSCI BIOTECH BIOCH, V63, P1671, DOI 10.1271/bbb.63.1671; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; KUSEL JP, 1965, BIOCHIM BIOPHYS ACTA, V98, P632, DOI 10.1016/0005-2760(65)90161-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; LOW P, 1991, J BIOL CHEM, V266, P19250; Michels PAM, 2005, MOL MEMBR BIOL, V22, P133, DOI 10.1080/09687860400024186; Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200; Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200; Ohnuma S, 1998, J BIOL CHEM, V273, P26705, DOI 10.1074/jbc.273.41.26705; Okada K, 1997, J BACTERIOL, V179, P3058, DOI 10.1128/jb.179.9.3058-3060.1997; Okada K, 1998, EUR J BIOCHEM, V255, P52, DOI 10.1046/j.1432-1327.1998.2550052.x; Okada K, 1997, J BACTERIOL, V179, P5992, DOI 10.1128/jb.179.19.5992-5998.1997; OKAMOTO T, 1985, J CHROMATOGR, V342, P35, DOI 10.1016/S0378-4347(00)84487-4; Olivier LM, 2000, BBA-MOL CELL BIOL L, V1529, P89, DOI 10.1016/S1388-1981(00)00139-6; Parsons M, 2004, MOL MICROBIOL, V53, P717, DOI 10.1111/j.1365-2958.2004.04203.x; Pena-Diaz J, 2004, MOL BIOL CELL, V15, P1356, DOI 10.1091/mbc.E03-10-0720; Porcel BM, 2000, GENOME RES, V10, P1103, DOI 10.1101/gr.10.8.1103; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; RANGANATHAN G, 1995, INT J PARASITOL, V25, P279, DOI 10.1016/0020-7519(94)00131-7; RASSAM MB, 1988, MOL BIOCHEM PARASIT, V29, P61, DOI 10.1016/0166-6851(88)90120-X; Rohloff P, 2004, J BIOL CHEM, V279, P52270, DOI 10.1074/jbc.M410372200; SAGAMI H, 1977, BIOCHEMISTRY-US, V16, P4616, DOI 10.1021/bi00640a014; Saiki R, 2005, FEBS J, V272, P5606, DOI 10.1111/j.1742-4658.2005.04956.x; Saiki R, 2003, EUR J BIOCHEM, V270, P4113, DOI 10.1046/j.1432-1033.2003.03804.x; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; SWIEZEWSKA E, 1993, J BIOL CHEM, V268, P1494; Szajnman SH, 2003, BIOORG MED CHEM LETT, V13, P3231, DOI 10.1016/S0960-894X(03)00663-2; TECLEBRHAN H, 1993, J BIOL CHEM, V268, P23081; Tekle M, 2002, BIOCHEM BIOPH RES CO, V291, P1128, DOI 10.1006/bbrc.2002.6537; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001; Urbina JA, 2002, CURR PHARM DESIGN, V8, P287, DOI 10.2174/1381612023396177; VAKIRTZILEMONIA.VC, 1963, COMP BIOCH PHYSL, V8, P133; YAMAUCHI K, 1991, NUCLEIC ACIDS RES, V19, P2715, DOI 10.1093/nar/19.10.2715; Zhang YW, 1997, J BACTERIOL, V179, P1417, DOI 10.1128/jb.179.4.1417-1419.1997	67	31	31	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39339	39348		10.1074/jbc.M607451200	http://dx.doi.org/10.1074/jbc.M607451200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17062572	hybrid			2022-12-25	WOS:000242898700041
J	Ooi, L; Belyaev, ND; Miyake, K; Wood, IC; Buckley, NJ				Ooi, Lezanne; Belyaev, Nikolai D.; Miyake, Katsuhide; Wood, Ian C.; Buckley, Noel J.			BRG1 chromatin remodeling activity is required for efficient chromatin binding by repressor element 1-silencing transcription factor (REST) and facilitates REST-mediated repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; GENOME-WIDE ANALYSIS; TARGET GENES; HISTONE ACETYLATION; EXPRESSION; COMPLEXES; REST/NRSF; SWI/SNF; DEACETYLASE; ACTIVATION	Chromatin remodeling enzymes such as SWI/SNF use the hydrolysis of ATP to power the movement of nucleosomes with respect to DNA. BRG1, one of the ATPases of the SWI/SNF complex, can be recruited by both activators and repressors, although the precise role of BRG1 in mechanisms of repression has thus far remained unclear. One transcription factor that recruits BRG1 as a corepressor is the repressor element 1-silencing transcription factor ( REST). Here we address for the first time the mechanism of BRG1 activity in gene repression. We found that BRG1 enhanced REST-mediated repression at some REST target genes by increasing the interaction of REST with the local chromatin at its binding sites. Furthermore, REST-chromatin interactions, mediated by BRG1, were enhanced following an increase in histone acetylation in a manner dependent on the BRG1 bromodomain. Our data suggest that BRG1 facilitates REST repression by increasing the interaction between REST and chromatin. Such a mechanism may be applicable to other transcriptional repressors that utilize BRG1.	Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England; Nagoya Univ, Dept Biotechnol, Nagoya, Aichi 4648603, Japan	University of Leeds; Nagoya University	Ooi, L (corresponding author), Univ Leeds, Inst Membrane & Syst Biol, Garstang Bldg, Leeds LS2 9JT, W Yorkshire, England.	L.Ooi@leeds.ac.uk	Wood, Ian/AAK-9423-2021; Buckley, Noel J/B-9675-2012	Wood, Ian/0000-0003-1886-2533; Buckley, Noel J/0000-0003-1152-0653; Miyake, Katsuhide/0000-0002-9925-6406; Ooi, Lezanne/0000-0001-9241-8268	Wellcome Trust [075168, 076391] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Belyaev ND, 2004, J BIOL CHEM, V279, P556, DOI 10.1074/jbc.M310353200; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Burkhart BA, 2005, J BIOL CHEM, V280, P6349, DOI 10.1074/jbc.M411147200; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Hudson BP, 2000, J MOL BIOL, V304, P355, DOI 10.1006/jmbi.2000.4207; Inayoshi Y, 2005, J BIOCHEM, V138, P457, DOI 10.1093/jb/mvi147; Inayoshi Y, 2006, J BIOCHEM, V139, P177, DOI 10.1093/jb/mvj015; Johnson R, 2006, NUCLEIC ACIDS RES, V34, P3862, DOI 10.1093/nar/gkl525; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kuwahara K, 2003, EMBO J, V22, P6310, DOI 10.1093/emboj/cdg601; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; Matsumoto S, 2006, DEV BIOL, V289, P372, DOI 10.1016/j.ydbio.2005.10.044; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Olguin P, 2006, J NEUROSCI, V26, P2820, DOI 10.1523/JNEUROSCI.5037-05.2006; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Paquette AJ, 2000, P NATL ACAD SCI USA, V97, P12318, DOI 10.1073/pnas.97.22.12318; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; Roberts SM, 1997, GENETICS, V147, P451; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Roopra A, 2004, MOL CELL, V14, P727, DOI 10.1016/j.molcel.2004.05.026; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Su XH, 2004, MOL CELL BIOL, V24, P8018, DOI 10.1128/MCB.24.18.8018-8025.2004; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; Sun YM, 2005, MOL BIOL CELL, V16, P5630, DOI 10.1091/mbc.E05-07-0687; Watanabe H, 2006, ONCOGENE, V25, P470, DOI 10.1038/sj.onc.1209068; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221; Wood IC, 2003, J MOL BIOL, V334, P863, DOI 10.1016/j.jmb.2003.10.017; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	48	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					38974	38980		10.1074/jbc.M605370200	http://dx.doi.org/10.1074/jbc.M605370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17023429	Green Accepted, hybrid			2022-12-25	WOS:000242898700003
J	Zhande, R; Zhang, WS; Zheng, YB; Pendleton, E; Li, Y; Polakiewicz, RD; Sun, XJ				Zhande, Rachel; Zhang, Wenshuo; Zheng, Yanbin; Pendleton, Elisha; Li, Yu; Polakiewicz, Roberto D.; Sun, Xiao Jian			Dephosphorylation by default, a potential mechanism for regulation of insulin receptor substrate-1/2, Akt, and ERK1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE-PHOSPHATASE 1B; LIVER TRANSCRIPTION FACTORS; OKADAIC ACID; SERINE/THREONINE PHOSPHATASES; GLUCOSE-TRANSPORT; GROWTH-FACTOR; CELL-CULTURE; PHOSPHORYLATION; SERINE	Protein phosphorylation is an important mechanism that controls many cellular activities. Phosphorylation of a given protein is precisely controlled by two opposing biochemical reactions catalyzed by protein kinases and protein phosphatases. How these two opposing processes are coordinated to achieve regulation of protein phosphorylation is unresolved. We have developed a novel experimental approach to directly study protein dephosphorylation in cells. We determined the kinetics of dephosphorylation of insulin receptor substrate-1/2, Akt, and ERK1/2, phosphoproteins involved in insulin receptor signaling. We found that insulin-induced ERK1/2 and Akt kinase activities were completely abolished 10 min after inhibition of the corresponding upstream kinases with PD98059 and LY294002, respectively. In parallel experiments, insulin-induced phosphorylation of Akt, ERK1/2, and insulin receptor substrate-1/2 was decreased and followed similar kinetics. Our findings suggest that these proteins are dephosphorylated by a default mechanism, presumably via constitutively active phosphatases. However, dephosphorylation of these proteins is overcome by activation of protein kinases following stimulation of the insulin receptor. We propose that, during acute insulin stimulation, the kinetics of protein phosphorylation is determined by the interplay between upstream kinase activity and dephosphorylation by default.	Univ Chicago, Endocrinol Sect, Chicago, IL 60637 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	University of Chicago	Sun, XJ (corresponding author), Univ Chicago, Endocrinol Sect, M-266,MC1027,5841 S Maryland Ave, Chicago, IL 60637 USA.	xsun@medicine.bsd.uchicago.edu		Zhang, Wenshuo/0000-0002-5124-799X	NIDDK NIH HHS [R01 DK060128] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; Brady MJ, 2001, RECENT PROG HORM RES, V56, P157, DOI 10.1210/rp.56.1.157; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; CARPENTER G, 1979, J BIOL CHEM, V254, P4884; COHEN PTW, 1993, BIOCHEM SOC T, V21, P884, DOI 10.1042/bst0210884; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Di Guglielmo GM, 1998, MOL CELL BIOCHEM, V182, P59, DOI 10.1023/A:1006883311233; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; Ducruet AP, 2005, ANNU REV PHARMACOL, V45, P725, DOI 10.1146/annurev.pharmtox.45.120403.100040; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gee CE, 2005, CELL MOL LIFE SCI, V62, P1120, DOI 10.1007/s00018-005-5008-4; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JADUS MR, 1991, J LEUKOCYTE BIOL, V49, P139, DOI 10.1002/jlb.49.2.139; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P926; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MISBIN RI, 1976, AM J PHYSIOL, V230, P171, DOI 10.1152/ajplegacy.1976.230.1.171; MOONEY RA, 1989, J BIOL CHEM, V264, P6850; Mora MEV, 2003, J AM COLL NUTR, V22, P487, DOI 10.1080/07315724.2003.10719326; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; RAY LB, 1988, J BIOL CHEM, V263, P12721; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rondinone CM, 1996, J BIOL CHEM, V271, P18148, DOI 10.1074/jbc.271.30.18148; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076; ZARET KS, 1990, MOL CELL BIOL, V10, P4582, DOI 10.1128/MCB.10.9.4582; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	61	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39071	39080		10.1074/jbc.M605251200	http://dx.doi.org/10.1074/jbc.M605251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17068339	hybrid			2022-12-25	WOS:000242898700013
J	Fitzgerald, C; Sikora, C; Lawson, V; Dong, K; Cheng, M; Oko, R; van der Hoorn, FA				Fitzgerald, Carolyn; Sikora, Curtis; Lawson, Vannice; Dong, Karen; Cheng, Min; Oko, Richard; van der Hoorn, Frans A.			Mammalian transcription in support of hybrid mRNA and protein synthesis in testis and lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER DENSE FIBERS; ORNITHINE-DECARBOXYLASE ANTIZYME; KINESIN LIGHT-CHAIN; GENOMIC ORGANIZATION; FIBROUS SHEATH; SPERM PROTEIN; GENE; EXPRESSION; CELLS; BINDS	Post-transcriptional mechanisms including differential splicing expand the protein repertoire beyond that provided by the one gene-one protein model. Trans-splicing has been observed in mammalian systems but is low level (sometimes referred to as noise), and a contribution to hybrid protein expression is unclear. In the study of rat sperm tail proteins a cDNA, called 1038, was isolated representing a hybrid mRNA derived in part from the ornithine decarboxylase antizyme 3 (Oaz3) gene located on rat chromosome 2 fused to sequences encoded by a novel gene on chromosome 4. Cytoplasmic Oaz3 mRNA is completely testis specific. However, in several tissues Oaz3 is transcribed and contributes to hybrid 1038 mRNA synthesis, without concurrent Oaz3 mRNA synthesis. 1038 mRNA directs synthesis of a hybrid 14-kDa protein, part chromosome 2- and part chromosome 4-derived as shown in vitro and in transfected cells. Antisera that recognize a chromosome 4-encoded C-terminal peptide confirm the hybrid character of endogenous 14-kDa protein and its presence in sperm tail structures and 1038-positive tissue. Our data suggest that the testis-specific OAZ3 gene may be an example of a mammalian gene that in several tissues is transcribed to contribute to a hybrid mRNA and protein. This finding expands the repertoire of known mechanisms available to cells to generate proteome diversity.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	University of Calgary; Queens University - Canada	van der Hoorn, FA (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	fvdhoorn@ucalgary.ca			Canadian Institutes of Health Research [82709, 11361] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		BALTZ JM, 1990, BIOL REPROD, V43, P485, DOI 10.1095/biolreprod43.3.485; Bhullar B, 2003, J BIOL CHEM, V278, P16159, DOI 10.1074/jbc.M213126200; Burmester S, 1996, MOL REPROD DEV, V45, P10, DOI 10.1002/(SICI)1098-2795(199609)45:1&lt;10::AID-MRD2&gt;3.0.CO;2-V; Caudevilla C, 2001, FEBS LETT, V507, P269, DOI 10.1016/S0014-5793(01)02957-X; Caudevilla C, 2001, NUCLEIC ACIDS RES, V29, P3108, DOI 10.1093/nar/29.14.3108; Eddy EM, 2003, MICROSC RES TECHNIQ, V61, P103, DOI 10.1002/jemt.10320; Finta C, 2002, J BIOL CHEM, V277, P5882, DOI 10.1074/jbc.M109175200; Fitzgerald CJ, 2006, MOL REPROD DEV, V73, P92, DOI 10.1002/mrd.20388; Hirano M, 2004, GENE, V342, P165, DOI 10.1016/j.gene.2004.08.016; Hoyer-Fender S, 2003, CYTOGENET GENOME RES, V103, P122, DOI 10.1159/000076299; Hoyer-Fender S, 1998, MOL REPROD DEV, V51, P167, DOI 10.1002/(SICI)1098-2795(199810)51:2&lt;167::AID-MRD6&gt;3.0.CO;2-O; IRONS MJ, 1982, ANAT RECORD, V202, P463, DOI 10.1002/ar.1092020405; Ivanov IP, 2000, P NATL ACAD SCI USA, V97, P4808, DOI 10.1073/pnas.070055897; Junco A, 2001, BIOL REPROD, V64, P1320, DOI 10.1095/biolreprod64.5.1320; Kierszenbaum AL, 2002, MOL REPROD DEV, V61, P1, DOI 10.1002/mrd.1124; KUHN R, 1991, MECH DEVELOP, V35, P143, DOI 10.1016/0925-4773(91)90064-D; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; OKO R, 1988, BIOL REPROD, V39, P169, DOI 10.1095/biolreprod39.1.169; Oosterhuis JH, 1999, J BIOL CHEM, V274, P11708, DOI 10.1074/jbc.274.17.11708; Petersen C, 2002, MOL REPROD DEV, V61, P102, DOI 10.1002/mrd.1136; SCHAFER M, 1993, MOL CELL BIOL, V13, P1708, DOI 10.1128/MCB.13.3.1708; Schalles U, 1998, DEV BIOL, V199, P250, DOI 10.1006/dbio.1998.8931; Shao XA, 2006, BIOINFORMATICS, V22, P692, DOI 10.1093/bioinformatics/bti795; Shao XP, 1999, DEV BIOL, V211, P109, DOI 10.1006/dbio.1999.9297; Shao XP, 2001, MOL REPROD DEV, V59, P410, DOI 10.1002/mrd.1047; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Song MS, 2005, J BIOL CHEM, V280, P3920, DOI 10.1074/jbc.M409115200; Takahara T, 2005, MOL CELL, V18, P245, DOI 10.1016/j.molcel.2005.03.018; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Tosaka Y, 2000, GENES CELLS, V5, P265, DOI 10.1046/j.1365-2443.2000.00324.x; Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248-4900(03)00033-9; Tovich PR, 2004, BIOL REPROD, V71, P1182, DOI 10.1095/biolreprod.104.030445; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; VERA JC, 1984, J BIOL CHEM, V259, P5970; Yang L, 2004, J BIOL CHEM, V279, P46253, DOI 10.1074/jbc.M408155200; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; Zhang C, 2003, DNA CELL BIOL, V22, P303, DOI 10.1089/104454903322216653; Zhang Y, 2004, DEV BIOL, V275, P23, DOI 10.1016/j.ydbio.2004.07.014	39	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38172	38180		10.1074/jbc.M606010200	http://dx.doi.org/10.1074/jbc.M606010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17040916	Green Accepted, hybrid			2022-12-25	WOS:000242709500009
J	Mei, ZZ; Xia, R; Beech, DJ; Jiang, LH				Mei, Zhu-Zhong; Xia, Rong; Beech, David J.; Jiang, Lin-Hua			Intracellular coiled-coil domain engaged in subunit interaction and assembly of melastatin-related transient receptor potential channel 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; HYDROGEN-PEROXIDE; TETRAMERIZATION DOMAIN; TERMINAL DOMAIN; CALCIUM INFLUX; TRP CHANNELS; ACTIVATION; PROTEIN; LTRPC2; MULTIMERIZATION	TRPM2 channels, activated by adenosine diphosphoribose and related molecules, are assembled as oligomers and most likely tetramers. However, the molecular determinants driving the subunit interaction and assembly of the TRPM2 channels are not well defined. Here we examined, using site-directed mutagenesis in conjunction with co-immunoprecipitation and patch clamp recording, the role of a coiled-coil domain in the intracellular C terminus of TRPM2 subunit in subunit interaction and channel assembly. Deletion of the coiled-coil domain resulted in severe disruption of the subunit interaction and substantial loss of the adenosine diphosphoribose-evoked channel currents. Individual or combined mutations to glutamine of the hydrophobic residues at positions a and d of the abcdef heptad repeat, key residues for protein-protein interaction, significantly reduced the subunit interaction and channel currents; the mutational effects on the subunit interaction and channel currents were clearly correlated. Furthermore, deletion of the coiled-coil domain in a pore mutant subunit abolished its dominant negative phenotypic functional suppression. These results provide strong evidence that the coiled-coil domain is critically engaged in the TRPM2 subunit interaction and such interaction is required for assembly of functional TRPM2 channel. The coiled-coil domain, which is highly conserved within the TRPM subfamily, may serve as a general structural element governing the assembly of TRPM channels.	Univ Leeds, Inst Membrane & Syst Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Jiang, LH (corresponding author), Univ Leeds, Inst Membrane & Syst Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England.	l.h.jiang@leeds.ac.uk	Jiang, Lin-Hua/AAU-1078-2020; Jiang, Lin-Hua/D-2030-2010	Jiang, Lin-Hua/0000-0001-6398-0411; Jiang, Lin-Hua/0000-0001-6398-0411; Beech, David/0000-0002-7683-9422	Wellcome Trust [072275] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arniges M, 2006, J BIOL CHEM, V281, P1580, DOI 10.1074/jbc.M511456200; Beck A, 2006, FASEB J, V20, P962, DOI 10.1096/fj.05-5538fje; Chang Q, 2004, J BIOL CHEM, V279, P54304, DOI 10.1074/jbc.M406222200; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Fonfria E, 2006, J RECEPT SIG TRANSD, V26, P159, DOI 10.1080/10799890600637506; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; Garcia-Sanz N, 2004, J NEUROSCI, V24, P5307, DOI 10.1523/JNEUROSCI.0202-04.2004; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Hellwig N, 2005, J CELL SCI, V118, P917, DOI 10.1242/jcs.01675; Hill K, 2006, NEUROPHARMACOLOGY, V50, P89, DOI 10.1016/j.neuropharm.2005.08.021; Hill K, 2004, NEUROPHARMACOLOGY, V47, P450, DOI 10.1016/j.neuropharm.2004.04.014; Hille B., 2001, ION CHANNELS EXCITAB, P131; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kuzhikandathil EV, 2001, J NEUROSCI, V21, P8697, DOI 10.1523/JNEUROSCI.21-22-08697.2001; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Ludwig J, 1997, EMBO J, V16, P6337, DOI 10.1093/emboj/16.21.6337; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mei ZZ, 2006, AM J PHYSIOL-CELL PH, V291, pC1022, DOI 10.1152/ajpcell.00606.2005; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Moran MM, 2004, CURR OPIN NEUROBIOL, V14, P362, DOI 10.1016/j.conb.2004.05.003; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Quirk JC, 2001, NEURON, V32, P13, DOI 10.1016/S0896-6273(01)00444-5; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schmitt N, 2000, EMBO J, V19, P332, DOI 10.1093/emboj/19.3.332; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; Schwake M, 2006, J NEUROSCI, V26, P3757, DOI 10.1523/JNEUROSCI.5017-05.2006; Schwake M, 2003, EMBO REP, V4, P76, DOI 10.1038/sj.embor.embor715; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Togashi K, 2006, EMBO J, V25, P1804, DOI 10.1038/sj.emboj.7601083; Tong Q, 2006, J BIOL CHEM, V281, P9076, DOI 10.1074/jbc.M510422200; Tsuruda PR, 2006, NEURON, V51, P201, DOI 10.1016/j.neuron.2006.06.023; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797; Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201; Zhong HN, 2003, P NATL ACAD SCI USA, V100, P5509, DOI 10.1073/pnas.0931279100	51	52	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38748	38756		10.1074/jbc.M607591200	http://dx.doi.org/10.1074/jbc.M607591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17060318	Green Accepted, hybrid			2022-12-25	WOS:000242709500073
J	Minond, D; Lauer-Fields, JL; Cudic, M; Overall, CM; Pei, DQ; Brew, K; Visse, R; Nagase, H; Fields, GB				Minond, Dmitriy; Lauer-Fields, Janelle L.; Cudic, Mare; Overall, Christopher M.; Pei, Duanqing; Brew, Keith; Visse, Robert; Nagase, Hideaki; Fields, Gregg B.			The roles of substrate thermal stability and P-2 and P-1 ' subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; C-TERMINAL DOMAIN; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; FIBROBLAST COLLAGENASE; MOLECULAR DETERMINANTS; NEUTROPHIL COLLAGENASE; FLUOROGENIC SUBSTRATE; CRYSTAL-STRUCTURES; 92-KDA GELATINASE	The hydrolysis of collagen (collagenolysis) is one of the committed steps in extracellular matrix turnover. Within the matrix metalloproteinase (MMP) family distinct preferences for collagen types are seen. The substrate determinants that may guide these specificities are unknown. In this study, we have utilized 12 triple-helical substrates in combination with 10 MMPs to better define the contributions of substrate sequence and thermal stability toward triple helicase activity and collagen specificity. In general, MMP-13 was found to be distinct from MMP-8 and MT1-MMP(Delta 279-523), in that enhanced substrate thermal stability has only a modest effect on activity, regardless of sequence. This result correlates to the unique collagen specificity of MMP-13 compared with MMP-8 and MT1-MMP, in that MMP-13 hydrolyzes type II collagen efficiently, whereas MMP-8 and MT1-MMP are similar in their preference for type I collagen. In turn, MMP-1 was the least efficient of the collagenolytic MMPs at processing increasingly thermal stable triple helices and thus favors type III collagen, which has a relatively flexible cleavage site. Gelatinases (MMP-2 and MMP-9(Delta 444-707)) appear incapable of processing more stable helices and are thus mechanistically distinct from collagenolytic MMPs. The collagen specificity of MMPs appears to be based on a combination of substrate sequence and thermal stability. Analysis of the hydrolysis of triple-helical peptides by an MMP mutant indicated that Tyr(210) functions in triple helix binding and hydrolysis, but not in processing triple helices of increasing thermal stabilities. Further exploration of MMP active sites and exosites, in combination with substrate conformation, may prove valuable for additional dissection of collagenolysis and yield information useful in the design of more selective MMP inhibitors.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; Florida Atlantic Univ, Coll Biomed Sci, Boca Raton, FL 33431 USA; Univ British Columbia, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Canadian Inst Hlth Res, Grp Matrix Dynam, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, London W6 8LH, England	State University System of Florida; Florida Atlantic University; State University System of Florida; Florida Atlantic University; University of British Columbia; Institute for Work & Health; University of British Columbia; University of British Columbia; University of British Columbia; University of Minnesota System; University of Minnesota Twin Cities; Imperial College London; University of Oxford	Fields, GB (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.	fieldsg@fau.edu	Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032; Minond, Dmitriy/0000-0003-2473-5944	NATIONAL CANCER INSTITUTE [R01CA098799] Funding Source: NIH RePORTER; NCI NIH HHS [CA 98799, R01 CA098799] Funding Source: Medline; PHS HHS [A4 40994] Funding Source: Medline; Wellcome Trust [057508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome TrustEuropean Commission)		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; BAICI A, 1982, RHEUMATOL INT, V2, P11, DOI 10.1007/BF00541264; Baronas-Lowell D, 2003, J LIQ CHROMATOGR R T, V26, P2225, DOI 10.1081/JLC-120023245; Bertini I, 2005, P NATL ACAD SCI USA, V102, P5334, DOI 10.1073/pnas.0407106102; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BORNSTEIN P, 1979, PROTEINS, V5, P411; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Chung LD, 2004, EMBO J, V23, P3020, DOI 10.1038/sj.emboj.7600318; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; Elkins PA, 2002, ACTA CRYSTALLOGR D, V58, P1182, DOI 10.1107/S0907444902007849; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; Falconi M, 2003, J COMPUT AID MOL DES, V17, P837, DOI 10.1023/B:JCAM.0000021883.44532.75; FIELDS CG, 1993, TETRAHEDRON LETT, V34, P6661, DOI 10.1016/S0040-4039(00)61669-6; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FIELDS GB, 2001, SYNTHETIC PEPTIDES U, P93; Gioia M, 2002, J BIOL CHEM, V277, P23123, DOI 10.1074/jbc.M110873200; Grant ME, 2002, COLLAGEN FAMILY STRU, P159, DOI DOI 10.1002/0471221929.CH2; GROSS J, 1974, BIOCHEM BIOPH RES CO, V61, P605, DOI 10.1016/0006-291X(74)91000-6; HASTY KA, 1987, ARTHRITIS RHEUM, V30, P695, DOI 10.1002/art.1780300613; Hay ED., 1991, CELL BIOL EXTRACELLU, P7; Henkel W, 1999, BIOCHEMISTRY-US, V38, P13610, DOI 10.1021/bi9905157; HORWITZ AL, 1977, P NATL ACAD SCI USA, V74, P897, DOI 10.1073/pnas.74.3.897; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Hurst DR, 2004, BIOCHEM J, V377, P775, DOI 10.1042/bj20031067; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Jozic D, 2005, J BIOL CHEM, V280, P9578, DOI 10.1074/jbc.M411084200; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Knauper V, 2001, EUR J BIOCHEM, V268, P1888, DOI 10.1046/j.1432-1033.2001.02062.x; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; Kroger M, 1997, GENE, V196, P175, DOI 10.1016/S0378-1119(97)00223-0; Lauer-Fields Janelle L, 2004, J Biomol Tech, V15, P305; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lauer-Fields JL, 2003, ANAL BIOCHEM, V321, P105, DOI 10.1016/S0003-2697(03)00460-3; Lauer-Fields JL, 2003, J BIOL CHEM, V278, P18140, DOI 10.1074/jbc.M211330200; Lauer-Fields JL, 2002, BIOL CHEM, V383, P1095, DOI 10.1515/BC.2002.118; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; Llano E, 1999, CANCER RES, V59, P2570; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; Maskos K, 2005, BIOCHIMIE, V87, P249, DOI 10.1016/j.biochi.2004.11.019; Matsuda A, 2003, J BIOL CHEM, V278, P36350, DOI 10.1074/jbc.M301509200; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; MILLER EJ, 1976, BIOCHEMISTRY-US, V15, P787, DOI 10.1021/bi00649a009; Miller EJ, 1984, EXTRACELLULAR MATRIX, P41; Minond D, 2004, BIOCHEMISTRY-US, V43, P11474, DOI 10.1021/bi048938i; Morrison CJ, 2006, J BIOL CHEM, V281, P26528, DOI 10.1074/jbc.M603331200; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Neumann U, 2004, ANAL BIOCHEM, V328, P166, DOI 10.1016/j.ab.2003.12.035; Nie J, 2003, CANCER RES, V63, P6758; Nishi Y, 2005, BIOCHEMISTRY-US, V44, P6034, DOI 10.1021/bi047887m; NIYIBIZI C, 1994, BIOCHEM BIOPH RES CO, V202, P328, DOI 10.1006/bbrc.1994.1931; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Ottl J, 1996, FEBS LETT, V398, P31, DOI 10.1016/S0014-5793(96)01212-4; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Overall CM, 2006, BRIT J CANCER, V94, P941, DOI 10.1038/sj.bjc.6603043; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pelman GR, 2005, J BIOL CHEM, V280, P2370, DOI 10.1074/jbc.M409603200; Persikov AV, 2004, PROTEIN SCI, V13, P893, DOI 10.1110/ps.03501704; Pirard B, 2006, J MED CHEM, V49, P51, DOI 10.1021/jm050363f; Rao BG, 2005, CURR PHARM DESIGN, V11, P295, DOI 10.2174/1381612053382115; Saffarian S, 2004, SCIENCE, V306, P108, DOI 10.1126/science.1099179; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEGEL IH, 1975, ENZYME KINETICS, P109; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sun HB, 2000, ANAL BIOCHEM, V283, P153, DOI 10.1006/abio.2000.4629; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; Tam EM, 2004, J BIOL CHEM, V279, P43336, DOI 10.1074/jbc.M407186200; Terp GE, 2002, J MED CHEM, V45, P2675, DOI 10.1021/jm0109053; Uchiyama S, 1997, CHEM PHYS LETT, V281, P92, DOI 10.1016/S0009-2614(97)01212-8; Van den Steen PE, 2006, J BIOL CHEM, V281, P18626, DOI 10.1074/jbc.M512308200; Vihinen P, 2005, CURR CANCER DRUG TAR, V5, P203, DOI 10.2174/1568009053765799; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; Woessner J.F., 2000, PROTEIN PROFILE SER; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656	98	78	80	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38302	38313		10.1074/jbc.M606004200	http://dx.doi.org/10.1074/jbc.M606004200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17065155	hybrid			2022-12-25	WOS:000242709500023
J	Pandorf, CE; Haddad, F; Roy, RR; Qin, AX; Edgerton, VR; Baldwin, KM				Pandorf, Clay E.; Haddad, Fadia; Roy, Roland R.; Qin, Anqi X.; Edgerton, V. Reggie; Baldwin, Kenneth M.			Dynamics of myosin heavy chain gene regulation in slow skeletal muscle - Role of natural antisense RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSCRIPTIONAL REGULATION; EXPRESSION; ORGANIZATION; TRANSCRIPTION; INACTIVITY; POLYMORPHISM; DENERVATION; MECHANISMS; DIVERSITY; PROTEIN	The evolutionarily conserved order of the skeletal muscle myosin heavy chain (MHC) genes and their close tandem proximity on the same chromosome are intriguing and may be important for their coordinated regulation. We investigated type II MHC gene regulation in slow-type muscle fibers undergoing a slow to fast MHC transformation in response to inactivity, 7 days after spinal cord isolation ( SI) in rats. We examined the transcriptional products of both the sense and antisense strands across the IIa-IIx-IIb MHC gene locus. A strand-specific reverse transcription (RT)-PCR approach was utilized to study the expression of the mRNA, the primary transcript (pre-mRNA), the antisense RNA overlapping the MHC genes, and both the intergenic sense and antisense RNAs. Results showed that them RNA and pre-mRNA of each MHC had a similar response to SI, suggesting regulation of these genes at the transcriptional level. In addition, we detected previously unknown antisense strand transcription that produced natural antisense transcripts (NATs). RT-PCR mapping of the RNA products revealed that the antisense activity resulted in the formation of three major products: aII, xII, and bII NATs(antisense products of the IIa, IIx, and IIb genes, respectively). The aII NAT begins in the IIa-IIx intergenic region in close proximity to the IIx promoter, extends across the 27-kb IIa MHC gene, and continues to the IIa MHC gene promoter. The expression of the aII NAT was significantly up-regulated in muscles after SI, was negatively correlated with IIa MHC gene expression, and was positively correlated with IIx MHC gene expression. The exact role of the aII NAT is not clear; however, it is consistent with the inhibition of IIa MHC gene transcription. In conclusion, NATs may mediate cross-talk between adjacent genes, which may be essential to the coordinated regulation of the skeletal muscle MHC genes during dynamic phenotype shifts.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Baldwin, KM (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	kmbaldwi@uci.edu			NIAMS NIH HHS [AR 30346] Funding Source: Medline; NINDS NIH HHS [NS 16333] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016333] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Adams GR, 1999, AM J PHYSIOL-REG I, V276, pR954; Ahlquist P, 2002, SCIENCE, V296, P1270, DOI 10.1126/science.1069132; Baldwin KM, 2001, J APPL PHYSIOL, V90, P345, DOI 10.1152/jappl.2001.90.1.345; Caiozzo VJ, 1996, J APPL PHYSIOL, V80, P1503, DOI 10.1152/jappl.1996.80.5.1503; Caiozzo VJ, 2003, AM J PHYSIOL-REG I, V285, pR570, DOI 10.1152/ajpregu.00646.2002; Chau YM, 2002, J CLIN ENDOCR METAB, V87, P2674, DOI 10.1210/jc.87.6.2674; Chen JJ, 2004, NUCLEIC ACIDS RES, V32, P4812, DOI 10.1093/nar/gkh818; COX RD, 1991, DEV BIOL, V143, P36, DOI 10.1016/0012-1606(91)90052-5; Di Maso NA, 2000, J APPL PHYSIOL, V88, P682, DOI 10.1152/jappl.2000.88.2.682; Di Maso NA, 2000, AM J PHYSIOL-REG I, V278, pR1099, DOI 10.1152/ajpregu.2000.278.4.R1099; Engstrom PG, 2006, PLOS GENET, V2, P564, DOI 10.1371/journal.pgen.0020047; Grossman EJ, 1998, MUSCLE NERVE, V21, P375, DOI 10.1002/(SICI)1097-4598(199803)21:3<375::AID-MUS12>3.3.CO;2-Y; Haddad F, 1997, MUSCLE NERVE, V20, P1487, DOI 10.1002/(SICI)1097-4598(199712)20:12<1487::AID-MUS2>3.0.CO;2-4; Haddad F, 2006, AM J PHYSIOL-HEART C, V290, pH2351, DOI 10.1152/ajpheart.01111.2005; Haddad F, 2003, J BIOL CHEM, V278, P37132, DOI 10.1074/jbc.M305911200; Haddad F, 2003, J APPL PHYSIOL, V95, P791, DOI 10.1152/japplphysiol.01113.2002; Haddad F, 1998, J APPL PHYSIOL, V85, P2227, DOI 10.1152/jappl.1998.85.6.2227; Hastings ML, 2000, J BIOL CHEM, V275, P11507, DOI 10.1074/jbc.275.15.11507; Huey KA, 2001, MUSCLE NERVE, V24, P517, DOI 10.1002/mus.1035; Huey KA, 2003, AM J PHYSIOL-CELL PH, V284, pC738, DOI 10.1152/ajpcell.00389.2002; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Kim VN, 2005, MOL CELLS, V19, P1; Knee R, 1997, NEUROCHEM INT, V31, P379, DOI 10.1016/S0197-0186(96)00108-8; Konig S, 2002, J BIOL CHEM, V277, P27593, DOI 10.1074/jbc.M203162200; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002; Luther HP, 2005, J MOL MED, V83, P26, DOI 10.1007/s00109-004-0613-5; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Munroe SH, 2004, J CELL BIOCHEM, V93, P664, DOI 10.1002/jcb.20252; Peters NT, 2003, RNA, V9, P698, DOI 10.1261/rna.2120703; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Prescott EM, 2002, P NATL ACAD SCI USA, V99, P8796, DOI 10.1073/pnas.132270899; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHUG J, 1997, CBILTR19971001V00; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Tufarelli C, 2006, PHILOS T R SOC B, V361, P67, DOI 10.1098/rstb.2005.1732; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Weiss A, 1999, P NATL ACAD SCI USA, V96, P2958, DOI 10.1073/pnas.96.6.2958; Wright C, 1997, J APPL PHYSIOL, V83, P1389, DOI 10.1152/jappl.1997.83.4.1389; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; YOON SJ, 1992, P NATL ACAD SCI USA, V89, P12078, DOI 10.1073/pnas.89.24.12078	43	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38330	38342		10.1074/jbc.M607249200	http://dx.doi.org/10.1074/jbc.M607249200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17030512	hybrid			2022-12-25	WOS:000242709500026
J	Pilquil, C; Dewald, J; Cherney, A; Gorshkova, I; Tigyi, G; English, D; Natarajan, V; Brindley, DN				Pilquil, Carlos; Dewald, Jay; Cherney, Anton; Gorshkova, Irina; Tigyi, Gabor; English, Denis; Natarajan, Viswanathan; Brindley, David N.			Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D-2-dependent phosphatidate generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER CELLS; BRONCHIAL EPITHELIAL-CELLS; PROTEIN-KINASE PATHWAY; ACID PRODUCTION; GROWTH-FACTOR; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHOLIPASE-D; PLASMA-MEMBRANE; GERM-CELLS; ACTIVATION	Lysophosphatidate (LPA) stimulates cell migration and division through a family of G-protein-coupled receptors. Lipid phosphate phosphatase-1 (LPP1) regulates the degradation of extracellular LPA as well as the intracellular accumulation of lipid phosphates. Here we show that increasing the catalytic activity of LPP1 decreased the pertussis toxin-sensitive stimulation of fibroblast migration by LPA and an LPA-receptor agonist that could not be dephosphorylated. Conversely, knockdown of endogenous LPP1 activity increased LPA-induced migration. However, LPP1 did not affect PDGF-or endothelin-induced migration of fibroblasts in Transwell chamber and "wound healing" assays. Thus, in addition to degrading exogenous LPA, LPP1 controls signaling downstream of LPA receptors. Consistent with this conclusion, LPP1 expression decreased phospholipase D (PLD) stimulation by LPA and PDGF, and phosphatidate accumulation. This LPP1 effect was upstream of PLD activation in addition to the possible metabolism of phosphatidate to diacylglycerol. PLD2 activation was necessary for LPA-, but not PDGF-induced migration. Increased LPP1 expression also decreased the LPA-, but not the PDGF-induced activation of important proteins involved in fibroblast migration. These included decreased LPA- induced activation of ERK and Rho, and the basal activities of Rac and Cdc42. However, ERK and Rho activation were not downstream targets of LPA- induced PLD2 activity. We conclude that the intracellular actions of LPP1 play important functions in regulating LPA- induced fibroblast migration through PLD2. LPP1 also controls PDGF-induced phosphatidate formation. These results shed new light on the roles of LPP1 in controlling wound healing and the growth and metastasis of tumors.	Univ Alberta, Dept Biochem, Signal Transduct Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ S Florida, Dept Neurosurg, Ctr Excellence Aging & Brain Repair, Coll Med, Tampa, FL 33612 USA; Univ Chicago, Sect Pulm & Crit Care, Dept Med, Chicago, IL 60637 USA	University of Alberta; University of Tennessee System; University of Tennessee Health Science Center; State University System of Florida; University of South Florida; University of Chicago	Brindley, DN (corresponding author), 357 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	david.brindley@ualberta.ca			NCI NIH HHS [CA 92160] Funding Source: Medline; NHLBI NIH HHS [R01 HL 71152, HL 61469, HL 079396, R01 HL 061751] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469, R01HL079396, R37HL079396, R01HL071152, R01HL061751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alderton F, 2001, J BIOL CHEM, V276, P13452, DOI 10.1074/jbc.M006582200; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Avila-Flores A, 2005, J BIOL CHEM, V280, P10091, DOI 10.1074/jbc.M412296200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; Burnett C, 2003, EMBO REP, V4, P793, DOI 10.1038/sj.embor.embor900; Chen JS, 2004, J BIOL CHEM, V279, P22076, DOI 10.1074/jbc.M311033200; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; Escalante-Alcalde D, 2003, DEVELOPMENT, V130, P4623, DOI 10.1242/dev.00635; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Garcia-Murillas I, 2006, NEURON, V49, P533, DOI 10.1016/j.neuron.2006.02.001; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Huijbregts RPH, 2000, TRAFFIC, V1, P195, DOI 10.1034/j.1600-0854.2000.010301.x; Humtsoe JO, 2003, EMBO J, V22, P1539, DOI 10.1093/emboj/cdg165; Imai A, 2000, J CLIN ENDOCR METAB, V85, P3370, DOI 10.1210/jc.85.9.3370; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Leung DW, 1998, DNA CELL BIOL, V17, P377, DOI 10.1089/dna.1998.17.377; Long J, 2005, BIOCHEM J, V391, P25, DOI 10.1042/BJ20050342; Long JS, 2006, BIOCHEM J, V394, P495, DOI 10.1042/BJ20051674; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Meacci E, 2003, BIOCHEMISTRY-US, V42, P284, DOI 10.1021/bi026350a; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; Morris KE, 2006, J BIOL CHEM, V281, P9297, DOI 10.1074/jbc.M511710200; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Pilquil C, 2001, PROSTAG OTH LIPID M, V64, P83, DOI 10.1016/S0090-6980(01)00101-0; Powner DJ, 2005, J CELL SCI, V118, P2975, DOI 10.1242/jcs.02432; PRECIADOPATT L, 1994, EUR J BIOCHEM, V223, P35, DOI 10.1111/j.1432-1033.1994.tb18963.x; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renault AD, 2004, SCIENCE, V305, P1963, DOI 10.1126/science.1102421; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sakai T, 1998, J BIOL CHEM, V273, P19378, DOI 10.1074/jbc.273.31.19378; Sciorra VA, 1999, MOL BIOL CELL, V10, P3863, DOI 10.1091/mbc.10.11.3863; Shen Z, 1997, CLIN CHEM, V43, P577; Sigal YJ, 2005, BIOCHEM J, V387, P281, DOI 10.1042/BJ20041771; Simon MF, 2002, J BIOL CHEM, V277, P23131, DOI 10.1074/jbc.M201530200; Smyth SS, 2003, J BIOL CHEM, V278, P43214, DOI 10.1074/jbc.M306709200; Starz-Gaiano M, 2001, DEVELOPMENT, V128, P983; Tanyi JL, 2003, CLIN CANCER RES, V9, P3534; Tanyi JL, 2003, CANCER RES, V63, P1073; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; Wang LX, 2003, J BIOL CHEM, V278, P39931, DOI 10.1074/jbc.M302896200; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Yue JM, 2004, CELL SIGNAL, V16, P385, DOI 10.1016/j.cellsig.2003.08.012; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0; Zhang QX, 2000, BIOCHEM J, V345, P181, DOI 10.1042/0264-6021:3450181; Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160; Zimmerberg J, 2000, TRAFFIC, V1, P366, DOI 10.1034/j.1600-0854.2000.010409.x	65	52	54	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38418	38429		10.1074/jbc.M601670200	http://dx.doi.org/10.1074/jbc.M601670200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17057224	hybrid			2022-12-25	WOS:000242709500035
J	Takahashi-Yanaga, F; Mori, J; Matsuzaki, E; Watanabe, Y; Hirata, M; Miwa, Y; Morimoto, S; Sasaguri, T				Takahashi-Yanaga, Fumi; Mori, Jun; Matsuzaki, Etsuko; Watanabe, Yutaka; Hirata, Masato; Miwa, Yoshikazu; Morimoto, Sachio; Sasaguri, Toshiyuki			Involvement of GSK-3 beta and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE PHOSPHODIESTERASE PDE1; MOLD DICTYOSTELIUM-DISCOIDEUM; MIRK PROTEIN-KINASE; GLYCOGEN-SYNTHASE; FACTOR-I; CANCER; DEGRADATION; INHIBITION; EXPRESSION; MORPHOGEN	Differentiation-inducing factors (DIFs) are putative morphogens that induce cell differentiation in Dictyostelium discoideum. We previously reported that DIF-3 activates glycogen synthase kinase-3 beta (GSK-3 beta), resulting in the degradation of cyclin D1 in HeLa cells. In this study, we investigated the effect of DIF-3 on cyclin D1 mutants (R29Q, L32A, T286A, T288A, and T286A/ T288A) to clarify the precise mechanisms by which DIF-3 degrades cyclin D1 in HeLa cells. We revealed that T286A, T288A, and T286A/ T288A mutants were resistant to DIF-3-induced degradation compared with wild-type cyclin D1, indicating that the phosphorylation of Thr(286) and Thr(288) were critical for cyclin D1 degradation induced by DIF-3. Indeed, DIF- 3 markedly elevated the phosphorylation level of cyclin D1, and mutations introduced to Thr(286) and/or Thr(288) prevented the phosphorylation induced by DIF-3. Depletion of endogenous GSK-3 beta and dual-specificity tyrosine phosphorylation regulated kinase 1B (DYRK1B) by RNA interference attenuated the DIF-3-induced cyclin D1 phosphorylation and degradation. The effect of DIF- 3 on DYRK1B activity was examined and we found that DIF- 3 also activated this kinase. Further, we found that not only GSK-3 beta but also DYRK1B modulates cyclin D1 subcellular localization by the phosphorylation of Thr(288). These results suggest that DIF- 3 induces degradation of cyclin D1 through the GSK-3 beta- and DYRK1B-mediated threonine phosphorylation in HeLa cells.	Kyushu Univ, Fac Med Sci, Dept Clin Pharmacol, Fukuoka 8128582, Japan; Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan; Kyushu Univ, Fac Dent Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan	Kyushu University; Ehime University; Kyushu University	Takahashi-Yanaga, F (corresponding author), Kyushu Univ, Fac Med Sci, Dept Clin Pharmacol, Fukuoka 8128582, Japan.	yanaga@clipharm.med.kyushu-u.ac.jp		Miwa, Yoshikazu/0000-0002-5687-7149; Morimoto, Sachio/0000-0001-9171-3636				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Barbieri F, 2004, ONCOLOGY-BASEL, V66, P310, DOI 10.1159/000078332; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Kakkar R, 1999, CELL MOL LIFE SCI, V55, P1164, DOI 10.1007/s000180050364; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kubohara Y, 1999, EUR J PHARMACOL, V381, P57, DOI 10.1016/S0014-2999(99)00548-8; Kwak YT, 2005, J BIOL CHEM, V280, P33945, DOI 10.1074/jbc.M506206200; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 2000, CANCER RES, V60, P3631; Lerner A, 2000, LEUKEMIA LYMPHOMA, V37, P39, DOI 10.3109/10428190009057627; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; MASENTO MS, 1988, BIOCHEM J, V256, P23, DOI 10.1042/bj2560023; Miwa Y, 2000, CIRC RES, V86, P68, DOI 10.1161/01.RES.86.1.68; Mori J, 2005, EXP CELL RES, V310, P426, DOI 10.1016/j.yexcr.2005.07.024; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimizu K, 2004, CANCER RES, V64, P2568, DOI 10.1158/0008-5472.CAN-03-3551; Skurat AV, 2004, J BIOL CHEM, V279, P2490, DOI 10.1074/jbc.M301769200; Takahashi-Yanaga F, 2003, J BIOL CHEM, V278, P9663, DOI 10.1074/jbc.M205768200; Utsunomiya T, 2001, ONCOLOGY-BASEL, V61, P226, DOI 10.1159/000055379; Yasmin T, 2005, BIOCHEM BIOPH RES CO, V338, P903, DOI 10.1016/j.bbrc.2005.10.018; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	31	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38489	38497		10.1074/jbc.M605205200	http://dx.doi.org/10.1074/jbc.M605205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17046823	hybrid			2022-12-25	WOS:000242709500043
J	Maeda, A; Maeda, T; Imanishi, Y; Sun, WY; Jastrzebska, B; Hatala, DA; Winkens, HJ; Hofmann, KP; Janssen, JJ; Baehr, W; Driessen, CA; Palczewski, K				Maeda, Akiko; Maeda, Tadao; Imanishi, Yoshikazu; Sun, Wenyu; Jastrzebska, Beata; Hatala, Denise A.; Winkens, Huub J.; Hofmann, Klaus Peter; Janssen, Jacques J.; Baehr, Wolfgang; Driessen, Carola A.; Palczewski, Krzysztof			Retinol dehydrogenase (RDH12) protects photoreceptors from light-induced degeneration in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEBER CONGENITAL AMAUROSIS; COUPLED RECEPTOR RHODOPSIN; ALL-TRANS-RETINOL; VISUAL CYCLE; PIGMENT EPITHELIUM; VERTEBRATE RETINA; DARK-ADAPTATION; IN-VIVO; SUBSTRATE-SPECIFICITY; RPE65	RDH12 has been suggested to be one of the retinol dehydrogenases (RDH) involved in the vitamin A recycling system (visual cycle) in the eye. Loss of function mutations in the RDH12 gene were recently reported to be associated with autosomal recessive childhood-onset severe retinal dystrophy. Here we show that RDH12 localizes to the photoreceptor inner segments and that deletion of this gene in mice slows the kinetics of all-trans-retinal reduction, delaying dark adaptation. However, accelerated 11-cis-retinal production and increased susceptibility to light-induced photoreceptor apoptosis were also observed in Rdh12(-/-) mice, suggesting that RDH12 plays a unique, non-redundant role in the photoreceptor inner segments to regulate the flow of retinoids in the eye. Thus, severe visual impairments of individuals with null mutations in RDH12 may likely be caused by light damage(1).	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Ophthalmol, Cleveland, OH 44106 USA; Univ Nijmegen, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands; Univ Nijmegen, Dept Biochem, NL-6525 EX Nijmegen, Netherlands; Humboldt Univ, Univ Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA	Case Western Reserve University; Case Western Reserve University; Radboud University Nijmegen; Radboud University Nijmegen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Palczewski, K (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, BRB Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.	kxp65@case.edu	Imanishi, Yoshikazu/E-8178-2010	Imanishi, Yoshikazu/0000-0003-4696-4836	NEI NIH HHS [R01 EY009339, P30 EY011373, R01 EY022658, K08 EY019031-01, EY09339, K08 EY019031, P30 EY11373] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339, R01EY022658, P30EY011373, K08EY019031] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPERN M, 1971, J PHYSIOL-LONDON, V217, P447, DOI 10.1113/jphysiol.1971.sp009580; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Belyaeva OV, 2005, BIOCHEMISTRY-US, V44, P7035, DOI 10.1021/bi050226k; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; Driessen C, 2003, VISION RES, V43, P3075, DOI 10.1016/S0042-6989(03)00483-8; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Fain G L, 2001, Prog Brain Res, V131, P383; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GREEN DG, 1975, J GEN PHYSIOL, V65, P483, DOI 10.1085/jgp.65.4.483; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Horrigan DM, 2005, J GEN PHYSIOL, V126, P453, DOI 10.1085/jgp.200509387; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; Jeon CJ, 1998, J NEUROSCI, V18, P8936; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; Martras S, 2004, EUR J BIOCHEM, V271, P1660, DOI 10.1111/j.1432-1033.2004.04058.x; Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; McCabe SL, 2004, J GEN PHYSIOL, V123, P521, DOI 10.1085/jgp.200409011; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; OHGURO H, 1993, P NATL ACAD SCI USA, V90, P3241, DOI 10.1073/pnas.90.8.3241; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Perrault I, 2004, AM J HUM GENET, V75, P639, DOI 10.1086/424889; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Rohrer B, 2003, INVEST OPHTH VIS SCI, V44, P310, DOI 10.1167/iovs.02-0567; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Song MS, 2003, J BIOL CHEM, V278, P40079, DOI 10.1074/jbc.M304910200; Thompson DA, 2005, HUM MOL GENET, V14, P3865, DOI 10.1093/hmg/ddi411; Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X; Travis G.H., 2007, ANN REV PHARM TOXICO, V47, P1; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; Wu BX, 2004, INVEST OPHTH VIS SCI, V45, P3857, DOI 10.1167/iovs.03-1302; Xiao M, 2000, J COMP NEUROL, V425, P545; Yzer S, 2006, INVEST OPHTH VIS SCI, V47, P1167, DOI 10.1167/iovs.05-0848	50	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37697	37704		10.1074/jbc.M608375200	http://dx.doi.org/10.1074/jbc.M608375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17032653	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000242477100047
J	Margittai, M; Langen, R				Margittai, Martin; Langen, Ralf			Side chain-dependent stacking modulates tau filament structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; SOLID-STATE NMR; MICROTUBULE-BINDING DOMAIN; PARALLEL BETA-SHEETS; AMYLOID FIBRILS; ALZHEIMERS-DISEASE; PROTEIN-TAU; NEURODEGENERATIVE TAUOPATHIES; ELECTRON-MICROSCOPY; AMINO-ACIDS	The misfolding of proteins into highly ordered fibrils with similar physical properties is a hallmark of many degenerative diseases. Here, we use the microtubule associated protein tau as a model system to investigate the role of amino acid side chains in the formation of such fibrils. We identify a region (positions 272-289) in the tau protein that, in the fibrillar state, either forms part of a core of parallel, in-register, beta-strands, or remains unfolded. Single point mutations are sufficient to control this conformational switch with disease mutants G272V and Delta K280 (found in familial forms of dementia) inducing a folded state. Through systematic mutagenesis we derive a propensity scale for individual amino acids to form fibrils with parallel, in-register, beta-strands. This scale should not only apply to tau fibrils but generally to all fibrils with same strand arrangement.	Univ So Calif, Zilkha Neurogenet Inst, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California	Langen, R (corresponding author), Univ So Calif, Zilkha Neurogenet Inst, Keck Sch Med, Dept Biochem & Mol Biol, 1501 San Pablo St,Rm 119E, Los Angeles, CA 90033 USA.	langen@usc.edu	Margittai, Martin/D-5039-2014	Margittai, Martin/0000-0003-1903-5927				Abraha A, 2000, J CELL SCI, V113, P3737; Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Chan JCC, 2005, BIOCHEMISTRY-US, V44, P10669, DOI 10.1021/bi050724t; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Gordon DJ, 2004, BIOPHYS J, V86, P428, DOI 10.1016/S0006-3495(04)74119-3; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; GRIFFITHS JM, 1995, J AM CHEM SOC, V117, P3539, DOI 10.1021/ja00117a023; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Hubbell WL, 1996, STRUCTURE, V4, P779, DOI 10.1016/S0969-2126(96)00085-8; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; Jayasinghe SA, 2004, J BIOL CHEM, V279, P48420, DOI 10.1074/jbc.M406853200; KIM CA, 1993, NATURE, V362, P270; Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679; Langen R, 1999, BIOCHEMISTRY-US, V38, P7918, DOI 10.1021/bi990010g; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Margittai M, 2004, P NATL ACAD SCI USA, V101, P10278, DOI 10.1073/pnas.0401911101; Merkel JS, 1999, STRUCT FOLD DES, V7, P1333, DOI 10.1016/S0969-2126(00)80023-4; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; Minoura K, 2004, EUR J BIOCHEM, V271, P545, DOI 10.1046/j.1432-1033.2003.03956.x; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Pawar AP, 2005, J MOL BIOL, V350, P379, DOI 10.1016/j.jmb.2005.04.016; Perez M, 1996, J NEUROCHEM, V67, P1183; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2004, J MOL BIOL, V335, P247, DOI 10.1016/j.jmb.2003.10.044; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Ross ED, 2005, NAT CELL BIOL, V7, P1039, DOI 10.1038/ncb1105-1039; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; Serag AA, 2002, NAT STRUCT BIOL, V9, P734, DOI 10.1038/nsb838; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; Street AG, 1999, P NATL ACAD SCI USA, V96, P9074, DOI 10.1073/pnas.96.16.9074; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; von Bergen M, 2006, BIOCHEMISTRY-US, V45, P6446, DOI 10.1021/bi052530j; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7	53	66	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37820	37827		10.1074/jbc.M605336200	http://dx.doi.org/10.1074/jbc.M605336200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17023423	hybrid			2022-12-25	WOS:000242477100059
J	Cuellar, H; Kim, JA; Unguez, GA				Cuellar, Heriberto; Kim, Jung A.; Unguez, Graciela A.			Evidence of post-transcriptional regulation in the maintenance of a partial muscle phenotype by electrogenic cells of S-macrurus	FASEB JOURNAL			English	Article						electric fish; electric organ; muscle proteins; muscle gene regulation	GYMNOTIFORM ELECTRIC FISH; CREATINE-KINASE; SKELETAL-MUSCLE; COMMUNICATION SIGNALS; MESSENGER-RNA; TROPONIN-T; EXPRESSION; ORGAN; PROTEINS; PROMOTER	Electrocytes, the current-producing cells of electric organs (EOs) in electric fish, are unique in that they derive from striated muscle and they possess biochemical characteristics of both muscle and non-muscle cells. In the freshwater teleost Sternopygus macrurus, electrocytes are multinucleated cells that do not contract yet retain expression of some proteins common to skeletal muscle cells. Given the role that transcriptional regulation plays in the activation of the myogenic program in vertebrates, we examined the expression patterns of several genes associated with multiple functions of skeletal muscle in mature electrocytes of S. macrurus. Our expression analyses detected transcripts for alpha-actin, alpha-acetylcholine (ACh) receptor (alpha-AChR), desmin, muscle creatine kinase (MCK), myosin heavy chain (MHC) isoforms, titin, tropomyosin, and troponin-T genes in the EO. However, immunolabeling studies revealed that electrocytes do not contain MCK, MHCs, or tropomyosin or troponin-T proteins. These results underscore the contribution of gene regulatory mechanisms in the maintenance of the muscle-like phenotype of EO that may be transcriptional-independent. We also report the classification and frequency of distinct transcripts from a random selection of 420 clones from an EO cDNA library. This is the first characterization of expressed genes in an EO, and it is an important step toward identifying mechanisms that affect different muscle protein systems for the evolution of highly specialized noncontractile tissues. Evidence of post-transcriptional regulation in the maintenance of a partial muscle phenotype by electrogenic cells of S. macrurus.-Cuellar, H., Jung, K. A., and Unguez, G. A. Evidence of post-transcriptional regulation in the maintenance of a partial muscle phenotype by electrogenic cells of S. macrurus.	New Mexico State Univ, Dept Biol, Las Cruces, NM 88003 USA	New Mexico State University	Unguez, GA (corresponding author), New Mexico State Univ, Dept Biol, Foster Hall, Las Cruces, NM 88003 USA.	gunguez@nmsu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM061222] Funding Source: NIH RePORTER; NCRR NIH HHS [RR16480-01] Funding Source: Medline; NIGMS NIH HHS [GM061222-05] Funding Source: Medline; PHS HHS [S06-GMO8136-27] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABE H, 1986, DEV BIOL, V118, P42, DOI 10.1016/0012-1606(86)90071-0; Arnegard ME, 2005, P ROY SOC B-BIOL SCI, V272, P1305, DOI 10.1098/rspb.2005.3101; Bass A.H., 1986, P13; Bastian J, 2004, NEURON, V41, P767, DOI 10.1016/S0896-6273(04)00071-6; Basyuk E, 2000, Nucleic Acids Res, V28, pE46, DOI 10.1093/nar/28.10.e46; BENNET MVL, 1971, ANN NY ACAD SCI, V54, P458; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; Brand-Saberi B, 2005, ANN ANAT, V187, P199, DOI 10.1016/j.aanat.2004.12.018; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Chakkalakal JV, 2003, BIOESSAYS, V25, P25, DOI 10.1002/bies.10205; Deschenes-Furry J, 2005, J BIOL CHEM, V280, P25361, DOI 10.1074/jbc.M410929200; EILERTSEN KJ, 1992, J CELL BIOL, V119, P549, DOI 10.1083/jcb.119.3.549; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; FABBRIZIO E, 1993, NEUROSCI LETT, V155, P51, DOI 10.1016/0304-3940(93)90671-7; Fortune ES, 2000, J NEUROSCI, V20, P7122, DOI 10.1523/JNEUROSCI.20-18-07122.2000; FOX GQ, 1978, J COMP NEUROL, V179, P677, DOI 10.1002/cne.901790313; Furlong EE, 2004, CURR OPIN GENET DEV, V14, P343, DOI 10.1016/j.gde.2004.06.011; HAGEDORN M, 1992, J NEUROBIOL, V23, P1446, DOI 10.1002/neu.480231007; Hoover F, 2002, MOL CELL NEUROSCI, V19, P125, DOI 10.1006/mcne.2001.1053; Keller TCS, 2000, ADV EXP MED BIOL, V481, P265; Kim JA, 2004, DEV GENES EVOL, V214, P380, DOI 10.1007/s00427-004-0421-5; Kiri A, 2002, J MUSCLE RES CELL M, V23, P119, DOI 10.1023/A:1020211729728; KIRSCHBAUM F, 1977, NATURWISSENSCHAFTEN, V64, P387, DOI 10.1007/BF00368748; Lange S, 2006, TRENDS CELL BIOL, V16, P11, DOI 10.1016/j.tcb.2005.11.007; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MOSS JB, 1994, J BIOL CHEM, V269, P12731; Nikcevic G, 2000, J MUSCLE RES CELL M, V21, P599, DOI 10.1023/A:1026507727700; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; Patterson JM, 1997, DEV BIOL, V186, P115, DOI 10.1006/dbio.1997.8580; Patterson JM, 1996, J COMP NEUROL, V370, P367, DOI 10.1002/(SICI)1096-9861(19960701)370:3<367::AID-CNE7>3.0.CO;2-2; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; Qi M, 1997, AM J PHYSIOL-CELL PH, V273, pC394, DOI 10.1152/ajpcell.1997.273.2.C394; QUEST AFG, 1990, FEBS LETT, V269, P457, DOI 10.1016/0014-5793(90)81215-A; Rome LC, 1996, P NATL ACAD SCI USA, V93, P8095, DOI 10.1073/pnas.93.15.8095; ROME LC, 1992, J EXP BIOL, V163, P259; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sisneros JA, 2000, J NEUROSCI, V20, P8586, DOI 10.1523/JNEUROSCI.20-22-08586.2000; Stoddard PK, 2003, J EXP BIOL, V206, P1353, DOI 10.1242/jeb.00252; SUGIURA T, 1990, BIOMED RES-TOKYO, V11, P87, DOI 10.2220/biomedres.11.87; Swoap SJ, 1998, AM J PHYSIOL-CELL PH, V274, pC681, DOI 10.1152/ajpcell.1998.274.3.C681; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Unguez GA, 1998, J COMP NEUROL, V399, P20; Unguez GA, 1998, J NEUROSCI, V18, P9924; VISCHER HA, 1989, J COMP NEUROL, V290, P16, DOI 10.1002/cne.902900103; Vracar-Grabar M, 2004, J MUSCLE RES CELL M, V25, P397, DOI 10.1007/s10974-004-1141-1; WALLIMANN T, 1990, PROG CLIN BIOL RES, V344, P877; WHITING PJ, 1987, J NEUROSCI, V7, P4005; WILKINSON JM, 1984, EUR J BIOCHEM, V143, P47, DOI 10.1111/j.1432-1033.1984.tb08337.x; Zakon HH, 1999, BRAIN BEHAV EVOLUT, V54, P61, DOI 10.1159/000006612; Zakon HH, 1996, DEV NEUROSCI-BASEL, V18, P115, DOI 10.1159/000111399; ZAKON HH, 1991, J COMP PHYSIOL A, V169, P493	54	13	13	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2540	+		10.1096/fj.06-6474fje	http://dx.doi.org/10.1096/fj.06-6474fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077280				2022-12-25	WOS:000242490700016
J	Jiang, H; Olson, MV; Medrano, DR; Lee, OH; Xu, J; Piao, Y; Alonso, MM; Gomez-Manzano, C; Hung, MC; Yung, WKA; Fueyo, J				Jiang, Hong; Olson, Melissa V.; Medrano, Diana R.; Lee, Ok-Hee; Xu, Jing; Piao, Yuji; Alonso, Marta M.; Gomez-Manzano, Candelaria; Hung, Mien-Chie; Yung, W. K. Alfred; Fueyo, Juan			A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation	FASEB JOURNAL			English	Article						leptomycin B; NES; NLS	HISTONE H1 PHOSPHORYLATION; LOCALIZATION SIGNAL; EXPRESSION; ONCOPROTEIN; TRANSPORT; PROMOTER; XENOPUS; TYPE-5; KINASE; REGION	Adenoviral E1A is a versatile protein that can reprogram host cells for efficient viral replication. The nuclear import of E1A is mediated by a nuclear localization signal; however, whether E1A can be actively exported from the nucleus is unknown. We first reported a CRM1-dependent nuclear export signal (NES) in E1A that is conserved in the group C adeno-viruses. We showed that CRM1 and E1A coimmunoprecipitated and that blockage of CRM1 function by leptomycin B or small interfering RNA resulted in the nuclear localization of E1A. Through mutational analyses, we identified an active canonical NES element within the E1A protein spanning amino acids 70-80. We further demonstrated that phosphorylation of adjacent serine (S) 89 resulted in the cytoplasmic accumulation of E1A. Interestingly, coincident with the accumulation of cells in the S/G(2)/M phase and histone H1 phosphorylation, E1A was relocated to the cytoplasm at the late stage of the viral cycle, which was blocked by the CDC2/CDK2 inhibitor roscovitine. Importantly, titration of the progenies of the viruses in infected cells showed that the replication efficiency of the NES mutant adenovirus was up to 500-fold lower than that of the wild-type adenovirus. Collectively, our data demonstrate the existence of a NES in E1A that is modulated by the phosphorylation of the S89 residue and the NES plays a role for an efficient viral replication in the host cells.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Jiang, H (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, 1515 Holcombe Blvd,Unit 1002, Houston, TX 77030 USA.	hjiang@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Alonso, Marta M/AAI-9457-2020	Hung, Mien-Chie/0000-0003-4317-4740; Alonso, Marta M/0000-0002-7520-7351; Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133				Alexandrow MG, 2005, J CELL BIOL, V168, P875, DOI 10.1083/jcb.200409055; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Doree M, 2002, J CELL SCI, V115, P2461; DUMONT DJ, 1993, J GEN VIROL, V74, P583, DOI 10.1099/0022-1317-74-4-583; DUMONT DJ, 1992, VIROLOGY, V189, P111, DOI 10.1016/0042-6822(92)90686-J; Fax P, 2001, VIROLOGY, V285, P30, DOI 10.1006/viro.2001.0926; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fontoura BMA, 2005, IUBMB LIFE, V57, P65, DOI 10.1080/15216540500078608; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jiang H, 2005, NEOPLASIA, V7, P723, DOI 10.1593/neo.04793; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; Kohler M, 2001, VIROLOGY, V289, P186, DOI 10.1006/viro.2001.1151; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Madison DL, 2002, J BIOL CHEM, V277, P38755, DOI 10.1074/jbc.M207512200; Mal A, 1996, J VIROL, V70, P2911, DOI 10.1128/JVI.70.5.2911-2921.1996; Mangel WF, 2003, CELL MOL LIFE SCI, V60, P2347, DOI 10.1007/s00018-003-2318-2; Padmanabhan R, 2003, CURR TOP MICROBIOL, V272, P365; RICHTER JD, 1985, P NATL ACAD SCI USA, V82, P8434, DOI 10.1073/pnas.82.24.8434; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Shimada A, 1998, BIOL CELL, V90, P519, DOI 10.1016/S0248-4900(99)80010-0; STANDIFORD DM, 1992, J CELL BIOL, V118, P991, DOI 10.1083/jcb.118.5.991; TREMBLAY ML, 1989, VIROLOGY, V169, P397, DOI 10.1016/0042-6822(89)90165-7; Vertegaal ACO, 2003, J BIOL CHEM, V278, P139, DOI 10.1074/jbc.M206267200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whalen SG, 1996, J VIROL, V70, P5373, DOI 10.1128/JVI.70.8.5373-5383.1996; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Wolff R, 1997, GENOME ANAL, V1, P1; Zhang ZY, 2001, MOL BIOL CELL, V12, P699, DOI 10.1091/mbc.12.3.699	39	10	10	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2603	+		10.1096/fj.06-6433fje	http://dx.doi.org/10.1096/fj.06-6433fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065226				2022-12-25	WOS:000242490700038
J	Mariggio, S; Sebastia, J; Filippi, BM; Iurisci, C; Volonte, C; Amadio, S; De Falco, V; Santoro, M; Corda, D				Mariggio, Stefania; Sebastia, Jordi; Filippi, Beatrice Maria; Iurisci, Cristiano; Volonte, Cinzia; Amadio, Susanna; De Falco, Valentina; Santoro, Massimo; Corda, Daniela			A novel pathway of cell growth regulation mediated by a PLA(2)alpha-derived phosphoinositide metabolite	FASEB JOURNAL			English	Article						glycerophosphoinositol; phosphatidylinositol; thyroid cells; phospholipases; cell signaling	CYTOSOLIC PHOSPHOLIPASE A(2); THYROID FRTL-5 CELLS; GLYCEROPHOSPHOINOSITOL 4-PHOSPHATE; SIGNALING PATHWAYS; ARACHIDONIC-ACID; EPITHELIAL-CELLS; IODIDE FLUXES; RAS; PROLIFERATION; RELEASE	The phosphoinositides have well-defined roles in the control of cellular functions, including cytoskeleton dynamics, membrane trafficking, and cell signaling. However, the interplay among the phosphoinositides and their diffusible derivatives that originate through phospholipase A(2) action (the lysophosphoinositides and glycerophosphoinositols) remains to be fully elucidated. Here we demonstrate that in PCCl3 rat thyroid cells, the intracellular levels of glycerophosphoinositol are finely modulated by ATP and norepinephrine through the P2Y metabotropic and alpha-adrenergic receptors, respectively. The enzyme involved here is phospholipase A(2) IV alpha (PLA(2)IV alpha), which in these cells specifically hydrolyzes phosphatidylinositol, forming lysophosphatidylinositol, glycerophosphoinositol, and arachidonic acid. This receptor-mediated activation of PLA(2)IV alpha leads to stimulation of PCCl3 cell growth. The involvement of a PLA2IV alpha-mediated pathway is demonstrated by inhibition of the increase in intracellular glycerophosphoinositol levels and cell proliferation by specific inhibitors, RNA interference, and overexpression of the dominant-negative PLA(2)IV alpha(1-522). Modulation of PCCl3 cell growth is not seen with inhibitors of arachidonic acid metabolism. In conclusion, these data characterize glycerophosphoinositol as a mediator of the purinergic and adrenergic regulation of PCCl3 cell proliferation, defining a novel regulatory cascade specifically involving this soluble phosphoinositide derivative and widening the involvement of the phosphoinositides in the regulation of cell function. Mariggio, S., Sebastia, J., Filippi, B. M., Iurisci, C., Volonte, C., Amadio, S., De Falco, V., Santoro, M., Corda, D. A Novel pathway of cell growth regulation mediated by a PLA(2)alpha-derived phosphoinositide metabolite.	Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Chieti, Italy; CNR, Santa Lucia Fdn, Rome, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, I-80125 Naples, Italy	Consorzio Mario Negri Sud; Consiglio Nazionale delle Ricerche (CNR); IRCCS Santa Lucia; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Mariggio, S (corresponding author), Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Via Nazl 8, I-66030 Chieti, Italy.	mariggio@negrisud.it; corda@negrisud.it	Volonté, Cinzia/N-6474-2013; Amadio, Susanna/K-5580-2016; Mariggio', Stefania/H-5467-2015; Corda, Daniela/K-6385-2016; DE FALCO, VALENTINA/C-2061-2015	Volonté, Cinzia/0000-0001-7362-8307; Amadio, Susanna/0000-0002-9266-4597; Mariggio', Stefania/0000-0002-6397-3016; Corda, Daniela/0000-0002-3614-751X; DE FALCO, VALENTINA/0000-0002-8972-7921; Filippi, Beatrice Maria/0000-0002-8816-1559	Telethon [GGP030295] Funding Source: Medline	Telethon(Fondazione Telethon)		ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Berenbaum F, 2003, J BIOL CHEM, V278, P13680, DOI 10.1074/jbc.M211570200; Berrie CP, 2002, EUR J CANCER, V38, P2463, DOI 10.1016/S0959-8049(02)00485-9; Berrie CP, 1999, EUR J BIOCHEM, V266, P413, DOI 10.1046/j.1432-1327.1999.00870.x; Bjorklund S, 2005, MOL CELL ENDOCRINOL, V231, P65, DOI 10.1016/j.mce.2004.12.001; Botitsi E, 1998, J LIPID RES, V39, P1295; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Buccione R, 2005, EUR J CANCER, V41, P470, DOI 10.1016/j.ejca.2004.11.011; BURCH RM, 1986, J BIOL CHEM, V261, P1236; Carlton JG, 2005, TRENDS CELL BIOL, V15, P540, DOI 10.1016/j.tcb.2005.08.005; Choy PC, 1997, BBA-LIPID LIPID MET, V1348, P124, DOI 10.1016/S0005-2760(97)00114-8; CORDA D, 1986, BIOCHEM BIOPH RES CO, V141, P1000, DOI 10.1016/S0006-291X(86)80143-7; Corda D, 2002, BBA-MOL CELL BIOL L, V1582, P52, DOI 10.1016/S1388-1981(02)00137-3; Corda D, 1996, ANTICANCER RES, V16, P1341; Di Cerbo A, 1999, BIOCHIMIE, V81, P415, DOI 10.1016/S0300-9084(99)80090-X; DIGIROLAMO M, 1991, ACTA ENDOCRINOL-COP, V125, P192, DOI 10.1530/acta.0.1250192; Downes CP, 2005, TRENDS CELL BIOL, V15, P259, DOI 10.1016/j.tcb.2005.03.008; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; Falasca M, 1997, MOL BIOL CELL, V8, P443, DOI 10.1091/mbc.8.3.443; FALASCA M, 1995, ONCOGENE, V10, P2113; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Herbert SP, 2005, MOL BIOL CELL, V16, P3800, DOI 10.1091/mbc.E05-02-0164; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; Klepeis VE, 2001, J CELL SCI, V114, P4185; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; Mancini R, 2003, MOL BIOL CELL, V14, P503, DOI 10.1091/mbc.E02-04-0179; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; MONCADA S, 1988, ANN NY ACAD SCI, V522, P454; MORRIS AJ, 1995, MOL PHARMACOL, V48, P532; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; Patton-Vogt JL, 1998, GENETICS, V149, P1707; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Rotman-Pikielny P, 2002, HUM MOL GENET, V11, P2625, DOI 10.1093/hmg/11.21.2625; Snoek GT, 1999, J BIOL CHEM, V274, P35393, DOI 10.1074/jbc.274.50.35393; Tornquist K, 1996, J CELL PHYSIOL, V166, P241; TORNQUIST K, 1991, MOL CELL ENDOCRINOL, V79, P147, DOI 10.1016/0303-7207(91)90105-2; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100	46	29	29	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2567	+		10.1096/fj.05-5397fje	http://dx.doi.org/10.1096/fj.05-5397fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17060404				2022-12-25	WOS:000242490700026
J	Newell, FS; Su, H; Tornqvist, H; Whitehead, JP; Prins, JB; Hutley, LJ				Newell, Felicity S.; Su, Hua; Tornqvist, Hans; Whitehead, Jonathan P.; Prins, Johannes B.; Hutley, Louise J.			Characterization of the transcriptional and functional effects of fibroblast growth factor-1 on human preadipocyte differentiation	FASEB JOURNAL			English	Article						obesity; adipogenesis; mitosis	HUMAN ADIPOCYTE DIFFERENTIATION; MITOTIC CLONAL EXPANSION; ADIPOSE-TISSUE; HIGH-CAPACITY; C/EBP FAMILY; CELL; ADIPOGENESIS; GAMMA; GATA; ROSIGLITAZONE	We recently established that fibroblast growth factor (FGF)-1 promotes adipogenesis of primary human preadipocytes (phPA). In the current report, we have characterized the adipogenic effects of FGF-1 in phPA and also in a human PA strain derived from an individual with Simpson-Golabi-Behmel syndrome (SGBS PA), which exhibit an intrinsic capacity to differentiate with high efficiency. In further studies, we compared these models with the well-characterized murine 3T3-L1 preadipocyte cell line (3T3-L1 PA). FGF-1 up-regulated the adipogenic program in phPA, with increased expression of peroxisome proliferator-activated receptor-gamma in confluent PA prior to induction of differentiation and increased expression of adipocyte markers during differentiation. Moreover, phPA differentiated in the presence of FGF-1 were more insulin responsive and secreted increased levels of adiponectin. FGF-1 treatment of SGBS PA further enhanced differentiation. For the most part, the adipogenic program in phPA paralleled that observed in 3T3-L1 PA; however, we found no evidence of mitotic clonal expansion in the phPA. Finally, we investigated a role for extracellular regulated kinase 1/2 (ERK 1/2) in adipogenesis of phPA. FGF-1 induced robust phosphorylation of ERK1/2 in early differentiation and inhibition of ERK1/2 activity significantly reduced phPA differentiation. These data suggest that FGF-1 treated phPA represent a valuable in vitro model for the study of adipogenesis and insulin action and indicate that ERK1/2 activation is necessary for human adipogenesis in the absence of mitotic clonal expansion.	Univ Queensland, Princess Alexandra Hosp, Ctr Diabet & Endocrine Res, Brisbane, Qld, Australia; Novo Nordisk AS, Diabet Biol, R&D, Malov, Denmark; Lund Univ, Univ Hosp MAS, Dept Clin Sci Diabet & Endocrinol, Malmo, Sweden	University of Queensland; Novo Nordisk; Lund University; Skane University Hospital	Prins, JB (corresponding author), Princess Alexandra Hosp, Ctr Hlth Res, Level 2,Bldg 35,Ipswich rd, Woolloongabba, Qld 4102, Australia.	jprins@cder.soms.uq.edu.au	Prins, Johannes B/M-5884-2013; Prins, Johannes/I-3610-2019; Newell, Felicity/AAN-1253-2020	Prins, Johannes B/0000-0001-9497-927X; Prins, Johannes/0000-0001-9497-927X; Whitehead, Jonathan/0000-0003-3978-3148				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Aubin D, 2005, INT J OBESITY, V29, P1006, DOI 10.1038/sj.ijo.0802961; Bell A, 2000, OBES RES, V8, P249, DOI 10.1038/oby.2000.29; Bertrand V, 2003, CELL, V115, P615, DOI 10.1016/S0092-8674(03)00928-0; Bost F, 2005, DIABETES, V54, P402, DOI 10.2337/diabetes.54.2.402; Cho YC, 2004, J CELL BIOCHEM, V91, P336, DOI 10.1002/jcb.10743; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Darimont C, 2003, BIOCHIMIE, V85, P1231, DOI 10.1016/j.biochi.2003.10.015; Entenmann G, 1996, AM J PHYSIOL-CELL PH, V270, pC1011, DOI 10.1152/ajpcell.1996.270.4.C1011; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fajas L, 2003, ANN MED, V35, P79, DOI 10.1080/07853890310009999; GREGOIRE F, 1990, BIOL CELL, V69, P215, DOI 10.1016/0248-4900(90)90348-7; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; HARRISON RF, 1991, P INT JOINT C NEURAL, V1, P1; Hauner H, 1998, INT J OBESITY, V22, P448, DOI 10.1038/sj.ijo.0800606; Hidai C, 2003, J MOL CELL CARDIOL, V35, P421, DOI 10.1016/S0022-2828(03)00019-1; Hutley L, 2004, DIABETES, V53, P3097, DOI 10.2337/diabetes.53.12.3097; Hutley LJ, 2003, EUR J CLIN INVEST, V33, P574, DOI 10.1046/j.1365-2362.2003.01178.x; Hutley LJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1037, DOI 10.1152/ajpendo.2001.281.5.E1037; HUTLEY LNF, 2001, ADIPOSE TISSUE PRIMA, P173; Kortum RL, 2005, MOL CELL BIOL, V25, P7592, DOI 10.1128/MCB.25.17.7592-7604.2005; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Neubauer M, 2004, FEBS LETT, V577, P277, DOI 10.1016/j.febslet.2004.10.020; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Patel NG, 2003, DIABETES, V52, P43, DOI 10.2337/diabetes.52.1.43; Perera RJ, 2006, GENE, V369, P90, DOI 10.1016/j.gene.2005.10.021; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; Tong Q, 2005, MOL CELL BIOL, V25, P706, DOI 10.1128/MCB.25.2.706-715.2005; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Wabitsch M, 2000, INT J CANCER, V88, P889, DOI 10.1002/1097-0215(20001215)88:6<889::AID-IJC8>3.0.CO;2-N; Wabitsch M, 2001, INT J OBESITY, V25, P8, DOI 10.1038/sj.ijo.0801520; Wolf G, 2003, NUTR REV, V61, P290, DOI 10.1301/nr.2003.aug.290-292; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	41	66	69	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2615	+		10.1096/fj.05-5710fje	http://dx.doi.org/10.1096/fj.05-5710fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17068114				2022-12-25	WOS:000242490700042
J	Perrin, D; Ballestar, E; Fraga, MF; Frappart, L; Esteller, M; Guerin, JF; Dante, R				Perrin, D.; Ballestar, E.; Fraga, M. F.; Frappart, L.; Esteller, M.; Guerin, J-F; Dante, R.			Specific hypermethylation of LINE-1 elements during abnormal overgrowth and differentiation of human placenta	ONCOGENE			English	Article						DNA methylation; repetitive elements; human; partial hydatidiform mole (PHM); triploid diandric embryos; 5-methylcytosine antibody	DNA METHYLATION; CPG ISLAND; 5-METHYLCYTOSINE CONTENT; HYPOMETHYLATION; CANCER; EXPRESSION; BRCA1; ASSOCIATION; PHENOTYPE; SEQUENCES	In human post-natal somatic cells, low global levels of DNA methylation have been associated with the hypomethylation of several repetitive elements, a feature that has been proposed to be a surrogate epigenetic marker. These data, mainly derived from the analysis of cancer cells, suggest a potential association between loss of cell-growth control and altered differentiation with hypomethylation of repetitive sequences. Partial hydatidiform moles (PHMs) can be used as an alternative model for investigating this association in a non-tumorigenic context. This gestational disease is characterized by abnormal overgrowth and differentiation of the placenta and spontaneous abortion. Here, we comprehensively analyse the DNA methylation of these trophoblastic tissues in both PHM and normal placenta at global and sequence-specific levels. Analysis of the global 5-methylcytosine content and immunohistochemistry indicate that PHM and normal placenta have identical global levels of DNA methylation. In contrast, bisulfite genomic sequencing shows that, whereas Alu, NBL2 and satellite 2 repetitive elements are equally methylated, LINE-1 sequences are hypermethylated in PHM tissues (similar to 2-fold relative to normal placenta). Interestingly, altered demethylation is also found in triploid diandric embryos that originate from dispermic fertilization of an oocyte, a common event responsible for most PHMs. In conclusion, alterations of DNA methylation do not seem to be randomly distributed in PHM, as several repeated elements remain unaltered, whereas LINE-1 sequences are hypermethylated. In addition, our findings suggest that the hypomethylation of repetitive elements in cancer is directly linked to the neoplasic process and not a simple consequence of loss of growth control observed in most of the cancer cells.	Ctr Leon Berard, INSERM Unite 590, Oncol Mol Lab, F-69373 Lyon 08, France; Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid, Spain; Hop Edouard Herriot, Anat Pathol Lab, Lyon, France; Univ Lyon 1, Lab Biol Reprod & Dev, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centro Nacional de Investigaciones Oncologicas (CNIO); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dante, R (corresponding author), Ctr Leon Berard, INSERM Unite 590, Oncol Mol Lab, 28 Rue Laennec, F-69373 Lyon 08, France.	dante@univ-lyon1.fr	Ballestar, Esteban/ABG-8561-2020; Fraga, Mario F/H-7824-2017; Esteller, Manel/L-5956-2014	Fraga, Mario F/0000-0001-8450-2603; Esteller, Manel/0000-0003-4490-6093; Ballestar, Esteban/0000-0002-1400-2440				[Anonymous], 2003, WHO CLASSIFICATION T; Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137; Chen HZ, 2005, J SOC GYNECOL INVEST, V12, P214, DOI 10.1016/j.jsgi.2005.01.009; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; GAMASOSA MA, 1983, BIOCHIM BIOPHYS ACTA, V740, P212, DOI 10.1016/0167-4781(83)90079-9; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087; Genest DR, 2001, INT J GYNECOL PATHOL, V20, P315, DOI 10.1097/00004347-200110000-00001; Ghabreau L, 2004, VIRCHOWS ARCH, V445, P129, DOI 10.1007/s00428-004-1059-4; HJELLE BL, 1982, NUCLEIC ACIDS RES, V10, P3459, DOI 10.1093/nar/10.11.3459; Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222; JEANPIERRE M, 1994, ANN GENET-PARIS, V37, P163; Judson H, 2002, NATURE, V416, P539, DOI 10.1038/416539a; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Magdinier F, 2002, MOL HUM REPROD, V8, P630, DOI 10.1093/molehr/8.7.630; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Nishiyama R, 2005, MOL CANCER RES, V3, P617, DOI 10.1158/1541-7786.MCR-05-0146; Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006; Tsien F, 2002, CYTOGENET GENOME RES, V98, P13, DOI 10.1159/000068543; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Young LE, 2004, ANIM REPROD SCI, V82-3, P61, DOI 10.1016/j.anireprosci.2004.05.020; Zaragoza MV, 2000, AM J HUM GENET, V66, P1807, DOI 10.1086/302951	32	39	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2518	2524		10.1038/sj.onc.1210039	http://dx.doi.org/10.1038/sj.onc.1210039			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043645				2022-12-25	WOS:000245831000013
J	De Gregorio, G; Coppa, A; Cosentino, C; Ucci, S; Messina, S; Nicolussi, A; D'Inzeo, S; Di Pardo, A; Avvedimento, EV; Porcellini, A				De Gregorio, G.; Coppa, A.; Cosentino, C.; Ucci, S.; Messina, S.; Nicolussi, A.; D'Inzeo, S.; Di Pardo, A.; Avvedimento, E. V.; Porcellini, A.			The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals	ONCOGENE			English	Article						phosphoinositide-3-kinase; signal trasduction; thyropropin receptor; protein kinase A; cAMP	DEPENDENT PROTEIN-KINASE; STIMULATING HORMONE TSH; DNA-SYNTHESIS; RAS; ACTIVATION; PATHWAYS; FIBROBLASTS; RECEPTOR; 3-KINASE; CELLS	Phosphatidylinositol 3-kinase (PI3K) is necessary for thyroid stimulating hormone (TSH)-induced cell cycle progression. To determine the molecular mechanism linking PI3K to TSH, we have identified a serine residue in p85 alpha(PI3K) phosphorylated by protein kinase A (PKA) in vitro and in vivo. Expression of an alanine mutant (p85A) abolished cyclic AMP/TSH- induced cell cycle progression and was lethal in thyroid cells (FRTL-5). The aspartic version of the p85 alpha(PI3K) (p85D) inhibited apoptosis following TSH withdrawal. The p85a PI3K wild type not the p85A bound PKA regulatory subunit RII beta in cells stimulated with cAMP or TSH. The binding of the aspartic version of p85a PI3K to RIIb was independent of cAMP or TSH stimulation. Similarly, binding of PI3K to p21Ras and activation of AKT, a downstream PI3K target, were severely impaired in cells expressing the p85A mutant. Finally, we found that the catalytic activity of PI3K was stimulated by TSH in cells expressing the wildtype p85a PI3K but not in cells expressing p85A. This latter mutant did not affect the epidermal growth factor-stimulated PI3K activity. We suggest that (1) TSH cAMP-induced PKA phosphorylates p85 alpha(PI3K) at serine 83, (2) phosphorylated p85 alpha(PI3K) binds RII beta-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets. This pathway is essential for the transmission of TSH - cAMP growth signals.	Univ Roma La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy; IRCCs Neuromed, Dipartimento Patol Mol, Pozzilli, Italy; Univ Naples Federico II, CNR, Ist Edocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Naples, Italy; Univ Naples Federico II, CNR, Ist Edocrinol & Oncol Sperimentale, Dipartimento Cellulaire, Naples, Italy	Sapienza University Rome; IRCCS Neuromed; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Porcellini, A (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale, Viale Regina Elena, I-00161 Rome, Italy.	avvedim@unina.it; antonio.porcellini@uniroma1.it	Porcellini, Antonio/E-1900-2011; Cosentino, Claudia/AAF-1100-2019; coppa, anna/N-3274-2016; Porcellini, Antonio/AAC-6097-2019; Di Pardo, Alba/AAC-9393-2020	Porcellini, Antonio/0000-0001-6882-9518; Di Pardo, Alba/0000-0002-9514-0086; coppa, anna/0000-0001-9758-5444				Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; COSENTINO C, 2006, IN PRESS ONCOGENE; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Porcellini A, 2003, J BIOL CHEM, V278, P40621, DOI 10.1074/jbc.M307501200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Suh JM, 2003, J BIOL CHEM, V278, P21960, DOI 10.1074/jbc.M300805200; Wang XM, 2005, J BIOL CHEM, V280, P16705, DOI 10.1074/jbc.M501819200	16	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2039	2047		10.1038/sj.onc.1210011	http://dx.doi.org/10.1038/sj.onc.1210011			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043656				2022-12-25	WOS:000245313400006
J	Turner, NC; Reis, JS; Russell, AM; Springall, RJ; Ryder, K; Steele, D; Savage, K; Gillett, CE; Schmitt, FC; Ashworth, A; Tutt, AN				Turner, N. C.; Reis-Filho, J. S.; Russell, A. M.; Springall, R. J.; Ryder, K.; Steele, D.; Savage, K.; Gillett, C. E.; Schmitt, F. C.; Ashworth, A.; Tutt, A. N.			BRCA1 dysfunction in sporadic basal-like breast cancer	ONCOGENE			English	Article						BRCA1; basal-like; breast cancer; ID4; metaplastic	PROMOTER REGION; METHYLATION; EXPRESSION; GENE; PHENOTYPE; HYPERMETHYLATION; CARCINOMAS; SUBTYPE; BARD1; ID4	Basal-like breast cancers forma distinct subtype of breast cancer characterized by the expression of markers expressed in normal basal/myoepithelial cells. Breast cancers arising in carriers of germline BRCA1 mutations are predominately of basal-like type, suggesting that BRCA1 dysfunction may play a role in the pathogenesis of sporadic basal-like cancers. We analysed 37 sporadic breast cancers expressing the basal marker cytokeratin 5/6, and age- and grade-matched controls, for downregulation of BRCA1. Although BRCA1 promoter methylation was no more common in basal-like cancers (basal 14% vs controls 11%, P = 0.72), BRCA1 messenger RNA expression was twofold lower in basal-like breast cancers compared to matched controls (P = 0.008). ID4, a negative regulator of BRCA1, was expressed at 9.1-fold higher levels in basal-like breast cancer (P < 0.0001), suggesting a potential mechanism of BRCA1 downregulation. BRCA1 downregulation correlated with the presence of multiple basal markers, revealing heterogeneity in the basal-like phenotype. Finally, we found that 63% of metaplastic breast cancers, a rare type of basal-like cancers, had BRCA1 methylation, in comparison to 12% of controls (P < 0.0001). The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer.	Breakthrought Breast Canc Res Ctr, Chester Beatty Labs, Inst Canc Res, London SW3 6JB, England; Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4100 Oporto, Portugal; Univ Porto, Fac Med, P-4100 Oporto, Portugal; Breast Pathol Lab, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Universidade do Porto; Universidade do Porto	Tutt, AN (corresponding author), Breakthrought Breast Canc Res Ctr, Chester Beatty Labs, Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.	andrew.tutt@icr.ac.uk	Schmitt, Fernando/A-5270-2008	Schmitt, Fernando/0000-0002-3711-8681; Schmitt, Fernando/0000-0003-1006-6946; Turner, Nicholas/0000-0001-8937-0873; Tutt, Andrew/0000-0001-8715-2901	Cancer Research UK [A8363] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Breast Cancer Now		Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Brody LC, 2005, NEW ENGL J MED, V353, P949, DOI 10.1056/NEJMcibr052331; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gillett CE, 2000, J PATHOL, V192, P549; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUVOS AG, 1973, NEW YORK STATE J MED, V73, P1078; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lambie H, 2003, J PATHOL, V200, P207, DOI 10.1002/path.1348; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Perez-Valles A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reis JS, 2006, HISTOPATHOLOGY, V49, P10, DOI 10.1111/j.1365-2559.2006.02467.x; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Simpson PT, 2004, J PATHOL, V202, P274, DOI 10.1002/path.1530; Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Staff S, 2003, CANCER RES, V63, P4978; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538	35	443	466	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2126	2132		10.1038/sj.onc.1210014	http://dx.doi.org/10.1038/sj.onc.1210014			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016441				2022-12-25	WOS:000245313400014
J	Lee, JY; Visser, F; Lee, JS; Lee, KH; Soh, JW; Ho, WK; Lytton, J; Lee, SH				Lee, Ju-Young; Visser, Frank; Lee, Jae Sung; Lee, Kyu-Hee; Soh, Jae-Won; Ho, Won-Kyung; Lytton, Jonathan; Lee, Suk-Ho			Protein kinase c-dependent enhancement of activity of rat brain NCKX2 heterologously expressed in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; NA+/CA2+ EXCHANGER; MOLECULAR-CLONING; GENE FAMILY; PHOSPHORYLATION SITES; CA2+ CLEARANCE; RECEPTOR; ACTIVATION; MEMBER; IDENTIFICATION	Different members of the Na+/Ca2++K+ exchanger (NCKX) family are present in distinct brain regions, suggesting that they may have cell-specific functions. Many neuronal channels and transporters are regulated via phosphorylation. Regulation of the rat brain NCKXs by protein kinases, however, has not been described. Here, we report an increase in NCKX2 activity in response to protein kinase C (PKC) activation. Outward current of NCKX2 heterologously expressed in HEK293 cells was enhanced by beta-phorbol dibutyrate (PDBu), whereas PDBu had little effect on activity of NCKX3 or NCKX4. The PDBu-induced enhancement ( PIE) of NCKX2 activity was abolished by PKC inhibitors and significantly reduced when the dominant negative mutant of PKC epsilon (K437R) was overexpressed. Moreover, PDBu accelerated the decay rate of the Ca2+ transient at the calyx of Held, where NCKX is the major Ca2+-clearance mechanism. Intracellular perfusion with alkaline phosphatase completely inhibited PIE. Consistently, beta-phorbol myristate acetate (PMA), but not 4 alpha-PMA, induced a 3-fold stimulation of P-32 incorporation into NCKX2 expressed in HEK293 cells. To investigate the sites involved, PIE of wild-type NCKX2 was compared with mutant NCKX2 in which the three putative PKC consensus sites were replaced with alanine, either individually or in combination. Double-site mutation involving Thr-476 (T166A/T476A and T476A/S504A) disrupted PIE, whereas single mutation of Thr-166, Thr-476, or Ser-504 or the double mutant T166A/S504A failed to completely prevent PIE. These findings suggest that PKC-mediated activation of NCKX2 is sensitive to mutation of multiple PKC consensus sites via a mechanism that may involve several phosphorylation events.	Seoul Natl Univ, Coll Med, Dept Physiol, Natl Res Lab Cell Physiol, Seoul 110799, South Korea; Inha Univ, Biomed Res Ctr Signal Transduct Networks, Dept Chem, Inchon 402751, South Korea; Univ Calgary, Libin Cardiovasc Inst Alberta, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	Seoul National University (SNU); Inha University; Libin Cardiovascular Institute Of Alberta; University of Calgary	Lee, SH (corresponding author), Seoul Natl Univ, Coll Med, Dept Physiol, Natl Res Lab Cell Physiol, 28 Yongon Dong, Seoul 110799, South Korea.	leesukho@snu.ac.kr	Ho, Won-Kyung/J-2798-2012; Lee, Kyu-Hee/C-5008-2012; Lee, Suk-Ho/D-6344-2012	Lee, Suk-Ho/0000-0003-4117-5619; Lytton, Jonathan/0000-0003-4770-2512				Beck EJ, 1998, J GEN PHYSIOL, V112, P71, DOI 10.1085/jgp.112.1.71; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Cai XJ, 2002, J BIOL CHEM, V277, P48923, DOI 10.1074/jbc.M208818200; Cai XJ, 2004, J BIOL CHEM, V279, P5867, DOI 10.1074/jbc.M310908200; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; Chung HJ, 2000, J NEUROSCI, V20, P7258; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Feraille E, 2000, MOL BIOL CELL, V11, P39, DOI 10.1091/mbc.11.1.39; Hilge M, 2006, MOL CELL, V22, P15, DOI 10.1016/j.molcel.2006.03.008; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hou YL, 2003, J BIOL CHEM, V278, P16706, DOI 10.1074/jbc.M300045200; Hu KL, 2003, NEURON, V38, P417, DOI 10.1016/S0896-6273(03)00256-3; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Katanosaka Y, 2005, J BIOL CHEM, V280, P5764, DOI 10.1074/jbc.M410240200; Kiedrowski L, 2004, NEUROREPORT, V15, P2113, DOI 10.1097/00001756-200409150-00023; Kiedrowski L, 2002, NEUROREPORT, V13, P1529, DOI 10.1097/00001756-200208270-00008; Kiedrowski L, 2004, J NEUROCHEM, V90, P117, DOI 10.1111/j.1471-4159.2004.02462.x; Kim MH, 2005, J NEUROSCI, V25, P6057, DOI 10.1523/JNEUROSCI.0454-05.2005; Kim MH, 2003, J NEUROSCI, V23, P11673; Kinjo TG, 2003, BIOCHEMISTRY-US, V42, P2485, DOI 10.1021/bi0270788; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kraev A, 2001, J BIOL CHEM, V276, P23161, DOI 10.1074/jbc.M102314200; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; Lee SH, 2002, J NEUROSCI, V22, P6891; Lencesova L, 2004, J BIOL CHEM, V279, P2885, DOI 10.1074/jbc.M310365200; Li XF, 2002, J BIOL CHEM, V277, P48410, DOI 10.1074/jbc.M210011200; Li XF, 2006, J BIOL CHEM, V281, P6273, DOI 10.1074/jbc.M512137200; LI ZP, 1991, J BIOL CHEM, V266, P1014; Lin DH, 2002, J BIOL CHEM, V277, P44278, DOI 10.1074/jbc.M203702200; Lou XL, 2005, NATURE, V435, P497, DOI 10.1038/nature03568; Murbartian J, 2005, J BIOL CHEM, V280, P30175, DOI 10.1074/jbc.M503862200; Qian HW, 1999, BIOCHEM J, V343, P637, DOI 10.1042/0264-6021:3430637; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Saitoh N, 2001, P NATL ACAD SCI USA, V98, P14017, DOI 10.1073/pnas.241333598; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Szerencsei RT, 2001, BIOCHEMISTRY-US, V40, P6009, DOI 10.1021/bi0102353; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	43	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39205	39216		10.1074/jbc.M606287200	http://dx.doi.org/10.1074/jbc.M606287200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17038313	hybrid			2022-12-25	WOS:000242898700028
J	Han, JM; Lee, MJ; Park, SG; Lee, SH; Razin, E; Choi, EC; Kim, S				Han, Jung Min; Lee, Min Ji; Park, Sang Gyu; Lee, Sun Hee; Razin, Ehud; Choi, Eung-Chil; Kim, Sunghoon			Hierarchical network between the components of the multi-tRNA synthetase complex: Implications for complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; EUKARYOTIC MULTISYNTHETASE COMPLEX; MACROMOLECULAR ASSEMBLAGE; STRUCTURAL-ANALYSIS; P43; LOCALIZATION; TRANSLATION; STABILITY; COFACTOR; MOTIF	The macromolecular tRNA synthetase complex consists of nine different enzymes and three non-enzymatic factors. This complex was recently shown to be a novel signalosome, since many of its components are involved in signaling pathways in addition to their catalytic roles in protein synthesis. The structural organization and dynamic relationships of the components of the complex are not well understood. Here we performed a systematic depletion analysis to determine the effects of structural intimacy and the turnover of the components. The results showed that the stability of some components depended on their neighbors. Lysyl-tRNA synthetase was most independent of other components for its stability whereas it was most required for the stability of other components. Arginyl- and methionyl-tRNA synthetases had the opposite characteristics. Thus, the systematic depletion of the components revealed the functional reason for the complex formation and the assembly pattern of these multi-functional enzymes and their associated factors.	Seoul Natl Univ, Natl Creat Res Initiat Ctr ARS Network, Coll Pharm, Seoul 151741, South Korea; Seoul Natl Univ, Imagene Co Biotechnol Incubating Ctr, Seoul 151741, South Korea; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Seoul National University (SNU); Seoul National University (SNU); Hebrew University of Jerusalem	Kim, S (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr ARS Network, Coll Pharm, Seoul 151741, South Korea.	sungkim@snu.ac.kr	Kim, Sunghoon/AAE-8314-2020	Han, Jung Min/0000-0003-3372-7575				Ahn HC, 2003, FEBS LETT, V542, P119, DOI 10.1016/S0014-5793(03)00362-4; Halwani R, 2004, J VIROL, V78, P7553, DOI 10.1128/JVI.78.14.7553-7564.2004; Kim JY, 2002, P NATL ACAD SCI USA, V99, P7912, DOI 10.1073/pnas.122110199; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; Kim T, 2000, J BIOL CHEM, V275, P21768, DOI 10.1074/jbc.M002404200; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; Ko YG, 2001, J BIOL CHEM, V276, P23028, DOI 10.1074/jbc.M101544200; Ko YG, 2001, J BIOL CHEM, V276, P6030, DOI 10.1074/jbc.M006189200; Ko YG, 2000, J CELL BIOL, V149, P567, DOI 10.1083/jcb.149.3.567; Lee SW, 2004, J CELL SCI, V117, P3725, DOI 10.1242/jcs.01342; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Norcum MT, 1999, J BIOL CHEM, V274, P12205, DOI 10.1074/jbc.274.18.12205; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; NORCUM MT, 1991, J BIOL CHEM, V266, P15398; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Park BJ, 2005, CELL, V120, P209, DOI 10.1016/j.cell.2004.11.054; Park BJ, 2006, CANCER RES, V66, P6913, DOI 10.1158/0008-5472.CAN-05-3740; Park SG, 2006, P NATL ACAD SCI USA, V103, P14913, DOI 10.1073/pnas.0602045103; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; Park SG, 2005, P NATL ACAD SCI USA, V102, P6356, DOI 10.1073/pnas.0500226102; Park SG, 2005, AM J PATHOL, V166, P387, DOI 10.1016/S0002-9440(10)62262-6; Park SG, 2002, J BIOL CHEM, V277, P45243, DOI 10.1074/jbc.M207934200; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; Sampath P, 2004, CELL, V119, P195, DOI 10.1016/j.cell.2004.09.030; VELLEKAMP G, 1985, J BIOL CHEM, V260, P9843	29	62	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38663	38667		10.1074/jbc.M605211200	http://dx.doi.org/10.1074/jbc.M605211200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17062567	hybrid			2022-12-25	WOS:000242709500062
J	Dragoni, I; Guida, E; McIntyre, P				Dragoni, Ilaria; Guida, Elizabeth; McIntyre, Peter			The cold and menthol receptor TRPM8 contains a functionally important double cysteine motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN RECEPTOR; CHANNEL; RESIDUES; REVEALS; IDENTIFICATION; TRAFFICKING; ACTIVATION; EXPRESSION; PROTEIN; ICILIN	We have investigated the glycosylation, disulfide bonding, and subunit structure of mouse TRPM8. To do this, amino-terminal c-myc or hemagglutinin epitope-tagged proteins were incorporated and expressed in Chinese hamster ovary cells. These modifications had no obvious effects on channel function in intracellular calcium imaging assays upon application of agonists, icilin or menthol, and cold temperatures. Unmodified TRPM8 migrates with an apparent mass of 129 kDa and can be glycosylated in Chinese hamster ovary cells to give glycoproteins with apparent masses of 136 and 147 kDa. We identified two potential N-linked glycosylation sites in TRPM8 (Asn-821 and Asn-934) and mutated them to show that only the site in the putative pore region at position 934 is modified and that glycosylation of this site is not absolutely necessary for cell surface expression or responsiveness to icilin, menthol, and cool temperatures. Enzymatic cleavage of the carbohydrate chains indicated that they are complex carbohydrate. The glycosylation site is flanked in the pore by two cysteine residues that we mutated, to prove that they are involved in a conserved double cysteine motif, which is essential for channel function. Mutation of either of these cysteines abolishes function and forces the formation of a non-functional complex of the size of a homodimer. The double cysteine mutant is also non-functional. Finally, we showed in Perfluoro-octanoic acid-polyacrylamide gels that TRPM8 can form a tetramer (in addition to dimer and trimer forms), consistent with current thinking that functional TRP ion channels are tetrameric.	Univ Melbourne, Dept Pharmacol, Carlton, Vic 3010, Australia; Novartis Inst Biomed Res, London WC1E 6BS, England	University of Melbourne; Novartis; University of London; University College London	McIntyre, P (corresponding author), Univ Melbourne, Dept Pharmacol, Grattan St, Carlton, Vic 3010, Australia.	pmci@unimelb.edu.au	Mcintyre, Peter/N-4109-2013	McIntyre, Peter/0000-0001-9506-5998				Andersson DA, 2004, J NEUROSCI, V24, P5364, DOI 10.1523/JNEUROSCI.0890-04.2004; Bandell M, 2006, NAT NEUROSCI, V9, P493, DOI 10.1038/nn1665; Brauchi S, 2004, P NATL ACAD SCI USA, V101, P15494, DOI 10.1073/pnas.0406773101; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cho HC, 2000, BIOCHEMISTRY-US, V39, P4649, DOI 10.1021/bi992469g; Chuang HH, 2004, NEURON, V43, P859, DOI 10.1016/j.neuron.2004.08.038; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Dietrich A, 2003, J BIOL CHEM, V278, P47842, DOI 10.1074/jbc.M302983200; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Funayama M, 1996, MOL BRAIN RES, V43, P259, DOI 10.1016/S0169-328X(96)00208-2; Green WN, 1997, J BIOL CHEM, V272, P20945, DOI 10.1074/jbc.272.33.20945; Jahnel R, 2003, EUR J BIOCHEM, V270, P4264, DOI 10.1046/j.1432-1033.2003.03811.x; Jahnel R, 2001, EUR J BIOCHEM, V268, P5489, DOI 10.1046/j.1432-1033.2001.02500.x; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jin YJ, 2004, NEUROSCI LETT, V369, P250, DOI 10.1016/j.neulet.2004.07.059; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kuzhikandathil EV, 2001, J NEUROSCI, V21, P8697, DOI 10.1523/JNEUROSCI.21-22-08697.2001; Lew MJ, 2006, TRENDS PHARMACOL SCI, V27, P274, DOI 10.1016/j.tips.2006.03.006; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Mei ZZ, 2006, AM J PHYSIOL-CELL PH, V291, pC1022, DOI 10.1152/ajpcell.00606.2005; MONTELL C, 2001, SCI STKE 2001; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Phillips E, 2004, J BIOL CHEM, V279, P17165, DOI 10.1074/jbc.M313328200; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Rosenbaum T, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-4; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Voets T, 2004, NATURE, V430, P748, DOI 10.1038/nature02732; Vyklicky L, 2002, NEUROSCIENCE, V111, P435, DOI 10.1016/S0306-4522(02)00051-9; Wanamaker CP, 2003, ANN NY ACAD SCI, V998, P66, DOI 10.1196/annals.1254.009	33	50	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37353	37360		10.1074/jbc.M607227200	http://dx.doi.org/10.1074/jbc.M607227200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17015441	hybrid			2022-12-25	WOS:000242477100012
J	Holmes, W; Jogl, G				Holmes, William; Jogl, Gerwald			Crystal structure of inositol phosphate multikinase 2 and implications for substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHATE MULTIKINASE; HEXAKISPHOSPHATE KINASE-2; HUMAN HOMOLOG; PROTEIN; 1,4,5-TRISPHOSPHATE; ARGRIII; BINDING; INSP(8); STRESS; SUITE	Inositol polyphosphates perform essential functions as second messengers in eukaryotic cells, and their cellular levels are regulated by inositol phosphate kinases. Most of these enzymes belong to the inositol phosphate kinase superfamily, which consists of three subgroups, inositol 3-kinases, inositol phosphate multikinases, and inositol hexakisphosphate kinases. Family members share several strictly conserved signature motifs and are expected to have the same backbone fold, despite very limited overall amino acid sequence identity. Sequence differences are expected to play important roles in defining the different substrate selectivity of these enzymes. To investigate the structural basis for sub strate specificity, we have determined the crystal structure of the yeast inositol phosphate multikinase Ipk2 in the apoform and in a complex with ADP and Mn2+ at up to 2.0 angstrom resolution. The overall structure of Ipk2 is related to inositol trisphosphate 3-kinase. The ATP binding site is similar in both enzymes; however, the inositol binding domain is significantly smaller in Ipk2. Replacement of critical side chains in the inositol-binding site suggests how modification of substrate recognition motifs determines enzymatic substrate preference and catalysis.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	Brown University	Jogl, G (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Box G-E129, Providence, RI 02912 USA.	Gerwald_Jogl@brown.edu	Jogl, Gerwald/AAJ-5783-2021	Jogl, Gerwald/0000-0002-5465-5315				Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASHFORD D, 1992, J MOL BIOL, V224, P473, DOI 10.1016/0022-2836(92)91009-E; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang SC, 2006, BIOCHEM BIOPH RES CO, V339, P209, DOI 10.1016/j.bbrc.2005.10.201; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; Choi K, 2005, CELL SIGNAL, V17, P1533, DOI 10.1016/j.cellsig.2005.03.021; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; El Bakkoury M, 2000, MOL MICROBIOL, V35, P15, DOI 10.1046/j.1365-2958.2000.01665.x; Frederick JP, 2005, P NATL ACAD SCI USA, V102, P8454, DOI 10.1073/pnas.0503706102; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; MESSENGUY F, 1991, MOL CELL BIOL, V11, P2852, DOI 10.1128/MCB.11.5.2852; Miller GJ, 2005, MOL CELL, V18, P201, DOI 10.1016/j.molcel.2005.03.016; Miller GJ, 2004, MOL CELL, V15, P703, DOI 10.1016/j.molcel.2004.08.005; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pesesse X, 2004, J BIOL CHEM, V279, P43378, DOI 10.1074/jbc.C400286200; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Resnick AC, 2005, P NATL ACAD SCI USA, V102, P12783, DOI 10.1073/pnas.0506184102; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Stevenson-Paulik J, 2002, J BIOL CHEM, V277, P42711, DOI 10.1074/jbc.M209112200; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Zhang T, 2001, FEBS LETT, V494, P208, DOI 10.1016/S0014-5793(01)02351-1	47	36	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38109	38116		10.1074/jbc.M606883200	http://dx.doi.org/10.1074/jbc.M606883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17050532	hybrid			2022-12-25	WOS:000242477100089
J	Kraunus, J; Zychlinski, D; Heise, T; Galla, M; Bohne, J; Baum, C				Kraunus, Janine; Zychlinski, Daniela; Heise, Tilman; Galla, Melanie; Bohne, Jens; Baum, Christopher			Murine leukemia virus regulates alternative splicing through sequences upstream of the 5 ' splice site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; LONG TERMINAL REPEAT; ROUS-SARCOMA-VIRUS; POLYPYRIMIDINE TRACT; SECONDARY STRUCTURE; RETROVIRAL VECTORS; GENE-EXPRESSION; REPLICATION; STEM; ELEMENT	Alternative splicing of the primary transcript plays a key role in retroviral gene expression. In contrast to all known mechanisms that mediate alternative splicing in retroviruses, we found that in murine leukemia virus, distinct elements located upstream of the 5' splice site either inhibited or activated splicing of the genomic RNA. Detailed analysis of the first untranslated exon showed that the primer binding site (PBS) activates splicing, whereas flanking sequences either downstream or upstream of the PBS are inhibitory. This new function of the PBS was independent of its orientation and primer binding but associated with a particular destabilizing role in a proposed secondary structure. On the contrary, all sequences surrounding the PBS that are involved in stem formation of the first exon were found to suppress splicing. Targeted mutations that destabilized the central stem and compensatory mutations of the counter strand clearly validated the concept that murine leukemia virus attenuates its 5' splice site by forming an inhibitory stem-loop in its first exon. Importantly, this mode of splice regulation was conserved in a complete proviral clone. Some of the mutants that increase splicing revealed an opposite effect on translation, implying that the first exon also regulates this process. Together, these findings suggest that sequences upstream of the 5' splice site play an important role in splice regulation of simple retroviruses, directly or indirectly attenuating the efficiency of splicing.	Hannover Med Sch, Dept Expt Hematol, D-30625 Hannover, Germany; Heinrich Pette Inst Expt Virol & Immunol, Dept Gen Virol, D-20251 Hamburg, Germany; Univ Hosp Eppendorf, D-20246 Hamburg, Germany; Childrens Hosp, Div Expt Hematol, Cincinnati, OH 45229 USA	Hannover Medical School; Heinrich Pette Institute; University of Hamburg; University Medical Center Hamburg-Eppendorf; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Bohne, J (corresponding author), Hannover Med Sch, Dept Expt Hematol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	bohne.jens@mh-hannover.de; baum.christopher@mh-hannover.de						AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Baraniak AP, 2003, MOL CELL BIOL, V23, P9327, DOI 10.1128/MCB.23.24.9327-9337.2003; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; BOUCK J, 1995, MOL CELL BIOL, V15, P2663; Bratt E, 2003, RNA, V9, P309, DOI 10.1261/rna.2750803; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Buratti E, 2004, MOL CELL BIOL, V24, P10505, DOI 10.1128/MCB.24.24.10505-10514.2004; Cabello-Villegas J, 2004, RNA, V10, P1388, DOI 10.1261/rna.7020804; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Coffin J, 1997, RETROVIRUSES; Cullen BR, 2003, TRENDS BIOCHEM SCI, V28, P419, DOI 10.1016/S0968-0004(03)00142-7; DANI C, 1984, EUR J BIOCHEM, V145, P299, DOI 10.1111/j.1432-1033.1984.tb08552.x; Erlwein O, 2003, J GEN VIROL, V84, P369, DOI 10.1099/vir.0.18761-0; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; Galla M, 2004, MOL CELL, V16, P309, DOI 10.1016/j.molcel.2004.09.023; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hammarskjold ML, 2001, CURR TOP MICROBIOL, V259, P77; Hildinger M, 1999, J VIROL, V73, P4083, DOI 10.1128/JVI.73.5.4083-4089.1999; Hoshi S, 2002, BIOCHEM BIOPH RES CO, V290, P1139, DOI 10.1006/bbrc.2001.6326; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; Kraunus J, 2004, GENE THER, V11, P1568, DOI 10.1038/sj.gt.3302309; LAZO PA, 1987, J VIROL, V61, P2038, DOI 10.1128/JVI.61.6.2038-2041.1987; Lee JT, 2004, GENE THER, V11, P94, DOI 10.1038/sj.gt.3302138; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; Logan AC, 2004, J VIROL, V78, P8421, DOI 10.1128/JVI.78.16.8421-8436.2004; Lund AH, 1997, J VIROL, V71, P1191, DOI 10.1128/JVI.71.2.1191-1195.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; Miller JT, 1997, J VIROL, V71, P7648, DOI 10.1128/JVI.71.10.7648-7656.1997; MOUGEL M, 1993, NUCLEIC ACIDS RES, V21, P4677, DOI 10.1093/nar/21.20.4677; Muh SJ, 2002, J BIOL CHEM, V277, P50143, DOI 10.1074/jbc.M207409200; OREILLY MM, 1995, VIROLOGY, V213, P373, DOI 10.1006/viro.1995.0010; Paca RE, 2001, J VIROL, V75, P7763, DOI 10.1128/JVI.75.16.7763-7768.2001; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; Roberts TM, 2000, J VIROL, V74, P8111, DOI 10.1128/JVI.74.17.8111-8118.2000; Roberts TM, 2003, J VIROL, V77, P11973, DOI 10.1128/JVI.77.22.11973-11984.2003; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; Trubetskoy AM, 1999, J VIROL, V73, P3477, DOI 10.1128/JVI.73.4.3477-3483.1999; Weil D, 2000, RNA, V6, P962, DOI 10.1017/S1355838200000479; Wodrich H, 2001, Results Probl Cell Differ, V34, P197; ZHANG L, 1995, VIROLOGY, V206, P1099, DOI 10.1006/viro.1995.1033; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	44	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37381	37390		10.1074/jbc.M601537200	http://dx.doi.org/10.1074/jbc.M601537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17038324	hybrid			2022-12-25	WOS:000242477100015
J	Zhang, WQ; Swanson, R; Xiong, Y; Richard, B; Olson, ST				Zhang, Weiqing; Swanson, Richard; Xiong, Yan; Richard, Benjamin; Olson, Steven T.			Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors - Evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-THROMBIN-III; FIBROBLAST-GROWTH; ANGIOGENESIS INHIBITOR; CONFORMATIONAL-CHANGE; PROTEINASE REACTIONS; CRYSTAL-STRUCTURE; HIGH-AFFINITY; TUMOR-GROWTH; COMPLEX; FGF	The anticoagulant serpin antithrombin acquires a potent antiangiogenic activity upon undergoing conformational alterations to cleaved or latent forms. Here we show that antithrombin antiangiogenic activity is mediated at least in part through the ability of the conformationally altered serpin to block the proangiogenic growth factors fibroblast growth factor (FGF)-2 and vascular endothelial growth factor (VEGF) from forming signaling competent ternary complexes with their protein receptors and heparan sulfate co-receptors on endothelial cells. Cleaved and latent but not native forms of antithrombin blocked the formation of FGF-2-FGF receptor-1 ectodomain-heparin ternary complexes, and the dimerization of these complexes in solution and similarly inhibited the formation of FGF-2-heparin binary complexes and their dimerization. Only antiangiogenic forms of antithrombin likewise inhibited I-125-FGF-2 binding to its low affinity heparan sulfate co-receptor and blocked FGF receptor-1 autophosphorylation and p42/44 MAP kinase phosphorylation in cultured human umbilical vein endothelial cells (HUVECs). Moreover, treatment of HUVECs with heparinase III to specifically eliminate the FGF-2 heparan sulfate co-receptor suppressed the ability of antiangiogenic antithrombin to inhibit growth factor-stimulated proliferation. Antiangiogenic antithrombin inhibited full-length VEGF(165) stimulation of HUVEC proliferation but did not affect the stimulation of cells by the heparin-binding domain-deleted VEGF(121). Taken together, these results demonstrate that antiangiogenic forms of antithrombin block the proangiogenic effects of FGF-2 and VEGF on endothelial cells by competing with the growth factors for binding the heparan sulfate co-receptor, which mediates growth factor-receptor interactions. Moreover, the inability of native antithrombin to bind this co-receptor implies that native and conformationally altered forms of antithrombin differentially bind proangiogenic heparan sulfate domains.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Zhang, WQ (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Rm 533A,Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.	zhang98@uic.edu		Richard, Benjamin/0000-0003-4531-1905	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R29HL039888, R37HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; AVIEZER D, 1994, J BIOL CHEM, V269, P114; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Chua CC, 2004, CIRC RES, V94, P316, DOI 10.1161/01.RES.0000112965.70691.AC; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kisker O, 2001, CANCER RES, V61, P7298; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; Larsson H, 2000, CANCER RES, V60, P6723; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MARCINIAK E, 1981, BRIT J HAEMATOL, V48, P325, DOI 10.1111/j.1365-2141.1981.tb02718.x; McKeehan WL, 1999, J BIOL CHEM, V274, P21511, DOI 10.1074/jbc.274.31.21511; Miao RQ, 2003, AM J PHYSIOL-CELL PH, V284, pC1604, DOI 10.1152/ajpcell.00524.2002; Miao RQ, 2002, BLOOD, V100, P3245, DOI 10.1182/blood-2002-01-0185; Mohammadi M, 2005, CURR OPIN STRUC BIOL, V15, P506, DOI 10.1016/j.sbi.2005.09.002; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; Natke B, 1999, Angiogenesis, V3, P249, DOI 10.1023/A:1009008824246; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PROX D, 2003, WORLD J SURG, V68, P47; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang WQ, 2006, CANCER RES, V66, P5047, DOI 10.1158/0008-5472.CAN-05-4449; Zhang WQ, 2005, BLOOD, V106, P1621, DOI 10.1182/blood-2005-02-0547; Zhang WQ, 2004, BLOOD, V103, P1185, DOI 10.1182/blood-2003-08-2920; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396	49	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37302	37310		10.1074/jbc.M604905200	http://dx.doi.org/10.1074/jbc.M604905200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17040907	hybrid			2022-12-25	WOS:000242477100007
J	Tormanen, H; Backstrom, E; Carlsson, A; Akusjarvi, G				Tormanen, Heidi; Backstrom, Ellenor; Carlsson, Anette; Akusjarvi, Goran			L4-33K, an adenovirus-encoded alternative RNA splicing factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROTEINS; TERMINATION; REGIONS; LEVEL	Splicing of the adenovirus IIIa mRNA is subjected to a strict temporal regulation during virus infection such that efficient IIIa 3' splice site usage is confined to the late phase of the infectious cycle. Here we show that the adenovirus L4-33K protein functions as a virus-encoded RNA splicing factor that preferentially activates splicing of transcripts with a weak 3' splice site sequence context, a sequence configuration that is shared by many of the late adenovirus 3' splice sites. Furthermore, we show that L4-33K activates IIIa splicing through the IIIa virus infection-dependent splicing enhancer element (3VDE). This element was previously shown to be the minimal element, both necessary and sufficient, for activation of IIIa splicing in the context of an adenovirus-infected cell. L4-33K stimulates an early step in spliceosome assembly and appears to be the only viral protein necessary to convert a nuclear extract prepared from uninfected HeLa cells to an extract with splicing properties very similar to a nuclear extract prepared from adenovirus late-infected cells. Collectively, our results suggest that L4-33K is the key viral protein required to activate the early to late switch in adenovirus major late L1 alternative splicing.	Uppsala Univ, Dept Med Biochem & Microbiol, BMC, S-75123 Uppsala, Sweden	Uppsala University	Akusjarvi, G (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, BMC, Box 582,Husargatan 3, S-75123 Uppsala, Sweden.	goran.akusjarvi@imbim.uu.se						AKUSJARVI G, 1981, NATURE, V292, P420, DOI 10.1038/292420a0; Akusjarvi G, 2003, CURR TOP MICROBIOL, V272, P253; AXELROD N, 1978, VIROLOGY, V87, P366, DOI 10.1016/0042-6822(78)90141-1; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Bourgeois CF, 2004, PROG NUCLEIC ACID RE, V78, P37, DOI 10.1016/S0079-6603(04)78002-2; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; Farley DC, 2004, J VIROL, V78, P1782, DOI 10.1128/JVI.78.4.1782-1791.2004; Fessler SP, 1999, VIROLOGY, V263, P507, DOI 10.1006/viro.1999.9951; Finnen RL, 2001, VIROLOGY, V289, P388, DOI 10.1006/viro.2001.1130; GAMBKE C, 1981, J VIROL, V40, P585, DOI 10.1128/JVI.40.2.585-593.1981; Gustin KE, 1998, J VIROL, V72, P7860, DOI 10.1128/JVI.72.10.7860-7870.1998; IMPERIALE M, 1995, CURR TOP MICROBIOL, P139; IWAMOTO S, 1986, J VIROL, V59, P112, DOI 10.1128/JVI.59.1.112-119.1986; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P2379, DOI 10.1093/nar/19.9.2379; KREIVI JP, 1994, NUCLEIC ACIDS RES, V22, P332, DOI 10.1093/nar/22.3.332; LAMOND AI, 1994, PRACT APPROACH SER, V135, P103; LARSSON S, 1992, J MOL BIOL, V225, P287, DOI 10.1016/0022-2836(92)90922-7; Lutzelberger M, 2005, J BIOL CHEM, V280, P25478, DOI 10.1074/jbc.M413737200; Moore DD, 1995, GLOB MOB SURV; Muhlemann O, 2000, MOL CELL BIOL, V20, P2317, DOI 10.1128/MCB.20.7.2317-2325.2000; MUHLEMANN O, 1995, J VIROL, V69, P7324; MUHLEMANN O, 1999, METH MOLEC MED, V21, P203; NEVINS JR, 1981, NATURE, V290, P113, DOI 10.1038/290113a0; Nilsson CE, 2001, EMBO J, V20, P864, DOI 10.1093/emboj/20.4.864; Ostapchuk P, 2006, J VIROL, V80, P6973, DOI 10.1128/JVI.00123-06; RUSSELL WC, 1977, J GEN VIROL, V34, P19, DOI 10.1099/0022-1317-34-1-19; SHAW AR, 1980, CELL, V22, P905, DOI 10.1016/0092-8674(80)90568-1	30	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36510	36517		10.1074/jbc.M607601200	http://dx.doi.org/10.1074/jbc.M607601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028184	hybrid			2022-12-25	WOS:000242220800006
J	Turmelle, YP; Shikapwashya, O; Tu, S; Hruz, PW; Yan, QY; Rudnick, DA				Turmelle, Yumirle P.; Shikapwashya, Olga; Tu, Shu; Hruz, Paul W.; Yan, Qingyun; Rudnick, David A.			Rosiglitazone inhibits mouse liver regeneration	FASEB JOURNAL			English	Article						partial hepatectomy; mouse model; cell cycle	ACTIVATED RECEPTOR-GAMMA; NECROSIS-FACTOR RECEPTOR; CELL-CYCLE ARREST; PPAR-GAMMA; PARTIAL-HEPATECTOMY; C/EBP-BETA; INTERLEUKIN-6-DEFICIENT MICE; HEPATOCYTE PROLIFERATION; SIGNAL-TRANSDUCTION; RAPID ACTIVATION	The remarkable regenerative potential of the liver is well known. Recent investigations have shown that this regenerative response is impaired in mouse models of fatty liver disease. Other studies demonstrate that mice engineered for liver-specific overexpression of the peroxisome proliferator activated receptor gamma (PPAR gamma) develop significant hepatic steatosis. These observations suggest that precise regulation of hepatic PPAR gamma activity may be essential for normal liver regeneration. To test this hypothesis, we analyzed the effects of PPAR gamma-activating thiazolidinediones on liver regeneration in the rodent partial hepatectomy model. Thiazolidinediones with different PPAR gamma-activating potencies were administered to mice, and those mice were subjected to partial hepatectomy and analyzed for resulting effects on hepatocellular proliferation and signaling pathways important during normal liver regeneration. The results showed that thiazolidinediones suppress liver regeneration with efficacies that correlate with their relative PPAR gamma-activating potencies. These studies provide the first evidence linking regulation of PPAR gamma activity and the hepatic regenerative response.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Rudnick, DA (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Box 8208, St Louis, MO 63110 USA.	rudnick_d@kids.wustl.edu		Hruz, Paul/0000-0002-1478-3355	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068219, K08DK002900, P30DK052574] Funding Source: NIH RePORTER; NICHD NIH HHS [T32-HD07409] Funding Source: Medline; NIDDK NIH HHS [DK068219, P30 DK52574, DK02900] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Bedoucha M, 2001, J HEPATOL, V35, P17, DOI 10.1016/S0168-8278(01)00066-6; BONINI JA, 1995, AM J PHYSIOL-ENDOC M, V269, pE759, DOI 10.1152/ajpendo.1995.269.4.E759; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Campbell JS, 2006, J IMMUNOL, V176, P2522, DOI 10.4049/jimmunol.176.4.2522; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DeAngelis RA, 2005, HEPATOLOGY, V42, P1148, DOI 10.1002/hep.20879; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIEHL AM, 1999, SCHIFFS DIS LIVER, P39; Enomoto N, 2005, ALCOHOL CLIN EXP RES, V29, p216S, DOI 10.1097/01.alc.0000192394.26573.10; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hernandez R, 2004, DIABETOLOGIA, V47, P1615, DOI 10.1007/s00125-004-1503-7; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hupfeld CJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE207, DOI 10.1152/ajpendo.2001.281.2.E207; Im SS, 2005, EXP MOL MED, V37, P101, DOI 10.1038/emm.2005.14; Kitamura S, 2001, INT J CANCER, V94, P335, DOI 10.1002/ijc.1470; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Kohlroser J, 2000, AM J GASTROENTEROL, V95, P272; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Lazar MA, 2005, BIOCHIMIE, V87, P9, DOI 10.1016/j.biochi.2004.10.021; Lebovitz HE, 2002, DIABETES-METAB RES, V18, pS23, DOI 10.1002/dmrr.252; Leclercq IA, 2003, GASTROENTEROLOGY, V124, P1451, DOI 10.1016/S0016-5085(03)00270-1; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; Liang CP, 2001, J BIOL CHEM, V276, P49066, DOI 10.1074/jbc.M107250200; Liao YJ, 2004, J BIOL CHEM, V279, P43107, DOI 10.1074/jbc.M407969200; Marcy TR, 2004, ANN PHARMACOTHER, V38, P1419, DOI 10.1345/aph.1E072; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Motomura W, 2004, INT J CANCER, V108, P41, DOI 10.1002/ijc.11561; Ohata M, 2004, ALCOHOL CLIN EXP RES, V28, p139S, DOI 10.1097/01.ALC.0000134412.38510.F7; Panigrahy D, 2003, EXPERT OPIN INV DRUG, V12, P1925, DOI 10.1517/13543784.12.12.1925; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Rudnick DA, 2005, HEPATOLOGY, V42, P1001, DOI 10.1002/hep.20931; Rudnick DA, 2001, P NATL ACAD SCI USA, V98, P8885, DOI 10.1073/pnas.151217998; Sakamoto T, 1999, HEPATOLOGY, V29, P403, DOI 10.1002/hep.510290244; Selzner M, 2000, HEPATOLOGY, V31, P35, DOI 10.1002/hep.510310108; Shao JY, 2002, CANCER RES, V62, P3282; Shteyer E, 2004, HEPATOLOGY, V40, P1322, DOI 10.1002/hep.20462; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Tolman KG, 2000, INT J CLIN PRACT, P29; Toyota M, 2002, LIFE SCI, V70, P1565, DOI 10.1016/S0024-3205(01)01524-7; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yamauchi H, 2003, EXP TOXICOL PATHOL, V54, P281, DOI 10.1078/0940-2993-00265; Yang SQ, 2001, HEPATOLOGY, V34, P694, DOI 10.1053/jhep.2001.28054; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zingarelli B, 2003, J IMMUNOL, V171, P6827, DOI 10.4049/jimmunol.171.12.6827; Zuo Y, 2006, J BIOL CHEM, V281, P7960, DOI 10.1074/jbc.M510682200	62	36	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2609	+		10.1096/fj.06-6511fje	http://dx.doi.org/10.1096/fj.06-6511fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077279				2022-12-25	WOS:000242490700040
J	Mamidipudi, V; Dhillon, NK; Parman, T; Miller, LD; Lee, KC; Cartwright, CA				Mamidipudi, V.; Dhillon, N. K.; Parman, T.; Miller, L. D.; Lee, K. C.; Cartwright, C. A.			RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints	ONCOGENE			English	Article						RACK1; Src; colon cancer; cell cycle regulation	PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; FAMILY KINASES; SAM68; RNA; PROGRESSION; ACTIVATION; SUBSTRATE; MITOSIS	Previously, we showed that Src tyrosine kinases are activated early in the development of human colon cancer and are suppressed as intestinal cells differentiate. We identified RACK1 as an endogenous substrate, binding partner and inhibitor of Src. Here we show (by over-expressing RACK1, depleting Src or RACK1 and utilizing cell-permeable peptides that perturb RACK1's interaction with Src) that RACK1 regulates growth of colon cells by suppressing Src activity at G(1) and mitotic checkpoints, and consequently delaying cell cycle progression. Activated Src rescues RACK1-inhibited growth of HT-29 cells. Conversely, inhibiting Src abolishes growth promoted by RACK1 depletion in normal cells. Two potential mechanisms whereby RACK1 regulates mitotic exit are identified: suppression of Src-mediated Sam68 phosphorylation and maintenance of the cyclin-dependent kinase (CDK) 1-cyclin B complex in an active state. Our results reveal novel mechanisms of cell cycle control in G1 and mitosis of colon cells. The significance of this work lies in the discovery of a mechanism by which the growth of colon cancer cells can be slowed, by RACK1 suppression of an oncogenic kinase at critical cell cycle checkpoints. Small molecules that mimic RACK1 function may provide a powerful new approach to the treatment of colon cancer.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Sch Med, Dept Med, M211 Alway Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu			NIDDK NIH HHS [DK43743, DK56339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339, R01DK043743, R29DK043743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Cartwright C, 1998, GASTROENTEROLOGY, V114, P1335, DOI 10.1016/S0016-5085(98)70443-3; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Fleury S, 2000, P NATL ACAD SCI USA, V97, P5393, DOI 10.1073/pnas.97.10.5393; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Itoh M, 2002, NUCLEIC ACIDS RES, V30, P5452, DOI 10.1093/nar/gkf673; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mamidipudi V, 2004, FEBS LETT, V567, P321, DOI 10.1016/j.febslet.2004.03.125; Miller LD, 2004, ONCOGENE, V23, P5682, DOI 10.1038/sj.onc.1207735; Moasser MM, 1999, CANCER RES, V59, P6145; PARK J, 1995, MOL CELL BIOL, V15, P2374; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Riley D, 2001, ONCOGENE, V20, P5941, DOI 10.1038/sj.onc.1204826; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010	33	62	64	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2914	2924		10.1038/sj.onc.1210091	http://dx.doi.org/10.1038/sj.onc.1210091			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072338				2022-12-25	WOS:000246210800011
J	Starczynowski, DT; Trautmann, H; Pott, C; Harder, L; Arnold, N; Africa, JA; Leeman, JR; Siebert, R; Gilmore, TD				Starczynowski, D. T.; Trautmann, H.; Pott, C.; Harder, L.; Arnold, N.; Africa, J. A.; Leeman, J. R.; Siebert, R.; Gilmore, T. D.			Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity	ONCOGENE			English	Article						c-Rel; Rel; NF-kB; malignant transformation; lymphoma; human mutation	NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR REL; CHICKEN SPLEEN-CELLS; FACTOR-KAPPA-B; C-REL; HODGKINS LYMPHOMA; ACTIVATION; KINASE; PROLIFERATION; ABERRATIONS	The human c-rel proto-oncogene (REL) encodes a subunit of the nuclear factor-kappaB(NF-kappa B) transcription factor. In this report, we have identified an identical point mutation in two human B-cell lymphomas (follicular (FL) and mediastinal) that changes serine (Ser) 525 (TCA) to proline (Pro) (CCA) within the REL transactivation domain. This mutation was not identified in a similarly sized cohort of healthy individuals. In the mediastinal B-cell lymphoma, the mutation in REL is of germ-line origin. In both tumors, the S525P mutant allele is over-represented. REL-S525P shows enhanced in vitro transforming activity in chicken spleen cells. REL-S525P has a reduced ability to activate the human manganese superoxide dismutase (MnSOD) promoter in A293 cells; however, the MnSOD protein shows increased expression in REL-S525P-transformed chicken spleen cells as compared to wild-type REL-transformed cells. Ser525 is a site for phosphorylation by I kappa B kinase (IKK) in vitro. The S525P mutation reduces IKK alpha- and tumor necrosis factor (TNF)alpha-stimulated transactivation by a GAL4-REL protein. Furthermore, REL-S525P-transformed chicken spleen cells are more resistant to TNF alpha-induced cell death than cells transformed by wild-type REL. These results suggest that the S525P mutation contributes to the development of human B-cell lymphomas by affecting an IKK alpha-regulated transactivation activity of REL.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Kiel, Hosp Schleswig Holstein, Dept Med Hematol & Oncol, Kiel, Germany; Univ Kiel, Hosp Schleswig Holstein, Inst Human Genet, Kiel, Germany; Univ Kiel, Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany	Boston University; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu	Arnold, Norbert/E-3012-2010; Siebert, Reiner/A-8049-2010	Arnold, Norbert/0000-0003-4523-8808; 	NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Fognani C, 2000, ONCOGENE, V19, P2224, DOI 10.1038/sj.onc.1203543; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Harris NL, 1999, ANN ONCOL, V10, P1419, DOI 10.1023/A:1008375931236; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; MITTLEMANN F, 1995, INT SYSTEM HUMAN CYT; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Sanchez-Valdepenas C, 2006, J IMMUNOL, V176, P4666, DOI 10.4049/jimmunol.176.8.4666; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schlegelberger B, 1999, DIAGNOSTIC CYTOGENET, P151, DOI DOI 10.1007/978-3-642-59918-7_9; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7	29	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2685	2694		10.1038/sj.onc.1210089	http://dx.doi.org/10.1038/sj.onc.1210089			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072339				2022-12-25	WOS:000246210600003
J	Tarze, A; Deniaud, A; Le Bras, M; Maillier, E; Molle, D; Larochette, N; Zamzami, N; Jan, G; Kroemer, G; Brenner, C				Tarze, A.; Deniaud, A.; Le Bras, M.; Maillier, E.; Molle, D.; Larochette, N.; Zamzami, N.; Jan, G.; Kroemer, G.; Brenner, C.			GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization	ONCOGENE			English	Article						apoptosis; mitochondria; VDAC; ANT; permeability transition; GAPDH	ADENINE-NUCLEOTIDE TRANSLOCASE; DEPENDENT ANION CHANNEL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TRANSITION PORE; CELL-DEATH; ADENYLATE TRANSLOCATOR; OUTER-MEMBRANE; VIRAL PROTEIN; CYCLOPHILIN-D; CYTOCHROME-C	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pleiotropic enzyme that is overexpressed in apoptosis and in several human chronic pathologies. Here, we report that the protein accumulates in mitochondria during apoptosis, and induces the pro-apoptotic mitochondrial membrane permeabilization, a decisive event of the intrinsic pathway of apoptosis. GAPDH was localized by immunogold labeling and identified by matrix- assisted laser desorption/ionization-time of flight and nano liquid chromatography mass spectroscopy/mass spectroscopy in the mitochondrion of various tissues and origins. In isolated mitochondria, GAPDH can be imported and interact with the voltage-dependent anion channel (VDAC1), but not the adenine nucleotide translocase (ANT). The protein mediates a cyclosporin A-inhibitable permeability transition, characterized by a loss of the inner transmembrane potential, matrix swelling, permeabilization of the inner mitochondrial membrane and the release of two pro-apoptotic proteins, cytochrome and apoptosis-inducing factor (AIF). This novel function of GAPDH might have implications for the understanding of mitochondrial biology, oncogenesis and apoptosis.	Univ Versailles, SQY, CNRS VMR 8159, F-78035 Versailles, France; INRA, UMR, STLO, Rennes, France; IGR, CNRS UMR 8125, Villejuif, France	UDICE-French Research Universities; Universite Paris Saclay; INRAE; UNICANCER; Gustave Roussy	Brenner, C (corresponding author), Univ Versailles, SQY, CNRS VMR 8159, 45 Ave Etat Unis, F-78035 Versailles, France.	cbrenner@genetique.uvsq.fr	Kroemer, Guido/AAY-9859-2020; Deniaud, Aurelien/L-5093-2019; KROEMER, Guido/B-4263-2013; Jan, Gwenael/K-6767-2014; LAROCHETTE, Nathanael/R-4298-2017; Tarze, Agathe/R-4379-2018	KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591; Tarze, Agathe/0000-0001-6101-069X				Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baker MA, 2004, J BIOL CHEM, V279, P4811, DOI 10.1074/jbc.M311020200; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Belzacq AS, 2003, CANCER RES, V63, P541; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Brassard J, 2004, VET MICROBIOL, V102, P87, DOI 10.1016/j.vetmic.2004.05.008; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Chuang DM, 1996, NAT MED, V2, P609, DOI 10.1038/nm0696-609; COLOMBINI M, 1983, J MEMBRANE BIOL, V74, P115, DOI 10.1007/BF01870500; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Cuezva JM, 2004, CARCINOGENESIS, V25, P1157, DOI 10.1093/carcin/bgh113; Fukuhara Y, 2001, NEUROREPORT, V12, P2049, DOI 10.1097/00001756-200107030-00051; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Gong YW, 1996, HEPATOLOGY, V23, P734, DOI 10.1053/jhep.1996.v23.pm0008666326; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Ishida A, 2005, ARCH BIOCHEM BIOPHYS, V435, P134, DOI 10.1016/j.abb.2004.11.022; Ishitani R, 1996, J PHARMACOL EXP THER, V278, P447; Ishitani R, 1998, MOL PHARMACOL, V53, P701, DOI 10.1124/mol.53.4.701; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Korge P, 1999, EUR J BIOCHEM, V265, P273, DOI 10.1046/j.1432-1327.1999.00724.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laschet JJ, 2004, J NEUROSCI, V24, P7614, DOI 10.1523/JNEUROSCI.0868-04.2004; Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205; LEE AC, 1994, J BIOL CHEM, V269, P30974; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; Mazzola JL, 2002, NEUROTOXICOLOGY, V23, P603, DOI 10.1016/S0161-813X(02)00062-1; Muller A, 2000, EMBO J, V19, P5332, DOI 10.1093/emboj/19.20.5332; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Patterson RL, 2005, P NATL ACAD SCI USA, V102, P1357, DOI 10.1073/pnas.0409657102; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; RYZLAK MT, 1988, BIOCHIM BIOPHYS ACTA, V954, P309, DOI 10.1016/0167-4838(88)90086-6; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Shi Y, 2003, BIOCHEM BIOPH RES CO, V303, P475, DOI 10.1016/S0006-291X(03)00359-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; Sirover MA, 1997, J CELL BIOCHEM, V66, P133, DOI 10.1002/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.3.CO;2-V; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tajima H, 1999, NEUROREPORT, V10, P2029, DOI 10.1097/00001756-199907130-00007; THINNES FP, 1994, BIOL CHEM H-S, V375, P315, DOI 10.1515/bchm3.1994.375.5.315; Tisdale EJ, 2004, J BIOL CHEM, V279, P54046, DOI 10.1074/jbc.M409472200; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wu SL, 1999, BBA-MOL CELL RES, V1452, P68, DOI 10.1016/S0167-4889(99)00120-2; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zizi M, 1998, BIOPHYS J, V75, P704, DOI 10.1016/S0006-3495(98)77560-5	62	268	282	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2606	2620		10.1038/sj.onc.1210074	http://dx.doi.org/10.1038/sj.onc.1210074			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072346				2022-12-25	WOS:000245831200008
J	Kreel, NE; Tabita, FR				Kreel, Nathaniel E.; Tabita, F. Robert			Substitutions at methionine 295 of Archaeoglobus fulgidus ribulose-1,5-bisphosphate carboxylase/oxygenase affect oxygen binding and CO2/O-2 specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; PYROCOCCUS-KODAKARAENSIS KOD1; BISPHOSPHATE CARBOXYLASE/OXYGENASE; CRYSTAL-STRUCTURE; HYPERTHERMOPHILIC ARCHAEON; PROTEIN; GENOME; MECHANISM; SUBSTRATE; SEQUENCE	Archaeoglobus fulgidus RbcL2, a form III ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco), exhibits unique properties not found in other well studied form I and II Rubiscos, such as optimal activity from 83 to 93 degrees C and an extremely high k(cat) value (23 s(-1)). More interestingly, this protein is unusual in that exposure or assay in the presence of oxygen and high levels of CO2 resulted in substantial loss (85-90%) of activity compared with assays performed under strictly anaerobic conditions. Kinetic studies indicated that A. fulgidus RbcL2 possesses an unusually high affinity for oxygen (K-i = 5 mu(M)); O-2 is a competitive inhibitor with respect to CO2, yet the high affinity for O-2 presumably accounts for the inability of high levels of CO2 to prevent inhibition. Comparative bioinformatic analyses of available archaeal Rubisco sequences were conducted to provide clues as to why the RbcL2 protein might possess such a high affinity for oxygen. These analyses suggested the potential importance of several unique residues, as did additional analyses within the context of available form I-III Rubisco structures. One residue unique to archaeal proteins (Met-295) was of particular interest because of its proximity to known active-site residues. Recombinant M295D A. fulgidus Rubisco was less sensitive to oxygen compared with the wild-type enzyme. This residue, along with other potential changes in conserved residues of form III Rubiscos, may provide an understanding as to how Rubisco may have evolved to function in the presence of air.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Plant Mol Biol Biotechnol Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.	tabita.1@osu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland WW, 1998, CHEM REV, V98, P549, DOI 10.1021/cr970010r; Dean J.A., 1999, LANGES HDB CHEM; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; ELLIS RJ, 1979, TRENDS BIOCHEM SCI, V4, P241, DOI 10.1016/0968-0004(79)90212-3; Ezaki S, 1999, J BIOL CHEM, V274, P5078, DOI 10.1074/jbc.274.8.5078; Finn MW, 2004, J BACTERIOL, V186, P6360, DOI 10.1128/JB.186.19.6360-6366.2004; Finn MW, 2003, J BACTERIOL, V185, P3049, DOI 10.1128/JB.185.10.3049-3059.2003; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUTTERIDGE S, 1995, PLANT CELL, V7, P809, DOI 10.1105/tpc.7.7.809; HARPEL MR, 1993, ANAL BIOCHEM, V209, P367, DOI 10.1006/abio.1993.1136; HARTMAN FC, 1993, ADV ENZYMOL RELAT AR, V6, P71; Horken KM, 1999, ARCH BIOCHEM BIOPHYS, V361, P183, DOI 10.1006/abbi.1998.0979; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LUNDQVIST T, 1991, J BIOL CHEM, V266, P12604; Maeda N, 1999, J MOL BIOL, V293, P57, DOI 10.1006/jmbi.1999.3145; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; Smith SA, 2003, J MOL BIOL, V331, P557, DOI 10.1016/S0022-2836(03)00786-1; Spreitzer RJ, 1999, PHOTOSYNTH RES, V60, P29, DOI 10.1023/A:1006240202051; TABITA FR, 1978, ANAL BIOCHEM, V84, P462, DOI 10.1016/0003-2697(78)90064-7; TABITA FR, 1974, J BIOL CHEM, V249, P3459; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Watson GMF, 1997, FEMS MICROBIOL LETT, V146, P13, DOI 10.1016/S0378-1097(96)00417-X; Watson GMF, 1999, J BACTERIOL, V181, P1569, DOI 10.1128/JB.181.5.1569-1575.1999; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG KYJ, 1994, PROTEIN SCI, V3, P64	32	26	27	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1341	1351		10.1074/jbc.M609399200	http://dx.doi.org/10.1074/jbc.M609399200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17074752	hybrid			2022-12-25	WOS:000243295200060
J	Bah, A; Garvey, LC; Ge, JP; Di Cera, E				Bah, Alaji; Garvey, Laura C.; Ge, Jingping; Di Cera, Enrico			Rapid kinetics of Na+ binding to thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOVALENT CATION ACTION; YEAST PYRUVATE-KINASE; HUMAN ALPHA-THROMBIN; CRYSTAL-STRUCTURE; MOLECULAR RECOGNITION; POTENT ANTICOAGULANT; MUTANT W215A/E217A; ENZYME CATALYSIS; PROTHROMBIN; SUBSTITUTION	The kinetic mechanism of Na+ binding to thrombin was resolved by stopped-flow measurements of intrinsic fluorescence. Na+ binds to thrombin in a two-step mechanism with a rapid phase occurring within the dead time of the spectrometer (< 0.5 ms) followed by a single-exponential slow phase whose k(obs) decreases hyperbolically with increasing [Na+]. The rapid phase is due to Na+ binding to the enzyme E to generate the E: Na+ form. The slow phase is due to the interconversion between E* and E, where E* is a form that cannot bind Na+. Temperature studies in the range from 5 to 35 C show significant enthalpy, entropy, and heat capacity changes associated with both Na+ binding and the E to E* transition. As a result, under conditions of physiologic temperature and salt concentrations, the E* form is negligibly populated (< 1%) and thrombin is almost equally partitioned between the E (40%) and E: Na+ (60%) forms. Single-site Phe mutations of all nine Trp residues of thrombin enabled assignment of the fluorescence changes induced by Na+ binding mainly to Trp-141 and Trp-215, and to a lesser extent to Trp-148, Trp-207, and Trp-237. However, the fast phase of fluorescence increase is influenced to different extents by all Trp residues. The distribution of these residues over the entire thrombin surface demonstrates that Na+ binding induces long-range effects on the structure of the enzyme as a whole, contrary to the conclusions drawn from recent structural studies. These findings elucidate the mechanism of Na+ binding to thrombin and are relevant to other clotting factors and enzymes allosterically activated by monovalent cations.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	enrico@wustl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413, R01HL073813] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58141, HL49413, HL73813] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; Bell R, 2000, J BIOL CHEM, V275, P29513, DOI 10.1074/jbc.M001759200; Bode W, 2006, BLOOD CELL MOL DIS, V36, P122, DOI 10.1016/j.bcmd.2005.12.027; BODE W, 1992, PROTEIN SCI, V1, P426; BOTTS J, 1953, T FARADAY SOC, V49, P696, DOI 10.1039/tf9534900696; Bush LA, 2006, J BIOL CHEM, V281, P7183, DOI 10.1074/jbc.M512082200; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; Carrell CJ, 2006, BIOPHYS CHEM, V121, P177, DOI 10.1016/j.bpc.2005.12.008; Carter WJ, 2004, J BIOL CHEM, V279, P26387, DOI 10.1074/jbc.M402364200; DANG QD, 1994, J PROTEIN CHEM, V13, P367, DOI 10.1007/BF01901692; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Davie EW, 2006, SEMIN THROMB HEMOST, V32, P3, DOI 10.1055/s-2006-939550; De Filippis V, 2005, BIOCHEM J, V390, P485, DOI 10.1042/BJ20050252; DEGEN SJF, 1995, THROMB HAEMOSTASIS, V73, P203; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Digits JA, 1999, BIOCHEMISTRY-US, V38, P2295, DOI 10.1021/bi982305k; EVANS HJ, 1966, ANN REV PLANT PHYSIO, V17, P47, DOI 10.1146/annurev.pp.17.060166.000403; Fuhrmann CN, 2006, J AM CHEM SOC, V128, P9086, DOI 10.1021/ja057721o; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; Henriksen RA, 1998, BLOOD, V91, P2026, DOI 10.1182/blood.V91.6.2026.2026_2026_2031; Johnson DJD, 2005, BIOCHEM J, V392, P21, DOI 10.1042/BJ20051217; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; Mengwasser KE, 2005, J BIOL CHEM, V280, P26997, DOI 10.1074/jbc.M502678200; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6803, DOI 10.1021/bi962870s; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6792, DOI 10.1021/bi962869t; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NEVILLE MC, 1967, ARCH BIOCHEM BIOPHYS, V118, P596, DOI 10.1016/0003-9861(67)90395-5; Nogami K, 2005, J BIOL CHEM, V280, P18476, DOI 10.1074/jbc.M412778200; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; ORTHNER CL, 1980, ARCH BIOCHEM BIOPHYS, V202, P63, DOI 10.1016/0003-9861(80)90406-3; Page MJ, 2006, THROMB HAEMOSTASIS, V95, P920, DOI 10.1160/TH06-05-0239; Page MJ, 2006, PHYSIOL REV, V86, P1049, DOI 10.1152/physrev.00008.2006; Papaconstantinou ME, 2005, J BIOL CHEM, V280, P29393, DOI 10.1074/jbc.C500248200; Pineda AO, 2006, J BIOL CHEM, V281, P32922, DOI 10.1074/jbc.M605530200; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Rouy S, 2006, BRIT J HAEMATOL, V132, P770, DOI 10.1111/j.1365-2141.2005.05920.x; Stanchev H, 2006, THROMB HAEMOSTASIS, V95, P195; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7131, DOI 10.1021/bi982919p; Woehl E, 1999, BIOCHEMISTRY-US, V38, P7118, DOI 10.1021/bi982918x; Xu J, 2004, BIOCHEM CELL BIOL, V82, P275, DOI 10.1139/o04-004; Yun TH, 2003, J BIOL CHEM, V278, P48112, DOI 10.1074/jbc.M306925200	62	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40049	40056		10.1074/jbc.M608600200	http://dx.doi.org/10.1074/jbc.M608600200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074754	hybrid			2022-12-25	WOS:000243033900034
J	Henderson, MJ; Munoz, MA; Saunders, DN; Clancy, JL; Russell, AJ; Williams, B; Pappin, D; Khanna, KK; Jackson, SP; Sutherland, RL; Watts, CKW				Henderson, Michelle J.; Munoz, Marcia A.; Saunders, Darren N.; Clancy, Jennifer L.; Russell, Amanda J.; Williams, Brandi; Pappin, Darryl; Khanna, Kum Kum; Jackson, Stephen P.; Sutherland, Robert L.; Watts, Colin K. W.			EDD mediates DNA damage-induced activation of CHK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; II-BINDING-PROTEIN; CELL-CYCLE; FHA DOMAIN; PHOSPHORYLATION EVENTS; CHECKPOINT PATHWAY; STRUCTURAL BASIS; BREAST-CANCER; BRCT DOMAIN; KINASE	EDD, the human orthologue of Drosophila melanogaster "hyperplastic discs," is overexpressed or mutated in a number of common human cancers. Although EDD has been implicated in DNA damage signaling, a definitive role has yet to be demonstrated. Here we report a novel interaction between EDD and the DNA damage checkpoint kinase CHK2. EDD and CHK2 associate through a phospho-dependent interaction involving the CHK2 Forkhead-associated domain and a region of EDD spanning a number of putative Forkhead-associated domain-binding threonines. Using RNA interference, we demonstrate a critical role for EDD upstream of CHK2 in the DNA damage signaling pathway. EDD is necessary for the efficient activating phosphorylation of CHK2 in response to DNA damage following exposure to ionizing radiation or the radiomimetic, phleomycin. Cells depleted of EDD display impaired CHK2 kinase activity and an inability to respond to DNA damage. These results identify EDD as a novel mediator in DNA damage signal transduction via CHK2 and emphasize the potential importance of EDD in cancer.	Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; Univ Cambridge, Gurdon Inst, Cambridge, England; Univ Cambridge, Dept Zool, Cambridge, England; Queensland Inst Med Res, Herston, Qld 4029, Australia; Appl Biosyst Inc, Adv Res & Technol Grp, Framingham, MA 01701 USA	Garvan Institute of Medical Research; University of Cambridge; University of Cambridge; QIMR Berghofer Medical Research Institute; Thermo Fisher Scientific; Applied Biosystems	Henderson, MJ (corresponding author), Childrens Canc Inst Australia, Expt Therapeut Program, POB 81,High St, Randwick, NSW 2031, Australia.	mhenderson@ccia.unsw.edu.au; r.sutherland@garvan.org.au	Sutherland, Robert L/A-8378-2008; Jackson, Stephen Philip/R-4548-2019; Khanna, Kum Kum/I-1747-2013; Saunders, Darren/B-7677-2008; henderson, Michelle/G-6657-2012; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Khanna, Kum Kum/0000-0001-8650-5381; Pappin, Darryl/0000-0002-8981-8401; Saunders, Darren/0000-0003-0924-0513; Munoz, Marcia/0000-0001-7603-0351				Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, SCIENCE, V294, P66, DOI 10.1126/science.1066237; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Byeon IJL, 2005, NAT STRUCT MOL BIOL, V12, P987, DOI 10.1038/nsmb1008; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Chehab NH, 2000, GENE DEV, V14, P278; Clancy JL, 2003, ONCOGENE, V22, P5070, DOI 10.1038/sj.onc.1206775; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Durocher D, 2000, COLD SPRING HARB SYM, V65, P423, DOI 10.1101/sqb.2000.65.423; Eblen ST, 2003, J BIOL CHEM, V278, P14926, DOI 10.1074/jbc.M300485200; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Ingvarsson S, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr435; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JH, 2003, MOL CANCER RES, V1, P674; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SB, 2001, CANCER RES, V61, P8062; Li HY, 2004, J MOL BIOL, V335, P371, DOI 10.1016/j.jmb.2003.10.032; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Lin WC, 2001, GENE DEV, V15, P1833; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mori Y, 2002, CANCER RES, V62, P3641; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Sarcevic B, 2002, EMBO J, V21, P2009, DOI 10.1093/emboj/21.8.2009; Saunders DN, 2004, MOL CELL BIOL, V24, P7225, DOI 10.1128/MCB.24.16.7225-7234.2004; Shieh SY, 2000, GENE DEV, V14, P289; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Williams RS, 2005, BIOCHEM CELL BIOL, V83, P721, DOI 10.1139/O05-153; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yamane K, 2003, CANCER RES, V63, P3049; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	73	49	50	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39990	40000		10.1074/jbc.M602818200	http://dx.doi.org/10.1074/jbc.M602818200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17074762	hybrid			2022-12-25	WOS:000243033900027
J	Pisareva, VP; Pisarev, AV; Hellen, CUT; Rodnina, MV; Pestova, TV				Pisareva, Vera P.; Pisarev, Andrey V.; Hellen, Christopher U. T.; Rodnina, Marina V.; Pestova, Tatyana V.			Kinetic analysis of interaction of eukaryotic release factor 3 with guanine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; INTERNAL RIBOSOMAL ENTRY; ELONGATION-FACTOR TU; TRANSLATION TERMINATION; ESCHERICHIA-COLI; TRANSFER-RNA; GTP-BINDING; FACTOR ERF3; CRYSTAL-STRUCTURE; EXCHANGE FACTOR	Eukaryotic translation termination is mediated by two release factors: eRF1 recognizes stop codons and triggers peptidyl-tRNA hydrolysis, whereas eRF3 accelerates this process in a GTP-dependent manner. Here we report kinetic analysis of guanine nucleotide binding to eRF3 performed by fluorescence stopped-flow technique using GTP/GDP derivatives carrying the fluorescent methylanthraniloyl (mant-) group, as well as thermodynamic analysis of eRF3 binding to unlabeled guanine nucleotides. Whereas the kinetics of eRF3 binding to mant-GDP is consistent with a one-step binding model, the double-exponential transients of eRF3 binding to mant-GTP indicate a two-step binding mechanism, in which the initial eRF3.mant-GTP complex undergoes subsequent conformational change. The affinity of eRF3 for GTP (K-d, similar to 70 mu M) is about 70-fold lower than for GDP (K-d, similar to 1 mu M) and both nucleotides dissociate rapidly from eRF3 (k(-1)(mant-GDP)similar to 2.4 s(-1); k(-2)(mant-GTP) similar to 3.3 s(-1)). Whereas not influencing eRF3 binding to GDP, association of eRF3 with eRF1 at physiological Mg2+ concentrations specifically changes the kinetics of eRF3/mant-GTP interaction and stabilizes eRF3.GTP binding by two orders of magnitude (K-d similar to 0.7 mu M) due to lowering of the dissociation rate constant similar to 24-fold (k(-1)(mant-GTP)similar to 0.14 s(-1)). Thus, eRF1 acts as a GTP dissociation inhibitor (TDI) for eRF3, promoting efficient ribosomal recruitment of its GTP-bound form. 80 S ribosomes did not influence guanine nucleotide binding/exchange on the eRF1.eRF3 complex. Guanine nucleotide binding and exchange on eRF3, which therefore depends on stimulation by eRF1, is entirely different from that on prokaryotic RF3 and unusual among GTPases.	Suny Downstate Med Ctr, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; Univ Witten Herdecke, Inst Phys Biochem, D-58448 Witten, Germany; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Witten Herdecke University; Lomonosov Moscow State University	Pestova, TV (corresponding author), Suny Downstate Med Ctr, Dept Microbiol & Immunol, 450 Clarkson Ave,Box 44, Brooklyn, NY 11203 USA.	tatyana.pestova@downstate.edu	Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879	NIGMS NIH HHS [R01 GM63940] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063940] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkalaeva EZ, 2006, CELL, V125, P1125, DOI 10.1016/j.cell.2006.04.035; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; BERGER W, 1994, BIOCHEMISTRY-US, V33, P11875, DOI 10.1021/bi00205a025; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Egea PF, 2004, NATURE, V427, P215, DOI 10.1038/nature02250; FERSHT A, 1999, STRUCTURE MECH PROTE, P151; Focia PJ, 2004, SCIENCE, V303, P373, DOI 10.1126/science.1090827; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Frolova L, 2002, RNA, V8, P129, DOI 10.1017/S1355838202013262; Frolova L, 1996, RNA, V2, P334; Frolova LY, 1999, RNA, V5, P1014, DOI 10.1017/S135583829999043X; Frolova LY, 2000, RNA, V6, P381, DOI 10.1017/S135583820099143X; Frolova LY, 1998, EUR J BIOCHEM, V256, P36, DOI 10.1046/j.1432-1327.1998.2560036.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gromadski KB, 2002, BIOCHEMISTRY-US, V41, P162, DOI 10.1021/bi015712w; Hauryliuk V, 2006, BIOCHIMIE, V88, P747, DOI 10.1016/j.biochi.2006.06.001; Hemsath L, 2005, METHODS, V37, P173, DOI 10.1016/j.ymeth.2005.05.014; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Inagaki Y, 2000, MOL BIOL EVOL, V17, P882, DOI 10.1093/oxfordjournals.molbev.a026368; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; Jagath JR, 1998, BIOCHEMISTRY-US, V37, P15408, DOI 10.1021/bi981523a; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Kobayashi T, 2004, J BIOL CHEM, V279, P45693, DOI 10.1074/jbc.M405163200; Kong CG, 2004, MOL CELL, V14, P233, DOI 10.1016/S1097-2765(04)00206-0; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; MILMAN G, 1969, P NATL ACAD SCI USA, V63, P183, DOI 10.1073/pnas.63.1.183; Moser C, 1997, P NATL ACAD SCI USA, V94, P11339, DOI 10.1073/pnas.94.21.11339; Nakamura Y, 2003, TRENDS BIOCHEM SCI, V28, P99, DOI 10.1016/S0968-0004(03)00006-9; Nakamura Y, 1996, CELL, V87, P147, DOI 10.1016/S0092-8674(00)81331-8; Peluso P, 2001, BIOCHEMISTRY-US, V40, P15224, DOI 10.1021/bi011639y; Pestova TV, 2003, GENE DEV, V17, P181, DOI 10.1101/gad.1040803; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Petry S, 2005, CELL, V123, P1255, DOI 10.1016/j.cell.2005.09.039; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; Salas-Marco J, 2004, MOL CELL BIOL, V24, P7769, DOI 10.1128/MCB.24.17.7769-7778.2004; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Shan SO, 2004, PLOS BIOL, V2, P1572, DOI 10.1371/journal.pbio.0020320; Song HW, 1999, J MOL BIOL, V285, P1245, DOI 10.1006/jmbi.1998.2387; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Wilden B, 2006, P NATL ACAD SCI USA, V103, P13670, DOI 10.1073/pnas.0606099103; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	54	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					40224	40235		10.1074/jbc.M607461200	http://dx.doi.org/10.1074/jbc.M607461200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17062564	hybrid, Green Published			2022-12-25	WOS:000243033900053
J	Javelle, A; Lupo, D; Zheng, L; Li, XD; Winkler, FK; Merrick, M				Javelle, Arnaud; Lupo, Domenico; Zheng, Lei; Li, Xiao-Dan; Winkler, Fritz K.; Merrick, Mike			An unusual twin-His arrangement in the pore of ammonia channels is essential for substrate conductance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TRANSPORTER AMTB; PROTEINS; MECHANISM; GLYCOPROTEIN; AMT/MEP/RH; FAMILY; GENES; FUNGI	Amt proteins constitute a class of ubiquitous integral membrane proteins that mediate movement of ammonium across cell membranes. They are homotrimers, in which each subunit contains a narrow pore through which substrate transport occurs. Two conserved histidine residues in the pore have been proposed to be necessary for ammonia conductance. By analyzing 14 engineered polar and non-polar variants of these histidines, in Escherichia coli AmtB, we show that both histidines are absolutely required for optimum substrate conductance. Crystal structures of variants confirm that substitution of the histidine residues does not affect AmtB structure. In a subgroup of Amt proteins, found only in fungi, one of the histidines is replaced by glutamate. The equivalent substitution in E. coli AmtB is partially active, and the structure of this variant suggests that the glutamate side chain can make similar interactions to those made by histidine.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Merrick, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Colney Lane, Norwich NR4 7UH, Norfolk, England.	mike.merrick@bbsrc.ac.uk		li, xiaodan/0000-0001-8647-7317				Andrade SLA, 2005, P NATL ACAD SCI USA, V102, P14994, DOI 10.1073/pnas.0506254102; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biswas K, 2005, MOL MICROBIOL, V56, P649, DOI 10.1111/j.1365-2958.2005.04576.x; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; Conroy MJ, 2005, BRIT J HAEMATOL, V131, P543, DOI 10.1111/j.1365-2141.2005.05786.x; Conroy MJ, 2004, EMBO REP, V5, P1153, DOI 10.1038/sj.embor.7400296; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Huang CH, 2005, P NATL ACAD SCI USA, V102, P15512, DOI 10.1073/pnas.0507886102; Javelle A, 2005, BIOCHEM J, V390, P215, DOI 10.1042/BJ20042094; Javelle A, 2004, J BIOL CHEM, V279, P8530, DOI 10.1074/jbc.M312399200; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Le Van Kim C, 2006, BLOOD REV, V20, P93, DOI 10.1016/j.blre.2005.04.002; Lin YC, 2006, J AM CHEM SOC, V128, P10876, DOI 10.1021/ja0631549; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Mayer M, 2006, J GEN PHYSIOL, V127, P133, DOI 10.1085/jgp.200509369; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Ripoche P, 2004, P NATL ACAD SCI USA, V101, P17222, DOI 10.1073/pnas.0403704101; Smith DG, 2003, MOL MICROBIOL, V50, P259, DOI 10.1046/j.1365-2958.2003.03680.x; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Thomas G, 2000, TRENDS GENET, V16, P11, DOI 10.1016/S0168-9525(99)01887-9; von Wiren N, 2004, TOP CURR GENET, V9, P95; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; Winkler F, 2006, PFLUG ARCH EUR J PHY, V451, P701, DOI 10.1007/s00424-005-1511-6; Zheng L, 2004, P NATL ACAD SCI USA, V101, P17090, DOI 10.1073/pnas.0406475101; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; Zidi-Yahiaoui N, 2005, BIOCHEM J, V391, P33, DOI 10.1042/BJ20050657	30	60	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39492	39498		10.1074/jbc.M608325200	http://dx.doi.org/10.1074/jbc.M608325200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17040913	hybrid, Green Published			2022-12-25	WOS:000242898700057
J	Jennings, JJ; Zhu, JH; Rbaibi, Y; Luo, X; Chu, CT; Kiselyov, K				Jennings, John J., Jr.; Zhu, Jian-hui; Rbaibi, Youssef; Luo, Xiang; Chu, Charleen T.; Kiselyov, Kirill			Mitochondrial aberrations in mucolipidosis type IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; CELL-DEATH; LYSOSOMAL COMPARTMENT; ENDOPLASMIC-RETICULUM; CARDIAC MYOCYTES; EPITHELIAL-CELLS; MAMMALIAN-CELLS; PLASMA-MEMBRANE; CATION CHANNEL; BATTEN-DISEASE	Mucolipidosis type IV is a genetic lysosomal storage disease associated with degenerative processes in the brain, eye, and other tissues. Mucolipidosis type IV results from mutations in the gene MCOLN1, which codes for the TRP family ion channel, mucolipin 1. The connection between lysosomal dysfunction and degenerative processes in mucolipidosis type IV is unclear. Here we report that mucolipidosis type IV and several unrelated lysosomal storage diseases are associated with significant mitochondrial fragmentation and decreased mitochondrial Ca2+ buffering efficiency. The mitochondrial alterations observed in these lysosomal storage diseases are reproduced in control cells by treatment with lysosomal inhibitors and with the autophagy inhibitor 3-methyladenine. This suggests that inefficient autophagolysosomal recycling of mitochondria generates fragmented, effete mitochondria in mucolipidosis. Mitochondria accumulate that cannot properly buffer calcium fluxes in the cell. A decrease in mitochondrial Ca2+ buffering capacity in cells affected by these lysosomal storage diseases is associated with increased sensitivity to apoptosis induced by Ca2+-mobilizing agonists and executed via a caspase-8-dependent pathway. Deficient Ca2+ homeostasis may represent a common mechanism of degenerative cell death in several lysosomal storage diseases.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kiselyov, K (corresponding author), Univ Pittsburgh, Dept Biol Sci, 4249 5th Ave, Pittsburgh, PA 15260 USA.	Kiselyov@pitt.edu	Chu, Charleen T/B-1601-2008	Chu, Charleen T/0000-0002-5052-8271; Kiselyov, Kirill/0000-0001-6683-2895	NINDS NIH HHS [NS40817] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040817] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altarescu G, 2002, NEUROLOGY, V59, P306, DOI 10.1212/WNL.59.3.306; Andersson M, 2000, INVEST OPHTH VIS SCI, V41, P2623; ARRINGTON D, 2006, IN PRESS AM J PHYSL; Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Aubry JP, 1999, CYTOMETRY, V37, P197, DOI 10.1002/(SICI)1097-0320(19991101)37:3<197::AID-CYTO6>3.0.CO;2-L; Bach G, 2001, MOL GENET METAB, V73, P197, DOI 10.1006/mgme.2001.3195; Bach G, 2005, PFLUG ARCH EUR J PHY, V451, P313, DOI 10.1007/s00424-004-1361-7; BACH G, 1988, ENZYME, V40, P40, DOI 10.1159/000469140; BARGAL R, 1989, CLIN CHIM ACTA, V181, P167, DOI 10.1016/0009-8981(89)90184-8; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; CHITAYAT D, 1991, AM J MED GENET, V41, P313, DOI 10.1002/ajmg.1320410310; Chu CT, 2006, J NEUROPATH EXP NEUR, V65, P423, DOI 10.1097/01.jnen.0000229233.75253.be; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Fares H, 2001, NAT GENET, V28, P64, DOI 10.1038/ng0501-64; FOLKERTH RD, 1995, J NEUROPATH EXP NEUR, V54, P154, DOI 10.1097/00005072-199503000-00002; Frei KP, 1998, NEUROLOGY, V51, P565, DOI 10.1212/WNL.51.2.565; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Haller T, 1996, CELL CALCIUM, V19, P157, DOI 10.1016/S0143-4160(96)90084-6; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jin S, 2005, J VIROL, V79, P14489, DOI 10.1128/JVI.79.23.14489-14497.2005; Jolly RD, 2002, NEUROCHEM INT, V40, P565, DOI 10.1016/S0197-0186(01)00128-0; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Karahashi H, 2000, BIOL PHARM BULL, V23, P140; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kiselyov K, 2005, J BIOL CHEM, V280, P43218, DOI 10.1074/jbc.M508210200; LaPlante JM, 2004, BIOCHEM BIOPH RES CO, V322, P1384, DOI 10.1016/j.bbrc.2004.08.045; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Lin L, 2001, BIOCHEM J, V357, P49, DOI 10.1042/0264-6021:3570049; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lubensky IA, 1999, AM J SURG PATHOL, V23, P1527, DOI 10.1097/00000478-199912000-00010; Mach L, 2002, BIOL CHEM, V383, P751, DOI 10.1515/BC.2002.078; Mancini GMS, 2000, J INHERIT METAB DIS, V23, P278, DOI 10.1023/A:1005640214408; Monteith GR, 1999, AM J PHYSIOL-CELL PH, V276, pC1193, DOI 10.1152/ajpcell.1999.276.5.C1193; Montero M, 2003, J BIOL CHEM, V278, P49972, DOI 10.1074/jbc.M308378200; Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087; Overbeeke R, 1998, APOPTOSIS, V3, P115, DOI 10.1023/A:1009649025439; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Persaud-Sawin DA, 2005, APOPTOSIS, V10, P973, DOI 10.1007/s10495-005-0733-6; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Schaheen L, 2006, DEV BIOL, V293, P382, DOI 10.1016/j.ydbio.2006.02.008; Schiffmann R, 1998, P NATL ACAD SCI USA, V95, P1207, DOI 10.1073/pnas.95.3.1207; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Slaugenhaupt Susan A., 2002, Current Molecular Medicine (Hilversum), V2, P445, DOI 10.2174/1566524023362276; Sleat DE, 2004, J NEUROSCI, V24, P9117, DOI 10.1523/JNEUROSCI.2729-04.2004; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Soyombo AA, 2006, J BIOL CHEM, V281, P7294, DOI 10.1074/jbc.M508211200; Srinivas SP, 2002, INVEST OPHTH VIS SCI, V43, P2341; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Stroikin Y, 2004, EUR J CELL BIOL, V83, P583, DOI 10.1078/0171-9335-00433; Stroikin Y, 2005, BIOGERONTOLOGY, V6, P39, DOI 10.1007/s10522-004-7382-y; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Tardy C, 2004, NEUROCHEM RES, V29, P871, DOI 10.1023/B:NERE.0000021232.05175.38; Terman A, 2004, ANN NY ACAD SCI, V1019, P70, DOI 10.1196/annals.1297.015; Terman A, 2003, EXP GERONTOL, V38, P863, DOI 10.1016/S0531-5565(03)00114-1; Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906; Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233; Winchester B G, 2001, Eur J Paediatr Neurol, V5 Suppl A, P11, DOI 10.1053/ejpn.2000.0428; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x; ZHU J, 2006, IN PRESS AM J PATHOL	70	117	122	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39041	39050		10.1074/jbc.M607982200	http://dx.doi.org/10.1074/jbc.M607982200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17056595	hybrid			2022-12-25	WOS:000242898700010
J	Juge, N; Yoshida, Y; Yatsushiro, S; Omote, H; Moriyama, Y				Juge, Narinobu; Yoshida, Yumi; Yatsushiro, Shouki; Omote, Hiroshi; Moriyama, Yoshinori			Vesicular glutamate transporter contains two independent transport machineries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; LACTOSE PERMEASE; ESCHERICHIA-COLI; BINDING SITE; EXPRESSION; MECHANISM; PROTEIN; INHIBITORS	Vesicular glutamate transporters (VGLUTs) are responsible for the vesicular storage of L-glutamate and play an essential role in glutamatergic signal transmission in the central nervous system. The molecular mechanism of the transport remains unknown. Here, we established a novel in vitro assay procedure, which includes purification of wild and mutant VGLUT2 and their reconstitution with purified bacterial F0F1-ATPase (F-ATPase) into liposomes. Upon the addition of ATP, the proteoliposomes facilitated L-glutamate uptake in a membrane potential (Delta psi)-dependent fashion. The ATP-dependent L-glutamate uptake exhibited an absolute requirement for similar to 4 mM Cl-, was sensitive to Evans blue, but was insensitive to D, L-aspartate. VGLUT2s with mutations in the transmembrane-located residues Arg(184), His(128), and Glu(191) showed a dramatic loss in L-glutamate transport activity, whereas Na+-dependent inorganic phosphate (Pi) uptake remained comparable to that of the wild type. Furthermore, Pi transport did not require Cl- and was not inhibited by Evans blue. Thus, VGLUT2 appears to possess two intrinsic transport machineries that are independent of each other: a Delta psi-dependent L-glutamate uptake and a Na+-dependent Pi uptake.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Lab Membrane Biochem, Okayama 7008530, Japan	Okayama University	Omote, H (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Lab Membrane Biochem, Okayama 7008530, Japan.	omote@pharm.okayama-u.ac.jp	Juge, Narinobu/M-1125-2018; OMOTE, Hiroshi/B-1635-2011	Juge, Narinobu/0000-0002-5825-6717; 				Abramson J, 2003, FEBS LETT, V555, P96, DOI 10.1016/S0014-5793(03)01087-1; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Aihara Y, 2000, J NEUROCHEM, V74, P2622, DOI 10.1046/j.1471-4159.2000.0742622.x; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; Fremeau RT, 2001, NEURON, V31, P247, DOI 10.1016/S0896-6273(01)00344-0; Fremeau RT, 2004, SCIENCE, V304, P1815, DOI 10.1126/science.1097468; Fremeau RT, 2002, P NATL ACAD SCI USA, V99, P14488, DOI 10.1073/pnas.222546799; Fremeau RT, 2004, TRENDS NEUROSCI, V27, P98, DOI 10.1016/j.tins.2003.11.005; Gras C, 2002, J NEUROSCI, V22, P5442; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; Hayashi M, 2001, J BIOL CHEM, V276, P43400, DOI 10.1074/jbc.M106244200; Herzog E, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-22-j0001.2001; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jung SK, 2006, BIOL PHARM BULL, V29, P547, DOI 10.1248/bpb.29.547; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morin P, 2004, EMBO J, V23, P4560, DOI 10.1038/sj.emboj.7600464; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P278, DOI 10.1006/abbi.1993.1423; MORIYAMA Y, 1995, J BIOL CHEM, V270, P22314, DOI 10.1074/jbc.270.38.22314; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Moriyama Y, 2004, J BIOCHEM, V135, P155, DOI 10.1093/jb/mvh018; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NI BH, 1994, P NATL ACAD SCI USA, V91, P5607, DOI 10.1073/pnas.91.12.5607; Reimer RJ, 2004, PFLUG ARCH EUR J PHY, V447, P629, DOI 10.1007/s00424-003-1087-y; ROSETH S, 1995, J NEUROCHEM, V65, P96; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Takamori S, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-22-j0002.2001; Takamori S, 2002, EMBO REP, V3, P798, DOI 10.1093/embo-reports/kvf159; Takamori S, 2006, NEUROSCI RES, V55, P343, DOI 10.1016/j.neures.2006.04.016; Thompson CM, 2005, CURR MED CHEM, V12, P2041, DOI 10.2174/0929867054637635; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verheijen FW, 1999, NAT GENET, V23, P462, DOI 10.1038/70585; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; Wojcik SM, 2004, P NATL ACAD SCI USA, V101, P7158, DOI 10.1073/pnas.0401764101; Wolosker H, 1996, J BIOL CHEM, V271, P11726, DOI 10.1074/jbc.271.20.11726; Wreden CC, 2005, J BIOL CHEM, V280, P1408, DOI 10.1074/jbc.M411295200	40	94	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39499	39506		10.1074/jbc.M607670200	http://dx.doi.org/10.1074/jbc.M607670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17046815	hybrid			2022-12-25	WOS:000242898700058
J	Paterou, A; Walrad, P; Craddy, P; Fenn, K; Matthews, K				Paterou, Athina; Walrad, Pegine; Craddy, Paul; Fenn, Katelyn; Matthews, Keith			Identification and stage-specific association with the translational apparatus of TbZFP3, a CCCH protein that promotes trypanosome life-cycle development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; AU-RICH ELEMENTS; MESSENGER-RNA; BLOOD-STREAM; CELL-CYCLE; C-ELEGANS; CAENORHABDITIS-ELEGANS; AFRICAN TRYPANOSOME; GENE-EXPRESSION; BRUCEI	The post-transcriptional control of gene expression is becoming increasingly important in the understanding of regulated events in eukaryotic cells. The parasitic kinetoplastids have a unique reliance on such processes, because their genome is organized into polycistronic transcription units in which adjacent genes are not coordinately regulated. Indeed, the number of RNA-binding proteins predicted to be encoded in the genome of kinetoplastids is unusually large, invoking the presence of unique RNA regulators dedicated to gene expression in these evolutionarily ancient organisms. Here, we report that a small CCCH zinc finger protein, TbZFP3, enhances development between life-cycle stages in Trypanosoma brucei. Moreover, we demonstrate that this protein interacts both with the translational machinery and with other small CCCH proteins previously implicated in trypanosome developmental control. Antibodies to this protein also co-immunoprecipitate EP procyclin mRNA and encode the major surface antigen of insect forms of T. brucei. Strikingly, although TbZFP3 is constitutively expressed, it exhibits developmentally regulated association with polyribosomes, and mutational analysis demonstrates that this association is essential for the expression of phenotype. TbZFP3 is therefore a novel regulator of developmental events in kinetoplastids that acts at the level of the post-transcriptional control of gene expression.	Univ Edinburgh, Inst Immunol & Infect Res, Sch Biol Sci, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Matthews, K (corresponding author), Univ Edinburgh, Inst Immunol & Infect Res, Sch Biol Sci, Ashworth Labs, Kings Bldg,W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	keith.matthews@ed.ac.uk		Walrad, Pegine B./0000-0002-2302-0720; Matthews FRS FMedSci FRSE, Professor Keith/0000-0003-0309-9184; Gilmour, Katelyn/0000-0003-4703-8172	Wellcome Trust [073358] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Brecht M, 1998, MOL BIOCHEM PARASIT, V97, P189, DOI 10.1016/S0166-6851(98)00151-0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Caro F, 2005, BIOCHEM BIOPH RES CO, V333, P1017, DOI 10.1016/j.bbrc.2005.06.007; Chekulaeva M, 2006, CELL, V124, P521, DOI 10.1016/j.cell.2006.01.031; Chen XM, 1999, MOL CELL, V3, P349, DOI 10.1016/S1097-2765(00)80462-1; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guedes S, 1997, DEVELOPMENT, V124, P731; Gunzl A, 2003, EUKARYOT CELL, V2, P542, DOI 10.1128/EC.2.3.542-551.2003; Hammarton TC, 2004, J BIOL CHEM, V279, P24757, DOI 10.1074/jbc.M401276200; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Hendriks EF, 2005, MOL MICROBIOL, V57, P706, DOI 10.1111/j.1365-2958.2005.04679.x; Hendriks EF, 2001, EMBO J, V20, P6700, DOI 10.1093/emboj/20.23.6700; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; MATTHEWS KR, 1995, J CELL SCI, V108, P2231; Matthews KR, 2005, J CELL SCI, V118, P283, DOI 10.1242/jcs.01649; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Morking PA, 2004, BIOCHEM BIOPH RES CO, V319, P169, DOI [10.1016/S0006-291X(04)00873-3, 10.1016/j.bbrc.2004.04.162]; Ogura K, 2003, DEVELOPMENT, V130, P2495, DOI 10.1242/dev.00469; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; Schmitz RJ, 2005, DEVELOPMENT, V132, P5471, DOI 10.1242/dev.02170; Sutton A, 2001, MOL CELL BIOL, V21, P3514, DOI 10.1128/MCB.21.10.3514-3522.2001; Tabara H, 1999, DEVELOPMENT, V126, P1; Tacahashi Y, 2003, NUCLEIC ACIDS RES, V31, P1744, DOI 10.1093/nar/gkg265; Tenenhaus C, 2001, GENE DEV, V15, P1031, DOI 10.1101/gad.876201; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Tu XM, 2005, MOL BIOL CELL, V16, P97, DOI 10.1091/mbc.E04-05-0368; Tu XM, 2005, J CELL SCI, V118, P4353, DOI 10.1242/jcs.02567; van Deursen FJ, 2001, MOL BIOCHEM PARASIT, V112, P163, DOI 10.1016/S0166-6851(00)00359-5; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; Wentz-Hunter K, 1995, Nucleic Acids Symp Ser, P226; Wickens M, 2003, SCIENCE, V300, P753, DOI 10.1126/science.1084512; ZIEGELBAUER K, 1990, EUR J BIOCHEM, V192, P373, DOI 10.1111/j.1432-1033.1990.tb19237.x	44	44	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39002	39013		10.1074/jbc.M604280200	http://dx.doi.org/10.1074/jbc.M604280200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17043361	Green Accepted, hybrid			2022-12-25	WOS:000242898700006
J	Imamura, H; Funamoto, S; Yoshida, M; Yokoyama, K				Imamura, Hiromi; Funamoto, Saeko; Yoshida, Masasuke; Yokoyama, Ken			Reconstitution in vitro of V-1 complex of Thermus thermophilus V-ATPase revealed that ATP binding to the A subunit is crucial for V-1 formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; ENTEROCOCCUS-HIRAE; ROTATION; BETA; IDENTIFICATION; RESOLUTION; SITE; (H+)-ATPASE	Vacuolar-type H+-ATPase (V-ATPase or V-type ATPase) is a multisubunit complex comprised of a water-soluble V1 complex, responsible for ATP hydrolysis, and a membrane-embedded V-o complex, responsible for proton translocation. The V1 complex of Thermus thermophilus V-ATPase has the subunit composition of A(3)B(3)DF, in which the A and B subunits form a hexameric ring structure. A central stalk composed of the D and F subunits penetrates the ring. In this study, we investigated the pathway for assembly of the V1 complex by reconstituting the V1 complex from the monomeric A and B subunits and DF subcomplex in vitro. Assembly of these components into the V1 complex required binding of ATP to the A subunit, although hydrolysis of ATP is not necessary. In the absence of the DF subcomplex, the A and B monomers assembled into A(1)B(1) and A(3)B(3) subcomplexes in an ATP binding-dependent manner, suggesting that ATP binding-dependent interaction between the A and B subunits is a crucial step of assembly into V1 complex. Kinetic analysis of assembly of the A and B monomers into the A(1)B(1) heterodimer using fluorescence resonance energy transfer indicated that the A subunit binds ATP prior to binding the B subunit. Kinetics of binding of a fluorescent ADP analog, N-methylanthraniloyl ADP(mant-ADP), to the monomeric A subunit also supported the rapid nucleotide binding to the A subunit.	Japan Sci & Technol Agcy, ATP Syst Project, ERATO, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology	Yokoyama, K (corresponding author), Japan Sci & Technol Agcy, ATP Syst Project, ERATO, Midori Ku, 5800-3 Nagatsuta, Yokohama, Kanagawa 2260026, Japan.	kyokoyama-ra@res.titech.ac.jp	Imamura, Hiromi/AAD-5109-2019; Yokoyama, Ken/AAJ-3582-2020	Imamura, Hiromi/0000-0002-1896-0443; Yokoyama, Ken/0000-0002-6813-1096				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Bernal RA, 2004, STRUCTURE, V12, P1789, DOI 10.1016/j.str.2004.07.017; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; Imamura H, 2005, P NATL ACAD SCI USA, V102, P17929, DOI 10.1073/pnas.0507764102; Imamura H, 2004, J BIOL CHEM, V279, P18085, DOI 10.1074/jbc.M314204200; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Kane PM, 2003, J BIOENERG BIOMEMBR, V35, P313, DOI 10.1023/A:1025724814656; Kane PM, 1999, J BIOL CHEM, V274, P17275, DOI 10.1074/jbc.274.24.17275; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P367; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; Lolkema JS, 2003, J BIOENERG BIOMEMBR, V35, P323, DOI 10.1023/A:1025776831494; Maegawa Y, 2006, ACTA CRYSTALLOGR D, V62, P483, DOI 10.1107/S0907444906006329; Malkus P, 2004, MOL BIOL CELL, V15, P5075, DOI 10.1091/mbc.E04-06-0514; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; Mori T, 2002, P NATL ACAD SCI USA, V99, P17203, DOI 10.1073/pnas.262578499; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; Murata T, 2002, J BIOCHEM, V132, P789, DOI 10.1093/oxfordjournals.jbchem.a003288; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; PENG SB, 1993, J BIOL CHEM, V268, P23519; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; Schafer IB, 2006, J MOL BIOL, V358, P725, DOI 10.1016/j.jmb.2006.02.057; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shimabukuro K, 2003, P NATL ACAD SCI USA, V100, P14731, DOI 10.1073/pnas.2434983100; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; Vasilyeva E, 1996, J BIOL CHEM, V271, P12775, DOI 10.1074/jbc.271.22.12775; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; XIE XS, 1988, J BIOL CHEM, V263, P9859; Yagi H, 2004, J AM CHEM SOC, V126, P16632, DOI 10.1021/ja045279o; Yokoyama K, 2005, J BIOENERG BIOMEMBR, V37, P405, DOI 10.1007/s10863-005-9480-1; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; YOSHIDA M, 1981, J BIOL CHEM, V256, P148	48	13	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38582	38591		10.1074/jbc.M608253200	http://dx.doi.org/10.1074/jbc.M608253200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17050529	hybrid			2022-12-25	WOS:000242709500053
J	Liu, J; Istvan, ES; Goldberg, DE				Liu, Jun; Istvan, Eva S.; Goldberg, Daniel E.			Hemoglobin-degrading plasmepsin II is active as a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTIC PROTEASE PLASMEPSIN-4; FALCIPARUM FOOD VACUOLE; PLASMODIUM-FALCIPARUM; CRYSTAL-STRUCTURE; SITE; DIMERIZATION; INHIBITION; DEGRADATION; ACTIVATION; SUBSTRATE	A family of aspartic proteases called plasmepsins is important for hemoglobin degradation in intraerythrocytic Plasmodium parasites. Plasmepsin II (PM II) is the best studied member of this family. PM II and its close orthologs and paralogs form homodimers with extensive interfaces in all known crystal structures. This raised the question whether the homodimer is the functional subunit of plasmepsins in solution. We have used gel filtration chromatography, site-directed mutagenesis, and analytical ultracentrifugation to study the oligomeric status of PM II in solution. Our results reveal that PM II exists mainly as a monomer in solution and that the monomer is fully functional for catalysis. A hydrophobic loop at the PM II monomer surface, which would be buried in a PM II dimer, is shown to be essential for the hemoglobin degradation capability of PM II.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, 660 S Euclid Ave,Campus Box 8230, St Louis, MO 63110 USA.	goldberg@borcim.wustl.edu	Liu, Jun/G-4889-2011	Liu, Jun/0000-0002-3347-5139	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 47798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asojo OA, 2003, J MOL BIOL, V327, P173, DOI 10.1016/S0022-2836(03)00036-6; Asojo OA, 2002, ACTA CRYSTALLOGR D, V58, P2001, DOI 10.1107/S0907444902014695; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bernstein NK, 2003, J MOL BIOL, V329, P505, DOI 10.1016/S0022-2836(03)00444-3; Cervantes S, 2004, J BIOL CHEM, V279, P36519, DOI 10.1074/jbc.M404832200; Clemente JC, 2006, ACTA CRYSTALLOGR D, V62, P246, DOI 10.1107/S0907444905041260; Dame JB, 2003, MOL BIOCHEM PARASIT, V130, P1, DOI 10.1016/S0166-6851(03)00137-3; FOWLER SD, 1995, FEBS LETT, V366, P72, DOI 10.1016/0014-5793(95)00501-Y; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Goldberg DE, 2005, CURR TOP MICROBIOL, V295, P275; Hogg T, 2006, J BIOL CHEM, V281, P25425, DOI 10.1074/jbc.M603776200; Hwang YS, 2005, J MED CHEM, V48, P2239, DOI 10.1021/jm049581j; Istvan ES, 2005, J BIOL CHEM, V280, P6890, DOI 10.1074/jbc.M412086200; LIN XL, 1989, J BIOL CHEM, V264, P4482; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Liu J, 2006, P NATL ACAD SCI USA, V103, P8840, DOI 10.1073/pnas.0601876103; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; Luker KE, 1996, MOL BIOCHEM PARASIT, V79, P71, DOI 10.1016/0166-6851(96)02651-5; Madabushi A, 2005, ACTA CRYSTALLOGR F, V61, P228, DOI 10.1107/S1744309105001405; Martins TM, 2006, ACTA TROP, V97, P212, DOI 10.1016/j.actatropica.2005.11.001; Merabet N, 2004, J MED CHEM, V47, P6392, DOI 10.1021/jm040833q; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; Omara-Opyene AL, 2004, J BIOL CHEM, V279, P54088, DOI 10.1074/jbc.M409605200; Ostermann N, 2004, J MOL BIOL, V342, P889, DOI 10.1016/j.jmb.2004.07.073; Pandey KC, 2005, P NATL ACAD SCI USA, V102, P9138, DOI 10.1073/pnas.0502368102; Prade L, 2005, J BIOL CHEM, V280, P23837, DOI 10.1074/jbc.M501519200; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; Wang SX, 2006, P NATL ACAD SCI USA, V103, P11503, DOI 10.1073/pnas.0600489103; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Xiao HG, 2006, PROTEIN EXPRES PURIF, V49, P88, DOI 10.1016/j.pep.2006.02.022	32	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38682	38688		10.1074/jbc.M608535200	http://dx.doi.org/10.1074/jbc.M608535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17040901	hybrid			2022-12-25	WOS:000242709500065
J	Nishitani, C; Mitsuzawa, H; Sano, H; Shimizu, T; Matsushima, N; Kuroki, Y				Nishitani, Chiaki; Mitsuzawa, Hiroaki; Sano, Hitomi; Shimizu, Takeyuki; Matsushima, Norio; Kuroki, Yoshio			Toll-like receptor 4 region Glu(24)-Lys(47) is a site for MD-2 binding - Importance of Cys(29) and Cys(40)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; GLYCOPROTEIN IB-ALPHA; LIPOPOLYSACCHARIDE-BINDING; STAPHYLOCOCCUS-AUREUS; CRYSTAL-STRUCTURE; CELL-SURFACE; DOMAIN; PROTEIN; CD14; LPS	Toll-like receptor 4 (TLR4) is a signaling receptor for lipopolysaccharide (LPS), but its interaction with MD-2 is required for efficient responses to LPS. Previous studies with deletion mutants indicate a critical role of the amino-terminal TLR4 region in interaction with MD-2. However, it is uncertain which region in the TLR4 molecule directly binds to MD-2. The purpose of this study was to determine a critical stretch of primary sequence in the TLR4 region that directly binds MD-2 and is critical for LPS signaling. The synthetic TLR4 peptide corresponding to the TLR4 region Glu(24)-Lys(47) directly binds to recombinant soluble MD-2 (sMD-2). The TLR4 peptide inhibited the binding of a recombinant soluble form of the extracellular TLR4 domain (sTLR4) to sMD-2 and significantly attenuated LPS-induced NF-kappa B activation and IL-8 secretion in wild type TLR4-transfected cells. Reduction and S-carboxymethylation of sTLR4 abrogated its association with sMD-2. The TLR4 mutants, TLR4(C29A), TLR4(C40A), and TLR4(C29A, C40A), were neither co-precipitated with MD-2 nor expressed on the cell surface and failed to transmit LPS signaling. These results demonstrate that the TLR4 region Glu(24)-Lys(47) is a site for MD-2 binding and that Cys29 and Cys40 within this region are critical residues for MD-2 binding and LPS signaling.	Sapporo Med Univ, Dept Biochem, Sch Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Hlth Sci, Sapporo, Hokkaido 0608556, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	Sapporo Medical University; Sapporo Medical University; Japan Science & Technology Agency (JST)	Kuroki, Y (corresponding author), Sapporo Med Univ, Dept Biochem, Sch Med, Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	kurokiy@sapmed.ac.jp						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Fujimoto T, 2004, J BIOL CHEM, V279, P47431, DOI 10.1074/jbc.M408724200; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Hyakushima N, 2004, J IMMUNOL, V173, P6949, DOI 10.4049/jimmunol.173.11.6949; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Matsushima N., 2005, DRUG DES REV, V2, P305, DOI DOI 10.2174/1567269054087613; Mitsuzawa H, 2001, J BIOL CHEM, V276, P41350, DOI 10.1074/jbc.M104177200; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nishitania C, 2005, BIOCHEM BIOPH RES CO, V328, P586, DOI 10.1016/j.bbrc.2005.01.021; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pugin J, 2004, BLOOD, V104, P4071, DOI 10.1182/blood-2003-04-1290; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Visintin A, 2005, J IMMUNOL, V175, P6465, DOI 10.4049/jimmunol.175.10.6465; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	23	25	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38322	38329		10.1074/jbc.M606904200	http://dx.doi.org/10.1074/jbc.M606904200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17056597	hybrid			2022-12-25	WOS:000242709500025
J	Singh, I; Shankaran, H; Beauharnois, ME; Xiao, ZH; Alexandridis, P; Neelamegham, S				Singh, Indrajeet; Shankaran, Harish; Beauharnois, Mark E.; Xiao, Zhihua; Alexandridis, Paschalis; Neelamegham, Sriram			Solution structure of human von Willebrand factor studied using small angle neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; X-RAY-SCATTERING; GLYCOPROTEIN IB-ALPHA; PLATELET-ADHESION; SELF-ASSOCIATION; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; FACTOR-VIII; BINDING; PROTEIN	von Willebrand factor (VWF) binding to platelets under high fluid shear is an important step regulating atherothrombosis. We applied light and small angle neutron scattering to study the solution structure of human VWF multimers and protomer. Results suggest that these proteins resemble prolate ellipsoids with radius of gyration (R-g) of similar to 75 and similar to 30 nm for multimer and protomer, respectively. The ellipsoid dimensions/radii are 175 x 28 nm for multimers and 70 x 9.1 nm for protomers. Substructural repeat domains are evident within multimeric VWF that are indicative of elements of the protomer quarternary structure (16 nm) and individual functional domains (4.5 nm). Amino acids occupy only similar to 2% of the multimer and protomer volume, compared with 98% for serum albumin and 35% for fibrinogen. VWF treatment with guanidine (.) HCl, which increases VWF susceptibility to proteolysis by ADAMTS-13, causes local structural changes at length scales < 10 nm without altering protein Rg. Treatment of multimer but not protomer VWF with random homobifunctional linker BS3 prior to reduction of intermonomer disulfide linkages and Western blotting reveals a pattern of dimer and trimer units that indicate the presence of stable intermonomer non-covalent interactions within the multimer. Overall, multimeric VWF appears to be a loosely packed ellipsoidal protein with non-covalent interactions between different monomer units stabilizing its solution structure. Local, and not large scale, changes in multimer conformation are sufficient for ADAMTS-13-mediated proteolysis.	SUNY Buffalo, Dept Chem & Biol Engn, Buffalo, NY 14260 USA; Pacific NW Natl Lab, Richland, WA 99354 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Neelamegham, S (corresponding author), SUNY Buffalo, Dept Chem & Biol Engn, 906 Furnas Hall, Buffalo, NY 14260 USA.	neel@eng.buffalo.edu	singh, indrajeet/A-2072-2015	Neelamegham, Sriram/0000-0002-1371-8500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL076211, R01HL077258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 76211, R01 HL077258, HL 77258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beaucage G, 1996, J APPL CRYSTALLOGR, V29, P134, DOI 10.1107/S0021889895011605; Bendetowicz AV, 1999, J BIOL CHEM, V274, P12300, DOI 10.1074/jbc.274.18.12300; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; CALMETTES P, 1994, BIOPHYS CHEM, V53, P105, DOI 10.1016/0301-4622(94)00081-6; CALMETTES P, 1993, J MOL BIOL, V231, P840, DOI 10.1006/jmbi.1993.1330; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Doggett TA, 2002, BIOPHYS J, V83, P194, DOI 10.1016/S0006-3495(02)75161-8; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Fischer BE, 1997, CELL MOL LIFE SCI, V53, P943, DOI 10.1007/s000180050115; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; Fukuda K, 2002, STRUCTURE, V10, P943, DOI 10.1016/S0969-2126(02)00787-6; Glinka CJ, 1998, J APPL CRYSTALLOGR, V31, P430, DOI 10.1107/S0021889897017020; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Gualfetti PJ, 1999, BIOCHEMISTRY-US, V38, P13367, DOI 10.1021/bi991296s; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; Hoshino M, 1997, FEBS LETT, V416, P72, DOI 10.1016/S0014-5793(97)01172-1; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; Kasirer-Friede A, 2004, BLOOD, V103, P3403, DOI 10.1182/blood-2003-10-3664; Kohn JE, 2004, P NATL ACAD SCI USA, V101, P12491, DOI 10.1073/pnas.0403643101; Kroll MH, 1996, BLOOD, V88, P1525; Kuhn W, 1934, KOLLOID Z, V68, P2, DOI 10.1007/BF01451681; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; LOSCALZO J, 1985, BIOCHEMISTRY-US, V24, P4468, DOI 10.1021/bi00337a031; Nishio K, 2004, P NATL ACAD SCI USA, V101, P10578, DOI 10.1073/pnas.0402041101; Novak L, 2002, BLOOD, V99, P2070, DOI 10.1182/blood.V99.6.2070; OHMORI K, 1982, J CELL BIOL, V95, P632, DOI 10.1083/jcb.95.2.632; Raghavachari M, 2000, COLLOID SURFACE B, V19, P315, DOI 10.1016/S0927-7765(00)00140-5; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Saenko E, 1999, J CHROMATOGR A, V852, P59, DOI 10.1016/S0021-9673(99)00491-4; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Savage B, 2002, P NATL ACAD SCI USA, V99, P425, DOI 10.1073/pnas.012459599; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; Segel DJ, 1998, BIOCHEMISTRY-US, V37, P12443, DOI 10.1021/bi980535t; Shankaran H, 2004, BIOPHYS J, V86, P576, DOI 10.1016/S0006-3495(04)74136-3; Shankaran H, 2003, BLOOD, V101, P2637, DOI 10.1182/blood-2002-05-1550; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SLAYTER H, 1985, J BIOL CHEM, V260, P8559; SOSNICK TR, 1992, BIOCHEMISTRY-US, V31, P8329, DOI 10.1021/bi00150a029; Spalla O, 2002, N-HOLLAND D, P49; TSAI HM, 1994, BLOOD, V83, P2171; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Ulrichts H, 2005, J THROMB HAEMOST, V3, P552, DOI 10.1111/j.1538-7836.2005.01209.x; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; Xiao ZH, 2006, BIOPHYS J, V90, P2221, DOI 10.1529/biophysj.105.065789; Yang Z, 2001, BIOCHEMISTRY-US, V40, P12515, DOI 10.1021/bi011394p; Zhou JM, 1997, FEBS LETT, V415, P183, DOI 10.1016/S0014-5793(97)01120-4	49	52	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38266	38275		10.1074/jbc.M607123200	http://dx.doi.org/10.1074/jbc.M607123200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17052980	hybrid			2022-12-25	WOS:000242709500019
J	Hwang, Y; Minkah, N; Perry, K; Van Duyne, GD; Bushman, FD				Hwang, Young; Minkah, Nana; Perry, Kay; Van Duyne, Gregory D.; Bushman, Frederic D.			Regulation of catalysis by the smallpox virus topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA DNA TOPOISOMERASE; ACTIVE-SITE TYROSINE; POXVIRUS TOPOISOMERASE; COVALENT CATALYSIS; MUTATIONAL ANALYSIS; MECHANISM; IB; CONTACTS; SPECIFICITY; RELAXATION	The poxvirus type IB topoisomerases catalyze relaxation of supercoiled DNA by cleaving and rejoining DNA strands via a pathway involving a covalent phosphotyrosine intermediate. Recently we determined structures of the smallpox virus topoisomerase bound to DNA in covalent and non-covalent DNA complexes using x-ray crystallography. Here we analyzed the effects of twenty-two amino acid substitutions on the topoisomerase activity in vitro in assays of DNA relaxation, single cycle cleavage, and equilibrium cleavage-religation. Alanine substitutions at 14 positions impaired topoisomerase function, marking a channel of functionally important contacts along the protein-DNA interface. Unexpectedly, alanine substitutions at two positions (D168A and E124A) accelerated the forward rate of cleavage. These findings and further analysis indicate that Asp168 is a key regulator of the active site that maintains an optimal balance among the DNA cleavage, religation, and product release steps. Finally, we report that high level expression of the D168A topoisomerase in Escherichia coli, but not other alaninesubstituted enzymes, prevented cell growth. These findings help elucidate the amino acid side chains involved in DNA binding and catalysis and provide guidance for designing topoisomerase poisons for use as smallpox antivirals.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Bushman, FD (corresponding author), Univ Penn, Sch Med, Dept Microbiol, 402C Johnson Pavill,3610 Hamilton Walk, Philadelphia, PA 19104 USA.	bushman@mail.med.upenn.edu		Perry, Kay/0000-0002-4046-1704; Bushman, Frederic/0000-0003-4740-4056				Bond A, 2006, MOL PHARMACOL, V69, P547, DOI 10.1124/mol.105.019067; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Davies DR, 2006, J MOL BIOL, V357, P1202, DOI 10.1016/j.jmb.2006.01.022; Gubser C, 2004, J GEN VIROL, V85, P105, DOI 10.1099/vir.0.19565-0; Harrison SC, 2004, P NATL ACAD SCI USA, V101, P11178, DOI 10.1073/pnas.0403600101; Hwang Y, 1998, J VIROL, V72, P3401, DOI 10.1128/JVI.72.4.3401-3406.1998; Hwang Y, 1999, J BIOL CHEM, V274, P9160, DOI 10.1074/jbc.274.14.9160; Hwang Y, 1999, MOL PHARMACOL, V55, P1049, DOI 10.1124/mol.55.6.1049; Hwang Y, 1999, VIROLOGY, V262, P479, DOI 10.1006/viro.1999.9920; Hwang Y, 2000, NUCLEIC ACIDS RES, V28, P4884, DOI 10.1093/nar/28.24.4884; Kornberg A., 1991, DNA REPLICATION; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P36091, DOI 10.1074/jbc.M102609200; Nagarajan R, 2005, BIOCHEMISTRY-US, V44, P11476, DOI 10.1021/bi050796k; Nagarajan R, 2006, BIOCHEMISTRY-US, V45, P5775, DOI 10.1021/bi060133i; Perry K, 2006, MOL CELL, V23, P343, DOI 10.1016/j.molcel.2006.06.015; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; Upton C, 2003, J VIROL, V77, P7590, DOI 10.1128/JVI.77.13.7590-7600.2003; Wittschieben J, 1998, NUCLEIC ACIDS RES, V26, P490, DOI 10.1093/nar/26.2.490; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978	32	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					38052	38060		10.1074/jbc.M608858200	http://dx.doi.org/10.1074/jbc.M608858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17032643	hybrid			2022-12-25	WOS:000242477100083
J	Robidoux, J; Kumar, N; Daniel, KW; Moukdar, F; Cyr, M; Medvedev, AV; Collins, S				Robidoux, Jacques; Kumar, Naresh; Daniel, Kiefer W.; Moukdar, Fatiha; Cyr, Michel; Medvedev, Alexander V.; Collins, Sheila			Maximal beta(3)-adrenergic regulation of lipolysis involves Src and epidermal growth factor receptor-dependent ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; PROTEIN-COUPLED RECEPTORS; NECROSIS-FACTOR-ALPHA; HUMAN FAT-CELLS; ADIPOSE-TISSUE; 3T3-L1 ADIPOCYTES; ADRENERGIC-RECEPTOR; EGF RECEPTOR; TYROSINE KINASE; RAT ADIPOCYTES	Catecholamine-stimulated lipolysis is primarily a beta-adrenergic and cAMP-dependent event. In previous studies we established that the beta(3)-adrenergic receptor (beta(3)AR) in adipocytes utilizes a unique mechanism to stimulate extracellular signal-regulated kinases 1 and 2 (ERK) by direct recruitment and activation of Src kinase. Therefore, we investigated the role of the ERK pathway in adipocyte metabolism and found that the beta(3)AR agonist CL316,243 regulates lipolysis through both cAMP-dependent protein kinase (PKA) and ERK. Inhibition of PKA activity completely eliminated lipolysis at low (subnanomolar) CL316,243 concentrations and by 75-80% at higher nanomolar concentrations. The remaining 20-25% of PKA-independent lipolysis, as well as ERK activation, was abolished by inhibiting the activity of either Src (PP2 or small interfering RNA), epidermal growth factor receptor (EGFR with AG1478 or small interfering RNA), or mitogen-activated protein kinase kinase 1 or 2 (MKK1/2 with PD098059). PD098059 inhibited lipolysis by 53% in mice as well. Finally, the effect of estradiol, a reported acute activator of ERK and lipolysis, was also totally prevented by PP2, AG1478, and PD098059. These results suggest that ERK activation by beta(3)AR depends upon Src and epidermal growth factor receptor kinase activities and is responsible for the PKA-independent portion of the lipolytic response. Together these results illustrate the distinct and complementary roles for PKA and ERK in catecholamine-stimulated lipolysis.	CllT Ctr Hlth Res, Div Biol Sci, Program Endocrine Biol, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Collins, S (corresponding author), CllT Ctr Hlth Res, Div Biol Sci, Program Endocrine Biol, 6 Davis Dr,Box 12137, Res Triangle Pk, NC 27709 USA.	scollins@ciit.org		Robidoux, JAcques/0000-0002-4809-4734; Medvedev, Alexander/0000-0001-6983-1687	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057698] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK57698] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BELFRAGE P, 1977, FEBS LETT, V75, P259, DOI 10.1016/0014-5793(77)80099-9; Birner-Gruenberger R, 2005, MOL CELL PROTEOMICS, V4, P1710, DOI 10.1074/mcp.M500062-MCP200; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Cho KJ, 2005, J CELL BIOCHEM, V96, P869, DOI 10.1002/jcb.20561; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; Dos Santos EG, 2002, ENDOCRINOLOGY, V143, P930; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; ENGFELDT P, 1982, J LIPID RES, V23, P715; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Frayn KN, 2003, INT J OBESITY, V27, P875, DOI 10.1038/sj.ijo.0802326; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garofalo MAR, 1996, J AUTONOM NERV SYST, V60, P206, DOI 10.1016/0165-1838(96)00037-9; Gerhardt CC, 1999, MOL PHARMACOL, V55, P255, DOI 10.1124/mol.55.2.255; Granneman JG, 1998, MOL PHARMACOL, V53, P856; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; GUILLAUME JL, 1994, EUR J BIOCHEM, V224, P761, DOI 10.1111/j.1432-1033.1994.00761.x; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HAUNER H, 1995, DIABETOLOGIA, V38, P764, DOI 10.1007/s001250050350; HIRSCH AH, 1984, J LIPID RES, V25, P665; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Holst LS, 1996, GENOMICS, V35, P441, DOI 10.1006/geno.1996.0383; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Juan CC, 2005, AM J PHYSIOL-ENDOC M, V288, pE1146, DOI 10.1152/ajpendo.00481.2004; KAWAMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P732, DOI 10.1073/pnas.78.2.732; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; LAFONTAN M, 1993, J LIPID RES, V34; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Martin NP, 2004, CELL SIGNAL, V16, P1397, DOI 10.1016/j.cellsig.2004.05.002; Migliorini RH, 1997, AM J PHYSIOL-REG I, V272, pR656, DOI 10.1152/ajpregu.1997.272.2.R656; MITZNEGG P, 1974, BIOCHEM PHARMACOL, V23, P2337, DOI 10.1016/0006-2952(74)90566-8; MIYOSHI H, 2006, J BIOL CHEM; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; ROSENBAUM M, 1993, J CLIN ENDOCR METAB, V77, P352, DOI 10.1210/jc.77.2.352; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Souza SC, 2003, J CELL BIOCHEM, V89, P1077, DOI 10.1002/jcb.10565; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415	50	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37794	37802		10.1074/jbc.M605572200	http://dx.doi.org/10.1074/jbc.M605572200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17032647	hybrid			2022-12-25	WOS:000242477100056
J	Schneider, J; Bajwa, P; Johnson, FC; Bhaumik, SR; Shilatifard, A				Schneider, Jessica; Bajwa, Pratibha; Johnson, Farley C.; Bhaumik, Sukesh R.; Shilatifard, Ali			Rtt109 is required for proper H3K56 acetylation - A Chromatin mark associated with the elongating RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H3 LYSINE-56 ACETYLATION; GENE-EXPRESSION; NUCLEOSOME; METHYLATION; PARTICLE	Histone acetylation has been shown to be required for the proper regulation of many cellular processes including transcription, DNA repair, and chromatin assembly. Acetylation of histone H3 on lysine 56 (H3K56) occurs both during the premeiotic and mitotic S phase and persists throughout DNA damage repair. To learn more about the molecular mechanism of H3K56 acetylation and factors required for this process, we surveyed the genome of the yeast Saccharomyces cerevisiae to identify genes necessary for this process. A comparative global proteomic screen identified several factors required for global H3K56 acetylation, which included histone chaperone Asf1 and a protein of an unknown function Rtt109 but not Spt10. Our results indicate that the loss of Rtt109 results in the loss of H3K56 acetylation, both on bulk histone and on chromatin, similar to that of asf1 Delta or the K56Q mutation. RTT109 deletion exhibits sensitivity to DNA damaging agents similar to that of asf1 Delta and H3K56Q mutants. Furthermore, Rtt109 and H3K56 acetylation appear to correlate with actively transcribed genes and associate with the elongating form of polymerase II in yeast. This histone modification is also associated with some of the transcriptionally active puff sites in Drosophila. Our results indicate a new role for the Rtt109 protein in the proper regulation of H3K56 acetylation.	St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63104 USA; So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA; St Louis Univ, Sch Med, Ctr Canc, St Louis, MO 63104 USA	Saint Louis University; Southern Illinois University System; Southern Illinois University; Saint Louis University	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.	shilatia@slu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069905] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01GM069905] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhaumik SR, 2003, METHOD ENZYMOL, V370, P445; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Gerber M, 2004, MOL CELL BIOL, V24, P9911, DOI 10.1128/MCB.24.22.9911-9919.2004; Gerber M, 2001, EMBO J, V20, P6104, DOI 10.1093/emboj/20.21.6104; Joshi AA, 2005, MOL CELL, V20, P971, DOI 10.1016/j.molcel.2005.11.021; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; Schneider J, 2004, METHOD ENZYMOL, V377, P227; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; SILVER LM, 1976, P NATL ACAD SCI USA, V73, P423, DOI 10.1073/pnas.73.2.423; Tenney K, 2006, P NATL ACAD SCI USA, V103, P11970, DOI 10.1073/pnas.0603620103; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011	20	171	173	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37270	37274		10.1074/jbc.C600265200	http://dx.doi.org/10.1074/jbc.C600265200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17046836	hybrid			2022-12-25	WOS:000242477100003
J	Kanamori, M; Kawaguchi, T; Berger, MS; Pieper, RO				Kanamori, Masayuki; Kawaguchi, Tomohiro; Berger, Mitchel S.; Pieper, Russell O.			Intracranial microenvironment reveals independent opposing functions of host alpha V beta 3 expression on glioma growth and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(V)BETA(3) INTEGRIN; GLIOBLASTOMA-MULTIFORME; MALIGNANT-MELANOMA; TUMOR-GROWTH; HUMAN-MODEL; CELLS; OVEREXPRESSION; INHIBITOR; MOLECULES; THERAPY	alpha V beta 3 integrins are overexpressed in the host-derived vasculature of glioblastoma multiform (GBM) and are believed to contribute to angiogenesis and tumor growth. To directly address the role of host alpha V beta 3 expression in GBM growth and behavior, we intracranially implanted integrin beta 3-expressing GBM cells into beta 3 wild type (WT) or beta 3 knock out ( KO) mice and monitored angiogenesis and growth. GBM in beta 3 WT animals had a vessel density greater than that in beta 3 KO animals, consistent with a pro-angiogenic, pro-tumorigenic view of host integrin function. GBM in beta 3 WT animals, however, were no larger than those in beta 3 KO animals, because GBM in beta 3 WT animals were infiltrated with a higher number of tumor necrosis factor alpha-secreting, apoptosis-inducing macrophages than the tumors in the corresponding beta 3 KO animals. The tumor-suppressive effects of host beta 3 expression could be reversed by macrophage depletion or by transplantation of bone marrow from beta 3 KO animals into beta 3 WT animals, both of which significantly increased tumor growth independently of tumor vessel density. Taken together, these results show that host alpha V beta 3 integrin expression has opposing actions in the intracranial setting, enhancing tumor vascularization and growth while independently enhancing macrophage-mediated tumor elimination. Appropriate management of these functions could lead to enhanced efficacy of anti-integrin based therapies for glioma.	Univ Calif San Francisco, Ctr Canc, Dept Neurol Surg, San Francisco, CA 94115 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Pieper, RO (corresponding author), Univ Calif San Francisco, Ctr Canc, Dept Neurol Surg, 2340 Sutter St,Rm N219, San Francisco, CA 94115 USA.		Kawaguchi, Tomohiro/AAD-9616-2019	Kawaguchi, Tomohiro/0000-0001-7622-1270	NATIONAL CANCER INSTITUTE [R01CA094989] Funding Source: NIH RePORTER; NCI NIH HHS [CA 94989] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bello L, 2001, NEUROSURGERY, V49, P380, DOI 10.1097/00006123-200108000-00022; Bello L, 2001, CANCER RES, V61, P7501; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; *CBTRUS, 2000, STAT REP PRIM BRAIN; Chatterjee S, 2000, J NEURO-ONCOL, V46, P135, DOI 10.1023/A:1006444300504; Chen GG, 2002, J NEURO-ONCOL, V57, P179, DOI 10.1023/A:1015763916020; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Doucey MA, 2003, J BIOL CHEM, V278, P26983, DOI 10.1074/jbc.M302709200; Gladson CL, 1996, J NEUROPATH EXP NEUR, V55, P1143, DOI 10.1097/00005072-199611000-00005; Guo P, 2001, CANCER RES, V61, P8569; Hagedorn M, 2002, CANCER RES, V62, P6884; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; LUDGATE CM, 1988, INT J RADIAT ONCOL, V15, P1091, DOI 10.1016/0360-3016(88)90189-7; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Natali PG, 1997, CANCER RES, V57, P1554; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Prados MD, 1998, INT J RADIAT ONCOL, V40, P57, DOI 10.1016/S0360-3016(97)00566-X; Reynolds AR, 2004, CANCER RES, V64, P8643, DOI 10.1158/0008-5472.CAN-04-2760; Reynolds KJ, 2002, J PROTEOME RES, V1, P27, DOI 10.1021/pr0100016; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SELIGMAN ARNOLD M., 1939, AMER JOUR CANCER, V37, P364; Sonoda Y, 2003, CANCER RES, V63, P1962; Sonoda Y, 2001, CANCER RES, V61, P6674; Taverna D, 2004, P NATL ACAD SCI USA, V101, P763, DOI 10.1073/pnas.0307289101; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	36	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37256	37264		10.1074/jbc.M605344200	http://dx.doi.org/10.1074/jbc.M605344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028191	hybrid			2022-12-25	WOS:000242220800086
J	Lewis, BM; Pexa, A; Francis, K; Verma, V; McNicol, AM; Scanlon, M; Deussen, A; Evans, WH; Rees, DA; Ham, J				Lewis, B. Mary; Pexa, Annette; Francis, Karen; Verma, Vandana; McNicol, Anne M.; Scanlon, Maurice; Deussen, Andreas; Evans, W. Howard; Rees, D. Aled; Ham, Jack			Adenosine stimulates connexin 43 expression and gap junctional communication in pituitary folliculostellate cells	FASEB JOURNAL			English	Article						CD73; AMP; NECA; pituitary gland	ANTERIOR-PITUITARY; PROLACTIN-RELEASE; ALKALINE-PHOSPHATASE; GROWTH-FACTOR; ATP RELEASE; CYCLIC-AMP; IN-VITRO; RECEPTORS; INHIBITION; HEMICHANNELS	Adenosine is known to stimulate interleukin (IL)-6 and vascular endothelial growth factor (VEGF) secretion from pituitary TtT/GF folliculostellate sheath (FS) cells indicating that it is an important paracrine regulator of anterior pituitary function. This study demonstrates that rodent anterior pituitary cell lines produce extracellular adenosine that is able to increase intercellular gap junction communication in FS cells. Ecto-5'-nucleotidase (CD73), the enzyme that generates adenosine from AMP, was demonstrated by immunocytochemistry in similar to 20% of anterior pituitary cells, and some of these cells colocalized with prolactin and growth hormone. CD73 mRNA and protein were detected in GH3 and MMQ (somatotroph-lactotroph lineages) and TtT/GF cells, and enzyme activity was demonstrated by the conversion of exogenously added fluorescent ethenoAMP to ethenoadenosine. Adenosine production, as measured by HPLC, was detected in GH3 (1 mu M/h) and MMQ (3 mu M/h) but not in TtT/GF cells. Adenosine (EC50:0.5 mu M) and NECA (universal adenosine receptor agonist; EC50 0.1 mu M) stimulated connexin 43 (Cx43) mRNA and protein expression within 1-2 h in TtT/GF cells. Adenosine and NECA also stimulated gap junctional intercellular communication (as assessed by transmission of Alexa Fluor 488) by 6- to 8-fold in comparison with untreated TtT/GF cells. In cocultures of MMQ and TtT/GF cells, Cx43 expression in TtT/GF cells increased in proportion to the number of MMQ cells plated out. These data suggest that adenosine, formed locally in the anterior pituitary gland can stimulate gap junction communication in FS cells.	Univ Cardiff Wales, Ctr Endocrine & Diabet Sci, Sch Med, Cardiff CF14 4XN, Wales; Univ Cardiff Wales, Dept Med Biochem & Immunol, Sch Med, Cardiff CF14 4XN, Wales; Med Fak Carl Gustav Carus, Inst Physiol, Dresden, Germany; Royal Infirm, Dept Pathol, Glasgow G31 2ER, Lanark, Scotland	Cardiff University; Cardiff University; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Royal Infirmary of Edinburgh	Ham, J (corresponding author), Univ Cardiff Wales, Ctr Endocrine & Diabet Sci, Sch Med, Cardiff CF14 4XN, Wales.	wmdjh@cardiff.ac.uk						ANANDSRIVASTAVA MB, 1985, NEUROENDOCRINOLOGY, V41, P113, DOI 10.1159/000124163; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; DORFLINGER LJ, 1985, ENDOCRINOLOGY, V117, P2330, DOI 10.1210/endo-117-6-2330; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Fauquier T, 2001, P NATL ACAD SCI USA, V98, P8891, DOI 10.1073/pnas.151339598; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Gramsch B, 2001, EXP CELL RES, V264, P397, DOI 10.1006/excr.2000.5145; Guerineau NC, 1998, J BIOL CHEM, V273, P10389, DOI 10.1074/jbc.273.17.10389; Haink G, 2003, J CHROMATOGR B, V784, P189, DOI 10.1016/S1570-0232(02)00752-3; HENTGES S, 2000, ENDOCRINOLOGY, V120, P75; HEURTAOCXAMPO I, 2005, ENDOCRINOLOGY, V146, P726; HILL MK, 1976, ENDOCRINOLOGY, V99, P1612, DOI 10.1210/endo-99-6-1612; Kabir N, 2005, ENDOCRINOLOGY, V146, P4054, DOI 10.1210/en.2005-0122; Kondo RP, 2000, J MOL CELL CARDIOL, V32, P1859, DOI 10.1006/jmcc.2000.1220; Kumari M, 1999, REGUL PEPTIDES, V79, P41, DOI 10.1016/S0167-0115(98)00143-8; Lampe PD, 2004, INT J BIOCHEM CELL B, V36, P1171, DOI 10.1016/S1357-2725(03)00264-4; Latini S, 1999, BRIT J PHARMACOL, V127, P729, DOI 10.1038/sj.bjp.0702591; Leybaert L, 2003, CELL COMMUN ADHES, V10, P251, DOI 10.1080/15419060390262985; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; Meme W, 2004, NEUROSCIENCE, V126, P95, DOI 10.1016/j.neuroscience.2004.03.031; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; Ohkubo S, 2000, BRIT J PHARMACOL, V131, P1667, DOI 10.1038/sj.bjp.0703750; Park GH, 2002, EXP MOL MED, V34, P184, DOI 10.1038/emm.2002.27; PICANCODINIZ DLW, 1989, BRAZ J MED BIOL RES, V22, P783; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; PORTER JC, 1995, P NATL ACAD SCI USA, V92, P5351, DOI 10.1073/pnas.92.12.5351; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; Rees DA, 2003, BRIT J PHARMACOL, V140, P764, DOI 10.1038/sj.bjp.0705488; Rees DA, 2002, ENDOCRINOLOGY, V143, P2427, DOI 10.1210/en.143.6.2427; SCORZIELLO A, 1993, J MOL ENDOCRINOL, V11, P325, DOI 10.1677/jme.0.0110325; Spychala J, 2000, PHARMACOL THERAPEUT, V87, P161, DOI 10.1016/S0163-7258(00)00053-X; Suadicani SO, 2003, GLIA, V42, P160, DOI 10.1002/glia.10197; Thompson LF, 2004, J EXP MED, V200, P1395, DOI 10.1084/Jem.20040915; Turner MS, 2004, CIRC RES, V95, P726, DOI 10.1161/01.RES.0000144805.11519.1e; VANBELLE H, 1987, AM J PHYSIOL, V252, pH886, DOI 10.1152/ajpheart.1987.252.5.H886; Vergara L, 2003, ACTA PHYSIOL SCAND, V179, P33, DOI 10.1046/j.1365-201X.2003.01198.x; Vitale ML, 2001, BIOL REPROD, V64, P625, DOI 10.1095/biolreprod64.2.625; Wynn J, 2002, ENDOCR RES, V28, P663, DOI 10.1081/ERC-120016983; YAMAMOTO T, 1993, HISTOCHEMISTRY, V100, P53, DOI 10.1007/BF00268878; YAMOMOTO T, 1993, HISTOCHEMISTRY, V100, P53; Yu WH, 1998, P NATL ACAD SCI USA, V95, P7795, DOI 10.1073/pnas.95.13.7795; ZIMMER AM, 1992, ANTIBODY IMMUNOCONJ, V5, P285	49	27	30	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2585	+		10.1096/fj.06-6121fje	http://dx.doi.org/10.1096/fj.06-6121fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065216				2022-12-25	WOS:000242490700032
J	Bultinck, J; Sips, P; Vakaet, L; Brouckaert, P; Cauwels, A				Bultinck, Jennyfer; Sips, Patrick; Vakaet, Luc; Brouckaert, Peter; Cauwels, Anje			Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock	FASEB JOURNAL			English	Article						inflammation; inducible NOS; bone marrow transplantation	NITRIC-OXIDE SYNTHASE; ALPHA-DEFENSINS; ENDOTOXIC-SHOCK; MESSENGER-RNA; MICE LACKING; IFN-GAMMA; SEPSIS; MACROPHAGES; INHIBITION; INDUCTION	Septic shock is the leading cause of death in noncoronary intensive care units and the 10th leading cause of death overall. Several lines of evidence support an important role for the vasodilator NO in hypotension, a hallmark of septic shock. However, NO may also positively or negatively regulate inflammation, apoptosis, and oxidative stress. These dual effects of NO may relate to its isoform specific production but also to differences in cellular and/or temporal expression. Via bone marrow transplantations, we examined the contribution of hematopoietic cells to the dramatically elevated NO levels seen in (septic) shock. Surprisingly, hematopoietic cells are not responsible at all for the production of circulating NO after systemic tumor necrosis factor or lipopolysaccharide challenge and contribute only marginally in a bacteremic (Salmonella) model of septic shock. Immunohistochemistry identified the nonhematopoietic sources of NO as hepatocytes, paneth cells, and intestinal and renal epithelial cells. In contrast, during granulomatous Bacillus Calmette-Guerin inflammation, the hematopoietic cell population represents the sole source of systemic NO. These mouse data demonstrate that, in contrast to the general conjecture, the dramatically elevated levels of NO during (septic) shock are not produced by hematopoietic cells such as monocytes/macrophages but rather by parenchymal cells in liver, kidney and gut.	Univ Ghent VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; Ghent Univ Hosp, Dept Radiotherapy, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University Hospital	Cauwels, A (corresponding author), Univ Ghent VIB, Dept Mol Biomed Res, Technol Pk 927, B-9052 Ghent, Belgium.	anje.cauwels@dmbr.ugent.be	Sips, Patrick Y/O-9993-2017; Vakaet, Luc/A-6467-2010; Sips, Patrick/AAS-8985-2021	Sips, Patrick Y/0000-0001-9241-5980; Sips, Patrick/0000-0001-9241-5980				Alam MS, 2002, INFECT IMMUN, V70, P3130, DOI 10.1128/IAI.70.6.3130-3142.2002; Albina JE, 1995, J LEUKOCYTE BIOL, V58, P643, DOI 10.1002/jlb.58.6.643; Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Annane D, 2000, LANCET, V355, P1143, DOI 10.1016/S0140-6736(00)02063-8; Arias M, 1997, Allergol Immunopathol (Madr), V25, P280; Arkovitz MS, 1996, J PEDIATR SURG, V31, P1009, DOI 10.1016/S0022-3468(96)90075-5; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; Avontuur JAM, 1998, CRIT CARE MED, V26, P660, DOI 10.1097/00003246-199804000-00012; Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bateman RM, 2003, CRIT CARE, V7, P359, DOI 10.1186/cc2353; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BUTTERY LDK, 1994, LAB INVEST, V71, P755; Cauwels A, 2005, CELL MOL LIFE SCI, V62, P1632, DOI 10.1007/s00018-005-5142-z; CAUWELS A, 1995, J IMMUNOL, V154, P2753; Cauwels A, 2000, IMMUNITY, V13, P223, DOI 10.1016/S1074-7613(00)00022-4; Ceppi ED, 1997, BIOCHEM SOC T, V25, P929, DOI 10.1042/bst0250929; Clark IA, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-6; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567-5769(01)00086-8; COOK HT, 1994, CLIN SCI, V87, P179, DOI 10.1042/cs0870179; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; Ehlers S, 1999, IMMUNOLOGY, V98, P313; EVANS T, 1993, CIRC SHOCK, V41, P77; Feihl F, 2001, PHARMACOL THERAPEUT, V91, P179, DOI 10.1016/S0163-7258(01)00155-3; GELLER DA, 1993, J SURG RES, V55, P427, DOI 10.1006/jsre.1993.1164; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hersch M, 2005, INTENS CARE MED, V31, P1132, DOI 10.1007/s00134-005-2680-7; Hickey MJ, 2002, FASEB J, V16, P1141, DOI 10.1096/fj.01-0764fje; Hoffman RA, 1997, AM J PHYSIOL-GASTR L, V272, pG383, DOI 10.1152/ajpgi.1997.272.2.G383; Johnson ML, 1998, WORLD J SURG, V22, P187, DOI 10.1007/s002689900368; Jungi TW, 1997, INFECT IMMUN, V65, P5279, DOI 10.1128/IAI.65.12.5279-5288.1997; Jungi TW, 1996, VET IMMUNOL IMMUNOP, V54, P323, DOI 10.1016/S0165-2427(96)05690-5; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kilbourn R G, 1997, Dis Mon, V43, P277; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; Kobayashi A, 1998, CHEST, V113, P1632, DOI 10.1378/chest.113.6.1632; KOLLS J, 1994, P SOC EXP BIOL MED, V205, P220; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; Laubach VE, 1998, AM J PHYSIOL-HEART C, V275, pH2211, DOI 10.1152/ajpheart.1998.275.6.H2211; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237; MILES AM, 1995, J LEUKOCYTE BIOL, V58, P616, DOI 10.1002/jlb.58.5.616; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; Oliveira SHP, 1998, PARASITE IMMUNOL, V20, P405, DOI 10.1046/j.1365-3024.1998.00159.x; Parmely MJ, 2001, INFECT IMMUN, V69, P2621, DOI 10.1128/IAI.69.4.2621-2629.2001; Peschon JJ, 1998, J IMMUNOL, V160, P943; Poon BY, 2003, CIRCULATION, V108, P1107, DOI 10.1161/01.CIR.0000086321.04702.AC; Robertson DAF, 2004, MICROCIRCULATION, V11, P503, DOI 10.1080/10739680490476321; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; SATO K, 1995, J LEUKOCYTE BIOL, V57, P36, DOI 10.1002/jlb.57.1.36; Schluter D, 1997, AM J PATHOL, V150, P1021; Schon T, 2004, INT J TUBERC LUNG D, V8, P1134; STENGER S, 1994, J EXP MED, V180, P783, DOI 10.1084/jem.180.3.783; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stumm MM, 2002, LIVER, V22, P441, DOI 10.1034/j.1600-0676.2002.01653.x; Thiemermann C, 1997, GEN PHARMACOL-VASC S, V29, P159, DOI 10.1016/S0306-3623(96)00410-7; TRACEY WR, 1995, J PHARMACOL EXP THER, V272, P1011; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; Veihelmann A, 2002, RHEUMATOLOGY, V41, P509, DOI 10.1093/rheumatology/41.5.509; Victor VM, 2003, FREE RADICAL RES, V37, P919, DOI 10.1080/1071576031000148727; Vos TA, 1997, GASTROENTEROLOGY, V113, P1323, DOI 10.1053/gast.1997.v113.pm9322528; WEINBERG JB, 1995, BLOOD, V86, P1184; Wu F, 2001, MICROCIRCULATION, V8, P415; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635	71	61	63	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2006	20	13					2363	+		10.1096/fj.06-5798fje	http://dx.doi.org/10.1096/fj.06-5798fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	100XD	17020927				2022-12-25	WOS:000241702600021
J	Bowie, ML; Troch, MM; Delrow, J; Dietze, EC; Bean, GR; Ibarra, C; Pandiyan, G; Seewaldt, VL				Bowie, M. L.; Troch, M. M.; Delrow, J.; Dietze, E. C.; Bean, G. R.; Ibarra, C.; Pandiyan, G.; Seewaldt, V. L.			Interferon regulatory factor-1 regulates reconstituted extracellular matrix (rECM)-mediated apoptosis in human mammary epithelial cells	ONCOGENE			English	Article						mammary epithelial cells; IRF-1; apoptosis; extracellular matrix; tamoxifen	INDUCED NUCLEAR FACTORS; CREB-BINDING PROTEIN; PROMOTER ELEMENT; GROWTH; EXPRESSION; IRF-1; TAMOXIFEN; ARREST; ALPHA; FASLODEX	Interactions between extracellular matrix (ECM) and mammary epithelial cells are critical for mammary gland homeostasis and apoptotic signaling. Interferon regulatory factor-1 (IRF-1) is a transcriptional regulator that promotes apoptosis during mammary gland involution and p53-independent apoptosis. We have recently shown that rapid cell surface tamoxifen (Tam) signa ling promotes apoptosis in normal human mammary epithelial cells that were acutely damaged by expression of human papillomavirus type-16 E6 protein (*HMEC-E6). Apoptosis was mediated by recruitment of CREB-binding protein (CBP) to the gamma-activating sequence (GAS) element of the IRF-1 promoter, induction of IRF-1 and caspase-1/-3 activation. Here, we show that growth factor-depleted, reconstituted ECM (rECM), similar to Tam, promotes apoptosis in *HMEC-E6 cells through induction of IRF-1. Apoptosis was temporally associated with recruitment of CBP to the GAS element of the IRF-1 promoter, induction of IRF-1 expression and caspase-1/-3 activation. Small interfering RNA-mediated suppression of IRF-1 protein expression in *HMEC-E6 cells blocked (1) induct ion of IRF-1, (2) caspase-1/-3 activation and (3) apoptosis. These observations demonstrate that IRF-1 promotes rECM-mediated apoptosis and provide evidence that both rECM and rapid Tam signaling transcriptionally activate IRF-1 through recruitment of CBP to the IRF- 1 GAS promoter complex.	Duke Univ, Dept Med, Durham, NC 27710 USA; Fred Hutchinson Canc Res Ctr, Dept Genom Shared Resources, Seattle, WA 98104 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Fred Hutchinson Cancer Center; Duke University	Seewaldt, VL (corresponding author), Duke Univ, Dept Med, Box 2628,MRSB, Durham, NC 27710 USA.	seewa001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R01CA114068, P50CA068438, R01CA088799, P30CA014236, R01CA098441] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA114068, R01CA098441, P30CA14236, P50CA68438, R01CA088799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; DARDENNE AJ, 1991, J PATHOL, V165, P213, DOI 10.1002/path.1711650304; Dietze EC, 2005, J CELL SCI, V118, P5005, DOI 10.1242/jcs.02616; Dietze EC, 2004, ONCOGENE, V23, P3851, DOI 10.1038/sj.onc.1207480; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Goodman RH, 2000, GENE DEV, V14, P1553; Gu ZP, 2002, CANCER RES, V62, P3428; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; KELLY JM, 1986, EMBO J, V5, P1601, DOI 10.1002/j.1460-2075.1986.tb04402.x; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pizzoferrato E, 2004, CANCER RES, V64, P8381, DOI 10.1158/0008-5472.CAN-04-2223; Porta C, 2005, ONCOGENE, V24, P605, DOI 10.1038/sj.onc.1208204; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 2001, J CELL BIOL, V155, P471, DOI 10.1083/jcb.200011001; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Yokota S, 2004, J VIROL, V78, P4591, DOI 10.1128/JVI.78.9.4591-4598.2004	36	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2017	2026		10.1038/sj.onc.1210013	http://dx.doi.org/10.1038/sj.onc.1210013			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016442				2022-12-25	WOS:000245313400004
J	Hu, TH; Chouinard, M; Cox, AL; Sipes, P; Marcelo, M; Ficorilli, J; Li, SY; Gao, H; Ryan, TP; Michael, MD; Michael, LF				Hu, Tonghuan; Chouinard, Michael; Cox, Amy L.; Sipes, Philip; Marcelo, Marialuisa; Ficorilli, James; Li, Shuyu; Gao, Hong; Ryan, Timothy P.; Michael, M. Dodson; Michael, Laura F.			Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHESIS; BILE-ACID; NUCLEAR RECEPTOR; FXR; TRANSCRIPTION; CHOLESTEROL; EXPRESSION; ARGININE; PLASMA; IDENTIFICATION	The farnesoid X receptor (FXR, NR1H4) is a bile acid- responsive nuclear receptor that plays critical roles in the transcriptional regulation genes involved in cholesterol, bile acid, triglyceride, and carbohydrate metabolism. By microarray analysis of hepatic genes from female Zucker diabetic fatty (ZDF) rats treated with the FXR agonist GW4064, we have identified dimethylarginine dimethylaminohydrolase-1 (DDAH1) as an FXR target gene. DDAH1 is a key catabolic enzyme of asymmetric dimethylarginine (ADMA), a major endogenous nitric-oxide synthase inhibitor. Sequence analysis of the DDAH1 gene reveals the presence of an FXR response element (FXRE) located 90 kb downstream of the transcription initiation site and within the first intron. Functional analysis of the putative FXRE demonstrated GW4064 dose-dependent transcriptional activation from the element, and we have demonstrated that the FXRE sequence binds the FXR-RXR heterodimer. In vivo administration of GW4064 to female ZDF rats promoted a dose-dependent and > 6-fold increase in hepatic DDAH1 gene expression. The level of serum ADMA was reduced concomitantly. These findings provide a mechanism by which FXR may increase endothelium-derived nitric oxide levels through modulation of serum ADMA levels via direct regulation of hepatic DDAH1 gene expression. Thus, beneficial clinical outcomes of FXR agonist therapy may include prevention of atherosclerosis and improvement of the metabolic syndrome.	Eli Lilly & Co, Cardiovasc Res, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Michael, LF (corresponding author), Eli Lilly & Co, Cardiovasc Res, Lilly Res Labs, DC0520, Indianapolis, IN 46285 USA.	laura_michael@lilly.com		Michael, Mervyn/0000-0002-0224-1065				Achan V, 2002, CIRC RES, V90, P764, DOI 10.1161/01.RES.0000014450.40853.2B; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Berkenstam A, 2005, CURR OPIN PHARMACOL, V5, P171, DOI 10.1016/j.coph.2005.01.003; Bishop-Bailey D, 2004, P NATL ACAD SCI USA, V101, P3668, DOI 10.1073/pnas.0400046101; Boger RH, 2003, CARDIOVASC RES, V59, P824, DOI 10.1016/S0008-6363(03)00500-5; Carello KA, 2006, AM J PHYSIOL-HEART C, V290, pH209, DOI 10.1152/ajpheart.00208.2005; Cariou B, 2005, FEBS LETT, V579, P4076, DOI 10.1016/j.febslet.2005.06.033; Cariou B, 2006, J BIOL CHEM, V281, P11039, DOI 10.1074/jbc.M510258200; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; Claudel T, 2003, GASTROENTEROLOGY, V125, P544, DOI 10.1016/S0016-5085(03)00896-5; Claudel T, 2005, ARTERIOSCL THROM VAS, V25, P2020, DOI 10.1161/01.ATV.0000178994.21828.a7; Dayoub H, 2003, CIRCULATION, V108, P3042, DOI 10.1161/01.CIR.0000101924.04515.2E; Dierkes J, 2004, ATHEROSCLEROSIS, V173, P239, DOI 10.1016/j.atherosclerosis.2003.12.004; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Grundy SM, 2006, NAT REV DRUG DISCOV, V5, P294, DOI 10.1038/nrd2005; Huang L, 2003, J BIOL CHEM, V278, P51085, DOI 10.1074/jbc.M308321200; Huynh NT, 2002, J AM COLL NUTR, V21, P422, DOI 10.1080/07315724.2002.10719245; Jacobi J, 2005, CIRCULATION, V111, P1431, DOI 10.1161/01.CIR.0000158487.80483.09; Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Ma K, 2006, J CLIN INVEST, V116, P1102, DOI 10.1172/JCI25604; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Malerod L, 2005, BIOCHEM BIOPH RES CO, V336, P1096, DOI 10.1016/j.bbrc.2005.08.237; Mallamaci F, 2004, J AM SOC NEPHROL, V15, P435, DOI 10.1097/01.ASN.0000106717.58091.F6; Nijveldt RJ, 2003, CLIN NUTR, V22, P17, DOI 10.1054/clnu.2002.0612; OGAWA T, 1989, J BIOL CHEM, V264, P10205; OGAWA T, 1987, BIOCHEM BIOPH RES CO, V148, P671, DOI 10.1016/0006-291X(87)90929-6; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; Ravani P, 2005, J AM SOC NEPHROL, V16, P2449, DOI 10.1681/ASN.2005010076; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Shulman AI, 2005, NEW ENGL J MED, V353, P604, DOI 10.1056/NEJMra043590; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Siroen MPC, 2005, HEPATOLOGY, V41, P559, DOI 10.1002/hep.20579; Stayrook KR, 2005, ENDOCRINOLOGY, V146, P984, DOI 10.1210/en.2004-0965; Stuhlinger MC, 2002, JAMA-J AM MED ASSOC, V287, P1420, DOI 10.1001/jama.287.11.1420; Teerlink T, 2002, ANAL BIOCHEM, V303, P131, DOI 10.1006/abio.2001.5575; Tran CTL, 2000, GENOMICS, V68, P101, DOI 10.1006/geno.2000.6262; Tran CTL, 2003, ATHEROSCLEROSIS SUPP, V4, P33, DOI 10.1016/S1567-5688(03)00032-1; Vallance P, 2004, ARTERIOSCL THROM VAS, V24, P1023, DOI 10.1161/01.ATV.0000128897.54893.26; Vallance P, 2002, NAT REV DRUG DISCOV, V1, P939, DOI 10.1038/nrd960; Willson TM, 2001, MED RES REV, V21, P513, DOI 10.1002/med.1023; Yu LQ, 2005, J BIOL CHEM, V280, P8742, DOI 10.1074/jbc.M411080200; Zhang YQ, 2006, P NATL ACAD SCI USA, V103, P1006, DOI 10.1073/pnas.0506982103; Zoccali C, 2006, CURR OPIN NEPHROL HY, V15, P314, DOI 10.1097/01.mnh.0000222701.22583.e8	52	68	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2006	281	52					39831	39838		10.1074/jbc.M606779200	http://dx.doi.org/10.1074/jbc.M606779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	119SP	17065154	hybrid			2022-12-25	WOS:000243033900010
J	Chung, WY; Carter, R; Hardy, T; Sack, M; Hirst, TR; James, RFL				Chung, Wen Yuan; Carter, Rachel; Hardy, Tara; Sack, Markus; Hirst, Timothy R.; James, Roger F. L.			Inhibition of Escherichia coli heat-labile enterotoxin B subunit pentamer (EtxB(5)) assembly in vitro using monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; GANGLIOSIDE GM1; DIARRHEA; BINDING; VIBRIO; MEMBRANE; PROTEIN; MODEL	Heat-labile enterotoxin (Etx) produced by certain strains of Escherichia coli is a major virulence factor related to cholera toxin. Both are hexameric proteins comprising one A-subunit and five B-subunits. The pentameric B-subunit of E. coli has a high affinity for G(M1)-ganglioside receptors on gut epithelial cells and is directly responsible for toxin entry. The pentameric B-subunit (EtxB(5)) is an exceptionally stable protein, being able to maintain its quaternary structure over a wide pH range (2.0 +/- 11.0). However, little is known about the formation of the pentameric structure ( EtxB(5)) from newly synthesized B-subunit monomers (EtxB(1)). We previously described and characterized a mAb(LDS47) that was shown to be highly specific for an N-terminal decapeptide region of EtxB(1) ( Amin, T., Larkins, A., James, R. F. L., and Hirst, T. R. ( 1995) J. Biol. Chem. 270, 20143-20150). Here we also describe a mAb (LDS16) with exquisite specificity for pentameric EtxB. In this study, we have used these two mAbs, in combination, to probe the in vitro assembly of EtxB(5) from EtxB(1). EtxB pentamers disassemble in highly acidic conditions, giving rise to monomeric B-subunits that can reassemble if placed in buffers of neutral pH. Using this in vitro assembly model, it was found that at a molar ratio of 1: 1; LDS47: EtxB, 50% of reassembly was inhibited, and that this inhibition increased to 90% at a ratio of 2:1. These results infer that the N-terminal decapeptide region (APQSITELCS) defined by the LDS47 antibody is crucial for competent pentameric B-subunit assembly and stabilization.	Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 9HN, Leics, England; Canc Res UK Clin Ctr, Southampton SO16 6YD, Hants, England; Rhein Westfal TH Aachen, D-52056 Aachen, Germany; Univ Bristol, Dept Pathol, Bristol BS8 1TD, Avon, England; Univ Bristol, Dept Microbiol, Bristol BS8 1TD, Avon, England	University of Leicester; Cancer Research UK; RWTH Aachen University; University of Bristol; University of Bristol	James, RFL (corresponding author), Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 9HN, Leics, England.	rj1@leicester.ac.uk	Sack, Markus/AAP-9252-2021; Sack, Markus/K-6681-2013	Sack, Markus/0000-0002-7380-9228; Chung, Wen Yuan/0000-0003-0970-0639				AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; AMIN T, 1995, J BIOL CHEM, V270, P20143, DOI 10.1074/jbc.270.34.20143; Cheesman C, 2004, BIOCHEMISTRY-US, V43, P1609, DOI 10.1021/bi0354987; DEMOL P, 1983, LANCET, V1, P516; ECHEVERRIA P, 1985, AM J TROP MED HYG, V34, P547, DOI 10.4269/ajtmh.1985.34.547; EVANS DG, 1977, J PEDIATR-US, V91, P65, DOI 10.1016/S0022-3476(77)80446-0; FINKELSTEIN RA, 1974, J IMMUNOL, V113, P145; FISHMAN PH, 1980, J BIOL CHEM, V255, P7657; FISHMAN PH, 1978, BIOCHEMISTRY-US, V17, P711, DOI 10.1021/bi00597a024; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HIRST TR, 1995, HDB NATURAL TOXINS, V8, P123; Hol Wim G. J., 1995, V8, P185; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; KOHLER G, 1975, NATURE, V256, P497; Kuziemko GM, 1996, BIOCHEMISTRY-US, V35, P6375, DOI 10.1021/bi952314i; Lesieur C, 2002, J BIOL CHEM, V277, P16697, DOI 10.1074/jbc.M110561200; Merritt EA, 1997, PROTEIN SCI, V6, P1516, DOI 10.1002/pro.5560060716; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; Ruddock LW, 1996, J BIOL CHEM, V271, P19118, DOI 10.1074/jbc.271.32.19118; SANDKVIST M, 1990, J BIOL CHEM, V265, P15239; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; Stephens JC, 1996, J IMMUNOL METHODS, V190, P163, DOI 10.1016/0022-1759(95)00265-0; YAMAMOTO T, 1987, J BACTERIOL, V169, P1352, DOI 10.1128/jb.169.3.1352-1357.1987	26	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39465	39470		10.1074/jbc.M606038200	http://dx.doi.org/10.1074/jbc.M606038200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17038315	hybrid			2022-12-25	WOS:000242898700054
J	Jin, YJ; Blue, EK; Gallagher, PJ				Jin, Yijun; Blue, Emily K.; Gallagher, Patricia J.			Control of death-associated protein kinase (DAPK) activity by phosphorylation and proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CHRONIC OBSTRUCTIVE UROPATHY; TUBULAR CELL APOPTOSIS; PROMOTER HYPERMETHYLATION; PHOSPHATIDIC-ACID; UBIQUITIN LIGASE; DOMAIN; ACTIVATION; EXPRESSION; DELETION	Activation of death-associated protein kinase (DAPK) occurs via dephosphorylation of Ser-308 and subsequent association of calcium/calmodulin. In this study, we confirmed the existence of the alternatively spliced human DAPK-beta, and we examined the levels of DAPK autophosphorylation and DAPK catalytic activity in response to tumor necrosis factor or ceramide. It was found that DAPK is rapidly dephosphorylated in response to tumor necrosis factor or ceramide and then subsequently degraded via proteasome activity. Dephosphorylation and activation of DAPK are shown to temporally precede its subsequent degradation. This results in an initial increase in kinase activity followed by a decrease in DAPK expression and activity. The decline in DAPK expression is paralleled with increased caspase activity and cell apoptosis. These results suggest that the apoptosis regulatory activities mediated by DAPK are controlled both by phosphorylation status and protein stability.	Indiana Univ, Sch Med, Dept Cellular & Integrated Physiol, Indianapolis, IN 46202 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71103 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrated Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pgallag@iupui.edu		Blue, Emily/0000-0001-8290-4473	NHLBI NIH HHS [R01 HL054118-05A2, R01 HL054118, HL54118] Funding Source: Medline; NIDDK NIH HHS [DK064466, T32 DK064466] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK064466] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai T, 2004, ONCOL REP, V11, P661; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chalfant CE, 2004, J LIPID RES, V45, P496, DOI 10.1194/jlr.M300347-JLR200; Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Foghsgaard L, 2002, J BIOL CHEM, V277, P39499, DOI 10.1074/jbc.M206669200; Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim WS, 2003, INT J MOL MED, V12, P827; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kishino M, 2004, J AM SOC NEPHROL, V15, P1826, DOI 10.1097/01.ASN.0000131527.59781.F2; Li J, 2005, CANCER-AM CANCER SOC, V104, P771, DOI 10.1002/cncr.21215; Narayan Gopeshwar, 2003, Mol Cancer, V2, P24, DOI 10.1186/1476-4598-2-24; Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Reddy AN, 2003, CANCER RES, V63, P7694; Schildhaus HU, 2005, INT J ONCOL, V26, P1493; Shamloo M, 2005, J BIOL CHEM, V280, P42290, DOI 10.1074/jbc.M505804200; Shimizu H, 2006, BIOCHEM J, V397, P355, DOI 10.1042/BJ20051521; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; Tereshko V, 2001, NAT STRUCT BIOL, V8, P899, DOI 10.1038/nsb1001-899; Yamamoto M, 2002, EUR J BIOCHEM, V269, P139, DOI 10.1046/j.0014-2956.2002.00029.x; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515; Yukawa K, 2005, INT J MOL MED, V15, P73; Yukawa K, 2005, INT J MOL MED, V16, P389; Yukawa K, 2004, INT J MOL MED, V13, P515; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951	38	50	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39033	39040		10.1074/jbc.M605097200	http://dx.doi.org/10.1074/jbc.M605097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17056602	hybrid, Green Accepted			2022-12-25	WOS:000242898700009
J	Buch-Pedersen, MJ; Rudashevskaya, EL; Berner, TS; Venema, K; Palmgren, MG				Buch-Pedersen, Morten J.; Rudashevskaya, Elena L.; Berner, Torben S.; Venema, Kees; Palmgren, Michael G.			Potassium as an intrinsic uncoupler of the plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CALCIUM-PUMP; PHOSPHORYLATED INTERMEDIATE; ADENOSINE-TRIPHOSPHATASE; ION TRANSPORT; BINDING-SITE; YEAST; K+; NA,K-ATPASE; MECHANISM	The plant plasma membrane proton pump (H+-ATPase) is stimulated by potassium, but it has remained unclear whether potassium is actually transported by the pump or whether it serves other roles. We now show that K+ is bound to the proton pump at a site involving Asp(617) in the cytoplasmic phosphorylation domain, from where it is unlikely to be transported. Binding of K+ to this site can induce dephosphorylation of the phosphorylated E1P reaction cycle intermediate by a mechanism involving Glu(184) in the conserved TGES motif of the pump actuator domain. Our data identify K+ as an intrinsic uncoupler of the proton pump and suggest a mechanism for control of the H+/ATP coupling ratio. K+-induced dephosphorylation of E1P may serve regulatory purposes and play a role in negative regulation of the transmembrane electrochemical gradient under cellular conditions where E1P is accumulating.	Royal Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark	University of Copenhagen	Buch-Pedersen, MJ (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	mob@kvl.dk	Palmgren, Michael/A-9808-2013; Venema, Kees/G-9558-2015	Palmgren, Michael/0000-0002-9982-6114; Venema, Kees/0000-0001-5177-6464				ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Baunsgaard L, 1996, PLANT J, V10, P451, DOI 10.1046/j.1365-313X.1996.10030451.x; Benito B, 2004, EUKARYOT CELL, V3, P359, DOI 10.1128/EC.3.2.359-368.2004; Berman MC, 2001, BBA-BIOMEMBRANES, V1513, P95, DOI 10.1016/S0005-2736(01)00356-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISKIN DP, 1986, PHYSIOL PLANTARUM, V68, P159, DOI 10.1111/j.1399-3054.1986.tb06612.x; BRISKIN DP, 1992, J EXP BOT, V43, P269, DOI 10.1093/jxb/43.3.269; BRISKIN DP, 1988, PLANT PHYSIOL, V88, P84, DOI 10.1104/pp.88.1.84; Buch-Pedersen MJ, 2003, J BIOL CHEM, V278, P17845, DOI 10.1074/jbc.M212729200; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; Bukrinsky JT, 2001, FEBS LETT, V494, P6, DOI 10.1016/S0014-5793(01)02301-8; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; EPSTEIN W, 1978, J BIOL CHEM, V253, P6666; GIBRAT R, 1990, PLANT PHYSIOL, V93, P1183, DOI 10.1104/pp.93.3.1183; Herscher CJ, 1996, BIOCHEM J, V315, P673, DOI 10.1042/bj3150673; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Lanfermeijer FC, 1998, PROTEIN EXPRES PURIF, V12, P29, DOI 10.1006/prep.1997.0788; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; MORSOMME P, 1996, EMBO J, V1465, P1; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; POST RL, 1972, J BIOL CHEM, V247, P6530; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; ROMERO PJ, 1984, BIOCHIM BIOPHYS ACTA, V778, P245, DOI 10.1016/0005-2736(84)90365-1; SACHS G, 1976, J BIOL CHEM, V251, P7690; Schachtman DP, 2000, BBA-BIOMEMBRANES, V1465, P127, DOI 10.1016/S0005-2736(00)00134-6; SHIGEKAWA M, 1985, J BIOL CHEM, V260, P1679; SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8; Sorensen TLM, 2004, J BIOL CHEM, V279, P46355, DOI 10.1074/jbc.C400414200; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VARA F, 1982, J BIOL CHEM, V257, P2826; VENEMA K, 1995, J BIOL CHEM, V270, P19659, DOI 10.1074/jbc.270.33.19659; Very AA, 2002, TRENDS PLANT SCI, V7, P168, DOI 10.1016/S1360-1385(02)02262-8; VILLALOBO A, 1982, J BIOL CHEM, V257, P1824; Wang GL, 2005, J BIOL CHEM, V280, P26508, DOI 10.1074/jbc.M503789200; YODA A, 1988, J BIOL CHEM, V263, P10320; YODA S, 1986, J BIOL CHEM, V261, P1147	47	50	52	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38285	38292		10.1074/jbc.M604781200	http://dx.doi.org/10.1074/jbc.M604781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17056603	hybrid			2022-12-25	WOS:000242709500021
J	Gaibelet, G; Planchenault, T; Mazeres, S; Dumas, F; Arenzana-Seisdedos, F; Lopez, A; Lagane, B; Bachelerie, F				Gaibelet, Gerald; Planchenault, Thierry; Mazeres, Serge; Dumas, Fabrice; Arenzana-Seisdedos, Fernando; Lopez, Andre; Lagane, Bernard; Bachelerie, Francoise			CD4 and CCR5 constitutively interact at the plasma membrane of living cells - A confocal fluorescence resonance energy transfer-based approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CCR5; PROTEIN-COUPLED RECEPTOR; HIV-1 ENTRY; T-CELLS; TYPE-1 ENV; CXCR4; BINDING; FUSION; INFECTION	Human immunodeficiency virus entry into target cells requires sequential interactions of the viral glycoprotein envelope gp120 with CD4 and chemokine receptors CCR5 or CXCR4. CD4 interaction with the chemokine receptor is suggested to play a critical role in this process but to what extent such a mechanism takes place at the surface of target cells remains elusive. To address this issue, we used a confocal microspectrofluorimetric approach to monitor fluorescence resonance energy transfer at the cell plasma membrane between enhanced blue and green fluorescent proteins fused to CD4 and CCR5 receptors. We developed an efficient fluorescence resonance energy transfer analysis from experiments carried out on individual cells, revealing that receptors constitutively interact at the plasma membrane. Binding of R5-tropic HIV gp120 stabilizes these associations thus highlighting that ternary complexes between CD4, gp120, and CCR5 occur before the fusion process starts. Furthermore, the ability of CD4 truncated mutants and CCR5 ligands to prevent association of CD4 with CCR5 reveals that this interaction notably engages extracellular parts of receptors. Finally, we provide evidence that this interaction takes place outside raft domains of the plasma membrane.	Inst Pasteur, Unite Pathogenie Virale Mol, F-75015 Paris, France; CNRS, IPBS, F-31062 Toulouse, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Lopez, A (corresponding author), Inst Pasteur, Unite Pathogenie Virale Mol, 28 Rue Dr Roux, F-75015 Paris, France.	Andre.Lopez@ipbs.fr	BACHELERIE, FRANCOISE/F-8823-2013; Lagane, Bernard/AAA-2205-2019; Arenzana-Seisdedos, Fernando/E-5835-2016; Lagane, Bernard/K-8446-2016	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Lagane, Bernard/0000-0002-3459-7867; Dumas, Fabrice/0000-0002-9164-4527				Amara A, 2003, J VIROL, V77, P2550, DOI 10.1128/JVI.77.4.2550-2558.2003; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; BARANGER R, 1991, ORG GEOCHEM, V17, P467, DOI 10.1016/0146-6380(91)90112-W; Basmaciogullari S, 2006, VIROLOGY, V353, P52, DOI 10.1016/j.virol.2006.05.027; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Cezanne L, 2004, J BIOL CHEM, V279, P45057, DOI 10.1074/jbc.M404811200; Chang MI, 2005, J VIROL, V79, P14748, DOI 10.1128/JVI.79.23.14748-14755.2005; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Daumas F, 2003, BIOPHYS J, V84, P356, DOI 10.1016/S0006-3495(03)74856-5; del Real G, 2002, J EXP MED, V196, P293, DOI 10.1084/jem.20020308; Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300; Doranz BJ, 1999, J VIROL, V73, P10346, DOI 10.1128/JVI.73.12.10346-10358.1999; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Finnegan CM, 2006, ANTIVIR RES, V69, P116, DOI 10.1016/j.antiviral.2005.11.002; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Freed EO, 2004, TRENDS MICROBIOL, V12, P170, DOI 10.1016/j.tim.2004.02.001; Furuta RA, 2006, MICROBES INFECT, V8, P520, DOI 10.1016/j.micinf.2005.08.004; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Kozak SL, 2002, J VIROL, V76, P1802, DOI 10.1128/JVI.76.4.1802-1815.2002; Kuhmann SE, 2000, J VIROL, V74, P7005, DOI 10.1128/JVI.74.15.7005-7015.2000; Lagane B, 2005, MOL PHARMACOL, V67, P1966, DOI 10.1124/mol.104.009779; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lee S, 2000, J VIROL, V74, P5016, DOI 10.1128/JVI.74.11.5016-5023.2000; Lemay J, 2005, NAT IMMUNOL, V6, P535, DOI 10.1038/ni0605-535a; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Martin-Garcia J, 2005, J VIROL, V79, P6703, DOI 10.1128/JVI.79.11.6703-6713.2005; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; MAZERES S, 1996, ANAL, V24, P20; Mkrtchyan SR, 2005, J VIROL, V79, P11161, DOI 10.1128/JVI.79.17.11161-11169.2005; Nguyen DH, 2002, BLOOD, V99, P4298, DOI 10.1182/blood-2001-11-0087; Nguyen DH, 2002, J IMMUNOL, V168, P4121, DOI 10.4049/jimmunol.168.8.4121; Paterlini MG, 2002, BIOPHYS J, V83, P3012, DOI 10.1016/S0006-3495(02)75307-1; PENG X, 1994, MOL PHARMACOL, V45, P546; Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200; Percherancier Y, 2003, J BIOL CHEM, V278, P3153, DOI 10.1074/jbc.M207371200; Platt EJ, 2005, J VIROL, V79, P4347, DOI 10.1128/JVI.79.7.4347-4356.2005; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Regoes RR, 2005, TRENDS MICROBIOL, V13, P269, DOI 10.1016/j.tim.2005.04.005; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Shnaper S, 2004, J BIOL CHEM, V279, P18526, DOI 10.1074/jbc.M304950200; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; Staudinger R, 2003, J BIOL CHEM, V278, P10389, DOI 10.1074/jbc.M212013200; Steffens CM, 2003, J VIROL, V77, P4985, DOI 10.1128/JVI.77.8.4985-4991.2003; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Toth PT, 2004, J PHARMACOL EXP THER, V310, P8, DOI 10.1124/jpet.103.064956; Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002; Wang XH, 2003, BIOCHEM BIOPH RES CO, V307, P1066, DOI 10.1016/S0006-291X(03)01315-9; Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; Wright W.D., 1929, T OPTICAL SOC, V30, P141, DOI [10.1088/1475-4878/30/4/301, DOI 10.1088/1475-4878/30/4/301]; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; Zaitseva M, 2005, J LEUKOCYTE BIOL, V78, P1306, DOI 10.1189/jlb.0105043	61	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37921	37929		10.1074/jbc.M607103200	http://dx.doi.org/10.1074/jbc.M607103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17035237	hybrid			2022-12-25	WOS:000242477100071
J	Ishmael, SS; Ishmael, FT; Jones, AD; Bond, JS				Ishmael, Susan S.; Ishmael, Faoud T.; Jones, A. Daniel; Bond, Judith S.			Protease domain glycans affect oligomerization, disulfide bond formation, and stability of the meprin A metalloprotease homo-oligomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; DIFFERENTIAL EXPRESSION; ASTACIN FAMILY; ALPHA-SUBUNIT; CELL-SURFACE; SECRETION; GLYCOSYLATION; ROLES; SITE; RECEPTOR	The meprin A homo-oligomer is a highly glycosylated, secreted zinc metalloprotease of the astacin family and metzincin superfamily. This isoform of meprin is composed of disulfide-bonded dimers of alpha subunits that further associate to form large, secreted megadalton complexes of 10 or more subunits. The aim of this study was to determine the sites of glycan attachment and to assess their ability to affect the formation and stability of the homo-oligomer. Nine of the ten potential N-linked glycosylation sites (Asn-41, Asn-152, Asn-234, Asn-270, Asn-330, Asn-426, Asn-452, Asn-546, and Asn-553) were found to be glycosylated in recombinant mouse meprin A using chemical and enzymatic deglycosylation methods and electrospray ionization mass spectrometry. Chemical cross-linking demonstrated that carbohydrates are at or near the noncovalent subunit interface. The removal of two glycans in the protease domain at Asn-234 and Asn-270, as well as one in the tumor necrosis factor receptor-associated factor domain at Asn-452, by a deglycosidase under nondenaturing conditions decreased the chemical and thermal stability of the homo-oligomer without affecting quaternary structure. Site-directed mutagenesis demonstrated that no single glycan was essential for oligomer formation; however, the combined absence of the glycans at Asn-152 and Asn-270 in the protease domain hindered inter-subunit disulfide bond formation, prevented noncovalent associations, and abolished enzymatic activity. These studies provide insights into the role of glycans in the biosynthesis, activity, and stability of this extracellular protease.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bond, JS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171, Hershey, PA 17033 USA.	jbond@psu.edu	Jones, Arthur D/C-2670-2013	Jones, A. Daniel/0000-0002-7408-6690	NIDDK NIH HHS [DK19691] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019691, R01DK019691, R56DK019691] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aricescu AR, 2006, EMBO J, V25, P701, DOI 10.1038/sj.emboj.7600974; Bell SL, 2003, BIOCHEM J, V373, P893, DOI 10.1042/BJ20030096; Bertenshaw GP, 2003, J BIOL CHEM, V278, P2522, DOI 10.1074/jbc.M208808200; Bertenshaw GP, 2002, BIOL CHEM, V383, P1175, DOI 10.1515/BC.2002.129; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; Chevallier S, 1996, BIOCHEM J, V317, P731, DOI 10.1042/bj3170731; Cismasiu VB, 2004, J BIOL CHEM, V279, P26922, DOI 10.1074/jbc.M313115200; Crisman JM, 2004, J IMMUNOL, V172, P4510, DOI 10.4049/jimmunol.172.7.4510; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Doll BA, 2002, BIOL CHEM, V383, P1167, DOI 10.1515/BC.2002.128; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Garrigue-Antar L, 2002, J BIOL CHEM, V277, P43327, DOI 10.1074/jbc.M207342200; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hirano M, 2005, J IMMUNOL, V175, P3177, DOI 10.4049/jimmunol.175.5.3177; Hoffmann D, 1998, FOLD DES, V3, P337, DOI 10.1016/S1359-0278(98)00046-7; IMPERIALI B, 1995, P NATL ACAD SCI USA, V92, P97, DOI 10.1073/pnas.92.1.97; Ishmael FT, 2005, J BIOL CHEM, V280, P13895, DOI 10.1074/jbc.M414218200; Ishmael FT, 2001, J BIOL CHEM, V276, P23207, DOI 10.1074/jbc.M102654200; JIANG WP, 1992, J BIOL CHEM, V267, P9185; Jones J, 2005, BBA-GEN SUBJECTS, V1726, P121, DOI 10.1016/j.bbagen.2005.07.003; Kadowaki T, 2000, J BIOL CHEM, V275, P25577, DOI 10.1074/jbc.M003521200; Lottaz D, 1999, CANCER RES, V59, P1127; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Matters GL, 2005, CLIN EXP METASTAS, V22, P331, DOI 10.1007/s10585-005-0660-5; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Norman LP, 2003, CURR TOP DEV BIOL, V54, P145, DOI 10.1016/S0070-2153(03)54008-X; RICKERT KW, 1995, CHEM BIOL, V2, P751, DOI 10.1016/1074-5521(95)90103-5; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Rudd PM, 2001, BIOCHEMISTRY-US, V40, P3759, DOI 10.1021/bi002625f; SOJAR HT, 1987, ARCH BIOCHEM BIOPHYS, V259, P52, DOI 10.1016/0003-9861(87)90469-3; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; Tamura T, 2002, FEBS LETT, V513, P153, DOI 10.1016/S0014-5793(02)02229-9; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; VILL JP, 2003, THESIS PENN STATE U; Villa JP, 2003, BIOCHEM SOC SYMP, V70, P53, DOI 10.1042/bss0700053; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704; Wormald MR, 1999, STRUCTURE, V7, pR155, DOI 10.1016/S0969-2126(99)80095-1	44	19	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37404	37415		10.1074/jbc.M602769200	http://dx.doi.org/10.1074/jbc.M602769200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17040911	hybrid			2022-12-25	WOS:000242477100017
J	Blazquez, C; Carracedo, A; Barrado, L; Real, PJ; Fernandez-Luna, JL; Velasco, G; Malumbres, M; Guzman, M				Blazquez, Cristina; Carracedo, Arkaitz; Barrado, Lucia; Jose Real, Pedro; Fernandez-Luna, Jose Luis; Velasco, Guillermo; Malumbres, Marcos; Guzman, Manuel			Cannabinoid receptors as novel targets for the treatment of melanoma	FASEB JOURNAL			English	Article						G protein-coupled receptor; antitumoral drug; experimental therapeutics; cell proliferation	ACTIVATED PROTEIN-KINASE; GLIOBLASTOMA-MULTIFORME; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; INDUCED APOPTOSIS; TUMOR-GROWTH; IN-VIVO; CANCER; CB1; STIMULATION	Melanoma causes the greatest number of skin cancer-related deaths worldwide. Despite intensive research, prevention and early detection are the only effective measures against melanoma, so new therapeutic strategies are necessary for the management of this devastating disease. Here, we evaluated the efficacy of cannabinoid receptor agonists, a new family of potential antitumoral compounds, at skin melanoma. Human melanomas and melanoma cell lines express CB1 and CB2 cannabinoid receptors. Activation of these receptors decreased growth, proliferation, angiogenesis and metastasis, and increased apoptosis, of melanomas in mice. Cannabinoid antimelanoma activity was independent of the immune status of the animal, could be achieved without overt psychoactive effects and was selective for melanoma cells vs. normal melanocytes. Cannabinoid antiproliferative action on melanoma cells was due, at least in part, to cell cycle arrest at the G1-S transition via inhibition of the prosurvival protein Akt and hypophosphorylation of the pRb retinoblastoma protein tumor suppressor. These findings may contribute to the design of new chemotherapeutic strategies for the management of melanoma.	Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain; Ctr Nacl Invest Oncol, Cell Div, Madrid, Spain; Ctr Nacl Invest Oncol, Canc Grp, Madrid, Spain; Marques Valdecilla Univ Hosp, Unit Mol Genet, Santander, Spain	Complutense University of Madrid; Hospital Universitario Marques de Valdecilla (HUMV)	Guzman, M (corresponding author), Univ Complutense Madrid, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain.	mgp@bbm1.ucm.es	Real, Pedro J./ABH-3493-2021; Velasco, Guillermo/AAU-9189-2020; Real, Pedro J./K-2994-2014; Velasco, Guillermo/H-5260-2012; Carracedo, Arkaitz/F-7029-2011; Malumbres, Marcos/E-8834-2011	Velasco, Guillermo/0000-0002-1994-2386; Real, Pedro J./0000-0001-7968-5353; Velasco, Guillermo/0000-0002-1994-2386; Carracedo, Arkaitz/0000-0001-5957-1260; Malumbres, Marcos/0000-0002-0829-6315; Guzman, Manuel/0000-0001-7475-118X				Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Blazquez C, 2004, CANCER RES, V64, P5617, DOI 10.1158/0008-5472.CAN-03-3927; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; Bouaboula M, 1996, EUR J BIOCHEM, V237, P704, DOI 10.1111/j.1432-1033.1996.0704p.x; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Chan PC, 1996, FUND APPL TOXICOL, V30, P109, DOI 10.1006/faat.1996.0048; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; del Pulgar TG, 2002, J BIOL CHEM, V277, P36527, DOI 10.1074/jbc.M205797200; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Grotenhermen F, 2003, CLIN PHARMACOKINET, V42, P327, DOI 10.2165/00003088-200342040-00003; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hall W, 2005, LANCET ONCOL, V6, P35, DOI 10.1016/S1470-2045(05)70024-3; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Iversen L, 2005, CURR OPIN PHARMACOL, V5, P69, DOI 10.1016/j.coph.2004.08.010; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; McAllister SD, 2005, J NEURO-ONCOL, V74, P31, DOI 10.1007/s11060-004-5950-2; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; National Cancer Institute, SEER CANC STAT REV 1; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Samson MT, 2003, J IMMUNOL, V170, P4953, DOI 10.4049/jimmunol.170.10.4953; Sanchez C, 2001, CANCER RES, V61, P5784; Sanchez C, 1998, MOL PHARMACOL, V54, P834, DOI 10.1124/mol.54.5.834; Segal NH, 2003, J CLIN ONCOL, V21, P1775, DOI 10.1200/JCO.2003.10.108; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Thompson JF, 2005, LANCET, V365, P687, DOI 10.1016/S0140-6736(05)17951-3; Tramer MR, 2001, BMJ-BRIT MED J, V323, P16, DOI 10.1136/bmj.323.7303.16; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451	47	194	206	4	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2633	+		10.1096/fj.06-6638fje	http://dx.doi.org/10.1096/fj.06-6638fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065222				2022-12-25	WOS:000242490700048
J	Chang, SH; Park, H; Dong, C				Chang, Seon Hee; Park, Heon; Dong, Chen			Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B ACTIVATOR ACT1; CUTTING EDGE; IL-17; INFLAMMATION; EXPRESSION; LINEAGE; PATHWAY; ALPHA	Interleukin (IL)-17, the founding member of the IL-17 cytokine family, is the hallmark of a novel subset of CD4(+)T cells that is regulated by TGF beta, IL-6, and IL-23. IL-17 plays an important role in promoting tissue inflammation in host defense against infection and in autoimmune diseases. Although IL-17 has been reported to regulate the expression of proinflammatory cytokines, chemokines, and matrix metalloproteinases, the signaling mechanism of IL-17 receptor has not been understood. An earlier study found that IL-17 activates NF-kappa B and MAPK pathways and requires TRAF6 to induce IL-6. However, it is unknown what molecule(s) directly associates with IL-17 receptor to initiate the signaling. We demonstrate here that IL-17 receptor family shares sequence homology in their intracellular region with Toll-IL-1 receptor (TIR) domains and with Act1, a novel adaptor previously reported as an NF-kappa B activator. MyD88 and IRAK4, downstream signaling components of TIR, are not required for IL-17 signaling. On the other hand, Act1 and IL-17 receptor directly associate likely via homotypic interaction. Deficiency of Act1 in fibroblast abrogates IL-17-induced cytokine and chemokine expression, as well as the induction of C/EBP beta, C/EBP beta, and I kappa B zeta. Also, absence of Act1 results in a selective defect in IL-17-induced activation of NF-kappa B pathway. These results thus indicate Act1 as a membrane-proximal adaptor of IL-17 receptor with an essential role in induction of inflammatory genes. Our study not only for the first time reveals an immediate signaling mechanism downstream of an IL-17 family receptor but also has implications in therapeutic treatment of various immune diseases.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA	University of Texas System; UTMD Anderson Cancer Center; University of Washington; University of Washington Seattle	Dong, C (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 7455 Fannin,Unit 906, Houston, TX 77030 USA.	cdong@mdanderson.org	dong, chen/B-3181-2009	dong, chen/0000-0002-0084-9130				Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Kanamori M, 2002, FEBS LETT, V532, P241, DOI 10.1016/S0014-5793(02)03688-8; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kramer JM, 2006, J IMMUNOL, V176, P711, DOI 10.4049/jimmunol.176.2.711; Novatchkova M, 2003, TRENDS BIOCHEM SCI, V28, P226, DOI 10.1016/S0968-0004(03)00067-7; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Qian YC, 2004, IMMUNITY, V21, P575, DOI 10.1016/j.immuni.2004.09.001; Qian YC, 2002, P NATL ACAD SCI USA, V99, P9386, DOI 10.1073/pnas.142294499; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shen F, 2005, J LEUKOCYTE BIOL, V77, P388, DOI 10.1189/jlb.0904490; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5	17	255	280	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35603	35607		10.1074/jbc.C600256200	http://dx.doi.org/10.1074/jbc.C600256200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17035243	hybrid			2022-12-25	WOS:000242100500004
J	Hurley, PJ; Wilsker, D; Bunz, F				Hurley, P. J.; Wilsker, D.; Bunz, F.			Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation	ONCOGENE			English	Article						ATR; IR; cell cycle; S-phase stasis; Chk1; Seckel	DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; S-PHASE; ATAXIA-TELANGIECTASIA; TUMOR-SUPPRESSOR; SECKEL-SYNDROME; CHECKPOINT PATHWAY; HUMAN CHK1; REPLICATION; DEFECTS	The vast majority of cancer cells have defective checkpoints that permit the cell cycle to progress in the presence of double-strand DNA breaks (DSBs) caused by ionizing radiation (IR) and radiomimetic drugs. ATR (ataxia telangiectasia-mutated and Rad3-related) has recently been shown to be activated by DSBs, although the consequences of this activity are largely unknown. In this report, we use advanced gene targeting methods to generate biallelic hypomorphic ATR mutations in human colorectal cancer cells and d demonstrate that progression of the cancer cell cycle after IR treatment requires ATR. Cells with mutant ATR accumulated a defined point at the beginning of the S phase after IR treatment and were unable to progress beyond that point, where as cells at later stages of the S phase during the time of irradiation progresseda and completed DNA replication. The prolonged arrest of ATR mutant cancer cells did not involve the ataxia telangiectasia mutated-dependent S-phase checkpoint, but rather closely resembled a previously characterized form of cell cycle arrest termed S-phase stasis. As ATR strongly contributed to clonogenic survival after IR treatment, these data suggest that blocking ATR activity might be a useful strategy for inducing S-phase stasis and promoting the radiosensitization of checkpoint deficient cancer cells.	Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA	Johns Hopkins University	Bunz, F (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, 1550 Orleans St,Room 453, Baltimore, MD 21231 USA.	fbunz@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA104253] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA104253] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Borel F, 2002, J CELL SCI, V115, P2829; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jirmanova L, 2005, CELL CYCLE, V4, P1428, DOI 10.4161/cc.4.10.2055; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kumar S, 2004, J BIOL CHEM, V279, P43574, DOI 10.1074/jbc.M407819200; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; McGowan CH, 2004, CURR OPIN CELL BIOL, V16, P629, DOI 10.1016/j.ceb.2004.09.005; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; O'Driscoll M, 2004, DNA REPAIR, V3, P1227, DOI 10.1016/j.dnarep.2004.03.025; OConnor PM, 1997, CANCER RES, V57, P4285; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Saleh-Gohari N, 2005, MOL CELL BIOL, V25, P7158, DOI 10.1128/MCB.25.16.7158-7169.2005; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Seckel H.P.G., 1960, BIRD HEADED DWARFS S; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	38	43	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2535	2542		10.1038/sj.onc.1210049	http://dx.doi.org/10.1038/sj.onc.1210049			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043640				2022-12-25	WOS:000245831200001
J	Herzig, M; Savarese, F; Novatchkova, M; Semb, H; Christofori, G				Herzig, M.; Savarese, F.; Novatchkova, M.; Semb, H.; Christofori, G.			Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling	ONCOGENE			English	Article						beta-catenin; cell adhesion; E-cadherin; Tcf; tumorigenesis; Wnt signaling	EPITHELIAL-MESENCHYMAL TRANSITION; CELL-ADHESION; TRANSGENIC MICE; SUPPRESSOR GENE; CANCER CELLS; TUMORIGENESIS; EXPRESSION; INVASION; OVEREXPRESSION; MUTATIONS	E-cadherin-mediated cell-cell adhesion is frequently lost during the development of malignant epithelial cancers. Employing a transgenic mouse model of beta-cell carcinogenesis (Rip1Tag2) we have previously shown that the loss of E-cadherin is a rate-limiting step in the progression from adenoma to carcinoma. However, the mere loss of cell adhesion may not be sufficient and additional signals are required to cause tumor cells to permeate the basal membrane and to invade surrounding tissue. Besides being an important component of the E-cadherin cell-adhesion complex, beta-catenin plays a critical role in canonical Wnt signaling. We report here that beta-catenin-mediated Wnt signaling does not contribute to tumor progression in Rip1Tag2 mice. E-cadherin downregulates beta-catenin/Tcf-mediated transcriptional activity by sequestrating beta-catenin into E-cadherin cell-adhesion complexes even in the presence of activated Wnt signaling. Upon loss of E-cadherin expression, beta-catenin is degraded and Tcf/beta-catenin-mediated transcriptional activity is not induced. Moreover, forced expression of constitutive-active beta-catenin or genetic ablation of Tcf/beta-catenin transcriptional activity in tumor cells of Rip1Tag2 transgenic mice does not affect tumor progression. Together, the data indicate that signals other than beta-catenin/Tcf-mediated Wnt signaling are induced by the loss of E-cadherin during tumor progression in Rip1Tag2 transgenic mice.	Univ Basel, Biomed Ctr, Dept Clin Biol Sci, Inst Biochem & Genet, CH-4058 Basel, Switzerland; Res Inst Mol Pathol, A-1030 Vienna, Austria; Lund Univ, Stem Cell Ctr, Lund, Sweden	University of Basel; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Lund University	Christofori, G (corresponding author), Univ Basel, Biomed Ctr, Dept Clin Biol Sci, Inst Biochem & Genet, Mattenstr 28, CH-4058 Basel, Switzerland.	gerhard.christofori@unibas.ch						BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Crnic I, 2004, CANCER RES, V64, P8630, DOI 10.1158/0008-5472.CAN-04-2523; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuphal F, 2006, EXP CELL RES, V312, P457, DOI 10.1016/j.yexcr.2005.11.007; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Orsulic S, 1999, J CELL SCI, V112, P1237; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Romagnolo B, 1999, CANCER RES, V59, P3875; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van de Wetering M, 2001, CANCER RES, V61, P278; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010	33	99	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2290	2298		10.1038/sj.onc.1210029	http://dx.doi.org/10.1038/sj.onc.1210029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043652				2022-12-25	WOS:000245466000005
J	Jiao, XY; Billings, PC; O'Connell, MP; Kaplan, FS; Shore, EM; Glaser, DL				Jiao, Xiangyang; Billings, Paul C.; O'Connell, Michael P.; Kaplan, Frederick S.; Shore, Eileen M.; Glaser, David L.			Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA; MORPHOGEN; PROTEIN; SURFACE; GLYPICAN; NOGGIN; INTERNALIZATION; GRADIENTS; MYOBLASTS; BINDING	Cell surface heparan sulfate proteoglycans (HSPGs) have been implicated in bone morphogenetic protein (BMP)-mediated morphogenesis by regulating BMP activity and gradient formation. However, the direct role of HSPGs in BMP signaling is poorly understood. Here we show that HSPGs directly regulate BMP2-mediated transdifferentiation of C2C12 myoblasts into osteoblasts. HSPGs sequester BMP2 at the cell surface and mediate BMP2 internalization. Depletion of cell surface HSPGs by heparinase III treatment or decreased glycosaminoglycan chain sulfation with sodium chlorate enhances BMP2 morphogenetic bioactivity. The addition of exogenous heparin, a widely used anticoagulant, reduced BMP2 signaling. Our results suggest that cell surface HSPGs mediate BMP2 internalization and modulate BMP2 osteogenic activity.	Univ Penn, Sch Med, Ctr Res FOP & Related Disorders, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Orthopaed, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Glaser, DL (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	david.glaser@uphs.upenn.edu	O'Connell, Michael/F-9236-2017; Shore, Eileen/D-2593-2009	O'Connell, Michael/0000-0002-8615-7660	NIAMS NIH HHS [R01 AR19160841] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahn J, 2003, J BONE JOINT SURG AM, V85A, P667, DOI 10.2106/00004623-200304000-00013; Belenkaya TY, 2004, CELL, V119, P231, DOI 10.1016/j.cell.2004.09.031; Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Colin S, 1999, MOL PHARMACOL, V55, P74, DOI 10.1124/mol.55.1.74; DEJONG JGN, 1989, CLIN CHEM, V35, P1472; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Egeberg M, 2001, BBA-MOL CELL RES, V1541, P135, DOI 10.1016/S0167-4889(01)00132-X; Glaser DL, 2003, J BONE JOINT SURG AM, V85A, P2332, DOI 10.2106/00004623-200312000-00010; Gonzalez-Gaitan Marcos, 2003, Cell, V115, P513, DOI 10.1016/S0092-8674(03)00932-2; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Hausser HJ, 2004, J CELL BIOCHEM, V91, P1062, DOI 10.1002/jcb.20007; Hogan B L, 1996, Harvey Lect, V92, P83; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Jasuja R, 2004, J BIOL CHEM, V279, P51289, DOI 10.1074/jbc.M408129200; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kirkpatrick CA, 2004, DEV CELL, V7, P513, DOI 10.1016/j.devcel.2004.08.004; Kolset SO, 1999, CELL MOL LIFE SCI, V56, P857, DOI 10.1007/s000180050031; Kreuger J, 2004, DEV CELL, V7, P503, DOI 10.1016/j.devcel.2004.08.005; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; MONREAL M, 1991, LANCET, V338, P706, DOI 10.1016/0140-6736(91)91292-3; Namiki M, 1997, J BIOL CHEM, V272, P22046, DOI 10.1074/jbc.272.35.22046; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Ohkawara B, 2002, CURR BIOL, V12, P205, DOI 10.1016/S0960-9822(01)00684-4; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Ruppert R, 1996, EUR J BIOCHEM, V237, P295, DOI 10.1111/j.1432-1033.1996.0295n.x; Selleck SB, 2001, SEMIN CELL DEV BIOL, V12, P127, DOI 10.1006/scdb.2000.0242; Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804; Shafti-Keramat S, 2003, J VIROL, V77, P13125, DOI 10.1128/JVI.77.24.13125-13135.2003; Street JT, 2000, CLIN ORTHOP RELAT R, P278; Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200; Takei Y, 2004, DEVELOPMENT, V131, P73, DOI 10.1242/dev.00913; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	38	133	140	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1080	1086		10.1074/jbc.M513414200	http://dx.doi.org/10.1074/jbc.M513414200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17020882	hybrid			2022-12-25	WOS:000243295200032
J	Bazirgan, OA; Garza, RM; Hampton, RY				Bazirgan, Omar A.; Garza, Renee M.; Hampton, Randolph Y.			Determinants of RING-E2 fidelity for Hrd1p, a membrane-anchored ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-ASSOCIATED DEGRADATION; HMG-COA REDUCTASE; ER-ASSOCIATED DEGRADATION; PROTEIN-QUALITY CONTROL; ENDOPLASMIC-RETICULUM; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; REGULATED DEGRADATION; OVERLAP EXTENSION; GENE DISRUPTION; FACTOR-RECEPTOR	A critical aspect of E3 ubiquitin ligase function is the selection of a particular E2 ubiquitin-conjugating enzyme to accomplish ubiquitination of a substrate. We examined the requirements for correct E2-E3 specificity in the RING-H2 ubiquitin ligase Hrd1p, an ER-localized protein known to use primarily Ubc7p for its function. Versions of Hrd1p containing the RING motif from homologous E3s were unable to carry out Hrd1p function, revealing a requirement for the specific Hrd1p RING motif in vivo. An in vitro assay revealed that these RING motifs were sufficient to function as ubiquitin ligases, but that they did not display the E2 specificity predicted from in vivo results. We further refined the in vitro assay of Hrd1p function by demanding not only ubiquitin ligase activity, but also specific activity that recapitulated both the E2 specificity and RING selectivity observed in vivo. Doing so revealed that correct E2 engagement by Hrd1p required the presence of portions of the Hrd1p soluble cytoplasmic domain outside the RING motif, the placement of the Hrd1p ubiquitin ligase in the ER membrane, and presentation of Ubc7p in the cytosolic context. We confirmed that these conditions supported the ubiquitination of Hrd1p itself, and the transfer of ubiquitin to the prototype substrate Hmg2p-GFP, validating Hrd1p self-ubiquitination as a viable assay of ligase function.	Univ Calif San Diego, Sect Cell & Dev Biol, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Hampton, RY (corresponding author), Univ Calif San Diego, Sect Cell & Dev Biol, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rhampton@biomail.ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051996] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51996-06] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JR, 2004, BIOCHEM BIOPH RES CO, V324, P166, DOI 10.1016/j.bbrc.2004.09.035; Amano T, 2003, GENE DEV, V17, P2436, DOI 10.1101/gad.1096603; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Chen B, 2006, P NATL ACAD SCI USA, V103, P341, DOI 10.1073/pnas.0506618103; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Cronin SR, 2000, J CELL BIOL, V148, P915, DOI 10.1083/jcb.148.5.915; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Flury I, 2005, EMBO J, V24, P3917, DOI 10.1038/sj.emboj.7600855; Gardner R, 1998, MOL BIOL CELL, V9, P2611, DOI 10.1091/mbc.9.9.2611; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gardner RG, 2005, CELL, V120, P803, DOI 10.1016/j.cell.2005.01.016; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Haynes CM, 2002, J CELL BIOL, V158, P91, DOI 10.1083/jcb.200201053; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaneko M, 2002, FEBS LETT, V532, P147, DOI 10.1016/S0014-5793(02)03660-8; Katoh S, 2003, J BIOL CHEM, V278, P15341, DOI 10.1074/jbc.M210531200; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mori S, 1997, EUR J BIOCHEM, V247, P1190, DOI 10.1111/j.1432-1033.1997.01190.x; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Ravid T, 2006, EMBO J, V25, P533, DOI 10.1038/sj.emboj.7600946; Saha T, 2006, ONCOGENE, V25, P693, DOI 10.1038/sj.onc.1209123; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Song BL, 2005, MOL CELL, V19, P829, DOI 10.1016/j.molcel.2005.08.009; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhong XY, 2004, J BIOL CHEM, V279, P45676, DOI 10.1074/jbc.M409034200	53	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					38989	39001		10.1074/jbc.M608174200	http://dx.doi.org/10.1074/jbc.M608174200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17035235	hybrid			2022-12-25	WOS:000242898700005
J	Nakahara, S; Hogan, V; Inohara, H; Raz, A				Nakahara, Susumu; Hogan, Victor; Inohara, Hidenori; Raz, Avraham			Importin-mediated nuclear translocation of galectin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING PROTEIN-35; SQUAMOUS-CELL CARCINOMA; BREAST EPITHELIAL-CELLS; PORE-TARGETING COMPLEX; CYTOPLASMIC GALECTIN-3; LOCALIZATION SIGNALS; PROSTATE-CANCER; LIVING CELLS; CYCLE ARREST; IN-VIVO	Galectin-3 (Gal-3), a member of a beta-galactoside-binding protein family, is involved in RNA processing and cell cycle regulation through activation of transcription factors when translocated to the nucleus. We have previously shown that Gal-3 can import into the nucleus through at least two pathways; via passive diffusion and/or active transport (Nakahara, S., Oka, N., Wang, Y., Hogan, V., Inohara, H, and Raz, A. (2006) Cancer Res. 66, 9995-10006). Here, we investigated the process mediated by the active nuclear transport of Gal-3 and have identified a nuclear localization signal (NLS)-like motif in its protein sequence, (HRVKKL228)-H-223, that resembles p53 and c-Myc NLSs ((SRHKKL383)-S-378, (322)AKRVKL(327)), respectively. Moreover, trimers of enhanced green fluorescence protein (3 x GFP) fused with this NLS-like sequence, which is too large to passively diffuse through the nuclear pores, accumulated in the cell nuclei. To gain insights into this newly identified nuclear import mechanism, the interaction between Gal-3 and importins (importins alpha and beta) that carry the NLS harboring nuclear proteins into the nucleus, was investigated. Pull-down assays and bimolecular fluorescence complementation (BiFC) analysis revealed that wild-type Gal-3, but not mutant Gal-3 (R224A), binds to importin-alpha. Down-regulation of importin-beta by RNA interference (RNAi) efficiently abrogates its nuclear accumulation. Furthermore, we provide evidence that impaired nuclear translocation of mutant Gal-3 protein (R224A) results in accelerated degradation compared with the wild-type protein. Thus, these results suggest that Gal-3 is translocated to the nucleus, in part, via the importin-alpha/beta route and that Arg(224) amino acid residue of human Gal-3 is essential for its active nuclear translocation and its molecular stability.	Wayne State Univ, Karmanos Canc Inst, Tumor Progress & Metastasis Program, Detroit, MI 48201 USA; Osaka Univ, Grad Sch Med, Dept Otolaryngol & Sensory Organ Surg, Suita, Osaka 5650871, Japan	Barbara Ann Karmanos Cancer Institute; Wayne State University; Osaka University	Raz, A (corresponding author), Wayne State Univ, Karmanos Canc Inst, Tumor Progress & Metastasis Program, Detroit, MI 48201 USA.	raza@karmanos.org			NCI NIH HHS [R37CA46120-19] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA046120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Birbach A, 2004, J CELL SCI, V117, P3615, DOI 10.1242/jcs.01224; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Califice S, 2004, ONCOGENE, V23, P7527, DOI 10.1038/sj.onc.1207997; Chen MH, 2005, J BIOL CHEM, V280, P10599, DOI 10.1074/jbc.M413194200; COWLES EA, 1990, J BIOL CHEM, V265, P17706; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Davidson PJ, 2006, GLYCOBIOLOGY, V16, P602, DOI 10.1093/glycob/cwj088; Davidson PJ, 2002, GLYCOBIOLOGY, V12, P329, DOI 10.1093/glycob/12.5.329; Ellerhorst JA, 2002, PROSTATE, V50, P64, DOI 10.1002/pros.10033; ENNIS HL, 1964, SCIENCE, V146, P1474, DOI 10.1126/science.146.3650.1474; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fukumori T, 2003, CANCER RES, V63, P8302; Gaudin JC, 2000, BIOL CELL, V92, P49, DOI 10.1016/S0248-4900(00)88763-8; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gong HC, 1999, CANCER RES, V59, P6239; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grinberg AV, 2004, MOL CELL BIOL, V24, P4294, DOI 10.1128/MCB.24.10.4294-4308.2004; Honjo Y, 2000, CLIN CANCER RES, V6, P4635; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Kim HRC, 1999, CANCER RES, V59, P4148; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Lin HM, 2002, ONCOGENE, V21, P8001, DOI 10.1038/sj.onc.1205820; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; Ma J, 2003, J BIOL CHEM, V278, P29252, DOI 10.1074/jbc.M304196200; Mathieu A, 2005, MODERN PATHOL, V18, P1264, DOI 10.1038/modpathol.3800416; Mazurek N, 2000, J BIOL CHEM, V275, P36311, DOI 10.1074/jbc.M003831200; Meyer GA, 2000, J BIOL CHEM, V275, P3857, DOI 10.1074/jbc.275.6.3857; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Nakahara S, 2006, CANCER RES, V66, P9995, DOI 10.1158/0008-5472.CAN-06-1772; Paron I, 2003, BIOCHEM BIOPH RES CO, V302, P545, DOI 10.1016/S0006-291X(03)00151-7; Puglisi F, 2004, CANCER LETT, V212, P233, DOI 10.1016/j.canlet.2004.03.006; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shibata T, 2005, ONCOL REP, V13, P235; Shimura T, 2004, CANCER RES, V64, P6363, DOI 10.1158/0008-5472.CAN-04-1816; Takenaka Y, 2004, MOL CELL BIOL, V24, P4395, DOI 10.1128/MCB.24.10.4395-4406.2004; Tsay YG, 1999, EXP CELL RES, V252, P250, DOI 10.1006/excr.1999.4643; Wang JL, 2004, BBA-GEN SUBJECTS, V1673, P75, DOI 10.1016/j.bbagen.2004.03.013; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	49	35	37	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39649	39659		10.1074/jbc.M608069200	http://dx.doi.org/10.1074/jbc.M608069200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17056590	hybrid			2022-12-25	WOS:000242898700072
J	Kim, HJ; Lim, HH; Rho, SH; Eom, SH; Park, CS				Kim, Hyun-Ju; Lim, Hyun-Ho; Rho, Seong-Hwan; Eom, Soo Hyun; Park, Chul-Seung			Hydrophobic interface between two regulators of K+ conductance domains critical for calcium-dependent activation of large conductance Ca2+-activated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BK CHANNEL; POTASSIUM CHANNELS; BETA-1 SUBUNIT; GATING RING; CA2+-DEPENDENT ACTIVATION; CA2+ SENSITIVITY; VOLTAGE SENSOR; MUTANT CYCLES; RCK DOMAIN; PERSPECTIVE	It has been suggested that the large conductance Ca2+-activated K+ channel contains one or more domains known as regulators of K+ conductance (RCK) in its cytosolic C terminus. Here, we show that the second RCK domain (RCK2) is functionally important and that it forms a heterodimer with RCK1 via a hydrophobic interface. Mutant channels lacking RCK2 are nonfunctional despite their tetramerization and surface expression. The hydrophobic residues that are expected to form an interface between RCK1 and RCK2, based on the crystal structure of the bacterial MthK channel, are well conserved, and the interactions of these residues were confirmed by mutant cycle analysis. The hydrophobic interaction appears to be critical for the Ca2+-dependent gating of the large conductance Ca2+-activated K+ channel.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Gwangju Inst Sci & Technol, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST); Gwangju Institute of Science & Technology (GIST)	Park, CS (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	cspark@gist.ac.kr		Rho, Seong-Hwan/0000-0002-8650-8205; Park, Chul-Seung/0000-0003-0209-1412				Ahluwalia J, 2004, NATURE, V427, P853, DOI 10.1038/nature02356; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armstrong Clay M, 2003, Sci STKE, V2003, pre10, DOI 10.1126/stke.2003.188.re10; Bao L, 2004, J GEN PHYSIOL, V123, P475, DOI 10.1085/jgp.200409052; Bao L, 2005, J GEN PHYSIOL, V126, P393, DOI 10.1085/jgp.200509346; Bao L, 2002, J GEN PHYSIOL, V120, P173, DOI 10.1085/jgp.20028627; Bezanilla F, 2002, J GEN PHYSIOL, V120, P465, DOI 10.1085/jgp.20028660; Bian S, 2001, P NATL ACAD SCI USA, V98, P4776, DOI 10.1073/pnas.081072398; Braun AP, 2001, J PHYSIOL-LONDON, V533, P681, DOI 10.1111/j.1469-7793.2001.00681.x; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; Cui JM, 2000, BIOCHEMISTRY-US, V39, P15612, DOI 10.1021/bi001509+; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Diaz L, 1998, J BIOL CHEM, V273, P32430, DOI 10.1074/jbc.273.49.32430; Dong JB, 2005, J BIOL CHEM, V280, P41716, DOI 10.1074/jbc.M508144200; Du W, 2005, NAT GENET, V37, P733, DOI 10.1038/ng1585; Duncan RK, 2003, J PHYSIOL-LONDON, V547, P357, DOI 10.1113/jphysiol.2002.029785; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Fettiplace R, 1999, ANNU REV PHYSIOL, V61, P809, DOI 10.1146/annurev.physiol.61.1.809; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ha TS, 2000, EUR J BIOCHEM, V267, P910, DOI 10.1046/j.1432-1327.2000.01076.x; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Horn R, 2002, J GEN PHYSIOL, V120, P449, DOI 10.1085/jgp.20028658; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Krishnamoorthy G, 2005, J GEN PHYSIOL, V126, P227, DOI 10.1085/jgp.200509321; Lim HH, 2005, MOL BIOL CELL, V16, P1013, DOI 10.1091/mbc.E04-06-0537; Ma ZM, 2006, J GEN PHYSIOL, V127, P309, DOI 10.1085/jgp.200509421; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; Moss BL, 2001, J GEN PHYSIOL, V118, P711, DOI 10.1085/jgp.118.6.711; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Niu XW, 2004, NEURON, V42, P745, DOI 10.1016/j.neuron.2004.05.001; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Petkov GV, 2001, J PHYSIOL-LONDON, V537, P443, DOI 10.1111/j.1469-7793.2001.00443.x; PICO A, 2003, THESIS ROCKEFELLER U; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; Roosild TP, 2004, TRENDS BIOCHEM SCI, V29, P39, DOI 10.1016/j.tibs.2003.11.008; Roosild TP, 2002, CELL, V109, P781, DOI 10.1016/S0092-8674(02)00768-7; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Schreiber M, 1999, NAT NEUROSCI, V2, P416, DOI 10.1038/8077; Shi JY, 2002, NATURE, V418, P876, DOI 10.1038/nature00941; Wang SX, 2003, J BIOL CHEM, V278, P2713, DOI 10.1074/jbc.M208411200; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Xia XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956; Yazejian B, 1997, J NEUROSCI, V17, P2990; Ye S, 2006, CELL, V126, P1161, DOI 10.1016/j.cell.2006.08.029; Zeng XH, 2005, J GEN PHYSIOL, V125, P273, DOI 10.1085/jgp.200409239; Zhang X, 2001, J GEN PHYSIOL, V118, P607, DOI 10.1085/jgp.118.5.607	55	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38573	38581		10.1074/jbc.M604769200	http://dx.doi.org/10.1074/jbc.M604769200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17040919	hybrid			2022-12-25	WOS:000242709500052
J	Hornemann, T; Richard, S; Rutti, MF; Wei, Y; von Eckardstein, A				Hornemann, Thorsten; Richard, Stephane; Ruetti, Markus F.; Wei, Yu; von Eckardstein, Arnold			Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY SENSORY NEUROPATHY; SPHINGOLIPID METABOLISM; ENZYME; TRANSFERASE; CERAMIDE; TOPOLOGY; PROTEIN; SPTLC1; CELLS; MICE	Serine-palmitoyltransferase (SPT) catalyzes the rate-limiting step of the de novo synthesis of sphingolipids. SPT is considered to be a heterodimer composed of two subunits, SPTLC1 and SPTLC2. Here we report the identification of a novel, third, SPT subunit (SPTLC3) that shows 68% homology to the SPTLC2 subunit. Quantitative real-time PCR revealed that SPTLC3 expression is highly variable between different human tissues and cell lines. The highest expression was observed in placenta tissue and human trophoblast cell lines. The overexpression of SPTLC3 in Hek293 cells, which otherwise have very little endogenous SPTLC3, led to a 2- to 3-fold increase in cellular SPT activity. Silencing of SPTLC3 expression in HepG2 cells or human trophoblast cells by transfecting SPTLC3-specific siRNA resulted in a significant reduction of cellular SPT activity. The expression of two SPT isoforms could be a cellular mechanism to adjust SPT activity to tissue-specific requirements of sphingolipid synthesis.	Univ Zurich Hosp, Inst Clin Chem, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Hornemann, T (corresponding author), Univ Zurich Hosp, Inst Clin Chem, Ramistr 100, CH-8091 Zurich, Switzerland.	thorsten.hornemann@usz.ch						Bejaoui K, 2001, NAT GENET, V27, P261, DOI 10.1038/85817; Dawkins JL, 2002, NEUROMUSCULAR DISORD, V12, P656, DOI 10.1016/S0960-8966(02)00015-9; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Dickson RC, 2000, METHOD ENZYMOL, V311, P3; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Han GS, 2004, J BIOL CHEM, V279, P53707, DOI 10.1074/jbc.M410014200; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hojjati MR, 2005, BBA-MOL CELL BIOL L, V1737, P44, DOI 10.1016/j.bbalip.2005.08.006; Ikushiro H, 2003, BBA-PROTEINS PROTEOM, V1647, P116, DOI 10.1016/S1570-9639(03)00074-8; Ikushiro H, 2001, J BIOL CHEM, V276, P18249, DOI 10.1074/jbc.M101550200; Johnson VJ, 2004, TOXICOLOGY, V201, P67, DOI 10.1016/j.tox.2004.04.019; Kuhlenbaumer G, 2002, J NEUROL, V249, P1629, DOI 10.1007/s00415-002-0946-3; Lightle S, 2003, ARCH BIOCHEM BIOPHYS, V419, P120, DOI 10.1016/j.abb.2003.08.031; MERRILL AH, 1985, J LIPID RES, V26, P617; Solomon JC, 2003, CELL DEATH DIFFER, V10, P193, DOI 10.1038/sj.cdd.4401136; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200	19	125	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37275	37281		10.1074/jbc.M608066200	http://dx.doi.org/10.1074/jbc.M608066200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17023427	hybrid			2022-12-25	WOS:000242477100004
J	Kimura, T; Tomura, H; Mogi, C; Kuwabara, A; Damirin, A; Ishizuka, T; Sekiguchi, A; Ishiwara, M; Im, DS; Sato, K; Murakami, M; Okajima, F				Kimura, Takao; Tomura, Hideaki; Mogi, Chihiro; Kuwabara, Atsushi; Damirin, Alatangaole; Ishizuka, Tamotsu; Sekiguchi, Akihiro; Ishiwara, Mitsuteru; Im, Doon-Soon; Sato, Koichi; Murakami, Masami; Okajima, Fumikazu			Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR-BI; MONOCYTE ADHESION; KAPPA-B; MIGRATION; BINDING; PROTEIN; EDG-1; HDL; PHOSPHORYLATION; ACTIVATION	We characterized the molecular mechanisms by which high density lipoprotein (HDL) inhibits the expression of adhesion molecules, including vascular cell adhesion molecule-1 and intercellular adhesion molecule-1, induced by sphingosine 1-phosphate (S1P) and tumor necrosis factor (TNF) alpha in endothelial cells. HDL inhibited S1P-induced nuclear factor kappa B activation and adhesion molecule expression in human umbilical vein endothelial cells. The inhibitory HDL actions were associated with nitric-oxide synthase (NOS) activation and were reversed by inhibitors for phosphatidylinositol 3-kinase and NOS. The HDL-induced inhibitory actions were also attenuated by the down-regulation of scavenger receptor class B type I (SR-BI) and its associated protein PDZK1. When TNF alpha was used as a stimulant, the HDL-induced NOS activation and the inhibitory action on adhesion molecule expression were, in part, attenuated by the down-regulation of the expression of S1P receptors, especially S1P(1), in addition to SR-BI. Reconstituted HDL composed mainly of apolipoprotein A-I and phosphatidylcholine mimicked the SR-BI-sensitive part of HDL-induced actions. Down-regulation of S1P(3) receptors severely suppressed the stimulatory actions of S1P. Although G(i/o) proteins may play roles in either stimulatory or inhibitory S1P actions, as judged from pertussis toxin sensitivity, the coupling of S1P(3) receptors to G(12/13) proteins may be critical to distinguish the stimulatory pathways from the inhibitory ones. In conclusion, even though S1P alone stimulates adhesion molecule expression, HDL overcomes S1P(3) receptor-mediated stimulatory actions through SR-BI/PDZK1-mediated signaling pathways involving phosphatidylinositol 3-kinase and NOS. In addition, the S1P component of HDL plays a role in the inhibition of TNF alpha-induced actions through S1P receptors, especially S1P(1).	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gunma 3718512, Japan; Gunma Univ, Grad Sch Med, Dept Clin Lab Med, Maebashi, Gunma 3718511, Japan; Pusan Natl Univ, Coll Pharm, Pharmacol Lab, Pusan 609735, South Korea	Gunma University; Gunma University; Pusan National University	Okajima, F (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gunma 3718512, Japan.	fokajima@showa.gunma-u.ac.jp		IM, DONG-SOON/0000-0001-8054-8946				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Assanasen C, 2005, J CLIN INVEST, V115, P969, DOI 10.1172/JCI23858; Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13; Bolick DT, 2005, ARTERIOSCL THROM VAS, V25, P2301, DOI 10.1161/01.ATV.0000186181.19909.a6; Bolick DT, 2005, ARTERIOSCL THROM VAS, V25, P976, DOI 10.1161/01.ATV.0000162171.30089.f6; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Gong M, 2003, J CLIN INVEST, V111, P1579, DOI 10.1172/JCI200316777; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Kimura T, 2006, CELL SIGNAL, V18, P841, DOI 10.1016/j.cellsig.2005.07.011; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Miura Y, 2004, J THROMB HAEMOST, V2, P1019, DOI 10.1111/j.1538-7836.2004.00737.x; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Nakamura T, 2005, P NATL ACAD SCI USA, V102, P13404, DOI 10.1073/pnas.0506679102; Nofer JR, 1998, ARTERIOSCL THROM VAS, V18, P861, DOI 10.1161/01.ATV.18.6.861; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Okajima F, 2002, BBA-MOL CELL BIOL L, V1582, P132, DOI 10.1016/S1388-1981(02)00147-6; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; Pace MC, 1999, AM J PHYSIOL-LUNG C, V277, pL106, DOI 10.1152/ajplung.1999.277.1.L106; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Profirovic J, 2005, J BIOL CHEM, V280, P32866, DOI 10.1074/jbc.M501361200; Rader DJ, 2003, AM J CARDIOL, V92, p42J, DOI 10.1016/S0002-9149(03)00615-5; Rohrer L, 2004, CURR OPIN LIPIDOL, V15, P269, DOI 10.1097/00041433-200406000-00006; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Shimamura K, 2004, EUR J PHARMACOL, V486, P141, DOI 10.1016/j.ejphar.2003.12.022; Siehler S, 2001, J BIOL CHEM, V276, P48733, DOI 10.1074/jbc.M011072200; Silver DL, 2004, REV ENDOCR METAB DIS, V5, P327, DOI 10.1023/B:REMD.0000045104.38104.8e; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Tamama K, 2002, CURR OPIN LIPIDOL, V13, P489, DOI 10.1097/00041433-200210000-00004; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	41	157	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37457	37467		10.1074/jbc.M605823200	http://dx.doi.org/10.1074/jbc.M605823200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17046831	hybrid			2022-12-25	WOS:000242477100022
J	Wu, JH; Goswami, R; Cai, XJ; Exum, ST; Huang, XW; Zhang, LS; Brian, L; Premont, RT; Peppel, K; Freedman, NJ				Wu, Jiao-Hui; Goswami, Robi; Cai, Xinjiang; Exum, Sabrina T.; Huang, Xuewei; Zhang, Lisheng; Brian, Leigh; Premont, Richard T.; Peppel, Karsten; Freedman, Neil J.			Regulation of the platelet-derived growth factor receptor-beta by G protein-coupled receptor kinase-5 in vascular smooth muscle cells involves the phosphatase Shp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-DEFICIENT MICE; SIGNAL-TRANSDUCTION; NEOINTIMAL HYPERPLASIA; ERK ACTIVATION; EGF RECEPTORS; PHOSPHORYLATION; PDGF; DESENSITIZATION; IDENTIFICATION; INVOLVEMENT	Smooth muscle cell (SMC) proliferation and migration are substantially controlled by the platelet-derived growth factor receptor-beta(PDGFR beta), which can be regulated by the Ser/Thr kinase G protein-coupled receptor kinase-2 (GRK2). In mouse aortic SMCs, however, we found that prolonged PDGFR beta activation engendered down-regulation of GRK5, but not GRK2; moreover, GRK5 and PDGFR beta were coordinately up-regulated in SMCs from atherosclerotic arteries. With SMCs from GRK5 knock-out and cognate wild type mice (five of each), we found that physiologic expression of GRK5 increased PDGF-promoted PDGFR beta seryl phosphorylation by 3-fold and reduced PDGFR beta-promoted phosphoinositide hydrolysis, thymidine incorporation, and overall PDGFR beta tyrosyl phosphorylation by similar to 35%. Physiologic SMC GRK5 activity also increased PDGFR beta association with the phosphatase Shp2 (8-fold), enhanced phosphorylation of PDGFR beta Tyr(1009) (the docking site for Shp2), and reduced phosphorylation of PDGFR beta Tyr(1021). Consistent with having increased PDGFR beta-associated Shp2 activity, GRK5-expressing SMCs demonstrated greater PDGF-induced Src activation than GRK5-null cells. GRK5-mediated desensitization of PDGFR beta inositol phosphate signaling was diminished by Shp2 knock-down or impairment of PDGFR beta/Shp2 association. In contrast to GRK5, physiologic GRK2 activity did not alter PDGFR beta/Shp2 association. Finally, purified GRK5 effected agonist-dependent seryl phosphorylation of partially purified PDGFR beta s. We conclude that GRK5 mediates the preponderance of PDGF-promoted seryl phosphorylation of the PDGFR beta in SMCs, and, through mechanisms involving Shp2, desensitizes PDGFR beta inositol phosphate signaling and enhances PDGFR beta-triggered Src activation.	Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Duke University	Peppel, K (corresponding author), Jefferson Med Coll, 1025 Walnut St,Rm 311, Philadelphia, PA 19107 USA.	karsten.peppel@jefferson.edu; neil.freedman@duke.edu	Cai, Xinjiang/F-4843-2010; Cai, Xinjiang/A-9617-2008	Cai, Xinjiang/0000-0001-8933-7133; Premont, Richard/0000-0002-8053-5026; Zhang, Lisheng/0000-0002-9276-6454	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064744, R01HL063288, R01HL077185, R01HL073005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016347] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64744, HL63288, HL73005, HL77185] Funding Source: Medline; NIDA NIH HHS [DA16347] Funding Source: Medline; NIGMS NIH HHS [GM59989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Doanes AM, 1998, BIOCHEM MOL BIOL INT, V45, P279; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hart CE, 1999, CIRCULATION, V99, P564, DOI 10.1161/01.CIR.99.4.564; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hildreth KL, 2004, J BIOL CHEM, V279, P41775, DOI 10.1074/jbc.M403274200; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Krasel C, 2001, J BIOL CHEM, V276, P1911, DOI 10.1074/jbc.M008773200; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; PARIS S, 1987, J BIOL CHEM, V262, P1970; Peppel K, 2005, CARDIOVASC RES, V65, P674, DOI 10.1016/j.cardiores.2004.10.031; Peppel K, 2002, J MOL CELL CARDIOL, V34, P1399, DOI 10.1006/jmcc.2002.2092; Peppel K, 2000, CIRCULATION, V102, P793, DOI 10.1161/01.CIR.102.7.793; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1978, J CELL PHYSIOL, V97, P497, DOI 10.1002/jcp.1040970325; Sano H, 2001, CIRCULATION, V103, P2955, DOI 10.1161/01.CIR.103.24.2955; Seo HS, 1997, ARTERIOSCL THROM VAS, V17, P3593, DOI 10.1161/01.ATV.17.12.3593; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Vinge LE, 2001, AM J PHYSIOL-HEART C, V281, pH2490, DOI 10.1152/ajpheart.2001.281.6.H2490; Wang Q, 2005, J BIOL CHEM, V280, P8397, DOI 10.1074/jbc.M410462200; Wang Y, 2004, J BIOL CHEM, V279, P8038, DOI 10.1074/jbc.M311494200; Weiss ER, 2001, J NEUROSCI, V21, P9175, DOI 10.1523/JNEUROSCI.21-23-09175.2001; Wu JH, 2005, J BIOL CHEM, V280, P31027, DOI 10.1074/jbc.M501473200; Zhang LS, 2004, ARTERIOSCL THROM VAS, V24, P2277, DOI 10.1161/01.ATV.0000147766.68987.0d; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37758	37772		10.1074/jbc.M605756200	http://dx.doi.org/10.1074/jbc.M605756200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17018529	hybrid			2022-12-25	WOS:000242477100053
J	Chatterji, U; Bobardt, MD; Gaskill, P; Sheeter, D; Fox, H; Gallay, PA				Chatterji, Udayan; Bobardt, Michael D.; Gaskill, Peter; Sheeter, Dennis; Fox, Howard; Gallay, Philippe A.			Trim5 alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SPECIES-SPECIFIC TROPISM; OWL MONKEY CELLS; RESTRICTION FACTOR; RETROVIRUS RESTRICTION; POSTENTRY RESTRICTION; HOST RESTRICTION; TYPE-1 INFECTION; SIMIAN CELLS; OLD-WORLD	The TRIM5 alpha(tripartite motif 5 alpha protein) has been linked to the cross-species restriction in human immunodeficiency virus type 1 (HIV-1) infection of non-human cells, but the mechanism by which this occurs remains to be fully elucidated. Here we demonstrate that the capsid (CA) protein of HIV-1 is more rapidly degraded in cells expressing monkey TRIM5 alpha than in cells expressing humanTRIM5 alpha. Other proteins encoded by Gag and Pol are not subject to TRIM5 alpha-mediated accelerated degradation. The accelerated CA degradation by TRIM5 alpha apparently occurs via a nonproteosomal pathway. TRIM5 alpha selectively accelerates degradation of the CA population, which reached the cytosol of restrictive cells, but not the CA population, which ended into the vesicular compartment. Given that cytosolic CA represents "productively" entered cores, whereas vesicular CA represents "nonproductively" entered cores, our findings suggest that TRIM5 alpha interrupts the infectious pathway of HIV-1 by acting on the incoming cytosolic CA. The mode of viral entry does not influence the accelerated degradation of cytosolic CA by TRIM5 alpha. Thus, this study reveals a correlation between TRIM5 alpha-mediated HIV-1 restriction and a selective degradation of cytosolic CA normally associated with productive viral entry.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Integrat Neurosci, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Gallay, PA (corresponding author), Scripps Res Inst, Dept Immunol, IMM-9,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gallay@scripps.edu	Liu, FL/D-1795-2009; Gaskill, Peter Jesse/O-5096-2019	Gaskill, Peter Jesse/0000-0003-0095-5424; Fox, Howard/0000-0003-2032-374X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER; NIAID NIH HHS [5P30 AI036214] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599; Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125; Chatterji U, 2005, J BIOL CHEM, V280, P40293, DOI 10.1074/jbc.M506314200; Corbeil A, 2001, GENOME RES, V11, P1198, DOI 10.1101/gr.GR-1802R; Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499; Diaz-Griffero F, 2006, VIROLOGY, V349, P300, DOI 10.1016/j.virol.2005.12.040; Forshey BM, 2005, J VIROL, V79, P869, DOI 10.1128/JVI.79.2.869-875.2005; Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002; Goff SP, 2004, MOL CELL, V16, P849, DOI 10.1016/j.molcel.2004.12.001; Hatziioannou T, 2004, P NATL ACAD SCI USA, V101, P10774, DOI 10.1073/pnas.0402361101; Hatziioannou T, 2004, J VIROL, V78, P6005, DOI 10.1128/JVI.78.11.6005-6012.2004; Hatziioannou T, 2003, EMBO J, V22, P385, DOI 10.1093/emboj/cdg042; Himathongkham S, 1996, VIROLOGY, V219, P485, DOI 10.1006/viro.1996.0276; Hofmann W, 1999, J VIROL, V73, P10020, DOI 10.1128/JVI.73.12.10020-10028.1999; Ikeda Y, 2004, J VIROL, V78, P11816, DOI 10.1128/JVI.78.21.11816-11822.2004; Javanbakht H, 2005, J BIOL CHEM, V280, P26933, DOI 10.1074/jbc.M502145200; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Keckesova Z, 2004, P NATL ACAD SCI USA, V101, P10780, DOI 10.1073/pnas.0402474101; Kootstra NA, 2003, P NATL ACAD SCI USA, V100, P1298, DOI 10.1073/pnas.0337541100; Marechal V, 1998, J VIROL, V72, P2208; MUNCK C, 2003, P NATL ACAD SCI USA, V99, P13843; Nisole S, 2004, P NATL ACAD SCI USA, V101, P13324, DOI 10.1073/pnas.0404640101; Owens CA, 2003, J VIROL, V77, P726, DOI 10.1128/JVI.77.1.726-731.2003; Owens CM, 2004, J VIROL, V78, P5423, DOI 10.1128/JVI.78.10.5423-5437.2004; Perez-Caballero D, 2005, J VIROL, V79, P15567, DOI 10.1128/JVI.79.24.15567-15572.2005; Perez-Caballero D, 2005, J VIROL, V79, P8969, DOI 10.1128/JVI.79.14.8969-8978.2005; Sayah DM, 2004, NATURE, V430, P569, DOI 10.1038/nature02777; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; SHIBATA R, 1995, J GEN VIROL, V76, P2723, DOI 10.1099/0022-1317-76-11-2723; Song B, 2005, J VIROL, V79, P3930, DOI 10.1128/JVI.79.7.3930-3937.2005; Song BW, 2005, J VIROL, V79, P6111, DOI 10.1128/JVI.79.10.6111-6121.2005; Stoye JP, 2002, P NATL ACAD SCI USA, V99, P11549, DOI 10.1073/pnas.192449399; Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Towers GJ, 2005, HUM GENE THER, V16, P1125, DOI 10.1089/hum.2005.16.1125; Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910; Wei BDL, 2005, J VIROL, V79, P5705, DOI 10.1128/JVI.79.9.5705-5712.2005; Wu XL, 2006, P NATL ACAD SCI USA, V103, P7465, DOI 10.1073/pnas.0510483103; Yap MW, 2006, J VIROL, V80, P4061, DOI 10.1128/JVI.80.8.4061-4067.2006; Yap MW, 2005, CURR BIOL, V15, P73, DOI 10.1016/j.cub.2004.12.042; Yap MW, 2004, P NATL ACAD SCI USA, V101, P10786, DOI 10.1073/pnas.0402876101; Ylinen LMJ, 2005, J VIROL, V79, P11580, DOI 10.1128/JVI.79.18.11580-11587.2005; Yu GY, 2005, J VIROL, V79, P644, DOI 10.1128/JVI.79.1.644-648.2005	43	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37025	37033		10.1074/jbc.M606066200	http://dx.doi.org/10.1074/jbc.M606066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028189	hybrid			2022-12-25	WOS:000242220800064
J	Kozma, K; Keusch, JJ; Hegemann, B; Luther, KB; Klein, D; Hess, D; Haltiwanger, RS; Hofsteenge, J				Kozma, Krisztina; Keusch, Jeremy J.; Hegemann, Bjorn; Luther, Kelvin B.; Klein, Dominique; Hess, Daniel; Haltiwanger, Robert S.; Hofsteenge, Jan			Identification and characterization of a beta 1,3-glucosyltransferase that synthesizes the Glc-beta 1,3-Fuc disaccharide on thrombospondin type 1 repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED FUCOSE; GROWTH FACTOR-LIKE; HAMSTER OVARY CELLS; HISTIDINE-RICH GLYCOPROTEIN; SITE-DIRECTED MUTAGENESIS; PROTEIN O-FUCOSYL-TRANSFERASE-1; CAENORHABDITIS-ELEGANS; C-MANNOSYLATION; FACTOR DOMAIN; PLASMINOGEN-ACTIVATOR	Thrombospondin type 1 repeats (TSRs) are biologically important domains of extracellular proteins. They are modified with a unique Glc beta 1,3Fuc alpha 1-O-linked disaccharide on either serine or threonine residues. Here we identify the putative glycosyltransferase, B3GTL, as the beta 1,3-glucosyltransferase involved in the biosynthesis of this disaccharide. This enzyme is conserved from Caenorhabditis elegans to man and shares 28% sequence identity with Fringe, the beta 1,3-N-acetylglucosaminyl-transferase that modifies O-linked fucosyl residues in proteins containing epidermal growth factor-like domains, such as Notch. beta 1,3-Glucosyltransferase glucosylates properly folded TSR-fucose but not fucosylated epidermal growth factor-like domain or the non-fucosylated modules. Specifically, the glucose is added in a beta 1,3-linkage to the fucose in TSR. The activity profiles of beta 1,3-glucosyltransferase and protein O-fucosyltransferase 2, the enzyme that carries out the first step in TSR O-fucosylation, superimpose in endoplasmic reticulum subfractions obtained by density gradient centrifugation. Both enzymes are soluble proteins that efficiently modify properly folded TSR modules. The identification of the beta 1,3-glucosyltransferase gene allows us to manipulate the formation of the rare Glc beta 1,3Fuc alpha 1 structure to investigate its biological function.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Friedrich Miescher Institute for Biomedical Research; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hofsteenge, J (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	jan.hofsteenge@fmi.ch	Hegemann, Björn/A-8761-2015	Hegemann, Björn/0000-0002-1009-2952; Luther, Kelvin/0000-0001-9438-9675	NIGMS NIH HHS [GM61126, R01 GM061126] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BJOERN S, 1991, J BIOL CHEM, V266, P11051; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; BUKO AM, 1991, P NATL ACAD SCI USA, V88, P3992, DOI 10.1073/pnas.88.9.3992; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CANEVASCINI S, 2006, EUROPEAN WORM MEETIN, P71; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Cheng Y, 2004, INT J CANCER, V109, P357, DOI 10.1002/ijc.11704; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Dong SM, 2005, J NEUROPATH EXP NEUR, V64, P948, DOI 10.1097/01.jnen.0000186940.14779.90; Dunham A, 2004, NATURE, V428, P522, DOI 10.1038/nature02379; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; Haltiwanger RS, 2002, BBA-GEN SUBJECTS, V1573, P328, DOI 10.1016/S0304-4165(02)00400-2; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; Heinonen TYK, 2003, BIOCHEM BIOPH RES CO, V309, P166, DOI 10.1016/S0006-291X(03)01540-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; Jacques C, 2005, J CLIN ENDOCR METAB, V90, P2314, DOI 10.1210/jc.2004-1337; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Menzel O, 2004, GENOMICS, V84, P320, DOI 10.1016/j.ygeno.2004.04.002; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Paakkonen K, 2006, PROTEINS, V64, P665, DOI 10.1002/prot.21030; Panin VM, 2002, J BIOL CHEM, V277, P29945, DOI 10.1074/jbc.M204445200; Rampal R, 2005, J BIOL CHEM, V280, P42454, DOI 10.1074/jbc.M509552200; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; SATO T, 2006, IN PRESS GLYCOBIOLOG; Shao L, 2002, GLYCOBIOLOGY, V12, P763, DOI 10.1093/glycob/cwf085; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Simantov R, 2005, MATRIX BIOL, V24, P27, DOI 10.1016/j.matbio.2004.11.005; Simantov R, 2001, J CLIN INVEST, V107, P45, DOI 10.1172/JCI9061; SMITH CA, 1984, J BIOL CHEM, V259, P4582; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P969, DOI 10.1016/j.biocel.2003.12.011; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	57	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36742	36751		10.1074/jbc.M605912200	http://dx.doi.org/10.1074/jbc.M605912200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17032646	hybrid			2022-12-25	WOS:000242220800031
J	Platara, M; Ruiz, A; Serrano, R; Palomino, A; Moreno, F; Arino, J				Platara, Maria; Ruiz, Amparo; Serrano, Raquel; Palomino, Aaron; Moreno, Fernando; Arino, Joaquin			The transcriptional response of the yeast Na+-ATPase ENA1 gene to alkaline stress involves three main signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE GENOME; SNF1 PROTEIN-KINASE; SALT TOLERANCE; PHOSPHATASE CALCINEURIN; GLUCOSE REPRESSION; ION HOMEOSTASIS; PLASMA-MEMBRANE; MAP KINASE; EXPRESSION	Adaptive response of the yeast Saccharomyces cerevisiae to environmental alkalinization results in remodeling of gene expression. A key target is the gene ENA1, encoding a Na+ ATPase, whose induction by alkaline pH has been shown to involve calcineurin and the Rim101/Nrg1 pathway. Previous functional analysis of the ENA1 promoter revealed a calcineurin-independent pH responsive region (ARR2, 83 nucleotides). We restrict here this response to a small (42 nucleotides) ARR2 5'-region, named MCIR (minimum calcineurin independent response), which contains a MIG element, able to bind Mig1,2 repressors. High pH-induced response driven from this region was largely abolished in snf1 cells and moderately reduced in a rim101 strain. Cells lacking Mig1 or Mig2 repressors had a near wild type response, but the double mutant presented a high level of expression upon alkaline stress. Deletion of NRG1 (but not of NRG2) resulted in increased expression. Induction from the MCIR region was marginal in a quadruple mutant lacking Nrg1,2 and Mig1,2 repressors. In vitro band shift experiments demonstrated binding of Nrg1 to the 5' end of the ARR2 region. Furthermore, we show that Nrg1 binds in vivo around the MCIR region under standard growth conditions, and that binding is largely abolished after high pH stress. Therefore, the calcineurin-independent response of the ENA1 gene is under the regulation of Rim101 (through Nrg1) and Snf1 (through Nrg1 and Mig2). Accordingly, induction by alkaline stress of the entire ENA1 promoter in a snf1 rim101 mutant in the presence of the calcineurin inhibitor FK506 is completely abolished. Thus, the transcriptional response to alkaline stress of the ENA1 gene integrates three different signaling pathways.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Oviedo, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain	Autonomous University of Barcelona; University of Oviedo	Arino, J (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Ed 5, E-08193 Barcelona, Spain.	Joaquin.Arino@uab.es	Ruiz, Amparo/AAZ-2317-2021; Arino, Joaquin/D-3756-2011	Ruiz, Amparo/0000-0002-3947-4540; Arino, Joaquin/0000-0002-6774-2987; Arino Carmona, Joaquin/0000-0002-0390-4270				Adams A, 1997, METHODS YEAST GENETI; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Garcia-Salcedo R, 2006, EUKARYOT CELL, V5, P1388, DOI 10.1128/EC.00154-06; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HIRATA D, 1995, MOL GEN GENET, V249, P257, DOI 10.1007/BF00290525; Idrissi FZ, 1998, J MOL BIOL, V284, P925, DOI 10.1006/jmbi.1998.2215; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kane PA, 2006, MICROBIOL MOL BIOL R, V70, P177, DOI 10.1128/MMBR.70.1.177-191.2006; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lamb TM, 2003, MOL CELL BIOL, V23, P677, DOI 10.1128/MCB.23.2.677-686.2003; Lamb TM, 2001, J BIOL CHEM, V276, P1850, DOI 10.1074/jbc.M008381200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MacIsaac KD, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-113; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; Mendizabal I, 2001, MOL GENET GENOMICS, V265, P801, DOI 10.1007/s004380100474; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Park SH, 1999, MOL CELL BIOL, V19, P2044; Penalva MA, 2002, MICROBIOL MOL BIOL R, V66, P426, DOI 10.1128/MMBR.66.3.426-446.2002; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Proft M, 1999, MOL CELL BIOL, V19, P537; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; Reynolds A., 1997, CURRENT PROTOCOLS MO; Rodriguez C, 2003, FEMS YEAST RES, V3, P77, DOI 10.1016/S1567-1356(02)00156-3; Ruiz A, 2006, MOL MICROBIOL, V62, P263, DOI 10.1111/j.1365-2958.2006.05370.x; Sambrook J, 2001, MOL CLONING LAB MANU; Sanz P, 2003, BIOCHEM SOC T, V31, P178; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Serrano R, 2004, J BIOL CHEM, V279, P19698, DOI 10.1074/jbc.M313746200; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; SU SSY, 1993, GENETICS, V133, P67; Tomas-Cobos L, 2004, J BIOL CHEM, V279, P22010, DOI 10.1074/jbc.M400609200; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; Viladevall L, 2004, J BIOL CHEM, V279, P43614, DOI 10.1074/jbc.M403606200; Vyas VK, 2005, EUKARYOT CELL, V4, P1882, DOI 10.1128/EC.4.11.1882-1891.2005; Vyas VK, 2001, GENETICS, V158, P563; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zhou H, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-5	50	69	70	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36632	36642		10.1074/jbc.M606483200	http://dx.doi.org/10.1074/jbc.M606483200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023428	hybrid			2022-12-25	WOS:000242220800020
J	Qian, H; Martin, RJ; Robertson, AP				Qian, Hai; Martin, Richard J.; Robertson, Alan P.			Pharmacology of N-, L-, and B-subtypes of nematode nAChR resolved at the single-channel level in Ascaris suum	FASEB JOURNAL			English	Article						anthelmintic; levamisole; nicotinic; ACh receptor; patch-clamp	NICOTINIC ACETYLCHOLINE-RECEPTORS; HUMAN HOOKWORM INFECTIONS; LEVAMISOLE RESISTANCE; GENE ENCODES; PYRANTEL; PARAHERQUAMIDE; ANTHELMINTICS; METHYRIDINE; EFFICACY; SUBUNIT	Pharmacological experiments on Ascaris suum have demonstrated the presence of three (N-, L-, and B-) subtypes of cholinergic receptor mediating contraction of body wall muscle in parasitic nematodes (1). In the present study, these ionotropic acetylcholine (ACh) receptors (nAChRs) were activated by levamisole and bephenium under patch-clamp conditions and competitively antagonized by paraherquamide and 2-desoxoparaherquamide. A number of recordings exhibited three separate current amplitude levels, indicating the presence of small, intermediate, and large conductance subtypes of receptor. The mean conductance of the small conductance subtype, G(25), was 22 +/- 1 pS; the intermediate conductance channel, G(35), was 33 +/- 1 pS; and the large conductance channel, G(45), was 45 +/- 1 pS. The small channel was not antagonized significantly by paraherquamide and was identified as the N- subtype. The intermediate channel was preferentially activated by levamisole rather than bephenium and antagonized by paraherquamide: the intermediate channel was identified as the L- subtype. The large conductance channel was preferentially activated by bephenium, antagonized more by 2-desoxoparaherquamde than by paraherquamide and was identified as the B- subtype. These observations reveal that the three channel subtypes have different selectivity for cholinergic anthelmintics. The different selectivity of these compounds should be considered when dealing with drug resistant infections.	Iowa State Univ, Dept Biomed Sci, Coll Vet Med, Ames, IA 50011 USA	Iowa State University	Martin, RJ (corresponding author), Iowa State Univ, Dept Biomed Sci, Coll Vet Med, 2008, Ames, IA 50011 USA.	rjmartin@iastate.edu	Martin, Richard John/A-1783-2011	Martin, Richard John/0000-0003-2422-1847	NIAID NIH HHS [R01 AI47194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albonico M, 2002, T ROY SOC TROP MED H, V96, P685, DOI 10.1016/S0035-9203(02)90352-4; Blaxter Mark L., 2001, P1, DOI 10.1079/9780851994239.0001; COLQUHOUN D, 1982, BRIT J PHARMACOL, V75, P77, DOI 10.1111/j.1476-5381.1982.tb08759.x; Culetto E, 2004, J BIOL CHEM, V279, P42476, DOI 10.1074/jbc.M404370200; Fleming JT, 1997, J NEUROSCI, V17, P5843; Hoekstra R, 1997, MOL BIOCHEM PARASIT, V84, P179, DOI 10.1016/S0166-6851(96)02793-4; HOLLAND CV, 1989, PARASITOLOGY, V99, P275, DOI 10.1017/S003118200005873X; Horton J, 2003, TRENDS PARASITOL, V19, P527, DOI 10.1016/j.pt.2003.09.007; Jones AK, 2004, BIOESSAYS, V26, P39, DOI 10.1002/bies.10377; Levandoski MM, 2005, INT J PARASITOL, V35, P925, DOI 10.1016/j.ijpara.2005.03.007; Martin RJ, 2004, INT J PARASITOL, V34, P1083, DOI 10.1016/j.ijpara.2004.04.014; Martin RJ, 1998, INT J PARASITOL, V28, P849, DOI 10.1016/S0020-7519(98)00048-4; Martin RJ, 2003, BRIT J PHARMACOL, V140, P1068, DOI 10.1038/sj.bjp.0705528; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Reynoldson JA, 1997, ACTA TROP, V68, P301, DOI 10.1016/S0001-706X(97)00106-X; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; Robertson AP, 1999, FASEB J, V13, P749, DOI 10.1096/fasebj.13.6.749; Robertson AP, 2002, J PHARMACOL EXP THER, V302, P853, DOI 10.1124/jpet.102.034272; ROBERTSON SJ, 1993, BRIT J PHARMACOL, V108, P170, DOI 10.1111/j.1476-5381.1993.tb13458.x; ROBERTSON SJ, 1993, PESTIC SCI, V37, P293, DOI 10.1002/ps.2780370310; Sacko M, 1999, T ROY SOC TROP MED H, V93, P195, DOI 10.1016/S0035-9203(99)90306-1; Touroutine D, 2005, J BIOL CHEM, V280, P27013, DOI 10.1074/jbc.M502818200; Towers PR, 2005, J NEUROCHEM, V93, P1, DOI 10.1111/j.1471-4159.2004.02951.x; *WHO, 2000, COMM DIS CONTR SCHIS; Wiley LJ, 1997, MOL BIOCHEM PARASIT, V90, P415, DOI 10.1016/S0166-6851(97)00179-5; YAMAZAKI M, 1981, TETRAHEDRON LETT, V22, P135, DOI 10.1016/0040-4039(81)80168-2; Zinser EW, 2002, J VET PHARMACOL THER, V25, P241, DOI 10.1046/j.1365-2885.2002.00423.x	27	58	62	4	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2606	+		10.1096/fj.06-6264fje	http://dx.doi.org/10.1096/fj.06-6264fje			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17056760				2022-12-25	WOS:000242490700039
J	Olmeda, D; Jorda, M; Peinado, H; Fabra, A; Cano, A				Olmeda, D.; Jorda, M.; Peinado, H.; Fabra, A.; Cano, A.			Snail silencing effectively suppresses tumour growth and invasiveness	ONCOGENE			English	Article						snail; E-cadherin; EMT; MET; tumorigenicity; invasion	TRANSCRIPTION FACTOR SNAIL; EPITHELIAL-MESENCHYMAL TRANSITIONS; CELL-ADHESION MOLECULE; E-CADHERIN EXPRESSION; GENE-EXPRESSION; REPRESSOR SNAIL; SUPERFAMILY; PROGRESSION; JUNCTIONS; INVASION	The transcription factor Snail has been recently proposed as an important mediator of tumour invasion because of its role in downregulation of E-cadherin and induction of epithelial-mesenchymal transitions (EMT). This behaviour has led to the consideration of Snail as a potential therapeutic target to block tumour progression. In this report, we provide evidence for this hypothesis. We show that silencing of Snail by stable RNA interference in MDCK-Snail cells induces a complete mesenchymal to epithelial transition (MET), associated to the upregulation of E-cadherin, downregulation of mesenchymal markers and inhibition of invasion. More importantly, stable interference of endogenous Snail in two independent carcinoma cell lines leads to a dramatic reduction of in vivo tumour growth, accompanied by increased tumour differentiation and a significant decrease in the expression of MMP-9 and angiogenic markers and invasiveness. These results indicate that use of RNA interference can be an effective tool for blocking Snail function, opening the way for its application in new antiinvasive therapies.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Dept Bioquim, Madrid 28029, Spain; IDIBELL, Inst Invest Bellvitge, Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Cano, A (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Dept Bioquim, C Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Peinado, Hector/A-6417-2013; Jordà, Mireia/Z-4519-2019; Olmeda, David/L-4270-2017	Peinado, Hector/0000-0002-4256-3413; Olmeda, David/0000-0001-5513-5621; Jorda, Mireia/0000-0003-3709-1850				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1992, Semin Cell Biol, V3, P169; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Espineda CE, 2004, MOL BIOL CELL, V15, P1364, DOI 10.1091/mbc.E03-09-0646; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Llorens A, 1998, LAB INVEST, V78, P1131; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Sefton M, 1998, DEVELOPMENT, V125, P3111; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	37	208	220	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1862	1874		10.1038/sj.onc.1209997	http://dx.doi.org/10.1038/sj.onc.1209997			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043660				2022-12-25	WOS:000245117700004
J	Cosentino, C; Di Domenico, M; Porcellini, A; Cuozzo, C; De Gregorio, G; Santillo, MR; Agnese, S; Di Stasio, R; Feliciello, A; Migliaccio, A; Avvedimento, EV				Cosentino, C.; Di Domenico, M.; Porcellini, A.; Cuozzo, C.; De Gregorio, G.; Santillo, M. R.; Agnese, S.; Di Stasio, R.; Feliciello, A.; Migliaccio, A.; Avvedimento, E. V.			p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival	ONCOGENE			English	Article						cAMP; PI3K; p21Ras; growth	CELL-CYCLE PROGRESSION; STIMULATING-HORMONE; SIGNALING PATHWAY; KINASE; ACTIVATION; RECEPTOR; FIBROBLASTS; EXPRESSION; BETA; TOR	Cyclic adenosine 3050 monophosphate (cAMP) and protein kinase A (PKA) cooperate with phosphatidylinositol 30 kinase (PI3K) signals in the control of growth and survival. To determine the molecular mechanism(s) involved, we identified and mutagenized a specific serine (residue 83) in p85 alpha(PI3K), which is phosphorylated in vivo and in vitro by PKA. Expression of p85 alpha(PI3K) mutants (alanine or aspartic substitutions) significantly altered the biological responses of the cells to cAMP. cAMP protection from anoikis was reduced in cells expressing the alanine version p85 alpha(PI3K). These cells did not arrest in G1 in the presence of cAMP, whereas cells expressing the aspartic mutant p85D accumulated in G1 even in the absence of cAMP. S phase was still efficiently inhibited by cAMP in cells expressing both mutants. The binding of PI3K to Ras p21 was greatly reduced in cells expressing p85A in the presence or absence of cAMP. Conversely, expression of the aspartic mutant stimulated robustly the binding of PI3K to p21 Ras in the presence of cAMP. Mutation in the Ser 83 inhibited cAMP, but not PDGF stimulation of PI3K. Conversely, the p85D aspartic mutant amplified cAMP stimulation of PI3K activity. Phosphorylation of Ser 83 by cAMP - PKA in p85 alpha(PI3K) was also necessary for estrogen signaling as expression of p85A or p85D mutants inhibited or amplified, respectively, the binding of estrogen receptor to p85 alpha and AKT phosphorylation induced by estrogens. The data presented indicate that: (1) phosphorylation of Ser 83 in p85a PI3K is critical for cAMP - PKA induced G1 arrest and survival in mouse 3T3. broblasts; (2) this site is necessary for amplification of estrogen signals by cAMP - PKA and related receptors. Finally, these data suggest a general mechanism of PI3K regulation by cAMP, operating in various cell types and under different conditions.	CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Cellulaire, Naples, Italy; Univ Naples 2, Dipartimento Patol Gen, Naples, Italy; Univ Roma La Sapienza, Dipartimento Sperimentale & Patol, I-00161 Rome, Italy; INM Neuromed, Pozzilli, Italy; Univ Naples Federico II, Dipartimento Neurosci, Sez Fisiol, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Universita della Campania Vanvitelli; Sapienza University Rome; IRCCS Neuromed; University of Naples Federico II	Avvedimento, EV (corresponding author), CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Via S Pansini 5, Naples, Italy.	avvedim@unina.it	Porcellini, Antonio/E-1900-2011; Porcellini, Antonio/AAC-6097-2019; Cosentino, Claudia/AAF-1100-2019; Migliaccio, Antimo/AAB-3376-2019	Porcellini, Antonio/0000-0001-6882-9518; Migliaccio, Antimo/0000-0002-4197-2055; Feliciello, Antonio/0000-0002-7932-2170; Di Domenico, Marina/0000-0002-6201-4200				Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Alvarez B, 2003, J BIOL CHEM, V278, P26466, DOI 10.1074/jbc.M300663200; Ariga M, 2000, BIOCHEM J, V348, P409, DOI 10.1042/0264-6021:3480409; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; DEGREGORIA G, 2006, IN PRESS ONCOGENE; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KNECHT M, 1984, ENDOCRINOLOGY, V115, P41, DOI 10.1210/endo-115-1-41; Kurokawa K, 1998, CELL STRUCT FUNCT, V23, P357, DOI 10.1247/csf.23.357; Lee Y. Z., 1998, Annals of Noninvasive Electrocardiology, V3, P244, DOI 10.1111/j.1542-474X.1998.tb00350.x; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; Porcellini A, 2003, J BIOL CHEM, V278, P40621, DOI 10.1074/jbc.M307501200; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Zurita-Martinez SA, 2005, EUKARYOT CELL, V4, P63, DOI 10.1128/EC.4.1.63-71.2005	23	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2095	2103		10.1038/sj.onc.1210027	http://dx.doi.org/10.1038/sj.onc.1210027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016431				2022-12-25	WOS:000245313400011
J	Dries, DR; Gallegos, LL; Newton, AC				Dries, Daniel R.; Gallegos, Lisa L.; Newton, Alexandra C.			A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; SWISS-MODEL; BETA-II; MEMBRANE; DELTA; PHOSPHORYLATION; ACTIVATION; MECHANISM; AFFINITY; LIGAND	The C1 domain mediates the diacylglycerol (DAG)-dependent translocation of conventional and novel protein kinase C (PKC) isoforms. In novel PKC isoforms(nPKCs), this domain binds membranes with sufficiently high affinity to recruit nPKCs to membranes in the absence of any other targeting mechanism. In conventional PKC (cPKC) isoforms, however, the affinity of the C1 domain for DAG is two orders of magnitude lower, necessitating the coordinated binding of the C1 domain and a Ca2+-regulated C2 domain for translocation and activation. Here we identify a single residue that tunes the affinity of the C1b domain for DAG-(but not phorbol ester-) containing membranes. This residue is invariant as Tyr in the C1b domain of cPKCs and invariant as Trp in all other PKC C1 domains. Binding studies using model membranes, as well as live cell imaging studies of yellow fluorescent protein-tagged C1 domains, reveal that Trp versus Tyr toggles the C1 domain between a species with sufficiently high affinity to respond to agonist-produced DAG to one that is unable to respond to physiological levels of DAG. In addition, we show that while Tyr at this switch position causes cytosolic localization of the C1 domain under unstimulated conditions, Trp targets these domains to the Golgi, likely due to basal levels of DAG at this region. Thus, Trp versus Tyr at this key position in the C1 domain controls both the membrane affinity and localization of PKC. The finding that a single residue controls the affinity of the C1 domain for DAG- containing membranes provides a molecular explanation for why 1) DAG alone is sufficient to activate nPKCs but not cPKCs and 2) nPKCs target to the Golgi.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr,0721, La Jolla, CA 92093 USA.	anewton@ucsd.edu		DRIES, DANIEL/0000-0002-0530-5212	NIGMS NIH HHS [GM-43154, 2T32 GM-07752, 2T32 GM-08326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326, R01GM043154, T32GM007752, R37GM043154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; BARTLETT GR, 1959, J BIOL CHEM, V234, P468; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Canagarajah B, 2004, CELL, V119, P407, DOI 10.1016/j.cell.2004.10.012; Carrasco S, 2004, MOL BIOL CELL, V15, P2932, DOI 10.1091/mbc.E03-11-0844; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Gallegos LL, 2006, J BIOL CHEM, V281, P30947, DOI 10.1074/jbc.M603741200; Giorgione JR, 2006, J BIOL CHEM, V281, P1660, DOI 10.1074/jbc.M510251200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hurley JH, 1997, PROTEIN SCI, V6, P477; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Insel PA, 2001, CLIN EXP PHARMACOL P, V28, P351, DOI 10.1046/j.1440-1681.2001.03452.x; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; KHANDWALA AS, 1971, BIOCHIM BIOPHYS ACTA, V233, P348, DOI 10.1016/0005-2736(71)90332-4; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; KOIVUNEN J, 2005, CANC LETT; Marquez VE, 2003, ACCOUNTS CHEM RES, V36, P434, DOI 10.1021/ar020124b; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Pak Y, 2001, J MED CHEM, V44, P1690, DOI 10.1021/jm000488e; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Pu YM, 2006, J BIOL CHEM, V281, P33773, DOI 10.1074/jbc.M606560200; Rodriguez-Alfaro JA, 2004, J MOL BIOL, V335, P1117, DOI 10.1016/j.jmb.2003.10.080; Saito Naoaki, 2003, Methods Mol Biol, V233, P93; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shen N, 2005, BIOCHEMISTRY-US, V44, P1089, DOI 10.1021/bi0476127; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	39	125	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					826	830		10.1074/jbc.C600268200	http://dx.doi.org/10.1074/jbc.C600268200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17071619	hybrid			2022-12-25	WOS:000243295200003
J	Gajjeraman, S; Narayanan, K; Hao, JJ; Qin, CL; George, A				Gajjeraman, Sivakumar; Narayanan, Karthikeyan; Hao, Jianjun; Qin, Chunlin; George, Anne			Matrix macromolecules in hard tissues control the nucleation and hierarchical assembly of hydroxyapatite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PHOSPHATE; IN-VITRO; DENTIN; PROTEIN-1; BIOMINERALIZATION; BONE; CRYSTALS; COLLAGEN; ODONTOBLAST; EXPRESSION	Biogenic minerals found in teeth and bones are synthesized by precise cell-mediated mechanisms. They have superior mechanical properties due to their complex architecture. Control over biomineral properties can be accomplished by regulation of particle size, shape, crystal orientation, and polymorphic structure. In many organisms, biogenic minerals are assembled using a transient amorphous mineral phase. Here we report that organic constituents of bones and teeth, namely type I collagen and dentin matrix protein 1 (DMP1), are effective crystal modulators. They control nucleation of calcium phosphate polymorphs and the assembly of hierarchically ordered crystalline composite material. Both full-length recombinant DMP1 and post-translationally modified native DMP1 were able to nucleate hydroxyapatite (HAP) in the presence of type I collagen. However, the N-terminal domain of DMP1( amino acid residues 1-334) inhibited HAP formation and stabilized the amorphous phase that was formed. During the nucleation and growth process, the initially formed metastable amorphous calcium phosphate phase transformed into thermodynamically stable crystalline hydroxyapatite in a precisely controlled manner. The organic matrix-mediated controlled transformation of amorphous calcium phosphate into crystalline HAP was confirmed by x-ray diffraction, selected area electron diffraction pattern, Raman spectroscopy, and elemental analysis. The mechanical properties of the protein-mediated HAP crystals were also determined as they reflect the material structure. Such understanding of biomolecule controls on biomineralization promises new insights into the controlled synthesis of crystalline structures.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA.	anneg@uic.edu	Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE 11657, DE 16533] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE016533] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BOSKEY AL, 1992, CLIN ORTHOP RELAT R, P244; Bradt JH, 1999, CHEM MATER, V11, P2694, DOI 10.1021/cm991002p; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; De Yoreo JJ, 2004, SCIENCE, V306, P1301, DOI 10.1126/science.1100889; Du C, 2005, SCIENCE, V307, P1450, DOI 10.1126/science.1105675; Eanes E D, 2001, Monogr Oral Sci, V18, P130; EANES ED, 1965, NATURE, V208, P365, DOI 10.1038/208365a0; Estroff LA, 2004, ORG BIOMOL CHEM, V2, P137, DOI 10.1039/b309731e; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; George A, 1998, EUR J ORAL SCI, V106, P221, DOI 10.1111/j.1600-0722.1998.tb02179.x; George A, 1995, Connect Tissue Res, V33, P67, DOI 10.3109/03008209509016984; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Gericke A, 2005, CALCIFIED TISSUE INT, V77, P45, DOI 10.1007/s00223-004-1288-1; Hao JJ, 2004, BONE, V34, P921, DOI 10.1016/j.bone.2004.01.020; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; He G, 2005, BIOCHEMISTRY-US, V44, P16140, DOI 10.1021/bi051045l; He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Jiang HD, 2005, J BIOL CHEM, V280, P42061, DOI 10.1074/jbc.M412280200; Jiang HD, 2004, J BIOL CHEM, V279, P41286, DOI 10.1074/jbc.M314027200; LINDE A, 1995, INT J DEV BIOL, V39, P213; Milenko M, 2004, J RES NATL INST STAN, V109, P553; Moroi H H, 1993, Int J Prosthodont, V6, P564; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Pach L, 1996, J MATER SCI, V31, P6565, DOI 10.1007/BF00356263; PAYNE KJ, 1988, BIOPOLYMERS, V27, P1749, DOI 10.1002/bip.360271105; Politi Y, 2004, SCIENCE, V306, P1161, DOI 10.1126/science.1102289; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Qin CL, 2003, J BIOL CHEM, V278, P34700, DOI 10.1074/jbc.M305315200; SANO H, 1994, J DENT RES, V73, P1205, DOI 10.1177/00220345940730061201; Sivakumar GR, 1999, MATER CHEM PHYS, V57, P238, DOI 10.1016/S0254-0584(98)00229-6; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; Tarasevich BJ, 2003, J PHYS CHEM B, V107, P10367, DOI 10.1021/jp027445p; Tartaix PH, 2004, J BIOL CHEM, V279, P18115, DOI 10.1074/jbc.M314114200; Tesch W, 2001, CALCIFIED TISSUE INT, V69, P147, DOI 10.1007/s00223-001-2012-z; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; Veis A, 2005, SCIENCE, V307, P1419, DOI 10.1126/science.1109440; VEIS A, 1993, J BONE MINER RES, V8, pS493; Vincent J, 1990, STRUCTURAL BIOMATERI	39	204	218	0	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2007	282	2					1193	1204		10.1074/jbc.M604732200	http://dx.doi.org/10.1074/jbc.M604732200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	123KQ	17052984	hybrid			2022-12-25	WOS:000243295200045
J	Bruns, K; Studtrucker, N; Sharma, A; Fossen, T; Mitzner, D; Eissmann, A; Tessmer, U; Roder, R; Henklein, P; Wray, V; Schubert, U				Bruns, Karsten; Studtrucker, Nicole; Sharma, Alok; Fossen, Torgils; Mitzner, David; Eissmann, Andre; Tessmer, Uwe; Roeder, Rene; Henklein, Peter; Wray, Victor; Schubert, Ulrich			Structural characterization and oligomerization of PB1-F2, a proapoptotic influenza A virus protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROTEIN; ENCODING GENE; HIV-1 VPR; PEPTIDES; TRANSCRIPTION; INDUCTION; INFECTION; APOPTOSIS; DEATH	Recently, a novel 87-amino acid influenza A virus protein with proapoptotic properties, PB1-F2, has been reported that originates from an alternative reading frame in the PB1 polymerase gene and is encoded in most known human influenza A virus isolates. Here we characterize the molecular structure of a biologically active synthetic version of the protein (sPB1-F2). Western blot analysis, chemical cross-linking, and NMR spectroscopy afforded direct evidence of the inherent tendency of sPB1-F2 to undergo oligomerization mediated by two distinct domains located in the N and C termini, respectively. CD and H-1 NMR spectroscopic analyses indicate that the stability of structured regions in the molecule clearly depends upon the hydrophobicity of the solvent. In aqueous solutions, the behavior of sPB1-F2 is typical of a largely random coil peptide that, however, adopts a-helical structure upon the addition of membrane mimetics. H-1 NMR analysis of three overlapping peptides afforded, for the first time, direct experimental evidence of the presence of a C-terminal region with strong a-helical propensity comprising amino acid residues Ile(55)-Lys(85) connected via an essentially random coil structure to a much weaker helix-like region, located in the N terminus between residues Trp(9) and Lys(20). The C-terminal helix is not a true amphipathic helix and is more compact than previously predicted. It corresponds to a positively charged region previously shown to include the mitochondrial targeting sequence of PB1-F2. The consequences of the strong oligomerization and helical propensities of the molecule are discussed and used to formulate a hypothetical model of its interaction with the mitochondrial membrane.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Heinrich Pette Inst, D-20251 Hamburg, Germany; Helmholtz Ctr Infect Res, Dept Biol Struct, D-38124 Braunschweig, Germany; Univ Bergen, Dept Chem, N-5007 Bergen, Norway; Humboldt Univ, Inst Biochem, D-10115 Berlin, Germany	University of Erlangen Nuremberg; Heinrich Pette Institute; Helmholtz Association; Helmholtz-Center for Infection Research; University of Bergen; Humboldt University of Berlin	Schubert, U (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	ulrich.schubert@viro.med.uni-erlangen.de	Sharma, Alok/AAE-4725-2022	Sharma, Alok/0000-0002-7668-3501				Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns K, 2003, J BIOL CHEM, V278, P43188, DOI 10.1074/jbc.M305413200; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Chanturiya AN, 2004, J VIROL, V78, P6304, DOI 10.1128/JVI.78.12.6304-6312.2004; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Garcia-Sastre A, 2001, VIROLOGY, V279, P375, DOI 10.1006/viro.2000.0756; Gibbs JS, 2003, J VIROL, V77, P7214, DOI 10.1128/JVI.77.13.7214-7224.2003; Henklein P, 2005, J PEPT SCI, V11, P481, DOI 10.1002/psc.641; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Holmes EC, 2006, SCIENCE, V313, DOI 10.1126/science.1131729; Lamb RA, 2001, NAT MED, V7, P1286, DOI 10.1038/nm1201-1286; Lowy RJ, 2003, INT REV IMMUNOL, V22, P425, DOI 10.1080/08830180305216; NEIDIG KP, 1990, J MAGN RESON, V88, P155, DOI 10.1016/0022-2364(90)90119-T; Neumann G, 2004, CURR TOP MICROBIOL, V283, P121; Obenauer JC, 2006, SCIENCE, V311, P1576, DOI 10.1126/science.1121586; Pande VS, 2004, NAT BIOTECHNOL, V22, P1240, DOI 10.1038/nbt1004-1240; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; Webby RJ, 2001, PHILOS T R SOC B, V356, P1817, DOI 10.1098/rstb.2001.0997; Webster RG, 1997, ARCH VIROL, P105; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P13; Zamarin D, 2006, J VIROL, V80, P7976, DOI 10.1128/JVI.00415-06; Zamarin Dmitriy, 2005, PLoS Pathogens, V1, P40; Zhao RY, 2005, INDIAN J MED RES, V121, P270	30	51	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2007	282	1					353	363		10.1074/jbc.M606494200	http://dx.doi.org/10.1074/jbc.M606494200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	121OI	17052982	hybrid			2022-12-25	WOS:000243166500040
J	Oddo, S; Vasilevko, V; Caccamo, A; Kitazawa, M; Cribbs, DH; LaFerla, FM				Oddo, Salvatore; Vasilevko, Vitaly; Caccamo, Antonella; Kitazawa, Masashi; Cribbs, David H.; LaFerla, Frank M.			Reduction of soluble A beta and Tau, but not soluble A beta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TG2576 MOUSE MODEL; ALZHEIMERS-DISEASE; MEMORY LOSS; IN-VIVO; IMMUNIZATION; PATHOLOGY; PEPTIDE; IMMUNOTHERAPY; DEFICITS; NEURODEGENERATION	Increasing evidence points to soluble assemblies of aggregating proteins as a major mediator of neuronal and synaptic dysfunction. In Alzheimer disease ( AD), soluble amyloid-beta (A beta) appears to be a key factor in inducing synaptic and cognitive abnormalities. Here we report the novel finding that soluble tau also plays a role in the cognitive decline in the presence of concomitant A beta pathology. We describe improved cognitive function following a reduction in both soluble A beta and tau levels after active or passive immunization in advanced aged 3xTg-AD mice that contain both amyloid plaques and neurofibrillary tangles (NFTs). Notably, reducing soluble A beta alone did not improve the cognitive phenotype in mice with plaques and NFTs. Our results show that A beta immunotherapy reduces soluble tau and ameliorates behavioral deficit in old transgenic mice.	Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	LaFerla, FM (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, 1109 Gillespie Neurosci Bldg, Irvine, CA 92697 USA.	laferla@uci.edu	Kitazawa, Masashi/AAI-1721-2021	Kitazawa, Masashi/0000-0003-2165-8197; Oddo, Salvatore/0000-0001-7304-7430	NIA NIH HHS [AG20241, AG0212982] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG020241] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIAGADA PV, 1992, NEUROLOGY, V42, P1681, DOI 10.1212/WNL.42.9.1681; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Cairns NJ, 2004, J PATHOL, V204, P438, DOI 10.1002/path.1650; Check E, 2002, NATURE, V415, P462, DOI 10.1038/415462a; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Cribbs DH, 2003, INT IMMUNOL, V15, P505, DOI 10.1093/intimm/dxg049; Das P, 2001, NEUROBIOL AGING, V22, P721, DOI 10.1016/S0197-4580(01)00245-7; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; Ganzer S, 2003, J NEURAL TRANSM, V110, P1149, DOI 10.1007/s00702-003-0017-7; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Higuchi M, 2002, NEUROMOL MED, V2, P131, DOI 10.1385/NMM:2:2:131; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Lalonde R, 2002, NEUROSCI BIOBEHAV R, V26, P91, DOI 10.1016/S0149-7634(01)00041-0; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; MANDELKOW E, 1995, NEUROBIOL AGING, V16, P347, DOI 10.1016/0197-4580(95)00026-B; Mandelkow EM, 2003, NEUROBIOL AGING, V24, P1079, DOI 10.1016/j.neurobiolaging.2003.04.007; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; McGaugh JL, 2002, NEUROBIOL LEARN MEM, V78, P539, DOI 10.1006/nlme.2002.4082; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Nitsch RM, 2004, ALZ DIS ASSOC DIS, V18, P185; Oddo S, 2006, J BIOL CHEM, V281, P1599, DOI 10.1074/jbc.M507892200; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Oddo S, 2006, AM J PATHOL, V168, P184, DOI 10.2353/ajpath.2006.050593; Oddo S, 2005, P NATL ACAD SCI USA, V102, P3046, DOI 10.1073/pnas.0408500102; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382	45	248	269	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39413	39423		10.1074/jbc.M608485200	http://dx.doi.org/10.1074/jbc.M608485200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17056594	hybrid			2022-12-25	WOS:000242898700049
J	Olson, E; Nievera, CJ; Klimovich, V; Fanning, E; Wu, XH				Olson, Erin; Nievera, Christian J.; Klimovich, Vitaly; Fanning, Ellen; Wu, Xiaohua			RPA2 is a direct downstream target for ATR to regulate the S-phase checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DNA-DAMAGE RESPONSE; POLYMERASE-ALPHA-PRIMASE; CELL-CYCLE CHECKPOINTS; STRAND BREAK REPAIR; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; BINDING PROTEIN; HELA-CELLS; IN-VITRO	Upon DNA damage, replication is inhibited by the S-phase checkpoint. ATR (ataxia telangiectasia mutated- and Rad3-related) is specifically involved in the inhibition of replicon initiation when cells are treated with DNA damage-inducing agents that stall replication forks, but the mechanism by which it acts to prevent replication is not yet fully understood. We observed that RPA2 is phosphorylated on chromatin in an ATR-dependent manner when replication forks are stalled. Mutation of the ATR dependent phosphorylation sites in RPA2 leads to a defect in the down-regulation of DNA synthesis following treatment with UV radiation, although ATR activation is not affected. Threonine 21 and serine 33, two residues among several phosphorylation sites in the amino terminus of RPA2, are specifically required for the UV-induced, ATR-mediated inhibition of DNA replication. RPA2 mutant alleles containing phospho-mimetic mutations at ATR-dependent phosphorylation sites have an impaired ability to associate with replication centers, indicating that ATR phosphorylation of RPA2 directly affects the replication function of RPA. Our studies suggest that in response to UV-induced DNA damage, ATR rapidly phosphorylates RPA2, disrupting its association with replication centers in the S-phase and contributing to the inhibition of DNA replication.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37232 USA	Scripps Research Institute; Vanderbilt University	Wu, XH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	xiaohwu@scripps.edu			NCI NIH HHS [CA102361] Funding Source: Medline; NIDDK NIH HHS [5 T32 DK007022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; An J, 2005, INT J CANCER, V117, P531, DOI 10.1002/ijc.21093; Ball HL, 2005, MOL BIOL CELL, V16, P2372, DOI 10.1091/mbc.e04-11-1006; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Dimitrova DS, 2000, EXP CELL RES, V254, P321, DOI 10.1006/excr.1999.4770; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; FANG F, 1993, J CELL SCI, V106, P983; Fanning E, 2006, NUCLEIC ACIDS RES, V34, P4126, DOI 10.1093/nar/gkl550; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Gottifredi V, 2005, SEMIN CELL DEV BIOL, V16, P355, DOI 10.1016/j.semcdb.2005.02.011; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; Liu JS, 2006, DNA REPAIR, V5, P369, DOI 10.1016/j.dnarep.2005.11.007; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Maude SL, 2005, CANCER RES, V65, P780; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; NICKERSON JA, 1990, P NATL ACAD SCI USA, V87, P2259, DOI 10.1073/pnas.87.6.2259; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Nuss JE, 2005, BIOCHEMISTRY-US, V44, P8428, DOI 10.1021/bi0480584; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Ott RD, 2002, MOL CELL BIOL, V22, P5669, DOI 10.1128/MCB.22.16.5669-5678.2002; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Perrault R, 2001, INT J RADIAT BIOL, V77, P593, DOI 10.1080/09553000110036773; Ramilo C, 2002, MOL CELL BIOL, V22, P2037, DOI 10.1128/MCB.22.7.2037-2046.2002; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Wang HY, 2001, CANCER RES, V61, P8554; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wu X, 2005, BIOCHEM J, V391, P473, DOI 10.1042/BJ20050379; Wu XM, 2005, ONCOGENE, V24, P4728, DOI 10.1038/sj.onc.1208674; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	67	125	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39517	39533		10.1074/jbc.M605121200	http://dx.doi.org/10.1074/jbc.M605121200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17035231	hybrid			2022-12-25	WOS:000242898700060
J	Vagin, O; Tokhtaeva, E; Sachs, G				Vagin, Olga; Tokhtaeva, Elmira; Sachs, George			The role of the beta(1) subunit of the Na,K-ATPase and its glycosylation in cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CYTOSKELETAL COMPLEX; KIDNEY EPITHELIAL-CELLS; BETA-SUBUNIT; CYTOPLASMIC DOMAIN; TIGHT JUNCTIONS; ALPHA-SUBUNIT; BLADDER-CANCER; MDCK CELLS; E-CADHERIN; POLARITY	Based on recent data showing that overexpression of the Na, K-ATPase beta(1) subunit increased cell-cell adhesion of nonpolarized cells, we hypothesized that the beta(1) subunit can also be involved in the formation of cell-cell contacts in highly polarized epithelial cells. In support of this hypothesis, in Madin-Darby canine kidney (MDCK) cells, the Na, K-ATPase alpha(1) and beta(1) subunits were detected as precisely co-localized with adherens junctions in all stages of the monolayer formation starting from the initiation of cell-cell contact. The Na, K-ATPase and adherens junction protein, beta-catenin, stayed partially co-localized even after their internalization upon disruption of intercellular contacts by Ca2+ depletion of the medium. The Na, K-ATPase subunits remained co-localized with the adherens junctions after detergent treatment of the cells. In contrast, the heterodimer formed by expressed unglycosylated Na, K-ATPase-1 subunit and the endogenous beta(1) subunit was easily dissociated from the adherens junctions and cytoskeleton by the detergent extraction. The MDCK cell line in which half of the endogenous beta(1) subunits in the lateral membrane were substituted by unglycosylated beta(1) subunits displayed a decreased ability to form cell-to-cell contacts. Incubation of surface-attached MDCK cells with an antibody against the extracellular domain of the Na, K-ATPase beta(1) subunit specifically inhibited cell-cell contact formation. We conclude that the Na, K-ATPase-1 subunit is involved in the process of intercellular adhesion and is necessary for association of the heterodimeric Na, K-ATPase with the adherens junctions. Further, normal glycosylation of the Na, K-ATPase-1 subunit is essential for the stable association of the pump with the adherens junctions and plays an important role in cell-cell contact formation.	VAGLAHS W LA, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Vagin, O (corresponding author), VAGLAHS W LA, Bldg 113,Rm 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	olgav@ucla.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058333, R01DK058333, R01DK046917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58333, DK46917] Funding Source: Medline; PHS HHS [D53642] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Barwe SP, 2005, MOL BIOL CELL, V16, P1082, DOI 10.1091/mbc.E04-05-0427; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Cereijido M, 2004, PHYSIOL REV, V84, P1229, DOI 10.1152/physrev.00001.2004; Contreras RG, 1999, J CELL SCI, V112, P4223; Contreras RG, 2004, J MEMBRANE BIOL, V198, P147, DOI 10.1007/s00232-004-0670-2; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495; Espineda C, 2003, CANCER-AM CANCER SOC, V97, P1859, DOI 10.1002/cncr.11267; Espineda CE, 2004, MOL BIOL CELL, V15, P1364, DOI 10.1091/mbc.E03-09-0646; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOTTARDI CJ, 1995, AM J PHYSIOL, V268, P285; Hallen S, 2002, BIOCHEMISTRY-US, V41, P7253, DOI 10.1021/bi012152s; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Kitamura N, 2005, P NATL ACAD SCI USA, V102, P2796, DOI 10.1073/pnas.0409344102; Kroepfl JF, 2001, J NEUROCHEM, V77, P1301, DOI 10.1046/j.1471-4159.2001.00343.x; Kwon O, 1998, J CLIN INVEST, V101, P2054, DOI 10.1172/JCI772; Larre I, 2006, P NATL ACAD SCI USA, V103, P10911, DOI 10.1073/pnas.0604496103; Laughery MD, 2003, J BIOL CHEM, V278, P34794, DOI 10.1074/jbc.M302899200; Lee DBN, 2006, AM J PHYSIOL-RENAL, V290, pF20, DOI 10.1152/ajprenal.00052.2005; Lipardi C, 2002, ENDOCRINOLOGY, V143, P1291, DOI 10.1210/en.143.4.1291; Liu JA, 2005, KIDNEY INT, V67, P1844, DOI 10.1111/j.1523-1755.2005.00283.x; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Popov Z, 2000, BRIT J CANCER, V83, P209; Rajasekaran AK, 2003, AM J PHYSIOL-RENAL, V285, pF388, DOI 10.1152/ajprenal.00439.2002; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P279, DOI 10.1091/mbc.12.2.279; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P3717, DOI 10.1091/mbc.12.12.3717; Rajasekaran SA, 1999, J UROLOGY, V162, P574, DOI 10.1016/S0022-5347(05)68629-6; Rajasekaran SA, 2004, MOL BIOL CELL, V15, P3224, DOI 10.1091/mbc.e04-03-0222; Rajasekaran SA, 2003, AM J PHYSIOL-CELL PH, V284, pC1497, DOI 10.1152/ajpcell.00355.2002; Rajasekaran SA, 2004, PANCREAS, V29, pE77, DOI 10.1097/00006676-200410000-00016; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Selak S, 2004, BIOCHEM BIOPH RES CO, V323, P1334, DOI 10.1016/j.bbrc.2004.09.010; Shoshani L, 2005, MOL BIOL CELL, V16, P1071, DOI 10.1091/mbc.E04-03-0267; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Vagin O, 2005, J BIOL CHEM, V280, P43159, DOI 10.1074/jbc.M508262200; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161; WILSON PD, 1991, AM J PHYSIOL, V260, P420	51	88	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2006	281	51					39573	39587		10.1074/jbc.M606507200	http://dx.doi.org/10.1074/jbc.M606507200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	117UL	17052981	hybrid			2022-12-25	WOS:000242898700065
J	Baraquet, C; Theraulaz, L; Guiral, M; Lafitte, D; Mejean, V; Jourlin-Castelli, C				Baraquet, Claudine; Theraulaz, Laurence; Guiral, Marianne; Lafitte, Daniel; Mejean, Vincent; Jourlin-Castelli, Cecile			TorT, a member of a new periplasmic binding protein family, triggers induction of the tor respiratory system upon trimethylamine N-oxide electron-acceptor binding in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE REGULATOR; UNORTHODOX SENSOR; REDUCTASE; RECEPTORS; GENES; EXPRESSION; CHAPERONE; OPERON; AGROBACTERIUM; SPECIFICITY	In anaerobiosis, Escherichia coli can use trimethylamine N-oxide (TMAO) as a terminal electron acceptor. Reduction of TMAO in trimethylamine (TMA) is mainly performed by the respiratory TMAO reductase. This system is encoded by the torCAD operon, which is induced in the presence of TMAO. This regulation involves a two-component system comprising TorS, an unorthodox histidine kinase, and TorR, a response regulator. A third protein, TorT, sharing homologies with periplasmic binding proteins, plays a key role in this regulation because disruption of the torT gene abolishes tor expression. In this study we showed that TMAO protects TorT against degradation by the GluC endoproteinase and modifies its temperature-induced CD spectrum. We also isolated a TorT negative mutant that is no longer protected by TMAO from degradation by GluC. Isothermal titration calorimetry confirmed that TorT binds TMAO with a binding constant of 150 mu M. Therefore, we conclude that TorT binds TMAO and that this binding promotes a conformational change of TorT. We also showed that TorT interacts with the periplasmic domain of TorS in both the presence and absence of TMAO but the TorT-TMAO complex induces a higher GluC protection of TorS than TorT alone. These results support the idea that TMAO binding to TorT induces a cascade of conformational changes from TorT to TorS, leading to TorS activation. We identified several homologues of the TorT protein that define a new family of periplasmic binding proteins. We thus propose that the members of this family bind TMAO or related compounds and that they are involved in signal transduction or even substrate transport.	CNRS, Inst Biol Struct & Microbiol, Chim Bacterienne Lab, F-13402 Marseille 20, France; CNRS, Inst Biol Struct & Microbiol, Lab Bioenerget & Ingn Prot, F-13402 Marseille 20, France; Aix Marseille Univ, CNRS, FRE 2737, Cismet, F-13385 Marseille 5, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Jourlin-Castelli, C (corresponding author), 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	jourlin@ibsm.cnrs-mrs.fr	Claudine, Baraquet/AAY-4483-2021	lafitte, daniel/0000-0001-9921-7522; Baraquet, Claudine/0000-0002-0173-7501; Mejean, Vincent/0000-0001-6533-5846; Jourlin-Castelli, Cecile/0000-0001-8581-2590				Ansaldi M, 2001, J BACTERIOL, V183, P2691, DOI 10.1128/JB.183.8.2691-2695.2001; Ansaldi M, 1999, MOL MICROBIOL, V33, P284, DOI 10.1046/j.1365-2958.1999.01468.x; Antoine R, 2005, J MOL BIOL, V351, P799, DOI 10.1016/j.jmb.2005.05.071; BARRETT EL, 1985, ANNU REV MICROBIOL, V39, P131, DOI 10.1146/annurev.mi.39.100185.001023; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dos Santos JP, 1998, J MOL BIOL, V284, P421, DOI 10.1006/jmbi.1998.2155; Felder CB, 1999, AAPS PHARMSCI, V1; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Genest O, 2006, BIOCHEM BIOPH RES CO, V339, P991, DOI 10.1016/j.bbrc.2005.11.107; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Gon S, 2001, J BIOL CHEM, V276, P11545, DOI 10.1074/jbc.M008875200; Gon S, 2002, J BACTERIOL, V184, P1262, DOI 10.1128/JB.184.5.1262-1269.2002; Gon S, 2001, P NATL ACAD SCI USA, V98, P11615, DOI 10.1073/pnas.211330598; Heddle J, 2003, J BIOL CHEM, V278, P50322, DOI 10.1074/jbc.M307941200; Ilbert M, 2003, J BIOL CHEM, V278, P28787, DOI 10.1074/jbc.M302730200; IobbiNivol C, 1996, BBA-PROTEIN STRUCT M, V1294, P77, DOI 10.1016/0167-4838(95)00271-5; Jack RL, 2004, EMBO J, V23, P3962, DOI 10.1038/sj.emboj.7600409; Jourlin C, 1996, MOL MICROBIOL, V20, P1297, DOI 10.1111/j.1365-2958.1996.tb02648.x; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; JOURLIN C, 1995, GENE, V152, P53, DOI 10.1016/0378-1119(94)00772-K; Jourlin C, 1996, J BACTERIOL, V178, P1219, DOI 10.1128/jb.178.4.1219-1223.1996; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Kneuper H, 2005, J BIOL CHEM, V280, P20596, DOI 10.1074/jbc.M502015200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Li XB, 2004, P NATL ACAD SCI USA, V101, P627, DOI 10.1073/pnas.0307645100; McCrindle SL, 2005, ADV MICROB PHYSIOL, V50, P147, DOI 10.1016/S0065-2911(05)50004-3; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Morris MC, 1999, J PEPT SCI, V5, P263, DOI 10.1002/(SICI)1099-1387(199906)5:6<263::AID-PSC191>3.3.CO;2-1; Neiditch MB, 2005, MOL CELL, V18, P507, DOI 10.1016/j.molcel.2005.04.020; Pang A, 2003, FEBS LETT, V550, P168, DOI 10.1016/S0014-5793(03)00866-4; Piszczek G, 2004, BIOCHEM J, V381, P97, DOI 10.1042/BJ20040232; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; Proctor LM, 2000, ENVIRON MICROBIOL, V2, P399, DOI 10.1046/j.1462-2920.2000.00121.x; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Raymond JA, 2002, COMP BIOCHEM PHYS B, V133, P29, DOI 10.1016/S1096-4959(02)00097-0; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; SHIMODA N, 1993, J BIOL CHEM, V268, P26552; SIMON G, 1994, J BACTERIOL, V176, P5601, DOI 10.1128/JB.176.18.5601-5606.1994; SIMON G, 1995, MOL MICROBIOL, V17, P971, DOI 10.1111/j.1365-2958.1995.mmi_17050971.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TAN YJ, 1995, J MOL BIOL, V254, P980, DOI 10.1006/jmbi.1995.0670; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Yancey PH, 2001, J EXP ZOOL, V289, P172, DOI 10.1002/1097-010X(20010215)289:3<172::AID-JEZ3>3.0.CO;2-J	46	54	54	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38189	38199		10.1074/jbc.M604321200	http://dx.doi.org/10.1074/jbc.M604321200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17040909	hybrid			2022-12-25	WOS:000242709500011
J	Kohno, Y; Okamoto, T; Ishibe, T; Nagayama, S; Shima, Y; Nishijo, K; Shibata, KR; Fukiage, K; Otsuka, S; Uejima, D; Araki, N; Naka, N; Nakashima, Y; Aoyama, T; Nakayama, T; Nakamura, T; Toguchida, J				Kohno, Yoshiki; Okamoto, Takeshi; Ishibe, Tatsuya; Nagayama, Satoshi; Shima, Yasuko; Nishijo, Kohichi; Shibata, Kotaro R.; Fukiage, Kenichi; Otsuka, Seiji; Uejima, Daisuke; Araki, Nobuhito; Naka, Norifumi; Nakashima, Yasuaki; Aoyama, Tomoki; Nakayama, Tomitaka; Nakamura, Takashi; Toguchida, Junya			Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas and regulated by an Ets family transcription factor, ELF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; GENE-EXPRESSION; CELL-LINE; JUNCTIONS; ESTABLISHMENT; INACTIVATION; MESENCHYME; RECEPTORS; STRANDS; FUSION	Synovial sarcoma, a soft tissue sarcoma that develops in adults, is pathologically subclassified into monophasic spindle synovial sarcoma and biphasic synovial sarcoma with epithelial components. The molecular mechanism building the epithelial components in biphasic synovial sarcoma is totally unknown. Here we investigated claudins, critical molecules in the tight junction, in biphasic synovial sarcoma. Expression profiles of 21 claudins in 17 synovial sarcoma tumor samples, including 9 biphasic tumors, identified claudin4, claudin7, and claudin10 as biphasic tumor-related claudins, and immunohistochemical analyses demonstrated the localization of these claudins in the epithelial component in biphasic tumors, with claudin7 the most closely associated with the epithelial component. The mRNA expression and protein localization of claudin7 coincided with those of the ELF3, an epithelia-specific member of the Ets family of transcription factors. Luciferase reporter assays demonstrated that the presence of the Ets-binding site at -150 in the promoter region of the claudin7 gene was critical for the transcriptional activity, and gel shift and chromatin immunoprecipitation assays confirmed the binding of ELF3 to the Ets site at -150. Inhibition of ELF3 expression by small interfering RNA simultaneously down-regulated the mRNA expression of the claudin7 gene, and the introduction of ELF3 expression in claudin7-negative cell lines induced mRNA expression of the claudin7 gene. Therefore, the induction of claudin7 expression by ELF3 appears critical to the formation of the epithelial structures in biphasic synovial sarcoma.	Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Surg Oncol, Kyoto 6068507, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Musculoskeletal Med, Nagoya, Aichi 4678601, Japan; Kansai Med Univ, Dept Orthoped Surg, Osaka 5708506, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Orthoped Surg, Osaka 5378511, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Nagoya City University; Kansai Medical University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyoto University	Toguchida, J (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	togjun@frontier.kyoto-u.ac.jp						Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Bronstein JM, 1996, NEUROLOGY, V47, P772, DOI 10.1212/WNL.47.3.772; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P757; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Imaizumi S, 1998, VIRCHOWS ARCH, V433, P435, DOI 10.1007/s004280050271; Ishibe T, 2005, CLIN CANCER RES, V11, P2702, DOI 10.1158/1078-0432.CCR-04-2057; JORGENSEN LJ, 1994, APMIS, V102, P191, DOI 10.1111/j.1699-0463.1994.tb04864.x; Katahira J, 1997, J BIOL CHEM, V272, P26652, DOI 10.1074/jbc.272.42.26652; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kiuchi-Saishin Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134875; Le Douarin NM, 2003, CURR OPIN GENET DEV, V13, P529, DOI 10.1016/j.gde.2003.08.002; LEADER M, 1987, CANCER, V59, P2096, DOI 10.1002/1097-0142(19870615)59:12<2096::AID-CNCR2820591222>3.0.CO;2-C; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Lejars F, 1910, REV CHIR, V41, P751; Loh YH, 2004, GENOME RES, V14, P1248, DOI 10.1101/gr.2400004; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MICKELSON MR, 1980, CANCER-AM CANCER SOC, V45, P2109, DOI 10.1002/1097-0142(19800415)45:8<2109::AID-CNCR2820450819>3.0.CO;2-V; MIETTINEN M, 1984, AM J PATHOL, V117, P18; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nagayama S, 2002, CANCER RES, V62, P5859; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; NOJIMA T, 1990, ACTA PATHOL JAPON, V40, P486; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Randall R Lor, 2005, Curr Treat Options Oncol, V6, P449, DOI 10.1007/s11864-005-0024-z; Saito T, 2004, ONCOGENE, V23, P8629, DOI 10.1038/sj.onc.1207960; Sato H, 2001, VIRCHOWS ARCH, V438, P23; SCHNEEBERGER EE, 1992, AM J PHYSIOL, V262, pL647, DOI 10.1152/ajplung.1992.262.6.L647; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; SONOBE H, 1992, LAB INVEST, V67, P498; Sonoda N, 1999, J CELL BIOL, V147, P195, DOI 10.1083/jcb.147.1.195; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2002, CURR OPIN CELL BIOL, V14, P531, DOI 10.1016/S0955-0674(02)00362-9; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WICK MR, 1993, SEMIN DIAGN PATHOL, V10, P118; Wiggan O, 2002, J CELL SCI, V115, P517; Yoshida N, 2000, MECH DEVELOP, V97, P27, DOI 10.1016/S0925-4773(00)00419-6; Zheng JY, 2003, J MEMBRANE BIOL, V194, P187, DOI 10.1007/s00232-003-2038-4	49	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	2006	281	50					38941	38950		10.1074/jbc.M608389200	http://dx.doi.org/10.1074/jbc.M608389200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	115BL	17060315	Green Submitted, hybrid			2022-12-25	WOS:000242709500091
J	Lake, AC; Vassy, R; Di Benedetto, M; Lavigne, D; Le Visage, C; Perret, GY; Letourneur, D				Lake, Andrew C.; Vassy, Roger; Di Benedetto, Melanie; Lavigne, Damien; Le Visage, Catherine; Perret, Gerard Y.; Letourneur, Didier			Low molecular weight fucoidan increases VEGF(165)-induced endothelial cell migration by enhancing VEGF(165) binding to VEGFR-2 and NRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; INDUCED TUBE FORMATION; THERAPEUTIC ANGIOGENESIS; ANTICOAGULANT ACTIVITIES; BROWN SEAWEEDS; PROLIFERATION; HEPARIN; FUCANS; INHIBIT; DISEASE	Therapeutic induction of angiogenesis is a potential treatment for chronic ischemia. Heparan sulfate proteoglycans are known to play an important role by their interactions with proangiogenic growth factors such as vascular endothelial growth factor (VEGF). Low molecular weight fucoidan (LMWF), a sulfated polysaccharide from brown seaweeds that mimic some biological activities of heparin, has been shown recently to promote revascularization in rat critical hindlimb ischemia. In this report, we first used cultured human endothelial cells (ECs) to investigate the possible ability of LMWF to enhance the actions of VEGF(165). Data showed that LMWF greatly enhances EC tube formation in growth factor reduced matrigel. LMWF is a strong enhancer of VEGF(165)-induced EC chemotaxis, but not proliferation. In addition, LMWF has no effect on VEGF(121)-induced EC migration, a VEGF isoform that does not bind to heparan sulfate proteoglycans. Then, with binding studies using I-125-VEGF(165), we observed that LMWF enhances the binding of VEGF(165) to recombinant VEGFR-2 and Neuropilin-1 (NRP1), but not to VEGFR-1. Surface plasmon resonance analysis showed that LMWF binds with high affinity to VEGF(165) (1.2 nM) and its receptors (5-20 nM), but not to VEGF(121). Pre-injection of LMWF on immobilized receptors shows that VEGF(165) has the highest affinity for VEGFR-2 and NRP1, as compared with VEGFR-1. Overall, the effects of LMWF were much more pronounced than those of LMW heparin. These findings suggested an efficient mechanism of action of LMWF by promoting VEGF(165) binding to VEGFR- 2 and NRP1 on ECs that could help in stimulating therapeutic revascularization.	X Bichat Hosp, Bat INSERM, INSERM U 698, Dept Bioengn, F-75018 Paris, France; Univ Paris 13, Inst Galilee, F-93430 Villetaneuse, France; Univ Paris 13, CNRS UMR 7033, F-93017 Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris 13; Universite Paris 13	Letourneur, D (corresponding author), X Bichat Hosp, Bat INSERM, INSERM U 698, Dept Bioengn, 46 Rue H Huchard, F-75018 Paris, France.	letourne@galilee.univ-paris13.fr	PERRET, gerard/A-7379-2008; Le Visage, Catherine/E-5460-2011; Di Benedetto, Melanie MD/C-1512-2018; Didier, letourneur/H-5268-2012	PERRET, gerard/0000-0003-0645-3337; Le Visage, Catherine/0000-0003-1816-1649; Di Benedetto, Melanie MD/0000-0003-1119-3752; Didier, letourneur/0000-0003-2197-9468				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; BELFORD DA, 1993, J CELL PHYSIOL, V157, P184, DOI 10.1002/jcp.1041570124; CASTELLOT JJ, 1984, J CELL PHYSIOL, V120, P315, DOI 10.1002/jcp.1041200309; Chabut D, 2003, MOL PHARMACOL, V64, P696, DOI 10.1124/mol.64.3.696; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Chevolot L, 1999, CARBOHYD RES, V319, P154, DOI 10.1016/S0008-6215(99)00127-5; CREPON B, 1987, BIOMATERIALS, V8, P248, DOI 10.1016/0142-9612(87)90111-6; Deux JF, 2002, ARTERIOSCL THROM VAS, V22, P1604, DOI 10.1161/01.ATV.0000032034.91020.0A; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1974, Adv Cancer Res, V19, P331, DOI 10.1016/S0065-230X(08)60058-5; Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329; Giraux JL, 1998, EUR J CELL BIOL, V77, P352, DOI 10.1016/S0171-9335(98)80094-0; Hamma-Kourbali Y, 2001, J BIOL CHEM, V276, P39748, DOI 10.1074/jbc.M101117200; Haroun-Bouhedja F, 2000, THROMB RES, V100, P453, DOI 10.1016/S0049-3848(00)00338-8; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Khan TA, 2003, EXPERT OPIN PHARMACO, V4, P219, DOI 10.1517/14656566.4.2.219; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Koyanagi S, 2003, BIOCHEM PHARMACOL, V65, P173, DOI 10.1016/S0006-2952(02)01478-8; Lake AC, 2003, AM J PATHOL, V162, P219, DOI 10.1016/S0002-9440(10)63813-8; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li J, 2003, MICROSC RES TECHNIQ, V60, P107, DOI 10.1002/jemt.10249; Logeart D, 1997, EUR J CELL BIOL, V74, P376; Logeart D, 1997, EUR J CELL BIOL, V74, P385; Luyt CE, 2003, J PHARMACOL EXP THER, V305, P24, DOI 10.1124/jpet.102.046144; Matou S, 2002, THROMB RES, V106, P213, DOI 10.1016/S0049-3848(02)00136-6; MCCAFFREY TA, 1992, BIOCHEM BIOPH RES CO, V184, P773, DOI 10.1016/0006-291X(92)90657-7; Millet J, 1999, THROMB HAEMOSTASIS, V81, P391; NARDELLA A, 2000, Patent No. 6028191; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Relf M, 1997, CANCER RES, V57, P963; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Senni K, 2006, ARCH BIOCHEM BIOPHYS, V445, P56, DOI 10.1016/j.abb.2005.11.001; Soeda S, 2000, BBA-MOL CELL RES, V1497, P127, DOI 10.1016/S0167-4889(00)00052-5; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002; Tang DG, 2004, SEMIN THROMB HEMOST, V30, P109; Tissot B, 2003, BBA-PROTEINS PROTEOM, V1651, P5, DOI 10.1016/S1570-9639(03)00230-9	42	93	97	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37844	37852		10.1074/jbc.M600686200	http://dx.doi.org/10.1074/jbc.M600686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17028197	hybrid			2022-12-25	WOS:000242477100062
J	Maeda, S; Sugita, C; Sugita, M; Omata, T				Maeda, Shin-ichi; Sugita, Chieko; Sugita, Mamoru; Omata, Tatsuo			A new class of signal transducer in His-Asp phosphorelay systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM SYNECHOCOCCUS PCC-7942; STRAIN PCC 7942; NITRATE TRANSPORT; OVERLAP EXTENSION; ESCHERICHIA-COLI; HISTIDINE KINASE; GENE; PROTEINS; DOMAIN; EXPRESSION	Nitrate transport activity of the LtnT permease of the cyanobacterium Synechococcus elongatus is activated when LtnA, a response regulator without an effector domain, is phosphorylated by LtnB, a hybrid histidine kinase. We identified a protein (LtnC) that is required for activation of LtnT. LtnC consists of an N-terminal histidine-containing phosphoacceptor (HisKA) domain, a receiver domain, and a unique C-terminal domain found in some cyanobacterial proteins. Because LtnC lacks an ATP-binding kinase domain of a histidine kinase, it is incapable of autophosphorylation, but LtnC is phosphorylated by LtnA. The histidine residue in the HisKA domain but not the aspartate residue in the receiver domain is essential for phosphorylation of LtnC and activation of LtnT. LtnC phosphorylation leads to oligomerization of the protein. Fusion of the C-terminal domain of LtnC to glutathione S-transferase, which forms oligomers, also activates LtnT, suggesting that oligomerization of the LtnC C-terminal domain causes LtnT activation. These results indicate that the C-terminal domain of LtnC acts as an effector domain that directs the output of the signal from the phosphorelay system. The two-step (His-Asp-His) phosphorelay system, composed of the LtnB, LtnA, and LtnC proteins, is distinct from the known phosphorelay systems, namely, the typical two-component system (His-Asp) and the multistep phosphorelay system (His-Asp-His-Asp), because the HisKA domain of LtnC is the terminal phosphoacceptor that determines the signal output. LtnC is a new class of signal transducer in His-Asp phosphorelay systems that contains a HisKA domain and an effector domain.	Nagoya Univ, Lab Mol Plant Physiol, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Ctr Gene Res, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Maeda, S (corresponding author), Nagoya Univ, Lab Mol Plant Physiol, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan.	maeda@agr.nagoya-u.ac.jp						AIBA H, 1989, J BIOL CHEM, V264, P8563; Anantharaman V, 2000, TRENDS BIOCHEM SCI, V25, P535, DOI 10.1016/S0968-0004(00)01672-8; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Carrick CS, 1998, GENE, V220, P21, DOI 10.1016/S0378-1119(98)00424-7; CLAPPER ML, 1991, BIOCHIM BIOPHYS ACTA, V1096, P209, DOI 10.1016/0925-4439(91)90007-V; DZELZKALNS VA, 1984, NUCLEIC ACIDS RES, V12, P8917, DOI 10.1093/nar/12.23.8917; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KUHLEMEIER CJ, 1983, PLASMID, V10, P156, DOI 10.1016/0147-619X(83)90068-9; Maeda S, 2006, J BIOL CHEM, V281, P5869, DOI 10.1074/jbc.M513196200; Maeda SI, 1997, J BIOL CHEM, V272, P3036, DOI 10.1074/jbc.272.5.3036; MIZUNO T, 1990, MOL MICROBIOL, V4, P1077, DOI 10.1111/j.1365-2958.1990.tb00681.x; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; OMATA T, 1991, PLANT CELL PHYSIOL, V32, P151, DOI 10.1093/oxfordjournals.pcp.a078059; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Suzuki I, 1996, J BACTERIOL, V178, P2688, DOI 10.1128/jb.178.9.2688-2694.1996; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; Varughese KL, 2002, CURR OPIN MICROBIOL, V5, P142, DOI 10.1016/S1369-5274(02)00305-3; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WILLIAMS JGK, 1983, GENE, V24, P37, DOI 10.1016/0378-1119(83)90129-4	26	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 8	2006	281	49					37868	37876		10.1074/jbc.M608680200	http://dx.doi.org/10.1074/jbc.M608680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	111TH	17040912	hybrid			2022-12-25	WOS:000242477100065
J	Daub, K; Langer, H; Seizer, P; Stellos, K; May, AE; Goyal, P; Bigalke, B; Schonberger, T; Geisler, T; Siegel-Axel, D; Oostendorp, RAJ; Lindemann, S; Gawaz, M				Daub, Karin; Langer, Harald; Seizer, Peter; Stellos, Konstantinos; May, Andreas E.; Goyal, Pankaj; Bigalke, Boris; Schoenberger, Tanja; Geisler, Tobias; Siegel-Axel, Dorothea; Oostendorp, Robert A. J.; Lindemann, Stephan; Gawaz, Meinrad			Platelets induce differentiation of human CD34(+) progenitor cells into foam cells and endothelial cells	FASEB JOURNAL			English	Article						atherothrombosis; vascular lesion; statins; stem cells; matrix metalloproteinases	COA REDUCTASE INHIBITORS; PPAR-ALPHA; MACROPHAGE ACTIVATION; MMP-9 SECRETION; MATRIX-METALLOPROTEINASE-9; INFLAMMATION; ADHESION; STATINS; MICE	Recruitment of human CD34(+) progenitor cells toward vascular lesions and differentiation into vascular cells has been regarded as a critical initial step in atherosclerosis. Previously we found that adherent platelets represent potential mediators of progenitor cell homing besides their role in thrombus formation. On the other hand, foam cell formation represents a key process in atherosclerotic plaque formation. To investigate whether platelets are involved in progenitor cell recruitment and differentiation into endothelial cells and foam cells, we examined the interactions of platelets and CD34(+) progenitor cells. Cocultivation experiments showed that human platelets recruit CD34(+) progenitor cells via the specific adhesion receptors P-selectin/PSGL-1 and beta(1)- and beta(2)-integrins. Furthermore, platelets were found to induce differentiation of CD34(+) progenitor cells into mature foam cells and endothelial cells. Platelet-induced foam cell generation could be prevented partially by HMG coenzyme A reductase inhibitors via reduction of matrix metalloproteinase-9 (MMP-9) secretion. Finally, agonists of peroxisome proliferator-activated receptor-alpha and -gamma attenuated platelet-induced foam cell generation and production of MMP-9. The present study describes a potentially important mechanism of platelet-induced foam cell formation and generation of endothelium in atherogenesis and atheroprogression. The understanding and modulation of these mechanisms may offer new treatment strategies for patients at high risk for atherosclerotic diseases. - Daub, K., Langer, H., Seizer, P., Stellos, K., May, A. E., Goyal, P., Bigalke, B., Schonberger, T., Geisler, T., Siegel-Axel, D., Oostendorp, R. A. J., Lindemann, S., Gawaz, M. Platelets induce differentiation of human CD34(+) progenitor cells into foam cells and endothelial cells.	Univ Klinikum Tubingen, Med Klin 3, D-72076 Tubingen, Germany; Univ Munich, Inst Prevent Cardiovasc Dis, Munich, Germany; Tech Univ Munich, Med Klin 3, Klinikum Rechts Isar, Munich, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Munich; Technical University of Munich	Gawaz, M (corresponding author), Univ Klinikum Tubingen, Med Klin 3, Otfried Muller Str 10, D-72076 Tubingen, Germany.	meinrad.gawaz@med.uni-tuebingen.de	Oostendorp, Robert A. J./K-9841-2018; Stellos, Konstantinos/G-8873-2011; Stellos, Konstantinos/AAF-2711-2020; Stellos, Konstantinos/ABH-1523-2021; Goyal, Pankaj/C-3567-2012; Geisler, Tobias/AAO-4472-2020	Oostendorp, Robert A. J./0000-0002-4947-0412; Stellos, Konstantinos/0000-0002-0194-0825				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bellosta S, 1998, ARTERIOSCL THROM VAS, V18, P1671, DOI 10.1161/01.ATV.18.11.1671; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; De Meyer GRY, 2002, CIRC RES, V90, P1197, DOI 10.1161/01.RES.0000020017.84398.61; Galt SW, 2001, CIRC RES, V89, P509, DOI 10.1161/hh1801.096339; Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196; Gawaz M, 2004, CARDIOVASC RES, V61, P498, DOI 10.1016/j.cardiores.2003.11.036; Heiss C, 2005, J AM COLL CARDIOL, V45, P1441, DOI 10.1016/j.jacc.2004.12.074; Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5; Jans DM, 2004, J CARDIOVASC PHARM, V43, P462, DOI 10.1097/00005344-200403000-00019; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Korporaal SJA, 2005, ARTERIOSCL THROM VAS, V25, P867, DOI 10.1161/01.ATV.0000158381.02640.4b; Langer H, 2006, CIRC RES, V98, pE2, DOI 10.1161/01.RES.0000201285.87524.9e; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; Massberg S, 2005, CIRCULATION, V112, P1180, DOI 10.1161/CIRCULATIONAHA.105.539221; Massberg S, 2006, J EXP MED, V203, P1221, DOI 10.1084/jem.20051772; Ott I, 2005, FASEB J, V19, P992, DOI 10.1096/fj.04-3219fje; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Relou IAM, 2003, CELL MOL LIFE SCI, V60, P961, DOI 10.1007/s00018-003-2249-y; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Schmidt R, 2006, CIRCULATION, V113, P834, DOI 10.1161/CIRCULATIONAHA.105.568162; Schmidt-Lucke C, 2005, CIRCULATION, V111, P2981, DOI 10.1161/CIRCULATIONAHA.104.504340; Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23; Shashkin P, 2005, CURR PHARM DESIGN, V11, P3061, DOI 10.2174/1381612054865064; Shu H, 2000, BIOCHEM BIOPH RES CO, V267, P345, DOI 10.1006/bbrc.1999.1968; Turner NA, 2005, FASEB J, V19, P804, DOI 10.1096/fj.04-2852fje; Urbich C, 2005, KIDNEY INT, V67, P1672, DOI 10.1111/j.1523-1755.2005.00261.x; Werner N, 2005, NEW ENGL J MED, V353, P999, DOI 10.1056/NEJMoa043814; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Xu QB, 2006, NAT CLIN PRACT CARD, V3, P94, DOI 10.1038/ncpcardio0396	31	165	170	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14					2559	+		10.1096/fj.06-6265fje	http://dx.doi.org/10.1096/fj.06-6265fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17077283				2022-12-25	WOS:000242490700023
J	de Lange, P; Farina, P; Moreno, M; Ragni, M; Lombardi, A; Silvestri, E; Burrone, L; Lanni, A; Goglia, F				de Lange, Pieter; Farina, Paola; Moreno, Maria; Ragni, Maurizio; Lombardi, Assunta; Silvestri, Elena; Burrone, Lavinia; Lanni, Antonia; Goglia, Fernando			Sequential changes in the signal transduction responses of skeletal muscle following food deprivation	FASEB JOURNAL			English	Article						mitochondria; fatty acid oxidation; UCP3; fasting	FATTY-ACID OXIDATION; ACTIVATED PROTEIN-KINASE; ACETYL-COA CARBOXYLASE; UNCOUPLING PROTEIN-3; METABOLIC SYNDROME; GENE-EXPRESSION; PPAR-DELTA; RAT; UCP3; INCREASES	Coping with reduced energy sources entails drastic morphological and functional changes in skeletal muscle, but the sequence of events required classification. We found that gastrocnemius muscle from food-deprived rats shows acute rises in peroxisome proliferator activated receptor (PPAR) gamma coactivator (PGC) -1 alpha/PPAR delta nuclear protein and myosin heavy chain (MHC) Ib protein, while type I fibers accumulate and the muscle tissue appears redder. AMP levels, phosphorylation of both AMP-activated protein kinase (AMPK) and its downstream target acetyl coenzyme A carboxylase (ACC) are induced within 6 h. Rapidly increased MyoD mRNA levels are followed by an increase in uncoupling protein (UCP) 3 (UCP3) transcription. Increased serum fatty acid levels coincide with increases in mitochondrial UCP3 protein levels and fatty acid oxidation. Accompanying this is a decrease in AMPK phophorylation, reversible upon nicotinic acid treatment, indicating that fatty acids may modulate this kinase's activity after the metabolic challenges posed by food deprivation.	Seconda Univ Studi Napoli, Dipartimento Sci Vita, I-81100 Caserta, Italy; Univ Studi Sannio, Dipartimento Sci Biol & Ambientali, Benevento, Italy; Univ Naples Federico II, Dipartimento Sci Biol, Naples, Italy	Universita della Campania Vanvitelli; University of Sannio; University of Naples Federico II	Lanni, A (corresponding author), Seconda Univ Studi Napoli, Dipartimento Sci Vita, Via Vivaldi 43, I-81100 Caserta, Italy.	antonia.lanni@unina2.it; goglia@unisannio.it	Ragni, Maurizio/AAB-1527-2020; de Lange, Pieter/GXA-3052-2022	Ragni, Maurizio/0000-0001-6548-741X; Silvestri, Elena/0000-0002-0592-9033; GOGLIA, Fernando/0000-0003-0468-9645; MORENO, Maria/0000-0002-6218-5501				Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; BELKHOU R, 1991, NUTR RES, V11, P365, DOI 10.1016/S0271-5317(05)80312-4; Bezaire V, 2005, FASEB J, V19, P977, DOI 10.1096/fj.04-2765fje; Brand MD, 2005, CELL METAB, V2, P85, DOI 10.1016/j.cmet.2005.06.002; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CHALLET E, 1995, PHARMACOL BIOCHEM BE, V50, P405, DOI 10.1016/0091-3057(94)00287-S; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; de Lange P, 2003, FASEB J, V17, P350, DOI 10.1096/fj.03-0342fje; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; GAHILL GF, 1976, CLIN ENDOCRINOL META, V5, P397; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; Gonzalez AA, 2004, AM J PHYSIOL-REG I, V287, pR1270, DOI 10.1152/ajpregu.00409.2004; GOODMAN MN, 1980, AM J PHYSIOL, V239, pE277; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Kaushik VK, 2001, AM J PHYSIOL-ENDOC M, V281, pE335, DOI 10.1152/ajpendo.2001.281.2.E335; Kyrolainen H, 2003, MED SCI SPORT EXER, V35, P45, DOI 10.1249/01.MSS.0000046149.03322.BB; Leverve XM, 2003, DIABETES METAB, V29, pS88; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Luquet S, 2004, BIOCHIMIE, V86, P833, DOI 10.1016/j.biochi.2004.09.024; MacLellan JD, 2005, DIABETES, V54, P2343, DOI 10.2337/diabetes.54.8.2343; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; Moreno M, 2003, FASEB J, V17, P1112, DOI 10.1096/fj.02-0839fje; MUNDAY MR, 1991, BIOCHEM J, V280, P733, DOI 10.1042/bj2800733; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; OGILVIE RW, 1990, STAIN TECHNOL, V65, P231, DOI 10.3109/10520299009105613; Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657; Putman CT, 2003, J PHYSIOL-LONDON, V551, P169, DOI 10.1113/jphysiol.2003.04069; RANDLE PJ, 1963, LANCET, V1, P785; Schrauwen P, 2004, INT J OBESITY, V28, P824, DOI 10.1038/sj.ijo.0802629; Solanes G, 2003, MOL ENDOCRINOL, V17, P1944, DOI 10.1210/me.2002-0395; Son C, 2001, ENDOCRINOLOGY, V142, P4189, DOI 10.1210/en.142.10.4189; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Van der Lee KAJM, 2001, J LIPID RES, V42, P1752; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WITTERS LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P413, DOI 10.1006/abbi.1994.1058; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	40	66	77	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2006	20	14								10.1096/fj.06-6025fje	http://dx.doi.org/10.1096/fj.06-6025fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	111YB	17065218				2022-12-25	WOS:000242490700030
J	Hagemann, IS; Narzinski, KD; Floyd, DH; Baranski, TJ				Hagemann, Ian S.; Narzinski, Kirk D.; Floyd, Desiree H.; Baranski, Thomas J.			Random mutagenesis of the complement factor 5a (C5a) receptor N terminus provides a structural constraint for C5a docking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; MAGNETIC-RESONANCE DATA; LIGAND-BINDING; 3-DIMENSIONAL STRUCTURE; RHODOPSIN STRUCTURE; BOVINE RHODOPSIN; AGONIST BINDING; DRUG DISCOVERY; ACTIVATION	The N terminus of G protein-coupled receptors has been implicated in binding to peptide hormones. We have used random saturation mutagenesis to identify essential residues in the N terminus of the human complement factor 5a receptor (C5aR). In a library of N-terminal mutant C5aR molecules screened for activation by C5a, residues 24-30 of the C5aR showed a marked propensity to mutate to cysteine, most likely indicating that sulfhydryl groups at these positions are appropriately situated to form disulfide interactions with the unpaired Cys27 of human C5a. This presumptive spatial constraint allowed the ligand to be computationally docked to the receptor to form a model of the C5a/C5aR interaction. When the N-terminal mutant C5aR library was rescreened with C5a C27R, a ligand incapable of disulfide interactions, no individual position in the N terminus was essential for receptor signaling. However, the region 19-29 was relatively highly conserved in the functional mutants, further demonstrating that this region of the C5aR makes a productive physiologic interaction with the C5a ligand.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Baranski, TJ (corresponding author), 660 S Euclid Ave,Campus Box 8127, St Louis, MO 63110 USA.	baranski@wustl.edu	Hagemann, Ian/ABB-2854-2021	Hagemann, Ian/0000-0002-3855-9745	NIGMS NIH HHS [R01 GM63720] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063720] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allegretti M, 2005, CURR MED CHEM, V12, P217, DOI 10.2174/0929867053363379; Bao LH, 2005, EUR J IMMUNOL, V35, P2496, DOI 10.1002/eji.200526327; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bissantz C, 2003, J RECEPT SIG TRANSD, V23, P123, DOI 10.1081/RRS-120025192; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Buck E, 2005, J BIOL CHEM, V280, P4009, DOI 10.1074/jbc.C400500200; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Erlanson DA, 2004, ANNU REV BIOPH BIOM, V33, P199, DOI 10.1146/annurev.biophys.33.110502.140409; Erlanson DA, 2000, P NATL ACAD SCI USA, V97, P9367, DOI 10.1073/pnas.97.17.9367; Fan QR, 2005, ENDOCRINE, V26, P179, DOI 10.1385/ENDO:26:3:179; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; GERARD C, 1981, J IMMUNOL, V127, P1978; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Horn F, 2003, NUCLEIC ACIDS RES, V31, P294, DOI 10.1093/nar/gkg103; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Huber-Lang MS, 2003, J IMMUNOL, V170, P6115, DOI 10.4049/jimmunol.170.12.6115; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KAWAI M, 1992, J MED CHEM, V35, P220, DOI 10.1021/jm00080a004; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; KICO JM, 2006, J BIOL CHEM, V281, P12010; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; MERY L, 1994, J BIOL CHEM, V269, P3457; MERY L, 1993, EUR J HAEMATOL, V51, P282; Mirny LA, 1999, J MOL BIOL, V291, P177, DOI 10.1006/jmbi.1999.2911; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Valdar WSJ, 2002, PROTEINS, V48, P227, DOI 10.1002/prot.10146; WALKER P, 1994, J BIOL CHEM, V269, P2863; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; WILLIAMSON MP, 1990, BIOCHEMISTRY-US, V29, P2895, DOI 10.1021/bi00464a002; Zhang XL, 1997, PROTEINS, V28, P261, DOI 10.1002/(SICI)1097-0134(199706)28:2<261::AID-PROT13>3.0.CO;2-G; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P172, DOI 10.1021/bi00427a025	52	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36783	36792		10.1074/jbc.M607686200	http://dx.doi.org/10.1074/jbc.M607686200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023413	hybrid			2022-12-25	WOS:000242220800036
J	Li, LO; Mashek, DG; An, J; Doughman, SD; Newgard, CB; Coleman, RA				Li, Lei O.; Mashek, Douglas G.; An, Jie; Doughman, Scott D.; Newgard, Christopher B.; Coleman, Rosalind A.			Overexpression of rat long chain acyl-CoA synthetase 1 alters fatty acid metabolism in rat primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; MESSENGER-RNA; PPAR-ALPHA; CHOLESTEROL ACYLTRANSFERASE-1; TRIACYLGLYCEROL SYNTHESIS; NUCLEAR FACTOR-4-ALPHA; NUTRITIONAL REGULATION; MICROSOMAL-ENZYMES; MEMBRANE-FRACTION	Long chain acyl-CoA synthetases (ACSL) activate fatty acids ( FA) and provide substrates for both anabolic and catabolic pathways. We have hypothesized that each of the five ACSL isoforms partitions FA toward specific downstream pathways. Acsl1 mRNA is increased in cells under both lipogenic and oxidative conditions. To elucidate the role of ACSL1 in hepatic lipid metabolism, we overexpressed an Acsl1 adenovirus construct (Ad-Acsl1) in rat primary hepatocytes. Ad-ACSL1, located on the endoplasmic reticulum but not on mitochondria or plasma membrane, increased ACS specific activity 3.7-fold. With 100 or 750 mu M [1-C-14] oleate, Ad-Acsl1 increased oleate incorporation into diacylglycerol and phospholipids, particularly phosphatidylethanolamine and phosphatidylinositol, and decreased incorporation into cholesterol esters and secreted triacylglycerol. Ad-Acsl1 did not alter oleate incorporation into triacylglycerol, beta-oxidation products, or total amount of FA metabolized. In pulse-chase experiments to examine the effects of Ad-Acsl1 on lipid turnover, more labeled triacylglycerol and phospholipid, but less labeled diacylglycerol, remained in Ad-Acsl1 cells, suggesting that ACSL1 increased reacylation of hydrolyzed oleate derived from triacylglycerol and diacylglycerol. In addition, less hydrolyzed oleate was used for cholesterol ester synthesis and beta-oxidation. The increase in [1,2,3-H-3] glycerol incorporation into diacylglycerol and phospholipid was similar to the increase with [C-14] oleate labeling suggesting that ACSL1 increased de novo synthesis. Labeling Ad-Acsl1 cells with [C-14] acetate increased triacylglycerol synthesis but did not channel endogenous FA away from cholesterol ester synthesis. Thus, consistent with the hypothesis that individual ACSLs partition FA, Ad-Acsl1 increased FA reacylation and channeled FA toward diacylglycerol and phospholipid synthesis and away from cholesterol ester synthesis.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Duke Univ, Dept Med & Pharmacol, Durham, NC 27710 USA; Duke Univ, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	rcoleman@unc.edu	Li, Lei/B-5164-2010; Mashek, Douglas/ABD-6844-2021; Core, Vector/CAF-4832-2022	Mashek, Douglas/0000-0001-7033-3386	NIDDK NIH HHS [P30-DK34987, P01-DK58398, DK59935] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059935, P30DK034987, P01DK058398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abo-Hashema KAH, 1999, J BIOL CHEM, V274, P35577, DOI 10.1074/jbc.274.50.35577; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cacicedo JM, 2005, DIABETES, V54, P1838, DOI 10.2337/diabetes.54.6.1838; Caviglia JM, 2004, J BIOL CHEM, V279, P11163, DOI 10.1074/jbc.M311392200; Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Coleman C, 2002, FORMULARY, V37, P15; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Gargiulo CE, 1999, J LIPID RES, V40, P881; Gibbons GF, 2004, BIOCHEM SOC T, V32, P59, DOI 10.1042/BST0320059; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; Hostetler HA, 2005, J BIOL CHEM, V280, P18667, DOI 10.1074/jbc.M412062200; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Knight BL, 2005, BIOCHEM J, V389, P413, DOI 10.1042/BJ20041896; Kuriyama H, 1998, HEPATOLOGY, V27, P557, DOI 10.1002/hep.510270233; Lankester DL, 1998, J LIPID RES, V39, P1889; Lewin TM, 2005, AM J PHYSIOL-ENDOC M, V288, pE835, DOI 10.1152/ajpendo.00300.2004; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Liang JJ, 2004, J BIOL CHEM, V279, P44938, DOI 10.1074/jbc.M408507200; Marszalek JR, 2004, J BIOL CHEM, V279, P23882, DOI 10.1074/jbc.M313460200; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Mashek DG, 2006, J BIOL CHEM, V281, P945, DOI 10.1074/jbc.M507646200; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E400002-JLR200; Mashek DG, 2006, J LIPID RES, V47, P2004, DOI 10.1194/jlr.M600150-JLR200; Mashek DG, 2006, CURR OPIN LIPIDOL, V17, P274, DOI 10.1097/01.mol.0000226119.20307.2b; Miller TA, 2005, BIOCHEM BIOPH RES CO, V336, P309, DOI 10.1016/j.bbrc.2005.08.088; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Muoio DM, 2000, AM J PHYSIOL-ENDOC M, V279, pE1366, DOI 10.1152/ajpendo.2000.279.6.E1366; POLOKOFF MA, 1977, J BIOL CHEM, V252, P1167; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Reddy JK, 2001, AM J PHYSIOL-GASTR L, V281, pG1333, DOI 10.1152/ajpgi.2001.281.6.G1333; Richards MR, 2006, J LIPID RES, V47, P665, DOI 10.1194/jlr.M500514-JLR200; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Ryu MH, 2003, J BIOCHEM MOL BIOL, V36, P312; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; Sheena V, 2005, J LIPID RES, V46, P328, DOI 10.1194/jlr.M400371-JLR200; SHIMOMURA I, 1992, BIOCHIM BIOPHYS ACTA, V1124, P112, DOI 10.1016/0005-2760(92)90086-B; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Spady DK, 2000, J BIOL CHEM, V275, P27005; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Taghibiglou C, 2002, BIOCHEM PHARMACOL, V63, P349, DOI 10.1016/S0006-2952(01)00918-2; Van Horn CG, 2005, BIOCHEMISTRY-US, V44, P1635, DOI 10.1021/bi047721l; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VEERKAMP JH, 1986, BIOCHEM MED METAB B, V35, P248, DOI 10.1016/0885-4505(86)90080-0; Waterman IJ, 2002, DIABETES, V51, P1708, DOI 10.2337/diabetes.51.6.1708; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457	54	86	90	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					37246	37255		10.1074/jbc.M604427200	http://dx.doi.org/10.1074/jbc.M604427200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028193	hybrid			2022-12-25	WOS:000242220800085
J	Li, SH; Chen, XF; Ruggiero, C; Ding, BJ; Smerdon, MJ				Li, Shisheng; Chen, Xuefeng; Ruggiero, Christine; Ding, Baojin; Smerdon, Michael J.			Modulation of Rad26- and Rpb9-mediated DNA repair by different promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; RNA-POLYMERASE-II; TRANSCRIPTIONALLY ACTIVE DNA; NUCLEOTIDE EXCISION-REPAIR; GLOBAL GENOMIC REPAIR; SACCHAROMYCES-CEREVISIAE; COCKAYNE-SYNDROME; IN-VIVO; TRANSCRIBED STRAND; BINDING PROTEIN	Rad26, the yeast homologue of human Cockayne syndrome group B protein, and Rpb9, a nonessential subunit of RNA polymerase II, have been shown to mediate two subpathways of transcription-coupled DNA repair in yeast. Here we show that Rad26- and Rpb9-mediated repair in the yeast GAL1 gene is differently modulated by different promoter elements. The initiation site and efficiency of Rad26- mediated repair in the transcribed strand are determined by the upstream activating sequence (UAS) but not by the TATA or local sequences. The role of UAS in determining the Rad26- mediated repair is not through loading of RNA polymerase II or the transcriptional regulatory complex SAGA. However, both the UAS and the TATA sequences are essential for confining Rad26- mediated repair to the transcribed strand. Mutation of the TATA sequence, which greatly reduces transcription, or deletion of the TATA or mutation of the UAS, which completely abolishes transcription, causes Rad26- mediated repair to occur in both strands. Rpb9-mediated repair only occurs in the transcribed strand and is efficient only in the presence of both TATA and UAS sequences. Also, the efficiency of Rpb9-mediated repair is dependent on the SAGA complex. Our results suggest that Rad26- mediated repair can be either transcription-coupled, provided that a substantial level of transcription is present, or transcription-independent, if the transcription is too low or absent. In contrast, Rpb9-mediated repair is strictly transcription-coupled and is efficient only when the transcription level is high.	Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA; Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University; Washington State University	Li, SH (corresponding author), Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA.	shli@lsu.edu	Chen, Xuefeng/C-3410-2013; Li, Shisheng/H-9126-2012; Ding, Baojin/J-5479-2015	Ding, Baojin/0000-0002-2149-2599	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004106, R01ES012718] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES004106, R01 ES012718, ES012718, ES04106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; Bhatia PK, 1996, J BACTERIOL, V178, P5977, DOI 10.1128/jb.178.20.5977-5988.1996; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRIEDBERG EC, 2006, DNA REPAIR MUTAGENES, P360; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Gregory SM, 2001, NUCLEIC ACIDS RES, V29, P3080, DOI 10.1093/nar/29.14.3080; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Li SS, 1996, CARCINOGENESIS, V17, P1549, DOI 10.1093/carcin/17.8.1549; Li SS, 2000, METHODS, V22, P170, DOI 10.1006/meth.2000.1058; Li SS, 2004, J BIOL CHEM, V279, P14418, DOI 10.1074/jbc.M312004200; Li SS, 2002, EMBO J, V21, P5921, DOI 10.1093/emboj/cdf589; Lloyd RS, 2005, MUTAT RES-FUND MOL M, V577, P77, DOI 10.1016/j.mrfmmm.2005.04.003; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LOMMEL L, 1991, MUTAT RES, V255, P183, DOI 10.1016/0921-8777(91)90052-Q; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; Reardon JT, 2005, PROG NUCLEIC ACID RE, V79, P183, DOI 10.1016/S0079-6603(04)79004-2; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; Tijsterman M, 1997, P NATL ACAD SCI USA, V94, P8027, DOI 10.1073/pnas.94.15.8027; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANGOOL AJ, 1994, EMBO J, V13, P53616; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Verhage RA, 1996, MOL CELL BIOL, V16, P496; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; Zheng Y, 2001, J BIOL CHEM, V276, P16786, DOI 10.1074/jbc.M010973200	39	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36643	36651		10.1074/jbc.M604885200	http://dx.doi.org/10.1074/jbc.M604885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17023424	Green Accepted, hybrid			2022-12-25	WOS:000242220800021
J	Matsuo, Y; Amano, S; Furuya, M; Namiki, K; Sakurai, K; Nishiyama, M; Sudo, T; Tatsumi, K; Kuriyama, T; Kimura, S; Kasuya, Y				Matsuo, Yuji; Amano, Shinya; Furuya, Mitsuko; Namiki, Kana; Sakurai, Kanako; Nishiyama, Mariko; Sudo, Tatsuhiko; Tatsumi, Koichiro; Kuriyama, Takayuki; Kimura, Sadao; Kasuya, Yoshitoshi			Involvement of p38 alpha mitogen-activated protein kinase in lung metastasis of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-SELECTIN EXPRESSION; HUMAN OVARIAN-CARCINOMA; CAMP-RESPONSE ELEMENT; MAP KINASE; P-SELECTIN; ENDOTHELIAL-CELLS; IN-VIVO; CANCER-CELLS; KAPPA-B; P38	To study the role of p38 mitogen-activated protein kinase ( p38) activity during the process of metastasis, p38 alpha(+/-) mice were subjected to an in vivo metastasis assay. The number of lung colonies of tumor cells intravenously injected in p38 alpha(-/-) mice was markedly decreased compared with that in wild-type (WT) mice. On the other hand, the time-dependent increase in tumor volume after subcutaneous tumor cells transplantation was comparable between WT and p38 alpha(+/-) mice. Platelets of p38 alpha(+/-) mice were poorly bound to tumor cells in vitro and in vivo compared with those of WT mice. E- and P-selectin mRNAs were markedly induced in the lung after intravenous injection of tumor cells. However, the induction of these selectin mRNAs in p38 alpha(+/-) mice was weaker than that in WT mice. Furthermore, the resting expression levels of E-selectin in lung endothelial cells and P-selectin in platelets of p38 alpha(+/-) mice were suppressed compared with those of WT mice. The number of tumor cells attached on lung endothelial cells of p38 alpha(+/-) mice was significantly reduced compared with that of WT mice. The transmigrating activity of tumor cells through lung endothelial cells of p38 alpha(+/-) mice was similar to that of WT mice. These results suggest that p38 alpha plays an important role in extravasation of tumor cells, possibly through regulating the formation of tumor-platelet aggregates and their interaction with the endothelium involved in a step of hematogenous metastasis.	Chiba Univ, Grad Sch Med, Dept Biochem & Mol Pharmacol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Respirol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Mol Pathol, Chuo Ku, Chiba 2608670, Japan; RIKEN, Antibiot Lab & Bioarchitect Res Grp, Wako, Saitama 3510198, Japan	Chiba University; Chiba University; Chiba University; RIKEN	Kasuya, Y (corresponding author), Chiba Univ, Grad Sch Med, Dept Biochem & Mol Pharmacol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	kasuya@faculty.chiba-u.jp		Kasuya, Yoshitoshi/0000-0003-0614-5836; Kimura, Sadao/0000-0001-6768-7474				Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Aguirre-Ghiso JA, 2004, CANCER RES, V64, P7336, DOI 10.1158/0008-5472.CAN-04-0113; Biancone L, 1996, J EXP MED, V183, P581, DOI 10.1084/jem.183.2.581; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Hale KK, 1999, J IMMUNOL, V162, P4246; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hickson JA, 2006, CANCER RES, V66, P2264, DOI 10.1158/0008-5472.CAN-05-3676; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Jackson JR, 1998, J PHARMACOL EXP THER, V284, P687; Janowska-Wieczorek A, 2005, INT J CANCER, V113, P752, DOI 10.1002/ijc.20657; Jayachandran M, 2005, AM J PHYSIOL-HEART C, V288, pH2355, DOI 10.1152/ajpheart.01108.2004; JIANG Y, 1994, J BIOL CHEM, V266, P17920; Jurasz P, 2004, BRIT J PHARMACOL, V143, P819, DOI 10.1038/sj.bjp.0706013; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x; Kato Y, 1997, CANCER RES, V57, P3040; Khatib AM, 2005, AM J PATHOL, V167, P749, DOI 10.1016/S0002-9440(10)62048-2; Khatib AM, 1999, CANCER RES, V59, P1356; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; Laferriere J, 2002, ANN NY ACAD SCI, V973, P562, DOI 10.1111/j.1749-6632.2002.tb04702.x; Ludwig RJ, 2004, CANCER RES, V64, P2743, DOI 10.1158/0008-5472.CAN-03-1054; MANNORI G, 1995, CANCER RES, V55, P4425; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIN O, 1984, J CELL PHYSIOL, V119, P327, DOI 10.1002/jcp.1041190311; Nicholson B, 2004, J CELL BIOCHEM, V91, P125, DOI 10.1002/jcb.10772; Otsu K, 2003, BIOCHEM BIOPH RES CO, V302, P56, DOI 10.1016/S0006-291X(03)00096-2; Palumbo JS, 2000, BLOOD, V96, P3302, DOI 10.1182/blood.V96.10.3302; Pan JL, 1998, J BIOL CHEM, V273, P10068, DOI 10.1074/jbc.273.16.10068; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Reimold AM, 2001, INT IMMUNOL, V13, P241, DOI 10.1093/intimm/13.2.241; Sakurai K, 2004, J RECEPT SIG TRANSD, V24, P283, DOI 10.1081/RRS-200040324; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Takanami-Ohnishi Y, 2002, J BIOL CHEM, V277, P37896, DOI 10.1074/jbc.M207326200; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Timar J, 2003, PATHOL ONCOL RES, V9, P49, DOI 10.1007/BF03033715; Voura EB, 1998, MICROSC RES TECHNIQ, V43, P265, DOI 10.1002/(SICI)1097-0029(19981101)43:3<265::AID-JEMT9>3.0.CO;2-Z; Westra J, 2005, INT IMMUNOPHARMACOL, V5, P1259, DOI 10.1016/j.intimp.2005.03.005; Yamada SD, 2002, CANCER RES, V62, P6717; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	44	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	2006	281	48					36767	36775		10.1074/jbc.M604371200	http://dx.doi.org/10.1074/jbc.M604371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	108DP	17028194	hybrid			2022-12-25	WOS:000242220800034
J	Lee, SB; Bae, IH; Bae, YS; Um, HD				Lee, Seung Bum; Bae, In Hwa; Bae, Yun Soo; Um, Hong-Duck			Link between mitochondria and NADPH oxidase 1 isozyme for the sustained production of reactive oxygen species and cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SIGNALING PATHWAY; SHORT INTERFERING RNAS; OXIDATIVE STRESS; ACTIVATION; APOPTOSIS; EXPRESSION; GROWTH; RAC1; LIPOPOLYSACCHARIDE; GENERATION	Although mitochondria and the Nox family of NADPH oxidase are major sources of reactive oxygen species (ROS) induced by external stimuli, there is limited information on their functional relationship. This study has shown that serum withdrawal promotes the production of ROS in human 293T cells by stimulating both the mitochondria and Nox1. An analysis of their relationship revealed that the mitochondria respond to serum withdrawal within a few minutes, and the ROS produced by the mitochondria trigger Nox1 action by stimulating phosphoinositide 3-kinase (PI3K) and Rac1. Activation of the PI3K/Rac1/Nox1 pathway was evident 4-8 h after but not earlier than serum withdrawal initiation, and this time lag was found to be required for an additional activator of the pathway, Lyn, to be expressed. Functional analysis suggested that, although the mitochondria contribute to the early (0-4 h) accumulation of ROS, the maintenance of the induced ROS levels to the later (4-8 h) phase required the action of the PI3K/Rac1/Nox1 pathway. Serum withdrawal-treated cells eventually lost their viability, which was reversed by blocking either the mitochondria-dependent induction of ROS using rotenone or KCN or the PI3K/Rac1/Nox1 pathway using the dominant negative mutants or small interfering RNAs. This suggests that mitochondrial ROS are essential but not enough to promote cell death, which requires the sustained accumulation of ROS by the subsequent action of Nox1. Overall, this study shows a signaling link between the mitochondria and Nox1, which is crucial for the sustained accumulation of ROS and cell death in serum withdrawal-induced signaling.	Korea Inst Radiol & Med Sci, Lab Radiat Tumor Physiol, Seoul 139706, South Korea; Ewha Womans Univ, Div Mol Life Sci, Ctr Cell Signalling Res, Seoul 120750, South Korea	Korea Institute of Radiological & Medical Sciences; Ewha Womans University	Um, HD (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Tumor Physiol, 215-4 Gongneung Dong, Seoul 139706, South Korea.	hdum@kcch.re.kr	Um, Hong-Duk/AAH-3733-2021					Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Aronis A, 2005, FREE RADICAL BIO MED, V38, P1221, DOI 10.1016/j.freeradbiomed.2005.01.015; BASS DA, 1983, J IMMUNOL, V130, P1910; Brandes RP, 2005, CARDIOVASC RES, V65, P16, DOI 10.1016/j.cardiores.2004.08.007; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cheng G, 2006, J BIOL CHEM, V281, P17718, DOI 10.1074/jbc.M512751200; Chiaramonte R, 2001, J CELL BIOCHEM, V82, P437, DOI 10.1002/jcb.1158; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; EMMENDORFFER A, 1990, J IMMUNOL METHODS, V131, P269, DOI 10.1016/0022-1759(90)90198-5; Eom SJ, 2001, MOL PHARMACOL, V59, P981, DOI 10.1124/mol.59.5.981; Felty Q, 2005, BIOCHEMISTRY-US, V44, P6900, DOI 10.1021/bi047629p; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hordijk PL, 2006, CIRC RES, V98, P453, DOI 10.1161/01.RES.0000204727.46710.5e; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim DK, 2000, EXP CELL RES, V257, P82, DOI 10.1006/excr.2000.4868; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lee SB, 2005, LIFE SCI, V78, P91, DOI 10.1016/j.lfs.2005.04.035; Lee SB, 2005, CELL SIGNAL, V17, P197, DOI 10.1016/j.cellsig.2004.07.001; MANGAN DF, 1991, J IMMUNOL, V146, P1541; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Ueyama T, 2006, MOL CELL BIOL, V26, P2160, DOI 10.1128/MCB.26.6.2160-2174.2006; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; Vrablic AS, 2001, FASEB J, V15, P1739, DOI 10.1096/fj.00-0300com; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Yoon YS, 2005, ONCOGENE, V24, P1895, DOI 10.1038/sj.onc.1208262; Yu L, 2006, TOHOKU J EXP MED, V209, P141, DOI 10.1620/tjem.209.141	44	149	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					36228	36235		10.1074/jbc.M606702200	http://dx.doi.org/10.1074/jbc.M606702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17015444	hybrid			2022-12-25	WOS:000242100500074
J	Stathopulos, PB; Li, GY; Plevin, MJ; Ames, JB; Ikura, M				Stathopulos, Peter B.; Li, Guang-Yao; Plevin, Michael J.; Ames, James B.; Ikura, Mitsuhiko			Stored Ca2+ depletion-induced oligomerization of stromal interaction molecule 1 (STIM1) via the EF-SAM region - An initiation mechanism for capacitative Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; CHANNEL FUNCTION; PLASMA-MEMBRANE; SEQUENTIAL ASSIGNMENT; ENDOPLASMIC-RETICULUM; LIGAND-BINDING; PROTEIN; SENSOR; ORAI1; CRAC	Stromal interaction molecule 1 (STIM1) has recently been identified as a key player in store-operated Ca2+ entry. Endoplasmic reticulum ( ER) luminal Ca2+ depletion results in STIM1 redistribution from ER membrane homogeneity to distinctly localized aggregates near the plasma membrane; these changes precede and are linked to cytoplasmic Ca2+ influx via Ca2(+) release-activated channels (CRACs). The molecular mechanisms initiating ER STIM1 redistribution and plasma membrane CRAC activity are not well understood. We recombinantly expressed the Ca2+-sensing region of STIM1 consisting of the EF-hand together with the sterile alpha-motif (SAM) domain (EF-SAM) to investigate its Ca2+-related conformational and biochemical features. We demonstrate that Ca2+-loaded EF-SAM ( holo) contains high alpha-helicity, whereas EF-SAM in the absence of Ca2+ (apo) is much less compact. Accordingly, the melting temperature (T-m) of the holoform is similar to 25 degrees C higher than apoform; heat and urea-derived thermodynamic parameters indicate a Ca2+-induced stabilization of 3.2 kcal mol(-1). We show that holoEF-SAM exists as a monomer, whereas apoEF-SAM readily forms a dimer and/or oligomer, and that oligomer to monomer transitions and vice versa are at least in part mediated by changes in surface hydrophobicity. Additionally, we find that the Ca2+ binding affinity of EF-SAM is relatively low with an apparent dissociation constant (K-d) of similar to 0.2 - 0.6 mM and a binding stoichiometry of 1. Our results suggest that EF-SAM actively participates in and is the likely the molecular trigger initiating STIM1 punctae formation via large conformational changes. The low Ca2+ affinity of EF-SAM is reconciled with the confirmed role of STIM1 as an ER Ca2+ sensor.	Ontario Canc Inst, Div Signalling Biol, Toronto, ON M5G 1L7, Canada; Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto, ON M5G 1L7, Canada; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of California System; University of California Davis	Ikura, M (corresponding author), MaRS Toronto Med Discovery Tower,Rm 4-804,101 Col, Toronto, ON M5G 1L7, Canada.	mikura@uhnres.utoronto.ca		Stathopulos, Peter B./0000-0002-0536-6656; Ikura, Mitsuhiko/0000-0002-9524-1303; Plevin, Michael/0000-0003-2057-8291	NATIONAL EYE INSTITUTE [R01EY012347] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demaurex N, 2003, CELL CALCIUM, V34, P109, DOI 10.1016/S0143-4160(03)00081-2; Draber P, 2005, TRENDS IMMUNOL, V26, P621, DOI 10.1016/j.it.2005.09.006; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Hoeflich KP, 2003, BIOCHEMISTRY-US, V42, P11634, DOI 10.1021/bi0350497; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1987, FEBS LETT, V219, P17, DOI 10.1016/0014-5793(87)81182-1; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Julenius K, 2002, PROTEINS, V47, P323, DOI 10.1002/prot.10080; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Lopez JJ, 2006, J BIOL CHEM, V281, P28254, DOI 10.1074/jbc.M604272200; Manji SSM, 2000, BBA-PROTEIN STRUCT M, V1481, P147, DOI 10.1016/S0167-4838(00)00105-9; Marchant JS, 2005, CURR BIOL, V15, pR493, DOI 10.1016/j.cub.2005.06.035; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; Masino L, 2000, PROTEIN SCI, V9, P1519, DOI 10.1110/ps.9.8.1519; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Muralidhar D, 2005, J BIOL CHEM, V280, P15569, DOI 10.1074/jbc.M414243200; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Pace C N, 1986, Methods Enzymol, V131, P266; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, CURR BIOL, V16, P1465, DOI 10.1016/j.cub.2006.05.051; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Thomas AP, 2000, NAT CELL BIOL, V2, pE126, DOI 10.1038/35017143; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; WANG AC, 1994, J MAGN RESON SER B, V105, P196, DOI 10.1006/jmrb.1994.1123; Williams RT, 2002, BBA-PROTEIN STRUCT M, V1596, P131, DOI 10.1016/S0167-4838(02)00211-X; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Wingard JN, 2005, J BIOL CHEM, V280, P37461, DOI 10.1074/jbc.M508541200; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	54	321	335	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	2006	281	47					35855	35862		10.1074/jbc.M608247200	http://dx.doi.org/10.1074/jbc.M608247200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106KX	17020874	hybrid			2022-12-25	WOS:000242100500032
